OA20932A

OA20932A - Modulators of cystic fibrosis transmembrane conductance regulator.

Info

Publication number: OA20932A
Application number: OA1201700130
Authority: OA
Inventors: Corey Anderson; Brian Richard Bear; Sara Sabina Hadida-Ruah; Andreas P Termin; Mark Thomas Miller; Vijay-alaksmi ARUMUGAM; Hayley Marie Binch; Jeremy J. Clemens; Thomas Cleveland; Timothy Richard Coon; Bryan A Frieman; Peter Diederik Jan Grootenhuis; Raymond Stanley GROSS; Khatuya Haripada; Pramod Virupax Joshi; Paul John Krenitsky; Chun-Chieh Lin; Gulin Erdogan Marelius; Vito Melillo; Jason Mccartney
Original assignee: Vertex Pharmaceuticals Incorporated
Priority date: 2014-10-06
Filing date: 2015-10-06
Publication date: 2023-07-24

Abstract

The present invention features a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application daims the benefît of priority under 35 U.S.C. § 119 to United States provisional patent application serial numbers 62/060,182, filed October 6, 2014; 62/114,767, filed February 11,2015; and 62/153,120, filed April 27, 2015, the entire contents of ail applications are incorporated herein by référencé.

TECHNICAL FIELD OF THE INVENTION

The présent invention features modulators of Cystic Fibrosis Transmembrane

Conductance Regulator (CFTR), pharmaceutical compositions, methods of treatment, and kits thereof.

BACKGROUND OF THE INVENTION

Cystic fibrosis (CF) is a récessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 children and adults in Europe.

Despite progress in the treatment of CF, there is no cure.

In patients with CF, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion sécrétion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death. In addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the CF associated gene, individuals with a single copy of the CF associated gene exhibit increased résistance to choiera and to déhydration resulting from diarrhea - perhaps explaining the relatively high frequency of the CF gene within the population.

Sequence analysis of the CFTR gene of CF chromosomes h as revealed a variety of disease causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al.

(1990) Ce 11 61:863:870; and Kerem, B-S. étal. (1989) Science 245:1073-1080; Kerem, B-S étal. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, greater than 1000 disease causing mutations in the CF gene hâve been identified (http://cftr2.org). The most prévalent mutation is a délétion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as F508del. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease.

The délétion of residue 508 in F508del prevents the nascent protein from folding correctly. This results in the inabiiity of the mutant protein to exit the ER, and traffic to the plasma membrane. As a resuit, the number of channels présent in the membrane is far less than observed in cells expressing wild-type CFTR. In addition to impaired trafficking, the mutation results in defective channel gating. Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport. (Quinton, P. M. (1990), FASEB J. 4: 2709-2727). Studies hâve shown, however, that the reduced numbers of F508del in the membrane are ftmctional, albeit less than wild-type CFTR. (Dalemans et al. (1991), Nature Lond. 354: 526-528; Denning et al., supra; Pasyk and Foskett (1995), J. Cell. Biochem. 270: 12347-50). In addition to F508del, other disease causing mutations in CFTR that resuit in defective trafficking, synthesis, and/or channel gating could be up- ordown-regulated to alter anion sécrétion and modify disease progression and/or severity.

Accordingly, there is a need for novel treatments of CFTR mediated diseases.

SUMMARY OF THE INVENTION

The invention features a compound of formula I:

I, or a pharmaceutically acceptable sait thereof, wherein, in dépend ently for each occurrence:

Ring A is a C6-C10 aryl ring; C3-CIO cycloalkyl ring; or a C3-Cl4 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring B is a C3-C10 cycloalkyl ring; a C6-C10 aryl ring; or a C4-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C6-C10 aryl ring; a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, NR, O, or S; or a C3-C10 cycloalkyl ring;

WisO, NR, or S;

X is O or NR;

Y is independently CRR, CO, O, S, SO, SO_2t S(O)NH or NR;

ZisNRorCHR;

Ri is halo; CN; F₅S; S1R3; OH; NRR; CI-C6 alkyi or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, S O, S O₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;C 1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; CI-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anyw'here from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 aîkylene)-R4 wherein up to four CH₂ units are optionally and independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R3 is halo; CN; OH; COiR; CHC6 alkyl or fluoroalkyl; C1*C6 alkenyl; C1-C6 alkynyl;

C1-C6 alkoxy or fîuoroalkoxy; or C6-CI0 aryl; C3-CIÜ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylenejTG wherein up to four CHs units are independently replaced with O, CO, S, SO, SO; or NR;

or two Rj groups taken together may form a =CHj or =O group;

R4 is H; azide; CF3; CHF2; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocyclo alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH;CO₂H; CO₂CHC6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl orheterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, 2 or 3;

o is 0, 1,2, 3, 4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5;

is a single bond or a double bond;

provided that the moieties containing ring B and ring C are substituted at adjacent positions on ring A.

The présent invention also features phannaceutical compositions thereof, which may include additional agents, and methods of treating CFTR mediated diseases, such as cystic fibrosis, comprising administering compounds of formula I to a subject in need thereof, The présent invention also features kits comprising compounds of formula I,

BRIEF DESCRIPTION OF DRAWINGS

F igure 1 discloses a list of CFTR mutations by name, protein name, and legacy name that in one aspect of the invention a patient may possess and be treatable by the compounds and compositions of the présent invention.

DETAILED DESCRIPTION OF THE INVENTION

Définitions

As used herein, “CFTR” stands for cystic fïbrosis transmembrane conductance regulator.

As used herein, “mutations” can refer to mutations in the CFTR gene or the CFTR protein. A “CFTR mutation” refers to a mutation in the CFTR gene, and a “CFTR mutation” refers to a mutation in the CFTR protein. A genetic defect or mutation, or a change in the nucléotides in a gene in general results in a mutation in the CFTR protein translated from that gene.

As used herein, a “F508del mutaion” or “F508del” is a spécifie mutation within the CFTR protein. The mutation is a délétion of the three nucléotides that comprise the codon for amino acid phenylalanine at position 508, resulting in CFTR protein that lacks fois phenylalanine residue.

The term CFTR gating mutation” as used herein means a CFTR mutation that results in the production of a CFTR protein for which the prédominant defect is a low channel open probability compared to nomral CFTR (Van Goor, F., Hadida S. and Grootenhuis P., “Pharmacological Rescue of Mutant CFTR fonction for the Treatment of Cystic Fibrosis”, Top. Med. Chem. 3: 91-120 (2008)). Gating mutations include, but are not limited to, G551D, GI78R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, and G1349D.

As used herein, a patient who is “homozygous” for a particular mutation, e.g. F508del, has the same mutation on each aîlele.

As used herein, a patient who is “heterozygous” for a particular mutation, e.g. F508del, has fois mutation on one allele, and a different mutation on the other allele.

As used herein, the term “modulator” refers to a compound that increases the activity of a biological compound such as a protein. For example, a CFTR modulator is a compound that increases the activity of CFTR. The increase in activity resulting from a CFTR modulator may be through a corrector mechanism or a potentiator mechanism as described below.

As used herein, the term “CFTR corrector” refers to a compound that increases the amount of fonctional CFTR protein to the cell surface, resulting in enhanced ion transport.

As used herein, the term “CFTR potentiator” refers to a compound that increases the channel activity of CFTR protein located at the cell surface, resulting in enhanced ion transport.

As used herein, the term “inducing,” as in inducing CFTR activity, refers to increasing CFTR activity, whether by the corrector, potentiator, or other mechanism.

As used herein, the term “active pharmaceutical ingrédient” or API refers to a biologically active compound.

A “patient,” “subject” or “individual” are used interchangeably and refer to either a human or non-human animal. The term includes mammals such as humans.

The terms effective dose or effective amount are used interchangeably herein and refer to that amount that produces the desired effect for which it is administered (e.g., improvement in CF or a symptom of CF or lessening the severity of CF or a symptom of CF). The exact amount will dépend on the purpose of the treatment, and wili be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

As used herein, the terms treatment, treating, and the like generally mean the improvement of CF or its symptoms or lessening the severity of CF or its symptoms in a subject. “Treatment,” as used herein, includes, but is not limited to, the following: increased growth of the subject, increased weight gain, réduction of mucus in the lungs, improved pancreatic and/or liver function, reduced cases of chest infections, and/or reduced instances of coughing or shortness of breath. Improvements in or lessening the severity of any of these conditions canbe readily assessed according to standard methods and techniques known in the art.

As used herein, the tenn “in combination with” when referring to two or more compounds or agents means that the order of administration includes the compounds or agents being administered prior to, concurrent with, or subséquent to each other to the patient.

As used herein, the phrase “option ally substituted” is used interchangeably with the phrase “substituted or unsubstituted.”

As described herein, compounds within the compositions of the invention can optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention (such as the compounds listed in Table 1). As described herein in formulae I-Id-ii , the variables R]-R₄in formulae I-Id-ii encompass spécifie groups, such as, for example, alkyl, alkenyl, alkynyl, alkoxy, heteroaryl, heterocyclic, cycloalkyl, and aryl, etc. Un les s otherwise noted, each of the spécifie groups for the variables Rr&4 can be optionally substituted with one or more group selected from halo, phospho, OH, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, fluoroalkyl, alkyl, alkenyl, alkynyl, nitro, CN, hydroxyi, and (Cl-C9alkylene)-E wherein up to 4 CH₂ units are independently replaced with O, S, SO₂, SO, CO, NH, Æ-alkyl, Malkenyl, or A-alkynyl, and E is H, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkoxy,CN, or CF₃, further wberein each of the aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is optionally substituted with one or more group selected from halo, alkyl, amino, CN, alkenyl, alkynyl, and alkoxy.

As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that resuit in the formation of stable or chemically feasible compounds. The term stable, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, détection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a température of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound.

As disclosed herein, substituents or variables (such as R and R_rR₄ in formula I-Id-ii) can be selected from more than one spécifie group. To the extent that one spécifie group for a variable may include or overlap with another spécifie group for the same variable, the narrower spécifie group is provisoed out from the broader spécifie group. In other words, double inclusion cannot exist.

In general, the term “substituted,” whether preceded by the terni “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Spécifie substituents are described above in the définitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can hâve a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent: can be either the same or different at every position. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that resuit in the formation of stable or chemically feasible compounds.

The phrase up to, as used herein, refers to zéro or any integer number that is equal or less titan the number following the phrase. For example, up to 3 means any one of 0, 1,2, and 3.

The terms “about” and “approximately”, when used in connection with doses, amounts, or weight percent of ingrédients of a composition or a dosage fonn, mean a dose, amount, or weight percent that is recognized by one of ordinary skill in the art to provide a pharmacologie al effect équivalent to that obtained from the specified dose, amount, or weight percent. Specifically the term “about” or “approximately” means an acceptable enor for a particular value as determined by one of ordinary skill in the art, which dépends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1,2, 3, or 4 standard déviations. In certain embodiments, the term “about” or “approximately” means within 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, or 0.05% of a given value or range.

The term “adjacent” as used herein refers to positions on the ring wherein the two ring atoms are bonded to each other. Two ring atoms with an intervening ring atom are not considered adjacent even when that intervening atom does not allow substitution due to valency.

The term aliphatic, aliphatic group, as used herein, means a straight-chain (i.e., unbranched) or branched hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups.

The term “spiro” as used herein, means a two-ring System wherein both rings share only one common atom.

The term cycloaliphaiic or “cycloalkyl” mean a monocyclic, bicyclic (fused or spiro), tricyclic (fused or spiro), orpropellane hydrocarbon that has a single point of attachment to the rest of the molécule, and that is completely saturated or contains one or more units of unsaturation, but noue of the individual rings in the monocyclic, bicyclic, or tricyclic hydrocarbon is aromatic, The single point of attachment can be on the saturated or unsaturated carbon. In some embodiments, cycloaljphatic or “cycloalkyl” refers to a monocyclic Ca-Cs hydrocarbon or bicyclic Cs-Cn hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but none of the individual ring in the monocyclic Cj-Cg hydrocarbon or fused bicyclic Cs-Ci2 hydrocarbon is aromatic, and that has a single point of attachment to the rest of the molécule wherein any individual ring in said bicyclic ring System has 3-7 members.

As used herein, an “alkyl” group refers to a saturated hydrocarbon group containing 120 (e.g,, 1 -6 or 1-12) carbon atoms. An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secbutyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl.

As used hereîn, an alkenyl group refers to a hydrocarbon group that contains 2-20 (e.g., 2-12, 2-6, or 2-4) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. The point of attachement can be on a saturated carbon or unsaturated carbon. Examples of an alkenyl group include, but are not limited to allyl, isoprenyl, 2-butenyl, and 2-hexenyl,

As used herein, an alkynyl group refers to a hydrocarbon group that contains 2-20 (e.g., 2-12, 2-6, or 2-4) carbon atoms and has at least one triple bond. An alkynyl group can be straight or branched. The point of attachement can be on a saturated carbon or unsaturated carbon. Examples of an alkynyl group include, but are not limited to, propargyl and butynyl.

As used herein, an “alkoxy” group refers to -O-alkyl, O-alkenyl, or O-alknyl, wherein alkyl, alkenyl, and alkynyl are as defmed above.

As used herein, “fluoroalkyl” or “fluoroalkoxy” refers to alkyl or alkoxy wherein one or more hydrogen is substituted with a fluoro.

As used herein, an “amino” refers to NHi which is optionally substituted with one or two groups independently selected from alkyl, cycloalkyl, and heterocycloalkyl.

The term “électron withdrawing group”, as used herein means an atom or a group that is electronegative relative to hydrogen. See, e.g., “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,” Jerry March, 4^(h Ed., John Wiley & Sons (1992), e.g., pp. 14-16, 18-19, etc. Exemplary such substituents include halo such as Cl, Br, or F, CN, COOH,CF₃, etc,

Unless otherwise specified, the term heterocycle, heterocyclyl, heterocycloaliphatic, heterocycloalkyl or heterocyclic as used herein means monocyclic, bicyclic (fused or spiro), tricyclic (fused or spiro), or propellane ring Systems in which one or more ring atoms in one or more ring members is an independently selected heteroatom and none of the individual rings in the System is aromatic. Heterocyclic rings can be saturated orcan contain one or more unsaturated bonds. In some embodîments, the heterocycle, heterocyclyl, heterocycloaliphatic, heterocycloalkyl or heterocyclic group h as three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the ring System contains 3 to 7 ring members. The point of attachment can be on the carbon or heteroatom.

The term heteroatom means oxygen, sulfur, nitrogen, phosphorus, or Silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or Silicon; the quatemized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as in A-substituted pyrrolidinyl)).

The term unsaturated, as used herein, means that a moiety has one or more units of unsaturation but is not aromatic.

The term alkoxy, or thio alkyl, as used herein, refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (alkoxy) or sulfur (thioalkyl) atom.

The term aryl used alone or as part of a larger moiety as in aralkyl, aralkoxy, or aryloxyalkyl, refers to monocyclic, bicyclic (fused), and tricyclic (fused or spiro) hydrocarbon ring Systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the System is aromatic and wherein each ring in the System contains 3 to 7 ring carbon atoms. The term aryl may be used interchangeably with the term aryl ring.

The terni heteroaryl, used alone or as part of a larger moiety as in heteroaralkyl or heteroarylalkoxy, refers to monocyclic, bicyclic (fused), and tricyclic (fused or spiro) ring Systems having a total of five to fourteen ring members, wherein at least one ring in the System is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term heteroaryl may be used interchangeably with the term heteroaryl ring or the term heteroaromatic.

The term alkylene refers to a straight or branched hydrocarbon chain that may be fully saturated or hâve one or more units of unsaturation and has two points of attachment to the rest of the molécule.

The term “prodrug, as used herein, represents a compound that is transformed in vivo into a compound according to any one of the formulae listed herein. Such a transformation can be affected, for example, by hydrolysîs in blood or enzymatic transformation of the prodrug form to the parent form in blood or tissue. Prodrugs of the compounds of the invention may be, for example, amides. Amides that may be utilized as prodmgs in the présent invention are phenyl ami des, aliphatic (C1-C24) amids, acyloxymethyl amides, ureas, carbamates, and amino acid amides. For example, a compound of the invention that contains an NH group may be acylated at this position in its prodrug form. Other prodrug forms include esters, such as, for example phenyl esters, aliphatic (C_rC24) esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 ofthe A.C.S. Symposium Sériés, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and Judkins étal., Synthetic Communications 26(23):4351-4367, 1996, each of which is incorporated in its entirety herein by reference. In some embodiments, the présent invention features a prodrug of any one of the formulas or compounds listed herein.

The term “isosteres” or “bioisosteres,” as used herein, refers to compounds resulting from the exchange of an atom or group of atoms to create a new compound with similar biologie al properties to the parent compound. The bioisosteric replacement may be physicochemically or topologically based. For example, an isosteric replacement for a carboxylic acid is CONHSOi(alkyl or aryl)) such as CONHSOiMe. A further discussion of isosterism is provided in R. Silverman, The Organic Chemistry of Drug Design and Drug Action, second édition, Elsevier Academie Press, 2004, incorporated in its entirety herein by référencé. In some embodiments, the présent invention features aisostere of any one ofthe formulas or compounds listed herein.

In the formulas and drawings, a line transversing a ring and bonded to an R group such as, for example, R₂ in the following formula

means that the R group can be bonded to any carbon, or if applicable, heteroatom such as N, of that ring, including any fused ring, as valency allows.

Within a terra définition as, for example, Rj through R₃ when a CH₂ unit or, interchangeably, a methylene unit may be replaced by O, CO, S, SO, SO₂, or NR; it is meant to include any CH₂ unit, including a CH, within a terminal methyl or methylene group. For example, -CH₂CH₂CH₂SH is within the définition of Cl -C9 alkylene-R4 wherein up to four CH, units are independently replaced by O, CO, S, SO, SO₂, or NR because the CH₂ unit of the terminal methyl group has been replaced by S. The analogous applies to such définitions as CH₂CH₂OH, -CH,CH₂CN, or-CH,CH₂NH₂.

Unless otherwise stated, structures depicted herein are also meant to include al] isomeric (e.g., enantiomeric, diastereomeric, and géométrie (or conformational)) forms ofthe structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochernie a] isomers as well as enantiomeric, diastereomeric, and géométrie (or conformational) mixtures of the présent compounds are within the scope ofthe invention. Where the enantiomers of a racemic mixture hâve been séparated, but the absoluté chemistry has not yet been determined, the compound’s structure is depicted with a wavy line.

Unless otherwise stated, ail tautomeric forms of the compounds of the invention are within the scope of the invention. Thus, included within the scope of the invention are tautomers of compounds of formulas I to Id-ii.

To the extent thaï a définition in the présent application differs from any définition in an application incorporated by reference, the définition in the présent application supercedes.

CFTR is a cAMP/ATP-mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it régulâtes anion flux across the membrane, as well as the activity of other ion channels and proteins. In epithelia cells, normal functioning of CFTR. is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucléotide binding domain. The two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.

In patients with cystic fibrosis, mutations in endogenously expressed CFTR lead to reduced apical anion sécrétion causing an imbalance in ion and fluid transport. The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients. In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death. In addition, the majority of males with cystic fibrosis are infertile and fertility is decreased among females with cystic fibrosis. In contrast to the severe effects of two copies of the CF associated gene, individuals with a single copy of the CF associated gene exhibit increased résistance to choiera and to déhydration resulting from diarrhea-perhaps explaining the relatively high frequency of the CF gene within the population.

Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of disease-causing mutations (Cutting, G. R. et al. (1990) Nature 346:366-369; Dean, M. et al. (1990) Cell 61:863:870; and Kerem, B-S. et al. (1989) Science 245:1073-1080; Kerem, B-S et al. (1990) Proc. Natl. Acad. Sci. USA 87:8447-8451). To date, greater than 1000 disease-causing mutations in the CF gene hâve been identified as reported by the scientific and medical literature. The most prévalent mutation is a délétion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as F5Ü8deI. This mutation occurs in approximately 70 percent of the cases ofcystic fibrosis and is associated with a severe disease. A more complété list of identified mutations can be found at www.cftr2.org.

These éléments work together to achieve directional transport across the epithelium via their selectîve expression and localization within the cell. Chloride absorption takes place by the coordinated activity of ENaC and CFTR présent on the apical membrane and the Na⁺-K⁺ATPase pump and Cl- channels expressed on the basolateral surface of the cell. Secondary active transport of chloride from the luminal side leads to the accumulation of intracellular chloride, which can then passively leave the cell via Cl' channels, resulting in a vectorial transport. Arrangement of Na⁺/2C17K⁺ co-transporter, Na⁺-K⁺-ATPase pump and the basolateral membrane K⁺ channels on the basolateral surface and CFTR on the luminal side coordinate the sécrétion of chloride via CFTR on the luminal side. Because water is probably never actively transported itself, its flow across epithelia dépends on tin y tran sep ithe liai osmotic gradients generated by the bulk flow of sodium and chloride.

Compounds of Formula I

In some embodiments the présent invention features a compound of formula I:

I, or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring A is a C6-C10 aryl ring; C3-C10 cycloalkyl ring; or a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring B is a C3-C10 cycloalkyl ring; a C6-C10 aryl ring; or a C4-C10 heteroaryl or 5 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

S, N, or NR;

Ring C is a C6-C10 aryl ring ; a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, NR, O, or S; or a C3-CIO cycloalkyl ring;

WisO, NR, orS;

X is O or NR;

Y is independently CRR, CO, O, S, SO, SO₂, S(O)NH orNR;

Zis NR orCHR;

Ri is halo; CN; F5S; S1R3; OH; NRR; C1-C6 alkyl or fluoroalkyi; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoro alkyl ;C1-C6 alkoxy or fluoroa!koxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; OH; CO₂R; C1-C6 alkyl or fluoroalkyi; CI-C6 alkenyl; C1-C6 alkynyl;

C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 aIkylene)-R4 wherein up to four CH; units are independently replacer! with O, CO, S, SO, SO; or NR;

or two R3 groups taken together may form a =CH₂ or =0 group;

R4 is H; azide; CF3; CHF₂; OR; CCH; CO?R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from i to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; C0₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5;

is a single bond or a double bond;

In another embodiment, the compounds of the invention are of formula I and the attendant définitions, provided that: i) when ring A is indole, n is not zéro and rings B and C are aryl unsubstituted by CF3 or halo; ii) when ring A is pyrazole, n is not zéro; iii) when ring A is pyridyl, ring B and ring C moieties are substituted at the 2- and 3- positions of the pyridyl ring, interchangeably; and iv) when ring A is imidazole, the ring B moiety is substituted at the 2position of the imidazole ring.

In some embodiments, the compounds of the présent inventions are in the form of a pharmaceutically acceptable prodrug.

In some embodiments, ring A is a C6-C10 aryl ring, such as a phenyl, indane, 1,2,3,4tetrahydronaphthalene, or naphthalene. In some emboidments, ring A is a C3-C11 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR, such as pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, 1,2,3,4-tetrahydroquinoline, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tctrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, 2,3,4,5-tetrahydro-lH-benzo[d]azepine, 1Hbenzo[d]imidazole, orimidazole ring.

In some embodiments, ring A is a group represented by the corresponding moieties

In some embodiments, ring B is a cycloalkyl ring, such as a cyclopropane, cyclobutane, cyclopentane, or cyclohexane. In some embodiments, ring B is a C6-C10 aryl ring, such as a phenyl. In some embodiments, ring B is a heroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR, such as pyridyl, pyridine2(lH)-one, pyrazole, indole, indoline, thiophene, dihydrobenzofuran, tetrahydrofuran , furan, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, 3-azabicyclo[3.1.0]hexane, (lR,4R)-2-oxa-5-azabicyclo[2,2.1]heptane, pyrrolidine, azetidine, piperidine, piperazine, or quinoline.

In some embodiments, ring B is a group represented by the corresponding moieties

shown in the compounds of Table 1. For example, ring B is

In some embodiments, ring C is a C6-C10 aryl ring, such as a phenyl, indane, or naphthalene. In some embodiments, ring C is a C3-C10 cycloalkyl ring, such as a cyclopropane, 10 cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane, or (1 s,4s)bicyclo[2,2.1]heptane, In some embodiments, ring C is a C3-C10 heteroaiyl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are indpependently N, NR, O, or S, such as indole, isoindoline, indoline, pyridyl, pyrrolidine, 2,5-dihydro-lH-pyrrole, morpholine, tetrahydro-2Hpyran, tetrahydrofuran, oxetane, piperidine, piperazine, azepane, azetidine, octahydrocyclopenta[c]pyrrole, octahydrocyclopenta[b]pyrrole, octahydro-lH-indole, octahydrolH-cyclopenta[b]pyridme, (ls,4s)-7-azabicyclo[2.2.1]heptane, 2-azabicyclo[4.1,O]heptane, (lS,4R)-2-azabicycio[2.2.1]heptane, (JR,5S)-8-azabicyclo[3.2.1]octane, 3,6-dihydro-2H-pyran, or (1 R,5S)-3-azabicyclo[3.2. l]octane.

[0073] In some embodiments, ring C is a group represented b y the corresponding moieties

In some embodiments, X is O. In some embodiments, X is NR. In some embodiments, X is NH.

In In some embodiments, Y is O. In some embodiments, Y is CRR, such as CH₂₎CH(C1-C6 alkyl), CH(CH₃), orCH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1-C6 alkynyl), or N(C1-C6 alkyl). In some embodiments, (Y)_o is a bond, O, NH, (CHi)^ O(CH₂)_m, where m=l-4, CH(CH₃), O-CH(CH₃), O-CH(CH₂CH₃), O-CH(CH₃)CH₂, OC(CH₃)₂CH₂, O-CH₂CH₂CH(CH₃), N(CH₃), NH-CH₂, N(CH₃)-CH₂, NCH(CH₃)₂-CH₂, N(CH₂CH₂CH₃)-CH₂, NH-CH(CH₃), N(CH₃)-CH(CH₃), or N(CH₂CCH)-CH₂CH₂.

In some embodiments, Rj is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indoie, aza-indole, azetidine, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example R, is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

In some embodiments, Ri is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from I to 4 carbon atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH; units are optionally and independently replaced with O, CO, S, SO, SO₂ or NR,

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH2CH₃, N(CH3)CH2CH2CH₂CH3, ch₃, ch₂oh, CH₂CH₃, CH₂CH₂CH₃, =0,

CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH3CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, 0CHF2, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH3)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is a group represented by the correspond in g moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, 5 CH2CH3, CH₂CF₃, CH2CH7CH3, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃,

CH₂OCH₃, CH(CH₃)₂, CCH, CH2CONH2, CO₂CH₃, -CH2N(CH₃)₂, COitBu, tBu, =CH₂, =0,

O r°^H

In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is 2.

In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

In some embodiments, p is 0. In some embodiments, p is I. In some embodiments, p is 2.

In some embodiments, ring A is

In some embodiments, ring A

, n is 1, and Ri is tBu.

In some embodiments, ring A is

phenyl. In some embodiments, ring A is

, n is 1, Ri is phenyl, and Y is O. In some embodiments, ring A is

In some emdodiments, ring A is

amino, and R₃ is CH3.

In some embodiments, ring A is

, n is I, and R] is pyridyl. In some embodiments, ring A is

In some embodiment, ring A is

, ring B is pyridyl, and ring C is pyrrolidine.

In some embodiments, ring A is

, n is 1, and Ri is pyrazole. In some embodiments, ring A is

In some embodiments, ring A is

, n is 1, and Rj is cycîoalkyL In some embodiments, ring A is

, n is 1, R] is cycloalkyl, and Y is O. In some emdodiments, ring A is

, ring B is pyridyl, and ring C is cycloalkyl. In some embodiments, Ri is cycloalkyl, Ri is alkoxy, and R 3 is CH3.

In some embodiments, ring A is , and n is 1. In some embodiments, ring A

is ^tzv' , n is 1, and R] is phenyl. In some embodiments, ring A is , nisl.andRi

is tBu. In some embodiments, ring A is ^t/v' , n is 1, R| is phenyl, and Y is O. In some :N embodiments, ring A is , n is 1, Ri is tBu, and Y is O. In one emdodiment, ring A is , ring B is pyridyl, and ring C is phenyl.

In some embodiments, ring A is

, and n is 1. In some embodiments, ring A is

, n is 1, and Rj is phenyl. In some embodiments, ring A is , n is 1, and R; is tBu. In some embodiments, ring A is

is phenyl, and Y is O. In some embodiments, ring A is

, n is 1, Ri is tBu, and Y is

O. In some emdodiment, ring A is

, ring B is pyridyl, and ring C is phenyl.

In some embodiments, ring A is

, and n is 1. Tn some embodiments,

ring A is

, n is 1, and R| is phenyl. In some embodiments, ring A is , n is 1, and Rj is tBu. In some embodiments, ring A is

, n is 1, R₍ is phenyl, and Y is O. In some embodiments, ring A is

, n is 1, Ri is tBn, and Y is

O. In one emdodiment, ring A is

, ring B is pyridyl, and ring C is phenyl.

In some embodiments, the présent invention features a compound of formula I-i:

or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring A is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring B is a C3-C10 heteroaryl ring wherein anywhere from I to 4 ring atoms are independently O, S, N, orNR;

Ring C is a C6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are optionally N, O, or S, or a C3-C10 cycloalkyl ring;

Xis OorNR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

ZisNRorCHR;

Ri is halo; CN; FsSîSiRatOH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-Rj wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6

CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or flnoroalkyl;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (Cl -C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; CNC6 alkoxy or fîuoroalkoxy; or C6-CI0 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a -CH₂ or =O group;

R4 is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 atyl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

n isÛ, 1, 2 or3;

o is 0, 1, 2, 3, 4, or 5;

p is 0, 1, 2, or3; and qis 0,1, 2, 3,4, or 5;

In some embodiments, the compound of formula I-i exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring A is a pyridyl, indole, indoïme, isoindoline, pyrazole, pyrimidine, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, or imidazole ring.

In some embodiments, ring B is pyridyl, pyridine-2(l//)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofuran, thiazole, pyrrolidinone, or quinoline.

shown in the compounds of Table I. For example, ring B is

Τη some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, tetrahydro-2Hpyran, azepane, tetrahydrofuran, pyrrolidine, naphthalene, piperidine, azetidine, or dihydroindene.

In some embodiments, ring C is a group represented by the corresponding moieties

shown in the compounds of Table 1. For example, ring C is

In some embodiments, X is O. In sonie embodiments, X is NR. In sonie embodiments, X is NH.

In some embodiments, Y is O. In some embodiments, Y is CH2. In some embodiments, Y is CH(CI-C6 alkyl). In some embodiments, Y is CH(CHj). In some embodiments, Y is CHfCHiCHa). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), or N(C 1-C6 alkyl).

In some embodiments, R, is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloaïkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, pyrazole, or thiophene ring, or a (Cl-C9 alkylene)-R4 wherein up to four CH2 units are independently replaced with O, CO, S,

SO, SO, or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl -C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH2OCH3, CN, CO2H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1, For example, Rj is CH₃, Cl, F, CN, OCH3, CF₃, CH₂CH₃, tBu,

F

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to4ring atoms are optionally O, S, N, or NR; and a (C1-C9 alkylenef-R^ wherein up to fourCH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR,

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0,

CH₃SO₂, CH₃SO₂NH, CF₃C0NH, CH₃C0NH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, 0CH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCFi, OCHFî, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(0)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, C6C10 aryl, or C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are 5 independently O, S, N, or NR,

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)_2î CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH_3j -CH₂N(CH₃)₂, COitBu, tBu, =CH₂, =0,

In some embodiments, o is 0,

In some embodiments, o is 1,

In some embodiments, o is 2,

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, n is2.

In some embodiments, p is 0.

In some embodiments, p is 1, In some embodiments, p is 2.

In some embodiments, the compound of formula I is a compound of formula I-ii:

O

I-ii, or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence;

Ring B is a C6-C10 aryl ring;

Ring C is a Câ-CIO aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are optionally N, O, or S, or a C3-C10 cycloalkyl ring;

X is O or NR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH orNR;

Z is NRorCHR;

Ri is halo; CN; F₃S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoro alkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cl -C6 alkyl or fluoroalkyl;CHC6 alkoxy or fîuoroalkoxy;CFC6 alkenyl; Cl-Câ alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

S, N, or NR; C3-C10 cycïoalkyl; or a (CI-C9 alkyl ene)-R₄ wherein up to four CH? units are independently replaced with O, CO, S, SO, SO₂ orNR;

or two R? groups taken together may form a =CH₂ or =0 group;

Ri is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycïoalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO? or NR;

or two R 3 groups taken together may form a =0¾ or =O group;

R₄ is H; azide; CF3; CHF₂; OR; CCH; CO?R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycïoalkyl; NRR, NRCOR, CONRR, CN, halo, orSO₂R;

R is independently H; OH; CO₂H; CO2CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; CI-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl orheterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycïoalkyl;

n is 0, 1,2 or 3;

o is 0, 1, 2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1, 2, 3, 4, or 5;

provided that the moieties containing ring B and ring C are substitnted at adjacent positions on ring A.

In some embodiments, the compound of formula I-ii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring A is a pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, pyrrolodine, aza-indole, pyrrole, oxazole, pyrazine, triazole, indazole, or imidazole ring.

shown in the compounds of Table 1. For example, ring A is

In some embodiments, ring B is phenyl or naphthalene.

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, azetidine, or dihydroindene.

shown in tire compounds of Table 1. For example, ring C is

In some embodiments, X is O. In another embodiment, X is NR. In some embodiments, X is NH.

In some embodiments, Y is O. In some embodiments, Y is CH₂, In some embodiments, Y is CH(CI-C6 alkyl). In some embodiments, Y is CH(CHa). In some embodiments, Y is CH(CH₂CH₃), In some embodiments, Y is NR, such as NH, N(C1-C6 alkynyl), or N(C1-C6 alkyl).

In some embodiments, R] is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 10 or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to fourCH₂ nuits are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl -C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH2OCH3, CN, COzH, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CH3, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring 10 atoms are independently O, S, N, or NR; or a (Cl -C9alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, -O,

CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)_3j OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, /—\ NH

N N— N Ο K NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂,

In some embodiments, R₃ is halo, CN, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, C6C10 aryl, or C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR,

In some embodiments, R₃ is a group represented by the corresponding moieties shown 15 in the compounds of Table 1. R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃,

CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃,

CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2.

In some embodiments, the invention features a compound of formula la:

4S

Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;

Xis OorNR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-Ri wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C 1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or -O group;

R is independently H; OH;CChH; CO2CI-C6 alkyl; Cl-Câ alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl orheterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, or 2;

0 is 0, 1,2, 3, 4, or 5;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3, 4, or 5.

In some embodiments, the compound of formula la exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine’2(li/)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, ring B is a group represented by the corresponding moieties shown in the

compounds of Table 1. For example, ring B is

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, pîperidine, or dihydroindene.

In some embodiments, ring C is is a group represented by the corresponding moieties

shown in the compounds of Table 1. For examp le, ring C is

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), orN(Cl-C6 alkyl).

In some embodiments, R] is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 10 or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (Cl -C9 alkylene)-R4 wherein up to four CH: units are independently repîaced with O, CO, S, S O, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, CJ-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1, For example, Ri is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

CH(CH₃)₂, OCH₂CH₂OCH₂CH₃.

In some embodiments, R2 is halo, OH, CN, azide, amino, C1-C6 alkyl or fltioroalkyl,

C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, S O, SO₂ or NR.

In some embodiments, R2 is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R2 is Cl, F, OH, CN, N₃, NH2, NH(CH₃), N(CH₃)₂,

N(CH₃)CH₂CH₂CH3, N(CH3)CH2CH2CH₂CHî, CH₃, CH₂OH, CH2CH3, CH2CH2CH3, =0, CHjSOi, CH3SO2NH, CF3CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)2CHOCONH, CH(CH₃)₂, CHF₃, 0CH₃, OCH2CH3, OCH2CH2CH3, OCH2CH₂CH(CH₃)2, OCF₃, OCHF2, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH3)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)2O(CH₂)2CH₃, C(O)CH₃, CH2CH2OH, CH2NH2, NH(CH₂)₂OH, i 0 N(CH₃)CH₂CH₂CH2OCH₃, NHCH2CH2COOH, NH(CH2)2N(CH₃)₂, NH(CH₂)2NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table I. For example, R₃is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃,

CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, co₂nh₂, och₂ch₃,

CH₂OCH_3j CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH_3j -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =O,

In some embodiments, o is 0.

In some embodiments, o is 1.

In some embodiments, o is 2.

In some embodiments, n is 0.

In some embodiments, o is 1.

In some embodiments, o is 2.

In some embodiments, p is 0.

In some embodiments, p is 1. In some embodiments, p is 2.

In some embodiments, ring B is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, R| is tBu. In some embodiments, ring B and ring C are phenyl and Ri is tBu. In some embodiments, Y is CH₂. In some embodiments, ring B and ring C are phenyl, R] is tBu, and Y is CH₂. In some embodiments, ring B, ring C, and Ri are phenyl and Y is CH₂.

In some embodiments, the invention features a compound of formula la-i:

or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence;

Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C6-C10 aryl ring, C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;

X is O or NR;

Y is CRR, CO, O, S, SO, S0₂, S(0)NH orNR;

Rj is halo; CN; F5S; SiRj; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; Cl -C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; orC3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; CI-C6 alkyl or fluoroalkyi;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo;CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R4 is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocyclo alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH;CO₂H; CO₂C1-C6 alkyl; CI-C6 alkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, or 2;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5.

in some embodiments, the compound of formula la-i exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2(l/f)-one, pyrazole, indole, aza20 indole, thiophene, dihydrobenzofuran, or quinoline.

shown in the compounds of Table 1. For example, ring B is ,

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, or dihydroindene.

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(CI-C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), orN(Cl-C6 alkyl).

In some embodiments, Ri is halo, CN, C1-C6 alkyl, CI-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH? units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN,

CO₂H, amino, atnido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, R] is a group represented by the corresponding moieties shown in the compounds of Table 1. For example,Ri is CH₃, Cl, F, CN, OCH₃, CFj, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or a (Cl -C9 alkyl ene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R, is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH_:OH, CH2CH3, CH₂CH₂CH₃, =O,

CH₃SO₂, CH₃SO₂NH, CF₃C0NH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, chf₂, och₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, 0CHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH,CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR.

In some embodiments, R₃ is a group represented by the corresponde g moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, 0CH₃, CF₃, CH₂CH₃, CH₂CF₃, CH2CH2CH3, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO2NH₂, OCH₂CH₃, CH2OCH3, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)2, CO₂tBu, tBu, =CH₂, =0,

In some embodiments, o is 0.

In some embodiments, o is 1. In some embodiments, o is 2.

is 2.

In some embodiments, n is 0.

In some embodiments, o is 1, In some embodiments, o

In some embodiments, p is 0.

In some embodiments, p is 1. In some embodiments, p is 2.

In some embodiments, the invention features a compound of fonnula la-ii:

Ring B is a C6-C10 aryl ring;

Ring C is a C6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-CIO cycloalkyl ring;

X is O or NR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoro alkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C1Û cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CHi units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocyclo alkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R îs independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocyclo alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, or 2;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3, 4, or 5.

In some embodiments, the compound of formula la-ii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or naphthalene.

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃), In some 5 embodiments, Y is CH(CH₂CH3). In some embodiments, Y is NR, such as NH, N(C1C6alkynyl), orN(Cl-C6 alkyl).

In some embodiments, Rj is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or

NR, wherein ail rings are optionally substituted with one or more groups selected from halo, C1 C6 alkyl, CI-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, R] is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CHa, Cl, F, CN, OCH3, CF3, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-CI0 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, Nj, NH₂, NH(CHa), N(CH₃)₂, N(CH₃)CH₂CH₂CHj, N(CHî)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, CH₂CH₂CH₃, =0,

CHjSOï, CH₃SO₂NH, CF3CONH, CH₃C0NH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, 0CH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂,

NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or

C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is CI, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃,

CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)_2s OCH(CH₃)₂, co₂h, CO₂NH₂, OCH₂CH₃,

CH₂OCHî, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

π I θί ^yO. ό* H?, , ^O.

In some embodiments, o is 0. In some embodiments, o is I, In some embodiments, o 5 is 2.

In some embodiments, n is 0. In some embodiments, o is 1. In some embodiments, o is 2.

In some embodiments, the compound of formula I is a compound of formula Ib:

Ib or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring C is a C6-C1Û aryl ring, C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

R! is halo; CN; F₅S; SiRj; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fhioroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R? is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH; units are independently replaced with O, CO, S, SO, SO; or NR;

or two R; groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-Câ alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO; or NR;

or two R 3 groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CFj; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH;CO₂H; CO₂C1-C6 alkyl; Cl-C6 alkyl; Cl-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently 0, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Ib exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(17ï)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, naphthalene, pyrrolidine, or dihydroindene.

shown in the compounds of Table 1. For example, ring C is

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C 1 C6 alkynyl), or N(C1-C6 alkyl).

In some embodiments, Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (CI-C9 aIkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, R₍ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CHj, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, Cl-Câ alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₂ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group representcd by the corresponding moieties shown in tlie compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH_3î CH₂CH₂CH₃, =0,

S2

CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF_2î OCH_3j OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, 0CHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂,

NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH_3î CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR.

In some embodiments, R₃ is a group represented by the correspondit!g moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, 15 CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃,

CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

In some embodiments, o is 0.

In some embodiments, o is 1. In some embodiments, o is 2.

In some embodiments, n is 0. In some embodiments, n is 1.

In some embodiments, n is 2.

In some embodiments, p is 0. In some embodiments, p is 1.

In some embodiments, p is 2.

In some embodiments, ring B is pyridyl. In some embodiments, ring B is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, ring B is pyridyl and ring C is phenyl. In some embodiments, Y is CH₂. In some embodiments, Y is O.

In some embodiments, Ri is aryl. In some embodiments, ring B, ring C, and R] are phenyl. In some embodiments, ring B is pyridyl, ring C is phenyl, and R| is phenyl. In some embodiments, ring B, ring C, and Ri are phenyl, and Y is CH₂. In some embodiments, ring B, ring C, and R| are phenyl, and Y is O. In some embodiments, ring B is pyridyl, ring C is phenyl, Ri is phenyl, and Y is CH₂. In some embodiments, ring B is pyridyl, ring C is phenyl, Rj is phenyl, and Y is O.

In some embodiments, ring C is heterocyclic. In some embodiments, ring C is pyrrolodine. In some embodiments, ring C is piperidine. In some embodiments, ring B is pyridyl, ring C is heterocyclic. In some embodiments, ring B is pyridyl, ring C is heterocyclo alkyl, and Ri is phenyl. In some embodiments, ring B is phenyl, ring C is heterocycloalkyl, and Rj is phenyl.

In some embodiments, Rj is heteroaryl. In some embodiments, ring C is pyrrolidine and Ri is heteroaryl. In some embodiments, ring C is pyrrolidine and Ri is pyrrozole. In some embodiments, ring B is pyridyl, ring C is pyrrolidine, and Rj is heteroaryl. In some embodiments, ring B is pyridyl, ring C is heterocycloalkyl, and Ri is pyridyl..

In some embodiments, R] is cycloalkyl. In some embodiments, ring B is pyridyl and Ri is cycloalkyl.

In some embodiments, the invention features a compound of formula Ib-i:

Ring C is aC6-C10 aryl ring , C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

R] is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH, units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R; is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroaIkyl;C 1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycïoalkyl; or a (C1-C9 alkyl ene)-R₄ wherein up to four CH? units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycïoalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R3 groups taken together may form a =CH₂ or =0 group;

R4 is H; azide; CF₃; CHF₂; OR; CCH; C0₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycïoalkyl ; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycïoalkyl;

n is 0, 1,2 or 3;

o is 0, 1, 2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Ib-i exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2(lH)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, ring B is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring B is

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, naphthalene, 5 pyrrolidine, or dihydroindene.

shown in tire compounds of Table 1. For example, ring C is

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(Cl-C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(CICôalkynyl), or N(C1-C6 alkyl).

In some embodiments, Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl5 C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, 5 C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to4ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, 10 N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0, CH₃SO₂, CH₃S0₂NH, CF₃C0NH, CH3CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF_3j OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

In some embodiments, Rj is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH2CONH2, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, -O,

In some embodiments, the invention features a compound of formula Ib-ii:

Ring B is a C6-C10 aryl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH orNR;

Ri is halo; CN; FjS; S1R3; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 a!kylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3*C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; CI-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylenepR₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or -O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; CI-C6 alkoxy or fîuoroalkoxy; orC6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a -CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl ; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; CNC6 alkyl; Cl -C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3, 4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Ib-ii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

In some embodiments, ring C is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring C is

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some 5 embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), orN(Cl-C6 alkyl).

In some embodiments, R] is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, orthiophene ring, or a (C1-C9 alkylene)-Ri wherein up to four CH₂ units are independently replaced with O, CO, S, S O, S0₂ or

NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, Cl -C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R] is CH₃, Cl, F, CN, 0CH₃, CF₃, CH₂CH₃, tBu,

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring 10 atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ orNR.

In some embodiments, R₂ is a group represented by the correspond in g moieties shown in tire compounds of Table 1. For example, R₂ is Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0,

100

CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH3CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH_3j OCH₂CH_3j OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH2CH₂CH₃), OCH(CH₃)₂,

NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH_2j NH(CH₂)₂OH,

N(CH₃)CH2CH₂CH₂OCH_3> NHCH2CH2COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, _{/χ /}NH

N N— N O y

NH(CH₂)₃NH₂, NH(CH₂)₂OCH_3s NHCH(CH₃)2, ^λu

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, 15 CH₂CH₃, CH₂CF_3j CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃,

101

In some embodiments, o is 0, In some embodiments, o is 1. In some embodiments, o 5 is 2.

In some embodiments, p is 0, In some embodiments, p is 1, In some embodiments, p is 2.

In some embodiments, the invention features a compound of fonnula Ib-iii:

or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence: Ring B is a C6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein 15 anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridine ring;

102

R, is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO, or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; CI-C6 alkyl or fluoroalkyl; CNC6 alkenyl; C1-C6 alkynyl; Cl -C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R3 groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; C0₂H; CO₂Cl-C6 alkyl; C1-C6 alkyl; Cl-C6 alkenyl; CNC6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, 2 or 3;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3,4, or 5.

In some embodiments, the compound of formula Ib-iii exists as a pharmaceutically acceptable prodrug.

103

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(l/f)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

shown in the compounds of Table 1. For example, ring B is

In some embodiments, ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, or pyrrolidine.

104

In some embodiments, R| is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl -C6 alkyl, C1-C6 alkoxy, Cl-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu, CH(CHj)₂, OCH₂CH₂OCH₂CH₃,

105

106

107

In some embodiments, Ri is halo, OH, CN, azide, amino, C1-C6 alkyl or ] 0 fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkyIene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR,

108

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, CH₂CH₂CH₃, =0, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCHî, OCH₂CH₃, OCH₂CH₂CH_3s OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)_3j OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, Cl -C6 alkoxy, 15 or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, co₂nh₂,

OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

109

In some embodiments, n is 0. In some embodiments, n is 1. In some =CH₂, —Ο,

embodiments, n is 2.

In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2,

In some embodiments, Ri is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, Rj is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Rj is phenyl, pyridine, or pyrazole, n is 1, Rj is alkyl, such as methyl, and q is 1,2, 3, or4.

In some embodiments, the invention features a compound of formula Ib-iii-1 :

or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence: Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

110

Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nîtrogen on Ring C is the point of attachaient to the pyridine ring;

R] is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH; units are independently replaced with O, CO, S, SO, SO; or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-CIO cycloalkyl;

R; is halo; OH; NRR; azide; CN; CO;R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroa!koxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH; units are independently replaced with O, CO, S, SO, SO; or NR;

or two R; groups taken together may form a =CH; or =O group;

R₃ is halo; CN; CO;R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH; units are independently replaced with O, CO, S, SO, SO; or NR;

or two R₃ groups taken together may form a =CH; or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO;R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO;R;

R is independently H; OH;CO;H; CO;C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C1Û cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and

111 q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Ib-iii-1 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2(lff)-one, pyrazole, indole, aza indole, thiophene, dihydrobenzofuran, or quinoline.

shown in the compounds of Table 1. For example, ring B is

In some embodiments, ring C is indole, piperidine, azepane, azetadine, indoline, isoindoline, orpyrrolidine.

In some embodiments, ring C is a group represented by the corresponding

moieties shown in the compounds of Table 1. For example, ring C is

112

In some embodiments, Ri is halo, CN, CI-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected front halo, C1-C6 alkyl, C1-C6 alkoxy, Cl-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH,

CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 he te rocyclo alkyl.

In some embodiments, R] is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R] is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃,

113

114

115

F

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms 10 are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table I. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CHj, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, ch₂ch₂ch₃,

116 =O, CH3SO2, CH3SO2NH, CF3CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)2, CHF₂, OCH_3îOCH2CH_3! OCH2CH2CH5, OCH2CH₂CH(CH₃)2, OCF₃, OCHF₂, OC(CH₃)3, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂,

NH(CH2)₂O(CH₂)2CH₃, C(0)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

N(CH3)CH2CH2CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or

NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH_:CF₃, CH₂CH₂CH3, OCH2CH(CH₃)2, OCH(CH₃)₂, CO₂H, CO2NH2,

OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH,CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

117

In some embodiments, Ri is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, R। is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In 10 some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R3 is alkyl, such as methyl, and q is 1, 2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-iii-2;

Ib-iii-2 or apharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring B is a C6-C10 aryl ring;

118

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; orC3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-CI0 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C 1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, S O, S O₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C 1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C1Û cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5,

119

In some embodiments, tbe compound of formula Ib-iii-2 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or naphthalene.

shown in tire compounds of Table 1. For example, ring C is

In some embodiments, R] is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected

120 from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH2OCH3, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

ht some embodiments, Rj is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CH3, Cl, F, CN, 0CH₃, CF₃, CH₂CH₃,

5 tBu, CH(CH₃)₂, OCH₂CH₂OCH₂CH₃, ξ _AA__C1 , △ , Cl, —\ 0 F , Cl , \ F 0 % ——OCF3 s /=\ y^-w^- ï A _ 1 fM. ₁₀ , /=\ . o-,^s _z k ξ -^J^CF₃ ~F * 7

t J 'jî J V) J J 2ά„ J ,y r ¹ .ό Φ V ôc s , Λ°-. ^s p oc L 0 y³ 2 J - φ \ - °\

121

122

123

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoro alkyl, CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C I-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, ch₂ch₂ch₃,

-O, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, chf₂, och₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)_2îOCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH_3j CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

124

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoro alkyl, CI-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or

NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R 3 is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, co₂nh₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂îBu, tBu,

In some embodiments, Ri is phenyl, pyridine, or pyrazole, and n is 1. ht some embodiments, Rj is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In

125 some embodiments, Ri is phenyl, pyridine, or pyrazole, n is I, R 3 is alkyl, such as methyl, and q is 1,2, 3, or 4,

In some embodiments, the invention features a compound of fonnula ib-iv:

Ri

Ib-iv or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroaikoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 a!kylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R3 is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fîuoroalkoxy; or C6-C10 aryl; C3-C1Û heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3

126

CIO cycloalkyl; or a (CI-C9 alkylene)-R₄ wherein up to four CH, units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or 5 heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O,

S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂CI-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3,4, or 5.

In some embodiments, the compound of formula Ib-iv exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(lFT)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzoftiran, or quinoline.

127

In some embodiments, ring C is indole, piperidine, azepane, azetadine, indoline.

isoindoline, or pyrrolidine.

Tn some embodiments, ring C is a group represented by the corresponding

moieties shown in the compounds of Table 1. For example, ring C is

128

In some embodiments, R] is a phenyl, thiophene, pyridine, or pyrazole.

In some embodiments, R| is a group represented by the corresponding moieties shown

129

130

131

In some embodiments, R? is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, orNR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃),

N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0, CH₃SO₂, CH₃SO₂NH, CF3CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)_2j CHF₂, OCH₃, OCH₂CH₃, OCH2CH2CH3, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF?, OC(CH₃)₃, OCH2CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH2)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH2NH2, NH(CH₂)₂OH,

N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH_2j

132

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, Cl -C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or

NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in tire compounds ofTable 1, For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

In some embodiments, RI is phenyl, pyridine, or pyrazole. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₃ is alkyl, such as methyl, and q is 1,2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-iv-1 :

133

Ri

Ib-iv-1 or a phannaceutically acceptable sait thereof, wherein, independently for each occurrence;

Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachment to the pyridîne ring;

Ri is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ri is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alky!ene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

or two R₃ groups taken together may form a =CH₂ or =0 group;

134

R₄is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; C0₂H; CO₂CHC6 alkyl; C1-C6 alkyl; Cl-C6 alkenyl; Cl-C6 5 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, ring B is pyridyl, pyridine-2( lÆ)-one, pyrazole, indole, aza10 indole, thiophene, dihydrobenzofirran, or quinoline.

In some embodiments, the compound of formula Ib-iv-1 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring C is indole, piperidine, azepane, azetadine, indoline, 20 isoindoline, or pyrrolidine.

135

In some embodiments, Rj is a phenyl, thiophene, pyridine, or pyrazole.

In some embodiments, Rj is a group represented by the corresponding moieties shown

136

137

138

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C 1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in thecompounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, CH₂0H, CH₂CH₃, CH₂CH₂CH₃, =0, CH₃S0₂, CH₃S0₂NH, CF₃C0NH, CH₃C0NH, CH₃CON(CH₃), tBuOCONH,

139 (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH_3î OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂,

OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃XCH₂CH₂CH₃), OCH(CH₃)₂,

NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH2CH2OH, CH₂NH₂, NH(CH₂)₂OH,

N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)2, NH(CH₂)₂NH₂,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or

NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1, For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH,

OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂,

OCH₂CH₃, CH₂OCH_3î CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

140

In sonie embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2,

In some embodiments, R| is phenyl, pyridine, or pyrazole. In some embodiments, Rj is phenyl, pyridine, or pyrazole, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R 3 is alkyl, such as methyl, and q is 1,2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-iv-2:

Ib-iv-2 or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring B is a C6-C10 aryl ring;

Ring C is a C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, and wherein one nitrogen on Ring C is the point of attachaient to the pyridine ring;

141

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cl-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere front 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or -O group;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

p is 0, 1, 2, or 3; and q is 0, 1, 2, 3,4, or 5.

In some embodiments, the compound of formula Ib-iv-2 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

In some embodiments, ring C is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring C is _; X—f , \z

142

In some embodiments, Ri is a phenyl, thiophene, pyridine, orpyrazole.

In some embodiments, R] is a group represented by the corresponding moieties shown

143

144

145

In some embodiments, R₂ is halo, OH, CN, azide, amino, Cl -C6 alkyl or fluoroalkyl, Cl-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CHj)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, ch₂ch₂ch₃, =0, CH₃SO₂, CH₃SO₂NH, CF₃C0NH, CH3CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH2CH2CH3, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH3, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

146

N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)_2î NH(CH₂)₂NH₂,

NR.

In some embodiments, R₃ is a group represented by the conresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF_3î CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, CO₂NH₂,

OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH_3j -CH₂N(CH₃)₂, CO₂tBu, tBu,

147

In some embodiments, p is 0. In some embodiments, p is 1, In some embodiments, p is 2,

In some embodiments, Rj is phenyl, pyridine, or pyrazole. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₃ is alkyl, such as methyl, and q is 1,2, 3, or 4,

In some embodiments, the invention features a compound of formula Ib-v;

or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence.

Ring B is aC6-C10 aryl ring or C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

148

S, N, or NR; C3-C10 cycloalkyl; or a(Cl-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; Cl -C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (Cl-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-CI0 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

n isO, 1, 2 or 3;

p is 0, 1, 2, or 3; and q is 0, 1, 2, 3,4, or 5.

In some embodiments, the compound of formula Ib-v exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofriran, or quinoline.

149

In some embodiments, R; is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R₄ wherein up to four CH, units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoro alkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH2OCH3, CN, CO₂H, amino, amido, C3-CIO heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R| is CH₃, Cl, F, CN, OCH₃, CF₃, CH,CH₃,

150

151

152

In some embodiments, R₂ is halo, OH, CN, azide, amino, Cl -C6 alkyl or fluoro alkyl, C1-C6 alkoxy or fluoroalkoxy, C3-CI0 heterocyclic ring wherein up to 4 ring atoms 10 are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH3), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, 15 =O, CH₃SO₂, CH₃SO₂NH, CF3CONH, CH3CONH, CH₃CON(CH3), tBuOCONH,

153 (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂,

OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂,

In some embodiments, R₃ is halo, CN, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or

NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH,

OCH₂CH₃, CH₂OCH_3j CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, ξ—A A N^T / ^N --^OH :CH₂, =O, ^S , O \

154

Ci / έ—O ξ-Ι- JO jQ 5-nO ¹ ï—y , ^A ,or X^.

In some embodiments, p is 0. In some embodiments, p is I, In some embodiments, p is 2.

In some embodiments, Ri is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, R] is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R₃ is alkyl, such as methyl, and q is 1,2,3, or4.

In some embodiments, the invention features a compound of formula Ib-v-1 :

Ri is halo; CN; F5S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6155

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-CI0 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ orNR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R41S H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycioalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to4ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, 2 or 3;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5,

In some embodiments, the compound of formula Ib*v-1 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2(l/f)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofiiran, orquinoline.

156

In some embodiments, Rj is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrintidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, C1-C6 alkyl, CRC6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH2OCH3, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, R] is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R] is CH₃, Cl, F, CN, OCH₃, CF3, CH₂CH₃,

157

158

159

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms 10 are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, 15 =O, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH,

160 (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH_3j OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-CIO heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

OCH₂CH₃, CH₂OCH₃, CH(CH₃)_2j CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, ch₂,=o, H”

161

In some embodiments, Rj is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R₃ is alkyl, such as methyl, and q is 1, 2, 3, or4.

In some embodiments, the invention features a compound of formula Ib-v-2:

Ib-v-2 or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring B is a C6-C10 aryl ring;

Ri is halo; CN; F₃S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; CRC6 alkenyl; Cl-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6

162

CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; orC3-C10 cycloalkyl;

Ri is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoro alkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

n is 0, 1, 2 or 3;

p is 0, 1, 2, or3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Ib-v-2 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

In some embodiments, Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9

163 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyi, C1-C6 fluoroalkoxy, OH, CH₂0H, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example. Ri is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

CH(CH₃)₂, OCH₂CH₂OCH₂CH₃, △ , Cl? *-0 0 F , Cl , \ F 10 °\ s_/=\ O M . /=\ — ξ—VjZ 1 '^'N’ Α-χ __ X/ , O? ?- V--, 0—,

F > “O, 1 jCo \ F Λ , F3CO , NC , / 9~ 0 / _s /⁼\ y-OH 0 -A, ξ __ΛΡ — N^Z Q ^_, cf₃₎ —<], 1 9s. 9s 9^ Cl N=\ ξ ^— Q /

164

165

166

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms 5 are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃,

-O. CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(0)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

167

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, CI-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, co₂nh₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

—N

In some embodiments, Ri is phenyl, pyridine, or pyrazole, and n is 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, n is 1, R₂ is amino or alkyl, and p is 0 or 1. In

168 some embodiments, R| is phenyl, pyridine, or pyrazole, n is I, R₃ is alkyl, such as methyl, and q is 1,2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-vi:

Ib-vi or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Rj is C6-C10 aryl or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

R₂ is halo; OH; NRR; azide; CN; CO2R; Cl -C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (Cl -C9 alkylene)-R₄ wherein up to four

CH, units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R, groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-

CIO cycloalkyl; or a (Cl-C9 alkyl ene)-R₄ wherein up to four CH2 units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

169

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocyclo alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, orSO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 5 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

p is 0, I, 2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Ib-vi exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(ljy>one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofiiran, or quinoline.

In some embodiments, ring B is a group represented by the correspond ing moieties

170

In some embodiments, Ri is a phenyl, thiophene, pyridine, or pyrazole.

171

172

173

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, ch₂ch₂ch₃, =0, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH_a)₂N(CH₃)₂, NH(CH₂)₂NH₂,

174

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR,

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is CI, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)_2j OCH(CH₃)₂, co₂h, CO₂NH₂,

In some embodiments, p is 0, In some embodiments, p is 1. In some embodiments, p is 2.

In some embodiments, the invention features a compound of formula Ib-vi-1 :

175

Ib-vi-1 or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C 1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C 1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; C0₂R; OH; C6-C10 aryl, C3-C10 heteroaiyl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

176

R is independently H; OH;CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Ib-vi-1 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine'2(l/7)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofuran, orquinoline.

In some embodiments, Ri is a group represented by the corresponding moieties shown

177

178

179

In some embodiments, R₂ is halo, OH, CN, azide, amino, Cl -C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, S O, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, Nj, NH₂, NH(CH₃),

N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃,

-O. CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH3CONH, CH₃CON(CH₃), tBuOCONH,

180 (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH_3j OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH_3j CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃₎ CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)_2î co₂h, co₂nh₂,

181

In some embodiments, p is 0. Tn some embodiments, p is I. In some embodiments, p is2.

In some embodiments, R, is phenyl, pyridine, or pyrazole. In some embodiments, R, is phenyl, pyridine, or pyrazole, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₃ is alkyl, such as methyl, and q is 1,2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-vi-2:

Ring B is a C6-C10 aryl ring;

Ri is C6-C10 aryl or C3-CI0 heteroaryl wherein anywhere from 1 to 4 ring atoms are 15 independently O, S, N, or NR;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cl -C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

182

S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C 6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R4 is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRC0R, C0NRR, CN, halo, or SO₂R;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Ib-vi-2 exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

In some embodiments, Ri is a phenyl, thiophene, pyridine, or pyrazole.

183

184

185

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, 15 =0, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH,

186 (CH₃)₂CHOCONH, CH(CH₃)₂, CHF_2j OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)_2jOCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, _(?NH N— è—N O V

NH(CH₂)₃NH₂, NH(CH₂>2OCH₃, NHCH(CH₃)₂, Y—/ , V-Z ,

OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

187

In some embodiments, R] is phenyl, pyridine, or pyrazole. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₂ is amino or alkyl, and p is 0 or 1. In some embodiments, Ri is phenyl, pyridine, or pyrazole, R₃ is alkyl, such as methyl, and q is 1,2, 3, or 4,

In some embodiments, the invention features a compound of formula Ib-vii:

Ib-viî or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

188

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fîuoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C 1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R3 groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; CHC6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fîuoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO? or NR;

p isO, 1,2, or 3;

q is 0, 1,2, 3, 4, or 5; and r is 0, 1,2, 3, 4, or 5,

In some embodiments, the compound of formula Ib-vii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(l/T)-one, pyrazole, indole, az a-indole, thiophene, dihydrobenzoftiran, or quinoline.

189

shown in the compounds of Table 1. For example, ring B is

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkyIene>R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table I. For example, R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, ch₂oh, ch₂ch₃, ch₂ch₂ch₃, =O, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, ch₂ch₂oh, CH₂NH₂, NH(CH₂)₂OH,

190

Tn some embodiments, R₃ is a group represented by the conesponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

191

In some embodiments, R₃ is halo.CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₅ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R 5 is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH3)_2î OCH₂C(CH₃)₃ OCH(CH₃)₂, co₂h, co₂nh₂, OCH2CH3, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO_atBu, tBu, <—Ο —^oh ch₂, =0, , x—/ ,

In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, ris 3. In some embodiments, r is 4. In some embodiments, r is 5.

In some embodiments, R5 is halo or alkoxy. In some embodiments, R₂ is amino or alkyl, R5 is halo or alkoxy, r is 1 or 2, and p is 0 or 1. In some embodiments, R5 is halo or alkoxy, R₃ is alkyl, such as methyi, r is 1 or 2, and q is 1, 2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-viii:

192

R₂ is halo; OH; NRR; azide; CN; CO₂R;C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R4 is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

193

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyi; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R_s is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyi; C1-C6 alkynyl; C1-C6 5 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

p is 0, 1,2, or 3;

q is 0, 1,2, 3,4, or 5; and r is 0, 1, 2, 3,4, or 5.

In some embodiments, the compound of formula Ib-viii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(l//)-one, pyrazole, indole, 15 aza-indole, thiophene, dihydrobenzofuran, or quinoline.

194

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms 5 are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂0H, CH₂CH₃, CH₂CH₂CH₃, =0, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃C0NH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF_a, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH_3j CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

195

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH2CF3, CH2CH₂CH₃, OCH2CH(CH₃)_2j OCH(CH₃)₂, CO2H, co₂nh₂, OCH2CH3, CII₂OCH₃, CH(CH₃)₂, CCH, CH2CONH2, CO2CH3, -CH₂N(CH3)2, CO₂tBu, tBu, =ch₂.=o, *~O. KO,K^oh, * -O,

In some embodiments, R5 is a group represented by the coiresponding moieties shown in the compounds of Table 1. For example, R5 is Cl, fl deuterium, F, CN, CH3, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH2CH2CH3, OCH₂CH(CH₃)2, OCH₂C(CH₃)₃ OCH(CH₃)2, CO2H, CO2NH2,

196

, r JQ s-O v , , ⁵ ,or

In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is

2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5.

In some embodiments, R5 is halo or alkoxy. In some embodiments, R₂ is amino or alkyl, R 5 is halo or alkoxy, r is 1 or 2, and p is 0 or 1. In some embodiments, Rs is halo or alkoxy, R₃ is alkyl, such as methyl, r is 1 or 2, and q is 1,2, 3, or 4.

In some embodiments, the invention features a compound of formula Ib-ix:

(R₅)r

Ib-ix or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence;

197

R₂ is halo; OH; NRR; azîde; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; Cl -C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =O group;

Rî is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R is independently H; OH; CO₂H;CO₂C1-C6 alkyl; C1-C6 alkyl; CI-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

Rs is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

p is 0, 1,2, or 3;

q is 0, 1, 2, 3, 4, or 5; and r is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Ib-ix exists as a pharmaceutically acceptable prodrug.

19S

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(l//)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein up to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, ch₂ch₂ch₃, =O, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF_2j OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

199

N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NHtCH_;hNH₂,

N— N 0

NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂,

In some embodiments, R₃ is halo, CN, Cl-C6 alkyl or fluoroalkyl, Cl-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, co₂h, co₂nh₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

200

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Rs is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH₂C(CH₃)₃ OCH(CH₃)₂, co₂h, CO₂NH₂,

OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂îBu, tBu,

=CH₂, =o,

In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5.

In some embodiments, R 5 is halo or alkoxy. In some embodiments, R₂ is amino or alkyl, R5 is halo or alkoxy, r is 1 or 2, and p is 0 or 1. In some embodiments, R 5 is halo or alkoxy, R₃ is alkyl, such as methyl, r is 1 or 2, and q is 1,2,3, or4.

In some embodiments, the invention features a compound of formula le:

201

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; CI-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

2Û2 or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; C0₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; C0₂H; CO₂C1-C6 alkyl; CI-C6 alkyl; CI-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1, 2, 3, 4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5.

| In some embodiments, the compound of formula le exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl, pyridyl, pyridine-2(iZf)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

H

203

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, 5 naphthalene, or dihydroindene.

In some embodiments, ring C a group represented by the corresponding moieties

sbown in tire compounds of Table 1. For example, ring C is

204

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1 10 Côalkynyl), or N(C 1-C6 alkyl).

In some embodiments, Ri is halo, CN, Cl -C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (CI-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, S0₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl205

C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, ami no, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Rj is CH₃, Cl, F, CN, OCH₃, CF₃, CH2CH3, tBu,

5 CH(CH₃)₂, OCH₂CH₂OCH₂CH₃, *-O~^o/ H ^X---\ / ' 0 F , Cl , \ F /=y_ 0^ S —OCF₃ s /=\ <T . /=, » J (¼ S /=\ 10 \ , w / ^-Q 0*/ ^X 0—, <ÇA~cf₃> »

0 *45 5 5 X—Z , , y, # ⁵ 1 1 z> :i < /— c, V F , H ^“O Ο , F₃CO , NC , / ^_/^0- °a / C /=\ VOH 0 ,___ / / “N 0 ^— ₅ cf₃₍ ‘'“vX —<]₅ Cl N=/ —ΛΛ -0 / F₃C OCF3 f

206

207

208

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to fourCH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example , R₂ isCl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0,

CH₃SO₂, CH₃SO₂NH, CFîCONH, CH3CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, 0CH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)_3j OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH_2j NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

209

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-CI0 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR.

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, C0₂H, CO₂NH₂, OCH₂CH₃, CH₂0CHî, CH(CH₃)₂, CCH, CH₂C0NH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

hCO, X ΖΛ 'λ Z o—<^z b —\ —Ç 10 \=/, F , \= » ? 7 JO JQ In some embodiments, o is 0. is 2. 15 In some embodiments, n is 0. is 2. In some embodiments, p is 0. is 2.

d ™ 'O ^OV<1 “ù __χΐ /‘N^| =Λ CN, —<3, \ k^0H O^', 0* *-0, In some embodiments, o is 1. In some embodiments, o In some embodiments, o is 1. In some embodiments, o In some embodiments, p is 1. In some embodiments, p

210

In some embodiments, ring B is phenyl. In some embodiments, ring C is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, R] is halo. In some embodiments, Ri is F. In some embodiments, R| is OCH₃. In some embodiments R₂ is amino. In some embodiments, R₃ is CH₃. In some embodiments, R? is amino and R₃ is CH₃. In some embodiments, Y is CH₃. In some embodiments, Y is O. In some embodiments, Ri is F, R₂ is amino, R₃ is CH₃, and Y is CH₂. In some embodiments, Y is O. In some embodiments, Ri is F, Ri is amino, R₃ is CH₃, and Y is O.

In some embodiments, the invention features a compound of formula Ic-i:

Ring C is a C6-C10 aryl ring, C3-Cl4 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C1Û heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cl-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; Cl -C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O,

211

S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene>R₄ wherein up ΐο four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a -CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-CIO heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH, units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycio alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH;CO₂H; CO,C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C1Û heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Ic-i exists as a pharniaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2(iH)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, ring B is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, ring B is ,

212

In some embodiments, ring C is phenyl, indole, cycïoalkyl, pyridyl, pyrrolidine, 5 naphthalene, or dihydroindene.

shown in thecompounds of Table 1. Forexampie, ring C is

213

h some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CHfCH}). In some embodiments, Y is CH(CH₂CH3). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), orN(Cl-C6 alkyl).

214

In some embodiments, R] is halo, CN, C1-C6 alkyl, CI-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substîtuted with one or more groups selected from halo, Cl5 C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃,

215

216

217

In some embodiments, R₂ is halo, OH, CN, azide, amino, Cl -C6 alkyl or fluoroalkyl, 5 CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR,

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1, For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, 10 N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0, CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃C0N(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH,

N(CH₃)CH₂CH_:CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, ___κ NH

N N— N O

NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂, x—/ , —⁷ , ,

218

In some embodiments, R₃ is halo, CN, CÎ-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is CI, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO2NH2, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH2CONH2, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

219

In some embodiments, n is 0. In some embodiments, o is 1. In some embodiments, o is 2,

In other embodiments, the invention features a compound of formula Ic-ii:

Ring B is aC6-C10 aryl ring;

Ring C is a C6-C10 aryl ring, C3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycïoalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

R] is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alky!ene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; orC3-C10 cycïoalkyl;

R? is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycïoalkyl; or a (Cl -C9 alkyl ene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

220

Rj is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; CI-C6 alkynyl; C1-C6 alkoxy or fîuoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two Rj groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; C0₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or S0₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; Cl -C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, 2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5,

In some embodiments, the compound of formula Ic-ii exists as a phanmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

In some embodiments, ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, or dihydroindene.

221

222

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some 5 embodiments, Y is CH(CH₂CH3). In some embodiments, Y is NR, such as NH, N(C 1Céalkynyl), or N(C1-C6 alkyl).

In some embodiments, Ri is halo, CN, CÏ-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (CI-C9 a!kylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or 10 NR, wherein ail rings are optionally substituted with one or more groups selected from halo, Cl C6 alkyl, C1-C6 alkoxy, Cl -C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂0H, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Ri is Ri is CH₃, Cl, F, CN, OCH₃, CF3, CH₂CH₃,

223

224

225

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring ] 0 atoms aie independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, Na, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂0H, CH₂CH₃, CH₂CH₂CH₃, =0,

226

CH₃SO₂, CH₃SO₂NH, CF₃CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, /—\ \ —NH

N N— N O K, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂, \, V—/ , ,

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, 15 CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH_2i OCH₂CH₃,

CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, C0₂CH₃, -CH₂N(CH₃)_2î CO₂tBu, tBu, =CH₂, =0,

227

'Ο Μ^οη 0^' ό* *-0 » Î » 5 Î Î » Î

In some embodiments, ο is 0. In some embodiments, o is 1. In some embodiments, o 5 is 2.

In some embodiments, n is 0. In some embodiments, 0 is 1. In some embodiments, o is 2.

In some embodiments, the invention feattires a compound of formula Id:

Id or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

228

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F5S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cl -C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaiyl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a -CH₂ or =O group;

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 a!kylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or he te roc yclo alkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H; OH; CO₂H; CO₂CHC6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycioalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

229 p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Id exists as a pharmaceutically acceptable prodrug.

.In some embodiments, ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, aza-indole, thiophene, dihydrobenzofuran, or quinoline.

In some embodiments, ring C is is a group represented by the corresponding moieties shown in thecompounds of Table 1. For example, ring C is

230

231

In some embodiments, Rj is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, S0₂ or

NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Rj is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

232

233

234

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring 10 atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-Ri wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

In some embodiments, R₂ is a group represented by the correspond in g moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, ch₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0,

235

CH₃SO₂, CH3SO2NH, CF3CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, 0CH3, OCHîCHî, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF3, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂,

In some embodiments, R 3 is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C3-C10 heteroaryl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR.

In some embodiments, R₃ is is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, 15 OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, co₂nh₂,

OCH₂CH₃, CH₂OCH₃, CH(CH₃)_2î CCH, CH₂CONH₂, CO₂CH₃, -CH₂N(CH₃)₂, CO₂tBu, tBu,

236

In some embodiments, o is 1.

In some embodiments, o

In some embodiments, o is 0.

is 2.

In some embodiments, n is 0.

In some embodiments, o is I,

In some embodiments, o is 2,

In some embodiments, p is 0.

In some embodiments, p is I.

In some embodiments, p is2.

In some embodiments, ring B is phenyl. In some embodiments, ring B is pyridyl. In some embodiments, ring C is phenyl. In some embodiments, ring B and ring C are phenyl. In some embodiments, ring B is pyridyl and ring C is phenyl. In some embodiments, Y is (2¾. In some embodiments, Y is O. In some embodiments, R₂ îs amino. In some embodiments, R₂ is OH. In some embodiments, R₂ is OCH3. In some embodiments, R₃ is CH3. In some embodiments, R₂ is amino and R₃ is CH3. In some embodiments, ring B is pyridyl, ring C is phenyl, and Y is CH₂. In some embodiments, ring B is pyridyl, ring C is phenyl, and Y is O.

In some embodiments, the invention features a compound of formula Id-i:

237

Id-i or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring B is a C3-C10 heteroaryl ring wherein anywhere from 1 to 4 ring atoms are 5 independently O, S, N, or NR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

R) is halo; CN; F₃S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or 10 fluoroalkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; (Cl-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or 15 fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyIene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

238

R₃ is halo; CN; CO₂R; Cl -C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to fourCH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two Rj groups taken together may form a =0¾ or =0 group;

n is 0, 1, 2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5.

In some embodiments, the compound of formula Id-i exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is pyridyl, pyridine-2( liT)-one, pyrazole, indole, azaindole, thiophene, dihydrobenzofiiran, or quinoline.

shown in the compounds of Table 1. For example, ring B is

239

shown in the compounds of Table 1. For example, ring C is

N

240

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1 -C6 alkyl). In some embodiments, Y is CH(CH₃). In some embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH,N(C1Côalkynyl), orN(Cl-C6 alkyl).

In some embodiments, Rj is halo, CN, CFC6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R4 wherein up to tour CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alky], C1-C6 alkoxy, C1-C6 fluoroalkyl. Cl-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN,

CO₂H, amino, amido, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

241

242

243

244

In some embodiments, R₂ is halo, OH, CN, azide, amino, CI-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR,

In some embodiments, R₂ is a group represented by the conesponding moieties shown in the compounds of Table 1. For example, R₂ is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH₂CH₂CH₂CH₃, CH₃, CH₂OH, CH₂CH₃, CH₂CH₂CH₃, =0,

CH₃SO₂, CH₃S0₂NH, CF₃C0NH, CH₃C0NH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, OCH₃, OCH₂CH₃, OCH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, OCF₃, OCHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, N(CH₃)CH₂CH₂CH₂OCH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH_a,

245

In some embodiments, R₃ is halo, CN, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy, or

is 0.

In some embodiments, o

In some embodiments, o is 1.

In some embodiments, o is 2.

In some embodiments, n is 0.

In some embodiments, o is 1.

In some embodiments, o is 2.

In some embodiments, p is 0. In some embodiments, p is 1, In some embodiments, p is 2.

In some embodiments, the invention features a compound of formula Id-ii:

246

Id-ii or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring B is a C6-C10 aryl ring;

Ring C is a C6-C10 aryl ring, C3-Cl4 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are indepednently N, O, or S, or a C3-C10 cycloalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH orNR;

Ri is halo; CN; F₃S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; Cl-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyl; CI-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-CI0 cycloalkyl; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring

247 wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C!0 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; Cl-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1,2, 3,4, or 5.

In some embodiments, the compound of formula Id-ii exists as a pharmaceutically acceptable prodrug.

In some embodiments, ring B is phenyl or napthalene.

248

249

In some embodiments, Y is O. In some embodiments, Y is CH₂. In some embodiments, Y is CH(C1-C6 alkyl). In some embodiments, Y is CH(CH₃). In some 5 embodiments, Y is CH(CH₂CH₃). In some embodiments, Y is NR, such as NH, N(C1Côalkynyl), or N(CI-C6 alkyl).

In some embodiments, R] is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, pyrazole, or thiophene ring, or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or 10 NR, wherein ail rings are optionally substituted with one or more groups selected from halo, ClC6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fîuoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, ami do, C3-C10 heteroaryl, and C3-C10 heterocycloalkyl.

In some embodiments, Ri is is a group represented by the corresponding moieties shown in the compounds of Table 1. For example, Rj is CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃,

250

251

252

In some embodiments, R₂ is halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, CI-C6 alkoxy or fluoroalkoxy, C3-C10 heterocyclic ring wherein anywhere from 1 to 4 ring 10 atoms are independently O, S, N, or NR; or a (C1-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR.

253

CH₃S0₂, CH₃S0₂NH, CF3CONH, CH₃CONH, CH₃CON(CH₃), tBuOCONH, (CH₃)₂CHOCONH, CH(CH₃)₂, CHF₂, 0CH3, 0CH₂CH₃, 0CH₂CH₂CH₃, OCH₂CH₂CH(CH₃)₂, 0CF₃, 0CHF₂, OC(CH₃)₃, OCH₂CH₂tBu, NHCH(CH₃)(CH₂CH₂CH₃), OCH(CH₃)₂, NH(CH₂)₂O(CH₂)₂CH₃, C(0)CH₃, CH₂CH₂0H, CH₂NH₂, NH(CH₂)₂0H,

N(CH₃)CH₂CH₂CH₂0CH₃, NHCH₂CH₂COOH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂,

In some embodiments, R₃ is a group represented by the corresponding moieties shown in the compounds of Table 1, For example, R₃ is Cl, I, deuterium, F, CN, CH₃, OH, OCH₃, CF₃, 1 5 CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH(CH₃)₂, OCH(CH₃)₂, CO₂H, CO₂NH₂, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CH₂CONH₂, CO2CH3, -CH₂N(CH₃)₂, CO₂tBu, tBu, =CH₂, =0,

254

In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is2.

In another embodiment, the présent invention provides compounds of formulas I to Idii that contain isotope-labelled forms thereof. An isotope-labelled form of a compound of formulas I to Id-ii is identical to this compound apart from the fact that one or more atoms of the compound hâve been replaced by an atom or atoms having an atomic mass or mass number which differs from the atomic mass or mass number of the atom which usually occurs in greater naturel abondance. Examples of isotopes which are readily commercially available and which can be incorporated into a compound of formulas I to Id-ii by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphores, fluorine and chlorine, for example ²H, ³H, ¹³C, ¹⁴C, ^l5N, ¹⁸0,¹⁷0,³¹P, ³²P, ³⁵S, ¹⁸F and ³⁶C1, respectively. A compound of formulas I to Id-ii, a prodrug thereof, or a pharmaceutically acceptable sait of either which contains one or more of the above-mentioned isotopes and/or other iso-topes of other atoms is intended to be pan of the présent invention. An isotope-labelled compound of formulas I to Id-ii can be used in a number of bénéficiai ways. For example, an isotope-labelled compound of formula I to In-i into which, for example, a radioisotope, such as ³H or ^l4C, has been incorporated is suitable for médicament and/or substrate tissue distribution assays. These radioisotopes, i.e. tritium (³H) and carbon-14 (^l4C), are particularly preferred owing to simple préparation and excellent

255 detectability. Incorporation ofheavier isotopes, for example deuterium (“H), into a compound of formulas I to Id-ii bas therapeutic advantages owing to the higher metabolic stability of this isotope-labelled compound. Higher metabolic stability translates dîrectly into an increased in vivo half-life or lower dosages, which under most circumstances would represent a preferred embodiment of the présent invention. An isotope-labelled compound of formulas I to Id-ii can usually be prepared by carrying out the procedures disclosed in the synthesis schemes and the related description, in the example part and in the préparation part in the présent text, replacing a non-isotope-labelied reactant by a readily available isotope-labelled reactant.

Deuterium (²H) can also be incorporated into a compound of formulas I to Id-ii for the purpose in order to manipulate the oxidative metabolism of the compound by way of the primary kinetic isotope effect. The primary kinetic isotope effect is a change of the rate for a Chemical reaction that results from exchange of isotopic nuclei, which in tum is caused by the change in ground state energies necessary for covalent bond formation after this isotopic ex ch ange. Exchange of a heavier isotope usually results in a lowering of the ground State energy for a Chemical bond and thus causes a réduction in tire rate-limiting bond breakage. If the bond breakage occurs in or in the vicinity of a saddle-point région along the coordinate of a multiproduct reaction, the product distribution ratios can be altered substantially. For explanation: if deuterium is bonded to a carbon atom at a non-exchangeable position, rate différences of kw/ko = 2-7 are typical. If this rate différence is successfully applied to a compound of formulas I to Id-ii that is susceptible to oxidation, the profile of this compound in vivo can be drastically modified and resuit in improved pharmacokinetic properties. For a further discussion, see S. L. Harbeson and R. D. Tung, Deuterium In Drug Discovery and Development, Ann. Rep, Med. Chem. 2011, 46, 403-417, incorporated in its en tire ty herein by reference.

When discovering and developing therapeutic agents, the person skilled in the art attempts to optimise pharmacokinetic parameters while retaining désirable in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic profiles are susceptible to oxidative metabolism. In vitro liver microsomal assays currently available piovide valuable information on the course of oxidative metabolism of this type, which in tum permits the rational design of deuterated compounds of formulas I to Id-ii with improved stability through résistance to such oxidative metabolism. Significant improvements in the pharmacokinetic profiles of compounds of formulas I to Id-ii are thereby obtained, and can be expressed quantitatively in

256 ternis of increases in the in vivo half-life (ti/₂), concentration at maximum therapeutic effect (C_niax), area under the dose response curve (AUC), and bioavailability; and in ternis of reduced clearance, dose and materials costs.

The following is intended to îllustrate the above: a compound of formulas I to Id-ii which lias multiple potential sites of attack for oxidative metabolism, for example benzylic hydrogen atoms and hydrogen atoms bonded to a nitrogen atom, is prepared as a sériés of analogues in which varions combinations of hydrogen atoms are replaced by deuterium atoms, so that some, inost or ail of these hydrogen atoms hâve been replaced by deuterium atoms. Half-life déterminations enable favoutable and accurate détermination of the extent to which the improvement in résistance to oxidative metabolism h as improved. In this way, it is determined that the half-life of the parent compound can be extended by up to 100% as the resuit of deuterium-hydrogen exchange of this type.

Deuterium-hydrogen exchange in a compound of formulas I to Id-ii can also be used to achieve a favorable modification of the métabolite spectrum of the starting compound in order to diminish oreliminate undesired toxic métabolites. For example, if a toxic métabolite arises through oxidative carbon-hydrogen (C-H) bond cleavage, it can reasonably be assumed that the deuterated analogue will greatly diminish or eliminate production of the unwanted métabolite, even if the particular oxidation is not a rate-determinîng step. Further information on the State of the art with respect to deuterium-hydrogen exchange may be found, for example in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J. Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985, Gillette et al, Biochemistry 33(10) 2927-2937, 1994, and Jarman et al. Carcinogenesis 16(4), 683-688, 1993.

In some embodiments, the compound of formula 1 is selected from Table 1:

Table 1.

257

25S

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273 i Ï93 ' Il ₁₉₅

274

275

276

277

278

279

280

287

288

286

'2

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

669

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

1045

104S

1047

345

346

347

348

349

350

351

352

353

354

355

356

357

358

1216 1217 1218

1222

1224

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

1909

1910

1911

1912

1913

1914

1916

1917

1918

1919

1920

1915

417

418

419

420

421

1971

1974

1977

1979

198D

1978

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

44]

442

443

444

445

2259

2262

446

447

448

449

450

451

2338 2339 2340

452

453

454

455

456

2390

2391

2392 2393 2394

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

2629

2630

2631

2632

2633

2635

2636

2637

2640

2638

2639

2634

477

47S

479

480

481

482

483

484

485

486

In one embodiment, the présent invention features any of the below numerated embodiments.

1. In one embodiment, the présent invention features a compound of formula I;

or pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring A is a C6-C10 mono- orbicyclic aryl ring, or C5-C10 mono- orbicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced by O, S, N, or NR;

Ring B is a C6-C10 aryl ring or C5-C10 heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced by O, S, N, or NR;

Ring C is a C6-C10 mono- orbicyclic aryl ring , C4-C10 mono- orbicyclic heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 carbon atoms may be replaced by N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

X is O or NR;

Y is CR₂,0, S, SO, SO₂, or NR;

Z is NR or CR₂;

Ri is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fîuoroalkoxy, (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR; C6-C10 mono- orbicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or

487

NR; or C3-C8 cycloalkyl, al] four of which may be substituted with halo, CI-C6 alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-CÎ0 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5-CI0 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two Rj along with the atoms to which they are attached form a C5-C8 cyclic or heterocyclic ring wherein up to 2 carbon atoms may be replaced with O, S, or NR;

R₂ is halo, OH, amino, azide, CN, C1-C6 alkyl or fluoroalkyi, C1-C6 alkoxy or fluoroalkoxy, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR, C3-C8 cycloalkyl; or a (C1-C8 alkyI)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR;

R s is halo, CN, CO₂R, C1-C6 alkyl, alkene, alkyne, or fluoroalkyi; Cl -C6 alkoxy, cycloalkoxy, or fluoroalkoxy; C6-C10 mono- or bicyclic aryl or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR, both of which may be substituted with halo, C1-C6 alkyl or fluoroalkyi, ClC6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, or NR; or or a (Cl -C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two R₃ may form a ^CH₂ or =0 group;

R₄ is H, CF_3t CO₂R, OH, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; N(R)₂, NRCOR, CON(R)₂, CN, halo, or SO₂R;

R is H, OH, C1-C6 alkyl, C6-C10 mono- or bicyclic aryl, C5-CW mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3

488

C8 cycioalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR;

n is 0, 1,2 or 3;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3; and qisO, 1,2, 3, 4, or 5;

2. In another embodiment, the présent invention features the compound of embodiment 1, wherein ring A is a pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, phenyl, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinolîne, pyrrolidine, aza-indole, pyrrole, oxazole, pyrazine, triazole, benzimidazole, indazole, or imidazole ring.

489

4. In another embodiment, the présent invention features the compound of any of embodiments to 3, wherein ring B is phenyl, pyridyl, pyridme-2(l/f)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

5. In another embodiment, the présent invention features the compound of any of embodiments

6. In another embodiment, the présent invention features the compound of any of embodiments to 5, wherein ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, piperidine, azetidine, or dihydroindene.

7. In another embodiment, the présent invention features the compound of any of embodiments

490

8. In another embodiment, the présent invention features the compound of any of embodiments ] to 7, wherein Y is 0.

9. In another embodiment, the présent invention features the compound of any of embodiments 10 1 to 7, wherein Y is CH₂.

10. In another embodiment, the présent invention features the compound of any of embodiments 1 to 7, wherein Y is CH(C1-C6 alkyl).

11. In another embodiment, the présent invention features the compound of any of embodiments 1 to 7, wherein Y is CH(CH₃).

12. In another embodiment, the présent invention features the compound of any of embodiments to 7, wherein Y is CH(CH₂CH₃).

491

13. In another embodiment, the présent invention features the compound of any of embodiments 1 to 7, wherein Y is N(C1-C6 alkyl).

14. In another embodiment, the présent invention features the compound of any of embodiments 1 to 7, wherein Y is N(CH₃).

15. In another embodiment, the présent invention features the compound of any of embodiments to 14, wherein R| is halo, CN, C1-C6 alkyl, Cl-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CHiOH, CH₂OCH₃, CN, CO₂H, amino, amido, C5-C10 heteroaryl, C5-C10 heterocycloalkyl, or a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

16. In another embodiment, the présent invention features the compound of any of embodiments 1 to 15, wherein Ri is selected from CH₃, CI, F, CN, OCH₃, CF₃, CH₂CH₃, tBu, CH(CH₃)₂,

492

493

494

17. In another embodiment, the présent invention features the compound of any of embodiments 1 to 16, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, ClC6 alkoxy or fluoroalkoxy, C5-CIO mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

18. In another embodiment, the présent invention features the compound of any of embodiments 1 to 17, wherein R₂ is selected from Ci, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF₃, OCHF₂, OCH(CH₃)₂, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, /---X /---\

N N— N Ο V

NHCH(CH₃)₂, V-/ , , L^,orCO₂H.

19. In another embodiment, the présent invention features the compound of any of embodiments 1 to 18, wherein R₃ is selected from halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C5CIO mono- or bicyclic heteroaryl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

20. In another embodiment, the présent invention features the compound of any of embodiments 1 to 19, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃,

CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃}₂, CCH, CO₂CH₃, tBu, =CH₂, =0,

495

21, In another embodiment, the présent invention features the compound of any of embodiments 1 to 20, wherein o is 0.

22. In another embodiment, the présent invention features the compound of any of embodiments 1 to 20, wherein o is 1.

23. In another embodiment, the présent invention features the compound of any of embodiments 1 to 20, wherein o is 2.

24. In another embodiment, the présent invention features the compound of any of embodiments 1 to 23, wherein n is 0.

25. In another embodiment, the présent invention features the compound of any of embodiments 1 to 23, wherein n is 1.

26. In another embodiment, the présent invention features the compound of any of embodiments 1 to 23, wherein n is 2.

27. In another embodiment, the présent invention features the compound of any of embodiments 1 to 26, wherein p is 0.

28, In another embodiment, the présent invention features the compound of any of embodiments 1 to 26, wherein p is 1.

29. In another embodiment, the présent invention features the compound of any of embodiments 1 to 26, wherein p is 2.

30. In another embodiment, the présent invention features the compound of embodiment 1, wherein the compound is of formula la:

496

Ring B is a C6-C10 aryl ring or C5-C10 heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced by O, S, N, orNR;

Ring C is a C6-C10 mono- or bicyclic aryl ring , C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein anywhere from I to 4 carbon atoms may be replaced by N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

XisOorNR;

Y is CR₂, O, S, SO, SO₂, orNR;

Ri is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, (C1-C8 alkyi)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR; C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or C3-C8 cycloalkyl, ail four of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5-C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; or a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ orNR; or two Ri along with the atoms to which they are attached form a C5-C8 cyclic or heterocyclic ring wherein up to 2 carbon atoms may be replaced with O, S, orNR;

497

R₂ is halo.OH, amino, azide, CN, C1-C6 alkyl or fluoroalkyl, Cl -C6 alkoxy or fluoroalkoxy, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR, C3-C8 cycïoalkyl; or a (CI-C8 a!kyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ orNR;

R₃ is halo, CN, CO₂R, C1-C6 alkyl, alkene, alkyne, or fluoroalkyl; C1-C6 alkoxy, cycloalkoxy, or fluoroalkoxy; C6-C10 mono- or bicyclic aryl or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR, both of which may be substituted with halo, Cl -C6 alkyl or fluoroalkyl, C1C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, or NR; or or a (Cl -C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, S O, S O₂ or NR; or two R₃ may form a =CH₂ or =0 group;

R₄ is H, CF₃, CO₂R, OH, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycïoalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; N(R)₂, NRCOR, CON(R)₂, CN, halo, or SO₂R;

R is H, OH, C1-C6 alkyl, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycïoalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR;

n is 0, 1,2 or 3;

o is 0, I, 2, or 3;

p is 0, 1,2, or 3; and q is 0, 1,2, 3,4, or 5.

498

31. In another embodiment, the présent invention features a compound of embodiment 30, wherein ring B is phenyl, pyridyl, pyridine-2(l/r)-one, pyrazole, indole, thiophene, dihydrobenzoftiran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

32. In another embodiment, the présent invention features a compound of embodiment 30 or 31,

33. In another embodiment, the présent invention features a compound of any of embodiments to 32, wherein ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, 10 piperidine, or dihydroindene.

34. In another embodiment, the présent invention features a compound of any of embodiments

499

35. In another embodiment, the present invention features a compound of any of embodiments to 34, wherein Y is O.

36. In another embodiment, the present invention features a compound of any of embodiments 30 to 34, wherein Y is CH₂.

37. In another embodiment, tlie present invention features a compound of any of embodiments 10 30 to 34, wherein Y is CH(C 1-C6 alkyl).

38. The compound of claim 30, wherein Y is CH(CH₃).

39. In another embodiment, the present invention features a compound of any of embodiments 30 to 34, wherein Y is CH(CH₂CH₃).

40. In another embodiment, the présent invention features a compound of any of embodiments 15 30 to 39, wherein R] is halo, CN, Cl-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C5-C10 heteroaryl, C5-C10 heterocycloalkyl, or a (ClC8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

500

41. In another embodiment, the présent invention features a compound of any of embodiments to 40, wherein R] is selected from CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu, CH(CH₃)₂,

Cl

R-, *-O. ⁵⁵

501

502

42. In another embodiment, the présent invention features a compound of any of embodiments to 41, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl,

C1-C6 alkoxy or fluoroalkoxy, C5-C10 mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (C1-C8 alkyl)-R₄ wherein up to three

CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

43. In another embodiment, the présent invention features a compound of any of embodiments to 42, wherein R₂ is selected from Cl, F, OH, CN, Nj, NH₂, NH(CH₃), N(CH₃)₂, CH₃,

CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF₃, OCHF₂, OCH(CH₃)₂, C(O)CH₃, CH₂CH₂OH,

503

CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, /—X /—\

N N— N O NHCH(CH₃)₂, X—f , X—f , l^,orCO₂H.

44. In another embodiment, the présent invention features a compound of any of embodiments 30 to 43, wherein R₃ is selected from halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

45. In another embodiment, the présent invention features a compound of any of embodiments to 44, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃,

CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂, =0,

CN

OH

46, In another embodiment, the présent invention features a compound of any of embodiments 30 to 45, wherein o is 0.

47. In another embodiment, the présent invention features a compound of any of embodiments 30 to 45, wherein o is 1.

48. In another embodiment, the présent invention features a compound of any of embodiments 30 to 47, wherein n is 0.

49. In another embodiment, the présent invention features a compound of any of embodiments 30 to 47, wherein n is 1.

50. In another embodiment, the présent invention features a compound of any of embodiments 30 to 47, wherein n is 2.

504

51. In another embodiment, the présent invention features a compound of any of embodiments 30 to 50, wherein p is 0.

52. In another embodiment, the présent invention features a compound of any of embodiments 30 to 50, wherein p is 1.

53. In another embodiment, the présent invention features a compound of any of embodiments 30 to 50, wherein p is 2.

54. In another embodiment, the présent invention features a compound of any of embodiments 30 to 53, wherein ring B is phenyl.

55. In another embodiment, the présent invention features a compound of any of embodiments 30 to 54, wherein ring B and ring C are phenyl.

56. In another embodiment, the présent invention features a compound of embodiment 1, wherein the compound is of formula Ib:

Ib or pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring C is a C6-C10 mono- orbicyclic aryl ring , C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 carbon atoms may be replaced by N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

Y is CR₂, O, S, SO, SO₂, orNR;

505

Ri is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR; C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or C3-C8 cycloalkyl, ail four of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5-C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two R] al on g with the atoms to which they are attached form a C5-C8 cyclic or heterocyclic ring wherein up to 2 carbon atoms may be replaced with O, S, or NR;

R₂ is halo, OH, amino, azide, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR, C3-C8 cycloalkyl; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR;

R₃ is halo, CN, CO₂R, C1-C6 alkyl, alkene, alkyne, or fluoroalkyl; C1-C6 alkoxy, cycloalkoxy, or fluoroalkoxy; C6-C10 mono- or bicyclic aryl or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR, both of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, ClC6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, orNR; or or a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two R₃ may form a =CH₂ or =O group;

R₄ is H, CF₃, CO₂R, OH, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3

506

C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; N(R)₂, NRCOR, CON(R)₂, CN, halo, or SO₂R;

R is H, OH, C1-C6 alkyl, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR;

n is 0,1,2 or 3;

o is 0, 1, 2, or 3;

p is 0, 1, 2, or 3; and qisO, 1,2, 3, 4, or 5.

57, In another embodiment, the présent invention features a compound of embodiment 56, wherein ring B is phenyl, pyridyl, pyridine-2(IH)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

58. In another embodiment, the presnt invention features a compound of embodiment 56 or 57,

59. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 58, wherein ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, or dihydroindene.

507

60. In another embodiment, the présent invention features a compound of any one of

embodiments 56 to 59, wherein ring C is

61. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 60, wherein Y is O.

62. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 60, wherein Y is CH₂.

508

63. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 60, wherein Y is CH(C1-C6 alkyl).

64. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 60, wherein Y is CH(CH₃).

65. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 60, wherein Y is CH(CH₂CH₃).

66. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 65, wherein Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO2H, amino, amido, C5-C10 heteroaryl, C5-C10 heterocycloaikyl, or a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

67. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 66, wherein R] is selected from CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

509

510

511

68. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 67, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C5-C10 mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (Cl -C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

69. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 68, wherein R₂ is selected from Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF₃, OCHF₂, OCH(CH₃)₂, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, _fK NH

N— N O K

NH(CH₂)₂OCH₃, NHCH(CH₃)₂, X—4 , X—f , L-<orCO₂H.

70. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 69, wherein R₃ is selected from halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

71. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 70, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂, =O, ⁿOO —^0H <|

512

72. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 71, wherein o is 0.

73. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 71, wherein o is 1.

74. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 71, wherein o is 2.

75. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 74, wherein n is 0.

76. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 74, wherein n is 1.

77. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 74, wherein n is 2.

78. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 77, wherein p is 0.

79. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 77, wherein p is 1.

80. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 77, wherein p is 2.

81. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 80, wherein ring B is pyridyl.

82. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 81, wherein ring B is phenyl.

513

83. In another embodiment, the présent invention features a compound of any one of embodiments 56 to 82, wherein ring B and ring C are phenyl,

84. In another embodiment, the présent invention features a compound of embodiment 1, wherein the compound is of formula le:

or pharmaceutically acceptable sait thereof, wherein, independently foreach occurrence:

Ring C is a C6-C10 mono- or bicyclic aryl ring , C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 carbon atoms may be replaced by N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

Y is CR₂, O, S, SO, SO₂, or NR;

Ri is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR; C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or C3-C8 cycloalkyl, ail four of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5-C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, orNR; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, S O, SO₂ or NR; or two Ri along

514 with the atoms to which they are attached form a C5-C8 cyclic or heterocyclic ring wherein up to 2 carbon atoms may be replaced with O, S, or NR;

R 3 is halo, CN, CO₂R, C1-C6 alkyl, alkene, alkyne, or fluoroalkyl; C1-C6 alkoxy, cycloalkoxy, or fluoroalkoxy; C6-C10 mono- or bicyclic aryl or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR, both of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, ClC6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, or NR; or or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two R₃ may form a =CH₂ or =0 group;

R₄ is H, CF₃, CO₂R, OH, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; N(R)₂, NRCOR, CON(R)₂, CN, halo, or SO₂R;

n is 0, 1, 2 or 3;

o is 0, 1,2, or 3;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3,4, or 5.

515

85. In another embodiment, the présent invention features a compound of embodiment 84, wherein ring B is phenyl, pyridyl, pyridine-2(177)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

86. In another embodiment, the présent invention features a compound of embodiment 84 or 85,

87. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 86, wherein ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, 10 naphthalene, or dihydroindene.

88. In another embodiment, the présent invention features a compound of any one of

516

89. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 88, wherein Y is O.

90. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 88, wherein Y is CH₂.

91. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 88, wherein Y is CH(C1-C6 alkyl).

92. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 88, wherein Y is CH(CH₃).

93. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 88, wherein Y is CH(CH₂CH₃).

94. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 93, wherein R] is halo, CN, CI-C6 alkyl, Cl-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fîuoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C5-C10 heteroaryl, C5-C10 heterocycloalkyl, or

517 a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or

NR.

95. In another embodiment, the present invention features a compound of any one of embodiments 84 to 94, wherein Rj is selected from CH₃, Cl, F, CN, OCH₃, CF₃, CH2CH3, tBu,

518

519

96. ïn another embodiment, the présent invention features a compound of any one of embodiments 84 to 95, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, Cl-C6 alkoxy or fluoroalkoxy, C5-C10 mono- or bicyclic heterocyclic ring wherein

520 up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (C1-C8 alkyI)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

97. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 96, wherein R₂ is selected from Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, 0CH₃, OCF₃, OCHF₂, OCH(CH₃)₂, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, /--_K y—_K NH

N N— N O \\

NH(CH₂)₂OCH₃, NHCH(CH₃)₂, —7 , λ—/ , i^,orCO₂H.

98. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 97, wherein R₃ is selected from halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy, or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

99. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 98, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂, =0,

100. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 99, wherein o is 0.

101. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 99, wherein o is 1.

102. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 99, wherein o is 2,

521

103. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 102, wherein n is 0.

104. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 102, wherein n is I.

105. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 102, wherein n is 2.

106. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 105, wherein p is 0.

107. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 105, wherein p is 1.

108. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 105, wherein p is 2.

109. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 108, wherein ring B is phenyl.

110. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 109, wherein ring C is phenyl.

111. In another embodiment, the présent invention features a compound of any one of embodiments 84 to 110, wherein ring B and ring C are phenyl.

112. In another embodiment, the présent invention features a compound of embodiment 1, wherein the compound is of formula Id:

522

Ring B is a C6-C10 aryi ring or C5-C10 heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced by O, S, N, or NR;

Y is CR₂, O, S, SO, SO₂, or NR;

Ri is halo, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR; C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or C3-C8 cycloalkyl, ail four of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, Cl -C6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5-C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; or a (C1-C8 alkyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two Ri along with the atoms to which they are attached form a C5-C8 cyclic or heterocyclic ring wherein up to 2 carbon atoms may be replaced with O, S, or NR;

R₂ is halo, OH, amino, azide, CN, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl or heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR, C3-C8 cycloalkyl; or a (C1-C8 a!kyl)-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR;

R₃ is halo, CN, CO₂R, C1-C6 alkyl, alkene, alkyne, or fluoroalkyl; C1-C6 alkoxy, cycloalkoxy, or fluoroalkoxy; C6-C10 mono- or bicyclic aryl or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR, both of which may be substituted with halo, C1-C6 alkyl or fluoroalkyl, ClC6 alkoxy or fluoroalkoxy, CN, CO₂H, amino, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C5C10 mono- or bicyclic heterocycloalkyl wherein up to 4 carbon atoms may be

523 replaced by O, S, or NR; or or a (C 1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR; or two R₃ may form a =CH₂ or =0 group;

R4 is H, CF₃, CO₂R, OH, C6-C10 mono- or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR; N(R)₂, NRCOR, CON(R)₂, CN, halo, or SO₂R;

R is H, OH, C1-C6 alkyl, C6-C10 mono - or bicyclic aryl, C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR; C3C8 cycloalkyl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced with O, S, or NR;

n is 0, 1,2 or 3;

o is 0, 1,2, or 3;

p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5,

113. In another embodiment, the present invention features a compound of embodiment 112, wherein ring B is phenyl, pyridyl, pyridine-2( 1 H)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

114. In another embodiment, the present invention features a compound of embodiment 112 or

524

115. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 114, wherein ring C is phenyl, indole, cycloalkyl, pyridyl, pyrrolidine, naphthalene, or dihydroindene.

116. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 115, wherein ring C is

117. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 116, wherein Y is O.

525

118. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 116, wherein Y is CH₂.

119. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 116, wherein Y is CH(C1-C6 alkyl).

120. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 116, wherein Y is CH(CH₃).

121. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 116, wherein Y is CH(CH₂CH3).

122. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 121, wherein Ri is halo, CN, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyriinidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C5-C10 heteroaryl, C5-C10 heterocycloalkyl, or a (C1-C8 alkyl)-R4 wherein up to three CH₂ units may be replaced with O, CO,S,SO, SO₂ orNR.

123. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 122, wherein Ri is selected from CH₃, Cl, F, CN, OCH₃, CF₃, CH₂CH₃, tBu,

CH(CH₃)_2;

526

527

528

124. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 123, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 alkyl or fluoroalkyl, C1-C6 alkoxy or fluoroalkoxy, C5-C10 mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (C1-C8 alkyl)-R₄wherein up to three CH₂ units may be replaced with O, CO, S, S O, S O₂ or NR.

125. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 124, wherein R₂ is selected from Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH_3j CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF_3j OCHF₂, OCH(CH₃)₂, C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, /—\ / X ^—NH

N N— N O V NH(CH₂)₃NH₂,NH(CH₂)₂OCH₃,NHCH(CH₃)₂, '—^f , —^z , or

CO₂H.

126. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 125, wherein R₃ is selected from halo, CN, C1-C6 alkyl or fluoroalkyl, ClC6 alkoxy, or C5-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

127. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 126, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂, =0,

529

128. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 127, wherein o is 0.

129. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 127, wherein o is 1.

130. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 127, wherein o is 2.

131. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 130, wherein n is 0.

132. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 130, wherein n is I.

133. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 130, wherein n is 2.

134. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 133, wherein p is 0.

135. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 133, wherein p is 1.

136. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 133, wherein p is 2.

137, In anotirer embodiment, the présent invention features a compound of any one of embodiments 112 to 136, wherein ring B is phenyl.

138. In another embodiment, the présent invention features a compound of any one of

530 embodiments 1J 2 to 137, wherein ring B is pyridyl.

J 39. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 13S, wherein ring C is phenyl.

140. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 139, wherein ring B and ring C are phenyl,

141. In another embodiment, the présent invention features a compound of any one of embodiments 112 to 140, wherein ring B is pyridyl and ring C is phenyl,

142. In another embodiment, the présent invention features a compound of embodiment 1, wherein the compound is selected from Table 1.

143. In another embodiment, the présent invention features a pharmaceutical composition comprising the compound ofany one of embodiments 1 to 142 and a pharmaceutically acceptable carrier.

144. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 143, further comprising one or more additional therapeutic agent(s).

145. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an antibiotic, an anti-infective agent, a CFTR modulator, or an antiinflammatory agent.

146. In another embodiment, the présent invention features the pharmaceutical composition of 20 embodiment 144, wherein the additional therapeutic agent is a CFTR modulator.

147. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is a CFTR corrector.

148. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is

531 or pharmaceutically acceptable sait thereof,

149. In another embodîment, the present invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

150. In another embodiment, the present invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

151. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is a CFTR potentiator.

152. In another embodiment, the present invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

532

153. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

154. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

155. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

156. In another embodiment, the présent invention features the pharmaceutical composition of embodiment 144, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

157. In another embodiment, the présent invention features a method of treating cystic fibrosis in a patient comprising administering to the patient an effective amount of the compound of any one of embodiments 1 to 142 or the pharmaceutical composition of any one of embodiments 143 to 156.

533

158. In another embodiment, the présent invention features the method of embodiment 157, further comprising administering to the patient one or more additional therapeutic agent(s) prior to, concurrent with, or subséquent to the compound of any one of embodiments 1 to 137 or the pharmaceutical composition of any one of embodiments 138 to 151.

159. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent.

160. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is a CFTR modulator.

161. In another embodiment, the présent invention features tire method of embodiment 158, wherein the additional therapeutic agent is a CFTR corrector.

162. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

163. In another embodiment, the présent invention features tire method of embodiment 158, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

164. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is

534

or a pharmaceutically acceptable sait thereof.

165. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is a CFTR potentiator.

166. In another embodiment, the présent invention features the method of embodiment 158, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

167. In another embodiment, the présent invention features the method of any one of embodiments 157 to 166, wherein the patient is homozygous in the F508del CFTR mutation.

168. In another embodiment, the présent invention features the method of any one of embodiments 157 to 166, wherein the patient is heterozygous in the F5O8del CFTR mutation.

169. In another embodiment, the présent invention features a kit comprising the compound of any one of embodiments 1 to 142 or the pharmaceutical composition of any one of embodiments 143 to 156, and instructions for use therof.

170. In another embodiment, the présent invention features the kit of embodiment 169, further comprising one or more additional therapeutic agent(s).

171. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent.

535

172. In another embodiment, the présent invention features the kit of embodiment 170, wherein the addition al therapeutîc agent is a CFTR modulator.

173. In another embodiment, the présent invention features the kit of embodiment 170, wherein the addition al therapeutîc agent is a CFTR corrector.

174. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutîc agent is

or a pharmaceutically acceptable sait thereof.

175. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutîc agent is

or a pharmaceutically acceptable sait thereof.

176. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutîc agent is

or a pharmaceutically acceptable sait thereof.

177. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutîc agent is a CFTR potentiator.

536

178. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutic agent is

H or a pharmaceutically acceptable sait thereof.

179. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

180. In anodier embodiment, the présent invention features the kit of embodiment 170, wherein

181. In another embodiment, the présent invention features the kit of embodiment 170, wherein the additional therapeutic agents are

H , or pharmaceutically acceptable salts thereof.

537

182. In another embodiment, the présent invention features the kit of embodiment 170, wherein

183. In another embodiment, the présent invention features the kit of any one of embodiments 5 169 to 182, wherein the compound of any one of embodiments 1 to 142 or the pharmaceutical composition of any one of embodiments 143 to 156 and the one or more additional therapeutic agent(s) are in separate containers.

184. In another embodiment, the présent invention features the kit of any one of embodiments 169 to 182, wherein the compound of any one of embodiments 1 to 142 or the pharmaceutical 10 composition of any one of embodiments 143 to 156 and the one or more additional therapeutic agent(s) are in the same container.

1S5. In another embodiment, the présent invention features the kit of embodiment 183 or 184, wherein the container is a bottle, vial, or blister pack, or combination thereof.

Methods of Preparing Compounds of Formula I

Compounds of the invention may be prepared by known methods and as illustrated in

Schemes I-XX1. Ring A, B, C and R, R_b R₂, R₃, R₄, X , Y, Z and n, o, p, q are as defined in the Spécification unless noted otherwise below for each individual scheme.

Scheme I

538

a) R₅ = OH, R₆ = NH₂: HATU, Et₃N or (i-Pr)₂NEt or K₂CO₃ or Na₂CO₃, DMF or CH₂Ci₂or NMP; R5 = OH, Ré = NH₂: SOC1₂, CH₂Cl₂and DMF (catalytic amount), then Et₃N, CH₂C1₂; R5 = NH₂, R₆ = Cl; NaH or Cs₂CO₃, DMF or THF; or pyridine, CH₂C1₂.

Scheme II

a) NaH or Cs₂CO₃, DMF or THF; or pyridine, CH₂C1₂.

Scheme III

a) R7 = CN or CO₂R’, Ré = halogen (Cl or Br), Y = bond, Rs = boronic acid or ester:

Pd(dppf)Cl₂*CH₂Cl₂, NaHCO₃ or Na₂CO₃, water, DMA or DME; Y = O or N(R’), R₈ = H: NaH or Cs₂CO₃ or KHMDS; DMF or DMSO or dioxane or DMF/THF; Y = O, R_s = H; Cu(OTf)₂,

539

Cs₂CO₃, toluene; Y - C(R’)(R”), R₈ = ZnBr: Pd(dppf)Cl₂*CH₂Cl₂ or Pd(PPh₃)₄ or Pd(OAc)₂and tBu₃P*HBF₄, THF; Y = C(R’)(R”), Rs = Cl or Br: K₂CO₃ or KOH, DMF or APrOH. b) KOH or NaOH or LiOH, water, FPrOH or EtOH or MeOH; or HCl in AcOH. c) H₂O₂, NaOH, EtOH; or KOH, EtOH.

Scheme IV

a) R₆ = Br, CN orCO₂R”: Cu(OAc)₂, pyridine, DCE; b) R₆= Br or is absent: n-BuLi, THF,

CO₂.

Scheme V

a) Cu(OTf)₂, Cs₂CO₃, toluene. Y = O, R_s= H.

Scheme VI

(R₂)p

a) Cl₂, water, CHC1₃; b) NH₃ or NH₄OH, MeOH or CH₂C1₂ or dioxane.

540

Scheme VII

a) R₆= halogen (Cl ), R₈ = B(OR”)₂, R9 - aprotecting group (rert-butyi)orwhen R_s is absent Ri= moiety containing N: EtOH, toluene, water, Na₂CO₃, Pd(PPh₃)4or NaH and DMF; b) TFA, 5 CH2CI2; c) CDL NaH, DMF ; d) C-moiety containing N, Y and R₈ are absent or R_s - NHR, NH₂ or NRR: K₂CO₃. DMSO or CsF, K₂CO₃, DMSO.

Scheme VIII

a) X= NH: (CH₃)₃COK, CH3CN, HMDS, V-chlorosuccinamide ; X = NCH₃or NR: CH₃NH₂ or

RNH₂, CH₃CN, A-chlorosuccinamide.

541

Scheme IX

a) R₆= halogen (Cl), Y = bond, Rs= B(OR”)₃: Pd(PPh₃)₄or PdfdppÇCÇ^CHjCl?, Na₂CO₃,

DMF, water or dioxane or DMA.

Scheme X

a) (R₂)_P---

a) CSI, CH₂C12,45 min, then Et₃N, B=moiety containing N.

Scheme XI

(Rl)n

P

a) R₆ = halogen (Cl), Y = bond or Y = O, R_s = B (OR” h : Pd(PPh₃)₄, Na_;CO₃, K₃CO₃ or K₃PO₄, DMF; R₆ - halogen (Cl), Y = bond, R₈ = H: CsF, DMSO, then R,= moiety containing N; Rr, = B(OR”)2, Y = C(R’)(R”), Rs = halogen (Br): Pd(dppf)Cl₂*CH₂Cl₂, K₂CO₃, DMF; R₆ = halogen (Cl), Rs = H or Rs is absent, R]= moiety containing N; frans-diammocyclohexane, DMF, Cul; R₆= halogen (Cl), Y = bond, Rs = B(0R”)₂, Ri= moiety containing C3-C8 cycloalkyl optionally ] 5 substituted: PEPPSI™-IPr catalyst, K₂CO₃, dioxane.

542

Scheme XII

a) R_É = halogen (F, Cl), Y = bond or Y = O, R₂ = NH₂, p = 1, X= O: NH₄0H; R₆ = NO₂, Y = O, R₂=NH₂,p= 1, X = O; CH3COOH, Zn; Ré = OMe, Y = C(R’)(R”), R₂îs =O,p= 1,X=O:

CH3COOH or dioxane, HBr or HCl; Rs = NO₂, R₂ = NH₂, p = 1, X = NH: MeOH, Pd/C; Rû = aldéhyde, X = O, Y = C(R’)(R”), R₂ = hydroxyalkyï: NaBH₄, MeOH.

Scheme ΧΠΙ

a) R = alkyl or H, Ré = halogen (Cl), Rg = NH₂ or OH, Y = O; DMA or NaH and DMF; R — alkyl, Ré= halogen (Cl), Rg= alkyne; DMF, Et₃N, PdCl₂(PPh3)₂, Cul, PPh₃; R = alkyl, Ré= halogen (Cl), Y = O, R₈ = ZnBr: Pd(dppf)Cl₂*CH₂Cl₂, then aq. sat, sol. of EDTA disodium sait and sat. aq. sol of NH₄C1.

Scheme XIV

a) Ré = halogen (I): (CH₃)₃CMgCl, CuCN, THF; b) 3-chlorobenzoperoxoic acid, CH₂Cl₂ c) R? = CN: TMSCN, Et₃N, CH₃CN.

543

Scheme XV

a) R₈ = Cl, Y = C(R’)(R”), o = 1, R - alkyl (e.g., methyl): methyl N-aminocarbamate, K₂CO₃, DMF; b) Rû= OH: dimethyl but-2-ynedioate , MeOH, then NaOMe c) Pyridine, toluene, triflic anhydride; d)Ri= boronic ester: Bis(pinacolato)diboron, KOAc, dioxane, Pd(dppf)Cl₂*CH₂Cl_2îDPPF e) Y = C(R’)(R”), o = 1, R = alkyl (e.g., methyl): Rs = boronic acid, K₂CO₃, dioxane, Pd(dppf)Cl₂*CH₂Cl₂.

544

Scheme XVI

a) R₆= halogen (Cl): CDI, NaH, DMF b) R_s is absent, Y or o = 0: C=moiety containing N or R_s= B(OR”)₂, Y oro = 0: K₂CO₃,DMSO orNa₂CO₃, DMF, water, Pd(PPh₃)₄, c) R_s = B(OR”)₂,

Pd(PPh₃)₄, K₂CO₃, DMF or Rg is absent: R|=moiety containing N, n = 1: CsF, DMSO.

Scheme XVII

a) R = alkyl (methyl, ethyl): 2-nitropropane, dioxane, benzyltrimethylammonium hydroxide b)

R₃ = gem-dimethyl group, q = 1, C = moiety containing N: NiClj 6H₂O, water, MeOH, NaBH₄;

c) Rio = H or D: LiAlH₄, THF or LiAlD₄, THF.

545

Scheme XVMI

a) NBS, DCE; b) R_f, = Cl: POC1₃, PC1₅; c) R₆ = Cl: KOH, waterj-PrOH; d) CDI and DMF, then a mixture containing the desired sulfonoamide and NaH in DMF; e) C=moiety containing N, Y or o =0: K₂CO₃,DMSO.

Scheme XIX

a)

a) Z - CH₂, Ri , = CO₂R, R = alkyl (methyl): NaH, DMF.

Scheme XX

a)Et₃N, (CH₃)₃COH, DPPA; b) MTBE, (CH₃)₂CHMgC) in THF, then SO₂; c) CH₃COONa, H₂NOSO₃H.

546

Scheme XXÏ

a) DMSO, SMOPS; b) THF/MeOH 1:1, NaOMe in MeOH; c) DMSO, H₂NOSO₃H, CH₃COONa.

Pharmaceutically Acceptable Salts and Prodru g s of Compounds of Formulas I-Id h will also be appreciated that certain compounds of the compositions of the présent invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable dérivative or a prodrug thereof. According to the présent invention, a pharmaceutically acceptable dérivative or a prodrug includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or dérivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a métabolite or residue thereof.

As used herein, the terrn pharmaceutically acceptable sait refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animais without undue toxicity, irritation, allergie response and the like, and are commensurate with a reasonable benefit/risk ratio. A “pharmaceutically acceptable sait” means any non-toxic sait or sait of an ester of a compound of this invention that, upon administration to a récipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active métabolite or residue thereof.

Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the

547 art such as ion exchange. Other pharmaceutically acceptable salts include adipate, algtnate, ascorbate. aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate. camphorate, camphorsulfonate, citrate, oyclopentanepropionate, digluconate, dodecylsullate. ethanesulfonate, formate, fumarate, glucoheptonale, glycérophosphate, gluconate, hemisulfate, beptanoate, 5 hexanoate, hydraiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate.

malale, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, mcotinate, nitrate, oleate, oxalate, palmitate, pamoate, peetinate, persulfale, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stéarate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkall métal, alkaline earth métal, ammonium and ^(Ct^alkyl). salts. This invention also envisions the quatemization of any batte nitrogenucontaining groups of the compounds disclosed herein. Water or oihsoluble or dispersable products may be obtained by such quatemization.

Représentative alkali or alkaline earth métal salts include sodium, lithium, potassium, calcium, magnésium, and the like. Further phannaceutically acceptable salts include, when appropnate, 15 irontoxic ammonium, quatemary ammonium, and amine calions fonned using couplerions such as halide, hydroxide, carboxylate. sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

Pharmaceutical Compositions

Phannaceutically Acceptable Vehicle, Adjuvant, or Carrier

In one aspect, lhe présent invetllion features a pharmaceutical composition comprising a compound of formula I or pharmaceutically acceptable sait or prodrug thereof, and a pharmaceutically acceptable vehicle, adjuvant, or carrier.

As described above, the pharmaceutical compositions of the présent invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used 25 herein, includes any and ali solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonie agents, thickening or emulsifymg agents, preservatives, solid binders, lubricants and lhe like, as suited to the particular dosage form desired. Remington; The Science and Practice ofPharmacy, 21 st édition, 2005, ed. D.B. Troy, Lippincott Wilhams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. 30 C. Boylan, 1988-1999, Marcel Dekker, New York, the contents ofeach of which is incorporated

548 by référencé herem, disclose varions carriers used in formulating pharmaceutically acceptable compositions and known techniques for the préparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples ofmaterials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stéarate, lecithin, sérum proteins, such as human sérum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloïdal silica, magnésium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylenepolyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its dérivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanutoil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnésium hydroxide and aluminum hydroxide; alginic acid; pyrogenfree water; isotonie saline; Ringeds solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnésium stéarate, as well as coloring agents, releasing agents, coating agents, sweetening, fiavoring and perfuming agents, preservatives and antioxidants can also be présent in the composition, according to the judgment of the formulator.

Additional Therapeutîc Agent(s)

In another embodiment, the pharmaceutical compositions of the présent invention further comprise one or more additional therapeutîc agent(s). In one embodiment, the additional therapeutîc agent is a CFTR modulator. In one embodiment, the additional therapeutîc agent is a CFTR corrector. In one embodiment, the additional therapeutîc agent is a CFTR potentiator. ht another embodiment, the pharmaceutical composition comprises a compound of formula 1 and one or more of the following additional therapeutîc agents.

549

In another embodiment, the additional therapeutic agent is selected from:

3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyl_Pyridin-2 yl)benzoic acid, or pharmaceutically acceptable sait thereof,

(R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyW 2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or a pharmaceutically acceptable sait thereof; or

4-(3-(1-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoqumolm-lyl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof and 3-(6-(1-(2,2 difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic 15 acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof and 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) _Cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

550

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof and (/ï)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyi)-6-flLioro-2-(l-hydroxy-2methylpropan-2-yl)-l H-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof and (7?)-l-(2,2difluorobenzo[d][l,3]dioxoI-5-yl)-2/-(I-(2,3-dihydroxypropyl)~6-fluoro-2-(l-hydroxy-2methylpropan-2-yI)-lH-indoi-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof and 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof and 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopiOpaiiecarboxamido) isoquinolin-î-yljbenzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (/ï)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-./V-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methy!propan-2-yI)-l H-indoI-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-1-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1 -(2,2-difluorobenzo[d][] ,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, (R)-l-(2,2-difhiorobenzo [d] [] ,3]dioxoI-5-yl)-/V-( 1-(2,3

551 dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yI)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxarmdo) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises À^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[-3-phenyMpipendyl]pyridine-3-carboxamide (Compound 233), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, (7?)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-/7-(l-(2,3-dÜLydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yI)cyclopropanecarboxamido) isoqumolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^f-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyI)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, (A)-l -(2,2diflu oroben zo [d] [ 1,3]dio xol-5-y 1)-M ( 1 - (2,3 -dihy droxypropy l)-6 -fluoro-2 -( 1 -hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxaimdo) ÎsoquinolÎn-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-fluoro-5-isobutoxy-phenyl)-N-(ÏH-pyrazol-3-ylsulfonyl)-2-(2,4_i6trîmethylphenoxy)pyridme-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (A)-1 -(2,2difluorobenzo[d][l,3îdÎoxol-5-yl)-W-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluoiObenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquiuolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

552

In another embodiment, the pharmaceutical composition of the présent invention comprises ?/-[(6-amino-2-pyridyI)suIfonyl]-6-ieri-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 228), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l ,3 ]dioxol-5-yl) cyclopropanecarboxamido)-35 methylpyridin-2~yl)benzoic acid, (7î)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-7V-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydraxy-2-methylpropan-2-yl)-IH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamîdo) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N- [(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,4,6trimethylpbenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridm-2-yl)benzoic acid, (i?)-l-(2,2difluorobenzo [d][ 1,3 ]dioxol-5-yl)-jV-( 1-(2,3 -dihydroxypropy I)-6-fluoro-2-( l-hydroxy-215 methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][I,3]dioxol-5-yl)cyclopropanecarboxamido) isoqumolin-I-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)suIfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(620 isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yl)benzoic acid, (/?)-l-(2,2difluorobenzo[d][I_f3]dioxol-5-y 1)-7/-(1-(2,3-dihydro xypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,225 difiuoroberLZo[d][l,3]dioxol-5-yl)cyclopropanecarboxarmdo) isoquinolm-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7/-[(6-ammo-2-pyridyI)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yI]pyridine-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][ 1,3]dioxol553

5-yl) cyclopropanecarboxamido)-3-methylpyndin-2-yl)benzoic acid, (Æ)-l-(2,2diflu oroben zo[d][l,3]d ioxol-5-yl)-N-( 1-(2,3 -dihydroxypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimethyl-2-(2,4,6-trîmethylphenoxy)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][i,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (A)-l-(2,2difluorobenzo[d][l,31dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises jV-(benzenesuIfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (/2)-1-(2,2difluorobenzo[d][l,3]dioxoI-5-yl)-AL(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yi)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxoI-5-yI)cyclopropanecarboxamido) isoquinolm-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)suIfonyl]-6-(4-methyleyclohexy 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; and acompound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yI)*N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2

554 difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-1-yi)benzoic acid, or pharmaceutically acceptable salis thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises W-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl) cycIopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (Æ)-l-(2,2diflu orobenzo[d][ 1,3 ]dioxol-5-yl)-N-( 1-(2,3-dihydroxypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indoI-5-yI)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-1-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(p-tolyl)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, (Æ)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A/-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)cyclopropanecarboxamido) isoquinolin-1-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 1660), orpharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[dJ[l,3]dioxol5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (f?)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-N-( 1-(2,3-dihydroxypropyl)-6-flu oro-2-(I-hydroxy-2methylpiOpan-2-yl)-lH-indol-5-yI)cyclopropane carboxamide, or 4-(3-(1-(2,2difluotObenzo[dl[],3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chIoropheny 1)-2-(2,4,6555 trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][I,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-1-(2,2difluorobenzo [d][l,3]dioxol-5-yl)-N-(i-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopiOpanecarboxamido) isoquinolin-I-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethylpropoxy)pyrazoI-l-yl]-2-[(4S)2,2,4-triinethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-( 1-(2,2-difluorobenzo[d][l,3]dioxol5-yl) cyclopropanecarboxamido)-3-methylpyridin-2~yl)benzoic acid, (Æ)-l-(2,2diflu oroben zo[d][ 1,3 ]dioxol -5 -y 1-(2,3 -dihydroxypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indoI-5-yl)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-jV-[[6-(methylamino)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (7?)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-N-( 1-(2,3-dihydroxypropyl)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecafboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(2-amino-3-pyridyI)suifonyl]-6-(3-isobutoxypyrazol-l-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2191), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol5-yl) cyclopropanecarboxamido)-3-methylpyrîdm-2-yI)benzoic acid, (R)-l-(2,2

556 dÎfluorobenzo[d][l,3]dioxol-5-yl)-jV-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l -hydroxy-2methylpropan-2-yl)-lHùndol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises jV-[(6-amino-2-pyridyI)sulfonyl]-6-(4-chloro-2-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l -(2,2difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyI)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indoI-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoîc acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyI)-2-(2,4,6tri me thylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycloprop anecarboxamido)-3 -methylpyridin -2-yl)benzoic acid, (Æ)-1 -(2,2difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l-(2,3-dîhydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cycIopropanecarboxamido) isoqumolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises 7V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,3-dimethyl-l-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (f?)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-/V-( 1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2

557 difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises M[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-1 -yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yi)benzoic acid, (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-7V-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yI)cyclopropane carboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecafboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises !V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopiOpoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyI)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1 -(2,2-difIuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l -(2,2difluorobenzo[d][l,3]dioxol-5-yl)-Aⁱ-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2metbylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2dîfluorobenzo[d][l,3]dioxol-5-yI)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-1-(2,2d ifluorobenzo[d][l,3]dioxol-5-y l)W-( 1-(2,3 -dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][I,3]dioxol-5-yl)cyclopropanecarboxamido) isoqumolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

558

In another embodiment, the pharmaceutical composition of the présent invention comprises /V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,7-dihydro5 H-quinoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-77-(]-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A-(4-aminothiazol-2-yl)sulfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, (/?)-1-(2,2-difluorobenzo[d][ 1,3]dioxol-5-yl)-17-(1-(2,315 dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, orpharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,4,620 trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2,2difluorobenzo [d][ 1,3 ]dioxo 1-5 -y I)-N-( 1-(2,3 -dihydroxypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-( 1-(2,225 difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido)isoquinolin-1 -yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-A-(lH-pyrazol-5-ylsuIfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 214), or pharmaceutically acceptable sait thereof; and a compound 30 selected from 3-(6-(l-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3

559 methylpyridin-2-yl)benzoic acid, (R)-l-(2,2-difluorobenz₀[d][1.3]dioxol-5-yl)-N-(l-(23dihydroxypiOpyl)-6-fhioro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(l-(2,2-difIuorobenzo[d)[l,3]dioxol-5-yl)cyclopropanecaiboxamido) isoquinolm-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceulical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(7-Iluoro-l,3-benzodioxol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345). or pharmaceutically acceptable sali thereof; and a compound selected from S-tô-a-tZ.ZHHfluowben^ cyclopropanecatboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2210 difluorobenzo[d][l,3)dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide. or 4-(3-(1-(2,2diftaorobenzo[dJ[l,3]dioxol-5-yl)cyclopropaneea*oxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenox_y)pyridine-3-carboxamide (Compound 8), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l <2,2difluorobenzo [d][ 1,3 ]dioxol-5-y l)-N-( 1-(2,3-dihydroxyprop yl)-6-fluoro-2-( l-hydroxy-220 methylpropan-2-yl)-lH-indol-5-yl)cycIopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N<3-aminophenyl)sulfonyl-5-feri-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazoIe-3- carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; and a compound selected from 3<6<l<2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyciopropanecarboxamido)-3methylpyridm-2-yl)benzoic acid, (R)-1-(2,2-difluorobenzo[d][ 1,3]dioxol-5-yl)<V-( 1-(2,3dihydroxypropyl)-6-fluoro-2<l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5-yl)cycIopropane carboxamide, or 4-(3-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-y l)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

560

I„ another embodtment. the pharmaeeutica! composition of the present invention . N 1(6 amino-7-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethylpbenoxy)pyri(line-3-carboxamÎde Componnd 281). or pharmaceutically acceptabta sa t , cHected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5 yl) thereof; and a compound selected trom J to _υ t cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, difluorobenzo[d]ll,3]dioxol-5-yl)-N-(l-(2.3-dihydroxypropyl)-6-nuoro-2-(l- y roxy methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or4-(3-(1-(2,2Z— pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the pmsent invention comprisesM₍6.amino-2-py^^^ «pheuoxy^dine^ a cpipripd from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) thereof; and a compound selected trom o (o t t _cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (_R)-l-(23difluorobenzo[dl[l,31dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hy mxy methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-( difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido)isoquinohn-l-yl)benzotcact , pharmaceutically acceptable salts thereof.

ta another embodiment, the pharmaceutical composition of the present invention

5H-quinoline-3-carboxamide (Componnd 197).or pham—aeoeprabie saltütemof; and a componnd selected from 3-(6-(1-(2,2-diflnorobenzo[d][l,31d.oxol-:>-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, («-H2.2difluorobenzo[d)[l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy- ntethylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,-- .

difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecaiboxamido) ^«in-l-yDbenzorc «f. or pharmaceutically acceptable salts thereof.

_ta another embodiment, the pharmaceutical composition of the present invention comprises 6-(4-chloro-3-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin-3'yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Componnd 136), or pharmaceut.eaUy acceptable

561 thereof; and a compound selected ta 3.(6-(l-(2,2.dinuorobe_nzoId][1.3]d,oxol-5-yl) _Cyclopropanecarboxamido)-3-methylpytidin-2.y1)benzoic acid, (/0-1-(2,2difhtombenzoldMUldiowl-d-ylW^ methylpropan-2-yl)-lH-îndol-5-yl)cyclopropane caaboxamide, or4-(3-(l-(2.25 difluorobenzo[d)(1.3]dioxol-5-yl)cyclopropanecatboxamido) isoquinolin-l.yDbenzotc actd, or pharmaceutically acceptable salts thereof.

In another embodiment. the pharmaceutical composition of the ptesent invention comprises 2-(2,5-dimethylpyrmUdm-l-yl)^^ p_yridin-3-yl)sutfonyl]pyridine-3-carboxamide (Compound 307). or phannaceuttcally acceptable ! 0 sait thereof; and a compound selected from 3-(6-(l-(2,2-dinuon>benzo[d][131dtoxol-5-y cyclopropaneca*oxamido)-3-methylpyddm-2-yl)benzoie acid, (R)-l-(2,2difluorobenzo[d][1.31dioxol-5-yl)-N-(l-(2,3-dihydroxypn>pyl)-6-fluon>-2-<l-hydroxymethylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolm-l-yDbenzo.c actd, or pharmaceutically acceptable salts thereof.

In another embodiment. the pharmaceutical composition of the présent invention comprises 6-(2-iluoro-5-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6-^, trimêthylphenoxy)pyridine-3-cart>oxamide (Compound 279). or pharmaceutically accepte s«l. thereof; and acompound selected from 3-(6-(1-(2,2-difluorobenzo[d][13]dtoxol-5-yl)

PO cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (8)-1-(2,2difluorobenzo[d][l,3]dtoxol·5yl)-N-(l-(2,3dihydroxypropyl)-6nuoro·2-(lhydroxy- methylpiopan-2-yl)-lH-indol-5-yl)cyclopro_Pane carboxamide, or 4-(3-(1-(2,2dÎfluorobenzo(d](l,3)dioxol-5-yl)cyclopropanecarboxamido) isoquinolm-1-yDb.nzme actd. or pharmaceutically acceptable salts thereof.

₂₅ In another embodiment. the phatmaceutical composition of the prnsent invention comprises 6-(4-chloro-3-propoxy-phenyl)-/V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6himethylphenoxy)pyridine-3-catboxamide (Compound 72). or pharmaeeuhcally acceptable sa thereof; and acompound selected from 3-(6-(1-(2,2-difluorobenzo(d][l,3]dioxol-5-yl) cyclopropanecarboxanûdo)-3-methylpyridm-2-yl)benzoic acid. (8)-1-(2,230 difluorobenzo[dltl.3)dioxol-5.yl)-N.(l-(2.3.dihydroxypropyl)-6-fluo_ro-2-(l-hydroxy562 methylpropan-2-yl)-lH-indo)-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l ,3]dioxol-5-yl)cyclopropanecarboxamido) isoqumolin-l-yï)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-isobutoxyphenyl)-N-[(2-oxo-l H-pyridm-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-caiboxnmide (Compound 125). or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6(l-(2,2-difluo_robenzo[d][13]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-W-(l-(2.3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-210 _methylpropan-2-yl)-lH-indol-5-yl)cyclopropancca*oxamide, or 4-(3-(1-(2.2difluorobenzo[d][l ,3)dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yDbenzotc acrd, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises TV-(benzenesulfonyl)-5-tert-butyl-2-((2,4,6-trimethyIphenyljmethyI]pyrazole-315 carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoi-5-yl)cyclo_Pïo_Pane carboxamide, or4-(3-(l-(2,2-diflüorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises IV-(3-aminophenyl)sulfonyl-4-iso_Pro_Pyl-2-((2,4,6-trimethylphenyI)methyl] isoindoline-l-carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridm-2-yl)benzoic acid, (R)-l-(2,2difluorobenzoLd][l,3]dioxol-5-yl)-/V-(l-(2,3-dihydroxypro_Pyl)-6-fiuoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-mdol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

563

In another embodiment, the pharmaceutical composition of the présent invention comprises N- [(2-methoxy-3-pyridyl)sul fon yl] -6 -( 1 -methyl cyclopropyl) -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; and a compound selected from 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (JS)-1 -(2,2difluorobenzo[d][l,3]dioxol-5-yl)-M-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methyIpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7'7-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethylpyiTolidm-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 361), or pharmaceutically acceptable sait thereof; and acompound selectedfrom 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (Æ)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l-(2,3-dihydroxypropyI)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l,3]dioxoI-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid, or pharmaceutically acceptable salts thereof.

In one embodiment, the above recited pharmaceutical compositions contain a pharmaceutically acceptable prodrug of the compound of the présent invention.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof; and 3-(6-(1(2,2-difluorobenzo[d][l,3]dioxol-5-yI) cyclopropan ecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2ditluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises IV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[-3-phenyl-l

564 pipe ri dyl]pyridine-3-carboxamide (Compound 233), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difIuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyI)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-fluoro-5-isobutoxy-phenyl)riV-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethyIphenoxy)pyridme-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises À^r-[(6-amino-2-pyridyl)sulfonyl]-6-reri-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 228), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2difluorobenzo[d][l,31dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition ofthe présent invention comprises jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6tri me thylphenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^f-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimetliylpyrrolidin-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][ 1,3]dioxol-5-yl) cyclopropanecarboxamido)-3methy]pyridin-2-yl)benzoic acid, or pharmaceuücally acceptable sait thereof.

565

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)snlfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimetlryl-2-(2,4,6-trimetliylphenoxy)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; and 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(benzenesulfony 1)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(45)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; and 3-(6-( 1 -(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cycIopropanecarboxamido)-3-methylpyridin-2-yi)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7V-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methylcyclohexyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; and 3-(6-(1 -(2,2-difluorobenzo[d][l ,3]dioxo 1-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; and 3-(6-(1 -(2,2-difkiorobenzo[d][l ,3]dioxoI-5-yl) cyclopropanecarboxamido)-3-methylpyridin2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(p-tolyI)-A^r-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; and 3-(6-(1 -(2,2

566 difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1660), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][î,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^F-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethy]propoxy)pyrazoI-l -yl]-2-[(4S)2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxoi-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-iV-[[6-(methylamino)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises À^,-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxypyrazol-l-yI)-2-[(4S)-2,2,4trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2191), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

567

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chIoro-2-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycIopropanecarboxamido)-3- methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises À^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyc!opropanecaiboxamido)-3- methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-(2,3-dimethyI-l-_Piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l ,3]dioxoI-5-yl) cyclopropanecarboxamido)-3-methyIpyridin15 2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises/V-[(6-ammo-2-pyridyl)suïfonyï]-2-[(2S,5R)-2,5-dimethyl_PyrToiidin-l-ylj-6-(3-fïuoro5-isobutoxy-pheny])pyridine-3-carboxamide (Compound 171), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecaiboxamido)-320 methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin25 2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difIuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin30 2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

568

In another embodiment, the pharmaceutical composition of the présent invention comprises 77-[(6-amino-2-pyridyl)su]fonyl]-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,7-dihydro5 H-quinoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; and 3(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises V-(4-aminothiazol-2-yl)sulfonyl-6-tert-biHyl-2-(2,4₎6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2d ifluorobenzo [d] [ 1,3 ]d ioxol -5 -yl) cyclopropanec arboxamido)-3 -methylpyridin-2-yl)benzo ic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A4(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-buty 1-27-( 1 H-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 214), or phannaceutically acceptable sait thereof; and 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yI) cycIopropanecarboxamido)-3-methylpyridm-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

fri another embodiment, the pharmaceutical composition of the présent invention comprises jV-[(6-amino-2-pyridyl)sulfonyl]-6-(7-fluoro-l,3-benzodioxol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 8), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][i,3]dioxoI-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

569

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(3-aminophenyl)sulfonyl-5-ierrtbutyb2-[(2A6-trimethyIphenyl)methyI]pyrazole-3carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2dîfluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 281), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycIopropanecarboxamido)-3methyIpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises Y-[(6-amino-2*pyridyl)suIfonyl]-6-(2-fluoiO-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 351), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecaiboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-(3-ammopyrazin-2-yl)3ulfonyl-8,8-dimethyl-2-(4-methyl-l-piperidyl)-6,7-dihydro5H-quinoline-3-carboxamide (Compound 197), or pharmaceutically acceptable sait thereof; and 3-(6-(i-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-isobutoxy-phenyl)-(V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethy!phenoxy)pyridine-3-carboxamide (Compound 136), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difIuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridm-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 2-(2,5-dimethylpyrroIidin-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-N-[(2-oxo-lHpyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 307), or pharmaceutically acceptable sait thereof; and 3-(6-(1 -(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropane carboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

570

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(2-fluoro-5-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 279), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-propoxy-phenyl)W-[(2-oxo-l H-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 72), or pharmaceutically acceptable sait thereof; and 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycIopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-isobutoxyphenyl)-A''-[(2-oxo-IH-pyridin-3-yl)suIfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 125), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecaiboxamido)-3methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^,-(benzenesulfonyl)-5-tert-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-y])benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(3-ammophenyl)sulfonyl-4-isopropyl-2-[(2,4,6-trimetliylphenyl)methyl] isoindoline-1-carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; and 3(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2yljbenzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7V-[(2-methoxy-3-pyridyl)sulfonyl]-6-(l-methylcyclopropyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; and 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

571

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethylpyiTolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 361), or pharmaceutically acceptable sait thereof; and 34641-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof; and (R)-l -(2,2di fluorobenzo[d][ 1,3 ]dioxol-5 -yl)4V-( 1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yI)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof; and (R)-l -(2,2difluorobenzo [d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-] H-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[-3-phenyl-lpiperidyl]pyndine-3-carboxamide (Compound 233), or pharmaceutically acceptable sait thereof; and (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-îndol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyI)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; and (7?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

572

In another embodiment. the pharmaceutical composition of the présent invention comprises 6-(3-fluoro-5-isobutoxy-phenyl)-iV-(lH-pyrazol-3-yIsulfoiiyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^,'-(]-(2,3-dihydroxypropyl)-6-fluoro2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-ierr-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 228), or pharmaceutically acceptable sait thereof; and (R)-1-(2,2d ifluorobenzo[d][ 1,3 ]dioxoI-5 -y 1)-77-(1 -(2,3 -dihydroxypropy l)-6-fluoro-2-( l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cycIopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; and (Λ)-1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)W-(1-(2,3-dihydroxypropyl)-6-fluoro2-(l -hydroxy-2-methylpiOpan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises ?7-[(6-amino-2-pyridyI)sulforiyl]-2-[(2S,5R)-2,5-dÎmethylpyrrohdin-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyI)-6fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridme-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methyIpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

573

In another embodiment, the pharmaceutical composition of the présent invention comprises /V-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimethyl-2-(2,4,6-trimethylphenoxy)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; and (Λ)-1-(2,2-difluorobenzo[d][ 1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(benzenesulfonyl)-6-(3-finoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; and (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-?/-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyI)sulfonyl]-6-(4-methylcyclohexyl)-2-(2,4,6tri me thylphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-N-(l-(2,3-dihydroxypropyl)-6-lluoro2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoFO-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; and (/?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(Ihydroxy-2-methylpropan-2-yl)-lH-Îndol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(p-tolyl)W-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-jV-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methyIpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

574

In another embodiment, the pharmaceutical composition of the présent invention comprises M [(2-amino-3-py ri dyl)sulfonyi]-6-(6-isop ropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1660), or pharmaceutically acceptable saltthereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-?/-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; and (Λ)-1-(2,2-difluorobenzo[d][l,3]dioxol-5^1)-27-(1-(2,3-djhydroxypropyI)-6-fluoro2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(2-amino-3-pyridyl)suifonyl]-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(4S)2,2,4-trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; and (Λ)-Ι -(2,2-difluorobenzo[d][I,3]dioxol-5-yl)-/7-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyc]opropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-7V-[[6-(methylamino)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-?/-(l-(2,3-dihydroxypropyl)-6-fIuoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cycIopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxypyrazol-l-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2191), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-dif]uorobenzo[d][l,3]dioxol-5-yI)-N-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methyIpropan-2-yI)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

575

In another embodiment, the pharmaceutical composition of the present invention comprises N- [(6-amino-2-pyridyl)suîfonyl]-6-(4-chloro-2-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; and (R)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N-[(6-amino-2-pyridyl) suIfonyl]-2-(2,3-dimethyl-1-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxok5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yI)-l H-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidm-l-yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][],3]dioxol-5-yl)-A''-(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-h ydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N-[(6-amino-2-pyndyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyI-l piperidyl)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; and (Z?)-l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypiOpyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

576

In another embodiment, the pharmaceutical composition of the présent invention comprises jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-(3-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises ?7-[(6-ammo-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,7-dihydro5H-quinoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy2-methylpropan~2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N-(4-ammothiazol-2-yl)sulfony!-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2difhiorobenzo[d][l,3]dioxol-5-yl)-7V-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises N- [(6-amino -2-pyridyl)sulfonyl] -6-(4-is opropylphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait thereof; and (Æ)-l -(2,2-difluorobenzo[d][l ,3]dioxol-5-yI)-2V-(l -(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-A^r-(lH-pyrazol-5-y]sulfonyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 214), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-7V-(l-(2,3-dihydroxypropyI)-6-fIuoro-2-(l-hydroxy-2methylpropan-2-yl)-l H-indol-5-y])cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

577

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(7-fluoro-1,3-benzodioxol-4-yI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345), or pharmaceutically acceptable sait thereof; and (R)-I -(2,2-difluorobenzo[d][l ,3]dioxol-5-yl)-N-(l -(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 8), or pharmaceutically acceptable sait thereof; and (Λ)-l-(2,2-difluorobenzo[d][l,3]dioxol·5-yl)-^^Γ-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises AM3-aminophenyl)sulfonyl-5-it^butyl-2-[(2,4,6-triinethylphenyl)methyl]pyrazole-3carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-y!)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide (Compound 281), or pharmaceutically acceptable sait thereof; and (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l-(2,3-dihydroxypropyl)-6-tluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-11 uoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 351), or pharmaceutically acceptable sait thereof; and (7?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-M(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpiOpan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

578

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(3-armnopyrazm-2-yl)sulfonyl-8,8-dimethyl-2-(4-methyl-l-piperidyl)-6,7-dihydro5 H-quinoline-3-carboxamide (Compound 197), or pharmaceutically acceptable sait thereof; and (A^,)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy2-methylpropan-2-yl)-1 H-indoh5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-isobutoxy-phenyI)-/7-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 136), or pharmaceutically acceptable sait thereof; and (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)W-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 2-(2,5-dimethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)4V-[(2-oxo-lHpyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 307), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-iV-(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-hydroxy-2-methylpropan-2’yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(2-fluoro-5-isobutoxy-phenyl)-lV-[(2-oxo-]H-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 279), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-iV-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-propoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyiidine-3-carboxamide (Compound 72), or pharmaceutically acceptable sait thereof; and (A’)-l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)-7V-(l-(2,3-dîhydroxypropyl)-6-fluoro2-(l-hydiOxy-2-methylpropan-2-yI)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

579

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-isobutoxyphenyl)-7/-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 125), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l ,3] dioxol-5-yl )-?/-( 1-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-IH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7/-(benzenesulfonyl)-5-tert-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; and (R)-1-(2,2difluoroben zo [d] [ 1,3 ]dio xol-5-yl)-//-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(I-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-(3-aminophenyI)sulfonyl-4-isopropyl-2-[(2,4,6-trimethylphenyl)methyl] isoindoline-1 -carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; and (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(2-methoxy-3-pyridyl)sulfonyl]-6-(l-methylcyclopropyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; and (Æ)-l-(2,2-difluoΓobenzo[d][l,3]dioxol·5-yl)-7V-(l-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises ?V-[(6-amjno-2-pyridyl)sulfonyl]-2-(2,2-dimethylpynOlidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 361), or pharmaceutically acceptable sait thereof; and (/?)-!-(2,2-difluorobenzo[d][I,3]dioxol-5-yl )-7/-(1-(2,3-dihydroxypropyl)-6-fluoro2-(l-hydroxy-2-methylpropan-2-yl)-lH-indo]-5-yl)cyclopropane carboxamide, or pharmaceutically acceptable sait thereof.

580

In another embodiment, the above recited pharmaceutical compositions contain a pharmaceutically acceptable prodrug of the compound of the présent invention.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of formula I, or pharmaceutically acceptable sait thereof; and N-(5hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-caiboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a compound of Table 1, or pharmaceutically acceptable sait thereof; and N-(5hydroxy-2,4-ditert-butyl-phenyl)-4-oxo4H-quinoline-3 -carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 233), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises iV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; and M(5-hydroxy-2,4-ditert-butyI-phenyl)-4-oxo-lH-quinoliue-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-fluoro-5-isobutoxy-phenyl)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; and 7V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-cai'boxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6’amino-2-pyridyl)sulfonyl]-6-iei-i-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 228), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy

581

2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; and A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises Z\A-[(6-arnmo-2-pyridyl)sulfony]]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; and 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy-2,4-dÎtert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises ?/-[(6-amino-2-pyrid_yl)sulfonyl]-8,8-d!methyl-2-(2,4,6-trimethylphenoxy)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; and 7V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(benzenesuIfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4[rimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; and A<5-hydroxy-2,4-dÎtert-butyl-phenyl)-4-oxo-lH-quÎnoline-3carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methylcyclohexy 1)-2-(2,4,6

582 trimethylphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; and jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-djmethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; and /V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(p-tolyl)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; and N-(5 -hydroxy2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1660), or pharmaceutically acceptable sait thereof; and ?/-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises ?7-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; and 7V-(5-bydroxy-2,4-ditert-butyl-phenyl)-4-oxo-IH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 7V-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(4S)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof.

5S3

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-buty]-77-[[6-(methylamino)-2-pyridyl]sulfooyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; and 77-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-H-I-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises M[(2-amino-3-pyridyI)sulfonyl]-6-(3-isobutoxypyrazol-l-yl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2191), or pharmaceutically acceptable sait thereof; and 7V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises Z7-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-2-fluoro-phenyl)-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; and 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises /V-[(6-amino-2-pyridyI)sulfonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; and 77-(5-h ydro xy-2,4-d itert-bu tyl-phenyl)-4-oxo-lH-quinoli ne-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises Z7-[(6-amino-2-pyridyl)sulfonyl]-2-(2,3-dimethyI-l-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; and A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 77-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l -yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171), or pharmaceutically acceptable sait thereof; and 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-cafboxamide, or pharmaceutically acceptable sait thereof.

584

In another embodiment, the pharmaceutical composition of the présent invention comprises 7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; and A-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-methyl-Ipiperidyl)pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; and A-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises ^^Γ-[(6-amino-2-pyridyl)su[fonyl]-2-(2,4-dimethylphenoxy)-8,8-dimethyl·6,7-dihydro5H-quînoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; and A-(5-hydroxy-2,4-ditert-buÎy]-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A-(4-aminothiazol-2-yl)suIfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; and A-(5-hydroxy2,4-ditert-butyl-phenyl)-4-oxo-IH-quînoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises jV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait thereof; and A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quînoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-tert-butyl-A'-(lH-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 214), or pharmaceutically acceptable sait thereof; and A-(5-hydroxy2,4-ditert-butyi-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or phannaceutically acceptable sait thereof.

585

In another embodiment, the pharmaceutical composition of the présent invention comprises A⁷-[(6-amino-2-pyridyl)sulfonyI]-6-(7-fluoro-l,3-benzodioxol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345), or pharmaceutically acceptable sait thereof; and A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises /V-[(6-amino-2-pyridyl)sulfonyI]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound S), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^r-(3-aminophenyl)sulfonyl-5-ierf-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; and 7V-(5-hydroxy2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, orpharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises A^T-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-chloro-3ûsopropoxy-phenyi)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 281), or pharmaceutically acceptable sait thereof; and TV-(5-hydroxy-2,4-ditert-butyI-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyI)suIfonyl]-6-(2-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 351), or pharmaceutically acceptable sait thereof; and A⁷-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

in another embodiment, the pharmaceutical composition of the présent invention comprises 7V-(3-am!nopyrazin-2-yl)sulfonyI-8,8-dimethyl-2-(4-methyl-l-piperidyl)-6,7-dihydro5H-qumoline-3-carboxamide (Compound 197), or pharmaceutically acceptable sait thereof; and Λ^/'-(5-hydroxy-2,4-diterl··butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

586

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-isobutoxy-phenyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 136), or pharmaceutically acceptable sait thereof; and 27-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 2-(2,5-dimethylpyriOlidm-l-yl)-6-(3-fluoro-5-Îsobutoxy-phenyl)-27-[(2-oxo-lHpyridin-3-yl)sulfonyI]pyridine-3-carboxamide (Compound 307), or pharmaceutically acceptable sait thereof; and 27-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(2-fluoro-5-isobutoxy-phenyl)-27-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 279), or pharmaceutically acceptable sait thereof; and 2V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(4-chloro-3-propoxy-phenyI)-77-[(2-oxo-lH-pyridin-3-yî)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 72), or pharmaceutically acceptable sait thereof; and 2V-(5-h ydroxy-2,4-ditert-bu tyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises 6-(3-isobutoxyphenyl)-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 125), or pharmaceutically acceptable sait thereof; and 27-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises /7-(benzenesulfonyl)-5-tert-butyl-2-[(2,4,6-trimethylphenyl)met]ryl]pyrazole-3carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; and 27-(5-hydroxy2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

587

In another embodiment, the pharmaceutical composition of the présent invention comprises N-(3-aminophenyl)sulfonyl-4-isopropyl-2-[(2,4,6-Îrimethylpheiiyl)methyl] isoindoline-1 -carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; and N(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(2-me thoxy-3-pyridyl )sulfonyl]-6-(!-me thylcyciopropy 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; and )V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumolme-3-carboxainide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethylpynolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 361), or pharmaceutically acceptable sait thereof; and N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the additional therapeutic agent is selected from the following table:

588

5S9

table:

Compounds disclosed in US Patent No, 7,407,976 (Col 13, In 35- col 66, In 67; Compounds 1-100 in Table 1 at col 67, In 1-col 127, In 42)

Compounds disclosed in US Patent No, 7,645,789 (Col 16, In 52-col 50, In 22; Compounds 1-322 in Table 1 at col 50, In 24-col 167, In 42)

Compounds disclosedin US Patent No. 7,659,268 (Col 16, In 20-col 70, In 52; Compounds 1-528 in Table 1 at col 70, In 53-coî 331, In 34)

Compounds disclosed in US Patent No. 7,671,221 (Col 16, Jn 12-col 54, In 48; Compounds 1 -1216 in Table 1 at col 54, In 49-col 699, In 27)

Compounds disclosed in US Patent No. 7,691,902 (Col 16, In 11-col 54, In 29; Compounds 1-959 in Table 1 at col 54, In 29-col 683, In 44)

Compounds disclosed in US Patent No. 7,741,321 (Col 16, In 25-col 72, In 17; Compounds 1-422 in Table 1 at col 72, Jn 20-col 279, In 15)

Compounds disclosed in US Patent No. 7,754,739 (Col 16, In 1-col 22, In 47; Compounds 1-2 in Table 1 at col 18, In 26-65)

Compounds disclosed in US Patent No. 7,776,905 (Col 16, In 23-col 38, In 40; Compounds 1-306 in Table 1 at col 38, In 45-col 96, In 40)

590

Compounds disclosed in US Patent No. 7,973,169 (Col 9, in 16-coI 40, In 40; Compounds 1-289 in Table 1 at col. 40, In 41-col 289, In 39)

Compounds disclosed in US Patent No. 7,977,322 (Col 6, In 26-col 37, In 47; Compounds 1-498 in Table 1 at col 37, In 50-col 14], In 40)

Compounds disclosed in US Patent No. 7,999,113 (Col 6, In 13-col 10, In 67; Compounds 1-13 in Table 1 at col 11, In 5-col 13, In 65)

Compounds disclosed in US Patent No. 8,227,615 (Col 6, In 10-col 29, In 66; Compounds 1-78 in Table 1 at col 30, In 1-col 46, In 48)

Compounds disclosed in US Patent No. 8,299,099 (Col 6, In 10-col 34, In 18; Compounds 1-47 in Table 1 at col 34, In 20-col 42, In 35)

Compounds disclosed in US Published Application No. 2006-0052358 (Paragraphs [0034][0056]; [0077 ]-[0240]; Compounds 1-320 in Table 1 atparagraph [0241])

Compounds disclosed in US Published Application No. 2009-0143381 (Paragraphs [0102][0263]; Compounds 1-28 in Table 1 atparagraph [0264])

Compounds disclosed in US Published Application No. 2009-0170905 (Paragraphs [0012][0013]; [0030]-[0051 ])

Compounds disclosed in US Published Application No. 2009-0253736 (Paragraphs [0031][0162]; Compounds 1-15 in Table 1 at paragraph [0163])

Compounds disclosed in US Published Application No. 2011-0263654 (Paragraphs [0012][0013]; [0066]-[0141])

Compounds disclosed in US Published Application No. 2011-0251253 (Paragraphs [0012][0013]; [0054]-[0079])

Compounds disclosed in PCT application WO2008141119 (Paragraphs [0100]-[0339];

Compounds 1-117 in Table 1 at paragraph [0340])_____________________________________

Compounds disclosed in US Application No. ] 1/047,361

Compounds disclosed in US Published Application No. 2013-0116238 (Paragraphs [0028][0044]; [0117]-[0128]), or combinations thereof.

In another embodiment, the additional therapeutîc agent is selected from

A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; or

591

H

A44-(7-azabicyclo[2.21]heptan-7-yI)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-l,4dihydroquinoline-3-carboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) a compound selected from 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (Æ)-l-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-indol-5-yI)cyclopropanecarboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide or A-(4-(7-azabicyclo[2.21]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5(trifluoromethyl)-l,4-dihydroquinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) a compound selected from 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (7?)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-/V-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2~yl)-lH-indol-5-yl)cyclopropanecarboxamide, or4-(3-(l-(2,2difhiorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from 7y-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide or A^,-(4-(7-azabicyclo[2.2!]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5(trifluoromethyl)-l,4-diliydroquinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(l-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl)

592 cycIopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c)A-(5-hydroxy-2,4-ditertbuty]-phenyI)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycIopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) A-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound offonnula I; b) (R)-l-(2,2-difluorobenzo[d][i,3]dioxol-5-yl)-A-(I(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) iV-(5-bydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) (A)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A-(l-(2,3dihydroxypropyl)-6-fIuoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinolme3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(1-(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) //-(S-hydroxy^^-ditertbutyI-phenyl)-4-oxo-lH-quinoline-3 -carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) 4-(3-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) 77-(5-hydroxy-2,4-ditertbuty]-phenyl)-4-oxo-lH-qumoline-3 -carboxamide.

593

Compounds disclosed in US Published Application No. 2005-0113423 (Paragraph [00146]; Compounds IA-l-IA-136 and Compounds 1-1 -1-21 in Tables 1 and 2 at paragraphs [0391 ][0392])_________________________

Compounds disclosed in US Published Application No. 2005-00596S7 (Paragraphs [00100]-[00101]; Compounds 1-405 in Table 1 at paragraph [0169])

Compounds 1 -108 disclosed in US Patent No. 7,598,412 (Col 22, In 14-col 79, In 20;Table n____________________________________________________ Compounds 1-485 disclosed in US Patent No. 7,495,103 (Col 51, In 1-col 63, In 43; Table n__ Compounds 1-718 disclosed in US Patent No. 8,354,427 (Col 51, In 3-col 71, In 46; Table 1)________________________ Compounds 1-233 disclosed in US Published Application No. 2007-0105833 (Paragraph [00145]; Table 1)

Compounds 1-26 disclosed in US Patent No. 8,242,149 (Col 46, In47-col57, In 37; Table υ_________________________________________

Compounds 1-18 disclosed in US Patent No. 8,314,256 (Col 21, In 1-col 26, In 19)

Compounds 1-14 disclosed in US Patent No. 8,399,479 (Col 36, In 20-col 38, In 40; Table 1) _______________________________________________ _ Compounds 1-18 disclosed in US Patent No. 8,188,283 (Col 38, In 43-col 43, In 36; Table n_____________________________________________________ Compounds 1-16 disclosed in US Published Application No. 2010-0249180 (Paragraph [0173]; Table 1)

Compounds 1-19 disclosed in US Published Application No. 2011-0008259 (Paragraph [0172]; Table 1)

Compounds 1-129 disclosed in US Patent No. 8,367,660 (Col 57, In 31-col 81, In 24; Table 1)

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) a compound selected from 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)-lV-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-indoI-5-yl)cycIopropanecarboxamide, or 4-(3-( 1-(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamjdo) isoquinolin-l-yl)benzoic acid; and c) a compound selected from N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide or N-(4-(7-azabicyclo[2.21 ]heptan-7-yl)-2-(trifluoromethyl)pheny])-4-oxo-510 (trifluoromethyl)-1,4-dihydroqumoline-3-carboxamide.

594

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) a compound selected from 3-(6-(1-(2,2difiuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methy]pyridin-2-yl)benzoic acid, (/f)-i-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yI)-IH-jndol-5-yI)cyclopropanecarboxamide, or 4-(3-( 1-(2,2difluoiObenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide or?7-(4-(7-azabicyclo[2.21]heptan-7-yl)-2-(trifluoromethyI)phenylM-oxo-5(trifluoromethyl)-l,4-dihydroquinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) a compound selected from 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (7?)-l-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l hydroxy-2-methylpropan-2-yl)-lH-indoI-5-yl)cyclopropanecarboxamide, or 4-(3-(] -(2,2difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from certain flavones and isoflavones, such as genistein, which are capable of stimulating CFTR-medîated chloride transport in épithélial tissues in a cyclic-AMP independent manner (See U.S. Pat. No. 6,329,422, incorporated herein by reference in its entirety); phenylglycine-01 (2-((2-1 H-mdol-3-yl-acetyl)-inethylamino]-N-(4-isopropylphenyl)-2phenylacetamide); felodipine (Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-l,4-dihydro3,5-pyridinedicarboxylate); sulfonamide SF-01 (6-(ethylphenylsuIfamoyl)-4-oxo-l ,4dihydroquinoline-3-carboxylic acid cycloheptylamide); and UCCF-152 (3-[2(ben zyloxy) phenyl]-5 -(chloromethyl)isoxaz oie).

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) A^r-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoIine-3 -carboxamide.

595

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yl)benzoic acid; and cjA-ÎS-hydroxy-î^-ditertbutyl-phenyl)M-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) (Æ)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) (2?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) A^L(5-hydroxy-2,4-ditert~buÎyl-phenyl)-4-oxo-lH-quinoline3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(l-(2,2-difIuorobenzo[d][l,3]dioxol-5yî)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) /V-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) 4-(3-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) yV-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-Îsopropoxy-3-pyridyI)-2-[-3-phenyi-lpiperidyl]pyridine-3-carboxamide (Compound 233), or pharmaceuticany acceptable sait thereof; b) A-(5-hydroxy-2,4-ditert-buty]-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)

596 cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 7V-[(6-amino-2-pyridyl)sulfonyI]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; b) Λ^,-(5-hydroxy-2,4-diterl·butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cycIopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(3-fluoro-5-isobutoxy-phenyl)-?7-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; b) 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinohne-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-[(6-amino-2-pyridyl)sulfonyl]-6-icrt-butyl-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 228), or phaimaceutically acceptable sait thereof; b) M(5-hydroxy2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; b) jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-dinuorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

597

In another embodiment, the pharmaceutical composition of the présent invention comprises a) M[(6-ammo-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l -yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; b) M(5-hydiOxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-caiboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-dîfluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

ïn another embodiment, the pharmaceutical composition of the présent invention comprises a) 2V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; b) N-(54rydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) À^r“[(6-amino-2-pyridyl)suIfonyl]-8,8-dimethyl-2-(2,4,6-trimethylphenoxy)-6,7dihydro-5H-quino!ine-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; b) )V-(5-hydroxy-2,4-dhert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 77-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl>2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-[(6-amino-2-pyridyl)sulfonyl]*6-(4-methylcyclohexyl)-2-(2,4,6

598 trimethylphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxaniide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; b) M(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][I,3]dioxoI-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) 6-(p-toly])-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; b) 7V-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-qumoIine-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d]Ll,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) A^l'-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yllpyridine-3-carboxamide (Compound 1660), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; b) Λ^Γ-(5-hydroxy-2,4-diterl·buty]-phenyI)-4-oxo-lH-qumoline-3-carboxaπΊide₁ or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)

599 cyclopropanecarboxamîdo)-3-meLhylpyridin-2-yl)benzoic acid, or phannaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(2-amîno-3-pyridyl)sulfonyI]-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(4S)5 2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo[d][I,3]dioxol-5-yI) cycIopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-tert-butyl-N-[[6-(methylammo)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 7V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxypyi*azol-l-yl)-2-[(4S)-2,2,4trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2191), or pharmaceutically acceptable sait thereof; b) ?/-(5-hydiOxv-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinolîne-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-[(6-amino-2-pyridyl)sulfonyI]-6-(4-chloro-2-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable 30 sait thereof.

600

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A'-[(6-amino-2-pyridyl)su!fonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; b) A^f-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1 -(2,2~difluorobenzo[d](l,3]dioxoh5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

ht another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyI)sulfonyI]-2-(2,3-dimethyl-1 -piperidy 1)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) jV-[(6-ammo-2-pyridyl)su!fonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l -yl]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171), orpharmaceutically acceptable sait thereof; b) jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2difluorobenzo [d] [ 1,3]dioxol -5 -yl) cyclopropanec arboxamido)-3 -methylpyridin-2-yl)benzo ic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amÎno-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-d!tert-buty]-phenyl)-4-oxo-lH-quÎnoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-ammo-2-pyridyI)sulfonyl]-6-(6-isopîOpoxy-3-pyridyl)-2-(3-metbyl-l

601 piperidy])pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamjde, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) jV-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimetbylphenoxy)-8_i8-dimethyl-6,7dihydro-5H-quinoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; b) ?/-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-dîfluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-(4-aminothiazol-2-yI)sulfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1 -(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-buty]-phenyl)-4-ox0-lH-quinoline-3-carboxaniide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difIuorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-teit-butyl-A^r-(lH-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 214), or pharmaceutically acceptable sait thereof; b) ?/-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait

602 thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) 77-[(6-amino-2-pyridyl)sulfonyl]-6-(7-fluoro-l ,3-benzodioxol-4-y])-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345), or pharmaceutically acceptable sait thereof; b) ?/-(5-hydroxy-2_:4-ditert-butyl-pheny!)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 8), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-dîtert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) A^r-(3-aminophenyl)sulfonyl-5-ferributyl-2-[(2,4,6-trimethylphenyl)methyl] pyrazole-3-carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; b) N-(5hydroxy-2,4-ditert-buty]-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 281 ), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridm-2-yl)betizoic acid, or pharmaceutically acceptable sait thereof.

603

In another embodiment, the pharmaceutical composition of the présent invention comprises a)2V-[(6-amino-2-pyridyl)sulfbny]]-6-(2-fliioro-5-isobutoxy-phenyI)-2-(2,4,6tri methylphenoxy)pyridine-3-carboxamide (Compound 351), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d]( 1,3 ]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-(3-aminopyrazin-2-yl)sulfony]-8,8-dimethyI-2-(4-methyl-1 -piperidyl)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 197), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(4-chloro-3-isobutoxy-phenyI)-N-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-(2,4,6trimethylplienoxy)pyridine-3-carboxamide (Compound 136), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-IH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-ditluorobenzo[d][ 1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyiidin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 2-(2,5-dimethylpynOlidin-l-yl)-6-(3-fIuoro-5-isobutoxy-phenyl)-/V-[(2-oxo-lHpyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 307), or pharmaceutically acceptable sait thereof; b) A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopiOpanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(2-fIuoro-5-isobutoxy-pheny])-iV-[(2-oxo-l H-pyridin-3-yl)sulfonyl]-2-(2,4,6

604 trimethyIphenoxy)pyridine-3-cmboxamide (Compound 279), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(4-chloro-3-propoxy-phenyl)-jV-[(2-oxo-l H-pyridin-3-yl)suIfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 72), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(3-isobutoxyphenyl)-Af-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 125), or pharmaceutically acceptable sait thereof; b) A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-(benzenesulfonyl)-5-tert-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; b) A^r-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 7V-(3-aminophenyl)sulfonyl-4-isopropyI-2-[(2,4,6-trimethylphenyl)methyl] isoindoline-1 -carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; b) Λ'(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)

605 cyciopropanecarboxamido)-3-methylpyridin-2-yl)benzoîc acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) Æ-[(2-methoxy-3-pyridyl)sulfonyl]-6-(l -methylcyclopropyl)-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-dîtert-butyl-phenyl)-4-oxo-1 H-quinoIine-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-ammo-2-pyridyl)sulfonyl]-2-(2,2-dimethylpyrrolidin-l-yl)-6-(3-fluoro-5îsobutoxy-phenyl)pyridine-3-carboxamide (Compound 361), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-pheuyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyl)suIfonyI]-6-(6-isopropoxy-3-pyridyl)-2-[-3-phenyl-] piperidyl]pyridine-3-carboxamide (Compound 233), or pharmaceutically acceptable sait thereof; b) Λ/-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (/?)-!-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 238), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-dîtert-butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-1-(2,2-dîfluorobenzo[d][l,3]dioxol-5-yl)-7V

606 (1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indo]-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(3-fluoro-5-isobutoxy-pheny 1)-77-(lH-pyrazol-3-ylsulfony 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 318), or pharmaceutically acceptable sait thereof; b) 7V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^T(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methyIpropan-2-yl)-IH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyl)sulfonyI]-6-ieri-butyl-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 228), or pharmaceutically acceptable sait thereof; b) 7V-(5-hydroxy2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (7?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-M(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-hydroxy-2-methylpropan-2-y])-lH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridy])sulfonyl]-6-(3-fluoro-5-isobutoxy-pheny 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 196), or pharmaceutically acceptable sait thereof; b) 77-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)-7V(l-(2,3-dihydroxypropyI)-6-fluoro-2-(I-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 7V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidm-l -yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 337), or pharmaceutically acceptable sait thereof; b) 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-cafboxamide, or pharmaceutically acceptable sait thereof; and c) (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-N( 1-(2,3-dihydroxypropy l)-6-fluoro-2-(l-hydroxy-2-me thylpropan-2-yl)-l H-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

607

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A4(6-amino-2-pyridyl)sulfbnyI]-6-(3-fluoro-5-isobLitoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-y l]pyridine-3-carboxamide (Compound 368), or pharmaceutically acceptable sait thereof; b) /7-(5-hydroxy-2,4-d.itert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) (//)-1-(2,2difluorobenzo[d][I,3]dioxoI-5-yl)W-(I-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yI)-lH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) /7-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimethyI-2-(2,4,6-trimethylphenoxy)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 182), or pharmaceutically acceptable sait thereof; b) 7V-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-IH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-dinuorobenzo[d][l,3]dioxol-5-yl)W(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yI)-IH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) //-(benzenesulfony!)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1356), or pharmaceutically acceptable sait thereof; b)7/-(5-hydroxy-2,4-diterributyl-phenyI)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) (//)-1-(2,2difluorobenzo[d][1,3]dioxol-5-yl)-//-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a)7V-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methylcyclohexy])-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide (Compound 172), or pharmaceutically acceptable sait thereof; b) A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (//)-1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)W( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)-1 H-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

608

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 2V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridi ne-3-carboxamide (Compound 639), or pharmaceutically acceptable sait thereof; b) jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (Z?)-l-(2,2-difluorobenzo[d][],3]dioxol-5-yl)-N-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(p-tolyl)W-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 300), or pharmaceutically acceptable sait thereof; b) 27-(5-hydroxy-2,4ditert-butyI-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (A)-l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)-jV-(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-hydroxy-2-methy]propan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-[(2-ammo-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidïn-1 -yl]pyridine-3-carboxamide (Compound 1660), or pharmaceutically acceptable sait thereof; b) AA5-hydroxy-2,4-ditert-butyl-pheny!)-4-oxo-lH-quinoline-3carboxamide, or phannaceutically acceptable sait thereof; and c) (7ï)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yI)-A^r-( 1-(2,3 -dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or phannaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 27-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 234), or pharmaceutically acceptable sait thereof; b) jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-2V(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

609

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^L[(2-amino-3-pyridyl)sulfonylJ-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(4S) 2,2,4-tnmethylpyrro]idin-l-yi]pyridine-3-carboxamide (Compound 1975), or pharmaceutically acceptable sait thereof; b) 77-(5-hydroxy-2,4-ditert-butyI-phenyl)-4-oxo-IH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) (Æ)-]-(2,2difluorobenzo[d][I,3]dioxol-5-yl)W-( 1-(2,3-dihydroxypropyl)-6-fluoro-2-( I-hydroxy-2methylpropan-2-y])-lH-indol-5-yI)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-tert-butyl-)V-[[6-(methy]ammo)-2-pyridyl]sulfonyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 262), or pharmaceutically acceptable sait thereof; b) M(5-hydroxy-2,4-ditert-butyl-pheny])-4-oxo-lH-qmnoIine-3-carboxarnide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N(l'(2,3-dihydroxypropyl)-6-fIuoio-2-(I-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A⁷-[(2-amino-3-pyridyl)sulfonyl]-ô-(3-isobuioxypyrazol-l-yI)-2-[(4S)-2,2,4tnmethylpyrrolidin-l~yl]pyridine-3-carboxamide (Compound 2191), or phamtaceutically acceptable sait thereof; b) V-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-yl)-7V-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-] H-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sali thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) M[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-2-fliioro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207), or pharmaceutically acceptable sait thereof; b) A⁷-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)W( 1-(2,3 -dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

610

In another embodiment, the pharmaceutical composition of the présent invention comprises a)77-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 320), or pharmaceutically acceptable sait thereof; b) 77-(5-hydiOxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-77(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) M[(6-amino-2-pyridyI)sulfonyl]-2-(2,3-dimethyl-l-piperidyl)-6-(6-isopropoxy-3pyndyI)pyridine-3-carboxamide (Compound 353), or pharmaceutically acceptable sait thereof; b) 7/-(5-hydroxy-2,4-ditert-buty]-phenyl)-4-oxo-lH-qüinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (jR)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-7V(l-(2,3-dihydroxypropyl)-6-fluoro-2-(]-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamîde, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 77-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171), or pharmaceutically acceptable sait thereof; b) 77-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoIine-3carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2difluorobenzo[d][l,3]dioxol-5-y 1)-77-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2methylpropan-2-yl)-lH-indo]-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 77-[(6-amino-2-pyridyl)sulfonyI]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyI)pyridine-3-carboxamide (Compound 114), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-diteit-butyl-phenyl)-4-oxo- lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (7?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-7V(l-(2,3-dihydroxypropyl)-6-fluoiO-2-(l-hydroxy-2-methy]propan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

611

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-ammo-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-(3-methy]-l piperidyl)pyridine-3-carboxamide (Compound 321), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyI-phenyl)-4-oxo-lH-quinoîine-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-jV(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) /V-[(6-amino-2-pyridyl)sulfony]]-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,710 dihydro-5 H-quinoline-3-carboxamide (Compound 15), or pharmaceutically acceptable sait thereof; b) N-(5-h ydroxy-2,4-ditert-bu tyl-phenyl)-4-oxo-1 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (J?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-M (l-(2,3-dihydroxypropyI)-6-fIuoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-(4-aminothiazol-2-yI)sulfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 265), or pharmaceutically acceptable sait thereof; b) V-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-A^r-(l-(2,3-dihydroxypropyl)-620 fhioro-2-(l-hydroxy-2-methylpropan-2-yl)-IH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) N-[(6-amino-2-pyridyl)sulfonyI]-6-(4-isopropylpheny 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 164), or pharmaceutically acceptable sait 25 thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)~4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (Â)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indoI-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention 30 comprises a) 6-tert-butyl-A^?-(lH-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3612 carboxamide (Compound 214), or pharmaceutically acceptable sait thereof; b) /V-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoIine-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (A^,)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-hydroxy-2-methyIpropan-2-yI)-lH-indol-5-yI)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) ÿV-[(6-amino-2-pyridyl)sulfonyl]-6-(7-fluoro-l ,3-benzodioxol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (fî)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl>M ( 1-(2,3-dihydroxypropyl )-6-fluoro-2-( 1-hydroxy-2-me thylpropan-2-yl)-lH-indol-5 yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) ?7-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 8), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof: and c) (R)-1-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)W( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-methylpropau-2-yl)-1 H-indol-5 yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) N-(3-aminophenyl)sulfonyl-5-feri-butyl-2-[(2,4,6-tiimetliylphenyl)methyl] pyrazole-3-carboxamide (Compound 110), or pharmaceutically acceptable sait thereof; b) N-(5hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-IH-quinolme-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][I,3]dioxol-5-yl)-N-(l-(2,3dihydroxypropyl)-6-fluoro-2-(I-hydroxy-2-methylpropan-2-yI)-lH-mdol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the present invention comprises a) M[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 281), or pharmaceutically acceptable sait thereof; b) M-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline*3-carboxamide, or

613 pharmaceutically acceptable sait thereof; and c) (2ï)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A’'-[(6-amino-2-pyridyI)sulfonyl]-6-(2-fluoro-5-isobutoxy-phenyI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 351), or pharmaceutically acceptable sait thereof; b) jV-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-]-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)-N(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-510 yl)cyclopropanecarboxamîde, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A^r-(3-aminopyrazin-2-yl)sulfonyI-8,8-dimethyl-2-(4-methyI-l-piperidyl)-6,7dihydro-5H-quinoline-3-carboxamide (Compound 197), or pharmaceutically acceptable sait thereof; b) A^f-(5-hydroxy-2,4-ditert-butyI-phenyl)-4-oxo-lH-quinoIine-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difIuorobenzo[d][l,3]dioxoI-5-yl)-N( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2-me thylpropan-2-yl)-1 H-indol-5 yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(4-chloro-3-isobutoxy-phenyl)-N-[(2-oxo-l H-pyridin-3-yl)sulfonyl]-2-(2,4,620 trimethylphenoxy)pyridine-3-carboxamide (Compound 136), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (Æ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)W(1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 2-(2,5-dimethylpyriOlidm-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[(2-oxo-lHpyridin-3-y])sulfonyl]pyridine-3-carboxamide (Compound 307), or pharmaceutically acceptable sait thereof; b) A^r-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qirinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r

614 (l-(2,3-dihydroxYpropyl)-6-flLioro-2-(l-hydiOxy-2-methylpropan-2-yl)-ÎH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(2-fluoro-5-isobutoxy-phenyl)-TV-[(2-oxo-lH-pyridin-3-yl)sulfonyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 279), or pharmaceutically acceptable sait thereof; b) A^,-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-7V(l-(2,3-dihydroxypropyl)-6-fluoro-2-(ï-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(4~chloro-3-propoxy-phenyl)-TV-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 72), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-IH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (JÏ)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-?V(l-(2,3-dihydroxypropy])-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 6-(3-isobutoxyphenyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 125), or phannaceutically acceptable sait thereof; b) A^,-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)*i-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N(l-(2,3-dihydroxypropyl)-6-fluoiO-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) Aⁱ-(benzenesulfonyl)-5-tert-butyl-2-[(2_!4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 45), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (/?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-/V-(l-(2,3-dihydroxypropyl)-6fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

615

In another embodiment, the pharmaceutical composition of the présent invention comprises a) 77-(3-ammophenyl)sulfonyl-4-isopropyl-2-[(2,4,6-trimethylphenyl)methyl] isoindoline-1-carboxamide (Compound 299), or pharmaceutically acceptable sait thereof; b) A(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-3 H-quinoline-3-carboxamide, or pharmaceutically acceptable sait diereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A-(l-(2,3dihydroxypropyl)-6-fiuoro-2-(l-hydroxy-2-methylpropan-2-yI)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A-[(2-methoxy-3-pyridyl)sulfonyl]-6-(l -methylcyclopropyl)-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (Compound 365), or pharmaceutically acceptable sait thereof; b) N- (5 -h ydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxoI-5-yl)-A(1-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or phannaceutically acceptable sait thereof.

In another embodiment, the pharmaceutical composition of the présent invention comprises a) A-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethylpynolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 361 ), or pharmaceutically acceptable sait thereof; b) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide, or pharmaceutically acceptable sait thereof; and c) (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide, or pharmaceutically acceptable sait thereof.

In another embodiment, the présent invention features a pharmaceutical composition comprising a) a compound of formula I; b) a compound selected from 3-(6-(1 -(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyIpyridin-2-yl)benzoic acid, (R)-]-(2,2-difluorobenzo[d][l,3]dioxol-5-yI)-A-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-lH-mdol-5-yl)cyclopropanecarboxamide, or4-(3-(l-(2,2difluorobenzo[d][l,3]dioxoI-5-yI)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) an additional CFTR corrector.

616

In another embodiment, the présent invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) a compound selected from 3-(6-(1-(2,2difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methyipyridin-2-yI)benzoic acid, (Æ)-l-(2,2-dif]uorobenzo[d][l,3]dioxol-5-yl)-N-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(lhydroxy-2-methylpropan-2-yl)-]H-indol-5-yl)cyclopropanecarboxamide, or 4-(3-(1-(2,2difluorobenzo[d][I,3]dioxol-5-yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) an additional CFTR corrector.

In another embodiment, the above recited pharmaceutical composition contain a pharmaceutically acceptable prodrug of the compound of the présent invention.

In another embodiment, the additional CFTR corrector from above is (N-(2-(5-chloro2-methoxy-phenylamino)-4’-methyl-[4,5’]bithiazolyl-2’-yl)-benzamide (corr-4a). In another embodiment, the additional CFTR corrector is a compound disclosed in published International Patent Application WO2014081820, incorporated herein in its entirety by reference.

In another embodiment, the présent invention features a pharmaceutical composition comprising a) a compound of formula I; b) N-(5-hydroxy-2,4-ditert-butyl-phenyI)-4-oxo-lHqu in oline-3-carboxamide or N-(4-(7-azabicycIo[2.21]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4oxo-5-(trifiuoromethyj)-1,4-dihydroquinoiîne-3-carboxamide; and a CFTR corrector selected from (N-(2-(5-chioro-2-methoxy-phenylamino)-4’-methyl-[4,5’]bithiazolyl-2’-yI)-benzamide (corr-4a), a compound disclosed in published International Patent Application WO2014081820, incorporated herein in its entirety by reference, a compound disclosed in Published International Patent Application No. WO2014086687, or a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; or Published International Patent Application No; WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO20J3038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference.

In another embodiment, the présent invention features a pharmaceutical composition comprising a) a compound of formula I; b) a compound selected from certain flavones and isoflavones, such as genistein, which are capable of stimulating CFTR-mediated chloride transport in épithélial tissues in a cyclic-AMP independent manner (See U.S. Pat. No. 6,329,422, incorporated herein by reference in its entirety); phenylglycine-01 (2-[(2-lH-indol-3-yl-acetyl)

617 methylamino]-N-(4-isopropylphenyI)-2-phenylacetamide); felodipine (Ethyl methyl 4-(2,3dichlorophenyl)-2,6-dimethyl-l,4-dihydro-3,5-pyridinedicarboxylate); sulfonamide SF-01 (6(ethylphenylsulfamoyl)-4-oxo-l,4-dihydroquinoline-3-carboxylic acid cycloheptylamide); and UCCF-152 (3-[2-(benzyloxy)phenyl]-5-(chloromethyl)isoxazole); and c) a CFTR corrector selected from (N-(2-(5-chloro-2-methoxy-phenylamino)-4’-methyl-[4,5’]bithiazolyl-2’-yI)benzamide (corr-4a), a compound disclosed in published International Patent Application WO2014081820, incorporated herein in its entirety by référencé, or a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; or Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378,

WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference.

In another embodiment, the présent invention features the pharmaceutical composition described above comprising a) a compound of formula I; b) a compound selected from 3-(6-(115 (2,2-difluorobenzo[d][I,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, (R)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l-(2,3-dihydroxypropyl)-6-fluoro-2-(l hydroxy-2-methylpropan-2-yl)-lH-indol-5-yl)cyclopropanecarboxamide, or 4-(3-(1-(2,2difluorobenzo[d][l ,3]dioxol-5-yl)cycIopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) an additional CFTR corrector, such as those, for example, specifically listed above; and further comprising d) a CFTR potentiator.

In another embodiment, the CFTR potentiator from above is A-(5-bydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoline~3-carboxamide or/7-(4-(7-azabicyclo [2.21 ]heptan-7-y l)-2(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-l,4-dihydroquinoline-3-carboxamide. In another embodiment, the CFTR potentiator from above is /V-(5-hydroxy-2,4-ditert-butyl-phenyl)25 4-oxo-l H-quinoline-3-carboxamide.

In another embodiment, the CFTR potentiator from above is selected from certain flavones and isoflavones, such as genistein, which are capable of stimulating CFTR-mediated chloride transport in épithélial tissues in a cyclic-AMP independent manner (See U.S. Pat. No. 6,329,422, incorporated herein b y reference in its entirety); phenylglycine-01 (2-[(2-lH~indol-330 yl-acetyl)-methylamino]-A-(4-isopropylphenyl)-2-phenylacetamide); felodipine (Ethyl methyl 4618 (2,3-dichloiOphenyl)-2,6-dimeîhyM,4-djhydro-3_:5-pyridinedicarboxylate); suifonamide SF-01 (6-(ethylphenylsulfamoyl)-4-oxo-l ,4-dihydroquinoline-3-carboxyIic acid cycloheptyiamide); and UCCF-152 (3-[2-(benzyloxy)phenyl]-5-(chloromethyl)rsoxazole).

In one embodiment, the additional therapeutic agent is selected from a compound 5 disclosed in Published Interanation al Patent Application No. WO2014078842 or

W02O12158885, or in United States Published Application No. US20140073667; ail published international patent applications and published US patent application are hereby incorporated in their entirety by référencé.

In one embodiment, the additional therapeutic agent is selected from a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880; WO2012154888; WO2012154967; WO2013112651 ; WO2013112699; or WO2012078902; ail published international patent applications are hereby incorporated in their entirety by référencé.

In one embodiment, the additional therapeutic agent is selected from a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and 15 Published International Patent Application No: WO2011113894, WO2013038373,

WO2013038378, WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by référencé.

In one embodiment, the additional therapeutic agent is slected from a compound 20 disclosed in WO2014210159 or WO20141522I3; ail published international patent applications are hereby incorporated in their entirety by référencé,

In one embodiment, the additional therapeutic agent is selected from a compound disclosed in Published International Patent Application No.: WO2014210159 or WO2014152213; ail published international patent applications are hereby incorporated in their 25 entirety b y référencé.

In one embodiment, the additional therapeutic agent is selected from a compound disclosed in Published International Patent Application No.: WO2015003083, WO2015007517, WO2015007519, or WO2015007516; ail published international patent applications are hereby incorporated in their entirety by référencé.

619

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound offonnula I; b) 3-(6-(1-(2,2-dîfluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO20I3038373, WO2013038378, WO201303838I, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference.

In another embodiment, the invention features a phannaceutical composition comprising a) a compound offonnula I; b) (7ï)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-jV-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l -hydroxy-2-methylpropan-2-yl)-lH-indol-5y])cyclopropanecarboxamide; and c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety b y reference.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound offonnula I; b)4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO20I3038386, or WO20I3038390; ali US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula 1; b) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published

620 international patent applications are hereby incorporated in their entirety by reference; and c) N(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3 -carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(1 -(2,2-difluorobenzo[d][l,3]dioxol-5-yI) cyclopropanecarboxamido)-3-methy]pyridin-2-yl)benzoic acid; c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety b y reference; and d) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) (7?)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO201 ! 113894, WO20I3038373, WO2013038378, WO201303838I, WO20I3038386, or WO201303 8390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference; and d) A-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; c) a compound disclosed in US Patent No. 8,247,436 or 8,476,269; US Patent Application No. 13/923,349; and Published International Patent Application No: WO2011113894, WO2013038373, WO2013038378, WO2013038381, WO2013038386, or WO2013038390; ail US patents, US patent applications, and published international patent applications are hereby incorporated in their entirety by reference; and d) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1 H-qu incline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) a compound disclosed in

621

Published International Patent Application No: WO2012078909; WO2012154880;

WO2012154888; WO2012154967; WO2013112651 ; WO2013112699; or WO2012078902; ail published international patent applications are hereby incorporated in their entirety by référencé.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) (/?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-N-(l(2,3-dihydroxypropyI)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880; WO2012154888; WO2012154967; WO2013112651; WO2013112699; or WO2012078902; ail published international paient applications are hereby incorporated in their entirety by référencé.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(1-(2,2-diHuorobenzo[d][l,3]dioxoI-5yl)cyclopropanecarboxamido) isoqumolm4-yl)benzoic acid; and c) a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880;

WO2012154888; WO2012154967; WO2013112651 ; WO2013112699; or WO2012078902; al! published international patent applications are hereby incorporated in their entirety by référencé.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; c) a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880; WO2012154888; WO2012154967; WO2013112651 ; WO2013112699; or WO2012078902; ail published international patent applications are hereby incorporated in their entirety by référencé; and d) M(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) (Z?)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methy]propan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; c) a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880; WO2012154888; WO2012154967; WO2013112651; WO2013112699; or WO2012078902; ail published international patent

622 applications are hereby incorporated in their entirety by référencé; and d) N-(5-hydroxy-2,4ditert-butyl-phenyl)-4-oxo-l H-quinoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(1-(2,2-difIuorobenzo[d][l,3]dioxol-55 yl)cyclopropanecarboxamido) isoquinolin-1 -yl)benzoic acid; c) a compound disclosed in Published International Patent Application No: WO2012078909; WO2012154880; WO20I2I54888; WO2012154967; WO2013112651; WO2013112699; or WO2012078902; al! published international patent applications are hereby incorporated in their entirety by reference; and d)N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide.

In another embodiment, the additional therapeutic agent is a compound disclosed in

Published International Patent Application No. WO2014099673 hereby incorporated in its entirety by reference, including but not limited to the foliowing compounds:

P-l;

P-2;

623

P-5;

624

0 ^Η=^Ν ζΎΊΠ NH OH OH OH ( OH OH _ho<^A^ohho<Ç^oh HO^ P-6; OH OH OH OH OH L ^NH o P-7; OH OH OH OH OH L ^NH ° 5 P-8;

NH O N N if γτ H H H J H^N^N^NH^ NH 0 -^/Zn^Vy⁰' H H H 1 H₂N''^KN^?TIH2 NH 0 -γΛγ H₂N^N^NH₂

625

OH OH OH OH r\V^N ΥΛ OH OH OH L OH OH OH Έ^Η H₂N s A/¹ ο P-9; OH OH OH OH ^N OH ÔH ÔH L OH OH OH ^NH ^>1 ° P-10; OH OH OH OH OH L ^kNH 0 5 P-l 1;

NH 0 N N χ H H J| 1 H₂N^N^NH₂ NH O ^{H H} II J H₂N N NH₂ NH 0 -N'^N'S'V^{01 H H} II J H₂N N NH₂

626

P-12;

P-13;

P-14;

627

P-16.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of fonnula I; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a phannaceutical composition comprising a) a compound of formula I; b) (Æ)-l-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-7V-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; b) (Λ)-1 - (2,2-difluorobenzo[d][1,3 ]dioxol-5-y 1)-77-( 1-(2,3

628 dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) 4-(3-(l-(2,2-difluorobenzo[d][l,3]dioxoI-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; and c) a compound selected from P-l to P-16 disclosed above.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxoT5-yl) cydopropanecarboxamido)-3-methyl pyridin-2-yl)benzoic acid; c) a compound selected from P-l to P-16 disclosed above; and d) N-fS-hydroxy-lX-ditert-butyl-phenylI-d-oxo-lH-quinoline-Scarboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound ofTable 1 ; b) 3-(6-(1-(2,2-difluorobenzo[d][l,3]droxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; c) a compound selected from P-l to P-16 disclosed above; and d) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-quinoline-3carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) (/î)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-A^r-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methyIpropan-2-yl)-lH-mdol-5yl)cyclopropanecarboxamide; c) a compound selected from P-l to P-16 disclosed above; and d) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lH-qumoline-3-carboxamide.

In another embodiment, the invention features a pharmaceutical composition comprising a) a compound of formula I; b)4-(3-(1-(2,2-difluorobenzo[d][l,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-l-yl)benzoic acid; c) a compound selected from P-l to

629

P-16 disclosed above; and d) N-(5-hydroxy-2,4-ditert-buty]-phenyl)-4-oxo-lH-quinoline-3carboxamide.

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of formula I; and b) a compound disclosed in United States Patent No. 8,865,902. In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; and b) a compound disclosed in United States Patent No. 8,865,902. In another embodiment, the compound disclosed in United States Patent No.

8,865,902 has the following structure:

wherein the compound disclosed in United States Patent No. 8,865,902 is any one of the compounds of the following table:

X¹

X²

X⁴

X⁵

X¹

Y1

Y²

Y³

γ4

Y⁵

γ(5

D

1)

D

cd₃

CD₃

CD,

cd₃

CD,

H

D

H

cd₃

CD,

cd₃

CD,

cd₃

H

D

H

CD,

cd.

CD,

CH,

ch.

H

D

H

CH,

ch₃

CH,

cd₃

CD,

H

D

H

CH,

H

CD,

H

cd.

CD,

CH,

II

H

II

CIL

CH,

CIL·,

CD,

CD.,

CD,

In another embodiment, the compound disclosed in United States Patent No. 8,865,902 is any one of the compounds of the following table:

630

X¹

X²

χ³

X⁴

X⁵

X⁶

γ7

Υ¹

Y²

γ3

γ4

Y⁶

π

Η

D

CD,

cd.

CD,

ΤΙ

II

D

19

CD,

cd.

CD,

cd₃

CD,

Η

II

Η

D

CD,

cd.

CD₃

ch.

CH,

Η

Ι-Ι

II

D

CH₃

CH,

ch₃

CD,

Η

II

D

CH,

ch₃

CH,

Η

II

Η

D

cd₃

CD,

ch₃

CH₃

Η

D

ch₅

CH,

ch.

cd₃

CD,

D

cd₃

CD,

cd₃

ch₃

CH,

D

»

D

ch₃

CH,

cd₃

CD,

D

Η

CD,

CH,

ch₃

CH,

D

Ι-Ι

II

CTI,

CH,

CD,

Η

II

ΤΙ

II

Ι-Ι

Η

D

CD,

cd.

CD,

II

Ι-Ι

II

Η

Ι-Ι

D

cd.

CD,

CH,

CH₃

Η

II

Η

D

ch₃

CH,

CII₃

CD,

cd₃

Η

D

Η

CD,

cd₃

CD,

cd₃

Η

II

Η

D

Η

cd₃

CD,

CH,

ch₃

Η

II

Η

D

Η

ch₃

CD,

cd₃

8,865,902

In another embodiment, the compound disclosed in United States Patent No. is any one of the compounds of the following table:

X¹

X“

X^

X⁴

X⁵

X^e

X⁷

Y^L

Y²

Y³

Y⁴

Y⁵

Y⁶

D

H

cd₃

CD,

CD₃

cd₃

CD,

D

ch₃

CH ₃

CH,

D

H

ch₃

CH,

D

H

D

CD,

D

H

CD,

D

H

D

CH,

^CH 3

CH,

D

H

CH,

CH 3

CH,

H

D

CH,

CH₃

CH,

631

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of formula I; and b) the compound:

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of Table 1 ; and b) the compound:

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) 3-(6-(1-(2,2-dinuorobenzo[d][J,3jdioxoI-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid; and c) the compound:.

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) 3-(6-( 1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yI)benzoic acid; and c) the compound:

632

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound selected from Compound 233, Compound 238, Compound 318, Compound 228, Compound 196, Compound 337, Compound 368, Compound 182, Compound 5 1356, Compound ] 72, Compound 639, Compound 300, Compound 1660, Compound 234,

Compound 1975, Compound 262, Compound 2191, Compound 207, Compound 320, Compound 353, Compound 171, Compound 114, Compound 321, Compound 15, Compound 265, Compound 164, Compound 214, Compound 345, Compound 8, Compound 110, Compound 281, Compound 351, Compound 197, Compound 136, Compound 307, Compound 279, Compound

72, Compound 125, Compound 45, Compound 299, Compound 365, or Compound 361; b) 3-(6(l-(2,2-difluorobenzo[d][l ,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2yl)benzoic acid; and c) the compound:

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of formula I; b) CR)-l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)JV-(l(2,3-dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl)cyclopropanecarboxamide; and c) the compound:

633

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound of Table 1; b) (Æ)-I-(2,2-difluorobenzo[d][] ,3]dioxoh5-yl)-V-(l-(2,3dihydiOxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-55 yl)cyclopropanecarboxamide; and c) the compound:

In some embodiments, the invention features a pharmaceutical composition comprising a) a compound selected from Compound 233, Compound 238, Compound 318, Compound 228, Compound 196, Compound 337, Compound 368, Compound 182, Compound 10 1356, Compound 172, Compound 639, Compound 300, Compound 1660, Compound 234,

Compound 1975, Compound 262, Compound 2191, Compound 207, Compound 320, Compound 353, Compound 171, Compound 114, Compound 321, Compound 15, Compound 265, Compound 164, Compound 214, Compound 345, Compound 8, Compound 110, Compound 281, Compound 351, Compound 197, Compound 136, Compound 307, Compound 279, Compound 15 72, Compound 125, Compound 45, Compound 299, Compound 365, or Compound 361; b) (Æ)l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-77-(I-(2,3-dihydroxypropyI)-6-fluoro-2-(l-hydroxy-2methyIpropan-2-yl)-] H-indol-5-yl)cyclopropanecarboxamide; and c) the compound;

634

H

In one embodiment, any of the below therapeutic agents can be used alone with a compound of formula 1 or Id, or in combination with any of the above described pharmaceutical compositions, or as a component in any of the above described pharmaceutical compositions.

In one embodiment, the additional therapeutic agent is selected from a mucolytic agent, bronchodialator, an antibiotic, an anti-infective agent, a CFTR modulator, or an antiinflammatory agent.

In one embodiment, any of the below therapeutic agents, which predominantly treat the symptoms a CFTR mediated disease, such as cystic fibrosis, rather than its underlying cause, can be used alone with a compound of formula L or in combination with any of the above described pharmaceutical compositions, or as a component in any of the above described pharmaceutical compositions.

In one embodiment, the additional therapeutic agent is an antibiotic. Exemplary antibiotics useful herein include tobramycin, including tobramycin inhaled powder (TIP), azithromycin, cayston, aztreonam, including the aerosolized form of aztreonam, amikacin, including liposomal formulations thereof, ciprofloxacin, including formulations thereof suitable for administration by inhalation, levoflaxacin, including aerosolized formulations thereof, and combinations of two antibiotics, e,g., fosfomycin and tobramycin.

In another embodiment, the additional therapeutic agent is a mucolyte. Exemplary mucolytes useful herein includes Pulmozyme®.

In another embodiment, the additional therapeutic agent is a bronchodialator, Exemplary bronchodiakors include albuterol, metaprotenerol sulfate, pirbuterol acetate, salmeterol, or tetrabuline sulfate.

635

In another embodiment, the additional therapeutic agent is effective in restoring lung airway surface liquid. Such agents improve the movement of sait in and ont of cells, allowing mucus in the lung airway to be more hydrated and, therefore, cleared more easily. Exemplary such agents include hypertonie saline, denufosol tetrasodium ([[(3S,5R)-5-(4-amino-2oxopyrimidin-l-yl)-34rydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5(2,4-dioxopyrimidin-l-yl)-3, 4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyhydroxyphosphoryl] hydrogen phosphate), or bronchitol (inhaled formulation of mannitol).

In another embodiment, the additional therapeutic agent is an anti-inflammatory agent, i.e., an agent that can reduce the inflammation in the lungs. Exemplary such agents useful herein include ibuprofen, docosahexanoic acid (DHA), sildenafîl, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.

In another embodiment, the additional therapeutic agent is a compound that augments or induces CFTR activity other than a compound of formula I, Exemplary such agents include ataluren (“PTC124®”; 3-[5-(2-fluorophenyl)-l,2,4-oxadiazol-3-yl]benzoic acid), sinapultide, lancovutide, depelestat (a human recombinant neutrophil elastase inhibitor), and cobiprostone (7{(2R, 4aR, 5R, 7aR)-2-[(3S)-l,l-difluoro-3-methylpentyl]-2-hydroxy-6oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid).

In another embodiment, the additional therapeutic agent is a nutrition al agent. Exemplary nutritional agents include pancrelipase (pancreating enzyme replacement), including Pancrease®, Pancreacarb®, Ultrase®, or Creon®, Liprotomase® (formerly Trizytek®), Aquadeks®, or glutathione inhalation. In one embodiment, the additional nutritional agent is pancrelipase.

In another embodiment, the additional therapeutic agent is a compound selected from gentamicin, curcumin, cyclophosphamide, 4-phenylbutyrate, miglustat, felodipine, nimodipine, Philoxin B, geniestein, Apigenin, cAMP/cGMP augmenters or inducers such as rolipram, sildenafîl, milrinone, tadalafil, amrinone, isoproterenol, albuterol, and almeterol, deoxyspergualin, HSP 90 inhibitors, HSP 70 inhibitors, proteosome inhibitors such as epoxomicin, lactacystin, etc.

In other embodiments, the additional therapeutic agent is a compound disclosed in WO 2004028480, WO 2004110352, WO 2005094374, WO 2005120497, orWO 2006101740,

636 incorporated herein in their entirety by reference. In another embodiment, the additional agent is a benzo[c]qumolizmium dérivative that exhibits CFTR inducing or augmenting activity or a benzopyran dérivative that exhibits CFTR inducing or augmenting activity. In anoHier embodiment, the additional agent is a compound disclosed in U.S. Pat. No. 7,202,262, U.S. Pat. No. 6,992,096, US20060148864, US2OO6O148863, US20060035943, US20050164973, WO2006110483, WO2006044456, WO2006044682, WO2006044505, WO2006044503, WO2006044502, or WO2004091502, incorporated herein in their entirety by reference. In another embodiment, the additional agent is a compound disclosed in WO2004080972, WO2004111014, WO2005035514, WO2005049018, WO2006099256, WO2006127588, or WO2007O44560, incorporated herein in their entirety by reference.

In another embodiment, the additional therapeutic agent is a compound disclosed in WO2014180562 or US20140274933, incorporated herein in their entirety by reference.

In another embodiment, the additional therapeutic agent is selected from the categories ENaC inhibitors, betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4antagonists, EGFR-inhibitors, dopamine agonîsts, H1-antihistamines, PAF-anlagonists, MAPkinase inhibitors, MPR4-Inhibitors, iNOS-Inhibitors, or SYK-Inhibitors, or double or triple

W 1 LJCZ 11J UWjllJ LJ IV J- W 1

In another embodiment, the additional therapeutic agent is an ENaC inhibitor selected from 3-amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridme-2-carboxylic acid (3,3,3-trifluoro2-hydroxy -2-methyl-propyI)-amide;

5-ammo-6'-methyl-3-trifluoromethyl-[2,3]bipyridinyF6-carboxyIic acid (3,3,3trifluoro-2-hydroxy -2-methyl-propyl)-amide;

3-amino-6-cycIopropyl-N-(3,3,3-trifluoro-2-hydroxy-2-methyIpropyl)-5(trifluoromethyl)picolinamide; 3-amino-6-methoxy-A^r-(3,3,3-trifluoro-2-hydroxy-2(trifluoromethyl)propyl)-5-(trifluoro methyl)picolinamide;

3-amino-6-(4-fluoro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3trifluoro-2-hydroxy -2-methyl-propyl)-amide;

3-amino-6-methoxy-5-tri fluoro methyl-pyridine-2-carboxy lie acid ((S-3,3,3-tri fluoro-2hydroxy-2-methyl-propyl)-amide;

637

3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxyIic acid ((R)-3,3,3-trifluoro2-hydroxy-2-methyl-propyl)-amide;

3-amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide;

3-amino-6-(2,4-dichloro-phenyl)-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)3,3,3-trifluoro -2-hydroxy-2-methyI-propyl)-amide;

3-amino-6-(4-fluoFO-phenyI)-5-trifluoromethyl·pyridine’2-carboxylic acid (2hydroxy-2-methyl-propyl)-amide;

3-amÏDO-5,6-bis-trifluoromethyl-pyridine-2-cai'boxylic acid ((S)-3,3,3-trifluoro-2hydroxy-2-methyl-propyl)-amide;

3-amino-5,6-bis-trifluoromethy]-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2bydroxy-2-methyl-propyl)-amide;

(S)-3-amino-6-ethoxyW-(3,3,3-trinuoro-2-hydroxy-2-niethylpropyl)-5-(trifluoro methyl)picolînamide;

3-amino-6-methoxy-5-trifIuoromethyl-pyridme-2-carboxyIic acid ((S)-3,3,3-trifluoro 2-hydroxy-2-methyI-propyl)-amide;

3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro 2-hydroxy-2-methyl-propyl)-amide;

3-amino-6-(4-fluoro-phenyl)-5-trifluoromethyI-pyridine-2-carboxylic acid (3,3,3trifluoro-2-hydroxy-2-methyl-piOpy])-amide;

3-amino-5,6-bis-trifluoromethyl-pyridine-2-carboxyIic acid ((S )-3,3,3-tri fl uoro -2hydroxy-2-methyl-propyl)-amide;

3-amino-5,6-bis-trifluoromethyl-pyridine-2-caiboxylic acid ((R)-3,3,3-trifluoro -2hydroxy-2-methyl-piOpyl)-amide, or pharmaceutically acceptable salts thereof.

Jn another embodiment, the additional agent is a compound disclosed in United States Patent No. 8,247,436 and International PCT Publication WO 2011 113894, incorporated herein in theirentirety by reference.

638

In another embodiment, the additionai therapeutic agent is a betamimetic selected from Albuterole, Arformoterole, Bambuterole, Bitolteroie, Broxaterole, Carbuterole, Clenbuterole, Fenoterole, Formoterole, Hexoprenaline, Ibuterole, Isoetharine, Isoprénaline, Levosalbutamole, Mabuterole, Mehiadrine, Metaproterenole, Milveterol, Orciprenaline, Pirbuterole, Procaterole, Reproterole, Rimiterole, Ritodrine, Salmefamole, Salmeterole, Soterenole, Sulphonterole, Terbutaline, Tiaramide, Tolubuterole, Zinterole, Nolomirole, and l-(2-chloro-4-hydroxyphenyl)-t-butylaminoethanole;

(-)-2~[7(S)-[2(R)’Hydroxy-2-(4-hydroxyphenyl)-ethylamino]-5,6,7,8-tetrahydro-2naphthyloxy]-N77-dimetbylacetamide hydrochloride monohydrate;

3-(4’{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylammo]-hexyloxy Rbutyl)-benzyl-sulfonamide;

5-[2-(5,6-Diethyl-indan-2-ylamino)-l-hydroxy-ethyl]-8-hydroxy-lH-qumoline-2-one;

-Hydroxy-7 - [2 - {[2- {[3 -(2-phenylethoxy)propyi] sulphonyl} ethyl] -amin o} ethy-I] 2(3H)-benzothiazolone;

-(2-Fluoro-4-hydroxyphenyl)-2-[4-(l -benzimidazolyI)-2-methyl-2-butylaminojethanol ;

l-[3-(4-Methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(l-benzimidazolyl)-2-methyl-2-butylamino]ethanol;

l-[2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin*8-yl]-2-[3-(4-N//-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol;

l-[2H-5-hydroxy-3-oxo-4H'l,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl2-propylamino]ethanoI;

l-[2H-5-hydroxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2melhyl-2-propylamino]ethanol;

l-[2H-5-hydiOxy-3-oxo-4H-l,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-l,2,4triazol-3-yl]-2-methyl-2-butylamino} éthanol;

5-Hydroxy-8-(l·hydroxy-2-isoproρylammobutyl)-2H-l,4-benzoxazin-3-(4H)-one;

639

-(4-Amino-3-chloro-5-trifluormethyIphenyl)-2-tett.-buiylamino)etl]anol;

6-Hydroxy-8-{ l-hydroxy-2-[2-(4-methoxy-phenyl)-! ,1 -dimethyl-ethylamino]-ethyl} 4H-benzo[l ,4]oxazin-3-one;

6-Hydroxy-8-{ l-hydroxy-2-[2-(4-phenoxy-acetic acid ethylester)-l,l-dimethylethylamino]-ethyl} -4H-benzo[ 1,4]oxazin-3-one;

6-Hydroxy-8-{ l-hydroxy-2-[2-(4-phenoxy-acetic acid)-],l-dimethy]-ethylamino]ethyl) -4H-benzo[I,4]oxazin-3-one;

8-{ 2-[l ,l-Diniethyl-2-(2,4,6-trimethylphenyl)-ethylamino]-l-hydroxy-ethy] ) -6hydroxy-4H-benzo[I,4]oxazin-3-one;

6-Hydroxy-8-{ 1 -h ydroxy-2-[2-(4-hydroxy-phenyl)-1,1 -dimethyl-ethylamino]-e-thyl }4H-benzo[l ,4]oxazin-3-one;

6-Hydroxy-8-{ l-hydroxy-2-[2-(4-isopropyl-phenyI)-l,ldimethyl-ethylamino]-ethyl)4H-benzo[l ,4]oxazin-3-one;

8-{2-[2-(4-Ethyl-phenyl)-l,l-dimethyl-ethylamino]-l-hydroxy-ethyl}-6-hydroxy-4Hbenzo[l ,4]oxazin-3-one;

8-{2-[2-(4-Ethoxy-pheny])-1,I-dimethyl-ethylamino]-l-hydroxy-ethyl}-6-hydroxy4H-benzo[l ,4]oxazin-3-one;

4-(4-{2-[2-Hydroxy-2-(6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-8-yl)ethylamino]-2-methyl-propy])-phenoxy)-butyric acid;

8-{2-[2-(3,4-Difluor-phenyl)-J,l-dimethyl-e*yJanüno]-I-hydroxy-elhyl}-6-hydroxy4H-benzo[l ,4]oxazin-3-one;

- (4-Ethox y-carbon yl amino -3-cyano -5 -fluorophenyl)-2-(tert-bu tyl amino )ethanol;

A^r-[2-l-Iydroxy-5-(] -hydroxy-2-{2-[4-(2-hydiOxy-2-phenyl-ethylamino)-phenyl]ethylaniino}-ethyl)-phenyl]-fbrmamide;

8-Hydroxy-5-(l-hydroxy-2-{2-[4-(6-methoxy-biphenyl-3-ylamino)-phenyl]-ethylamino} -ethyl)-1 H-quinolin-2-one;

640

8-HydiOxy-5-[l-hydroxy-2-(6-phenethylamÎno-hexylamÎno)-ethyl]-lH-quinolin-2one;

5-[2-(2-{4-[4-(2-Amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-lhydroxy-ethyl]-8-hydroxy-lH-quinolin-2-one;

[3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyI-phenyl)-ethylamÎno]hexyloxy}-butyl)-5 -methyl-phenyl]-urea;

4-(2-{6-[2-(2,6-Dichloro-benzyloxy)-ethoxy]-hexyIamîno}-l-hydroxy-ethyl)-2hydroxymethyl-phenole;

3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamÎno]-hexyloxy}-butyl)-benzenesulfonamide;

3-(3 - {7 - [2-Hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethylamino]-heptyloxy}-propyl)-benzenesulfonamide;

4-(2-{6-[4-(3-Cyclopentanesu]fonyl-phenyl)-buÎoxy]-hexylaniino}-l-hydroxy-ethyl)2-hydroxymethyl-phenole;

N-Ad aman tan-2-y 1-2- (3 - {2- [2-hydroxy-2- (4-h ydroxy-3 -hydroxymethyl-pheny I)ethylamino]-propyl}-pbenyl)-acetamide;

(R,S)-4-(2-{ [6-(2,2-Difluoro-4-phenylbutoxy)hexyI]amino}-l -hydroxy-ethyl)-2(hydroxymethyl)phenol;

(R,S)-4-(2-{ [6-(2,2-Difluoro-2-phenylethoxy)hexyI]amino}-l-hydroxy-ethy])-2(hydroxymethyl)phenol;

(R,S)-4-(2-{ [4,4-Difluoro-6-(4-phenylbutoxy)hexyl]ammo}-l-hydroxy-ethyl)-2(hydroxy-methyl)phenol ;

(R,S)-4-(2-{ [6-(4,4-Difluoro-4-phenylbutoxy)hexyl]amino}-l-bydroxy-ethyl)-2(hydroxymethyl)phenol;

(R,S)-5-(2-{ [6-(2,2-Difluoro-2-phenylethoxy)hexyl]amÎno}-l-hydroxy-ethyl)-8hydroxyquinolin-2(lH)-one;

641 (R,S)-[2-([ 6-[2,2-Dif]noro-2-(3-methylpheny])ethoxy]hexyl} amino)-l -hydroxyethylj2-(hydroxymethyl)phenol;

4-(l R)-2-{ [6-(2,2-Dinuoro-2-phenylethoxy)hexyl]amino}-l -hydroxyethyl)-2(hydroxymethyl)phenol;

(R,S)-2-(Hydroxymethyl)-4-(l -h ydroxy-2-{ [4,4,515-tetrafluoro -6-(3-phenylpropoxy)hexyl]amino}ethyl)phenol;

(R,S)-[5-(2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxy-ethy]-)-2hydroxy-phenyl]formamîde;

(R,S)-4-[2-((6-[2-(3-Bromophenyl)-2,2-diflLioroethoxy]hexyl}amino)-l-hydroxyethyl]-2-(hydroxymethyl)phenol;

(R,S)-77-[3-(l,l-Difluoro-2-{[6-({2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]-ethyl}ammo)hexyl]oxy]ethyljphenyl]urea;

3-[3-(l,l-difluoro-2-{ [6-({2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino )hexyl] oxy} eth y 1 )pheny 1] imid azolidine-2,4 -dione ;

(R,S)fo-[2-({6-[2,2-difluoro-2-(3-methoxyphenyI)ethoxy]hexyl}amino)-l -hydroxyethyl]-2-(hydroxymethyl)phenol;

5-((1 R)-2-{ [6-(2,2-difluoro-2-phen ylethoxy)hexyl]amino}-1-hydro xyethyl)-8hydroxyqvimolin-2(lH)-one;

4-((1 R)-2-[ [4,4-Difluoro-6-(4-phenylbutoxy)hexyl]amino}-I -hydroxy-ethyl)-2(hydroxymethyl)phenol;

(R,S)M-(2-{ [6-(3,3-Difluoro-3-phenylpropoxy)hexyl]armno}-l-hydroxy-ethyl-)-2(hydroxymethyl)phenol;

(R,S)-(2-{ [6-(2,2-Difluoro-2-phenylethoxy)-4,4-difluorohexyl]amino}-lhydroxyethyl)-2-(hydroxymethyl)phenol;

(R,S)-4-(2-{ [6-(2,2-difluoro-3-phenylpropoxy)hexyl]amino}-l-hydroxyethyl)-2(hydroxy-methyl)phenol;

642

3-[2-(3-Chloro-phenyl)-ethoxy]-A^r-(2-diethylamino-ethyl)-A^r-{2-[2-(4-hydroxy-2-oxo2,3-dihydro-benzothiazol-7-yl)-ethyIamino]-ethyl}-propionamide;

jV-(2-Diethylamino-ethyl)-M(2-[2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)ethylamino]-ethyl}-3-(2-naphthalen-l-yI-ethoxy)-propionamide;

7-[2-(2-{3-[2-(2-Chloro-phenyl)-ethy]amino]-propylsu]fany!]-ethylamino)-l-hydroxyethyl]-4-hydroxy-3H-benzothiazol-2-one; or

7-[(lR)-2-(2-{3-[2-(2-Chloro-phenyl)-ethylammo]-propylsulfanyl}-ethyIamino)-l~ hydroxyethyl]-4-hydroxy-3H-benzothiazol-2-one; optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-ptoluenesulfonate.

In one embodiment, the additional therapeutic agent is an anticholinergic selected from Tiotropium salts, preferably the bromide sait, Oxitropium salts, preferably the bromide sait, Flutropium salts, preferably the bromide sait, Ipratropium salts, preferably the bromide sait, Aclidinium salts, preferably the bromide sait, Glycopyrronium salts, preferably the bromide sait, Trospium salts, preferably the chloride sait, Tolterodin. From the above mentioned salts the pharmaceutically active part is the cation, possible anions are chloride, bromide, iodide, sulfate, phosphate, methansulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate. Further examples of preferred anticholinergics are selected from among

2,2-Diphenylpropionic acid tropenole ester-methobromide;

2,2-Diphenylpropionic acid scopine ester-methobromide;

2-Fluor-2,2'Diphenylacetic acid scopine ester-methobromide;

2-Fluor-2,2-Diphenylacetic acid tropenole ester-methobromide;

3,3^,,4,4^,-Tetralluorbenzil acid tropenole ester-methobromide;

3,3',4,4'-Tetrafluorbenzil acid scopine ester-methobromide;

643

4,4'-Difluorbenzil acid tropenole ester-methobromide;

4,4'-Difluorbenzil acid scopine ester-methobromide;

3,3'-Difluorbenzil acid tropenole ester-methobromide;

3,3'-Difluorbenzil acid scopine ester-methobromide;

9-Hydroxy-fluorene-9-carbon acid tropenole ester-methobromide;

9-Fluor-fluorene-9-carbon acid tropenole ester-methobromide;

9-Hydroxy-fluorene-9-carbon acid scopine ester-methobromide;

9-Fluor-fluorene-9-carbon acid scopine ester methobromide;

9-Methyl-fluorene-9-carbon acid tropenole estermethobromide;

9-Methyl-fluorene-9-carbon acid scopine estermethobromide;

Benzil acid cyclopropyl tropine ester-methobromide;

2,2-Diphenylpropionic acid cyclopropyl tropine ester-methobromide;

9-Hydroxy-xanthene-9-carbon acid cyclopropyl tropine ester-methobromide;

9-Methyl-fluorene-9-carbon acid cyclopropyl tropine ester-methobromide;

9-Methyl-xanthene-9-carbon acid cyclopropyl tropine ester-methobromide;

9-Hydroxy-fluorene-9-carbon acid cyclopropyl tropine ester-methobromide;

4,4'-Difluorbenzil acid methylester cyclopropyl tropine ester-methobromide;

9-Hydroxy-xanthene-9-carbon acid tropenole ester-methobromide;

9-Hydroxy-xanthene-9-carbon acid scopine ester methobromide;

9-Methyl-xanthene-9-carbon acid tropenole ester-methobromide;

9-Methyl-xanthene-9-carbon acid scopine estermethobromide;

9-Ethyl-xanthene-9-carbon acid tropenole ester methobromide;

9-Difluormethyl-xanthene-9-carbon acid tropenole ester-methobromide; or

9-Hydroxymethyl-xanthene-9-carbon acid scopine ester methobromide.

644

In one embodiment, the additional therapeutic agent is a corticosteroid selected from Beclomethasone, Betamethasone, Budesonide, Butixocorte, Ciclesonide, Deflazacorte, Dexamethasone, Etiprednole, Flunisolide, Fluticasone, Loteprednole, Mometasone, Prednisolone, Prednisone, Rofleponîde, Triamcmolone, Tipredane, {20R-16alphaJ7aIpha-[butyhdenebis(oxy)]-6alpha,9alpha-difluoro4 Ibeta-hydroxy-

17beta-(methylthio)androsta*4-en-3-one};

9-fluoro-l lbeta,17,21-trihydroxy-l 6alpha-methylpregna-l ,4-diene-3,20-dione 21* cyclohexanecarboxylate 17-cyclopropanecarboxylate;

16,17-butylidenedioxy-6,9-difluoro-l 1-hydiOxy-17-(methylthio)androst-4-en-3-one;

1Û F]umso]ide-21-[4’-(nitrooxymethyl)benzoate];

6,9*Difluoro-17-[(2-furanylcarbonyl)oxy]-l l-hydroxy-16-methyl-3*oxo-androsta-l,4* dien-17-carbothion acid (S)-fluoromethylester;

6,9-Difluoro-l l-hydroxy-16-methyI-3-oxo-17-propionyloxy-androsta-l,4-dien-17carbothion acid (S)-(2-oxo-teÎrahydro-furan-3S-yl)ester; or

6alpha,9alpha-difiuoro-l 1 beta-hydroxy-16alpha-methyl*3-oxo* 17alpha-(2,2,3,3* tertamethylcyclopropylcarbonyl)oxy-androsta-l ,4-diene-17beta-carboxylic acid cyanomethyl ester; optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Examples for preferred salts and dérivatives are alkali salts, i.e. sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acétates, dichloro acétates, propionates, dihydrogenphosphates, palmitates, pivalates or forçâtes.

In one embodiment, the additional therapeutic agent is a PDE4-inhibitor selected from Enprofylline, Theophylline, Roflumilaste, Ariflo (Cilomilaste), Tofimilaste, Pumafentrine, Lirimilaste, Apremilaste, Arofylline, Atizorame, Oglemilastum, Tetomilaste;

5-[(jV-(2,5-dichloro-3-pyridmyl)*carboxamide]-8-methoxy-quinolme;

5-[iV*(3,5-dichloro-1-oxido-4-pyridinyl)-carboxamide]-8-methoxy-2-(triflüoromethylj-quinoline;

A-(3,5-dichloropyrid-4-yl)-Ll -(4-fluorobenzyl)-5-hydroxy-indoIe-3-yl]glyoxyl acid amide);

645

9-[(2-fluorophenyl)methyl]-N-methyl-2-(trinuoromethyl)-9H-purine~6-amine;

4-[(2R)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]-pyridine;

jV-[(3 R)-3 A6,7-te trahydro-9-methyW-oxo-1-phenylpyrrolo [3,2,1-jk][l,4]benzodiazepin-3-yl]-4-Pyridinecarboxamide;

4-[6,7-diethoxy-2,3-bis(hydroxymethyl)-l-naphthalenyl]-l-(2-methoxyethyl)-2(lH)pyridinone;

2-[4-[6,7-diethoxy-2,3-bis(hydroxymethyl)-I-naphthalenyl]-2-pyridmyl]-4-(3pyridinyl)-l (2H)-Phthalazinone;

(3-(3-cyclopenyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H-purine;

beta-[3-(cyclopentyloxy)-4-inethoxyphenyl]-l,3-dihydro-l,3-dioxo-2H-isoÎndole-2propanamide;

-ethyl -2 -methoxy-7-methyl -5-propyl-imidazo [ 1,5 - a] pyri do [3,2-e] pyraz in-6 (-5 H)one;

5-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-[(3-methyIphenyI)methyl] (3S,5S)-2piperidinone;

4-[l-[3,4-bis(difluoromethoxy)_Pheny]]-2-(3-methyl-l-oxido-4-pyridinyl)ethyl]alpha,alpha-bis(trifluoromethyl)-BenzenemetlianoI;

A^/-(3,5-Dich]oro-l-oxo-pyridine-4-yl)-4-difluoiOmethoxy-3-cyclopropylmethoxybenzamide;

(-)p-[(4aR*,10bS*)-9-Ethoxy-l,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[s][l,6]naphthyridin-6-yl]-N7V-diisopropylbenzamide;

(R)-(+)-l-(4-Bromobenzyl)-4-[(3 -cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidone;

3-(Cyclopentyloxy-4-methoxyphenyI)-l-(4-N'-[7V-2-cyano-S-metbyl-isothioureido]benzyl)-2-pyrrolidone;

cis[4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-l-carbon acid];

2-Carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difliioromethoxyphenyl)cyclohexan-1-one;

646 cis[4-Cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-l-ol];

(R)-(+)-Ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidine-2-yliden]acetate;

(S)-(-)-Ethyl[4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidine-2-yliden]acetate;

9-CycIopentyl-5,6-dihydro-7-ethyl-3-(2-thienyl)-9H-pyrazolo[3,4-c]-l,2,4triazolo[4,3-a]pyridine; or

9-Cyclopentyl-5,6-dihydro-7-ethyl-3-(tert-butyl)-9H-pyrazolo[3,4-c]-l,2,4triazolo[4,3-a]pyridine; optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

In one embodiment, the additional therapeutic agent is a LTD4-antagonist selected from Montelukast, Pranlukast, Zafirlukast, Masikulast, L-733321 (see compound 2ab of D. Guay et al, Bioorg. Med. Chem. Lett. 8 (1998)453-458);

(E)-8-[2-[4-[4-(4-Fluorophenyl)butoxy]phenyl]ethenyI]-2-(lH-tetrazole-5-yl)-4H-lb e nz op y ra ï i -4 -o ne ;

4-[6-Acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]-butyric acid;

-(((R)-(3-(2-(6,7-Difluoro-2-quinolinyl)ethenyI)phenyl)-3-(2-(2-hydroxy-2propyl)phenyl)thio)methylcyclopropane-acetîc acid;

l-(((l(R)-3(3-(2-(2,3-Dichlorothieno[3,2-b]pyridin-5-yl)-(E)-ethenyl)phenyl)-3-(2-(lhydroxy-l-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid; or

[2-[[2-(4-tert-Butyl-2-thiazolyl)-5-benzofuranyl]oxymethyl]phenyl]acetic acid; optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

647

Further examples for optionally preferred salts and dérivatives are alkali salts, i.e. sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acétates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.

In one embodiment, the additional therapeutic agent is an EGFR-inhibitor selected from Cetuximab, Trastuzumab, Panitumumab Gefitinib, Canertinib, Erlotinib, Mab ICR-62;

4-[(3~Chlor-4-fluorophenyl)amino]-6-{[4-(morphoIine-4-yl)-l-oxo-2-butene-lyl]amino)-7-cyclopropylmethoxy-qumazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{[4-(N,N-diethylamino)-l-oxo-2-butene-lyl]amino}-7-cyclopropylmethoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyI)amino]-6-{[4-(N,N-dimethylamino)-l-oxo-2-butene-ly]]amino}-7-cyclopropylmethoxy-quinazoline;

4-[(R)-(l-Phenyl-ethyl)amino]-6-{[4-(morpholine-4-yl)-l-oxo-2-butene-l-yl]amino}-7-cyclopentyloxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morphoIine-4-yl)-loxo-2-butene-l-yl]amino}-7-cyclopropylmethoxy-quin azoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{[4-((R)-6-methyl-2-oxo-moipholine-4-yl)-loxo-2-butene-l-yl]amino}-7-[(S)-(tetrahydrofuran-3-yl)oxy]-quinazoIine;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{[4-((R)-2-methoxyrnethy]-6-oxo-morpholine4-yl)-l-oxo-2-butene-l-yl]amino}-7-cyclopropylmethoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-[2-((S)-6-methyl-2-oxo-moiphoIme-4-yl)ethoxy] -7 -methoxy-q uin azoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-((4-j7V-(2-methoxy-ethyl)-A^r-methyl-amino]-loxo-2-butene-I-yl}amino)-7-cyclopropylmethoxy-qu in azoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ [4-(N,N-dimethyIamino)-l-oxo-2-butene-1yl]amino}-7-cyclopentyloxy-quinazoline;

4-[(R)-(i-Phenyl-ethyl)amino]-6-{[4-(NJV-bis-(2-methoxy-ethyl)-amino)-l-oxo-2butene-l-yl]amino}-7-cycIopropylmethoxy-quinazoline;

648

4-[(R)-( 1 -Phenylethyllaminol-ô-ii 4-[A'^r-(2-me thoxy-ethyll-rV-e tliyl-amino]-1 -oxo-2butene-1-yl} amino)-7-cyclopropylmethoxy-qumazoline;

4-[(R)-(l -Phenyl-ethyI)amino]-6-({4-[Ak(2-methoxy-ethÿl)-N-methyl-amino]-l-oxo2-butene-1 -yl} amino)-7-cyclopropylmethoxy-quinazoline;

4-[(R)-(l-Phenyl-ethyl)amino]-6-({4-[N-(tetrahydropyran-4-yl)W-methyl-amino]-loxo-2-butene-l-yl}amino)-7-cyclopropyImethoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ [4-(N,7V-dimethylamino)-l-oxo-2-butene-l yl]amino}-7-((R)-tetrahydrofuran-3-yloxy)-quinazoline;

4-[(3-Chlor-4-fiuorophenyl)amino]-6-{[4-(N,?/-dimethylamino)-l-oxo-2-butene-lyl]ammo}-7-((S)-tetrahydiOfuran-3-yloxy)-qujnazolme;

4-[(3-Chlor-4-fluorophenyl)amino]-6-({4-[A^r-(2-medioxy-etbyl)-A^r-metliyl-amino]-loxo-2-butene-l -yl}amino)-7-cyclopentyloxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ [4-(A^,-cyclopropyl-A^z-methyl-amino)-l-oxo-2butene-l-yI]amino}-7-cyclopentyloxy-quinazoline;

4-[(3-Chîor-4-fluoiOpheny])amitio]-6-{[4-(N,yV-dimethylamino)-l-oxo-2-butene-1y]]amino}-7-[(R)-(tetrahydrofuran-2-yl)methoxy]-qninazolme;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ [4-(N,?/-dimethyIamino)-l-oxo-2-butene-lyljamino) -7-[(S)-(ietrahydrofuran-2-yl)methoxy]-qumazoIine;

4-[(3-Ethinyl-phenyl)amino]-6,7-bjs-(2-methoxy-ethoxy)-quinazoline;

4-[(3-Chlor-4-flüorophenyl)aniino]-7-[3-(morpholine-4-yl)-propyloxy]-6[(vinylcarbonyl)amino]-quinazoline;

4-[(R)-(l-Phenyl-ethyl)amino]-6-(4-hydroxy-pIienyl)-7H-pyrroIo[2,3-d]pyriniidine;

3-Cyano-4-[(3-chlor-4-fkiorophenyl)armno]-6-{ [4-(N,/V-dimethylamino)-l-oxo-2butene-1 -yljamino}-7-ethoxy-quinoline;

4-{ [3-Chlor-4-(3-fluoi-benzyloxy)-phenyl}amino}-6-(5-{[(2-methansulfbny]ethyl)amino]methyl} -furan-2-yl)quinazolme;

649

4-[(R)-(]-Phenyl-ethyl)amino]-6-{[4-((R)-6-methyl-2-oxo-morphoIine-4-yl)-l-oxo-2butene-l-yl]amino}-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ [4-(moipholine-4-yl)-l-oxo-2-butene-ly 1 ] amino} -7 -[(tetrahydro fu ran -2 -y l)methoxy] -q uinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-({4-[N,77-bis-(2-methoxy-ethyl)-amino]-l-oxo2-butene-l-yl)anüno)-7-[(tetrahydrofuran-2-yl)methoxy]-quinazo]ine;

4-[(3-Ethinyl-phenyl)amino]-6-{[4-(5,5-dimethyl-2-oxo-morpholine-4-yl)-l-oxo-2butene-i-yl]animo}-qiimazoline;

4-[(3-Chlor-4-fluorophenyl)amiiio]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)ethoxy]-7-me thoxy-q uinazoline;

4-((3-Chlor-4-fluorophenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)ethoxy]-7-[(R)-(tetraliydrofuran-2-yl)methoxy] -q uinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-7-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)ethoxy]-6-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{2-[4-(2-oxo-morpholine-4-yl)-piperidin-l-yl]ethoxy}-7-methoxy~qumazoline;

4-((3-Chlor-4-fiuorophenyl)amino]-6-[l-(tert-butyloxycarbonyl)-piperidine-4-yloxy]7-methoxy-quinazoIine;

4-[(3-Chlor-4-fluorophenyI)amino]-6-(trans-4-amino-cyclohexane-l-yloxy)-7methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(trans-4-methansulfonylamino-cyclohexane-lyIoxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(tetrahydropyran-3-yloxy)-7-methoxyqninazoline;

4-((3-Chlor-4-fluorophenyl)amino]-6-(l-methyl-piperidine-4-yloxy)-7-methoxyquin azoline;

650

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ 1 - [(morpholine-4-yl)carbonyl]-piperidine-4yloxy} -7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-[l-[(methoxymethyl)carbonyl]-piperidine-4yloxy [-7-methoxy-quinazoline;

4-[(3-Chior-4-fluorophenyl)amino]-6-(piperidine-3-yloxy)-7-metboxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)aimno]-6-[l-(2-acetylamino-ethyl)-piperidine-4-yloxy]-7metho xy-quin azol ine ;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-ethoxyquin azol ine;

4-[(3-Chlor-4-fluorophenyl)amino]-6-((S)-tetrahydrofuran-3-yloxy)-7-hydroxyquinazoliïie;

4-[(3-Chlor-4-fiuorophenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methoxyethoxy)-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{trans4-[(dimetliylamino)suIfonylâmino]cyclohexane-1 -yloxy} -7 -methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-[trans-4-[(morphoIine-4-yl)carbonylamino]cyclohexane-1 -yloxy }-7-methoxy-quinazoIine;

4-[(3-Chlor-4-iluorophenyl)amino]-6-{trans-4-[(morpholîne-4-yl)sulfonyiamino]cyclohexane-1 -yloxy} -7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-acetyl-aminoethoxy)-quinazoline;

4-[(3-Chlor-4-fluorophenyI)amino]-6-(tetrahydropyran-4-yloxy)-7-(2-methanesulfonylamino-ethoxy)-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{ l-[(piperidine-l-yl)carbonyI]-piperidine-4yloxy [-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(l-aminocarbonylmethyl-piperLdine-4-yloxy)-7methoxy-quinazoline;

651

4-[(3-Chlor-4-fluorophenyl)aniino]-6-(cis-4-{/7-[(ÎetrahydiOpyran-4-yl)carbonyl]-A^rmethyl-amino}-cyclohexane-l-yloxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4-tluorophenyl)amino]-6-(cis-4-{M[(moiy>holine-4-yl)carbonyi]-jVmethyl-amino}-cyclohexane-l-y]oxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4-lΊuoIΌphenyl)amino]-6-(cis-4-{A-[(πlOΓpholine-4-yl)sulfonyl]-Λ^,methyl-amino}-cyclohexane-l-yloxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4“fluorophenyI)ammo]-6-(irans-4-ethansu]fonylamino-cyclohexane-Iyloxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(l -methansulfony]-pjperidine-4-yloxy)-7ethoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(l-methansuIfonyl-piperidine-4-yloxy)-7“(2methoxy-ethoxy)-quinazoline;

4-[(3-Chlor*4-fluorophenyi)amino]-6-[l-(2-methoxy-acety])-piperidine-4-y^oxy]-7(2-methoxy-ethoxy)-quinazoIine;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(cis-4-acetylamino-cyclohexane-l-yloxy)-7me thoxy-qu m azolme,

4-[(3-Ethinyl-phenyl)amino]-6-[l-(tert-buty]oxycarbcmyl)-piperidine-4-yloxy]-7methoxy-qumazoline;

4-[(3-Ethinyl-phenyI)amino]’6-(tetrahydropyran-4-yloxy]-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(cis-4-{A-[(piperidine-l-yl)carbonyl]-A-methylamino}-cyclohexane-l-yloxy)-7-methoxy-quinazoline;

4-[(3-ChIor-4-fluorophenyl)ammo]-6-(cis-4-{M[(4-methyl-piperazine-l-yl)carbonyl]-^^Γ-methyl·amino}-cyclohexane-l-yloxy)-7-methoxy-quinazoliπe;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{cis-4-[(moipholine-4-yl)carbonylamino]cyclohexane-l-yloxy}-7-metlioxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{l-[2-(2-oxopyrrolidine-l-yl)ethyl]-piperidine4-yloxy}-7-meihoxy-quinazoline;

652

4-[(3-Chlor-4-fluorophenyl)amino]-6-{l-[(morpholine-4-yl)carbonyl]-piperidine-4yloxy)-7-(2-methoxy-ethoxy)-quinazoline;

4-[(3-EthinyI-phenyI)amino]-6-(l-acetyl-piperidine-4-yloxy)-7-meÛioxy-quina2oline;

4-[(3-Ethinyl-phenyl)amino]-6-(l-methy]-piperidine-4-yloxy)-7-methoxy-quinazoIine;

4-[(3-Ethinyl-phenyl)amino]-6-(l-methansulfonyl-piperidine4-yloxy)-7-niethoxyquin azoline;

4-[(3-Clilor-4-fluorophenyI)amino]-6-(]-methyl-piperidine-4-yloxy)-7-(2-metlioxyethoxy)-qumazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(l-isopropyloxycarbonyl-piperidine-4-yloxy)-7methoxy-quinazoline;

4-[(3-C!ilor-4-fluorophenyl)amino]-6-(cis-4-methyïamîno-cyclohexane-l-y]oxy)-7methoxy-chinazolme;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{cis-4-[A6(2-methoxy-acetyl)W-methy]-amino]cyclohexane-]-yloxy}-7-methoxy-quin azoline;

4-[(3-Ethinyl-phenyl)amino]-6-(piperidine-4-yloxy)-7-methoxy-quinazoline;

4-[(3-EthinyI-phenyl)amino]-6-[I-(2-methoxy-acetyl)-piperidine-4-yloxy]-7-methoxyquin azoline;

4-[(3-Ethinyl-phenyl)amino]-6-{ l-[(morpholine-4-yl)carbonyl]-piperidine-4-yloxy}7-methoxy-quinazoline;

4*[(3-Chlor-4-fluorophenyl)amino]-6-{l-[cis-2,6-dimethyl-morpholine-4-yl)carbonyl]-piperidine-4-y]oxy}-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-{l-[(2-metliy]-morpholme-4-yl)carbony-l]piperidine^l-yloxy}-7-methoxy-quinazo!ine;

4<(3-Chlor-4-mioiOphenyl)amino]-6-U-[(S,S)-(2-oxa-5-aza-bicyclo^ yl)carbonyl]-piperidine-4-yIoxy}-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyI)amino]-6-{l-[(A-methyl-A-2-methoxyethyl-aniino)carbonyl]-piperidine-4-y[oxy)-7-methoxy-quinazoline;

653

4-[(3-Chlor-4-fluorophenyl)amino]-6-(l-eihyl-piperidine-4-y!oxy)-7-methoxyquinazoline;

4-[(3-Ch]or-4-fluorophenyl)arnmo]-6-{l-[(2-methoxyethyl)carbonyl]-piperidine-4yloxy}-7-methoxy-quiiiazoline;

4-[(3-Chlor-4-fluorophenyl)amiao]-6-{ l-[(3-methoxypropyI-amino)-carbony]]piperidine-4-yloxy}-7-methoxy-quinazoline;

4-[(3-ChIor-4-fluorophenyl)amino]-6-[cis-4-(A^r-methansulfonylyV-methyl-amino)cyclohexane-l-yloxy]-7-methoxy-quinazoIine;

4-[(3-Chlor-4-fluorophenyl)amino]-6-[cis-4-(?/-acetylW-methyl-amino)-cyclohexaiie1 -yloxy]-7-methoxy-quinazolme;

4-[(3-Chlor-4-fluorophenyl)ammo]-6-(trans-4-methy]amino-cyclohexane-l-yloxy)-7methoxy-quinazoline;

4-[(3-Chlor-4-f]uorophenyl)amino]-6-[trans-4-GV-methansulfoiiyl-ïV-methyl-amino)cyclohexane-l-yloxy]-7-niethoxy-quinazoIine;

4-[(3-ChIor-4-fluorophenyl)aniino]-6-(trans-4-dimethyIamiiio-cyclohexane-l-yloxy)V-methoxy-quinazolins '

4-[(3-Chlor-4-fIuorophenyl)ammo]-6-(trans-4-[A^r-[(morpholine-4-yl)carbony- 1]Wmethybamino}-cyclohexane-l-yloxy)-7-methoxy-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-[2-(2,2-dimethyl-6-oxo-morpholine-4-yl)ethoxy]-7-[(S)-(tetrahydrofuran-2-yl)methoxy]-quinazoline;

4-[(3-Chlor-4-fluorophenyl)amino]-6-(]-methansulfonyl-piperidine-4-yloxy)-7methoxy-quinazolîne; or

4-[(3-Chlor-4-fluorophenyI)amino]-6-(l-cyano-piperidine-4-yloxy)-7-niethoxyquinazoline; opüonally in racemic form, as e nantie mers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

654

In another embodiment, the additional therapeutic agent is a dopamine antagonist selected from Bromocriptine, Cabergoline, Alpha-Dihydroergocryptine, Lisuride, Pergolide, Pramipexole, Roxindole, Ropiuirole, Talipexole, Terguride and Viozane, optionally in racemic fonn, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydro sulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofnmarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

In another embodiment, the additional therapeutic agent is an antiallergic agent selected from Epinastine, Cetirizine, Azelastine, Fexofenadine, Levocabastine, Loratadine, Mizolastine, Ketotifene, Emedastine, Dimetindene, Clemastine, Bamipine, Cexchlorpheniramine, Pheniramine, Doxylamine, Chlorphenoxamine, Dimenhydrinate, Diphenhydramine, Promethazine, Ebastine, Olopatadine, Desloratidine and Meclozine, optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

In one embodiment, the additional therapeutic agent is an MAP kinase inhibitor selected from Bentamapimod, Doramapimod, 5-Carbamoylindole, 6-[(aminocarbonyl)(2,6difluorophenyl)amino]-2-(2,4-difIuorophenyI)-3-pyridine carboxamide, a!pha-[2-[[2-(3pyridinyl)ethyl]amino]-4-pyrimidinyI]-2-benzothiazole acetonitrile, 9,12-Epoxy-1Hdiindolo[l,2,3-fg:3',2',l'-kl]pyrrolo[3,4-i][l,6]benzodiazo-cine-10-Carboxylic acid, or 4-[3-(4chlorophenyl)-5-(l-methyl-4-piperidinyl)-lH-pyrazole-4-yl]-pyrimidine, optionally in racemic form, as enantiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, bydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

655

In one embodiment, the additional therapeutîc agent is an MRP4-Inhibitor selected from MAcetyl-dinitrophenyl-Cysteine, cGMP, Cholate, Diclofenac, Déhydroépiandrostérone 3glucuronide, Déhydroépiandrostérone 3-sulphate, Dilazep, Dinitrophenyl-S-glutathione, Estradiol 17-beta-glucuronide, Estradiol 3,17-disulphate, Estradiol 3-glucuronide, Estradiol 3sulphate, Estrone 3-sulphate, Flurbîprofen, Folate, N5-formyI-tetrahydrofolate, Glycocholate, Glycolithocholic acid sulphate, Ibuprofen, Indomethacin, Indoprofen, Ketoprofen, Lithocholic acid sulphate, Methotrexate, (E)-3-[[[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-[3d i methy lamino)-3-oxopropyï]thio] me thyl]thio]-propan oie acid, alpha-Naphthyl-beta-Dglucuronide, Nîtrobenzyl mercaptopurine riboside, Probenecid, Valspodar, Sildenafil, Sulfinpyrazone, Taurochenodeoxycholate, Taurocholate, Taurodeoxycholate, Taurolithocholate, Tau ro lithocholic acid sulphate, Topotecan, Trequinsin, Zaprinast or Dipyridamol, option al ly in racemic form, as enantiomers, diastereomers or as pharmaceutically acceptable salts, solvatés or hydrates, Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydro sulfate, hydrophosphate, hydromethansulfonate, hydro nitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

In one embodiment, the additional therapeutîc is an iNOS-Inhibitor selected from S(2-Aminoemyi)isothio-urea, Aminoguanidine, 2-Aminomethylpyridine, 5,6-dihydro-6-methyl4H-1,3-thiazine-2-amine (AMT), L-Canavanin, 2-Iminopiperiditie, S-Isopropylîsothiourea, SMethylîsothiourea, S-Ethylisothiourea, S-Methylthiocitrulline, S-Ethylthiocitmlline, L-NA (N“Nitro-L-arginin), L-NAME (N“-Nitro-L-argininmetli y lester), L-NMMA (N“ -Monomethyl-Larginin), L-NIO (N“ -Iminoethyl-L-ornithin), L-NIL (N® -iminoethyl-lysin), (S)-6-Acetimidoylamino-2-amino-hexanoic acid (lH-tetrazole-5-yl)-amide;

A4[3-(aminomethy])phenyl]methyI]-ethanimidamide;

(S)-4-(2-acetimidoylamino-ethylsulfanyl)-2-amino-buturic acid;

2-[2-(4-Methoxy-pyridine-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine;

2-((R)-3-amino-l-phenyl-propoxy)-4-chlor-5-fluorbenzonitrile;

2'((lR,3S)-3-amino-4-hydroxy-l-thiazoIe-5-yl-buMsulfanyl)-6-trifluoromethylnicotinomtrile;

656

2-((1 R,3S)-3-amino-4-hydroxy-I-thiazole-5-yl-butylsulfanyl)-4-chlor-benzoniirile;

2-((lR,3S)-3-amino-4-hydroxy-l-thiazole-5-yFbutylsulfanyl)-5-chlor-benzonitrile;

(2S,4R)-2-amino-4-(2-chlor-5-trifluoromethyl-phenylsulfanyl)-4-thiazole-5-yl-butanel-ol;

2-((1 R,3S)-3-amino-4-hydroxy-I-thiazole-5-yl-butylsulfanyl)-5-chlor-nicotinonitrile;

4-((S)-3-amino-4-hydroxy-l-phenyl-butylsulfanyl)-6-methoxy-nicotînonitrile; or substituted 3-phenyl-3,4-dihydro-l-isoquinolinamine as for instance lS,5S,6R)-7-Chlor-5methyl-2-aza-bicyclo[4.1.0]hept-2-ene-3-ylamin(4R,5R)-5-Ethyl-4-methyl-thiazondine-2ylideneamine, (lS,5S,6R)-7-Chlor-5-methyl-2-aza-bicyclo[4.1.0]hept-2-ene-3-ylamm, (4R,5R)5-Ethyl-4-methyI-thiazolidme-2-ylideneamine, (4R,5R)-5-EthyI-4-methyl-seIenazolidine-2ylideneamine, 4-Aminotetrahydrobioptenue, (E)-3-(4-Chlor-phenyl)-Æ-(l-{2-oxo-2-[4-(6trifluormethyl·pyrimidme-4-yloxy)-piperidine-l-yI]-ethylcarbamoyl}-2-pyridine-2-yI-ethyl)acrylamide, 3-(2,4-Difluor-phenyl)-6-[2-(4-îmidazole-l-ylmethyl-phenoxy)-ethoxy]-2-phenylpyridine, 3-{[(Benzo[l,3]dioxol-5-ylmethyl)-carbamoyl]-meihyl}-4-(2-imidazole-l -ylpyrimidine-4-yl)-piperazine-l-carbon acid methylester, or(R)4-(24midazole-l-yl-6-methylpyrimidine-4-yl)-pyrrolidine-2-carbon acid (2-benzo[l,3]dioxol-5-yl-ethyl)-amide, optionally in racemic form, as enamiomers, diastereomeres or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate. Further examples of preferred iNOS-Inhibitors which may be mentioned include antisense-Oligonucleotide, especially those antisenseOligonucleotide binding iNOS-coding nucieic acids, examples therefore are disclosed in WO 01/52902, incorporated herein by reference in its entirety.

In another embodiment, the additional therapeutic agent is a SYR-inhibitor selected from

2-[(2-aminoethyI)amino]-4-[(3-bromophenyl)ammo]-5-pyrimidinecarboxamide;

2-[[7-(3,4-dimethoxyphenyl)imidazo[l,2-c]pyrimidine-5-yI]amino]-3pyridinecarboxamide;

657

	6-[[5-fluoro-2-[3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl2H-pyrido[3,2-b]-l ,4-oxazin-3(4H)-one; N-[3-bromo-7-(4-methoxyphen y l)-l,6-naphthyridine-5-yl]-l ,3-propanediamine; \| 7-(4-methoxyphenyI)-77-methy[-l ,6-naphthyridine-5-amine;
5	N-[7-(4-methoxyphenyl)-l,6-naphthyridine-5-yl]-l,3-propanediamine; A^r-[7-(2-thienyl)-l,6-naphthyridine-5 -yl-l,3-propanediamine: M[7-[4-(dimethylammo)phenyl]-l,6-naphthyridine-5-yI]-l,2-ethanediamine; 7V-[7-(4-methoxyphenyl)-2-(trifluoromethyl)-l,6-naphthyridme-5-yl]-l,3propanedi amine;
10	7V-[7-(4-methoxyphenyl)-3-phenyl-l,6-naphthyridme-5-yI]-l,3-propanediamme; 77-(7-phenyl -1,6-n aphthyridine-5 -y 1 ) -1,3-propanediamine ; 1 /7-[7-(3-fluorophenyl)-l,6-naphthyridine-5-yl]-l,3-propanediamine; 77-[7-(3-chlorophenyl)-l,6-naphthyridme-5-yl]-l,3-propanediamine; Z7-[7-[3-(trifluoromethoxy)phenyl]-l ,6-naphthyridine-5yl]-l,3-propanediamine;
15	77-[7-(4-fluorophenyl)-l,6-naphthyridine-5-yl]-l,3-propanediamine; /7-[7-(4-fluorophenyl)-l,6-naphthyridine-5-yl]-l,3-propariediamme; 77-[7-(4-chlorophenyl)-l ,6-naphthyridine-5-yl]-l,3-propanediamine; N-[7-(4'-methyl[l,r-biphenyl]-4-yl)-l,6-naphthyridine-l,3-propane-diamine; N-[7-[4-(diniethylamino)phenyl]-l,6-naphthyridme-5-yl]-l,3-propanediamine;
20	/V-[7-[4-(diethylamino)phenyl]-l,6-naphthyridine-5-yl]-l,3-propane-diamine; N-[7-[4-(4-morpholinyl)phenyl]-l,6-naphthyridine-5-yl]-l,3-propanediamine; N-[7-[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]-l,6-naphthyridine-5-yl]-l,3propanedi amine; /7-[7-(4-bromo phenyl)-1,6-naphthyridine-5-yl]-l,3-propanedi amine;
25	N-[7-(4-methylphenyl)-1,6-naphthyridîne-5-yI]-1,3-propanediamine;

658 jV-[7-[4-(methylthio)pheny]]-l,6-naphthyridine-5-yl]-l,3-propanediamine;

Af-[7-[4-(i-methylethyl)phenyI]-i,6-naphthyridine-5-yl]-l,3-propanediamine;

7-[4-(dimethylamino)phenyl]W-methyl-l,6-naphthyridine-5-amme;

7-[4-(dimethylamino)phenyl]-N,jV-dimethyl-l,6-naphthyridine-5-amine;

?V-[7-[4-(dimethyiamino)phenyl]-l ,6-naphthyridine-5-yl]-l,4-butanediamine;

N-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-l,5-pentanediamine;

3-[[7-[4-(dimethyîamino)phenyl]-l,6-naphthyridine-5-yl]oxy]-l-propanole;

4-[5-(4-aminobutoxy)-l,6-naphthyridine-7-yl]-N,?7-dimethyI-benzenamine;

4-[[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]ammo]-l-butanole;

:V-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-N-methyl-l,3propanediamine;

AAP-^-idimethylaminojphenylJ-bô-naphthyridine-S-ylJ-N’-methyl-I.Spropanedi amine;

7V-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-N,N'-dimethyl-l,315 propanediamine;

l·amino-3-[[7-[4-(dimethylamino)phenyl]-I,6-naphthyridine-5-yl]amino]-2propanole;

A'-[7-[4-(dirnethylaniino)plienyl]-I,6-naphthyridine-5-yl]-2,2-dimethybl,3propanediamine;

^{20 2}4MdimeÜiylammo)phenyl]-AX(3-pyridinylniethyi)-l,6-naphthyridine-5-amine;

A4(2-aminophenyI)methyl]-7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-arnine;

A47-[6-(dimethylam.ino)[lJ'-biphenyl]-3-yl]-l,6-naphthyridine-5-ylH,3propanediamine;

/7-[7-[3-chloro4-(diethyIamino)phenyl]-l,6-naphthyridiiie-5-yl]-1,3 -propanediamine;

²⁵ 7V-[7-[4-(dimethyIamino)-3-methoxyphenyl]-l,6-naphthyrid!ne-5-yl]-I,3propanediamine;

659

7V-[7-[4-(diethylamino)phenyI]-3-methyl-] ,6-naphthyridine-5-yl]-l ,3-propan edi amine;

N-[7-(3'-fluoro[l,l '-biplienyl]-3-yl)-I,6-naphthyridine-5-y]]-l,2-ethanediamine;

N-[7-(4-methoxyphenyl)-l,6-naphthyridine-5-yl]-l,6-naphthyridine-l,3propanediamine;

N,N’-bis(3-aminopropyI)-7-(4-methoxyphenyl)-2,5-diamine;

?/-[7-(4-methoxyplienyl)-2-(phenyImethoxy)-l,6-naphthyridine-5-yI]-l,6naphthyridine-l,3-propanediamine;

-(3-aminopropyl)-7-(4-methoxyphenyl)-N2-(phenylmethyl)-2,5-diamme;

/V-[7-(2-naphthalenyl)-l,6-naphthyridine-5-yl]-l,3-propanediamine;

N-[7-(2'-fluoro[l,r-bipheny]]-4-y])-l,6-naphth_yridine-5-yl]-l,3-propanediamine;

77-(7-(3,4,5-trime thoxyphenyl)-l,6-naphthyridine-5-yl]-1,3-propanediamine;

A'^,-[7-(3,4-dimethylphenyl)-l ,6-naphthyridme-5-yl]-l,3-propanediamine;

l-amino-3-[[7-(2-naphtha]enyl)-l,6-naphthyridine-5-yl]amino]-2-propanole;

l-amino-3-[[7-(2'-fluoro[I,r-biphenyl]-4-yl)-l,6-naphthyridine-5-yl]aminol-215 propanole;

l-amino-3-[[7-(4'-methoxy[l,r-biphenyl]-4-yl)-l ,6-naphthyridine-5-yl]amino]-2propanole;

l-amino-3-[[7-(3,4,5-trimethoxyphenyl)-l,6-naphthyridine-5-yl]amino]-2-propanole;

-amino-3-[[7-(4-bromophenyl)-i,6-naphthyridine-5-yl]amino]-2-propanole;

;V-[7-(4'-methoxy[l,r-biphenyl]-4-yl)-l,6-naphthyridine-5-yl]-2,2-dimethyl-l,3propanediamine;

l-[[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]amino]-2-propanole;

2-[[2-[[7-[4-(dimethy]amino)phenyl]-l,6-naphthyridine-5-yl]amino]-ethyl]thio]ethanole;

7-[4-(dimethylamino)phenyl]-N-(3-methyl-5-isoxazolyl)-l ,6-naphthyridine-5-amine;

7-[4-(dimediy]amino)phenyl]-7V-4-pyrirnidniyl-l,6-naphthyridine-5-amine;

660

À47-[4-(dimethylamino)phenyl]-l,6-naphÜiyridine-5-yIH,3-cyclchexæ

N,/V-dimethyl-4-[5-(l-piperazinyl)-l,6-naphthyridine-7-yï]-benzenamine;

4-[5-(2-metlioxyethoxy)-l,6-naphthyridme-7-yl]-N,N-dimethybbenzeneamine;

1-[7-[4-(dimethy]ammo)phenylJ-l,6-naphthyridine-5-yl]-4-piperidinole;

l-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-3-pynOlidinole;

7-[4-(dimethylamino)phenyl]-M(2-furanylmethyl)4,6-naphthyridine-5-amine;

7-[4-(dimethylamino)phenyl]W-[3-(liI-imjdazole-l-yI)propyl]-l,6-naphthyridine-5amine;

-[7-[4-(dimethylamino)phenyl]-1,6-naphthyridme-5-yl]-4-piperidme carboxamide;

l-[3-[[7-[4-(dimethy]amino)phenyl]-J,6-naphthyridine-5-yl]amino]propyI]-2pyrrolidinone;

Af-L3’-[5-[(3-aminopropyl)amino]-l ,6-naph±yridine-7-yI][l ,r-biphenyl]-3-yl]acetamide;

jV“[7-(4'-fIuoro[l,r-bipheayl]-4-yl)-l,6-naphthyridine'5-yI]-l,3-propanediamine;

A^445-[(3-ammopropyl)ammo]-l,6-naphthyridine-7-yl][l,r-biphenyl]-3-yl]acetamide;

/V’[7-[4-(l,3-benzodioxol·5-yl)phenyl]-l,6-naphthyridine-5-yl]-l,3-propanediamiπe;

A47-[4-(24hienyl)phenyl]-l,6-naphthyridine-5-yl]-I,3-propanediamine;

A^r-[7-[4-fluoro-3-(trifluoiOmethyl)pheny]]-l,6maphthyridine-5-yl]-l,3propanediamine;

A[7-[4-(3-pyridinyl)pheiiyl]-l,6-naphthyndine-5-yl]-l,3-propanediamine;

N-[7-(l ,3-benzodioxol-5-yl)-l ,6-naphthyridine-5-yl]-l ,3-propanediamine;

N-[7-(6-methoxy-2-naphrhalenyl)-l,6-naphthyiidi[ie-5-yl]4,3-piOpanediamme;

7-[4-(dimethyIamino)phenyl]W-(4-pyridinylmethyl)-l,6-naphthyridine-5-amine;

3-[[7-[4-(dimediylammo)pheny]]-l,6-naphthyridine-5-yl]methylamino]propanenitrile;

661

7-[4'(dimethylamino)phenyl]-N-[l-(phenylmethyl)-4-piperidiriyl]-l,6-naphthyridine5-amine;

N-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-l,2-cyclohexanediamine;

jV-[7-[4-(dimethylamino)phenyl]-l,6-naphthyridine-5-yl]-l,2-cycIohexanediamine, (lR,2S)-reI-;

A^[7-[4-(dimethylamino)phenyl]-l ,6-n aphthyridine-5-y 1]-1 ,2-benzene dimethan amine;

N-[7 - [4-(diethyl ami no )phenyl] -1,6-n aphthyridine-5 -yl] -1,4-butanediam ine ;

Y-[7-[3',5’-bis(trifluoromethyl)[l,l'-biphenyl]-4-yl]-l,6-napbthyr- idine-5-yl]-,3propanediamine;

A^r-[7-(3'-methoxy[l,r-biphenyl]-4-yl)-l,6-naphthyridine-5-yl]-l,3-propane-diamine;

A-[7-(3'-fluoro[l,r*biphenyl]-4-yl)-l,6-naphthyridine-5-yl]-l,3-propanediamine;

4-[[7 -[4- (dime th ylamino)phenyl] -1,6 -n aphthyridine -5 -yl]oxy]-1 -butanole;

7V-[7-[4-(dimethylamino)phenyI]-l,6-naphthyridine-5-yl]-l,4-cyclohexanedi amine;

7-[4-(dîmethylamino)phenyl]4V-(2,2,6,6-tetramethyl-4-piperidinyl)-l,6-naphthyridine-5-amme;

^-[7-[3-bromo-4-(dimeÎhyl amino )phenyl]-1,6-n aphthyridine-5-y 1]-1,3-propanediamine;

A-P-fl-methyl-lH-indole-S-ylj-Rô-naphthyridine-S-yll-ljS-propanediamine;

N-[7-[3-(trifluoromethyl)phenyl]-1,6-n aphthyridine-5-y 1J-1,3-propanedîamine;

A^r-[7-[4-(trifluoromethyl)phenyl]-l,6-naphthyridine-5-yI]-l,3-propanediamine;

N-[7-(3-bromo-4-methoxyphenyl)-l,6-naphthyridine-5-yl]-l,3-propanediamine;

N-[7-[4-[[3-(dimethylamino)propyl]methylamino]phenyl]-l ,6-naphthyridine-5-yl]1,4-cyclohexanediamine;

/V-[7-[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]-l,6-naphÜiyridine-5-yl]-I,4cyclohexanediamine;

662

N-[7-[4-(dimethylarmno)-3-methoxyphenyl]-l ,6-naphthyridine-5-yl]-l,4-cyclohexanediamine;

A⁷-[7-[4-(4-morpholmyl)phenyipi,6-naphthyridine-5-yl]-l,4-cyclohexanediamine;

N-[7-[3-bromo-4-(4-morpholinyl)phenyl]-l,6-naphthyridine-5-yl)-I,4-cyclohexanediamine;

4-[[7-[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]-l,6-naphthyridine-5-yl]oxy]cyclohexanole;

A47-[3-bromO“4-(4-moipholinyl)_Phenyl]-l,6-naphthyridine-5-yl]-l,3-propanediamine;

N,A^r-dimethyl-4-[5-(4-methyl-l-piperazinyl)-l_i6-naphthyridine-7-yl]-benzenamine;

4-[[7-[4-[[3-(dimethylamino)propyl]methylamino]phenyl]-l,6-naphthyridine-5yl]oxy]-cyclohexano!e;

N-[7-[4-[[2-(dimethylamino)ethyl]methylamino]phenyl]-l,6-naphthyridine-5-y]]-l,4butanediamine; or

[3-[[5-[(3-aminopropyl)amino]-7-(4-methoxy_Phenyl)-I,6-naphthyridine-2-yl]amino]propyl]’Carbamic acid-1,1-dimethylethyl ester, optionally in racemic form, as enantiomers, diastereomers or as pharmaceutically acceptable salts, solvatés or hydrates. Preferred are salts selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethansulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.

In another embodiment, the additional therapeutic agent is an agent that inhibits the interaction between CAL (also known as CFTR-associated ligand) and mutant CFTR proteins. In one embodiment, the agent that inhibits interaction between CAL and mutant CFTR proteins is a peptide or peptidomimetic (e.g., 6 to 20 residues in length). In another embodiment, the agent that inhibits interaction between CAL and mutant CFTR proteins is a peptide or peptidomimetic disclosed in US Published Patent Application No. US2014/0100155 Al, incorporated herein by référencé in its entirety.

663

In one aspect, die pharmaceutical compositions of the invention can be administered to a patient once daily or about every twenty four hours. Altematively, the pharmaceutical compositions of the invention can be administered to a patient twice daily. Altematively, the pharmaceutical composition of the invention can be administered about every twelve hours. These pharmaceutical compositions are administered as oral formulations containing about 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, or 400 mg of a compound of Formula I. In this aspect, the pharmaceutical compositions further comprise a filler; a disintegrant; a surfactant; a binder; or a lubricant, or combinations thereof.

It will also be appreciated that the pharmaceutical compositions of the invention, including the pharmaceutical compositions comprising combinations described previously, can be employed in combination thérapies; that is, the compositions can be administered concurrently with, prior to, or subséquent to, one or more other desired therapeutic agents or medical procedures.

These combinations are useful for treating the diseases described herein including cystic fibrosis. These combinations are also useful in the kits described herein.

The amount of additional therapeutic agent présent in or with the compositions of this invention will be no more tban the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally présent in a composition comprising that agent as the only therapeutically active agent.

Therapeutic Uses of the Compounds of Formula I-Ij and Pharmaceutical Compositions Thereof

In one aspect, the invention also provides a method of treating, lessening the severity of, or symptomatically treating a disease in a patient, the method comprising administering an effective amount of the pharmaceutical composition of the invention to the patient, preferably a mammal, wherein the disease is selected from cystic fibrosis, asthma, smoke induced COPD, chrome bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male

664 infertility caused by congénital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergie bronchopulmonary aspergillosis (ΑΒΡΑ), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis defïciencies, such as protein C defïciency and Type I hereditary angioedema, lipid processing defïciencies (such as familial hypercholesterolemia, Type 1 chylomicronemia, and abetalipoproteinemia), lysosomal storage diseases (such as I-cell disease/pseudo-Hurler), mucopolysaccharidoses, Sandhof/TaySachs, Crigler-Najjar type Π, polyendocrinopathy/hyperinsulinemia, Diabètes mellitus, Laron dwarfism, myeloperoxidase defïciency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1, congénital hyperthyroidism, osteogenesis imperfecta, hereditary

1Û hypofibrinogenemia, ACT defïciency. Diabètes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases (such as Alzheimer’s disease, Parkinson’s disease, amyotrophie latéral sclerosis, progressive supranuclear palsy, and Pick’s disease), several polyglutamine neurological disorders (such as Huntington’s, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonie dystrophy), spongiform encéphalopathies (such as hereditary Creutzfeldt-Jakob disease (due to prion protein processing defect)), Fabry disease, Gerstmann-Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogmn’s disease, osteoporosis, osteopenia, bone healing and bone growth (including bone repair, bone régénération, reducing bone résorption and increasing bone déposition), Gorham's

Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent’s disease, epilepsy, lysosomal storage disease, Angelman syndrome, and Primary Ciliary Dyskinesia (PCD), a tenu for inherited disorders of the structure and/or function of cilia, including PCD with situ s in versus (also known as Kartagener syndrome), PCD without situs in versus and ciliary aplasia.

In another embodiment, the method of treating, lessening the severity of, or symptomatically treating a disease in a patient of the invention comprises administering an effective amount of the pharmaceutical composition of the invention, provided that in formula I and the attendant définitions: i) when ring A is indole, n is not zéro and rings B and C are aryl unsubstituted by CF₃ or halo; ii) when ring A is pyrazole, n is not zéro; iii) when ring A is pyridyl, ring B and ring C moieties are substituted at the 2- and 3- positions of the pyridyl ring,

665 interchangeably; and iv) when ring A is imidazole, the ring B moiety is substituted at the 2position of the imidazole ring.

In one aspect, the invention also provides a method of treating, lessening the severity of, or symptomatically treating a disease in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the disease is selected from generalized epilepsy with ferbrile seizures plus (GEFS-+-), general epilepsy with ferbile and aferbrile seizures, myotonia, paramyotonia congénital, potassium-aggravated myotonia, hyperkalemic periodic paralysis, LQTS, LQTS/Brugada syndrome, autosomal-dominant LQTS with deafhess, autosomal-recessive LQTS, LQTS with dysmorphie features, congénital and acquired LQTS, Timothy syndrome, persistent hyperinsulinémie hypolglycemia of infancy, dilated cardiomyopathy, autosomaldominant LQTS, Dent disease, Osteopetrosis, Bartter syndrome type ΙΠ, central core disease, malignant hyperthermia, and catecholaminergic polymorphie tachycardia.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation N1303K, ΔΙ507, or R56OT.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation G551D. In another embodiment, the patient is homozygous in G551D. In another embodiment, the patient is heterozygous in G551D. In another embodiment, the patient is heterozygous in G551D, wherein the other CFTR genetic mutation is any one of F5O8del, G542X, N1303K, WI282X, RI 17H, R553X, 1717-1G->A, 621 + 1G->T, 2789+5G->A, 3849+10kbC->T, R1162X, G85E, 312O+1G->A, ΔΙ507, I898+1G->A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711 + 1G->T. In another embodiment, the patient is heterozygous in G551D, wherein the other CFTR genetic mutation is F5O8del. In another embodiment, the patient is heterozygous in G551D, wherein the other CFTR genetic mutation is R117H.

666

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation F508deL In another embodiment, the patient is homozygous in F508del. In another embodiment, the patient is heterozygous in F508del. In another embodiment, the patient is heterozygous in F5O8del, wherein the other CFTR genetic mutation is any one of G551D, G542X, N1303K, W1282X, R117H, R553X, 1717-1G->A, 621 + 1 G->T, 2789+5G->A, 3849+10kbC->T, RI 162X, G85E, 312O+1G->A, ΔΙ507, 1898+1G->A, 3659delC, R347P, R560T, R334W, A455E, 2184delA, or 711 + 1G->T, In another embodiment, the patient is heterozygous in F5O8del, wherein the other CFTR genetic mutation is G551D. In another embodiment, the patient is heterozygous in F508del, wherein the other CFTR genetic mutation is RI 17H.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, GI244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, RW70W, F1074L, DI 10E, D1270N, DH52H, 1717-1G->A, 621+1 G->T, 312O+1G->A, 1898+1 G->A, 711+1 G->T, 2622+lG->A, 4O5+1G->A, 406-1 G-> A, 4005+lG->A, 1812-1G>A, 1525-1 G->A, 712-1G->T, 1248+1G->A, 1341 + 1G->A, 3121-1G->A, 4374+1 G->T, 38501G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA>G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A, 1811+1G>C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R. In one embodiment of this aspect, the invention provides a method of treating CFTR comprising administering Compound 1 to a patient possessing a human CFTR mutation

667 selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from El93K, Fl052V and G1069R. In some embodiments of this aspect, the method produces a greater than 10-fold increase in chloride transport relative to baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H. In one embodiment of this aspect, the method produces an increase in chloride transport which is greater or equal to 10% above the baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 621 + 1G->T, 312O+1G->A, 1898+1G->A, 711+1G->T, 2622+lG->A, 405+1G>A, 4Û6-1G->A, 4OO5+1G->A, 1812-1G->A, 1525-lG->A, 712-1G->T, 1248+1G->A, 1341+1G->A, 3121-IG->A, 4374+lG->T, 385O-1G->A, 2789+5G->A, 3849+10kbC->T, 327226A->G, 711+5G->A, 3120G->A, 181 l+1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A, 1811 + 1 G->C, 1898+5G->T, 385O-3T->G, IVS14b+5G>A, 1898+1 G->T, 4005+2T->C and 62i+3A->G. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 181 l+1.6kbA->G, 2789+5G~>A, 327226A->G and 3849+10kbC->T. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient

668 comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 2789+5G->A and 3272-26A->G.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S125IN, E193K, F1052V, G1069R, RI 17C, DU OH, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, DI 10E, D127ON, DI 152H, 1717-1G->A, 621+1G->T, 312O+1G->A, 1898+1 G-> A, 711+1 G->T, 2622+1 G->A, 405+1 G-> A, 406-1 G-> A, 4005+1 G->A, 1812-1G>A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341 + 1G->A, 3121-1G->A,4374+1G->T, 38501G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 181 l + 1.6kbA>G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A, 1811+10>C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1 G->T, 4005+2T->C and 621+3A->G, and a human CFTR mutation selected from F508deI, RI 17H, and G551D.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G55IS, G970R, G1244E, SI255P, G1349D, S549N, S549R, S125IN, E193K, F1052V and G1069R, and a human CFTR mutation selected fromF508del, R117H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251 N, and a human CFTR mutation selected from F508del, RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient

669 possesses the CFTR genetic mutation is selected from El93K, F1052V and G1069R, and a human CFTR mutation selected from F508del, RI 17H, and G551D. In some embodiments of this aspect, the method produces a greater than 10-fold increase in chloride transport relative to baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from RI I7C, D110H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1O74L, D110E, D1270N and D1152H, and a human CFTR mutation selected from F508del, RI17H, and G551D. In one embodiment of this aspect, the method produces an increase in chloride transport which is greater or equal to 10% above the baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 621+1G->T, 3120+lG->A, 1£9S+1G->A, 71 1+1G->T, 2622+IG->A, 405+1G>A, 406-1 G->A, 4OO5+1G->A, 1812-1G->A, 1525-1 G->A, 712-1 G->T, 1248+1G->A, 1341+1G->A, 3121-IG->A, 4374+lG->T, 3850-lG->A, 2789+5G->A, 3849+10kbC->T, 327226A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 17I6G/A, 1811+1G->C, I898+5G->T, 3850-3T->G, IVS14b+5G>A, 1898+1 G->T, 4005+2T->C and 621+3A->G, and a human CFTR mutation selected from F508de], RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 181 l+1.6kbA->G, 2789+5G->A, 3272-26A->G and 3849+10kbC->T, and a human CFTR mutation selected from F5O8del, RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective

670 amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 2789+5G>A and 3272-26 A->G, and a human CFTR mutation selected from F5O8del, RI 17H.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fîbrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, SI255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, RIÛ70W, F1074L, DI 10E, D1270N, DI 152H, 1717-1G->A, 621+1G->T, 312O+1G->A, 1898+1G->A, 711+1G->T, 2622+lG->A, 4O5+1G->A, 4O6-1G->A, 4OO5+1G->A, 1812-1G>A, 1525-1G->A, 712-1G->T, 1248+1 G->A, 1341 + 1G->A, 312MG->A, 4374+lG->T, 38501G->A, 2789+5G->A, 3849+10kbC->T,3272-26A->G, 7U+5G->A, 3120G->A, 1811+1.6kbA>G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, I716G/A, 1811+1G>C, 1898+5G->T, 3850-3T->G, lVS14b+5G->A, 1898+1G->T, 4005+2T->C and 621+3A->G, and a human CFTR mutation selected from F5O8del, RI 17H, and G551D,

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, SI251N, EI93K, F1052V and G1069R. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fîbrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S,G970R, GI244E, S1255P, GI349D, S549N, S549R and S1251N. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fîbrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from E193K,

671

Fl 052V and G1069R. In some embodiments of this aspect, the method produces a greaterthan 10-fold increase in chloride transport relative to baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, DI 10E, D1270N and DI 152H. In one embodiment of this aspect, the method produces an increase in chloride transport which is greater orequal to 10% above the baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 621+1 G->T, 312O+1G->A, 1898+1G->A, 711+1G->T, 2622+1 G->A, 405+1G>A, 4O6-1G->A, 4OO5+1G->A, 1812-1G->A, 1525-1G->A, 712-1G->T, 1248+1G->A, 1341+1 GoA, 3121-1 G->A, 4374+lG->T, 385O-1G->A, 2789+5G->A, 3849+10kbC->T, 327226A->G, 711+5G->A, 3120G->A, 181 !+1.6kbA->G, 711+3A->G, 1898+3 A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G>A, 1898+1 G->T, 4005+2T->C and 621+3A->G. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1G->A, 1811+1.6kbA->G, 2789+5G->A, 327226A->G and 3849+10kbC->T. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 2789+5G->A and 3272-26A->G.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an

672 effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G17SR, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V, G1069R, RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, DI 10E, D1270N, DI 152H, 1717-1G->A, 621+1G->T, 3120+1 G->A, 1898+1G->A, 711+1G->T, 2622+ 1G->A, 405+1 G->A, 406-1G->A, 4005+1 G->A, 1812-1G>A, 1525-1G->A, 712-1G->T, I248+IG->A, 1341+1G->A, 3121-1G->A, 4374+lG->T, 38501G->A, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 181I+1.6kbA>G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A, 1811+1G>C, 1898+5G->T, 3850-3T->G, IVSI4b+5G->A, 1898+1 G->T, 4005+2T->C and 621+3A->G, and a human CFTR mutation selected from F5O8del, RI 17H, and G551D, and one or more human CFTR mutations selected from F508del, RI 17H, and G551D.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N, E193K, F1052V and G1069R, and one or more human CFTR mutations selected from F508del, RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R and S1251N, and one or more human CFTR mutations selected from F5O8deI, RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from E193K, Fl052V and G1069R, and one or more human CFTR mutations selected from F508del, RI 17H, and G551D. In some embodiments of this aspect, the method produces a greater than IO-fold increase in chloride transport relative to baseline chloride transport.

673

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from

RI 17C, DI 10H, R347H, R352Q, E56K, P67L, L206W, A455E, D579G, S1235R, S945L, R1070W, F1074L, D110E, D1270N and D1152H, and one or more human CFTR mutations selected from F508del, RI 17H, and G551D. In one embodiment of this aspect, the method produces an increase in chloride transport which is greater or equal to 10% above the baseline chloride transport.

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717 -1 G->A, 621+1 G->T, 3120+1 G->A, 189 8+1 G->A, 711+1 G->T, 2622+1 G->A, 405+1 ΰ15 >A, 406-1 G->A, 4005+1 G->A, 1812-1 G->A, 1525-1 G->A, 712-1 G->T, 1248+1G->A,

1341 + 1G->A, 3121-1G->A, 4374+1 G->T, 3850-1 G->A, 2789+5G->A, 3849+10kbC->T, 327226A->G, 711+5G->A, 3120G->A, 181 l + 1.6kbA->G, 711+3A->G, 1898+3A->G, 1717-8G->A, 1342-2A->C, 405+3 A->C, 1716G/A, 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G>A, 1898+1 G->T, 4005+2T->C and 621+3A->G, and one or more human CFTR mutations selected from F5O8del, RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 1717-1 G->A, 1811 + 1.6kbA->G, 2789+5G->A, 3272-

26A->G and 3849+10kbC->T, and one or more human CFTR mutations selected from F508del,

RI 17H, and G551D. In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation is selected from 2789+5G->A and 3272-26A->G, and one or more human CFTR mutations selected from F508del, RI 17H, and G551D.

674

In one aspect, the présent invention is directed to a method of treating, lessening the severity of, or symptomatically treating cystic fibrosis in a patient comprising administering an effective amount of the pharmaceutical composition or tablet of the invention to the patient, preferably a mammal, wherein the patient possesses the CFTR genetic mutation selected from Figure 1.

In certain embodiments, the composition of the présent invention is useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia. The presence of residual CFTR activity at the épithélial surface can be readily detected using methods known in the art, e.g., standard electrophysiological, biochemical, or histochemical techniques. Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary Cf concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be readily detected in patients heterozygous or homozygous for a variety of different mutations, including patients homozygous or heterozygous for the most commun mutation, F508del, as well as other mutations such as the G551D mutation, or the RI 17H mutation. In certain embodiments, compositions of the présent invention are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit little to no residual CFTR activity. In certain embodiments, compositions of the présent invention are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients who exhibit little to no residual CFTR activity in the apical membrane of respiratory epithelia.

In another embodiment, the compositions of the présent invention are useful for treating or lessening the severity of cystic fibrosis in patients who exhibit residual CFTR activity using pharmacologie al methods. In another embodiment, the compositions of the présent invention are useful for treating or lessening the severity of cystic fibrosis in patients who hâve residual CFTR activity using gene therapy. Such methods increase the amount of CFTR présent at the cell surface, thereby inducing a hitherto absent CFTR activity in a patient or augmenting the existing level of residual CFTR activity in a patient.

In one embodiment, the compositions of the présent invention are useful for treating or lessening the severity of cystic fibrosis in patients within certain génotypes exhibiting residual

675

CFTR. activity, e.g., Class I imitations (not synthesized), class H mutation (misfolding), class ΙΠ mutations (impaired régulation or gating), class IV mutations (altered conductance), or class V mutations (reduced synthesis).

In one embodiment, compositions of the présent invention are useful for treating, lessening the severity of, or symptomatically treating cystic fibrosis in patients within certain clinical phenotypes, e.g., a moderate to mild clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of epithelia, Such phenotypes include patients exhibiting pancreatic sufficiency.

In one embodiment, the compositions of the présent invention are useful for treating, lessening the severity of, or symptomatically treating patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis and congénital bilateral absence of the vas deferens, or mild lung disease wherein the patient exhibits residual CFTR activity.

In one embodiment, the compositions of the présent invention are useful for treating, lessening the severity of, or symptomatically treating patients diagnosed with pancreatic sufficiency, idiopathic pancreatitis and congénital bilateral absence of the vas deferens, or mild lung disease wherein the patient has wild type CFTR.

In addition to cystic fibrôsis, modulation of CFTR activity may be bénéficiai for other diseases not directly caused by mutations in CFTR, such as secretory diseases and other protein folding diseases mediated by CFTR. These include, but are not limited to, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjôgren’s Syndrome. COPD is characterized by airflow limitation that is progressive and not fully réversible. The airflow limitation is due to mucus hypersécrétion, emphysema, and bronchiolitis. Activators of mutant or wild-type CFTR offer a potential treatment of mucus hypersécrétion and impaired mucociliary clearance that is common in COPD. Specifically, increasing anion sécrétion across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimized periciliary fluid viscosity. This would lead to enhanced mucociliary clearance and a réduction in the symptoms associated with COPD. Dry eye disease is characterized by a decrease in tear aqueous production and abnormal tear film lipid, protein and mucin profiles. There are many causes of dry eye, some of which include âge, Lasik eye surgery, arthritis, médications, c hernie al/thermal bums, allergies, and diseases, such as cystic fibrosis and Sjôgrens's syndrome. Increasing anion

676 sécrétion via CFTR would enhance fluid transport from the comeal endothélial ce Ils and secretory glands surrounding the eye to increase comeal hydration. This would help to alleviate the symptoms associated with dry eye disease. Sjôgrens's syndrome is an autoimmune disease in which the immune System attacks moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut. Symptoms, include, dry eye, mouth, and vagina, as well as lung disease. The disease is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dennatomyositis. Defective protein trafficking is believed to cause the disease, for which treatment options are limited. Augmenters or inducers of CFTR activity may hydrate the various organs afflicted by the disease and help to elevate the associated symptoms.

In one embodiment, the invention relates to a method of augmenting or inducing anion channel activity in vitro or in vivo, comprising contacting the channel with a composition of the présent invention. In another embodiment, the anion channel is a chloride channel or a bicarbonate channel. In another embodiment, the anion channel is a chloride channel.

The exact amount required will vary from subject to subject, depending on the species, âge, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression dosage unit fonn as used herein refers to a physically discrète unit of agent appropriais for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physicîan within the scope of Sound medical judgment. The spécifie effective dose level for any particular patient or organism will dépend upon a variety of factors including tire disorder being treated and the severity of the disorder; the activity of the spécifie compound employed; the spécifie composition employed; the âge, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excrétion of the spécifie compound employed; the duration of the treatment; drugs used in combination or coincidental with die spécifie compound employed, and like factors well known in the medical arts. The tenu “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.

677

In recent years a number of attempts hâve been made to treat cystic fibrosis using gene therapy. Gene therapy is the insertion, alteration, or removal of genes within an individual’s cells and biological tissues to treat disease. It is a technique for correcting defective genes that are responsable for disease development. The most common form of gene therapy in volves the insertion of functional genes into an unspecified genomic location in order to replace a mutated gene, but other forms involve directly correcting the mutation or modifying normal gene that enables a viral infection. Although the technology is still in its infancy, it bas been used with some success.

Cystic fibrosis is a good candidate for gene therapy as it is primarily caused by mutations in a single gene. A normal copy of the gene could be delivered to patients via topical delivery to the lung, not requiring invasive techniques or surgery. A gene complémentation approach would aslo directly target the cause of the disease and could correct many aspects of the complex lung pathology.

Soon after the cloning of the CFTR gene, proof-of-principle was established when the Ci-conductance defect was corrected after delivery of a functional copy of human wild-type CFTR DNA to cells isolated from cystic fibrosis patients. To date, a number of trials for cystic fibrosis gene therapy hâve been tested in humans. These early studies were concemed mainly with safety issues.

In one embodiment, the invention features a method of treating cystic fibrosis comprising administering to the patient a compound of formula I to Id in conjunction with gene therapy. The gene therapy can be as disclosed in In tentation Published Patent Application No. WO2013061091, incorporated herein in its entirety by reference. Administration may be prior, concomitant, or subséquent administration of a compound of formula I - Id, or any of the pharmaceutical compositions of the présent invention.

In another embodiment, the gene therapy features administering to the patient 1 mL to iess than 10 mLs of a complex of (i) a non-viral CpG dinucleotide-free plasmid comprising nucleic acid encoding a CFTR polypeptide operatively linked to hCEFI promoter, wherein the plasmid is at a concentration of 2 mg/mL to 3 mg/mL, and (ii) GL67A lipid mixture at a concentration of 10 mg/mL to 20 mg/mL.

678

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formula I - Id and (ii) 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formula I-Id and (ii) (R)-l-(2,2-difîuorobenzo[d][l,3]dioxol-5-yl)-jV-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-lH-indol-5yl )cyclopropanec arboxamide.

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formula I- Id and (ii) 4-(3-(1-(2,2-difluorobenzo[d][ 1,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-1-yfjbenzoic acid.

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formulaI - Id; (ii) 3-(6-(l-(2,2-difluorobenzo[d][!,3]dioxoI-5-yl) cyclopropanecarboxamido)-3-methyipyridin-2-yl)benzoic acid; and (iii) ?/-(5-hydroxy-2,4-ditertbutyl-phenyl)-4-oxo-lH-quinoline-3-carboxamide.

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formula I- Id; (ii) (Æ)-I-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)-iV-(l-(2,3dihydroxypropyl)-6-fluoro-2-(l-hydroxy-2-methylpropan-2-yl)-]H-indol-5yl)cyclopropanec arboxamide; and (iii) N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-lHquinoline-3-carboxamide.

In one embodiment, gene therapy is administered to a patient with cystic fibrosis prior, concomitant, or subséquent administration of a pharmaceutical composition comprising (i) a compound of formula I- Id; (ii) 4-(3-(1 -(2,2-difluorobenzo[d][1,3]dioxol-5yl)cyclopropanecarboxamido) isoquinolin-1-yl)benzoic acid; and (iii) M(5-hydroxy-2,4-ditertbutyl-phenyI)-4-oxo-l H-quinoline-3-carboxamide.

679

Kits

In another aspect, the présent invention features a kit comprising a compound and/or pharmaceutical composition of the présent invention and instructions for use thereof.

In another embodiment, the kits of the présent invention further comprise one or more 5 additional therapeutic agent(s). In another embodiment, the additional therapeutic agent is selected from a mucolytîc agent, bronchodialator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent. In another embodiment, the additional therapeutic agent is a CFTR modulator. In another embodiment, the additional therapeutic agent is a CFTR corrector.

In another embodiment, the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

In another embodiment, the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

In another embodiment, the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

680

In another embodiment, the additional therapeutic agent is a CFTR potentiator. In another embodiment, the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

In another embodiment, the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

In another embodiment, the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

In another embodiment, the additional therapeutic agents are

V H X A 0 jT Α/Αχ^ΟΗ Q a-oh La. j OH and H pharmaceutically acceptable salts thereof. In another embodiment, the additional therapeutic V ^H ΓΊί ^0H r- N N - Aï/ J¹ Q X ï iA ï Y A f _O-^J y o ca OO and H 15 pharmaceutically acceptable salts thereof.

OH I Â H , or agents are OH I Â T H , or

681

In another embodiment, the kits of the présent invention are drawn to kits wherein the compounds or the pharmaceutical compositions of the présent invention and the one or more additional therapeutic agent(s) are in separate containers.

In another embodiment, the kits fo the présent invention are drawn to kits wherein the compounds or the pharmaceutical compositions of the présent invention and the one or more additional therapeutic agent(s) are in the same container.

In another embodiment, the container is a bottle, vial, or blister pack, or combination thereof.

Anywhere in the présent application where a name of a compound may not correctly de scribe the structure of the compound, the structure supersedes the name and go vems.

EXAMPLES

PREPARATION I: Λ⁷-(3-aminophenyI)suIfonyl-6-ier/-buty 1-2-(2,4,6trimethy]phenyI)pyridine-3-carboxamide (Compound 26)

Step 1: 6-ierAbutyI-2-chloro-pyridine-3-carbonitriIe

2,2-Dimethylpropanoic acid (50. mL, 870 mmol), 2-chloropyridine-3-carbonitrile (30 g, 220 mmol) and AgNO₃ (9.2 g, 54 mmol) were suspended in 10% aq. H₂SO₄ (300 mL). A solution of ammonium peroxydi sulfate (91 g, 430 mmol) and water (480 mL) was added to the mixture dropwise through an addition formel, The mixture was stirred at room température overnight. The pH of reaction mixture was adjusted to -8-9 with 30% NH₄OH (-250 mL) and the mixture was extracted with ethyï acetate (3 x 300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated, The residue was subjected to silica gel column chromatography (0-25% ethyl acetate/hexanes) to give 6-rert-butyI-2-chIoropyridine-3-carbonitrile (37 g, 83%) as a clear oil which solidified upon standing. 'H NMR (400 MHz, CDCh)S 7.83 (d, 7= 8.1 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 1.29 (s, 9H). ESI-MS m/z cale. 194.1, found 195.0 (M+l)⁺; Rétention time: 1.66 min (3 min run),

Step 2: 6-for/-biityl-2-(2,4,6-trimcthylphenyl)pyridine-3-carbonitriIe

682

A mixture of 6-ieri-butyl-2-chloro-pyridine-3-carbon itrile (400. mg, 2.06 mmol), (2,4,6-trimethylphenyl)boromc acid (506 mg, 3.08 mmol), Pd(dppf)₂C12*CH₂C12 (75 mg, 0.10 mmol), NaHCO₃ (173 mg, 2.06 mmol) and DME (2 mL) was heated at 120 °C in a microwave 5 reactor for 30 min. The mixture was partitioned between CH₂C12 and water. The layers were separated and the aqueous layer was extracted with CH2C1₂ (2x). The combined organics were dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-20% ethyl acetate/hexanes) to give 6-feri-butyl-2-(2,4,6trimethylphenyl)pyridine-3-carbonitrile (225 mg, 39%). ESI-MS m/z cale. 278.2, found 279,4 10 (M+I)⁺; Rétention time: 0.84 min (3 min run).

Step 3: 6-te/’i-butyl-2-(2,4,6-trimethy]phenyl)pyridiiie-3-carboxylic acid

A mixture of6-rm-buty 1-2-(2,4,6-t rime thyIphenyI)pyridine-3-carboni tri le (225 mg, 0.808 mmol), KOH (2.0 mL of 4.0 M, 8.0 mmol) and EtOH (2.3 mL) was heated at 90 °C for 2.5 15 d. The mixture was acidifïed with conc. HCl to ~pH 2 before it was concentrated underreduced pressure. The residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 6-teri-butyl-2-(2,4,6-trimethylphenyl)pyridine-3-carboxylic acid (40 mg, 17%) as a white solid. ESI-MS m/z cale. 297.2, found 298.4 (M+l)⁺; Rétention time: 1.77 min (3 min run).

²θ Step 4: TV-fS-ammophenyljsulfonyl-ô-rerf-butyl-Z-tl^ô trinielhylphenyl)pyridine-3-carboxamide (Compound 26)

683

Sodium (3-nitrophenyl)sulfonyIazanide (60. mg, 0.27 mmol) was added to a mixture of 6-terrbutyl-2-(2,4,6-trimethylphenyl)pyridine-3-carboxyIic acid (40. mg, 0.13 mmol), A[ (d i m ethy 1 am in o) -1 H~ 1,2,3-tri az ol o - [4,5 - b ] pyrid i n -1 -y 1m e th yl eue ]-N- me thy I m eth an am i n ium hexaflu orophosphate A-oxide (51 mg, 0.13 mmol) and A,A-dimethylformamide (800.0 pL) at room température. The mixture was allowed to stir at 70 °C ovemight before il was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05% HCl ) to give the nitro intei médiate, 6-reri-butyLA-(3-nitrophenyl)sulfor)yl-2-(2,4,6-trimethylphenyl)pyridine-3carboxamide. The nitro intermediate was taken up in ace tic acid (1 mL) before Zn (8.8 mg, 0.13 mmol) was added. The mixture was stirred at room température for 30 min before it was filtered. The filtrate was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCI) to give A-(3-aminophenyl)sulfonyl-6-iert-butyl-2-(2,4,6-trimethylphenyl)pyridme-3carboxamide (Compound 26) (] 3 mg, 22%). ESI-MS m/z cale. 451.2, found 452.5 (M+l)⁺; Rétention time: 1,81 min (3 min run).

PREPARATION 2: N- (3-aminophenyl)sulfonyl-6-^rt-buty 1-2-(4chlorophenyl)pyridine-3-carboxamide (Compound 223)

Step 1: 6-/ert-butyl-2-cI]loro-pyridine-3-carboxamide

To a mixture of 6-terFbutyl-2-chIoro-pyridine-3-carbonitrile (6.81 g, 35.0 mmol) and NaOH (38.5 mL of 1.0 M, 38.5 mmol) in EtOH (175 mL) was slowly added hydrogen peroxide (19.9 mL of 30% w/v, 175 mmol). The réaction mixture was stirred at room température for 45 min. before additional hydrogen peroxide (19.9 mL of30% w/v, 175 mmol) was added. After 1 h, the mixture was slowly quenched with saturated sodium bisulfite solution, diluted with water, and extracted with ethyl acetate. The combined extracts were washed with water, dried over

684 sodium sulfate, and evaporated to give 6-teri-butyl-2-chloro-pyridine-3-carboxamide (7.21 g, 97%) as a white solid. ESI-MS m/z cale. 212.1, found 212.9 (M+l)⁺; Rétention time: 0.46 min (1 min run).

Step 2: 6-te;ï-buty]-2-chloro-7V-(3 -ni trophenyl)sulfonyI-pyridine-3 -carboxamide

To a solution of 6-(terr-butyl)-2-chloronicotinamide (3.19 g, 15.0 mmol) and 3nitrobenzenesulfonyl chloride (3.32 g, 15.0 mmol) in THF (100.0 mL) was slowly added NaH (1.80 g, 60%, w/w, 45.0 mmol) in portions. The mixture was allowed to stir for 2h at room température before it was quenched with saturated aqueous ammonium chloride solution. The 10 mixture was extracted with ethyl acetate (3x). The combined extracts were washed with water, dried over sodium sulfate, and evaporated. The residue was taken up in diethyl ether. The solids were fïltered, washed with diethyl ether, and dried under vacuum. The filtrate was evaporated and the residue was purified by silica gel chromatography (1-11% methanoRCH₂Cl₂). The two batches (solid from ether and product from coluinn) were combined to give 6-(terr-butyI)-215 chloroW-((3-nitrophenyl)sulfonyl)nicotinamide (3.56 g, 60%) as light yellow solid. ESI-MS m/z cale. 397.1, found 398.0 (M+I )⁺; Rétention time: 0.66 min (1 min run).

Step 3: A^r-(3-aminophenyl)sulfonyl-6-/ert-butyl-2-chloro-pyridine-3-carboxamide

To a solution of 6-(rert-butyl)-2-chloro-iV-((3-niÎrophenyl)sulfonyl)nicotinamide (1.40 20 g, 3.52 mmol) in glacial acetic acid (140 mL) was added zinc (5.76 g, 88.0 mmol). The reaction mixture was allowed to stir at room température for 1 h before it was fïltered and concentrated under reduced pressure. The crude product was subjected silica gel column chromatography (05% methanol/CH₂Cl₂) to provide y-(3-aminophenyl)sulfonyl-6-tert-butyl-2-chloro-pyridine-3carboxamide (1.12 g, 87%) as an orange sticky foam. ESI-MS m/z cale. 367.1, found 368.6

685 (M+l )⁺; Rétention time: 1.09 min (3 min run).

Step 4: A-(3-aininophenyl)siiIfonyI-6-rerr-butyl-2-(4-dilorophenyl)pyridine-3carboxamide (Compound 223)

To (4-chlorophenyl)boronic acid (26 mg, 0.16 mmol) was added a solution of7V-(3aminophenyl)suIfonyl-6-ierTbutyl-2-chloro-pyrid ine-3-carboxamide (50. mg, 0.14 mmol) in DMA (0.5 mL). Na₂CO₃ (136 pL, 2.0 M, 0.27 mmol) and dichloro[I,l'bis(diphenylphosphino)ferrocene]palladium (Π) dichloromethane adduct (5 mg, 0.007 mmol) were added and the vessel was sealed under nitrogen gas and heated under microwave irradiation at 120 °C for 20 minutes. The réaction mixture was cooled to room température, filtered and subjected to preparatory-HPLC (10-99% water/CH₃CN with 0.05 mM HCl) to give M(3aminophenyl)sulfonyI-6-rerrbuty]-2-(4-çhlorophenyl)pyridine-3-carboxamide (Compound 223) (15 mg, 25%). ESI-MS m/z cale. 443.1, found 444.1 (M+l)⁺; Rétention time: 1.81 min (3 min run).

The following compounds were synthesized using the procedures described herein: A-(3-aminophenyl)sulfonyl-6 Te rt-butyl-2-(4-tert-butylphenyl)pyridine-3-carboxamide (Compound 252),

N- (3 -aminophenyl) su Ifony 1-8,8-dimethyl-2-phenyI-6,7 -dihydro-5/TquinoIine-3-carboxamide (Compound 685), (3-aminophenyl)sulfonyl-[8,8-dimethy]-2-(p-to]yl)-6,7-dihydro-5/Tqumolme-3carbonyl]azanide (Compound 1231),

A-(4-aminophenyî)sulfonyl-6-rerr-butyI-2-(cyclohexen-l-yl)pyridine-3-carboxamide (Compound 880), ^4-aminophenyl)sulfonyl-8,8-dimethyl-2-phenyl-6,7-dihydro-5H-quino!ine-3-carboxamide (Compound 1190),

686

77-[(6-amino-2-pyridyl)sulfonyl]-6-ferr-butyl-2-(4-fluoiOphenyl)pyridine-3-carboxamide (Compound 417),

77-(3-amino phenyl)sulfony 1-6-rerr-butyl-2-indan-5-yl-pyridine-3-carboxamide (Compound 308),

77-(3-aminophenyl) su lfonyI-6-ierr-butyl-2-(3,4-dimethylphenyl)pyridine-3-carboxamide (Compound 274),

77-(3 -aminophenyl)sulfonyl-6-ierr-butyl-2-(3-ieri-butylphenyl)pyridine-3-carboxamide (Compound 229),

7V-(3-aminopheny])sulfonyI-6-/eri-butyl-2-(3,5-dimethylphenyl)pyridme-3-carboxamide (Compound 52),

77- (3 -am ino phenyl) sulfonyl-6-terr-butyl-2 -(4-is opropylphenyl)pyrid ine-3 -c arboxamide (Compound 314),

77-(3-a minophenyl)sulfonyl-6-ier/-butyl-2-(4-ethylphenyl)pyridine-3-carboxamide (Compound 359),

77-(3 -aminophen yl)sulfoîlyl·6-ter^butyl-2-[4-(tri fl uoro me thyl)phenyl]pyrid ine-3-carboxamide (Compound 129), /7-(3-aminophenyl)sulfonyl-6-7er/-butyl-2-(3-fluoro-5-methyl-phenyI)pyridine-3-carboxamide (Compound 237),

77-(3-aminophenyl)sulfonyl-6-rerr-bu tyl-2-(p-tolyl)pyridine-3-carboxamide (Compound 301),

77-(3-aminophenyl)sulfonyl-6-rert-butyl-2-(4-fluoro-3-methyl-phenyl)pyridine-3-carboxamide (Compound 177),

27-(3-aminophenyl)sulfonyl-6-reri-butyI-2-(3-fluoro-4-methyl-phenyl)pyridine-3-carboxamide (Compound 349),

77-(3-aminophenyl)sulfonyl-6-ferr-butyl-2-(2,4-dimethylphenyl)pyridine-3-carboxamide (Compound 5),

77-(3-ammophenyljsulfonyl-ô-terr-butyl-2-(m-tolyl)pyridine-3-carboxamide (Compound 282),

77-(3-aminophenyl)sulfonyl-6-rei7-butyl-2-(4-fluorophenyl)pyridine-3-carboxamide (Compound 46),

687

A4-Vaminophenyl)siüfenyI-6-rm-buîyl-2-(2-fluoro-5-meihyl^henyljpyridme-3^ (Compound 1350) (Commpound 1350),

A^r-(3-aminophenyI)sulfony 1-6-tert-butyl-2-(3,4-difluorophenyl)pyridine-3-carboxamide (Compound 1217),

AL(3-aminophenyl)sulfonyl-6-terAbutyI-2-(o-tolyI)pyridine-3-carboxamide (Compound 1036),

N- (3 -am in ophenyl)sulfonyI-6-terAbutyl-2-(4-me thoxyphenyl)pyridine-3-carboxamide (Compound 550),

W(3-aminophenyl)sulfony]-6-teri-butyl-2-(2-fluoro-4-methyl-phenyl)pyridine-3-carboxamide (Compound 1331),

W(3-aminophenyI)sulfonyl-6-ierr-butyl-2-phenyl-pyridine-3-carboxamide (Compound 542), and

W(3-aminophenyl)sulfonyl-6-terrbutyI-2-(3,4-difluorophenyl)pyridme-3-carboxamide (Compound 1217).

PREPARATION 3: A^r-(benzenesulfonyl)-64erAbutyl-2-(p-toIyl)pyridine-3carboxamide (Compound 74)

Step I: 6-^ri-butyl-2-cIiloro-pyridine-3-carboxyIic acid

O

A solution of KOH (S.65 g, 154 mmol) in water (25 mL) was added to a solution of 6iert-butyl-2-chloro-pyridine-3-carbonitrile (5.00 g, 25.7 mmol) in isopropanol (25 mL). The reaction mixture was allowed to stir at 90 °C ovemight. After cooling to room température, the reaction mixture was diluted with ethyl acetate (75 mL) and was extracted with aqueous NaOH (1 N, 3x75 mL). The combined aqueous layers were acidified to pH 3 with the addition of aqueous HCl (1 N, 200 mL) and were extracted with ethyl acetate (2x75 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated to give 6-rerr-butyl-2chloro-pyridine-3-carboxylic acid (5.25 g, 96%) as a yellow solid. ESI-MS m/zcalc. 213.1, found 214.4 (M+l)⁺; Rétention time: 1.09 min (3 min run). 'H NMR (400 MHz, CDC1₃) 5 10.39 (s, 1H), 8.26 (d, 7=8.1 Hz, 1H), 7.36 (d, 7 = 8.1 Hz, 1H), 1.38 (s, 9H).

688

Step 2: 64eri-butyl-2-(p-toI_yï)pyridine-3-carboxyiic acid

6-rerZ-Butyl-2-cbloro-pyridme-3-carboxylic acid (1,35 g, 6,32 mmol) and ptolylboronic acid (1,03 g, 7.58 mmol) were suspended in DMA (14 mL). Aqueous sodium carbonate (6.3 mL of 2.0 M, 13 mmol) was added folio wed by dichloro[l,l'bis(diphenylphosphino)ferrocene]palladium (Π) dichloro methane adduct (231 mg, 0.312 mmol). The reaction vessel was sealed under nitrogen and heated to 140 °C for 1.5 h in a microwave reactor. The reaction mixture was diluted with ethyl acetate (50 mL) and was washed with aqueous NaOH (1 M, 4x50 mL). The combined aqueous layers were acidified to pH 3 with 1 N HCl and then extracted with ethyl acetate (5x50 mL). The organic layers were combined, dried over sodium sulfate, fïltered, and concentrated underreduced pressure. The residue was subjected to silica gel column chromatography (0-30% ethyl acetate/hexane) to gîve 6-rm-bmyl2-(p-tolyl)pyridine-3-carboxylic acid (740 mg, 43%) as a white solid. ESI-MS m/z cale. 269.1, found 270.5 (M+l)⁺; Rétention time; 1.53 min (3 min run).

The following compounds cari be synthesîzed using Lhe procedures described above: 8,8-dimethyl-2-(p-toiyl)-5,6,7,8-tetrahydroquinoline-3-carboxylic acid.

Step 3: N-(benzenesulfonyl)-6-tcr/-butyl-2-(p-tolyl)pyridine-3-carboxamide (Compound 74)

To benzenesulfonamide (23 mg, 0.14 mmol) was added 6-im-butyl-2-(ptolyl)pyridine-3-carboxylic acid (35 mg, 0.13 mmol) in N.N-dimethylformamide (400 pL). A solution ofN-[(dimethyIamino)-17/-l,2,3-triazolo-[4,5-i']pyridin-l-ylmethyIene]-A^rmethylmethanaminium hexaflu orophosphate A^-oxide (54 mg, 0.14 mmol) in N,Ndimethylformamide (125 pL) was added followed by solid potassium carbonate (54 mg, 0.39 mmol). The reaction mixture was allowed to stir at 80 °C for 1 h. Additional N689

[(dimethy!amino)-lH-l,2,3-triazolo-[4,5-6]pyridin-l -ylmethyIene]-A-methylmethanaminium hexafluorophosphate A-oxide (0.5 eq) was added and the reaction mixture was allowed to stir ovemight at 80 °C. The mixture was cooled, filtered and subjected to preparatory-HPLC (1099% water/acetonitrile with 0.05 mM HCl) to give A-(benzenesulfonyl)-6-ierz-butyl-2-(ptolyl)pyridine-3-carboxamide (Compound 74) (28 mg, 53%). ESI-MS m/z cale. 408.2, found 409.3 (M+l)⁺; Rétention time: 1.93 min (3 min run).

The following compounds can be synthesized using the procedures described herein: 6-Arf-butyl-A-(3-ethyIphenyl)suIfonyl-2-(p-tolyI)pyridine-3-carboxamide (Compound 50), 6-Ze^buty l-A-(3-methoxyphenyl)sulfonyl-2-(p-tolyI)pyrid in e-3-carboxamide (Compound 327), 6-rer^butyl-A-(4-methoxyphenyl)sulfonyl-2-(p-tolyl)pyridine-3-carboxamide (Compound 206), 6-/errbutyl-A-(4-cyanophenyl)sulfonyl-2-(p-toIyl)pyridine-3-carboxamide (Compound 288), 6-to7-butyl-2-(p-tolyl)-A-(2-pyndylsulfonyI)pyridine-3-caiboxamide (Compound 407), 6-Art-bu tyl -2 -(p-tolyl) -A-( 1 H-pyrazol-5 -ylsu lfonyl)pyridine-3 -c arboxamide (Compound 632), 6-teri-butyl-A-[(5-methyl-2-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3-carboxamide (Compound 1355), 6-Ar/-butyl-A-(2-cyanophenyl)sulfonyl-2-(p-tolyl)pyridme-3-carboxamide (Compound 623), 6-tert-butyTA-(2-methoxyphenyl)sulfonyl-2-(p-tolyî)pyridine-3 -carboxamide (Compound 1124), A-(4-aminophenyl)sulfony]-8,8-dimethyl-2-(p-tolyl)-6,7-dihydro-5A-quinoiine-3-c arboxamide (Compound 1307),

6-tm-butyl-A-(2-hydroxyphenyl)sulfony 1-2-(p-tolyl)pyridine-3-carboxamide (Compound 1175), A-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimethyl-2-(p-tolyl)-6,7-dihydro-5H-quinoline-3carboxamide (Compound 444),

8,8-dimethy]-2-(p-tolyl)W-(lH-pyrazol-5-ylsulfonyl)-6,7-dihydro-5//-quinolme-3-c arboxamide (Compound 1292),

6-A^butyl-A-(4-hydroxyphenyl)sulfonyl-2-(p-tolyI)pyridine-3-carboxamide (Compound 809), 6-teri-butyl-jV-(3-hydroxyphen y l)suIfonyI-2-(p-tolyl)pyridine-3-carboxamide (Compound 1265), 6-zcrt-butyl-A-[(6-methoxy-3-pyridyl)suIfonyI]-2-(p-tolyl)pyridine-3-carboxamide (Compound

690

512),

A^,-[(6-amino-3-pyridyl)sulfonyl]-8,8-djmethy]-2-(p-tolyl)-6,7-dihydro-5U-quinolme-3carboxamide (Compound 635),

6-(3-fluoro-5-isopropoxy-phenyl)-2-(p-toIyl)-7V-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 849),

Y-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isopropoxy-phenyl)-2-(p-tolyl)pyridine-3carboxamide (Compound 722),

6-(3-fluoro-5-isopropoxy-phenyl)-A^r-[(2-methoxy-3-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3carboxamide (Compound 798),

6-feri-butyI-77-(1 H-pyrazoM-ylsuIfonyI>2-(2,4,6-trimethylphenoxy)pyridine-3 -carboxamide (Compound 401),

6-(4-fluorophenyl)-77-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 518),

77-[(2-methoxy-3-pyridyI)sulfbnyl]-8,8-dimethy]-2-(2,4,6-trimethylphenoxy)-6,7-dihydro-577quinoline-3-carboxamide (Compound 423),

6-ic77-butyl-77-[[6-(difluorometliy])-2-pyridyl]sulfonyl]-2-(2,4,6-trimetliylphenoxy)pyridine-3carboxamide (Compound 501),

7V-[(2-methoxy-3-pyridyl)sulfonyl]-2,6-bis(p-toIyl)pyridme-3-carboxamide (Compound 524), 6-(6-me thoxy-5-methyl-3-pyridyl)-77-[(2-methoxy-3-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3carboxamide (Compound 861),

6-ferAbutyl-A-[(6-methoxy-2-pyridyl)suIfonyl]-2-(p-toIyl)pyridine-3-carboxam (Compound 75), and

M(4-aminophenyl)sulfonyl-6-rm-butyl-2-(p-tolyl)pyridme-3-carboxamide (Compound 297).

PREPARATION 4: A-[(6-amiiro-2-pyridyl)sulfonyI]-6-/er/-butyl-2-(ptolyI)pjTidine-3-carboxamide (Compound 58)

Step 1: 6-^'Abutyl-iV-[(6-nuoro-2-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3carboxamide

691

A^-diisopropyl ethyl amine (104 pL, 0.5940 mmol) was added to a mixture of 6-tertbutyl-2-(p-tolyl)pyridine-3-carboxylic acid (80. mg, 0.30 mmol), 6-fluoropyridme-2-sulfonamide (58 mg, 0.33 mmol), N-[(dimethyl ami no)-\H-1,2,3 4riazolo-[4,5-6]pyridm4-ylmethylene]-jVmethylmethanaminium hexafluorophosphate M-oxide (136 mg, 0.356 mmol) and N,N~ dimethylformamide (800 pL) at room température. The mixture was heated at 70 °C ovemight before it was cooled. The mixture was partitioned between ethyl acetate and IN HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (0-20% ethyl acetate/hexanes) to give 6-teri-butyl-A-[(6-fluoro-2-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3-carboxamide (66 mg, 38%) as a yellowish solid. ESI-MS m/z cale. 427.1, found 428.4 (M+l)⁺; Rétention time: 0.7 min (1 min ron).

Step 2: 7V-[(6-amino-2-pyridyI)sulfonyl]-6-ierAbutyl-2-(p-tolyl)pyrÎdine-3carboxamide (Compund 58)

A mixture of 6-tert-butyl-A-f(6-fluoro-2-pyridyl)sulfonyl]-2-(p-tolyl)pyridine-3carboxamide (55 mg, 0.13 mmol) and NH₄OH (30%, 860 pL) was heated at 150 °C for 30 min in a microwave reactor. The mixture was concentrated and the residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give A-Kô-amino^pyridyI)sulfonyl]-6-rez7-butyl-2-(p-tolyl)pyridine-3-carboxamide (Compound 58) (17 mg, 31%). ESI-MS m/z cale. 424.2, found 425.4 (M+l)*; Rétention time: 1.63 min (3 min run).

The following compounds can be synthesized using the procedures described herein: 27-[(6-amino-2-pyridyl)suIfonyl]-6-rerr-butyl-2-(m-tolyl)pyridme-3-carboxamide (Compound

692

31).

TA [(6-ami n o-2-pyridyl)sulfonyl]-6-feri-butyl-2-(cyclopenten-l-yl)pyridine~3-carboxamide (Compound 529),

Y-[(6-amino-2-pyridyI)sulfonyl]-6-reri-butyl-2-(cycIohexen-l-yl)pyridine-3-carboxamide (Compound 478),

Y-[(6-amino-2-pyridyl)sulfonyI]-6-(4-ethoxyphenyl)-2-(p-tolyl)pyridine-3-cafboxamide (Compound 409),

N- [(6-amino-2-pyridyl)sulfonyl]-6-ierrbutyI-2-(4-fluorophenyl)pyridi ne-3-carboxamide (Compound 417), and /7-[(6-amino-2-pyridyl)sulfbnyl]-6-ierf-butyl-2-phenyl-pyridine-3-carboxamide (Compound 334).

PREPARATION 5: 6-phenethyl-2-(2,4₎6-trÎmethy]phenoxy)pyridine-3carboxylic acid

Step 1: methyl 6-chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

O

NaH (60%, 2.13 g, 53.3 mmol) was added to a solution of 2,4,6-trimethylphenol (6.60 g, 48.5 mmol) and MAMimethylformamide (150 mL) at 0 °C. The mixture was stirred for 15 min before a solution of methyl 2,6-dichloronicotinate (10.0 g, 48.5 mmol) in N,Ndimethylformamide (20 mL) was added dropwise. The mixture was allowed to stir for 1 h at room température before water was added. The mixture was extracted with ethyl acetate (2x). The combined extracts were washed with water and brine, dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-50% CHiCh/hexanes) to give methyl 6-chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

693 (3.58 g, 24%). ESLMS Wzcalc. 305,1, found 306,2 (M+l)⁺; Rétention time: 0.87 min (1 min run).

Step 2: methyl 6-phcncihyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

Bromo-(2-phenylethyl)zinc (3.9 mL of 0.5 M, 2,0 mmol) and dichloro[l,Tbis(diphenylphosphino)ferrocene]palladium (Π) dichloromethane adduct (36 mg, 0.049 mmol) were stirred at room température under an atmosphère of nitrogen for 20 min, Methyl 6-chloro2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (150 mg, 0.49 mmol) was added to the reaction mixture and it was then heated at 150 °C for 10 minutes in a micro wave reactor, A saturated aqueous solution of ethylenediaminetetraacetic acid disodium sait (2 mL) and a saturated aqueous solution of ammonium chloride were added to the reaction mixture. After stirring for 30 minutes, the layers were separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were evaporated to dryness and the residue was subjected to preparatory-HPLC (20-80% acetonitrile/water with 5 mM HCl) to yield methyl 615 (2-phenylethyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (56 mg, 31%). ESI-MS m/z cale. 375.2, found 376.4 (M+l)⁺; Rétention time: 0.87 min (1 min run).

Step 3: 6-phenethyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid

Methyl 6-(2-pheny!ethyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (56 mg,

0.15 mmol) was dissolved in methanol (5mL). NaOH (245 pL of 4.0 M, 0.98 mmol) was added

694 and the mixture was stirred at room température ovemight. The solvent was removed and the pH of the residue was adjusted to -3 with IN HCl. The precipitate was filtered, washed with water and dried to give 6-phenethyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (21 mg, 36%). ESI-MS m/z cale. 361.2, found 362.5 (M+l)⁺; Rétention time: 0.77 min (1 min run).

The following compound can be synthesized using the procedures described herein: 6-benzyl-2-(2,4,6-trimethyIphenoxy)pyridine-3-carboxylic acid.

PREPARATION 6: A-[(6-amÎno-2-pyridyl)su]fonyl]-6-ferAbutyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 228)

Step 1: 6-h?rAbutyl-2-(2,4,6-trimethylphe no xy)pyrïdine-3-carbonitrile

6-to7-Butyl-2-chloro-pyridine-3-carbonitrile (5.00 g, 25.7 mmol), 2,4,6trimethylphenol (3.50 g, 25.7 mmol), K₂CO₃ (3.91 g, 28.3 mmol) and ΛζΝ-dimethylformarnide (10 mL) wcrc added to a 40 mL vial. The mixture was stirred ovemighi al 95 °C. The reaction mixture was diluted with H₂O (10 mL) and was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The residue was subjected to silica gel column chromatography (0-20% ethyl acetate/hexanes) to give 6-terLbutyl-2-(2,4,6-trimeÛiylphenoxy)pyridine-3-carbonitrile (6.70 g, 84%) as a white solid. ESI-MS m/z cale. 294.2, found 295.2 (M+l)⁺; Rétention time: 2.31 min (3 min run). ‘H NMR (400 MHz, DMSO) δ 8.31 (d, 7 = 8.0 Hz, 1H), 7.25 (d,7=7.9 Hz, 1H), 6.96 (s, 2H), 2.27 (s, 3H), 2.00 (s, 6H), 1.07 (s, 9H).

Step 2: 6-terf-buty 1-2-(2,4,6-trimethylphenoxy)pyridÎne-3-carboxylie acid

695

Ο

A mixture of 6-iirr-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carbonitrile (4.50 g, 15.3 mmol), KOH (5.15 g, 91.7 mmol), EtOH (135 ml) and H₂O (32 mL) was heated at 90 °C ovemight. Additional KOH (2.00 g, 35.6 mmol) was added and the mixture was heated at 90 °C 5 overnight. The mixture was cooled to room température, concentrated and acidified to pH -2 with 2N HCl. The solids were collected via filtration and were placed in a vacuum oven at 50 °C ovemight to give 6-toAbuty 1-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (4.64 g, 96%). ’HNMR (400 MHz, DMSO) δ 8.14 (d, J = 7.8 Hz, 1H), 7.08 (d, 7 = 7.8 Hz, 1H), 6.91 (s, 2H), 2.26 (s, 3H), 1.97 (s, 6H), 1.04 (s, 9H).

Step 3: 6-iert-butyl-A^r-[(6-fluoro-2-pyridyl)sulfonyl]-2-(2,4,6 trim ethy Iphe noxy )py ridine-3-carboxamid e

TV-ethyl-A-isopropylpropan-2-amine (560 pL, 3.19 mmol) was added to a mixture of 6-terT-butyl-2-(2,4,6-trimethylphenoxy)pyridme-3-carboxylic acid (500. mg, 1.56 mmol), 615 fluoropyridme-2-sulfonamide (309 mg, 1.76 mmol), TV-[(dimethylamino)-lH-l,2,3-triazolo-[4,5i>]pyridin-l -ylmethyleneJ-TV-methylmethanaminium hexafluorophosphate N-oxide (728 mg, 1.91 mmol) and jV,N-dimethylfomiamide (5 ntL) at room température. The mixture was heated at 70 °C ovemight before it was cooled. The mixture was partitioned between ethyl acetate and IN HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (3x).

The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-20% ethyl

696 acetate/hexanes), then a second purification by silica gel column chromatography (0-10% ethyi acetate/hexanes) to give 6-te77-butyI-jV-[(6-fluoro-2-pyridyl)sulfonyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (230 mg, 23%) as a white solid. ESI-MS wi cale. 471.2, found 472,4 (M+l)⁺; Rétention time: 2,32 min (3 min run).

Step 4: N-[(6-amino-2-pyridyI)sulfonyl]-6-terr-butyl-2-(2,4,6 trimethylphenoxy)pyridine-3-carboxamide (Compound 228)

6-to7-Butyl-A^r-[(6-fluoro-2-pyridyI)sulfonyl]-2-(2,4,6-triniethylphenoxy)pyridine-3carboxamide (77 mg, 0.16 mmol) was dissolved in ammonium hydrexide (10 mL of 30 %w/w) and irradiated in the microwave reactor for 1 h at 150 °C. The mixture was evaporated and the crude material was purified by preparatory-HPLC (10-99% acetonitrile/water with 5 μΜ HCI). The material was further purified by silica gel chromatography (0-100% ethyi acetate/hexanes) to give N-[(6-ammo-2-pyridyl)sulfonyl]-6-/ert-butyI-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 228) (27 mg, 35%), ’H NMR (400 MHz, DMSO) δ 12.10 (s, 1 H), 8.01 (d, 7 = 7.8 Hz, 1H), 7.67 -7.58 (m, 1 H), 7.20 (d,7=7.3 Hz, IH),?.]! (d,7= 7.9 Hz, 1H), 6.90 (s,2H), 6.69 (d,7= 8.6 Hz, 1 H), 6.49 (s, 2H), 2.26 (s, 3H), 1.97 (s, 6H), 1.05 (s, 9H). ESI-MS ιη/z cale. 468.2, found 469.3 (M+l )⁺; Rétention time: 2.11 min (3 min run).

The following compounds can be synthesized using the procedures described herein: 6-tm-butyl-jV-(lH-indol-4-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 275), A^r-(benzenesulfonyl)-6-/ez7-butyl-2-(2-isopropylphenoxy)pyridine-3-carboxamide (Compound 147), 6-rer/-buty]W-[[6-(dimethylamino)-2-pyridyl]sulfony]]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 468), /V-[(6-amino-2-pyridyl)sulfonylJ-6-(l, 1,2,2,2-pentafluoroethyl)-2-(2,4,6tri methylphenoxy)py ri dine-3-carboxamide (Compound 853),

697

7/-(4-aminophenyl)suIfonyl-6-(l-metlryIcycIopropyl)-2-(2,4,6-trimethyiphenoxy)pyridine-3carboxamide (Compound 1297),

TV- (2-aminothiazol-4-yl)sulfonyl-6-rer/-buty 1-2-(2,4,6-trimethylphenoxy)pyridine-3 -carboxamide (Compound 1294),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l-methylcyclopropyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 1310),

A4(6-amino-2-pyridyI)sulfonyI]-5-(l-methylcyclopropyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 854),

M (3-aminophenyl)sulfony 1-6-(1-methylcyclopropyl)-2-(2,4,6-trimeÎhyIphenoxy)pyridine-310 carboxamide (Compound 826),

6-(3-fluoro-5-isopropoxy-phenyl)-A^r-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6tnmethylphenoxy)pyridme-3-carboxamide (Compound 914), 77-[(6-amino-2-pyridyl)sulfonyl]-6-prop-l-ynyl-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 1172),

6-rerr-bu tyl-7V-(2-me thylpyrazol -3 -y l)su lfonyl-2-(2,4,6 -trime thylphenoxy)p yridine-3 carboxamide (Compound 911),

7V-[(6-amino-2-pyridyl)sulfonyl]-5,6-dimethyl-2-(2,4,6-trimethy]phenoxy)pyridine-3carboxamide (Compound 841),

W6-(2-hydroxyethylamino)-2-pyridyl]sulfonyl]-6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine20 3-carboxamide (Compound 595),

A^r-[[6-(dimethyIamino)-2-pyridyl]suIfonyl]-6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 869),

N-[[6-(2-aminoethylamino)-2-pyridyl]sulfonyl]-6-phenyI-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1027),

[[6-(me thylamino)-2-pyridyl] su lfonyl]-6-phenyl-2-(2,4,6-tri me thylphenoxy)pyridine-3carboxamide (Compound 1032),

A4[6-(2-dimethylaminoethylamino)-2-pyridyl]sulfbnyl]-6-phenyl-2-(2,4,6trimethylphenoxy)pyridîne-3-carboxamide (Compound 1122),

N-[(6-cyano-2-pyridyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,4,630 trimethylphenoxy)pyridine-3-carboxamide (Compound 771),

N-[(6-amino-2-pyridyl)sulfonyl]-4-methyl-6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3698 carboxamide (Compound 1102),

6-i<?r/-butyI-A^r-[[6-(2-hydroxyethylamino)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 916), 6-ierr-butyl-A^r-[[6-(2-dimethyIaminoethylamino)-2-pyridyl]suIfonyl]-2-(2,4,6trimethylpbenoxy)pyridine-3-carboxamide (Compound 947),

6-[[6-(3-fluoro-5-isobutoxy-pheny 1)-2-(2,4,6-trimethylphenoxy)pyridi ne-3carbonyI]sulfamoyl]pyridine-2-carboxylic acid (Compound 461),

6-(3-fluoro-5-isobutoxy-phenyl)-7V-[[6-(hydroxymethyl)-2-pyridyl]sulfonyl]-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 1340), /V-[[6-(2-aminoethylamino)-2-pyridyl]sulfbnyI]-6-ierLbutyl-2-(2,4,6*trimethylphenoxy)pyridine3-carboxamide (Compound 1054),

V-[(6-amino-2-pyridyl)sulfonyI]-6-me thyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1137),

7V-(2-azidoph en yl)sulfonyl-6-rerf-butyl-2-(2,4,6-trimethylphenoxy)pyridîne-3-carboxamide, 6-methyl-jV-(lH-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 670), /V-[(6-amino-2-pyridyl)sulfonyI]-5-phenethyI-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1253), iV-[(6-amino-2-pyridyl)sulfonyi]-6-[l-(trifliioromethyl)cycIopropyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 621),

À^r-[(6-amino-2-pyridyl)sulfonyl]-5-benzyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1233),

À^r-[[6-(isopropylamîno)-2-pyridyl]sulfonyl]-6-methyl-2-(2,4,6-trimeûiylphenoxy)pyridine-3carboxamide (Compound 482),

A^r-[[6-(2-methoxyethylamino)-2-pyridyl]sulfonyl]-6-methyl-2-(2,4,6-trimethyIphenoxy)pyridine3-carboxamide (compound 372),

N-[(6-amino-2-pyridyl)sulfbnyl]-8,8-dimethyl-2-(2,4,6-trimethylphenoxy)-6,7-dihydro-5/7qu in oline-3-carboxamide (Compound 182), /V-(benzenesulfonyI)-6-rerributyl-2-(2,4,6-trime thylphenoxy)pyridine-3-carboxamide (Compound 34] ),

6-iert-butyl-7V-[3-(methylamino)phenyl]sulibnyl-2-(2,4,6-trimethylphenoxy)pyridine-3699 carboxamide (Compound 289),

6-iert-butyl-A'-[3-(dimethylamino)phenyl]sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 311),

6-iert-butyl-?/-(2-cyanophenyl)suIfonyl -2-(2,4 _i6-trimethylphenoxy)pyridine-3 -carboxamide (Compound 78), jV-(benzenesulfonyl)-6-ieri-butyl-2-(l-methylindol-7-yl)oxy-pyridine-3-carboxamide (Compound 326),

6-ier/-butyl-iV-(l-methylindol-4-yl)sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 146),

7V-[(6-amino-5-fluoro-2-pyridyI)sulfonyl]-6-reïï-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide,

6-ieri-butyl-A^r-[(6-methoxy-2-pyridyl)sulfony]]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 34),

6-rm-butyl-AH4-pyridy!sulfony 1)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 117),

A^r-[(2-amino-3-pyridyI)sulfonyl]-6-ierAbutyI-2-(2,4,6-trimetbylphenoxy)pyridine-3-carboxamide (Compound 235),

A/-[(6-armno-2-pyndyl)sulfbnyI]-2-(2,4-dimethylphenoxy)-o-(3-iluüro-5-isobutoxyph en yl)pyridine-3-carboxamide (Compound 590),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyIphenoxy)pyridine3-carboxamide (Compound 778),

6-iert-butyl-A^r-(2-methoxyphenyl)sulfony 1-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 115),

6-rert-butyl-7V^r-[(2-methoxy-3-pyridyl)suIfonyl]-2-(2,4,6-îrimethylphenoxy)pyridine-3carboxamide (Compound 191),

6-mr/-butyl-AQV-pyridyl su Ifonyl)-2-(2,4,6-trime thylphenoxy)pyridi ne-3 -carboxamide (Compound 222),

N-[(2-amino-4-pyridyl)sulfonyl]-6-ierr-butyl-2-(2,4,6-trimethy]phenoxy)pyridine-3-carboxamide (Compound 283),

6-rert-butyl-77-[(2-methoxy-4-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 217),

700

6-ter/-butyl-jV-(3-pyridylsulfony 1)-2-(2,4,6-trin)ethylphenoxy)pyridine-3-carboxamide (Compound 330),

6-mrr-butyl-79-(3-methoxyphenyl)sulfony 1-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 56),

AA(benzenesulfonyI)-6-(trifluorometliyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 244), 6-/err-butylW-[(3-methoxy-2-pyridyl)sulfonyl]-2-(2,4,6-trimetliylphenoxy)pyridine-3carboxamide (Compound 92),

Y- (benzenesulfon yI)-2-benzyloxy-6-ieri-butyl-pyri dine-3 -carboxamid e (Compound 130), 6-ier/-butyl-2-(2,4-dimethylphenoxy)-N-[(2-methoxy-3-pyridyl)sulfonyllpyridine-3carboxamide (Compound 89), !V-[(6-amino-2-pyridyl)sulfonyl]-6-ierAbutyl-2-(2,4-dimethylphenoxy)pyridme-3-carboxamide (Compound 204),

A^4-aminophenyl)sulfonyl-6-teri-butyl-2-(2,4,6-trimethylphenoxy)pyridme-3-carboxamide (Compound 11),

A43-aminophenyl)sulfbnyl-6-teri-butyl-2-(l-phenylethoxy)pyridine-3-carboxamide (Compound 219),

A4(6-amÎno-2-pyridyl)sulfonyI]-2-(2,4,6-trimethylphenoxy)-5,6,7,8-tetrahydroquinoline-3carboxamide (Compound 285), /V-[(5-ammo-3-pyridyl)sulfonyl]-6-rÉ’rEbutyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxainide (Compound 163),

A^r-(3-aminophenyl)sulfonyl-6-rert-butyI-2-(2-methylphenoxy)pyridine-3-carboxamide (Compound 296),

A^r-(3-aminophenyl)suIfonyl-6-ierr-butyl-2-(4-cyano-2,6-dimethyl-phenoxy)pyridine-3carboxamide (Compound 111), 79-(3-aminophenyl)sulfonyl-6-terr-butyl-2-(2,4-dimethylphenoxy)pyridine-3-carboxamide (Compound 251),

M-[(6-ammo-2-pyridyl)sulfonyl]-2-(2,3-dimethylcydopentoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridme-3-carboxamide (Compound 503), /V-(benzenesulfbnyl)-6-teri-butyl-2-(3-methoxyphenoxy)pyndme-3-carboxamide (Compound 101),

701

6-teri-butyl-7V-[(6-oxo-lH-pyridm-2-yl)sulfbnyl]-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 305),

N-(3-ammophenyl)sulfcmyl-6-Zert-butyl-2-(2-cyano-4,6-dimethyl-phenoxy)pyridine-3carboxamide (Compound 221),

N-(3-aminophenyl)sulfony 1-2-(2,6 -dimethyl phenoxy)-6-(triflu orometh yl)pyridine-3carboxamide (Compound 243),

N-(3-ammophenyl)sulfonyl-6-(trifluoromethyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 96), 6-re^butyl-N-[(4-oxo-l//-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 107),

N-(benzenesulfonyl)-6-te ri-butyl-2-(2-pyridyl me thoxy)pyridine-3-carboxamide (Compound 154),

6-tert-butyl7V-[(2-oxo-l/7-pyridin-4-yl)sulfbnyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 113),

6-tert-butyl-2-(2,4 -di methylpheno xy)-N- [ (2-hydroxy-3 -pyridy l)sulfon yl ]py ridine-3 carboxamide,

N-[(6-amino-2-pyridyl)sulfonyl]-6-(Îrifluoromethyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 175),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(trifluoromethyl)pyridine-3carboxamide (Compound 246),

N-[(6-amino-2-pyridyl)sulfonyl]-6-cyclopropyl-4-(trifIuoromethyl)-2-(2,4,6trimethylphenoxy)pyri dîne-3-carboxamide (Compound 54), jV-(3-aminophenyl)sulfonyl-6-terr-butyl-2-phenoxy~pyridme-3-carboxamide (Compound 272), N-(3-aminophenyI)sulfbnyl-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 13),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3methylcyclopentoxy)pyridine-3-carboxamide (Compound 452),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-phenoxy-pyridine-3carboxamide (Compound 376),

702 jV-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[l-(3fluorophenyl)ethoxy]pyridme-3-carboxamide (Compound 562),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-[(3-ethyloxetan-3-yl)methoxy]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 618),

M[[6-(3-ami nopropylamino)-2-pyridyI]sulfonyl]-6-me thyl-2-(2,4,6-trime thylphenoxy)pyridine3-carboxamide (Compound 982),

N-[[6-(cyclopropylamino)-2-pyridyl]sulfonyl]-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 594),

6-methyl-N-[[6-(methylamjno)-2-pyridyl]sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 646),

N-[[6-(2-aminoethylamino)-2-pyridyl]sulfonyl]-6-methyl-2-(2,4,6-trime thylphenoxy)pyridine-3carboxamide (Compound 792),

6-methyl·Λ^r-[(6-morpholino-2-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 883),

6-methyl·N-[[6-(4-methylpiperazin-l-yl)-2-pyridyl]sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1018),

N-[[6-(dimethylamino)-2-pyridyl]suIfonyl]-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1250),

2-(2,4-dimethylphenoxy)W-[(2-methoxy-3-pyridyl)sulfonyl]-8,8-dimethyl-6,7-dihydro-5/7quinoline-3-carboxamide (Compound 1347),

2-(2,4-dimethylphenoxy)-8,8-dimethylW-(lH-pyrazol-3-ylsulfonyl)-6,7-dihydro-5H-quinoIme3-carboxamide (Compound 1246),

6-ieri-butyl-N-[(2-methoxy-6-methyl-3-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1153),

8,8-dimethyl-N-(lH-pyrazol-5-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)-6,7-dihydro-5Hquinoline-3-carboxamide (Compound 715),

703

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobuÎoxy-phenyl)-2-(oxetan-2ylmethoxy)pyridine-3-carboxamide (Compound 640),

A-[(6-amino-2-pyridyl)stdfonyI]-6-iÎTrtbutyl-2-(cyclohexoxy)pyridine-3-carboxamide (Compound 649),

2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxy-phenyl)-A-(lH-pyrazoI-5-ylsulfonyl)pyridine3-carboxamide (Compound 671),

6-(3-fluoro-5-isobutoxy-phenyl)-2-phenoxy-A-(lH-pyrazol-5-ylsu]fbnyl)pyridine-3-carboxamide (Compound 679),

A-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-tetrahydropyran-3-yloxypyridine-3-carboxamide (Compound 706),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methylphenoxy)-W-(lH-pyrazol-5-ylsu]fonyl)pyridine-3carboxamide (Compound 738),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methylphenoxy)-A-(ÎH-pyrazol-5-ylsulfonyi)pyridine-3carboxamide (Compound 758),

A-[(6-ammo-2-pyridyl)sulfbnyl]-6-rert-butyl-2-(2-cyano-4,6-dimethyl-phenoxy)pyridine-3carboxamide (Compound 767),

A-[(6-ammo-2-pyridyl)sulfonyl]-2-[(2,2-difluorocyclopropyl)methoxy]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 769),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[l-(o-tolyl)ethoxy]pyridine3-carboxamide (Compound 782),

A-[(6-ammo-2-pyridyl)$ulfonyl]-6-(3-fluoiO-5-isobLitoxy-phenyl)-2-[(3-methyloxetan-3yl)methoxy]pyridine-3-carboxamide (Compound 824),

A-[(6-ammo-2-pyridyl)sulfonyl]-6-firf-buiyl-2-(2,4-difluorophenoxy)pyridine-3-carboxamide (Compound 829),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[l-(4fluorophenyl)ethoxy]pyridme-3-carboxamide (Compound 867),

704 /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(oxetan-3-yloxy)pyridine-3carboxamide (Compound 872),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-iluoro-5-isobutoxy-phenyl)-2-(l-phenyletlioxy)pyridine-3carboxamide (Compound 874),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2,2-dimethylcyclopropyl)niethoxy]-6-(3-fluoro-5isobutDxy-phenyl)pyridine-3-carboxamide (Compound 894),

A^F-[(6-amino-2-pyridyl)sulfony!]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(tetrahydropyran-4ylmethoxy)pyridine-3-carboxamide (Compound 933),

2V-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-difluorocyclohexoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 961),

N- [(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro -5-isobutoxy-phenyl)-2-(1-me thyl-2-pheny Ιέ thoxy)pyridine-3-carboxamide (Compound 967),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylcyclohexoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 978),

N-[(6-amino-2-pyridyl)sulfonyl]-6-terf-butyl-2-(2-isopropylphenoxy)pyridine-3-carboxamide (Compound 1031),

N- [(6-amino-2-pyridyl)sulfonyl]-6-rert-butyl-2-(l-phenylpropoxy)pyridine-3 -carboxamide (Compound 1045),

N- [(6-annno-2-pyridyl)sulfonyl]-6-terAbutyl-2-phenoxy-pyridine-3-carboxamide (Compound 1046),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3-fiuorooxetan-3yl)methoxy]pyridine-3-carboxamide (Compound 1053),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(l-phenylpropoxy)pyridine3-carboxamide (Compound 1068),

A^,-[(6-amino-2-pyridyl)suIfonyl]-6-ierr-butyl-2-(l-methylindol-7-yl)oxy-pyridine-3-carboxamide (Compound 1071),

705

N-[(6-amino-2-pyridyl)sulfonyI]-2-[[(lR,5S)-3-bicyclo[3.1 O]hexanyl]oxy]-6-(3-fluoro-5isobutoxy-phenyl)pyridi ne-3-carboxamide (Compound 1077),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-fert-butyI-2-(4-cyano-2,6-dimethyl-phenoxy)pyridine-3carboxamide (Compound 1089),

ZV-[(6-amino-2-pyridyl)sulfonyl]-6-rei-i-butyl-2-(4-fluoro-2-methyl-phenoxy)pyridine-3carboxamide (Compound 1104),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2methylcyc lob exoxy)py ri dine-3-carboxamide (Compound 1108), )V-[(6-amino-2-pyridyl)sulfonyl]-6-fÊ ri-bu tyl-2-(cyclobutoxy)pyridine-3-carboxamide (Compound 1154),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(l-cyclopropylethoxy)-6-(3-f]uoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1165),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(lR,2R,4S)-norboman-2yl]oxy-pyridine-3-carboxamide (Compound 1216),

7V-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-norboman-2-yloxy-pyridme3-carboxamide (Compound 1227),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(cyclopropylmethoxy)-6-(3 -fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1229),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(l-cyclobutylethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1238),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-rerr-butyI-2-(2,6-dimethylphenoxy)pyridine-3-carboxamide (Compound 1243), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(cyclobeptoxy)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 1263),

V-[(6-amino-2-pyridyl)sulfbnyl]-6-rert-butyI-2-(l -methyl-2-phenyl-ethoxy)pyridine-3carboxamide (Compound 1314),

706

N- [(6 - amino-2 -py ridy 1) sulfony 1] -6-n?ri-butyl-2- (2-methylphenoxy )pyridine-3 -c arboxamide (Compound 1318),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-tetrahydropyran-4-yloxypyridine-3-carboxamide (Compound 1324),

N- [(6-amino-2-pyndyl)sulfonyl]-6-?m-butyl-2-norbornan-2-yloxy-pyridine-3 -c arboxamide (Compound 1349),

A4(6-amino-2-pyridyl)suifonyl]-7,7-dimethyl-2-(2,4,6-trimethyIphenoxy)-6,8-dihydro-5f/quinoline-3-carboxamide (Compound 665),

Æ-[(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dimethylcyclopentoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 416),

N-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-tetrahydrofuran-3-yloxypyridine-3-carboxamide (Compound 433),

N-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4methylcyclohexoxy)pyridine-3-carboxamide (Compound 438),

N-[(6-amino-2-pyridyl)sulfonyl]-6-ierFbutyl-2-[(4S)-2,2,4-trimethylpynOlidin-l-yl]pyridine-3carboxamide (Compound 985),

A^[(6-amino-2-pyridyl)sulfonyI]-6-im-butyl-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 1461),

3-[[6-ieri-butyI-2-(2,4,6-trimethylphenoxy)pyridine-3-carbonyl]sulfamoyl]benzoic acid (Compound 205),

N-(3-aminophenyl)sulfonyl-6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3-c arboxamide (Compound 231),

N-[(6-arnino-2-pyridyl)sulfonyI]-6-phenethyI-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 268),

N-[(6-amino-2-py ri d y l)sulfonyl]-6-benzyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1),

N-(benzenesuIfonyl)-2-(2,4,6-trimethylphenoxy)quinoline-3-carboxamide (Compound 215), N-[(6-amino-2-pyridyl)sulfonyl]-8-methyl-2-(2,4,6-trimethylphenoxy)quinoline-3-carboxamide (Compound 70),

707

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)quinoline-3-carboxamide (Compound 91),

Æ-(3-aminophenyI)sulfonyl-2-(2,4,6-tri methylphenoxy)quinoline-3-carboxamide (Compound 260),

N-(4-pyndylsulfonyl )-2-(2,4,6-trimethylphenoxy)quinoline-3-carboxamide (Compound 240), 6-ferTbutyl4V-(lH-pyrazol-5-ylsulfonyI)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 214),

6-rm-butyl-A'-[[6-(methyl amino )-2-pyridyl]sulfbnyl]-2-(2,4,6-t rime thylphenoxy)pyridine-3carboxamide (Compound 262), and

A-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,7-dihydro-5/A quinoline-3-carboxamide (Compound 15).

PREPARATION 7: 6-terAbutyLV-(2-hydroxyphenyl)sulfony 1-2-(2,4,6trîmethylphenoxy)pyridine-3-carboxamide (Compound 131)

6Tert-Butyl-)V-(2-methoxyphenyI)sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 115) (99 mg, 0.21 mmol) was taken up in CH2CI2 (10 mL). The mixture was cooled to -78 °C before BBr₃ (1.0 mL, IM, 1.0 mmol) was added slowly. The mixture allowed to warm to room température overnight. The reaction mixture was diluted with saturated NaHCO₃ (10 mL) and was extracted with ethyl acetate (2x5 mL). The organic layers were dried over sodium sulfate and concentrated. The residue was subjected to preparatoryHPLC (20-80% acetonitrile/water with 5 mM HCl) to give 6-mrAbutyl-/V-(2hydroxyphenyl)sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3~carboxamide (Compound 131) (63 mg, 66%). 'H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 11.04 (s, 1H), 8.05 (d, J = 7.8 Hz, 1 H), 7.83 (d, 7=7.9 Hz, 1 H), 7.52 (s, 1 H), 7.16 (d,J= 7.9 Hz, 1 H), 7.02 (s,2H), 6.93 (s, 2H), 2.26 (s, 3H), 1.98 (s, 6H), 1.04 (s, 9H). ESI-MS m/z cale. 468.2, found 469.0 (M+l)⁺; Rétention time: 2.16 min (3 min run).

708

The following compound can be .synthesîzed using the procedures described herein: 6-fcr/-butyl-A^r-(3-hydroxyphenyl)su]fonyl-2-(2,4,â-trimethylphenoxy)pyridine-3-carboxamide (Compound 47) and

6-(3-iluoro-5-isobutoxy-phenyI)W-(3-hydroxyphenyl)sulfonyl-2-(2,2,4trimethy]pyrrolidin-!-yl)pyridine-3-carboxamide (Compound 395).

PREPARATION 8: 6-rerAbutyl-2-(l-phcnylethyl)pyridine-3-carboxylic acid Step 1: 6-ier/-butyl-2-(l-phenylethyl)pyridine-3-carbonitriIe

X T

J T ____

A mixture of bromo(l-phenylethyl)zinc (4.1 mL of0.5 M, 2.1 mmol) and dîchloro[l,I '-bis(diphenylphosphino)fenocene]palladiuni (II) dichloromethane adduct (38 mg, 0.051 mmol) was stirred at room température under an atmosphère of nitrogen for 20 min. 6rer/-Butyl-2-chloro-pyridine-3-carbonitri]e (100 mg, 0.51 mmol) was added and the reaction mixture was heated at 150 °C for 10 min in a microwave reactor. The mixture was concentrated and the residue was subjected to silica gel column chromatography (0-20% ethyl acetate/hexanes) to give 6-ierrbutyl-2-(l-phenylethyl)pyridine-3-carbonitrile (120 mg, 80.%). ESI-MS m/z cale. 264.2, found 265.4 (M+l)⁺; Rétention time: 2.28 min (3 min run).

Step 2: ô-ieri-butyl^-tl-phenylethyllpyridîne-j-carboxylic acid

A mixture of 6-/err-butyl-2-(l -phenylethyl)pyridine-3-carbonitrile (120 mg, 0.45 mmol), KOI-I (1.1 mL of 4.0 M, 4.4 mmol) and EtOH (1,2 mL) was heated ai 90 °C overnight. The mixture was concentrated and conc. HCl was added to the residue. The solïds were collected

709 and washed with water. The solids were placed in a vacuum oven at 60 °C ovemight to give a 1:1 mixture of 6-terLbutyl-2-(l-phenylethyI)pyridine-3-carboxylic acid [ESI-MS m/z cale.

283.2, found 284.3 (M+l)⁺; Rétention time: 0.78 min (1 min run)] and 6-tert-butyl-2-(lphenylethyl)pyridine-3-carboxamide [ESI-MS m/z cale. 282.2, found 283.4 (M+l)⁺; Rétention time: 0.69 min (1 min run)].

The following compound cari be synthesized using the procedures described herein: 6 -terf-butyl-2 -[(2,4,6-trimethylphenyl)meth yl ]p yri dine-3 -c arboxylic acid, N-(3-aminophenyl)sulfonyl-6-terr-butyI-2-(l-phenylethyl)pyridine-3-carboxamide (Compound 271), and M(3-aminophenyl)sulfonyl-6-rm-butyl-2-[(2,4,6-trimethylpheny!)methyl]pyridine-3carboxamide (Compound 346).

PREPARATION 9: 6-ferEbutyl-3-[(2,4,6-trimethylphenyl)methyl]pyridine-2carboxylic acid Step 1: 5'bromo-2-to7-butylpyridÎne

/eri-Butylmagnesium chloride (60 mL of a 1.0 N solution in THF, 60 mmol) was slowly added to a greenish suspension of CuCN (2.7 g, 30 mmol) in THF (60 mL) cooled to -78 °C and the resulting gray mixture was stirred at -78 °C for 1 h. A solution of 5-bromo-2iodopyridine (4.3 g, 15 mmol) in THF (10 mL) was then added. The reaction mixture was stirred at -78 °C for 1 h then at 0 °C for 3 h before being allowed to warm up gradually to room température ovemight. Ammonium hydroxide (80 mL of 20%) was added and the resulting mixture was filtered and washed with ethyl acetate (100 mL). The filtrate was washed with brine (40 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-10% ethyl acetate/heptanes) to afford 5-bromo-2-ferfbutylpyridine (2.2 g, 68%; contains 20% heptanes) as a colorless oil. ’H NMR (300 MHz, CDC1₃)§ 1.43 (s, 9H), 7.23 (dd, J = 8.5, 0.9 Hz, 1H),7.71 (dd, J = 8.5, 2.3 Hz, 1 H), 8.60 (d,J = 2.3 Hz, 1H). [M+H]⁺= 214.0.

Step 2: 5-bromo-2-teri-butylpyridine-A^T-oxide

710 © I I ⁰ ^^'Br ^^Br

3-ChIorobenzoperoxoic acid (4.40 g of 77% grade, 17.9 mmol) was added to a solution of 5-bromo-2-te ri-bu tyl pyridine (3.70 g, 13.8 mmol) in dichloromehtane (45 mL). The reaction mixture was stirred at room température ovemight. Ca(OH)₂ (4.1 g, 44 mmol) was added and the resulting mixture was then stirred at room température for 30 min before being filtered through a pad of Celite. The filtrate was concentrated under reduced pressure and the résidu e was purified by silica gel chromatography (0-50% ethyl acetate/heptanes) to afford 5bromo-2-mri-butylpyridine-A-oxide (2.7 g, 85%) as a white solid. ’H NMR (300 MHz, CDCI3) 5 1.48 (s, 9H), 7.19 (d, 7= 8.8 Hz, 1 H), 7.31 (dd,7 = 8.8, 1.8 Hz, 1H), 8.33 (d, J= 1.8 Hz, 1H). [M+H]⁺= 230.0.

Step 3: 6-icri-butyIpyridine-2-carbonitrile

Θ

I ° I

Sx, ,N, .CN

XX ^^Br ^^^Br

Trimethylsilanecarbonitrile (8.8 mL, 70 mmol) and EtjN (7.4 mL, 53 mmol) were added to a solution of 5-bromo-2-terr-butylpyridme-N-oxide (2.7 g, 12 mmol) in acetonitrile (20 mL) at room température. The reaction mixture was then heated at 100 °C ovemight. Additional trimethylsilanecarbonitrile (2.4 mL, 19 mmol) and Et^N (2.1 mL, 15 mmol) were added and the reaction mixture was heated at reflux again ovemight. Most of the acetonitrile was removed under reduced pressure and the residue was dissolved in ethyl acétate (100 mL). The organic layer was washed with a saturated aqueous solution of NaHCOj (20 mL), brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-15% ethyl acetate/heptanes) to afford 3-bromo-6-iertbutylpyridme-2-carbonitrile (2.6 g, 93%) as a colorless oil. 'H NMR (300 MHz, CDCI3) δ 1.34 (s,9H), 7.42 (d, 7 = 8.5 Hz, 1 H), 7.89 (d, 7= 8.5 Hz, 1H). [M+H]⁺ = 238.9.

Step 4: 6-ierEbutyl-3-[(2,4,6-trimethylphenyl)methyI]pyridine-2-carbonitrile

711

JX.N^.CN

CN ______ jj

Tetrakis(triphenylphosphine)palladium(0) (530 mg, 0.46 mmol) was added to a solution of 3-bromo-6-ieri-butylpyridine-2-carbomtrile (1.1 g, 4.6 mmol) in THF (12 mL) in a sealed tube. The mixture was evacuated and backfilled with nitrogen three times, then a stock solution of (2,4,6-trimethylphenyl)methyIzinc bromide (9.2 mL of a 1.0 M solution in THF, 9.2 mmol) was added at room température. The orange solution was stirred ai 60 °C ovemight. The reaction mixture was quenched with 5% citric acid (20 mL) and the resulting mixture was extracted with ethyl acetate (2 x 40 mL). The combined organic layers were washed with water (2x15 mL), brine (15 mL), dried over MgSOn filtered and concentrated under reduced pressure. The residue was purified by silîca gel chromatography (5-30% ethyl acetate/heptanes) to afford 6-ierrtbutyl-3-[(2,4,6-trimeihylphenyl)methyl]pyridine-2-carbonitrile (1.2 g, 89%) as a white solid. ’H MMR (300 MHz, CDC1₃) δ 1.32 (s,9H),2.17 (s, 6H), 2.30 (s, 3H),4.17 (s, 2H), 6.91 (s, 2H), 6.97 (d, 7=8.5 Hz, 1 H), 7.32 (d, 7 = 8.5 Hz, 1H). [M+H]⁺= 293.2.

Step 5: 6-terAbutyl-3-[(2,4,6-trimethylphenyl)methyl]pyridine-2-carboxylic acid

6-/e?7-Buty]-3-[(2,4,6-trimethylphenyl)methyl]pyridme-2-carbonitriIe (900. mg, 3.08 mmol) was dissolved in ace tic acid (8 mL). Concentrated HCl (8 mL) was added and the reaction mixture was stirred al 120 °C for 3 d. Additional ace tic acid (2 mL) and concentrated HCl (2 mL) were added and the réaction mixture was stirred at 120 °C for another 24 h. Most of tire acetic acid was removed under reduced pressure and the resulting heterogeneous mixture was basified with 25% aqueous NaOH to a pH of about 8-10. An aqueous solution of 5% citric acid

712 (20 rnL) was then added and the aqueous layer was extracted with methyl tert-butyl ether (2x50 mL). The combined organic layers were washed with water (2 x 20 mL), brine (20 mL), dried over MgSO₄, filtered and concentrated under redueed pressure. The residue was purified by silica gel chromatography (0-50% ethyl acetate/heptanes) to afford 6-iert-butyl-3-[(2,4,6trimethylphenyl)methyl]pyridine-2-caiboxylic acid (660 mg, 68.8%) as a white solid. ’H NMR (300 MHz, CDC1₃) δ 1.36 (s, 9H), 2.12 (s, 6H), 2.31 (s,3H),4.57 (s,2H),6.91 (s, 2H),7.07 (d,7 = 8.2 Hz, 1H), 7.39 (d, 7=8.2 Hz, 1H), 12.25 (brs, 1H). [M+H]⁺= 312.2.

The following compounds can be synthesized using the procedures described herein: jV-(benzenesulfonyl)-6-Ari-butyl-3-[(2,4,6-trimethylphenyl)methyl]pyridine-2-carboxamide (Compound 22), and 2V-(3-aminophenyl)sulfonyl-6-AA-butyl-3-[(2,4,6trimethylphenyl)methyI]pyridine-2-caiboxamide (Compound 313).

PREPARATION 10: 6-Art-butyl-3-(2,4,6-trimethylphenoxy)pyridine-2carboxylic acid

Step 1: 6-Ar/-butyl-3-(2,4,6-trimethylphenoxy)pyridine-2-carbonitrile

A mixture of 3-bromo-6-reri-butylpyridme-2-carbonitrile (1.0 g, 4.2 mmol), 2,4,6trimethylphenol (0.57 g, 4.2 mmol) and Cs₂CO₃ (2.0 g, 6.3 mmo!) in DMSO (8 mL) was heated at 100 °C ovemight. Once cooled to room température, ethyl acetate (70 mL) was added and the organic layer was washed with water (2 x 20 mL), brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography, (030% ethyl acetate/heptanes to afford 6-ierr-butyl-3-(2,4,6-trimethylphenoxy)pyridine-2carbonitrile (1.0 g, 81%) as a white solid. 'H NMR (300 MHz, CDCH) δ 1.33 (s, 9H), 2.08 (s, 61-1),2.30 (s, 3H), 6.73 (d, 7 = 9.1 Hz, 1 H), 6.92 (s, 2H), 7.32 (d, 7= 8.8 Hz, 1H). [M+H]⁺ = 295.1.

Step 2: 6-Ar/-butyl-3-(2_t4,6-trimethylphenoxy)pyridine-2-carboxylic acid

713

6-reri-Butyl-3-(2,4,6-trimethylphenoxy)pyridine-2-carbonitrile (700 mg, 2,38 minol) was dissolved in acetic acid (9 mL). Concentrated HCl (9 mL) was added and the reaction mixture was heated at 120 °C for 2 d. Once cooled to room température, the reaction mixture was concentrated to dryness under reduced pressure. The residue was suspended in water (20 mL) and 2N NaOH (3 mL) was added to provide a clear aqueous solution. The aqueous layer was washed with methy] tert-butyl ether (2x10 mL), acidified by the addition of 5% citric acid (20 mL) and the resulting mixture was extracted with ethyl ace ta te (2 x 50 mL). The combined organic layers were washed with water (2 x 20 mL), brine (20 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was triturated with heptanes (10 mL) at 0 °C to afford 6-rërz-butyl-3-(2,4,6-trimethylphenoxy)pyridine-2-carboxylic acid (574 mg, 77%) as an off-white solid. ’HNMR (300 MHz, CDC1₃) δ 1.37 (s, 9H), 2.08 (s, 6H), 2.30 (s, 3H),6.89 6.92 (m, 3H), 7.42 (d,J = 8.9 Hz, 1 H), 11.68 (brs, 1H). [M+H]⁺= 314.2.

The following compounds can be synthesized using the procedures described herein: jV-(3-aminophenyl)sulfonyl-6-teri-butyl-3-(2,4,6-trimethylphenoxy)pyridine-2-carboxamide (Compound 106) and A^r-(benzenesulfonyI)-6-teri-butyL3-(2,4,6-trimethylphenoxy)pyridine-2carboxamide (Compound 350).

PREPARATION II: /V-(3-aminophcnyl)sulfonyl-5-cyano-6-methy]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxaimde (Compound 124)

Step 1: ethyl 5-cyano-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxylate

714

Ο

Ethyl 2-chloro-5-cyano-6-methyi-pyridine-3-carboxylate (518 mg, 2.31 mmol), 2,4,6trimethylphenol (377 mg, 2.77 mmol), and césium carbonate (1.50 g, 4.61 mmol) were combined in 7V,?7-dimethylformamide (5 mL) and heated at 90 °C for 1 h. The reaction mixture was cooled and partitioned between ethyl acetate and IN HCl. The organics were separated, washed with brine, dried over sodium sulfate and evaporated to give ethyl 5-cyano-6-methyl-2(2,4,6-trimethylphenoxy)pyridine-3-carboxylate. ESI-MS m/zcalc. 324.2, found 325.2 (M+l)⁺; Rétention time: 0.77 min (1 min run).

Step 2: S-cyano-ô-methyl-Z-tZ/kô-trimethylphenoxyjpyridine-S-carhoxyiic acid

Crude ethyl 5-cyano-6-methy 1-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate was dissolved in methanol (12 mL) before NaOH (12 mL of 1.0 M, 12 mmol) was added. The mixture was heated at 70 °C for 3 h. The mixture was cooled and made acidic by the addition of 1 N HCl. The resulting precipitate was collected by filtration. The solid was further dried to give 15 5-cyano-6-methyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (500 mg, 73% for 2 steps). ESI-MS m/z cale. 296.1, found 297.4 (M+l)⁺; Rétention time: 0.63 min (1 min run).

Step 3: 5-cyano-6-methyl-A^r-(3-nitrophenyl)sulfonyl-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide

715

5-Cyano-6-methy]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (65 mg, 0,22 mmol), [(3-nitrophenyl)sulfonylamino]sodium (98 mg, 0.44 mmol), 7V-[(dimethylamino)-lHl,2,3-triazoIo-[4,5-/>]pyridin-l-ylmethylene]-A^r-methylmethanaminium hexafluorophosphate Noxide (170 mg, 0.44 mmol) and Α,Ν-dimethylformamide (1 mL) were combined and the mixture was stirred at room température for 1 h. The reaction mixture was diluted with water (1 mL) and was extracted with ethyl acetate (2x5 mL). The organic layers were dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparatory-HPLC (20-80% acetonitrile/water with 5 mM HCl) to give 5-cyano-6-methyl-N-(3-nitrophenyl)sulfony 1-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide. ESI-MS m/z cale. 480.1, found 481.5 (M+l)⁺; Rétention time: 0.73 min (1 min run).

Step 4: A^T-(3-amînophenyl)sulfonyl-5-cyano-6-methyI-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamîde (Compound 124)

5-Cyano-6-methyl-?/-(3-nitrophenyl)sulfonyl-2~(2,4,6-trimethylphenoxy)pyridine-3carboxamide (from step 3) was dissolved in methanol (10 mL) before 10% Pd/C (12 mg, 0.011 mmol) was added. The mixture was stirred under a balloon ofhydrogen at room température for 2 h. The mixture was filtered and concentrated. The residue was subjected to preparatory-HPLC (25-75% acetonitrile/water with 5 mM HCl) to give M-(3-aminophenyl)sulfonyl-5-cyano-6metliyl-2-(2,4,6-trimethylphenoxy)pyridme-3-carboxamide (Compound 124) (15 mg, 15% for 2 steps). ESI-MS m/z cale. 450.1, found 451.0 (M+l)⁺; Rétention time: 1.68 min (3 min run).

716

PREPARATION 12: N-U-aminophenyl)sulfony 1-6-ierZ-butyl-2-(2,4,6trimethylphenoxy)pyridÎnc-3-carboxamide (Compound 322)

Step 1: 6-terAbutyl-A^r-(2-nitrophenyl)suIfonyl-2-(2,4,6trîmethylphenoxy)pyridine-3-carboxamide

6-feri-Butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (50. mg, 0.16 mmol), 2-nitrobenzenesulfonamide (32 mg, 0.16 mmol), A-[(dimethylamino)-lH-l,2,3-triazolo^^-iJpyridin-l-ylmethylenel-A-methylmethanaminium hexafluorophosphate TV-oxide (91 mg, 0.24 mmol), ethyldiisopropy lamine (56 pL, 0.32 mmol) and NMP (1 mL) were combined. The mixture was heated at 75 °C for 16 h before it was cooled to room température. The réaction mixture was diluted with water (1 mL) and extracted with ethyi acetate (2x5 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparatory-HPLC (30-90% acetonitrileÂvater with 5 mM HCl) to give 6-tertbutyl-TV-(2-mtrophenyI)sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide. ESI-MS m/z cale. 497.2, found 498.4 (M+l)⁺; Rétention time: 0.89 min (1 min run).

Step 2: TV-(2-aminophenyl)sulfony 1-6-tcri-buty 1-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 322)

6-rert-Butyl-/V-(2-nitrophenyl)sulfbnyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (23 mg, 0.046 mmol) was dissolved in EtOH (5 mL) before 10% Pd/C (2 mg, 0.02

717 mmol) was added. The mixture was stirred under a balloon ofhydrogen at room température for 2h. The mixture was filtered and the filtrate was concentrated. The residue was subjected to preparatory-HPLC (20-80% acetomtrile/water with 5 mM HCl) to give N-(2aminophenyl)sulfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 322) (4.8 mg, 33%). ’H NMR (400 MHz, DMSO) δ 8.06 (s, 1H), 7.74 (s, 1H), 7.36 (s, 1H), 7.20 (s, 1H), 6.99 (s, 2H), 6.87 (s, 1H), 6.72 (s, 1H), 2.34 (s, 3H), 2.04 (s, 6H), 1.33 (s, 2H), 1.13 (s, 9H). ESI-MS m/z cale. 467.2, found 468.0 (M+I)⁺; Rétention time: 2.25 min (3 min run).

The following compounds can be synthesized using the procedures described herein: N- (3-aminophenyl)sulfonyl-6-iert-butyl-2-(2,6-dimethylphenoxy)pyridine-3 -carboxamide (Compound 286), N- (4-aminophenyl)sulfonyl-6-ierr-butyî-2-cyclohexyl-pyridine-3 -carboxamide (Compound 537), N-(3-aminophenyI)sulfonyl-6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 294) and A-(3-amino-l-methyl-pyrazol-4-yl)suIfonyl-6-tert-butyl-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 41).

PREPARATION 13: 6-to/7-biityl-AQ(2-oxo-l//-pyirêlin-3-ybstilfonylb^ trimethy]phenoxy)pyridine-3-carboxamide (Compound 51)

6-ieA-butyl-N-[(2-methoxy-3-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 191) (45 mg, 0.093 mmol) was dissolved in dioxane (1 mL) before aq HCl (0.5 mL of 4.0 M, 2.0 mmol) was added. The reaction mixture was heated at 90 °C for 1 h before it was cooled and concentrated. The residue was subjected to preparatory-HPLC (2080% acetonitrile/water with 5 μΜ HCl) to give 6-/ert-butyl-A^r-[(2-oxo-lH-pyridin-3yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 51) (19 mg, 20.%). 'H NMR (400 MHz, DMSO) δ 12.57 (s, 1 H), 11.83 (s, 1H), 8.27 (dd, J = Ί3, 2.1 Hz, 1H), 8.07 (d, 7 = 7.8 Hz, 1 H), 7.83 (d, 7 = 6.3 Hz, 1 H), 7.16 (d,7 = 7.9 Hz, 1 H), 6.93 (s, 2H), 6.46 (t,7 =

718

6.8 Hz, 1H), 2.27 (s, 3H), 1.99 (s, 6H), 1.05 (s, 9H). ESI-MS m/zcalc. 469.2, found 470.3 Rétention time: 1.95 min (3 min mn),

The following compound can be synthesized using the procedures described herein: 6-reri-butyT2 -(2,4-dimethylphenoxy) -N-[ (2 -oxo-1 H-pyridin-3 -y l)su lfonyl]pyridine -3- carboxamide (Compound 55),

7,7-dimethyl-2V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6-tiimethylphenoxy)-6,8-dihydro-5Hquinoline-3-carboxamide (Compound 1199),

2-(2,4-dimethylphenoxy)-8,8-dimethy]-A^r-[(2-oxo-l/7-pyridin-3-yl)sulfonyl]-6,7-dihydro-577quinoline-3-carboxamide (Compound 634),

8,8-dimethyI-77-[(2-oxo-l/7-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)-6,7-dihydro-5Hquinoline-3-carboxamide (Compound 899),

6-(l-methylcyclopropyI)-N-[(2-oxo-I/7-pyridm-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1226),

6-to7-buty 1 -N- [ (4-me thyl-2-oxo-1 H-pyrid in-3 -yl)s ulfo nyl]-2-(2,4,6-trimethylphenoxy)pyrid ine15 3-carboxamide (Compound 1311),

6-(4-e thoxy-3-fluoro-phenyl)-N- [(2-oxo-l#-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 901),

6-(4-methyIcyclohexyl)-7V- [(2-oxo-1 ZApyridinG-ylJsulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 743),

6-(4,4-dimethyl cyclohexyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1091),

6-(4 A-difluorocyclohexyDW- [(2-oxo-l#-pyrid in-3-yl)sulfonyl] -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1329), and

6-cyclohexyl-N-[(2-oxo-l H-pyridin-3-yl)suIfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-325 carboxamide (Compound 1357).

PREPARATION 14: 6-Fluoropyridine-2-sulfonamîde Step 1; 2-(BenzyIthio)-6-fluoi'Opyridine

719

To a solution of BnSH (18.1 g, 146 mmol) in THF (1.12 L) was added. 60% NaH (6.60 g, 165 mmol) portionwise over 10 minutes. The reaction mixture was stirred at room température for 15 minutes after which time a solution of 2,6-difluoropyridine (13.7 mL, 150. mmol) in THF (100 mL) was added dropwise over 10 minutes. The resulting clear solution was stirred at room température for 2 h. The reaction mixture was quenched with H₂O (250 mL) and the résultant mixture was extracted with Et₂O (800 mL). The organic layer was washed with H₂O (400 mL) and brine (250 mL), dried over Na₂SO₄ and concentrated to dryness. The residue was purified by silica gel column chromatography (100% hexanes followed by a gradient of 1-10% ethyl acetate in hexanes) to give 2-(benzylthio)-6-fluoropyridine (32.0 g, 100%). 'H NMR (CDC1_3j 250 MHz) 6 7.56 (q, J = 8.0 Hz, 1H), 7.43-7.40 (m, 2H), 7.39-7.21 (m, 3H), 7.03 (dd, J = 7.5, 2.3 Hz, 1H), 6.60 (dd, J = 7.8, 2.5 Hz, IH), 4.41 (s, 2H).

Step 2: 6-Fiuoropyridine-2-suIfonyl chloride

2-(Benzylthio)-6-fluoropyridine (32.0 g, 146 mmol) was dissolved in CHC1₃ (500 mL) and H₂O (400 mL) was added. Chlorine was slowly bubbled through the reaction mixture for 2 h. (Note: a 30% aq. NaOH trap (1-1.5L) was used, followed by a sat. aq. Na₂S₂O₃ (1-1.5 L) trap to neutralize the excess Cl₂). The reaction mixture became warm during the addition and a yellow suspension fonned. The reaction was carefully quenched (exothermic and foaming) with a solution of Na₂S₂O₅ (200 g) in H₂O (450 mL). The layers were separated and the aqueous layer was extracted once with CHC1₃ (200 mL). The organic layers were combined and washed with H₂O (300 mL), dried over Na₂SO₄ and concentrated to dryness to afford impure 6fluoropyridine-2-sulfony] chloride as a brownish oil. This material was used as such in the next step.

Step 3: 6-Fluoropyridine-2-sulfonamide

720

Crude 6-fiuoropyridine-2-sulfonyl chloride (from step 2) was dissolved in CH2CI2 (1 L) and the solution was cooled to -78°C. Ammonia was bubbled through the solution for 25 min. The mixture was stirred for 1 h at room température and the precipitated product was removed by filtration and washed with CH2CI2 (2x). The filtrate and washings were combined and concentrated to -50 mL and filtered; the solid was washed with C^CL/hexanes (50/50 mL) and dried to afford 6-fluoropyridine-2-suIfonamide (12.0 g, 46% yield, purity -90%) as a grey solid. ’H NMR (DMSO, 250 MHz) δ 8.27 (q, 7=8.0 Hz, 1H), 7.88 (dd, 7=7.5, 2.1 Hz, 1H), 7.66 (s, 2H), 7.48 (dd, 7=8.0,2.4 Hz, 1 H).

PREPARATION 15: /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-5-fluoropheny 1)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1255)

Step 1: 6-chloro-2-(2,4,6-trimethyIphenoxy)pyridine-3-carboxylie acid

To a solution of 2,4,6-trimethyIphenol (13.6 g, 100 mmol) in A(N-dimethylformamide (300 mL) at 0-5 °C, was carefully added NaH solid (60% in minerai oil, 8.80 g, 220 mmol). After the résultant suspension was stirred at the same température for 15 min, solid 2,6-dichloronicotinic acid (19.2 g, 100 mmol) was added. The reaction mixture was stirred at room température for 20 min and then at 80 °C ovemight. The mixture was cooled to room température before it was poured into a cold NaHSO₄ solution (24.0 g in 200 mL water). The résultant suspension was stirred at room température for 30 min. The precipitate was collected by filtration, washed with water, followed by Et2O/hexanes (200/500 mL), and dried at 40 °C under vacuum to give 6-chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid as a brownish solid (19.2 g, 66%). ¹H NMR (400 MHz, DMSO) δ 13.38 (s, 1 H), 8.28 (d,7 = 7.9 Hz,

721

114),7.27 (d,7= 7.9 Hz, 1H),6.94 (d,7= 1.1 Hz, 2H), 2.27 (s, 3H), 1.99 (s, 6H), ESI-MS m/z cale. 291.1, found 292.0 (M+l)⁺; Rétention time: 2.34 min (3 min run).

Step 2: ô-chioro-N-Hô-fluoro-l-pyridyUsulfonyll^-tl^^ trimethylphenoxy)pyridine-3-carboxamide

6-Chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (23.7 g, 81.4 mmol) was added to a mixture of N-[(dimethylamino)-1//-1,2,3-triazolo-[4,5-δ ]pyridin-l-ylmethylene]N-methylmethanaminium hexafluorophosphate N-oxide (35.0 g, 92.1 mmol), 6-fluoropyridine-2sulfonamide (16.5 g, 93.8 mmol) and ethyldiisopropylamine (36 mL) in MN-dimethylformamîde (400 mL) at 5 °C. The resulted mixture was stirred at room température ovemight before it was quenched with 1 N HCl (150 mL). The mixture was diluted with water (450 mL) and the résultant solîds were colléeted by filtration and washed with water (500 mL), methanol (200 mL) and Et₂O (400 mL). The solid was purified by silica gel column chromatography (0-4% methanol/CHiCh) to afford 6-chloro-A^r-[(6-fiuoro-2-pyridyl)suIfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide as a white solid (22.2 g, 60%). ’H NMR (CDC1₃, 250 MHz) Ô 8.36 (dd, 7=15.7,7.5 Hz, 1H), 8.14 (d, 7=7.5 Hz, 1H), 8.08 (d, 7=8.0 Hz, 1 H), 7.58 (d, 7=8.2 Hz, 1 H), 7.29 (d, 7=7.8 Hz, 1 H), 6.91 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6Ή).

Step 3: A^r-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-(2,4,6trimethylphenoxy)pyridine“3-carboxamide

722

6-Chloro-A^r-[(6-fluoro-2-pyridyl)su!fonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (12.0 g, 26.7 mmol) was mixed with NH₄OH (28-30%, 250 mL) and DMSO (200 mL) in a IL pressure vessel at 0 °C. The container was sealed and heated at 92 °C (oil bath) for 2 d, and at 85 °C for another 2 d. Solvents (water and DMSO) were removed and the residue was suspended in a mixture solvent of ŒLClo/ethyl acetate/methanol (25/25/25 mL). The suspension was sonicated at room température for 15 min and was fiItered. The solids were washed with CHiCE/ethyl acetate/methanol (10/10/10 mL) and dried to give A4(6-amino-2pyridy l)sulfonyl]-6-chIoro-2-(2,4,6-tri methylphenoxy)pyridine-3-carboxamide as a white solid (6.8g, 57%). ’H NMR(CDC1₃, 250 MHz) δ 8.10 (d, 7=7.8 Hz, IH), 7.64 (t, 7=7.8 Hz, 1H), 7.27 (d, 7=8.0 Hz, IH), 7.21 (d, 7=7.2 Hz, 1H), 6.92 (s, 2H), 6.71 (d, 7=8.5 Hz, 1H), 6.60 (br, s, 2H),2.26 (s,3H), 1.98 (s, 6H).

Step 4: Λ^Γ-[(6-ηηιίηο-2-ργΓίΰγ1)5υΚοην1]-6-(3-6ί1ιοχγ-5-ΠυθΓθ-ρ1ιεηγ1)-2-(2,4,6trim e thy lplienoxy)p yridine-3-carboxamide (Compound 1255)

A vial containing a mixture of ?A((6-aminopyridin-2-y])suIfony])-6-chloro-2(mesityloxy)-nicotinamide (30. mg, 0.067 mmol), 3-ethoxy-5-fluoro-benzeneboronic acid (25 mg, 0.13 mmol), Pd(PPh₃)₄ (5.0 mg), K₃PO₄ (2.0 M, 0.13 mL) and A/AMimethylformamide (0.6 mL) was flushed with nitrogen and sealed. The mixture was then heated at 80 °C overnight before it was cooled and diluted with DMSO (0.3 mL). The mixture was subjected to preparatory-HPLC (30-90% acetonîtrile/water with 5 μΜ HCl) to give A⁷-[(6-amino-2pyridyl)sulfonyl]-6-(3-ethoxy-5-fluoro-phenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1255) (20 mg, 54%). ESI-MS m/z cale. 550.2, found 551.5 (M+l)⁺; Rétention time: 3.15 min (5 min run).

The foHowing compounds can be synihesized using the procedures described herein: A^f-[(6-amjrio-2-pyridyl)sulfonyl]-6-(2-feri-butylphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3

723 carboxamide (Compound 364),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-cyclopropyl-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 1050),

N- [(6-amino-2-pyridyl)suIfonyl]-6-(3,4-dimethylphenyl) -2-(2,4,6-trime thylphenoxy)pyridine-3carboxamide (Compound 399),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 639),

N- [(6-amino-2-pyridyl)sulfonyl]-4-(3-fluoro-5-isobutoxy-pheny 1)-2-(2,4,6trimethylphenoxy)benzamide (Compound 1549),

TV-[(6-ami no-2-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)-6-vinyl-pyridine-3-carboxamide (Compound 430),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-hydroxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 505),

A^r-[(6-amino-2-pyridyl)sulfony]]-6-(6-methyl-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 513), /V-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-4-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 514),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methylindazol-4-yl)-2-(2,4,6-trimethyIphenoxy)pyridine3-carboxamide (Compound 451),

N- [[6- (amin omethyl)-2 -pyridy 1] su Ifony 1] -6 - (3 -flu oro-5 -isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 871),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-[2-methyl-5-(trifluoromeihyl)pyrazoi-3-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 457),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 463), yV-[(6-amino-2-pyridyl)sulfonyl]-5-(3-fluoro-5-isobutoxy-phenyl)-3-(2,4,6trimethylphenoxy)pyridine-2-carboxamide (Compound 1456),

724

A-[(6-amino-2-pyridyl)sulfonyl]-6-(l-propylpyrazol-4-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 469),

A-[(6-amino-2-pyridy])sulfonyl]-6-(4,4-dimethylcyclohexyl)-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (Compound 538),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(4,4-difiuorocyclohexyl)-2-(2,4,6-Îrimethylphenoxy)pyridine3-carboxamide (Compound783),

A-[(6-amino-2-pyridyl)sulfonyl]-6-ethyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 963),

A-[(6-amino-2-pyridyl)sulfonyl]-6-isopropyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1232),

A-[(6-amino-2-pyridyl)sulfonyl]-6-cyclopentyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1280), lV-[(6-amino-2-pyridyI)suIfbnyl]-6-(3-methoxypropyI)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 791),

A-[(6-amino-2-pyridyl)sulfonyl]-6-pentyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 862),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(2-ethoxyethyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 929),

A-[(6-amino-2-pyridyl)sulfonyl]-6-cyclohexyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1131),

A-[(6-amino-2-pyridyl)sulfonyi]-6-[2-(l-piperidyl)pyrimidin-5-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 475),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-methoxy-4-methyl-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 375),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(5-fluoro-2-methoxy-3-pyridyl)-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 387),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(2,4-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3

725 carboxamide (Compound 439),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(2-hydroxy-3-methyl-phenyl)-2-(2,4,6trime thylphenoxy)pyridine-3-carboxamide (Compound 450),

79-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(morpholinomethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 465),

Y- [(6 -ami n o-2-pyridyl)sulfonyl] -6-(2-methoxy-3 -metliyl-phenyl )-2-(2,4,6trimethylphenoxy)pyrîdine-3-carboxamide (Compound 477),

A''-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-2-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 396),

N- [(6-amino-2-pyridyl) sulfonyl] -6 -(4-is opropoxyphenyl)-2- (2,4,6 -trime thylphenox y)pyrid in e- 3 carboxamide (Compound 436),

6-(2-nuoro-4-methoxy-phenyl)-N-(l H-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 374),

6-[2-methyl-5-(trifluoromethyl )pyrazoî-3-yl]-79-(1 H-pyrazol-3-ylsulfonyl )-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 391),

6-(4-fluoro-2-methoxy-phenyI)-79-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 405),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-6-(l-isobutylpyrazol-4-yl)pyridine-3carboxamide (Compound 381),

6-(4-isopropoxyphenyl)-79-[(2-oxo-l#-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 494),

6-( 1,3 -b enzodioxol4-y 1)-79- [(2-oxo- IH-pyridin-3 -yl)sulfonyl]-2-(2,4,6 trimethylphenoxy)pyridme-3-carboxamide (Compound 525),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(4-fluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 93),

79-[(6-amino-2-pyridyl)sulfonyl]-6-(l-methyIindol-4-yl )-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 386),

726

77-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(cyanomethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 388),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-methoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 413), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methoxypyrimidin-5-yl)-2-(2,4,6trime thylphenoxy)pyridine-3-carboxamide (Compound 449),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methoxy-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 531),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[3-fluoro-4-(isopropylcarbamoyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 543),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-(5-ethoxy-2-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 599),

7V-[(6-ammo-2-pyridyI)sulfonyl]-6-(2,6-dimethoxy-4-methyl-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 629),

N-[(6-amino-2-pyridyl)sulfonyI]-6-[4-(cyanomethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxarmde (Compound 638),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluoro-3-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 661),

N-[(6-amino-2-pyridyl)sulfdnyl]-6-(m-toi yl)-2-(2,4,6-trime thylphenoxy)pyridine-3-carboxamide (Compound 672),

A^r-[(6-amino-2-pyridyl)sulfbnyl]-6-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 673),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 682),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(l-piperidylmethyl)phenyl]-2-(2,4,6trimethylpbenoxy)pyridine-3-carboxamide (Compound 686),

N- [(6-amino-2-p y ridyl)sulfonyl]-6-[2-(2,2,2-tri fl uoroethoxy)-3-pyridyl] -2-(2,4,6

727 trimethylphenoxy)pyridme-3-carboxamide (Compound 697),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(5-fluoro-2-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine -3 -carboxamide (Compound 700),

77-[(6-amino-2-pyridyI)sulfonyl]-6-(3,4-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 725),

N-[(6-amino-2-pyridyl)sulfonyr|-6-[2-fluoro-5-(hydroxymethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine -3 -carboxamide (Compound 727),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-tetrahydropyran-4-yl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 748), /V-[(6-amino-2-pyridyï)sulfonyl]-6-(4-hydroxy-3-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 768),

77-[(6-amino-2-pyridyl)sulfonyI]-6-[6-(dimethylamino)-3-pyridyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 787),

6-[3-(aminomethyl)phenyl]-.iV-[(6-amino-2-pyridyi)suIfbnyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 801),

7V-[(6-amino-2-pyridyl)sulfbnyI]-6-(2,5-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 803),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(morpholinomethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 810),

A^r-[(6-ammo-2-pyridyl)sulfbnyl]-6-(3,5-dimethoxyphenyI)-2-(2,4,6-trimethylphenoxy)pyridme3-carboxamide (Compound 828),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-fluoro-2-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 830), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methyl-2-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 1272), iV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methyl-2-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 730),

728

N-[(6-amino-2-pyridyl)sulfbnylj-6-(5-me thyl-2-pyridyl)-2-(2,4,6-trime thylphenoxy)pyridine-3carboxamide (Compound 1290),

N-[(6-amino-2-pyridyl)suIfonyl]-6~(4-ethoxy-2-fluoro-phenyl)-2-(2,4,6tri me thy Ip h enoxy)p y ridine-3-carboxamide (Compound 602),

6-(6-methoxy-5-methyl-3-pyridyl)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimeth y] phenoxy)pyridine-3-carboxamide (Compound 1044),

2-(2,4-dimethylphenoxy)-6-(p-tolyl)-A^r-(l H-pyrazol-3-ylsulfony])pyridine-3-carboxamide (Compound 610),

2-(2,4-dimethylphenoxy)-6-(6-methoxy-5 -methyl-3-pyridyI)-N-(lH-pyrazol-3ylsulfonyl)pyridine-3-carboxamide (Compound 892),

2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-isopropoxy-phenyl)-N-(lH-pyrazol-3ylsulfonyl)pyridine-3-carboxamide (Compound 1213),

2-(2,4-dimeihylphenoxy)-6-(4-ethoxyphenyl)-A^r-(lH-pyrazol-3-ylsulfbnyl)pyridine-3carboxamide (Compound 813),

A^r-[(6-amino-2-pyridyl)sulfony]]-6-(4-chloro-3-propoxy-phenyl)-2-(2,4,6tri me thy lphenoxy)pyridine-3-carboxamide (Compound 535),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-2-hydroxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 866), /V-[(6-ammo-2-pyridyl)suIfonyl]-2-(2,4-dimethylphenoxy)-6-(4-ethoxyphenyl)pyrÎdine-3carboxamide (Compound 641),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-isopropoxyphenyl)pyridine-3-carboxamide (Compound 1150),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethyIphenoxy)-6-(p-tolyl)pyridine-3-carboxamide (Compound 1015),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethylphenyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 1118),

A^r-[(6-amiuo-2-pyridyl)sulfonyl]-6-(3-isopropylphenyl)-2-(2,4,6-trimetliylphenoxy)pyridine-3729 carboxamide (Compound 1016),

7V-[(6-amino-2-pyridyl)sulfonyI]-6-[3-(trifluoromethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 709), (Compound 709)

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethylphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 900),

7V-[(6-amino-2-pyridyl)sulfbnyl]-6-[4-(trifluoromethyl)phenyl]-2-(2,4,6trimethylphenoxylpyridine-3-carboxamide (Compound 548), /V-[(6-amÎno-2-pyridyl)sulfbnyl]-2-(2,4-dimethylphenoxy)-6-(6~methoxy-5-inethyl-3pyridyl)pyrid ine-3-carboxamide (Compound 533),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-chloro-2-methoxy-4-pyridyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 1284),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methoxy-2-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1034),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxy-2-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1133), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 1138), jV-[(6-amino-2-pyridyl)suIfonyl]-6-(5-fluoro-2-methoxy-4-pyridyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1277), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-4-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 860),

N-[(6-aniino-2-pyridyl)sulfonyl]-6-(2-isopropylpyrazol-3-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1317),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-hydroxy-4-methyl-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 793),

A'-[(6-amino-2-pyridyl)sulfonyl]-6-(4-propoxyphenyl)-2-(2,4,6-trimethylplienoxy)pyridine-3carboxamide (Compound 996),

730

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxy-3-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 1268), /V-[(6~amino-2-pyridyI)sulfonyl]-6-(2-chlorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1221),

AL[(6-amino-2-pyridyl)sulfonyl]-6-(3,4-dihydro-2iApyran-6-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 937), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-4-methyl-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1000),

7V-[(6-amino-2-pyridyl)sulfbnyl]-6-(cyclopenten-l-yl)-2-(2,4,6-trimethylphenoxy)pyridine-310 carboxamide (Compound 1330),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-2-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 897), (Compound 897)

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(2-fluoro-4-methyl-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 875),

N-[(6-amino-2-pyridyl)sulfonyr|-6-isopropenyl-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 1211),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(5-cbloro-2-methoxy-3-pyridyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 993),

6-(l-isobuÎylpyrazol-4-yl)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylpbenoxy)pyridine-320 carboxamide (Compound 577), /V-[(6-amino-2-pyridyI)sulfonyl]-6-(2-pyridyI)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1278),

A^r-(lH-pyrazol-3-ylsulfonyl)-6-(2-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1353),

6-(3-etlioxy-5-fluoro-phenyI)-N-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 585),

N- [(6-amino-2-pyridyl)sulfbnyl]-6-(6-isopropoxy-3-pyridyl )-2-(2,4,6731 tnmethylphenoxy)pyridine-3-carboxamide (Compound 1163),

A^,-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1173),

A^r-[(6-amino-2-pyridyl)siilfonyl]-6-(3-chlorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1295), ;V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine~3carboxamide (Compound 570),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-fIuoro-2-hydroxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 622),

M[(6-amino-2-pyridyl)sulfonyl]-6-(3,6-dihydro-2H-pyran-4-y 1)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 976), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(3,5-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1325),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2,4-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 950),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[l -methyl-3-(trifluoromethyl)pyrazol-4-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 812),

A^F-[(6-amino-2-pyridyl)sulfonyl]-6-(5-chloro-6-methoxy-3-pyridyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1332),

7V-[(6-amino-2-pyridyl)suIfbnyl]-6-(2,6-dimethoxy-3-pyridyI)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 754),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropoxy-3-pyridyl)-2-(2,4,6tnmethylphenoxy)pyridine-3-carboxamide (Compound 909),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(trifluoromethyl)-l/7-pyrazol-4-yl]-2-(2,4,6tri me thylphenoxy)pyridine-3 -carboxamide (Compound 582), ?/-[(6-ammo-2-pyridyI)sulfonyl]-6-[4-(dimethylaminomethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 962),

732 jV-[(6-amino-2-pyridyl)sulfonyl]-6-(5-cyano-2-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1111),

N-[(6-amino-2-pyridyl)sulfonyI]-6-(5-fluoro-6-methoxy-3-pyridyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 612),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(2-ethoxypyrimidin-5-yl)-2-(2,4,6trimethylphenoxy)pyndine-3-carboxamide (Compound 1130),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methoxy-5-methyl-3-pyridyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 705),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methoxy-2-methyl-3-pyridyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 1212),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(2-ethoxy-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 718),

N-[(6-ami no-2-pyridyl)sulfony 1)-6-(1,3-benzodioxol-4-y 1)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 974),

A^r-[(6-amino-2-pyridyI)sulfonyl]-6-(l,3-benzodioxol-5-yl)-2-(2,4,6-tnmethylphenoxy)pyridine3-carboxamide (Compound 1207),

A^f-[(6-amino-2-pyridyI)sulfonyl]-6-(4-benzyloxy-2-fluoro-phenyl)-2-(2,4,6trimediy]phenoxy)pyridine-3-carboxamide (Compound 1113),

M-[(6-amino-2-py ri dyI)su!fonyl]-6-(5-fluoro-2-hydro xy-pheny 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1409), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(l-isopropylpyrazol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 808),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(5-methoxy-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1115), /V-[(6-ammo-2-pyridyl)sulfonyl]-6-(l-ethylpyrazol-4-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1312),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l,5-dimethylpyrazoI-4-yl)-2-(2,4,6733 trimethylphenoxy)pyridine-3-carboxamide (Compound 584),

6-phenyl-77-(IH-pyrazol-5-yIsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 784),

6-(4-methoxyphenyl)-?7-(lH-pyrazo!-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1033),

77-[(2-metho xy-3-pyridyl)sulÎbnyl]-6-pheny 1-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 939),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(lH-indazol-5-yl)-2-(2,4,6-trimethylplienoxy)pyridine-3carboxamide (Compound 856), jV-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-cyanophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 886), jV-[(6-amino-2-pyridyl)sulfbnyl]-6-(4-fluoro-3-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 919),

N-[(6-amino-2-pyridyl)sulfbnyI]-6-(2-fiuoro-6-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 920),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(4-cyano-3-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3 -carboxamide (Compound 923), ?7-[(6-amino-2-pyridyl)sulfonyl]-6-(2,5-dimethylpyrazol-3-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 938),

77-[(6-amino-2-pyridyI)sulfonyl]-6-(2-fluoro-4-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 956),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-(lH-indol-4-yÎ)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 977),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(2,5-difluoro-4-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 984),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(p-toly 1)-2-(2,4,6-tri methylphenoxy)pyridine-3-carboxamide (Compound 1035),

734

M[(6-amino-2-pyridyl)sulfonyl]-6-(2,3-dihydrobenzofuran-5-yl)-2-(2,4,6trimeÎhylphenoxy)pyridine-3-carboxamide (Compound 1084),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(l-methylindol-6-yD-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1056),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methylpyrazol-3-yl)-2-(2,4,6-trimethyiphenoxy)pyridine3-carboxamide (Compound 1057),

A^/,-[(6-amino-2-pyridyl)suIfonyI] -6-(o-toIyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1120),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(cyclopropyiamino)pyriimdm-5-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1126),

M-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(dimethylamino)pyrimidin-5-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1139), (V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-4-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1140),

A^r-[(6-amîno-2-pyridyl)sulfonyl]-6-(3,4-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1146),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(l-hydroxy-l-methyl-ethy!)phenyI]-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 1147),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l-isobutylpyrazol-4-yI)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1177),

N’[(6-ammo-2-pyridyl)sulfonyl]-6-(2-fluoro-5-methoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1178),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(6-ethoxy-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1185),

A^z-[(6-amino-2-pyridyl)sulfonyl]-6-(4-hydroxy-2-methyl-phenyl)-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 1204),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2,5-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine735

3-carboxamide (Compound 1225),

6-[4-(aminomethyl)phenyl]-7/-[(6-amino-2-pyridyI)sulfbnyl]-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 1228),

A^r-[(6-a]nino-2-pyridyl)sulfonyI]-6-(2,3-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1244), /V-[(6-amÎno-2-pyridyl)sulfonyl]-6-(3-hydroxy-4-methoxy-phenyl)-2-(2,4,6trimethyIphenoxy)pyridine-3 -carboxamide (Compound 1251),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-5-fluoro-phenyl)-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide (Compound 1255),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(2-pyrrolidm-l-yÎpyrimidin-5-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1275),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l-methylmdazol-5-yl)-2-(2,4,6-trimethyIphenoxy)pyridine3-carboxamide (Compound 1276),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methylindazol-6-yl)-2-(2,4,6-trimethyIphenoxy)pyridine3-carboxamide (Compound 1299), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methoxy-5-methyl-phenyl)-2-(2,4,6tri me thylphenoxy)pyridine-3-carboxamide (Compound 1320),

Æ-[(6-amino-2-pyridyl)sulfonyl]-6-(2,6-dimethoxypheny 1)-2-(2,4,6-trimethylpheiioxy)pyridiiie3-carboxamide (Compound 1326),

N-[(6-amino-2-pyridyl)sulfonyl]-6-( 1 -isopentylpyrazol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine~3-carboxamide (Compound 1336),

N~ [(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxypheny 1)-2-(2,4,6-trime thylphenoxy )pyridine-3carboxamide (Compound 1337), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(4-hydroxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 1344),

Aⁱ'-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(hydroxymethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 786),

736

A^(6-amÎno-2-pyndyl)sulfonyl]-6-(3-hydroxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridÎne-3carboxamide (Compound 908),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(hydroxymethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1183),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(2,3-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 485),

Λ^Γ-[(6-ami no-2-pyridyl)sulfonyl]-6-(2,4-dimethoxypyrimidin-5-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 499),

A- [(6-amino-2-pyridyl)sulfonyl] -6 -phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3 -carboxamide (Compound 203),

A-[(6-amino-2-pyridyI)sulfonyl]-6-(4-methoxyphenyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 17),

A-[(6-amino-2-pyridyl)suIfony]]-â-(3-ethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 61),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(2,6-dimethylphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 97),

A-[(6-amino-2-pyridyl)sulfbnyl]-6-(2-ethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 250),

N- [(6-amino-2-pyrid y l)sulfon yl]-6-(3-furyl) -2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 284),

7V-[(6-amino-2-pyridyl)sulfbnyI]-6-[6-(trifluoromethyl)-3-pyridyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 132),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(4-cyanophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 216),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3,4-dihydro-277-l,5-benzodioxepm-7-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 14),

M[(6-amino-2-pyridyl)sulfonyl]-6-[4-(methoxymethyl)phenyl]-2-(2,4,6737 trime thylphenoxy)pyridine-3-carboxamide (Compound 66),

N- [(6-ami no-2-pyridyl)sulfonyl]-2-(2,4-dimethylphenoxy)-6 -phenyl -pyridine-3 -carboxamide (Compound 340), jV-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(methoxymethyI)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 69),

Z7-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropyIpyrimidin-5-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 64),

Y-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methyl-3-pyridyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 513),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-[3-(hydroxymethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridirie-3-carboxamide (Compound 786),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-hydroxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 908),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(hydroxymethyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1183), ?7-[(6-amino-2-pyridyl)sulfouyl]-6-(5-ethoxy-2-fluoro-phenyI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 599), jV-[(6-amino-2-pyridyl)sulfonyI]-6-[4-(dimethylcarbamoyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide,

7V^,-[(6-amino-2-pyridyl)sulfonyl]-6-[3-fluoro-5-(methylcarbamoyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3 -carboxamide,

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methylindazol-4-yl)-2-(2,4,6-trimethyIphenoxy)pyridine3-carboxamide (Compound 451),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(3,5-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 828),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-(2,5-dimethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1225),

738

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(l-isopentylpyrazol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1336),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(l-propylpyrazol-4-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 469),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-hydroxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 505),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(l-isobutylpyrazol-4-yl)-2-(2,4,6-Îrimethylphenoxy)pyridine3-carboxamide (Compound 1177), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3,4-difluorophenyl)-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 725),

Aⁱ-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(2-cyanoethylcarbamoyl)phenyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide,

N-[(6-amino-2-pyridyl) sulfony 1]-6- [3- fluoro-4-(isopropylcarbamoyl)phenyl]-2-(2,4,6trimeÎhylpbenoxy)pyridine-3-caiboxamide (Compound 543),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(l-methyl-2tetrahydropyran-4-yl-ethoxy)pyridine-3-carboxamide (Compound 1361),

ÎV-[(6-amino-2-pyridyl)sulfonyl]~2-( 1,1-dîmethyI-2-phenyl-ethoxy )-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1365),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(l-cyclopentyIethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1374),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(cyclohexylmethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1395),

TV-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2methylcyclobutoxy)pyridme-3-carboxamide (Compound 406),

N-[(6-ammo-2-pyridyl)sulfonyl]-2-(2-cyclobutyleihoxy)-6-(3-fluoro-5-isobLitoxypbenyl)pyridine-3-carboxamide (Compound 1418),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-phenethyloxy-pyridine-3739 carboxamide (Compound 1426), /7-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[ 1-(3pyridyl)ethoxy]pyridine-3-carboxamide (Compound 1434),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopentylethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1440),

77-[(6-ammo-2~pyridyl)sulfonyl]-2-(cyclopropoxy)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 1446),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(cyclopentyImethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1450),

7V-[(6-amino-2-pyridyI)sulfonylj-2-(cyclopentoxy)-6-(3-fluoro-5-isobutoxy-pbenyl)pyridine-3carboxamide (Compound 1451), ?/-[(6-amino-2-pyridyl)suIfonyl]-2-(3,3-diiluorocyclobutoxy)-6-(3 -fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1458),

7V-[(6-amino-2-pyiidyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)*2*[(3S)-tetrahydrofuran-3yl]oxy-pyridine-3-carboxamide (Compound 1464),

77-[(6-amino-2-pyridyi)sulfonyl]-2-(2-cyclohexylethoxy)-6-(3-fluoro-5-isobiitoxyphenyl)pyridine-3-carboxamide (Compound 1465),

N-[(6-amin0-2-pyridyl)sulfonyl]-2-(cyclQhexoxy)-6-(3-fluoro-5-isobutoxy--phenyl)pyridine-3carboxamide (Compound 1477),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(I-benzylcyclobutoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1479),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fiuoro-5-isobutoxy-phenyl)-2-(tetrahydrofuran-3ylmethoxy)pyridine-3-carboxamide (Compound 1499),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopropylcyclobutoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1530),

À''-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-benzyloxycyclobuloxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1559),

740

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(tetrahydropyran-2ylmethoxy)pyridine-3-carboxamide (Compound 1570),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2,4-dimethyl-3-pyridyl)oxy]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1574),

ÎV-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-îsobutoxy-phenyl)-2-(2-tetrahydropyran~4ylethoxy)pyridine-3-carboxamide (Compound 1579),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(cyclobutoxy)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 1580),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)4etrahydrofuran-310 yl]oxy-pyridine-3-carboxamide (Compound 1592),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-tetrahydrofuran-2ylethoxy)pyridine-3-carboxamide (Compound 1604),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(4pyridyl)ethoxy]pyridine-3-carboxamide (compound 1605), ] 5 A-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2methoxycyclohexoxy)pyridine-3-carboxamide (Compound 1622),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(2pyridyl)ethoxy]pyridine-3-carboxamide (Compound 1625),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethylcyclopentoxy)-6-(3-fluoro-5 -isobutoxy20 phenyl)pyridine-3-carboxamide (Compound 1629),

A-[(6-amino-2-pyridyl)suIfonyl]-2-[l-(2,2-dimethylcycIopropyl)propoxy]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1639),

A-[(6-amino-2-pyridy!)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(lmethylcyclobutoxy)pyridme-3-carboxamide (Compound 1644),

A-[(6-animo-2-pyridyl)sulfonyl]-6-(3-f]uoro-5-isobutoxy-phenyl)-2-[2-(3pyridyl)ethoxy]pyridme-3-carboxamide (Compound 1654),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(tetrahydrofuran-2741 ylmethoxy)pyridine-3-carboxamide (Compound 1661),

V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(lmethylcyclopropyl)methüxy]pyridine-3-carboxamide (Compound 1668),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-tetrahydropyran-2ylethoxy)pyridine-3-carboxamide (Compound 1680),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopropylethoxy)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1685),

A⁷-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 8), /V-[(6-amino-2-pyridyl)sulfonyl]*6-(2,6-dimethylpheuyl)-2-(2,4,6-trimeLhylphenoxy)pyridine-3carboxamide (Compound 97),

A^/,-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxy-3-fluoro-phenyl)-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (Compound 161),

AA[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 164),

N--[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 196), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-2-fluoro-phenyI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 207),

7Z-[(6-amino-2-pyrÎdyI)sulfonyl]-6-(4-chlorophenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 234),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 238),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 281),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 320),

742 /V-[(6-ammo-2-pyridyl)sulfonyl]-6-(7-fluoro-l,3-benzodioxol-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 345),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trime thylphenoxy)pyridine-3-carboxamide (Compound 351),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methylcycIohexyI)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 172),

6-(p-tolyl)-ZV-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6-trimethylphenoxy)pyridi ne-3-carboxamide (Compound 300),

6-(3-fluoro-5-isobutoxy-phetiyl)-7V-(lH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 318), and

6-(4-ethoxyphenyl)-)V-(lH-pyrazol-3-ylsuIfonyl)-2-(2,4,6-trimethy]phenoxy)pyridiiie-3carboxamide (Compound 190),

PREPARATION 16: ;V-(3-aminophenyJ)siilionyl-5-phenyl-2-t2,4,6trnnethylphenoxy)pyridîne-3-carboxamide (Compound 1321)

Step 1: methyl 5-bromo-2-(2,4,6-tnmethylphenoxy)pyridnie-3-carboxylate

O

2,4,6-Tri methyl phénol (2.68 g, 19.7 mmol) and 60% NaH (870 mg, 22 mmol) were combiner! in an anhydrous mixture of MN-dimethylformamide (24 mL) and THF (2.4 mL). The reaction mixture was stirred at room température for 15 minutes under an atmosphère of nitrogen. Methyl 5-bromo-2-chloro-pyridine-3-carboxylate (4.93 g, 19.7 mmol) was added and the reaction mixture was heated at 60 °C for 1 h. The reaction mixture was then allowed to cool to room température. The reaction mixture was diluted with water and was extracted with ethyl acetate. The ethyl acetate layer was washed three rimes with water and then was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (0-50%

743 ethyl acetate/hexanes) to yîeld methyl 5-bromo-2-(2,4,6-trimethylphenoxy)pyridine-3carboxylate (5.50 g, 73%) as a faint yellow solid. ESI-MS m/z cale. 349.0, found 350.3 (M+l)⁺; Rétention time: 2.09 min (3 min run).

Step 2: methyl 5-bromo-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

Methyl 5-bromo-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (2.60 g, 6.76 mmol) was combined in a mixture of methanol (12.95 mL) and water (17.27 mL) containing sodium hydroxide (810 mg, 20.3 mmol). The resulting suspension was heated at 60 °C for 3 h. The reaction mixture was cooled to room température and was made acidic with 6 M hydrochloric acid. The resulting precipitate was filtered, washed with water and dried in a vacuum oven at 60 °C ovemight to yield 5-bromo-2-(2,4,6-trimethylphenoxy)pyridine-3carboxylic acid (2.24 g, 98%) as a white solid. ESLMS m/z cale. 335.0, found 338.2 (M+l)⁺; Rétention time: 1.75 min (3 min run).

Step 3: methyl 5-bromo-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

5-Bromo-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (89 mg, 0.26 mmol), phenylboronic acid (39 mg, 0.32 mmol), Pd(PPh₃)j (31 mg, 0.026 mmol), and K₂CO₃ (530 pL of 2.0 M, 1.1 mmol) were combined in DME (2.5 mL). The reaction mixture was briefly sparged with nitrogen, capped, and heated at 80 °C for 2 h. The réaction mixture was allowed to cool to room température and the layers were separated. The organic layer was subjected to

744 preparatory-HPLC (1-99% acetonitrile/water with 5 pM HCl) to give 5-phenyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxylic acid (54 mg, 61 %) as a white solid. ESI-MS m/z cale. 333,1, found 334.4 (M+l)⁺; Rétention time: 0.72 min (1 min run).

Step 4: A/-(3-nitrophcnyl)sulfonyl-5-phenyl-2-(2,4,6-trimcthylphenoxy)-pyridine3-carboxamide <λΡ ΛΑ no₂

5-Phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (54 mg, 0.16 mmol), (3-nitrophenyl)sulfonylazanide sodium (73 mg, 0.32 mmol), TV-[(dimethylamino)-l/7-l,2,3triazolo-[4,5-£]pyridm-l-y]methylene]-A^r-methylmethananiinium hexafluorophosphate A^r-oxide (62 mg, 0.16 mmol) and ^N-dimethylfomiamide (1 mL) were combined. The reaction mixture was stirred at room température for 72 h. The crude mixture was subjected to preparatory-HPLC (1-99% acetonitrile/water with 5 μΜ HCI) to give A^r-(3-nitrophenyI)sulfonyl-5-phenyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (51 mg, 61%) as a white solid. ESI-MS m/z cale. 517.1, found 518.5 (M+l )⁺; Rétention time: 2.04 min (3 min run).

Step 5: A^r-(3-aminophenyI)sulfonyl-5-phenyl-2-(2,4,6-trimethylphenoxy)py ri dîne-3-carboxamide

A^f-(3-nitrophenyl)sulfonyl-5-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (51 mg, 0.099 mmol) was suspended in acetic acid (2 mL) containing zinc (10 mg, 0.15 mmol). The reaction mixture was heated at 65 °C for 30 min. The hot reaction mixture was

745 filtered and then allowed to cool to room température. The mixture was concentrated and the residue was subjected to preparatory-HPLC (1-99% acetonitrile/water with 5 mM HCl) to give 7V-(3-aminophenyl)sulfonyI-5-phenyl-2-(2,4,6-tnmethylphenoxy)pyridine-3-carboxamide (Compound 1321) (18 mg, 38%) as a white solîd. ESI-MS m/z cale. 487.2, found 488.5 (M+l)⁺; Rétention time: 2.74 min (3 min run).

The following compound can be synthesized using the procedures described herein: 77-[(6-amino-2-pyridyl)sulfonyl]-5-(2-propylphenyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 429),

77-[(6-ammo-2-pyridyl)sulfonyl]-5-(2-isopropylphenyI)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 865),

77-[(6-amino-2-pyridyl)sulfonyl]-5-(2-ierf-butylphenyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 868),

77-(3-ammophenyI)sulfonyl-6-7ert-butyl-4-methoxy-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 959),

77-[(6-amino-2-pyridyl)sulfonyl]-5-(o-tolyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 817), and

77-[(6-amino-2-pyridyl)sulfonyl]-5-(2-ethylph&nyl)-2-(2,4,6-trimethyIphenoxy)pyridine-3carboxamide (Compound 945).

PREPARATION 17: 7V-(3-aminophenyl)sulfonyl-6-h?rAbuty 1-2-(77,2dimethylanilino)pyridine-3-carboxamide (Compound 193)

Step 1: 6-tert-butyl-2-(7V,2-diinethylanilino)pyridine-3-carbomtrile

A mixture of 6-ferpbutyl-2-chloro-pyridine-3-carbonitriIe (100. mg, 0.514 mmol), 77,2-dimethylaniline (76 pL, 0.62 mmol), KHMDS (1.2 mL of0.5 M, 0.62 mmol) and dioxane (1.5 mL) was heated at 100 °C for 20 min. The mixture was partitioned between ethyl acétate

746 and IN HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organics were washed with brine, dried over magnésium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-25% ethyl acetate/hexanes) to give 6-fôrf~butyl-2-(N,2-dimethylanilmo)pyridine-3-carbomtrile (40 mg, 26%). ESI-MS m/z cale. 279.2, found 280.4 (M+l)⁺; Rétention time: 2.28 min (3 min run).

Step 2: 6-i<’ri-biityl-2-(N,2-dimethylaniIino)pyrïdine-3-carboxamide

A mixture of 6-fcrr-butyl-2-(M,2-dimethylanilmo)pyridme-3-carbonitrile (40 mg, 0.14 mmol) and KOH (340 pL of 4.0 M, 1.4 mmol) in EtOH (1.2 mL) was heated at 90 °C ovemight. The mixture was concentrated, acidified with 2N HCl and the solids were collected to give an off-white solid. The solids were placed in a vacuum oven at 55 °C ovemight to give 6-tertbutyl-2-(N,2-dimethylanilino)pyridine-3-carboxamide (40 mg, 30%) as an off-white solid. ESIMS m/z cale. 297.2, found 298.4 (M+l)⁺; Rétention time; 0.68 min (1 min run).

Step 3: 6-tert-butyl-2-(N,2-dimethylamlino)-ïV-(3-nitrophenyl)sulfonyl-pyridine3-carboxamide

Sodium hydride (16 mg, 60%, 0.40 mmol) was added to a mixture of 6-teri-butyl-2(N,2-dimethylanilino)pyridine-3-carboxamide (40. mg, 0.13 mmol) and MN-dimethylformamide (1 mL). The mixture was allowed to stir for 15 min before 3-nitrobenzenesulfonyl chloride (45 mg, 0.20 mmol) was added. The mixture was allowed to stir for 1H before adding two drops of methsanol. The mixture was filtered and subjected to preparatory-HPLC (10-99%

747 acetonitrile/water with 0.05 mM HCl) to give 6-i£ri-butyl-2-(N,2-diniethylanilino)-A/-(3nitroph en yl)sulfonyl-pyridine-3-carboxamide. ESI-MS m/z cale. 482.2, found 483.3 (M+l)⁺;

Rétention time: 0.82 min (1 min run).

Step 4: AMS-aminophenyljsulfonyl-Ô-reri-butyl-Z-i/V^-dimethylanilinojpyridine 5 3-carboxamide (Compound 193)

Zinc (9.0 mg, 0.13 mmol) was added to a mixture of 6-rerZ-butyl-2-(N,2dimethylanilino)-N-(3-nitrophenyl)sulfonyl-pyridine-3-carboxamide and acetic acid (1 mL) at room température. The mixture was allowed to stir for 20 min before it was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mMHCl) to give A-(3aminophenyl)sulfonyl-6-ierr-buty 1-2-(A,2-dimethylanilino)pyridine-3-c arboxamide (Compound 193) (1.2 mg, 2% for 2 steps). ESI-MS m/z cale. 452.2, found 453.3 (M+l)⁺; Rétention time: 1.90 minutes (3 min run).

The foliowing compound can be synthesized using the procedures described herein:

/y-(3-aminophenyI)sulfonyl-6-rc/-r-butyl-2-(N-methylanilino)pyridine-3-carboxamide (Compound 85).

PREPARATION 18: N-(3-aminophenyl)sulfonyl-5-/_i>r/-butyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 110)

Step 1: ethyl 5-awrbutyl-2-[(2.4,6-trimethylphenyl)inethyl]pvra/.()le-3 20 carboxylate

748

To a mixture of ethyl 5-feri-butyl-4/7-pyrazole-3-carboxylate (500. mg, 2.55 mmol) and MA-dimethylformamide (5 mL) was added 2-(bromomethyI)-l,3,5-trimethyl-benzene (543 mg, 2.55 mmol) and K2CO3 (704 mg, 5.10 mmol). The réaction mixture was heated at 80 °C ovemight. Additional 2-(bromomethyl)-l,3,5-trimethyl-benzene (200 mg, 1.02 mmol) and

K2CO3 (704 mg, 5.10 mmol) were added and the mixture was heated at 80 °C for another 18 h. The mixture was cooled to room température before water (20 mL) was added. The mixture was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over sodium sulfate, fïltered and concentrated. The residue was subjected to silica gel column chromatography (0-50% ethyl acetate/hexanes) to give ethyl 5-teC-butyl-2-[(2,4,610 trimethylphenyl)methyl]pyrazole-3-carboxylate (642 mg, 77%). ESI-MS m/z cale. 328.2, found 329.4 (M+l)⁺; Rétention time: 0.99 min (1 min run).

Step 2: 5-reri-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxylic acid

Ethyl 5-ier/-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxylate (5.00 g, 15 15.2 mmol) and NaOH (4.87 g, 122 mmol) were combined in a THF (20 mL) and water (20 mL). The mixture was heated at 60 °C for 3 h. The reaction mixture was made acidic by the addition of 6 M HCl and was extracted with ethyl acetate. The organics were washed with brine, dried over sodium sulfate and evaporated to give 5-terEbuty]-2-[(2,4,6-trimethylphenyI)methyI]pyrazole-3-carboxylic acid (4.38 g, 96%). 'H NMR (400 MHz, DMSO) δ 13.23 (s, 1H), 20 6.83 (s, 2H), 6.68 (s, 1H), 5.64 (s, 2H), 2.24 (s, 6H), 2.2] (s, 3H), 1.15 (s, 9H). ESI-MS m/z cale.

0.2, found 301.4 (M+l)⁺; Rétention time: 2.21 min (3 min run).

Step 3: 5-ie7'i-butyl-/V-(3-nitrophenyl)sulfony 1-2-((2,4,6-trimethylphenyl) methyl]pyrazole-3-carboxamide

749

5-reri-Butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazoIe-3-carboxylic acid (108 mg, 0.356 mmol), 3-nitrobenzenesulfonamide (109 mg, 0.539 mmol), N-[(dimethylamino)-lÆ-l,2,3triazolo-[4,5-Z>]pyridin-l -ylmethyleneJ-N-methylmethanaminium hexafluorophosphate A^r-oxide (137 mg, 0.356 mmol), and triethylamine (100 pL, 0.719 mmol) were combined in X/Vdimethylfonnamide (2.3 mL) and heated at 60 °C for 16 h. The reaction mixture was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mMHCl) to give 5-tertbutyI-/7-(3-nitrophenyl)sulfonyl-2-[(2,4,6-trimethylphenyl)-methyf|pyrazole-3-carboxamide (105 mg, 60.9%). ES LM S m/z cale. 484.2, found 485.3 (M+l )⁺; Rétention time: 2.27 min (3 min run).

4: A^T-(3-aminophenyl)sulfonyl-5-h’ri-butyl-2-[(2,4_i6-trimethylphcnyl)methyl]pyrazole-3-carboxamide

5-ierr-Butyl-A^r-(3-nitiOphenyl)sulfonyL2-[(2,4,6-trimethylphenyl)methyl]-pyrazole-3carboxamide (105 mg, 0.217 mmol) was dissol ved in m éthanol (9 mL) with Pd/C (38 mg, 0.036 mmol) under a balloon of hydrogen and the mixture was stirred for 30 min. The reaction mixture was filtered, evaporated, and the residue was purified by LC/MS utilizing a gradient of 10-99% acetonitrile in 5 mM aqueous HCl to yield yV-(3-aminophenyl)sulfonyl-5-tei7-butyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 110) (72 mg, 44%). ’H NMR (400 MHz, DMSO) 5 7.26 (t, J = 7.9 Hz, 1H),7.21 (t, J = 2.0 Hz, 1H), 7.12-7.06 (m, 1H), 7.01 (s, 1H), 6.89 -6.83 (m, 1 H), 6.77 (s,2H),5.45 (s, 2H), 2.17 (s, 3H), 2.11 (s, 6H), 1.14 (s, 9H). ESI

750

MS m/z cale. 454,2, found 455,4 (M+l)⁺; Rétention time: 2.06 min (3 min run).

The following compounds can be synthesized using the procedures described herein:

3-(rert-butyl)-l-(l-mes itylethyl)-//-(phenylsulfonyl)-l/2-pyrazoîe-5-carboxamide (Compound 201),

A^f-(3-aminophenyl)sulfonyl-3-tert-butyl-1-((2,4,6-trimethylphenyl)metliyl]pyrazole-4carboxamide,

3-(teri-butyl)-l-(2-fluoro-5-(trifluoromethyl)benzyl)-?/-(phenylsulfonyl)-l//-pyrazole-5carboxamide (Compound 35),

3-(terr-butyl)-//-((3-(dimethylamino)phenyl)sulfonyl)-l-(2,4,6-trimethylbenzyI)-l/7-pyrazole-5carboxamide (Compound 270), //-((3-aminophenyl)sulfonyl)-3-(terf-butyl)-l-(2,4,6-trichlorobenzyl)-l//-pyrazole-5carboxamide (Compound 303),

3-(terrbutyl)-l-(2,6-dimethylbenzyl)-?/-((l-methyl-l/7-indol-4-yl)sulfonyl)-l/7-pyrazole-5carboxamide (Compound 210), //-((3-aminophenyl)sulfonyl)-3-(terf-butyl)-l-(4-(teri-butyl)-2,6-dimethylbenzyl)-l//-pyrazole5-carboxamide (Compound 156),

3-(4-(difluoromethyl)phenyl)-l-(2,6-dimethylbenzyl)-//-(phenylsulfonyl)-l//-pyrazole-5carboxamide (Compound 119), //-(3-aminophenyI)sulfonyl-5-te ri-butyl-4-methoxy-2-[(2,4,6-trime thylphenyl)methyl] pyrazole3-carboxamide (Compound 1305), /V-((3-aminophenyl)sulfonyl)-3-(terr-butyI)-l-(2-chloro-6-(trifluoromethyl)benzyl)-l//-pyrazole5-carboxamide (Compound 189),

3-(tertebutyl)-//-((3-(dimethylamino)-2-methylphenyl)sulfonyl)-l-(2,4,6-trimethylbenzyl)-l/Zpyrazole-5-carboxamide (Compound 104), //-((3-amino-2-methylphenyl)sulfonyl)-3-(terr-butyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5carboxamide (Compound 123),

- (terrbu tyl)-7/-( ( 1-methyl-1//-indol-7-yl)sulfo nyl )-l-(2-methy 1-3-(trifluoromethyl)benzy 1)-1//

751 pyrazole-5-carboxamide (Compound 276),

3-(fm-butyl)-AMm-tolylsulfonyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5 -carboxamide (Compound 80),

N-((3-ammo-4-iluorophenyI)sulfonyl)-3-(rerr-butyl)-l-(2,6-dimethylbenzyl)-lH-pyrazole-5carboxamide (Compound 150),

3-(mrt-buty 1)-N- (qu inolin-5-ylsulfonyl)-1-(2,4,6-tri methyl benzyl)-lH-pyrazole-5 -carboxamide (Compound 352),

N- ((3 - ami n ophenyl )sulfo nyl)-3-(te rt-butyl)-1-(2,3,5,6 -tetramethylbenzyl)-1 H-pyrazole -5 carboxamide (Compound 317),

3-(tert-buiyl)-l-(2,6-dimethylbenzyl)-N-(thiophen-2-ylsulfonyl)-177-pyrazole-5-carboxamide (Compound 77),

3-(ierr-butyl)-N-(phenylsulfonyI)-l-(2,4,6-trichlorobenzyl)-l/f-pyrazole-5-carboxamide (Compound 145),

3-(ier/-butyl)-l-(2,6-dimethylbenzyl)-A^r-((2-methoxy-3-methylphenyl)sulfonyl)-177-pyrazole-5carboxamide (Compound 59),

N-(3-arainophenyl)s u lfonyl-5-ierr-butyl-2 - [2-(2,4,6-trimethylphenyl)ethy 1] pyrazole-3 carboxamide (Compound 7),

3-pm-butyl)-A^f-(phenylsulfonyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5-carboxamide,

3-(reri-butyl)-l-(naphthalen-l-ylmethyl)-N-(phenylsulfonyl)-177-pyrazole-5-carboxamide (Compound 328),

3-(ierf-butyl)-7V-((3-(methyIamino)phenyl)sulfonyl)-l-(2,4,6-trimethylbenzyl)-l/f-pyrazole-5carboxamide (Compound 249),

3-(rer/-butyl)-jV-((l-(2-hydroxyethyl)-lH-indoî-4-yl)sulfonyl)-l-(2,4,6-trimethylbenzyl)-lHpyrazole-5-carboxamide (Compound 188),

N-((3-aminophenyl)sulfonyl)-3-(reri-butyl)-4-methyl-l-(2,4,6-trimethylbenzyl)-lH-pyrazole-5carboxamide (Compound 20),

S-freri-butylj-l-ÎZjô-dimethylbenzylj-N-fiZ-fluorophenyljsuIfonylj-lH-pyrazole-S-carboxamide

752 (Compound 57),

3-(n?rr-butyl)-A'-((2-cyanophenyl)sulfonyl)-l-(2,4,6-trimethylbenzy])-lZ/-pyrazole-5carboxamide (Compound 266),

3-(zerrtbutyl)W- ((3-hydroxyphenyl)sulfonyl)-1-(2,4,6-tri me thylbenzyl)-l/Z-pyrazole-5carboxamide (Compound 84),

3-(feri-buty])-1 -(2,6-dimethylbenzyl)-A^r-(phenyIsuIfonyl)- lH-pyrazole-5-carboxamide (Compound 257),

A^r-((3-amino-4-methy]phenyl)sulfonyI)-3-(terr-butyl)-I-(2,6-dimethy]benzyl)-lH-pyrazo]e-5carboxamide (Compound 312),

1-(3-(l//-pyrrol-i-yl)benzyl)-3-(rert-butyl)-A^r-(phenyisuifonyl)-l//-pyrazole-5-carboxamide (Compound 108),

3-(/eri-butyl)-l-(5-fluoro-2-(ù*ifluoromethyl)benzyl)-77-(phenylsulfonyl)-l//-pyrazole-5carboxamide (Compound 3),

N-((3-acetylphenyl)sulfonyl)-3-(rerf-butyl)-I-(2,4,6-trimethylbenzyl)-l//-pyrazole-5carboxamide (Compound 332),

Λ/-(( lW-indol-4-yl)sulfonyl)-3-(te rr-butyl)-l-(2-methyl-3-(trifluoromethyl)benzyl)-l//-pyrazole5-carboxamide (Compound 60),

3-(iert-butyI)-N-((2,6-difluorophenyl)sulfonyl)-l-(2,6-dimethy]benzyl)-l//-pyrazole-5carboxamide (Compound 170), /V-((4-aminophenyl)suIfonyl)-3-(terf-butyl)-l-(2,6-dimethylbenzyl)-lZ/-pyrazoIe-5-carboxamide (Compound 81),

A^r-((3-aminophenyl)sulfonyl)-3-(rert-butyl)-l-(2-fluoro-6-(trif]uoromethyl)benzyl)-l//-pyrazoIe5-carboxamide (Compound 239),

N-((3-amin ophenyl)s u lfonyl)-3-(te rf-butyl)-l-(l-(o-tolyl)ethyl )-1//-pyrazole-5-carboxamide (Compound 342),

A-((6-aminopyridin-2-yl)sulfonyl)-3-(ier/-butyl)-4-methyl-1-(2,4,6-trimethylbenzy 1)-1//pyrazole-5-carboxamide (Compound 356),

753

77-((2-aminophenyl)sulfonyl)-3-(tert-buÎyl)-l-(2,6-dimethylbenzyl)-l//-pyrazole-5-carboxamide, 77-((3-aminophenyl)sulfony])-3-(ierr-butyl)-l-(l-cyclohexyIethyl)-lH-pyrazole-5-carboxamide (Compound 287),

77-((3-aminophenyl)suIfonyl)-3-(fert-butyl)-l-(l-phenylpropyl)-17f-pyrazole-5-carboxamide (Compound 165),

3-(mτ-bιUyl)-N-((4-hydfoxyphenyl)sulfonyI)-l·(2,4,6-trimethylbenzyl)4^i'-pyrazole-5carboxamide (Compound 269),

AL((3-aminophenyl)sulfonyl)-3-(l-methylcycIopropyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5carboxamide (Compound 158),

3-(ferr-butyl)-l-(2-methyl-3-(trifluoromethyl)benzyl)W-(phenylsulfonyl)-lH-pyrazole-5carboxamide (Compound 98),

77- ((3-aminophenyl)sulfonyl)-3-(terr-butyl)-l -(2,6-dimethylbenzyl)-l//-pyrazole-5 -carboxamide (Compound 185),

77-((3-aminophenyl)sulfonyl)-3-isobutyl-l-(2,4,6-trimethylbenzyI)-12i-pyrazole-5-carboxamide (Compound 167),

3-(tert-butyl)-?7-((2,3-dihydrobenzofuran-7-yl)sulfonyl)-l-(2,6-dimethylbenzyl)-lH-pyrazole-5carboxamide (Compound 211),

7V-((6-aminopyridin-2-yl)sulfonyl)-3-(te rt-butyl)-1-(2,4,6-trimethyIbenzyl)-lH-pyrazoie-5carboxamide (Compound 173),

3-(tcr/-butyl)-l -(2-methoxyphenethyl)4V-(phenyîsulfotiyl)-l#-pyrazole-5 -carboxamide (Compound 157),

77-((1 H-indazol-4-yl)sulfonyl)-3-(mrt-butyI)-l -(2,6-dimethylbenzyl)-l//-pyrazole-5-carboxamide (Compound 86),

AA(benzenesulfonyl)-5-teri-butyl-2-[(l-methylindol-4-yl)methy]]pyrazoIe-3-carboxamide (Compound 245),

3-(rcrAbuty])-M((3-methoxypyridÎn-2-yl)sulfonyl)-l-(2,4,6-trimethylbenzyl)-lZ7-pyrazole-5carboxamide (Compound 44),

754

N-((3-aminopheny])sulfonyI)-3-(te^butyI)-l-(naphthalen-l-ylmethyI)-l//-pyrazole-5carboxamide (Compound 295),

M((3-aminophenyI)sulfonyl)-3-(/m-butyl)-1-((1 -methyl-l/7-indoI-7-yl)methyl)-l//-pyrazole-5carboxamide, ³^^m ^bul·Ό-l-(2,6-dπnethylbenzyl)-7V-((2-(meίhydamino)pyridin-4-yl)sultony])-l/^pyrazole^^ carboxamide,

5-ferr-butyl-2-[(2,6-dimethylphenyl)methyl]W-(2-methoxyphenyl)sulfonyl-pyrazole-3carboxamide (Compound 1551), l-((17Z-indol-7-yl)methyl)-N-((3-aminophenyI)sulfonyl)-3-(ferAbutyl)-l//-pyrazo carboxamide, ^*K²-^amino-3-pyridyl)suIfonyl]-5-zerr-butyl-2-[(2,4,6-trimethy]phenyl)methyI]pyrazole-3carboxamide (Compound 1106),

Y-((3-aminophenyl)sulfonyl)-3-(/e/-z-butyl)-l-((l-medrylcyclohexyl)methyl)-l//-pyrazole-5carboxamide,

W-aminophenyl)_Sulfonyl-5-^butyl-2-[(2,4,6-trimethylphenyl)me^ carboxamide (Compound 1653), ³4Av7-bLityIM-(4-(Ztvr-butyd)-2,6-dimeÜiylbenzyl)-A^(pdienylsulfonyI)-l//pyrazole-5carboxamide,

3-(Zez7-butyl)-A^r-((3-ethylphenyl)sulfonyI)-l -(2,4,6-trimethylbenzyl)-l/f-pyrazole-520 carboxamide,

3-(rerr-butyl)-A-((3-chlorophenyl)sulfonyl)-1-(2,4,6-trimethylbenzyl)-]//-pyrazole-5carboxamide,

A43-ammophenyI)sulfonyl-5-im-butyl-2-(l-phenyIethyl)pyrazole-3-carboxamide (Compound

799),

N-((3-ammophenyl)sulfonyl)-3-isopropyl-1-(2,4,6-trimethyIbenzyl)-l/f-pyrazole-5carboxamide,

5-^rr-buty]-2-[(2,6-dimetl₁ylphenyl)methyl]-M[3-(2-methylpyrimidin-4-yl)pl₁enyl]sulfonyl755 pyrazole-3-carboxamide (Compound 1496),

77-((3-aminophenyl)sulfonyl)-3-(rert-butyl)-l-(2,4-dichlorobenzyl)-l//-pyrazole-5-carboxamide, 3-(teri-butyl)-JV-((3-fluorophenyl)sulfbnyI)-1-(2,4,6-trimethyîbenzyl)-l//-pyrazole-5carboxamide,

3-(/e^buty])-N-((2-methoxyphenyl)suIfonyl)-l-(2,4,6-trimethylbenzyl)-l/Apyrazole-5carboxamide,

3<rm-butyl)-M((3-cyanophenyI)sulfonyl)-l-(2,4,6-trimethyIbenzyl)4/f-pyrazoIe-5carboxamide,

77-((4-aminophenyl)sulfonyl)-3-(ierAbutyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazoIe-5- carboxamide,

À^r<(2-mninophcnyI)sulfonyl)-3-(im-butyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5carboxamide,

3-(/errbutyl)-77-(pyridin-4-ylsulfonyl)-l-(2,4,6-trimethylbenzyl)-l//-pyrazole-5-carboxamide,

- (ierf-b uty 1)-77-((3-me thoxyphenyl)sulfony 1)-1-(2,4,6-trimethylbenzyl)-l//-pyrazole-5- carboxamide,

77- ((3-aminophenyl)sulfonyl)-3-(rm-butyl)-l -(2,4-dimethylbenzyl)-l//-pyrazole-5 -carboxamide, 5-rerr-butyl-77-(lH-indol-4-ylsulfonyl)-2-[(2,4,6-trimethy]phenyl)methyl]pyrazole-3- carboxamide (Compound 180),

3-(iert-butyl)-l-(5-methyl-2-(trifluoromethyl)benzyl)-7V-(phenylsulfbnyl)-U7-pyrazole-520 carboxamide (Compound 304),

77-((3-aminophenyl)sulfonyl)-1-(2,4,6-trimeÎhylbenzyl)-l/7-benzo[i/]imidazole-2-carboxamide (Compound 71),

N-(3-aminophenyl)sulfonyl-5-^r/-butyl-2-[(]-methylindoI-4-yl)methyl]pyrazole-3-carboxamide (Compound 927),

5-/erAbutylW-[(2-methoxy-3-pyridyl)sulfonyl]-2-[(2₎4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 759),

5-terAbutyl-2-[(2,6-dimethylphenyl)methyl]-N-(3-thienylsulfonyl)pyrazole-3-carboxamide

756 (Compound 603),

N-(2-aminophenyl)sulfonyl·5-ί^r^butyl·2-[(2,6-dimeίhylphenyl)methyl]pyrazoie-3-carboxamide (Compound 88),

5-terr-butyl-2-[(2,6-dimethylphenyl)methyl]W-(lH-mdoI-7-y lsulfonyl)pyrazole-3-carboxamide (Compound 1358),

N-(3-aminophenyl)sulfbny]-5-te ri-butyl-2-(l H-in doi-7-yImethyl)pyrazole-3-carboxamide (Compound 1256),

N- (3 -aminopheny l)su Ifonyl-5 -te rAbu tyl-2-[( 1 -me thylindol -7 -y l)methyl]py razole-3 -c arboxamide (Compound 755),

5-terAbmyl-2-[(2,6-dimediylphenyl)methyl]W-[[2-(methylamino)-4-pyridyl]sulfonyl]pyrazoIe3-carboxamide (Compound 821),

ÀA(3-aminophenyl)sulfonyl-5-terAbutyl-2-[(l-methylcycIohexyI)methyI]pyrazole-3-carboxamide (Compound 1152),

A^r-(benzenesulfonyl)-5-terAbutyl-2-[(4-/err-butyl-2,6-dimethyl-phenyl)methyl]pyrazole-3carboxamide (Compound 443),

A43-aminophenyl)sulfonyl-5-terAbuÎyl-2-[(lR)-l-phenylethyl]pyrazole-3-carb.oxamide (Compound 540),

N-[(2-amino-3-pyridyl)sulfonyl]-5-terAbutyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide,

Abutyl-2-[(2,6-dimethylphenyl) me thyl]-iV-(3-thienylsulfonyl)py razole-3-carboxamide (Compound 603),

5-terAbutylW-[(2-methoxy-3-pyridyl)sulfonyl]-2-[(2,4,6-trimethy!phenyl)methyl]pyrazole-3carboxamide (Compound 759),

5-terAbutyl-2-[(2,6-dimediylphenyl)methyl]-A^r-(2-furylsuIfonyl)pyrazole-3-carboxamide (Compound 1468),

W<4-(aminomethyl)phenyl]sulfonyl-5-terAbutyI-2-[(2,4,6-trimethylphenyl)methyÎ]pyrazole-3carboxamide (Compound 1670),

757

-/err-butyl-yV-(4-pyridyl sulfony 1)-2 - [ (2,4,6 -trimethylphenyl)meth yl]pyrazo le-3 -carboxamide (Compound 1585),

77-(3-aminophenyl)sulfbny 1-5-te rr-butyl-2-[(2,4-dichlorophenyl)methyl]pyrazole-3-carboxamide (Compound 797),

5-terr-butyl-77-(3-ethylphenyl)sulfonyl-2-[(2,4,6-trimethylphenyl)methyI]pyrazole-3carboxamîde (Compound 823),

77-(3-aminophenyl)sulfonyI-5-teri-butyl-2-(l-phenyIethyl)pyrazole-3-carboxamide,

5-terr-butyI-7/-(3-chIorophenyl)sulfonyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 472),

77-(2-aminophenyl)sulfonyl-5-tete-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 1167),

N-(3-aminophenyl)sulfonyl-5-isopropyI-2-[(2,4,6-trimethy]phenyl)methyI]pyrazole-3carboxamide (Compound 566),

7Z-(lH-pyrazol-3-ylsulfonyl)-3-[(2,4,6-trimethylphenyI)met]iyl]-l,2,4,5-tetrahydro-3benzazepine-4-carboxamide (Compound 628),

N-[(2-oxo-l /7-pyridm-3-yl)sulfonyl]-3-[(2,4,6-trimethylphenyl)methyl]-l ,2,4,5-tetrahydro-3benzazepine-4-carboxamide (Compound 662), jV-[(6-morpholino-2-pyridyl)sulfonyI]-3-[(2,4,6-trimethylphenyl)methyl]-l,2,4,5-Îetrahydro-3benzazepine-4-carboxamide (Compound 669),

M-[[6-(methylamino)-2-pyridyl]sulfonyl]-3-[(2,4,6-trimethyIphenyl)methyl]-l,2,4,5-tetrahydro3-benzazepine-4-carboxamide (Compound 747),

A4[6-(2-hydroxyethylamino)-2-pyridyl]sulfonyl]-3-[(2,4,6-trimethylphenyl)methyl]-l,2,4,5tetrahydro-3-benzazepine-4-carboxamide (Compound 838),

AA[(2-methoxy-3-pyridyI)sulfonyl]-3-[(2,4,6-trimethylphenyl)methyl]-l,2,4,5-tetrahydro-3benzazepine-4-carboxamide (Compound 876),

7A[(6-methoxy-2-pyridyl)sulfony]]-3-[(2,4,6-trimethylphenyl)methyl]-l,2,4,5-tetrahydro-3benzazepine-4-carboxamide (Compound 948),

758

A^r-(benzenesulfonyI)-3-[(2,4,6-trimethylphenyl)methyl]-l ,2,4,5-tetrahydro-3-benzazepine-4carboxamide (Compound 1039),

A-[(6-amino-2-pyndyl)sulfonyl]-3-[(2,4,6-trimethylphenyl)methyI]-l ,2,4,5-tetrahydro-3benzazepine-4-carboxamide (Compound 1055),

ÎV-(2-pyridylsulfonyl)-3-[(2,4,6-trimethylphenyl)methyl]-l,2,4,5-tetrahydro-3-benzazepine-4carboxamide (Compound 1093), ?A(3-aminophenyl)sulfonyl-5-te rt-butyl-2-[(l-methylindol-4-yl)methyl]pyrazole-3-carboxamide (Compound 927), and

A-(benzenesulfonyl)-5-te ri-buty 1-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 45).

PREPARATION 19: 5-Zi'/7-biityl-A^,-[3-(hydro.\ymethyl)phenyl]sulfony]-2-[('2,4,6trimethylphenyl)metliyl]pyrazole-3-carboxamide (Compound 39)

A solution of 3-(ieri-Butyl)-A-((3-formylphenyI)sulfonyl)-l -(2,4,6-trimethylbenzyl)l//-pyrazo!e-5-carboxamide (prepared following procedures described herein, 50 mg, 0.11 mmol) and anhydrous methanol (5 mL) was cooled to 0 °C. The mixture was purged with nitrogen before adding sodium borohydride (7.6 mg, 0.20 mmol). The mixture was allowed to warm to room température and was stirred ovemight. The reaction mixture was again cooled to 0 °C before adding additional sodium borohydride (7.6 mg, 0.20 mmol). The mixture was warmed to room température and was allowed to stir for 4 h. Solvents were removed and the crude residue was taken up in DMSO and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 5-im-butyl-M[3-(hydroxymethyl)phenyl]suIfonyi2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 39) (28 mg, 56%). ’H NMR (400 MHz, DMSO) δ 12.51 (s, IH),7.99 (s, 1H), 7.87 (d, J = 7.7 Hz, 1H),7.63 (dt,J = 15.3, 7.7 Hz, 2H), 7.01 (s, 1H), 6.75 (s, 2H), 5.42 (s, 2H), 4.63 (s, 2H), 2.16 (s, 3H), 2.07 (d, J =

759

6.4 Hz, 6H), 1.14 (s, 9H). ESI-MS m/z cale. 469.2, found 470.0 (M+l)⁺; Rétention rime: 2,12 min (3 min nin).

PREPARATION 20: A-(benzenesulfonyl)-2-[(2,6-dimethylpheny])methyl]-5-(2metlioxyphenyl)pyrazole-3-carboxaniîde (Compound 347)

Step 1 : methyl A^r-[(2,6-dimethylphenyl)niethylammo]carbaniate

2-(Chloromethyl)-l,3-dimethyl-benzene (25.0 g, 162 mmol), methyl Naminocarbamate (29.1 g, 323 mmol) and K₂CO₃ (33.5 g, 243 mmol) were combined in Wdimethylformamide (150 mL) and heated at 80 °C for 2 h. The reaction mixture was concentrated and the crude material was partitioned between ethy! acetate and water. The organics were separated, washed with brine and dried over sodium sulfate. The mixture was filtered and the fîltrate was concentrated. The residue was subjected to si]ica gel column chromatography (0-60% ethyl acetate/hexanes) to give methyl 77-((2,6- dimethylphenyl)methylamino]carbamate (18.0 g, 53%). ESI-MS m/z cale. 208.3, found 209.2 (M+l)⁺; Rétention time: 0.41 min (1 min run).

Step 2: methyl 2-[(2,6-dimethylphenyl)methy]]-5-hydroxy-pyrazole-3carboxylate

Metliyl A4(2,6-dimethylphenyl)methylamino]carbamate (18.0 g, 86.4 mmol) was suspended in methanol (126 mL) and dimethyl but-2-ynedioate (10.6 mL, 86.4 mmol) was added. The reaction mixture was stirred at reflux for 2 h and was then cooled to room température. Sodium methoxide (20.5 mL of 25 %w/v, 95.1 mmol) was added and the reacüon

760 mixture was again heated at reflux. After 1 h, the mixture was cooled to room température and was added drop-wise to a flask containing IM aq. HCl (300 mL) in an ice water bath. The resulting precipitate was collected by vacuum filtration. The solids were dissolved in CHiCh and the excess water was separated and the organic layer was dried over sodium sulfate and evaporated to give methyl 2-[(2,6-dimethylphenyl)methyl]-5-hydroxy-pyrazole-3-carboxylate (21.6 g, 96%). ‘H NMR (400 MHz, DMSO) δ 10.05 (s, 1 H), 7.10 (dd, J = 8.4, 6.5 Hz, 1 H), 7.02 (d, J = 7.5 Hz, 2H), 6.06 (s, 1H), 5.57 (s, 2H), 3.85 (s, 3H), 2.24 (s, 6H). ESI-MS m/z cale.

260.1, found 261.4 (M+l)⁺; Rétention time: 0.57 min (1 min run).

Step 3: 2-[(2,6-diniethylphenyl)methyl]-5-(trifluoromethyLsulfonyloxy)-pyrazole3-carboxylate

Methyl 2-[(2,6-dimethylphenyl)methyl]-5-hydroxy-pyrazole-3-carboxylate (8.40 g, 32.3 mmol) and pyridine (3.13 mL, 38.7 mmol) were combined in toluene (84,00 mL) and cooled in a sait water / ice bath. Tri flic anhydride (5.98 mL, 35.5 mmol) was added drop-wise keeping the température below 0 °C. After the addition was complété, the reaction mixture was warmed to room température and stirred for 1 h. The reaction mixture was quenched with water (30 mL) and the layers were separated. The aqueous layer was extracted with toluene (1 x 40 mL). The organics were combined and washed with water (40 mL), dried over sodium sulfate, filtered and evaporated to give methyl 2-[(2,6-dimethylphenyl)methyl]-5(trifiuoromethylsulfonyloxy)-pyrazole-3-carboxylate (12.4 g, 98%) ESI-MS m/z cale. 392.1, found 393.2 (M+l)⁺; Rétention time: 0.82 min (1 min run).

Step 4: 2-[(2,6-dimethylphenyl)methyl]-5-(4,4,5_t5-tetramethyl-I,3,2dioxaborolan-2-yI)pyrazole-3-carboxylate

761

A suspension of methyl 2-[(2,6-dimethyIphenyl)methyl]-5(trifluoromethyIsulfonyloxy)pyrazole-3-carboxylate (12.1 g, 30.7 mmol), 4,4,5,5-tetramethyl-2(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (8.59 g, 33.8 mmol) and KOAc (9.05 g, 92.2 mmol) in dioxane (240 mL) was degassed for 10 min. Dichloro[l,l'bis(diphenylphosphino)ferrocene]palladium (U) dichloromethane adduct (1.26 g, 1.54 mmol) and l,r-bis(diphenylphosphino)ferrocene (852 mg, 1.54 mmol) were added and the reaction was degassed for an additional 10 min. The reaction mixture was heated at 100 °C for 4 h. The mixture was concentrated to -100 mL total volume and was diluted with toluene (250 mL) and water (100 mL). The mixture was filtered through apad of Celite to remove small bïack particulates. The organics were separated, washed with water (100 mL) and dried over sodium sulfate. The organics were filtered through a plug of silica (100 g) and the silica was washed with another 1 L of toluene, The toluene was evaporated to give methyl 2-((2,6dimethylphenyI)methyl]-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyrazole-3-carboxylate (10.6 g, 93%). 'H NMR (400 MHz, Chloroform-d) δ 7.27 (s, 1H), 7.09 (dd,7 = 8.2, 6.7 Hz, 1H), 7.00 (d, 7= 7.4 Hz, 2H), 5.86 (s, 2H), 3.81 (s, 3H), 2.25 (s, 6H), 1.32 (s, 12H).

Step 5: 2-((2,6-dimethylphenyl)methyl]-5-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)pyrazoIe-3-carboxylic acid

Methyl 2-((2,6-dimethylphenyl)methyl]-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)pyrazole-3-carboxylate (7.00 g, 14.2 mmol) was dissolved in THF (53 mL) and NaOH (43 mL of 1.0 M, 43 mmol). The reaction mixture was heated at 60 °C for 2 h and was concentrated.

762

The resulting solid was partitioned between ethyl acetate and a 1 N HCl solution. The organics were separated, washed with brine, dried over sodium sulfate and evaporated to give2rf(2,6dimethylphenyl)meth.yI]-5-(4,4,5,5-tetràmethyl-l,3,2-dioxaborolan-2-yl)pyrazole-3-carboxylic acid (5.5 g, 98%). 'HNMR (400 MHz, DMSO) δ 13.44 (s, 1 H), 7.13 (dd, 7=8.3, 6.6 Hz, 1H), 7.07 -7.02 (m, 3H),5.81 (s, 2H), 2.23 (s, 6H), 1.24 (s, 12H). ESI-MS hî/z cale. 356.2, found 275.4 (M+l)⁺; Rétention time: 0.42 min (1 min run). Note: found mass is [-pinacol+H],

Step 6: A-(benzenesulfonyl)-2-[(2,6-diinetliylphenyl)methyl]-5-(4,4,5,5· tetramethy 1-1,3,2-dioxaboroIan-2-yI)pyrazole-3-carboxamide

2-[(2,6-Dimethylphenyl)methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dîoxaborolan-2yl)pyrazole-3-carboxylic acid (4.14 g, 11.6 mmol), N-[(dimethylamino)-lH-l ,2,3-triazolo-[4,56]pyridin-l-y!mediylene]-N-methylmethanaminium hexafluorophosphate N-oxide (4.42 g, 11.6 mmol) and ethyldiisopropylamine (6.07 mL, 34.9 mmol) were combined in CH2CI2 (116 mL). Benzenesulfonamide (2.19 g, 13.9 mmol) was added and the reaction mixture was stirred for 16 h before it was diluted with CH2CI2 and washed with IN HCl. The organics were further washed with brine, dried over sodium sulfate, fïltered and evaporated. The crude material was purified by silica gel chromatography (0-100% ethyl acetate/hexanes) to give N-(benzenesulfonyl)-2[(2,6-dimethylphenyl)methyl]-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole-3carboxamide (4.14 g, 72%). ESI-MS m/z cale. 495.2, found 414.4 (M+l)⁺; Rétention time: 0.68 min (1 min run). Note: found mass is minus the pinacol ester.

Step 7: jV-(benzenesulfonyl)-2-[(2,6-diinethylphenyl)methyl]-5-(2methoxyphenyI)pyrazole-3-carboxamide (Compound 347)

763

N-(B en zenesulfonyl)-2-[(2,6-dimethylphenyl)methy 1]-5-(4,4,5,5-te trame thyl-1,3,2dioxaborolan-2-yl)pyrazole-3-carboxamide (50 mg, 0.10 mmol), l-bromo-2-methoxybenzene (19 mg, 0.10 mmol), dichloro[l,l'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (4 mg, 0.005 mmol), and 2M aq. K₂CO₃ (0.20 mL, 0.40 mmol) were combined in N.AMimethylformamide (0.6 mL) and heated at 70 °C for 2 h. The reaction mixture was cooled, filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mMHCl) to give N-(benzenesulfonyI)-2-[(2,6-dimethylphenyl)methyl]-5-(2methoxyphenyl)pyrazo le-3-carboxamide (Compound 347). ESI-MS m/z cale. 475.2, found 476.3 (M+l)⁺; Rétention time: 2.08 min (3 min run).

N-(benzenesulfonyl)-2-[(2,6-dimethyIphenyl)methyl]-5-[2-(trifluoromethoxy)phenyl]pyrazole-3carboxamide (Compound 149),

A^r-(benzenesulfonyl)-5-(4-chloro-3-methoxy-phenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 37),

77-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(3-isopropoxyphenyl)pyrazole-3carboxamide (Compound 133),

77-(benzenesulfonyï)-2-[(2,6-dimethylphenyl)methyl]-5-[3-(trifluoromethoxy)phenyi]pyrazole-3carboxamide (Compound 225),

A^r-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]pyrazole-3carboxamide (Compound 316),

A^r-(benzenesulfonyl)-5-[3-(difluoromethyl)pheiiyl]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 315),

A-fbenzenesu Ifonyl)-5-(2,4-dimethoxyphenyl )-2-((2,6-dimethyl phenyl) methyl]pyrazole-3764 carboxamide (Compound 135),

N-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(l-methylindol-4-yl)pyrazole-3carboxamide (Compound 363),

A^r-(3-aminophenyl)sulfonyl-5-(2,6-dimethylpheny])-2-[(2,4,6-trimethylphenyl)methyl]pyrazole3-carboxamide (Compound 209),

A/-(benzenesuIfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(m-tolyl)pyrazole-3-carboxamide (Compound 202),

N-(3-aminophenyl)sulfonyI-5-(2-fIuoro-3-methyI-phenyl)-2-[(2,4,6-trimethylphenyl)methyl] pyrazole-3-carboxamide,

N-(3-aminophenyl)sulfony 1-5-pheny 1-2-[(2,4,6-trimethylphenyl)methyl]pyrazoIe-3-carboxamide (Compound 367),

V-(benzenesuIfonyl)-5-[3-(dimethylamino)phenyl]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 178), /V-(benzenesulfonyl)-5-[4-(diethylamino)phenyl]-2-[(2,6-dimethylpheny])methyl]pyrazoIe-3carboxamide (Compound 162),

N-(benzenesulfbnyl)-2-[(2,6-dimethylphenyl)methyl]-5-(4-fluorophenyl)pyrazole-3-carboxamide (Compound 333),

V-(benzenesulfonyI)-2-t(2,6-dimethylphenyl)methyl]-5-(3-methoxyphenyl)pyrazoIe-3carboxamide (Compound 176),

N-(benzenesulfonyl)-5-(4-dimethylammophenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 76),

A7-(benzenesulfonyl)-5-(2-cyanophenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 99),

A^r-(benzenesulfony])-2-[(2,6-dimethylphenyl)methyl]-5-(3-fluoro-4-methoxy-phenyI)pyrazole-3carboxamide (Compound 43),

N-(benzenesuIfonyl)-2-[(2,6-dimethylphenyl)niethyl]-5-(4-methoxyphenyl)pyrazoIe-3carboxamide (Compound 49),

765

V-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-[3-(trifluoromethyl)phenyl]pyrazole-3carboxamide (Compound 220), )V-(berLzenesulfbnyl)-5-(3-chlorophenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 83), yV-(benzenesulfonyI)-5-(2-chlorophenyl)-2-[(2,6-dimethy]phenyl)methyI]pyrazole-3carboxamide (Compound 339),

N-(benzenesulfbnyl)-5-(2,5-dimethoxyphenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 100), /V-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-[4-(trifluoromethoxy)phenyl]pyrazoIe-3carboxamide (Compound 159), ethyl 2-[4-[5-(benzenesulfbnylcarbamoyl)-l-[(2,6-dimethylphenyl)methyl]pyrazoI-3yl] phenyl] acetate (Compound 21), ?V-(benzenesulfonyI)-2-[(2,6-dimethylphenyl)methyl]-5-[5-(5-methyl-l,2,4-oxadiazol-3-yl)-2thienyl]pyrazole-3-carboxamide (Compound 151),

A^r-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(2-ethoxyphenyl)pyrazole-3carboxamide (Compound 152), jV-(3-aminophenyl)sulfonyl-5-(2-methoxy-3-methyl-phenyl)-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 208),

A^,-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl] -5-(2-fluorophenyl)pyrazole-3-carboxamide (Compound 109), zV-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(2-isopropoxyphenyl)pyrazole-3carboxamide (Compound 277),

N- (benzenesulfonyl)-5-(4-chlorophenyI)-2-[(2,6-dimethylphenyl )m ethyl] pyrazole-3carboxamide (Compound 28),

A^r-(benzenesulfony])-2-[(2,6-dimethylphenyl)methyI]-5-(4-ethoxyphenyl)pyrazole-3carboxamide (Compound 29),

N-(benzenesulfbnyl)-2-[(2,6-dimethylphenyl)methyl]-5-(3-ethoxyphenyl)pyrazole-3766 carboxamide (Compound 280),

N-(3-aminophenyl)suIfonyl-5-(2-methoxyphenyl)-2-(l-phenylethyl)pyrazole-3-carboxamide (Compound 40),

M(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(5-fluoro-2-meÎhoxy-phenyl)pyrazole-3carboxamide,

N-(benzenesulfbnyl)-2-[(2,6-dimethylphenyl)methyl]-5-[2-(trifluoromethyl)phenyl]pyrazole-3carboxamide (Compound 369),

N-(benzenesulfbnyl)-2-[(2,6-dimethylphenyl)methyl]-5-(p-tolyl)pyrazole-3-carboxamide (Compound 199),

A^r-(benzenesulfonyl)-5-[2-(dimethylamino)phenyl]-2-[(2,6-diinethylphenyl)methyl]pyrazole-3carboxamide (Compound 128),

A^r-(benzenesulfonyi)-2-[(2,6-dimethylphenyl)methyl]-5-(3-fluorophenyl)pyrazole-3-caiboxamide (Compound 166),

N-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(l-methylindol-5-yl)pyrazole-3carboxamide (Compound 263),

A-(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyI]-5-[6-(l-piperidyl)-3-pyridyl]pyrazole-3carboxamide (Compound 329),

N-(benzenesulfony 1)-2-((2,6-dimethy]phenyl)methyl]-5-(4-fluoro-2-methoxy-phenyl)pyrazole-3carboxamide (Compound 155), /V-(benzenesulfonyI)-2-[(2,6-dimethylphenyI)methyl]-5-[3-(morpholinomethyI)phenyI]pyrazole3-carboxamide (Compound 302),

M(3-aminophenyl)sulfonyl-5-(2-methoxy-3-pyridyl)-2-[(2,4,6-trimethylphenyl)methyl]pyrazole3-carboxamide (Compound 122),

N-(benzenesulfonyl)-2-[(2,6-dimefoyIphenyl)methyl]-5-(3-thienyl)pyrazole-3-carboxamide (Compound 357),

N-(3-aminophenyl)sulfonyl-5-(4-methoxyphenyl)-2-(l-phenylethyl)pyrazole-3-carboxamide (Compound 1024),

767

3-[5-(benzenesulfonylcarbamoyl)-l-[(2,6-dimethylphenyl)methyl]pyrazoT3-yl]benzoic acid (Compound 343), //-(benzenesulfonyl)-5-(3-/erAbutoxyphenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 744),

M-(b enzenesulfon yl )-5 -(4#-1,3 -benzodioxin-7 -yl)- 2- [(2,6-dimethylpheny l)methyl]py razole-3 carboxamide (Compound 1621),

A'-(benzenesuIfonyl)-5-[2-(dimethylamino)pyrimidin-5-yl]-2-[(2,6dimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 1678), //-(benzenesulfonyl)-5-(5-chloro-3-fluoro-2-methoxy-phenyl)-2-[(2,6-dimethylphenyI)methyl] pyrazole-3-carboxamide,

A''-(benzenesulfonyl)-5-(5-chloro-3-fluoro-2-methoxy-phenyl)-2-[(2,6dimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 379),

A/-(benzenesulfonyl)-5-(3-teFi-butoxyphenyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 744),

AL(benzenesulfonyl)-2-[(2,6-dimethylphenyl)methyl]-5-(4-isopropoxyphenyl)pyrazole-3carboxamide (Compound 1478),

A-(benzenesulfonyl)-2-[(2,6-dimethyIphenyl)methyl]~5-(4-oxochromen-3-yl)pyrazole-3carboxamide (Compound 1501),

A^r-(3-aminophenyl)sulfonyl-5-(4-methoxyphenyl)-2-(I-phenylethyl)pyrazole-3-carboxamide (Compound 1024)

N- (3 -aminophenyl)sulfonyl-5-(2 -fluoro-3-methyl-phenyl )-2-[(2,4,6trimethyIphenyl)methyI]pyrazole-3-carboxamide (Compound 293), and

Y'(benzenesulfonyl)-2-[(2,6-dimetliylphenyl)methyl]-5-(5-fluoro-2-methoxy-phenyl)pyrazole-3carboxamide (Compound 27).

PREPARATION 21: 5-Benzyloxy-2-[(2,4,6-trimethylphenyl)methy]]pyrazole-3carboxylic acid

Step 1: methyl 3-(benzyloxy)-l-(2,6-diniethylbenzyl)-lZNpyrazole-5-carboxylate

768

To a solution of methyl 5-hydroxy-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxylate (250 mg, 0.911 mmol) and K₂CO₃ (315 mg, 2.28 mmol) in XA^-dimethyliormamide (5 mL) was added benzyl bromide (130 pL, 1.09 mmol) and the reaction mixture was stirred at room température for 16 h. The mixture was concentrated and the resulting solids were parti tioned between ethyl acetate and water. The organics were separated, washed with brine, dried over sodium sulfate and evaporated to give methyl 3-(benzyIoxy)-L(2,6-dimethylbenzy[)l/f-pyrazole-5-carboxylate. ESI-MS m/z cale. 364.2, found 365.4 (M+l)⁺; Rétention time: 0.90 min (1 min run).

Step 2: 5-benzyIoxy-2-[(2,4,6-triniethylphenyl)methyl]pyrazole-3-carboxylic acid

Methyl 3-(benzyloxy)-l-(2,6-dimethylbenzyI)-I/f-pyrazole-5-carboxylate (from step 1) was dissolved in methanol (3 mL) before 1N NaOH (3 mL) was added. The reaction mixture was heated for 2 h at 60 °C and concentrated. The crude mixture was partitioned between ethyl acetate and 1 N HCl. The organics were separated, washed with brine, dried over sodium sulfate, and evaporated to yield 5-benzyloxy-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxylic acid (295 mg, 92% for 2 steps) ESI-MS m/z cale. 350.2, found 351.4 (M+I)⁺; Rétention time: 0.79 min (1 min run).

The following compound can be synthesized using the procedures described herein; 3-(l-phenylethoxy)-l-(2,4,6-trimethylbenzyl)-lH-pyrazole-5-caiboxylic acid, N-(3-aminopheny])suifonyl-5-benzyloxy-2-[(2,4,6-trimethylpheny])methy]]pyrazole-3769 carboxamide (Compound 42), and

A-(3-aminophenyl)sulfonyl-5-(l -phenylethoxy)-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 278).

PREPARATION 22: A-(3-aminophenyl)sulfonyl-5-(3,3-dimethylbutyl)-2-[(2,6dimethylplienyI)methyl]pyrazole-3-carboxamide (Compound 323)

Step 1 : S-lXELSjS-dimethylbut-l-enylj-Z-IXZjô-dimethylphenyllmethylJpyrazole3-carboxylate

Methyl 2-[(2,6-dimethylphenyl)methyl]-5-(trifluoromethyIsulfbnyloxy)pyrazole-3carboxylate (500. mg, 1.27 mmol), [(E)-3,3-dimethyIbut-I-eny]]boronic acid (196 mg, 1.53 mmol), dichloro[l,r-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane (52 mg, 0.064 mmol), and 2M K₂CO₃ (1.9 mLof 2.0 M, 3.8 mmol) were combined in dioxane (10 mL) and irradiated in a microwave reactor for 30 min at 120 °C. The reaction mixture was diluted with ethyl acetate and was filtered through a pad of Celite. The filtrate was washed with water, brine, dried over sodium sulfate and concentrated. The crude material was purified by silica gel column chromatography (0-60% ethyl acetateZhexanes) to give methyl 5-[(E)-3,3-dimethy]but-l enyl]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-carboxylate (300. mg, 72%) ESI-MS m/z cale. 326.2, found 327.5 (M+l)⁺; Rétention time: 0.94 min (1 min run).

Step 2: 5-[(E)-3,3-dimethylbut-l-enyl]-2-[(2_>6-dimethylplienyl)methyl]pyrazole3-carboxylate

770

Methyl 5-[(£0-3,3-dimethylbut-l-enyl]-2-[(2,6-dimethylphenyI)methyI]pyrazole-3carboxylate (300. mg, 0.919 mmol) was dissolved in THF (3 mL) before adding NaOH (3,0 mL of 1.0 M, 3.0 mmol). The reaction mixture was heated for 2 h at 60 °C and then concentrated. The resulting solid was partitioned between ethyl acetate and an aqueous solution of 1 N HCl. The organics were separated, washed with brine, dried over sodium sulfate and concentrated to give 5-[(E)-3,3-dimethylbut-l-enyl]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-carboxylic acid (198 mg, 69%). ESI-MS m/z cale. 312.2, found 313.5 (M+l)⁺; Rétention time; 0.77 min (1 min run).

S tep 3 : (^)-3-(3,3 -dimethylbut-1 -en-1 -y 1) -N-((3-nitrophenyl)s ulfony 1)-1 - (2,4,6trimethylbenzyl)-lH-pyrazole-5-carboxamide

5-[(£)-3,3-dimethylbut-l-enyl]-2-[(2,6-dimethyIphenyl)meÎhyl]pyrazole-3-carboxylic acid (50. mg, 0.16 mmol), 3-nitrobenzenesulfonamide (32 mg, 0.16 mmol), ^-[(dimethylamino)lH-l,2,3-triazolo-[4,5-à]pyridm-I-ylmethylene]-MmethyImethanaminium hexafluorophosphate N-oxide (61 mg, 0.16 mmol), and ethyldiisopropylamine (84 pL, 0.48 mmol) were combinedin MAMimethylfbrmamide (1 mL) and stirred at room température for 16 h. The reaction mixture was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mMHCi) to give (£)-3-(3,3-dimethylbut-l -en-l-yl)-N-((3-nitrophenyl)sulfonyl)-l -(2,4,6-trimethylbenzyl)H7-pyrazole-5-carboxamide (23 mg, 29%). ESI-MS m/z cale. 496.2, found 497.2 ⁺; Rétention time: 0.85 min (1 min run).

Step 4: AM3-aminophenyl)sulfonyl-5-(3,3-diniethylbutyl)-2-[(2,6dimcthylphenyl)methyl]pyrazole-3-carboxamîde (Compound 323)

771

A mixture of (£')-3-(3,3-dimethylbut-l-en-l-yl)-N-((3-nitrophenyl)suIfonyl)-I-(2,4,6trimethylbenzyO-lH-pyrazole-S-carboxamide (23 mg, 0.046 mmol), methanol (2 mL) and 10% Pd/C (17 mg, 0.016 mmol) at room température was placed under a balloon of hydrogen The mixture was stirred for 30 min before it was filtered. The fil trate was subjected to preparatoryHPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give A^l'-(3-aminophenyI)sulfonyl-5(3,3-dimethylbutyl)-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 323) (4.0 mg, 17%). ESI-MS m/z cale. 46S.2, found 469.0 (M+l)⁺; Rétention time: 2.11 min (3 min run).

N-(3-ammophenyl)sulfonyl-2-[(2,6-dimethylphenyl)methyl]-5-norboman-2-yl-pyrazole-3carboxamide (Compound 370), N-[(6-ammo-2-pyridyI)sulfonyl]-7-ethyl-2-[(2,4,6-trimethyIphenyl)methyl]indazole-3carboxamide (Compound 1086), and

N-(3-aminophenyl)sulfonyl-5-cyclopentyl-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 105).

[ PREPARATION 23: 1 -tert-butyl-3-((2,4,6-trimethylphenyOmethylj-lHpyrazoIe-4-carboxyfic acid

I Step 1: (£)-l-ieri-butyI-2-[2-(2,4,6-trimethylphenyI)ethylidene]hydrazine

772

Acetic acid (0.2 mL) was added to a mixture of 2-(2,4,6-trimethylphenyl)acetaldehyde (0.80 g, 4.9 mmol) and ί-butylhydrazine hydrochloride (0.73 g, 4.9 mmol) in methanol (10 mL). The mixture was stirred at room température for 24 h. The réaction mixmre was concentrated under reduced pressure and the residue was treated with ether (20 mL) to give a precipitate which was collected by filtration. The solid was suspended in ethyl acetate (150 mL), the pH adjusted to >7 by adding saturated NaHCO₃, the organic layer washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to afford (£)-l-tert-butyl-2-[2-(2,4,6trimethylphenyl)ethylidene]hydrazine (0.80 g, 70.%) as a yellow oil. ’H NMR (300 MHz, DMSOt/₆)S 1.22 (s, 9H), 2.18 (s, 3H), 2.23 (s, 6H), 3.68 (d,J=5.2 Hz, 2H), 6.85 (s, 2H), 8.24 (t, J =5.2 Hz, 1H), U.39(brs, 1H). ESI-MS m/z cale. 232.2, found 233.2 (M+l)⁺; Rétention time: 1.75 min (5 min run).

Step 2: ethyl I-iert-butyl-3-[(2,4,6-trimethylphenyl)methyl]-ll^:7-pyrazole-4carboxylate

A mixture of (E)-l-rert-butyl-2-[2-(2,4,6-trimethylphenyl)ethylidene]hydrazine (0.86 g, 3.7 mmol) and ethylpropiolate (0.44 g, 4.5 mmol) in acetonitrile (3 mL) and acetic acid (3 mL) was stirred at room température for 2 d. The reaction mixture was concentrated under reduced pressure and the residue was taken up with ethyl acetate (100 mL) before it was washed with saturated NaHCO₃, brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel, eluting with 30% ethyl acetate in heptane to afford ethyl lTerr-butyl-3-[(2,4,6-trimethylphenyl)methyl]-lif-pyrazole-4carboxylate (0.40 g, 33%) as a yellow solid. ESI-MS m/z cale. 328.2, found 329.2 (M+l)⁺; Rétention time: 2.92 min (5 min run).

Step 4: lTcrt-butyl-3-[(2,4,6-trimethylphenyl)methyI]-127-pyrazole-4-carboxylic acid

773

A mixture of ethyl l-iei7-butyl-3-[(2,4,6-trimethylpheny])methyl]-l//-pyrazo]e-4carboxylate (0.34 g, 1.0 mmol) and LiOHH₂O (0.22 g, 5.2 mmol) in methanol (4 mL) and water (4 mL) was heated at reflux for 3 h. The reaction mixture was concentrated under reduced pressure and the pH of the aqueous layer adjusted to -3 with 5% citric acid. The aqueous layer was extracted with ethyl acetate (150 mL), washed with brine, dried over Na₂SO4, fîltered and concentrated under reduced pressure. The residue was purified by Cis column chromatography, eluting at 80% methanol in water to afford l-ren-butyL3-[(2,4,6-trimethylphenyl)methyl]-177pyrazole-4-carboxylic acid (0.23 g, 74%) as a yellow solid. ESI-MS m/z cale. 300.2, found 301.2 (M+l)⁺; Rétention time; 2.41 min (5 min run).

A^f-(benzenesulfonyl)-I-te ri-butyl-3-[ (2,4,6-t rime thylphenyl)methyl]pyrazole-4carboxamide (Compound 63) and

N-(3 -aminophenyl) su Ifony 1-1 -ierbbuty 1-3-[(2,4,6-trimethylphenyl)m ethyl ]pyrazole-4carboxamide (Compound 324).

PREPARATION 24; 1 -/eri-Buty 1-4-((2,4,6-trime thylphenyl)m ethyl]4HpyrazoIe-3-carboxylic acid

Step 1: 4-bromo-l-terr-biityl-117-pyrazole-3-carboxylic acid

O O

Concentrated sulfuric acid (0.24 mL, 4.3 mmol) was added to a suspension of4bromo-l/Lpyrazole-3-carboxylic acid (860 mg,4.3 mmol) in f-BuOH (2.1 mL, 22 mmol). The reaction mixture was stirred at 100 °C for 2 h. Most of the solvent evaporated during the heating

774 and a while solid remained in the flask. After cooling to room température, the pH was adjusted to -4 by adding saturated aq. NaHC0₃. The aqueous layer was extracted with ethyl acetate (2 x 40 mL), The combined organic layers were washed with brine (20 mL), dried over MgSO₄, filtered and concentrated underreduced pressure to afford 4-bromo-l-tert-butyl- 1H-pyrazole-3carboxylic acid (LO g, 89%) as a white solid, ’H NMR (300 MHz, DMSO) δ 1.52 (s, 9H), 8.23 (s, 1H), 12.92 (brs, 1H).

Step 2: methyl 4-bromo-I-ierributyl-l/Z-pyrazole-3-carboxyIate

Potassium carbonate (1.1 g, 8.0 mmol) and iodomethane (0,3 mL, 4.8 mmol) were added to a solution of 4-bromo-l-ter/-butyl-lH-pyrazole-3-carboxylic acid (980 mg, 4.0 mmol) in MA-dimethylformamide (6 mL). The reaction mixture was stirred at room température ovemight. A 5% ci trie acid solution (20 mL) was added and the aqueous layer was extracted with ethyl acetate (60 mL). The organic layer was washed with water (2x15 mL), brine (15 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-30% ethyl acetate/hexanes) to afford methyl 4bromo-l-ter/-butyl-lH-pyrazoIe-3-carboxylate (1.1g, quantitative) as a colorless oil. ’H NMR (300 MHz, CDCi₃) δ 1.57 (s, 9H), 3.94 (s, 3H), 7.61 (s, 1H).

Step 3: methyl l-terributy]-4-[(2,4,6-triniethylphenyl)methy]]-17/-pyrazole-3carboxylate

Palladium acetate (45 mg, 0.20 mmol) and ⁱBu₃P HBF₄ (120 mg, 0.40 mmol) were added to a solution of methyl 4-bromo-l-ieri-butyl-lH-pyrazole-3-carboxylate (1.1 g, 4.2 mmol)

775 in tetrahydrofuran (10 mL) in a sealed tube. The reaction vessel was evacuated and backfilled with nitrogen three times. A solution of freshlyprepared (2,4,6-trimethylphenyl)methyl zinc bromide (8.0 mL of a 1.0M solution in THF, 8.0 mmol) was added at room température. The orange-red solution was stirred at room température ovemight. The resulting black reaction mixture was quenched with 5% citric acid solution (20 mL) and extracted with ethyl acetate (2 x 40 mL). The combined organic layers were washed with water (2x15 mL), brine (15 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (5 to 30% ethyl acetate/hexanes) to give methyl l-terhbutyl-4[(2,4,6-trimethylphenyl)methyl]-I/f-pyrazole-3-carboxylate (1.1 g, 87%) as a white solid. ’H NMR (300 MHz, CDC1₃) 6 1.47 (s, 9H), 2.19 (s, 6H), 2.29 (s, 3H), 3.96 (s, 3H), 4.05 (s, 2H), 6.67 (s, IH), 6.87 (s, 2H).

Step 4: l-Zeri-butyl-4-[(2,4,6*trimethylphenyl)niethyl]-lJ7-pyrazole-3-carboxj'lic acid

A mixture of l-«r^butyl-4-[(2,4,6-trimethylphenyl)methyl]-]/7-pyrazole-3c arboxylate ( 1.00 g, 3.18 mmol), LiOH H₂O (667 mg, 15.5 mmol), THF ( 10 mL) and water ( 10 mL) was stirred in a sealed tube at 60 °C for 4 h. The mixture was acidified by adding 5% citric acid (30 mL) and was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were washed with water (2x15 mL), brine (15 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was triturated with a mixture of methyl tertbutyl ether (2 mL) and heptanes (2 mL) to afford l-rcrt-butyL4-[(2,4,6-trimethylphenyi)methyl]1 W-pyrazoIe-3-carboxylic (769 mg, 81%) as a white solid. ^]H NMR (300 MHz, DMSO) δ 1.41 (s, 9H), 2.14 (s, 6H), 2.21 (s, 3H), 3.94 (s, 2H), 6.80 (s, 1H), 6.84 (s, 2H), 12.60 (s, 1H).

The following compound can be synthesized using the procedures described herein:

N-(3-aminophenyl)sulfonyl-l-ferrbutyl-4-[(2,4,6-trimethyIphenyl)methyl]pyrazole-3

776 carboxamide (Compound 366).

PREP A RATION 25: l-feri-butyl-3-(2₎4,6-trimethylphenoxy)-lH-pyrazole-4carboxylic acid

Step 1: l-teri-butyl-L7/-pyrazol-3-ol

tert-Butylhydrazine hydrochloride (3.03 g, 24.3 mmol) was added to pyridine (30 mL) and the mixture was stirred for 1 h at room température. The mixture containing insoluble mater! al was cooled to 5 °C then 3,3-diethoxypropanoyl chloride (3.27 g, 24.3 mmol) was added dropwise. The mixture was then was heated at 80 °C for 48 h before it was cooled to room température. The mixture was diluted with ethyl acetate and the organic phase was washed with 5% aq. NaHCO₃ and brine before it was dried over anhydrous Na₂SO₄. The solids were filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (5-50% ethyl acetate/heptanes) to give a solid which was tritnrated in heptanes (1 x 10 mL), filtered and dried to afford l-reri-butyl-lA-pyrazol-3-ol (1.38 g, 44%) as anoff-white solid. ^[H NMR(300MHz, CDC1₃) δ 1.54 (s,9H), 5.57 (d, 7 = 2.2 Hz, 1 H), 7.24 (d, J ~ 2-2 Hz, IH), 12.11 (br. s, 1H). ESLMS m/z cale. 140.1, found 141.2 (M+l)⁺; Rétention time: 1.12 min (5 min run).

Step 2: 4-bromo-l-fori-butyl-IH-pyrazol-3-oI

To l-iérrbutyl-l//-pyrazol-3-ol (1.30 g, 9.27 mmol) in dichloromethane (20 mL) was added NaHCO₃ (0.97 g, 11. mmol). The mixture was cooled to 0 °C and a solution of bromine (1.56 g, 9.74 mmol) in dichloromethane (10 mL) was added dropwise. The mixture was stirred for 60 min at 0-10 C before it was diluted with ethyl acetate. The organic phase was washed with 5% NaHCO₃, 1 % Na₂S₂O₃, 5% NaHCO₃. brine and dried over anhydrous Na₂SO₄. The solid was filtered off and the solvent was removed under reduced pressure to afford 4-bromo-l-tertbutyl-lA-pyrazol-3-ol (1.87 g, 92% yieïd) as an off-white solid. *H NMR (300 MHz, CDC1₃) S

777

1.53 (s, 9H), 7.31 (s, 1 H), 11.58 (br. s, 1H). ESI-MS m/z cale. 218.0, found 219.1/221.1 (M+l)⁺; Rétention time: 1.52 min (5 min run).

Step 3: 4-bronio-l-/€’ri-biitj l-3-(2,4,6-trimethylphenoxy)-lf7-pyrazole

1-2-Dichloroethane (125 mL) was added to flame-dried 4Â molecular sieves (4.81 g) and air was bubbled through the mixture for 15 minutes. 4-Bromo-l-ieri-butyl-lH-pyrazol-3-ol (1.75 g, 7.99 mmol) was added foliowed by 2,4,6-trimethyIphenylboronic acid (3.27 g, 20.0 mmol), pyridine (1.94 mL, 24.0 mmol) and copper (II) acetate (2.18 g, 12.0 mmol). The reaction mixture was stiired under an air atmosphère for 72 h at room température before being diluted with ethyl acetate. The organic phase was washed with 10% NH4OH, brine and dried over anhydrous NaySCL. The solid was filtered off and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (5-75% dichloromethane/heptanes) to afford 4-bromo-l-fert-butyl-3-(2,4,6-trimethylphenoxy)-lHpyrazole (1.35 g, 50%) as pale yellow solid. 'H NMR (300 MHz, CDCI3) 51.41 (s, 9H), 2.15 (s, 6H), 2.27 (s, 3H), 6.83 (s, 2H), 7.34 (s, 1H). ESI-MS m/z cale. 336.1, found 337.1/339.1 (M+l)⁺; Rétention time: 2.54 min (5 min run).

Step 4: 1 -^rributyl-3-(2,4,6-trimethylphenoxy)-lH-pyrazole-4-carboxylic acid

To a solution of 4-bromo-l-im-butyl-3-(2,4,6-trimethylphenoxy)-Iif-pyrazole (1.00 g, 2.96 mmol) in THF (8 mL) cooled at -78 °C was added dropwise a 2.5 M solution ofnbuthyllithium in hexanes (1.36 mL, 3.41 mmol). The mixture was stirred for 30 minutes at -78

778 °C and then CO2 was bubbled through the solution for 45 min after which a chunk of dry ice was added to the reaction mixture. The reaction mixture was allowed to warm from -78 °C to -60 °C over 3 h. The reaction mixture was quenched by the addition of water (5 mL) at 0 °C before it was diluted with ethyl acetate (50 mL). Citric acid (5%, aq.) was added under stirring to obtain pH of 4. The mixture was extracted with ethyl acetate. The combined organic extracts were washed with 5% aq. citric acid, 3% HCI, H₂O and brine and dried over an hydrous Na₂SO₄. The solid was filtered off and the solvent was removed under reduced pressure. The residue was triturated twice in heptanes/methyl tert-butyl ether (8 mL/0.5 mL) then purified by silica gel column chromatography 0-20% methanol/dichloromethane) to afford 1-tm-butyl-3-(2,4,6trimethy]phenoxy)-lW-pyrazole-4-carboxyJic acid (480 mg, 53% yield) as white solid. 'H NMR (300 MHz, CDC1₃)Ô 1.42 (s,9H),2.15 (s, 6H), 2.28 (s, 3H), 6.85 (s,2H),7.91 (s, 1H). ESI-MS m/z cale. 302.2, found 303.2 (M+l)⁺; Rétention time: 3.94 min (5 min run).

The foliowing compounds can be synthesized using the procedures described herein:

M[(6-amino-2-pyridyl)sulfonyl]-l-/frr-butyl-3-(2,4,6-trimethyIphenoxy)pyrazole-4-carboxamide (Compound 256) and N-(3-ammophenyI)sulfonyl-l-terFbutyl-3-(2,4,6trimethylphenoxy)pyrazole-4-carboxamide (Compound 325).

PREPARATION 26: A-(3-aminophenyl)sulfonyl-6-cyano-l-[(2,4,6trimethyIphenyl)methyl]indole-2-carboxamide (Compound 1082)

Step 1: methyl 6-cyano-1-(2,4,6-trimethyIbenzy])-l//-indole-2-carboxylate

Methyl 6-cyano-l fi-indole-2-carboxylate (467 mg, 2.33 mmol) was dissolved in N,Ndimethylformamide (25 mL) and cooled in an ice bath. NaH (60%, 112 mg, 2.80 mmol) was added and the reaction mixture was stirred for 10 min. 2-(Chloromethy 1)-1,3,5-trimethylbenzene (472 mg, 2.80 mmol) was added and the reaction mixture was allowed to warm to room température and was stirred for 12 h. The réaction mixture was poured into ice water and was made acidic with the addition of 1 N HCl. The resulting precipitate was collected to give methy]

779

6-cyano-l-(2,4,6-trimethylbenzyl)-lH-indole-2-carboxylate. ESI-MS m/zcalc. 332.2, found

333.2 (M+l)⁺; Rétention time:0.81 min (1 min run).

Step 2: 6-cyano-l-[(2,4,6-trimethylphenyl)methyI]indole-2-carboxylic acid

Methyl 6-cyano-l-(2,4,6-trimethylbenzyl)-lH-indole-2-carboxylate (from step 1) was stirred in a mixture of methanol (20 mL), THF (10 mL) and NaOH (9.34 mL of 1.0 M, 9.34 mmol) for 30 min. The reaction mixture was cooled in an ice bath and was acidified with 6 M HCl to a pH of 1. The mixture was extracted with ethyl acetate. The organics were washed with brine, dried over sodium sulfate and evaporated to give 6-cyano-i-[(2,4,6trimethylphenyl)methyI]indole-2-carboxylic acid (740 mg, 99% over two steps). ESI-MS m/z cale. 318.1, found 319.2 (M+l)⁺; Rétention time: 0.68 min (1 min run).

Step 3: 6-cyano-)V-((3-nitrophenyl)sulfony 1)-1-(2,4,6-trimethylbenzyl)-lH-indole2-carboxamîde

6-Cyano-l-[(2,4,6-îrimethylphenyl)methyl]mdole-2-carboxy]ic acid (35 mg, 0.11 mmol), (3-nitrophenyl)sulfonylazanide sodium (37 mg, 0.16 mmol), A^r-[(dimethylamino)-lHl,2,3-triazolo-[4,5-b]pyridin-l-yImethylene]-)V-methylmethanaminium hexafluorophosphate Noxide (42 mg, 0.11 mmol), and K₂CO₃ (46 mg, 0.33 mmol) were combined in N,Ndimethylformamide (1 mL). The reaction mixture was heated at 60 °C for 2 h and was concentrated. The crude material was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 6-cyano-A^r-((3-nitrophenyl)sulfouyl)-l-(2,4,6-trimethylbenzyl)-lW

780 in do le-2-carboxamide. ESI-MS m/z cale. 502,1, found 503.2 (M+l)⁺; Rétention time: 0.75 min (1 min run).

Step 4: tV-(3-aminophenyl)suIfonyl-6-cyano-l-[(2,4,6 trimethy]phenyl)methyl]indole-2-carboxamide (Compound 1082)

6-Cyano-?7-((3-nitrophenyI)sulfonyl)-l -(2,4,6-trimethylbenzyl)-127-indole-2carboxamide (from step 3) was mixed with methanol (2 mL) and 10% Pd/C (12 mg, 0.011 mmol) under a balloon of hydrogen. After 1 h, the reaction mixture was filtered and the filtrate was concentrated. The residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mMHCl) to give 77-(3-ami nophenyl)sulfonyl-6-cyano-l -[(2,4,6trime thylph en yI)methyl]indole-2-carboxamide (Compound 1082) (6.8 mg, 13% over two steps) ESI-MS m/z cale. 472.2, found 473.2 (M+l)⁺; Rétention time: 1.71 min (3 min mn).

jV-(benzenesülfonyl)-6-chloro-l-[(2,4,6-trimethylpheny])methyl]indole-2-carboxamide (Compound 10),

77-(benzenesulfonyl)-5-methoxy-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 241), ?7-(benzenesulfonyl)-4-chloro-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 127),

77-(benzenesulfonyl)-4-fluoro-l-(l-phenylethyI)indole-2-carboxamide (Compound 160), /7-(benzenesulfonyl)-6-methyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 12),

77-(benzenesulfonyl)-5-chloro-I-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 137),

781

ZV-(benÎenesulfonyi)-4-riuorG-l!-[(2,4,â-trimeïhyiphenyI)methyI]indole-2-carboxamide (Compound 87),

77-(benzenesulfonyl)-5-methyl-l -[(2,4,6-triniethylphenyl)methyljindole-2-carboxamide (Compound 248), jV-(benzenesulfonyl)-4-methyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 143),

7V-(benzenesulfonyl)-7-methyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 354),

Λ^Γ-(benzeπesulfonyl)-5-fluoro-l-[(2,4,6-trimethylpl·lenyl)πΊethyl]indole-2-carboxamide (Compound 33), /V-(3-aminophenyl)suIfonyl-4-chloro-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 362), /V-(3-aminophenyl)sulfonyl·4-methoxy-l-[(2,4,6-trimethyiphenyl)methyl]indole-2-carboxamide (Compound 120), jV-[(6-amino-2-pyridyî)sulfonyl]-5-ethyl-l-[(2,4,6-trimethylphenyl)methyljindole-2-carboxamide (Compound 179),

N-(benzenesulfonyl)-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 264),

M(benzenesulfonyl)-l-[(2,6-dimeihylphenyl)methyl]-4-methoxy-indole-2-carboxamide (Compound 290),

N-(benzenesu Ifon yl)-4-methoxy-l-[ (2,4,6-trimethylphenyl)methyl] indole-2-carboxamide (Compound 348),

A43-aminophenyl)sulfonyl-5-chloro-l-[(2,4,6-trimethylphenyl)methyI]indole-2-carboxamide (Compound 344),

N-(3 -aminophenyl)sulfonyl-5-methyl-I-[(2,4,â-trimethylphenyl)methyl]indoIe-2-carboxamide (Compound 259),

N-(3-ammophenyl)sulfonyl-6-chloro-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 9),

782

M-(3-aminophehyl)sulfonyl-6-f]uoro-l - [(2,4-,6-trimethy!phenyl)mêthyl]indole-2-carboxamide i < (Compound 142), _L .

A-(benzenesu lfonyl)-6-fluoro-l-[(2,4,6-trimethylphenyl)methyl]indoIe-2-carboxamide (Compound 212),

A-(3-aminophenyl)sulfonyl-4-fluoro-l-(l-phenylethyl)indole'-2-carboxamide (Compound 186),

A-(3-aminophenyl)sulfony]-4-methyl-l-[(2,4,6-trimethylphenyl)methyl]indoIe-2-carboxamide (Compound 144),

A-(3-aminophenyI)sulfonyI-I-[(2,6-dimethylphenyl)methyl] A-me thoxy-indole-2-carboxamide (Compound 168),

A-(3-aminophenyl)sulfonyl-4-fîuoro-l-[(2,4,6-trimethylphenyl)methyl]indole-2-caiboxamide (Compound 181),

A-(3-me thoxyphenyl)sulfonyl-1-((2,4,6-trimethyIphenyl)methyl]indole-2-carboxamide (Compound 335),

A-(3-aminophenyl)sulfony]-7-methyl-l-[(2,4,6-trimethylphenyl)methyI]indole-2-carboxamide (Compound 194),

A-(3-aminophenyl)sulfonyl-5-methoxy-l-[(2,4,6-trimethylphenyl)methyI]indole-2-c arboxamide (Compound 336),

A-(2-methoxyphenyl)sulfonyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 183),

A-[(6-methoxy-2-pyridyl)sulfonyl]-l-[(2,4,6-trimethylphenyl)methyl]indo!e-2-carboxamide (Compound 253),

A-(3-ammophenyl)sulfonyl-5-fluoro-l-[(2,4,6-trimethylpbenyl)methyI]indole-2-carboxamide (Compound 153),

A-(3-aminophenyl)sulfoüyl-6-methyl-l-[(2,4,6-trimethy]phenyl)methyl]indole-2-carboxamide (Compound 62),

A-(benzenesulfonyl)-3-methyI-l-[(2,4,6-trimethylphenyl)methyl]indole-2-c arboxamide (Compound 232),

783

A6(3-aminophenyl)sulfonyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 148),

N-(2-hydroxyphenyl)sulfonyl-]-[(2,4,6-trimethylphenyl)methyl]indo]e-2-carboxanude (Compound 112),

N-(benzenesulfonyl)-5,6-dimethoxy-I -[(2,4,6-tri methylphenyl)methyl]indole-2-carboxamide (Compound 198),

N-(4-aminophenyl)sulfonyl-1-((2,4,6-trime thylphenyl)methyl] in dole-2-carboxamide (Compound 134),

N-(benzenesulfonyl)-l-[(2,6-dimethylphenyl)methyl]indoIe-2-carboxamide (Compound 2), 7W-aminophenyl)sulfonyl-4-cyano-l-[(2,4,6-trimethy]phenyl)methyl]indoIe-2-caiboxamide (Compound 306),

A^r-[(2-methoxy-3-pyridyl)sulfonyl]-5-methyl-l-[(2,4,6-trimethylphenyl)methyl]indoIe-2carboxamide (Compound 267),

4-fiuoro-l “(l-phenylethyI)-N-(4-pyridylsulfonyl)indoIe-2-carboxamide (Compound 192),

AH(2-methoxy-3-pyridyl)sulfony]]-l-[(2,4,6-trimethylphenyl)methyI]indoJe-2-carboxaniide (Compound 18),

N-(3-aminophenyl)suIfonyl-l-[(2,6-dimethylphenyl)methyl]indole-2-carboxamide (Compound 331),

N-(2-pyridylsulfonyl)-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 247), W-cyanophenyl)sulfonyl-l-[(2,4,6-trimethylphenyl)methyl]indoIe-2-carboxamide (Compound 358),

4-chloroW-(4-pyridylsulfonyl)-I-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 82),

6-methylW-(4-pyridylsulfonyI)-l-[(2,4,6-trimethylphenyI)methyl]indole-2-caiboxamide (Compound 38),

4-methoxy-M(4-pyridylsulfonyl)-I-[(2,4,6-trimethyl_phenyl)methyl]indole-2-caiboxamide (Compound 36),

784

4-fluoro-N-(4-pyridylsulfonyI)-l -[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 298),

7\^r-(4-pyridyIsulfonyl)-l-[(2,4,6-trimethylphenyl)methyî]indole-2-carboxamide (Compound 227),

5-methyl-2V-(4-pyridylsulfonyl)-l-[(2,4,6-trime thylphenyl) methyl] indole-2-carboxamide (Compound 25),

A43-ammophenyl)su]fonyl-3-methyl-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 118),

V-(3-aminophenyI)sulfonyl-l-[(2,6-dimethylphenyl)methyl]-6-methoxy-indole-2-carboxamjde (Compound 116),

AA[(3-methoxy-2-pyridyl)sulfonyl]-l-[(2,4,6-trimethylphenyl)methyI]mdole-2-carboxainide (Compound 258),

5-chloro-A^r-(4-pyridylsulfony])-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 65),

6-chloro-27-(4-pyridylsulfonyl)-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 24),

A^r-[(6-amino-2-pyridyl)sulfonyl]-l-[(4-cyano-2,6-dimethyl-phenyl)methyI]-5-methyl-indole-2carboxamide (Compound 67),

V-[(4-amino-2-pyridyl)sulfonyl]-l -[(2,4,6-trimethylphenyI)methyl]indo le-2-carboxamide (Compound 23), zV-(3-aminophenyl)sulfonyl-5-cyano-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 291),

W(3-aminophenyl)sulfonyl-5,6-dimethoxy-l-[(2,4,6-trimethylphenyl)methyl]indole-2carboxamide (Compound 598),

W(3-aminophenyl)sulfonyl-6-cyano-l -[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 1082),

N-[(2-amino-4-pyridyl)sulfonyl]-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxamide (Compound 627),

785

M[(6-amino-2-pyridyl)sulfonyl]-5-isopropyl-1-((2,4,6-trimethylphenyl)methyl]indole-2carboxamide (Compound 404),

M[(6-amino-2-pyridyl)sulfonyI]-5-methyH-(p-tolyl)mdole-2-carboxamide (Compound 653),

AF(3-aminophenyl)sulfonyl-5,6-dimethoxy-1-((2,4,6-trimethylphenyl)methyl]indole-2carboxamide (Compound 598),

V-(benzenesulfonyl)- l-[(2,6-dimethyIphenyl)methyl]pyrrolo[2,3-b]pyridine-2-carboxamide (Compound 1291),

A4(2-amino-4-pyridy l)sulfonyl]-l- [(2,4,6-trimethylphenyl)methyl]indole-2 -carboxamide (Compound 627), (2R)-A4(6-amino-2-pyridyl)sulfbnyl]-l-[(2,4,6-trimethylphenyl)methyl]mdoline-2-carboxamide (Compound 462), (2R)-M(benzenesulfonyl)-l-[(2,4,6-trimethylphenyl)methyI]indoIine-2-carboxamide (Compound 918),

N- [(6-amino-2-pyridyI)sulfbnyl] -5 -propyl-1-((2,4,6-trimethylphenyl )methyl]indole-2 carboxamide (Compound 1158),

N- [(6-amino-2-pyridyl)suIfonyl] -5 -ethyi-1-((2,4,6-trimethylphenyl)methyl]pyrrolo [2,3b]pyridine-2-carboxamide (Compound 816),

N-(3-ammophenyl)sulfonyl-l-[(2,4,6-trimethylphenyl)merhyl]pyrrolo[2,3-b]pyridine-2carboxamide (Compound 184), and

N-(benzenesulfonyl)-l-[(2,6-dimethylphenyl)methyl]pyrrolo[2,3-b]pyridine-2-carboxamide (Compound 1291 ).

PREPARATION 27: 4-methoxy-l-[(2,4,6-trimethylphenyl)methy]]pyrrolo[3,2c]pyridine-2-carboxylic acid

Step 1: methyl 4-chloro-l-[(2,4,6-trimethylphenyl)methyl]pynOlo[3,2-c]pyndine2-carboxylate

786

NaH (60%, 62 mg, 1.5 mmol) was added to a mixture ofmethyl 4-chIoro-17/pynOlo[3,2“C]pyridine-2-carboxylate (250. mg, 1.19 mmol) and AtV-dimethylformamide (5 mL) at 0 °C. The mixture was allowed to stir for 15 min at 0 °C before a solution of 2(chloromethyl)-l,3,5-trimethyl-benzene (260. mg, 1.54 mmol) in AUV-dimethylformamide (1 mL) was added dropwise. The mixture was allowed to stir for 1H at room température, then 4h at 60 °C. The mixture was partitioned betweeu IN HCl and ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were washed with brine (2x), dried over magnésium sulfate, filtered and concentrated under reduced pressure. The clear residue was subjected to silica gel column chromatography (0-20% ethyl acetate/hexanes) to give methyl 4-chloro-l-[(2,4,6trimethylphenyl)methyl]pyiTolo[3,2-c]pyridine-2-carboxyIate (370 mg, 91 %). ESI-MS m/z cale. 342.1, found 343.4 (M+l )⁺; Rétention time: 2.09 min (3 min run).

Step 2: methyl 4-methoxy-l-[(2,4_>6-trimethylphenyl)methyl]pyrrolo[3,2c]pyridine-2-carboxylate

A mixture ofmethyl 4-ch]oro-l-[(2,4,6-trimethylphenyl)methyl]pynOlo[3,2c]pyridine-2-carboxylate (130. mg, 0.379 mmol) and NaOMe (7.6 mL of 0.50 M, 3.8 mmol) was heated at 110 °C for 30 min in the microwave. The mixture was concentrated to give methyl 4methoxy-l-[(2,4,6-trimethylphenyl)methyl]pyrrolo[3,2-c]pyridine-2-carboxylate (56 mg, 15%) as awhitesolid. ESI-MS m/z cale. 338.2, found 339.4 (M+l)⁺; Rétention time: 0.64 min (1 min

787 run).

Step 3: 4-methoxy-1-((2,4,6-trimethylphenyl)methyl]pyrrolo[3^-c]pyridine-2carboxylic acid

Lithium hydroxide (160 pL of2.0 M, 0.32 mmol) was added to a mixture of methyl 4-methoxy-l-[(2,4,6-trimethylphenyl)methyl]pyrrolo[3,2-c]pyridine-2-carboxylate (50. mg, 0.15 mmol) and EtOH (1 mL) at room température. The mixture was allowed to stir at room température ovemight. The mixture was concentrated and the residue was partitioned between IN HCl and CH2CI2. The layers were separated and the aqueous layer was extracted with CH2CI2 (3x). The combined organics w*ere washed with brine, dried over magnésium sulfate, fîltered and concentrated. The residue was taken up in A'A-dimethylformamide and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 4-methoxy-1 -[(2,4,6trimethylphenyl)methyl]pyrrolo[3,2-c]pyridine-2-carboxylic acid (39 mg, 81%) as a white solid. ESI-MS m/z cale, 324.2, found 325.4 (M+l)⁺; Rétention time: 0.52 min (1 min run).

The foliowing compound can be synthesized using the procedures described herein: N-(3-aminophenyl)sulfonyl-4-methoxy-1-((2,4,6-trimethylphenyl)methyl]pyrroIo [3,2-c]pyridine2-carboxamide (Compound 943) and

N-[(6-amino-2-pyridyl)sulfonyl]-4-methoxy-l-((2,4,6-trimethy]phenyl)methyl]pyrrolo[2,3b]pyridine-2-carboxamide (Compound 539)

PREPARATION 28: 2-((2,4,6-trimethylphenyI)methyl]isoindoline-l-carboxylic acid hydrochloiide

788

A suspension of isoindoline-l-carboxylic acid (100 mg, 0,613 mmol) and KOH (103 mg, 1.84 mmol) in isopropanol (600 pL) was stirred until a solution was formed. 2(Chloromethy 1)-1,3,5-trimethyl-benzene (114 mg, 0.674 mmol) was added and the reaction mixture was stined for 3 h. The mixture was concentrated and the residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 2-((2,4,6trimethylphenyl)methyl]isoindoline-l-carboxylic acid hydrochloride (99 mg, 49%). ’H NMR (400 MHz, DMSO) δ 7.39 - 7.33 (m, IH), 7.34 - 7.25 (m, 3H), 6.87 (s, 2H), 4.97 (s, IH), 4.34 3.94 (m, 4H), 2.40 (s, 6H), 2.23 (s, 3H). ESI-MS m/z cale. 295.2, found 296.2 (M+1 )⁺; Rétention time: 0.43 min (1 min run).

N-(3-aminophenyl)suIfonyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 90),

V-(4-pyridylsulfonyl)-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 94),

A⁷-[(6-amino-2-pyridyl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 73),

A⁷-(3-me thoxyphenyl)sulfonyl-2-[(2,4,6-trime thylphenyl)methyl] isoindoline-1-carboxamide (Compound 16),

N-(benzenesulfonyl)-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 6),

N~(3-hydroxypheny])sulfony 1-2-((2,4,6-trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 254),

A^r-[(6-methoxy-2-pyridyI)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide

789 (Compound 174),

N-[(6-0XO-lH-pyridin-2-yl)sulfonyl]-2-[(2,4,6-trimethy]phenyl)methyl]isoindoline-lcarboxamide (Compound 319),

N-[(2-methoxy-3-pyridyl)suIfonyI]-2-[(2,4,6-trimetbylpheny l)methyl]isoindo line-1-carboxamide (Compound 218),

N-(2-me thoxyphenyI)sulfonyl-2-[(2,4,6-trimethylphenyl)raethyl]isoindo line-1-carboxamide (Compound 79),

M(2-pyridylsulfonyl)-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 48),

N-[(6-methoxy-3-pyridyI)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isomdoline-l-carboxamide (Compound 200),

N-(3-aminophenyl)sulfonyl-2-(l-phenylethyI)isoindoline-l-carboxamide (Compound 187),

M (4-aminophenyl)sulfonyl-2-[(2,4,6-tri methylphenyl)methyl]isoindoline-l -carboxamide (Compound 121),

N- [(4-ammo-2-pyridyl)s u Ifonyl]-2-[(2,4,6-tnmethylphenyl )methyl] isoindolin e-1 -carboxamide (Compound 32),

N-(2-aminophenyl)sulfony 1-2-[(2,4,6-trimethyIphenyl)methyl]isoindo line-1-carboxamide (Compound 230), ^[(6-amino-2-pyridyl)sulfonyl]-5-methyl-2-[(2,4,6-trimethylphenyl)methyl]-3,4-dihydro-l//isoquinoline-3-carboxamide (Compound 95),

N-(3-ammophenyl)suIfonyl-2-[(2,4,6-trimethylphenyl)methyl]-3,4-dihydro-lZ/-isoqumoline-3carboxamide (Compound 213),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[l-(2,4,6-trimethyIphenyI)ethyI]isoindoIme-l-cm-boxamide (Compound 1186),

N-(benzenesulfonyl)-l-[(2,4,6-trimethylphenyl)methyl]-2,3,4,5-tetrahydro-l-benzazepine-2carboxamide (Compound 604),

A^f-[(6-amino-2-pyridyI)suIfonyl]-l-methyl-2-[(2,4,6-trimethy]phenyl)methyl]isoindo]ine-l790 carboxamide (Compound S95),

N-[(3-hydroxy-2-pyridyl)sulfonyl]-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 377),

N-[(6-amino-2-pyridyl)suIfbnyl]-4-ethoxy-2-[(2-fluoro-6-methyl-phenyl)methyl]-l-methylisoindoline-1-carboxamide (Compound 1392),

N-(3-amino-4-propyl-phenyl)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6trime thylphenyl)methyl] isoindoline-1-carboxamide (Compound 1367), ^-(3-amino-4 -i sopropyl-phen yl)su Ifony 1-4-ethoxy-1 -methyl-2-((2,4,6 trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 1562),

N-(3-amino-4 -ethyl -phenyl)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1584),

Ar-[(6-amino-2-pyridyl)sulfonyl]-4-ethoxy-l-methyI-2-(o-tolylmethyi)isoindoline-l-carboxamide (Compound 1408)

4-ethoxy-A^r-indoIin-5-ylsulfbnyl-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1422)

Y-(2-aminophenyl)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoIine-lcarboxamide (Compound 1457)

V-(4-aminophenyI)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1480)

4-ethoxy-l-methy]-M[[6-[(2,2,2-trifluoroacetyI)amino]-2-pyridyl]sulfbnyl]-2-[(2,4,6trimethylphenyl)methyl]isoindoline-1-carboxamide (Compound 1616)

N- [(6-ac etamido-2-pyri dyl)sulfonyl] -4-ethoxy-l -methyl-2- [(2,4,6 trimethylphenyl)methyl]isoindoline-I-carboxamide (Compound 1415)

7V-[(6-ammo-3-pyridyl)sulfony]]-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-1-carboxamide (Compound 1413)

4-ethoxy-A^r-(2-hydroxyphenyl)sulfonyl-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindolme1-carboxamide (Compound 1509)

791

4-ethoxy-N-(4-hy droxy phenyl )sulfony 1-1-me thy 1-2 - [(2,4,6-trimethy lphenyl)meth y] ] isoindolineI-carboxamide (Compound 1453)

4-ethoxy-1-methyl-A-(3-pyridylsulfonyl)-2-[(2,4,6-trime thylphen yl)methyl]isoindo line-1carboxamide (Compound 1669)

N-[(6-amino-5-chloro-2-pyridyl)sulfonyl]-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-I-carboxamide (Compound 1596)

4-ethoxy-N-(3-methoxyphenyl)sulfonyI-l-methyl-2-[(2A6-trimethylpheny])methyl]isoindolineI-carboxamide (Compound 1470)

N-[(6-amino-2-pyridyl)sulfonyl]-4-ethoxy-2-[(3-fluoro-5-isobutoxy-phenyl)methyl]-l-methylisomdoline-l-carboxamide (Compound 1681)

4-ethoxy-1-methyl W-thiazoI-5-ylsulfonyl-2-[(2,4,6-trimethyIphenyl)methyl]isoindoline-lcarboxamide (Compound 1606)

4-etho xy-A41H-indol-6-ylsulfonyl)-I-me thy 1-2-[(2,4,6-trime thylphenyl)methyl] isoindoline-1carboxamide (Compound 1393)

V- [[6-(difluoro me thyl)-2 -pyridyl] su Ifonyl]-4-ethoxy-1 -meth y 1-2-[(2,4,6 trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1597)

4-ethoxy-/V-[(3-hydroxy-2-pyridyl)sulfonyI]-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindo line-1-carboxamide (Compound 1642) (Compound 377)

4-ethoxy-1 -methyl-jV-thiazoI-4-ylsuIfonyl -2-[(2,4,6-trimethylphenyl)methyI] isoindoline-1carboxamide (Compound 1542)

4-ethoxy- l-methylW-(4-pyridyIsulfonyl)-2-[(2,4,6- trime thylphenyl)methyl] isoindoline-1carboxamide (Compound 1449)

4-ethoxy W-( 1 H-indol-4-ylsulfonyl)-l-methyl-2-[(2,4,6-trimethylphenyl)methyI] isoindoline-1carboxamide (Compound 1666)

À^r-(2-acetamidothiazol-5-yl)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1555)

4-etho xyW-(3-fluoro-2-me thoxy-phenyl)su lfonyl-1 -methyl-2-[(2,4,6792 trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1403)

4-ethoxy-l-methyI-7\^r-(2-pyridylsulfonyl)-2-[(2,4,6-trimethylphenyI)methyl]isoindolme-lcarboxamide (Compound 1474)

4-edioxy-l-methy]-N-thiazol-2-ylsulfonyI-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1546)

4-ethoxy-A^r-(3-fhiorophenyI)sulfonyl-l-methyl-2-[(2_t4₎6-trimethylphenyl)methyl]isomdolme-lcarboxamide (Compound 1425)

A-[(2-amino-3-pyridyl)sulfony]]-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1591)

M[(6-amino-2-pyridyl)suIfonyl]-4-ethoxy-2-[(6-isopropoxy-3-pyridyl)methyl]-l-methylisoindolîne-1 -carboxamide (Compound 1662)

A4(6-amino-2-pyridyI)suIfonyl]-2-[(2,6-dimethylphenyl)methyl]-4-ethoxy-l-methylisoindoline-l-carboxamide (Compound 1498)

2- [(2,6 - dime thylphenyl)methyl] -4-ethoxyW- [(6-fl uoro -2 -pyridyl)su Ifonyl]-1 -methyl - isoindoline-1-carboxamide (Compound 1676)

M[(6-amino-2-pyridyl)sulfonyl]-2-[(6-chloro-3-pyridyl)methyl]-4-ethoxy-l-methyl-isoindoline1-carboxamide (Compound 1565)

N-(benzenesulfonyl)-4-ethoxy-l-methyI-2-[(2,4,6-trimethylpheny[)methy]]isoindoline-lcarboxamide (Compound 1539)

N-(3-aminophenyl)sulfonyl-4-ethoxy-l-me thyl-2-[ (2,4,6-trimethy lphenyl)methyl]isoindoli ne-1carboxamide (Compound 1454)

M-[(6-amino-2-pyridyI)sulfonyl]-4-ethoxy-2-[(4-isopropylphenyl)methyl]-I-methyl-isoindolme1-carboxamide (Compound 1576)

4-ethoxy-Aq(6-fluoro-2-pyridyl)sulfonyl]-2-[(4-isopropylphenyl)methyl]-l-methyl-isomdolme1-carboxamide (Compound 1655) (V-[(6-amino-2-pyridyl)sulfotiyl]-4-ethoxy-2-[(4-fluorophenyl)methyl]-I-methyl-isoindolme-lcarboxamide (Compound 1433)

793

4-ethoxy-2-[(4-fluorophenyl)methyl]-A-[(6-fluoro-2-pyridyl)sulfonyl]-l-methyI-isoindoline-lcarboxamide (Compound 1583)

A-[(6-amino-2-pyridyl)sulfonyl]-4-ethoxy-2-[(3-fluoro-5-methoxy-phenyl)methyl]-l-methylisoindoline-l-carboxamide (Compound 1421)

4-ethoxy-2-[(3-fluoro-5-methoxy-phenyl)methyl]-iV-[(6-fluoro-2-pyridy])sulfonyl]-l-methylisoindoline-l-carboxamide (Compound 1428) (lS)-A-[(6-amino-2-pyridyl)sulfonyl]-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-1-carboxamide (Compound 1372) (Compound 1346) ( lR)-A-[(6-ami uo-2-pyridyl)sulfonyl]-4-ethoxy-l-me thy 1-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1582) (Compound 1346) (lS)-4-ethoxy-l-methyl-A-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1541) (Compound 1237) (Compound410) (lR)-4-ethoxy-l-methyl-A-[(2-oxo-lH-pyridin-3-yl)su!fonyl]-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1476) (Compound 1237) (Compound 410)

N- (3 -amino -4-chloro-pheny l)sulfonyl-4-ethoxy-l -methyl-2-((2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1587)

A-(3-amino-4-fluoro-phenyI)sulfonyl-4-ethoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1394)

A43-aminopyrazin-2-yl)sulfonyl-l-methyI-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 480), l-methyl-A-[(2-oxo-U7-pyridin-3-yl)sulfony]]-2-[(2,4,6-tnmethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1237),

A^3-aminophenyl)sulfonyl-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1273),

A-(benzenesulfonyl)-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 873),

794

I-metliyl-N-(lH-pyrazol-5-ylsulfonyl)-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 378),

AH(6-ammo-2-pyridyl)sulfonyl]-l-methyl-2-(o-tolylrnethyl)isomdofine-1-carboxamide (Compound 666),

A⁷-[(2-methoxy-3-pyridyl)sulfonyl]-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 765), ?/-[(6-amino-2-pyridyi)sulfonyl]-2-[(2,6-dimethylphenyl)methyl]-l-methyl-isoindoline-lcarboxamide (Compound 790),

N-[(3-methoxy-2-pyridyl)sulfonyl]-l-methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 825),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2,4-dimethylphenyl)methyl]-l-methyl-isoindoline-lcarboxamide (Compound 1058), /V-[(2-metboxy-3-pyridyl)sulfonyl]-3,3-dimethyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline1-carboxamide (Compound 1235),

4-ethoxy-l-methyMV-[(2-oxo-li/-pyridin-3-yl)sulfonyl]’2-[(2,4,6trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 1237) (Compound 410), //-[(6-amino-2-pyridyl)sulfonyI]-7-methoxy-1-methy 1-2-((2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1075),

N-[(6-amino-2-pyridyl)sulfonyl]-6-methoxy-l-methyl-2-[(2,4,6trimethylpbenyl)methyl]isoindoline- 1-carboxamide (Compound 474),

N-[(6-amino-2-pyridyl)sulfonyl]-4-methoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1161),

N-[(6-amino-2-pyridyl)sulfonyl]-5-methoxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 406),

4-ethoxy-N-[(2-methoxy-3-pyridyl)sulfonyl]-i-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-1-carboxamide (Compound 765) (Compound 648), /V-[(6-amino-2-pyridyl)sulfonyl]-4-ethoxy-l-methyl-2-[(2,4,6795 trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 1346),

A^r-(3-amino-4-methyl-phenyl)sulfonyl-3,3-dimethyl-2-[(2,4,6trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 448), iV-(5 -amino-2 -methyl-phenyl)s ulfonyl-3,3 -dimethy 1-2- [(2,4,6trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 840),

7V-[(6-amino-2-pyridyI)sulfonyl]-7-hydroxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 394),

A''-[(6-amino-2-pyridyl)sulfonyl]-6-hydroxy-l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 885), /9-[(6-amino-2-pyridyl)sulfonyl]-4-hydroxy-l-methyl-2-[(2,4,6tri methylph en yl)methyl] isoindolin e-1 -carboxamide (Compound 1338),

A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]-l,3,4,5-tetrahydro-2benzazepine-3-carboxamide (Compound 855),

W-[(2-methoxy-3-pyridyl )su!fonyl]-2-[(2,4,6-tri methyl phenyl)methyl]-l ,3,4,5 -tetrahydro-2benzazepme-3-carboxamide (Compound 1342),

N-[(6-amino-2-pyridyl)su]fonyl]-2-[(2,4,6-trimethylphenyl)methyl]-l,3,4,5-tetrahydro-2benzazepine-3-carboxamide (Compound 690),

3,3-dimethyl-/V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isoindoline1-carboxamide (Compound 1085),

N-[(6-amino-2-pyridyl)sulfonyl]-3,3-dimethyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 1101), /V-(benzenesulfonyl)-2-[(2,4,6-trimethylphenyl)methyl]-l,3,4,5-tetrahydro-2-benzazepine-lcarboxamide (Compound 674),

A^T-[(6-amino-2-pyridyl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]-l,3,4,5-tetrahydro-2benzazepine-l-carboxamide (Compound 696),

M(3-aminophenyl)sulfonyl-2-[(2,4,6-trimethylphenyl)methyl]-3,4-dihydro-l/7-isoquinoline-lcarboxamide (Compound 309), and

796 (2S,4R)-jV-[(6-amino-2-pyridyl)sulfonyi]-4-phenyl-l-[(2,4,6-trimethylphenyl)methyl] pyrrolidine-2-carboxamide.

PREPARATION 29; 4-isopropyLN-[i2-oxo-lH-pyridin-3 -yI)sulfonyl] -2-[(2,4,6trimethylphenyl)niethyl]isoindoline-l-carboxamide (Compound 103)

Step 1: 2,6-dibromobenzaIdehyde

Br O

To a solution of iPr₂NH (21.2 mL, 150 mmol) in THF (180 mL) at 0 °C was slowly added n-BuLi (1.6 M, 94 mL, 150 mmol). The reaction mixture was stined at 0 °C for 30 min and then cooled to -78 °C. 1,3-Dibromobenzene (17,6 g, 74.6 mmol) in THF (80 mL) was slowly added over 20 min. The mixture was stirred at -78 °C for 30 min and N,Ndimethyiformamide (1 L6 mL, 150 mmol) was added. The mixture was stirred for 1 h, then treated with H₂SO₄ (2.5 M, 350 mL), and extracted with ethyl acetate/Et₂O (50/50, 3 x 300 mL), The combined extract w^rere dried over MgSO4 and fîltered. The hltrate was concentrated to give 2,6-dibromobenzaldehyde (17.6 g, 89%). ^!H NMR (250 MHz, CDC13) δ 10.3 (s, 1H),7.65 (d, 7=8.0 Hz, 2H), 7.23 (t, 7= 8.1 Hz, 1H).

Step 2: methyl (2,6-dibromobenzyl)gIycinate

To a solution of glycine methyl ester hydrochloride (21.0 g, 167 mmol), 2.6dibromobenzaldehyde (16.9 g, 64.4 mmol) and triethylamine (21.0 mL, 142 mmol) in dichloroethane (380 mL) were added acetic acid (8.40 mL, 145 mmol) and NaBH(OAc)₃ (33.5 g, 158 mmol). The mixture was stirred at room température under an argon atmosphère for 20 h. Additional glycine methyl ester hydrochloride (8.10 g, 64.4 mmol), triethylamine (9.52 g, 64.4 mmol), acetic acid (3.73 mL, 64.4 mmol) and NaBH(OAc)₃ (13.7 g, 64.4 mmol) were added and the reaction mixture was stirred for another 10 h. The reaction mixture was quenched by adding IN NaOH, and the product was extracted with dichioromethane. The organic extracts were

797 washed with brine, dried over sodium sulfate, fdtered, and the solvent was removed in vacuo. The residue was purified by a plug filtration through a silica gel pad (0-50% ethyl acetate/hexanes to give methyl methyl (2,6-dibromobenzyl)glycinate (13.3g, 62%) as an oil. ^lH NMR (CDC1₃,250 MHz) δ 7.52 (d, J = 8.0 Hz, 2H), 6.98 (t, J= 8.0, 1H), 4.20 (s, 2H), 3.70 (s, 3H), 3.50 (s, 2H).

Step 3: methyl A-(2,6-dibroniobenzyl)-/V-(2,4,64rimethyIbenzyl)glycinate

A mixture of methyl (2,6-dibromobenzyl)glycinate (13.3 g, 39.5 mmol), 2,4,6trimethylbenzyl bromide (7.32 g, 43.4 mmol), K₂CO₃ (12.0 g, 86.8 mmol), and Lil (300 mg) in acetonitrile (300 mL) was stirred at 60 °C for 24 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography (0-20% ethyl acetate/hexanes) to give methyl /V-(2,6-dibromobenzyl)-A-(2,4,6-trimethylbenzyl)g]ycinate (18.0 g, 97%) as an oil which solidified on standing. ^!H NMR (CDC1₃,250 MHz) δ 7.54 (d, J = 7.8 Hz, 2H), 7.00 (t, J = 8.0, 1H), 6.79 (s, 2H), 4.34 (s, 2H), 4.04 (s, 2H), 3.71 (s, 3H), 3.50 (s, 2H), 2.23 (s, 3H), 2.18 (s, 6H).

Step 4: methyl 44)romo-2-(2,4,64rimethylbenzyl)isoindoline-l-carboxylate

A mixture of methyl 7V-(2,6-dibromobenzyl)-N-(2,4,6-irimethylbenzyl)glycinate (16.0 g, 34.1 mmol), Cs₂CO₃ (33.3 g, 102 mmol) and Pd(PPh₃)₄ (2.0 g, 1.7 mmol) in THF (200 mL) was stirred at 110 °C in a sealed vessel for 60 h. Some THF (-50 mL) was removed by flushing with N₂ before Cs₂CO₃ (6.5 g, 20 mmol) and Pd(PPh₃)₄ (400 mg, 0.34 mmol) were added. The

798 reaction mixture was stirred at 110 °C for 24 h. The mixture was poured into water and was extracted with Et₂O. The organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified b y silica gel column chromatography (5-20% CH₂Cl₂/hexanes) to give methyl 4-bromo-2-(2,4,6-trimethylbenzyl)isoindoline-l-carboxylate (2.9 g, 22%). MS: 389 [M+l]⁺.

Step 5: 4-bromo-2-(2,4₎6-tri]nethylbenzy])isoindoline-l-carboxylic acid hydrochloride

Methyl 4-bromo-2-(2,4,6-trimethyIbenzyl)isoindo]ine-l-carboxylate (2.9 g, 7.4 mmol) was combined in a mixture of methanol (45 mL) and water (20 mL) containing sodium hydroxide (900. mg, 22.5 mmol). The resulting suspension was heated at 80 °C for 1 h. The reaction mixture was concentrated to remove the methanol. Water (50 mL) was added and the mixture was extracted with Et₂O. The aqueous phase was adjusted to pH -2 with 6N HCl and was then extracted with CH₂C1₂. The extract was dried overNa₂SO₄, filtered and concentrated. The residue was purified b y silica gel column chromatography (0-5% methanol/CH₂Cl₂) and then subjected to preparatory-HPLC (10-100% acetonitrile/water with 0.05 mM trifluoroacetic acid) to give the desired product as the trifluoroacetic acid sait. The material was dissolved in methanol (30 mL) and was treated with HCl (IM, 10 mL). The mixture was then concentrated to dryness. The solid was suspended in CH₂C1₂ (15 mL), sonicated for 10 min and filtered. The solid was washed with Et₂O and hexanes, and dried to give 4-bromo-2-(2,4,6trimethylbenzyl)isoindoline-l-carboxylic acid hydrochloric acid (1.5 g, 49%). ’H NMR (DMSO, 250 MHz) δ 7.65 (d, 7 = 7.8 Hz, IH), 7.51 (d,7=7.8, JH),7.39(m, 1 H), 6.95 (s, 2H), 5.87 (s, 1H), 4.68 (s, 2H), 4.52 (d, 7= 10.8 Hz, 1H), 4.30 (d, 7= 10.8 Hz, 1H), 2.46 (s, 6H), 2.26 (s,3H). MS: 375 [M+l]⁺.

Step 6: 4-îsopropenyl-2-[(2,4,6-trimethyIphenyl)inethyl]isoindoline- 1-carboxylic

799 acid hydrochloride

4-Bromo-2-[(2,4,6-trimethylphenyl)methy]]isoindoline-1-carboxylie acid hydrochloride (374 mg, 0.914 mmol), 2-isopropenyI-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (269 mg, 1.60 mmol) and césium carbonate (652 mg, 2.00 mmol) in dioxane (9 mL) and water (900 pL) was degassed with astream ofnitrogen for 1 min before adding dichloro[l,rbis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (73 mg, 0.10 mmol). The reaction mixture was degassed with a stream of nitrogen for 1 min and the mixture was stirred at 120 °C for 2 h. The reaction mixture was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 4-isopropeny]-2-[(2,4,6trimethylphenyl)methyl]isoindo line-1-carboxy lie acid hydrochloric acid (180 mg, 48%). ESIMS m/z cale. 335.2, found 336.2 (M+l)⁺; Rétention time: 0.53 min (1 min run).

S tep 7: 4-is op ropy 1-2-((2,4,6-trimethy ]phenyl)methyl]isoindoline-l -ca rboxyli c acid hydrochloride

A mixture of 4-(prop-l-en-2-yI)-2-(2,4,6-trimethylbenzyl)isoindoline-l-carboxylic acid hydrochloride (43 mg, 0.12 mmol) and 10% palladium on carbon (5 mg, 0.005 mmol) in methanol (3 mL) was stirred under an atmosphère of hydrogen for 5 h. The reaction mixture was filtered and subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to 20 give 4-isopropyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxyIic acid hydrochloride

800 (28 mg, 65%) as a colorless solid. ESI-MS m/z cale. 337.2, found 338.2 (M+l)⁺; Rétention time:

0.55 min (1 min run).

Step 8: 4-isopropyl-A^r-[(2-methoxy-3-pyridyl)sulfonyl]-2-[(2,4,6trimethylphenyl)mcthyl]isoindoline-l-carboxamidc (Compound 218)

A mixture of 4-isopropyl-2-(2,4,6-trimethylbenzyl)isoindoline-l-carboxylic acid hydrochloride (28 mg, 0.075 mmol) and sodium carbonate (24 mg, 0.22 mmol) in N,Ndîmethylformamide (1 mL) was degassed with a stream of nitrogen for 1 min before adding N[(dimethylamino)-lH-l,2,3-triazolo-[4,5-b]pyridin-l-ylmethyleue]-77-methylmethanaminium hexafluorophosphate N-oxide (34 mg, 0.090 mmol). The mixture was degassed for 1 min and 2methoxypyridine-3-sulfonamide (21 mg, 0.11 mmol) was added to the reaction mixture. The mixture was degassed for 1 min before it was stirred at room température for 17 h. The reaction mixture was fiitered and subjected to preparatory-HPLC (10-99% acetonitriie/water with 0.05 mM HCl) to give 4-isopropy 1-/7-[(2-methoxy-3-pyridyl)sulfonyl]-2-[(2,4,615 trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 218) (16 mg, 42%). ESI-MS m/z cale. 507.2, found 508.4 (M+l)⁺; Rétention time: 0.68 min (1 min run).

Step 9: 4-isopropyl-A^r-[(2-oxo-lE/-pyridin-3-yI)sulfonyl]-2-[(2,4,6trimethylphenyl)methyl]isoindoline-l -carboxamide (Compound 103)

A mixture of4-isopropyl-iV-((2-methoxypyridin-3-yI)sulfonyl)-2-(2,4,6801 trimethylbenzyl)isoindoline-l-carboxamide (16 mg, 0.032 mmol) in acetic acid (1 mL) and HBr (46 pL of 33 %w/v, 0.19 mmol) (in acetic acid) was stirred at 50 °C for 1 h. The solvent was evaporated and the residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 4-isopropyI-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(2,4,65 trimethylphenyl)methyl]isoindoline-l-carboxamide (Compound 103) (12 mg, 69%). ESI-MS m/z cale. 493.2, found 494.3 (M+l)⁺; Rétention time: 1.44 min (3 min run).

The folio wing compounds can be synthesized using the procedures described herein: 77-(3-aminophenyl)suIfonyl-4-ethyl-2-[(2,4,6-trimethylphenyî)methyl]isoindoiine-l -carboxamide (Compound 30),

77-[(2-oxo-17Z-pyridin-3-yl)sulfonyl]-4-phenyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-lcarboxamide (Compound 508),

77-[(2-methoxy-3-pyridyl)sulfonyl]-4-phenyl-2-[(2,4,6-trimethylphenyl)methyl]isomdoline-lcarboxamide (Compound 427),

7V-[(6-amino-2-pyridyl)sulfonyl]-4-phenyl-2-[(2,4,6-trimethylphenyl)methyl]isoindolme-l15 carboxamide (Compound 554), and

7V-(3-ammophenyI)sulfonyl-4-isopropyl-2-[(2,4,6-trimethylphenyl)methyl]isoÎndoline-lcarboxamide (Compound 299).

PREPARATION 30: 2-(ieri-butyl)-4-(mesityloxy)pyrimidine-5-carboxylic acid Step 1: ethyl 2-(fori-butyl)-4-hydroxypyrimidine-5-carboxylate

In EtOH (40 mL) was placed f-butylcarbamidine hydrochloride (3.71 g, 27.2 mmol).

A solution ofNaOEt (21% in EtOH, 8.80 g, 27.2 mmol) was added and the resulting mixture was stirred 15 min at room température. Diethyl ethoxymethylenemalonate (5.87 g, 27.2 mmol) was added and the reaction mixture was stirred at room température ovemight. The reaction mixture was heated at reflux for 1 h and then the solvent was removed. The residue was dissolved in water (100 mL) and the pH adjusted to 3-4 with NaHSO₄ (IM). The solid was

802 coilected by filtration, washed with water (50 mL) and dried. The fikrate and washings were combined and extracted with ethyl acetate (2 x 150 mL). The combined extracts were dried over Na₂SO₄, filtered and concentrated. The residue plus the solid coilected during filtration were stibjected to cohimn chromatography on silica gel, eluted with CH₂Cl₂/hexanes/methanol (50/50/0 to 45/45/10) to afford ethyl 2~(terLbutyl)-4-hydroxypyrimidine-5-carboxylate (2.85 g, 60%). ’H NMR (250 MHz, CDC1₃) S 8.74 (s, 1H), 4.36 (q, 7= 7.3 Hz, 2H), 1.43 (s, 9H), 1.37 (t, 7 = 7.2 Hz, 3H).

Step 2: ethyl 2-(ierLbutyl)-4-chloropyrimidine-5-carboxylate

At 0 °C, Et₃N (1.1 mL) was added to POC1₃ (32 mL), followed by the addition of ethyl 2-Mri-butyl-4-hydroxypyrimidine-5-carboxylate (3.70 g, 16.5 mmol). The mixture was stirred at 40 °C for 1 h and the excess POC1₃ was removed under vacuum. The residue was carefully poured into ice (400 mL) and was extracted with CH₂C1₂. The extract was washed with NaHCO₃and water, dried overNa₂SO₄, filtered and concentrated. The crade material was subjected to silica gel cohimn chromatography (10-90% CH₂Cl₂/hexanes) to afford ethyl 2-(teri-butyl)-4chloropyrimidine-5-carboxylate (3.8 g, 95%) as a liquid. (M+l)⁺ = 243.4.

Step 3: 2-terAbutyl-4-(2,4,6-trimethylphenoxy)pyriniidine-5-carboxylate

2,4,6-Trimethylphenol (2.10 g, 15.4 mmol) and sodium hydride (60%, 690 mg, 17.3 mmol) were combined in an anhydrous mixture of ACV-dimethylformamide (20 mL) and tetrahydrofuran (2 mL). The reaction mixture was stirred at room température for 15 min under an atmosphère of nitrogen. Ethyl 2-terr-butyL4-chloropyrimidine-5-carboxylate (3.80 g, 15.7

803 mmol) was added and the reaction mixture was heated at 60 °C for 1 h. The reaction mixture was then allowed to cool to room température. The reaction mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was washed three times with water, dried over sodium sulfate, fîltered and concentrated. The cnide material was purified by silica gel cohimn chromatography (0-30% ethyl acetate/hexanes) to yield ethyl 2-terNb uty 1-4-(2,4,6trimethy]phenoxy)pyrimidine-5-carboxyIate (3.1 g, 58%) as a liquid. ESI-MS m/z 351 (M-i-l)⁺; ’H NMR (250 MHz, CDC1₃) δ 9.07 (s, IH), 6.88 (s, 2H), 4.43 (q, 7= 7.2 Hz, 2H), 2.30 (s, 3H), 2.21 (s, 6H), 1.40 (t, 7 = 7.2 Hz, 3H), 1.17 (s, 9H).

Step 4: 2-/crr-biityl-4-(2,4,6-trÎmethyIphenoxy)pyrimidine-5-carboxylic acid

Ethyl 2-tez7-butyl-4-(2,4,6-trimethylphenoxy)pyrimidine-5-carboxylate (3.1 g, 9.1 mmol) was combined in a mixture of methanol (25 mL) and water (30 mL) containing sodium hydroxide (1.2 g, 30 mmol). The resuking suspension was heated at 60 °C for 3 h. The reaction mixture was cooled to room température and was made acidic with 6M hydrochloric acid. The resulting precipitate was fîltered, washed with water and dried to yield 2-n?rt-butyl-4-(2,4,6trimethylphenoxy)pyrimidine-5-carboxylic acid (2.2 g, 77%) as a white solid. ESI-MS m/z 315 (M+l)⁺; 'H NMR (250 MHz, DMSO) δ9.01 (s, IH), 6.95 (s, 2H), 2.27 (s,3H), 1.98 (s, 6H), 1.11 (s, 9H).

The foliowing compound can be synthesized using the procedures described herein: N-(3 -aminophenyl)sulfonyl-2-/eri-butyl-4-(2,4,6-trimethylphenoxy)pyrimidine-5-carboxamide (Compound 68).

PREPARATION 31: 4-rerMiutvl-l-[(2,4,6-trimethylphenyl)methyl]-l/7imidazole-2-carboxylic acid

Step 1: 4-icri-butyl-lH-imidazoIe

804

A mixture of l-bromo-3,3-dimethylbutan-2-one (2.00 g, 11.2 mmol) in formamide (10 mL) was heated between 160-180° C in a sealed tube equipped with a safety pressure release mechanism for 5 h. The mixture was cooled to room température and was poured into 10% aqueous sodium bicarbonate (30 mL). The solution was extracted with dichloromethane (2 x 30 mL). The combined organic layers were washed with 10% potassium carbonate, brine, dried over NajSCh , filtered and concentrated under reduced pressure to provide 4-tert-butyl-lH-imidazole (1.37 g, 99%) as an oil. ‘H NMR (300 MHz, CDCR) δ 1.31 (s, 9H), 6.76 (s, 1H), 7.56 (s, 1H), 9.63 (br.s„ IH).

Step 2: 4-te rAbutyl-1-((2,4,6-trimethyl phenyl )methyI]-lH-imidazo le

To 4-tert-butyl-lZ7-imidazole (1.37 g, 11.0 mmol ) and césium carbonate (7.20 g, 22.0 mmol ) in acetonitrile (24 mL) was added 2-(bromomethyl)-l,3,5-trimethyl benzene (1.58 g, 9.38 mmol). The resulting suspension was stirred at room température ovemight. Heptane (10 mL) was added to the reaction mixture before it was filtered through a pad of silica and washed with a 1:1 mixture of ethyl acetate:heptane. The eluent was concentrated to provide 4-teri-butyll-[(2,4,6-trimethylphenyl)methy]]-177-imidazole (1.47g, 52%) as an oil. ’H NMR (300 MHz, DMSO) SL 15 (s, 9H), 2.26 (s, 6H), 2.29 (s, 3H), 5.02 (s, 2H), 6.43 (s, 1 H), 6.90 (s, 2H), 7.23 (s, 1H).

Step 3: 4-te/7-bntyI-1-((2,4,6-trimethylphenyl)methyl]-lH-iinidazole-2-carboxylie acid

805

To a solution of 4-zerZ-butyl-l-[(2,4,6-trimethylphenyl)methyl]-177-imidazole (1.40 g, 5.46 mmol) in anhydrous THF (40 mL) was added n-BuLi (2.5 M, 2.62 mL, 6.55 mmol) at 78 °C. The reaction mixture was stirred at -78 °C for 1H. A piece of dry ice was added in one portion at -78 °C. The solution was stirred for 20 min at -78 °C, and then the reaction mixture was allowed to reach to room température and was stirred under a CO₂ atmosphère for 2 h. The mixture was quenched with water (50 mL) andlN HCl (7 ml) and then stirred for 10 min. The mixture was extracted with ethyl acetate (100 mL). The organic layer was separated from the aqueous phase and then concentrated under reduced pressure. The residue was triturated with CH₂C1₂, concentrated, and then triturated again with methyl zerZ-butyl ether. The solid was washed with methyl Zerz-buty 1 ether and dried under reduced pressure to provide 4-Zerz-butyl-l [(2,4,6-trimethyIphenyl)methyl]-llⁱ/-imidazole (588 mg, 34%) as a white solid. ’H NMR (300 MHz, CDC1₃) 61.23 (s, 9H), 2.16 (s, 6H), 2.22 (s, 3H), 5.76 (s, 2H), 6.27 (s, 1H), 6.91 (s, 2H).

The folio wing compound can be synthesized using the procedures described herein: jV-(3-aminophenyl)sulfonyl-4-Z£ri-butyl-l-[(2,4,6-trimethylphenyl)methyl]imidazole-2carboxamide (Compound 255).

PREPARATION 32: 4,4-dimethyl-2-[(2,4,6-trimethylphenyl)inethyl]-l,3dihydroisoquinoline-l-carboxylic acid

Step 1: methyl (2-methyl-2-phenylpropyl)carbamate \/ H

N h₂ ^N γ-°\ ο

Methyl carbonochloridate (518 pL, 6.70 mmol) was added to a solution of 2-methyI2-phenyl-propan-l-amine (1.00 g, 6.70 mmol) and pyridine (813 pL, 10.1 mmol) in CH₂C1₂ (25 mL) at 0 °C. The mixture was allowed to stir at room température for 1 h before it was quenched with 1N HCl. The mixture was washed with 1N HCl (2 x 25 mL), brine, dried over sodium

806 sulfate, fîltered and concentrated to give methyl (2-methyl-2-phenylpropyl)carbamate (911 mg, 66%). ESI'MS m/z cale. 207.1, foimd 208.4 (M+i)⁺; Rétention time: 0.54 min (1 min run).

Step 2: 2-methoxycarbonyl-4,4-dimethyl-l,3-dihydroisoquinoline-l-carboxylic acid

Methyl (2-methyh2-phenylpropyI)carbamate (911 mg, 4.40 mmol) was suspended in acetic acid (15 mL) and H2SO4 (5 mL). The mixture was cooled to 0 °C before oxaldehydic acid hydrate (679 mg, 7.37 mmol) was added. The reaction mixture was allowed to warm to room température over 1H and was stirred at room température for an additional 2 h. The reaction mixture was poured over ice which and the mixture was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, fîltered and concentrated to give 2-(meÎhoxycarbonyI)-4,4-dimethyM,2,3,4-tetrahydroisoquinoline-lcarboxylic acid (1.1 g, 79%) as a white solid. ’H NMR (400 MHz, CDC1₃) δ 7.55 (s, 1H), 7.45 7.17 (m, 3H), 5.66 (d, 7 = 35.8 Hz, 1 H), 3.90 (d, 7 = 94.9 Hz, 4H), 3.33 (s, 1H), 1.28 (d, 7= 51.5 Hz, 6H), ESI-MS m/z cale. 263.1, found 264.0 (M+l)⁺; Rétention time: 1.27 min (3 min run).

Step 3: 4,4-dimethyl-2,3-dihydro-l/7-isoquinoline-l-carboxylic acid

lodo (trime thyl)silane (254 pL, 1.78 mmol) was added to 2-methoxycarbonyl-4,4dimethyLl,3-dihydroisoquinoline-l-carboxylic acid (412 mg, 1.49 mmol) in chloroform (10 mL). The mixture was heated at 65 °C for 2 h. Additional iodo(trimethyl)silane (254 pL, 1.78 mmol) was added and the reaction mixture was heated at 65 °C for 2 h. The reaction mixture was concentrated and the residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 4,4-dimethyl-2,3-dihydro-17Lisoquinoline-l-carboxylic acid (261 mg, 85%). ESLMS m/z cale. 205.1, found 206.4 (M+l)⁺; Rétention time: 0,27 min (1 min run).

807

Step 4: 4_>4-dimetliyl-2-[(2,4₎6-trîmetIiylphenyl)methyI]-l,3-dibydroisoqiiinolinel-carboxylic acid

A suspension of 4,4-dimethyl-2,3-dihydro-lf/-isoquinoline-l-carboxylic acid (260 mg, 1.27 mmol) and KOH (213 mg, 3.80 mmol) in isopropanol (1.6 mL) was stirred at room température for 20 min. 2-(Chloromethyl)-l,3,5-trimethylbenzene (235 mg, 1.39 mmol) was added and the reaction mixture was stirred for 3 h. The mixture was concentrated and the residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 4,4dimethyl-2-(2,4,6-trimethylbenzyl)-l,2,3,4-tetrahydroisoquinoline-l-carboxylic acid. ESI-MS m/z cale. 337.2, found 338.0 (M+l)⁺; Rétention time: 1.42 min (3 min mn).

The following compound can be synthesized using the procedures described herein: A^r-[(6-amino-2-pyridyl)sulfonyl]-4,4-dimethyl-2-[(2,4,6-trimethylphenyI)methyl]-l,3dihydroisoquinoline-l-carboxamide (Compound 140).

PREPARATION 33: 4-/ert-butyl-2-(2,4,6-trimethy]pbenoxy)benzoic acid

A mixture of 2-bromo-4-zerz-butyl-benzoic acid (500 mg, 1.95 mmol), 2,4,6trimethylphenol (397 mg, 2.92 mmol), Cs₂CO₃ (1.27 g, 3.89 mmol), Cu(OTf), (49 mg, 0.097 mmol) and tokiene (10 mL) was combined in a microwave vîal before it was sealed and heated at 125 °C for 4 h. The mixture was cooled to room température and was partitioned between ethyl acetate (50 mL) and water (50 mL). The layers were separated and the aqueous layer was made

808 acid by the addition of IN HCl. The aqueous layer was extracted with ethyl acetate (2 x 30 mL). Thecombined organics were dried over magnésium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-3% methanol/CH₂Cl₂) to give 4Zert-butyl-2-(2,4,6-trimethylphenoxy)benzoic acid (250 mg, 39%) as a white solid. ESI-MS m/z cale. 312.2, found 313.4 (M+l)⁺; Rétention time: 2.14 min (3 minrun). ’H NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.07 (dd, J = 8.2, 1.8 Hz, 1H), 6.99 (s, 2H), 6.35 (d, J = 1.7 Hz, 1 H), 2.28 (s, 3H), 2.01 (s, 6H), 1.10 (s, 9H).

The following compounds can be synthesized using the procedures described herein: A-(3-aminophenyl)sulfonyI-4-fert-butyl-2-(2,4,6-trimethylphenoxy)benzamide (Compound 224) and W[(6-amino-2-pyridyl)sulfonyl]-4-/ert-butyL2-(2,4,6-trimethyIphenoxy)benzamide (Compound 102).

PREPARATION 34: 4-rerAbutyl-l-[(2,4,6-triniethyIphenyl)methyl]-lLApyrroIe2-carboxylic acid

Step I: ethyl 5-ter/-buty 1-24(2,4,6-trimethylphenyl)methy]]pyrazole-3carboxylate

To a solution of gallium trichloride (4.00 g, 22.7 mmol) in carbon disulfide (30 mL) at room température were added ethyl pyrrole-2-carboxylate (2.87 g, 20.6 mmol) and 2-chloro-2methylpropane (2.50 mL, 23.0 mmol). The mixture was then heated at reflux for 45 min. The reaction mixture was cooled to room température and was poured onto a mixture of ice and IN HCl. The aqueous layer was extracted with dichloromethane, The organic layer was washed with saturated NaHCO₃, dried over Na₂SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-10% ethyl acetate/heptanes) to afford 4-to7-butyl-lZZ-pyrrole-2-carboxylate (260 mg, 7%), ethyl 5-terTbutyl-lH-pyrroIe-2-carboxyIate (2.1 g, 52%) and ethyl 3,5-di-ierr-butyl-]//-pyrrole-2-carboxylate (352 mg, 7%) each isolated as white solids. Ethyl 4-/m-butyl-lH-pyrrole-2-carboxylate: ’H NMR (300 MHz, CDC1₃) δ 1.25 (s, 9H), 1.35 (t, 7 = 7.1 Hz, 3H), 4.30 (q, 7 = 7.1 Hz, 2H), 6.76 (dd, 7 = 2.7, 1.8 Hz, 1H), 6.85 (dd, 7 = 2.3, 1.9 Hz, 1H), 8.83 (br. s, 1H).

809

Step 2: ethyl 4-teJAbutyl-l-[(2,4,6-trmicthylphenyl)inethyl]-lH-pyrroIe-2carboxylate

Sodium hydride (24 mg as a 60% dispersion in minerai oil, 0.60 mmol) was added to a solution of ethyl 4-to7-buty]-lH-pyrrole-2-carboxylate (0.10g, 0.51 mmol) in N,Ndimethylformamide (3 mL) at 0 °C. The mixture was allowed to stir at 0 °C for 5 min before it was stirred at room température for 30 min. 2,4,6-Trimethylbenzyl bromide (0.12 g, 0.55 mmol) was added portion-wise and the mixture was stirred at room température for 20 h. The reaction mixture was quenched at 0 °C with aqueous saturated NH₄C1 (4 mL). The mixture was extracted with ethyl acetate (80 mL) and the organic layer was washed with brine (2x30 mL) and water (30 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-15% ethyl acetate/heptanes) to afford 4-teri-butyl-l[(2A64rimethylphenyl)methyI]-lH-pyrrole-2-carboxylate (161 mg, 98%) as a white solid. ’H NMR (300 MHz,CDCl₃)Ô 1.12(s,9H), 1.38 (t, J = 7.1 Hz, 3H),2.20 (s, 6H), 2.31 (s, 3H),4.31 (q, 7 = 7.1 Hz, 2H), 5.47 (s,2H),6.1l (d,J = 2.1 Hz, 1H),6.91 (s, 2H), 6.92 (d, J=2.1,1H).

Step 3: 4-rert-butyl-l-[(2,4,6-trimethylphenyl)methylJ-l/7-pyrrole-2-carboxy]ic acid

To a solution of ethyl 4-rerrbutyl-l-[(2,4,6-trimethylphenyl)methyl]-17ï-pyriOle-2carboxylate (97 mg, 0.29 mmol) in methanol (6.3 mL) at room température was added a 1.0 N solution of NaOH (5.5 mL) and the mixture was heated at reflux for 4 hours. The mixture was

810 cooled at room température and diluted with water (40 mL). The pH was adjusted to 4-5 using 1.0 N HCl and the aqueous layer was extracted with ethyl acetate (120 mL). The organic layer was washed with water (2 x 40 mL), dried over Na₂SO4, filtered and concentrated under reduced pressure. The solid was triturated with diethyl ether to provide 4-mrt-butyl-l-[(2,4,6trimethylphenyl)methyI]-lf/-pyrrole-2-carboxylic acid (74 mg, 84%) as a white solid. ^JH NM R (300 MHz, CDC1₃) δ 1.12 (s, 9H), 2.21 (s, 6H), 2.32 (s, 3H), 5.47 (s, 2H), 6.18 (d, J = 2.0 Hz, 1H), 6.91 (s,2H), 7.06 (d, J= 2.0 Hz, 1H).

The following compounds can be synthesized using the procedures described herein: N-(benzenesulfonyl)-4-mrr-butyl-l-[(2,4,6-trimethylphenyl)methyl]pynOle-2-carboxamide (Compound 242) and A^r<3-aminophenyl)sulfonyl-4-Zm-butyl-l-[(2,4,6trimethy]phenyl)methyl]pyrroIe-2-carboxamide (Compound 195).

PREPARATION 35: 2-(ie/Abutyl)-5-(2,4,6-trimethylbenzyl)oxazo!e-4-carboxylic acid

Step 1: ethyl 2-hydroxy-2-pivalamidoacetate

OEt

Acetic acid (2.61 g, 44.5 mmol) was added to a suspension of trimethylacetamide (9.00 g, 89.1 mmol) and ethyl glyoxylate (50% in toluene, 27.6 g, 133 mmol) in THF (60 mL). The mixture was heated at reflux for 16 h before it was cooled and concentrated to dryness. The residue was treated with heptanes and diethyl ether (10:1 ratio, 110 mL) to give a precipitate which was removed by filtration. The filtrate was concentrated to afford ethyl 2-hydroxy-2pivalamidoacetate (16.8 g) as a colorless oil. 'H NMR (300 MHz, CDC1₃) δ 1.22 (s,9H),2.27 1.35 (m, 3H), 3.63 -3.75 (m, 1H), 4.20 - 4.36 (m, 2H), 5.50 - 5.60 (m, 1H), 6.65 (brs, 1H). LCMS analysis: (M+l)⁺ = 204.1.

Step 2: ethyl 2-chloro-2-pivalamidoacetate

811

Thionyl chloride (28,6 g, 242 mmol) was added to a solution of ethyl 2-hydroxy-2pivalamidoacetate (18.6 g, 80.8 mmol) and MN-dimethylformamide (1 mL) in CH2CI2 (100 mL) at 0 °C. The mixture was stirred at room température for 16 h before it was concentrated to dryness to afford ethyl 2-chloro-2-pivalamidoacetate (20 g, 64%) as a yellow oil. NMR (300 MHz, CDC1₃) 6 1.27 (s, 9H), 1.29 - 1.37 (m, 3H), 4.20 - 4.36 (ni, 2H), 6.25 (d, J = 9.8, 1H), 6.85 (brs, 1H).

Step 3: ethyl 5'aminO’2-(feri-butyI)oxazole-4-carboxyIate

Diethylaluminum cyanide (IN in toluene, 76,6 mL, 76.7 mmol) was added to a solution ofethyl2-chIoiO-2-(2,2-dimethylpropanamido)acetate (11.3 g, 2.71 mmol) in THF (110 mL) at 0 °C. The mixture was stirred at room température for 16 h before sat. aqueous NH₄C1 (4 mL) was added to the reaction mixture. The mixture was filtered through Celite and the filtrate was extracted with ethyl acetate (200 mL). The organic layer was washed with brine, dried over Na₂SO4, filtrated and concentrated. The residue was purified by silica gel column chromatography (50% ethyl acetate/heptane) to afford ethyl 5-amino-2-rerAbutyl-l ,3-oxazole-4carboxylate (3.21 g, 30%) as a yellow solid. ’HNMR (300 MHz,CDCl₃)8 1.32 (s,9H), 1.33 1.38 (m, 3H), 4.28 - 4.38 (m, 2H), 5.42 (br s, 2H). LC-MS analysis: [M+H]⁺ = 213.1.

Step 4: ethyl 5-bromo-2-(tert-butyl)oxazole-4-carboxylate

A mixture of ethyl 5’armno-2-rerl·butyl-l,3-oxazole-4-carboxylate (1.50 g, 7.06 mmol) and CuBr₂ (1,59 g, 7.12 mmol) in acetonitrile (25 mL) was stirred at room température for 1 h followed by addition of /eri-butyl nitrite (0.94 g, 9.2 mmol). The mixture was stirred at room température for 1 h, and then heated at 65 °C for 2.5 h, Brine was added to the reaction mixture and it was extracted with diethyl ether (200 mL), The organic layer was washed by brine spiked with a few drops of IN HCl, dried over Na₂SO₄₁ filtrated and concentrated, The residue

812 was purified by silica gel column chromatography (15% ethyl acetate/hexanes) to afford ethyl 5bromo-2-teri-butyl-l,3-oxazole-4-carboxylate (1,31 g, 56%) as a yellow oil. *H NMR (300 MHz, CDC1₃) δ 1.19 - 1.23 (m, 3H), 1.25 (s, 9H), 4.38 (q, J = 6.8 Hz, 2H). LC-MS analysis: (M+l )⁺ = 276.0.

Step 5: ethyl 2-(terAbutyl)-5-(2,4,6-tnmethylbenzyl)oxazole-4-carboxylate

A mixture of ethyl 5-bromo-2-ier/-butyl-l,3-oxazole-4-carboxylate (1,15 g, 4.18 mmol), Pd(OAc)₂ (0.09 g, 0.4 mmol) and 'BuP-HBF₄ (0.24 g, 0.83 mmol) in THF (10 mL) was evacuated and back-filled with N₂ three times. The mixture was cooled to 0 °C and (2,4,610 trimethylbenzyl)zinc(II) bromide (IM in THF, 8.36 mL, 8.36 mmol) was added slowly. The mixture was allowed to warm to room température and it was stirred for 16 h. The mixture was concentrated and the residue was subjected to silica gel column chromatography (15% ethyl acetate/heptanes) to afford ethyl 2-tert-butyl-5-[(2,4,6-trimetbylphenyI)methyl]-l,3-oxazole-4carboxylate (0.48 g, 31 %) as yellow oil. ^lH NMR (300 MHz, CDC1₃) Ô 1.27 (s, 9H), 1.41 (t, J = 6.9 Hz, 3H), 2.25 (s, 3H), 2.31 (s, 6H), 4.35 (s, 2H), 4.42 (q, J = 7.2 Hz, 2H), 6.85 (s, 2H). LCMS analysis: (M+l)⁺= 300.2.

Step 6: 2-(te/ï-butyl)-5-(2,4,6-trimethy]benzyl)oxazole-4-carboxylic acid

A mixture of ethyl 2-ter/-butyl-5-[(2,4,6-trimethylphenyl)methyl]-l,3-oxazole-420 carboxylate (0.48 g, 1.5 mmol) and LiOH.H₂O (0.30 g, 7.3 mmol) in THF (4 mL) and water (4

813 mL) was stirred at room température for 16 h. The mixture was diluted with ethyl acetate (150 mL) the the pH was adjusted -4 tising 5% citric acid. The organic layer was washed with brine, dried over Na^SCL filtrated and concentrated. The residue was triturated with diethyl ether and hexanes (8:1, 9 mL) to give 2-rert-butyl-5-[(2,4,6-trimethylphenyl)methy]]-l,3-oxazole-45 carboxylic acid (0.33 g, 75%) as a white solid. ^lH NMR (300 MHz, CDCh) δ 1.28 (s, 9H), 2.25 (s, 3H), 2.33 (s, 6H), 4.37 (s, 2H), 6.85 (s, 2H). LC-MS analysis: (M+l)⁺= 302.2.

The following compound can be synthesized using the procedures described herein: A-(3-aminophenyl)sulfonyl-2-reri-butyl-5-[(2,4,6-trimethylphenyl)methyl]oxazole-4carboxamide (Compound 360).

PREPARATION 36: lithium 3-terAbutyl-I-[(2,4,6-triniethylphenyl)methyI]-l// 1,2,4-triazole-S-earboxylate

Step 1: 2,2-dimethyl-A’-[(lE)-2,4,6-triinethylphenyl)methylÎdene]propanehydrazide

To a solution of 2,4,6-trimethylbenzaldehyde (2.96 g, 20.0 mmol) in 1,2dichloroethane (16 mL) at room température was added 2,2-dimethylpropiomc acid hydrazide (2.32 g, 20.0 mmol) and the mixture was stirred for 2 h at room température during which time a white precipitate formed. Diethyl ether (30 mL) was added to facilitate précipitation and stirring was continued for I h. Filtration over a fritted funnel, foliowed by washing of the solids with diethyl ether (30 mL) and drying under high vacuum afforded 2,2-dimethylW’-[(lE)-2,4,6trimethylphenyl)methyiidene]propanehydrazide (4.33 g, 88%) as a white solid. ’H NMR (300 MHz, CDCh) 51.33 (s, 9H), 2.28 (s, 3H), 2.45 (s, 6H), 6.87 (s, 2H), 8.52 (br. s, IH), 8.61 (br. s, 1H). (M+l)⁺= 247.2.

Step 2: 2,2-dimeihyl-A’-[(2,4,6-Îriniethylphenyl)methyl]-propanehydrazide

814

To a solution of 2,2-dimethyl-/7’-[(lE)-2,4,6-trimethylphenyl)methy]idene]propanehydrazide (4.33 g, 17.6 mmol) in methanol (90 mL) was added 10% palladium on carbon (dry basis, 230 mg, 0.21 mmol). The reaction mixture was purged with hydrogen (3 cycles of vacuum/hydrogen) then stirred at room température for 2 h under an atmosphère of hydrogen. The reaction mixture was filtered over Celite, washed with methanol and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-35% ethyl acetate/heptanes) to afford 2,2-dimethyl-?/’-[(2,4,6-trimethylphenyl)methy]]propanehydrazide (3.76 g, 86%) as a white solid. ’H NMR (300 MHz, CDC1₃) Ô 1.20 (s, 9H), 2.26 (s, 3H), 2.43 (s, 6H), 3.97 (s, 2H), 4.59 (br. s, 1H), 6.86 (s, 2H), 7.14 (br. s, 1H). (M+l )⁺ = 249.2.

Step 3: ethyl 3-te7^butyl-l-[(2,4,6-tnmethylphenyl)methyl]-l//-I,2,4-triazole-5carboxylate

Triethyloxonium tetrafluoroborate (3.42 g, 18.0 mmol) was added portion-wise to a solution of ethyl thiooxamate (2.28 g, 17.1 mmol) in CH₂C1₂ (35 mL). The resulting mixture was 15 stiired at room température for 20 h. The mixture was then cooled to 0 °C, and a solution of2,2dimethyl-A’-[(2,4,6-trimethylphenyl)methyl]propanehydrazide (4.48 g, 18.0 mmol) and triethylamine (2.5 mL, 18 mmol) in CH2CI2 (20 mL) was added slowly, followed by an additional portion of triethylamine (1.3 mL, 9.0 mmol). The reaction mixture was then heated at reflux for 20 h. The crude mixture was concentrated under reduced pressure and the resulting 20 yellow oil was purified by silica gel column chromatography (0-40% ethyl acetate/heptanes) to afford a solid. Reverse phase chromatographie séparation with mixtures of 40% to 95% CH₃CN in water containing 0.1 % formic acid afforded ethyl 3-terz-buty]-I-[(2,4,6trimethyIphenyl)methyl]-lH-l,2,4-triazole-5-caiboxylate (620 mg, 11 %) as a white solid. ’H NMR (300 MHz, CDC1₃) δ 1.29 (s, 9H), 1.43 (t, 7=7.1 Hz, 3H), 2.27 (s, 3H),2.31 (s, 6H),4.49 25 (q, 7= 7.1 Hz, 2H), 5.71 (s, 2H), 6.86 (s, 2H). (M+l)⁺= 330.2.

815

Step 4: lithium 3-terAbatyl-l-[(2,4,6-trimethylphenyl)niethy!]-!£?-1,2,4-triazole 5-carboxylate

To a flask containing ethyl 3-/ert-butyl-l-[(2,4,6-trimethylphenyl)methyl]-177-l,2,4triazole-5-carboxylate (110 mg, 0.33 mmol) and LiOH monohydrate (17 mg, 0.40 mmol) were successively added THF (2 mL) and water (1 mL) followed by one drop of methanol. The mixture was stiired at room température for 1 h. The volatiles (mostly THF and methanol) were removed under reduced pressure, then the mixture was frozen in a dry-ice / acetone bath and freeze-dried to afford lithium 3-te^butyl-l-[(2,4,6-trimethylphenyl)methyl]-lFLl,2,4-triazole-5carboxylate (98 mg , 95%) as a white solid. ’H NMR (300 MHz, CD₃OD) δ 1.24 (s, 9H), 2.24 (s, 3H), 2.33 (s, 6H), 5.73 (s, 2H), 6.82 (s, 2H).

The following compound can be synthesized using the procedures described herein: N-(3-aminophenyl)sulfonyl-5-reri-butyL2-[(2,4,6-trimethylphenyI)inethyl]-l,2,4-triazole-3carboxamide (Compound 261).

PREPARATION 37: 5-(ie/AbutyI)-3-(mesityloxy)pyrazine-2-carboxylic acid Step 1: 3,3-dimethylbutane-l,2-diamine dihydrochloride

A mixture of 2-amino-3,3-dimethyl-butyronitrile hydrochloride (2.94 g, 20.0 mmol), HCl (sat. in EtOH, 10 mL), PtO₂ (600 mg) and methanol (200 mL) at room température was treated with hydrogen (50 psi) for 18 h. The reaction mixture was filtered through a pad of Celite and the filtrate was evaporated to give 3,3-dimethylbutane-l ,2-diamine dihydrochloride as a white solid (3.9 g, 79%).

816

Step 2: ethyl 5-(te/7-butyl)-3-hydroxypyrazine-2-carboxylate

A mixture of 3,3-Dimethyl-butane-l,2-diamine dihydrochloride (3.9 g, 21 mmol), 2oxo-mal oui c acid diethyl ester (3.45 mL, 22.7 mmol), Et₃N (5.8 mL, 41 mmol) and EtOH (400 mL) was heated at reflux for 20 h. Ail volatiles were removed and the residue was subjected to silica gel column chromatography (0-30% ethyl acetate/hexanes) (0/100 to 30/70) to give ethyl 5-(tert-butyl)-3-hydroxypyrazine-2-carboxylate (0.59 g, 13%) as a sticky oil, which solidifîed on standing. ^]H NMR (250 MHz, CDC1₃) Ô 8.36 (s, 1H), 4.55 (q, J = 7.2 Hz, 2H), 1.49 (t, 7=7.2 Hz, 3 H), 1.41 (s, 9H).

Step 3: ethyl 5-(teH-butyI)-3-chloropyrazine-2-carboxylate

A mixture of ethyl 5-(terLbutyl)-3-hydroxypyrazine-2-carboxylate (590. mg, 2.63 mmol) and POC1₃ (10 mL) was heated at reflux for 5 h. The excess POC1₃ was removed under reduced pressure and the residue was partitioned between ethyl acetate and aq. NaHCO₃ (pH adjusted to ~6 by addition of sodium carbonate). The organic phase was separated, dried over NaiSOj, filtered and concentrated. The crude material was purified by silica gel column chromatography (0-30% ethyl acetate/hexanes) to give ethyl 5-(tm-butyl)-3-chloropyrazine-2carboxylate (90 mg, 14%). ^]H NMR (250 MHz, CDC1₃) Ô 8.59 (s, 1H), 4.49 (q, J = 7.2 Hz, 2H), ] .44 (t, J = 7.2 Hz, 3H), 1.40 (s, 9H).

Step 4: 5-te/i-butyl-3-(2,4,6-trimethylphenoxy)pyrazine-2-carboxylic acid

817

2,4,6-Trimethylphenol (51 mg, 0.38 mmol) and sodium hydride (18 mg, 0.45 mmol) were combined in anhydrous 77,Mdi methyl formamide (3 mL). The reaction mixture was stirred at room température for 15 min under an atmosphère of nitrogen. Ethyl 5-im-butyl-3-chloro5 pyrazine-2-carboxylate (90. mg, 0.37 mmol) in tetrahydrofuran (1 mL) was then added and the réaction mixture was heated at 60 °C for 1 h. To this mixture was added water (1 mL) and NaOH (120 mg). The resuked mixture was stirred at 70 °C for 1 h and was cooled to room température. The mixture was treated with HCl (1 M) to pH 3 and the mixture was extracted with ethyl acetate (3x). The combined extracts were concentrated to about 1 mL (N,N10 dimethylformamide présent). The residue was subjected to preparatory-HPLC (10-99% acetonitrile/water with 0.05 mM HCl) to give 5-ierr-butyl-3-(2,4,6-trimethy]phenoxy)pyrazine-2carboxylic acid (55 mg, 47%). 'HNMR (250 MHz, DMSO) δ 8.41 (s, 1H), 6.94 (s, 2H), 2.26 (s, 3H), 1.97 (s,6H), 1.11 (s, 9H).

The following compound can be synthesized using the procedures described herein: 15 77-(3-aminophenyl)sulfonyl-5-terr-butyl-3-(2,4,6-trimeth y] phenoxy)pyrazine-2-carboxamide (Compound 141).

PREPARATION 38: 5-(ieri-buty])-3-(mesityloxy)pyrazine-2-carboxylic acid Step 1: ethyl 6-(teri-butyl)-4-chloronicotinate

O o

HN^Y^OEt N^<:^pOEt

A solution of ethyl 6-ieri-butyl-l,4-dihydro-4-oxopyridine-3-carboxylate (1.0 g, 4.5 mmol) and phosphoms oxychloride (10 mL) was heated at 1 10 °C for 1.5 h, The reaction solution was cooled to room température and was concentrated under reduced pressure. The

818 residue was cooled to 0 °C before water (20 mL) and enough saturated aqueous NaHCO₃ were carefully added to bring the mixture to pH -8. The mixture was extracted with ethy] acetate (3x). The combined organics were dried over MgSO₄, filtered, and concentrated under vacuum to give ethyl 6-(ieri-butyl)-4-chloronicotinate (0.80 g, 73%) as a brown oil. ’H NMR (CDC1₃, 250 MHz) 6 8.99 (s, 1 H), 7.40 (s, 1 H), 4.41 (m, 2H), 1.36 (m, 12H). LC-MS: (M+l)⁺= 242.2.

Step 2: ô-ieH-butyl-4-(2,4,6-trimethylphenoxy)pyridine-3-carboxy]ate

To a solution of 2,4,6-trimethylphenol (0.43 g, 3.1 mmol) in jM/V-dimethyiformamide (4 mL) and THF (1 mL) was added slowly 60% NaH (0.15 g, 3.9 mmol). The mixture was stirred at room température for 25 min before ethyl ethyl 6-(f^butyI)-4-chloronicotinate (0.74 g, 3.1 mmol) was added. The réaction mixture was stirred at 60 °C for 1 h before it was cooled to room température and quenched by adding water. The mixture was extracted with ethyl acetate (3x). The combined organic extracts were concentrated and the residue was purified by silica gel column chromatography (0-20% ethyl acetate/hexanes) to afford ethyl 6-/m-butyl-4(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (0.45 g, 43%) as a light yellow oil. LC-MS:

(M+l)⁺= 341.9.

Step 3: 6-terMwty 1-4-(2 A6-trimethylphenoxy)pyridine-3-carboxy lie acid

A solution of 6-(Zer/-butyl)-4-(mesityloxy)nicotinate (0.74 g, 2.2 mmol) and sodium hydroxide (0.21 g, 5.2 mmol) in EtOH (2 mL) and water (1 mL) was stirred at room température

819 for 3 h. The réaction was concentrated and the residue was acidified with concentrated HCl to about pH 3. The crude materîal was purified by silica gel column chromatography (ethyl acetate) to give 6-mrr-biity 1-4-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (0.38 g, 55%) asawhitesoîid. 'H NMR (CDC1₃, 250 MHz) 5 9.22 (s, 1H), 6.96 (s, 2H), 6.24 (s, 1H),2.34 (s, 3H), 2.09 (s, 6H), 1.22 (s, 9H). LC-MS: (M+l)⁺ = 314.1.

The foliowing compound can be synthesized using the procedures described herein: N-(3-aminophenyl)suIfonyl-6-ieri-butyl-4-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 338).

PREPARATION 39:7V-[(6-amino-2-pyndyl)sulfonyl]-6-(3-fluoro-5-isobutoxj'phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 368) and 7V-[(6-aniino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-pbenyl)-2-[(4jR)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1289)

Step I: tert*buty] 2-chloro-6-(3-nuoro-5-isobutoxy-phenyl)pyridine-3-carboxylate

tert-Butyl 2,6-dichloropyridine-3-caiboxylate (15.0 g, 60.5 mmol) and (3-fluoro-5-isobutoxyphenyl)boronic acid (13.46 g, 63.48 mmol) were combined and fully dissolved in éthanol (150 mL) and toluene (150 mL), A suspsension of sodium carbonate (19.23 g, 181.4 mmol) in water (30 mL) was added. Tetrakis(triphenylphosphine)palladium (0) (2.096 g, 1.814 mmol) was added under nitrogen. The reaction mixture was allowed to stir at 60 °C for 16 hours. Volatiles were removed under reduced pressure. The remaining solids were partitioned between water (100 mL) and ethyl acetate (100 mL). The organic layer was washed with brine (Ix 100 mL). dried over sodium sulfate, filtered and concentrated under reduced pressure. The materîal was subjected silica gel column chromatography on a 330 gram silica gel column, 0 to 20% ethyl acetate in hexanes gradient. The matériel was repurified on a 220 gram silica gel column, isocratic 100% hexane for 10 minutes, then aO to 5% ethyl acetate in hexanes gradient to yield ierLbutyl 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylate (18.87 g, 49.68

820 mmol, 82.2%) was obtained as a colorless oil. 'H NMR (400 MHz, DMSO-d₆) <5 8.24 (d, 7 = 8.0 Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 7,48 (dd, 7 = 9.4,2.0 Hz, 2H), 6.99 (dt,7 = 10.8,2.2 Hz, 1H), 3.86 (d,7 = 6.5 Hz, 2H), 2.05 (dt, 7= 13.3,6.6 Hz, 1H), 1.57 (d, 7 = 9.3 Hz, 9H), 1.00 (t,7= 5.5 Hz, 6H). ESI-MS m/z cale. 379.13504, found 380.2 (M+l)⁺; Rétention time: 2.57 minutes.

Step 2: 2-chloro-6-(3-fluoro-5-isobutoxy-phenyI)pyridine-3-carboxylic acid

tert-Butyl 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylate (18.57 g, 48.89 mmol) was dissolved in dichlorometbane (200 mL). Trifluoroacetic acid (60 mL, 780 mmol) was added and the re action mixture was allowed to stir at room température for 1 hour. The reaction mixture was stirred at 40 °C for 2 hours. The reaction mixture was concentrated under reduced pressure and taken up in ethyi acetate (100 mL). It was washed with a saturated aqueous sodium bicarbonate solution (1 x 100 mL) and brine (Ix 100 mL), dried over sodium sulfate, fîltered and concentrated under reduced pressure. The crude product was suspended in ethyi acetate (75 mL) and washed with aqueous HCl (1 N, Ix 75 mL). The organic layer was dried over sodium sulfate, fîltered and concentrated under reduced pressure. The remaining solid (17.7 g) was stirred as a slurry in dichlorometbane (35 mL) at 40 °C for 30 minutes. Aller cooling to room température, the remaining slurry was fîltered, and then rinsed with cold dichlorometbane to give 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridme-3-carboxylic acid (11.35 g, 35.06 mmol, 72%) as a white solid. 'HNMR (400 MHz, DMSO-cL) δ 13.76 (s, 1H), 8.31 (d, 7= 8.0 Hz, 1H), 8.17 (d, J = 8.1 Hz, 1 H), 7.54 - 7.47 (m,2H),7.00 (dt, 7 = 10.8, 2.3 Hz, 1H), 3.87 (d,7= 6.5 Hz, 2H), 2.05 (dt, 7 = 13.3, 6.6 Hz, 1 H), 1.01 (d, 7 = 6.7 Hz, 6H). ESI-MS m/z cale. 323.1, found 324.1 (M+l)⁺; Rétention time: 1.96 minutes.

Step 3: A^r-[(6-amino-2-pyridyI)sulfonyl]-2-chloro-6-(3-fluoiO-5-Îsobutoxyphenyl)pyridine-3-carboxamide

821

2-Chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylic acid (3,00 g, 9,27 mmol) was dissolved in Ν,Λ/dimethylformamide (30,00 mL), and l,l'-carbonyldiimidazole (2.254 g, 13.90 mmol) was added to the solution. The solution was allowed to stir at 65 °C for 1 hour. In a separate flask, sodium hydride (444.8 mg, 11.12 mmol) was added to a solution of 6aminopyridine-2-sulfonamide (1.926 g, 11.12 mmol) in A(A^r-dimethylformamide (15.00 mL). This mixture was stirred for one hour before being added to the prior reaction mixture. The final reaction mixture was stirred at 65 °C for 15 minutes. Volatiles were removed under reduced pressure. The remaining oil was taken up in ethyl acetate and washed with aqueous HCl (1 N, Ix 75 mL) and brine (3x 75 mL), The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The remaining white solid (4.7 g) was fiilly dissolved in isopropanol (120 mL) in an 85 °C water bath. The colorless solution was allowed to slowly cool to room température with slow stirring over 16 hours. The crystalline solids that had formed were collected by vacuum filtration, and then rinsed with cold isopropanol (50 mL). Upon drying, /7-[(6-amino-2-pyridyl)sulfonyl]-2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridme-3carboxamide (3.24 g, 6.765 mmol, 73%) was obtained as a white solid. ^!H NMR (400 MHz, DMSO-î/₆)Î 12.78 (s, 1H), 8.15 (d, 2 = 8.0 Hz, 1H), 8.09 (d, 2= 7.9 Hz, 1H), 7.73 - 7.63 (m, 1H), 7.49 (dd,2=8.6,1.9 Hz, 2H),7.21 (d, J = 7.3 Hz, 1H), 6.99 (dt, 2 = 10.7,2.2 Hz, lH), 6.74 (d, 2 =8.4 Hz, 1H), 6.64 (s,2H),3.86 (d,2 = 6.5 Hz, 2H), 2.05 (dp, 2= 13,3,6.5 Hz, 1H), 1.02 (dd,2= 12.7,6.4 Hz, 6H).

Step 4:7V-[(6-anuno-2-pyridyl)sulfonyl]-6-(3-nuorO-5-isobutoxy-phenyl)-2-[(4R)2,2,4-trîmethy]pyrrolidin-l-yl]pyri(line-3-carboxamide (Compound 1289) and ÎV-[(6-amino2-py ri dyl)sulfonyl]-6-(3-11 no ro-5 -isobutoxy -phenyl) -2-[ (45)-2,2,4-trimethy lpyrrolidin-1yl]pyridine-3-carboxainide

822

V-[(6-Amino-2-pyridyl)suIfonyl]-2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (309 mg, 0.645 mmol) was dissolved in dimethylsulfbxide (3.708 mL) and potassium carbonate (445.9 mg, 3.226 mmol) was slowly added, followed by 2,2,4trimethylpyrrolidine (146.0 mg, 1.290 mmol). The reaction mixture was sealed and heated at 150 °C for 72 hours. The reaction was cooled down, diluted with water (50 mL), extracted 3 times with 50 mL portions of ethyl acetate, washed with brine, dried over sodium sulfate, fîltered and evaporated to dryness. The crude material was dissolved in 2 mL of dichloromethane and purified by on silica gel using a gradient of 0 to 80% ethyl acetate in hexanes. The stereoisomers were separated usmg supercritical fluid chromatography on a ChiralPak AD-H (250 x 4.6 mm), 5μπι column using 25% isopropanol with 1.0% diehtylamine in CO₂ at a flow rate of 3.0 mL/min. The separated enationmers were separately concentrated, diluted with ethyl acetate (3 mL) and washed with IN aqueous hydrochloric acid. The organic layers were dried over sodium sulfate, fîltered, and evaporated to dryness to give the pure compounds as pale yeilow solids.

The first compound to eluet from the SFC conditions given above gave //-[(6-amino2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-[(4Æ)-2,2,4-trimethylpyrrolidin-lyI]pyridine-3-carboxamide (Compound 1289) (Hydrochloric Acid (1)) 'h NMR (400 MHz, DMSO-d6) δ 12.47 (s, 1 H), 7.78 (d, 7 = 8.0 Hz, 1 H), 7.69 - 7.57 (m, JH), 7.56 -7.46 (m, IH), 7.41 (dt, J = 10.1, 1.8 Hz, 1 H), 7.26 (d, J = 8.0 Hz, IH), 7,2] (d, J = 7.2 Hz, IH), 6.89 (dt,7 = 10.7, 2.3 Hz, 1 H), 6.69 (d, 7 = 8.3 Hz, IH), 3.83 (d, 7 = 6.7 Hz, 2H), 2.61 (dq, 7 = 9.7, 4.9 Hz, 2H), 2.24 (d,7 = 15.8 Hz, IH), 2.06 (dq,7 = 13.3, 6.7 Hz, 1 H), 1.93 - 1.82 (m, IH), 1.61 (s, 3H), 1.59 (s, 3H), 1.48 - 1.33 (m, IH), 1.32 - 1.20 (m, 2H), 0.99 (d,7 = 6.6 Hz, 6H), 0.88 (d,7 = 6.2 Hz, 3H). ESI-MS m/z cale. 555.2, found 556.4 (M+1)⁺; Rétention time: 2,76 minutes.

The second compound to eluet from the SFC conditions described above gave N-[(6amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Hydrochloric Acid (])) 'H NMR (400 MHz, Chloroform-d) δ 15.49 (s, 1 H), 8.49 (d, 7 = 8.2 Hz, IH), 7.75 - 7.56 (m, 3H), 7.34 (t, 7 = 1.8 Hz, IH), 7.30 (dt,7 = 9.4, 1.9 Hz, 1 H), 6.75 - 6.66 (m, 2H), 3.95 (s, IH), 3.78 (d, J = 6.5 Hz, 2H), 3.42 (s, 1 H), 2.88 - 2,74

823 (m, 1H), 2.23 (dd, J = 12.5, 8.0 Hz, 1H), 2.17 - 2.08 (m, 1H), 1.98 - 1.87 (m, 1H), 1.55 (s, 3H), 1.39 (s, 3H), 1.31 (d, J = 6.7 Hz, 3H), 1.05 (d, J = 6.7 Hz, 6H). ESI-MS m/z cale. 555.2, found 556.4 (M+l )⁺; Rétention üme: 2.77 minutes. Ab soluté stereochemistry was confirmed b y X-ray crystallography.

The following compound can be synthesized using the procedures described herein: ?V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 114),

A/-[(6-amino-2-py ri dyl)sulfonyl]-2-[(43)-2,2,4-trimethylpyrrolid in-l-yl]pyridine-3-carboxamide (Compound 946),

A-[(6-amino-4-methyl-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1472),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-phenylbutoxy)pyridine-3carboxamide (Compound 1686),

A^r-[(6-amino-2-pyridy])sulfonyl]-2-[l-(l-naphthyl)ethylamino]pyridine-3-c arboxamide (Compound 1769),

TV-[(6-amino-2-pyridyI) sulfony 1]-2-[2-(o-tolyl)azepan-l-yl]pyridine-3-carboxamide (Compound 1772), jV-[(6-amino-2-pyridyl)sulfonyl]-2-[3-(cyclopropylmetbyl)-2,2-dimethyl-pyrrolidin-Iyl]pyridine-3-carboxamide (Compound 1794),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(3-benzyl-2,2-dimetliyl-pyrrolidin-l-yI)pyridine-3carboxamide (Compound 2275),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[l-[2-(tnfluoromethyl)phenyl]ethoxy]pyridme-3carboxamide (Compound 2501),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[2-(l,3-benzoxazol-2-yl)phenoxy]pyridine-3-carboxamide (Compound 2544), /V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2-cyclohexylcyclohexyl)amino]pyridine-3-c arboxamide (Compound 2599),

824

A-[(6-amino-2-pyridyl)sulfonyl]-2-(3-phenyl-1 -piperidyl)pyridîne-3-carboxamide (Compound 2615),

6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[(6-methoxy-4-methyl-2-pyridyl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1482),

6-(3-fluoro-5-isobiitoxy-pbenyl)-A^r-tetrahydrofuran-3-ylsulfonyl-2-[(4S)-2,2,4trimethylpyrrolidin-1-y l]pyridine-3-carboxamide (Compound 1640), ?7-cyclopropylsulfonyl-6-(3-fluoro-5-isobuÎoxy-phenyl)-2-[(4S)-2,2,4-trimethy]pyrrolidin-lyl]pyridine-3-carboxamide (Compound 1525),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-K2S,5R>2,5-dimethylpyiTO!idin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)-4-methoxy-pyridine-3-carboxamide (Compound 1254),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 171),

N-[(6-Ammo-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidm-]-yl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide,

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-[(3R)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 233),

2-(2,5-dimethylpynOlidin-l-yl)-6-(3-f]uoro-5-isobutoxy-phenyl)-A-[(2-oxo-177-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 307), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-methyl-l-piperidyl)pyridine-3carboxamide (Compound 321),

A4(6-ammo-2-pyridyl)sulfonyl]-6-ter/-butyl-2-[(2,4-dimethyl-3-pyridyl)oxy]pyridine-3carboxamide (Compound 460), ?7-[(6-amino-2-pyridyl)sulfonyl]-2-(2,3-dimethyl-l-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridîne-3-carboxamide (Compound 353),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(l-piperidyl)-/V-(lH-pyrazol-5-yl$ulfonyl)pyridine-3carboxamide (Compound 355),

825

7V-[(6-ammo-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-[(2R)-2-meniylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1354),

77-[(6-ammo-2-pyridyl)sulfbnyl]-6-(6-isopropoxy-3-pyridyl)-2-(3,3,4-trimethyl-lpîperidyl)pyridine-3-carboxamide (Compound 435),

6-(4-ethoxyphenyl)-2-(4-methyl-l-piperidyl)-77-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 445),

7V-[(6-amino-2-pyridyl)sulfbnyl]-2-[(2R,3R)-2,3-dimethylpynOlidin-l-yl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 441),

2V-[(6-amino-2-pyridyl)su]fonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[4-(4pyridyl)butoxy]pyrid ine-3-carboxamide (Compound 1687),

77-[(6-amino-2-pyridyI)sulfonyl]-2-(2,2-dimethyI-4-oxo-pyrrolidm-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-dihydropyridine-3-carboxamide,

77-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyl-3-0 xo-pyrrolidin-1-y 1)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-djhydropyridine-3-carboxamide,

7V-[(6-amino-2-pyiidyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[4-(3pyridyl)butoxy]pyridine-3-carboxamide (Compound 1690), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[4-(2pyridyl)butoxy]pyridine-3-carboxamide (Compound 1688),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-pyrazol-lylpropoxy)pyridine-3-carboxamide (Compound 1692),

77- [(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isob utoxy-pheny 1)-2-(3 -phenylbutoxy)py ridine-3carboxamide (Compound 1689), ?7-[(6-aimno-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[3-(2pyridyl)propoxy]pyridine-3-carboxamide (Compound 1693),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[3-(3pyridyl)propoxy]pyridine-3-carboxamide (Compound 1691),

826

A^L[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-phenylpropoxy)pyridine3-carboxamide (Compound 1694), /V-[(6-ammo-2-pyridyl)su!fonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2,2,3-trimethylpyrro]idin’lyl)pyridine-3-carboxamide (Compound 464),

79-[(6-amino-2-pyridyl)sulfonyl]-2-[(lR,4S)-3-azabicyclo[2.2.1]heptan-3-yI]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 476),

A^r-[(6amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[3-(2-pyridyl)-Ipiperidyl]pyridine-3-carboxamide (Compound 489),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(trifluorometbyl)-2-[(4S)-2,2,4-trimethylpyrroîidin-lyl]pyridîne-3-carboxamide (Compound 1556),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2,4,4-tetrametliylpyrrolidin-l-yI)-6(trifluoromethyl)pyridine-3-carboxamide (Compound 1635),

A-[(6-amino-2-pyridyl)sulfonyl]-5-(tri fluoromethyl)-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1550), /V-[(6-amino-2-pyridyl)sulfonyl]-6-methyl-2-[(4S)-2,2,4-trimethylpynOlidin-l-yl]pyridine-3carboxamide (Compound 1420),

7V-[(6-amino-2-pyridyl)sulfonyi]-6-methoxy-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1536), iV-[(6-amino-2-pyridyl)sulfonyl]-5-fluoro-2-[(4S)-2,2,4-trimethylpynOlidin-l-yl]pyridme-3carboxamide (Compound 1607),

A^r-[(6-amino-2-pyridyl)suIfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]-6,7-dihydro-5Hcyclopenta[b]pyridine-3-carboxamide (Compound 1386), //-[(ô-aminod-pyridyBsulfonylJTZ-fcyclopropylmethyltpropyBaminoJ-ô-fô-isopropoxy-Spyridyl)pyridine-3-carboxamide (Compound 500), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyi)-2-(2-methyl-4-phenyl-pyrrolidÎn-lyl)pyridine-3-carboxamide (Compound 502),

827

N- [(6-amino-2-pyridyl)sulfony 1] -6 -(6-isopropoxy-3-pyridyl)-2 -(2-phenylpyrrolidin-1 yl)pyridine-3-carboxamide (Compound 509),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3,3,5-trime thyl-1piperidyl)pyridine-3-carboxamide (Compound 520), ?7-[(6-ammo-2-pyridyl)sulfonyi]-2-(3-azabicyclo[2.2.1]heptan-3-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 521),

27-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-propyl-l-piperidyl)pyridine-3carboxamide (Compound 522), /7-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R,4S)-4-fluoro-2-methylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1362)

77-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-[(3S)-2,2,3-trimethylpyirolidin-lyl]pyridine-3-carboxamide (Compound 557),

77-[(6-ammo-2-pyridyl)sulfonyl]-2-[3-(3,4-difluorophenyl)-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 558),

7V-[(6-amino-2-pyridyl)suIfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(l-piperidyl)pyridme-3carboxamide (Compound 567), ?7-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[2-(methoxymethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 574),

7V-[(6-ammo-2-pyridyl)sulfonyl]-2-(6-azaspiro[2.5]octan-6-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 578),

77-[(6-amino-2-pyridyl)sulfbnyl]-2-indolin-l-yl-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 588),

77-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2,4,4-tetramethylpyrrolidin-l-yi)-5(trifluoromethyl)pyridine-3-carboxamide (Compound 1638),

W [(6-ænino-2-pyridyl)sulfbnyl]-2-(2,2,4,4-tetramethylpyrrolidin-l-yl)-4(trifluoromethyl)pyridine-3-carboxamide (Compound 1658),

828

N-[(6-ammo-2-pyridyl)sulfonyï]-2-(6,6-dimethyI-3-azabicyc!o[3.1.0]hexan-3-yl)-6-(6isoprGpoxy-3-pyridyl)pyridine-3-caiboxamîde (Compound 596),

A^T-[(6-amino-5-hydroxy-2-pyridyl)sulfonyl]-6-(3-fl uoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yI]pyridine-3-carboxamide (Compound 1563),

N-[(6-amino-5-hydroxy-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrroIidin-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 1375),

N-[(6-amino-5-benzyloxy-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-diniethylpyrrolidin-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 1588),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide,

AI-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1593), ?/-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4R)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1444), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(2-terr-butyIpyrrolidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 597),

A4(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dimethyl-3-phenyl-pynolidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 601),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[4-(methoxymethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 606),

N-[(6-amino-2-pyridy])sulfonyl]-2-(4-ethyl-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 619),

A/-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2-methyl-3-phenyl-pyrrolidin-lyl)pyridine-3-carboxamide (Compound 625),

N-[(6-ammo-5-benzyloxy-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1429),

829 //-[(6-ainino-2-pyridyl)sulfonyl]-2-(3-benzylpyrrolidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 647),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[3-(2,2,2-trifluoroethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 656),

7/-[(6-amino-2-pyridyl)suIfonyl]-2-(3-benzyl-2-methyl-pyrrolidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 658),

7/-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2-methyl-2,3,3a,4,5,6,7,7aoctabydroindol-l-yI)pyridine-3-carboxamide (Compound 675), /V-[(6-amino-2-pyridyl)su!fonyl]-2-(3-azabicyclo[3.1.1]heptan-3-yI)-6-teri-butyl-pyridine-3carboxamide (Compound 1401),

6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[(6-methoxy-2-pyridyl)sulfonyI]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1483),

N-[(6-amino-2-pyiidyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(3-methyldiazirin~3yl )ethyl-prop-2-ynyl -amino]pyridine-3 -carboxamide,

N-[(6-amîno-2-pyridyl)sulfonyI]-2-[(2S,5S)-2,5-dimethylpyirolidin-l-yl]-6-(6-isopropoxy-3pyridyi)pyridine-3-carboxamide (Compound 687),

A^L[(6-amino-2-pyridyl)sulfbnyJ]-2-(2,4-dimethylpyrroIidin-i-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 689),

6- (3 -fluoro-5 -isobutoxy-phenyl) -N-(3-methoxyphenyI) sulfonyl-2- [(4S) -2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1452), /V-(benzenesulfonyl)-6-(3-fluoro-5 -isobutoxy-phenyl )-2-[(4R)-2,2,4-trimethylpyrro lidin-1yl]pyridine-3-carboxamide (Compound 1396),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspîro[2.5]octan-7-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 703), /V-[(6-amino-2-pyridyl)suIfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2-isopropylpynOlidin-lyl)pyridine-3-carboxamide (Compound 724),

830

77-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(3-oxa-7-azaspiro[3.5]nonan-7yl)pyridine-3-carboxamide (Compound 729),

À^r-[(6-amino-2-pyridyl)suifonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2-phenyl-l-piperidyI)pyridine-3carboxamide (Compound 731),

2-(3,3a,4,5,6,6a-hexahydro-2//-cyclopenta[b]pyrrol-l-yl)-A-[(6-amino-2-pyridyl)sulfonyl]-6-(âisopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 732), ?7-[(6-amino-2-pyridyl)sulfbnyI]-2-(7-azaspiro[3.5]nonan-7-yl)-6-(6-isopropoxy-3pyridyl)pyrîdine-3-carboxam!de (Compound 733),

77-[(6-ammo-2-pyridyl)sulfonyI]-6-(6-isopropoxy-3-pyridyl)-2-(4-methyl-l-piperidyl)pyridine-3carboxamide (Compound 736),

77-[(6-amino-2-pyridyl)sulfbnyI]-2-[cyc]opropylmethyl(methyl)amino]-6-(6-isopropoxy-3pyridyi)pyridine-3-carboxamide (Compound 740), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(4-phenyl-l-piperidyI)pyridine-3carboxamide (Compound 742),

Y-[(6-amino-2-pyridyl)sulfony]]-2-(3-fluoro-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 745),

Z7-[(6-ammo-2-pyridyl)suifonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3R)-3-methyl-lpiperidyl]pyridine-3-carboxamide (Compound 757),

M[(6-ammo-2-pyridyl)sulfonyI]-2-[(2R,3S)-2,3-dimethylpyrro]idin-] -yl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 764),

Z7-[(6-amÎno-2-pyridyl)suIfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(l-phenyIethylamino)pyridine-3carboxamide (Compound 766),

6-(3-fluoro-5-isobutoxy-phenyl)-7V-(3-methoxyphenyl)sulfonyl-2-(2,2,4-trimethylpyrrolidin-ly!)pyridine-3-carboxamide (Compound 1171),

6-(3-fluoro-5-isobutoxy-phenyl)-N-[(6-oxo-l)7-pyridm-2-yl)sulfonyl]-2-(2,2,4trimethylpyrrolidm-l-yl)pyridine-3-carboxamide (Compound 1308),

831

A^L(3-ammophenyl)sulfbnyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethy]pyrro]idin-lyl)pyridine-3-carboxainide (Compound 1184),

A^r-(benzenesulfonyI)-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 620),

6-(3-fluoro-5-isobutoxy-phenyl)-/V-(2-pyridylsulfonyl)-2-(2,2,4-trimethylpynOlidm-lyl)pyridine-3-carboxamide (Compound 1063),

A^r-(3-ammophenyl)sulfonyl-2-(4,4-dimethyl-]-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1014),

2-(4,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-A'-(3-methoxyphenyl)sulfbnylpyridine-3-carboxamide (Compound 510),

N-(benzenesulfbnyl)-2-(4,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 583),

6-(3-fluoro-5-isobutoxy-phenyI)4V-[(6-methoxy-2-pyridyl)sulfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2430),

2-(4,4-dimethyM-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)4V-[(6-oxo-l/7-pyridin-2yl)suïfonyl]pyri dîne-3-carboxamide (Compound 775),

2-(4,4-dimethyl-l -pipendyl)-6-(3-fluoro-5-isobutoxy-pbenyl)-N-(2-pyridylsulfonyl)pyridine-3carboxamide (Compound 1069),

2-(4,4-dimethyl-l -piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-/V-[(6-methoxy-2pyridyl)sulfbnyl]pyridine-3-carboxamide (Compound 1090), /7-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)~2-[(4S)-2,2,4-trimethylpyiTolidin-Iyl]pyridine-3-carboxamide (Compound 811), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-spiro[lH-isobenzofuran-3,4'piperidine]-1 '-yl-pyridme-3-carboxamide (Compound 818), /7-[(6-amino-2-pyridyl)sdfonyl]-2-(2,2-dimethylpynOlidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 834),

832

A-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3S)-3-methyl-l piperidyl]pyridine-3-carboxamide (Compound 836),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[3-(cyclopropylmethoxy)-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 858),

A-[(6-ammo-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3S)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 864),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[4-(cyclopropylmethoxy)-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 884),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-difluoro-I-piperidyl)-6-(6-isopropoxy-3pyridyI)pyridine-3-carboxamide (Compound 889),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 903),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(4-fluoro-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 913),

A-[(6-amino-2-pyridyI)sulfonyl]-6-(6-isopropoxy-3-pyridyI)-2-(2,2,4,4-tetramethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 915), /V-[(6-amino-2-pyridyl)suIfonyl]-2-[(lS,4R)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 921),

A4(6-amino-2-pyridyi)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2,3,5-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 925),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopropylpyrrolidm-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 928),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(indan-l -ylamino)-6-(6-isopropoxy-3-pyridyI)pyridine-3carboxamide (Compound 935),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(azepan-l-yl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 940),

833

7V-[(6-amino-2-pyridyI)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(4R)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 949),

7V-[(6-amino-2-pyridyl)sulfony]]-2-(3-ethynyl-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine3-carboxamide (Compound 954),

7V-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-ethoxy-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 960),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(3,3-diethyl-l-piperidyl)-6-(6-isopropoxy-3-pyridyI)pyridme3-carboxamide (Compound 971), /V-[(6-armno-2-pyridyl)sulfonyl]-2-(3,4-dimethyl-l-piperidyl)-6-(6dsopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 979),

7V-[(6-amino-2-pyridyl)sulfdnyI]-2-(8-azaspiro[3.4]octan-8-yl)-6-(6-isopropoxy-3pyridyI)pyridine-3-carboxamide (Compound 987),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3R)-2,2,3-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 992),

N-[(6-amino-2-pyridyI)sulfonyl]-2-(2-benzylpyrroIidm-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 994), /V-[(6-amino-2-pyridyl)sulfbnyl]-2-(4-benzyloxy-l-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1012),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(3-ethyl-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 1023), /7-[(6-amino-2-pyridyl)su]fonyl]-2-[cyclopentyl(methyl)amino]-6-(6-isopropoxy-3pyridyl)pyrid ine-3-carboxamide (Compound 1025),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(benzylamino)-6-(6-isopropoxy-3-pyrjdyl)pyridine-3carboxamide (Compound 1026),

A^r-[(6-amino-2-pyridyl)suIfony]]-6-(6-isopropoxy-3-pyridyl)-2-(2,2,5-trimethylpynOlidm-lyl)pyridine-3-carboxamide (Compound 1040),

834

W-Kô-amino^-pyridyllsulfonylJ-ô-tô-isopropoxy-S-pyridyl^-IArtrifluoromethyl)-!piperidyl]pyridine-3-carboxamide (Compound 1043), ^-[(ô-amino^-pyridyOsulfonylJ^-isoindoIin^-yl-ô-iô-isopropoxy-S-pyridyllpyridine-Scarboxamide (Compound 1072), //-[(ô-amino^-pyridylisulfonylj-ô-tô-isopropoxy-S-pyridylj^-td-phenoxy-l-piperidyllpyridine3-carboxamide (Compound 1080), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyI)’2-[(3S)-3-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1081), ?/-[(6-amino-2-pyridyl)sulfbnyl]-2-(2-ethylpyrrolidin-l-yI)-6-(6-isopropoxy-3-pyridyl)pyridine3-carboxamide (Compound 1087),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridy])-2-(3-phenoxypyrrolidin-lyl)pyridine-3-carboxamide (Compound 1092),

2-(3,3a,4,5,6,6a-hexahydro-l//-cyclopenta[c]pyrroI-2-yl)-A^r-[(â-amino-2-pyridyl)sulfonyl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 1107),

A^,-[(6-amino-2-pyndyl)sulfonyi]-6-(6-isopropoxy-3-pyridyl)-2-(3-phenylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 1112),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[3-(methoxymethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 1116),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(3-cyclopropyl-I-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1132),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-dimethyl-l-piperidyl)-6-(6-isopropoxy-3pyridyI)pyridine-3-carboxamide (Compound 1134),

M[(6-ammo-2-pyridyl)sulfonyl]-2-[(3S,5S)-3,5-dimethyl-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1136),

N-[(6-amino-2-pyridyI)sulfonyl]-2-[(3R,5S)-3,5-dimethyl-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1145),

835 iV-[(6-amino-2-pyridyl)sulfonyI]-6-(6-isopropoxy-3-pyridyl)-2-(2-methyI-l-piperidyI)pyridine-3carboxamide (Compound 1182),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(6-isopropoxy-3pyridyl)pyridîne-3-carboxamide (Compound 1198),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-iert-butylpyrrolidin-l-yl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1206),

N-[(6-amino-2-pyridyl)suIfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3R)-3-phenyl-lpipe ri dyl]pyridine-3-carboxamide, jV-[(6-amino-2-pyridyl)sulfonyl]-2-(4-ethoxy-l-piperidyl)-6-(6-isopropoxy-3-pyridyl)pyridine-3carboxamide (Compound 1214),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(2R)-2(trifluoromethyl)pyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1230),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyI)pyridine-3-carboxamide (Compound 1247),

M[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(2S)-2(trifluoromethyl)pyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 1248),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(6-isopropoxy-3-pyridyl)-2-(2-methylpynOlidin-lyl)pyridine-3-carboxamide (Compound 1271),

A^f-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[3-(trifluoromethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 1274), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(3,3-dimethyl-l-piperidyI)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1283),

A4(6-amino-2-pyridyI)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(3R)-3-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1322),

A^f-[(6-amino-2-pyridyI)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-(2,3,3-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 1327),

836 /7-[(6-amino-2-pyridyl)sulfonyl]-2-[3-(3-chIoropheiiyl)-l-piperidyl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1339),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(3-ethyI-3-methyl-l-piperidyl)-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1341),

A-[(6-amino-2-pyridyI)sulfonyl]-2-(7-azaspiro[2.4]heptan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1333),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(3R,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 371),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyi)-2-(l-piperidyl)pyridine-310 carboxamide (Compound 380),

2-(3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrol-l-yl)W-[(6-amino-2-pyridyl)sulfonyI]-6-(3Ruoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 383), methyl (2S)-1-[3-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2pyridyl]pyrrolidine-2-carboxylate (Compound 385),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Îsobutoxy-phenyl)-2-[(2R)-2(trifluoromethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 398),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methyl-lpiperidyl] pyridine-3-carboxamide (Compound 408),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(azepan-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)pyridme-320 carboxamide (Compound 418),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[3-(methoxymethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 419),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azabicycIo[2.2.1 ]heptan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 420),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 421),

837

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(8-oxa-4azaspiro[4.4]nonan-4-yl)pyridine-3-carboxamide (Compound 424),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-lpiperidyl)pyri dîne-3-carboxamide (Compound 425), /V^,-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-phenylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 447),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dihydropynOl-l-yl)-6-(3-fluoro-5 -isobutoxyphenyl)pyridine-3-carboxamide (Compound 453),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5S)-2,5-dimethylpyrrolidîn-l-yI]-6-(3-fluoro-5isobutoxy-phenyI)pyridine-3-carboxamide (Compound 458),

N-[(6-amino-2-pyridyl )sulfonyl]-2-(3-benzylpyrrolidin-l-yl)-6-(3-fl uoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 473),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2-methylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 479), iV-[(6-amino-2-pyridyl)$uIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-4-phenylpynOlidin-l-yl)pyridine-3-carboxamide (Compound 488),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-pheny])-2-[4-(trifluoromethyl)-3azabicyclo[3.1.0]hexan-3-yl]pyridine-3-carboxamide (Compound 490), jV-[(6-amino-2-pyridyl)sulfonyI]-2-[2-(l,l-dimethylpropyl)pyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 493),

7'/-[(6-amîno-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 496),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[l-cyclopropylethyl(methyl)amino]-6-(3-fIuoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 516),

A^z-[(6-amino-2-pyridyl)sulfbnyl]-2-(6-azaspiro[3.3]heptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyI)pyridine-3-carboxamide (Compound 527),

838

77-[(6-amino-2-pyridyl)sulfonyl]-2-(3-ethyl-3-methyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 530),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-2,2,3trimethylpyrrolidin-l -yl]pyridme-3-carboxamide (Compound 547),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 555),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3,3,5-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 560),

A4(6-armno-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3,3,4-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 575),

A^r-[(6-amino-2-pyridyl)sulfonyI]-2-[(lR,5S)-3-azabicyclo[3.2.1]octan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 581),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4-dimethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 587),

N- [(6 -amino-2-pyridy l)sulfonyl]-6-(3- fluoro-5-isobu toxy-phenyl)-2-pyrro]idin-l-yl-pyridine-3carboxamide (Compound 592),

W-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopropylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 593),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(6,6-dimethyl-3-azabicyclo[3.1.0]hexan-3-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 609),

A^r-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-ferr-butylpyrrolidm-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 611 ),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-(2-terr-buty]pyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 613),

A^r-[(6-amino-2-pyridyl)suli'onyl]-2-(4-ethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 615),

839

ZV-[(6-ammo-2-pyridyl)sulfonylJ-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-phenyl-lpiperidyl] pyridine-3-carboxamide (Compound 651),

A'-K6-amino-2-pyridyI)suIfonyl]-2-(3-cycIopropyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 655),

M[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-2,2,3trimethylpyrrolÎdin-l-yl]pyridine-3-carboxamide (Compound 657), jV-[(6-amino-2-pyridyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(2-pyridyl)pyiro]idin-lyl]pyridine-3-carboxamide (Compound 659),

N-[(6-amino-2-pyridyi)suifonyl]-2-(2-benzyl-2-methyl-pyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 663),

A4(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-methy]pyrrolidin-lyl]pyridine-3-carboxamide (Compound 678),

A4(6-amino-2-pyridyl)sulfonyl]-2-(3-azabicyclo[2.2.1]heptan-3-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 680),

M[(6-amino-2-pyridyl)sulfonyl]-2-[cyclobutyl(methyl)amjno]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 683),

N-[(6-amino-2-pyridyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 684),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 694),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dimethyl-3-phenyl-pyrrolidin-l-yl)-6-(3-fiuoro-5isobutoxy-phenyI)pyridine-3-carboxamide (Compound 711),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2(methoxymethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 719),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,3-dimethylpyrrolidm-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridi ne-3 -carboxamide (Compound 720),

840

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 735),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5R>2,5-dimethylpyreo!idin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 751),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(2’benzylpyiTo]idin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3 -carboxamide (Compound 772),

7\A[(6-amino-2-pyridyl)sulfonyl]-2-[2,2-dimethyl-3-(trifluoromethyl)pyrrolidin-I-yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 780),

N-[(6-amino-2-pyridyI)sulfonyl]-2-(2,3-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 837),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(8-azaspiro[3.4]octan-8-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 845),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,2,4,4tetramethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 850),

2-(3,3a,4,5,6,6a-hexahydro-l/7-cycIopenta[c]pyrrol-2-yl)-AA[(6-amino-2-pyridyl)suIfonyl]-6-(3fIuoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 857),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2-phenylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 859),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropylmethyl(propyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 881),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(3,3-diniethyl-l-pÎperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 887),

A4(6-amino-2-pyridyl)sulfonyl]-2-(4-azabicyclo[3.1.0]hexan-4-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 906),

TV-[(6-amino-2-pyridyl)sulfonyl]-2-[(]S,4R)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 924),

841

V-[(6-amino-2-pyridyl)sulfonyl]-2-(9-azaspiro[4.4]nonan-9-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 926), /V-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-ethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 931),

Ad[(6-annno-2-pyridyl)suIfonyl]-2-[(lR,5S)-8-azabicyclo[3.2.1]octan-8-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 934), ^-[(6-amino-2-pyridyl)sulfonyI]-2-(7-azaspiro[2.5]octan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 953),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(3-benzyl-2-methyl-pyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxypli enyl)pyridîne-3-carboxamide (Compound 969), /V-[(6-amino-2-pyridy])sulfonyl]-2-(6-azaspiro[2.5]octan-6-yl)-6-(3-fîuoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 973),

N-[(6-amin o-2-pyridyl)su Ifonyl]-6-(3-fluoro-5-isob u toxy-phenyl)-2-(4-methy 1-1piperidyl)pyridine-3-carboxamide (Compound 991),

M[(6-amino-2-pyridyl)sulfbnyl]-2-(2,2-dimethyl-l-piperidyl)-6-(3-fluoiO-5-isobutoxyphenyl)pyndine-3-carboxamide (Compound 1004),

2V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[methyl-[(lmethylcyclopropyl)methyl]amino]pyridine-3-carboxamide (Compound 1009),

M[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropylmethyl(methyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1010),

V-[(6-amino-2-pyridyl)sulfonyl]-2-(3,5-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1013),

A^r-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1051),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(6-azaspiro[2.4]heptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1061),

842

Z9-[(6-amino-2-pyridyl)sulfonyÎ]-ô-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2,3,3trimethylpyrrolidin-l-yljpyridine-3-carboxamide (Compound 1065), lV-[(6-ammo-2-pyridyI)sulfonyl]-2-(2,2-dimethyl-4-oxo-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-dihydropyridine-3-carboxamide,

79-[(6-amino-2-pyridyI)sulfonyl]-2-[(2S)-2-rerr-butylpyrrolidin-l-yl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1097),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fIuoro-5-isobutoxy-phenyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 1098),

A^r-[(6-amino-2-pyridyl)sulfonyr]-2-[cyclopropyl(methyl)ammo]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1117),

A'-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,3-trimethy]pyrrolidm-lyI)pyridine-3-carboxamide (Compound 1121),

A^r-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2,3,3trime tirylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1144),

79-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2(methoxymethyl)pyrrolidin-I-yl]pyridme-3-carboxamide (Compound 1149),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,3,3-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 1156),

79-[(6-amino-2-pyridyl)sulfbnyl]-2-[cyclopropylmethyl(isopropyl)amino]-6-(3-fluoiO-5isobutoxy-phenyl)pyridme-3-carboxamide (Compound 1157),

A^z-[(6-amino-2-pyndyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methylene-lpiperidyl)pyridine-3-carboxamide (Compound 1162),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(5R)-2,2,5trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1166),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R)-2-terr-butylpyrrolidin-l-yl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1170),

843

À^r-[(6-amino-2-pyridyl)sullOnyl]-2-[(lR,4S)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1180), /V-[(6-amino-2-pyridyl)sulfonyl J-2-(2,2-dimethyl-3-oxo-pyrrolidin-1-y 1)-6-(3-fluoro-5isobutoxy-phenyl)-1,2-dihydropyridine-3-carboxamide,

N-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-methyl-lpiperidyl]pyridine-3-carboxamide (Compound 1193),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-[l-(3-chlorophenyl)ethyl-methyl-amino]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1205),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(3S,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobütoxyphenyl)pyridine-3-carboxamide (Compound 1210), jV-[(6-ammo-2-pyridyl)suIfonyl]-2-(2-ethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1218), jV-[(6-amino-2-pyridyl)sulfonyl]-2-(2-ethyl-5-methyI-pyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1222),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(5S)-2,2,5trimethylpyiTolidin-l -yl]pyridine-3-carboxamide (Compound 1241),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fiuoro-5-isobutoxy-phenyl)-2-(2-isopropylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1258),

N-[(6-ammo-2-pyridyI)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2-phenylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1260), ?/-[(6-amino-2-pyridyl)sulfonyrj-2-(8-azaspiro[3.5]nonan-8-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1264),

N- [(6-amino-2 -pyridyl)sulfbnyl ] -2-(3,3-dimethylmorpho lin-4-y 1)-6-(3-fluoro-5-isobu toxyphenyl)pyridine-3-carboxamide (Compound 1267), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1279),

844 jV-[(6-amino-2-pyridyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4R)-2,2,4trimethylpynOlidin-I-yI]pyridine-3-carboxamide (Compound 1289),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspiro[3.5]nonan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1303), /7-[(6-amino-2-pyridyl)suIibnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2(trifluoromethyl)pyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1304),

2-(2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b]pyridin-l-yl)-/9-[(6-amino-2-pyridyl)sulfonyl]-6-(3fl uoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1313), jV-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-3-phenylpynolidin-l -yl)pyridine-3-carboxamide (Compound 1319) A^r-[(6-amino-2-pyridyl)sulfonyl]-2(7-azaspiro[2.4]heptan-7-yl)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1333),

N-[(6-amino-2-pyridyI)sulfonyl]-2-[(3R,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 371),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluQro-5-isobutoxy-phenyl)-2-(l-piperidyl)pyridine-3carboxamide (Compound 380),

2-(3,3a,4,5,6,6a-hexahydro-27Acyclopenta[b]pynOl-l -yl)-A^(6-amino-2-pyridyl)sulfonyl]-6-(3fIuoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 383), methyl (2S)-l-[3-[(6-amino-2-pyridyl)sulfbnylcarbamoyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2pyridyl]pyrrolidine-2-carboxylate (Compound 385), iV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fIuoro-5-isobutoxy-phenyl)-2-[(2R)-2(trifluoromethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 398),

A^r-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-[(3R)-3-methyl-lpiperidyl]pyridine-3-carboxamide (Compound 408),

M-[(6-amino-2-pyridyl)sulibnyl]-2-(azepan-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 418),

Z7-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[3-(methoxymethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 419),

845 /7-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 420),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2-methyIpyrrolîdin-lyl]pyridine-3-carboxamide (Compound 421 ),

ΛΓ- [(6-am in o-2-pyridyl) sulfonyl] -6-(3 -fluoro~5-isobutoxy-phenyI)-2-(8 -ox a-4azaspiro[4.4]nonan-4-yl)pyridme-3-carboxamîde (Compound 424),

A'-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 425),

A^z-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-phenylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 447),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dihydropyrrol-i-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 453),

77-[(6-aniino-2-pyridyl)sulfonyl]-2-[(2S,5S)-2,5-dimethyIpynOlidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 458),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(3-benzylpyrroIidin-l-yI)-6-(3-fluoro-5-isobutoxypheny])pyridine-3-carboxamide (Compound 473),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 479),

N-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-4-phenylpyrrolidin-1 -yl)pyridine-3-carboxamide (Compound 488),

7V-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[4-(trifluoromethyI)-3~ azabicyclo[3.1.0]hexan-3-yl]pyridine-3-carboxamide (Compound 490), /7-[(6-amino-2-pyridyi)sulfonyl]-2-[2-(l,l-dimethylpropyl)pyrrolidÎn-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 493),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5-trimethyIpyrrolidin-lyl)pyridine-3-carboxamide (Compound 496),

846

M[(6-amino-2-pyridyl)sulfonyI]-2-[l-cyclopropylethyl(meihyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 516),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(6-azaspiro[3.3]heptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyi)pyridine-3-carboxamide (Compound 527),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(3-ethy]-3-methyl-I-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 530),

A4(6-arnino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-2,2,3trimethyIpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 547),

A^r-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethylpyiTolidin-lyI)pyridine-3-carboxamide (Compound 555),

A^r-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3,3,5-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 560),

[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-pheny 1)-2-(3,3,4-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 575),

A4(6-amino-2-pyridyI)sulfonyl]-2-[(lR,5S)-3-azabicyclo[3.2.1]octan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 581),

N- [(6-amino-2-pyridyl)suIfonyl]-2-(2,4-dimethyIpyrrolidin-l-yl )-6-(3-fluoro-5-isobu toxyphenyl)pyridine-3-carboxamide (Compound 587),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-pyrrolidin-l-yl-pyridine-3carboxamide (Compound 592),

A4(6-amino-2-pyridyl)sulfony[]-2-(2-cyclopropylpyiTolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 593),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-(6,6-dimethyI-3-azabicyclo[3.1.0]hexan-3-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 609),

A^F-[(6-amino-2-pyridyl)sulfonyl]-2-(3-rert-butylpyrrolidm-I-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 611),

847

A-[(6-amino-2-pyridyl)sulfbnyl]-2-(2-terrbutylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 613),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(4-ethyI-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 615),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 651),

N- [(6-amino-2-pyridyl)sulfonyl]-2-(3 -cyclopropyl-1 -pi peridyI)-6-(3-fluoro-5-isobu toxyphenyl)pyridme-3-carboxamide (Compound 655),

A-[(6-ammo-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobuioxy-pbenyI)-2-[(3R)-2,2,3trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 657),

A-[(6-amino-2-pyridyI)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(2-pyridyl)pyrrolidm-lyljpyridine-3-carboxamide (Compound 659),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(2-benzyl-2-methyl-pyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 663),

A-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-methyIpyrrolidin-lyl]pyridine-3-carboxamide (Compound 678),

A-[(6-amino-2-pyridyl)sulfonyl]~2-(3-azabicyclo[2.2.1]heptan-3-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 680),

À^r-[(6-amino-2-pyndyI)sulfonyl]-2-[cyclobutyl(methyl)ammo]-6-(3-fluoro-5-isobutoxyphenyl)pyndine-3-carboxamide (Compound 683),

A-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-phenyl-1piperidyl]pyridine-3-carboxamide (Compound 684),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 694),

A-[(6-amino-2-pyridyl)sulfbnyI]-2-(2,5-diinediyI-3-phenyl-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 711),

848 //-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2(methoxymethyl)pyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 719),

N-[(6-amino-2-pyridyl)su]fonyl]-2-(2,3-dimethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 720),

A^r-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 735),

7V-[(6-amino-2-pyridyI)sulfonyl]-2-[(2R,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyI)pyridine-3-carboxamide (Compound 751), //-[(6-amino-2-pyridyl)sulfonyl]-2-(2-benzylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 772),

7V-[(6-ammo-2-pyridyl)sulfonyl]-2-[2,2-dimethyl-3-(trifluoromethyl)pyrrolidin-l-yl]-6-(3-ftuoro5-isobutoxy-phenyl)pyridine-3-cai'boxamide (Compound 780), /V-[(6-amino-2-pyridyl)sulfbnyl]-2-(2,3-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 837),

A^?-[(6-amino-2-pyndyl)sulfonyl]-2-(8-azaspiro[3.4]octan-8-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridme-3-carboxamide (Compound 845),

2V-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-pheny 1)-2-(2,2,4,4tetramethylpynOlidin-l-yl)pyridine-3-carboxamide (Compound 850),

2-(3,3a,4,5,6,6a-hexahydro-lH-cyclopenta[c]pynOl-2-yI)-/V-[(6-amino-2-pyridyl)sulfonyl]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 857),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-phenylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 859),

A^r-[(6-amino-2-pyridyI)sulfonyl]-2-[cyclopropylmethyl(propyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 881),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(3,3-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridîne-3-carboxamide (Compound 887),

849 /V-[(6-amino-2-pyridyl)3ulfonyl]-2-(4-azabicyclo[3.î.0]hexLm-4-yi)-6-(3-fluorG-5-£Eobutoxyphenyl)pyndme-3-carboxamide (Compound 906),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(lS,4R)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 924),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-(9-azaspiro[4.4]nonan-9-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 926),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-(3-ethylpyrrolidin-l-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 931),

77-[(6-amino-2-pyridyl)sulfonyl]-2-[(lR,5S)-8-azabicycio[3.2.1]octan-8-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 934), /7-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspiro[2.5]octan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 953),

N- [(6-amino-2-pyridyl) sulfonyl]-2-(3 -benzyI-2-methyl-pyrroIidin-1 -y 1)-6-(3 -fluoro -5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 969),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(6-azaspiro[2.5]octan-6-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 973),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 991),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyM-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1004),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[methyl-[(lmethyIcyclopropyI)methyI]amino]pyridine-3-carboxamide (Compound 1009),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropylmethyl(methyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1010),

77-[(6-armno-2-pyridyl)sulfonyl]-2-(3,5-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1013),

850

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methylpyiTolÎdm-lyl]pyridine-3-carboxamide (Compound 1051),

M[(6-amino-2-pyridyI)sulfonyl]-2-(6-azaspiro[2.4Jheptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1061), jV-[(6-amîno-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2,3,3triniethyipyrrolidm-l-yI]pyridine-3-carboxamide (Compound 1065),

M[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyl-4-oxo-pyrrolidin-I-yl)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-dihydropyridine-3-carboxamide,

7V-[(6-amino-2-pyridyl)sulfonyI]-2-[(2S)-2-/eri-butylpyrrolidin~l-yl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1097),

A^r-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-isopropyl-lpiperidyl)pyridine-3-carboxamide (Compound 109S), ïV-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropyl(methyl)ainino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1117), /V-[(6-amÎno-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,3-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1121),

V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobuloxy-phenyI)-2-[(2S)-2,3,3trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1144),

V-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2(methoxymethyl)pyrrolidin-l -yl]pyrîdine-3-carboxamide (Compound 1149),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,3,3-trimethylpyiTolidin-lyl)pyrîdine-3-carboxamide (Compound 1156), )V-[(6-ammo-2-pyridyl)suIfonyl]-2-[cyclopropylinethyl(isopropyl)ammo]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1157),

N-[(6-amino-2-pyridyl)suifonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2--(4-methylene-lpiperidyl)pyridine-3-carboxamide (Compound 1162),

851

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoiO-5-isobutoxy-phenyl)-2-[(5R)-2,2,5trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1166),

N-[(6-amino-2-pyridyl)sulfbnyi]-2-((2 R)-2-teri-butylpyrrolidin-l-yl]-6-(3-fluoro-5-isobutoxyph en yl)pyri dine-3-carboxamide (Compound 1170),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(lR,4S)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1180), jV-[(6-ammo-2-pyridyl)sulfbnyl]-2-(2,2-dimethyl-3-oxo-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-dihydropyridine-3-carboxamide,

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-pbenyi)-2-[(3S)-3-methyl-lpiperidyl]pyridine-3-carboxamide (Compound 1193),

N-[(6-aminO“2-pyridyl)suIfonyl]-2-[l-(3-chlorophenyl)ethyI-methyl-amino]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1205), /V-[(6-ammo-2-pyridyl)sulfonyl]-2-[(3S,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobutoxyph en yl)pyridine-3-carboxamide (Compound 1210),

A^r-[(6-iUnmo-2-pyridy])sulfonyl]-2-(2-ethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1218),

7'Z-((6-amino-2-pyridyl)sulfonyl]-2-(2-ethyl-5-methyi-pynOlidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyI)pyridine-3-carboxamide (Compound 1222),

N-[(6-ammo-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(5S)-2,2,5trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1241),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-isopropylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1258),

A^f-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2-phenylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1260),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(8-azaspiro[3.5] nonan-8-yl )-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1264),

852

A^r-[(6-amino-2-pyridy0sulfonyl]-2-(3,3-dimethylmoipho!in-4-yi)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1267),

A4(6-amino-2-pyridyl)sulfonyl]-2-(4_s4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1279),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4R)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 12S9),

77-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspiro[3.5]nonan-7-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1303),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-[(2S)-2(trifluoromethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 1304),

2-(2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b]pyridm-l-yl)-jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3fluoro-5-isobutoxy-phenyI)pyridme-3-carboxamide (Compound 1313),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-3-phenylpynOlidin-l-yl)pyridine-3-carboxamide (Compound 1319),

A^r-[(6-amino-2-pyridyl)suIfonyl]-2-(4-methyl-l-piperidyl)-6-(p-tolyl)pyridine-3 -carboxamide (Compound 802),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6-methoxy-5-methyl-3-pyridyl)-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 863),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxyphenyl)-2-(4-methyl-l-piperidyl)pyridine-3carboxamide (Compound 910),

6-(3-fluoro-5-isopropoxy-phenyl)-2-(4-methyl-l-piperidyl)-N-(IH-pyrazol-3ylsulfonyl)py ri dîne-3-carboxamide (Compound 1042),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspiro[2.4]heptan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1333),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-[(3R,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 371),

853

7/-[(6-amino-2-pyndyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenYl)-2-(l-piperidyl)pyridine-3carboxamide (Compound 380),

2-(3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrol-l-yl)-N-[(6-amino-2-pyridyl)sulfonyl]-6-(3fiuoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 383), methyl (2S)-l-[3-[(6-ammo-2-pyridyl)sulfony]carbamoyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2pyridyl]pyrrolidine-2-carboxylate (Compound 385),

77-[(6-amino-2-pyrîdyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2(trifluoromethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 398),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methyl-lpiperidy]]pyridine-3-carboxamide (Compound 408),

A4(6-ammo-2-pyridyI)sulfonyl]-2-(azepan-l-yl)-6-(3-iluoro-5-isobutoxy-phenyl)pyridine-3carboxamide (Compound 418),

N- [(6-amino -2 -pyridyl)sulfonyl] -6-(3- fluoro-5-isobutoxy-phenyl)-2-[3 -(methoxymethyl)-1 piperidyl]pyridine-3-carboxamide (Compound 419),

A4(6-ammo-2-pyridyl)sulfonyl]-2-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 420),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-[(2S)-2-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 421),

N-[(6-amino-2-pyridyl)suIfonyi]-6-(3-fluoro-5-isobuto xy-pheny I)-2-(8-oxa-4azaspiro[4,4]nonan-4-yl)pyridine-3-carboxamide (Compound 424),

A^r-[(6-amino-2-pyridyI)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 425),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-phenylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 447),

A4(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dihydropynOl-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 453),

854 ?7-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5S)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 458),

A^r-[(6-amino-2-pyiïdyl)sulfbnyl]-2-(3-benzylpyrrolidin-l“yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 473),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl_PynOlidin-ly l)pyridine-3-carboxamide (Compound 479),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2-methyl-4-phenylpyrrolidin-1 -yl)pyridine-3-carboxamide (Compound 488),

A''-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-[4-(trifluoromethyl)-310 azabicyclo[3.1.0]hexan-3-yl]pyridine-3-carboxamide (Compound 490),

7V-[(6-amino-2-pyridyl)suIfonyl]-2-[2-(l,l-dimethyIpropyI)pyrrolidin-l -yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3~carboxamide (Compound 493),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 496),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[l-cyclopropylethyl(methyl)amino]-6-(3-fluoro-5-isobutoxyphenyI)pyridine-3-carboxamide (Compound 516),

À^r-[(6-amino-2-pyridyl)sulfonyI]-2-(6-azaspiro[3.3]heptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyI)pyridine-3-carboxamide (Compound 527), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(3-ethyl-3-methyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy20 phenyl)pyridine-3-carboxamide (Compound 530),

7V-[(6-amino-2-pyridyI)sulfbnyl]-6-(3-iluoro-5-isobutoxy-phenyl)-2-[(3S)-2,2,3trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 547),

77-[(6-arnino-2-pyridyl)sulfbiiyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethylpyrrolidm-l yl)pyridine-3-carboxamide (Compound 555),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobiitoxy-phenyl)-2-(3,3,5-trimethyI-lpiperidyI)pyridine-3-carboxamide (Compound 560),

855

V- [(6-ami n o-2-pyridyl)sulfonyl]-6-(3-fl uoro-5-isobntoxy-pheny 1)-2-(3,3,4-trimethyl-1piperidyl)pyridine-3-carboxamide (Compound 575),

A-[(6-amino-2-pyridyl)suIfonyl]-2-[(lR,5S)-3-azabicyclo[3.2.1]octan-3-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 581),

A-[(6-ammo-2-pyridy])sulfonyl]-2-(2,4-dimethylpyirolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 587),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-pyrrolidin-l-yl-pyridine-3carboxamide (Compound 592),

A-[(6-amino-2-pyridyl)sulfonyl]-2-(2-cyclopropylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 593),

A4(6-amino-2-pyridyl)suIfonyl]-2-(3-terAbutylpynOlidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 611),

A-[(6-amino-2-pyridy])sulfonyl]-2-(2-terZ-butylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 613),

A-[(6-amino-2-pyridyI)sulfonyl]-2-(4-ethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-c arboxamide (Compound 615),

A-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyi)-2-[(3R)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 651),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(3-cyclopropyI-l-piperjdyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 655), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-flLioro-5-isobutoxy-phenyl)-2-[(3R)-2,2,3trimethy]pynOlidin-l-yl]pyndine-3-carboxamide (Compound 657),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-(2-pyridyl)pyrrolidin-lyl]pyridine-3-carboxamide (Compound 659),

856

TV-[(6-amino-2-pyridyl)sulfonyl]-2-(2-benzyl-2-methyl-pyrrolidin-I-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 663),

N-[(6-amino-2-pyridyl)suifony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-methylpyrrolidin-lyI]pyridine-3-carboxamide (Compound 678),

7V-[(6-ammo-2-pyridyl)sulfonyl]-2-(3-azabicyclo[2.2.1 ]heptan-3 -y 1)-6-(3-fl uoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 680), iV-[(6-ammo-2-pyridyl)sulfbnyl]-2-[cyclobutyl(rnethyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 683),

7V-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-phenyl-lpiperidyl]pyridine-3-carboxamide (Compound 684),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-methylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 694), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(2,5-dimethyl-3-phenyl-pynolidm-l-yl)-6-(3-fluoro-5isobutoxy-pheny])pyridine-3-carboxamide (Compound 711), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2(methoxymethyl)pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 719),

A^r-[(6-amino-2-pyridyI)sulfonyl]-2-(2,3-dimethylpyrrolidm-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 720),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-methyl-lpiperidyl)pyridme-3-carboxamide (Compound 735),

7/-[(6-ammo-2-pyridyl)sulfbnyl]-2-[(2R,5R)-2,5-dimethylpyrrolidin-l-y]]-6-(3-:fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 751),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2-benzylpyrrolidin-l-yl)-6-(3-fluoiO-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 772),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[2,2-dimeÜiyl-3-(trifluoromethyl)pynOlidin-1-yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 780),

857

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,3-dimethyl-l-piperjdyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 837), jV-[(6-amino-2-pyridyI)sulfonyl]-2-(8-azaspiro[3.4]octan-8-yl)-6-(3-fluoro-5-isobutoxyph en yl)pyridine-3-carboxamide (Compound 845),

TV-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4,4tetramethylpynO!idin-I-yl)pyridine-3-carboxamide (Compound 850),

2-(3,3a,4,5,6,6a-hexahydro-177-cyclopenta[c]pyrrol-2-yl)W-[(6-amino-2-pyridyl)sulfonyI]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 857),

7/-[(6-amino-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-phenylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 859),

V-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropylmethyI(propyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 881),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(3,3-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 887),

TV-[(6-amino-2-pyridyl)sulfony]]-2-(4-azabicyclo[3.1.0]hexan-4-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 906),

7V-[(6-amino-2-pyridyl)sulfonyI]-2-[(IS,4R)-3-azabicyclo[2.2.1]heptan-3-yl]-6-(3-fIuoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 924),

Aⁱ-[(6-amino-2-pyridyl)sulfonyI]-2-(9-azaspiro[4.4]nonan-9-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 926),

7V-[(6-amino-2-pyrjdyl)sulfonyi]-2-(3-ethylpyrrolidin-l-yI)-6-(3-fluoro-5-isobutoxyphenyI)pyridine-3-carboxamide (Compound 931),

V-[(6-amino-2-pyridyl)sulfonyI]-2-[(lR,5S)-8-azabicyclo[3.2.1]octan-8-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 934),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(7-azaspiro[2.5]octan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 953),

858

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(3-benzyl-2-methyl-pynOlidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 969),

7V-[(6-amino-2-pyridyI)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methyl-lpiperidyI)pyridine-3-carboxamide (Compound 991),

N-[(6-amino-2-pyridyI)sulfonyl]-2-(2,2-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1004),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[methyI-[(lmethylcyclopropyl) me thyl]amino]pyridine-3-carboxamide (Compound 1009),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropylmethyl(methyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1010),

[(6-amino-2-pyridyl)sulfony 1)-2-(3,5-dirnethyl-i-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1013), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methylpyrroljdin-lyl]pyridine-3-carboxamide (Compound 1051), iV-[(6-amino-2-pyridyl)sulfonyl]-2-(6-azaspiro[2.4]heptan-6-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1061),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-iluoro-5-isobutoxy-phenyl)-2-[(2R)-2,3,3trimethylpynolidin-l-yl]pyridine-3-carboxamide (Compound 1065),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyl-4-oxo-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyi)-l,2-dihydropyridine-3-carboxamide,

A^r-[(6-amino-2-pyridyI)sulfonyl]-2-[(2S)-2-ieri-butylpyrrolidin-l-yl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1097),

A7-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-isopropyl-lpiperidyl)pyridîne-3-carboxamide (Compound 1098),

859

N-[(6-amino-2-py ri dyl)sulfonyl}-2-[cyclopropyI(methyl)amino]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1117),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-lluoro-5-isobutoxy-pheny 1)-2-(2,2,3-îrimethylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 1121),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2,3,3trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1144),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2(methoxymethyl)pyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1149),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,3,3-trimethylpyrrolidin-l10 y])pyridine-3-carboxamide (Compound 1156),

A^,'-[(6-amino-2-pyridyl)sulfonyl]-2-[cyclopropyImethyl(isopropyl)amino]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1157),

A7-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-plienyl)-2-(4-methylene-lpiperidyl)pyridine-3-carboxamide (Compound 1162),

N-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobütoxy-phenyl)-2-[(5R)-2,2,5trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1166),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R)-2-terFbutylpynOlidin-l-yl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1170),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(lR,4S)-3-azabicycio[2.2.1]heptan-3-yi]-6-(3-fluoro-520 isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1180),

A4(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dÎmethyl-3-oxo-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)-l,2-dihydropyridme-3-carboxamide, /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)-3-methyI-lpiperidyl]pyridine-3-carboxamide (Compound 1193), /V-[(6-amino-2-pyridyl)su]fbnyl]-2-[l-(3-chlorophenyl)ethyI-methyl-amino]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1205),

860

AM{6-amino-2-pyridyl)suIfonyl]-2-[(3S,5S)-3,5-dimethyl-l-piperidyl]-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1210), jV-[(6-amino-2-pyridyl)sulfonyl]-2-(2-ethylpyrrolidin-l-yl)-â-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1218),

A'-[(6-amino-2-pyridyI)sulfonyl]-2-(2-ethyi-5-methyl-pyrrolidin-l-yI)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1222), ?/-[(6-amino-2-py ridyl)su Ifbnyl]-6-(3-fin oro-5-isobutoxy-ph en yl)-2-[(5 S )-2,2,5trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1241), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-îsopropylpyrrolidin-l10 yl)pyridine-3-carboxamide (Compound 1258), /V-[(6-amino-2-pyridyl)sulfonyI]-6-(3-iluoro-5-jsobutoxy-pheny!)-2-[(2S)-2-phenylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 1260),

M-[(6-aniino-2-pyridyI)sulfonyl]-2-(8-azaspiro[3.5]nonan-8-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1264),

N- [(6-amino-2-pyridyI)sulfonyl]-2-(3,3 -dimethylmorpholin-4-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1267),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobuÎoxyphenyl)pyridine-3-carboxamide (Compound 1279),

A-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-pbenyl)-2-[(4R)-2,2,420 trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1289), /V-[(6-amino-2-pyridyI)suIfonyl]-2-(7-azaspiro[3.5]nonan-7-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1303),

ZV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-plienyl)-2-[(2S)-2(trifiuoromethyl)pyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1304),

2-(2,3,4,4a,5,6,7,7a-octahydrocyclopema[b]pyridin-l-yl)-A^r-[(6-amino-2-pyridyl)sulfbnyl]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1313),

861 :V-[Ç6-amino-2-pyridyl)suifonyl]-6-(3-iluoro-5-isobutoxy-phenyl)-2-(2-methyl-3-phenylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1319),

2-(2,5 -dimethyl-3-phenyl-pyrrolid in-l-yl)-6-(3-fl uoro-5-isobutoxy-pheny 1)-7/-( lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1348),

2-[(3,3-difluorocyclobutyl)methylamino]-6-(3-fluoro-5 -isobutoxy-phenyl)W-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 393),

2-[(2S,5R)-2,5-dimethylpyirolidin-l -yl]-6-(3-fluoro-5-isobutoxy-pbenyl)-77-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 415),

6-(3-fluoro-5-isobutoxy-pheny 1)-/7-(lH-pyrazol-5-ylsulfonyl)-2-[4-(tri fluoromethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 426),

2-(3-ethynyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-77-(lH-pyrazol-5-ylsuifonyl)pyridine3-carboxamide (Compound 431),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyl-I-piperidyI)-77-(lH-pyrazol-5 -ylsulfonyl)pyridine3-carboxamide (Compound 442),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-isopropyl-l-piperidyl)-77-(lH-pyrazol-5yIsulfonyl)pyridine-3-carboxamide (Compound 498),

6-(3 - fl uo ro-5-isobutoxy-pheny 1)-77-( 1/7-pyrazol-5-ylsulfonyl)-2-spiro[l/7-isobenzofuran-3,4'piperidme]-r-yl-pyridme-3-carboxamide (Compound 506),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-oxa-8-azaspiro[3.5]nonan-8-yl)-77-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 519),

2-(3,4-dimethyl-l-piperidyI)-6-(3-fluoiO-5-isobutoxy-phenyl)-jV-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 528),

6-(3 -fluoro-5-isobutoxy-phenyl)-2-(4-isopropyl-l-piperidyl)-77-(lH-pyrazoI-5ylsulfonyl)pyridine-3-carboxamide (Compound 553),

2-[4-(cyanomethyl)-l-piperidyl]-6--(3-fluoro-5-isobutoxy-phenyl)-Z7-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 556),

862

2-(3,3-difiuoropyrrolidin-l-yl)-6-(3-f]uoro-5-isobutoxy-pheny])-7V-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 565),

2-(2-ethylpyrrolidin-l-yl)-6-(3-flLioro-5-isobutoxy-phenyl)-A-(lH-pyrazoi-5-ylsulfonyl)pyridine3-carboxamide (Compound 591),

2-[(3R,5S)-3,5-dimethyl-l-piperidyI]-6-(3-fluoro-5-isobutoxy-phenyl)-A-(lH-pyrazoI-5yl su lfonyl)pyridi ne-3-carboxamide (Compound 642),

6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3R)-3-methyl-l-piperidyl]-A-(lH-pyrazol-5yl su ifonyl)pyridme-3-carboxamide (Compound 668),

6-(3-fluoro-5-isobutoxy-phenyl)-A-(lH-pyrazol-5-yIsulfonyl)-2-[3-(2-pyridyl)-lpiperidyl]pyridine-3-carboxamide (Compound 677),

6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2S)-2-phenylpyrrolidin-l-yI]-A-(lH-pyrazol-5ylsulfbnyl)pyridine-3-carboxamide (Compound 716),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-iluoro-l-piperidyl)-A-(lH-pyrazol-5-ylsulfonyl)pyridine3-carboxamide (Compound 728),

2-(azepan-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-A-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 734),

6-(3-fluoro-5-isobutoxy-phenyl)-2-indolin-l-yl-A-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 739),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-methoxy-l-piperidyl)-A-(lH-pyrazol-5ylsulfonyl)pyiidme-3-carboxamide (Compound 749),

6-(3-f1uoro-5-isobutoxy-phenyl)-2-(3-methyl-l-piperidyl)-A-(lH-pyrazol-5-ylsulfonyl)pyridine3-carboxamide (Compound 756),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methoxy-4-methyl-l-piperidyl)-A-(lH-pyrazol-5ylsulfonyl)pyridîne-3-carboxamide (Compound 774),

2-(3-ethoxy-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-A'-(lH-pyrazoI-5-ylsu]fonyl)pyridine3-carboxamide (Compound 843),

863

6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-fluoro-ï -piperidy 1)-27-(] H-pyrazol-5-ylsulfonyl)pyridine3-carboxamide (Compound 878),

6-(3-fluoro-5-isobutoxy-phenyl)-77-(lH-pyrazol-5-ylsulfonyl)-2-(2,2,4-trimethy]pyrrolidin-lyl)pyridine-3-carboxamide (Compound 904),

6-(3-fluoro-5-isobutoxy-phenyl)-77-(IH-pyrazol-5-ylsulfonyl)-2-[3-(trifluoromethyl)-lpiperidyl]pyridi ne-3-carboxamide (Compound 907),

6-(3-fluoro-5-isobutoxy-phenyl)-2-[(3S)'-3-phenyM-piperidyl]-/7-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 912),

2-[(3R,5R)-3,5-dimethy]-l-piperidyl]-6-(3-fluoro-5-isobutoxy-pbenyl)-?7-(lH-pyrazol-5ylsulfonyl)pyridîne-3-carboxamide (Compound 942),

2-(7-azaspiro[3.5]nonan-7-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-7V-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 944),

6-(3-fluoro-5-isobutoxy-phenyl)-77-(lH-pyrazol-5-ylsulfonyl)-2-(2,3,3-trimethylpyiTolidin-lyl)pyridine-3-carboxamide (Compound 952),

6-(3 -fluoro-5-isobutoxy-phenyl)-2-[4-(methoxymethyl)-l-piperidyl]-/7-(lH-pyrazoI-5ylsulfonyl)pyridine-3-carboxamide (Compound 975),

6-(3-flLioro-5-isobutoxy-phenyl)-2-isoindolin-2-yl-2V-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 981),

6-(3-fluoro-5-isobutoxy-phenyl)-2V-(lH-pyrazol-5-ylsulfonyl)-2-(2,2,3-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 997),

2-(3,3 -dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-77-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1005),

2-(4,4-difluoro-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-?7-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1006),

6-(3-fluoro-5-isobutoxy-phenyl)-2-[3-(methoxymethyl)-l-piperidyl]-/7-(lH-pyrazol-5ylsuîfonyl)pyridine-3-carboxamide (Compound 1028),

864

2-(4-eüiyl-l -pipendyl)-6-(3-fluoro-5-isobutoxy-_PhenyI)-N-(iH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 1030),

6-(3-fluoro-5-isobutoxy-phenyI)-N-(lH-pyrazol-5-ylsulfonyl)-2-[(4S)-2,2,4-trimethylpyrTOlidml-yl]pyridine-3-carboxamide (Compound 1041),

6-(3-fluoro-5-isobutoxy-phenyl)-2-[(2R)-2-phenylpyrroIidin-l-yl]-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1060),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methyl-l-piperidyl)-A^r-(lH-pyrazol-5-ylsuIfonyl)pyridine3-carboxamide (Compound 1083),

2-[4-(cyclopropylmethoxy)-l-piperidyI]-6-(3-fluoro-5-isobutoxy-phenyl)-A^r-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1088),

2-(4,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-7V-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1110),

2-(2,6-dimethylmorpholin-4-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-jV-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1119),

2-(6-azaspiro[2.5]octan-6-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1127),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methyIpyrrolÎdin-l-yl)-7V-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1142),

2-(4-ethoxy-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-7V-(lH-pyrazol-5-ylsulfonyl)pyridme3-carboxamide (Compound 1155),

2-(2,3 -dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1169),

6-(3-fluoro-5-isobutoxy-phenyI)-7V-(lH-pyrazol-5-ylsulfbnyl )-2-(3,3,4-trimethyI-lpiperidyl)pyridine-3-carboxamide (Compound 1174),

6-(3-0uoro-5-isobutoxy-phenyl)-N-(lH-pyrazol-5-ylsulfonyl)-2-[(4R)-2,2,4-tnmethylpynolidinl-yl]pyrîdme-3-carboxamide (Compound 1176),

865

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-methoxy- 1-piperidyl )-7/-(1 H-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1245),

2-(2-benzyIpyrTolidin-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)W-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1257),

6-(3-fluoro-5-isobutoxy-phenyl)W-(lH-pyrazol-5-ylsulfonyl)-2-[[3(trifluoromethyl)cyclohexyl]amino]pyridine-3-carboxamide (Compound 1281),

2-(8-azaspiro[3.4]octan-8-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-V-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1282),

6-(6-isopropoxy-3-pyridyl)-A^r-(lH-pyrazol-5-ylsulfonyI)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridi!ie-3-carboxamide (Compound 1352),

2-(3-cyc]opropyl-l-piperidyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2V-(lH-pyrazol-5ylsulfonyI)pyridine-3-carboxamide (Compound 1286),

2-(2,2-dimethylpyrrolidin-l-yl)-6-(3-fluoro-5-isobutoxy-phenyl)-A^r-(IH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1302),

6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-phenyl-l-piperidyl)-7V-(lH-pyrazol-5-ylsulfonyl)pyridine3-carboxamide (Compound 1315),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isopropoxy-phenyl)-2-(4-methyl-lpiperidyl)pyridme-3-carboxamide (Compound 600), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isopropoxy-phenyl)-2-(2,2,4-trimethylpyiToIidinl-yl)pyridine-3-carboxamide (Compound 972),

A^[(6-amino-2-pyridyl)sulfbnyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5isopropoxy-pheny])pyridine-3-carboxamide (Compound 1123),

N-(4-aminophenyl)sulfonyl-6-rerr-butyl-2-(l-piperidyl)pyridine-3-carboxamide (Compound 753),

A^r-(4-aminophen_yl)sulfonyl-2-(benzylamino)-6-i<’rrbutyl-pyiidine-3-carboxamide (Compound 1064),

866

7V-(4-aminophenyl)sulfonyl-6-rert-butyl-2-(4-methoxy-l-piperidyl)pyridine-3-carboxamide (Compound 1298),

N-(4-aminophenyl)sulfonyl-6Tert-butyl-2-[(4-meihyItetrahydropyran-4yl)methylamino]pyridine-3-carboxaniide (Compound 752),

7V-(4-ammophenyl)suIfonyl-6Tert-butyl-2-(4-methyl-l-piperidyl)pyridine-3-carboxamide (Compound 1037),

N-[(6-amino-2-pyridyl)sulfbnyl]-6T£ri-butyl-2-(4-methyl-l-piperidyl)pyridine-3-carboxamide (Compound 794),

77-[(6-ammo-2-pyridyl)sulfbnyl]-6-/m-butyl-2-(3.3-dimethylbuÎoxy)pyridine-3-carboxamide,

N-[(6-amino-2-pyridyl)sulfonyl]-6Teri-butyl-2-(3-methyl-l-piperidyl)pyridine-3-carboxamide (Compound 1008),

N-[(6-ammo-2-pyridyI)sulfonyl]-6-/£ri-butyl-2-[4-(methoxymethyl)-l-piperidyI]pyridine-3carboxamide (Compound 986),

77-[(6-amino-2-pyi-idyl)sulfonyl]-6-m?T-butyl-2-(3,5-dimethyl-l-piperidyljpyridine-3carboxamide (Compound 617),

Λ^Γ-[(6-amino-2-pyridyl)sulfbnyI]-6-mr^butyl-2-[4-(l-hydroxy-l-metl^yl-ethyl)-lpiperidyl]pyridine-3-carboxamide (Compound 1038),

77-[(6-amino-2-pyridyl)sulfonyl]-6-ieri-butyl-2-(4-methoxy-l-piperidyl)pyridme-3-carboxamide (Compound 1164),

Z7-[(6-amino-2-pyridyl)sulfonyl]-6-terTbutyl-2-(4-ethoxy-l-piperidyl)pyridme-3-carboxamide (Compound 1200),

2-[(4-methyïtetrahydropyran-4-yl)methylamino]-6-(p-tolyl)-77-(lH-pyrazol-3ylsuIfony])pyridine-3-carboxamide (Compound 879)

À^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(4-methyltetrahydropyran-4-yl)methylamino]-6-(ptolyl)pyridine-3-carboxamide (Compound 1196),

Z7-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-2-[(2S,5R)-2,5-dimethylpyriOlidici-l-yl]pyridme-3carboxamide (Compound 373),

867 /V-[(6-amino-2-pyridyl)sulfonyI]-6-terributyl-2-[(3S)-3-phenyl-l-piperidyl]pyridine-3carboxamide (Compound 1261), jV-[(2-amino-3-pyridyl)sulfonyI]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 1316),

N- [(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyndy 1)-2-((4 R)-2,2,4-trime thylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1240),

À^r-[(2-amino-3-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethyIpyrrolidÎu-l-yl]-6-(3-fiuoro-5isobutoxy-phenyi)pyridine-3-carboxamide (Compound 1159),

TV- [(6 -amino-2-pyridyl)sulfonyl]-6-me thyI-2-[(3 S )-3-phenyl-l-piperidyl]pyridine-3 -carboxamide (Compound 532),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-teri-butyI-2-[(3R)-3-phenyl-l-piperidyl]pyridine-3carboxamide (Compound 626),

2-[(2S,5R)-2,5-dimethy]pyrrolidm-l-yl]-6-(6-isopropoxy-3-pyridyl)-/V-(lH-pyrazol-5ylsulfonyl)pyridîne-3-carboxamide (Compound 1074),

6-(6-isopropoxy-3-pyridyI)-2-[(3R)-3-phenyl-l -piperidyl]-A^r-(lH-pyrazol-5-ylsulfonyl)pyridine3-carboxamide (Compound 741),

6-(6-isopropoxy-3-pyridyl)-2-[(3S)-3-phenyl-l-piperidyl]-7V-(lH-pyrazol-5-yîsulfbnyl)pyridine3-carboxamide (Compound 776),

2-[(3R,5S)-3,5-dimethyl-l-piperidyl]-6-(6-isopropoxy-3-pyridyl)-TV-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 446),

2-[(3R,5R)-3,5-dimetliyl-l-piperidyl]-6-(6-isopropoxy-3-pyridyl)-N-(lH-pyrazol-5yîsulfonyl)pyridine-3-carboxamide (Compound 990),

6-(6-isopropoxy-3-pyridyl)-2-(4-methyl-l-piperidyl)-TV-(lH-pyrazol-5-ylsulfonyl)pyridine-3carboxamide (Compound 534),

7V-(benzenesulfonyl)-6-(3-fluoro-5-isobu toxy-phenyl )-2-((43)-2,2,4-trime thylpyrrolidin-1yl]pyridine-3-carboxamide,

868

M-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-azabicyclo[2.2.2]octan-3-y])-6-(3-fluQro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1657),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(3S)-2,2-dideuterio-3_î5,5-trimethy]-pyrrolidin-l-yl]-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1400),

A^r-[(6-amino-2-pyridyl)suIfonyl]-2-(3-azabicyclo[3.1.1]heptan-3-yl)-6-(3-fluoro-5-isobutoxyph en yl)pyridine-3-carboxamide (Compound 1529),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,5,5-trimethylmorpholin4-yl)pyridine-3-carboxamide (Compound 1548),

N-[(6-amino-2-pyridyl)sulfbny]]-2-(5,7-dimethylindolin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1572),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(4R)-4-ethyl-2,2-dimethyl-pyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1611),

AH(6-amino-2-pyridyl)sulfonyl]-2-[(4S)-4-ethyl·2,2-dimethyl·pyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1612),

N-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5,5tetramethylmorpholin-4-yI)pyridine-3-carboxamide (Compound 1675),

N- [(6- amino-2-pyridyl)sulfonyl] -2-(3,5-diisopropylpyrazol-l-yl )-6-(3-fluoro-5-isobu toxyphenyl)pyridine-3-carboxamide (Compound 1387),

7V-[(6-amino-2-pyridyI)sulfonyl]-2-(3,3-difiuoroazetidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2155),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-methylazetidin-lyl)pyridine-3-carboxamide (Compound 1840),

N-[(6-amino-2-pyridyl)sulfbnyl]-2-(3-fluoroazetidin-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2128),

Y-[(6-amino-2-pyridyl)sulfonyl]-2-(6,6-dimethyl-7-azaspiro[3.4]octan-7-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 2589),

869

7V-[(6-ammo-2~pyridyI)sulfonyl]-2-(5-azabicyclo[4.1.0]hept;m-5-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridîne-3-carboxamide (Compound 2376), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(6-methyl-3azabicyclo[3.1 .l]heptan-3-yl)pyridine-3-carboxamide (Compound 2224),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[[l-(2-hydroxy-2-methylpropyl)cyclopropyl]methylamino]pyridine-3-carboxamide (Compound 1723),

ZV-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(6-methyl-8azaspiro [3.4] oc tan-8-yi)pyridine-3-carboxamide (Compound 2552),

A'^,-[(6-amino-2-pyridyl)suIfonyl]-2-(2,2-dimethylazetidin-l-yI)-6-(3-fîuoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1928),

Z7-[(6-amino-2-pyridyl)sulfonyl]-2-(3,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2532) (Isomer 1) (Compound 2178) (Isomer 2) (Compound 2062) (Isomer 3) (Compound 1863) (Isomer 4), ?7-[(6-amino-2-pyridyl)sulfbnyl]-2-(2,5-dimethyl-l-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2451) (Isomer 1) (Compound 1993) (Isomer 2) (Compound 1864) (Isomer 3) (Compound 1855) (Isomer 4),

Z7-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-hydroxy-lpiperidyl)pyridine-3-carboxamide (Compound 2323),

N- [(6-amino-2-pyridyl)sulfonyl] -2-[cyclohexylmeth yl (methyl )amino]-6-(3-fluoro-5-isobuto xyphenyl)pyridine-3-carboxamide (Compound 2289),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 1995),

7V-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(4-isopropyl-2,2-dimethylpyiTolidin-l-yl)pyridine-3-carboxamide (Compound 2201),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-BLAHyl-pyridine-3carboxamide (Compound 1821),

N-[(6-amiuo-2-pyridyl)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(5-methyl-7azaspiro[2.4]heptan-7-yl)pyridine-3-carboxamide (Compound 1754),

870

A/-[(6-amino-2-pyridyl)suifonyl]-2-(4-teri-butyi-2,2-dimethyl-pyrrolidin-l-yi)-6-(3-fIuoro-5isobutoxy-phenyl)pyridi ne-3-carboxamide (Compound 2538), tert-butyl (2R)-l-[3-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2pyridyl]pyrrolidine-2-carboxylate (Compound 2216), tert-butyl (2S)-l-[3-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2pyridyl]pyrrolidine-2-carboxylate (Compound 2204), /V-[(6-amino-2-pyridyl)sulfony]]-6-(3-fluoiO-5-isobutoxy-phenyl)-2-(2,2,4-trimethyl-lpiperidyl)pyridine-3-carboxamide (Compound 2581),

A^r-[(6-amino-2-pyridyî)sulfonyl]-2-(4,4-difluoro-2,2-dimethyI-pyrroIidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 2631),

ZV^,-[(6-amino-2-pyridyl)sulfonyl]-2-(5,5-dimethyl-6-azaspiro[24]heptan-6-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1746), jV-[(6-ammo-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3-methylazetidin-lyl)pyridine-3-carboxamide (Compound 2117),

N-[(6-amino-2-pyridyl)sulfonyI]-2-[2,2-dimethyl-4-(trifluoromethyl)pyrrolidin-l-yl]-6-(3-fluoro5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 1788),

77-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[2-methyl·5(trifluoromethyl)-1 -piperidyI]pyridine-3-carboxamide (Compound 1835),

77-[(6-amino-2-pyridyl)sulfonyl]-2-(3,5-dimethylazepan-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridme-3-carboxamide (Compound 2479),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-dimethylazepan-l-yl)-6-(3-fluoro-5 -isobutoxyphenyl)pyridine-3-carboxamide (Compound 2171),

A^r-[(6-amino-2-pyridyl)sulfbnyl]-2-(3,3-dimethylazepan-l-yl)-6-(3-flLioro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1901),

A^r-[(6-amino-2-pyridyI)sulfonyl]-2-(cyclohexylmethylamino)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2375),

871 zV-[(6-amino-2-pyridyl)sulfonyI]-6-zerz-butyl-2-(l-piperidyl)pyridme-3-carboxatnide (Compound 571), and

AH(6-ammo-2-pyridyl)sulibnyl]-2-(2,2“dimethylpynOlidin-l-yl>6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 361).

PREPARATION 40: 2-(BeirzenesiiIfonyl)-3-|5-Zcr/-butYl-2-|(2,6 dimethylphenyl)methyl]pyrazol-3-yl]-3-oxo-propanoate (Compound 4)

5-icri-Butyl-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-carboxylic acid (100 mg, 0.35 mmol) was dissolved in thionyl chloride (26 pL, 0.35 mmol) and a drop of Odimethylformamide was added. The mixture was stirred for lh and evaporated to give the acid chloride.

A mixture of the acid chloride (40 mg, 0.13 mmol), methyl 2-(benzenesulfonyl)acetate (28 mg, 0.13 mmol) and NaH (60%, 5.3 mg, 0.13 mmol) in //M-dimethylformamide (1 mL) were stirred at room température for 15 min. The mixture was filtered and purified by reversephase preparatory-HPLC (10-99% CH3CN/H2O, HCl modifier) to give 2-(benzenesulfonyI)-3[5-icri-butyl-2-[(2,6-dimethylphenyl)methyl]pyrazol-3-yl]-3-oxo-propanoate (Compound 4). ESI-MS m/z cale. 482.6, found 483.4 (M+l)*; Rétention time: 2.41 min (3 min run).

PREPARATION 41: 6-(3“isoButoxyphenyl)-iV-[(2-oxo-17î-pyridÎn-3-yl)sulfonyl]2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 125)

Step 1: 6-cliloro-A^,'-[(2-methoxy-3-pyridyI)suIfonyl]-2-(2,4,6trÎmethylphenoxy)pyridine-3-carboxamide

872

6-Chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxyIic acid (5.09 g, 17.5 mmol) was dissolved in thionyl chloride (6.36 mL, 87.3 mmol), CH2CI2 (1 mL) and N,Ndimethylformamide (one drop). The reaction mixture was stirred for 30 min before it was concentrated to give the acid chloride.

The acid chloride was dissolved in CH2CI2 (1 mL) and was added to solution of2methoxypyridine-3-sulfonamide (3.69 g, 17.5 mmol) in CH2CI2 (1 mL) containing triethylamine (7.30 mL, 52.4 mmol) at 0 °C. The mixture was allowed to stir at room température ovemight before it was diluted with CH2CI2 and washed with IN HCl, saturated NaHCO₃, and then brine. The organic layer was dried over sodium sulfate and concentrated to give 6-chloro-77-[(2methoxy-3-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (6.20 g, 77%) ESI-MS m/z cale. 461.1, found 462.2 (M+l)⁺; Rétention time: 0.74 min (1 min run).

Step 2: 6-ehloro-.V4t2-ox<)-H/-pyi‘idin-3-yl)sulfonyl]-2-(2,4,6triniethylphenoxy)py ri dine-3-carboxamide

A mixture of 6-chloro-A-[(2-methoxy-3-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (500 mg, 1.08 mmol), 1,4-dioxane (10 mL) and HCl (2.71 mL of 4 M, 10.8 mmol) was heated at 90 °C for 3.5 h. The volatiles were removed to give 6-ch loro-A-[(2-oxo-lH-pyridin-3-y l)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3

873 carboxamide (372 mg, 77%) ESI-MS m/z cale. 447.1, found 448.2 (M+l)⁺; Rétention time: 0.63 min (1 min run).

Step 3: 6-(3-isoButoxyphenyI)-(V- [(2 -oxo-1 ί/-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridiIle-3-carboxamide (Compound 125)

A mixture of 6-chloro-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2_J4,6trimethyiphenoxy)pyridine-3-carboxamide (56 mmol, 0.10 mmol), 3-îsobutoxyphenyI boronic acid (39 mg, 0.2 mmol), Pd(PPh₃)₄ (7 mg, 0.006 mmol), K₂CO₃( 2 M, 200 pL, 0.4 mmol) and MN-dimethylformamide (1 mL) was flushed with nitrogen and sealed. The mixture was then stirred at 80 °C for 18h. The résultant solid was diluted with water and filtered. Then solid was taken up in ethyl acetate, filtered and concentrated to give 6-(3-isobutoxyphenyl)-7V-[(2-oxo-lHpyridin-3-yl)sulfonyl]-2-(2,4,6-trime thylphenoxy)pyridine-3-carboxamide (Compound 125). ESI-MS m/z cale. 561.2, found 562.2 (M+l)⁺; Rétention time: 2.23 min (3 min run).

6-(4-chloro-3-propoxy-phenyl)-A^r-[C2-oxo-lH-pyridin-3-yl)sulfonyI]-2-(2,4,6tri methyl phenoxy)pyridine-3-carboxamide (Compound 72),

2-(2,4-dimethylphenoxy)-6-(4-ethoxyphenyl)-N-[(2-oxo-I/7-pyridin-3-yl)sulfon.yl]pyridine-3carboxamide (Compound 517),

6-(4-chloro-3-isobutoxy-phenyl)-?/-[(2-oxo-ll^c/-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylpbenoxy)pyridine-3-caiboxamide (Compound 136),

6-(2,5-difluorophenyl)-N-[(2-oxo-177-pyridin-3-yi)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 545),

6-(3,4-difluorophenyl)-N-[(2-oxo-IZ7-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimeÎhylphenoxy)pyridme3-carboxamide (Compound 546),

874

-(2-fluoro-5 -propoxy-phenyl)-N- [(2-oxo-lH-pyridin-3-yl)sulfonyl] -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 552),

6-(4-fluorophenyl)-N-[(2-oxo-llï-pyridin-3-yI)suIfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 561),

6-(4,4-dimethylcyclohexen-l-yl)-)V-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (Compound 573),

6-(4-chlorophenyl)-N-[(2-oxo-l#-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 579),

6-(3-fluoro-5-isobutoxy-phenyl)-AXlH-indol4-ylsulfonyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 549),

2-(4,4-dimethyl-J -pipe ridy 1)-6-(3-fluoro-5-isobutoxy-phenyl)-N-(3-hydro xyphenyl)sulfo nylpyridine-3-carboxamide (Compound 1309),

2-(4,4-dimethyl-l-piperidyl)-6-(3-f]uoro-5-isobutoxy-phenyl)-N-(lH-indol-4ylsulfonyl)pyridine-3-carboxamide (Compound 1323), jV-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(6-methoxy-3pyridyl)pyridine-3-carboxamide (Compound 726), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(3,5-dimethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1471), isopropyl 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(2,4,6-trimethylphenoxy)-2-pyridyl]3,6-dihydro-2H-pyridine-l-carboxylate (Compound 1366), ?/-[(6-amino-2-pyridyI)sulfonyl]-6-(4-ethylcyclohexen-l-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1370),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(l-benzyl-3,6-dihydro-2H-pyridin-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1389),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l,2-dimethylprop-l-enyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1390),

875

A^r-[(6-amino-2-pyndyI)sulfonyl]-6-[4-(trifluoromethyl)cyclohexen-l-yl]-2-(2,4,6trimethylphenoxy)pyridi ne-3-carboxamide (Compound 1402), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(4,7,7-trimethyl-3 -bicyclo[2.2.1]hept-2-enyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1410),

A^r-[(6-amino-2-pyridyi)sulfonyl]-6-(2,3-dihydrofuran-4-yl)-2-(2,4,6-trîmethylphenoxy)pyridine3-carboxamide (Compound 1412), ethyi 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(2,4,6-trimethylphenoxy)-2pyridyl]cyclohex-3-ene-l-carboxylate (Compound 1432),

A^r-[(6-amino-2-pyridyI)sulfonyl]-6-(l,4-dioxaspiro[4.5]dec-8-en-9-y 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1437), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(6,6-dimethyl-2,3-dihydropyran-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1460),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(cyclohepten-l-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1513), /V-[(6-amino-2-pyridyl)sulfonyI]-6-(3-bicyclo[2.2.1]hept-2-enyl)-2-(2,4,6- — trimethylphenoxy)pyridine-3-caiboxamide (Compound 1518),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(5,5-dimethyl-3-oxo-cyclohexen-l-yI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1528),

A^z-[(6-amino-2-pyridyl)sulfonyl]-6-(5,5-dimethyl-2-oxo-cyclohexyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1427),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-cycloheptyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1376),

7V-[(6-amino-2-pyridyl)sulfonyr[-6-(2,2-dimethyltetrahydropyran-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1466),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethylcyclohexyl)-2-(2,4,6-trimethy]phenoxy)pyridine-3carboxamide (Compound 1475),

876

TV-[(6-aniino-2-pyridyl)sulfonyl]-6-(l,2-dimethylpropyI)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1486),

V-[(6-amino-2-pyridyl)sulfonyl]-6-(3,3-dimethyl-5-oxo-cyclohexyl)-2-(2,4,6trimethylphenoxy)pyridine-3 -carboxamide (Compound 1492),

ZV-[(6-amino-2-pyridyl)sulfonyl]-6-(3,6-dihydro-2H-thiopyran-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1517),

N-[(6-amino-2-pyridyl)sulfonyI]-6-[4-(trifluoromethyl)cyclohexyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1519), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylcyclohexen-l-yl)-2-(2,4,6irimethylphenoxy)pyridine-3-carboxamide (Compound 1630), 6-(4-acetylcyclohexyl)-A4(6-amino-2-pyridyl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1631),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(l,7,7-trimethylnorboman-2-yl)-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 1650),

AA[(6-amino-2-pyridyl)sulfbnyl]-6-[l-(2-methylpropanoyl)-3,6-dihydro-2H-pyridin-4-yi]-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1540), )V-[(6-amino-2-pyridyl)sulfonyl]-6-(l,4-dioxaspiro[4.5]dec-8-en-8-yl)-2-(2,4,6trimethy!phenoxy)pyndine-3-carboxamide (Compound 1558), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3,3-dimethyi-6-oxo-cyclohexen-l-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1598),

TV-[(6-amino-2-pyridyl)sulfonyI]-6-(2,2,5,5-tetramethyl-3-furyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1609),

6-(4-acetylcyclohexen-l-yl)-N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1615),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(L,2,3,6-tetrahydropyridin-4-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1643),

877

6-(l-acetyl-3,6-dihydro-2H-pyiidin-4-yl)-M[(6-amino-2-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1649),

N- [(6-ammo-2-pyridyl)sulfonyl]-6- [3 -isopropoxy-5- (trifluoro me thy l)phenyl]-2-((45)-2,2,4trimethylpyrrolidin-1 -yI]pyridine-3-carboxamide (Compound 1674),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-5-methyl-phenyl)-2-[(4S)-2,2,4trimethylpytrolidin-l-yl]pyridine-3-carboxamîde (Compound 1488),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-[3-ethoxy-5-(trifluoromethyl)phenyI]-2-((4S)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1569),

N-[(6-amino-2-pyiidyl)sulfonyl]-6-(3-isopropoxy-5-methyl-phenyl)-2-[(4S)-2,2,410 trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1671),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxy-5-methyl-phenyl)-2-[(4S)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1646),

A^,-(2-azidophenyl)sulfonyl-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fiuoro-5-isobutoxyphenyl)pyridine-3-carboxamide, /V-(2-azidophenyl)sulfonyl-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yI]-6-(6-isopropoxy-3pyridyl)pyridine-3 -carbo xamide, /7-[(6-amino-2-pyridyl)sulfbnyl]-6-cyclohexyl-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]pyridine3-carboxamide (Compound 704),

6-(4-fluoro-2-methoxy-phenyl)-iV-[(2-oxo-l/7-pyridin-3-yI)sulfonyl]-2-(2,4,620 trimethylphenoxy)pyridine-3-carboxamide (Compound 608),

6-(4-fluoro-3-methoxy-phenyl)-A^?-[(2-ox0-lH-pyridin-3-yl)sulfony!]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 624),

6-(3-fluoro-5-isopropoxy-pheny!)-77-((2-oxo-1 H-pyridin-3-yl)sulfonyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 645),

6-(3-fluoro-5-methoxy-phenyl)-jV-[(2-oxo-li/-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 652),

878 iV-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-6-phenyl-2-(2.4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 654),

6-(2-fluoro-5-methoxy-phenyl)-?Z-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 762),

6-(2-fluoro-3-isobutoxy-phenyl)-N-[(2-oxo-liCpyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 804),

6-(3,5 -difluorophenyl)-N-[ (2-o xo-lH-pyridin-3-yl) su Ifonyl]-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 815),

6-(4-ethylphenyl)-N-[(2-oxo-177-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 831),

6-(3-ethoxy-5-fluoro-phenyl)-)V-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 835),

6-(2-fluoro-4-methoxy-phenyl)-7V-[(2-oxo-177-pyridin-3-yl)sulfbnyl]-2-(2,4,6trimethylph en oxy)pyridine-3-carboxamide (Compound 839),

6-(2-chlorophenyl)-7/-[(2-oxo-177-pyridin-3-yl)sulfbny!]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 877),

6-(cyclohexen-l-yl)-A^f-[(2-oxo-lZ7-pyridin-3-yI)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridme-3carboxamide (Compound 882),

6-(2,5 -dime th oxyphenyl ) -N- [(2-oxo-1 H-pyridin-3 -yl )sulfonyl] -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 888),

6-(3-ethoxy-4-fluoro-phenyl)-N-[(2-oxo-17/-pyridin-3-yl)sulfbnyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 917),

6-(6-methoxy-5-methyl-3-pyridyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 930),

6-(6-ethoxy-3-pyridyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 932),

879

6-(1 -metliylindol-6-yl)-?/-[(2-oxo4H-pyridin-3-yl)sulfonyl]-2 -(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 936),

-(2-chloro-3-propoxy-phenyl)-?/- [(2-oxo-l//-pyridin-3-yl)sulfonyl] -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 955),

6-(3-butoxy-2-chIoro-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimeth y lphenoxy)pyridine-3-carboxamide (Compound 964),

6-(4-methoxyphenyl)-A^r-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 980),

6-(3 -ch loro-4-propoxy-phenyl)4V-[(2-oxo- lH-pyridin-3 -yI)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 999),

6-(4-isopropylphenyl)-A^r-[(2-oxo-lH'-pyridin-3-yI)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridme3-carboxamide (Compound 1002),

6-[4-(cyclopropylmethoxy)phenylj4V-[(2-oxo-lH-pyridÎn-3-yI)sulfoi)yl]-2-(2,4,6trimethy]phenoxy)pyridine-3-carboxamide (Compound 1007),

6-(3-fluoro-4-propoxy-phenyI)4V-[(2-oxo-]H-pyridin-3~yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1022),

6-(4-methylcyclohexen-l-yl)-N-[(2-oxo-l#-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1052),

6-(4-isobu toxyphenyl) - V- [(2 -oxo-1 f/-pyridin-3 -y 1) su lfonyI]-2- (2,4,6-tri methyl pheno xy )pyridine3-carboxamide (Compound 1079),

6-(3-chlorophenyl)-N-[(2-oxo-l#-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethyiphenoxy)pyridine-3carboxamide (Compound 1095),

6-[3-(cyclopropylmethoxy)phenyl]-A^r-[(2-oxo-l/7-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1105),

2-(2,4-dimethylphenoxy)-jV-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-(p-tolyl)pyridine-3carboxamide (Compound 1129),

880

A-[(2-oxo-IZ/-pyridin-3-yl)sulfonyI]-6-(3-propoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1143),

6-(5-fluoro-2-methoxy-phenyl)-A-[(2-oxo-l//-pyridin-3-yl)sulfonyl]-2-(2,4,6tri methylphenoxy)pyridine-3 -carboxamide (Compound 1151),

6-(4-ethoxyphenyl)-A-[(2-oxo-l//-pyridin-3-yl)sulfonyl]-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1179),

6-(4-butoxy-3-fluoro-phenyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1187),

6-(3-isopropoxyphenyl)-A- [(2-oxo -IH-pyridin-3 -yl)sulfonyl]-2-(2,4,6 trimethylphenoxy)pyridine-3-carboxamide (Compound 1188),

6-(2-chloro-5-isobutoxy-phenyl)-A-[(2-oxo-li7-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethyiphenoxy)pyridine-3-carboxamide (Compound 1201),

A-[(2-oxo-lH-pyridin-3-yl)SLilfonyl]-6-(4-propoxyphenyl)-2-(2,4,6-tnmethylphenoxy)pyridine3-carboxamide (Compound 1202),

6-(2,3-difluorophenyl)-A-[(2-oxo-l/7-pyridin-3-yl)sulfbnyl]-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1296),

A-[(2-oxo-177-pyridîn-3-yl)sulfonyl]-6-(p-toIyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1300),

6-(5-ethoxy-2-fluoro-phenyl)-A-[(2-oxo-î/7-pyridin-3-yl)sulfbnyl]-2-(2,4,6tri methylphenoxy)pyridine-3-carboxamide (Compound 1301),

6-(3-fluoro-5-isobutoxy-phenyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 169),

2-[(2R,5S)-2,5-dimethy]pymolidin-l-yI]-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-(ptolyl)pyridine-3-carboxamide (Compound 392),

6-(6-isopropoxy-3-pyridyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4R)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 403),

881

2-[(2S,5R)-2,5-dimethyIpynOlidin-l-yl]-6-(3-fluoro-5-isopropoxy-phenyl)-A^r-[(2-oxo-lHpyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 487),

6-(3-fluoro-5-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridioe-3-carboxamide (Compound 492),

6-(6-isopropoxy-3-pyridyl)W-[(2-oxo-lH-pyndin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimetliylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 497),

2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-isobutoxyphenyl)-7V-[(2-oxo-ltf-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 511),

6-[3-(cyclopropylmethoxy)-5-fluoro-phenyl]-2-[(2S,5R)-2,5-dimethylpyrroIidin-l-yl]-N-[(2-oxolH-pyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 541),

6-[3-(2,2-dimethylpropoxy)-5-fluoro-phenyl]-2-t(2S,5R)-2,5-dimethyIpyrrolidin-l-yl]-N-[(2oxo-127-pyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 572),

2-[(2S,5R)-2,5-dimethylpyn:olidm-l-yI]-6-(4-isopropylphenyl)-A4(2-oxo-liFpyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 589),

6-(3-fluoro-5-isobutoxy-phenyl)W-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4R)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 605),

2-[(2S,5R)-2,5-dimethylpyrrolidm-l-yl]-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-phenyl-pyridine3-carboxamide (Compound 660),

6-[3-(cyclopropylmethoxy)-5-fluoro-phenyI]-2-(4-methyl-l-piperidyl)-N-[(2-oxo-lH-pyridin-3yl)sulfonyl]pyrîdine-3-carboxamide (Compound 664),

2-[(2S,5R)-2,5-dimethylpyirolidm-l-yl]-6-(3-fluoro-5-isopentyloxy-phenyl)-N-[(2-oxo-l/7pyridin-3-yl)sulfonyt]pyridine-3-carboxamide (Compound 688),

2-[(2S,5R)-2,5-dimethylpyrrolidm-l-yI]-6-(2-fiuoro-5-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin3-yl)sulfbnyl]pyridine-3-carboxamide (Compound 721),

6-(3-fluoro-5-isopropoxy-phenyl)-2-(4-methyl-l-piperidyl)-?7-[(2-oxo-177-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 737),

882

6-(4-chlorophenyl)-2-[(2S,5R)-2,5-diinethylpynOlidin-l-yl]-jV-[(2-oxo-lH-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 760),

2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-(6-isopropoxy-3-pyridyl)4V-[(2-oxo-lH-pyridin-3yl) su lfonyl]pyridine-3-carboxamide (Compound 770),

2-[(2S,5R)-2,5-dimethylpyiTOHdin-l-yl]-6-(6-methoxy-2-pyridyl)-A-[(2-oxo-lH-pyrid!n-3yI)sulfonyl]pyridine-3-carboxamide (Compound 781),

2-[(2S,5R)-2,5-dimethy]pynOlidin-l-yI]-6-(4-isobutoxyphenyl)-N-[(2-oxo-lH-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 891),

6-(4-chloro-3-isobutoxy-phenyl)-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-N-[(2-oxo-lH-pyridin3-yl)sulfonyl]pyridine-3-carboxamide (Compound 902),

6-[3-(cyclobutylmethoxy)-5-fluoro-phenyl]'2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-2V-[(2-oxolH-pyridin-3-yl)sulfonyl]pyridine-3-carboxamide (Compound 922),

6-(4-chloro-3-isobutoxy-phenyl)-2-(4-methyl-l-piperidyl)TV-[(2-oxo-l/7-pyridin-3yl)sulfbnyl]pyridine-3-carboxamide (Compound 941),

6-(3-isobutoxyphenyl)-2-(4-methyl-l-piperidyl)-/7-[(2-oxo-l//-pyridm-3-yl)sulfbnyl]pyridine-3carboxamide (Compound 958),

6-(4-chloro-3-isopropoxy-phenyl)-2-[(2S,5R)-2,5 -dimethylpyrrolidin-l-yl]-N-[(2-oxo-l/7pyridin-3-yl)sullbnyl]pyridme-3-carboxamide (Compound 1001),

6-(4-isobmoxyphenyl)-2-(4-methyl-l-piperidyl)-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]pyridine-3carboxamide (Compound 1017),

2-[(2R,5S)-2,5-dimethylpyiTolidin-l-yl]-6-(3-ethoxy-5-fluoro-phenyl)-N-[(2-oxo-lW-pyridin-3yl)sulfonyl]pyridine-3-carboxamide (Compound 1096),

8,8-dimethyl-2-(4-methyl-l-piperidyl)-Z7-[(2-oxo-lH-pyridm-3-yI)sulfonyl]-6,7’dihydro-5/fquinoline-3-carboxamide (Compound 1195),

6-(4-chloro-3-propoxy-phenyl)-2-[(2R,5S)-2,5-dimethylpyrTolidin-l-yl]-A^r-[(2-oxo-17ï-pyridin3-yl)sulfonyl]pyridine-3-carboxamide (Compound 1293),

883

6-(3-fluoro-5-isobutoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(3S)-3-phenyl-lpiperidylJpyridine-3-carboxamide (Compound 481),

6-(2-methoxy-5-methyl-phenyl)-N-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2530),

6-(3-etlroxyphenyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2235),

6-(4-met]ioxy-2-methyl-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2469),

6-(4-ethoxyphenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrro]idin-lyl]pyridine-3-carboxamide (Compound 2207),

6-(2-methoxy-3-methyl-phenyl)-/7-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidiii-l-yl]pyridine-3-carboxamide (Compound 1880),

6-isobutyl-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridîne3-carboxamide (Compound 2467),

6-(3-methoxy-4-methyl-phenyl)-.Z7-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-y]]pyridme-3-carboxamide (Compound 2440),

6-(3-isopropoxyphenyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrroIidinl-yl]pyridine-3-carboxamide (Compound 2549),

6-(4-isopropoxyphenyl)-/V-[(2-oxo-IH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1774),

6-(2-isobutoxyphenyl)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2629),

6-(3-fluoro-4-methoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrûl!din-l-yl]pyridine-3-carboxamjde (Compound 2219),

6-(3-isobutoxypIienyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine~3-carboxamide (Compound 2267),

884 ô-(2-fluoro-6-methoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2422),

6-(4-isobutoxyphenyl)-Ab[(2-oxo-lH-pyridin-3-yl)sulfon y] ]-2-[(4S)-2,2,4-trime thylpyrrolidin-1yl]pyridine-3-carboxamide (Compound 2153),

6-(2-fluoro-3-methoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trime thylpyrrolidin-1-y l]pyridine-3-carboxamide (Compound 2222),

6-(5-fluoro-2-methoxy-phenyl)-A7[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1830),

A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-[3-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4-

Îrimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1934),

6-(2-fluoro-5-methoxy-pheny])-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2606),

77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-[4-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxarmde (Compound 2234),

6-(4-fluoro-2-methoxy-phenyl)-M[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2356),

6-(3-fiuoro-5-methoxy-phenyl)-A^,'-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]py ri dine-3-carboxamide (Compound 2527),

N-[(2-oxo-l H-pyridin-3-yl)sulfonyl]-6-[3-(trifiuoromethyl)phenyl]-2-[(4S)-2,2,420 trime thylpyrrolidin-1-y l]pyri dine-3-carboxamide (Compound 2144),

6-(2-fluoro-4-methoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1858),

6-(3-fluoiO-2-methoxy-phenyl)-M[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trime thylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1779),

6-(4-fluoro-3-methoxy-phenyl)-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1780),

885

6-(2-naphthyl)-TV-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolÎdin-lyl]pyridine-3-carboxamîde (Compound 1803),

6-(l-naphthyl)-TV-[(2-oxo-lH-pyridin-3-yl)sulft>nyl]-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 2007),

6-(2,4-dimethylphenyl)-)V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin1 -yl]pyridine-3-carboxamide (Compound 2037),

N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-(2,3,5-trifiuorophenyl)-2-[(4S)-2,2,4-trimethylpynOlidinl-yl]pyridine-3-carboxamide (Compound 1837),

N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-(2,4,5-trifluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1981),

6-(2,3-dihydro-l,4-benzodioxin-6-yl)-N-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2516),

6-(2-hydroxy-3 -methyl-phenyl)-JV-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2300),

6-(3-ethoxy-5-methyl-phenyI)-TV-[(2-oxo-lH-pyridin-3-yl)sulfbnyl]-2-[(4S)-2,2,4tri methylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2512),

6-(2,3-dimethylphenyl)-N-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2073),

6-(2-hydroxy-5-methyl-phenyl)-N-[ (2-oxo-lH-pyridin-3-y l)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2174),

6-(5-fluoro-2-methyl-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyI]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2067),

6-(2-ethoxy-5-methyl-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2410),

6-(4-methoxy-2 .ô-dimethyl-phenylj-N- [(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2575),

886

6-[3-(hydroxymethyl)-5-methoxy-phenyl]-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2247),

6-(2,3 -d imethoxyphenyl)-?/-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1786),

6-(2,5-dimethoxyphenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1752),

6-(2-hydroxy-4-methyI-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimetbylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2148),

6-(3,5-dimethoxyphenyl)-A4(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1878),

6-(2-ethoxy-5-fluoro-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4tnmethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2051),

6-(5-ethoxy-2-fluoro-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2138),

6-(3-ethoxy-2-fluoro-phenyl)-AA[(2-oxo-lH-pyridin-3-y0sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1802),

6-(2-ethoxy-4-fluoro-phenyl)-/V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimeÎhylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1867),

6-(3,5-dîme thylphenyI)-N-[(2-oxo-lH-pyridÎn-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolîdinl-ylJpyridine-3-carboxamide (Compound 2626),

6-(3-ethoxy-5-fluoro-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfbnyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yI]pyridine-3-carboxamide (Compound 2278),

6-(3-ethoxy-4-fluoro-phenyl)-N- [(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2459),

6-(3,4 -di me th yl phenyl) -N- [(2- oxo -1 H-pyridin-3 -yl)sulfonyl]-2- [ (4 S )-2,2,4 -trimethyl pyrrol idinl-yl]pyridine-3-carboxamide (Compound 2154),

887

6-(4-me thyl-l-naphthyl)-N-[ (2-oxo-IH-pyridin-3-y l)sulfonyl]-2-[(4S )-2,2,4-trlmethylpynO)idinl-yl]pyridine-3-carboxamide (Compound 1811),

6-(2-isopropylphenyl)-7V-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2635),

6-(4,5-difluoro-2-methoxy-phenyl)-?/-[(2-oxo-l H-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1904),

6-(3,5-difluoro-2-methoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2496),

6-(2,3-difluoro-4-methoxy-pheny])uV-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2567),

6-(3,5 -difluoro-4-methoxy-phenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1801),

6-(3,4-difluoro-5-methoxy-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4tri me thylpyrrolid in-l-yl]pyridine-3-carboxamide (Compound 1914),

6-(2,5-difluoro-4-methoxy-phenyl)-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1913),

6-(4-hydroxy-3,5-dimethyI-phenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2556),

6-(lH-indol-5-yl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyI]pyridine-3-carboxamide (Compound 1982),

6-(lH-mdoM-yl)-M[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2636),

6-(6-ethoxy-4-methyl-2-pyridyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxanHde (Compound 1745),

6-(3 -fluoro-4-methyl-pheuyl)-A^r-[(2-oxo-lH-pyridin-3-yl)suIfbnyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2084),

888

6-(2-fluoro-4-methyl-phenyl)-_IM-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 2000),

6-(3-fluoro-2-methyl-phenyl)-7V-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridÎne-3-carboxamide (Compound 2491),

6-(2-chlorophenyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethyipyrrolidin-lyl]pyridine-3-carboxamide (Compound 1784),

6-(3-fluoro-5-methyl-phenyl)-W-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 2348),

6-(2-ίluolΌ-5-methy^pheny])-A-[(2-oxo·lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyirolidin-l-yl]pyridine-3-carboxamide (Compound 1946),

6-(3-chloiOphenyI)W-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrol.idin-lyl]pyridine-3-carboxamide (Compound 1791),

6- (3,4-d ifl uorophenyl) W-[(2-oxo-1 H-pyridin-3 -yl) sulfony l]-2-[(4S)-2,2,4-trimethylpyrrolidin-1 yl]pyridine-3-carboxamide (Compound 2284),

6-(4-chlorophenyl)-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2028),

6-(2,4-difluorophenyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2159),

6-(2,3-difluoropheny 1)-7/-((2-oxo-1 H-pyridin-3-y l)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l yl]pyridine-3-carboxamide (Compound 2162),

6-(3,5-difluorophenyI)-7V-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2652),

6-(2,5 -difluorophenyl)-A-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1954),

6-(2-fluoroph en yl)-A-[(2-oxo-1 H-pyridin-3-yl)sulfonyl]-2-[(45)-2,2,4-trimethylp yrrolidin-Iyl]pyridine-3-carboxamide (Compound 2542),

889

6-(2-isopropoxyphenyl)-M[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridme-3-carboxamide (Compound 2541),

6-(3-cyanophenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2185),

6-(3-fluorophenyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1925),

6-(4-fIuorophenyl)-N-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1807),

N- [(2-oxo-lH-pyridin-3 -yl)sulfonyl]-6-[2-(trifluoro methyl)phenyl]-2-[(43)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1960),

6-(2-methoxy-3-pyridyl)-V-[(2-oxo-lH-pyridm-3-yl)sulfonyi]-2-[(4S)-2,2,4-trimethylpyrrolidml-yl]pyridine-3-carboxamide (Compound 2454), y-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-[4-(trifluoromethyl)cyclohexyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2315),

N-[(2-oxo-lH-pyridin-3-yl)sulibnyl]-6-[4-(trifiuoromethyl)cyclohexyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1710),

6-(2,5-dinieÜiylphenyl)-/V-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyndine-3-carboxamide (Compound 1990),

6-(o-tolyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethy!pyrrolidin-l-y]]pyridine3-carboxamide (Compound 2176),

6-(4-fluoro-3-methyl-phenyl)-7/-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2456),

6-(5-fluoro-6-methoxy-3-pyridyl)-N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2444),

6-(6-methoxy-2-pyridyl)W-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethyIpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2101),

890

6-(2,6-dimethoxy-3-pyridyl)-//- [(2-oxo- lH-pyridin-3-yl)sulfonyl]-2-[(4 S )-2,2,4trimethylpyiTolidin-1 -yl]pyridine-3-carboxamide (Compound 1853),

6-(3-isopropylphenyl)-7/-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2498),

6-(4-isopropylphenyl)W- [(2-oxo-lH-pyridin-3-y l)sulfonyl]-2-[(4S )-2,2,4- trime thylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2483),

6-(5-fluoro-2-hydroxy-phenyl)-//-[(2-oxo-IH-pyridin-3-yI)sulfonyl]-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caîboxamide (Compound 2295),

6-(2-methoxyphenyl)-?/- [(2-oxo-lH-pyridin-3-yl)sulfonyl] -2-[(4 S )-2,2,4-trime thylpytrolid in-110 yl]pyridine-3-carboxamide (Compound 2485),

6-(2,3-dihydrobenzofuran-7-yl)-//-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2583),

6-(4-methoxy-3-methyl-phenyl)-77-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrro!idm-l-yl]pyridine-3-carboxamide (Compound 2369),

6-(2-ethoxyphenyl)-N-[(2-oxo-lH-pyridm-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyiTolidin-lyl]pyridine-3-carboxamide (Compound 1848),

6-(3 -fl uoro-5-isobuto xy-phenyl)-2-(4-m ethyl -1-p iperidyl)-//-[ (2 -oxo-1 H-pyridin-3yl)sulfonyI]pyridine-3-carboxamide (Compound 422), and

6-(2-fluoro-5-isobu toxy-pheny !)-//-[ (2-oxo-UY-pyridîn -3-yl)sulfonyl] -2-(2,4,6 20 trimethylphenoxy)pyridine-3-carboxamide (Compound 279).

PREPARATION 42: //-(3-aminopyrazin-2-yl)sulfonyl-8,8-dimethyl-2-(4-methyll-piperidyll-ôJ-dihydro-SH-quinoline-S-carboxamide (Compound 197)

Step 1: 8,8-dimethyl-2-(4-methyl-l-piperidyl)-6,7-dihydiO-5ZZ-quinoline-3carbonitrile

891

A mixture of 2-chloro-8,8-dimethyl-6,7-dihydro-5H-quinoline-3-carbonitrile (1.00 g, 4.51 mmol) and 4-methylpiperidine (4.29 mL, 36.3 mmol) was stirred at 100 °C for 1 h. The reaction mixture was diluted with water and was extracted with ethyl acetate (3x). The combined extracts were washed with water, dried over sodium sulfate, and evaporated. The residue was purified by silica gel chromatography with 0-5% ethyl acetate in hexanes to give 8,8-dimethyl-2(4-methylpiperidin-l-yl)-5,6,7,8-tetrahydroquinoline-3-carbonitriIe (1.00 g, 78%) as acolorless oil. ES1-MS m/z cale. 283.2, found 284.3 (M+l)*; Rétention time: 0.94 min (1 min run).

Step 2: 8,8-dimethyI-2-(4-methyl-l-piperidyD-6,7-dihydro-5//-(|uinoline-3carboxylic acid

A solution of 8,8-dimethyl-2-(4-methylpiperidin-l-yl)-5,6,7,8-tetrahydroquinoIme-3carbonitrile (0.80 g, 2.8 mmol) and KOH (1.6 g, 28 mmol) in éthanol (5.6 mL) was heated at reflux for 4 d. The reaction mixture was neutralized with 1 M HCl, and the solids were fîltered, washed with water, and dried under vacuum to give 8,8-dimethyl-2-(4-methylpiperidin-l-yl)5,6,7,8-tetrahydroquinoline-3-carboxylic acid (0.71 g, 83%) as a tan solid. ESI-MS m/z cale. 302.2, found 303.3 (M+l)⁺; Rétention time: 0.58 min (1 min run).

Step 3: N-(3-chlorûpyrazin-2-yI)sulfonyl-8,8-dimethyl-2-(4-methyl-l-pipcridyl)6,7-dihydro-577-quÎnoline-3-carboxamide

A solution of 8,8-dimethyl-2-(4-methylpiperidin-l-yl)-5,6,7,8-tetrahydroquinoline-3carboxylic acid (0.11 g, 0.36 mmol), 7V-[(dimethylamino)-lH-L2,3-triazolo-[4,5-b]pyridin-l ylmethyleneFA-methylmethanaminium hexafluorophosphate A-oxide (170 mg, 0.44 mmol) and sodium carbonate (77 mg, 0.73 mmol) in MY-dimethylformamide (1.8 mL) was stirred for 5 min

892 before 3-chloropyrazine-2-sulfonamide (110 mg, 0.55 mmol) was added. The reaction mixture was stirred for 20 h, filtered, and subjected to preparatory-HPLC (1-99% CH₃CN/water) to give N-(3-chloropyrazin-2-yl)sulfonyl-8,8-dimethyl-2-(4-methyl-l-piperidyl)-6,7-dihydro-5Hquinoline-3-carboxamide (75mg, 43%). ESI-MS m/z cale. 477.2, found 478.3 (M+l)⁺; Rétention time: 0.65 min (1 min run).

Step 4: 7V-(3-Ammopyrazin-2-yl)sulfonyl-8,8-dimethyl-2-(4-methyl-l-pipendy))6,7-dihydro-5H-quinoline-3-carboxamide

N-(3-Chloropyrazm-2-yl)sulfonyI-8,8-dimethyl-2-(4-methyLI-piperidyl)-6,7-dihydro-5Hquinoline-3-carboxamide (35 mg, 0.073 mmol) and ammonium hydroxide (1 mL, 26 mmol) was heated in a sealed vial in an micro wave reactor at 120 °C for 20 min. The reaction mixture was concentrated, the residue was taken up in DMSO and subjected to preparatory-HPLC (1-99% CH₃CN/water) to give A^3-aminopyrazin-2-yl)suIfonyl-8,8-dimethyl-2-(4-methyl-l-piperidyl)6,7-dihydro-5ZAqumoline-3-carboxamide (Compound 197) (8.7 mg, 26%). ESI-MS m/z cale. 458.2, found 459.3 (M+l)⁺; Rétention time: 1.67 min (3 min run).

A-(3-ammopyrazin-2-yl)suIfony]-8,8-dimethyl-2-(p-tolyl)-6,7-dihydro-5ff-quinoIine-3carboxamide (Compound 707),

N- (3 -aminopyrazin -2-yl) su Ifony 1-6-(4 -ethoxyphenyl) -2-(p-tolyl)pyridine-3 -carboxamide (Compound 819),

N-(3-aminopyrazin-2-yl)sulfonyl-6-(3-fluoro-5-isopropoxy-phenyl)-2-(p-tolyl)pyridine-3carboxamide (Compound 1351),

N-(3-aminopyrazin-2-yl)sulfonyl-2,6-bis(p-tolyI)pyridine-3-carboxamide (Compound 820), N-(3-amiπopyrazm-2-yl)sulfonyl·8,8-dimethyl-2-(p-tolyl)-6,7-dihydro-5H-quinohne-3carboxamide (Compound 707),

893

N-(3-aminopyrazin-2-yl)sulfonyl-2-(2,4-dimethylphenoxy)-6-(4-etlioxyphenyl)pyridine-3carboxamide (Compound 434),

N-[(6-amino-3-pyridyl)sulfonyl]-6-te ri-butyl-2-(p-tolyI)pyridine-3-carboxamide (Compound 702),

N-(6-aminopyrazin-2-yl)sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 586),

N-(3-aminopyrazin-2-yl)sulfonyl-8,8-dimeÎhyl-2-(2,4,6-trimethylphenoxy)-6,7-dihydro-5#quinoline-3-carboxamide (Compound 1223), /V-(3-aminopyrazin-2-yl)sulfonyl-2-(2,4-dimethylphenoxy)-8,8-dimethyl-6,7-dihydro-57/quinoline-3-carboxamide (Compound 1239), iV-(3-ammopyrazin-2-yl)sulfonyl-6-ter/-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1208),

N-(3-ammopyrazin-2-yl)sulfbnyl-2-(2,4-dimethylphenoxy)-6-(3-:fluoro-5-isopropoxyphenyl)pyridine-3-carboxamide (Compound 559),

N- (3 -aminopyrazin-2-yl)sulfony] -2-(2,4-dimethylphenoxy)-6 - (p -tolyl)pyrid ine-3-carboxamide (Compound 607),

N-(3-aminopyrazin-2-yl)sulfony 1-2-(2,4-dimethylphenoxy)-6-(l-isobutylpyrazol-4-yl)pyridine-3carboxamide (Compound 713),

N-(3 -aminopyrazin-2-yl)sulfonyl-2-(2,4-dimethylphenoxy)-6-(6-methoxy-5-methyl-3pyridyl)pyridine-3-carboxamide (Compound 893),

N-(3-aminopyrazin-2-yl)sulfonyl-6-(3-fluoro-5-isopropoxy-phenyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 989),

N-(3-aminopyrazin-2-yl)sulfonyl-6-(4-ethoxyphenyl)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1019),

N-(3 -aminopyrazin-2-yl)sulfonyl-6-(p-tolyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1047),

894

77-(3-aminopyrazin-2-yl)sulfonyl-6-( 1 -isobutylpyrazoL4-yi)-2-(2A6 -trime thylpheno xy)pyridine3-carboxamide (Compound 1103), /7-(3 -aminopyrazin-2-y!)sulfonyl-6-(6-methoxy-5-methyl-3-pyri dyl) -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1249), /7-(3-aminopyrazin-2-yl)sulfonyl-2-[(4-methyl tetrahyd ropyran-4-yl)me thylamino]-6-(ptolyl)pyridine-3-carboxamide (Compound 1066), /7-(3-aminopyrazin-2-yl)sulfonyl-6-(4-ethoxyphenyl)-2-[(4-methyltetrahydropyran-4yl)methylamino]pyridine-3-carboxamide (Compound 1203), /7-(3-aminopyraz in-2-yl)sulfony 1-6-(1-isobutyl pyrazol-4-yl)-2-(4-methyl-l-piperidyi)pyrid ine-3 carboxamide (Compound 1288),

77-(3-aminopyrazin-2-yl)sulfonyl-6-(6-methoxy-5-methyl-3-pyridyl)-2-(4-metliyl-lpiperidyl)pyridine-3-carboxamide (Compound 1191),

77-(3-aminopyrazin-2-y I)sulfonyl-2-(4-methyl-l-piperidyl)-6-(p-tolyl)pyrid ine-3-carboxamide (Compound 1084),

N-(3-aminopyrazin-2-yl)sulfonyl-6-(3-fluoro-5-isopropoxy-phenyl)-2-(4-methyl-lpiperidyI)pyridine-3-carboxamide (Compound 699),

77-(3-aminopyrazin-2-yl)sulfonyl-6-(4-ethoxyphenyI)-2-(4-methyl-l-piperidyl)pyridine-3carboxamide (Compound 507),

8,8-dimethyl-2-(4-methyl-l-piperidyl)-77-(lH-pyrazol-5-yisulfonyl)-6,7-dihydro-5j7-quinoline-3carboxamide (Compound 800),

77-[(6-amino-2-pyridyl)suIfonyl]-8,8-di me thyl-2-(4-methyl-l-piperidy 1)-6,7-dihydro-577quinoIine-3-carboxamide (Compound 750), and /7-[(2-amino-3-pyridyl)sulfonyl]-6-tert-butyl-2-(p-tolyl)pyridine-3-carboxamide (Compound

636),

PREPARATION 43: N-[(3-Aminophenyl)s ulfonimidoy]]-6-ie/7-buty 1-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 292)

Step 1: sodium 3-nitrobenzene-l-sulfinate

895

To a colorless solution of sodium sulfite (6.26 g, 49.6 mmol) in water (50 mL) at SO °C, were added 3-nitrobenzenesulfonyl chloride (5.00 g, 22.6 mmol) and sodium carbonate (4.30 g, 40.6 mmol). The reaction mixture was stirred at 80 °C for 2h. The reaction mixture was 5 concentrated under reduced pressure. The residue was suspended in éthanol (45 mL) and heated at 80 °C for 1H. The reaction mixture was cooled to room température and filtered to remove most of the salts. The filtrate was concentrated under reduced pressure to give sodium 3-nitrobenzene-l-sulfinate (4.20g, 89% yield, containing some salts). *H NMR (300 MHz, CDC1₃) δ 7.68 (t, 7 = 7.8 Hz, 1H), 8.02 (dt, 7 = 7.7, 1.4 Hz, 1H), 8.21-8.28 (m, 1H), 8.47 - 8.51 (m, 1H). [M+H]⁺= 188.0.

Step 2: methyl 3-nitrobenzene-l-sulfinate

Thionyl chloride (3.27 mL, 45.0 mmol) was added to a solution of sodium 3nitrobenzene-l-sulfmate (3.14 g, 15.0 mmol) in dichloromethane (21 mL) at 0 °C, After 20 minutes at 0 °C, the reaction mixture was allowed to warm to room température and stirred for 3h. The reaction mixture was concentrated and dried under vacuum to give a residue (3.08 g, 15 mmol). To the residue was added dichloromethane (5 mL) and methanol (100 mL) at 0 °C. After 10 minutes at this température, triethylamine (6.27 mL, 45.0 mmol) was added and the mixture was stirred at room température ovemight. The mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (50 mL), washed with water (25 mL), brine (25 mL), dried over anhydrous sodium sulfate and concentrated to give methyl 3nitrobenzene-l-sulfinate (1.40 g, 46% yield). ’H NMR (300 MHz, CDC1₃) δ 3.52 (s, 3H), 7.71 (t, 7-7.8 Hz, 1 H), 7.98 (dt,7 = 7.7, 1.4 Hz, 1 H), 8.21 -8.28 (m, 1H), 8.47-8.51 (m, 1H). [M+H]⁺= 202.0.

Step 3: 6-teri-butyl-AMS-nitrobenzenesulfiny 1)-2-(2,4,6-trimethyIphenoxy) pyridine-3-carboxamide

896

To a solution methyl 3-nitrobenzene-l-sulfmate (1.35 g, 6.70 mmol) in dimethylformamide (8.0 mL) was added methyl 3-nitrobenzene-l-sulfmate (697 mg, 2.68 mmol), followed by césium carbonate (2.18 g, 6.69 mmol). The mixture was stirred ovemight at 5 60 °C. The mixture was diluted with ethyl acetate (60 mL), washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material was purified by chromatography on silica gel, eluting with 10 - 20% ethyl acetate in heptane to give 6-rert-butyl-N-(3-nitrobenzenesulfmyl)-2-(2,4,6-trimethylphenoxy)-pyridine-3-carboxamide (725 mg, impure). This material was used in the next step without further purification. [M+H]⁺10 =482.1.

Step 4: G-rcjAhiityl-AQiminoQ-nitrophvnyljoxo- )Asuli’anyl]-2-(2,4,64rimethylphenoxy)pyridine-3-carboxamide

To a solution of 6-fôrt-butyl-)V-(3-mtrobenzenesulfmyl)-2-(2,4,6-trimethylphenoxy)15 pyridine-3-carboxamide (724 mg, 1.50 mmol) and potassium ierAbutoxide (337 mg, 3.00 mmol) in acetonitrile (7.5 mL) was added hexamethyldisilazane (0.94 mL, 4.5 mmol), followed by Nchlorosuccinimide (0.60 g, 4.5 mmol). After stirring for 15 min, additional hexamethyldisilazane (0.94 mL, 4.5 mmol), followed by V-chlorosuccinimide (0.60 g, 4.5 mmol) were added. The mixture was stirred until TLC indicated completion. The mixture was concentrated and the residue was purified by flash chromatography, eluting with 20 — 50% ethyl acetate in heptane to give 6-feA-butyl-N-[imino(3-nitrophenyl)oxo- X⁶-sulfanyl]-2-(2,4,6-trimethyl-phenoxy)pyridine

897

3-carboxamide (95 mg, 3% over two steps). ‘HNMR (300 MHz, CDC1₃) 5 1.07 (s, 9H), 2.03 (s, 6H), 2.30 (s, 3H), 6.87 (s, 2H), 6.98 (d, 7 = 8.0 Hz, 1 H), 7.74 (t, 7 = 8.2 Hz, 1H), 8.30 (d, 7 = 8.0 Hz, 1H), 8.41 - 8.53 (m, 2H), 8.95 (s, 1H). [M+H]⁺ = 497.2.

Step 5: N-[(3-amÎnophenyl)sulfoniniidoylJ’6-^rr-butyl-2-(2_J4,6 trimethylphenoxy)pyridine-3-carboxamide

To a solution of 6-ieri-butyl-/V-[imino(3-nitrophenyl)oxo-X⁶-sulfanyi]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (90 mg, 0.18 mmol) in methanol (2.6 mL) was added 10% Pd/C (19 mg, 0.018 mmol) and the mixture was stirred at room température for 3h. The solvent was removed under vacuum and the crude material was purified by flash chromatography eluting with 20 - 50% ethyl acetate ! heptane to give M[(3-aminophenyl)sulfonimidoyI]-6-tert-butyl-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (52 mg, 62% yield). *H NMR (300 MHz, CDCI3) § 1.01 (s,9H), 1.92 (s, 6H), 2.22 (s, 3H), 5.57 (br. s, 2H), 6.73 (d,7 = 8.1 Hz, 1H),6.85 (s, 2H), 6.97-7.07 (m, 2H), 7.11-7.20 (m, 2H), 7.56 (br. s, 2H), 8.09 (d, 7 = 7.8 Hz, 1H). [M+H]⁺= 467.2.

Step 6: 7V-[(3-aminophenyl)sulfomniidoyl]-6-tert-butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 19 and Compound 53)

/V-[(3-Aminophenyl)suIfonimidoyl]-6-terCbutyl’2-(2,4,6-tômethylphenoxy)pyridine3-carboxamide (30 mg, 0.064 mmol) was taken up in methanol (1.8 mL) and CH₂C1₂ (0.4 mL). The solution was subjected to chiral SFC (30 pL injections; column: Chiralpak AS-H (250 x 10 mm),5pm; mobile phase: 25% methanol w/20mM NH₃, 75% CO₂; flow: 10 mL/min) to give N

898

[(3-aminophenyl)sulfonimidoyI]-6-ie.’7-butyl-2-(2,4,6~trimethylpheROXÿ)-p.yridirie-3carboxamide [peak 1, enantiomer 1, 97.9% ee, ’H WR (400 MHz, Çhloroform-d) δ 8.27 (d, J = 7.9 Hz, 1H), 7.49 - 7.36 (m, 2H), 7.22 (t, J = 7.9 Hz, 1H), 6.92 (d, 7 = 7.8 Hz, 1H), 6.87 - 6.75 (m, 3H), 3.89 (s, 2H), 2.29 (s, 3H), 2.02 (s, 6H), 1.06 (s, 9H)] and N-[(3ami nophenyl)sulfonimidoyl]-6-mrZ-butyl-2-(2,4,6-trimethylphenoxy)pyridine -3-carboxamide [peak 2, enantiomer 2, 96% ee, 'H NMR (400 MHz, Chloroform-d) δ 8.27 (d, 7 = 7.9 Hz, 1H), 7.49 - 7.33 (m, 2H), 7.23 (t, 7 = 7.9 Hz, 1H), 6.92 (d, 7 = 7.9 Hz, 1H), 6.88 - 6.74 (m, 3H), 3.89 (s, 2H), 2.29 (s, 3H), 2.02 (s, 6H), 1.06 (s, 9H)].

The following compounds can be prepared using the procedures described herein:

N-[S-(3-aminophenyI)-N-methyl-sulfommidoyl]-6-teï'rbutyl-2-(2,4,6tnmethylphenoxy)pyridine-3-carboxamide (Compound 568),

N-(3-amjnophenyl)suifonyl-5-ZcrLbutyl-2-[l-phenylethyl]pyrazole-3-carboxamide canbe separated to give N-(3-aminophenyl)sulfonyl-5-n?rAbutyl-2-[(lS)-l-phenyIethyl]pyrazole-3* carboxamide (Compound 138) and N-(3-aminophenyl)sulfonyl-5-iert-butyl-2-[(lR)-lphenylethyl]pyrazole-3-carboxamide (Compound 540) using Chiralcel OJ-H (250 x 10mm), 5pm column;

N-(3-aminophenyl)suIfonyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide canbe separated to give (15)-N-(3-aminophenyl)sulfonyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoline1-carboxamide (Compound 126) (Compound 126) and (lR)-7V-(3-ammophenyl)sulfonyT2[(2,4,6-trimethylphenyl)methyl]isoindolme-l-carboxamide (Compound 310) using Chiralpak AD-H (250 x 10mm), 5pm column.

PREPARATION 44: A^r-[(6-Amino-3-fluoro-2-pyridyl)sulfonyl]-6-/cr/-butyl-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamîde (Compound 226)

Step 1: 2-(benzyIthÎo)-3,6-difluoropyridine

To a solution of 2,3,6-trifluoropyridine (532 mg, 4.00 mmol) and phenyl methanethiol (470 pL, 4.00 mmol) in THF (20 mL) was added NaH (60%, 176 mg, 4.40 mmol) in portions.

899

After 1 li, the mixture was.quenched with saturated aqueous ammoniumchloride and extracted with ethyl acetate (3x)7 The combinéd extracts were washed with water, dried over sodium sulfate, and evaporated. The residue was purified by silica gel chromatography with 0-20% ethyl acetate in hexanes to give 2-(benzylthio)-3,6-difluoropyridine (0.63 g, 66%) as a colorless oil. ESI-MS m/z cale. 237.0, found 237.9 (M+l)⁺; Rétention time: 0.72 min (1 min run).

Step 2: 3,6-difluoropyridine-2-sulfonyl chloride

Chlorine was bubbled through a vigorously stirred solution of 2-(benzylthio)-3,6difluoropyridine (0.27 g, 1.1 mmol) in chloroform and water for min, and the reaction mixture was stirred for 1 h. Chlorine was bubbled through the mixture for another 15 min, and the reaction mixture was stirred for 2 h. The reaction mixture was quenched with saturated aqueous sodium metabisulfite solution and extracted with dichloromethane (3x). The combinéd extracts were washed with water, dried over sodium sulfate, and evaporated to give cmde 3,6difluoropyridine-2-sulfonyl chloride (50% pure, 0.49 g) as a colorless oil. ESI-MS m/z cale. 213.0, found 213.8 (M+l)⁺; Rétention time: 0.47 min (1 min run).

Step 3: 3,6-difluoropyridine-2-sulfonamide

A solution of 5,6-difluoropyridine-2-sulfonyl chloride (0.35 g, 1.6 mmol) in dioxane (4 mL) was cooled in an ice bath before ammonia (6.6 mL of 0.5 M in dioxane, 3.3 mmol) was added. The reaction was stirred for 3 h and the solvent was evaporated. The residue was purified by silica gel chromatography with 0-50% ethyl acetate in hexanes to give 3,6-difluoropyridine-2sulfonamide (72 mg, 23%) as a colorless solid. ESI-MS m/z cale. 194.0, found 194.8 (M+l)⁺; Rétention time: 0.15 min (1 min run).

Step 4: 6-ie/7-butyl-2V-[(3,6-difluoro-2-pyridy])sulfonyl]-2-(2,4,6trimethylphenoxy)pyridîne-3-carboxamide

900

A solution of 6-tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid (107 mg, 0.340 mmol), 3,6-difluoropyridine-2-sulfonamide (66 mg, 0.34 mmol), A4(dimethylamino)lH-l,2,3-triazo]o-[4,5-b]pyridin-l-ylmethylene]-/V-methylmethanaminium hexafluorophosphate

N-oxide (194 mg, 0.510 mmol) and sodium carbonate (72 mg, 0.68 mmol) in N,Ndimethylformamide (2 mL) was stirred at room température for 18 h. The reaction was diluted with water and extracted with ethyl acetate (3x). The combined extracts were washed with water, dried over sodium sulfate, and evaporated. The residue was purified by silica gel chromatography with 0-5% methanol in dichloromethane to give 6-(tert-butyl)-7V-((3,610 difluoropyridin-2-y!)sulfonyI)-2-(mesityIoxy)nicotinamide (33 mg, 18%) as a colorless solid. ESI-MS m/z cale. 489.2, found 490.2 (M+l)⁺; Rétention time: 0.85 min (1 min run).

Step 5: AMtô-ammo-S-iluoro-l-pyrÎdyljsulfonylj-ô-teri-butyl-S-tiAôtrimethylphenoxy)pyridine-3-carboxamide

A mixture of 6-terAbutyl-N-[(5,6-difluoro-2-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (15 mg, 0.028 mmol) and ammonium hydroxide (1.0 mL of 30 %w/v, 8.6 mmol) was heated in a sealed vessel in a microwave reactor at 130 °C for 30 min and 150 °C for 60 min. The solvent was evaporated and the residue was subjected to preparatory-HPLC (30%-99% acetonitrile / water (5 mM HCl)) to give M-[(6-amino-3-fluoro-220 pyridyl)suIfonyl]-6-teri-butyl-2-(2,4,6-trimethylphenoxy)pyridme-3-carboxamide (0.7 mg, 5%). ESI-MS m/z cale. 486.2, found 487.3 (M+l)*; Rétention time: 2.15 min (3 min run).

901

PREPARATION45: (2S,470-A-[(6-Amino-2-pyridyl)sulfonyI]-4-phenyEl[(2,4,6-trinicthylphenyl)methyl]pyrrolidine-2-carboxamide (Compound 236)

Step 1: (2S,4R)-4-phenylpyrrolidme-2-carboxylic acid trifluoroacetic acid sait

(2S,4/()-1-(B oc)-4-Phenylpyrrolidine*2-carboxylie acid (1.01 g, 3.47 mmol) was dissolved in trifluoroacetic acid (20 ml) and was stirred for 1 hour at room température. The reaction mixture was concentrated under reduced pressure and the resulting residue was left under high vacuum for 18 h. The residue was triturated in a minimal amount of diethyl ether and placed in an ultrasound bath for 1 hour, filtered and then dried under high vacuum to provide (2S,4R)-4-phenylpyrrolidine-2-carboxylic acid trifluoroacetic acid sait (999 mg, 99%) as solid. [M+H]⁺ = 192.2. ’HNMR (3OOMHz,CDC1₃) δ 1.94-2.11 (m, 1H), 2.61-2.75 (m, 1H), 3.09-3.22 (m, 1H), 3.42-3.59 (m, 1H), 3.59-3.73 (m, 1H), 4.35-4.48 (m, 1H), 7.15-7.40 (m, 5H), 8.5210.23 (br. s. 2H).

Step 2: (2S,4R)-4-phenyl-l-[(2,4,6-trmiethyIphenyl)methyi]pyrrolîdîne-2carboxylic acid

(2S4R)-4-Phenylpyrroiidine-2-carboxylic acid trifluoroacetic acid salts (999 mg, 3.47 mmol) and potassium hydroxide (1.17g, 20.8 mmol) were dissolved in isopropanol (25 mL) and heated at 40 °C. A solution of 2-(bromomethyl)-l ,3,5-trimethylbenzene (849 mg, 3.99 mmol) in iso-propanol (20 mL) was added over 60 min via a syringe. The reaction was stirred for addition al 2h at this température. The reaction mixture was treated with concentrated HCl until the pH was between 3 and 4. The resulting solid was filtered off and the filtrate was concentrated

902 under reduced pressure. The résultant solid was dissolved in dichloromethane and was purified on silica gel (0-10% methanol in ethyl acetate). Upon dilution of the residue with dichloromethane, the silica was filtered off and the filtrate was concentrated under reduced pressure to provide (2S'-4/ï)-4-phenyl-l-[(2,4,6-trimethylphenyl)methyl]pyrrolidine-2-caiboxylic acid (1.1g, 98%) as a solid. [M+H]⁺= 324.2. “H NMR (3OOMHz,CDC1₃) δ 2.22 (s, 3H), 2.272.34 (m, lH), 2.38(s, 6H), 2.59-2.94 (m, l H), 2.96-3.30 (m, 1 H), 3.36 (t, J= 11,2Hz, 1H), 3.473.80 (m, 1 H), 4.05 (m, 1H), 4.20 (d, 7=13.4Hz,lH), 4.35 (d, 7=13.4Hz,lH), 6.83 (s, 2H), 7.057.33(m, 5H).

Step 3: (2S,47f)-A-[(6-fluoro-2-pyridyl)sulfonyl]-4-pIienyl-l-[(2,4,6trîm ethylpheny l)me thy 1] py rro lidine -2-ca rbo xamide

(2S,4/?)-4-Phenyl-l-[(2,4,6-trimethy]phenyl)methyl]pyrrolidine-2-carboxylic acid (75 mg, 0.23 mmol), 6-fluoropyridine-2-sulfonamide (192 mg, 1.09 mmol), A-[(dimethylamino)-lH1,2,3-triazolo-[4,5-b]pyridin-l-ylmethylene]-A-methylmethanaminium hexafluorophosphate Aoxide (497 mg, 1.31 mmol), and ethyldiisopropylamine (380 pL, 2,18 mmol) were combined in A,A-dimethylformamide (1.440 mL) and heated at 60°C for 16 h. The reaction mixture was diluted with water (1 mL) and was extracted with ethyl acetate (2 x 5mL). The organic layers were dried over sodium sulfate, filtered and concentrated. The residue was subjected to preparatory-HPLC utilîzing a gradient of 30-90% acetonitrile in 5 mM aq HCl to give (2S,4R)-A[(6-fluoro-2-pyridyl)sulfonyl]-4-phenyl-I-[(2,4,6-trimethylphenyl)methyl]pyrroIidine-2carboxamide. ¹H NMR (400 MHz, DMSO)5 9.18 (s, 1 H), 8.16 (d, 7 = 7.8 Hz, 1H), 7.85 (d, 7 = 9.1 Hz, 1H), 7.30 (s, 7H), 6.88 (s, 2H), 4.40 (s, 2H), 4.24 (s, 1H), 3.81 (s, 1H), 3.33 - 3.21 (m, 2H),2.76(s, 1H), 2.37 (s,6H),2.21 (s, 3H), 2.00 (s, 1H).

Step 4: (2S,4Æ)-A-[(6-amino-2-pyrîdyl)sulfonyl]-4-phenyl-l-[(2,4,6trimethyIphenyl)niethy]]pyrrolidme-2-carboxamide

903

(2S,4R)-Æ-[(6-Fluoro-2-pyridyl)sul fa nyl]-4-phenyl-1 -[(2,4,6tri me thylphenyl)methyl]pyrrolidine-2-carboxamide (from step 3) was suspended in NFUOH (2 mL of 30 %w/v, 17 mmol). The mixture was heated in a microwave at 150 °C. The reaction mixture was concentrated, redissolved in DMSO and subjected to preparatory-HPLC utilizing a gradient of 1-60% acetonitrile in 5 mM aq HCl to give (2S,4R)-ZV-[(6-amino-2-pyridyl)sulfonyl]4-phenyI-l-[(2,4,6-trimethyIphenyl)methyl]pyrroIidine-2~carboxamide (Compound 236) (7.5 mg, 7% over two steps). ^[H NMR (400 MHz, MeOD) δ 7.84 (s, 1 H), 7.33 (s, 7H), 6.99 (d, J = 8.7 Hz, 1H), 6.90 (s, 2H), 4.60 (d, J = 35.7 Hz, 2H), 4.41 (s, 1H), 3.98 (s, 1H), 3.76 (s, 1H), 3.67 -3.55 (m, 1H), 2.90 (dt, J - 12.8,6.3 Hz, 1 H), 2.41 (d,J = 14.1 Hz, 7H), 2.24 (s, 4H). ESI-MS m/z cale. 478.2, found 479.0 (M+I)⁺; Rétention time: 1.41 min (3 min run).

(2R,4S)-N-[(6-amino-2-pyridyl)sulfonyl]-4-phenyl-l-[(2,4,6trimethylphenyl)methyl]pyrrolidine-2-carboxamide (Compound 467) and (2S,4S)-7V-[(6-amino-2-pyridyl)sulfonyl]-4-phenyi-l-[(2,4,6-trimethylphenyl)methyl]pyrrolidine2-carboxamide (Compound 870)

PREPARATION 46: Α-(4-Απιΐηο11)Ϊ2ζο1-2-γ1)5π1Γοηγ1-6-ί£7·/-ΒπΙγ1-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 265)

Step 1: ^ri-butyl thiazol-4-ylcarbamate

A mixture of thiazole-4-carboxyIic acid (8.16 g, 63.2 mmol) and triethylamine (9.7 mL, 70 mmol) in ferf-butanol (320 mL) was treated with diphenyl phosphoryl azide (15 mL, 70

904 mmol) and heated gradually in an oil bath to 100 °C and stirred for 17 h. Once cooled, the crude reaction mixture was concentrated under reduced pressure to remove most of the volatiles. The residue was transferred to a 1.0-L separatory funnel with ethyl acetate (300 mL) and the organic layer was washed with water (2 x 200 mL) and brine (2 x 100 mL). The organic layer was then 5 dried over anhydrous sodium sulfate, fdtered and concentrated under reduced pressure. The residue was purified silica gel chromatography, eluting from 0% to 50% ethyl acetate in heptanes. The résultant gummy solid was triturated with heptanes, filtered, washed with heptanes and dried under high vacuum to afford zm-butyl thiazol-4-ylcarbamate (3.42 g, 27%) as a white solid. Ή NMR (300 MHz, CDC1₃) δ 1.54 (s, 9 H), 7.30 (br. s, 1 H), 8.33 (br. s, 1 H), 10 8.58 (d, 7= 2.3 Hz, 1 H). [M-C₄H₈+H]⁺ = 145.1.

Step 2: tert-butylA^r-(2-sulfamoy]-l,3-thiazol-4-yI)carbaniate

NHBoc NHBoc

A solution of ieri-butyl thiazol-4-ylcarbamate (1.50 g, 7.49 mmol) in methyl ier/-butyl ether (35 mL) was cooled in an ice bath and treated slowly with iso-propylmagnesium chloride (11 mL of a 2.0 M solution in THF, 22 mmol). A voluminous white solid appeared. After 20 minutes in the ice bath, sulfur dioxide was gently bubbled into the reaction mixture for 5 minutes then the reaction mixture was stirred at room température for 1 h. The crude reaction mixture was concentrated under reduced pressure to remove most of the volatiles and the solid obtained was suspended in water (80 mL) and cooled in an ice bath. Sodium acetate (3.40 g, 41.5 mmol) and hydroxylamine-O-sulfonic acid (3.39 g. 30.0 mmol) were successîvely added. The ice-bath was removed and the reaction was left to stir at room température for 45 h. The reaction mixture was transferred to a separatory tunnel and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with 5% aqueous sodium bicarbonate (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting from 0% to 75% ethyl acetate in heptanes, to provide 1.2 g of a solid that was contaminated with isopropylsulfonamide. The solid was dissolved in methanol (3 mL) and water (2 mL) was added dropwise with stirring. The precipitate was filtered, washed with water and dried under high

905 vacuum to afford teri-butyl /V-(2-suIfamoyl-l,3-thiazol-4-yl)carbamate (0.90 g, 43%) as a white solid. 'H NMR (300 MHz, DMS0-7_s) δ 1.46 (s, 9 H), 7.56 (s, 2 H), 9.12 (s, 1 H), 9.24 (s, 1 H). [M-C₄H_s+H]⁺ = 224.0.

Step 3: 2V-[2-[[6-/er/-Butyl-2-(2_ï4,6-trimethy)phenoxy)pyrîdine-3 carbonyl]sulfamoyl]thiazol-4-yl]carbaniate

NHBoc

K₂CO₃ (45 mg, 0.35 mmol) was added to a mixture of 6-fer/-butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxylic acid (44 mg, 0.14 mmol), ierAbutyl N~(2sulfamoylthiazo!-4-y])carbamate (39 mg, 0.14 mmol), N-[(dimethylamino)-lH-l,2,3-triazolo[4,5-b]pyridin-l -ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (64 mg, 0.17 mmol) and N,M-dimethylformamide (1 mL) at room température. The mixture was stirred at 60 °C for 3 h before it was cooled to room température. The mixture was partitioned between ethyl acetate and IN HCI. The layers were separated and the aqueous layer was extracted with ethyl acetate (2x). The combined organics were washed with brine, dried over magnésium sulfate, filtered and concentrated. The residue was subjected to silica gel column chromatography (0-50% ethyl acetate/hexanes), then subjected to preparatory-HPLC(10-99% acetonitrile/water with 0.05 mM HCl) to give terf-buty] N-[2-[[6-ter/-butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carbonyl]sulfamoyl]thiazol-4-yl]carbamate as a white solid. ESIMS m/z cale. 574.2, found 575.4 (M+l)⁺; Rétention time: 2.48 min (3 min run).

Step 4: 7V-(4-Aminothiazol-2-yl)sulfonyI-6-icri>butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide

906

Trifluoroacetic acid (11 pL, 0.14 mmol) was added to a mixture of terr-butyl 7V-[2[[6-ierf-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carbonyl]sulfamoyl]thiazol-4-yl]carbamate (from step 3) and CH₂C1₂ (5 mL) at room température. The mixture was allowed to stir for 1H before it was concentrated under reduced pressure. The residue was subjected to preparatoryHPLC(10-99% acetonitrile/water with 0.05 mM HCl) to give W(4-aminothiazol-2-yi)sulfonyl-6rerr-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3 -carboxamide (Compound 265). ESI-MS m/z cale. 474.1, found 475.5 (M+l)⁺; Rétention time: 2.11 min (3 min run). ^!H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1 H), 9.07 (s, 1 H), 8.00 (d, J = 7.8 Hz, 1 H), 7.13 (d, J = 7.8 Hz, 1H), 6.91 (s, 2H), 6.81 (s, 2H), 2.25 (s, 3H), 1.96 (s, 6H), 1.04 (s, 9H).

The following compounds can be prepared using the procedures described herein:

N-(4-aminothiazol-2-yl)sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethyIpynOlidm-lyl)pyridine-3-carboxamide (Compound 842) and N-(4-aminothiazol-2-yl)sulfonyl-2-(4,4dimethyl-l-piperidyl )-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound

1168)

PREPARATION 47: jV-[(6-Ainino-2-pyridyl)su]fonyl]-6-(fi’rt-butylaniino)-2(2,4,6-trimethylphenoxy)pyridine-3-carboxainide (Compound 273)

Step 1: methyl 6-(/erAbiitylamino)-2-(niesityloxy)pyridine-3-carboxylate

907

A mixture of methyl 6-chloro-2-(mesityloxy)pyridine-3-carboxylate (170 mg, 0.58 mmol) and i-butylamine (4.0 mL, 38 mmol) in 500 mL dimethylacetamide was heated in a microwave at 150 °C for 4 h. The cru de mixture was purifie d by silica gel column chromatography eluting with a gradient of 0-40% ethyl acetate/hexanes to afford methyl 6-(terrbutylamino)-2-(mesityloxy)pyridine-3-carboxyIate (76 mg, 38% yieid) as an orange solid. LCMS:(M+H)⁺ = 342.5.

Step 2: 6-(Art-butylamino)-2-(mesityloxy)pyridine-3-carboxyIic acid

A mixture of methyl 6-(rert-butylammo)-2-(mesityIoxy)pyridine-3-carboxylate (76 mg, 0.22 mmol) and sodium hydroxide (14 mg, 0.34 mmol) in methanol (1.0 mL), THF (1.0 mL), and water (0.50 mL) was heated at 60 °C for 7 h. A few drops of concentrated HCl were added, solid formed, everything was rotary evaporated, and dried under vacuum to give crude 6(ieri-butylamino)-2-(mesityloxy)pyridine-3-carboxylic acid (98 mg) as a white solid. LC-MS: (M+H)⁺ = 329.3.

Step 3: 6-(/er/-butylamino)-2-(mesityloxy)-A-((6-nitropyridin-2yl)sulfonyl)nicotinamide

A mixture of crude 6-(im-butylammo)-2-(mesityloxy)pyridine-3-carboxylic acid (0.22 mmol), 6-nitropyridine-2-sulfonamide (58 mg, 0.29 mmol), A-[(dimethyIamino)-lH-l,2,3triazolo-[4,5-b]pyridin-l-ylmethylene]-A-methylmethanaminium hexafluorophosphate A-oxide

908 (0.12 g, 0.33 mmol), ethyldiisopropylamine (0.16 mL, 0.92 mmol) and X^-dimethylformamide (1 mL) was stirred in acapped vial at 70 °Cfor 6 h and then at room température for 18 h. LCMS at that point showed mostly the activated acid. An additional 70 mg of 6-nitropyridine-2sulfonamide and 0.080 mL of ethyldiisopropylamine were added. The mixture was stirred at 70 °C for 4 h and the crude was purified twice by silica gel column chromatography eluting with a gradient of 0-20% methanol/dichlorometliane to give 6-(^rt-butylamino)-2-(mesityloxy)-N-((6nitropyridin-2-yl)sulfonyl)nicotinamide (34 mg, 30% yield) as a light yellow solid. LC-MS: (M+H)⁺ = 514.5.

Step 4: 7V-[(6-amino-2-pyridyI)sulibnyl]-6-(terAbutylamino)-2-(2,4,6trïmethylphenoxy)pyridine-3-carboxamide

A mixture of 6-(r£rt-butylamino)-2-(mesityloxy)-N-((6-nitropyridin-2yl)sulfonyl)nicotinamide (34 mg, 0.064 mmol) and iron métal (48 mg, 0.86 mmol) in THF (0.7 mL), EtOH (0.35 mL), cône. HCl (0.06 mL) and water (0.06 mL) was heated at 60 °C for 50 min. The mixture was fîltered hot and was washed with methanol. The filtrate was rotary evaporated to give 120 mg of crude material which was purified by reverse phase HPLC to give N-[(6-amino-2-pyridyl)sulfonyl]-6-(tei-f-butylamino)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 273) (7.2 mg, 23%). LC-MS: (M-tH)⁺ = 484,5.

PREPARATION 48: 6-(ierAbutoxy)-2-(mesÎtyloxy)nicotinic acid

909

To a solution of t-butanol (0.70 mL, 7.3 mmol, 11 eq) in 1.0 mL of N,Ndimethylformamide was added portion-wise 60% NaH (320 mg, 8.0 mmol, 12 eq). After bubbling stopped, about 10 min, 6-chloro-2-(mesityloxy)pyridine-3-carboxylic acid 7 (0.20 g, 0.69 mmol, 1.0 eq) was added to the reaction mixture. The mixture was heated in a capped via! at 100 °C for 22 hr. After cooling to room température, a couple of drops of concentrated hydrochloric acid was added and the reaction mixture was evaporated to dryness. The cru de material was purified by column chromatography using 25 g of silica gel and eluting with a gradient of 0-30% methanol in dichlormethane over 15 minutes. The product-containing fractions were combined and concentrated to afford 6-teri-butoxy-2-(mesityloxy)pyridine-3carboxylic acid (109 mg, 48% yield) as a light yellow solid. LC-MS: (M+H)+ = 330.1.

2V-[(6-amino-2-pyridyl)suIfonyl]-6-(isopropylamino)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 650),

7/-[(6-amino-2-pyridyI)su!fonyl]-6-(2-methylpyrrolidin-l-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1553),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-pyrroIidin-l-yl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 746),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l-piperidyl)-2-(2,4,6-tiimethylphenoxy)pyridine-3carboxamide (Compound 785),

A^f-[(6-amino-2-pyridyl)sulfonyl]-6-morpholmo-2-(2_:4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 966),

A-[(6-amino-2-pyridyI)sulfonyl]-6-(methylamino)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 983), jV-[(6-amino-2-pyridy])suIfonyl]-6-(ethylamino)-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1128),

A'^,-[(6-amino-2-pyridyl)sulfonyl]-6-(dimethylamino )-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 1306),

910 jV-[(6-amino-2-pyrÎdyl)sulfonyl]-6-edioxy-2-(2,4,6-trimeÎhylphenoxy)pyridine-3-carboxamide (Compound 637),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-methoxy-2-(2_>4,6-trimethyiphenoxy)pyridme-3-carboxamide (Compound 806),

A^r-[(6-amino-2-pyridyl)sulfonyl]-8,8-dimethyl-2-(2,4,6-trimethylphenoxy)-5,7dihydropyrano[4,3-fe]pyridine-3-carboxamide (Compound 714),

2V-[(6-amino~2-pyridyl)sulfonyl]-6-[isobutyl(methyl)amino]-5-methyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1416),

AA[(6-amino-2-pyridyl)sulfonyl)-6-[(2R,5S)-2,5-dimethylpyrrolidin-l-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1494), ?7-[(6-amino-2-pyridyl)sulfonyl]-5-methyl-6-(2-methylpyrrolidin-l-yl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1516),

N-[(6-amino-2-pyridyl)sulfonyl]-5-fluoro-2,6-bÎs[(4S)-2,2,4-trimethylpyrrolidm-l-yI]pyridine-3carboxamide (Compound 1673),

N-[(6-amino-2-pyridyl)sulfonyl]-6-isopropoxy-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3carboxamide (Compound 1573),

N-[(6-amino-2-pyridyl)sulfonyl]-6~[(2R,5S)-2,5-dimethylpyrroIidin-l-yl]-5-methyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1589),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-isopropoxy-2-(2,4,6-Îrimethylphenoxy)pyridine-3carboxamide (Compound 968), and

2V-[(6-amino-2-pyridyl)sulfonyl]-6-feri-butoxy-2-(2,4,â-trimethylphenoxy)pyndine-3carboxamide (Compound 1070).

PREPARATION 49: A^r-[(6-amino-2-pyridyl)sulfonyl]-6-/eri-butyl-2-cyclopentylpyrïdine-3-carboxamide (Compound 1219)

Step 1: 6-(teri-Butyl)-2-(cyclohex-l-en-l-yl)-2V-((6-fliioropyridin-2yl)sulfonyl)nicotinamide

911

6-rert-butyl-2-chloroW-[(6-fluoro-2-pyridyl)sulfonyl]pyridine-3-carboxamide (75 mg, 0.20 mmol), 1-cyclohexenylboronic acid (25.41 mg, 0.2017 mmol), sodium carbonate (201.7 pL of2 M, 0.4034 mmol), dichloro[l,T-bis(diphenylphosphino)ferrocene]païladium (Π) dichloromethane adduct (7.376 mg, 0.01008 mmol) in dioxane (900.0 pL) were added to a microwave reactor vial. The vial was purged with nitrogen, capped and heated to 120 °C for 30 minutes in a microwave reactor. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 10 mL). The organic layers were dried over sodium sulfate, concentrated, and purified by HPLC utilizing a gradient of 0-70% acetonitrile in 5 mM aq HCl to give the product (19.7 mg, 23%) ESI-MS m/z cale. 417.5, found 418.4 (M+l)⁺; Rétention time: 0.64 min (1 min run),

Step 2: 6-(iert-butyl)-2-cyclohexylW-((6-fluoropyridjn-2-yl)sulfonyI)nicotinamîde

6-(rerr-Butyl)-2-(cyclohex-l-en-l-yl)-//-((6-fluoropyridin-2-yl)sulfonyl)nicotinamide (19.7 mg, 0.047 mmol) was dissolved in methanol (10 mL) and palladium on carbon (12.64 mg, 0.01188 mmol) was added. The mixture was stirred under a hydrogen balloon at room température for 16 hours. The cru de material was filtered, concentrated, and purified by HPLC utilizing a gradient of 20-80% acetonitrile in 5 mM aq HCl to give 6-(ierr-butyl)-2-cyclohexyL //-((ô-fluoropyridin^-yDsulfonyBnicotmamide.

The following compound can be synthesized using the procedures described herein: N- (4-aminophenyl)sulfony 1-6-ieri-butyl-2 -cyclopentyl-pyridine-3 -carboxamide (Compound 1003),

912

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(3,3,5,5tetramethylcyclopenten-l-yl)pyridine-3-carboxamide (Compound 1502),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[4(trifluoromethyi)cyclohexen-l -yl]pyridine-3-carboxamide (Compound 1667),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,6,6-tetrarnethyl-32Ypyran-4-yl)pyridine-3-carboxamide (Compound 1368),

N-[(6-amino-2-pyridyl)sulfonyl]-2-(4,4-dimethylcyclohexen-l-yl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 1493), and

N’-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,5,5-tetramethyl-3furyl)pyridine-3-carboxamide (Compound 1531).

Step 3: N-[(6-amino-2-pyridyl)sulfonyl]-6-ier/-butyl-2-cyclohexyl-pyridine-3carboxamide (Compound 411)

6-(/er/-butyl)-2-cyclohexyl-A^L((6-fIuoropyridin-2-yl)sulfonyl)nicoÎinamide was suspended in ammonium hydroxide (ImL of 28 %w/v, 8.56 mmol). The mixture was stirred in a microwave reactor for 0.5 h at 150 °C. The reaction mixture was concentrated, redissolved in DMSO and purified by HPLC utilizing a gradient of 10-65% acetonitrile in 5 mM aq HCl to give N-[(6-amino-2-pyridyl)sulfonyl]-6-terAbutyl-2-(cyclohexen-l-yi)pyridine-3-carboxamide 'H NMR (400 MHz, MeOD) S 8.56 (d, 7 = 8.4 Hz, 1H), 7.98 (d,J=8.4 Hz, lH),7.87(s, 1 H), 7.43 (d,7 = 7,2 Hz, 1 H), 7.03 (d, 7 =8.7 Hz, 1H), 6.08 (s, 1 H), 2.31 (s, 2H), 2.20 (s, 2H), 1.69 (d,7 = 17.3 Hz, 4H), 1.53 (s, 9H). ESI-MS m/z cale. 414.17255, found 415.0 (M+l)⁺; Rétention time: 1.48 minutes.

The following compound can be synthesized using the procedures described herein: N-[(6-amino-2-pyridyl)sulfonyl]-6-ierAbutyl-2-cyclopentyi-pyridme-3-carboxamide (Compound

913

1219).

PREPARATION 50: 6-terEbutyI-A-[(l-methyl-2-oxo-3-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 667)

6-tert-butyl-TV- [(2-oxo -lH-pyridin-3 -yl)sulfonyl]-2-(2,4,6-trime thylphenoxy)p yridine3-carboxamide (28 mg, 0.060 mmol) was dissolved in Ν,Ν-dimethylformamide with potassium carbonate (24.72 mg, 0.1789 mmol) and a solution of iodomethane (8.464 mg, 3.712 pL, 0.05963 mmol) was added dropwise. The solution was stirred for 4 h at room température. The reaction mixture was filtered and purified by LC/MS utilizing a gradient of 10-99% acetonitrile in 5 mM aq HCl to yield 6-terLbutyL7V-[(l-methyl-2-oxo-3-pyridyl)sulfonyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 667) (2 mg, 0.004 mmol, 7%) ESI-MS m/z cale. 483.1828, found 484.3 (M+l)⁺; Rétention time: 2.13 minutes.

PREPARATION 51: methyl 2-(mesityloxy)-6-(prop-l-yn-l-yl)nicotinate

Prop-l-yne (25.78 pL, 0.4543 mmol) was bubbled through a solution of MNdimethylformamide (2mL) and triethylamine (409.6 pL, 2.939 mmol) and then added to a mixture of methyl 6-chloro-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (150. mg, 0.491 mmol), dichloropalladium; triphenylphosphane (34.44 mg, 0.04907 mmol), copper (I) iodide (14.02 mg, 0.07362 mmol) and triphenyl phosphine (17.05 pL, 0.07359 mmol) in deoxygenated N.A-dimethylformamide (2 mL) under continous nitorgen flow. The resulting solution was

914 purged with propyne and capped. The reaction was then stirred at 105 °C for 16 hours. The cooled mixture was diluted with ethyl acetate and passed through a plug of celite, washing with ethyl acetate (10 mL). Water (7.5 mL) was added to the filtrate and the layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined organic extracts were washed with a saturated aqueous solution of sodium chloride (10 mL) and dried over sodium sulfate. After filtration the solvent was removed under reduced pressure to give a dark brown residue. The residue was purified by column chromatography on silica gel eluting 0-100 % ethyl acetate in hexanes to yield methyl 6-prop-l-ynyl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxylate (102.4 mg, 0.331 mmol, 72.9%) ESI-MS m/z cale. 309.1365, found 310.2 (M+ï)⁺; Rétention time: 0.76 minutes.

Préparation 52: AMiô-amino-Z-pyridyRsulfonyll-ô-IXtrifluoromethyllpyrazol-lyI]-2-(2,4,6-trimethy]phenoxy)pyridine-3-carboxamide (Compound 676)

N-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (30. mg, 0.067 mmol), 5-(tri fl uoro methyl)-1 H-pyrazole (27.41 mg, 0.2014 mmol), potassium carbonate (19.49 mg, 0.1410 mmol) and trans-diaminocyclohexane (1.534 mg, 1.613 pL, 0.01343 mmol) were combined in AW-dimethylformamide. At this point copper(I) iodide (0.6393 mg, 0.003357 mmol) was added and tire reaction was heated at 150 °C in the microwave for 2 hours. The reaction was fïltered and purified by LC/MS utilizing a gradient of 10-99% acetonitrile in 5 mM aq HCl to yield 7V-[(6-amino-2-pyridyl)sulfonyl]-6-[3(trifluoromethyl)pyrazol-l-yl]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 676)(8 mg, 0.01 mmol, 20%)’H NMR (400 MHz, DMSO-d₆) δ 12.54 (s, 1H), 8.32 (d, J= 8.1 Hz, 1 H), 7.85 (dd, 7 = 2.6, 1.1 Hz, 1H), 7.69 - 7.62 (m, 2H), 7.22 (dd, 7= 7.4, 0.8 Hz, 1H),6.99 (d, 7 =2.6 Hz, 1H),6.97 (s, 2H), 6.72 (d, 7 = 8.4 Hz, 1H), 6.56 (s, 2H), 2.28 (s, 3H), 2.03 (s, 6H). ESI-MS m/z cale. 546.1297, found 547.2 (M+l)⁺; Rétention time: 2.1 minutes.

915

The followîng compound can be synthesized using the procedures described herein:

N-[(6-amino-2-pyridyl)sulfonyl]-6-pyrazol-l-yl-2-(2,4,6-trimethylphenoxy)pyridine-3carboxamide (Compound 564),

Z/-[(6-amino-2-pyridyl)sulfonyl]-6-[5-methyl-3-(trifIuoromethy])pyrazol-l-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 633),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(trifluoromethyl)pyrazol-l-yl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 691), and

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methylpyrazol-l-yl)-2-(2,4,6-trimethylphenoxy)pyridine3-carboxamide (Compound 1220).

PREPARATION 53: methyl 2-(mesityloxy)-6-(l-methylcyclopropyI)nicotinate

In a microwave vial, trimethylsulfoxonium iodide (5.2 g, 23 mmol), was suspended in anhydrous DMSO (26 mL) under nitrogen. Sodium hydride 60% inoil (1.0 g, 26 mmol) was added and the resulting solution was left stirring 10 min. at room température. Methyl 6-(propl-en-2-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (2.6 g, 8.4 mmol) was added dissolved in anhydrous THF (8 mL) and left stirring at room température 18 hours. The reaction mixture was partîtioned between water (100 mL) and ethyl acetate (3 x 100 mL), separated, then the organic phase was concentrated under reduced pressure and the resulting residue was purifïed on silica gel using 0 to 10% ethyl acetate in heptane which provided the desired product methyl 6-(l-methylcyclopropyl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (1.59 g, 58% ) as a oil. ESI-MS m/z cale. 325.2, found 326.2 (M+J )⁺; ’H NMR (300 MHz, CDC1₃) ppm: 0.60 (m, 2 H), 0.84 (m, 2 H), 1.36 (s, 3 H), 2.01 (s, 6 H), 2.28 (s, 3 H), 3.92 (s, 3 H), 6.83 (s, 2 H), 6.96 (d, J = 7.9 Hz, 1 H), 8.16 (d, J =7.9 Hz, 1 H).

916

PREPARATION 54: ethyl 2-(mesityloxy)-6-(l-(trifiuoromethyI) cyclopropyl)nicotinate

Step 1: ethyl l-tmesityloxyl-ô-ia-OrifluoroniethyDAS-dihydro-Slï-pyrazol-Syl)nicotinate

( Préparation of a solution of diazomethane in ethyl ether: Mnitriso-W-methylurea(1.87 g, 15.8 mmol) was added to a biphasic mixture of 40% aqueous K OH (6.7 mL) and diethyl ether (20 mL) cooled in an ice-bath. The mixture was stirred in the ice-bath for 20 min (tums yellow), and then cooled in a dry-ice/acetone bath. Once the aqueous layer was frozen, the ether layer was decanted and the yellow solution was kept under nitrogen until ready to use.

The above solution of diazomethane (15.8 mmol) was added dropwise to a solution of ethyl 6-(3,3,3-trif]uoroprop-l-en-2-yl)-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (1.5 g, 3.95 mmol) in ethyl ether (20 mL) at 0 °C. The yellow colorof the diazomethane spontaneously disappeared upon addition. The réaction was stirred at 0 °C for 30 min, and TLC showed starting material was completely consumed. Acetic acid (1 mL) was added to quench excess the diazomethane until it turns colorless and bubbles évolution ceased. The mixture was then diluted with ethyl acetate (50 mL), washed with saturated aqueous sodium bicarbonate (20 mL), brine (20 mL), dried over anhydrous sodium sulfate and concentrated to give ethyl 2-(mesityloxy)-6(3-(trifluoiOmethyl)-4,5-dihydro-3iï-pyrazol-3-yl)nicotinate as a pale yellow oil (1.7 g). ’H NMR (300 MHz, CDC1₃) ppm, 1.40 (t, J = 6.9 Hz, 3 H), 1.68 - 1.92 (m, 2 H), 1.98 (br s, 6 H), 2.31 (s, 3 H), 3.90-4.10 (m, 1 H), 4.43 (q, J = 6.9 Hz, 2 H), 4.64 (ddd, J = 18.1,9.5,4.2 Hz, 1 H), 6.87 (s, 2 H), 7.57 (d, J = 7.8 Hz, 1 H), 8.31 (d, J = 7.8 Hz, 1 H). LCMS: [M+H]⁺=422.2.

917

Step 2: ethyl 2-(mesityloxy)-6-(l-(trifluoroniethyl)cyclopropyl)nicotinate

Ethyl 2-(mesityloxy)-6-(3-(trifluoromethyl)-4,5-dihydro-3/Apyrazol-3-yl)mcotinate (1.7 g, crude, 3.9 mmol) was dissolved in m-xylene (25 mL). The solution was gently refluxed for 2 hours. TLC shows reaction complété. The solvent was removed and the residue was purified by silica gel chromatography, eluting with a mixture of ethyl acetate and heptanes (010%), to afford 1.6 g, crude (quantitative yield).as an unseparable mixture (1:1) of ethyl 6-[l (trifluoromethyl)cyclopropyl]-2-(2,4,6-trimethyiphenoxy)pyridine-3-carboxylate, and ethyl 6-[1,1,1 -tri fl uorobut-2-en-2-yl]-2-(2,4,6-trimethylphenoxy)pyridine-3-cafooxylate (undefîned stereochemistry of the olefîn). In order to remove the alkene, the mixture of 6-[I(trifluorornethyl)cyclopropyl]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate and ethyl 6[(2Z or 2E)-1,1 ,l-trifluorobut-2-en-2-yl]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (1.5 g, 3.81 mmol, 1:1) was dissolved in fert-butanol (5 mL). Water (3 mL) was added foliowed by citric acid (549 mg, 2.86 mmol) and potassium osmium(VI) oxide dehydrate (1.4 mg). Finally, 4inethylmorpholme N-oxide monohydrate (568 mg, 4.2 mmol) was added. The mixture was stirred at room température ovemight. LCMS shows 50% conversion. Potassium osmium(VI) oxide dehydrate (1.4 mg) was added and the reaction was continued stirred until HPLC showed reaction was complété (approximately 40 hours). The reaction was concentrated to remove most of the ierz-butanol. The resulting aqueous mixture was diluted with ethyl acetate (60 mL) and washed with water (10 mL), brine (10 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting with a mixture of ethyl acetate and heptanes (0-10% then 50%), to afford ethyl 6-[l (trifluoromethyl)cyclopropyl]-2-(2,4,6-trimethylphenoxy)pyridme-3-carboxylate (600 mg, 40% ) as a white solid. ’H NMR (300 MHz, CDC1₃) ppm 0.96 - 1.05 (m, 2 H), 1.15 - 1.23 (m, 2 H), 1.39 (t, 7 = 7.2 Hz, 3 H), 2.01 (s, 6 H), 2.29 (s, 3 H), 4.41 (q,7 = 7.2 Hz, 2 H), 6.85 (s, 2 H), 7.25 (d, 7 = 8.2 Hz, 1 H), 8.21 (d, 7= 8.2 Hz, 1 H). LCMS: [M+H]⁺ = 394.0.

918

PREPARATION 55: ethyl 2-(mesityloxy)-6-(perfluoroethyl)nîcotinate

In a sealed tube, 3-(ethoxycarbonyl)-2-(mesityIoxy)pyridine 1-oxide (1.85 g, 6.14 mmol) was dissolved in anhydrous tetrahydrofuran (18.5 mL) with flame dried (under high vacuum) césium fluoride (93 mg, 0.05 mmol) then trimethyl(pentafluoroethyl)silane (3.53 g, 18.4 mmol) was added at 0 °C and the reaction mixture was stirred at room température under nitrogen for 5 days. Distilled water (10 mL) and ethyl acetate (50 mL) were added to the crude material. The organic phase was separated, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The resulting residue was purified on silica gel using 010% ethyl acetate in heptane to provide ethyl 6-(pentafluoroethyl)-2(2,4,6trimethylphenoxy)pyridine-3-carboxylate (480 mg, 25%) as an oil. [M + H]⁺ = 404.1 ’H NMR (300 MHz, CDC1₃) ppm: 1.41 (t, 7=7.1 Hz, 3 H), 2.03 (s, 6 H), 2.29 (s, 3 H), 4.45 (q,7 = 7.1 Hz, 2H), 6.87 (s, 2 H), 7.39 (d, 7 = 7.7 Hz, 1 H), 8.36 (d, 7 = 7.8Hz, 1 H).

PREPARATION 56: iert-butyl (4-suifamoylthiazol-2-yl)carbamate Step 1: lithium (ferAbutoxycarbonyl)(4-sulfinatothîazol-2-yl)amide

O

Methyllithium (0.70 mL, 1.6 M in diethyl ether, 1.1 mmol) was added to a solution of zerz-butyl N-(4-bromo-l ,3-thiazol-2-yl)carbamate (279 mg, 1.00 mmol) in anhydrous tetrahydrofuran (2 mL) and anhydrous diethyl ether (2 mL) at -78 °C. After 5 min, ferf-butyl lithium (1.2 mL, 1.7 M in pentane, 2 mmol) was added at -78 °C. A light yellow suspension was formed. After 20 min, sulfur dioxide (gas) was bubbled into the reaction at -78 °C for 5 min. A yellow clear solution was obtained, The reaction was allowed to slowly warm up to room température and stirred ovemight. The reaction mixture was concentrated to dryness and the

919 residue was triturated with diethyl ether (10 mL) to afford a light yellow solid (390 mg), which is a mixture of lithium (tert-butoxycarbonyl)(4-sulfmatothiazol-2-yl)amide and lithium bromide. [M+Na]⁺= 287.0.

Step 2: /eW-butyl (4-suIfamoylthiazol-2-yl)carbamate

O

Hydroxylamine-O-sulfonic acid (147 mg, 1.2 mmol) was added to a solution of lithium 2~{[(tert-butoxy)carbonyl]amino)-l,3-thiazole-4-sulfinate (330 mg, containing lithium bromide, 0.91 mmol) and sodium acetate(148 mg, 1.8 mmol) in water (4 mL) atO °C. The reaction was stirred at room température for 2 hours. Copious amounts of solids precipitated out. HPLC showed complété conversion, The mixture was stirred at 0 °C for 5 min. The solid was filtered off, washed with cold water (1 mL) and dried under high vacuum to afford terPbutyl N(4-carbamoyl-l ,3-thîazol-2-yl)carbamate (130 mg, 51%) as a white solid. ‘H NMR (300 MHz, DMSO-dâ) δ 1.49 (s, 9 H), 7,43 (s, 2 H), 7,67 (s, 1 H), 11,84 (br. s, 1 H). [M+Na]⁺= 302.0.

PREPARATION 57: terAbutyl ((6-sulfamoylpyridin-2-yl)methyl)carbamate

A solution of 6-cyanopyridine-2-sulfonamide (1.00 g, 5.46 mmol) in methanol (25 mL) and ammonia (5 mL of a 7.0 N solution in methanol, 35 mmol) was treated with a spatula of Raney-Nickel (2800, slurry in water), The flask was purged three times with hydrogen then left to stir at room température under one atmosphère of hydrogen for 18 hours. The crude reaction mixture was filtered over a pad of celite, washed with methanol, and concentrated under reduced pressure. The residue was taken up in dichloromethane (25 mL) and treated successively with triethylamine (1.52 mL, 10.9 mmol) and di-terAbutyl dicarbonate (1.55 g, 7.10 mmol). After about 1 hour, tetrahydrofuran (10 mL) was added in an attempt to help solubilize the reaction mixture. After another hour, the reaction was concentrated under reduced pressure, transie rred to

920 a 250-mL separatory tunnel with water (50 mL) and extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on 40g of silica gel utilizing a gradient from 50% to 100% ethyl acetate in heptanes to afford tm-butyl ((6sulfamoylpyridin-2-yl)methyl)carbamate (217 mg, 14%) as a white solid. *H NMR (300 MHz, Acetone-7₆) ppm L43 (s, 9 H), 4.43 (d, 7=6.0 Hz, 2 H), 6.48 - 6.77 (m, 3 H), 7.58 (d, 7 = 7.8 Hz, 1 H), 7.83 (d,7 = 7.8 Hz, 1 H), 7.97 - 8.10 (m, 1 H). [M+Na]⁺= 310.1.

PREPARATION 58: A-(2-aminothiazol-5-yI)sulfonyl-6-ieri-butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1148)

In a 4mL vial a solution of A-(2-acetamidofhiazoI-5-yI)sulfonyl-6-ie7-f-butyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (14.6 mg, 0.0269 mmol) and aqueous hydrochloric acid (268.5 pL of4 M, 1.074 mmol) in dioxane (277.4 pL) was stirred at 90 °C for 1 hour. The reaction mixture was cooled and purified directly b y re verse-phase préparative chromatography utilizing a C18 column and a gradient of 30-99 acetonitrile in water containing 5 mM hydrochloric acid to afford A-(2-aminothiazol-5-yl)sulfonyl-6-Zeri-biityl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1148) (5.9 mg, 0.012 mmol, 45%) as a white solid. ^!H NMR (400 MHz, DMSO) S 12.10 (s, 1H), 8.02 (s, 2H), 7.95 (d, 7 = 7.8 Hz, 1H), 7.67 (s, 1H), 7.12 (d,7= 7.8 Hz, I H), 6.90 (s, 2H), 2.25 (s, 3H), 1.97 (s, 7H), 1.04 (s, 10H). ESIMS m/z cale. 474.1, found 475.2 (M+l)⁺; Rétention time: 2.11 minutes.

PREPARATION 59: 6-(to Lbutyl)-2-(mesityloxy)-4-methoxy-A-((3nitroplienyl)sulfonyl)nicotinamide

921

In a 10 mL microwave vessel was added 6-ierr-butyl-?/-(3-nitrophenyl)sulfonyl-2(2,4,6-trin'ethylphenoxy)pyridine-3-carboxamide (85 mg, 0.17 mmol) dissolved in anhydrous metbanol (684.1 mg, 864.9 pL, 21.35 mmol) and xylene (850.0 pL) and to it was added diacetoxypalladium (3.835 mg, 0.01708 mmol), (diacetoxyiodo)benzene (165.0 mg, 0.5124 mmol), and 4 Angstrom molecular sieves. The mixture was heated in an oil bath to 100 °C for 18 hours. A second aliquot of diacetoxypalladium (3.835 mg, 0.01708 mmol) was added and the réaction mixture heated in an oil bath to 100 °C for an additional 48 hours. The mixture was allowed to cool and the mixture was filtered and the resulting solution was purified by reversephase préparative chromatography utilizing a Cl8 column and a gradient of 30-99 acetonitrile in water containing 5 mM hydrochloric acid to afford 6-Mri-butyl-4-methoxy-?/-(3mtrophenyl)sulfonyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (20.7 mg, 0.0388 mmol, 23%). ’H NMR (400 MHz, DMSO) δ 12.89 (s, 1 H), 8.61 (t, J = 2.0 Hz, 1H), 8.49 (d,J = 8.2 Hz, 1H), 8.36 (d, J = 8.1 Hz, 1 H), 7.92 (t, J =8.1 Hz, IH), 6.82 (s, 2H), 6.72 (s, IH), 3.84 (s, 3H), 2.22 (s,3H), 1.86 (s, 6H), 1.03 (s, 10H). ESI-MS m/z cale. 527.1726, found 528.2 (M+l)⁺; Rétention time: 2.2 minutes.

PREPARATION 60: 2-chloro-8,8-dimethyl-7,8-dihydro-5H-pyrano[4^Z»]pyridine-3-carbonitrile

S te p 1: 5 -(hy dr oxy methy lene)-3,3 -dimethyltetr ahy d ro -4//-py ran-4 -one ⁰ ?

ΗΟ^γγ·'

To a solution of 3,3-dimethyltetrahydropyran-4-one (1.8 g, 14 mmol) in ether (50 mL) was added ethyl formate (1.040 g, 1.134 mL, 14.04 mmol). The mixture was cooled to 0 °C. Sodium ethoxide (1.051 g, 15.44 mmol) was added at 0 °C. The mixture was allowed to warm to

922 room température, stirred overngiht and then evaporated to dry nés s, The crude material was used directly in next step without further purification.

Step 2: 2-hydrûxy-8,8-diinethyI-7,8-dihydro-5H-pyrano[4,3-ft]pyridine-3 carbonitrile

To a suspension of 5-(hydroxymethylene)-3,3-dimethyl-tetrahydropyran-4-one (2.2 g, 14 mmol) in pyridine (100 mL) was added 2-cyanoacetamide (1.177 g, 14.00 mmol). The mixture was heated at reflux ovemight. The reaction mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted thee times with ethyl acetate, and then three times with a 2:1 mixture of dichloromethane and isopropanol. The combined organic layers were washed with brine, dried over magnésium sulfate, filtered, and evaporated to dryness. The residue was washed with methanol to yield the product (205 mg, 1.00 mmol,7.l%). 'H NMR (400 MHz, Chlorofonn-iï) 4 7.55 (s, 1H), 4.54 (s, 2H), 3.61 (s, 2H), 3.49 (s, 1H), 1.42 (s, 6H).

Step 3: 2-cMoro-8,8-dimethyl-7,8-dihydro-5/f-pyrano[4,3-Z>]pyridine-3carbonitrile

A mixture of 2-hydroxy-8,8-dimethyl-7,8-dihydro-5#-pyrano[4,3-i>]pyridine-3carbonitrile (240. mg, 1.17 mmol) in phosphorous oxychloride (2.5 mL, 26.82 mmol) was heated to 105 °C for 6 hours, The reaction mixture was evaporated to dryness. The residue was added dropwise to water, and then extracted three times with ethyl acetate. The combined organic layers were washed with brine, dried over magnésium sulfate, filtered, and concentrated to dryness. The crade material was purified by silica gel column chromatography (0-10% ethyl acetate in hexanes) to provide 2-chloro-8,8-dimethyl-7,8-dihydro-5H^f-pyrano[4,3-&]pyridine-3

923 carbonitrile (240. mg, 1.08 mmol, 92.3%) as a yellow solid. 'H NMR (400 MHz, Chlorofonn-d) <5 7.57 (s, 1H), 4.78 (d, J = 0.9 Hz, 2H), 3.71 (s, 2H), 1.33 (s, 6H).

PREPARATION 61: 6-(AH-biityl)-2-(mesityloxy)A nitrophenylsulfonimidoyDnicotînamide

OO 0

To a solution of rac-6-rerrbutyl-A-(3-nitrobenzenesulfinyl)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (253 mg, 0.525 mmol) in acetonitrile (4.1 mL) was added A-chlorosuccinimide (217 mg, 1.63 mmol) at 0 °C. The mixture was then stirred at room température until no more starting material was left (about 1 hour). Methylamine (0.79 mL of a 2.0 M solution in THF, 1.6 mmol) was added to the reaction at 0 °C and the mixture was stirred for 1 hour at room température and then quenched by the addition of water (3 mL). The mixture was extracted with ethyl acetate (2x10 mL), the organic layers were combined, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified on 25 g of silica gel utilizing a gradient of 0% to 45% ethyl acetate in heptanes to afford 6-(terLbutyl)2-(mesityloxy)-A-(A-metbyl-3-nitrophenylsuIfonimidoyl)nicotinamide (170 mg, 63% yield) as a white solid. 'H NMR (300 MHz, CDC1₃) ppm 1.06 (s, 9 H), 2.02 (s, 6 H), 2.28 (s, 3 H), 2.78 (s, 3 H), 6.83 (s, 2 H), 6.91 (d, J = 7.8 Hz, 1 H), 7.74 (t, 7=8.0 Hz, 1 H), 8.24 (d, 7 = 8.0 Hz, 1 H), 8.38 (d, 7 = 8.3 Hz, 1 H), 8.45 (d, J = 7.7 Hz, 1 H), 8.83 - 8.87 (m, 1 H). [M+H]⁺ = 511.1.

| PREPARATION 62: A-[(6-amino-2-pyridyl)sulfonyl]'6'(5-metlioxy-2-methyl2-(2,2,4’trimethylpyrrolidin-l-yI)pyridine-3'Carboxamide (Compound 470)

Step 1: A-((6-aminopyridin-2-yl)sulfonyl)-2,6-dichloronicotinamide

924

2,6-dichloro-pyridine-3-carboxylic acid (20.2 g, 105 mmol) was dissolved in N.Ndimethylformamide (200 mL) and stirred under nitrogen and CDI (25.5 g, 158 mmol) was added in one portion. The reaction was warmed to 65 °C and heated for 1 h. In a separate vessel, 6aminopyridine-2-sulfonamide (18.2 g, 105 mmol) was dissolved in AV-dimethylformamide (100 mL) under nitrogen and NaH (4.40 g, 60%, 110 mmol) was added in portions to mitigate gas évolution and the reaction was stirred for 1 h. The two reactions were combined in one portion at 65 °C. The reaction was stirred for 30 min and evaporated to remove most of N,Ndimethylformamide. The residue was poured over ice and made acidic (pH=~3) by the addition of 6M HCl. Solid was collected by filtration and washed with water (100 mL) and methanol (30 mL) and combined to the following crude material after dried. The filtrate and washing were combined and extracted with ethyl acetate (3 x 500 mL). The organics were washed once with brine (500 mL), dried over sodium sulfate and evaporated. The crude material was suspended in a mixture solvent of dichloromethane/ethyl acetate/methanol (30/30/30 mL), the suspension sonicated for 30 min, and filtered. The solid washed with ether (2 x 150 mL) and dried to give 19.8 g white solid (54%). The filtrate was further concentrated to afford 6.0 g (16%) of product. LCMS: 347 [M+H]+; ^!H NMR (DMSO-7₆, 250 MHz): 8.11 (d, J = 7.5 Hz, 1H), 7.80-7.55 (m, 2H),7.19 (d, J = 7.2 Hz, 1H),6.75 (d,J = 8.5 Hz, 1H),6.71 (s, 2H) ppm

Step 2: tV-((6-aminopyridin-2-yl)sulfonyl)-6-chlorû-2-(2,2,4-trimethylpyrrolidinl-yl)nicotinamide

O

ÎV-[(6-amino-2-pyridyl)sulfonyl]-2,6-dichloro-pyridine-3-carboxamide (1.02 g, 2.94 mmol), 2,2,4-trimethylpyrrolidine (Hydrochloric Acid (1)) (1.319 g, 8.814 mmol), and potassium carbonate (2.030 g, 14.69 mmol) were combined in dimethylsulfoxide (8.160 mL) and heated at 100 °C for 16 h. The reaction was diluted with water and the pH was adjusted to 7. The aqueous mixture was extracted with ethyl acetate (3 x 100 mL). The organics were combined, washed with brine, dried over sodium sulfate and evaporated. The crude material was purified by silica gel chromatography eluting with 0-100% ethyl acetate in hexanes to yield 7V-[(6-amino-2

925 pyridyl)sulfonyl]-6-chlorO“2-(2,2,4-trimethylpyrrolidin-I-yl)pyridjne-3-carboxamide (700. mg, 1.65 mmol, 56.2%) ESI-MS m/z cale. 423.1132, found 424.2 (M+l)⁺; Rétention time: 0.63 minutes.

Step 3:

N-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (42 mg, 0.10 mmol), (5-methoxy-2-methyl-phenyl)boronic acid (25 mg, 0.15 mmol), tetrakis(triphenylphosphine)palladium (0) (11 mg, 0.010 mmol), and 2M aqueous potassium carbonate (0.2 mL, 4 mmol) were combined in ^ZV-dimethylformamide (1 mL) and irradiated in the micro wave reactor for 20 min at 120 °C. The reaction was filtered and purified by LC/MS utilizing a gradient of 10-99% acetonitrile in 5 mM aq HCI to yield ^-[(ô-amino^pyridyl)sulfonyl]-6-(5-methoxy-2-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 470) as a hydrochloric acid sait (12 mg, 0.022 mmol, 22%). ESI-MS m/z cale. 509.21, found 510.5 (M+l)⁺; Rétention time: 1.42 minutes.

The following compound can be synthesized using the procedures described herein: A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(o-toIyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyrÎdîne-3carboxamide (Compound 761),

N-(benzenesulfonyl)-6-(3-fluoro-5-hydroxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1538),

N-[(6-amino-2-pyridyl)sulfonyI]-6-cyclo_PropyL2-[(4S)-2,2,4-trimethylpyiTolidm-l-yl]pyridine3-carboxamide (Compound 1627),

N-[(6-amino-2-pyndyl)sulfonyl]-6-(3-fluoro-5-hydroxy-phenyl)-2-[(4S)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1636) /V-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropyIphenyl)-2-[(4S)-2,2,4-trimethylpyrn>lidin-lyl]pyridine-3-carboxamide (Compound 630),

926

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-isopropyIphenyl)-2-[(4R)-2,2,4-triniethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 890),

N-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 852), /V-[(6-amino-2-pyridyl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrrolidm-l-yl]pyridine-3-carboxainide (Compound 946),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2,4-diniethylphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridi ne-3-carboxamide (Compound 614),

Zeri-butyl 5-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-[(4S)-2,2,4-trimethylpyrrolidin-1 -yl]2-pyridyl]-3,6-dihydro-2//-pyridine-1 -carboxylate (Compound 1371),

N-[(6-amino-2-pyridyl)sulfbnyl]-3-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-5-(6-isopropoxy-3pyridyl)pyrazine-2-carboxamide (Compound 1651),

A'-[(6-amino-2-pyridyl)sulfonyl]-5-(3-fluoro-5-isobutoxy-phenyl)-3-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyrazine-2-carboxamide (Compound 1526), jV-[(6-ammo-2-pyridyl)sulfonyl]-6-norboman-2-yl-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1378),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-isopropenyl-2-[(4S)-2,2,4-trimethylpyiTolidin-l-yl]pyridine3-carboxamide (Compound 1423),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(6,6-dimethyl-2,3-dihydropyran-4-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1369),

N-[(6-ammo-2-pyridyl)suïfonyl]-6-(3,4-dihydro-2H-pyran-6-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1438), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(2,3-dihydrofuran-4-yI)-2-[(4S)-2₎2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 1455),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-(l,2-dimethylpropyl)-2-[(4S)-2,2,4-trimethylpyiTolidm-lyl]pyridine-3-carboxamide (Compound 1489),

927

N-[(6-amino-2-pyndyl)sulfonyl]-6-tetrahydropyran-2-yl-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 1500),

N-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-6-Îetrahydropyran-2-yl-2-[(4S)-2,2,4-trimethylpyrrolidin-l yl]pyridine-3-carboxamide (Compound 1503),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(l,2-dimetbylprop-l-enyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-y]]pyridine-3-carboxamide (Compound 1510),

Λ⁷-[(6-amino-2-pyridyl)sulfony 1)-6-(3,4-dîhydro-2H-pyran-5-yl)-2-[ (43)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1524),

7/-[(6-amino-2-pyridyl)sulfonyl]-6-tetrahydrofuran-3-yl-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1534), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-tetrahydropyran-3-yl-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1632),

6-(l-acetyl-4-piperidyl)-7V^,-[(6-amino-2-pyridyl)sulfonyl]-2-[(4S)-2,2,4-trimeÜiylpyrrolidin-lyljpyridine-3-carboxamide (Compound 1634) (Compound 946),

N- [(6-amino-2-pyridyl)sulfonyl]-6-[4-(trifluoromethyl)cyclohexen-l-yl]-2-[(43)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1664),

A^r-[(6-amino-2-pyridyl)sulfonyl)-6-(2-cycIopropylethyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1677),

Λ⁷-[(6-amino-2-pyridyl)sulfony 1)-6-(4-(tri fluoromethyl)cyclohexyl)-2-[(43)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1672),

N-[(6-amino-2-pyridyi)sulfonyl]-6-(2-hydroxy-5,5-dimethyl-cyclohexyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1439),

N- [(6-amino-2-pyridyl)sulfony 1)-6-(3,3 -dimethyl -6-oxo-cy cl ohexen-l-yl)-2- [(43)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1462),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-isopropyl-2-[(4S)-2,2,4-trimethy]pyrrolidin-l-yl]pyridine-3carboxamide (Compound 1505),

928

Ari[(6-amino-2-pyridyl)sulfonyll-6-ethyl-2-[(4S)-2,2,4-trimethylpyr^ carboxamide (Compound 1507),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3,6-dihydro-2H-pyran-4-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1594),

N-[(6-amino-2-pyridyl)sulfonyi]-6-tetrahydropyran-4-yl-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1595),

N-[(6-amino-2-pyridyl)sulfonyl]-6-isobutyl-2-[(4S)-2,2,4-trimethylpyiToiidin-Lyl]pyridme-3carboxamide (Compound 1599), p?ri-butyl 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]2-pyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate (Compound 1624), _JV-[(6-amino-2-pyndyl)sulfonyI]-6-(2-methylprop-l-enyl)-2-[(4S)-2,2,4-Îrimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1683), rerAbutyl4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-[(4S)-2,2,4-trimethylpyrrolidm-l-yl]2-pyridyl]-2,3-dihydropyrrole-l-carboxylate (Compound 1684), jV-[(6-amino-2-pyridyl)suIfonyl]-6-(4-fluoro-2-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 822),

AA[(6-amino-2-pyridyl)sulfonyl]-6-phenyl-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 1334),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-fluorophenyl)-2-(2,2,4-Îrimethylpyrro]idin-l-yl)pyridine3-carboxamide (Compound 712),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-5-fluoro-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1099),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(p-to]yl)-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 456),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-(2,2,4-trimethylpynolidin-lyl)pyridine-3-carboxamide (Compound 695),

929

W-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluoro-5-isobutoxy-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1194),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-chloro-3-propoxy-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 644),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(2,2,4-trimethylpynOlidinl-yl)pyridine~3-carboxamide (Compound 1021),

W[(6-amino-2-pyridy])su!fonyl]-6-(4-isobutoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 440),

A4(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(2,2,4-ÎrimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 693),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-cliIoro-3-isopropoxy-phenyl)-2-(2,2,4-trimethylpynOlidinl-yl)pyridine-3-carboxamide (Compound 504),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isopropoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1020),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1100),

N-[(6-amÎno-2-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-(4-methyl-l-piperidyl)pyridine-3carboxamide (Compound 847),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluoro-5-isobutoxy-phenyl)-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 1109),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxyphenyl)-2-(4-methyl-l-piperidyl)pyridine-3carboxamide (Compound 1094),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyl)-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 1266), jV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-propoxy-phenyl)-2-(4-methyl-lpiperidyl)pyridine-3-carboxamide (Compound 692),

930

N-[(6-amino-2-pyridyl)sulfbnyi]-6-(3-isobutoxyphenyl)-2-(4-metliyI-l-piperidyl)pyridine-3carboxamide (Compound 777),

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-phenyl-pyridine-3carboxamide (Compound 805),

A^r-[(6-amino-2-pyrjdy])sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(4fluorophenyl)pyridine-3-carboxamide (Compound 1029),

7/-[(6-ammo-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(4methoxyphenyl)pyridine-3-carboxamide (Compound 1215),

N-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5S)-2,5-dimethyIpyiTolidin-l-y]]-6-(3-ethoxy-5-fluorophenyl)pyridine-3-carboxamide (Compound 551),

N-[(6-amino-2-pyridy])sulfonyl]-6-(4-cblorophenyl)-2-[(2S,5R)-2,5-dimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 459),

W-[(6-amino-2-pyridyI)sulfonyl]-6-(4-chloro-3-isobutoxy-phenyI)-2-[(2S,5R)-2,5dimethylpynOlidm-l-y]]pyridme-3-carboxamide (Compound 1197),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(4isobutoxyphenyl)pyridine-3 -carboxamide (Compound 563),

Y-[(6-amino-2-pyridyl)suIfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-(4isopropylphenyi)pyridine-3-carboxamide (Compound 1343),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-isopropoxy-phenyl)-2-[(2S,5R)-2,5dimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (Compound 788),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-propoxy-phenyl)-2-[(2R,5S)-2,5dimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 773),

M[(6-ammo-2-pyridyl)sulfbnyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l-y]]-6-(2-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 807),

N-[(6-ammo-2-pyridyl)suIfonyl]-2-[(2S,5R)-2,5-dimethyIpyriOlidin-l-yl]-6-(3isobutoxyphenyl)pyridine-3-carboxamide (Compound 957),

93] /V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(6-methoxy-2pyridyl)pyriâine-3-carboxamide (Compound 1141),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5S)-2,5-dimethylpyrrolidin-l -yl]-6-(p-tolyl)pyridine-3carboxamide (Compound 1078),

A^r-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(4-fluoro-3-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -y l]pyrîdine-3-carboxamide (Compound 2472),

N-[(3S)-3-aminopyrrolidin-l-yl]sulfonyI-6-(3-fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2587),

N-[(3S)-3-aminopyrrolidin-l-yl]sulfonyI-6-(2-fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1967),

V‘[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(3-fluoro-2-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2199),

À^r-[(3S)-3-aminopyiTolidin-l-yl]sulfonyl-6-(m-tolyl)-2-[(4S)-2,2,4-trimeÎhylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2339),

N-[(3S)-3-aminopynOlidm-l-yl]sLilfony]-6-(3-fluoro-5-methyl-phenyI)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1819),

V-[(3S)-3-aminopyrrolidm-l-yI]sulfonyl-6-(2-fluoro-5-methyl-phenyI)-2-[(4S)-2,2,4trimethylpyrrolidin-I -yl]pyridme-3-carboxamide (Compound 2016),

A^r-[(3S)-3-aminopyrrolidin-I-yl]suIfonyl-6-(2-methoxyphenyl)-2-[(4S)-2,2,4tnmetlrylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2666), iV-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(3-methoxyphenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2240),

A^r-[(3S)-3-aminopyn-olidin-l-yl]sulfonyl-6-(3,4-difluorophenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2229),

N-[(3S)-3-aminopyrrolidin-l -yl]sulfonyl-6-(4-methoxyphenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2327),

932

TV-[(3S)-3-aminopyrrolidin-l -yl]suIfbnyl-6-(2,4-difluorophenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1947),

A^r-[(3S)-3-aminopyrrolidm-l-yI]sulfonyl-6-(2-ethoxyphenyl)-2-[(4S)-2,2,4-trimethyIpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2050),

7/-[(3S)-3-ammopyrrolidm-l-yl]sulfonyl-6-(2,3-difluorophenyl)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2110),

7V-[(3S)-3-aminopyrrolidm-l-yl]sulfonyl-6-(3-ethoxyphenyl)-2-[(4S)-2,2,4-trimethyIpynOlidinl-yl]pyridine-3-carboxamide (Compound 2570),

7V-[(3S)-3-aminopyiTOlidm-l-yl]sulfonyl-6-(3,5-difluorophenyl)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridme-3-carboxamide (Compound 1716), jV-[(3S)-3-aminopyrroIidm-l-yl]sulfonyl-6-(4-ethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin1 -yl]pyridine-3-carboxamide (Compound 2525),

7V-[(3S)-3-aminopynOlidin-l-yl]sulfonyl-6-{2,5-difluorophe[iyI)-2-[(4S)-2,2,4trimethylpyrrolidm-1 -yl]pyridine-3-carboxamide (Compound 2489),

7V-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(2-isopropoxyphenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1897),

N-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(3-isopropoxyphenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2156),

7V-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(4-isopropoxyphenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2120),

N-[(3S)-3-aminopyrrolidin-l-yl]sulfbnyl-6-[2-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4tri me thylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2070), /V-[(3S)-3-aminopyrroIidin-l-yl]sulfonyl-6-phenyl-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 1725), /V-[(3S)-3-aminopyrroIidin-l-yl]sulfonyl-6-[3-(trifluorometlioxy)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2029),

933

AH(3S)-3-aminopyrrolidin-l -y]]sulfonyl-6-(2-fluorophenyl)-2-[(4S)-2,2,4-trinietliylpyiTOlidÎii-lyl]pyridine-3-carboxamide (Compound 2045),

N-[(3S)-3-aminopynOlidin-l-yl]sulfony]-6-[4-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4trimethylpyiTolidin-1-yl]pyridine-3-carboxamide (Compound 1763),

A^,-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(3-fluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2414), ïV-[(3S)-3-aminopynroIidin-l-yl]sulfbnyl-6-[3(trifluoromethyl)phenyl]-2-[(4S)-2,2₎4trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2220),

A^r-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-[4-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1900), /V-[(3S)-3-aminopynolîdin-l-yl]sulfonyl-6-(3,5-dimethylphenyl)-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1839),

7V-[(3S)-3-ammopyrrolidin-l-yl]sulfonyl-6-(3,4-dimethylphenyl)-2-[(4S)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 2605), /V-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(2,3-dimethylphenyi)-2-[(4S)-2,2,4trimethylpyrrolidin-l -yljpyridîne-3-carboxamide (Compound 2225),

7V-[(3S)-3-aminopyiTolidin-l-yl]sulfonyl-6-(2,5-dimethylphenyl)-2-[(4S)-2,2,4trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1736), (V-[(3S)-3-aminopyrrolidin-l-yl]sulfonyl-6-(5-fluoro-2-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2490),

2-[(2R,5S)-2,5-dimethylpyrrolidin-l -yl]-6-(3-ethoxy-5-fluoro-phenyl)-A^r-(lH-pyrazol-5ylsulfonyl)pyridme-3-carboxamide (Compound 382),

2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-isobutoxyphenyl)-/'/-(lH-pyrazol-5ylsulfony!)pyridine-3-carboxamide (Compound 710),

2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(2-fluoro-5-isobutoxy-phenyl)-A^r-(lH-pyrazol-5ylsuIfonyl)pyridîne-3-carboxamide (Compound 681),

934

6-(4-chloro-3-propoxy-phenyl)-2-[(2R_:5S)-2,5-dimethylpyrrolidin-l-yl]-4/-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 832),

6-(4-chloro-3-isobutoxy-phenyl)-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-A^r-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1234),

2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-(6-methoxy-2-pyridyl)-77-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1236),

6-(4-chloro-3-isopropoxy-phenyI)-2-[(2S,5R)-2,5-dimethylpyrro]idin-l-yl]-77-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 701),

2-[(2S,5 R)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5-isopropoxy-phenyl)-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1285),

2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(4-isobutoxyphenyl)-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 1335),

2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-(4-isopropylphenyl)-N-(lH-pyrazol-5ylsulfonyl)pyridine-3-carboxamide (Compound 414), /V-[(6-ammo-2-pyridyI)sulfbnyl]-6-(3-fluoro-5-isobutoxy-phenyl)-5-methyl-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1269), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-5-methyl-2-(2,2,4trimethylpynOlidin-l-yl)pyridine-3-caiboxamide (Compound 995),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxyphenyl)-5-methyl-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 455),

AT-[(6-amino-2-pyridyl)sulfonyl]-6-(3-methoxyphenyl)-5-methyl-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 833),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(4-fluorophenyl)-5-methyl-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 763),

A^r-[(6-amino-2-pyridyl)suIfonyl]-2-[(2R,5S)-2,5-dimethylpyrrolidin-l-yl]-6-(3-fluoro-5isobutoxy-phenyl)-5-methyl-pyridine-3-carboxamide (Compound 483),

935

A^f-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5S)-2,5-dimethylpynOlidin-l-yi]-6-(6-isopropoxy-3pyridyl)-5-methyl-pyridine-3-carboxamide (Compound 486),

N- [(6-ammo-2-pyridyl)sulfonyl]-6-(5-methoxy-2-methyl-phenyl)-5-methyl-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1287), ?7-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidm-l-yl]-6-(3-fluoro-5isobutoxy-phenyî)-4-methoxy-pyridine-3-carboxamide (Compound 1254), iV-[(6-amino-2-pyridyl)sulfonyl]-6-(4-pyridyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 643),

A^r-[(6-amino-2-pyridyl)sulfony]]-6-(6-isopropyl-3-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 896), ?/-[(6-amino-2-pyridyl)su]fonyl]-6-(2-isopropyl-4-pyridyl)-2-(2,2,4-triniethylpyrrolidm-lyl)pyrîdine-3-carboxamide (Compound 1262),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(l-isopropylpyrazol-4-yI)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1067),

7V-[(6-amino-2-pyridyl)sulfbnyl]-6-(l-isobutylpyrazol-4-yl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 631),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropylpyrazol-3-yl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1242),

N-[(6-ammo-2-pyridyl)sulfony]]-6-[2-[isobutyl(methyi)ammo]-4-pyridyl]-2-(2,2,4trimethyIpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 898),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxypyrazin-2-yl)-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 1252),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(5-isopropoxypyrazin-2-yl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 965)

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropoxypyrimidin-5-yl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 844),

936

A-[(6-amino-2-pyridyl)sulfonyl]-6-(64sobutoxy-2-methyl-3-pyridyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 616),

A-[(6-amino-2-pyridyI)sulfonyl]-6-[3-fluoro-5-(2-hydroxy-2-niethyl-propoxy)phenyl]-2-[(4S)2,2,4-trimethylpyirolidm-l-yl]pyridine-3-carboxamide (Compound 1424),

A-(benzenesulfbnyl)-6-[3-fluoro-5-(3-hydroxy-2-methyl-propoxy)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1515),

7y-[(6-ammo-2-pyridyl)sulfbnyl]-6-[3-fluoro-5-(3-hydroxy-2-methyI-propoxy)phenyl]-2-[(4S)2,2,4-trimethylpyrrolidm-l-yI]pyridine-3-carboxamide (Compound 1567),

A-(benzenesulfonyl)-6-[3-fluoiO-5-(2-hydroxy-2-methyl-propoxy)phenyl]-2-[(4S)-2,2,410 trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1581),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimeÎhylpynOlidin-l-yl]-6-(5-isopropoxy-3pyridyl)pyridine-3-carboxamide (Compound 400),

A-[(6-amino-2-pyridyl)sulfonyI]-6-[5-(cyclopentoxy)-3-pyridyl]-2-[(2S,5R)-2,5dimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 495),

A-[(6-ammo-2-pyridyI)sulfonyl]-6-(2-meihoxy-3-pyridyl)-2-(2,2,4-trimethylpyrrolidin-l yl)pyridine-3-carboxamide (Compound 526),

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-â-(5-isobutoxy-3pyridyl)pyridine-3-carboxamide (Compound 1224),,

A-[(6-amino-2-pyridyl)sulfonyl]-6-[(E)-2-cydopropylvinyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l20 yl]pyridine-3-carboxamide (Compound 1379),

A-[(2-ammo-3-pyridyl)sulfonyl]-6-(2,3-difluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2291),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-ethoxyphenyl)-2-[(4S)-2,2,4-trimethylpynoHdm-lyl]pyridine-3-carboxamide (Compound 1822),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(2,5-difluoropheny])-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2105),

937

N-[(2-amino-3-pyridyl)sulfonyl]-6-(4-ethoxy-3-fluoro-phenyI)-2-[(4S)-2,2,4-trimethylpyiT01idinl-yl]pyridine-3-carboxamide (Compound 2403),

M[(2-amino-3-pyridyl)sulfonyl]-6-(2,4-dimeihylphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 1871), /V-[(2-amino-3-pyridyl)sulfonyl]-6-(2-fluoro-5-metbyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidml-yl]pyridine-3-carboxamide (Compound 2205),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(2-isopropoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2623),

7V-[(2~amino-3-pyridyl)suIfonyl]-6-(5-ethoxy-2-fluoro-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridme-3-carboxamide (Compound 2149),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(3-ethoxy-2-fluoro-phenyl)-2-[(4S)-2,2,4-trimethyIpyrrolidm] -yl]pyridme-3-carboxamide (Compound 1847),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(2-ethoxy-4-fluoro-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-caiboxamide (Compound 1808), jV-[(2-amino-3-pyridyl)suIfonyl]-6-(3-ethoxy-5-fluoro-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidiul-yl]pyridine-3-carboxamide (Compound 2018),

7V-[(2-amino-3-pyiÎdyl)sulforLyl]-6-(3-ethoxy-4-fluoro-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2665),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-chlorophenyl)-2-[(4S)-2,2,4-trimethy]pyrrolidin-lyl]pyridine-3-carboxamide (Compound 2183), iV-[(2-amino-3-pyridyI)sulfonyl]-6-(4-methyl-l-naphthyI)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2126),

ZV-[(2-amino-3-pyridyl)sulfonyl]-6-[2-(trifhioromethoxy)phenyl]-2-[(4S)-2,2,4trimethylpynolidin-l-yl]pyridine-3-carboxamide (Compound 2539),

N-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l -ylJpyridine-3-carboxamide (Compound 2245),

938

7V-[(2-amino-3-pyridyl)sulfonyl]-6-[4-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4trime thylpynolidin-1-y l]py ri dine-3-carboxamide (Compound 2223),

N-[(2-amino-3-pyridyl)sulfonyl]-6-[2-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2040),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(4,5-difluoro-2-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2334), /V-[(2-ammo-3-pyridyI)suIfonyl]-6-[3-(trifluoromethyI)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2593),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(3,5-difluoro-2-methoxy-phenyI)-2-[(4S)-2,2,410 trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2006),

Ab[(2-amino-3-pyridyl)sulfbnyl]-6-(o-tolyI)-2-[(4S)-2,2,4-trimethylpynOlidin-]-yl]pyridine-3carboxamide (Compound 1766),

A'-[(2-amino-3-pyridyl)sulfonyI]-6-[4-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4tri methylpyrrolid in-1 -y l]pyridine-3-carboxamide (Compound 2048),

AA[(2-amino-3-pyridyl)sulfbnyl]-6-(2,3-difluoro-4-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2302),

TV-[(2-amino-3-pyridyl)sulfbnyl]-6-(3,5-difluoro-4-methoxy-phenyI)-2-[ (43)-2,2,4trimethylpyiroIidin-l-yl]pyridine-3-carboxamide (Compound 2457),

N- [(2-amino-3 -pyridyl)sulfonyl] -6-(3,4-di fl uoro-5-methoxy-phenyI)-2-[(4S )-2,2,420 trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1998),

TV-[(2-amino-3-pyridyl)sulfonyl]-6-(4-methoxy-2,3-dimethyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2450),

N-[(2-amino-3-pyridyI)suIfonyl]-6-(2,4-difluoiOphenyI)-2-[(4S)-2,2,4-trimethylpyrroIidm-lyl]pyridine-3-carboxamide (Compound 2447),

A4(2-amino-3-pyridyl)sulfonyl]-6-(3-methoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2164),

939

A-[(2-amino-3-pyridyl)sulfbnyrj-6-(lH-indol-6-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2054),

N- [(2-ammo-3-pyridyl)suIfonyl]-6-(3-ethoxy-5 -methyl -phenyl )-2-[(4S )-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2241),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(l-methylindol-6-yl)-2-[(4S)-2,2,4-Îrimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2401),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(2-cyanophenyl)-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridîne-3-carboxamide (Compound 2437), tert-butyl 2-[5-[(2-amino-3-pyridyl)sulfonylcarbamoyl]-6-[(4S)-2,2,4-trimethylpyrrolidin-l-yI]2-pyridyl]indole-l-carboxylate (Compound 2657),

A^r-[(2-amino-3-pyridyl)suIfonyl]-6-(2-iluorophenyI)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1790), jV-[(2-amino-3-pyridyl)suifbnyl]-6-(4-ethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyirolidin-lyl]pyridine-3-carboxamide (Compound 1945),

2V-[(2-amino-3-pyridyl)sulfbnyl]-6-(3-fluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-Iyl]pyridine-3-carboxamide (Compound 1873),

7V-[(2-amino-3-pyridyl)sulfonyI]-6-(3-cyanophenyl)-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1824), jV-[(2-aniino-3-pyridyl)sulfonyl]-6-(4-fluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2435),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(4-cyanophenyl)-2-[(45)-2,2,4-trimethyl pyrrolidin-1yi]pyridine-3-carboxamide (Compound 2096),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(2-hydroxy-4-methyl-phenyl)-2-[(4S)-2,2,4tri methylpyrrolid in-1-y l]pyridine-3-carboxamide (Compound 1731),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-2-hydroxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2446),

940

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(lH-pyrrDlo[2,3-b]pyridin-5-yl)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1714),

N-[(2-amiiio-3-pyridyl)sulfonyl]-6-(l-isopropylpyrazol-4-y])-2-[(4S)-2,2,4-trimethylpyrrolidin1-yl]pyridine-3-carboxamide (Compound 2290), jV-[(2-amino-3-pyridyl)sulfbnyl]-6-(4-methoxy-2,6-dimethyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2607),

A^r-[(2-amino-3-pyridyI)suIfonyl]-6-(l-isobutylpyrazol-4-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-]yl]pyridine-3-carboxamide (Compound 2231 ),

A4(2-ammo-3-pyridyl)sulfbnyl]-6-(6-methoxy-3-pyridyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2244),

N-[(2-ammo-3-pyridyl)sulfonyl]-6-(2-methoxy-3-pyridyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1980),

A^?-[(2-amino-3-pyridyl)sulfonyl]-6-(2-methoxy-4-pyridyl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2646),

AT-[(2-amin o-3-pyridyl)sulfbnyl]-6-[6-(dimethylamino)-3-pyridyî]-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2319),

A4(2-amino-3-pyridyl)sulfonyl]-6-(6-methoxy-2-methyl-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1866),

M[(2-amino-3-pyridyl)sulfonyl]-6-[3-(hydroxymethyl)-5-methoxy-phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-1-y I]pyridine-3-carboxamide (Compound 2065),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(6-methoxy-5-methyl-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2564),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(4-isoquinoIyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2418),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(5-fluoro-6-methoxy-3-pyndyl)-2-[(4S)-2,2,4trimethylpynOlidm-l-yl]pyridine-3-carboxamide (Compound 2628),

941

A-[(2-aimno-3-pyridyl)sulfonyI]-6-(3,4-diiluorophenyl)-2-[(4S)-2,2,4-trime thylpyrrolidin-1yl]pyridine-3-carboxamide (Compound 1854),

A-[(2-ami no-3-pyridyl)sulfonyl]-6-(6-methoxy-2-pyridyl)-2-[(4S)-2,2,4-trime thylpyrrolidin-1 yl]pyridine-3-carboxamide (Compound 2268),

A-[(2-amino-3-pyridyl)suIfonyl]-6-(2,6-dimethoxy-3-pyridyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2091),

A-[(2-amino-3-pyridyl)sulfonyI]-6-(3,5-difluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 2272),

A-[(2-amino-3-pyridy])snlfonyl]-6-(2,3-dimethylphenyl)-2-[(4S )-2,2,4-trimethylpynOlidin-l yl]pyridine-3-carboxamide (Compound 1713),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(4-chlorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2367),

A-[(2-amino-3-pyridyl)suIfonyl]-6-(3,5-dimethylisoxazol-4-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2215),

A-[(2-ammo-3-pyridyl)sulfonyl]-6-(4-hydroxy-2-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyn'Olidin-Î-yl]pyridine-3-carboxamide (Compound 1999),

A-[(2-amino-3-pyridyl)sulfonyI]-6-[4-(difluoromethyl)phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2644),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(m-tolyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-l-yl]pyridine-3carboxamide (Compound 1829),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(p-tolyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 2132),

A-[(2-ammo-3-pyridyl)sulfonyl]-6-(4-fluoro-2-hydroxy-phenyl)-2-[(4S)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2653),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(5-fluoro-2-hydroxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2046),

942

N- [(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-5-hydro xy-pheny l)-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2349),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2,5-dimethyIphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1951),

N-[(2-amino-3-pyridyl)sulfonyi]-6-(2,3-dihydrobenzofuran-7-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2163),

N-[(2-ammo-3-pyridyI)sulfonyl]-6-(4-methoxy-3-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1747),

7V-[(2-ammo-3-pyridyl)sulfonyl]-6-(2-hydroxy-3-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2592),

N-[(2-amino-3-pyiidyl)sulfonyl]-6-(2-hydroxy-5-methyl-phenyl)-2-[(4S)-2,2,4trimethylpynOlidm-l-yl]pyridine-3-carboxamide (Compound 2426),

A^r-[(2-amino-3-pyridyl)sulfonyI]-6-(2-methoxy-3-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2380),

N-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(hydiOxymethyl)phenyl]-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1738),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-methoxy-4-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2379),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(5-fluoro-2-methyI-phenyl)-2-[(4S)-2,2,4-triniethylpynOJidjnl-yl]py ri dine-3-carboxamide (Compound 2660),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(2-hydroxy-3-metboxy-phenyl)-2-[(4S)-2,2,4trimethylpynOlidm-l-yl]pyridine-3-carboxamide (Compound 2158),

Y-[(2-amino-3-pyridyl)sulfonyI]-6-(2-methoxy-5-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyri dine-3-carboxamide (Compound 2413), /V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-4-methoxy-phenyI)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1851),

943

N-[(2-amino-3-pyridyl)sulfonyl]-6-isobutyl-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 2150),

A^,-[(2-amino-3-pyridyl)sulfonyl]-6-(2-fluoro-6-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2033),

N-[(2-amÎno-3-pyridyl)sulfonyl]-6-(2-fluoro-3-methoxy-phenyl)-2’[(4S)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2562), //-[(2-amino-3-pyridyl)sulfonyl]-6-(3,4-dimethoxyphenyI)-2-[(4S)-2,2,4-trimethylpyrrolidin-l yl]pyridine-3-carboxamide (Compound 2664),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(5-fluoro-2-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2189),

Z7-[(2-amino-3-pyridyl)suIfonyl]-6-(4-fluoro-3-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyn-olidinl-yl]pyridine-3-carboxamide (Compound 2052),

AT-[(2-aniino-3-pyridyI)sulfbnyl]-6-(2-fluoro-5-methoxy-phenyl)-2-[(4S)-2,2,4trime thylpynolid in-1 -yl]pyridine-3-carboxamide (Compound 2474),

A^r-[(2-amino-3-pyridyI)sulfonyl]-6-(4-fluoro-2-methoxy-phenyl)-2-[(4S)-2,2,4irimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2482), /V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fiuoro-5-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-caiboxamide (Compound 1869),

A^r-[(2-amino-3-pyridyl)sulfonyI]-6-(2-fluoro-4-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyiTolidin-1-yl]pyridine-3-carboxamide (Compound 1818),

N- [(2-amino-3-pyridyl)sulfonyI]-6-(3-fluoro-2-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2355),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-[4-(hydroxymethyl)phenyl]-2-[(4S )-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2590),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(4-fluoro-3-methoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2124),

944

N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin1-yl]pyridine-3-carboxamide (Compound 2345),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-naphthyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine3-carboxamide (Compound 2280),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(l-naphthyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine3-carboxamide (Compound 1857),

N-[(2-amino-3-pyridyl)sulfonyl]-6-phenyl-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1958),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-chlorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2066),

N-[(2-amino-3-pyridyi)sulfonyl]-6-(3,5-dimethylphenyl)-2-[(4S)-2,2,4-trimethylpynOlidm-lyl]pyridine-3-carboxamide (Compound 2127),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2,4,5-trifluorophenyl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2035),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2613),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2,3-dihydro-l,4-benzodioxin-6-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2522),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-isopropylphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2172),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(4-methoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2667),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-ethoxy-5-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1964),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isopropoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2515),

945

Æ-[(2-amino-3-pyridyl)sulfonyl]-6-(3,4-dimethylphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2017), ?/-[(2-amino-3-pyridyl)sulfonyl]-6-(4-isopropoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1903),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-2-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1944),

N-[(2-ammo-3-pyridyl)sulfonyl]-6-(2-isobutoxyphenyl)-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 2448),

N-[(2-amino-3-pyridyl)sulfbnyl]-6-(3-isopropylphenyl)-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1991),

2V-[(2-amino-3-pyridyl)sulfonyl]-6-(2,6-dimethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1994), /7-[(2-amino-3-pyridyl)sulfonyl]-6-(4-isopropylphenyl)-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 2368),

AH(2-amino-3-pyridyl)sulfonyl]-6-(2,3-dimethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 2436),

AM(2-amino-3-pyridyl)sulfonyl]-6-(2-hydroxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2257),

7/-[(2-amino-3-pyridyl)sulfonyl]-6-(2,5-dimethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2195),

W-[(2-amino-3-pyridyl)sulfonyl]-6-(3-hydroxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1820),

W-[(2-amino-3-pyridyl)sulfonyl]-6-[2-(hydroxymethyl)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1706),

V-[(2-amino-3-pyridyl)sulfonyl]-6-(4-hydroxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1712),

946

7V-[(2-amino-3-pyridyl)suIfonyl]-6-(2,4-dimethoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1705),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-fluoro-5-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2505),

A^r-[(2-amino-3-pyridyI)sulfonyl]-6-(2-methoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridme-3-carboxamide (Compound 1962),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(3,5-dimethoxypheEiyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 1825), iV-[(2-ammo-3-pyridyl)sulfonyl]-6-(4-methoxy-2-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-I -yl]pyridine-3-carboxamide (Compound 2494),

7V-[(2-amino-3-pyridyl)sulfonyI]-6-[2-(hydiOxymethyl)-4-methoxy-phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1707), (V-[(2-amino-3-pyridyl)sulfonyl]-6-(2,4-dimethoxypyrimidin-5-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2008),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-fluoro-3-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrondinl-yl]pyridine-3-carboxamide (Compound 1930),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3“fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyirolidml-yl]pyridme-3-carboxamide (Compound 1922),

N-[(6-ammo-2-pyridyl)suîfonyl]-6-(4-ethoxy-2,5-dimethyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-I -yl]pyridine-3-carboxamide (Compound 2227), (V-[(6-amino-2-pyridyl)sulfonyl]-6-(2-fluoro-4-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1910),

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-2-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin1-yl]pyridine-3-carboxamide (Compound 2616),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(4-isopropoxypyrazol-l-yl)-2-[(4S)-2,2,4-trimethyIpyrrolidinl-yl]pyridine-3-carboxamide (Compound 2658),

947

N-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5 -methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin I-y l]pyridine-3-carboxamide (Compound 2638),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2,2-difluoro-l,3-benzodioxol-5-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2104),

A^F-[(6-amino-2-pyndyl)sulfonyl]-6-(3-hydroxy-5-methyI-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-y]]pyridine-3-carboxamide (Compound 2232), iV-[(6-amino-2-pyriclyl)siilfonyl]-6-(2,4-difluorophenyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 2372),

A4(6-amino~2-pyridyl)sulfonyl]-6-(3,5-difluorophenyl)-2-[(4S)-2,2,4’trimethylpyrrolidm-ly] ]pyridine-3-carboxamide (Compound 2236),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-hydroxy-3-methyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-]-yl]pyridine-3-carboxamide (Compound 2203), jV-[(6-ammo-2-pyridyl)sulfonyl]-6-(2~hydroxy-5-methyl-phenyl)-2-[(4S )-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2034),

7V-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluorophenyl)-2-[(4S)-2,2,4-trimethylpyiTolidin-lyl]pyridine-3-carboxamide (Compound 2566),

M[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-2-hydroxy-phenyl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2386), jV-[(6-amino-2-pyridyI)sulfonyl]-6-(2-hydroxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2555),

M[(6-amino-2-pyridyl)sulfonyl]-6-(2-hydroxy-4-methyl-phenyl)-2-[(4S )-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2043),

A^r-[(6-ammo-2-pyridyl)sulfonyl]-6-(3,4-difluorophenyI)-2-[(4S)-2,2,4-trimethylpyrrolidin-Iyl]pyridine-3-carboxamide (Compound 2559),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyI]pyridine-3-carboxamide (Compound 1969),

948 iV-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(trifluoromethoxy)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1785),

N- [(6-amino-2-pyridyl)sulfonyl]-6-(3,5-difluoro-4-isopropoxy-phenyl )-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2608),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-ethoxy-4,5-dimethyl-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1931),

N-[(6-amino-2-pyridyI)sulfonyl]-6-[3-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4triniethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2392),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(3,5-dimethylphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l10 yl]pyridine-3-carboxamide (Compound 1771),

N-[(6-amino-2-pyridy))suïfonyl]-6-(5-methyl-2-propoxy-phenyl)-2-[(4S )-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2085), jV-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2296),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2,3-dimethylphenyl)-2-[(4S)-2,2,4-trimethyIpyrrolÎdin-lyl]pyridine-3-carboxamide (Compound 2287),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(l-isobutyipyrazol-3-yl)-2-[(4S)-2,2,4-trimethylpyrrolidm-Iyl]pyridine-3-carboxamide (Compound 2114), iV-[(6-ammo-2-pyridyl)sulfbnyl]-6-[3~(trifluoromethoxy)phenyl]-2-[(4S)-2,2,420 trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 2366),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[4-(difluoromethoxy)-3 -methyl-phenyl]-2-[(4S)-2,2,4irimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2543),

A^r-[(6-amino-2-pyridyl)sulfony]]-6-(5-fluoro-2-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpynOlidinl-yl]pyridine-3-carboxamide (Compound 2394),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-ethoxy-2-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 536), and

949

N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-methoxy-2,5-dimethyl-phenyl)-2-(2,2,4trimethylpyrrolidm-] -yl)pyridine-3-carboxamide (Compound 1259).

PREPARATION 63: M[(6-amino-2-pyridyl)sulfonyl]-6-[6(cyclopropyliiiethoxy)-3-pyridyl]-2“[(2S,5R)-2,5-dÎmethyIpyrrolidm-l-yl]pyridine-3carboxamide (Compound 789)

V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dÎmethyIpyrrolidin-l-yl]-6<6-fluoro3-pyridyl)pyridine-3-carboxamide (50. mg, 0.11 mmol) and cyclopropylmethanol (77 mg, 1.1 mmol) were combined in DMSO (1 mL), cooled down to 0 °C and NaH (12.75 mg, 0.5315 mmol) was added to the reaction mixture. The mixture was heated to 90 °C for 3h. The réaction mixture was fîltered and then purified using a reverse phase HPLC-MS method using a Luna C18 column (50 x 21.2 mm, 5 pm particle size) sold by Phenomenex (pn: 00B-4252-P0-AX), and a dual gradient run from 1-99% mobile phase B over 15.0 minutes. Mobile phase A = H₂O (containing 5 mM HCl). Mobile phase B = CH₃CN. Flow rate = 35 mL/min, injection volume = 950 pL, and column température = 25 °C. The UV absorption at 254nm is used to collect fractions. The desired fractions were collected, neutralized with 20mL of NaHCO₃, extracted with ethyl acetate, washed with brine, dried over sodium sulfate, fîltered, and concentrated to give A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(cyclopropylmethoxy)-3-pyridyl]-2-[(2S,5R)-2,5dimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 789) (24 mg, 0.046 mmol, 42%). IH NMR (400 MHz, DMSO-r/₆) δ 8.78 (d, J = 2.4 Hz, IH), 8.28 (dd, J = 8.7, 2.5 Hz, IH), 7.60 7.42 (m,2H), 7.01 (bs, 2H), 6.87 (d, 7 = 8.7 Hz, IH), 6.51 (d, 7 =8.6 Hz, 1H),6.23 (bs, 2H), 4.23 (s, 2H),4.13 (d,7 = 7.1 Hz, 2H), 1.86 (bs, 2H), 1.56 (bs, 2H), 1.25 (dddd, 7 = 11.9, 7.3, 5.4, 2.6 Hz, 1 H), 1.04 (d, 7 = 6.1 Hz, 6H), 0.59 - 0.49 (m, 2H), 0.36 - 0.26 (m, 2H). ESI-MS m/z cale. 522.2049, found 523.3 (M+l)⁺; Rétention time: 1.96 minutes

950

77-[(6-amino-2-pyridyl)sulfbnyl]-6-[6-(2,2-dimethylpropoxy)-3-pyridyl]-2-[(2S,5R)-2,5dimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1270), ?7-[(6-amino-2-pyridyl)suIfonyl]-6-(6-isobutoxy-4-methyl-2-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1656),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxy-4-methyl-2-pyridyl)-2-[(4S)-2,2,4trimethyIpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1512),

77-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-4-methyl-2-pyridyl)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1637), ,„

77-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(dilluoromethoxy)-3-pyridyl]-2-[(2S,5R)-2,510 dimethylpyrroIidin-I-y!]pyridine-3-carboxamide (Compound 1679),

77-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,5S)-2,5-dimethylpyrrolidin-l -yl]-6-(6-isobutoxy-2methyl-3-pyridyl)pyridine-3-carboxamide (Compound 1537),

77-[(6-amino-2-pyridyl)sulfbnyI]-6-[6-[2-(2-ethoxyeihoxy)ethyl-methyl-amino]-5-methyl-3pyridyl]-2-[(4S)-2,2,4-trimethylpyiTolidin-l-yl]pyridme-3-carboxamide (Compound 2684),

À^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-ethoxyethyl(methyl)amino]-5-methyl-3-pyridyl]-2[(4S)-2,2,4-trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 2685),

77-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2-eÎhoxyethylamino)-5-mediyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 2686),

77-[(6-ammo-2-pyridyl)sulfonyl]-2-[(2R,5S)-2,5-dimethylpyrrolidm-l-yl]-6-(6-isopropoxy-220 methyl-3-pyridyl)pyridine-3-carboxamide (Compound 1623),

77-[(6-ammo-2-pyridyl)sulfbnyl]-2-[(2R,5S)-2,5-dimethylpyrrolidin-l-yl]-6-(6-isopropoxy-4methyl-3-pyridyl)pyridine-3-carboxamide (Compound 1514), /7-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-[6-(isobutylamino)3-pyridyl]pyridine-3-carboxamide (Compound 1398),

77-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[[(lS)-l,3-dimethylbutyl]amino]-3-pyridyl]-2-[(2S,5R)2,5-dimethylpyrrolidin-i-yl]pyridine-3-carboxamide (Compound 1463),

951

7V-[(6-ænino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-[6[isobutyl(methyl)amino]-3-pyridyl]pyridine-3-carboxamide (Compound 1506),

N-[(6-anuno-2-pyridyl)sulfbnyl]-2-[(2R,5S)-2,5-dimethylpynOlidin-l-yi]-6-[6-(lethylpropylamino)-3-pyridyl]pyridine-3-carboxamide (Compound 1397),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[[(lS)-l,2-dimethylpropyl]amino]-3-pyridyl]-2-[(2S,5R)2,5-dimethylpynOlidin-l -yl]pyridine-3-carboxamide (Compound 1399),

TV-[(6-amino-2-pyridyl)su!fbnyI]-6-[6-[isopropyl(methyl)amino]-5-methyl-3-pyridyl]-2-[(4S)2,2,4-trimethylpyrrolidm-l -yl]pyridine-3-carboxamide (Compound 2687),

N-[(6-armno-2-pyridyl)sulfonyl]-6-[6-(isopropylamino)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethyIpyiTolidm-l-yl]pyridine-3-carboxamide (Compound 2688),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[6-!ethyl(methyl)amino]-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2689),

7V-[(6-amino-2-pyridyl)suIfbnyl]-6-[6-[[(l R)-l,2-dimethylpropyl]amino]-3-pyridyl]-2-[(2S,5R)2,5-dimethylpynOlidin-I -yl]pyridine-3-carboxamide (Compound 1442),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[[(lR)-l,3-dimethylbutyl]amino]-3-pyridyl]-2-[(2S,5R)2,5-dimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1527),

7V-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyreoIidin-l-yl]-6-(4-isobutoxy-2pyridyl)pyridine-3-carboxamide (Compound 389), iV-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isobutoxy-2-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 397), methyl 2-[[5-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-[(2S,5R)-2,5-dimethylpyrrolidin-l yl]-2-pyridyl]-2-pyridyl]oxy]propanoate (Compound 723),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(6-isobutoxypyrazm-2-yl)-2-[(4S)-2,2,4-trimethylpyrroIidin1-y l]pyridine-3-carboxamide (Compound 1523), ?V-[(6-amino-2-pyridyi)sulfonyI]-6-[6-[isobutyl(methyl)amino]-3-pyridyl]-2-(2,2,4trimethylpynOlidin-l-yl)pyridine-3-carboxamide (Compound 412),

952

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-] -yl]-6-(6-isobutoxy-2pyridyl)pyridine-3-carboxamide (Compound 432),

A^L[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isopropylainino)-3-pyridyl]-2-(2,2,4-trime thylpynolidin1 -yl)pyridine-3-carboxamide (Compound 437),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isobutoxy-3-pyridyl)~2-(2,2,4-trimethylpyiTolidin-lyl)pyridine-3-carboxamide (Compound 471 ),

7/-[(6-amino-2-pyridyi)sulfonyl]-2-[(2S,5R)-2,5-dimethylpynOlidin-l-yl]-6-(6-isobutoxy-3pyridyl)pyridine-3-carboxamide (Compound 544),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isobutylamino)-3-pyridyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 569),

A-[(6-amino-2-pyridyi)suIfonyl]-6-[6-(l-ethylpropoxy)-2-pyridyl]-2-(2,2,4-trimetliylpyrrolidinl-y[)pyridine-3-carboxamide (Compound 580),

2V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-2-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridîne-3-carboxamide (Compound 708),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(l,2-dimethylpropoxy)-2-pyridyl]-2-(2,2dimethylpyrrolidin-l-yl)pyridine-3-caiboxamide (Compound 717),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2,2-dimethylpropoxy)pyrazin-2-yl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 779),

77-[(6-amino-2-pyridyl)suIfonyl]-6-[6-(diethylamino)-3 -pyridyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 796),

A^r-[(6-amino-2-pyridyl)sulfbnyl]-6-(6-isopropoxy-2-methyl-3-pyridyl)-2-(2,2,4trimethylpyrrolidm-l-yl)pyridine-3-carboxamide (Compound 814),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[isobutyl(methyl)amino]-2-methyl-3-pyridyl]-2-(2,2,4trimethylpyrrolidin-l-yI)pyridine-3-carboxamide (Compound 827),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(l,3-dimethylbutoxy)-2-pyridyl]-2-(2,2dimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 846),

953

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopentyloxy-3-pyridyl)-2-(2,2,4-trimethylpyrroliciin-lyl)pyridine-3-carboxamide (Compound 848),

2V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isobutoxy-4-methyl-3-pyridyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 851), /7-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-4-methyl-3-pyridyl)-2-(2,2,4trimethylpyrrolidîn-l-yl)pyridine-3-carboxamide (Compound 905),

77-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isopropylamino)-2-pyridyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 951),

77-[(6-amino-2-py ridyl)sulfon y 1]-6-(6-isobutoxypyrazin-2-yl )-2-(2,2,4-trimethylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 988),

77-[(6-amino-2-pyridyi)sulfbnyl]-2-(2,2-dimethylpyrroIidin-l-yI)-6-(6-isobutoxy-2pyridyl)pyridine-3-carboxamide (Compound 1011),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isobutylamino)-2-pyridyl]-2-(2,2,4-trimethylpyiTolidin-lyl)pyridine-3-carboxamide (Compound 1059),

77-[(6-amino-2-pyridyl)sulfonyI]-6-[6-(2,2-dimethylpropoxy)-2-pyridyl]-2-(2,2,4trimethylpyrrolidin-1-yl)pyridine-3-carboxamide (Compound 1062),

77-[(6-ammo-2-pyridyl)sulfonyl]-6-[6-(l-ethylpropoxy)-3-pyridyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 1076),

7V-[(6-amino-2-pyridyl)suIfonyl]-6-(6-isopentyloxy-2-pyridyl)-2-(2,2,4-trimethylpyirolidm-lyl)pyridine-3-carboxamide (Compound 1135),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-[6-(2,2-dimethylpropoxy)-4-methyl-3-pyridyi]-2-(2,2,4trimethylpyrrolidin-1-yl)pyridine-3-carboxamide (Compound 1160),

N- [(6-ami no-2-pyridyl)sulfonyl] -6-[6-(2,2-dimethy lpropoxy)-3 -pyridyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1181),

77-[(6-amino-2-pyridyl)sulfbnyl]-6-[6-(2,2-dimethylpropoxy)-2-pyridyl]-2-(2,2dimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1328),

954

A^(6-amino-2-pyridyl)sulfonyl]-6-[6-(diethylamino)-2-pyridyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1345),

77-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(l,3-dimethylbutoxy)-4-pyridyl]-2-(2,2,4crimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 384), /7-[(6-amino-2-pyridyl)sulfonyI]-6-[2-(isobuty]amino)-4-pyridyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 523),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-propoxy-4-pyridyl)-2-(2,2,4-trimethyIpyrrolidin-lyl)pyridine-3-carboxamide (Compound 491 ),

A^r-[(6-amino-2-pyridyl)su!fonyl]-6-(2-isobutoxy-4-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1192),

A4(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropoxy-4-pyridyl)-2-(2,2,4-trimethylpyiTolidin-lyl)pyridine-3-carboxamide (Compound 402),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isobutoxy-4-pyridyl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 1618),

2V-[(6-armno-2-pyridyl)sulfonyl]-6-[6-(2,2-dimethylpropoxy)-3-methyl-2-pyridyl]-2-(2,2,4trimethylpyiTolidin-l-yl)pyridine-3-carboxamide (Compound 1645),

A^r-[(6-amino-2-pyridyl)su]fonyl]-6-(6-isobutoxy-3-methyl-2-pyridyI)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1659),

A^r-[(6-amino-2-pyridy])sulfonyl]-6-[6-(2,2-dimethylpropoxy)-2-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1663),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2,2-dimethylpropoxy)-5-methyl-2-pyridyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridme-3-carboxamide (Compound 1610),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxy-5-methyl-2-pyridyl)-2-(2,2,4-trimethylpyn-olidinl-yl)pyridine-3-carboxamide (Compound 1363),

M[(6-amino-2-pyridyl)sulfonyl]-6-[6-(diethylamino)-3-methyl-2-pyridyl]-2-(2,2,4trimethylpyrroIidin-l-yl)pyridine-3-carboxamide (Compound 1383),

955 jV-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isobutylamino)-3-methyl-2-pyridyl]-2-(2,2,4trimethylpyrrohdin-l-yl)pyridine-3-carboxamide (Compound 1417),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2,2-dimethylpropoxy)-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1504),

N-[(6-amino-2-pyridyl)sulfbnyl]-6-[6-(cyclobutoxy)-3-pyridyl]-2-[(2S,5R)-2,5dimethylpyrrolidin-]-yl]pyridine-3-carboxamide (Compound 428), jV-[(6-amino-2-pyridyl)sulfonyI]-2-[(2S,5R)-2,5-djmethylpynOlidin-l-yl]-6-[6-(2-hydroxy-lmethyl-ethoxy)-3-pyridyl]pyridine-3-caiboxamide (Compound 998),

TV-[(6-ammo-2-pyridyl)sulfonyl]-6-[6-[(lR)-2-benzyloxy-l-methy]-ethoxy]-3-pyridyl]-2[(2S,5R)-2,5-dimethylpyrrolidin-l -y I]pyridine-3-carboxamide (Compound 576),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxy-5-methyl-3 -pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1727),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(diethylamino)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1915),

TV-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]-5-methyl-3-pyridyl]2-[(4S)-2,2,4-trimethylpynolidin-l-y l]pyridine-3-carboxamide,

V-[(6-amino-2-py ridy l)sulfonyl]-6-(6-isobutoxy-5-methyl-3-pyridyl )-2-[(4S )-2,2,4tri methylpyrrolidin-l-y l]pyridine-3-carboxamide (Compound 1741),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-[6-[isobutyl (methyl )amino]-5-methyl-3-pyridyl]-2-[(4S)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2279), /V-[(6-amino-2-pyridyl)sulfonyl]-6-[5-methyl-6-[(lR)-l-methylpropoxy]-3-pyridyl]-2-[(4S)2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2576), /V-[(6-amino-2-pyridyl)sulfonyl]-6-(6-isopropoxy-5-methyl-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2170),

N-[(6-amino-2-pyridyI)sulfonyl]-6-[6-[2-(2-ethoxyethoxy)ethoxy]-5-methyl-3-pyridyl]-2-[(4S)2,2,4-trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 1715),

956 /V-[(6-amino-2-pyridyI)sulfonyl]-6-[5-meÜiyl-6-[(lS)-l-methylpropoxy]-3-pyridy]]-2-[(4S)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 1728), /7-[(6-amino-2-pyridyl)sulfbnyl]-6-[6-[2-[2-(2-isopropoxyethoxy)ethoxy]ethoxy]-5-methyl-3pyridyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1787),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-(3-but-3-ynyldiazirin-3-yl)ethoxy]-5-methyl-3-pyridyl]2-[(4S )-2,2,4-trime thylpyrrolidin-1-y l]pyridine-3-carboxamide, iV-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2-ethoxyethoxy)-5-methy]-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2404),

A^/,-[(6-ammo-2-pyridyI)sulfonyI]-6-[6-(2-isopropoxyethoxy)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1973), ?/-[(6-amino-2-pyridyI)sulfonyl]-6-[6-(2-methoxyethoxy)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2582),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(2-ethoxyethoxy)-6-methyl-4-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1948),

7V-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(2-isopropoxyethoxy)-6-methyl-4-pyridyl]-2-[(4S)-2,2,4trimethylpyrroIidin-l-ylJpyridine-3-carboxamide (Compound 2079),

7Z-[(6-amino-2-pyridyl)sulfonyl]-6-[2-(diethylamino)-6-methyl-4-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1739),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isobutoxy-6-methyl-4-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2010),

A^l'-[(6-amino-2-pyiidyl)sulfonyl]-6-[2-[2-(2-ethoxyethoxy)ethoxy]-6-methyI-4-pyridyl]-2-[(4S)2,2,4-trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1812), iV-[(6-amino-2-pyridyI)sulfbnyl]-6-(2-ethoxy-6-methyl-4-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2364),

N-[(6-amino-2-pyridyl)sulfonyl]-6-(2-isopropoxy-6-methyl-4-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l -yl]pyridme-3-carboxamide (Compound 2306),

957

79-[(6-amino-2-pyridyl)sulfonyl]-6-(2-methoxy-6-methyl-4-pyridyl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 1748),

A^?-[(2-amino-3-pyridyI)sulfonyl]-6-(6-isopropoxy-5-methyl-3~pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1702),

N-[(2-ammo-3-pyridyl)sulfonyl]-6-[6-(2-ethoxyethoxy)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2497), /V-[(2-ammo-3-pyridyl)sulfonyl]-6-(6-ethoxy-5-methyI-3-pyridyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2651),

A^r-[(2-amino-3-pyridyl)sulfbnyl]-6-[6-[2-(2-ethoxyethoxy)ethoxy]-5-methyl-3-pyridyl]-2-[(4S)2,2,4-trimethylpynOlidin-l-yl]pyridine-3~carboxamide (Compound 1783),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-[6-(2-isopropoxyethoxy)-5-methyl-3-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 1695),

N-[(6-ammo-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5-dimethylpyrrolidin-l-yl]-6-[6-[(lmethylcyclopropy])methoxy]-3-pyridyl]pyridine-3-carboxamide (Compound 454), and

N-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(cyclopropoxy)-3-pyridyl]-2-[(2S,5R)-2,5dimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1125).

PREPARATION 64: 1-Methyl-2-((2,4,6-trimethyIphenyl)methyl]isoindoline-lcarboxylîc acid

Step 1: 2-Benzyl l-(teri-butyl) I-methylisoîndoline-l,2-dicarboxylate

A solution of iercbutyl 2-[benzyloxycarbonyl-[(2bromophenyl)methyl]amino]propanoate (2.69 g, 6.00 mmol) in dioxane (30 mL) was purged withnitrogen for 2 minutes. 2-(2-Diphenylphosphanylphenyl)-N79-dimethyl-aniline (228.9 mg,

958

0.6000 mmol) was added under nitrogen followed by the addition of tris(dibenzylideneacetone)dipalladium(O) (274.7 mg, 0.3000 mmol). Lithium terf-butoxide (960.7 mg, 12.00 mmol) was added to the reaction mixture. The mixture was heated to 90 °C for 16 hours, diluted with ethyi acetate and fîltered. The residue was purified by silica gel column chromatography (0-10% ethyi acetate in hexanes) to provide 2-benzyl l-(ieri-butyl) 1methylisoindoline-l,2-dicarboxylate (1.4 g, 3.8 mmol, 63%). ESI-MS m/z cale. 367.17834, found 368.4 (M+l)⁺; Rétention time: 2.75 minutes.

Step 2: terAbutyl I-methylîsomdoline-l-carboxylate

A solution of 2-benzyl 1-(teri-butyl) ]-methylisoindoline-l,2-dicarboxyIate (718 mg, 1.95 mmol) in methanol (50 mL) was purged with nitrogen for 2 minutes. Palladium on carbon (10% w/w, 104.0 mg, 0.09770 mmol) was added and the mixture was placed under an atmosphère of hydrogen for 16 hours. The catalyst was removed via filtration through celite and the fîltrate was concentrated to dryness to provide /erAbutyi l-methylisoindoline-l-carboxylate (400. mg, 1.71 mmol, 87.7%). The crude material was used directly in next step without further purification.

Step 3: l-methyl-2-[(2,4,6-trimethyIpheny])methyl]isoindoline-l-carboxylic acid

_ To a solution of tert-butyl l-methylisoindolme-l-carboxylate (1.5 g, 6.4 mmol) in acetonitrile (75.00 mL) was added 2-(chîoromethyl)-l,3,5-trimethyLbenzene (1.084 g, 6.429

959 mmol) and césium carbonate (4.190 g, 12.86 mmol). The mixture was heated at 90 °C ovemight, and then partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic îayers were washed with brine, dried over magnésium sulate, filtered, and concentrated to dryness. The crude material was purified by silica column chromatography utilizing a gradient of 0-5% ethyl acetate in hexanes to provide ieri-butyl 1methyl-2-[(2,4,6-trimethylphenyl)methyl]isoindoIine-l-carboxylate. This material was then dissolved in dioxane (3.2 mL) and hydrochloric acid in dioxane (5 mL of 4 M, 20.00 mmol) was added to the mixture. The mixture was stirred for 16 hours at room température. The mixture was then stirred at 70 °C for 1 hour. The reaction mixture was cooled to room température, the precipitate was filtered and washed with dioxane to give an off-white solid. l-methyl-2-[(2,4,6trimethylphenyl)methyl]isoindolme-Lcarboxylic acid (0.98 g, 3.2 mmol, 49%) ESI-MS m/z cale. 309.17288, found 310.5 (M+l)⁺; Rétention time: 1.18 minutes (3 min run).

PREPARATION 65: Ethyl 5-methyl-l-(p-tolyl)-lH-indole-2-carboxylate

A mixture of ethyl 5-methyl-lH-indole-2-carboxylate (2.032 g, 10.00 mmol), 1-iodo4-methyl-benzene (2.180 g, 10.00 mmol), iodocopper (95.22 mg, 0.5000 mmol), N1,N2dimethylcyclohexane-l,2-diamme (284.5 mg, 315.4 pL, 2.000 mmol), and potassium phosphate (4.458 g, 21.00 mmol) in toluene (50.00 mL) was heated to reflux for 22 hours. The cooled reaciton was filtered and evaporated. The green residue was purified by silica gel chromatography with 0-15% ethyl acetate in hexanes to give ethyl 5-methyl-l-(p-toIyl)-lAindole-2-carboxylate (1.43 g, 4.875 mmol, 48.74%) as a colorless oil. ESI-MS m/z cale. 293.14, found 294.2 (M+l)⁺; Rétention time: 0.83 minutes (1 minute run).

PREPARATION 66: A-[(6-amino-2-pyridyI)sulfonyl]-5-bromo-2-[(2S,5R)-2,5* dimethylpyrroIidin-l-yl]-6-(6-isopropoxy-3-pyridyI)pyrîdine-3-carboxamide (Compound 390)

960

N^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5/ï)-2,5-dimethylpyrrolidm-l-yl]-6-(6isopropoxy-3-pyridyl)pyridine-3-carboxamide (147.4 mg, 0.2887 mmol) in acetic acid (1.5mL) was treated with bromine (69.20 mg, 22.31 pL, 0.4330 mmol) and stirred at room température for 1 hour. The resulting yellow suspension was diluted with water (20 mL), quenched to pH 2-3 by addition of saturated aqueous sodium bicarbonate and extracted with dichloromethane. The crude material was purified by chromatography over silica gel (12g) with a linear gradient of 0 to 5% methanol in dichloromethane to give Λ^(6-amino-2-pyridyl)sulfonyl]*5-bromo-2-[(25,5/02,5-dimethyIpyiTolidin-l-yl]-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 390) (90. mg, 0.14 mmol, 50.%) as a yellow foam. ^]H NMR (400 MHz, DMSO-rfe) <5 12.80 (s, 1 H), 8.52 (dd, 7 = 2.5,0.7 Hz, 1H), 8.02 (dd, 7 = 8.7, 2.5 Hz, 1H),7.85 (s, 1 H), 7.64 (t, 7 = 7.8 Hz, 1H), 7.23 (d, 7=7.2 Hz, 1H), 6.83 (dd, 7 = 8.6, 0.7 Hz, 1 H), 6.72 (d, 7= 8.4 Hz, 1H),6.51 (s, 2H), 5.32 (p, 7 = 6.2 Hz, 1H),3.95 (s, 2H), 1.97 - 1.82 (m, 2H), 1.64 (dd, 7 = 8.9, 5.3 Hz, 2H), 1.33 (d,7 = 6.2 Hz, 6H), 1.04 (d,7 = 6.1 Hz, 6H). ESI-MS /n/zcalc. 588.1154, found 589.0 (M+l)⁺; Rétention time: 2.25 minutes.

PREPARATION 67: 3-(ierObutyl)-4-methoxy-l-(2,4,6-trimethylbenzyl)-lHpyrazole-5-carboxylic acid

Step 1; 3-(terAbutyl)7V-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)-l-(2,4,6triniethylbenzyl)-lH-pyrazole-5-carboxamide

In a 20 mL sealed tlask containing 5-tert-buty 1-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxylic acid 1 (500. mg, 1.66 mmol) was addedM

961 methylpyrrolidinone (5.000 mL) and diisopropylamine (537.7 mg, 724.7 pL, 4.160 mmol) folio wed by a propylphosphonic anhydride solution (2.118 mL of 50 %w/v, 3.328 mmol) and 2,3,5,6-tetrafluoro-4-(trifluoromethyl)aniline (426.5 mg, 1.830 mmol) and the resulting mixture was stirred at 80 °C for 16 hours. The material was diluted with ethyl acetate (10 mL), washed with water and the organic layer was extracted. The organic layer was washed twice with a saturated aqueous solution of sodium bicarbonate, followed by brine. The material was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The resulting crude material was adsorbed to celite and purified by silica gel column chromatography ((40 g ) using a gradient ofO to 50% ethyl acetate) to afford 5-teri-butyl-N-[2,3,5,6-tetrafluoro-4(trifluoromethyl)phenyl]-2-[(2,4,6-trimetliylphenyl)methyl]pyrazo le-3-carboxamide (748 mg, 1.44 mmol, 86.4%). ESI-MS m/z cale. 515.1808, found 516.2 (M+l)⁺; Rétention time: 2.58 minutes. 'H NMR (400 MHz, DMSO) δ 10.92 (s, 1H), 7.01 (s, 1H), 6.83 (s, 2H), 5.64 (s, 2H), 2.27 (s, 6H), 2.21 (s, 3H), 1.20 (s, 9H).

Step 2: 3-(teri-butyI)-4-methoxy-A⁷-(2,3,5,6-tetrafluoro-4(trifliioromethyl)phenyl)-l-(2,4,6-trimethylbenzyl)-lJT-pyrazole-5-carboxamide

5-rerr-Butyl-/V-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)pheny]]-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (200. mg, 0.388 mmol), anhydrous methanol (1.554 g, 1.965 mL, 48.50 mmol), xylene (2.000 mL), diacetoxypalladium (8.711 mg, 0.03880 mmol), (diacetoxyiodo)benzene (374.9 mg, 1.164 mmol), and 4Amolecular sieves were combined in a capped 10 mL vial. The mixture was heated in an oil bath to 100 °C for40 hours. The mixture was allowed to cool was diluted with water, extracted three limes with dichloromethane (10 mL), and the combined organics were washed with a saturated aqueous sodium bicarbonate solution and then a saturated aqueous solution of sodium chloride. The organic layer was dried over sodium sulfate and then purified by silica gel column chromatography (24 g) utilizing a gradient of 0 to 50% ethyl acetate in hexanes to afford 5-tert

962 butyl-4-methoxy-A-[2,3,5,6-tetrafluoro-4-(trilluoromethyl)phenyl]-2-[(2,4,6trimethylphenyl)methyl]pyrazoIe-3-carboxamide (161 mg, 0.295 mmol, 76.1%) as an off-white solid. ESI-MS m/z cale. 545.19135, found 546.2 (M+l)⁺; Rétention time: 2.4 minutes. ’H NMR (400 MHz, DMSO) <5 10.76 (s, 1H), 6.83 (s, 2H), 5.39 (s, 2H), 3.79 (s, 3H), 2.28 (s, 6H), 2.20 (s, 3H), 1.25 (s, 9 H).

Step 3: Methyl S-frerAbutylM-niethoxy-l-fZ^jô-trimethylbenzylj-lH-pyrazole-Scarboxylate

5-ierLbutyl-4-methoxy-A-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]-2-[(2,4,6tri methylphen yl)methyl]pyrazole-3-carboxamide (161 mg, 0.295 mmol) was dissolved in an hydrous tetrahydrofuran (3.220 mL) and to the mixture was added (bis(trimethylsi!yl)amino)Iithium (442.7 pL of 1 M in tetrahydrofuran, 0.4427 mmol) at 0 °C and the resulting mixture was allowed to stir for 10 minutes. Then methyl chloroformate (83.66 mg, 68.41 μL, 0.8853 mmol) was added and the reaction mixture was allowed to stir for one hour, and then concentrated under reduced pressure, The residue was redissolved in anhydrous tetrahydrofuran (3.220 mL) and then the mixture was cooled to 0 °C in an ice water bath.

Sodium methoxide (319.0 pL of 25 %w/v in methanol, 1.476 mmol) was added and the reaction mixture was stirred for 10 minutes. The mixture was diluted with water, extracted three times with ethyl acetate (lOmL) and the combined organics were washed with brine. The mixture was dried over sodium sulfate, and then purified by reverse-phase préparative chromatography utilizing a gradient from 10 to 99% acetonitrile in water containing 5 mM aqueous hydrochloric acid to yield methyl 3-(teri-butyI)-4-methoxy-l-(2,4,6-trimethylbenzyl)-lA-pyrazole-5carboxylate (25.8 mg, 0.0749 mmol, 25.4%) as an off-white solid. ESI-MS m/z cale. 344.21, found 345.2 (M-l-1 )⁺; Rétention time: 1.92 minutes.

963

Step 4: 3-(£e/*Abutyl)-4-methoxy-l-(2,4,6-trimethylbenzyl)-U7-pyrazole-5carboxylic acid

To methyl 3-(icrt-butyl)-4-methoxy-1-(2,4,6-trimethylbenzyI)-lH-pyrazole-5carboxylate (30. mg, 0.087 mmol) in anhydrous tetrahydrofuran (600.0 pL) was added sodium hydroxide (108.9 pL of4 M, 0.4355 mmol), the mixture was heated to 70 C and stirred for 3 hours. The mixture was allowed to cool and then it was purified directly by reverse-phase préparative chromatography utilizing a gradient from 10 to 99% acetonitrile in water containing 5 mM aqueous hydrochloric acid to yield 3-(terAbutyl)-4-methoxy-l-(2,4,6-trimethylbenzyl)177-pyrazole-5-carboxylic acid (27.3 mg, 0.0826 mmol, 95%) as an off- white solid. ESI-MS m/z cale. 330.19434, found 331.2 (M+l)⁺; Rétention time: 2.08 minutes.

PREPARATION 68: N-[amino-(6-amino-2-pyridyl)-oxo-$l^A{6}-suIfanylidene]-6tert-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 1602) (Compound 1481) (Compound 515)

Step I: 2-fluoro-6-[(6-fluoropyridin-2-yl)disulfanyl]pyridine

A mixture of 2-fluoro-6-hydroxypyridine (1.13 g, 10.0 mmol) and phosphores pentasulfide (4.44 g, 20.0 mmol) in toluene (50 mL) was refluxed for 18 hours. Once cooled, the flask was placed in an ice bâtir and quenched with water (50 mL) and then basified to a pH of about 8-9 with 25% NaOH. The mixture was fîltered over celite to remove some solids that were still présent and washed with water (50 mL) and ethyi acetate (200 mL). The biphasic mixture was transferred to a 1.0-L sépara tory tunnel, extracted and the layers were sépara ted. The aqueous layer was extracted again with ethyi acetate (100 mL), and the organic layers were then

964 combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica-gel column chromatography, eluting from 0% to 10% ethyl acetate in heptanes to afford 2-fluoro-6-[(6-fluoropyridin-2yl)disulfanyl]pyridine (304 mg, 23.7% yield) as a colorless oil. ^!H NMR (300 MHz, CDC1₃):

ppm 6.75 (ddd, J = 8.0, 2.7, 0.5 Hz, 1 H), 7.49 (ddd, J = 7.7,2.1,0.6 Hz, 1 H), 7.72 (q, J = 7.9 Hz, 1 H). [M+H]⁺= 257.0.

Step 2: 6-rn +but vhAH R’-fhioropYridin-2-yIjsulfinyl]-2-(2,4,6 triniethylphenoxy)pyridine-3-carboxamide

To a solution of 2-fluoro-6-[(6-fluoropyridm-2-y])disulfanyl]pyridine (744 mg, 2.90 mmol) and 6-ierz-butyl-2-(2,4,6-trime thylphenoxy)pyridine-3-carboxamide (906 mg, 2.90 mmol) in pyridine (10 mL) and acetonitrile (10 mL) was added bromine (0.172 mL, 3.36 mmol) dropwise at 0 °C. After complété addition, the mixture was stirred at room température ovemight. Additional bromine (0.087 mL, 1.7 mmol) was added at room température and the mixture was stirred for an additional hour. Solvent was then removed under reduced pressure and pyridine was further co-evaporated with toluene (10 mL) two times under reduced pressure. The residue was purified by silica gel column chromatography (24g) column, eluting from 0% to 25% ethyl acetate in heptane to afford 6-im-butylJV-[(6-fluoropyridin-2-yi)sulfinyI]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (850 mg, 64% yield) as an off-white solid. ^JH NMR (300 MHz, CDC1₃): ppm 1.08 (s, 9 H), 2.00 (s, 6 H), 2.29 (s, 3 H), 6.86 (s, 2 H), 7.03 - 7.89 (m,

H), 7.12 (d, 7=8.0,1 H), 7.99-8.11 (m, 2 H), 8.53 (d, 7 = 8.0 Hz, 1 H). ^,9FNMR (282 MHz, CDCI3): ppm -64.8 (s, 1 F). [M+H]⁺= 456.1.

Step 3: ô-Oerr-biitylj-A-tb-iluoropyridine-Z-sulfonïmidûyl)-!(mesÎtyloxy)nicotinamide

965

To a solution of 6-ieri-butyl-A^r-[(6-fluoropyridin-2-yl)sulfinyl]-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (419 mg, 0,920 mmol) in dichloromethane (10 mL) was added rm-butyl hypochïorite (94.8 pL, 0.87 mmol) at 0 °C. The mixture was stirred at this température for 2 days. The solvent was then removed under reduced pressure at below 21 °C. The crude product was used directly in the next step without further purification. The residue was dissolved in acetonitrile (11 mL) then hexamethyldisilazane (1.09 mL, 5.22 mmol) was added at 0 °C. The mixture was stirred for 1 hour at room température then quenched by the addition of water (3 mL). The mixture was extracted with ethyl acetate (2 x 20 mL), dried over sodium sulfate, fîltered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography column (24g), eluting from 0% to 5% methanol in dichloromethane, to afford 6-(iert-butyl)-M(6-fluoropyridine-2-sulfonimidoyl)-2(mesityloxy)nicotinamide (286 mg, 70% yield) as a white solid. ^lH NMR (300 MHz, CDCh): ppm 1.08 (s, 9 H), 2.03 (s, 6 H), 2.29 (s, 3 H), 6.84 (s, 2 H), 6.97 (d, J = 8.0 Hz, 1 H), 7.16 (ddd, J = 8.0, 2.6, 0.8 Hz, 1 H), 7.94 - 8.11 (m, 2 H), 8.35 (d, J = 8.0 Hz, 1 H). ¹⁹F NMR (282 MHz, CDC1₃): ppm -64.1 (s, 1 F). [M+H]⁺= 471.1.

Step 4: 6-(/eri-butyl)-AM6-((2,4-dimethoxybenzyl)amïno)pyridme-2su]fonimidoy])-2-(mesityloxy)nicotinamidc

A mixture of 6(iirPbutyl)-A^r-(6-((2,4-dimethoxybenzyl)amino)pyridine-2sulfonimidoyl)-2-(mesityIoxy)nicotinamide (400. mg, 0.850 mmol), 2,4-dimethoxybenzyl amine

966 (0.25 mL, 1.7 mmol) and triethylamine (0.24 mL, 1.7 mmol) in dimethylsulfoxide (10 mL) was stirred at 100 °C ovemight. After completion, the mixture was diluted with ethyl acetate (20 mL), washed with brine (2 x 10 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography on a 25g column, eluting from 0% to 100% acetonitiile in water containing 0.1% formic acid to afford 6(teri-buty])-jV-(6-((2,4-dimethoxybenzyl)amino)pyridme-2-sulfommidoyl)-2(mesityloxy)nicotinamide (426 mg, 81.1% yield) as a yellow foam. ^!H NMR (300 MHz, CDC1₃): ppm 1.07 (s, 9 H), 2.03 (s, 6 H), 2.27 (s, 3 H), 3.77 (s, 3 H), 3.82 (s, 3 H), 4.42 (s, 2 H), 5.18 5.35 (br. s., 1 H), 6.36 (dd, J = 8.3, 2.3 Hz, 1 H), 6.45 (d, J = 2.3 Hz, 1 H), 6.52 (d, J = 8.3 Hz, 1 H), 6.81 (s, 2 H), 6.94 (d, J = 7.9 Hz, 1 H), 7.18 (d,7=8.3Hz, 1 H), 7.28 (d, J = 7.4 Hz, 1 H), 7.45 (dd, J = 8.5, 7.4 Hz, 1 H), 8.38 (d, 7 = 7.9 Hz, 1 H). [M+H]⁺= 618.2.

Step 5: /V-(6-aminopyrîdine-2-sulfoninridoyl)-6-(ieri-butyl)-2(mesityloxy)nicotinamide

To a stirred solution of/V-[amino(6-{[(2,4-dimethoxyphenyl)methyl]amino}pyridm-2yl)oxo-λ⁶-sulfanylidene]-6-terΛb^tyl·2-(2,4,6-trimethylphenoxy)pyridme-3-carboxamide (420 mg, 0.68 mmol) in dichloromethane (50 mL) was added trifluoroacetic acid (12 mL) and the mixture was stirred until LCMS indicated completion. The reaction mixture was diluted with dichloromethane (20 mL) and water (20 mL) and the pH was adjusted to greater than 6 by adding solid NaHCO3. The mixture was extracted with dichloromethane (2 x 20 mL) and the combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure, The residue was purified by reverse-phase column chromatography on a 25g column, eluting from 0% to 100% acetonitiile in water containing 0.1% formic acid to afford ZV-(6aminopyridine-2-sulfonimidoyl)-6-(teri-butyl)-2-(mesityloxy)nicotinamide (90. mg, 28% yield) as a white solid. ^!H NMR (300 MHz, CDC13 + 5 drops of DMSO-ri₆) ppm 0.96 (s, 9 H), 1.90 (s,

967

H), 2.17 (s, 3 H), 5.78 (br. s., 2 H), 6.59 (d, J = 8.2 Hz, 1 H), 6.71 (s, 2 H), 6.82 (d, J = 7.8 Hz, 1 H), 7.19-7.31 (m, 3 H), 7.36-7.47 (m, 1 H), 8.15 (d, 7=7.8 Hz, 1 H). [M+H]⁺= 468.1.

Step 6: A-[(S)-amino(6-aminopyridin-2-yl)oxo-X⁶-sulfanyIidene]-6-ierf-butyl-2(2,4,6-trimethy]phenoxy)pyridine-3-carboxamide and A-[(R)-amino(6-aminopyridin-2yl)oxo-X⁶-sulfanylidene]-6-ieri-butyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide

A-(6-aminopyridine-2-sulfonimidoyl)-6-(i£rZ-butyl)-2-(mesÎtyloxy)nicotinamide was dissol ved in a methanol and dimethylsulfoxide mixture (4:1 (v/v)) to an approximate concentration of 16 mg/mL. The solution was subjected to chiral SFC (70 pL injections; column: Chiralpak OD-H (250 x 21.2 mm),5pm; mobile phase: 20% methanol, 80% CO₂; flow: 10.0 mL/min) to giveA-[(S)-amino(6-aminopyridin-2-yl)oxo-X⁶-sulfanylidene]-6-Zer/-butyl-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (peak 1, enantiomer I, 98% ee), andA-[(Æ)amino(6-aminopyndin-2-yl)oxo-X⁶-sulfanylidene]-6-Zert-butyl-2-(2,4,6trimethylphenoxy)pyridîne-3-carboxamide (peak 2, enantiomer 2, 97.3% ee). Absolute stereochemistry is inknown.

PREPARATION 69: (R)-l-(2,4,6-trimethylbenzyl)indoline-2-carboxylic acid

A suspension of (/ï)-indoline-2-carboxylic acid (300. mg, 1.84 mmol) and potassium hydroxide (309.5 mg, 5.517 mmol) was stined in isopropanol (2.010 mL) for 20 minutes. The reaction mixture was stirred for 20 minutes and was treated with 2-(chloromethy 1)-1,3.5 trimethyl-benzene (341.2 mg, 2.023 mmol). The reaction mixture was stirred overnight. The

968 reaction mixture was diluted with ethyl acetate and water. The mixture was extracted with ethyl acetate and the aqueous layer was acidified to pH 5 and extracted again with ethyl acetate. The combined organics were washed with water, brine, dried over sodium sulfate, filtered and concentrated to yield (R)-l-(2,4,6-trimethylbenzyl)indoline-2-carboxylic acid (220. mg, 0.745 mmol, 40.5%) as a white solid. ESI-MS m/z cale. 295.15723, found 296.5 (M+l)⁺; Rétention time: 1.79 minutes.

PREPARATION 70: toi-butyl 2,3,4,5-tetrahydro-lH-l-benzazepine-2carboxylate

Step I: 3-(2-bromophenyl)propan-l-oï

A solution of 3-(2-bromophenyl)propanoic acid (1.0 g, 4.4 mmol) in anhydrous tetrahydrofuran (5.0 mL) was treated with borane-tetrahydrofuran complex in tetrahydrofuran (1.0 M, 7.0 mL, 7.0 mmol) at 0 °C over a period of 15 minutes. The mixture was stirred at 0 °C for an additional 1 hour. After complet! on, the résidu al borane was quenched by the cautious addition of water (1 mL) and the solvent was removed under vacuum. The resulting residue was dissolved in ether (20 mL) and the organic layer was washed with water (20 mL), brine (20 mL), dried over sodium sulfate, filtered, and concentrated under pressure to afford 3-(2bromophenyl)propan-I -oi as a colorless oil (938 mg, quantitative yield). This compound was used in the following step without further purification.

[001864] Step 2: Synthesis of l-bromo-2-(3-bromopropyI)benzene

To a solution of 3-(2-bromophenyl)propan-l-ol (938 mg, 4.36 mmol) and triphenylphosphine (2.29 g, 8.72 mmol) in anhydrous dichloromethane (25 mL) was added 1Vbromosuccinimide (1.63 g, 9.16 mmol) at 0 “C and the mixture was stirred at room température for 2 hours. After completion, the reaction was quenched by the addition of water (20 mL) and the organic layer was separated and dried over sodium sulfate, filtered and concentrated under pressure. The residue was purified by silica gel chromatography (40 g), eluting from 0% to 10%

969 ethyl acetate in heptanes to afford l-bromo-2-(3-bromopropyl)benzene as a yellow oil (830 mg, 68.5% yield). ^lH NMR (300 MHz, CDCR) ppm 2.13 - 2.24 (m, 2 H), 2.90 (t, J = 7.7 Hz, 2 H), 3.43 (t, J = 6.5 Hz, 2 H), 7.04 - 7.12 (m, 1H), 7.20 - 7.28 (m, 2 H), 7.54 (d, J = 7.7 Hz, 1 H). [M+H]⁺ = 279.1.

Step 3: tert-butyl 2-amino-5-(2-bromophenyl)pentanoate

To a suspension of potassium hydroxide (1.27 g, 22.6 mmol) in dimethylsulfoxide (10 mL) cooled in a cold water bath was added AQdiphenylmethylenejglycine teri-butyl ester (2.23 g, 7.55 mmol). Th en, l-bromo-2-(3-bromopropyl)benzene (938 mg, 4.36 mmol) in dimethyl sulfoxide (10 mL) was added dropwise and the mixture was stirred at room température for 1 hour. After completion, the mixture was diluted with ethyl acetate (100 mL) and the solution was filtered. The mixture was washed with water (3x50 mL), brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. After drying under high vacuum, the residue was dissolved in tetrahydrofuran (78 mL). To this solution was added 1 N HCI (75.7 mL, 75.7 mmol) dropwise at 0 °C and the mixture was stirred at this température for an additional 2 hours. The resulting mixture was then neutralized by addition of solid sodium bicarbonate and extracted with dichloromethane (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under pressure. The residue was purified by silica gel chromatography (80 g) eluting from 0% to 10% ethyl acetate in heptanes to afford tert-butyl 2-amino-5-(2bromophenyl)pentanoate as a yellow oil (2.21 g, 86.4% yield over two steps). ’H NMR (300 MHz, CDC1₃) ppm 1.45 (s, 9 H), 1.60 - 1.81 (m, 2 H), 2.70 - 2.78 (m, 2 H), 3.33 - 3.39 (m, 2 H), 7.00-7.09 (m, 1 H), 7.18 - 7.24 (m, 2 H), 7.51 (d,J=8.1 Hz, 1 H). [M+H]⁺ = 328.1.

Step 4: terNbutyl 2,3,4,5-tetrahydro-lH-l-benzazepine-2-carboxylate

970

A mixture ofterr-butyl 2-amino-5-(2-b~oniophenyl)pentanoate (1.7 g, 5.2 mmol), palladium acetate (116 mg, 0.518 mmol), triphenylphosphine (408 mg, 1.55 mmol), and césium carbonate (3.4 g, 10. mmol) in toluene (80 mL) was stirred at 110 °C ovemight. After completion, the mixture was dihited with ethyl acetate (100 mL) and washed with water (50 mL), brine (50 mL), dried over sodium sulfate, fîltered, and concentrated under reduced pressure, The residue was purified by silica gel chromatography (80 g) eluting from 0% to 20% ethyl acetate in hep taries to afford tert-butyl 2,3,4,5-tetrahydro-177-1 -benzazepine-2-carboxylate as a yellow oil (527 mg,4L0%). 'H NMR (300 MHz, CDC1₃) ppm 1.46-1.57 (m, 10 H), 1.66-1.82 (m, 1 H), 1.94-2.08 (m, 1 H), 2.24-2.36 (m, 1 H), 2.65-2.77 (m, 1 H), 2.78-2.91 (m, 1 H), 3.44 (dd, J = 10.7, 2.3 Hz, 1 H), 4.50 (br. s, 1 H), 6.79-6.88 (m,2 H), 7.01-7.11 (m, 2 H). [M+H]⁺ = 248.2

PREPARATION 71: 5-ethyl-l-[(2,4,6-trimethylpbenyl)methyl]pyrrolo[2^b]pyridine-2-carboxylate

A solution ofmethyl 5-bromo-l-[(2,4,6-trimethylphenyl)methyl]pyrrolo[2,3b]pyridine-2-carboxylate (150. mg, 0.387 mmol),l,2-dimethoxyethane (1.35 mL) 4,4,5,5tetramethyl-2-vinyl-l,3,2-dioxaborolane (119.3 mg, 0.7746 mmol), and potassium carbonate (187.4 mg, 1.356 mmol) in 1,2-dimethoxyethane (1.35 mL) and water (0.45 mL) was degassed and put under nitrogen. The reaction mixture was treated with tetrakis(tripheny]phosphine)palladium (0) (44.75 mg, 0.03873 mmol) and irradiated in a micro wave reactor at 120 °C for 30 minutes. The mixture was diluted with water and extracted three times with ethyl acetate. The combined organics were washed with brine, dried oer sodium sulfate, fîltered, and concentrated under reduced pressure. The resulting crude methyl 1 -[(2,4,6trimethylphenyl)methyl]-5-vinyl-pyrrolo[2,3-b]pyridine-2-carboxylate was dissolved in methanol (12.45 mL) and put under a nitrogen atmosphère before being treated with wet 10% palladium on carbon (41.22 mg, 0.03873 mmol). The mixture was evacuated and put under a

971 hydrogen atmosphère for 16 hours. The reaction mixture was put under a nitrogen atmosphère and filtered through celite to afford the crude product which was purified on 12 g of silica gel utilizing a gradient of 0-40% ethyl acetate in hexanes to yield methyl 5-ethyl-l-[(2,4,6trimethylphenyl)methyl]pyrrolo[2,3-b]pyridine-2-carboxylate ESI-MS m/z cale. 336.18378, found 337.5 (M+l)⁺; Rétention time: 2.24 minutes.

PREPARATION 72:

Step 1: Synthesis of 2-(2-bromophenyl)propan-2-amine

Méthylmagnésium bromide (54.9 mL, 164.8 mmol, 3M in diethyl ether) was added to a solution of 2-bromobenzonitrile (10.0 g, 54.9 mmol) in diethyl ether (200 mL) and the reaction mixture was stirred at room température under nitrogen. After 30 minutes, titanium isopropoxide (16.3 mL, 54.9 mmol) was added and resulting mixture was refluxed ovemight. Once cooled to 0 °C, 2N NaOH (400 mL) was added and resulting mixture was stirred at room température for 30 minutes. The solution was diluted with saturated aqueous sodium bicarbonate (400 ml.), extracted using methyl ZcrAbutyl ether (3 x 2Û0 mL). The organic layers were combined and concentrated under reduced pressure. The residue was dissolved in 1N hydrochloric acid (75 mL) and washed with methyl terr-butyl ether (150 mL), The aqueous layer was basified to pH 10-11 using 2N sodium hydroxide and the resulting solution was extracted with methyl Zeri-butyl ether (3 x 200 mL). The organic layers were combined, dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 2-(2-bromophenyl)propan-2-amine (9.0 g, 77% yield) as orange oil. ^!H NMR (300 MHz, CDC1₃): ppm 1.66 (s, 6 H), 7.02 - 7.10 (m, 1 H), 7.13 7.43 (m, 1 H), 7.55-7.61 (m, 2 H). [M+H]⁺= 214.0.

Step 2: Synthesis offe/ributyl 2-{[2-(2-bromophenyl)propan-2-yl]amino}acetate

972 tert-Butyl 2-bromoacetate (6.24 mL, 42.2 mmol) was slowly added to a solution of2(2-bromophenyl)propan-2-amine (9.04 g, 42.22 mmol) and potassium carbonate (14.6 g, 105.6 mmol) in dry tetrahydrofuran ( 100 mL) at 0 °C and reaction mixture was stirred at 50-55 °C for 16 hours. Once cooled to room température, reaction mixture was diluted with brine (100 mL) and extracted using ethyl acetate (3 x 100 mL). The organic layers were combined, dried over anhydrous magnésium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting from 0% to 20% ethyl acetate in heptanes to afford tert-butyl 2-{[2-(2-bromophenyl)propan-2-yl]amino}acetate (4.5 g, 32% yield) as a yellow oil. Ή NMR (300 MHz, CDC1₃) ppm 1.43 (s, 9 H), 1.63 (s, 6 H), 2.94 (s, 2 H), 7.09 (dt,7=7.6, 1.7 Hz, 1 H), 7.22-7.31 (m, 1 H), 7.43 (dd,7=7.9, 1.6 Hz, 1 H), 7.58 (dd,7 = 7.9,1.4 Hz, 1 H). [M+H]⁺= 328.1.

Step 3: tert-butyl 2-{[(benzyloxy)carbonyI][2-(2-bromophenyl)propan-2yl}amino}acetate

Diisopropylethylamine (5.48 mL, 31.4 mmol) was added to a solution of teri-butyl 2{[2-(2-bromophenyl)propan-2-yl]amino}acetate (4.48 g, 13.7 mmol) in dichloromethane (50 mL) and solution was cooled to 0 °C. Benzyl chloroformate (3.51 mL, 24.6 mmol) was added dropwise at 0 °C and reaction mixture was stirred at room température overnight. The reaction mixture was diluted with dichloromethane (50 mL) and washed with 5% aqueous citric acid (2 x 50 mL) and brine (50 mL). The organic layer was dried over anhydrous magnésium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting from 0% to 10% ethyl acetate in heptane to afford tert-butyl 2-{[(benzyloxy)carbonyI][2(2-bromophenyl)propan-2-yl]amino}acetate (4.2 g, 67% yield) as a yellow oil. ’H NMR (300 MHz, CDC1₃): ppm 1.41 (s, 6 H), 1.55 (s, 3 H), 1.78 (s, 2 H), 1.84 (s, 4 H), 4.21 (s, 1.3 H), 4,32 (s, 0.7 H), 4,83 (s, 0.7 H), 4.99 (s, 1.3 H), 6.70-7.62 (m, 9 H). [M+H]⁺ = 484.1.

973

Step 4: 2-benzyl I-tert-butyl 3,3-dimethyl-2,3-dihydro-lH-isoindole-l,2dicarboxylate

Tris(dibenzylideneacetone)dipalladium(O) (87 mg, 0.10 mmol), 2'5 (diphenylphosphino)4V,N'-dimethyI-(l,l '-biphenyl)-2-amine (PhDavePhos) (73 mg, 0.19 mmol) and lithium tert-butoxide (0.31 g, 3.81 mmol) were added in order to a solution of teri-butyl 2{[(benzyloxy)carbonyl][2-(2-bromopheuyl)propan-2-yl]amino} acetate (0.88 g, 1.90 mmol) in dioxane (10 mL) previously degased and purged with nitrogen. The reaction mixture was stirred at 90 °C overnight. Once cooled at room température, the reaction mixture was diluted with ethyl 10 acetate (20 mL), fïltered and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting from 0% to 10% ethyl acetate in heptane to afford 2-benzyl 1ierf-butyl 3,3-dimethyl-2,3-dihydro-lH-isoindoIe-l,2-dicarboxylate (0.31 g, 43% yield) as an orange oil. ’HNMR (300 MHz, CDC1₃): ppm 1.31 (s, 6H), 1.45 (s, 3H), 1.65 (s, 1H), 1.73 (s, IH), 1.76 (s, 2H), 1.81 (s, 2H), 5.11-5.47 (m, 3H), 7.12-7.48 (m, 9H). [M+Na]⁺ = 404.2.

PREPARATION 73: 6-hydroxy-l-methylW-((6-nitropyridin-2-yl)sulfonyl)-2 (2,4,6-trimethylbenzyl)isoîndoline-l-carboxamide

974

Under an atmosphère of nitrogen, 6-methoxy-i-methyl-jV-[(6nitro-2pyridyl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isomdoline4-carboxamide (333 mg, 0.635 mmol) was dissolved in dichloromethane (30 mL). The mixture was cooled to -78 °C, and tribromoborane (5.046 g, 1.904 mL of 1 M, 1.904 mmol) was added to the reaction mixture dropwise. The mixture was slowly warmed to room température and stinred for 16 hours. The reaction mixture was added to approximately 50 mL of ice. The layers were separated, and the aqueous layerwas extracted with dichloromethane (3x5 mL). The combined organic layers were dried over sodium sulfate, concentrated, and purified on a column of silica gel utilizîng a gradient of 0 to 100% ethyl acetate in hexanes to yield 6-hydroxy-l-methyl-7V-[(6-nitro-2pyridyl)sulfonyl]-2-[(2,4,6-trimethylphenyl)methyl]isoindoline-l-carboxamide (90.7 mg, 0.178 mmol, 28.0%) ESI-MS /n/zcalc. 510.15732, found 511.5 (M+l)⁺; Rétention time: 0.56 minutes

PREPARATION 74: terf-butyl 2,3,4,5-tetrahydro-lH-benzo[c]aze_Pine-3carboxylate

Step 1: 3, 4-dihydro-lH-2-benzopyran-l-one

O

To a solution of isochroman (15.0 g, 112 mmol) in dichloromethane (1.4 L) stirred at room température was added, over 15 minutes, a homogeneous mixture of potassium permanganate (106 g, 672 mmol) and manganèse dioxide (58.0 g, 672 mmol), prepared by grinding potassium permanganate and then mixing with manganèse dioxide using a pestle and mortar. The suspension was vigorously stirred for 4 days at room température, and then filtered through a pad of Celite. The filtrate was concentrated and the residue was purified by silica chromatography, elutmg with a mixture of heptanes and ethyl acetate (0 to 20%) to provide 3,4dihydro-lH-2-benzopyran-l-one (8.2 g, 49% yield) as a colorless oil. ’H NMR (CDC1₃, 300 MHz) ppm 3.06 (t, J = 6.0 Hz, 2 H), 4.52 (t, J = 6.0 Hz, 2 H), 7.20 - 7.30 (m, 1 H), 7.38 (t, J 7.6 Hz, 1 H), 7.53 (t, J= 7.6 Hz, 1 H), 8.06 (d, 7 = 7.6 Hz, 1 H).

Step 2: ethyl 2-(2-bromoethyl)benzoate

975

Ο ο

Phosphorus tribromide (1.05 mL, 11.0 mmol) and bromine (0.62 mL, 12 mmol) were slowly added to a solution of 3,4-dihydro-l//-2-benzopyran-l-one (1.5 g, 10. mmol) in carbon tetrachloride (15 mL) cooled in an ice-water bath. The mixture was then stirred at room température for 16 hours. The resulting orange suspension was stiired at 60 °C for 3 hours. The red mixture was then cooled down and éthanol (10 mL) was slowly added at 0 °C (exothermic!). The reaction mixture (orange solution) was stirred for one hour. The reaction mixture was partitioned between dichloromethane (50 mL) and water (20 mL), The organic phase was separated and washed with brine (10 mL), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica chromatography, eluting with a mixture of ethyl acetate and heptanes (0 to 10%) to afford ethyl 2-(2-bromoethyl)benzoate (2.0 g, 78% yield) as a pale yellow oil. ’H NMR (300 MHz, CDC1₃) ppm 1.41 (t, 7 = 6.9 Hz, 3 H), 3.50 (t, 7 = 6,9 Hz, 2 H), 3.64 (t, 7 = 6.9 Hz, 2 H), 4.38 (q, 7 = 6.9 Hz, 2 H), 7.27 - 7.39 (m, 2 H), 7.45 (t, 7 = 7.5 Hz, 1 H), 7.96 (d, 7=7.5 Hz, 1 H).

Step 3: ethyl 2-(3-amino-4-ethoxy-4-oxobutyl)benzoate

The reaction was run in two separate batches.

N-(Diphenylmethylene)glycine ethyl ester (4.17 g, 15.6 mmol) was added to a suspension of finely powdered potassium hydroxide (2.63 g, 46.8 mmol) in dimethylsulfoxide (20 ml) cooled with an ice-water bath (an orange mixture was obtained). Then ethyl 2-(2bromoethyl)benzoate (4.0 g, 15.6 mmol) was added dropwise. The reaction was stiired at room température for 60 minutes and then diluted with ethyl acetate (150 mL). The solution was decanted into a séparation funnel and the solid (KOH) was discarded. The organic phase was

976 washed with water (3 x 50 mL,) brine, dried over anhydrous Na₂SOi and concentrated under reduced pressure, The second batch was run in a similar way: ethyl 2-(2-bromoethyl) benzoate (9.3 g, 36.1 mmol), N-fdiphenylmethylenejglycine ethyl ester (9.65 g, 36.1 mmol), potassium hydroxide (6.08 g, 108.3 mmol) and dimethylsulfoxide (50 mL).

The crude products of the two batches were combined (19 g) and dissolved in tetrahydrofuran (50 mL). The solution was cooled with an ice-water bath and 1 N HCI aqueous solution (60 mL) was added. The mixture was stirred at room température for 30 minutes. Water (50 mL) and ethyl acetate (50 mL) were added, the biphasic mixture was extracted and the two phases were separated. The aqueous phase was then basified with 2 N NaOH aqueous solution (30 mL) at 0 °C and the resulting aqueous solution was extracted with ethyl acetate (2 x 50 mL). The organic layers were combined, washed with brine (20 mL), dried over anhydrous Na₂SO₄and concentrated under reduced pressure. The residue was purified with silica chromatography, eluting with a mixture of methanol and dichloromethane (0-7%) to give ethyl 2-(3-amino-4ethoxy-4-oxobutyl)benzoate (6.6 g, 46% yield) as a yellow oiL ’H NMR (300 MHz, CDC1₃) 1.27 (t, 7 = 7.1 Hz, 3 H), 1.41 (t, 7 = 7.1 Hz, 3 H), 1.75 - 1.93 (m, 1 H), 1.97-2.14 (m, 1 H), 2.95 3.15 (m, 2 H), 3.42 - 3.54 (m, 1 H), 4.17 (q, 7 = 7.1 Hz, 2 H), 4.35 (q,7 = 7.1 Hz, 2 H), 7.207.30 (m, 2 H), 7.41 (t, 7 = 7.5 Hz, 1 H), 7.88 (d, 7 = 7.5 Hz, 1 H). LCMS: [M+H]⁺ = 280.2.

Step 4: Synthesis of ethyl l-oxo-2,3,4_f5-tetrahydro-lH-2-benzazepine-3carboxylate

O

Sodium métal (823 mg, 35.8 mmol) was added to anhydrous éthanol (270 mL, dried with 3 Â molecular sieves) in a flask at room température. The mixture was stirred at room température until ail the sodium had disappeared. Then a solution of ethyl 2-(3-amino-4-ethoxy4-oxobutyl)benzoate (5.0 g, 18 mmol) in anhydrous éthanol (30 mL) was added at room température. The reaction was stirred at room température for two days and then cooled with an ice-water bath. Thionyl chloride (10 mL) was slowly added (reacts violently) and the reaction was refluxed for 2 hours. The solvent was removed under reduced pressure and tbe residue was

977 taken up into ethyl acetate (100 mL), washed with saturated aqueous sodium bicarbonate (30 mL), brine, dried overNa₂SO4 and concentrated under reduced pressure. The residue was purified by silicachromatography, eluting with a mixture of ethyl acetate and heptanes (10 to 100%) to afford ethyl l-oxo-2,3,4,5-tetrahydiO-lH-2-benzazepme-3-carboxylate (2.9 g, 69% yield) as a yellow oil. ’H NMR (300 MHz, CDC1₃) ppm 1.24 (t, J = 6.7 Hz, 3 H), 2.07 - 2.25 (m, 1 H), 2.26 - 2.43 (m, 1 H), 2.70 - 2.84 (m, 1 H), 2.89 - 3.08 (m, 1 H), 3.80 - 3.95 (m, 1 H), 4.20 (q, J = 6.7 Hz, 2 H), 6.69 (s, 1 H), 7.20 (d, J = 7.2 Hz, 1 H), 7.33 (t, J = 7.2 Hz, 1 H), 7.41 (t, J = 7.2 Hz, 1 H), 7.70 (d, J = 7.2 Hz, 1 H). LCMS: [M+Hf = 234.1.

Step 5: terNbutyl l-oxo-2,3,4,5-tetrahy(lro-l£7-2-benzazepine-3-carboxylate

Butyl lithium (17.4 mL of 2.5 M in hexanes, 43.4 mmol) was added to a solution of anhydrous rert-butanol (4.7 mL, 50. mmol, distilled and then dried over potassium carbonate) in anhydrous tetrahydrofuran (40 mL) at -78 °C in a pressure tube under nitrogen. The mixture was stirred at room température for 10 min, then a solution of ethyl l-oxo-2,3,4,5-tetrahydro-lH-215 benzazepine-3-carboxylate (2.9 g, 12 mmol) in anhydrous tetrahydrofuran (10 mL) was added and the mixture was stirred at 30 °C ovemight. Volatiles were removed under reduced pressure and the residue was taken up into a mixture of water (40 mL) and dichloromethane (100 mL). The two phases were separated and the organic phase was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica chromatography, eluting with a mixture of ethyl acetate and heptanes (0 to 30%) to give ieri-butyl 1 -oxo-2,3,4,5tetrahydro-1 W-2-benzazepine-3-carboxylate (L4 g, 43% yield) as a white solid. 'H NMR (300 MHz, CDC1₃) ppm 1.44 (s, 9 H), 1.99 - 2.23 (m, 1 H), 2.32 (tt, J = 12.7, 6.3 Hz, 1 H), 2.77 (dd, J = 13.7, 6.3 Hz, 1 H), 2.89-3.11 (m, 1 H), 3.68 - 3.88 (m, 1 H), 6.64 (br. s„ 1 H), 7.21 (d,J=7.3 Hz, 1 H), 7.29-7.49 (m, 2 H), 7.71 (d, J = 7.5 Hz, 1 H). [M+H]⁺ = 262.1.

Step 6: ZcrNbutyl l-methoxy-4>5-dihydro- Z/-2-benzazepine-3-carboxylate

978

The reaction was run in two identical batches. 4 Â molecular sieves were added to a sealed tube. The tube was flame-dried under vacuum and then flushed with nitrogen. After the tube was cooled to room température, terr-butyl l-oxo-2,3,4,5-tetrahydro-lH-2-benzazepme-3carboxylate (522 mg, 2.00 mmol) was added followed by anhydrous dichloromethane (9 mL) and trime thyl oxonium tetrafluoroborate (296 mg, 2.00 mmol). The mixture was stirred at 30 °C for 16 hours. The mixture was quenched with a saturated aqueous sodium bicarbonate solution (30 mL). The resulting mixture was extracted with ethyl acetate (2 x 40 mL). The organic phases were combinéd and washed with brine (20 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue of the two batches were combinéd and purified by silica chromatography, eluting with a mixture of ethyl acetate and heptanes (0 to 30%) to provide tertbutyl l-methoxy-4,5-dihydro-3H-2-benzazepine-3-carboxylate (900. mg, 3.27 mmol, 81.7% yield) as a colorless oil. ^!H NMR (300 MHz, CDC1₃) ppm 1.43 (s, 9 H), 2.33-2.49 (m, 2 H), 2.58 - 2.70 (m, 2 H), 3.50 (dd, J= 11.0, 7.2 Hz, 1 H), 3.96 (s, 3 H), 7.20 - 7.28 (m, 1 H), 7.30 - 7.40 (m, 2 H), 7.41 - 7.47 (m, 1 H). LCMS: [M+H]⁺=276.1.

Step 7: teri-butyl 2,3,4,5-tetrahydro-lH-2-benzazepine-3-carboxylate o^z

Sodium cyanoborohydride (821 mg, 13.1 mmol) was added to a solution of tert-butyl l-methoxy-4,5-dihydro-37/-2-benzazepine-3-carboxylate (900. mg, 3.27 mmol) in acetic acid (3 mL) at 0 °C. The mixture was stirred at room température for 2 hours. The mixture was diluted with ethyl acetate (40 mL) and cooled with an ice-waterbath. An aqueous solution ofNaOH (25% w/v) was slowly added to adjust the pH to about 8. The two phases were separated and the aqueous phase was extracted with ethyl acetate (40 mL). The organic phases were combinéd, washed with brine (10 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica chromatography, eluting with a mixture of ethyl

979 acetate and dichloromethane (0 to 50%) to give tert-butyl 2,3,4,5-tetrahydro-lH-2-benzazepine3-carboxylate (610. mg, 2.47 mmol, 75.5% yield) as a yellow oil. 'H NMR (300 MHz, CDCR) ppm 1.46 (s, 9 H), 1.53 - 1.66 (m, 1 H), 2.17-2.37 (m, 1 H), 2.79-2.99 (m, 1 H), 2.99 - 3.18 (m, 1 H), 3.65 (dd, J = 10.6, 2.9 Hz, 1 H), 3.93 (d, J = 15.1 Hz, 1 H), 3.97 (d, J = 15.1 Hz, 1 H), 7.06 -7.21 (m, 4 H). [M+H]⁺ = 248.1.

PREPARATION 75: l-[(4-methoxyphenyl)methyl]-2-oxopyrrolidine’3sulfonamide

Step 1: 2,4-dibromo-)V-[(4-methoxyphei]yl)]nethyl]butananiide

O O

To a solution of 2,4-dibromobutanoyl chloride (5.00 g, 18.9 mmol) in dichloromethane (250 mL) at 0 °C was added triethylamine (2.38 g, 23.6 mmol) followed by 4methoxybenzyl amine (2.59 g, 18.9 mmol) and the mixture was stirred at 0 °C for 2 hours, The reaction was then poured at 0 C into a solution of 5% ci trie acid (80 mL) at pH = 3-4 and diluted with dichloromethane (100 mL) and water (50 mL). The organic layer was separated and the aqueous player was extracted again with dichloromethane (50 mL). The combined organic layer was dried over Na₂SÛ4, filtered and concentrated under reduced pressure to afford crude 2,4dibromo-A-[(4-methoxyphenyl)methyl]butanamide (7.09 g, 103%) as a brown solid. ’H NMR (300 MHz, CDCR) ppm 2.41 - 2.55 (m, 1 H), 2.64 - 2.84 (m, 1 H), 3.52 - 3.61 (m, 2 H), 3.80 (s, 3 H), 4.36 - 4.44 (m, 2 H), 4.55 (dd, J = 9.0,4.8 Hz, 1 H), 6.54 (br. s, 1 H), 6.85 - 6.91 (m, 2 H), 7.19 - 7.23 (m, 2 H). [Μ+Η]⁺ = 366.0.

Step 2: 3-bromo-l-[(4-inethoxyphenyl)methyl]pyrrolidin-2-one

980

To a solution of 2,4Mibromo-M[(4-methoxyphenyl)methyl]butanamide (3.25 g, 8.90 mmol) in tetrahydrofuran (120 mL) and N,N-dimethylformamide (12 mL) was added sodium hydride (427 mg of 60% dispersion in minerai cil, 17.8 mmol) portionwise at 0 ^DC and the mixture was stirred at room température for 2.5 hours. The reaction mixture was cooled again to

0 °C and quenched carefully with an aqueous 5% citric acid solution (10 mL). The volatiles were then removed under reduced pressure. The reaction mixture was diluted with water and dichlorometbane and the aqueous layer was extracted twice with dichlorometbane. The combined organic layers were dried over Na₂SO4, fîltered, concentrated under reduced pressure and co-evaporated with heptanes as a co-solvent (twice) to afford crude 3-bromo-l-[(4- methoxyphenyl)methyl]pyrroljdin-2-one (2.5 g, 99%) as a pale yellow oil. ’H NMR (300 MHz, CDC1₃) ppm 2.22 - 2.32 (m, 1 H), 2.47 - 2.60 (m, 1 H), 3.14 - 3.21 (m, 1 H), 3.35 - 3.44 (m, 1 H), 3.80 (s, 3 H), 4.33 - 4.52 (m, 3 H), 6,84 - 6.87 (m, 2 H), 7.15 - 7.20 (m, 2 H). [M+H]⁺ = 284.0.

Step 3: methyl 3-({l-[(4-methoxyphenyl)methyl]-2-oxopyrrolidin-3 15 yl}sulfonyl)propanoate

To a solution of 3-bromo-l-[(4-methoxyphenyl)methyl]pyriOlidin-2-one (2.50 g, 8.80 mmol) in dimethylsulfoxide (50 mL) was added sodium 1-methyl 3-sulfinopropanoate (1.53 g,

8.80 mmol) and the reaction was stirred at room température for three days. The solution was diluted with water (400 mL) and extracted with dichlorometbane (2 x 250 mL). The combined organic layer was washed with water (150 mL), brine (100 mL), dried over Na₂SO4, fîltered and concentrated under reduced pressure to afford crude methyl 3-({ l-[(4-methoxyphenyl)methyl]-2oxopyrrolidin-3-yl}sulfonyI)propanoate (2.5 g, 80.% yield). ^lH NMR (300 MHz, CDC1₃) ppm

2.31 - 2.45 (m, 1 H), 2.65 - 2.75 (m, 1 H), 2.85 - 3.05 (m, 2 H), 3.26 (dt, J = 9.4, 3.8 Hz, 1 H), .41 - 3.50 (m, 1 H), 3.74 (s, 3 H), 3.79 (s, 3 H), 3.77 - 3.92 (m, 2 H), 4.01 (dd, J = 10.2,4.6 Hz, 1 H), 4.44 (s, 2 H), 6.87 (d, 8.6 Hz, 2 H), 7.16 (d, J = 8.5 Hz, 2 H). [M+H]⁺ = 356.1.

981

Step 4: sodium l-[(4-methoxyphenyl)methyl]-2-oxopyrrolidine-3-sulfînate

To a solution of methyl 3-({ l-[(4-methoxyphenyl)methyl]-2-oxopyrrolidin-3yl)sulfonyl)propanoate (2.50 g, 7.03 mmol) in a 1:1 (v/v) mixture of tetrahydrofuran and methanol (40 mL) was added sodium methoxide (3.39 mL of 25 wt. % in methanol, 14.S mmol) and the reaction was stirred at room température for 4 hours. The reaction mixture was then concentrated under reduced pressure to remove the methyl acrylaie and kept under reduced pressure to provide crude sodium 1-[(4-methoxyphenyl)methyl]-2-oxopyrioIidine-3-sulfinate that was used direct]y in the next step without further purification [M+H]⁺ = 270.0 (sulfinic acid).

Step 5: Synthesis of l-[(4-inethoxyphenyI)methy]]-2-oxopyrrolidine-3sulfonamîde

To a solution of crude sodium L[(4-methoxyphenyl)methyl]-2-oxopyrrolidine-3sulfinate (2.05 g, 7.03mmoi) in dimethylsulfoxide (20 ml) was added a solution of hydroxylamine-O-sulfonic acid (3.98 g, 35.2 mmol) and sodium acetate (2.19 g, 26,7 mmol) in water (7 mL) at 0 °C. The reaction was stirred for 16 hours at room température then diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate (2 x 100 mL). The

982 combined organic layer was washed with brine (75 mL), dried over Na₂SO₄, fîltered and concentrated under reduced pressure. The crude material was purified by silica-gel chromatography using 0% to 10% methanol in dichloromethane (containing 1% NH₄OH) to afford l-[(4-meihoxyphenyl)methyl]-2-oxopyrrolid ine-3-su Ifonamide (1.3 g, 63% yield) as a pale brown solid. ‘H NMR (300MHz, CDCI3) ppm 2.29- 2.73 (m, 2 H), 3.14 - 3.34 (m, i H), 3.34-3.51 (m, 1 H), 3.80 (s, 3 H), 3.89 - 4.11 (m, 1 H), 4.30-4.61 (m, 2 H), 5.25 (br.s.,2H), 6.75 - 6.98 (m, 2 H), 7.10 - 7.22 (m, 2 H). [M+H]⁺ = 285.1.

PREPARATION 76: 6-(3-fluoro-5-isobutoxy-phenyl)-A-(2-oxopyrrolidin-3yl)sulfonyl-2-(2,2,4-trimetIiylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 466)

6-(3-fluoro-5-isobutoxy-phenyl)-N-[l-[(4-methoxyphenyl)methyl]-2-oxo-pyrrolidin-3 yl ] sulfony 1-2-(2,2,4-trimethy Ipyrrolidin-l-y l)pyrid ine-3-carboxamide (32.7 mg, 0.0490 mmol) was dissolved in a mixture of tri fl uoro acetic acid (0.9319 mL) and dichloromethane (0.9319 mL). Trifluoromethanesulfonic acid (25.75 mg, 15.18 pL, 0.1716 mmol) was then added and the mixture and stirred at ambient température for 20 hours. The reaction mixture was concentrated, then diluted with dimethylsulfoxide and purified by reverese-phase chromatography utilizing a C18 column and a gradient of 1-99% acetonitrile in 5 mM aq HCl to yield 6-(3-fluoro-5isobutoxy-phenyl)-M(2-oxopyrrolidin-3-yl)sulfonyl-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine3-carboxamide (Compound 466) ^!H NMR (400 MHz, DMSO-d₆) 5 8.27 (d, J = 19.3 Hz, 1H), 7.94 (d, J =8.0 Hz, 1 H), 7.72 (d, 7 = 8.0 Hz, 1 H), 7.51 (s, 1 H), 7.43 (d,7= 10.1 Hz, 1 H), 7.28 (dd, 7 = 14.4, 8.0 Hz, 1 H), 6.90 (dt, 7 = 10.6, 2.3 Hz, 1 H), 4.61 - 4.44 (m, 1 H), 3.84 (d, 7 = 6.7 Hz, 2H), 3.40 -2.86 (m, 4H), 2.16- 1.91 (m, 2H), 1.71 - 1.60 (m, 7H), 1.60- 1.49 (m, 1H), 1.16 (s, IH), 1.06 - 0.96 (m, 10H). ESI-MS m/z cale. 546.2312, found 547.3 (M+l)⁺; Rétention time: 1.87 minutes

PREPARATION 77: S-isopropyl-l-fZ^^-trimethylbenzyll-lH-indole-Zcarboxylic acid and 5-propyl-l-(2,4,6-trimethylbenzyl)-lH-indoIe-2-carboxyIic acid

983

Step 1: 5-bromo-l-[(2,4,6-trimethylphenyl)methyl]indole-2-carboxylic acid (0.7000 g, 1.880 mmol), [l,l'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (68.78 mg, 0.09400 mmol), aqueous sodium carbonate (1.880 mL of 2 M, 3.760 mmol), and 2-isopropenyl-4,4,5,5-tetramethyLl,3,2-dioxaborolane (315.9 mg, 1.880 mmol) in dioxane (5 mL) were added to a microwave reactor vial. The vial was purged with nitrogen, capped and heated to 120 °C for 45 minutes in a microwave reactor. The reaction mixture was diluted with water and extracted with ethyl acetate (2 x 10 mL). The organic layers were dried over sodium sulfate, concentrated, and purified by re verse-phase chromatography utilizing a C18 column and a gradient of 30-90% acetonitrile in 5 mM aq HCl to give a mixture of products which could not be separated under these spécifie condition. This materîal was dissolved in methanol (10 mL) and palladium on carbon (20.01 mg, 0.01880 mmol) was added to the reaction mixture The mixture was stirred under an atmosphère of hydrogen for 4 hours. The mixture of crude products was filtered, through a pad of silica gel with 100 mL of 15% methanol in dichloromethane and used for the next step without further manipulation. ESI-MS m/z cale. 335.19, found 336.5 (M+l)⁺; Rétention time: 0.84 minutes.

PREPARATION 78: (4A)-2,2,4-trimethylpyrroIidine Step 1: Methyl 2,4-dimethyI-4-nitropeiitanoate

A 1-L three-necked flask was fitted with a dropping funnel, and a thermometer. A solution of 2-nitropropane (178 g, 2.00 mol) in dioxane (100 mL) and a 40% aqueous solution of benzyltrimethylammonium hydroxide (Triton B, 20.0 mL, 420. mmol) were added to the flask. The flask was heated to 70 °C in an oil bath and methyl méthacrylate (200. g, 212.3 mL, 2.00

984 mol) was added via a dropping fimnel over 45 minutes. The température rose to about 100 °C during the addition then dropped to - 90 °C. The mixture was then heated at 100 °C for 4 hours. The reaction mixture was cooled to room température and 1 N hydrochloric acid (80 mL) was added. Water (500 mL) and diethyl ether (1000 mL) were added to the reaction flask. The mixture was poured into a separatory tunnel and organic layer was washed with water (2 x 400 mL), brine (400 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a yellow liquid. The product was distilled through a short path distillation apparatus to give a pale yellow liquid (356 g, 94%) (oil bath température 150 °C, an oil pump, collecting température 100 to 108 °C). ‘H NMR (CDCI₃, 250 MHz): δ 3.67 (s, 3H), 2.55-2.35 (m, 2H),2.10- 1.90 (m, 1H), 1.58 (s, 3H), 1.53 (s, 3H), 1.18 (d, 7=6.5 Hz, 3H).

Step 2: (lîj-SjSjS-trimethylpyrrolidin-Z-one and (5)-3,5,5-trîmethylpyrrolidin-2one

A solution of methyl 2,4-dimethyl-4-nitro-pentanoate (100. g, 528.5 mmol), nickel(II) chloride hexahydrate (25.12 g, 105.7 mmol), water (28.57 g, 28.57 mL, 1.586 mol) and methanol (1.200 L) was cooled to 0 to 5 °C. Sodium borohydride (49.98 g, 1.321 mol) was slowly added to the reaction mixture while maintaining the reaction température below 20 °C. The addition was exothermic with steady and prolonged gas génération. THe réaction mixture was allowed to stand for 14 days. A solution of potassium carbonate (146.1 g, 1,057 mol) in water (1.000 L) was slowly added to the reaction mixture. The reaction mixture was then filtered through a pad of celite. The pad was then washed with three 100 mL portions of methanol. The reaction mixture was then concentrated under reduced pressure to remove the methanol. Methyl tertbutyl ether (1 L) was added. The layers were separated and the aqueous layer was extracted twice with 400 mL portions of methyl ier/-butyl ether. The combined organic layers were dried over sodium sulfate, filtered, and evaporated to dryness. This material was then portioned between methyl ieri-butyl ether and an aqueous solution of sodium chloride. The organic layer was separated, dried over magnésium sulfate, filtered, and then evaporated to dryness to yield 41.5 g (61.7%) o f an off-white solid. The stereoisomers were separated using supercri tic al fluid

985 chromatography on a ChiralPak AS-H (250 x 4.6 mm), 5 pm column using 10% methanol in CO₂at a flow rate of 3.0 mL/min.

Step 3: ( !R)-2,2,4-triinethylpy: ro!idine

A solution of (3Æ)-3,5,5-trimethylpyrrolidm-2-one (20.0 g, 157 mmol) in tetrahydrofnran (200.0 mL) was cooled to 0 to 5 °C. Lithium aluminum hydride (8.006 g, 236.0 mmol) was added in portions over 10 minutes while maintain the température of the reaction mixture below °C. The addition was somewhat exothermic and degassing was observed. The suspension was heated to reflux for 9.5 hours. After cooling to room température au addition al portion of lithium 10 aluminum hydride (1.601 g, 1.746 mL, 47.19 mmol) was added to the reaction mixture. The mixture was then heated to reflux for 2.5 hours. The reaction mixture was cooled to 7 °C and an aqueous solution of sodium sulfate (27.93 mL of 20 % w/v, 39.32 mmol) was slowly added to the reaction mixture. The reaction mixture was then diluted with 200 mL of methyl ieri-butyl ether and ffltered through a pad of celite. The filtrate was dried over sodium sulfate, filtered, and 15 concentrated at ambient pressure to remove the ethers. The crude material was purified by distillation (28 °C/50 torr) to afford 10. g (56%) of a colorless liquid. 1H NMR (400 MHz, Chloroform-tZ)^ 3.11 (dd,7 = 10.8,7.3 Hz, 1H),2.51 (dd, J = 10.9,8.1 Hz, 1 H), 2.32 - 2.15 (m, 1H), 1.80 (dd, 7= 12.4,8.1 Hz, 1H), 1.65 (s, 1H), 1.19 (s, 3H), 1.17-1.08 (m, 4H), 1.01 (d,7 = 6.8 Hz, 3H). The absolute stereochemistry was determined by X-ray crystallography of the (2R)~ 20 2-(2-chlorophenyl)-2-hydroxy-acetic acid sait.

The following compounds can be synthesized using the procedures described herein (5)-4-ethyl-2,2-dimethylpyrrolidine, and (Æ)-4-ethyl-2,2-dimethylpyrrolidine

The following compounds can be synthesized using the procedures described herein 25 using lithium aluminum dueterohydride:

(S)-2,2,4-trimethylpyrrolidine-5,5-z/2afid,

986 (R)-2,2,4-trimethy]pyrrolidine-5,5-if2

Préparation 79: 3-Isobutoxy-lH-pyrazole Step 1: l-(3-isobutoxy-JH-pyrazol-l-yl)ethan-l-one

A 4 mL vial was charged with L(3-hydroxypyrazol-l-yl)ethanone (100. mg, 0.793 mmol), potassium carbonate (164.3 mg, 1.189 mmol) and anhydrous DMF (1.000 mL). ΙΟ romo-2-methyl-propane (119.5 mg, 94.84 pL, 0.8722 mmol) was added, the vial was capped and the mixture was stirred at room température for 16 hours. The reaction was stirred at 80°C for one hour. The mixture was diluted with ethyl acetate (50 ml) and water (25 mL) and the two phases were separated. The aqueous phase (pH = 9-10) was further extracted with ethyl acetate (20 mL). The combined extracts were dried over sodium sulfate and the solvents evaporated to give 100 mg of a crude oil. The product was dissolved in dichloromethane and purifîed by flash chromatography on silica gel (4 g column ) using a gradient of ethyl acetate (0 to 50 % over 15 minutes) in hexanes. The pure fractions were combined and the solvents removed under reduced pressure to provide l-(3-isobutoxypyrazol-l-yl)ethanone (78 mg, 0.43 mmol, 54%) as a colorless oil.

ESI-MS m/z cale. 182.10553, found 183.2 (M+l)⁺; Rétention time: 1.34 minutes. ’H NMR (400 MHz, Chloroform-d) δ 8.05 (d,J=3.0 Hz, 1H),5.96 (d, 7=3.0 Hz, 1 H), 3.99 (d,7=6.6 Hz, 2H),2.58 (s, 3H), 2.09 (dp, 7= 13.4, 6.7 Hz, 1H), LOI (d, 7=6.7 Hz, 6H).

Step 2: 3-Isobutoxy-lH-pyrazole

987 l-(3-Isobutoxy-l//-pyrazol-l-yl)ethan-l-one (72 mg, 0.40 mmol) was treated with methanol (1 mL) and NaOH (65.85 pL of 6 M, 0.3951 mmol) at room température for 1 hour. The volatiles were removed under reduced pressure. The residue was taken up in ethyl acetate (25 mL) and brine (20 mL)and two phases were separated. The aqueous phase was further extracted with ethyl acetate (20 mL) and the combined extracts were dried over sodium sulfate. After évaporation of the solvent, 3-isobutoxy-l/7-pyrazole (55 mg, 0.39 mmol, 99%) was isolated as a colorless viscous oil. ESI-MS m/z cale. 140.09496, found 141.2 (M+l )⁺; Rétention time: 0.86 minutes. ^]H NMR (400 MHz, Chloroform-d) <5 7.34 (d, J= 2.4 Hz, 1H), 5.71 (d, J = 2.5 Hz, 1H), 3.90 (d, J = 6.6 Hz, 2H), 2.08 (dq, 13.3, 6.7 Hz, 1 H), 1.00 (d, J = 6.7 Hz, 6H).

The following compounds can be synthesized using the procedures described herein

-isobutoxy-5 -methyl-1 //-pyrazole,

4-îsobutoxy-1 //-pyrazole, and

3-isobutoxy-4-methyl-1 //-pyrazole

Préparation 80: TV-[(6-amino-2-pyridyl)suIfonyï]-6-(3-isobutoxypyrazol-l-yl)-2[(4$)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1620)

Step I : fer/-Buty] 2-chloro-6-(3-isobutoxypyrazol-l-yl)pyridine-3-carboxylate

A 4 mL vial was charged under nitrogen with with 3-isobutoxy-l/7-pyrazole (131.5 mg, 0.9383 mmol) and anhydrous DMF (1 mL). Sodium hydride (37.48 mg, 0.9370 mmol, 60% in minerai oil) was added and the mixture was stirred until gas évolution stopped. tert-Butyl 2,6dichloropyridine-3-carboxylate (155 mg, 0.625 mmol) was added. The vial was capped and the mixture was stirred at 100 °C for 4 hours. LCMS showed the presence of two mono addition isomers (ratio approx. 60:40) and a major product being a double addition product. The reaction mixture was diluted with ethyl acetate (30 mL) and water (20 mL) and tire two phases were separated. The aqueous phase was further extracted with ethyl acetate (25 mL). The combined extracts were dried over sodium sulfate and the solvent removed under reduced pressure to give

988

247 mg of crude solid. The residue was dîssolved in dichloromethane and subjected to flash chromatography on silica gel (40 g column ) using a gradient of ethyl acetate (0 to 20% over 20 minutes) in hexanes to yield zcrz-butyl 2-chloro-6-(3-isobutoxypyrazol-I-yl)pyridine-3carboxylate (58 mg, 0.1649 mmol, 26.39%) (off-white solid). ESI-MS m/z cale. 351.13498, found 352.4 (M+l)⁺; Rétention time: 2.25 minutes.

Step 2: AMXô-amino-l-pyridyDsuIfonylJ-Z-chJoro-ô-ÎS-isobutoxypyrazol-lyl)pyridine-3-carboxamide

A 100 mL round bottom flask containing tert-butyl 2-chloro-6-(3-isobutoxypyrazol-lyl)pyridine-3-carboxylate (58 mg, 0.16 mmol) was treated with dichloromethane (600 pL) and trifluoracetic acid (180 μL, 2.336 mmol). The mixture was stirred at 45°C for 1.5 hours. The volatiles were removed under reduced pressure to give a white solid. Anhydrous DMF (500 pL) was then added to the 100 mL flask containing the acid under an atmosphère of nitrogen and the mixture was stirred at 40°C. l,l'-Carbonyldiimidazole (32.09 mg, 0.1979 mmol) was added and the mixture was stirred at 40 °C for 1 hour. A separate 4 mL vial under nitrogen was charged with 6-aminopyridine-2-sulfonamide (34.27 mg, 0.1979 mmol) and anhydrous DMF (500 pL). NaH (7.915 mg, 0.1979 mmol, 60% oil dispersion) was added. After gas évolution had stopped, the vial was capped and it was stirred at 40°C for I hour. This mixture was added to the first flask and the mixture was stirred at room température for 2 hours. The reaction was quenched with ice and water an neutralized with acetic acid (148.6 mg, 140.7 pL, 2.474 mmol, final pH = 4). The resulting white solid was filtered, washed with water and dried under reduced pressure. AM(6-amino-2-py ri dyifsulfonyl]-2-chloro-6-(3-isobu toxypyrazol-1 -yl)pyridine-3-carboxamide (57 mg, 0.13 mmol, 77%) was isolated as a white solid. ESI-MS m/z cale. 450.0877, found 451.3 (M+l )⁺; Rétention time: 1.54 minutes

989

Step 3: .V-[(6-mnino-2-pyriûyl)siilf(myï |-îi-(3-isobiii()xypyrazol-i-yl)-2-[ (45)-2,2,4irimethyIpyrroîidin-l-yI]pyridine-3-carboxamide (Compound 1620)

A 4 mL via! was charged under nitrogen with A-[(6-amino-2-pyridyl)sulfonyl]-2chloro-6-(3-isobutoxypyrazol-l-y l)pyridine-3-carboxamide (57 mg, 0.13 mmol), CsF (96.00 mg, 0.6320 mmol), potassium carbonate (87.35 mg, 0.6320 mmol), (45)-2,2,4-tri methy Ipyrroli dîne (47.64 mg, 0.3792 mmol) and anhydrous dimethylsulfoxide (200 pL). The vial was capped and the contents were stirred at 150°C for 4 hours. The mixture was diluted with water (200 uL), Nmethylpyrrolidinone (600 uL) and the mixture was fïltered. The compound was purified by reverse phase préparative HPLC using a gradient of acetonitrile in water (1 to 99% over 15 minutes) in 5 mM aqueous ammonium formate. The pure fractions were combined, a few drops of brine was added and the organic solvents were removed under reduced pressure. The solid that crashed out was extracted with dichloromethane (3 x 20 mL). The combined extracts were dried over sodium sulfate, fïltered, and the solvents were removed under reduced pressure to give 28 mg of material that still contained an impurity. The material was purified a second time by préparative HPLC using a gradient of acetonitrile in water (1 to 99% over 15 minutes) in 5 mM aqueous hydrochloric acid. The product was isolated using the same extraction procedure. After concentration ofthe dichloromethane, a solid was obtained by adding hexanes. Evaporation of the solvents gave A^,-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxypyrazo]-l-yl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yllpyridine-3-carboxamîde (Compound 1620) (18 mg, 0.03394 mmol, 26.86%) as an off-white solid. ESI-MS m/z cale. 527.23145, found 528.5 (M+l)⁺; Rétention time: 1.77 minutes. 'H NMR (400 MHz, Chloroform-d) δ 13.87 (broad s, 1H), 8.29 (d, J = 8.0 Hz, 1H)8.2I (d, 7 = 2.9 Hz, 1H), 7.65 - 7.58 (m, 2H), 7.52 (d,7=8.5 Hz, 1H), 6.65 (p,7=3.8 Hz, 1H), 5.95 (d, 7 = 2.8 Hz, 1 H), 4.80 (broad s, 2H), 4.02 (d,7 = 6.6 Hz, 2H), 3.52 - 3,41 (m, 1H), 3.15 (dd,7= 10.5,8.1 Hz, 1H), 2.69-2.50 (m, 1H), 2.18 - 2.02 (m, 2H), 1.72 (dd,7= 12.3, 9.7 Hz, 1H), 1.45 (s, 3H), 1.39 (s, 3H), 1.19 (d, 7 = 6.6 Hz, 3H), 1.02 (d,7 = 6.7 Hz, 6H).

990

W[(6-amino-2-pyridyl)sulfonyl]-6-(3-iscbutoxy-5-methyi-pvrazol-1-yi)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1407),

N-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(c_yclobutylmethoxy)pyrazol-l-yl]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 2694),

7V-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(cyclopropylmethoxy)pyrazol-l-yl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2695),

V-[(2-ammo-3-pyridyl)sulfonyl]-6-[3-(2,2-diniethy]propoxy)-4-meth_yl-pyrazol-l-yl]-2-[(4S)2,2,4 -tri meth ylpy rrol idin-1 -y l]pyridine-3 -carboxam ide (Compound 2699),

W[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutylpyrazol-l -yl)-2-[(45)-2,2,4-trimeth ylpyrrolidin-1yl]pyridine-3-carboxamide (Compound 1411),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(5-isobutylpyrazoI-l-yl)-2-[(45)-2,2,4-trimethylpyrrolidin-ly]]pyridine-3-carboxamide (Compound 1431),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(4-isobutoxypyrazoI-l-yl)-2-[(45)-2,2,4-trimethylpyrrolidinl-y]]pyridine-3-carboxamide (Compound 1443),

Z7-[(6-amino-2-pyridyl)sulfonyl]-â-(3-ethoxy-5-methyl-pyrazol-l-yl)-2-[(45)-2,2,4trimethylpyrrolidin-1 -y l]pyridine-3-carboxamide (Compound 1473), and /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isobutoxy-4-methyl-pyrazol-l-yl)-2-[(45)-2,2,4trimethylpyrroiidin-I-yl]pyridine-3-carboxamide (Compound 1532)

Préparation 81: A^r-[(6-amino-2-pyrîdyl)sullOnyl]-6-ieri-butyl-5-(3,4-dihydro-2H pyran-5-yl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1487)

Step 1: 5-bromo-6-i<?rt-butyl-2-hydroxypyridine-3-carbonitrile

N-Bromosuccinimide (10.3 g, 57.9 mmol) was added to 6-rerf-butyl-2hydroxypyridine-3-carbonitrile (6.8 g, 38.6 mmol) in 1,2-dichloroethane (50 mL) and the reaction mixture was refluxed for 3h. Water was added and extracted twice with

991 dichloromethane (2 x 50 mL). The organic'phase was washed with water, dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography (100% dichloromethane to 10% methanol/90% dichloromethane) to provide 5bromo-6-icrt-butyl-2-hydroxypyridine-3-carbonitrile in 65% yield (6.4 g) as a white solid. ’H NMR (300 MHz, DMS0-rf₆) ppm 1.43 (s, 9H), 8.36 (s, 1H). [M+H]⁺ = 255.0,257.0.

Step 2: 5-bromo-6-teri-butyl-2-chloropyridine-3-carbonitrile

Phosphores oxychloride (30.3 mL, 325 mmol) and phosphores pentachloride (20.3 g, 97.6 mmol) were added to 5-biOmo-6-terLbutyl-2-hydroxypyridine-3-carbonitrile (8.30 g, 32.5 mmol) and the reaction mixture was refluxed for 2 days. The reaction mixture was cooled to room température and concentrated under reduced pressure. Water was added to the residue, extracted 3 times with ethyl acetate (75-mL portions), washed with brine (75 mL), dried with anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (100% heptanes to 50% ethyl acetate/50% heptanes) to provide 5-bromO’6-tert-butyl-2-chloroxypyridine-3-carbonitrile in 39% yield (3.5 g) as an off-white solid. 'HNMR (300 MHz, CDC1₃) ppm 1.52 (s,9H), 8.08 (s, IH). [M+H]⁺= 273.0, 275.0.

Step 3: 5-bromo-6-teri-butyl-2-chloropyridine-3-carboxylic acid

Potassium hydroxyde (4.3 g, 77 mmol) in water (15 mL) was added to 5-bromo-6-tertbutyl-2-chloroxypyridine-3-carbonitrile in 2-propanol (15 mL) and the reaction mixture was heated at 90 °C for 16 hours. Ethyl acetate (50 mL) was added and extracted 3 times with IN sodium hydroxide (3 x 50 mL). The aqueous phase was acidified to pH ~4 with 10% hydrochloric acid and the aqueous phase was extracted 3 times with ethyl acetate (3 x 75 mL), and washed with brine (100 mL). The desired compound was présent in ail organic phases so they were combined, dried with anhydrous sodium sulfate, filtered and concentrated under

992 reduced pressure. The crude compound was purified by reverse phase chromatography (methanol/water, 0 to 100%) to afford 5-bromo-6-tert-butyl-2-chloropyridme-3-carboxylic acid (2.3 g, 61% yield) as an off-white solid. ^]H NMR (300 MHz, CDC1₃) ppm 1.53 (s, 9H), 8.46 (s, 1H). [M+H]⁺= 292.0, 294.0.

[ Step 4:7V-[(6-amino-2-pyridyl)sulfonyl]-5-bromo-6-tert-butyï-2-chloro-pyridinc3-carboxamide

To a stirred solution of 5-bromo-6-tert-butyl-2-chloro-pyridine-3-carboxylic acid (500.0 mg, 1.709 mmol) in dry DMF (3.5 mL) in a 50 mL round-bottom flask was added 1,1'carbonyldiimidazole (346.3 mg, 2.136 mmol) in one portion under nitrogen at ambient température. The reaction was warmed to 45 °C and stirred for 1.5 h. In a separate 50 mL roundbottom flask, 6-aminopyridine-2-sulfonamide (369.9 mg, 2.136 mmol) was dissolved in dry DMF (2.5 mL) under nitrogen and sodium hydride (60 % in minerai oil) (85.43 mg, 2.136 mmol) was added in portions to mitigate gas évolution at ambient temerature. The heterogeneous mixture was warmed to 40 °C and stirred for 1 hour. This mixture was added to the stirred activated acid mixture in one portion at 45 °C. Heating was stopped and the reaction was stirred for an additional hour. The reaction mixture from was slowly (over 2 minutes) added to ice-cold water (50 mL) in a 100 mL round-bottom flask, and placed in an ice bath. Then acetic acid (528.5 mg, 500.5 pL, 8.801 mmol) was added and the mixture stirred vigorotisly for 10 minutes and the solids were filtered and washed with water (3 x 20 mL). The solids were slurried in hexanes (20 mL) and filtered. The solid was further and dried to furnish desired coupled product as white solid. 7/-[(6-amîno-2-pyridyI)sulfonyl]-5-bromo-6-tert-butyl-2-chloro-pyridine-3carboxamide (585 mg, 1.31 mmol, 76.5%) ¹H NMR (400 MHz, DMSCWri δ 8.87 (s, 1H), 8.15 (s, 1 H), 7.60 (d, 1.5 Hz, 1H), 7.54 (t, J = 7.8 Hz, 1H),7.O9 (d, 7=7.3 Hz, 1H), 6.58 (d,7 =

8.3 Hz, 1H), 6.35 (s, 2H), 1.46 (s, 9H)ESI-MS m/z cale. 445.9815, found 449.2 (M+l)⁺; Rétention time: 1.52 minutes

993

Step ô: V-[((!-ainino-2-pyi-ÎdyI.)siilfonylj-5-br(iin<!-6-terl-l)utyl-2-(2.2,4 trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1628)

2,2,4-TrimethylpyiTolidiue (252.9 mg, 2.234 mmol) and potassium carbonate (617.5 mg, 4.468 mmol) were added to a solution of 7V-[(6-amino-2-pyridyl)sulfonyl]-5-bromo-6-terrbutyl-2-chloro-pyridine-3-carboxamide (500.0 mg, 1.117 mmol) in anhydrous DMSO (4.0 mL) in a 20 mL reaction vial. The vial was capped under a nitrogen atmosphère and heated in a preheated oil bath at 145 °C for 24 h. The reaction vessel was removed and allowed to cool to ambient temerature. The reaction mixture was poured onto a mixture of ice and water (50 mL) with stirring. The resulting reaction mixture was then adjusted to a pH of about 6.0 with 1 M aqueous HCl. The mixture was vigorously stirred for 15 minutes. The soild was filtered, washed with water (4 x 20 mL), and dried under vacuum to yield the desired product as white soild.

N-[(6-amino-2-pyridyl)sulfonyl]-5 -bromo-6-ierFbutyi-2-(2,2,4-trimethylpynOlidm-lyl)pyridine-3-carboxamide (Compound 1628) (495 mg, 0.944 mmol, 84.5%) ’H NMR (400

MHz, DMSO-7_fi) δ 12.49 (s, 1H), 8.52 (s, lH),7.70(s, 1H), 7.49 (s, 1 H), 7.07 (d, J = 7.2 Hz,

H), 6.53 (s, 1 H), 6.20 (s,2H),3.37 (dd, J = 11.6, 8.2 Hz, 1 H), 2.77 (dd, J = 11.6, 8.9 Hz, 1H), 2.16 (dt, 7 = 12.5, 6.4 Hz, 1H), 1.99 (dd, 7 = 12.9, 7.6 Hz, 1H), 1.81 (dd, 7= 11.8,5.5 Hz, 1H), 1.51 (s, 3H), 1.48 (s, 3H), 1.44 (s, 9H), 0.87 (d,7 = 6.3 Hz, 3H). ESI-MS m/z cale. 523.12524, found 526.1 (M+l)⁺; Rétention time: 1.43 minutes

Step 6: N-[(6-ainino-2-pyridyI)suIfonyI]-6-/erributyl-5-(3₎4-dihydro-27/-pyran-5 yl)-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3-carboxamide (Compound 1487)

994

A 4 mL vial was charged with a stir bar, AM(6-amino-2-pyridyl)sulfonyl]-5-bromo-6tert-butyl-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3-carboxamide (Compound 1628) (29 mg, 0.055 mmol) and vinylboronic acid 34.85 mg, 0.1659 mmol ). Then DMF (0.5 mL) and water (0.1 mL) were added, followed by potassium carbonate (30.57 mg, 0.2212 mmol). Nitrogen was bubbled through the vial for 1 min. Then tetrakis(triphenylphosphme)palladium (0) (6.389 mg, 0.005529 mmol) was added and nitrogen was bubbled through the solution for another 1 min, sealed with a screw cap under nitrogen and heated at 130 °C (extemal température) for 13 h. The reaction mixture was filtered through a syringe filter dise, and purified by reverse phase HPLC utilizing a gradient of 10 to 99 percent acetonitrile in water containing 5 mM HCl to yield 77-[(6amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(3,4-dihydro-277-pyran-5-yI)-2-(2,2,4trimethylpynOlidin-l-yl)pyridme-3-carboxamide (Compound 1487) (3.3 mg, 0.0058 mmol, 11%) as the hydrochloric acid sait. ESI-MS m/z cale. 527.26, found 528.3 (M+1 )⁺; Rétention time: 1.21 minutes

A-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[4-(trifluoromethyl)cyclohexen-l-yI]-2-[(4S)2,2,4-trimethylpynOlidin-l -yI]pyridine-3-carboxamide (Compound 1380),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-3,3-dimethyibut-l-enyl]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1613),

A-[(6-amino-2-pyridyl)sulfonyI]-6-tert-butyl-5-[(E)-2-cycIohexylvinyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1484),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-hex-l-enyI]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1377),

N-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-5-methylhex-l-enyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1682),

N-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-cyclopentylvinyI]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 1633),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-2-[(4S)2,2,4-trimethylpyrrolidm-l-yl]pyridme-3-carboxamide (Compound 1566),

995 (E)-3-[5-[(6-amino-2-pyridyI)sulfonylcarbamoyl]-2-tert-butyl-6-[(4S)-2,2,4-trimethylpyrrolidinl-yl]-3-pyridyl]prop-2-enoic acid (Compound 1547),

A⁷-[(6-amino-2-pyridyI)sulionylj-5-(3-bicyclo[2.2.1 ]hept-2-enyl)-6-tert-butyl-2-(2,2,4trimetliylpyrrolidin-l-yl)pyridine-3-carboxamide,

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-phenyl-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 1364),

N-[(6-ammo-2-pyridyl)sulfonyl]-5-phenyl-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 1384),

N-[(6-amino-2-pyridyl)sulfonyl]-5-(4,7,7-trimethyl-3-bicyclo[2.2.1]hept-2-enyl)-2-(2,2,4trimethylpyrTolidin-l-yl)pyridine-3-carboxamide (Compound 1544),

A^r-[(6-amino-2-pyridyI)sulfonyl]-5-[(E)-2-cyclopropylvinyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 1571), /V-[(6-amino-2-pyridyl)sulfbnyl]-5-(l,2-dimethylprop-l-enyl)-2-(2,2,4-trimethyIpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1590), ÿV-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-(4-methoxyphenyl)vinyl]-2-(2,2,4trimethylpyiTolidm-l-yl)pyridine-3-carboxamide,

7V-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-pent-l -enyl]-2-(2,2,4-trimethylpyrrolidin-ly] )pyridine-3-carboxamide,

IV-[(6-amino-2-pyridyl)sulfonyl]-5-(3-bicyclo[2.2.] ]hept-2-enyl)-6-tert-butyl-2-(2,2,4trimethylpyrrolidin-l-yl)py ri dine-3-carboxamide, ethyl (E)-3-[5-[(6-amino-2-pyridyl)sulfonylcarbamoy]]-2-tert-butyl-6-(2,2,4-trimethylpyrrolidin1 -yl)-3-pyridyl]prop-2-enoate,

A/-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-ethoxyvinyl]-2-(2,2,4-trimethylpyrrolidin1 -yl)pyrîdine-3-carboxamide,

A^r-[(6-amino-2-pyridyl)sulfonyI]-6-tert-butyi-2-(2,2,4-trimethylpynOlidin-l-yl)-5-vinyl-pyridine3-carboxamide,

996

A'-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-cyclopropylvinyl]-2-(2,2_:4trimethylpyrrolidm-l-yl)pyridine-3-carboxamide,

AH(6-ammo-2-pyiidyl)suifonyl]-6-tert-butyl-5-[(E)-pent-l-enyl]-2-(2,2,4-uiniethylpyrrolidin-lyl)pyridine-3-carboxamide,

N-[(6-aimno-2-pyridyl)sulfbnyl]-6-tert-butyl-5-[(E)-2-(4-methoxyphenyl)vinyl]-2-(2,2,4trimethylpynOlidin-l-yl)pyridine-3-carboxamide,

7V-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[(E)-2-cycIopropylvinyl]-2-(2,2,4trimethylpyrrolidm-l-yI)pyridine-3-carboxamide,

77-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-2-(2,2,4-tnmethylpyrrolidin-l-yl)-5-vinyl-pyridine3-carboxamide,

N-[(6-amino-2-pyridyl)suIfonyl]-6-tert-butyl-5-[(E)-2-ethoxyvinyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide, ethyl (E)-3-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-2-tert-butyl-6-(2,2,4-trimethylpyrrolidm] -yl)-3-pyridyl]prop-2-enoate,

N-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(2-methylprop-l-enyl)-2-(2,2,4trimethylpyirolidin-1-yl)pyridine-3-carboxamide (Compound 1561), benzyl 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-2-tert-butyl-6-(2,2,4-trimethylpyrrolidin-lyl)-3-pyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate (Compound 1404), tert-butyl 3-[5-[(6-ammo-2-pyridyl)sulfonylcarbamoyI]-2-tert-butyl·6-(2,2,4-trimethylpyπΌlίdinl-yl)-3-pyridyl]-8-azabicyclo[3.2.1]oct-3-ene-8-carboxylate (Compound 1388),

5-(4-acetyicyclohexen-l-yl)-N-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-2-(2,2,4trimethylpyrroIidin-l-yl)pyridine-3-carboxamide (Compound 1461),

A'-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(l,4-dioxaspiro[4.5]dec-8-en-8-yl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1459), /V-[(6-ammo-2-pyridyl)sulfbnyl]-5-bromo-6-tert-butyl-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1628),

997 /V-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(2,2,6,6-tetramethyl-3H-pyran-4-yl)-2-(2,2,4trimethylpyiTOlidm-l-yI)pyridine-3-caiboxamide (Compound 1647), ïV-[(6-ammo-2-pyridyl)sulfonyl]-6-Lert-butyl-5-(4,7,7-tiimethyl-3-bicyclo[2.2.1]hept-2-enyl)-2(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3-carboxamide (Compound 1578),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(3,4-dihydro-2H-pyran-6-yl)-2-(2,2,4trimethyIpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1485), jV-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(5,5-dimethyl-3-oxo-cyclohexen-l-yl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1405), ?/-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(l,4-dioxaspiro[4.5]dec-8-en-9-yl)-2-(2,2,410 trimethyIpyiTolidiii-l-yl)pyridine-3-carboxamide (Compound 1469), tert-butyl 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-2-tert-butyl-6-(2,2,4-trimethylpyrrolidinl-yl)-3-pyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate (Compound 1522),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(l -methyl-3,6-dihydro-2H-pyridin-4-yl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1382),

4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-2-tert-butyl-6-(2,2,4-trimethylpyrrolidin-l-yl)-3pyridyl]cyclohex-3-ene-l-carboxylic acid (Compound 1381),

N-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-cyano-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1419),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyI-5-(3,6-dihydro-2H-pyran-4-yl)-2-(2,2,420 trimethylpyrrolidin-1 -yl)pyridine-3-carboxamide (Compound 1495),

A-[(6-amino-2-pyridyl)sulfbnyl]-5-(3-methoxy-5-methyl-phenyl )-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2499),

A^r-[(6-amino-2-pyridyl)sulfonyl]-5-[(E)-hex-l-enyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1916),

A^r-[(6-amino-2-pyridyl)sulfonyl]-5-(3-isobutoxy-5-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2558),

998

N-[(6-amino-2-pyridyl)sulfonyl]-5-[2-(triflLioromethyl)phenyl]-2-(2,2,4-trimethylpynOlidin-l yl)pyridine-3-carboxamide (Compound 1921),

A^T-[(6-amino-2-pyridyl)sulfonyi]-5-(3-chlorophenyl)-2-(2,2,4-trimethylpyrrolidin-l-yi)pyridine3-carboxamide (Compound 2429),

7V-[(6-armno-2-pyridyI)sulfonyl]-5(3-cyanophenyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme3-carboxamide (Compound 1849),

A^r-[(6-amino-2-pyridyI)sulfonyl]-5-(4-methoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1792),

A^r-[(6-amino-2-pyridyl)sulfonyl]-5-(3-tert-butyl-5-methyl-phenyl)-2-(2,2,4-tnmethylpyrTolidinl-yl)pyridme-3-carboxamide (Compound 2322),

N-[(6-amino-2-pyridyl)sulfonyl]-5-[4-[l-(hydroxymethyl)cyclopropyl]phenyI]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2112), /V-[(6-amino-2-pyridyl)suifonyl]-5-(4-tert-butylphenyl)-2-(2,2,4-trimethylpyn'olidm-lyl)pyridine-3-carboxamide (Compound 2463), ethyl 3-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-6-(2,2,4-trimethylpyiTOlidîn-l-yl)-3-pyridyl]4-methoxy-benzoate (Compound 2134),

N-[(6-amino-2-pyridyl)sulfonyl]-5-(4-chloropbenyI)-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridme3-carboxamide (Compound 2399),

A^r-[(6-amino-2-pyridyl)sulfonyl]-5-(3-chloro-5-methoxy-pheuyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2545), iV-[(6-amino-2-pyridyl)su]fonyI]-5-(2-methoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1735), /V-[(6-ammo-2-pyridyl)sulfonyl]-5-(4-cyanophenyl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2304),

AA[(6-ammo-2-pyridyl)suIfonyl]-5-(4-isopropylphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1809),

999 _JV-[(6-amino-2-pyridyl)sulfonyl]-5-(2-isopropoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2283), /V-[(6-amino-2-pyridyI)sulfonyl]-5-[3-(2-methQxyethoxymethyl)phenyl]-2-(2,2,4trimethylpyrrolidm-l-yl)pyridine-3-carboxamide (Compound 1943),

7V-[(6-amino-2-pyridyl)sulfonyl]-5-(3-isobutoxyphenyl)-2-(2,2,4-trimethylpyrroIidin-lyI)pyridine-3 -carboxamide (Compound 2089),

A^r-[(6-amino-2-pyridyI)suIfonyI]-5-(4-isobutylphenyl)-2-(2,2,4-trimethylpyrrolidin-lyI)pyridine-3-carboxamide (Compound 2395), zV-[(6-amino-2-pyridyl)sulfbnyl]-5-(lH-indazol-4-yl)-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2157),

N~ [(6-amino-2-pyridyl)sulfonyl] -5- [4-(l-hydroxy-1 -methyl-ethyl)phenyl] -2-(2,2,4trimethyIpyrrolidin-l-yI)pyridine-3-carboxamide (Compound 2547),

Y-[(6-amino-2-pyridyl)sulfonyl]-5-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-2-(2,2,4trimethylpyrrolidin-1 -yOpyridine-3-carboxamide (Compound 2014), (V-[(6-amino-2-pyridyl)sulfonyl]-5-[3-(cyclopentoxy)phenyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 1918),

N-[(6-amino-2-pyridyI)sulfonyl]-5-(6-ethoxy-3-pyridyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2384),

N- [(6-amino-2-pyridyl)sulfonyl]-5-(o-toly 1)-2-(2,2,4-trime thylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1701),

A^r-[(6-amino-2-pyridyl)sulfonyl]-5-[4-(l-cyano-l-methyl-ethyl)phenyl]-2-(2,2,4trimethylpyrroIidin-l-yl)pyridine-3-carboxamide (Compound 2521),

A^r-[(6-amino-2-pyridyl)sulfony]]-5-(6-methoxy-3-pyridyl)-2-(2,2,4-trimethylpyrrolidin-]yl)pyridine-3-carboxamide (Compound 1886), /V-[(6-amino-2-pyridyI)sulfonyl]-5-[3-(cyclopentoxy)-5-methyl-phenyl]-2-(2,2,4tri me thylpyrrolid in-l-yl)pyridine-3-carboxamide (Compound 2313),

1000

N-[(6-amino-2-pyridyl)sulfonyl]-5-(4-dimethylaminophenyl)-2-(2,2,4-trm^ yl)pyridine-3-carboxamide (Compound 2288),

N-[Ç6-amino-2-pyridy])sulfonyl]-5-(l-isobutylpyrazol-3-yl)-2-(2,2,4-trimethylpynOlidm-ly!)pyridine-3-carboxamide (Compound 2303),

N-[(6-amino-2-pyridyl)sulfonyl]-5-(4-methoxycyclohexen-l-yl)-2-(2,2,44rimethylpyirolidin-lyl)pyridine-3-carboxamide (Compound 1920), /V-[(6-amino-2-pyridyl)sulfonyl]-5-(2-cyanophenyl)-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine3-carboxamide (Compound 2584), ^-[(6-amino-2-pyridyl)sulfonyl]-5-(3-chIoro-5-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidin-l10 yl)pyridine-3-carboxamide (Compound 1963), ^4(6-ammo-2-pyridyl)sulfonyl]-5-[4-(trifl uoromethoxy)phenyl]-2-(2,2,4-triniethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2649),

N-[(6-amino-2-pyridyl)sulfonyl]-5-(2-ethoxyphenyl)-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine3-carboxamide (Compound 2557),

N-[(6-amino-2-pyridyl)sulfonyl]-5-(3,5-dimethylphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridme-3-carboxamide (Compound 2093), tert-butyl 4-[5-[(6-amino-2-pyridyl)sulfony]carbamoyl]-6-(2,2,4-trimethylpyrrolidin-I-yI)-3pyridyl]-3,6-dihydro-2H-pyridine-l-carboxyiate (Compound 2129),

N-[(6-amino-2-pyridyI)sulfonyl]-5-(4-methylcyclohexen-l -yl)-2-(2,2,4-trimethylpyirolidin-l20 yl)pyridine-3-carboxamide (Compound 2361),

M[(6-amino-2-pyridyl)sulfonyl]-5-(3-isopentyloxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1894), ^[(6-amino-2-pyridyl)sulfonyl]-5-[3-(trifluoromethyl)phenyl]-2-(2,2,4-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 1950),

N-[(6-amino-2-pyridyl)su]fonyl]-5-[(E)-5-methylhex-l-enyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2647),

1001

Aⁱ-[(6-amino-2-pyndyI)sulfonyl]-5-(6-methoxy-2-pyridyI)-2-(2,2,4-trimethylpyrrolidin-Iyl)pyridine-3-carboxamide (Compound 1861),

V-[(6-amino-2-pyridyl)sulfonyl]-5-[3-isopropoxy-5-(trifluoromethyl)phenyI]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1815),

A4(6-ami no-2-pyridyl)suIfonyl]-5-(3-fluoro-5-methoxy-phenyl )-2-(2,2,4-trime th yl pyrro lidin-1 yl)pyridine-3-carboxamide (Compound 2431), /V-[(6-amino-2-pyridyl)sulfonyl]-5-(l,l,4,4,7-pentamethyItetralin-6-yl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1759),

A-[(6-amino-2-pyridyl)sulfonyI]-5-(3-isopropoxy-5-methyl-pbenyl)-2-(2,2,4-trimethylpyrrolidin10 l-yl)pyridine-3-carboxamide (Compound 1889),

V-[(6-amino-2-pyridyl)sulfonyl]-5-(3,5-dichlorophenyl)-2-(2,2,4-trimethylpyrrolidin-Iyl)pyrid in e-3-carboxamide (Compound 1721),

V-[(6-amino-2-_Pyridyl)sulfonyl]-5-(2-isobutoxyphenyl)-2-(2,2,4-trime thylpyirolidm-1yl)pyridine-3-carboxamide (Compound 1979), ^-[(6-amino-2-pyridyI)sulfonyl]-5-(5-benzyloxy-2-methyl-phenyl)-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2588),

A4(6-ammo-2-pyridyl)sulfonyI]-5-(3-isopropoxyphenyl)-2-(2,2,4-trime thylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 1804), ^[(6-amino-2-_Pyridyl)sulfonyl]-5-(3,5-difluorophenyI)-2-(2,2,4-trimethylpyrrolidin-l20 yl)pyridine-3-carboxamide (Compound 2259),

AH(6-amino-2-pyridy[)sulfbnyl]-5-[4-(hydroxymethyl)phenyl]-2-(2,2,4-trimethylpyjTolidin-lyl)pyridine-3-carboxamide (Compound 2088),

A^f-[(6-arnino-2-pyridyl)sulfonyl]-5-[4-(trifluoromethy])cyclohexen-l-yl]-2~(2,2,4trimethylpyrrolidin-l-yi)pyridine-3-carboxamÎde (Compound 2510),

M[(6-amino-2-pyridyI)sulfonyl]-5-(m-to]yi)-2-(2,2,4-trimethylpy_ITolidin-l-yl)pyridine-3carboxamide (Compound 2184),

1002

A-[(6-amino-2-pyridyl)sulfonyl]-5-(2-chloropheny])-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamîde (Compound 2312),

A-[(6-amino-2-pyridyl)sulfonyl]-5-[4-(tri fluoromethyl)phenyl]-2-(2,2,4-trime thylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2337),

A-[(6-amino-2-pyridyl)sulfonyI]-5-(2-chloro-5-isopropoxy-phenyl)-2-(2,2,4-trimethylpyrrolidinI-yI)pyridine-3-carboxamide (Compound 2210),

A-[(6-ammo-2-pyridyI)sulfonyl]-5-(3-methoxyphenyl)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2031),

A-[(6-amino-2-pyridyi)suIfonyl]-5-(3-tert-butylphenyl)-2-(2,2,4-trimethyîpyrrolidin-lyl)pyridine-3-carboxamide (Compound 21S0),

A-[(6-amino-2-pyridyl)sulfonyl]-5-[(E)-2-(4-methoxyphenyl)vinyl]-2-(2,2,4-trimethylpyn-olidin1-yl)pyridine-3-carboxamide (Compound 1726),

A-[(6-amino-2-pyridyl)su]fonyl]-5-(3-bicyclo[2.2J]hept-2-eny])-2-(2,2,4-triinethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 1888),

A-[(6-amino-2-pyridyl)sulfonyI]-5-(3-ethoxy-5-methyl-phenyl)-2-(2,2,4-trimethylpymolidin-lyl)pyridine-3-carboxamide (Compound 1843),

A-[(6-amino-2-pyridyI)sulfonyl]-5-(3-methyl-4-propoxy-phenyl)-2-(2,2,4-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 2095),

A-[(6-amino-2-pyridy])sulfonyl]-5-[(E)-2-cyclohexylvinyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2063),

A-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(cyclohexen-l-yl)-2-(2,2,4-trimethylpyrrolidin-l yl)pyridine-3-carboxamide (Compound 1601), and

A-[(6-amino-2-pyridyI)sulfonyl]-6-tert-butyl-5-(l-methylpyrazol-4-yl)-2-(2,2,4trimethylpyiTolidin-l-yl)pyridine-3-carboxamide (Compound 1441)

Préparation 82: terAbutyl A-[l-[[6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4triniethylpyrrolidin-l-yl)pyridine-3-carbonyl]sulfanioyl]-3-metliyl-3-piperidyl]carbamate (Compound 1520)

1003

A solution of 6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxylic acid (40,45 mg, 0.1000 mmol) and chlorosulfonyl isocyanate (16.98 mg, 10.44 μL, 0.1200 mmol) in dichloromethane (1.000 mL) was stirred for 45 minutes. Triethylamine (15.18 mg, 20.91 pL, 0.1500 mmol) and feri-butyl-N-(3-metbyL3piperidyl)carbamate (32.15 mg, 0.1500 mmol) were added, and the raction was stirred for three days. The reaction was purified by silica gel chromatography with 0-5% methanol in dichloromethane to give tert-butyl (l-(A-(6-(3-fluoro-5-isobutoxyphenyl)-2-(2,2,4trimethylpynOlidin-l-yl)nicotinoyl)sulfamoyI)-3-methylpiperidm-3-yl)carbamate (34 mg, 0.050 mmol, 50.%) as a colorless solid.

A4(3R)-3-aminopyrrolidin-]-yl]sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1360),

A^r-(3-acetamidopyrrolidin-l-yl)sulfoiiyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1391),

N-[[3-(dimethyIamino)-l-piperidyl]sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,2,4trimethylpyrrolidm-l-yl)pyridine-3-carboxamide (Compound 1414),

A4[(3S)-3-amino-I-piperidyl]suIfonyl]-6-(3-fiuoro-5-isobutoxy-pheny])-2-[(4S)-2,2,4triniethylpyrroIidin-I-yl]pyridine-3-carboxamide (Compound 1435),

A- [(3-amino-3-methyl-1 -piperidyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1445),

1004

A-[(3-ammo-l-piperidyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyI)-2-(2,2,4-trimethylpynOlidin l-yl)pyridine-3-carboxamide (Compound 1447)

A-(3-aminopyrro!idin-l-yI)sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1467),

6-(3-fluoro-5-isobutoxy-phenyl)-A-[[3-(methyIamino)-l-piperidyl]suIfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1508),

A-[(5-amino-3-azabicyclo[3JO]hexan-3-yl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)2,2,4-trimethyIpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1521),

A-[34acetyl(methyi)amino]pynOlidin-l-yl]sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1533),

6-(3-fluoro-5-isobutoxy-phenyI)-A-[(3-methoxy-l-piperidyl)sulibnyl]-2-[(4S)-2,2,4trimethylpyrrolidin-]-yl]pyridine-3-carboxamide (Compound 1545),

6-(3-f]uoro-5-isobutoxy-phenyl)-A-[3-(methylamino)pyrrolidin-l-yI]sulfonyl-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-caiboxamide (Compound 1554),

A-[(3S)-3-ammopyirolidin-l-yi]sulfonyL6-(3-fluoro-5-isobutoxy-plienyl)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1557),

6-(3-fluoro-5-isobutoxy-pheny])-A-(3-methylsulfony]pynOlidin-l-yl)sulfonyl-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1560),

A-[(3-acetamido-l-piperidyl)sulfonyI]-6-(3-fluoro-5-iso bu toxy-pheny 1)-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1586),

6-(3-fluoro-5-isobutoxy-phenyl)-A-[[3-(methanesulfonamido)-l-piperidyl]suIfonyl]-2-(2,2,4trimethylpyiTolÎdin-l-yl)pyridine-3-carboxamide (Compound 1600),

6-(3-fluoro-5-isobutoxy-phenyi)-A-[(3-hydroxy-l-piperidyl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridme-3-carboxamide (Compound 1608), ^-[[(3R)-3-amino-l-piperidyl]sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimeιhylpyπΌlidin-l·yl]pyridine-3-carboxamide (Compound 1614),

1005

6-(3-fluoro-5-isobutoxy-phenyl)-Mpyrrolidin-by]su]fonyl-2-[(4S)-2,2,4-trimethylpynOlidin-lyl]pyridine-3-carboxamide (Compound 1619), and

6-(3-fluoro-5-isobutoxy-phenyl)-A^r-(3-hydroxypyrrolidin-l-yl)suIfonyl-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1648),

6-(3 -fluoro-5-isobutoxy-phenyl)W-(3-hydroxy-3-methyl-azetidin-1 -yl)sulfonyl-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-caiboxamjde (Compound 2398),

6-(3-fluoro-5-isobutoxy-phenyl)W-(2-pyridylsulfanioyl)-2-[(4S)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide,

6-(3-fluoro-5-isobutoxy-phenyl)-jV-[[(4S)-2-oxa-5-azabicycIo[2.2.1]heptan-5-yl]suIfonyl]-210 [(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine*3-carboxamide (Compound 1789),

6-(3-fluoro-5-isobutoxy-phenyl)W-[[(3R)-3-piperidyl]su]famoy]]-2-[(4S)-2,2,4tn me thylpyrrolidin-1-y l]pyridine-3-carboxamide (Compound 2677),

N-[(6-amino-2-pyridyl)sulfamoy]]-6-(3-fluoro-5-isobutoxy“phenyl)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide,

6‘(3-fiüoro-5-isobutoxy~phenyi)-AM3-pyridylsulfamoyl)-2-[(4S)-2,2,4-trimethyîpynOlidixi-IyI]pyridine-3-carboxamide (Compound 1448),

6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[(2-methoxy-3-pyridyl)sulfamoyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1359),

6-(3-f]uoro-5-isobutoxy-phenyI)-W-[[(lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]sulfonyI]-220 [(4S)-2,2,4-trimethylpynolidin-l-yl]pyridine-3-carboxamide (Compound 2347),

N-(3,3-difIuoropyrrolidin-l-yl)sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethylpyrroHdin-l-yl]pyridine-3-carboxamide (Compound 1956),

6-(3-fluoΓO-5-isobutoxy-phenyI)-7V-[(3,3,3-trifluoro-2-hydroxy-2-methyl·propyl)sulfamoyl]-2[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridiiie-3-carboxamide, ^(3,8-diazabicyclo[3.2.1]octan-3-ylsulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4trimethyïpynO]idin-l-yl]pyridine-3-carboxamide (Compound 2237),

1006

6-(3-fluoro-5-isobutoxy-phenyl)-A-[(3R)-3-hydroxypynOlidin-l-yl]sulfony 1-2-[(45)-2,2,4trimethylpyrrolidin-1-y]]pyridine-3-carboxamide (Compound 2427),

A-[(3R,4R)-3,4-dihydroxypyrrolidin-l-yl]sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2534),

6-(3-fluoro-5-isobutoxy-phenyl)-A4[(3S)-pyrrolidin-3-yl]sulfamoyl]-2-[(4S)-2,2,4trime thylpyrrolid in-1-y ]]pyridine-3-carboxamide (Compound 1935),

A-[(5-amino-3,3-difluoro-l-piperidyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-pheny])-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2209),

6-(3-fluoro-5-isobutoxy-phenyl)-A-[(6-methoxy-2-pyridyl)sulfamoyl]-2-[(4S)-2,2,410 tri methylpyrrolidin-l-yI]pyridine-3 -carboxamide,

6-(3-fluoro-5-isobutoxy-phenyl)-A-[[(3R)-pyrroIidin-3-yl]suIfamoyl]-2-[(4S)-2,2,4tri me t h y Ipy rro 1 id in -1 -y 1] py ri d i n e- 3 -c arb o x am ide,

6-(3-flnoro-5-isobutoxy-pheny])W-[(3S)-3-fluoropyrroIidin-l-yI]sulfonyl-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2228),

6-(3-fluoro-5-isobutoxy-phenyl)-A-[(3R)-3-methoxypyrrolidin-l -yl]sulfonyl-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1893),

A-[(3,3-difluoro-5-hydroxy-l-piperidyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S)-2,2,4 trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2508),

6-(3-fluoro-5-isobutoxy-phenyl)W-[[(3S)-3-piperidyl]sulfamoyl]-2-[(4S)-2,2,420 trimethylpyrrolidin-1 -y l]pyridine-3 -carboxamide,

A-[(3R)-3-aminopyiro]idin-]-yl]sulfonyl-2-(2-benzyl-2-methyl-pyrrolidm-l-yl)-6-(3-fluoro-5isobutoxy-phenyI)pyridine-3-carboxamide (Compound 2325) (Isomer 1, R or S stereoisomer)

A4(3R)-3-aminopyrrolidin-Nyl]sulfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2phenylpyrrolidin-1 -y!)pyridine-3-carboxamide (Compound 2477) (Isomer 2, R or 5 stereoisomer)

Préparation 83: 1 -[3-fluoro-5-(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2 yl)phenoxy]-2-niethyl-propan-2-ol

1007

Step 1: l-(3-bromo-5-fluoro-phenoxy)-2-methyl-propan-2-ol

To 3-bromo-5-fluoro-phenol (9.0 g, 47 mmol), and 1-cbloro-2-methyl-propan-2-ol (5.116 g, 47.12 mmol), aqueous sodium hydroxide (37.69 g, 94.24 mmol) was added and the reaction mixture was heated at 120 °C for 5 days in a pressure vessel. The reaction was cooled and then extracted three times with ethyl acetate. The combined organic layer was dried over sodium sulfate, filtered, and the solvent was evaporated under reduced pressure. The crude product was purified on 220 g of silica gel utiüzing a gradient of 0 to 10% ethyl acetate in dichloromethane. The impure product was repurified on 220 g of gold silica gel utilizing a gradientof 0 to 10% ethyl acetate in dichloromethane to yield l-(3-bromo-5-fluoro-phenoxy)-2. methyl-propan-2-ol (4.75 g, 18.0 mmol, 38%). ESI-MS m/z cale. 262.00046, found 263.0 (M+1)⁺; Rétention time; 1.57 minutes (3 min run).

Step 2: l-[3-Fluoro-5-(4,4,5,5-tetramethyl-13_J2-dioxaborolan-2-yl)phenoxy]-2methyl-propan-2-ol

F F

To I-(3-bromo-5-fluoro-phenoxy)-2-methyl-propan-2-ol (5.250 g, 19.95 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-y])-l,3,2-dioxaborolane (7.598 g, 29.92 mmol) in a flask was added potassium acetate (4.894 g, 49.87 mmol) and [1,1 ’Bis(diphenylphosphino)ferrocene]palladium(n) dichloride dichloromethane adduct (729.9 mg, 20 0.9975 mmol) foliowed by dioxane (32.58 mL). The suspension was degassed for 10 minutes by sparging with nitrogeu and then the reaction was heated in an oil bath at 85 °C for 3 h, The reaction was diluted with ethyl acetate, filtered, and concentrated. The crude product was purified on 330 g of silica gel utilizing a gradient of 0 to 50% ethyl acetate in hexane to yield I[3-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]-2-methyl-propan-2-oI (5.23

1008 g, 16.86 mmol, 84.52%). The product was not pure and it was used in the next step without further purification. ESI-MS m/z cale. 310.17517, found 311.5 (M+l)⁺; Rétention time: 1.895 minutes (3 min run).

Préparation 84: 3-[3-fluoro-5-(4,4,5,5-tetraniethyl-l,3,2-dioxaborolan-2 5 yl)phenoxy]-2-methyl-propan-I-ol

Step 1: 3-(3-bromo-5-fluoro-phenoxy)-2-methyl-propan-l-ol

To a stirred solution of 3-bromo-5-fluoro-phenoI (2.270 g, 11.88 mmol), 2methylpropane-l,3-diol (1.071 g, 11.88 mmol) and triphenylphosphane (3.428 g, 3.028 mL, 10 13.07 mmol) in tetrahydrofuran (71.82 mL) at 0 °C was added diisopropyl azodicarboxylate (2.643 g, 2.532 mL, 13.07 mmol). The ice bath was removed and the reaction was stirred at 55 ^CC for 18 h. The reaction was diluted with ethylacetate and washed twice with sodium bicarbonate and twice with brine. The organic layer was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The crude product was purified on 220 g of 15 silica gel utilizing a gradient of Oto 15% ethyl acetate in dichloromethane to yield 3-(3-bromo5-fluoro-phenoxy)-2-methyLpropan-l-ol (1.73 g, 6.57 mmol, 55.3%) as acolorless liquid. ’H NMR (400 MHz, DMSO-îZô) δ 7.09 - 7.03 (m, IH), 7.03 - 6.98 (m, 1H), 6.87 (dt, J = ] 1.2, 2.3 Hz, 1 H), 4.57 (t, J = 5.3 Hz, 1H), 3.97 (dd, J= 9.5,5,9 Hz, 1H), 3,85 (dd, J = 9.5, 6,3 Hz, 1H), 3.48 - 3.34 (m, 2H), 2.05 - 1.84 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H). ESI-MS m/z cale. 262.00046, 20 found 265.0 (M+l)+; Rétention time: 1.58 minutes (3 min run).

Step 2: 3-[3-fluoro-5-(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2-yl)phenoxy]-2niethyl-propan-l-ol

1009

To 3-(3-bromo-5-fluoro-phenoxy)-2-methyl-propan-l-ol (1.7 g, 6.5 mmol) and 4A5,5-tetramethyl-2-(4,4,5,5-tetraniethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (2.461 g, 9.692 mmol) in a flask was potassium acetate (1.585 g, 16.15 mmol) and [1,1'Bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (236.3 mg, 0.3230 mmol) followed by dioxane (10.55 mL). The suspension was degassed for 10 min by bubbling nitrogen through the reaction mixture and then the reaction was heated in an oil bath at 85 °C for 2.5 h. The reaction was diluted with ethyl acetate, filtered, and concentrated. The crude product was purified on 220 g of silica gel utilizing a gradient of 0 to 50% ethyl acetate in hexane to yield 3-[3-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]-2-methylpropan-l-ol (1.77 g, 5.71 mmol, 88%) as an orange viscous liquid. The product contained some impurity. It was used in the next step without further purification. ESI-MS m/z cale. 310.17517, found 311.2 (M+l)⁺; Rétention time: 1.81 minutes (3 min run).

Préparation 85: 5-(Benzyloxy)-6-nitropyridine-2-sulfonamide Step 1: 3-Benzyloxy-6-bromo-2-nitro-pyridine

To a solution of 6-bromo-2-nitro-pyridin-3-ol (1.36 g, 6.21 mmol) in N,jVdimethylformamide (15 mL) was added potassium carbonate (1.717 g, 12.42 mmol) followed by the addition of bromomethylbenzene (1.115 g, 775.4 pL, 6.520 mmol). The mixture was heated at 60 °C ovemight, and partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate three times. The combined organic layers were washed three times with water, brine, dried over magnésium sulfate, filtered, and concentrated to dryness. The crude material was suspended in hexane, collected via filtration and air dried to provide 3-benzyloxy-6bromo-2-nitro-pyridine (1.61 g, 5.21 mmol, 83.8%) as a yellow solid. ’H NMR (400 MHz, Chloroform-d) δ 7.60 (d, J = 8.7 Hz, 1 H), 7.45 - 7.29 (m, 6H), 5.25 (s, 2H).

Step 2: Methyl 3-[(5-benzyloxy-6-nitro-2-pyridyl)sulfonyI]propanoate

1010

A mixture of 3-benzyloxy-6-bromo-2-nitro-pyridine (585 mg, 1.89 mmol) and (3methoxy-3-oxo-propyl)sulfmyloxysodium (329.5 mg, 1.892 mmol) in dimethylsulfoxide (5 mL) was purged with nitrogen for 2 minutes. lodocopper (720.7 mg, 3.784 mmol) was added to the reaction mixture. The mixture was heated at 80 °C ovemight, partîtioned between ethyl acetate and a saturated aqueous solution of ammonium chloride. The resulting precipitate was removed by filtration and washed with ethyl acetate. The aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed three times with water, brine, dried over magnésium sulfate, fïltered and concentrated to dryness. The crude material was purified by column chromatography (40-60% ethyl acetate in hexanes) to provide methyl 3-[(5-benzyloxy-6nitro-2-pyridyl)sulfonyl]propanoate (210. mg, 0.552 mmol, 29.2%) as a pale yellow solid. ’H NMR (400 MHz, Chlorofoim-i/) δ 8.20 (d, J= 8.6 Hz, 1H), 7.68 (d, 7 = 8.7 Hz, 1H), 7.50 - 7.31 (m, 5H), 5.35 (s, 2H), 3.75 - 3.63 (m, 5H), 2.87 (t, 7 = 7.5 Hz, 2H).

Step 3: 5-(Benzyloxy)-6-nïtropyridine-2-sulfonamide

Tetrahydrofuran (10 mL) was added to a suspension of methyl 3-[(5-benzyloxy-6nitro-2-pyridyI)sulfonyl]propanoate (1.141 g, 3.000 mmol) in methanol (20 mL). The resulting solution was cooled to 0 °C. Sodium methoxide (6.000 mL of 0.5 M in methanol, 3.000 mmol) was added in a dropwise manner. The mixture was stirred at room température for 15 minutes.

The mixture was evaporated to dryness to provide a light brown solid. This solid was then suspended in dichloromethane (30 mL) and A-chlorosuccinimide (400.6 mg, 3.000 mmol) was added to the reaction mixture. The mixture was stirred at room température for 10 minutes. The reaction was recharged with Mchlorosuccinimide (80.12 mg, 0.6000 mmol). The mixture tumed clear. The mixture was stirred at room température for 5 minutes. The resulting solution was

1011 added to ammonia (36 mL of 0.5 M, 18.00 mmol) at 0 °C. The mixture was stirred at room température for 30 minutes, and then partitioned between dichloromethane and water. The aqueous layer was extracted three times with dichloromethane. The combined organic layera were washed with brine, dried over magnésium sulfate, fîltered, and concentrated to dryness to provide a yellow solid (342 mg). The crude material was used directly in next step without further purification. ESI-MS m/z cale. 309.04, found 310.3 (M+I)⁺; Rétention time; 1.10 minutes (3 min run).

Préparation 86: A-|(6-anHno-2-pvridyl)sulforiylJ-3-flii()ro-4-(3-niH)ro-5isobutoxy-phenyI)-2-(2,2,4-trimethylpyrrolidin-I-yl)benzamide (Compound 1497)

Step I : /V-[(6-aminO'2-pyridyl)sulfonyl]-4-bromo-23-dÎfluoro-benzamide

To 4-bromo-2,3-difluoro-benzoic acid (2.66 g, 11.2 mmol) in N, Ndimethylfoimamide (2.3 mL) was added at room température di(imidazol-I-yl)methanone (2.7 g 17 mmol) and reaction was heated at 65 °C for 1 hour. Separately to 6-aminopyridine-2sulfonamide (2.4 g, 14.0 mmol) in N, Mdimethylformamide (2 mL) was added sodium hydride (561 mg, 14.0 mmol) at 0 °C and stirred for 10 minutes for 1 hour. The reaction was cooled back to 0 °C and the adduct from above was added and the reaction was heated at 65 °C for 1.5 hours. The reaction was cooled to room température and diluted with ethyl acetate and washed with a brine solution. The organics were separated, dried and concentrated to give a residue which was purified with silica gel eluting with 0 to 100% ethyl acetate in hexanes to give N-[(6-amino-2pyndyl)sulfonyl]-4-bromo-2,3-difluoro-benzamide (3.8 g, 9.7 mmol, 86%) as product. ESLMS m/z cale 390.94 , found 392.0 (M+1)⁺; Rétention time: 1.1 minutes (3 min run)

Step 2: A4(6-amino-2-pyridyl)sulfonyl]-2,3-difluoro-4-(3-fluoro-5-isobutoxyphenyl)benzamide

1012

F

To mixture of A4(6-amino-2-pyridyl)sulfonyI]-4-bromo-2,3-difluoiO-benzamide (700. mg, 1.79 mmol), (3-fluoro-5-isobutoxy-phenyl)boronic acid (568 mg, 2.68 mmol), and potassium carbonate (740 mg, 5.4 mmol) in a vial was added [Ι,Γ5 bis(diphenylphosphino)ferrocene]palladium(ll) dichloride (130.6 mg, 0.1785 mmol) and A, Ndimethylformamide (4.8 mL) and water (] .2 mL) and the reaction mixture was stirred under nitrogen at 100 °C for 16 hours. The reaction mixture was cooled, filtered over pad ofcelite and the filtrate was diluted with ethyl acetate and a brine solution. The organics were separated, dried over sodium sulfate, and concentrated to give a residue which was purified with silica gel using 5 10 to 100% ethyl acetate in dichloromethane to give A4(6-amino-2-pyridyl)sulfonyI]-2,3-difluoro4-(3-fh!oro-5-isobutoxy-phenyl)benzamide (174 mg, 0.363 mmol, 20.3%) ’H NMR (400 MHz, Methanol-^) δ 7.64 - 7.53 (m, 2H), 7.29 (d, 7 = 7.4 Hz, 1H), 7.25 - 7.18 (m, 1H), 6.90 (d,7= 2.7 Hz, 1 H), 6.88 - 6.81 (m, IH), 6.73 (dt, 7 = 10.8, 2.3 Hz, 1H), 6.64 (d, J = 8.3 Hz, 1H), 3.79 (d, 7 = 6.4 Hz, 2H), 2.07 (hept, 7 = 6.7 Hz, I H), 1.04 (d, 7 = 6.7 Hz, 6H). ESI-MS m/z cale 479.11 , 15 found 480.2 (M+])⁺; LCMS rétention time: 1.8 minutes (3 min run).

Step 3: iV-[(6-amÎno-2-pyridy])sulfonyl]-3-fluoro-4-(3-fluoro-5-isol)utoxy-pheny])2-(2,2,4-trimethy]pyrrolidin-l-yI)benzamide (Compound 1497)

To mixture of 2,2,4-trimethyIpynrolidine (35.41 mg, 0.3128 mmol) and A-[(6-ammo20 2-pyndyl)suIfonyl]-2,3-difluoro-4-(3-fluoro-5-isobutoxy-phenyl)benzamide (30.00 mg, 0.06257 mmol) was added l-methylpyrrolidin-2-one (0.3 mL) and the reaction mixture was heated 190

1013 °C for 2 hours. The reaction mixture was cooled and purified by reverse phase HPLC utilizing a gradient of 10 to 99 percent acetonitrile in water containing 5 mM ammonium formate to yield //-[(6-amino-2-pyridyl)suIfonyl]-3-fluoro-4-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4trimethylpyrrolidin-l -yl)benzamide (Compound 1497) (7.6 mg, 0.013 mmol, 4.2%) 'H NMR (400 MHz, MethanoUZOJ 8.03 (dd, J= 8.3, 1.2 Hz, 1H), 7.68 (dd, J = 8.5, 7.3 Hz, 1H), 7.59 (dd, 7= 8.3, 7.1 Hz, 1H), 7.38 (dd, J = 7.4, 0.8 Hz, 1H), 6.93-6.82 (m, 2H), 6.82-6.74 (m, 2H), 3.92 (t, 7= 9.4 Hz, 1H), 3.79 (d, 7= 6.4 Hz, 2H), 2.84 - 2.72 (m, 1H), 2.23 (dd,7= 12.6, 7.3 Hz, 1H), 2.12-2.02 (m, 1H), 1.87 (t, 7= 11.7 Hz, JH), 1.38 (s, 3H), 1.24 (d, 7= 6.6 Hz, 6H), 1.04 (d, 7 = 6.7 Hz, 6H). ESI-MS m/z cale. 572.23, found 573.1 (M+l)⁺; LCMS rétention 10 time; 1.77 minutes (3 min run).

Préparation 87:7V-[(6-amino-2-pyridyI)sulfonyl]-5-chloro-6-(3-fiuoro-5 iso b u toxy-p h eny Ii-2-[ (4.5)-2,2,4-( ri mcdhylpyrrolidm (Compound 1641)

7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(4S )-2,2,415 trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (56.79 mg, 0.1022 mmol) and Nchlorosuccinimide (13.65 mg, 0.1022 mmol) in dichloromethane (400 pL) was stirred at reflux ovemight. The dichloromethane was evaporated under a stream of nitrogen, and the residue was dissolved in dimethyl sulfoxide and purified by préparative HPLC chromatography utilizing a gradient of 10 to 99 percent acetonitrile in water to give A-[(6-amino-2-pyridyl)sulfonyl]-520 chloro-6-(3-fIuoro-5-isobutoxy-phenyÎ)-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1641) (18 mg, 0.030 mmol, 29.5%) ’H NMR (400 MHz, DMSO-7₆) S 12.59 (s, 1H), 7.80 (s, 1H),7.64 (dd, 7= 8.4, 7.3 Hz, 1H), 7.27 -7.18 (m, 1H), 7.10-6.99 (m, 2H), 6.93 (dt, 7 = 11.0, 2.3 Hz, 1H), 6.70 (dd, 7 = 8.4, 0.8 Hz, 1H), 6.54 (s, 2H), 3.80 (d, 7= 6.6 Hz, 2H), 2.65 - 2.53 (m, 2H),2.22 (dt, 7 = 11.5, 5.9 Hz, 1H), 2.08- 1.96 (m, 1 H), 1.84 (dd,7 =

12. 0,5.6 Hz, 1H), 1.57 - 1.33 (m, 7H), 0.97 (d,7= 6.7 Hz, 6H), 0.86 (d, 7= 6.3 Hz, 3H). ESIMS m/z cale. 589.19257, found 590.0 (M+l)⁺; Rétention time: 3.06 minutes.

Préparation 88:2V-[(6-anrino-2-pyridyl)sulfony]]-5-chloro-2-[(4S)-2_J2,4triπlethylpyrΓoIidin-l-yl]pyridine-3-carboxamίde (Compound 1603)

1014

A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 946) (40.0 mg, 0.102 mmol) and N-chlorosuccinimide (13.65 mg, 0.1022 mmol) in dichloromethane (400 pL) was stirred at reflux for 3 days. The réaction mixture 5 was directly purified by chromatography over silica gel (4g) with a linear gradient of 0 to 5% methanol in dichloromethane to give N-[(6-mnino-2-pyndyl)sulfonyl]-5-chloro-2-[(45j-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1603) (25 mg, 0.058 mmol, 57%) 'HNMR (400 MHz, DMSCM₀) δ 12.54 (s, 1 H), 8.27 - 8.00 (m, 1H), 7.72 - 7.54 (m, 2H),7.18 (d, 7= 7.2 Hz, 1H), 6.66 (d,7 = 8.4 Hz, 1H), 6.50 (s, 2H), 2.55 (s, 2H), 2.17 (dq, 7= 13.0,7.1, 10 6.7 Hz, 1H), 1.83 (dd, 7 = 11.8,5.6 Hz, 1H), 1.47 (d, 7 = 7.1 Hz, 6H), 1.37 (t, 7 = 12.1 Hz, 1H),

0.85 (d, 7= 6.3 Hz, 3H). ESI-MS m/z cale. 423.1132, found 424.0 (M+l)⁺; Rétention time: 1.75 minutes.

Préparation 89:A4(6-acetamido-2-pyridyl)suIfonyl]-6-(3-fluoro-5-isobutoxyphenyl)-2-[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1652)

Y-[(6-amino-2-pyridyI)sulfonyI]-6-(3-fluoro-5-isobu toxy-phenyI)-2-[(45)-2,2,4trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (56.78 mg, 0.1022 mmol) in pyridine (161.7 mg, 165.3 pL, 2.044 mmol) was treated with acetic anhydride (104.3 mg, 96.40 pL, 1.022 mmol) and heated to 45 °C for 2.5 hours. The reaction mixture was diluted with a 9:1 (v/v) mixture of dimethyl sulfoxide in water and purified by préparative HPLC chromatography to give /V-[(6acetamido-2-pyridyl)sulfony]]-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(45)-2,2,4trime thylpyrrolid in-1-y I]pyridine-3-carboxamide (Compound 1652) (22 mg, 0.036 mmol, 35%)

1015 'H NMR (400 MHz, DMSO-âk) δ 12.68 (s, 1H), 10.87 (s, 1H), 8.35 (d, J= 8.4 Hz, 1H), 8.17 8.05 (m, 1H), 7.88 - 7.80 (m, 2H), 7.51 - 7.45 (m, 1H), 7.42 (ddd, J = 10.2, 2.4, 1.3 Hz, 1H), 7.30 (d, 7=8.0 Hz, 1H), 6.90 (dt,7= 10.7,2.3 Hz, 1 H), 3.83 (d,7=6.6 Hz, 2H), 2.60 (dd,7= 10.2, 7.2 Hz, 1H), 2.52 (d, 7 = 5.3 Hz, 1 H), 2.14 (s, 4H), 2.07 - 2.00 (m, 1H), 1.87 (dd,7= 11.8,5.6

Hz, 1H), 1.59 (d, 7= 6.0 Hz, 6H), 1.41 (t, 7= 12.1 Hz, 1 H), 0.99 (d, 7 = 6.7 Hz, 6H), 0.77 (d, 7 = 6.3 Hz, 3H). ESI-MS m/z cale. 597.2421, found 598.0 (M+l)⁺; Rétention time: 2.83 minutes.

Préparation 90: A4(6-aminopyridin-2-yl)sulfonyl)-6-chloro-2-(3-fluoro-5îsobutoxyphenyl)nicotinaniide

Ιθ A mixture of7V-((6-aminopyridin-2-yl)sulfonyl)-2,6-dichloronicotinamide (2.6 g, 7.4 mmol) and 2-(3-fluoro-5-isobutoxyphenyl)-4,4,5,5-tetramethyl-l ,3,2-dioxaborolane (2.3 g, 7.7 mmol) in 12 mL ofTV.N-dimethylformamide and 3 mL of water was heated under nitrogen to 70 °C for 30 minutes and then tetrakis(triphenylphosphine)palladium(0) (0.20 g, 0.17 mmol) and sodium carbonate (4.8 g, 45 mmol) were added to the reaction mixture. The mixture was stirred at 70 °C for 18 hours and then purified by silica gel chromatography eluting with a gradient of 40 to 100% ethyl acetate in hexanes. The product was further purified on reverse phase HPLC and a white solid was isolated as N-((6-aminopyridin-2-yl)sulfonyl)-6-chIoro-2-(3-fluoro-5isobutoxyphenyDnicotinamide (0.37 g, 0.77 mmol, 14%). ^lH NMR (DMSO-7₀, 250 MHz): Ô 8.03 (d, 7= 8.3 Hz, 1 H), 7.62 (m, 2H),7.11 (d,J = 7.3 Hz, 1 H), 6.93 (m,2H),6.81 (d,7=9.3

Hz, 1 H), 6.73 (d, 7= 8.5 Hz, 1 H), 3.87 (d, 7= 6.5 Hz, 2H), 2.02 (m, 1H), 1.00 (d, 7 = 6.5 Hz, 6H) ppm. LC-MS: (M+H)⁺= 479.1

Préparation 91: A-((6-aminopyridm-2-yl)sulfûnyl)-6-chloro-6'-isopropoxy-[2,3’bipyridine]-3-carboxamide

1016

A mixture of the sulfonamide N-((6-aminopyridin-2-yl)sulfonyI)-2,6dichloronicotinamide (2.1 g, 6.0 mmol) and 2-isopropoxy-5-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yI)pyridine (1.7 g, 6.6 mmol) in 12 mL ofTVW-dimethylformamide and 3 mL of water was heated under nitrogen at 70 °C for 20 minutes and added tetrakis(triphenylphosphine)palladium(0) (0.15 g, 0.13 mmol) and sodium carbonate (1.9 g, ] 8 mmol). The mixture was stirred at 70 °C for 19 hours. The reaction mixture was evaporated to dryness, and the crude product was purified by silica gel chromatography utilizing a gradient of 40 to 100% ethyl acetate in hexanes. The product was further purified on reverse phase HPLC and a white solid was isolated as 7V-((6-aminopyridin-2-yI)sulfonyl)-6-chloro-6'-isopropoxy[2,3'-bipyridine]-3-carboxamide (0.72 g, 1.6 mmol, 27%). ’H NMR (DMSO-7₆, 250 MHz): δ 8.33 (s, 1 H), 8.06 (d, 7=8.0 Hz, IH), 7.64 (m, 3H), 7.15 (d, J = 7.3 Hz, 1 H), 6.93 (m, 2H), 6.80 (d, 7=7.3 Hz, 1H), 6.69 (d,7= 8.8 Hz, 1H), 5.27 (m, 1H), 1.32 (d,7=6.3 Hz, 6H)ppm.

Préparation 92: ïV-[(6-amino-2-pyridyl)su]fonyl]-2-(6-isopropoxj -3-pyridyl)-6[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1436)

jV-((6-aminopyridin-2-yl)sulfonyl)-6-chloro-6'-isopropoxy-[2,3'-bipyridine]-3carboxamide (0.050 g, 0.1 Immol) and césium floride (0.085 g, 0.56 mmol) were combined in dimethyl sulfoxide (0.5 mL). The reaction mixture was stirred at 150 °C for 16 hours. (4S)2,2,4-trimethylpyrrolidine (0.0379 g, 0.335 mmol) was added to the réaction mixture and the mixture was stirred at 150 °C for 10 hours. The crude product was purified by reverse phase HPLC utilizing a gradient of 10 to 99% acetonitrile in water to yield A^r-[(6-amino-2

1017 pyndyl)3ulfonyl]-2-(6-isopropoxy-3-pyridyl)-6-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridme-3carboxamide (Compound 1436) (0.0026 g, 0.0050 mmol, 4.5%). ESI-MS m/z cale. 424.2, found 525.3 (M+l)⁺; Rétention time: 1.89 minutes.

V-[(6-amino-2-pyridy])sulfonyl]-2-(3-f]uoro-5-isobutoxy-phenyl)-6-[(45)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1409), /V-[(6-amino-2-pyridyl)sulfonyl]-2-(3-fiuoro-5-isobutoxy-phenyl)-6-[(4A)-2,2,4trimethylpyiTolidin-1-yl]pyridine-3-carboxamide (Compound 1385),

A^r-[(6-amino-2-pyridy])sulfonyl]-2-(6-isopropoxy-3-pyridyl)-6-[(4R)-2,2,4-tnmethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 1491).

Préparation 93: _JV-[(6-amino-2-pyridyI)sulfonyl]-6-cyano-2-[(4S)-2₎2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1564)

[(2-Di-mrr-butylphosphino-2',4 ',6 '-triis opropyl-1,1 '-biphenyl)-2-(2 '-amino-1,1 'biphenyl)] palladium(II) methanesulfonate (4.186 mg, 0.005270 mmol), di-tm-butyl-[2-(2,4,6triisopropylphenyl)phenyl]phosphane (2.238 mg, 0.005270 mmol), Potassium hexacyanoferrate(II) trihydrate (22.26 mg, 0.05270 mmol), and W-[(6-amino-2py ri dyI)sulfonyl]-6-chloro-2-[(45)-2,2,4-trime thy Ip yrroli din-1 -yl]pyridi ne-3-carboxamide (Compound 852) (44.7 mg, 0.1054 mmol) were added to a vial and the vial was purged with nitrogen. Deoxygenated dioxane (500 pL) and a solution of potassium carbonate (263.6 pL of 0.05 M, 0.01318 mmol) was added to reaction mixture, the head space was purged with nitorgen and the sealed vial was stirred at 100 °C for 1 hour, The crude product was purified by reverse phase HPLC utilizing a gradient of 10 to 99% acetonitrile in water to yield 7V-[(6-amino-2pyridyl)sulfonyl]-6-cyano-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1564) (1.8 mg, 0.0043 mmol, 4.1%) ESI-MS m/z cale. 414,1474, found 415.2 (M+l)⁺; Rétention time: 1.49 minutes.

1018

Préparation 94: A^r-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5dîniethylpyrrolidin-l-y]]-6-(3-fluoro-5-isobutoxy-phenyl)-4-hydroxy-pyridine-3carboxainide (Compound 1430)

In a nitrogen purged flask, A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2S,5R)-2,5~ dimethy]pyrroIidin-l-yl]-6-(3-fluoro-5-isobutoxy-phenyl)-4-methoxy-pyridine-3-carboxamide (Compound 1254) (17.5 mg, 0.0306 mmol) was dissolved in dichloromethane (1,577 mL). The mixture was cooled to -78°C, and tribromoborane (811.2 mg, 306,1 pL of 1 Μ, 0.3061 mmol) was added to the reaction mixture in a dropwise manner. The mixture was slowly warmed to room température, The mixture was stirred ovemight at ambient température. The reaction mixture was added to ice (~ 5 mL). The layers were separated, and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried over sodium sulfate, concentrated, and purified by reverse phase HPLC utilizing a gradient of 1-99% acetonitrile in 5 mM aqueous hydrochloric acid. The compound was further puried on silica gel using dichloromethane as the eluent to yield iV-[(6-ammo-2-pyridyl)suIfonyl]-2-[(2S,5R)-2,5dimethylpyn-olidin-l-yI]-6-(3-fluoro-5-isobutoxy-phenyl)-4-hydroxy-pyridine-3-carboxamide (Compound 1430) (3.2 mg, 0.0057 mmol, 19%) as an off -white solid. ESI-MS m/z cale, 557.2108, found 558.3 (M+l)⁺, Rétention time: 1.84 minutes.

Préparation 95: 4-Bromo-2-(mesityIoxy)benzoic acid

Step 1: 4-Bromo-2-(mesityIoxy)benzonitrile

1019

A mixture of 4-bromo-2-fluoro-benzonitrile (1.2 g, 6.0 mmol), 2,4,6-trimethylphenol (780 mg, 6.1 mmol), potassium carbonate (2.50 g, 18.1 mmol), and dimethylsulfoxide (9.0 mL) were microwave irradiated at 140 °C for 2 hours. Water (20 mL) was added and the resulting mixture was stirred for 5 minutes. The resulting suspension was filtered and the solid was washed with water and dried under vacuum at 50 °C for 16 hours to yield 4-bromo-2(mesityloxy)benzonitrile (1.8 g, 95%) as a brown solid. ^]H NMR (CDC1₃, 250 MHz): 7.50 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 8.2 Hz, 1H), 6.94 (s, 2H), 6.61 (s, 1H), 2.33 (s, 3H), 2.10 (s,6H)ppm,

Step 2: 4-Bromo-2-(mesityloxy)benzoic acid

4-biOmo-2-(mesityloxy)benzonitri]e (1.8 g, 9.0 mmol) was suspended in éthanol (6 mL) and water (12 mL), containing sodium hydroxide (3.0 g, 75 mmol). The mixture was stirred at 90 °C for 16 hours. Hydrochloric acid (6M, 13 mL) was added to the reaction mixture followed by water (20 mL) and the suspension was stirred for 10 minutes, filtered, and washed with water and hthen hexanes to yield 4-bromo-2-(mesityloxy)benzoic acid as an off-white solid (1.7 g, 5.1 mmol, 57%). *H NMR (DMSO-7₆, 250 MHz): 7.74 (d, 7= 8.2 Hz, 1H), 7.28 (d,7 = 8.2 Hz, 1H), 7.01 (s, 2H), 6.41 (s, 1H), 2.28 (s, 3H), 2.02 (s, 6H) ppm.

Préparation 96: 6-Methoxy-4-methylpyridine-2-suIfonamide Step 1: 2-Benzy]suIfanyl-6-cliloro-4-methylpyridine

2,6-Dichloro-4-methyl-pyridine (4.74 g, 29.3 mmol) was dissolved in tetrahydrofuran (47.40 mL) with phenylmeflianethiol (3.634 g, 3.435 mL, 29.26 mmol) and 2-methylpropan-2olate (Sodium Ion (1)) (29.26 mL of 2 M, 58.52 mmol) was added to the reaction mixture. The

1020 réaction was stirred for 16 hours and partîtioned between water and ethyl acetate. The organics were separated, washed with brine, dried over sodium sulfate and evaporated. The crude material was used without fu rther purification. 2-BenzylsulfanyI-6-chloro-4-methyl-pyridine (6.91 g, 27.7 mmol, 94.5%) ESI-MS m/z cale. 249.0379, found 250.0 (M+l)⁺ ; Rétention time: 0.78 minutes.

Step 2: 6-Chloro-4-methylpyridine-2-sulfonamide

A biphasic mixture of2-benzylsulfanyI-6-chloro-4-methyI-pyridîne (6.87 g, 27.5 mmol) in dichloromethane (41.22 mL), water (13.74 mL), and aqueous hydrochloric acid (2.751 mL of 1 M, 2.751 mmol) was cooled in a sait water ice bath. ( Note: Aqueous hydrochloric acid is added to avoid an otherwise delayed exotherm upon the chlorine addition. ). Chlorine (7.800 g, 110.0 mmol) was bubbled through the solution (3 times at 2 minute intervals) over an hour. The reaction was stirred at 0 °C. After 1.5 hours (reaction monitored by UPLC) the reaction was added dropwise to an ice bath cooled solution of ammonium hydroxide (41.32 mL of 28 %w/v, 330.1 mmol) . The réaction was warmed to room température and stirred for 15 minutes. The reaction mixture was partîtioned between ethyl acetate (60 mL) and water (20 mL). The organics were separated, and the aqueous layer was extracted twice with ethyl acetate ( 60 mL portions). The organics were combinéd, washed with brine, dried over sodium sulfate and evaporated. The resulting solid was triturated with dichloromethanr (30 mL) and filtered. The solid was washed with minimal dichloromethane to give 6-chIoro-4-methyl-pyridine-2-suIfonamide as an off white solid (3.18 g, 15.4 mmol, 56.0%) 'H NMR (400 MHz, DMSO-d₆) δ 7.78 (dd, J = 1.3, 0.7 Hz, 1H), 7.66 - 7.63 (m, 1H), 7.59 (s, 2H), 2.45 (s, 3H). ESI-MS m/z cale. 205.99167, found 206.9 (M+l)⁺ ; Rétention time: 0.3 minutes .

Step 3: 6-MetIioxy-4-methylpyridine-2-su)fonamide

1021

6-Chloro-4-methylpyridine-2-sulfonamide (500. mg, 2.42 mmol) was dissolved in sodium methoxide in methanol (2.537 g, 2.615 mL of 25 % w/v, 12.10 mmol) and heated at 65 °C. After 1 hour, ail starting material was gone and two products had formed. The reaction mixture was partitioned between ethyl acetate and a saturated aqueous ammonium chloride solution. The organics were separated, washed with water, brine, dried over sodium sulfate and evaporated to diyness. The crude product was purifïed by silica gel chromatography eluting with 0 to 100% ethyl acetate in hexanes to give 6-methoxy-4-methylpyridine-2-sulfonamide (126 mg, 0.623 mmol, 25.7%) ESI-MS m/z cale. 202.04121, found 203.0 (M+l)⁺ ; Rétention time: 0,32 minutes.

Préparation 97: 6-Amino-4-methylpyridine-2-sulfonamide

6-Chloro-4-methylpyridine-2-sulfonaniide (500. mg, 2.42 mmol) was dissolved in aqueous ammonium hydroxide (3.029 mL of 28 %w/v, 24.20 mmol) and irradiated in a microwave reactor for 1 hour at 150 °C. The reaction was evaporated and the solid was washed with water and methanol to remove excess ammonium hydroxide. The resulting solid was a mixture of product and starting material. The mixture was taken on to the next step without further purification. 6-amino-4-methylpyridine-2-sulfonamide (200. mg, 1.07 mmol, 44.2%) ESI-MS m/z cale. 187.04155, found 188.0 (M+l) ⁺ ; Rétention time; 0.21 minutes.

PREPARATION 98: 4_î4,5^-Tetramethy]-2-(3,3,5,5-tetramethylcycIopenten-l-yl)13,2-dioxaborolane

Step 1: 3,3.,5-trnnethyI-5-trimethylstannyl-cycIohexanone

O

1022

To a stirring solution of trimethyl(trimethylstannyl)stannane (3.555 g, 2.250 mL, 10.85 mmol) in tetrahydrofuran (50 mL) at -20 °C was added methyllithium (4.964 g, 6.781 mL of 1.6 M, 10.85 mmol) and the mixture was stirred at -20°C for 15minutes. Next the 3,5,5-trimethylcyclohex-2en-l-one (1.00 g, 7.24 mmol) was slowly added and the reaction mixture was warmed to 0^DC, 5 stirred 30 minutes, and then quenched with methanol (695.6 mg, 879.4 pL, 21.71 mmol). The reaction mixture was warmed to room température and diluted with water then extracted twice with diethyl ether. The combined organic layers were dried (sodium sulfate), filtered and concentrated to a yellow oil which was purified by silica gel chromatography using 100% hexanes as eluent followed by 100% dichloromethane as eluent to yield 3,3,5-trimethyl-510 trimethylstannyl-cyclohexanone (2.01 g, 6.63 mmol, 91.7%) as a clear oil. ‘H NMR (400 MHz, CDC1₃) â 2.59 - 2.45 (m, IH), 2.21 -2.12(m, 3H), 1.92 (d,J= 14.2 Hz, IH), 1.59 (d, J =14.2 Hz, IH), 1.28 (s, 3H), 1.07 (s, 3H), 1.00 (s, 3H), 0.13 (d, J = 1.1 Hz, IH), 0.07 (s, 9H), 0.01 (d, J = 1.1 Hz, IH).

Step 2: 2,2,4,4-Tetramethylcyclopentanone

O

To a stirring solution of 3,3,5-trimethy 1-5-trimethylstannyl-cyclohexanone (4.17 g, 13.8 mmol) in the dichloromethane (79.23 mL) under a nitrogen atmosphère at 0 °C was added (dropwise) tetrachlorotitanium (2.610 g, 2.183 mL, 13.76 mmol) giving a dark brown color on addition. Upon completion of addition the reaction mixture was a brown suspension which was 20 stirred 20 minutes at 0 °C and then quenched by the addition of a solution of saturated aqueous sodium bicarbonate (Caution: Gas évolution, reaction became biphasic with a puiple suspension as die aqueous layer). The resulting mixture was extracted twice with dichloromethane, dried (magnésium sulfate), filtered and carefully concentrated to a clear oil. Purified by silica gel chromatography eluting with 100% giving 2,2,4,4-tetramethylcycIopentanone (1.67 g, 11.9 25 mmol, 86.6%) as a clear oil.

Step 3: 4,4,5,5-TetrLnnethy)-2-(.L3,5,5-tetran)ethvIcyclopenten-l-vl)-1.3.2dioxaborolanc

1023

To 2,2,4,4-tetramethylcyclopentanone (1.67 g, 11.9 mmol) was added tetrahydrofuran (16.70 mL) and the reaction was chilled to -78 °C. The reaction was stirred for 10 minutes and lithium bis(trimethylsilyl)amide (14.29 mL of 1 M, 14.29 mmol) was added dropwise and the reaction was allowed to stir at -78 °C for 1 hour. 1,1,1-Trifluoro-A-phenyl-A(trifluoromethylsulfonyl)methanesulfonamide (5.105 g, 14.29 mmol) dissolved in tetrahydrofuran (12.5 mL) was added dropwise and the reaction was allowed to warm to room température and stir 16 hours. The reaction was quenched with a saturated aqueous solution of sodium chloride and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to an orange syrup. The crade orange syrup was added to a mixture of bis(pinacol)diboron (4.535 g, 17.86 mmol), [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(ll), complex with dichloromethane (871.5 mg, 1.191 mmol) and potassium acetate (3.507 g, 35.73 mmol) in dimethylformamide (16.70 mL). The reaction was purged with nitrogen and heated to 65 °C for 16 hours. The reaction was quenched with a saturated aqueous solution of sodium chloride and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to dryness. The crude product was purifîed by silica gel chromatography using a gradient from 100% hexanes to 40% ethyl acetate in hexanes giving 4,4,5,5-tetramethyl-2-(3,3,5,5-tetramethylcyclopenten-l-yl)-l,3,2dioxaborolane (651 mg, 2.60 mmol, 21.8%) as a white solid.

PREPARATION 99: A-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fIuoro-5-isobutoxyphenyl)-2-(2,2,4,4-tetramethy]cyclopentyl)pyridine-3-carboxaniide (Compound 2492) (Isomer ]) (Compound 2374) (Isomer 2)

Step 1: ethyl 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carhoxylate

1024

2-Chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylic acid (5.077 g, 15.53 mmol) was dissolved in ethyl alcohol (50.26 mL) and thionyl chloride (2.218 g, 1.360 mL, 18.64 mmol) was added dropwise. The resulting solution was slowly heated to 76 °C (reflux) and stirred at 76 °C for 5 hours, The brownish solution was concentrated to remove solvent. The crude residue was redissolved in ethyl acetate and extracted with saturated aqueous sodium bicarbonate. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were extracted with saturated aqueous brine, dried over sodium sulfate, concentrated and purified by silica gel chromatography using a gradient from 100% hexanes to 100% ethyl acetate 10 giving ethyl 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylate (3.64 g, 10.3 mmol, 66.6%) as a white solid.

Step 2: Ethyl 6-(3-fluoro-5-isobutoxy-phenyl)-2-(3,3,5,5-tetramethylcyclopentenl-yl)pyridine-3-carboxyIate

A mixture of ethyl 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylate (841.8 mg, 2.393 mmol), 4,4,5,5-tetramethy 1-2-(3,3,5,5-tetramethylcy cl ope nten-l-yl )-1,3,2dioxaborolane (598.7 mg, 2.393 mmol), [1,I'bis(diphenylphosphino)ferrocene]dichloropal]adium(ll), complex with dichloromethane (525.3 mg, 0.7179 mmol), and sodium carbonate (760.9 mg, 7.179 mmol) in dioxane (10.77 mL) and water (1.196 mL) was heated in a sealed vessel at 150 °C for 16 hours. The reaction was fîltered and the solids were washed with ethyl acetate. The extract was evaporated and the residue was purified by silica gel chromatography using a gradient from 100% hexanes to 25% ethyl acetate

1025 in bexanes to give ethyl 6-(3-fluoro-5-isobutoxy-pheny 1)-2-(3,3,5,5-tetramethylcyclopenten-1yl)pyridine-3-carboxylate (460.3 mg, 1.047 mmol, 43.75%) as a light yellow solid.

Step 3: 6-(3-Fhioro-5-isobutoxy-pheny 1)-2-(3,3,5,5-te tram ethylcy clopenten-1 yl)pyridine-3-carboxylic acid

A solution of ethyl 6-(3-fluoro-5-isobutoxy-pheny 1)-2-(3,3,5,5tetramethylcyclopenten-l-yl)pyridine-3-carboxylate (460.3 mg, 1.047 mmol) and sodium hydroxide (2.617 mL of 1 M, 2.617 mmol) in tetrahydrofiiran (2.606 mL) and water (2.606 mL) was stirred at 50 °C for 6.5 hours. The reaction was cooled to room température and then neutralized with IM hydrochloric acid and extracted twice with ethyl acetate. The combined extracts were dried over sodium sulfate and evaporated to give 6-(3-fluoro-5-isobutoxy-phenyl)2-(3,3,5,5-tetramethylcyclopenten-l-yl)pyridine-3-carboxylic acid (389.1 mg, 0.9455 mmol, 90.32%) as yellow needles.

Step 4: 6-(3-Fluoro-5-isobutoxy-phenyl)-2-(2,2,4,4tetramethylcyclopentyl)pyridine-3-carboxyIic acid

A mixture of 6-(3-fluoro-5-isobutoxy-phenyi)-2-(3,3,5,5-tetramethylcyclopenten-1 yl)pyridine-3-carboxylic acid (389.1 mg, 0.9455 mmol), palladium hydroxide (79.67 mg, 0.5673 mmol) and ammonium formate (1.192 g, 18.91 mmol) in éthanol (10 mL) were combined in a microwave vial and heated to 85 °C for 3hours. The reaction mixture was cooled to room température, uncapped, ammonium formate (1.192 g, 18.91 mmol) and palladium hydroxide (79.67 mg, 0.5673 mmol) were added, nitrogen was bubbled through the solution for 2 minutes,

1026 and the vial was capped and retumed to the micro wave reactor at 85 °C for 4 additional hours. The re action was fîltered through celite élu tin g with methanol and concentrated under reduced pressure. The mixture was then diluted with IN aqueous hydrochloric acid and washed with twice with ethyi acetate. The organic layers were combined, dried (sodium sulfate), fîltered and concentrated to a clear oil with some white solid présent. The crude material was purified by silica gel chromatography using a gradient from 100% dichloromethane to 20% methanol in dichlorometbane followed by 20% methanol in ethyi acetate giving 6-(3-fluoro-5-isobutoxyphenyl)-2-(2,2,4,4-tetramethylcyclopentyl)pyridine-3-carboxylic acid (52.3 mg, 0.126 mmol, 13.4%) as a white solid.

Step 5:N-[(6-amino-2-pyridy])sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl)-2(2,2,4,4-tetramethylcyclopentyl)pyridine-3-carboxamide (Compound 2492) (Isomer 1) (Compound 2374) (Isomer 2)

A solution of 6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4,4tetramethylcyclopentyl)pyridine-3-carboxylic acid (52.0 mg, 0.126 mmol) and carbonyl diimidazole (30.58 mg, 0.1886 mmol) in dimethylformamide (0.5 mL) was stirred at 45°C for 90 minutes. A separate solution of 6-aminopyridme-2-sulfonamide (43.54 mg, 0.2514 mmol) and sodium hydride (10.06 mg, 0.2514 mmol) in dimethylformamide (0.5 mL) which was stirred at 45 °C for 45 minutes was then added and the resulting mixture was stirred at 45 °C for 2hours. The reaction was fîltered and purified using a reverse phase HPLC-MS inethod using a Luna Cl8 (2) column (75 x 30 mm, 5 pm particle size) sold by Phenomenex (pn: 00C-4252-U0-AX), and a dual gradient run from 1 to 99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = acetonitrile, flow rate = 50 mL/min, injection volume = 950 pL and column température = 25 °C) giving 7V-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5isobutoxy-phenyl )-2-(2,2,4,4-tetramethylcy cl opentyl)pyridine-3-carboxamide (Compound 2492) (Isomer 1) (Compound 2374) (Isomer 2) hydrochloride (51 mg, 0.084 mmol, 67%) as an offwhite solid ^!H NMR (400 MHz, DMSO-t/₆) ô 12.63 (s, 1H), 7.91 (dd, J = 20.4, 8.2 Hz, 2H), 7.66

1027 (t,J = 7.9 Hz, 1 H), 7.57 (s, 1 H), 7.51 (d, J = 9.8 Hz, 1H),7.25 (d,7=7.3 Hz, 1 H), 6.93 (d,7 = 10.7 Hz, 1 H), 6.73 (d, 7= 8.4 Hz, 1 H), 6.51 (s,2H),3.86 (d, 7=6.6 Hz, 2H), 3.58 (dd, J = 12.2, 6.5 Hz, 1 H), 2.55 (d,7= 12.3 Hz, 1 H), 2.06 (dt,J= 13.2,6.6 Hz, 1H), 1.63 (dd, 7 = 12.4, 6.4 Hz, 1H),1.5O (d, J =13.0 Hz, 1H), 1.39 (d, J = 12.9 Hz, 1H), 1.15 (s, 3H), 1.08 - 0.93 (m, 9H), 0.80 (s, 3H), 0.69 (s, 3H). ESI-MS m/z cale. 568.25195, found 569.3 (M+l)⁺; Rétention time: 2.4 minutes.

PREPARATION 100: 4,4,5,5-tetramethyl-2-[(5S}-3,3.5-trimethyIcyclohexen-1ylj-l,3,2-dioxaborolane

Step 1: (5R)-3,3^-Trimethylcyc)ohexanone

To a round bottom flask purged with nitrogen was added copper (II) acetate (14.53 mg, 0.08000 mmol), [(4S)-4-[5-bis(3,5-diterr-butyl-4-methoxy-phenyl)phosphanyl-l,3benzodioxol-4-yl]-4,5,6,7-tetrahydro-l,3-benzodioxol-5-yl]-bis(3,5-di/erAbuty]-4-methoxyphenyl)phosphane (47.34 mg, 0.04000 mmol), and toluene (27.64 mL). The reaction was stirred at room température for 90 minutes. Polymethylhydrosiloxane (4.8 mL) was added and the reaction was allowed to stir at room température for 30 minutes. 3,5,5-Trimethylcyclohex-2-en1-one (5.528 g, 6.009 mL, 40.00 mmol) was then added dropwise and the reaction was allowed to stir for 90 minutes at room température. The reaction was poured into a solution of 3M sodium hydroxide and allowed to stir vigorously for 2 hours. The crude reaction was extracted with ethyl acetate and dried over sodium sulfate. The solvent was removed and tire crude product was taken onto the next step without further purification to give (5R)-3,3,5-trimethyIcyclohexanone (5.1 g, 36 mmol, 91%) ESI-MS m/z cale. 140.12012, found 141.2 (M+l)⁺; Rétention time: 1.44 minutes was a pale oil.

Step 2: 4,4,5,5-tetramethy]-2-[(5S)-3,3,5-trimethy]cycloIiexen-l-y]]-l,3,2dioxaborolane

1028

To crude (5R)-3,3,5-trimethylcyclohexanone (2.85 g, 20.3 mmol) was added tetrahydrofuran (28.50 mL) and the reaction was chilled to -78 °C. The reaction was stirred for 10 minutes and lithium bis(trimethylsilyl)amide (24.38 mL of 1 M, 24.38 mmol) was added dropwise and the reaction was allowed to stir at -78 °C for 1 hour. l,l,l-Trifluoro-N-phenyl-/V(trifluoromethylsulfonyl)methanesulfonamide (8.710 g, 24.38 mmol) dissolved in tetrahydrofuran (20 mL) was added dropwise and the reaction was allowed to warm to room temperatre and stir for 16 hours. The reaction was quenched with brine and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to a yellow oil. The crude vinyl triflate was used in the next step without fiirther purification. The crude vinyl triflate was added to a mixture of bis(pinacol)diboron (7.740 g, 30.48 mmol), bis(diphenylphosphino)ferrocene]dichloropalladium(ll), complex with dichloromethane (1.487 g, 2.032 mmol), potassium acetate (5.983 g, 60.96 mmol) in NN-dimethylfonnamide (28.50 mL). The reaction was purged with nitrogen and heated to 65 °C for 16 hours. The reaction was quenched with brine and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and evaporated. The crude product was purified by silica gel chromatography utilizing a gradient of 0 to 40% ethyl acetate in hexanes to yield 4,4,53-tetramethyl-2-[(55)-3,3,5trimethylcyclohexen-l-yl]-l,3,2-dioxaborolane (2.2 g, 8.8 mmol, 43%) as a mixture of regioisomers ESI-MS m/z cale. 250.2104, found 251.6 (M+l)⁺; Rétention time: 2.17 minutes

PREPARATION 101: N-[(6-aimno-2-pyridyl)sulfonyl]-6-[(15,25)-2(methoxymethyl)cyclopropyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1575)

Step l:A^r-[(6-aniino-2-pyridyl)sulfony]]-6-[(15,2S)-2(methoxymethyI)cyclopiOpyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1575) and A^r-[(6-ainîno-2-pyridyl)sulfonyl]-6-[(lR,2/f)-2(methoxymethy])cyclopropyl]-2-[(4S)-2,2,4-triniethy!pyrrolidin-I-yl]pyridine-3carboxamide

1029

To a microwave vial was added AM(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-[(4S)2,2,4-trimethylpyrrolidin-l-y I]pyridine-3-carboxamide (Compound 852) trifluoroacetic acid sait (100 mg, 0.186 mmol), [1,3-Bis(2,6-Diisopropylphenyl)imidazol-2-ylidene](3chloropyridyl)palladium(II) dichloride (6.3 mg, 0.0093 mmol) and dioxane (600 pL). The reaction was purged with nitrogen for 2 minutes and trans 2-[(lS’,2S)-2(methoxymethyl)cyclopropyl]-4,4,5,5-tetramethyLl,3,2-dioxaborolane (68.99 mg, 0.325 mmol) was added followed by an aqueous 2M solution of potassium carbonate (279 pL of 2 M, 0.558 mmol). Then the reaction was irradiated to 120 °C over 16 hours in the microwave reactor. The reaction mixture was allowed to cool, filtered and then purified directly by reverse-phase préparative chromatography utilizing a C18 column and HPLC-MS method 1 to 99 acetonitrile in water containing 5 mM hydrochloric acid to afford two compounds. Compound 1 (2.26 mg, 0.0044 mmol, 2.39%) ESI-MS m/z cale. 473.2097, found 474.2 (M+l)⁺ ; Rétention time: 1.13 minutes. Compound 2 (0.86 mg, 0.0018 mmol, 0.97%) ESI-MS m/z cale. 473.2097, found 474.2 (M+l) ⁺; Rétention time: 1.26 minutes as a light yellow solid.

Préparation 102: A^r-[(3S)-3-aminopyrrolidin-l-yI]suIfonyl-6-chloro-2-[(4S)-2,2,4 trimethylpyrroïidin-l-yl]pyridine-3-carboxamide

Step 1: 6-chloro-2-[(4S)-2,2,4-trimethylpyrroIidin-l-yl]pyridine-3-carboxy]ic acid

6-chloro-2-fluoro-pyridine-3-carboxyIic acid (1.50 g, 8.545 mmol) and (4S)-2,2,4trimethylpyrrolidine (Hydrochloric Acid) (1.534 g, 10.25 mmol) were combined in DMSO (4.500 mL). Potassium carbonate (2.362 g, 17.09 mmol) was added. Note: Substantial bubbling was observed upon mixing. The reaction mixture was sealed and heated at 90 °C ovemight. The

1030 reaction mixture was diluted with EtOAc (50 mL) and washed with aqueous 0.5 N HCl. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to a yellow oil. To remove any residual solvents, the oil was subjected to a stream of nitrogen gas for 1 hour, resulting in a crystalline solid. The product was used in the next step without further 5 purification. ESI-MS m/z cale. 268.09787, found 269.2 (M+l)⁺; Rétention time: 1.49 minutes

Step 2: tert-butyl AM(3S)-l-[[6-ehloro-2-[(4S)-2,2,4-lriinethyipvrrolidin-l yl]pyridine-3-carbonyl]suIfamoyl]pyrrolidin-3-yl]carbamate

6-chloro-2-[(4S)-2,2,4-trimethylpyrrolidin-I-yl]pyridine-3-carboxylic acid (L61 g,

5.99 mmol) was dissolved in dichloromethane (8 mL), warmed to 40 °C and A(oxo methyl en e)sulfamoyl chloride (1.017 g, 625.5 pL, 7.189 mmol) was added. Note: Substantial bubbling was observed during addition. After 3 minutes of stirring at 40 °C, addition al dichloromethane (10 mL) was added followed by tert-butyl A^[(3S)-pyrrolidîn-3y]]carbamate (2.80 g, 15.0 mmol). Bubbling was observed. After ovemight stirring at 40 °C, the reaction mixture was diluted with EtOAc (75 mL) and washed with water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was îsolated by silica gel column chromatography: 0 to 40% EtOAc/hexane gradient on a 80 grain silica gel column. tert-butyl M[(3S)-l-[[6-chk)ro-2-[(4S)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carbonyl]sulfamoyl]pyrrol!din-3-yl]carbamate (965 mg, 1.87 mmol, 31.2%) was obtained as a lightly brown foaming solid. ^!H NMR (400 MHz, DMSO-rk) δ 11.92 (s, 1H), 7.62 (d, 7=7.9 Hz, lH),7.18(s, 1H), 6.61 (d,7 = 7.9 Hz, 1 H), 3.96 (s, 1 H), 3.653.45 (m, 3H), 3.14 (dd, 7 = 9.7, 5.9 Hz, 1H),3.O3 (t, J = 10.3 Hz, 1H), 2.97 - 2.85 (m, 1 H), 2.33 (s, 1H), 2.04 (dd, 7= 12.7, 5.7 Hz, 1H), 1.92 (dd, 7= 11,4,5.1 Hz, 1H), 1.78 (dd,7= 12.6,6.9 Hz, 1H), 1.54 (d, 7=6.1 Hz, 6H), 1.38 (s, 9H), 1.01 (d,7= 6.3 Hz, 3H), 0.83 (s, 1H). ESI-MS m/z cale. 515.1969, found 516.4 (M+l)⁺; Rétention time: 0.77 minutes.

1031

Step 3; 7V-.[(3S)-3-ammopy rrolidin-l-yî]suIfonyl-â-cMoro-2-[(4S) -2,2,4trimethyipyrrolidin-l-yl]pyridine-3-carboxamide

tert-butyl iV-[(3S)-l-[[6-ch]oro-2-[(4S)-2,2,4-trirnethylpyrrolidin-l-yl]pyridine-3carbonyI]sulfamoyI]pyiTolidin-3-yl]carbamate (100 mg, 0.1938 mmol) was dissolved in CH2C12 (1 mL), and TFA (1 mL, 12.98 mmol) was added. The solution was allowed to stir at room température for 30 minutes. Volatiles were removed under reduced pressure. The crude product was used in the next step without further purification.

Préparation 103: /V-[(6-amino-2-pyridyl)sulfonyl]-6-[l-(tert-buty]carbamoy])-3,6dihydro-2H-pyridin-5-yl]-2-[(4S)-2,2,4-trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2568)

To a stirred solution of ?A[(6-amino-2-pyridyl)sulfonyl]-6-(l ,2,3,6-tetrahydropyridin5-yl)-2-[(4 S )-2,2,4-trime thylpynoïid in-l-yl]pyridine-3-carboxamide (Hydrochloric Acid (2)) (27 mg, 0.037mmol) in anhydrous dichloromethane (1.0 mL), triethyl amine (50 pL, 0.3587 mmol) and 2-isocyanato-2-methyl-propane (8.0 mg, 0.081 mmol) were added at 0 °C under nitrogen. The yellow solution was stirred at ambient temerature for 2 hours. The volatiles were removed under reduced pressure and the residue was purified by reverse-phase HPLC to furnish A-[(6amino-2-pyridyl)sulfonyl]-6-[l-(tert-butylcarbamoyl)-3,6-dihydro-2H-pyridin-5-yl]-2-[(4S)2,2,4-trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2568) (Hydrochloric Acid

1032 (1)) (9.2 mg, 0.013 mmol; 41%) ESI-MS m/z cale. 569.27844, found 570.4 (M+l)⁺; Rétention . time: 1.3 minutes | The following compounds can be synthesized using the procedures described herein

V-[(6-amino-2-pyridyl)suIfonyl]-6-tert-butyl-5-[I-(cyclohexylcarbamoyl)-3,6-dihydro-2Hpyridin-4-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2520)

Préparation 104:/V-[(6-amino-2-pyridyl)sulfonyI]-6-[l-(2,2-dimethylbutanoyI) 3,6-dihy d ro-2H-pyridin-5-y IJ-2- [(4S )-2,2,4 -trime thy lpyrrolidîn-1 -yl]pyridine-3 carboxamide (Compound 2612)

To a stirred solution ofA4(6-amino-2-pyridyl)suIfonyl]-6-(l,2,3,6-tetrahydropyridin5-yl)-2-[(4S)-2,2,4-trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Hydrochloric Acid (2)) (27 mg, 0.037 mmol) in anhydrous dichloromethane (1.0 mL), triethyl amine (50. pL, 0.36 mmol) and 2,2-dimethylbutanoyl chloride (11 mg, 0.082 mmol) were added at 0 °C under nitrogen. The yellow solution was stirred at ambient temerature for 2 hours. The volatiles were removed under reduced pressure and the residue was purified from reverse-phase HPLC to fumish N-[(6-amino2-pyridyl)sulfonyI]-6-[l-(2,2-dimethylbutanoyI)-3,6-dihydro-2H-pyridin-5-yl]-2-[(4S)-2,2,4trime thy lpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2612) (Hydrochloric Acid (])) (6.7 mg, 0.011 mmol, 27%) ESI-MS m/z cale. 568.2832, found 569.7 (M+l)+; Rétention time: 1.44 minutes

The following compounds can be synthesized using the procedures described herein /V-[(6-amino-2-pyridyI)sulfonyI]-6-[l-(3-chlorobenzoyl)-3,6-dihydro-2H-pyridin-5-yl]-2-[(4S)2,2,4-trimethyIpyrroljdin-l-yl]pyridine-3-carboxamide (Compound 1984),

A4(6-amino-2-pyridyl)suIfonyl]-6-[l-(l-piperidylsulfonyl)-3,6-dihydro-2H-pyridin-5-y]]-2[(4S)-2,2,4-triinethy]pyrrolidin-]-yl]pyridine-3-carboxamide (Compound 1942),

1033

V-[[6-[(2-phenyIacetyI)amino]-2-pyridyl]sulfonyl]-6-[l-(2-phenylacetyl)-3,6-dihydro-2Hpyridin-5-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2243), isopropyl 77-[6-[[6-(l ,2,3,6-tetrahydropyridin-5-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l yl]pyridine-3-carbonyl]suIfamoyl]-2-pyridyl]carbamate (Compound 2624), isopropyl 5-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyI]-6-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]2-pyridyl]-3,6-dihydro-2H-pyridine-I-carboxylate (Compound 2622),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[l-(3,3-dimethyIbutanoyI)-3,6-dihydro-2H-pyridin-5-yI]-2[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2650),

A4(6-amino-2-pyridyI)suIfonyl]-6-tert-butyl-5-[l-(2-cyclohexylacetyl)-3,6-dihydro-2H-pyridin10 4-yl]-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2596), isopropyl 4-[5-[(6-amino-2-pyridyl)sulfonylcarbamoyl]-2-tert-butyl-6-[(4S)-2,2,4trimethylpyrrolidin-1 -yI]-3-pyridyl]-3,6-dihydro-2H-pyridine-l-carboxylate (Compound 2027),

A4(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[l-(2-phenylacetyl)-3,6-dihydro-2H-pyridin-4yl]'2-[(4S)-2,2,4-trimethylpynOlidin-I-yl]pyridine-3-carboxamide (Compound 2417),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-[l-(3,3-dimethyIbutanoyl)-3,6-dihydro-2Hpyridîn-4-yl]-2-[(4S)-2,2,4-trimethyIpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2344), W-[(6-amino-2-pyridyl)sulfonyl]-6-[l-(2-cyclohexylacetyl)-3,6-dihydro-2H-pyridin-5-yl]-2[(4S)-2,2,4-trimethylpyrrolidin-I-y]]pyridine-3-carboxamide (Compound 2633) and,

AA[(6-amino-2-pyridyl)sulfbnyl]-6-(l-isobutylsulfonyl-3,6-dihydro-2H-pyridin-5-yl)-2-[(4S)20 2,2,4-trime thylpyrrolid in-1-y l]pyridine-3-carboxamide (Compound 1882)

Préparation 105:A4(6-amino-2-pyridyl)siilfonyl]-5-fluoro-6-[(3R)tetrahydrofuran-3-yI]oxy-2-[(4S)-2,2,4-trimethyl_Pyrro]idin-l-yl]pyridine-3-carboxamide (Componnd 2281)

1034

To a 4 mL via] was added NaH (10. mg, 0.25 mmol), (3R)-tetrahydrofuran-3-ol (27.63 mg, 25.19 pL, 0.3136 mmol), and DMSO (800 pL). The mixture was stirred at ambient température for 2 minoutes. M[(6-amino-2-pyridyl)sulfonyl]-6-chloro-5-fluoro-2-[(4S)-2,2,4trimethylpyrToIidin-l-yl]pyridine-3-carboxamide (Hydrochloric Acid (1)) (30. mg, 0.063 mmol) was then added to the vial and the reaction was stirred at 150 °C for 2 hours. The reaction mixture was filtered and purified by préparative HPLC (1-99% acetonitrile over 30 minutes with 5 mM HCl modifier) to give W6-amino-2-pyridy])sulfonyl]-5-fluoro-6-[(3R)-tetrahydrofuran3-yl]oxy-2-[(4S)-2,2,4-trimethylpyrrolidin-I-yl]pyridine-3-carboxamide (Compound 2281) (Hydrochloric Acid (1)) (9 mg, 0.02 mmol, 30%) ^fH NMR (400 MHz, DMSO-î/₆) 0 12.29 (s, IH), 7.66 - 7.57 (m, 2H), 7.17 (d, J = 7.3 Hz, IH), 6.66 (d, J = 8.3 Hz, IH), 6.41 (s, 2H), 5.55 5.48 (m, IH), 3.94 - 3.83 (m, 2H), 3.83 - 3.76 (m, 2H), 2.56 (d, J = 10,6 Hz, IH), 2,44 (t, J = 8.7 Hz, IH), 2.32-2.16 (m, 1 H), 2.10 - 2.02 (m, IH), 1.84 (dd, J = 11.8, 5.6 Hz, IH), 1.53 (s, 3H), 1.44 (s, 3H), 1.37 (t, J= 12.0 Hz, 1 H), 0.85 (d, J =63 Hz, 3H). ESI-MS m/z cale. 493.1795, found 494,3 (M+l)⁺; Rétention time: 1,08 minutes

The following compounds can be synthesized using the procedures described herein //[(6-amino-2-pyridyl)sulfonyl]-6-[(lR)-l,2-dimethylpropoxy]-5-fluoro-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2020),

2V-[(6-amino-2-pyridyl)sulfonyl]-6-(l-cyclohexylethoxy)-5-fluoro-2-[(4S)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1730),

W-[(6-amino-2-pyridyl)sulfonyl]-5-fluoro-6-[(3S)-tetrahydrofiiran-3-yl]oxy-2-[(4S)-2,2,4trimethylpyrrolid in-l-yl]pyridine-3-carboxamide (Compound 2056),

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(l-cyclopentylethoxy)-5-fluoro-2-[(4S)-2_J2,4trimeÎhyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1966), /V^f-[(6-amino-2-pyridyl)sulfony]]-5-fluoro-6-(l-retrahydropyran-4-ylethoxy)-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1891),

A-[(6-amino-2-pyridyl)sulfony]]-6-(cycIopentoxy)-5-fluoro-2-[(4S)-2,2,4-trimethylpyrrolidin-]yl]pyridine-3-carboxamide (Compound 2100),

M[(6-amino-2-pyridyl)su1fonyl]-6-(2,2-dimethylmorpholin-4-yl)-5-fiuoro-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2586), and

1035

W-[(6-amino-2-pyridyl)su]fonyl]-5-fluoro-6-[l-(4-pyridyI)ethoxy]-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2212)

Préparation 106: 6-tert-butyl-.V- [ [6-[(4 -m ethoxyphenyl)nidhoxy]-2pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxaniide (Compound 2724) (Isomer 1) (Compound 2428) (Isomer 2)

6-Gercbutyl)W-((6-chIoropyridin-2-yl)su]fonyI)-2-(2,2,4-trimethyIpyiTolidin-lyl)nicotinamide (100. mg, 0.215 mmol) and (4-methoxyphenyl)methanol (59.6 mg, 0.431 mmol) were dissolved in anhydrous anhydrous dimethyl sulfoxide (1 mL), and then césium carbonate (210 mg, 0.645 mmol) was added to the reaction mixture The resulting mixture was heated at 130 °C for 24 hours and cooled to room température. Water (10 mL) and aqueous hydrogen chloride solution (IN) was added unti] pH value of solution was around 2. Reaction solution was extracted with ethyl acetate, and the extract was washed with brine, dried over sodium sulfate and fïltered. Solvents were removed under the reduced pressure. The residue obtained was purified by reverse-phase HPLC utilizing a gradient of 0.1% trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile. Factions were lyophilized to afford ô-tert-butylW[[6-[(4-methoxyphenyI)methoxy]-2-pyridyl]suIfony]]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine3-carboxamide (Compound 2724) (Isomer 1) (Compound 2428) (Isomer 2) (35.2 mg, 0.0621 mmol, 28.9%). MS (ESI, m/z): [M+H]⁺567.3,

N-[[6-[2-(4-fluorophenyI)ethoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine3-carboxamide (Compound 1704), jV-[[6-(3-phenylpyrrolidin-l-yl)-2-pyridyl]su!fonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1708),

1036

A^r-[[6-[metliyl(propyl)amino]-2-pyridyI]sulfonyI]-2-(2,2,4-triiuethyIpyrro]idin-l-yl)pyridine-3carboxamide (Compound 1711),

N-[[6-[(4-methoxyphenyl)methyl-methyl-amino]-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-1 -yl)pyridine-3-carboxamide (Compound 1717),

A^r-[(6-tert-butoxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1718),

A^r-[[6-(3-methoxy-5-methyl-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1719),

7V-[[6-(2-cyanophenoxy)-2-pyridyl]sulfbnyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1720),

N-[[6-(4-isopropylanilino)-2-pyridyl]sulfonyI]-2-(2,2,44rimethylpynolidin-l-yl)pyridine-3carboxamide (Compound 1722),

N-[[6-(4-cyclopentyIpiperazin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1733),

A^r-[[6-(pyrrolidin-3-ylmethoxy)-2-pyridyI]sulfonyÎ]-2-(2,2,4-Îrimethylpyrrolidin-l-yi)pyridine-3carboxamide (Compound 1734),

N-[[6-(4-acetyl-2-methoxy-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1744), jV-[[6-(3,5-dimethyl-l-pjperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1749), jV-[[6-(l-naphÎhy]oxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1751),

N-[(6-prop-2-ynoxy-2-pyridyl)siilfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1753),

7\^r-[[6-(3-phenyl-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-ÎrimethylpyjTolidin-l-yl)pyridine-3carboxamide (Compound 1755),

1037

A^r-[[6-(4-tert-butylanilino)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpynOlidÎn-l-yl)pyridine-3carboxamide (Compound 1756),

A4(6-[4-(dimethylammo)anilino]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyriOlidin-l-y])pyridine3-carboxamide (Compound 1757), jV-[[6-(3,4-dimethoxyphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1761),

N-[[6-(tetrahydrofuran-2-ylmethoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidin-lyl)pyrid ine-3-carboxamide (Compound 1764),

A4(6-(cyclohexylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpynOlidin-l-yl)pyridine-3carboxamide (Compound 1767), ^[[6-((2,5-difluorophenyl)meÎhylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTolidin-lyl)pyrid ine-3-carboxamide (Compound 1770), tert-butyl 4-[6 - [[2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3-carbon yl]sulfamoyl]-2pyridyl]piperazine-l-carboxylate (Compound 1773),

7/-((6-(1 ,3-benzothiazol-6-ylamino)-2-pyridyl]sulfonyl]-2-{2,2,4-trimethyIpyrrolidin-lyl)pyrid ine-3-carboxamide (Compound 1775), ^-((6-(3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1776),

A-[[6-[(5-phenylisoxazol-3-yl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pynOlidin-lyl)pyridine-3-carboxamide (Compound 1777),

7/-[[6-[(3-chloro-4-methoxy-phenyl)metboxy]-2-pyridyl]sulfonyl]-2-(2,2,44rimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 1778),

A^r-[[6-(3-ethynylphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrol!din-l-yï)pyridine-3carboxamide (Compound 1782),

77-((6-(2,4,5-trifluoroaniImo)-2-pyridyl]suIfonyI]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1796),

1038

A^r-[[6-[(2-fluorophenyl)methoxy]-2-pyridyl]su]fonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1798),

A^r-[[6-(2-cyclohexylethoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1800),

A4[6-[3-(methoxymethyl)-l-piperidyl]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1805),

M[[6-(2,4-dichIorophenoxy)-2-pyridy]]sulfonyl]-2-(2,2,4-trimethyIpynOlidin-l-yl)pyridine-3carboxamide (Compound 1806),

N-[[6-(4-fluorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1813),

A4[6-(l,3-benzodioxol-5-ylmethylamino)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyiToIidin-lyl)pyridine-3-carboxamide (Compound 1814),

N-[[6-[4-(2-pyridyl)piperazin-l-yl]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpynolidin-lyl)pyridine-3-carboxamide (Compound 1816),

N-[[6-(lH-indol-5-ylamino)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpynOlidm-l-yl)pyridine-3carboxamide (Compound 1823), /V-[[6-(8-quinolylamino)-2-pyridyI]sulfbnyl]-2-(2,2,4-trimethylpynO]idin-l-yl)pyridine-3carboxamide (Compound 1826),

N-[[6-[benzyl(methyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1827), /V-[[6-(3-ethoxyphenoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1828), /V-[[6-(3-chloro-4-fluoro-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-iyI)pyridine-3-carboxamide (Compound 1831),

M[[6-(l,3,4,9-tetrahydropyrido [3,4-b] in dol-2-y l)-2-pyridyl] su] fonyl]-2-(2,2,4trimethy]pynOlidm-l-yl)pyridine-3-carboxamide (Compound 1833),

1039

N-[[6-(cyclopentoxy)-2-pyridyI]sulfbnyl]-2-(2,2,4-trimethylpynO]idin-l-yl)pyridine-3carboxamide (Compound 1834),

A^r-[(6-isoindolin-2-yl-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1838),

AH[M3-chloroanilino)-2-pyndyl] su Ifonyl]-2-(2,2,4-tri me thylpyrrolid in-l-yl)pyridine-3carboxamide (Compound 1841),

À4[6-[(lR)-l-phenylethoxy]-2-pyridyl]su]fonyI]-2-(2,2,4-trimethylpyrrolidm-I-yl)pyridine-3carboxamide (Compound 1842),

N-[[6-[(4-ethyI-2-pyridyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidm-l-yl)pyridine3-carboxamide (Compound 1862),

A-[[6-(thia2ol-2-yImethyIamino)-2-pyridyl]sulfonyI]-2-(2,2,4-triniethylpyn-olidin-l-yl)pyridine3-carboxamide (Compound 1865),

N-[[6-[ethyl(2-methoxyethyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTolidm-lyl)pyridine-3-carboxamide (Compound 1870),

A^r-[[6-(2-chloroanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1872),

N-[[6-(3,4-dihydro-2H-pyran-2-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1874),

M[[6-(7-quinolyloxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimeÎhyIpynOlidin-l-yl)pyridme-3carboxamide (Compound 1875),

N-[[6-[(l-acetylindolin-5-yl)amino]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 1877), jV-[[6-[3-(A^r-methylanilino)propylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1879),

A^r-[[6-[(E)-but-2-enoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 1881),

1040

A- [[6-(3 -me thyIcyclopentoxy)-2-pyridyl]sulfonyl] -2-(2,2,4-trime thylpyrrolidin-1 -y l)pyridiue-3carboxamide (Compound 1884),

A-[[6-(p-tolylmethylamino)-2-pyridyl]sulfony]]-2-(2,2,4-trime thy]pyrrolidin-l-yl)pyri dine-3carboxamide (Compound 1892),

A-[[6-(2-methylanilino)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1898), ^-[[6-[(2-chloro-4-fluoro-phenyI)metboxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1899),

A-[[6-(4-isopropylphenoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trime thylpyrrolidin-1-y l)pyridine-3carboxamide (Compound 1902),

A-[[6-(l-phenylethylamino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1905),

A-[[6-(2,3-dichloroanilino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1906),

A-[[6-(cyclobexoxy)-2-pyridy]]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1908),

A-[[6-(indan-5-ylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 1909),

A-[[6-(l -phenyl ethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin- J -yl)pyridine-3carboxamide (Compound 1917),

A-[[6-(l~cycIohexylethoxy)-2-pyridyl]sulfonyi]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1919),

A-[[6-(4-ethoxyphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1924),

A-[[6-(3-tert-butylphenoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidin-1-yl)pyridme-3carboxamide (Compound 1926),

1041

A^[6-[(2,4-dichlorophenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trirnethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1929), iV-[[6-(azepan-l-yl)-2-pyridyl]sulfonyl] -2-(2,2,4-trimethylpyrrolid in-l-yl)pyridine-3 carboxamide (Compound 1932),

A^f-[[6-(3-isoquinolylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1933), jV-[[6-(l-methyIcyclopentoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimeîhylpyrrolidin-l-yl)pyridme-3carboxamide (Compound 1936),

V-[[6-[4-(l, 3-dioxoIan-2-ylmethyl)piperazm-] -yl]-2-pyridyl]sulfonyI]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1937),

A^r-[[6-(benzylaraino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1938),

A^r-[[6-(tetrahydropyran-2-ylmethoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyI)pyridine-3-carboxamide (Compound 1939),

N-[[6-[(3-methoxyphenyl)methyl-methyl-amino]-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrroIidin-l-yl)pyridine-3-carboxamide (Compound 1940), /V-[[6-(2-chloro-5-fluoro-anilmo)-2-pyridy!]sulfony]]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1941),

A^r-[[6-(3-acetylanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine-3carboxamide (Compound 1949),

N-[[6-[[3-(trifluoromethyl)phenyl]methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1953),

N-[(6-tetralin-5-yloxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1955),

V-[[6-[(5-chloro-3-pyridyI)oxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 1957),

1042

A^r-[[6-(2-meihoxyanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyirolidin-l-yl)pyridine-3carboxamide (Compound 1959),

Æ-[[6-K2-methoxyphenyl)methoxy]-2-pyridyl]suIfbnyl]-2-(2,2,4-irimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 1965),

A4[6-[(2,4-dichlorophenyl)methylammo]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 1968),

Aq[6-[(4-tert-butylcycIohexyl)amino]-2-pyridyI]sulfbnyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1971),

AM[6-[(3-methoxyphenyl)melhoxy]-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 1972),

Aq[6-[4-(trifluoromedioxy)aniIino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidm-lyl)pyridine-3-carboxamide (Compound 1977),

N-[[6-[methyI(phenethyl)ammo]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-]-yl)pyridine3-carboxamide (Compound 1978),

N-[[6-[(2-chlorophenyI)methylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrroIidin-lyI)pyridine-3-carboxamide (Compound 1983),

A4[6-(4-pentylpiperazin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1985),

M-[[6-(l,3-dihydrobenzo[de]isoquinolin-2-yl)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 1986),

M-[[6-(4-phenyl-l-piperidyl)-2-pyridyl]sulfbnyl]-2-(2,2,4-trimethyIpynOlidin-l-yl)pyridme-3carboxamide (Compound 1987),

A4[6-(3-methylcyclohexoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme-3carboxamide (Compound 1988),

Æ-[[6-(2-quinoly]oxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridme-3carboxamide (Compound 1989),

1043

A^r-[[6-(3-thienylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 1992), /V-[[6-[[(l R)-1 -cyc]oliexyIethyl]amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l yl)pyridine-3-carboxamide (Compound 1996),

V-[[6-[(6-methylcyclohex-3-en-l-yl)methoxy]-2-pyridyl]snlfonyl]-2-(2,2,4-trimethylpyrroIidinl-yI)pyridine-3-carboxamide (Compound 2001),

N-[[6-(lH-indol-5-yloxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2003),

M[[6-(2-thienylmethylamino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethyIpyrroIidin-l-yI)pyridme-3carboxamide (Compound 2004),

A4[6-[methyI-[2-(3-pyridyl)ethy]]amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyirolidin-lyl)pyridine-3-carboxamide (Compound 2005),

N-[[6-(3,4,4a,5,6,7,8,8a-octahydro-lH-isoquinolin-2-yl)-2-pyridyl]suIfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2011),

N-[[6-[[3-(dimetliylamino)phenyl]methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynolidin-lyl)pyridine-3-carboxamide (Compound 2012),

7V-[[6-(l,3-benzodioxoI-5-yloxy)-2-pyridyl]sulfonyn-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine3-carboxamide (Compound 2013),

A^r-[[6-(2-fluorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimeÎhylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2015), /V-[[6-(2-cyclohexylpropoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2019),

A^r-[[6-(4-phenylanilino)-2-pyridy]]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2023),

V-[[6-[(2S)-2-(methoxymethyl)pyrrolidin-l-yl]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2024),

1044

N-[[6-(3,3-dimethylbutoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidm-l-yl)pyridine-3carboxamide (Compound 2025),

A4[6-(cycIopentylmethylammo)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2026),

N-[[6-(3-methyl-l-piperidyl)-2-pyridyl]sulfony]]-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine-3carboxamide (Compound 2030),

A^r-[[6-(tetrahydropyran-4-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-Iyl)pyridine-3-carboxamide (Compound 2032),

A^r-[[6-(3,3-dimethylcyclohexoxy)-2-pyridyl]suIfonyl}-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2038),

7V-[[6-(3,4-dimethoxyanilino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyiTolidin-l-yI)pyridine-3carboxamide (Compound 2041),

7V-[[6-[cyc]opropylmethyl(methyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4“trimethylpyrro]idin-lyl)pyridine-3-carboxamide (Compound 2044),

A^r-[[6-[l-(l-naphthyI)ethylamino]-2-pyridyI]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2049),

N-[[6-(cyclopentyIamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyriOlidin-l-yl)pyridine-3carboxamide (Compound 2053),

2V-[[6-[2-(trifluoromethyl)pyrrolidin-l -yl]-2-pyridyl]sulfonyl]-2-(2,2,44rimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2055),

TV-[[6-(l-methylcycloheptoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2057),

N-[[6-(1,7,7-trimethyInorbornan-2-yl)oxy-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pyrrolidin-lyl)pyridine-3-carboxamide (Compound 2059), ethyl 3-[[6-[[2-(2,2,4-trimethy]pyrroIidin-l-yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]amino]benzoate (Compound 2060),

1045

A-[[6-(3,4-dichlorophenoxy)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyiTolidin-l-yI)pyridme-3carboxamide (Compound 2061),

A-[[6-[(3-chlorophenyl)methylamino]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 2064),

A-[[6-(2-pyridylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-J-yI)pyridine-3carboxamide (Compound 2068),

A-[[6-[2-(4-methoxyphenyl)ethylamino]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2072),

A-[[6-(5-quinolylammo)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridiue-3carboxamide (Compound 2074),

A-[(6-isopentyloxy-2-pyridyl)suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2075),

A-[[6-(4-cyanophenoxy)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2076),

A-[[6-[(3S)-l-benzyIpyrrolidin-3-yl]oxy-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2078),

A-[[6-[(4-methyl-2-pyridyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2082),

A-[[6-(2-tert-butylphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-y])pyridine-3carboxamide (Compound 2083),

A-[[6-[4-(l-piperidyl)aniIino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2087),

A-[[6-[(2-methoxyphenyl)methyl-methyï-amino]-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-1 -yl)pyridine-3-carboxamide (Compound 2090),

A-[[6-(2-phenylpyrrolidin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine-3carboxamide (Compound 2094),

1046

N-[[6-(3,4-dihydro-lH-isoquinolin-2-yI)-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2098),

Y4[6-[(2,4-difluorophenyl)methoxy]-2-pyridyl]siilfbnyI]-2-(2,2,4-trimethylpyrro lidin-1yl)pyridine-3-carboxamide (Compound 2099),

N-[[6-(4-fluoroanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2102),

Λ4[6-(2,4,6-trifluoro an ilino)-2-pyridyl] sulfony l]-2-(2,2,4-trimethylpyrro lidin-l-yI)pyridine-3carboxamide (Compound 2106), /V-[[6-(4-benzyl-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2107),

N- [[6-(3-isopropylphenoxy )-2-pyridyl]s ul fo nyI]-2-(2,2,4-trimethylpyrro lidin-1 -yl)pyri dine-3 carboxamide (Compound 2108), /V-[[6-[(lS,2S)-2-methylcyclopenÎoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyI)pyridine-3-carboxamide (Compound 2109),

N-[[6-[(l-phenylpyrazol-4-yl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 2111),

7V-[[6-(2,3-dihydro-l,4-benzodioxin-3-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2115),

JV-[[6-(3-methylpyrrohdin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2116),

N-[[6-[(4-pyrazol-l-ylphenyl)methoxy]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2118),

N-[[6-(4-phenylbutylamino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme-3carboxamide (Compound 2119), ethyl 4-[[6-[[2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]amino]benzoate (Compound 2122),

1047

77-((6-(3 -benzylpyrrolidin-l-yI)-2-pyridyl]suIfonyl] -2-(2,2,4-trimethylpyrrolidin-l-y l)pyridine-3carboxamide (Compound 2123),

7V-[[6-(i,l-dimethyIbutoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyn-olidm-l-yl)pyridme-3carboxamide (Compound 2130),

77-[[6-(tetrahydrofaran-2-ylmethylammo)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l yl)pyridine-3-carboxamide (Compound 2131),

77-[[6-(3-methoxypropylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2135),

77-[[6-(l-naphthylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-I-yl)pyridine-3carboxamide (Compound 2136), /7-[[6’(2-methyl-2-pyrrol-l-yl-propoxy)-2-pyridy]]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2137), methyl 6- [[6- [[2- (2,2,4 -trime thylpyrrolid in -1 -yl )pyridine-3 -c arbonyl] sulfamoyl j-2pyridyl]amino]pyridine-3-carboxylate (Compound 2140),

N-[[6-(3-tert-butylamlino)-2-pyridyl]sulfonyl]-2-(2,2,4-triraethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2142), ?/-[[6-[3-(trifluoromethoxy)anilino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2143), /7-[[6-(4-chlorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2145), ?7-[[6-[2-(2-thienyI)ethylamino]-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2146), /7-[(6-cyclohex-2-en-l-yloxy-2-pyridyl)sulfbnyl]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridine-3carboxamide (Compound 2147),

77-[[6-(2-naphÜiylmethoxy)-2-_Pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTo1idin-l-yl)pyridine-3carboxamide (Compound 2151),

1048

A-[[6-(3-methoxy-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2152),

A-[[6-[(4,6-dimethyl-2-pyridyl)ammo]-2-pyridyl]suIfbnyl]-2-(2,2_!4-trimethylpyrroIjdin-lyl)pyridine-3-carboxamide (Compound 2160),

M[[6-[2-(3-thienyl)ethoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2161),

A-[[6-(3-chloro-2-fluoro-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyI)pyridine-3-carboxamide (Compound 2165),

A-[[6-(3,3-difluoropyrrolidm-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trirnethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2166),

A^r-[(6-buîoxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3-carboxamide (Compound 2167), jV-[[6-[(3-methoxyphenyl)methylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynO]idin-lyl)pyridine-3-carboxamide (Compound 2168),

A- [[6-(1,3-benzodioxol-5-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylp yrrolidin-1yl)pyridine-3-carboxamide (Compound 2169), iV-[[6-(4-isopropylcycloliexoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrro]idin-l-yl)pyridine3-carboxamide (Compound 2173),

A-[[6-[4-(4-pyridylmethyI)piperazm-l-yl]-2-pyridyl]suIfonyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2175),

7V-[[6-(3-chloro-5-cyano-phenoxy)-2-pyridy]]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2177),

A-[[6-(2,5-dimethoxyamlino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2179),

7V-[[6-(2-thienylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2181),

1049

A4[6-[(4-chloro-2-fluoro-phenyl)methoxy]-2-pyridyI]sulfonyI]-2-(2,2,4-triniethyIpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2182),

A^r-[[6-[(lS)-l-phenylethoxy]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2186),

N- [[6-[(4-isopropylphenyl)methylamino]-2-pyridyl]suIfonyl] -2-(2,2,4-trime thylpyrrolidin-1 yl)pyridine-3-carboxamide (Compound 2187),

V-[[6-(cyclobutylmethoxy)-2-pyridy]]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2188),

N-[[6-(2,3-dihydro-l,4-benzodioxin-6-ylamino)-2-pyridyl]sulfony]]-2-(2,2,4-trimethyIpyrrolidinl-yI)pyridine-3-carboxamide (Compound 2190),

[[6-[(1-methyl indol-5-yl)amino]-2-pyridyl] s ulfonyl]-2-(2,2,4-trime thylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2193),

ÎV-[[6-(l-methylbutylamino)-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridine-3carboxamide (Compound 2197), /V-[[6-[(2-methyI-l,3-benzothiazol-5-yI)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidinl-yl)_Pyridine-3-carboxamide (Compound 2198), /V-[[6-(isopropylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2200),

N-[[6-(cyclooctylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrTolidin-l-yl)pyridine-3carboxamide (Compound 2202), /V-[[6-(2-phenoxyethylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2206),

7V-[[6-(4-phenylpiperazin-l-yI)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2208),

A-[(6-decalin-2 -yloxy-2-pyridyl )sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2211),

1050

A^[6-(4-ethoxyanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2214),

N- [[6 - (2,4 -dich loroanilino)-2-py ridyl] sulfonyl] -2-(2,2,4-trimethylpyrrolid in-1 -yl)pyridine-3 carboxamide (Compound 2217),

7V-[[6-[(2-methylcyclohexy])amino]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-lyl)pyrîdine-3-carboxamide (Compound 2218),

N- [[6- [ 1 -(methoxymethyl)propy lamino] -2-pyridyl] sulfonyl] -2-(2,2,4-trimethylpyrrolid in-1 yl)pyridine-3-carboxamide (Compound 2221),

N-[[6-[4-(]-methylbutyl)piperazin-l-yl]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2226),

M[[6-(2_:3-dimethoxypheRoxy)-2-pyridyl]sulfonyi]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2233),

A^r-[[6-(4-methoxyphenoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimeihylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2239),

7V-[[6-(l,3-benzodioxoM-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2249), /7-[[6-(cycIohexylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2250), tert-butyl 2-[methyl-[6-[[2-(2,2,4-trimethylpyrroljdin-l-yl)pyridine-3-carbonyl]sulfamoyI]-2pyridyl]amino]acetate (Compound 2251), /7-[[6-(cycloheptoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine-3carboxamide (Compound 2252), ethyl 4-[[6-[[2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]amino]piperidine-l-carboxylate (Compound 2253),

M[[6-(4-pyrazin-2-ylpiperazin-l-yl)-2-pyridyl]sulfonyl] -2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2254),

1051

7V-[(6-indolin-l-yl-2-pyridyl)suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2255),

TV-[[6-(6-metlioxy-3,4-dihydro-lH-isoquinolin-2-yl)-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2260),

TV-[[6-[[2-(trifluoromethyl)phenyl]methoxy]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-ly!)pyridine-3-carboxamide (Compound 2261),

TV- [[6- [2 -(4-chlorophenyI)ethylamino] -2-pyri dyl]sulfonyl] -2-(2,2,4-trime thylpyrro J id in -1 yl)pyridine-3-carboxamide (Compound 2262),

TV-[[6-[3-(5-methyl-l,2,4-oxadiazol-3-yl)phenoxy]-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrroIidm-l-yl)pyridine-3-carboxamide (Compound 2263),

TV-[[6-[(3-chlorophenyl)methoxy]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2264),

TV-[[6-(l-naphthylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2270),

TV-[[6-[(2-chlorophenyI)metlioxy]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine3-carboxamide (Compound 2273),

ZV-[[6-(5-isoquinolylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-triniethyIpyrrolidin-I-yl)pyridine-3carboxamide (Compound 2274),

TV-[[6-(3,5-difluoroanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2282),

N-[[6-[4-(6-methyl-2-pyridyl)piperazin-l-yl]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrro]idin-lyl)pyridine-3-carboxamide (Compound 2285),

TV- [[6- [(4-tert-bu tylpheny l)methoxy]-2-pyri dyl]su Ifonyl] -2-(2,2,4-trimeth ylpyrrol idin -1 yl)pyridine-3-carboxamide (Compound 2286),

TV-[[6-[4-(trifluoromethyl)anilino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyîpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2292),

1052

W6-(3,5-dimelhoxyphenoxy)-2-pyridyl]sulfonylJ-2<2A4-t^^ carboxamide (Compound 2293),

A^r-[[6-[(6-methyl-2-pyridyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroUdin-lyl)pyridine-3-carboxamide (Compound 2294),

TV-[[6-(3-benzyl-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpynOlidin-l-yl)pyridine-3carboxamide (Compound 2297),

TV-[[6-(2-chlorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yI)pyridine-3carboxamide (Compound 2298),

TV-[[6-[(3-cyanophenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine10 3-carboxamide (Compound 2299),

TV-[[6-(2-ethyIbuty]amino)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2305),

N-[[6-[buty](methyI)amino]-2-pyridyI]sulfony]]-2-(2,2,4-trimethylpyrrolidm-l-yI)pyridine-3carboxamide (Compound 2307),

TV'[[6-(2-furylmethoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme-3carboxamide (Compound 2308),

7V-[[6-(2,6-dimethoxyphenoxy)-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2309),

7V-[[6-[(2-methoxypheny])methylammo]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidm-l20 yl)pyridine-3-carboxamide (Compound 2310), /V-[[6-(4-ammophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynolidin-I-yl)pyridine-3carboxamide (Compound 2314),

TV-[[6-(3-cyano-4-fluoro-anilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroljdin-l-yl)pyridine3-carboxamide (Compound 2316),

7V-[(6-cyclopent-3-en-l-yloxy-2-pyridyl)sulfbnyl]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridine-3carboxamide (Compound 2317),

1053

Λ4[6-[[(1 R)-1,2-di methylpropyl]amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2318),

N-[[6-(3-methylphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2320), (3S)-2-[6-[[2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3-caibonyl]sulfamoyl]-2-pyridyl]-3,4dihydro-lH-isoquinoline-3-carboxylic acid (Compound 2321),

N- [[6- (2-methy Imo rpholin -4-y 1 )-2 -pyridyl] sulfonyl]-2-(2,2,4-trimethylpyrrolidin-1 -yl)pyridine3-carboxamide (Compound 2324),

A^r-[[6-(4-acetylanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2328),

V-[[6-(2-tetrahydropyran-4-yIethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy lpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2329),

A^r-[[6-(4-methyl-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTOlidin-l-yl)pyridine-3carboxamide (Compound 2330),

N- [[6- (3 -fluoroph eno xy)-2-pyridyl] sulfonyl]-2- (2,2,4-trimethy Ipyrrol idin-1 -yl)pyridine-3carboxamide (Compound 2332), ?/-[[6-(8-quinolyloxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2333), tert-butyl V-[4-[[6-[[2-(2,2,4-trimethy Ipyrrolidin-1 -yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]amino]butyl]carbamate (Compound 2335),

Am6-(4~methylcyclohexoxy)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2336),

W[[6-(lH-indol-4-yloxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2338),

N-[[6-(3,3 a,4,5,6,6a-hexahydro-l H-cy clopenta[c]pyrro 1-2-yl)-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-1-y l)pyridine-3-carboxamide (Compound 2340),

1054

AA[[6-(3,4-difluoroanilino)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethyIpynOlidm-l-y])pyridine-3carboxamide (Compound 2341),

7V-[[6-(cyclopropylmethoxy)-2-pyridy]]suIfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2342), /7-[[6-[2-methoxyethyl(propyI)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-iyl)pyridine-3-carboxamide (Compound 2343), ?Z-[[6-[isopentyl(methyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme3-carboxamide (Compound 2346),

77-[[6-(2,2-difluoroethylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2350),

V- [[6- (3 -isopropoxyanilino) -2-pyridyl ]sulfo nyl]-2- (2,2,4-trimethylpyiroli din-1 -yl)py ridine-3 carboxamide (Compound 2353),

7V-[[6-(2-ethoxyethylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2354),

7V-[[6-(3,5-dimethoxyanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2357),

N- [[6- [2 -(2-pyridyl )ethy lamino]-2-pyridyl]sulfonyl]-2-(2,2,4 -tri methylpyrrolidin -1 -y l)pyridine3-carboxamide (Compound 2359),

77-[[6-[[6-(trifluoro methyl)-2-pyridyl]meth ylamino]-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridiae-3-carboxamide (Compound 2365),

77-[[6-(cyclobutoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2371),

TV-[[6-[(3-chlorophenyl)methyl-methyl-amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2378),

7V-[[6-[3-(trifluoromethyl)anilmo]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2381),

1055

N-[[6-(3,4-dihydro-2H-quinolin-l-yl)-2~pyridyl]sulfonyl]-2-(2,2_!4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2382),

N-[[6-[4-(2-dimethylaminoetliyl)-l-piperidyl]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 2383),

A^r-[[6-(5-chloroindolin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2385),

AH[6-(3-acetamidoani]ino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2387),

A4[6-(lH-mdazol-5-ylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyiTolidm-l-yl)pyridine-3carboxamide (Compound 2389),

N-[[6-[(2,6-dichlorophenyl)methoxy]-2-pyridyl ]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2390),

A-[[6-(m-tolylme thylamino)-2-pyridyl] sulfonyl]-2-(2,2,4-trimethylp yrrolidin-1-yl)pyridine-3carboxamide (Compound 2391),

A-[[6-[(3S)-3-fluoropyrrolidin-l-yl]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 2393),

7V-[[6-(tetrahydrofiiran-3-yhnethoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrohdin-Iyl)pyridine-3-carboxamide (Compound 2396),

A^r-[[6-[2-(trifluoromethyl)anilino]-2-pyrîdyl]sulfonyi]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine3-carboxamide (Compound 2397), tert-butyl 2V-methyl-jV-[2-[[6-[[2-(2,2,4-trimethylpyrTolidin-l-yl)pyridine-3-carbonyl]suIfamoyl]2-pyridyl] amino]ethyl]carbamate (Compound 2400), ^-[[6-[(3,4-dichlorophenyl)methoxy]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolîdin-lyl)pyridine-3-carboxamide (Compound 2402),

M[[6-[(l-benzylpyrrolidin-3-yl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 2407),

1056 ι

V-[[6-[]-(2-fluorophenyl)etlioxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2408),

M[[6-[(3-fluorophenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrondin-l-yl)pyridine3-carboxamide (Compound 2409),

W[[6-(2,2-dimethylpropoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2412),

V-[[6-[(4-isopropylphenyl)methoxy]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2415),

V-[[6-[(6-methoxy-2-pyridyl)amino]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-110 yl)pyridine-3-carboxamide (Compound 2420),

V-[[6-[(3,5-difluorophenyl)methylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethy]pyrrolidin-lyl)pyridine-3-carboxamide (Compound 2421),

V-[[6-(4-hexylpiperazin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-y l)pyri dîne-3carboxamide (Compound 2423),

V-[[6-[(4-methoxyphenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l yl)pyridine-3-carboxamide (Compound 2428),

A4(6-methoxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme-3-carboxamide (Compound 2430),

N-[[6-(3-acetamidophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-y])pyridine-320 carboxamide (Compound 2433),

N-[[6-[(I-methylcyclopropyl)methoxy]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2434), tert-butyl V-[4-[[6-[[2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3-carbonyl]suIfamoyI]-2pyridyl]amino]cyclohexyl]carbamate (Compound 2439),

V-[[6-(4-iniidazol-l-ylphenoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-î-yl)pyridine3-carboxamide (Compound 2441),

1057 methyl 1 -[6-[ [2-(2,2,4 -tri methylpyrrolidin-1 -y] )pyridine~3 -carbonyl]sulfamoyl] -2pyridyl]piperidine-4-carboxylate (Compound 2442),

A4[6-[3-(dimethylamino)phenoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-Iyl)pyridine-3-carboxamide (Compound 2443),

A4[6-(3-quinolylammo)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2449),

A4[6-[2-(4-piperidyl)ethoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2452),

A4[6-(4-fluoro-l-piperidyI)-2-pyridyI]sulfony]]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2453),

N-[[6-(4-methylphenoxy)-2-pyridyl]sulfbnyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2460),

N-[[6-(3-chlorophenoxy)-2-pyridyl]sulfbnyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2461),

N-[[6-[(3,5-difluorophenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2462),

7y-[(6-morpholmo-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrroîidin-l-yl)pyridine-3-carboxamide (Compound 2464),

A4[6-[2-(3-methoxyphenyl)ethylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-triinethylpyrroIidm-lyl)pyridine-3-carboxamide (Compound 2465),

N-[[6-[[6-(trifluoromethyl)-3-pyridyl]amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-Iyl)pyridine-3-carboxamide (Compound 2466),

N-[[6-[(lR)-l-methyl-2-phenyl-ethoxy]-2-pyridyl]su]fonyl]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 2470),

N-[[6-[[6-(trifluoromethyi)-3-pyridyl]methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidinl-yI)pyridine-3-carboxamide (Compound 2476),

1058

A-[[6-(3-cyanoanilmo)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyiTolidm-l-yl)pyri dine-3carboxamide (Compound 2484),

A-[[6-(2-isopropylphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridme-3carboxamide (Compound 2486), ethyl l-[6-[[2-(2,2,4-trimethylpyrroIidin-l-y])pyridme-3-carbonyl]sulfamoyI]-2pyridyl]piperidine-4-carboxylate (Compound 2488), methyl 3-[[6-[[2-(2,2,4-trimethylpyrroIidm-l-yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]ammo]benzoate (Compound 2493), tert-butyl 3- [[6- [[2- (2,2,4 -trimethylpy rrol idin -1 -y l)pyridine-3-carbony 1] su Ifamoy 1] -2pyridyl]amino]propanoate (Compound 2495),

A-[[6-[2-(p-tolyl)ethylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrTolidin-l-yl)pyridine-3carboxamide (Compound 2502),

A-[[6-(5-chloro-2-methoxy-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 2503),

A-[[6-[4-(2-pyridylmethyl)piperazin-l-yl]~2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyn-olidm-lyl)pyridine-3-carboxamide (Compound 2504), methyl 4-[6-[[2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3-carbonyl]su!famoyl]-2pyridyl]piperazine-l-carboxylate (Compound 2506),

A-[[6-(3-furyImethoxy)-2-pyridyl]sulfbnyI]-2-(2,2,4-triinethylpyrTolidin-l-yl)pyridme-3carboxamide (Compound 2507),

A-[(6-phenoxy-2-pyridyl)sulfbnyI]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridme-3-carboxamide (Compound 2509),

A-[[6-(2,6-difluoroanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyrî dine-3carboxamide (Compound 2513),

A-[[6-[3-(dimethylamino)anilino]-2-pyrÎdyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2517),

1059 i

A'-[[6-(7-flüoro-3,4-dihydro-lH-isoquinolin-2-yl)-2-pyridyl]sulfonyl]-2-(2,2,4trimethylpyrrolidm-Lyi)pyridine-3-carboxamide (Compound 2518),

A^r-[[6-(Loxotetralin-6-yl)oxy-2-pyridyl]sulfonyl]-2-(2_J2,4-trimethylpyrrolidin-I-yl)pyridme-3carboxamide (Compound 2523),

A4[6-[(4-fluorophenyI)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2524),

A4[6-(3-ethoxyanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2526),

N-[(6-propoxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxamide ] 0 (Compound 2528),

N-[[6-(3-butoxypropylamino)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidm-l-y])pyridine-3carboxamide (Compound 2529),

M-[[6-[4-(diethyIamino)anilino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2531),

M-[[6-[(3,4-difluorophenyl)methoxy]-2-pyridyl]sulfbnyI]-2-(2,2,4-trimethylpyrTOlidin-lyl)pyridine-3-carboxamide (Compound 2533), jV- [[6- (me thylamino)-2-pyri dyl]su 1 fonyl]-2-(2,2,4-trimethylpyrrolidin-l -y l)pyridine-3 carboxamide (Compound 2535), tert-butyl (2R)-1 -[6 -[ [2-(2,2,4-trimethyIpyrrolidin-1 -yl)pyridine-3 -c arbon yl]sul famoyl] -220 pyridyl]pyrrolidine-2-carboxylate (Compound 2536), tert-butyl A4 (3R)-l-[6-[ [2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carbonyI]sulfamoyl]-2pyridyl]pyrrolidin-3-yl]carbamate (Compound 2537),

M[[6-(4-oxazol-5-ylani]ino)-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyirolidin-l-yl)pyridme-3carboxamide (Compound 2546),

Λ4[6-[3-(3-methylpyrazol·l-yl)propylamino]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrτolidin-lyl)pyridine-3-carboxamide (Compound 2550),

1060

A^r-[[6-(3-methoxyphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2551),

A-[(6-pyrrolidin-l-yI-2-pyridyl)sulfonyl]-2-(2,2,4-ÎrimethylpynOlÎdin-l-yl)pyridine-3carboxamide (Compound 2561),

A-[[6-(4-pyrroM-ylphenoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2563), ^[[6-(4-(1-ethylpropyl)piperazin-l’yI]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-1yl)pyridine-3-carboxamide (Compound 2565),

A^r-[[6-(3-acetyIphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2569),

M[[6~(3-chloro-4-meÜioxy-anilino)-2-pyridyl]sulfony!]-2-(2,2_:4-trimethylpyrrolidm-lyl)pyridine-3 -carboxamide (Compound 2571),

A-[[6-(3-niethylanilino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimeÜiylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2572), j7-[[6-(cyclopropylamino)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2574),

A-[[6-[(4-methoxyphenyl)methylamino]-2-pyridyl]suIfonyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2579),

A-[[6-(5-flu oroisoindolin-2-yl)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yI)pyridme-3carboxamide (Compound 2580),

A-[[6-[(4-ch]orophenyl)meÎhoxy]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethyîpyrrolidm-l-yl)pyridine3-carboxamide (Compound 2585),

A^r-[[6-(2-chIoro-5-fluoro-phenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-lyl)pyridine-3-carboxamide (Compound 2591),

A-[[6-(chroman-3-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2595),

1061

A^r-[[6-(2-furylmethylamino)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2597),

N- [ [6- (5 -chloro-2 -fluoro-phenoxy)-2-pyridyl]sulfonyl] -2 -(2,2,4-trime th ylpyrrolidin-1 yl)pyridine-3-carboxamide (Compound 2598),

N-[[6-[(3-pyrrol-l-ylphenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2600),

N-[[6-(4-cyclohexylpiperazin-I-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2601),

A^r-[[6-(2-propoxyethylamino)-2-pyridyl]sulfony]]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2602),

2V-[[6-(2-methylpyrrolidin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2609), /V-[[6-[(4-ethynylphenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-lyl)pyridine-3-carboxamide (Compound 2610), /V-[[6-(2-naphthyloxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2611),

N- [(6-ethoxy-2-pyridyl )sulfonyl]-2-(2,2,4-trimeth ylpyrrolidin-1 -yl)pyrid i ne-3 -carboxamide (Compound 2617),

A4[6-[[4-(trifluoromethyl)phenyl]methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2618),

M[(6-benzyloxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimetliylpyrroIidin-l-yI)pyridine-3-carboxamide (Compound 2619),

M[[6-(4-butyl-l,4-diazepan-l-yI)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyrîdine3-carboxamide (Compound 2620),

N-[[6-(4-pyrimidin-2-ylpiperazin-l-yl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimeth ylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2621),

1062

V[[6-[2-(2-fInorophenyl)eûioxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimelhylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2625),

W6-(4H-l,3-benzodioxm-2-ylmethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynrolidin-lyl)pyridine-3-carboxamide (Compound 2627), ^[[6-(2-cyclopentylethoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-y])pyridine-3carboxamide (Compound 2630),

[6-[2-(2-chlorophenyl)ethylamino]-2-pyridyl] su lfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2632),

A-Œ6-(2-methoxyphenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-310 carboxamide (Compound 2637),

A4(6-anilino-2-pyridyl)sulfonyI]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridine-3-carboxamide (Compound 2639),

A-[[6-[(2,3-difluorophenyl)methylamino]-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2640),

W6-[4-(trinuoromethyl)-l-piperidyI]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-ly])pyridine-3-carboxamide (Compound 2641),

A-[[6-[2-(4-ethoxyphenyI)ethylamino;|-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2642),

M[[6-[(2-methyl-8-qumo!yl)oxy]-2-_Pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine20 3-carboxamide (Compound 2643),

N-[[6-[(5-ch]oro-2-methoxy-pheQyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2645),

A4[6-(3-methylbut-2-enoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yI)pyridine-3carboxamide (Compound 2648),

A^r-[[6-(2,4,6-trif]uorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2654),

1063

N- [[6- [(5 -c hloro-2-pyridyl)amin o] -2-pyri dyl] su lfonyl]-2-(2,2,4-trimethylpyrrolidin-1 yl)pyridine-3-carboxamide (Compound 2656),

A^,-[[6-(2-cyanoanilino)-2-pyridyl]sulfonyl]-2-(2,2₎4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2659),

N-[[6-[(5-chloro-2-pyridyl)oxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2747), /7-[[6-[2-(4-pyridyl)ethylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-Îrimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2746), (V-[[6-(2-aminoethoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethyl pyrrolidin-l-yl )pyri dine-3carboxamide (Compound 2754),

N-[(6-but-2-ynoxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethyIpyrrolidin-l-yI)pyridine-3-carboxarrûde (Compound 2753),

AH[6-[3-methoxypropyI(methyl)amino]-2-pyridyl]sulfbnyl]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 2745),

W-[[6-(4-methoxy-l-piperidyl)-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2743),

N-[[6-(l-oxomdan-5-yl)oxy-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrroIidin-l-y])pyridine-3carboxamide (Compound 2744),

Y-[[6-[(6-methyl-2-pyridyl)oxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine3-carboxamide (Compound 2742),

N-[[6-(4-acetylphenoxy)-2-pyridyl]sulfony]]-2-(2,2,4-trimethyîpyiTolidin-l-yl)pyridme-3carboxamide (Compound 2741),

Y-[[6-[(2-methyl-l,3-benzothiazo]-5-yl)oxy]-2-pyridyl]sulfonyl]-2-(2,2_J4-trimethyIpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2740), /^r-[[6-[[(lR)-l,2,2-trimethylpropyl]amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2757),

1064

I methyl 4-[[6-[[2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carbonyl]sulfamoyl]-2pyridyl]oxy]benzoate (Compound 2739),

N-[[6-(2,l,3-benzoxadiazol-5-yloxy)-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2738),

N-[[6-(44ert-butoxyphenoxy)-2-pyridyI]sulfony]]-2-(2,2,4-trimethylpyrroIidin-l-yl)pyridine-3carboxamide (Compound 2751),

N-[[6-[isobutyl(methy])amino]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2758),

N-[[6-(diethylamino)-2-pyridyl]suIfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-310 carboxamide (Compound 2737), _JV-[[6-(3-cyanophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,44rimethylpyrrolidin-l-yl)pyridine-3carboxamide (Compound 2736), _JV-[[6-[isopropyl(methyl)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yI)pyridine3-carboxamide (Compound 2735), tert-butyl M[4-[ [6-[[2-(2,2,4-trimethy lpyrrolidin-1-yi)pyridine-3-carbonyl] sulfamoyl]-2pyridyl]amino]phenyl]carbamate (Compound 2755),

M[[6-[2-(3-fluorophenyI)ethoxy]-2-pyridyl]sulfonyI]-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine3-carboxamide (Compound 2752),

A4[6-[2-(l-piperidyl)phenoxy]-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-320 carboxamide (Compound 2750),

N-[[6-(2-methyl- i -piperidyl)-2-pyridy l]sulfony 1)-2-(2,2,4-trimethylpynOlidin-l -yI)pyridine-3carboxamide (Compound 2759),

N-[[6-[cycIopropylmethyl(prDpyI)amino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrTolidm-lyI)pyridine-3-carboxamide (Compound 2734),

N-[[6-[(2,5-dimethoxyphenyl)methyIammo)-2-pyndyI]sulfonyl)-2-(2,2,44rjniethylpyrrolidin-lyl)pyridine-3-carboxamide (Compound 2733),

1065 i

(

Aⁱ-[(6-phenethyloxy-2-pyridyl)su!fonyJ]-2-(2,2,4-trimethylpynOlidin-l-yl)pyridine-3carboxamide (Compound 2732),

W6-(2,3-dichlorophenoxy)-2-pyridyl]sulfonyl]-2-(2,2,4-trirnethylpyrrolidin-l-yI)pyridine-3carboxamide (Compound 2731),

7/-((6-(3-chloro-5-fluoro-phenoxy)-2-pyridyI]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-1yI)pyridine-3-carboxamide (Compound 2730),

N-[[6-[(2-chlorophenyI)methyl-methyl-ammo]-2-pyridyI]suIfonyl]-2-(2,2,4-trimethylpyrrolidinl-yI)pyridine-3-carboxamide (Compound 2756),

TV-[(6-chroman-4-yloxy-2-pyridyl)sulfonyI]-2-(2,2,4-trimethylpyrrolidin-l-yl)pyridine-310 carboxamide (Compound 2749),

N-[(6-(3-(trifluoromethyl)phenoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-1yl)pyridine-3-carboxamide (Compound 2729),

N-[[6-[(2-chloro-6-fluoro-phenyl)methoxy]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpyrrolidin-lyl)pyridme-3-carboxamide (Compound 2728),

6-tert-butyl-M[(6-isopentyloxy-2-pyridyl)sulfonyl]-2-(2,2,4-trimethylpyrrolidm-l-yl)pyridine-3carboxamide (Compound 2727),

A4[6-(l,3-benzodioxol-5-ylrnethoxy)-2-pyridy]]sulfonyl]-6-tert-butyl-2-(2,2,4trimethyIpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2725),

7/-[[6-[(E)-but-2-enoxy]-2-pyridyl]sulfonyl]-6-tert-butyl-2-(2,2,4-trimethylpynOlidin-l20 yl)pyridine-3-carboxamide (Compound 2726),

6-tert-butyl-M[[6-[(4-methoxyphenyl)methylamino]-2-pyridyI]sulfonyl]-2-(2,2,4trimethyIpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2723),

N-[[6-[(3,4-dimethoxyphenyI)methylamino]-2-pyridyl]sulfonyl]-2-(2,2,4-trimethylpynOlidin-lyl)pyridine-3-carboxamide (Compound 2662), and

N-[[6-(3,5-dichlorophenoxy)-2-pyridyl] su Ifonyl]-2-(2,2,4-trimethylpyiTolidin-l-yl)pyridine-3carboxamide (Compound 2663)

PREPARATION 107: TV-[(2-oxo-1 /7-pyridin-3-y l)su Ifonyl]-6-phenyl-2-((45)-2,2,4

1066 trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2445)

Step 1: 2-Methoxypyridine-3-sulfonamide

2-Chloropyridine-3-sulfonyl chloride (5.00 g, 23.6 mmol) was dissolved in ammonia in methanol (16.8 mL of 7 Μ, 117.9 mmol) and the reaction mixture was stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure and dissolved in sodium methoxide (24.9 mL of 25 %w/v, 115.1 mmol) and heated to 60 °C over 2 days. The reaction mixture was evaporated and the residue was partîtioned between ethyl acetate and IN HCl. The organics were separated, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography eluting with 0-100% ethyl acetate in hexanes to give 2-methoxypyridine-3sulfonamide (3.12 g, 70%) ESI-MS m/z cale. 188.02556, found 189.0 (M+l/; Rétention time: 0.23 minutes

Step 2: 2,6 -dichloro-N- [(2-methoxy-3 -pyridyl) sulfonyl]pyridine-3 -carboxamide

A mixture of 2,6-dichloropyridine-3-carboxylic acid (2.00 g, 10.4 mmol), thionyl chloride (7.45 g, 4.56 mL, 62.5 mmol), and DMF (0.1 mL) was stirred at 45 °C for 5 hours. The reaction was concentrated under reduced pressure, dissolved in dichloromethane (5.30 mL) and slowly added to a solution of 2-methoxypyridine-3-sulfonamide (1.96 g, 10.4 mmol) and triethylamine (3.16 g, 4.36 mL, 31.3 mmol) in dichloromethane (5.30 mL) cooled in an ice bath. The reaction mixture was stirred ovemight, then diluted with dichloromethane and washed with 1 M HCl (20 mL x 1), water (20 mL), dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (0-5 % methanol in dichloromethane). The resulting solid was dissolved in dichloromethane and washed with sodium bicarbonate (~ pH 5), the organic layers were dried over sodium sulfate and

1067 evaporated under reduced pressure to give 2,6-dichloro-A^f-[(2-methoxy-3pyridyI)sulfonyl]pyridine-3-carboxamide (3.50 g, 93%) ESI-MS m/z cale. 360.9691, found 362.0 (Μ+Ί )⁺; Rétention time: 0.46 minutes.

Step 3: 2,6-dichloro-/V-[(2-oxo-lH-pyridin-3-yl)suIfonyl]pyridine-3-carboxamide

Cl

A mixture of 2,6 -dichloro-2V-[(2-methoxy-3-pyridyI)sulfonyl]pyridine-3carboxamide (0.76 g, 2.10 mmol) and HCl (5.25 mL of 4 M in dioxane, 21.0 mmol) in dioxane (5 mL) was stirred at 90 °C for 90 minutes. The solvent was evaporated under reduced pressure to give 2,6-dichloro-jV-((2-oxo-l ,2-dihydropyridin-3-yl)sulfonyl)nicotinamide (0.72 g, 99%) as a tan solid.

Step 4: 6-chloro-/V-[(2-oxo-l//-pyridin-3-yI)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide ci

To 2,6-dichloro-A-[(2-oxo-12/-pyridin-3-yl)sulfonyl]pyridine-3-carboxamide (HCI sait) (4.04 g, 10.5 mmol), (45)-2,2,4-trimethylpyrrolidine (HCl sait) (2,36 g, 15.8 mmol), and K₂CO₃ (7.26 g, 52.5 mmol) was added DMSO (8.86 mL) and the reaction mixture was heated at 120 C for 24 h. The reaction mixture was diluted with ethyl acetate and the résidu al potassium carbonate was filtered. The organics were washed with 0.1 M aqueous HCl (150 mL). The pH of aqueous layer was brought to 5 by the addition of aqueous HCl, and then washed with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give 6-chloro-A^f-[(2-oxo-lH-pyridin-3-yl)sulfonyl]1068

2-[(45)-2,2,4-trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (4.15 g, 94%).

Step 5: //-[(2-oxo-l//-pyridin-3-yl)sulfonyl]-6-phenyl-2-[(45)-2,2,4trimethylpyiT01idin-l-yI]pyridine-3-carboxamide (Compound 2445)

6-chloro-7/- [(2-oxo-lW-pyridin-3-yI)suIfonyl] -2-[(45)-2,2,4-trimethylpynolid in l-yl]pyridine-3-carboxamide (30.0 mg, 0.07 mmol), phenylboronic acid (10.3 mg, 0.08 mmol), [l,3-bis(2,6-diiwpropylphenyI)-2H-imidazol-2-yl]-dichIoro-(3-chloro-l-pyridyl)palladium (4.80 mg, 0.01 mmol), and 2M K₂CO₃ (177 uL, 0.35 mmol) were combined in DMF (1.0 mL) and heated at 120 °C for 16 h. The reaction mixture was filtered and purified by LC/MS utilizing a gradient of 10-99% acetonitrile in 5 mM aq HCl to yield 7V-[(2-oxo-l//-pyridin-3-yl)sulfonyl]-6phenyl-2-[(45)-2,2,4-trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2445). ESIMS m/z 467.4 (M+l)⁺; Rétention time: 1.13 minutes; 1H NMR (400 MHz, DMSO-d6)Ô 12.59 (s, 1H), 12.53 (d, J = 6.3 Hz, 1H), 8.24 (dd, J = 7.2, 2.2 Hz, 1H), 8.08 - 8.02 (m, 2H), 7.83 (dt, J = 6.6, 3.3 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1 H), 7.54 - 7.46 (m, 2H), 7.46 - 7.40 (m, 1H), 7.19 (d, J =

8.0 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 2.82 - 2.63 (m, 2H), 2.30 - 2.18 (m, 1H), 1.89 (dd,J = 11.8, 5.5 Hz, 1H), 1.62 (s, 6H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).

6-(m-tolyl)-M[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrroIidm-l-yl]pyridine3-carboxamide (Compound 2424), 6-(2-hydroxyphenyl)-7/-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2[ ¢45)-2,2,4-trimethyIpyrrolidin-l-yl]pyridine-3 -carboxamide (Compound 2480), N-[(2-oxo-l//-pyridin-3-yl)sulfonyI]-6-[4-(trifluoromethyl)phenyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-y]]_Pyridine-3-carboxamide (Compound 1799), //-[(2-oxo-l/7-pyridin-325 yl)sulfonyI]-6-(p-toly])-2-[(45)-2,2,4-trimethylpyrroIidm-l -yI]pyridine-3-catboxamide (Compound 2438),

1069

6-(3-niethoxyphenyï)-A-[(2-oxo-1H-pyridin-3-yl)sulfonyl]-2-[(45)-2,2,4-trimethy]pyiToIidin-lyl]pyridine-3-carboxamide (Compound 1927), A-[(2-oxo-lA-pyridjn-3-yl)sulfonyI]-6-[2(trifluoromethoxy)phenyl]-2-[(45)-2,2,4-trimethylpynOlidin-l-yI]pyridine-3-carboxamide (Compound 2514),

6-[3-(hydroxymethyl)phenyl]-A-[(2-oxo-17/-pyridin-3-yl)suIfonyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1997), 6-(4-methoxyphenyl)-A-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2080),

A-(benzenesuIfonyl)-6-(6-methoxy-2-pyridyl)-2-[(45)-2,2,4-trimethyIpyirolidin-l-yl]pyridine-3carboxamide (Compound 2411),

6-(3-fluoro-5-Mobutoxy-phenyl)-A-(3-hydrox}phenyl)sulfonyI-2-[(4S)-2,2,4-trimethyIpynO]idinl-yl]pyridine-3-carboxamide (Compound 1885),

A-(benzenesulfonyI)-6-(2-hydroxy-3-methyl-phenyl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2133),

6-(3-fluoro-5-isobutoxy-phenyl)-A-(4-hydroxyphenyl)sulfony]-2-[(4S)-2,2,4-trimethylpynOlidinl-yl]pyridine-3-carboxamide (Compound 1750),

6-(3-fluoro-5-isobutoxy-phenyl)-A-(2-hydroxypheny])suIfony]-2-[(4S)-2,2,4-trimethylpynOlidinl-yl]pyridine-3-carboxamide (Compound 1836),

6-(3 -fluoro-5-isobu toxy-phenyl)-A-(4-methoxyphenyl)suIfonyI-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1876),

A-(benzenesulfonyl)-6-phenyl-2-[(45)-2,2,4-trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (Cornpound 2092),

A-(benzenesulfonyl)-2-[(3S)-2,2-dideuterio-3,5,5-trimethyl-pyrrolidin-]-yi]-6-(3-fluoro-5Î5obutoxy-phenyl)pyridine-3-carboxamide (Compound 2560),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(4-ethoxy-3-methyl-phenyl)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 1860),

A-[(2-amino-3-pyridyl)sulfonyl]-6-[l-methyl-3-(trifluoromethyl )pyrazol-4-yl]-2-[(45)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 1740),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(lA-indol-5-yl)-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2125),

1070

I

A^r-((2-ammo-3-pyridyI)suifonyl]-6-[2-(dimethylamino)pyrimidin-5-yl]-2-[(45)-2,2,4trimethylpyrrolidin-1-y l]pyridme-3-carboxamide (Compound 2021),

N-[(2-amino-3-pyridyl)sulfonyl]-6-(l/f-mdol-4-y 1)-2-((45)-2,2,4-trime thy Ipyrrolidin-1yl]pyridine-3-carboxamide (Compound 2478), /7-[(2-amino-3-pyridyl)sulfonyl]-6-(4-hydroxy-3,5-dimethyl-phenyI)-2-[(4S)-2,2,4trimethylpyrrolidin-l-yljpyridine-3-carboxamide (Compound 1923), Z7-[(2-amino-3-pyridyl)sulfonyl]-6~ [2-methyl-5-(trifluoromethyl)pyrazol-3-yI]-2-[(45)-2,2,4trimethylpyiTolidin-1 -yl]pyridine-3 -carboxamide (Compound 2416), /V-[(2-amino-3-pyridyl)sulfonyl]-6-(2-ethoxy-6-fluoro-phenyl)-2-((45)-2,2,4-trimethylpyrrolidin10 l-yI]pyridine-3-carboxamide (Compound 2103), N-[(2-amino-3-pyridyl)sulfonyl]-6-(2-ethoxy-5-fluoro-phenyl)-2-[(45)-2,2,4-trimethylpyrTolidinl-yl]pyridine-3-carboxamide (Compound 2071), /7-[(2-amino-3-pyridyl)sulfonyI]-6-(6-methyl-3-pyridyl )-2-((45)-2,2,4-trimethylpyrrolidin-ly l]pyridine-3-carboxamide (Compound 2363),

N-[(2-amino-3-pyridyI)sulfonyl]-6-( 1-methylindo 1-5-yl )-2-((45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2352), jV-[(2-amino-3-pyridyl)sulfonyl]-6< 1,3,5-trime thylpyrazol-4-yl)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2668),

N-[(2-amino-3-pyridyl)sulfony 1(-6-(2,5-difluoro-4-methox y-phenyl)-2-[ (45)-2,2,420 trimethylpyrrolidin-1 -yl]pyridine-3-caiboxamide (Compound 2388), N-[(2-amino-3-pyridyI)sulfonyl]-6-(6-hydroxy-2-naphthyl)-2-[(45)-2,2,4-trimethylpynolidin-lyl]pyridine-3-carboxamide (Compound 2468),

N-[(2-ammo-3-pyridyl)sulfonyl]-6-(4-hydroxy-3-methoxy-phenyl)-2-[(45)-2,2,4trimethyIpyn-olidin-l-yI]pyridine-3-carboxamide (Compound 2614),

N-[(6-ammo-2-pyridyl)sulfonyl]-6-(6-methoxy-5-methyl-3-pyridyl)-2-((45)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2086), 6-(3-fluoro-5-riobutoxy-phenyl)-AZ-(3-pyridylsulfonyI)-2-[(45)-2,2,4-trimethylpyrrolidin-Iyl]pyridine-3-carboxamide (Compound 2377),

6-(3-fluoro-5-riobutoxy-phenyl)-V-(2-pyridylsulfony 1)-2-( (45)-2,2,4-trimethylpyrrolid in-130 yI]pyridine-3-carboxamide (Compound 1832),

1071

6-(3,5 -dimethylphenyl)W-[(6-isopentyloxy-2-pyridyI)sulfonyl]-2- [(45)-2,2,4trimethylpynOljdm-l-yl]pyridine-3-carboxamide (Compound 2707) and 2-[(25,57ï)-2,5-dimethylpyrrolidin-l -yl]-6-(3-fluoro-5-isobutoxy-phenyl)W-[(2-oxo-1 H-pyridin3-yl)sulfonyl]pyridine-3-carboxamide (Compound 307).

PREPARATION 108: A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-zypbutoxypyrazol1 -yl)-2- [(45)-2,2,4-trime thylpyrrol idin-1 -yl]pyrid ine-3-c arboxamide (Compound 2191)

Step 1: l-(3-hydroxypyrazol-I-yl)ethanone

O^Hά--- λ HO^Z l/7-pyrazol-5-ol (1.02 g, 12.1 mmol) and pyndine (5.0 mL, 61.8 mmol) were stirred at 95°C and a solution of acetic anhydride (1.24 g, 1.14 mL, 12.1 mmol) in pyridine (2.0 mL, 24.7 mmol) was added dropwise over a period of 3 minutes. The reaction mixture was then stirred at 95 C for an additional 1.5 h. The solvents were removed under reduced pressure and the solid residue was triturated with diethylether (30 mL), filtered, washed with diethylether and dried under high vacuum to give l-(3-hydroxypyrazol-I-yl)ethanone (1.34 g, 88%) as a yellow solid. ESI-MS m/z cale. 126.04293, found 127.1 (M+l)⁺; Rétention time: 0.3 minutes; 1H NMR (400 MHz, DMSO-d6) δ 10.92 (s, 1H), 8.12 (d, J = 2.9 Hz, 1H), 6.00 (d, J = 3.0 Hz, 1H), 2.48 (s, 3H).

Step 2: l-(3-AobutoxypyrazoI-l-yl)ethanone

To l-(3-hydroxypyrazol-l-yl)ethanone (1.25 g, 9.91 mmol), potassium carbonate (2.06 g, 14.9 mmol) and anhydrous DMF (10 mL) under nitrogen atmosphère was added l-bromo-2-methyI-propane (1.49 g, 1.19 mL, 10.9 mmol). The reaction was stirred at 80°C for 2 hours. The reaction mixture was diluted with EtOAc (50 ml) and water (25 mL) and two phases were separated. The aqueous phase (pH = 9-10) was further extracted with EtOAc

1072 (20 mL). The combined extracts were dried over sodium sulfate and the solvents evaporated. The resulting oil was purified by silica gel column chromatography using a gradient of EtOAc (0 to 30 %) in hexanes to give l-(3-wobutoxypyrazol-1-yl)ethanone (1.24 g, 69%) as a colorless oil. ESI-MS m/z cale. 182.10553, found 183.3 (M+l)⁺; Rétention time: 1.35 minutes; 1H NMR (400 5 MHz, Chloroform-d) δ 8.05 (d, J = 3.0 Hz, 1H), 5.96 (d, J = 3.0 Hz, 1H), 3.99 (d, J = 6.6 Hz, 2H), 2.58 (s, 3H), 2.08 (dq, J = 12.9, 6.4 Hz, 1H), 1.01 (d, J = 6.7 Hz, 6H).

Step 3: S-Aobutoxy-lH-pyrazole

I-(3-Aobutoxypyrazol-l-yl)ethanone (1.24 g, 6.82 mmol) was treated with

MeOH (20 mL) and NaOH (1.14 mL of 6 M, 6.82 mmol) (6N aqueous) at room température for 2 hours. The volatiles were removed under reduced pressure. The residue was taken in EtOAc (25 mL) and brine (20 ml) and two phases were separated. The aqueous phase was further extracted with EtOAc (2 x 25 mL) and the combined extracts were dried over sodium sulfate and concentrated under reduced pressure to give 3-teobutoxy-l/7-pyrazole (955 mg, 99%) as a slightly colored viscous oil. ESI-MS m/z cale. 140.09496, found 141.2 (M+l)⁺; Rétention time: 0.86 minutes; 1H NMR (400 MHz, Chloroform-d) δ 9.25 (veiy broad s, 1H), 7.35 (d, J = 2.5 Hz, 1H), 5.73 (d, J = 2.5 Hz, 1H), 3.91 (d, J = 6.7 Hz, 2H), 2.15 - 2.02 (m, 1H), 1.06 - 0.98 (m, 6H).

Step 4: tertebutyl 2-chloro-6-(3-Aobutoxypyrazol-l-yl)pyridine-3-carboxylate

NaH (64 mg, 1.6 mmol) (60 % oil suspension) was added to 3-tec>butoxy-lHpyrazole (224 mg, 1.60 mmol) in anhydrous DMF (2 mL). The réaction mixture was stirred umil

1073 gas évolution stopped. Tert-butyl 2,6-dichloropyridine-3-carboxylate (330 mg, 1.33 mmol) was added and the reaction mixture was stiired at 100°C under nitrogen for 30 minutes. The reaction mixture was diluted with EtOAc (50 mL) and water + brine (40 mL) and the two phases were separated. The aqueous phase was further extracted with EtOAc (2 x 30 mL). The combined extracts were dried over sodium sulfate and the solvent removed under reduced pressure to give a residue, which was purified by silica gel column chromatography using a gradient of AcOEt (0 to 20%) in hexanes to give Zert-butyl 2-chloro-6-(3-i4obutoxypyrazoLl-yl)pyridine-3carboxylate (235 mg, 50%) as an off-white solid). ESI-MS m/z cale. 351.13498, found 352.2 (M+I)⁺; Rétention time: 2.34 minutes, 1H NMR (400 MHz, Chloroform-d) δ 8.35 (d, J = 2.8 Hz, 1 H), 8.18 (d, J = 8.4 Hz, 1 H), 7.70 (d, J = 8.4 Hz, 1 H), 5.97 (d,J = 2.9 Hz, 1 H), 4.02 (d, J = 6.6 Hz, 2H), 2.12 (dp, J = 13.4,6.7 Hz, 1H), 1.62 (s, 9H), 1.03 (d, J = 6.7 Hz, 6H).

Step 5: 2-chloro-6-(3-rtobutoxypyrazol-l-yl)pyridine-3-caiboxylic acid

Tert-butyl 2-chIoro-6-(3-isobutoxypyrazol-l-yl)pyridine-3-carboxylate (203 mg, 0.57 mmol), DCM (2 mL) and TFA (615 pL, 7.98 mmol) were stirred at 40-45°C for 3 hours. The volatiles were remove under reduced pressure to give 2-chloro-6-(3-isobutoxypyrazoLlyl)pyridine-3-carboxylic acid (170 mg, 100%) as a white solid. ESI-MS m/z cale. 295.07236, found 296.3 (M+l)⁺; Rétention time: 1.64 minutes; 1H NMR (400 MHz, DMSO-d6) δ 13.58 (s, 1 H), 8.41 (d, J = 2.9 Hz, 1 H), 8.38 (d, J = 8.4 Hz, 1 H), 7.73 (d, J = 8.4 Hz, 1H), 6,20 (d, J = 2.9 Hz, 1 H), 4.02 (d, J = 6.6 Hz, 2H), 2,06 (hept, J = 6.6 Hz, 1 H), 0.98 (d, J = 6.7 Hz, 6H).

Step 6: A^r-[(2-amino-3-pyridyl)sulfony]]-2-chloro-6-(3-Î5obutoxypyrazol-1* yl)pyridine-3-carboxamide

1074

DMF (1.2 mL) was added to 2-chloro-6-(3-Mobutoxypyrazol-l-yl)pyridine-3carboxylic acid (128 mg, 0.43 mmol) and CDI (87 mg, 0.54 mmol) under an atmosphère of nitrogen. The reaction mixture was stirred at 40°C under nitrogen for 1 hour. 2-aminopyridine-35 sulfonamide (91 mg, 0.53 mmol) was dissol ved under nitrogen in an hydrous DMF (1.2 mL) and NaH (21 mg, 0.53 mmol) (60% oil suspension) was added and the reaction mixture was stirred under nitrogen until gas évolution stopped and then stirred at 40°C for 45 minutes. The two reaction mixtures were combined and stirred at room température for 1.5 hours. Water and ice was added, followed by acetic acid (400 pL, 7.03 mmol). The resulting solid was filtered, washed with water and dried to giveV-[(2-amino-3-pyridyI)sulfonyl]-2-chloro-6-(3i.wbutoxypyrazol-l-yl)pyridine-3-carboxamide (189 mg, 97%) as a white solid. ESI-MS m/z cale. 450.0877, found 451.4 (M-i-l)-f-; Rétention time: 1.42 minutes.

Step 7: W [(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxypyrazol-l-yl )-2- [(45)2,2,4-trimethyIpynOlidin-l-yl]pyridme-3-carboxamide (Compound 2191)

N-[(2-amino-3-pvridyl)sulfonyl]-2-chloro-6-(3-i\obutoxypyrazol-l-yl)pyridine-3carboxamide (177 mg, 0.39 mmol), (45)-2,2,4-trimethyIpyrrolidine (HCI sait) (237 mg, 1.58

1075 mmol), K₂CO₃ (327 mg, 2.37 mmol) and anhydrous DMSO (550 pL) were heated at 150°C for 6 hours under an atmosphère of nitrogen. The reaction mixture was then cooled and a stirred mixture of water (40 mL) and acetic acid (400 pL, 7.034 mmol) was added dropwise. The resulting yellow solid was fïltered and washed with water. The solid was dissolved in dichloromethane and the organic phase was dried over sodium sulfate and concentrated under reduced pressure. The resulting solid was purified by silica gel column chromatography using a gradient of MeOH (0 to 10%) in DCM, followed by purification by reverse phase préparative HPLC using a gradient of MeCN in water (1 to 99% over 15 min) and HCI as a modifier to give N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-EobutoxypyrazoI-l-yl)-2-[(45)-2,2,4-trime thylpyrrolidin10 l-yl]pyridine-3-carboxamide (Compound 2191) (77 mg, 36%) as a pale yellow solid. ESI-MS m/z cale. 527.23145, found 528.3 (M+l)⁺; Rétention time: 1.55 minutes; 1HNMR (400 MHz, DMSO-d6) 6 12.45 (broad s, 1H), 8.28 - 8.22 (m, 1H), 8.20 (d, J = 2.7 Hz, 1H), 8.06 - 7.99 (m, 1 H), 7.84 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 7.7, 4.9 Hz, 1H), 6.69 (br s, 2H), 6.12 (d, J = 2.6 Hz, 1H), 3.98 (d, J = 6.6 Hz, 2H), 2.45 (d, J = 8.6 Hz, 2H), 2.13-2.01 (m , 15 2H), 1.90 - 1.79 (m, 1H), 1.55 (s,3H), 1.53 (s, 3H), 1.38 (t, J = 12.1 Hz, 1 H), 0.98 (d, J = 6.8 Hz,

6H), 0.74 (d, J = 6.2 Hz, 3H).

PREPARATION 109: /V-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2dimeth ylpropoxy)pyrazol-l-yl]-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1975) ²⁰ Step 1: l-[3-(2,2-dîmethyIpropoxy)pyrazol-l-yl]ethanone

To a suspension of l-(3-hydroxypyrazoLl-yl)ethanone (1.21 g, 9.60 mmol) in anhydrous THF (20 mL) was added triphenyl phosphine (2.78 g, 10.6 mmol) and 2,2dimethylpropan-l-ol (846 mg, 9.60 mmol). The reaction mixture was cooled down in an ice-bath under nitrogen. DIAD (2.1 mL, 10.7 mmol) was added dropwise via a sylinge over 3 min. The reaction mixture was then stirred under nitrogen warming to room température ovemight. The reaction mixture was diluted with ethyl acetate (100 mL) and the combined organic phase was washed with aqueous saturated sodium bicarbonate (2 x 50 mL), brine (50 mL) and dried over

1076 sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate ¢0 to 30 %) in hexanes. to provide 1[3-(2,2-dimethylpropoxy)pyrazol-l-yl]ethanone (967 mg, 51%) as a yellow solid. ESI-MS m/z cale. 196.12119, found 197.3 (M+l)⁺; Rétention time: 1.62 minutes; 1HNMR (400 MHz,

Chloroform-d) δ 8.05 (d, J = 3.0 Hz, 1H), 5.97 (d, J - 3.0 Hz, 1H), 3.89 (s, 2H), 2.58 (s, 3H), 1.03 (s, 9H).

Step 2: 3-(2,2-dimethylpropoxy)-lH-pyrazole

l-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]ethanone (960 mg, 4.89 mmol), MeOH 10 (15 mL) and NaOH (815 pL of 6 M, 4.89 mmol) (6N aqueous) were stirred at room température for 21 hours. The volatiles were removed under reduced pressure. The residue was taken in EtOAc (25 mL) and brine (20 ml) and two phases were separated. The aqueous phase was further extracted with EtOAc (2 x 25 mL) and the combined organic extracts were dried over sodium sulfate and evaporated under reduced pressure to give 3-(2,2-dimethylpropoxy)-17/15 pyrazole (719 mg, 95%) as an off-white solid. ESI-MS m/z cale. 154.11061, found 155.3 (M+l)⁺; Rétention time: 1.13 minutes; 1H NMR (400 MHz, Chlorofomi-d) δ 7.36 (d, J = 2.4 Hz, 1H), 5.74 (d, J = 2.5 Hz, 1H), 3.81 (s, 2H), 1.02 (s, 9H).

Step 3: Teri-butyl 2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]pyridine-3carboxylate

NaH (95 mg, 2.375 mmol) (60 % oil suspension) (slight exothenn noticed) was added to 3-(2,2-dimethylpropoxy)-l//-pyrazole (363 mg, 2.35 mmol) in anhydrous DMF(3 mL)

1077 and the reaction mixture was stirred until gas évolution stopped. TerAbutyl 2,6dichloropyridme-3-carboxylate (530 mg, 2.14 mmol) was added portionwise and the reaction mixture was stirred at 100°C under nitrogen for 1 hour. The reaction mixture was diluted with EtOAc (60 mL) and water + brine (60 mL) and the two phases were separated. The aqueous phase was further extracted with EtOAc (2 x 30 mL). The combined extracts were dried over sodium sulfate and the solvent removed under reduced pressure. The residue was purified by silica gel column chromatography using a gradient of EtOAc (0 to 20% over 40 min) in hexanes to give teiAbutyl 2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazol-I-yl]pyridine-3-carboxylate (497 mg, 64%) as a yellow solid. ESI-MS m/z cale. 365.1506, found 366.2 (M+l)⁺; Rétention time: 2.44 minutes.

Step 4: 2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazol-l -yl]pyridine-3-carboxylic acid

Tert-butyl 2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yI]pyridme-3carboxylate (497 mg, 1.36 mmol), DCM (5 mL) and TFA (1.5 mL, 19.5 mmol) were stirred at 40°C for 4 hours. The volatiles were removed by évaporation under reduced pressure to give 2chloro-6-[3-(2,2-dimethylpropoxy)pyrazol- l-yI]pyridme-3-carboxylic acid (413 mg, 98%) as a white solid. ESI-MS m/z cale. 309.088, found 310.1 (M+l)⁺; Rétention time: 1.8 minutes; 1H NMR (400 MHz,DMSO-d6) S 13.58 (s, 1H), 8.42 (dd, J = 2.8, 0.8 Hz, JH), 8.38 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 6.22 (dd, J = 2.8, 0.8 Hz, 1H), 3.93 (s, 2H), 1.01 (s, 9H).

Step 5: M-[(2-amino-3-pyridyl)suIfonyI]-2-chloro-6-[3-(2,2dimethylpropoxy)pyrazol-l-yl]pyridine-3-carboxamide

1078

DMF (1 mL) was added to 2-chloro-6-[3-(2,2-dimeth ylpropoxy)pyrazol-1yl]pyridine-3-carboxylic acid (105 mg, 0.34 mmol) and CDI (69 mg, 0.43 mmol) and the reaction mixture was stirred at 40°C under nitrogen for 1 hour. In a separate 4 mL vial, 25 aminopyridine-3-sulfonamide (73 mg, 0.42mmol) was dissolved under nitrogen in anhydrous DMF (1 mL). NaH (22 mg, 0.55 mmol) (60% oil suspension) was added and the reaction mixture was stirred under nitrogen until gas évolution stopped, then stirred at 40°C for one hour. The two reaction mixtures were combined and stirred at room température for 4 hours. Water and ice was added, followed by acetic acid (400 pL, 7.034 mmol). The resultîng solid was filtered, washed with water and dried to give A-[(2-amino-3-pyridyl)sulfonyl]-2-chloro-6-[3(2,2-dimethylpropoxy)pyrazol-l-y]]pyridine-3-carboxamide (150 mg, 95%) as a white solid. The product was used for the next step without any further purification. ESI-MS m/z cale. 464.10336, found 465.2 (M+l)⁺; Rétention time: 1.5 minutes.

Step 6: A-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethyIpropoxy)pyrazoI-l15 yI]-2-[(45)-2_f2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1975)

A-[(2-amino-3-pyridyl)sulfonyl]-2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazo 1-1

1079 yl]pyridine-3-carboxamide (150 mg, 0.32 mmol), (45)-2,2,4-trimethylpyrrolidine (HCl sait) (195 mg, 1.30 mmol), K₂CO₃ (274 mg, 1.98 mmol) and anhydrous DMSO (480 pL) were stirred at 150°C for 7.5 hours under an atmosphère of nitrogen. The reaction mixture was poured into a mixture of water (25 mL) and acetic acid (400 pL, 7.034 mmol)and the resulting yellow solid was separated by filtration. The wet solid was dissolved in DCM, the organic phase was dried over sodium sulfate and the solvents evaporated to give a crude glas s, which was purified by silica gel column chromatography using a gradient of MeOH (0 to 10%) in DCM. Evaporation of the solvent gave an off-white solid which was dissolved in MeOH (3 mL) and purified by reverse phase préparative HPLC using a gradient of MeCN in water (I to 99% over

15 min) and HCl as a modifier (3 x 950 uL injections) to give A-[(2-amino-3-pyridyl)suIfonyl]6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(45)-2,2,4-trimethylpynOlidin-l-yl]pyridine-3carboxamide (Compound 1975) (75 mg, 42%) as a tan solid. ESI-MS m/z cale, 541.24713, found 542.3 (M+l)⁺; Rétention time: 1.65 minutes; 1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1 H), 8.24 (dd,J = 4.7,1.9 Hz, IH), 8.20 (d, J = 2.8 Hz, 1H), 8.03 (dd, J = 7.8,1.9 Hz, 1 H), 7.84 (d, J= 8.3 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.69 (broad s, 2H),

6.14 (d, J = 2.7 Hz, 1H), 3.89 (s, 2H), 2.45 (d,J = 8.9 Hz, 2H), 2.12 (brs, 1H), 1.85 (dd, J = 11.9, 5.4 Hz, 1H), 1.55 (s, 3H), 1.53 (s, 3H), 1.43 - 1.33 (m, 1H), 1.00 (s, 9H), 0.74 (d,J = 6.2 Hz, 3H).

The foliowing compounds can be synthesîzed using the procedures described 20 herein:

V-[(2-amino-3-pyridyl)sulfonyl]-6-(3-ziobutylpyrazol-l-yl)-2-[(45)~2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2036),

7V-[(2-ammo-3-pyridy])sulfonyl]-6-[4-(2,2-dimethylpropoxy)pyrazol-l-yi]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2406),

6-(3-N^ropoxypyrazo 1-1-yl)-7V-[(2-oxo-l/Z-pyridin-3-yl)sulfonyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-y[]pyridine-3-carboxamide (Compound 2360),

A^r-(benzenesulfonyl)-6-(4-riobutoxypyrazol-l -y I)-2-[(4 5)-2,2,4-trimethylpyrrolidin-1 yl]pyridine-3-carboxamide (Compound 1912),

N- [(2-amino- 3 -pyri dyl)sulfonyl] -6 - (3-ethoxy-4-me thyl -pyrazol-1 -yl)-2- [(45) -2,2,430 trime thylpyrrolid in-I-y l]pyridine-3-carboxamide (Compound 2248),

1080

2V-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2-ethoxyethoxy)pyrazoI-l-yl]-2-[(45)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1742),

A-[(6-amino-2-pyridyl)sulfbnyl]-6-[4-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2603),

6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-A-[(2-oxo-lH-pyridin-3-yI)sulfonyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2578),

M[(2-amino-3-pyridyI)sulfonyl]-6-(4-iiObutoxypyrazo!-l-yl)-2-[(45)-2,2,4-trimethylpyrrolidinl-yl]pyridine-3-carboxamide (Compound 1895),

6-(3-irobutoxy-4-methyl-pyrazoî-1-yl)-A- [(2-oxo-1 H-pyridin-3-yl)s ulfonyI]-2-[(45)-2,2,410 trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 1743),

7V-[(2-amjno-3-pyridyI)sulfonyI]-6-(3-isopropoxypyrazol-l-yI)-2-[(45)-2,2,4-trimethylpyrroIidinl-yl]pyridine-3-carboxamide (Compound 1844),

A-[(2-amino-3-pyridyl)sulfonyl]-6-[3-[(2S)-2-methylbutoxy]pyrazol-l-yl]-2-[(45)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 2458),

A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-j-cc-butoxypyrazol-l-yl)-2-[(4S)-2₎2,4-trimethylpyreolidinl-yl]pyridine-3-carboxamide (Compound 1970),

A-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(3-hydroxy-2-methyI-propoxy)pyrazol-l-yl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2192),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-isopropoxypyrazol-l-yl)-2-[(45)-2,2,4-trimethyIpyrrolidin20 l-yl]pyridine-3-carboxamide (Compound 1709), A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-frobutoxy-4-methyl-pyrazol-l-yl)-2-[(45)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1758), A-cyclopropylsulfonyl -6-[3 - (2,2-dimethylpropoxy)pyrazol-1 -yl] -2-((45)-2,2,4tri me thylpyrrolid in -1-yl]pyridine-3-carboxamide (Compound 2554),

6-(4 -isobutoxypyrazoI-l-yl)-A-[(2-oxo-1 H-pyridin-3-yl)suIfonyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1760), A-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxy-5-methyl-pyrazol-l-yI)-2-[(45)-2,2,4trimethylpyrrolidin-l-y]]pyridine-3-carboxamide (Compound 2238),

1081

N-[(2-amino-3-pyridyl)sulfonyl]-6-[3-[2-(2-ethoxyethoxy)ethoxy]pyrazol-l-yl]-2-[(4S)-2_î2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2326),

N-[(2-amino-3-pyridyl)suIfonyl]-6-(3-/jobutoxypyrazol-l-yl)-2-(6-methyl-8-azaspiro[3.4]octan8-yl)pyridine-3-carboxamide (Compound 2604) (Isomer 1) (Compound 2481) (Isomer 2) (Compound 2194) (Isomer 3) (Compound 2615) (Isomer 4), A^r-[(2-amino-3-pyridyl)sulfonyl]-6-[3-[2,3,3,3-tetradeuterio-2(trideuteriomethyI)propoxy]pyrazoI-]-yi]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1887),

6-(3-ethoxy-4-methyl-pyrazol-l-yI)-iV-[(2-oxo-l/Apyridin-3-yl)sulfbnyi]-2-[(45)-2,2,4trimethylpyrrolidin-1-y I]pyridine-3-carboxamide (Compound 1856),

6-(3-/Tobutoxypyrazol-I-yl)-?V-[(2-oxo-lZ/-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1896),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yI]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1952),

V-[(2-amino-3-pyridyl)sulfonyl]-6-[3-[3,3,3-trideuterio-2,2bis(trideuteriomethyl)propoxy]pyrazol-l-yl]-2-[(4S)-2,2_J4-trimethylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 2703),

N-[(2-amino-3-pyridyl)suIfonyl]-6-[3-(I-methylpropoxy)_Pyrazol-l-yl]-2-[(45)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2704),

N-(benzenesulfonyl)-6-[3-(2,2-dimethylpropoxy)pyrazol-]-yl]-2-[(45)-2,2,4-trimethylpyrtolidinI-yl]pyridine-3-carboxamide (Compound 1114),

A^r-[(2-amino-3-pyridyl)sulfonyl]-6-(3-cyclopropylpyrazol-l-yl)-2-[(4S)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2701),

N-cyclopropylsulfonyl-2-[(2S,57?)-2,5-dimethylpyrrolidin-l-yI]-6-(3-phenylpyrazol-lyl)pyridine-3-carboxamide (Compound 2676),

A^r-cyclopropylsulfonyl-6-(3-phenylpyrazol-l-yl)-2-[(4S)-2,2,4-trimethyIpyrrolidin-]-yl]pyridine3-carboxamide (Compound 2674),

V-[(2-amÎno-3-pyridyl)sulfonyl]-6-(3-phenyïpyrazoI-l-yl)-2-[(4S)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2702),

M[(2-amino-3-pyridyl)sulfonyl]-2-[(2S,5Æ)-2,5-dimethylpyrrolidin-l-yl]-6-(3-isobutoxypyrazoll-yl)pyridine-3-carboxamide (Compound 1732),

1082

A-[(37?)-3-aminopyrrolid in-l-yl]sulfonyl-6-(3-isobutoxypyrazol-l-yI )-2 - [(45)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxarnide (Compound 2716), A^r-cyclopropylsulfonyl-6-[3-(2-pyridyl)pyrazol-]-yl]“2-[(45)-2,2,4trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2718), jV-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethylpropoxy)-4-methyl-pyrazol-l-yl]-2-[(45)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2699), A-[(2-amino-3-pyridyI)sulfonyl]-6-[3-(cyclobutylmethoxy)pyrazol-l-yI]-2-[(45)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2694) and A4(2-amino-3-pyridyl)sulfonyl]-6-[3-(cyclopropylmethoxy)pyrazo]-l-yl]-2-[(4S)-2,2,410 trimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 2695).

PREÏ^ARATION 110:N-[(2-amino-3-pyridyl)sulfonyl]-6-(3-isobutoxypyrazol· l-yI)-2-(6-methyl-8-azaspiro [3.4]octan-8-yl)pyridine-3-carboxamide (Compound 2604) (Isomer 1, R or 5 stereoisomer) and A4(2-amino-3-pyridyl)sutfonyl]-6-(3-isobutoxypyrazol-l-yl)-2-(6methyl-8-azaspiro[3.4]octan-8-yl)pyridine-3-carboxamide (Compound 2481) (Isomer 2, R or 5 15 steieoisomer)

The stereoisomers were separated using supercritical fluid chromatography on a ChiralPak AD-H (250 x 10 mm), 5pm column using 30% methanol in CO₂ at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated, diluted with ethyl acetate (3 20 mL) and washed with IN aqueous hydrochloric acid. The organic layers were dried over sodium sulfate, filtered, and evaporated to dryness to give the pure compounds. SFC Peak I : A-[(2amino-3-pyridyl)sulfonyl]-6-(3-wobutoxypyrazol-l-yl)-2-(6-methyl-8-azaspiro[3.4]octan-8yDpyridine-3-carboxamide (Compound 2604) (Compound 2481) ESI-MS m/zcalc. 539.23145, found 540.2 (M+l) ⁺ ; Rétention time: 1.67 minutes . SFC Peak 2: jV-[(2-amino-325 pyridyI)sulfonyl]-6-(3-isobutoxypyrazol-l-yl)-2-(6-methyl-8-azaspiro[3.4]octan-8-yl)pyridine-3carboxamide (Compound 2604) (Isomer 1, R or S stereoisomer) (Compound 2481) (Isomer 2, R or S stereoisomer) ESI-MS m/z cale. 539.23145, found 540.2 (M+l) ⁺ ; Rétention time: 1.67 minutes.

1083

A-[(2-amino-3-pyridyl)sulfonyl]-6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-2-[6-methyl-8azaspiro[3.4]octan-8-yl]pyridine-3-carboxamide (Compound 2358) (Isomer 1, λ or 5 stereoisomer), followed by SFC column chromatography using ChiralPak AS-H (250 x 10 mm), 5pm, using as eluent 38% MeOH (no modifier) in CO₂,

N-[(2-amino-3-pyridyl)suIfonyl]-6-[3-[(l-methylpropoxy)pyrazol-l-yl]-2-[(45)-2_î2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 2594) (Isomer 2, R or S stereoisomer) using ChiralPak IA (250 x 4.6 mm), 5pm; Mobile phase: 25 % MeOH:EtOH (50:50; 0.1% TFA) in CO₂.

PREPARATION 111:4-(2,2-dimethyIpropoxy)-lZZ-pyrazole

Step 1: ΑΆ-butyl 4-hydroxypyrazole-l-carboxylate

To Zert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazole-lcarboxylate (25 g, 85 mmol) in THF (170 mL) at 0 °C was added sodium hydroxide (85 mL of 2 M, 170 mmol) followed by hydrogen peroxide (19.27 mL of 30 %w/v, 170.0 mmol) and the reaction mixture was stirred at 0 °C for 10 min and RT for 45 min. The reaction mixture was cooled to 0 °C and diluted with DCM and 2 M HCl was added till pH 2 was reached. The organics were separated, dried and concentrated under reduced pressure to give Zeri-butyl 4hydroxypyrazole-l-carboxylate (15 g 100%) as yellow solid. ESI-MS m/z cale 184.19, found 185.0 (M+l)⁺; LCMS rétention time (3 min run) 0.63 min.

Step 2: 4-(2,2-dimethylpropoxy)-lH-pyrazole

1084

Το terr-butyl 4-hydroxypyrazole-1 -carboxylate (1000 mg, 5.429 mmol) and Ph₃P (2.136 g, 8.144 mmol) in THF (2.500 mL) was added 2,2-dimethylpropan-l-ol (717.9 mg, 8.144 mmol) at 0 °C. To the réaction mixture was added DIAD (1.647 g, 1.578 mL, 8.144 mmol) in THF (2 mL). The reaction mixture was stirred at 60 °C for 16h , then cooled and diluted with DCM and washed with 6 M HCl solution. The organics were separated, dried and concentrated to give a residue which was purified by silica gel column chromatography using 5-100% EAhexanes followed by 5-40% EA-DCM to give_ (çri-butyl 4-(2,2-dimethylpropoxy)pyrazole-lcarboxylate (435.5 mg) ESI-MS m/z cale 254.16 , found 255.4 (M+l)⁺; LCMS rétention time (3 min run) = 1.82 min; 1HNMR (400 MHz, Chloroform-d) δ 7.57 (d, J = 1.0 Hz, 1H),7.51 (d, J = 1.0 Hz, IH), 3.52 (s, 2H), 1.64 (s, 9H), 1.00 (s, 9H). To fm-butyl 4-(2,2dimethylpropoxy)pyrazole-l-carboxylate (435.5 mg, 1.712 mmol) in DCM (0.2 mL) was added 4M HCl-dixoane (2 mL). After 5h at RT, the solvent was removed under reduced pressure and the residue was triturated with diethyl ether to give 4-(2,2-dimethylpropoxy)-177-pyrazole (HCl sait) (210 mg, 20%) ESI-MS m/z cale 154.11 , found 155.4 (M+l)^+: LCMS rétention time(3 min run) 1.13 min.

PREPARATION 112: 3-isobutoxy-4-methyl-1 H-pyrazole

Step 1: l-(3-hydroxy-4-methyl-pyrazol-l-yl)ethanone

4-methyl-l#-pyrazol-3-ol (1.0 g, 10.2 mmol) and pyridine (4.0 mL, 49.5 mmol) were heated at 95°C. A solution of acetic anhydride (1.0 g, 961.2 pL, 10.2 mmol) in pyridine (1.5 mL, 18.6 mmol) was added dropwise over a period of 2 minutes. The reaction mixture was then stirred at 95°C for an additional 2 hours. The solvents were removed under reduced pressure and the solid residue was triturated with diethylether (30 mL), filtered, washed with diethylether and dried to give 1 -(3-hydroxy-4-methyI-pyrazoI-l -yl)ethanone (1.2 g, 86%) as a white solid. ESI-MS m/z cale. 140.05858, found 141.1 (M+l)⁺; Rétention time 0.39 minutes; IH NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H),7.92 (q, J = 1.1 Hz, 1 H), 2.43 (s,3H), 1.88 (d, J = 1.2 Hz, 3H).

Step 2: l-(3-/sobutoxy-4-methyl-pyrazol-l-yl)ethanone

1085

-Bromo-2-methyl-propane (658 mg, 522 pL, 4.80 mmol) was added to l-(3hydroxy-4-methyLpyrazol-l-yl)ethanone (612 mg, 4.37 mmol), potassium carbonate (905 mg, 6.55 mmol) and anhydrous DMF (5 mL) under nitrogen atmosphère. The reaction mixture was stirred at 80 °C for 2.5 hours, then diluted with EtOAc (50 ml) and water (25 mL) and two phases were separated. The aqueous phase (pH = 9-10) was further extracted with EtOAc (20 mL). The combined extracts were dried over sodium sulfate and the solvents evaporated to give a crude oil. The oil was purified by silica gel column chromatography using a gradient of AcOEt (0 to 30 %) in hexanes to provide l-(3-ûobutoxy-4-methyl-pyrazoI-l-yl)ethanone (726 mg, 85%) asacolorless liquid. ESI-MS m/z cale. 196.12119, found 197.3 (M+l)⁺; Rétention time: 1.57 minutes; 1H NMR (400 MHz, Chloroform-d) δ 7.82 (s, 1H), 4.01 (d, J = 6.6 Hz, 2H), 2.53 (s, 3H), 2.10 (sep, J = 6.7 Hz, 1H), 1.95 (d, J = 1.0 Hz, 3H), 1.01 (d, J = 6.7 Hz, 6H).

Step 3: 3-Ai7butoxy-4-methyl-l/f-pyrazole

l-(3-isobutoxy-4-methyl-pyrazol-l-yl)ethanone (726 mg, 3.70 mmol) was treated with MeOH (10 mL) and NaOH (617 pL of 6 M, 3.70 mmol) (6N aqueous) at room température for 2 hours. The volatiles were removed under reduced pressure. The residue was taken in EtOAc (25 mL) and brine (20 ml) and two phases were separated. The aqueous phase was further extracted with EtOAc (2 x 25 mL) and the combined extracts were dried over sodium sulfate. After évaporation of the solvent, 3-Zsobutoxy-4-methyl-1/ï-pyrazole (564 mg, 99%) was isolated as a slightly colored viscous oil. ESI-MS m/z cale. 154.11061, found 155.0 (M+l)⁺; Rétention time: 1.17 minutes; 1H NMR (400 MHz, Chloroform-d) δ 8.83 (broad s, 1H), 7.16 7.09 (m, 1 H), 3.95 (d, J = 6.7 Hz, 2H), 2.09 (m, 1H), 1.95 (d, J = 0.9 Hz, 3H), 1.01 (d, J = 6.7 Hz, 6H).

The following compounds can be prepared following the procedures described

1086 herein:

3-(2-ethoxyethoxy)-l//-pyrazole, (5)-3-(2-methylbutoxy)-l//-pyrazole,

-(sec-butoxy)-1 //-pyrazole,

3-((1 //-pyrazo 1-5 -yl)oxy)-2-methylpropan-1 -ol,

5-isopropoxy-1//-pyrazole,

5-i'jobutoxy-3-methyl-1 //-pyrazole,

-(2- (2 -ethoxye thoxy)ethoxy)- l//-pyrazole and

3-(2-(methyl-d3)propoxy-2,3,3,3-d4)-l/7-pyrazole

PREPARATION 113:N-[(6-amino-2-pyridyl)sulfonyl]-3-fluoro-4-(3-fluoro-5Aobutoxy-phenyl)-2-[(45)-2,2,4-trimethyIpyrrolidin-J -yl]benzamide (Compound 2634)

Step 1; N-[(6-amino-2-pyridyl)sulfonyl]-4-bromo-2,3-difluoro-benzamide

Br

h

To 4-bromo-2,3-difluoro-benzoic acid (2,66 g, 11.2 mmol) in DMF (2.30 mL) was added at RT di(imidazol-l-yl)methanone (2.73 g, 16.8 mmol) and reaction mixture was heated at 65 °C for 1 h. Separately to 6-aminopyridine-2-sulfonamide (2.43 g, 14.0 mmol) in DMF (2 mL) was added sodium hydride (561 mg, 14.0 mmol) at 0 °C.and stirred for 10 min and RT for lh. The reaction mixture was cooled back to 0 °C and the CDI adduct was added and reaction mixture was heated at 65 °C for 1.5 h, then cooled to RT and diluted with ethyl acetate and washed with brine solution. The organics were separated, dried and concentrated under reduced pressure to give a residue which was purified by silica gel column chromatography eluting with 0-100% ethyl acetate-hexanes to give A-[(6-amino-2-pyridyl)sulfonyl]-4-bromo-2,3difluoro-benzamide (3.80 g, 986%). ESI-MS m/z cale 390.94 , found 394.2 (M+4)⁺; LCMS

1087 rétention time (3 min run) 1.13 min.

Step 2: A-[(6-amino-2-pyridyl)sulfonyl]-2,3-difluoro-4-(3-fluoro-5-/sobutoxyphenyl)benzamide

To mixture of A4(6-amino-2-pyridyl)sulfonyl]-4-bromo-2,3-difluoro-benzamide (1.3 g, 3.3 mmol) and (3-fluoro-5-/sc»butoxy-phenyl)boronic acid (1.1 g, 5.0 mmol) and K₂CO₃(1.4 g, 9.9 mmol) was added cyclopentyl(diphenyl)phosphane;dichloropalladium;iron (243 mg, 0.33 mmol) and DMF (8.S mL) and water (2.2 mL) and the reaction mixture was stirred under nitrogen at 100 °C for 16 h. The reaction mixture was cooled, filtered overpad of Celite and filtrate was diluted with ethyl acetate and brine solution. The organics were separated, dried and concentrated to give a residue which was purified by silica gel column chromatography using 5100% ethyl acetate-DCM as eluent to give A4(6-amino-2-pyridyl)sulfonyl]-2,3-difluoiO-4-(3fluoro-5-isobutoxy-phenyl)benzamide (356 mg, 22%). 1H NMR (400 MHz, Methanol-d4) S 7.64 -7.53 (m, 2H), 7.29 (d, J = 7.4 Hz, 1 H), 7.25 - 7.18 (m, 1 H), 6.90 (d, J = 2.7 Hz, IH), 6.88 - 6.81 (m, 1H), 6.73 (dt, J = 10.8,2.3 Hz, IH), 6.64 (d, J = 8.3 Hz, 1H), 3.79 (d, J = 6.4 Hz, 2H), 2.07 (hept, J = 6.7 Hz, 1H), 1.04 (d, J = 6.7 Hz, 6H); ESI-MS m/z cale 479.11 , found 480.2 (M+l)⁺; LCMS rétention time (3 min run) 1.78 min.

Step 3:A^?-[(6-ammo-2-pyridyl)sulfonyl]-3-fluoro-4-(3-fluoro-5-zjobutoxyphenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-l -yl]benzamide (Compound 2634)

1088

To A-[(6-amino-2-pyridyl)suIfonyl]-2,3-difluoro-4-(3-fluoro-5-âsobutoxyphenyl)benzamide (356 mg, 0.74 mmol) and K₂CO₃ (277 mg, 2.00 mmol) in NMP (650 μΐ) was added (45)-2,2,4-trimethylpyrroIidine (HCl sait) (150 mg, 1.00 mmol) and the reaction mixture was stirred at 195 °C for 5 h, then cooled and filtered and diluted with EtOAc and brine solution. The organics were separated, dried and concentrated under reduced pressure to give a residue which was purified using silica gel column chromatography using 0-15% MeOH-DCM to give A^r-[(6-amino-2-pyridyl)sulfonyI]-3-fluoro-4-(3-fluoro-5-i\i)butoxy-phenyl)-2-[(4S)-2,2_i4trimethylpyrrolidin-1 -yl]benzamide (Compound 2634) (42 mg, 2%) 1H NMR (400 MHz, Methanol-d4) δ 7.69 (s, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.08 (dd, J = 7.3,0.8 Hz, 1H), 6.62-6.51 (m, 2H), 6.44 (dd, J = 19.3, 9.7 Hz, 2H), 3.58 (s, 1H), 3.49 (d, J = 6.4 Hz, 2H),2.52 (t, J = 0.8 Hz, IH), 2.45 (s, 1H), 1.90 (s, 1H), 1.82-1.69 (m, 2H), 1.53 (s, 1H), 1.04 (s, 3H), 0.92 (s, 6H), 0.74 (d, J = 6.7 Hz, 6H). ESI-MS m/z cale 572.2 , found 573.3 (M+l)⁺; LCMS rétention time (3 min run) 1.91 min.

PREPARATION 114: V-[(6-amino-5-hydroxy-2-pyridyl)sulfonyl]-2-(2,6dimethylphenoxy)-6-(3-fluoro-5-wobutoxy-phenyl)pyridine-3-carboxamide (Compound 2331) Step 1: 6-bromo-2-nitro-pyridin-3-ol

Br

A solution of phenyl trimethyl ammonium tribromide (8.45 g, 22.3 mmol) in THF (68 mL) was added dropwise to a stirred solution of 2-nitropyridin-3-ol (3.00 g, 21.4 mmol) and trîethylamine (4.33 g, 5.97 mL, 42.8 mmol) in THF (91 mL) at -40 °C. The addition was done over a period of 5 minutes and the reaction mixture was kept at -40 °C for 1 h

1089

IN HCl and aq. Na₂S₂O₃ were added and the aq. phase was extracted with dichloromethane. The combined organic phase was washed with brine, dried over MgSO₄, filtered and the filtrate evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluted with 30 to 100% EtOAc/Hexanes to afford the title compound as a yellow solid.

Step 2: 3-benzyloxy-6-bromo-2-nitro-pyridine

Br

To a solution of 6-bromo-2-nitro-pyridin-3-ol (5.04 g, 23.0 mmol) in DMF (40 mL) was added potassium carbonate (6.36 g, 46.0 mmol) followed by the addition of bromomethylbenzene (4.13 g, 2.87 mL, 24.2 mmol). The reaction mixture was heated at 60 °C ovemight, then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with water (3x), brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude material was suspended in hexane, collected via filtration and air dried to provide 3-benzyloxy-6-bromo-2-nitro-pyridine (6.22 g, 87%) as a yellow solid.

Step 3: methyl 3-[(5-benzyloxy-6-mtro-2-pyridyl)sulfonyl]propanoate

A mixture of 3-benzyloxy-6-bromo-2-mtro-pyridine (6.21 g, 20.1 mmol) and (3-methoxy-3-oxo-propyl)sulfinyloxysodium (3.50 g, 20.1 mmol) in DMSO (50 mL) was purged with nitrogen for 2 minutes. lodocopper (7.66 g, 40.2 mmol) was added. The reaction

1090 mixture was heated at 80 °C for 24 h, then partîtioned between EtOAc and sat. NH4CI. The resulting precipitate was removed via filtration and washed with EtOAc. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with water (3x), brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (40-60% EtOAc-Hex) to provide methyl 3-[(5benzyloxy-6-nitro-2-pyridyl)sulfonyl]propanoate (2.50 g, 33%) as a brown solid.

Step 4: 5-benzyloxy-6-nitro-pyridine-2-sulfinate

THF (1 mL) was added to a suspension of methyl 3-[(5-benzyloxy-6-nitro-2pyridyl)sulfonyl]propanoate (76 mg, 0.2 mmol) in MeOH (2 mL). Sodium methoxide (400 pL of 0.5 M, 0.2 mmol) (in MeOH) was added dropwise. The reaction mixture was stirred at room température for 30 minutes, then evaporated under reduced pressure to provide a light brown solid. The crude material was used directly in next step without further purification,

Step 5: 5-benzyloxy-6-nitro-pyridine-2-sulfonamide

To a solution of amino hydrogen sulfate (3.68 g, 32.5 mmol) and sodium acetate (5.32 g, 65.0 mmol) in water (40 mL) was added 5-benzyloxy-6-nitro-pyridine-2-sulfmate (sodium sait) (2.06 g, 6.5 mmol) in MeOH (25 mL). The reaction mixture was stirred at room température ovemight, then partîtioned between water and EtOAc. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over

1091

MgSO₄, fîltered and concentrated under reduced pressure to provide 5-benzyloxy-6-nitropyridine-2-sulfonamide (1.10 g, 55%) as a crude material. The crade material (light yellow solid) was used directly in next step without further purification.

Step 6:A-[(5-benzyloxy-6-nitro-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-65 (3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide

To a mixture of 5-benzyloxy-6-nitro-pyridine-2-suIfonamide (155 mg, 0.50 mmol), 2-(2,6-dimethy]phenoxy)-6-(3-fluoro-5-iic>butoxy-phenyl)pyridine-3“Carboxylic acid (248 mg, 0.60 mmol) and HATU (228 mg, 0.60 mmol) in DMF (10 mL) was added potassium 10 carbonate (207 mg, 1.50 mmol). The reaction mixture was heated at 60 °C for 7 h, partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with water (3x), brine, dried over MgSO₄, fîltered and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (20-40% EtOAc-Hex) to provide A-[(5-benzyloxy-6-nitro-2-pyridyl)sulfonyl]-2-(2,615 dimethylphenoxy)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (220 mg, 63%) as a yellow solid.

Step 7:À^r-[(6-amino-5-benzyloxy-2-pyridyl)suffonyl]-2-(2,6-dimethylphenoxy)6-(3-fluoro-5-ijobutoxy-phenyl)pyridine-3-carboxamide (Compound 1762)

1092

To a solution of A^r-[(5-benzyloxy-6-nitro-2-pyridyl)sulfonyl]-2-(2,6dimethylphenoxy)-6-(3-fluoro-5-Nobutoxy-phenyl)pyridine-3-carboxamide (215 mg, 0.31 mmol) in dioxane (4 mL) and éthanol (2 mL) was added Fe (171 mg, 3.07 mmol) and HCl (511 pL of 6 M, 3.07 mmol). The reaction mixture was heated at 65 °C for 30 min. The iron was removed and the precipitate was colïected via filtration. The filtrate was concentrated to dryness, dissolved in DMSO, fîltered and purified by préparative HPLC to provide N-[(6-amino-5benzyIoxy-2-pyridyl)sulfonyI]-2-(2,6-dimethylphenoxy)-6-(3-fluoro-5-Nobutoxyphenyl)pyridine-3-carboxamide (Compound 1762) (25 mg, 12%) 1H NMR (400 MHz, DMSO10 d6) δ 12.23 (s, 1H),8.13 (d, J = 7.8 Hz, 1H),7.81 (d, J = 7.9 Hz, 1 H), 7.57 - 7.46 (m, 2H), 7.45 -

7.23 (m, 5H), 7.23 - 7.04 (m, 5H), 6.83 (dt, J = 10.9, 2.3 Hz, 1H), 6.33 (s, 2H), 5.24 (s, 2H), 3.61 (d, J = 6.6 Hz, 2H), 2.05 (s, 6H), 1.98 (dt, J = 13.4, 6.7 Hz, 1 H), 0.96 (d, J = 6.6 Hz, 6H). ESIMS m/z cale. 670.22614, found 670.0 (M+l)⁺; Rétention time: 3.6 minutes.

Step 8: N-[(6-amino-5-hydroxy-2-pyridyl)sulfonyI]-2-(2,6-dimethylphenoxy)-615 (3-fluoro-S-i.wbutoxy-phenyljpyridi ne-3-carboxamide (Compound 2331)

1093

To a suspension of A4(6-amino-5-benzyloxy-2-pyridyl)sulfonyl]-2-(2,6dimethylphenoxy )-6-(3-fluoro-5-fsO butoxy-phenyl )pyridine-3-carboxamide (Compound 1762) (21 mg, 0.03 mmol) in MeOH (20 mL) was added EtOAc (1 mL). The solution was purged with nitrogen for 2 min. Pd (3. mg, 0.003 mmol) was added. The reaction mixture was stirred under an atmosphère of hydrogen at room température ovemight. The Pd catalyst was removed via filtration. The filtrate was concentrated to dryness. The residue was re-dîssolved in DMSO and purified by préparative HPLC to provide A-[(6-ammo-5-hydroxy-2-pyridyl)sulfonyl]-2-(2,6dimethylphenoxy)-6-(3-fltioro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 2331) (5.0 mg, 24%). ESI-MS m/z cale. 580.1792, found 580.0 (M+l)⁺; Rétention time: 3.15 minutes.

PREPARATION 115; ZV*[(6-amino-2-pyridyl)sulfonyl]-2-(3*fluoro-5-ijobutoxyphenyl)-4-[(45)-2,2,4-trimethylpyrroIidin-l-yl]py ri midine-5-carboxamide (Compound 2121) Step 1: 2,4-dichloro-/V-((6-nitropyridin-2-yl)sulfonyl)pyrimidine-5-carboxamide

A solution of 2,4-dichIoropyrimidine-5-carboxylic acid (4.56 g, 23.8 mmol) in thionylchloride (30 mL) was refluxed for 1 hour, and evaporated to remove thionylchloride. The residue was dissolved in dichloromethane (50 mL), and 6-nitropyridine-2-sulfonaniide (5.14 g, 23.7 mmol) was carefully added followed by trimethylamine (10 mL). The reaction mixture was stirred at room température for 30 min and concentrated. The crade material was purified by chromatography on silica gel, eluted with 30-100% of ethyl acetate in hexanes, to give the desired product (9.1 g, 100%).

Step 2:2V-((6-aminopyridin-2-yl)suIfonyI)-2,4-dichloropyrimidine-5-carboxamide

A mixture of 2,4-dichloro-A^r-((6-nitropyridin-2-yl)sulfonyl)pyrimidine-5carboxamide (1.7 g, 4.5 mmol, 1.0 eq) and iron (2.6 g, 47 mmol, 10 eq) in HCl (1.9 mL 23 mmol, 5.1 eq), éthanol (6 mL), tetrahydrofuran (6 mL), and water (0.90 mL) was heated at 60 °C for 1 hour. The reaction mixture was filtered through celite and washed with methanol and ethyl

1094 acetate. The fîltrate was concentrated under reduced pressure to give the desired compound (1.7 g, 100%) LC-MS: (M+H)⁴ = 348.0.

Step 3: (5)-A'-((6-aminopyridin-2-yl)sulfonyl)-2-chloro4-(2_:2,4trimethylpyrrolidm-l-yl)pyrimidine-5-carboxamide

A mixture of A^r-((6-aminopyridin-2-yl)sulfonyl)-2,4-dichloropyrimidine-5carboxamide (0.60 g, 1.7 mmol, 1.0 eq), (5)-2,2,4-trimethylpyrrolidine hydrochloride (0.26 g, 1.8 mmol, 1.0 eq), and potassium carbonate (0.96 g, 7.0 mmol, 4.0 eq) in 4.0 mL of dimethylsulfoxide was heated in a capped vial at 125 °C for 20 hours. The reaction mixture was purified chromatography on silica gel, and eluting with a gradient of 0-80% of methanol in ethyl acetate to give (5)-N-((6-aminopyridin-2-yl)sulfonyI)-2-chloro-4-(2,2,4-trimethylpyrrolidin-lyl)pyrimidme-5-carboxamide as a brown solid (0.22 g, 30% yield). 'H NMR (DMSO-r/₆, 250 MHz); δ 8.04 (m, 1 H), 7.48 (t, 7 = 7.3 Hz, 1H), 7.04 (d,7=7.0 Hz, 1 H), 6.51 (d,7 = 8.3 Hz, 1H), 6.25 (s, br, 2H), 2.99 (m, 1H), 2.84 (m, 1H), 2.14 (m, 1H), 1.84 (m, 1H), 1.50 (s, 3H), 1.47 (s, 3H), 1.38 (m, 1H), 0.85 (d,7 = 6.3 Hz, 3H)ppm. LC-MS: (M+H)⁺= 424.9.

Step 4: A-[(6-amino-2-pyridyI)sulfonyI]-2-(3-fluoro-5-ï.sobutoxy-phenyl)-4-[(45)2,2,4-trimethyIpyrrolidin-1-yl]pyrimidine-5-carboxamide (Compound 2121)

To A-[(6-amino-2-pyridyl)sulfony I]-2-chloro-4-((45)-2,2,4-trimethylpyrrolidin-1 20 yl]pyrimidîne-5-carboxamide (70 mg, 0.1647 mmol), cyclopentyl(diphenyl)phosphane;dichloropalladium;iron (12.05 mg, 0.01647 mmol), and dioxane (840.0 pL) was added (3-fluoro-5-iiobutoxy-phenyl)boronic acid (69.84 mg, 0.3294 mmol), followed by sodium carbonate (247.0 pL of 2 M, 0.4941 mmol) under an atmosphère of nitrogen. The reaction mixture was irradiated at 120°C in the microwave for 1 hour. The reaction

1095 mixture was filtered and then purified directly by reverse-phase préparative chromatography utilizing a C18 column and HPLC-MS method 10-99 A1B1 (Acetonitrile-Water + 5 mmolar HCl, 30 min medrod) to afford as a tan solid, A-[(6-amino-2-pyridyl)sulfonyl]-2-(3-fluoro-5iiobutoxy-phenyl)-4-[(4S)-2,2_J4-trimethylpyrrolîdin-l-yl]pyrimidine-5-carboxamide (Compound 2121) (14 mg, 15%) ESI-MS m/z cale. 556,2268, found 557.2 (M+l)⁺; Rétention time: 1.71 minutes. 1H NMR (400 MHz, DMSO) δ 8.53 (s, 1H), 7.73 (s, 3H), 7.70 - 7.63 (m, 1H), 7.59 (d, J = 9.7 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 7.07 (d, J = 10.6 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 3.86 (d, J = 6.6 Hz, 2H), 2.86 - 2.74 (m, 1H), 2.69 (t, J = 10.9 Hz, 1H), 2.34 - 2.18 (m, 1H), 2.13 1.99 (m, 1H), 1.95 (dd, J = 11.9, 5.5 Hz, 1H), 1.63 (d, J = 23.9 Hz, 6H), 1.50 (t, J = 12.2 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.90 (d, J = 6.3 Hz, 3H).

PREPARATION 116: M[(6-amino-2-pyridyl)sulfonyl]~6-iert-butyi-2-(2,2dimethyI-3-tetrahydropyran-4-yl-pyrrolidin-l -yl)pyridine-3-carboxamide (Compound 2425) (Compound 2266) (racemic mixture)

In a 5 mL micro wave vial was combined the /V-[(6-amino-2-pyridyl)sulfonyl]-6ZerAbutyl-2-chIoro-pyridme-3-carboxamide (85 mg, 0.2305 mmol) and fluorocesium (175.0 mg, 42.53 pL, 1.152 mmol) in DMSO (510.0 pL) followed by K₂CO₃ (318.6 mg, 2.305 mmol) and 2,2-dimethyl-3-tetrahydropyran-4-yl-pyrrolidine (169.0 mg, 0.9220 mmol). The vial was capped and heated to 150°C in an oil bath for 16 hours. Additional fluorocesium (175.0 mg, 42.53 pL, 1.152 mmol), K₂CO₃ (318.6 mg, 2.305 mmol) and 2,2-dîmethyl-3-tetrahydropyran-4-ylpyrrolidine (169.0 mg, 0.9220 mmol) was added and heated to 165°C for 16 additional hours. The reaction mixture was filtered and then purified directly by reverse-phase préparative chromatography utilizing a Cl 8 column and HPLC-MS method 10-99% acetonitrile-water + 5 mmolar HCl to afford /V-[(6-ammo-2-pyridyl)sulfonyl]-6-terf-butyL2-(2,2-dimethyl-3tetrahydropyran-4-yl-pyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2425) (Compound 2266) (80 mg, 66%)as a light yellow solid, ESI-MS m/z cale. 515.25665, found 516.2 (M+l)⁺;

1096

Rétention time: 1.31 minutes. IH NMR (400 MHz, DMSO) δ 12.47 (s, IH), 7.70 - 7.52 (m, 2H), 7.17 (dd, J = 7.3, 0.5 Hz, IH), 6.78 - 6.59 (m, 2H), 5.14 (s, 2H), 3.84 (d, J = 3.5 Hz, 2H), 3.30 (d, J = 10.7 Hz, 2H), 2.84 (t, J = 10.0 Hz, IH), 2.68- 2.55 (m, 1 H), 2.07 (s,4H), 1.87- 1.73 (m, IH), 1.65 (dd, J = 30.6, 10.5 Hz, 2H), 1.55 (d, J = 8.6 Hz, 6H), 1.49 (s, 3H), 1.28 (d, J = 6.6 Hz, 10H).

The stereoisomers were separated using supercritîcal fluid chromatography on a ChiralPak AS-H (250 x 10 mm), 5pm column using 12 % MeOH in CO₂ at a flow rate of 10.0 ml ./min. The separated enantiomers were separately concentrated to dryness to give the pure compounds.

The following compounds can be prepared in the manner described herein: Y-[(6-amino-2-pyridyl)suIfonyI]-6-reH-butyl-2-(3-cyclopropyl-2,2-djmethyl-pyrrolidin-l10 yl)pyridine-3-carboxamide (Compound 2577) (Isomer 1, Λ or 5 stereoisomer) (Compound 2022) (Isomer 2, R or S stereoisomer),

N-[(6-amino-2-pyridyl)sulfonyl]-6-fcrr-butyl-2-[3-(cyclopropylmethyI)-2,2-dimethyl-pyrrolidml-yl]pyridine-3-carboxamide (Compound 2242), 7V-[(6-arnino-2-pyridyI)sulfonyI]-2-(3-benzyl-2,2-dimethyI-pyrroIidin-l-yl)-6-terr-butyl15 pyridine-3-carboxamide (Compound 1852), (V-[(6-armno-2-pyridyl)sulfonyl]-6-terAbutyl-2-(3-cyclopropyl-2,2-dimethyl-pyrrolidin-lyl)pyridine-3-carboxamide (Compound 2577) (Isomer 1, R or S stereoisomer) (Compound 2022) (Isomer 2, R or S stereoisomer),

N- [(6-amino-2-pyridyl)sulfonyl]-6-ierr-buty] -2-(2,2-dimethyl-3-tetrahydropyran-4-yl-pyiTolidin20 t-yl)pyridine-3-carboxamide (Compound 2425) (Isomer 1, R or S stereoisomer) (Compound

2266) (Isomer 2, R or S stereoisomer),

6-f eri-butyl-7V-[(2-oxo-l/7-pyrid in-3-yl)sulfonyl]-2-((45)-2,2,4-trimeth y lpyrrolidin-1yl]pyridine-3-carboxamide (Compound 1765)

PREPARATION 117: N-[(6-amino-2-pyridyl)sulfonyl]-6-terï-buty]-5-(225 cyclopentyl-l,2-dihydroxyethyl)-2-[(45)-2,2,4-trimethylpyrrolidm-1-yl]pyridine-3-carboxamide (Isomer 1, R or S stereoisomer) and A^r-[(6-amino-2-pyridyl)sulfonyl]-6-/er/-butyl-5-(2cy clopentyl-1,2-dihydroxyethyl)-2-[ (4 5)-2,2,4-tri methylpyrrolid in -1-yl]pyridine-3-carboxamide (Isomer 2, R or S stereoisomer)

1097

To a solution of A-[(6-amino-2-pyridyI)sulfonyl]-6-terr-butyl-5-[(E)-2cyclopentylvinyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamÎde (Compound 1633) (8 mg, 0,01 mmol) in acetone (1,0 mL) and water (0.5 mL), were added 4methylmorpholine A-oxide (16 mg, 0.14 mmol) and osmium tetroxîde (15 pL of 2.5 %w/v, 0.001 mmol), in that order, and the reaction mixture was stirred under air at ambient température. After 2 h, the reaction mixture tumed to a clear solution, and was concentrated to a light yellow paste. The paste was dissolved in DMSO (1 mL) and purified by reverse-phase HPLC-MS method to furnish the two diastereomeric diols as white solids. Isomer 1: A-[(6-amino-2pyridyl)sulfonyl]-6-terr-bütyi-5-(2-cyclopeîityLl,2-dihydroxy-ethyl-2-[(4S)-2,2,4trimethylpyrrolidin-1 -yI]pyridine-3-carboxamide (HCl sait) (2 mg, 23%) ESI-MS m/z cale, 573.29846, found 574.4 (M+l)⁺; Rétention time: 1.51 minutes; Isomer 2: A-[(6-amino-2pyridyl)sulfonyl]-6-teA-butyl-5-(2-cyclopentyl-l,2-dihydroxy-ethyl-2-[(4S)-2,2,4trimethyIpyrrolidin-I-yl]pyridine-3-carboxamide (HCl sait) (4 mg, 47%) ESI-MS m/z cale. 573.29846, found 574.4 (M+l)⁺; Rétention time: 1.55 minutes | The following compounds can be prepared in the manner as described herein:

A-[(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-(2-cycIopentyl-I,2-dihydroxyethyl)-2-[(4S)2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2661) (Isomer 1), A-[(6-amino-2-pyridyl)sulfonyl]-6-ter/-butyl-5-(l,2-dihydroxy-3,3-dimethylbutyl-2-[(4S)-2,2,4trimeîhylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2069) (Isomer 2), A-[(6-amino-2-pyridyl)sulfonyl]-6-/erLbutyl-5-(2-cyclohexyl-l,2-dihydroxyethyl-2-[(4S)-2,2,4trimethylpyrrolidm-l-yl]pyridine-3-carboxamide (isomer 1), A-[(6-amino-2-pyridyl)sulfonyl]-6-icrr-butyl-5-(2-cyclohexyl-l,2-dihydroxyethyl-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (isomer 2),

PREPARATION 118: 6-methoxy-A-[(2-oxo-lH-pyridin-3-yl)suIfonyl]-2-[(4S)2,2,4-tri methylpyrrolidin-1 -yl]quinoline-3-carboxamide (Compound 2419)

1098

Step 1: 2-chloro-6-methoxy-M-[(2-oxo-lH-pyridin-3-yl)sulfonyI]qumoline-3carboxamide

2-Chloroquinoline-3-carboxylic acid (62 mg, 0.3 mmol) and CDI (73 mg, 0.5mmol) were combined in DMF (2 mL) and stirred at 40 °C for 2 hours. In a separate vial, NaH (15 mg, 0.4 mmol) was added to 2-methoxypyridine-3-sulfonamide (71 mg, 0.4 mmol) in DMF (1 mL). The solutions were combined and stirred overnight at ambient température. The reaction mixture was taken up in EtOAc and washed with HCl (1 N, 1 x 5 mL). The aqueous layer was back washed with EtOAc (2 x 10 mL), the combined organic layers were washed with brine (Ix 10 mL) and dried over sodium sulfate, filtered and concentrated under reduced pressure. The solid was dissolved in 1,4-dioxane (2 mL) with 4M HCl (750 uL, 4.0 mmol) and heated to 90 °C for 2 hours. The reaction mixture was cooled, the solvent was removed under reduced pressure to yield a solid, which was triturated with ethyl acetate to give the desired compound (89 mg, 79%). ESI-MS m/z 394.2 (M+l)⁺, rétention time 0.39 minutes.

Step 2 : ô-methoxy-A- [(2-oxo-1 A-pyridin-3 -yl)su Ifonyl] -2-((45)-2,2,4trimethylpyrrolidin-l-yl]quinoline-3-carboxamide (Compound 2419) (Compound 2405)

2-Chloro-A-methylsulfonyl-quinoline-3-carboxamide (40 mg, 0.1 mmol), potassium carbonate (69 mg, 0.5 mmol), and (45)-2,2,4-trimethylpyrrolidine (HCl sait) (30 mg, 0.2 mmol) was suspended in DMSO (1 mL). The reaction was heated at 120 °C for 2 days, then cooled, diluted with DMSO-methanol, filtered, and then purified via reverse phase HPLC-MS method using a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H?O (5 mM TFA), mobile phase B = acetonitrile) to give the desired compound (8 mg, 17%). ESI-MS m/z 471.3 (M+l)⁺, rétention time 1.19 minutes.

1099

6-methyl-A^r-[(2-oxo-lH-pyridin-3-yl)sulfonyl]-2-[(4S)-2,2,4-trimethylpyrroIidin-l-yl]quinoline3-carboxamide (Compound 2471),

A^r-[(6-amino-2-pyrïdyl)sulfonyl]-7-methyl-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]qumoline-3carboxamide (Compound 2519), ?/-[(6-amino-2-pyridyI)sulfonyl]-6-methoxy-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]quinoline-3carboxamide (Compound 2196), /V-[(6-amino-2-pyridyl)sulfonyl]-6-methyl-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]quinoIine-310 carboxamide (Compound 2548),

A^r-[(2-oxo-l/7-pyridin-3-yI)sulfonyl]-2-[(45)-2,2,4-trimethylpynOlidin-l-yl]quinoIine-3carboxamide (Compound 2405), N-[(6-amino-2-pyridyl)sulfonyl]-2-[(45)-2,2,4-trimethylpynOlidin-l-yI]quinoIme-3-carboxamide (Compound 2265) and

N-[(2-methoxy-3“pyridyl)sulfonyl]-7-methyl-2-[(4S)-2,2,4-trimethyIpyrrolidin-l -yl]quinoline-3carboxamide (Compound 1859)

PREPARATION 119: A-[(6-amino-2-pyridyl)sulfonyl]-5-flLioro-6-isopropoxy2-(2,2,4-trimethylpyrrolidm-l-y])pyridine-3-carboxamide (Compound 2230)

Step 1; N-[(6-amino-2-pyridyl)sulfonyl]-2,6-dichloro-5-fluoro-pyridine-320 carboxamide

Cl

Cl OH

H₂N

2,6-DichloiO-5-fluoro-pyridine-3-carboxylic acid (5.0 g, 23.8 mmol), CDI (6.8 g,

41.9 mmol) and DMF (30 mL) were stiired at 60°C for 50 min. In a separate flask, 6ammopyridine-2-sulfonamide (5.2 g, 29.8 mmol), NaH (1.2 g, 29.8 mmol), and DMF (25 mL).

The reaction mixture was stirred at 60°C for 1 hour. The contents containing 6-aminopyridme-2sulfonamide was added dropwise to the activated acid at room température. The reaction mixture

1100 was stirred for 16 hours at room température. The reaction mixture was then placed in an ice bath, diluted with water (300 mL), and adjusted pH to 2. The resulting slutry was vigorousîy stirred for 30 min. The precipitate was filtered, washed with water (50 ML x 3) and hexanes (56 mL x 3), and dried in vacuo to fumish //-t(6-amino-2-pyridyl)sulfonyl]-2,6-dichIoro-5-fluoropyridine-3-carboxamide (6.9 g, 79%),

Step 2: N-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-5-fluoro-2-(2,2,4trimethylpyrrolidin-l-yl)pyridme-3-carboxamide

To a solution ofV-[(6-amino-2-pyridyl)suIfonyl]-2,6-dichlorû-5-fiuoro-pyridine3-carboxamide (1.0 g, 2,7 mmol) in DMSO (8 mL) was added 2,2,4-trimethylpyrrolidine (HCl sait) (820 mg, 5,5 mmol) and K2CO3 (2.3 g, 16.4 mmol). The reaction was stirred at 150°C for 16 hours. The reaction mixture was filtered and purified via prep HPLC (1-99% ACN, 15 min, HCl modifier) to afford A4(6-amino-2-pyridyl)sulfonyl]-6-chloro-5Tluoro -2-(2,2,4trimethylpyrro!idin-l-yl)pyridme-3-carboxamide (HCl sait) (200 mg, 30%).

Step 3: A-[(6-amino-2-pyridyl)sulfonyl]-5-fluoro-6-Aopropoxy-2-(2,2,4trimethylpyrrolidin-l-yI)pyridine-3-carboxamide (Compound 2230)

/V-[(6-amino-2-pyridyl)sulfony]]-6-chloro-5-fluoro-2-(2,2,4-trimethylpyrrolidin-lyl)pyridine-3-carboxamide (HCl sait) (50 mg, 0.10 mmol), Aopropanol (31mg, 40 pL, 0.52 mmol), NaH (10 mg, 0.24 mmol), and DMSO (lmL). The reaction mixture was stirred at

1101

150°C for 2 hours. The reaction mixture was then filtered and purified via prep HPLC (1-99% ACN, 15min, HCL modifier) to yield N^(6-amino-2-pyridyl)suIfonyl]-5-fluoro-6-wopropoxy-2(2,2,4-trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2230) (HCI sait) (13 mg, 23%) 1HNMR (400 MHz, DMSO-d6) δ 12.26 (s, 1 H), 7.66 - 7.55 (m, 2H), 7.17 (dd, J = 7.3, 0.7 Hz, IH), 6.66 (dd, J = 8.4, 0.8 Hz, 1H), 6.41 (s,2H),5.26 (p, J = 6.1 Hz, 1 H), 2.60 - 2.51 (m, 1 H), 2.49-2.40 (m, 1 H), 2.33 (p, J = 1.8 Hz, 0H), 2.20 (s, 1H), 1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.51 (s, 3H), 1.45 (s, 3H), 1.43 - 1.30 (m, 4H), 1.29 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H). ESI-MS m/z cale. 465.1846, found 466.3 (M+l)⁺; Rétention time: 1.38 minutes.

A4(6-ammo-2-pyridyl)sulfonyl]-6-(l-cyclopropylethoxy)-5-fluoro-2-(2,2,4-trimethylpyrrolidinl-yl)pyridine-3-carboxamide (Compound 2373) and

A4(6-amino-2-pyridyl)sulfonyl]-6-(I,2-dimethylpropoxy)-5-fluoro-2-(2,2,4-trimethylpyrrolidmI-yl)pyridine-3-carboxamide (Compound 1810)

PREPARATION 120: A-[(3R)-3-aminopyrrolidin-l -yl]sulfonyl-6-(3-fluoro-5isObutoxy-phenyI)-2-(p-io/y/)pyridme-3-carboxamide (Compound 2276)

Step 1; 2-chloro-6-(3-fluoro-5-!iobutoxy-phenyl)pyridine-3-carboxylic acid

2,6-Dichloropyridine-3-carboxylic acid (1.000 g, 4.861 mmol) in IPA (30 mL), K₂CO₃ (6.075 mL of 2 M, 12.15 mmol) and dichloropalladium;triphenylphosphane (341.2 mg, 0.4861 mmol) was added. The reaction mixture was heated to 80 °C under an atmosphère of nitrogen and (3-fluoro-5-zsobutoxy-phenyI)boronic acid (1.082 g, 5.104 mmol) in IPA (30 mL) was added slowly over 1 hour. The reaction mixture was heated for a further 4 h. The reaction mixture was cooled, 6 M HCl (2 mL) was added and then pH adjusted to 2-3 with additional 6 M HCl. The organic phase was collected, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by revere phase column chromatography using 10-80% ACN in Water (with TFA modifier) to give the desired compound. ESI-MS m/z 324.0 (M+l)⁺;

1102

Rétention time: 1.0 minutes.

Step 2: 6-(3-fluoro-5-Z.sï?biitoxy-phenyl)-2-(p-4o/yZ)pyridine-3-carboxylic acid

A mixture of 2-chloro-6-(3-fluoro-5-iô^,obutoxy-phenyl)pyridme-3-carboxylic acid 5 (324 mg, 1.00 mmol),p-ioZy/boronic acid (272 mg, 2.00 mmol), K₂CO₃ (415 mg, 3.00 mmol), and tetrakis(triphenylphosphine)palladium (0) (116 mg, 0.10 mmol) in DMF (10 mL) was degassed underastream of nitrogen and stirred at 120 °C for 16 hours. A forther aliquot of tetrakis(triphenylphosphine)palladium (0) (116 mg, 0.10 mmol) was added, and the reaction mixture was stirred at 150 °C for 17 hours. The reaction mixture was diluted with water, adjusted 10 to pH 5 with 1 M HCl, and extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel chromatography using 0-5% methanol in dichloromethane as eluent to give 6-(3-fluoro-5-i$obutoxy-phenyl)-2-(p-io/yZ)pyridine-3-carboxylic acid (314 mg, 83%).

Step 3: A-[(3Æ)-3-aminopynOlidin-l-yl]sulfonyl-6-(3-fluoro-5-/.robutoxy-

H

A solution of 6-(3-fluoro-5-z.sobutoxyphenyl)-2-(p-ro/y/)mcotinic acid (38 mg, 0.1 mmol) and 7V-(oxomethylene)sulfamoyl chloride (17 mg, 10 pL, 0.1 mmol) in

1103 dichloromethane (1 mL) was stirred for an hour, then teri-butyl ?/-[(3R)-pyrTolidm-3yl]carbamate (28 mg, 0.2 mmol) and triethylamine (15 mg, 21 pL, 0.2 mmol) were added. After 17 hours, HCl (200 pL of 4 M, 0.8 mmol) (in dioxane) was added, and the reaction mixture was stirred for two hours.The reaction mixture was filtered and purified using a reverse phase HPLC5 MS method using a Luna Cl 8 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCI), mobile phase B = CH₃CN. Flow rate = 50 mL/min, and column température = 25 °C) to give the desired compound. ESI-MS m/z 527.4 (M+I)⁺; Rétention time: 1.62 minutes.

PREPARATION 121: ?/-[(2-acetamido-3-pyridyl)sulfonyl]-6-(6-LÎopropoxy-310 pyridyl)-2-[(45)-2,2,4-trimethylpyrro lidin-l-yl]pyridine-3-carboxamide (Compound 1976)

N-[(2-amino-3-pyridyl)sulfonyl]-6-(6-iJopropoxy-3-pyridyI)-2-[(45)-2,2,4trimethylpyrrolidin-1 -yl]pyridine-3-catboxamide (80 mg, 0.1525 mmol) in pyridine (800 pL, 9.891 mmol) was treated with acetic anhydride (400 pL, 4.239 mmol) and stirred at room température ovemight. The product was isolated by prep. HPLC to give M[(2-acetamido-3pyridyl)suIfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(45)-2,2,4-trimethyipyrrolidm-l-yI]pyridine-3carboxamide (Compound 1976) (HCl sait) (20 mg, 21%) 1H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1 H), 8.67 (d, J =4.7 Hz, 1H), 8.43 (d,J = 7.9 Hz, 1 H), 8.30 (d, J = 9.0 Hz, 1 H), 7.84 (d, J = 8.0 Hz, 1H), 7.53 -7.42 (m, 1H),7.28 (d, J = 8.0 Hz, 1 H), 6.87 (d, J = 8.7 Hz, 1 H), 5.31 (p, J =

6.3 Hz, 1 H), 2.41 (s, 2H), 2.25 (s, 3H), 2.18 (dt, J = 16.2, 7.6 Hz, 1H), 1.88 (dd, J = 12.1, 5.8 Hz,

1H), 1.55 (d, 1 = 4.4 Hz, 6H), 1.42 (t, J = 12.0 Hz, 1H), 1.31 (d, J = 6.1 Hz, 6H),0.74 (d, J = 6.3 Hz, 3H). ESI-MS m/z cale. 566.23114, found 567.0 (M+l)⁺; Rétention time: 2.19 minutes.

PREPARATION 122;7V-[(2-amino-3-pyridyl)sulfonyl]-6-(6-ethoxy-4-methyl-2pyridyl)-2-[(45)-2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2256)

Step 1: 2-chloro-6-(6-fluoro-4-methyl-2-pyridyl)pyridine-3-carboxylic acid

1104

2,6-Dichloronicotinic acid (661 mg, 3.44 mmol), (6-fluoro-4-methyI-2pyridyl)boronic acid (560 mg, 3.62 mmol), K₂CO₃ (4.13 mL of 2 M, 8.26 mmol) in IFA (20 mL) was added Pd(PPh₃)₂Cl₂ (48.3 mg, 0.07 mmol). The reaction mixture was placed under an atmosphère of nitrogen and heated to 80 °C for 10 h. The reaction mixture was fîltered, the solvent was evaporated under reduced pressure and the crude mixture was purified by reverse phase column chromatography using 10-80% acetonitrile in water (TFA modifier) to give the desired compound. ESI-MS m/z 267.0 (M+l)⁺; Rétention time: 0.82 minutes.

Step 2: 2whloro-6-(6-ethoxy-4-methyl-2-pyridy!)pyridine-3-carboxylic acid

2-chIoro-6-(6-fluoro-4-methy]-2-pyridyl)pyridine-3-carboxylic acid (4.2 g, 15 mmol) was dissolved into a solution of sodium ethoxide (25 mL of 21 %w/v,79 mmol) in éthanol. The reaction mixture was heated to 75 °C and stirred for 3 hours. The reaction mixture was diluted with EtOAc (75 mL) and washed with water (Ix 75 mL) with some brine (20 mL). The aqueous layer was extracted with EtOAc (Ix 75 mL). The organic layers were combined, dried over sodium sulfate, fîltered and concentrated under reduced pressure to give an orange solid. The solid was redissolved in EtOAc (75 mL) and aqueous NaOH solution (1 M, 75 mL). The aqueous layer was isolated and acidified to pH 2, extracted with EtOAc (2x 75 mL). The final organic layers were dried over sodium sulfate, fîltered and concentrated under reduced pressure. The obtained solid was purified by silica gel column chromatography column, using 010% MeOH/DCM as eluent to give 2-chloro-6-(6-ethoxy-4-methyl-2-pyridyl)pyridine-3carboxylic acid (1.17 g, 25%) as a white solid. ESI-MS m/z cale. 292.06146, found 293.1 (M+l)⁺; Rétention time: 1.72 minutes.

Step 3: A^r-[(2-amino-3-pyridyl)sulfonyl]-2-chloro-6-(6-ethoxy-4-methyl-21105 pyridyl)pyridine-3-carboxamide

2-chIoro-6-(6-ethoxy-4-methyl-2-pyridyl)pyridine-3-carboxylic acid (200 mg, 0.68 mg ) was dissolved in DMF (2.5 mL). CDI (123 mg, 0.75 mmol) was added, and the reaction mixture was allowed to stîr at 60 °C for 1 hour. In a separate flask, sulfonamide was dissolved in DMF (600 pL), and NaH (34 mg, 0.85 mmol) was added and the reaction mixture was stirred for 45 minutes at room température. The activated carboxylîc acid mixture was then added to the deprotonated sulfonamide. The final reaction mixture was stirred at 60 °C ovemight. After cooling to room température, the reaction mixture was diluted with EtOAc (50 mL) and washed with water (1 x 50 mL) and brine (2x 75 mL). The organic layer was dried over sodium sulfate, fîltered and concentrated under reduced pressure to give the desired compound (297 mg, 97%). ESI-MS m/z 448.0 (M+l)⁺; Rétention time: 0.53 minutes.

Step 4: 7V-[(2-amino-3-pyridyl)sulfonyl]-6-(6-ethoxy-4-methyl-2-pyridyI)-2[(45)-2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2256)

2-chloro-6-(6-ethoxy-4-methyl-2-pyridyl)-N-methylsulfonyl-pyridine-3carboxamide (60 mg, 0.13 mmol) and (45)-2,2,4-trime thylpyrrolidine (free base, 45 mg, 0.4 mmol) were combined in DMSO (100 pL). Potassium carbonate (55 mg, 0.4 mmol) was added and the reaction mixture was heated ovemight at 140 °C, then 165 °C for 3 hours. The réaction

1106 mixture was purified using a reverse phase HPLC method using aLuna C18 (2) column (50 x 21,2 mm, 5 pm particle size) and a dual gradient run from 10-99% mobile phase B over 15.0 minutes (mobile phase A = water (de-ionized, no acid modifier), mobile phase B = acetonitrile) to give the desired compound. ESI-MS m/z 525.3 (M+l)⁺; Rétention time: 1.57 minutes.

PREPARATION 123:A-[(2-amino-3-pyridyI)sulfonyl]-6-[6-(diethylamino)-2pyridyl}-2-[(45)-2,2,4-trimethyIpyrrolidm-l-yl]pyridine-3-carboxamide (Compound 1845)

Step 1: A-[(2-amino-3-pyridyl)sulfonyl]-6-(6-fluoro-2-pyridyI)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide

A mixture of A-[(2-amino-3-pyridyl)sulfonyl]-6-chIoro-2-[(45)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (0.12 g, 0.28 mmol), (6-fluoro-2pyridyl)boronic acid (0.06 g, 0.42 mmol), [1.Γbis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (0.02 g, 0.02 mmol), and Na₂CO₃ (0.09 g, 0.85 mmol) in DMF (2.2 mL) and water (566 pL) was degassed under a stream of nitrogen and stirred at 100 °C for 20 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography using 0-5% methanol in dichloromethane as eluent to give N- [(2-amin o-3 -pyridyl)sulfonyl]-6-(6-fluoro-2-pyridyI)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (0.11 g, 80%) as yellow solid.

Step 2:A-[(2-ammo-3-pyridyl)suIfbnyf]-6-[6-(diethy]ammo)-2-pyridyl]-2-[(45)2,2,4-trimethylpyiTolidin-l-yl]pyridine-3-carboxaniide (Compound 1845)

1107

A solution of A-[(2-amino-3-pyridyl )suIfonyl]-6-(6-fluoro-2-pyridyl )-2-((45)2,2,4-trimethylpyrTo!idin-l-yI]pyridine-3-carboxamide (30 mg, 0.06 mmol) and diethylamine (1 mL, 9.67 mmol) was stirred in a sealed vessel at 120 °C for 17 hours, then 150 °C for 22 hours. The diethylamine was removed under vacuum, and the residue was purified using a reverse phase HPLC-MS method using a Luna C18 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run from 25-75% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give the desired compound. ESI-MS m/z 483.5 (M+l)⁺; Rétention time: 0.88 minutes

The foliowing compounds can be synthesized using the procedures described herein

A-[(2-amino-3-pyridyl)sulfonyI]-6-[6-(2,2-dimethylpropylamino)-2-pyridyl]-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2500), A-[(6-amino-2-pyridyl)sulfony]]-6-(6-(diethylamino)-5-methyi-2-pyridyl]-2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 1907),

A- [(6-amino-2-py ri dyi)sulfonyl] -6 - [6-(riobutyl amino)-5-me thyl-2 -pyridyl] -2-(2,2,4trimethylpyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2362), A-[(6-amino-2-pyridyl)sulfonyI]-6-[6-(diethylamino)-4-methyl-2-pyridyl]-2-[(45)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2002),

6-(6-e thoxy-4-methyl-2-pyridyl)-A-(lA-pyrazol-3-yl su Ifonyl )-2-((45)-2,2,4-trimethylpyrrolid inl-yl]pyridine-3-carboxamide (Compound 2487),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-(2-ethoxyethoxy)ethoxy]-4-methyl-2-pyridyl]-2-[(45)2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1696),

1108 /V-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2-isopropoxyethoxy)-4-methyI-2-pyridyl]-2-[(45)-2,2,4trimethylpyrrolidin-1-yl]pyridine-3-carboxamide (Compound 1703),

A4(6-amino-2-pyridyl)sulfonyl]-6-[6-(2-ethoxyethoxy)-4-methyl-2-pyridyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1700),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[isopropyl (methyl)amino]-5-me thyI-3-pyridyI]-2-[(45)2,2,4-trimethylpyrrolidin-l -y I]pyridine-3-carboxamide (Compound 2687),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(isopropylammo)-5-methyl-3-pyridyl]-2-[(45)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2688)

A4(6-amino-2-pyridyl)sulfonyl]-6-[6-[ethyl(methyl)ammo]-5-methyl-3-pyridyl]-2-[(45)-2,2,410 trimethylpyrrolidin-1 -yl]pyridine-3-carboxamide (Compound 2689),

N-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-ethoxyethyl(methyl)amino]-5-methyl-3-pyridyl]-2[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridîne-3 -carboxamide (Compound 2685),

A-[(6-amino-2-pyridyl)sulfonyl]-6-[6-[2-(2-ethoxyethoxy)ethyl-methyl-amino]-5-methyl-3pyridyl]-2-[(45)-2,2,4-trimethylpyrrolidin-1-y lJpyridine-3-carboxamide (Compound 2684) and

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[6-(2-ethoxyethylamino)-5-methyl-3-pyridyl]-2-[(45)-2,2,4trimethylpyirolidin-l -yl]pyridine-3-carboxamide (Compound 2686).

PREPARATION 124:A^r-(benzenesulfonyl)-6-(6-ethoxy-4-methyl-2-pyridyl)-2(2,4,6-trimethyIphenoxy)pyridine-3-carboxamide (Compound 2455)

²⁰ AA[(2-amino-3-pyridyl)sulfonyl]-2-chloro-6-(6-ethoxy-4-methyl-2pyridyl)pyri dîne-3-carboxamide (50 mg, 0.1 mmol) and 2,4,6-trimethyl-phenol (45 mg, 0.3 mmol) were dissolved in DMSO (175 pL) and dioxane (175 pL). Sodium hydride (13mg, 0.3 mmol) was added and the reaction mixture was heated under micro wave irradiation at 150 °C for 20 minutes. The reaction mixture was purified using a reverse phase HPLC method using a

Luna C18 (2) column (50 x 21.2 mm, 5 pm particle size) and a dua] gradient run from 10-99% mobile phase B over 15.0 minutes (mobile phase A = water (de-ionized, no acid modifier),

1109 mobile phase B = acetonitrile) to give N-(benzenesulfonyl)-6-(6-ethoxy-4-methyl-2-pyridyI)-2(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 2455). ESI-MS m/z 532.5 (M+l)⁺; Rétention time: 2.52 minutes.

The following compounds can be synthesized using the procedures described herein :

N- [(6-amino-2-pyridyl)sulfonyl]-6-(6-ethoxy-4-methyl-2 -pyridy 1)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 2511), N-[(2-amino-3-pyridyl)sulfonyl]-6-(6-ethoxy-4-methyl-2-pyridyI)-2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1795), 6-(6-ethoxy-4-methyl-2-pyridyI)-A^r-(l_JH-pyrazol-3-ylsulfonyl)-2-(2,4,6trimethylphenoxy)pyridme-3-carboxamide (Compound 2301) and 6-(6-e thoxy-4-meth yl-2-pyridyl) -A- [(2-oxo-l/Z-pyridin-3-yl)sulfonyl] -2-(2,4,6trimethylphenoxy)pyridine-3-carboxamide (Compound 1768).

PREPARATION 125; N-[(2-amino-3-pyridyl)suIfonyI]-6-tetrahydropyran-2-yl2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyrid in e-3-carboxamide (Compound 1697)

Step l:N-[(2-amino-3-pyridyl )sulfonyl]-2,6-dîchloro-pyridine-3-carboxamide θγθ_Η et m ~ ^C'V —Cl

2,6-dichloropyridine-3-carboxylic acid (1.5 g, 7.8 mmol) and CD1 (1.9 g, 11.7 mmol) in DMF (17 mL) was stirred at 60 °C. In a separate vial, 2-aminopyridine-3-sulfonamide (1.7 g, 9.8 mmol) and NaH (0.4 g, 9.8 mmol) in DMF (8 mL) was stirred at ambient température. The two reaction mixtures were combined and stirred ovemight at room température. The reaction mixture was taken up in EtOAc and washed with HCl (1 N, 1 x 25 mL) and the aqueous layer was washed with EtOAc (4 x 20 mL). The combined organic layers were washed with brine (1x15 mL) and dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting solid that crashed was washed with ethyl acetate and the mother liquor was concentrated, the residue was washed with ethyl acetate and hexanes to obtain N-[(2-ammo-3-pyridyl)sulfonyl]-2,6-dichloro-pyridine-3-carboxamide (2.5 g, 94%) as a white solid. 1HNMR (400 MHz, DMSO-d6) δ 8.28 - 8.12 (m, 2H), 8.07 (d,J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1 H), 6.87 (dd, J = 7.7, 5.4 Hz, 1H).

1110

Step 2: M[(2-ammo-3-pyridyI)sulfonyl]-6-chloro-2-[(4S)-2,2,4trimethylpynOlidin-l-yI]pyridine-3-carboxamide

Cl

DMSO (17 mL) was added to N-[(2-amino-3-pyridyl)sulfonyl]-2,6-dichloro5 pyridine-3-carboxamide (2.1 g, 6.0 mmol), (45)-2,2,4-trimethylpyrroIidine (HCl sait) (1.1g, 7.3 mmol), and potassium carbonate (3.3g, 24 mmol). The reaction mixture was sealed and stirred at 120°C for 2 days. The reaction mixture was allowed to cool and then diluted with ethyl acetate (40 mL) and water (60 mL). To the aqueous layer, aq HCl was added to pH 7 and then washed with ethyl acetate (5 x 50 mL). The combined organic layers were concentrated to half volume then washed with brine and dried over sodium sulfate, filtered and evaporated under reduced pressure to give N-[(2-amino-3-pyridyl)sulfonyl]-6-chloro-2-[(45)-2,2,4-trimethylpyrrolidin-1yl]pyridine-3-carboxamide (2.5 g, 100%) as a yellow powder. 1H NMR (400 MHz, DMSO-d6) 5 8.26 (dd,J=4.8, 1.8 Hz, 1 H), 8.06 (dd,J = 7,9, 1.8 Hz, 1H),7.71 (d,J = 7.9 Hz, 1 H), 6.79 (dd, J = 7.9, 4.8 Hz, 1H), 6.64 (d, J = 7.9 Hz, 1H), 2.46 - 2.34 (m, 2H), 2.19 - 2.03 (m, 1H), 1.82 (dd,

J = 12.1,5.6 Hz, 1 H), 1.47 (d, J = 3.3 Hz, 6H), 1.36 (t, J = 12.2 Hz, 1 H), 0.74 (d, J = 6.3 Hz, 3H).

Step 3: N-[(2-amino-3-pyridyl)suIfonyl]-6-(3,4-dihydro-2H-pyran-6-yl)-2-[(4S)2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1699)

A4(2-amino-3-pyridyl)sulfony]]-6-chloro-2-[(45)-2,2,4-trimethylpyrrolidin-l20 yl]pyridine-3-carboxamide (32 mg, 0.08 mmol), 2-(3,4-dihydro-2H-pyran-6-yI)-4,4,5,5tetramethyl-1,3,2-dioxaborolane (19 mg, 0.09 mmol), and 1,3-bis(2,6-diAopropy]pheny 1)-4,5dihydroimidazole; 3-chloropyridine; dichloropalladium (3 mg, 0.005 mmol, 5 mol%) was

1111 dissolved in EtOH (600 pL) and solution of potassium carbonate (150 pL, 2M) was added. The reaction mixture was heated at 120°C for 16 hours under an atmosphère of nitrogen. The reaction mixture was cooled, filtered and purified via LC/MS utilizing a gradient of 25-75% acetonitrile in 5 mM aq HCl. Sodium carbonate was added to collected fractions (pH 7-8) and the solvents were removed to dryness to yield the desired compound. ESI-MS m/z 472.3 (M+l)⁺; Rétention time: 1.18 minutes

Step 4: jV-[(2-amino-3-pyridyI)sulfonyl]-6-tetrahydropyran-2-yl-2-[(4S)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-caiboxamide (Compound 2351)

T o A-[(2- ami no-3 -pyridy l)sulfonyl] -6 -(3,4-dihydro-2H-pyran-6-yI) -2- [(45)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 1699) (37 mg,0.08 mmol) in EtOH (3 mL), palladium on carbon (8 mg, 0.008 mmol, 10w/w%) was added. The reaction mixture was stirred under an atmosphère of hydrogen 16 hours at ambient température. The reaction mixture was filtered and evaporated to dryness, dissolved in DMSO-methanol and purified via reverse phase HPLC-MS method using a dual gradient run from 1-99% mobile phase B over 15.0 minutes. Mobile phase A = H₂O (5 mM TFA) Mobile phase B = acetonitrile to yield /7-[(2-amino-3-pyridyl)sulfonyl]-6-tetrahydropyran-2-yl-2-[(45)-2,2,4-trimethylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2351). ESI-MS m/z 474.4(M+1)⁺; Rétention time: 1.15 minutes.

77-[(2-amino-3-pyridyl)sulfonyl]-6-(l,2-dimethylpropyl)-2-[(45)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 1911)

A-[(2-amino-3-pyridyl)sulfonyl]-6-(5,5-dimethyl-2-oxo-cyclobexyI)-2-[(45)-2,2,4trimethylpyrroIidin-]-yl]pyridine-3-carboxamide (Compound 1793) /7-[(2-amino-3-pyridyl)sulfonyl]-6-norboman-2-yl-2-[(45)-2,2,4-trimethylpyiTolidm-]yl]pyridine-3-carboxamide (Compound 2097)

1112

N-[(2-amino-3 -pyridyl)sulfbnyl]-6-tetrahydropyran-4-yl-2-[(45)-2,2,4 -trimethylpyrrolidin-1yI]pyridine-3-carboxamide (Compound 1850)

TV-[(2-amino-3-pyridyI)sulfonyl]-6-(2-cyclopropylelhyl)-2-[(45)-2,2,4-trirnethylpyrrolidm-lyl]pyrid ine-3-carboxamide (Compound 2553) 7V-[(2-amino-3-pyridyl)sulfonyl]-6-(2-hydroxy-5,5-dimethyI-cyclohexyl)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxarnide (Compound 2047) iV-(benzenesulfonyl)-6-tetrahydropyran-2-yl-2-[(45)-2,2,4-trimetliylpyrrolidin-l-yl]pyridine-3carboxamide (Compound 1868)

TV-(b enzenesulfonyl)-6-frobuty 1-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2246)

7/-(benzenesulfonyl)-6-tetrahydrofuran-3-yl-2-[(4S)-2,2,4-trimethyIpyrrolidin-l-yl]pyridine-3carboxamide (Compound 2277)

M-[(2-amino-3-pyridyl)sulfony]]-6-tetrahydropyran-3-yl-2-[(45)-2,2,4-trimeÜiylpyrroIidin-lyl]pyridine-3-carboxamide (Compound 2311)

M-[(6-amino-2-pyridyl)sulfonyl]-6-(3-bicyclo[2.2.1]hept-2-enyl)-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2709) A-[(2-amino-3-pyridyl)sulfonyl]-6-[4-(trifluoromethyl)cyclohexyl]-2-[(45)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2077) (Isomer 1, cis ortrans stereoisomer)

TV-[(2-amin o-3-pyridyl)sulfonyl]-6-[4-(trifluorom ethyl)cyclohex yI]-2-[(45)-2,2,4trimethy]pyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2432) (Isomer 2, cis or trans stereoisomer).

PREPARATION 126: A-[(2-amino-3-pyridyl)sulfonyl]-6-tetrahydropyran-2-y]2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2351) (Isomer 1,R5 or 55 stereoisomer) and A-[(2-amino-3-pyridyl)sulfonyl]-6-tetrahydropyran-2-yl-2-[(45)-2,2,4trimethylpyrrolidiii-l-yI]pyridine-3-carboxamide (Compound 2351 ) (Isomer 2, Λ5 or 55 stereoisomer)

1113

The stereoisomers were separated using supercritical fluid chromatography on a Phenomenex LUX-4 (250 x 10 mm), 5pm column using 48 % EtOH/IPA (50/50) in CO₂ at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated to dryness to give the pure compounds. SFC Peak 1: A^r-[(2-ami no-3-pyridyl)sulfonyi]~6-tetrahy drop yran-2-yl-2-[(45)-2,2,4trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2351) ESI-MS m/z 474.4(M+1)⁺; Rétention time: 1.15 minutes. SFC Peak 2: ZV-[(2-amino-3-pyridyI)sulfonyl]-6-tetrahydropyran2-yI-2-[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2351) ESI-MS m/z 474.4(M+l)⁺; Rétention time: 1.15 minutes.

The following compounds can be synthesized using the procedures described herein: A-[(2-amino-3-pyridyl)sulfonyl]-6-[2-tetrahydropyran-2-yl]-2-[(4S)-2,2,4-trimethyIpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2672) (Isomer 1, RS or SS stereoisomer) and A^r-[(2-amino-3-pyridyl)sulfonyl]-6-[2-tetrahydropyran-2-yl]-2-[(4S)-2,2,4-trimethyIpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2675) (Isomer 2, RS or SS stereoisomer).

PREPARATION 127: Λ^Γ-[(6-amino-2-pyridyl)sulfonyl]-6-rer^butyl·2-(3cyclopropy 1-2,2-dimethyl-pyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2577) (Compound 2022) (Isomer 1, R or S stereoisomer) and ?V-[(6-amino-2-pyridyl)sulfonyl]-6-ierE butyl-2-(3-cyclopropyl-2,2-dimethyI-pyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2577) (Compound 2022) (Isomer 2, R or S stereoisomer)

The stereoisomers were separated using supercritical fluid chromatography on a ChiralPak AD-H (250 x 10 mm), 5pm column using 22% EtOH/MeOH (90:10, 20 mM NH₃) in CO₂at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated, diluted with ethyl acetate (3 mL) and washed with IN aqueous hydrochloric acid. The organic layers were dried over sodium sulfate, fïltered, and evaporated to dryness to give the pure compounds. SFC Peak 1: A-[(6-amino-2-pyridyl)sulfonyl]-6-ierr-butyl-2-(3-cyclopropyl-2_!2dimethyl-pyrrolidin-l-yI)pyridine-3-carboxamide (Compound 2577) (Compound 2022) 1H NMR (400 MHz, DMSO) δ 12.35 (s, 1H), 7.59 (d, J = 7.7 Hz, 2H),7.14 (d, J = 6.7 Hz, 1 H), 6.73

1114

- 6.58 (m, 2H), 6.43 (s, 2H), 2.79 (s, 1H), 2.62 (s, IH), 1.80 - 1.59 (m, 2H), 1.56 (s, 3H), 1.51 (s, 3H), 1.27 (s,9H), 1.13- 1.03 (m, 1H),O.71 -0.58 (m, 1H), 0.56 - 0.46 (ni, 1 H), 0.46 - 0.33 (m, 1H), 0.24 (td, J = 9.2, 5.0 Hz, 1H), 0.12 - 0.01 (m, 1H) . SFC Peak 2: N-[(6-amino-2pyridyl)sulfonyl]-6-terAbutyl-2-(3-cyclopropyl-2,2-dimethyl-pyrrolidin-l-yl)pyridine-3carboxamide (Compound 2577) (Compound 2022) 1H NMR (400 MHz, DMSO) δ 12.35 (s, 1H), 7.58 (d, J = 7.1 Hz, 2H), 7.14 (d, J = 7.1 Hz, 1H), 6.77 - 6.56 (m, 2H), 6.42 (s, 2H), 2.79 (s, 1H), 2.66 (dd,J= 12.3, 10.5 Hz, 1H), 1.69 (d, J = 20.9 Hz, 2H), 1.56 (s, 3H), 1.51 (s, 3H), 1.27 (s, 9H), 1.17 - 1.05 (m, 1 H), 0.73 - 0.63 (m, 1H), 0.58 - 0.47 (m, 1H), 0.40 (dd, J = 8.2, 3.9 Hz, 1H), 0.24 (dd, J = 9.0, 4.1 Hz, 1 H), 0.07 (dd, J = 9.0,4.0 Hz, 1H).

PREPARATION 128 : Ν'- [(6-amino-2-pyridyl)sulfonyl] -6-terAbuty 1-2-(2,2dimethyI-3-teÎrahydropyran-4-yl-pyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2425) (Compound 2266) (Isomer 1, R or S stereoisomer) and N-[(6-amino-2-pyridyl)sulfonyl]-6-teributyl-2-(2,2-dimeÎhyl-3-îetrahydropyran-4-yl-pyrrolidin-l-yl)pyridine-3-carboxamide (Compound 2425) (Compound 2266) (Isomer 2, R or S stereoisomer)

The stereoisomers were separated using supercritical fluid chromatography on a ChiralPak AD-H (250 x 10 mm), 5pm column using 12% MeOH in CO₂at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated, diluted with ethyi acetate (3 mL) and washed with IN aqueous hydrochloric acid. The organic layers were dried over sodium sulfate, fîltered, and evaporated to dryness to give the pure compounds. SFC Peak 1 : N-[(6amino-2-pyridyI)sulfonyl]-6-/eri-butyl-2-(2,2-dimethyl-3-tetrahydropyran-4-yl-pyrrolidin-lyl)pyridine-3-carboxamide (Compound 2425) (Compound 2266) ESI-MS m/z cale. 515.25665, found 516.2 (M+l) ⁺ ; Rétention time: 1.31 minutes. SFC Peak 2:7V-[(6-amino-2pyridyl)sulfonyl]-6-terAbuty]-2-(2,2-dimethyI-3-tetrahydropyran-4-yl-pynOlidin-l-yl)pyridine3-carboxamide (Compound 2425) (Compound 2266) ESI-MS m/z cale. 515.25665, found 516.2 (M+l) ⁺ ; Rétention time; 1.31 minutes . 1H NMR (400 MHz, DMSO) δ 12.48 (s, 1 H), 7.70 1115

7.52 (m, 2H), 7.17 (dd, J = 73,0.5 Hz, 1H),6.7O (dd, J = 9.7, 8.5 Hz, 2H), 5.19 (s, 2H), 3.84 (td, J = 11.1,3.7 Hz, 2H), 3.38 -3.18 (m,2H), 2.84 (t, J = 10.0 Hz, 1 H), 2.68 - 2.55 (m, 1 H), 2.07 (s, 4H), 1.81 (t, J = 6.4 Hz, 1H), 1.65 (dd, J = 30.6, 10.5 Hz, 2H), 1.55 (d, J = 8.6 Hz, 6H), 1.49 (s, 3H), 1.28 (d, J = 6.6 Hz, 10H).

PREPARATION 129: A-[(6-amino-2-pyri dyl)sulfonyl]-2-(3,4-dimethyl-lpiperidyI)-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (Compound 2532) (Isomer 1) (Compound 2178) (Isomer 2) (Compound 2062) (Isomer 3) (Compound 1863) (Isomer 4)

Step 1 : A^r-[(6-ammo-2-pyridyl)sulfonyl]-2-chloro-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide

hⁿh

2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)_Pyridine-3-carboxyhc acid (3.91 g, 9.66 mmol) was dissolved in DMF(31mL) was stirred under nitrogen and CDI (2.35 g, 14.5 mmol) was added in one portion. The reaction mixture was warmed to 65 °C and heated for 1 h.

Meanwhile in a separate vessel, 6-aminopyridine-2-suIfonamide (2.09 g, 12.1 mmol) was slurried in DMF (15 mL) under nitrogen and NaH (483 mg, 12.1 mmol) added portionwise to mitigate gas évolution and the reaction was stirred for 1 h. The two reactions were combined in one portion at 65 °C. The reaction was stirred for 15 min and evaporated. The reaction mixture was poured overice and acidified (ph=4) by the addition of 6M HCL The resulting mixture was extracted with ethyl acetate (1 L). The organics were washed with brine (2 x 500 mL), dried over sodium sulfate and evaporated under reduced pressure. The crude material was purified by silica gel column chromatography eluting with 0-100% ethyl acetate in hexanes to give A-[(6-amino-2pyridyl)sulfonyl]-2-chloro-6-(3-fiuoro-5-teobutoxy-phenyI)pyridine-3-carboxamide (4.02 g, 887%) ESI-MS m/z cale. 478.08777, found 479.1 (M+l)⁺; Rétention time: 0.7 minutes.

Step2:iV-[(6-amino-2-pyridyl)sulfonyI]-2-(3,4-dimethyl-l-piperidyl)-6-(3-fluoro* 5-iiobutoxy-phenyI)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863)

1116

N-[(6-amino-2-pyridyl)sulfonyl]-2-chIoro-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (100 mg, 0.21 mmol) and fluorocesïum (156 mg, 38.5 μL, 1,04 mmol) in DMSO (600 pL) foliowed by K₂CO₃ (289 mg, 2.09 mmol) and 3,4dimethylpiperidine (118 mg, 1.04 mmol). The reaction mixture was sealed and heated to 150°C ovemight, then 165°C for 6 hours. The reaction mixture was fïltered and then purified directly by reverse-phase HPLC-MS usinglO-99% Acetonitrile-Water + 5 mmolar HCl as eluent to afford /7-[(6-amino-2-pyridyI) sulfonyl]-2-(3,4-dimethyl-I-piperidyl)-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863) (86 mg, 74%), as a light yellow solid ESI-MS m/z cale. 555.23157, found 556.2 (M+l)⁺; Rétention time: 2.0 minutes. IH NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 7.81 (d, J = 7.9 Hz, 1 H), 7.65 (t, J = 7.8 Hz, 1 H), 7.50 - 7.41 (m,3H),7.22 (d, J = 7.3 Hz, 1 H), 6.91 (d, J = 10.9 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.47 (s, 1H), 3.85 (d, J = 6.5 Hz, 2H), 3.51 (d, J = 8.5 Hz, 1H), 3.40 (d, J = 12.8 Hz, 1H), 3.13 (d, J = 11.8 Hz, 1 H), 2.97 (d,J = 6.0 Hz, 1H), 2.06 (d,J = 9.3 Hz, 1H), 1.89- 1.72 (m, 2H), 1.42 (s, 2H), 1.00 (d,J = 6.7 Hz, 6H), 0.87 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H

Step 3: N-[(6-amino-2-pyridyl)sulfonyl]-2-(3,4-dimethyl-l-piperidy 1)-6-(3fluoro-5-ùobutoxy-phenyl)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863) (Isomers 1-4, RR, RS, SS, or SR stereoisomer)

The stereoisomers were separated using supercritical fluid chromatography on a

ChiralCel OZ-H (250 x 10 mm), 5pm column using 25% MeOH:EtOH 50:50 in CO₂ at a flow

1117 rate of 10,0 mL/min. The separated enantiomers were separately concentrated to give the pure compound. SFC Peak 1: M[(6-ammo-2-pyridyi)sulfonyl]-2-(3,4-dimethyl-l-piperidyl)-6-(3fluoro-5-iiobutoxy-phenyl)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863) ESI-MS m/z cale. 555.23157, found 556.2 (M+l)⁺;

Rétention time: 2.02 minutes. SFC Peak 2 (jV-[(6-amino-2-pyridyl)sulfonyl]-2-(3,4-dimethyl-lpiperidyl)-6-(3-fluoro-5-ùobutoxy-phenyl)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863) ESI-MS m/z cale. 555.23157, found 556.2 (M+l)⁺; Rétention time: 2.01 minutes. SFC Peak 3 V-[(6-amino-2-pyridyl)sulfonyl]-2(3,4-dimethyl-l-piperidyl)-6-(3-fluoro-5-i.vobutoxy-phenyI)pyridine-3-carboxamide (Compound 2532) (Compound 2178) (Compound 2062) (Compound 1863) ESI-MS m/z cale. 555.23157, found 556.2 (M+l)⁺; Rétention time: 1.96 minutes. SFC Peak 4 ESI-MS m/z cale. 555.23157, found 556.2 (M+l)*; Rétention time: 1.96 minutes. IH NMR (400 MHz, DMSO) δ 12.66 (s, IH), 7.79 (d, J = 7.8 Hz, 1 H), 7.63 (t, J = 10.7 Hz, IH), 7.45 (d, J = 11.6 Hz, 3H), 7.20 (d, J = 6.5 Hz, IH), 6.90 (d, J = 10.7 Hz, IH), 6.70 (d, J =7.1 Hz, IH), 6.44 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H),3.50(s, IH), 3.38 (s, IH), 3.12 (d, J = 13.0 Hz, 1H),2.96 (s, IH), 2.08- 1.98 (m, IH), 1.80 (s, 2H), 1.41 - 1.37 (m, IH), 1.30- 1.22 (m, IH), 1.00 (d, J = 6.7 Hz, 7H), 0.86 (d, J = 6.5 Hz, 4H), 0.76 (d, J = 6.6 Hz, 3H).

A^r-[(6-amino-2-pyridyI)sulfonyl]-2-(2,5-dimethyl-l-piperidyI)-6-(3-fluoro-5-ii'<?butoxyphenyl)pyridine-3-carboxamide (Compound 2451) (Compound 1993) (Compound 1864) (Compound 1855) (Isomers 1-4, stereoisomers AU?, RS, SS, SR), using as SFC ChiralCel OZ-H (250 x 10 mm), 5pm column and eluent 25% MeOH (20 mM NH₃) in CO2

Ar-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-ijobutoxy-phenyl)-2-(6-methyl-8azaspiro[3.4]octaA^f-8-yl)pyridine-3-carboxamide (Compound 2552) (Isomer 1, R or S stereoisomer) (Compound 2269) (Isomer 2, R or S stéréo isomer), using as SFC ChiralPak IA (250 x 10 mm), 5pm column and eluent 22% EtOH (0.1% TFA) in CO2

N-[(6-amino-2-pyridy])sulfonyl]-2-(2-ethyl-2,4-dimethyl-pyrroljdin-l-yl)-6-(3-fluoro-5Îjobutoxy-phenyl)pyridine-3-carboxamide (Compound 2213) (Compound 2058) (Compound 1817) (Compound 1729) (Isomers 1-4, stereoisomers RR, RS, SS, SR), using as SFC ChiralCel OZ-H (250 x 10 mm), 5pm column and eluent 22% IPA:EtOH 50:50 in CO₂

1118

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyl-4-(trifluoromethyl)pyrrolidin-l-yl)-6-(3-fluoro5-ïsobutoxy-phenyl)pyridine-3-carboxamide (Compound 2271) (Isomer 1,7? or S stereoisomer) using as S FC Chiral Cel OZ-H (250 x 10 mm), 5pm column and eluent 25 % MeOH:EtOH (50:50) in CO₂.

PREPARATION 13 0: N- [(6-amino-2-pyridyl)sulfonyl] -6 -(3 -fl uoro-5 -isobutoxyphenyl)-5-iodo-2-[(4S)-2,2,4-trimethylpyrroIidin-Lyl]pyridine-3-carboxamide (Compound 2009)

77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-iSi?butoxy-phenyl)-2-[(4S)-2,2,4trimethylpyn‘olidin-l-yl]pyridine-3-carboxamide (100 mg, 0.18 mmol) was dissolved in CH₂C1₂(700 pL) and was treated with l-iodopyrrolidine-2,5-dione (44 mg, 0.19 mmol). The reaction mixture was allowed to stir at40 °C for 30 minutes. The volatiles were evaporated under a slow stream of nitrogen gas. The reraaining residue was redisse!ved in DMSO, filtered and purified by reverse-phase HPLC using a Luna C18 (2) column (50 x 21.2 mm, 5 pm particle size) and a dual gradient run from 30-99% mobile phase B over 15.0 minutes (mobile phase A = water (deionized, no acid modifier), mobile phase B = acetonitrile) to give the desired compound. ESI-MS m/z cale, 681.1282, found 682.2 (M+l)⁺; Rétention time: 2.26 minutes,

PREPARATION 131: /V-[(6-amino-2-pyridyl)sulfonyl]-6-(3’fluoro-5-fsobutoxyphenyl)-A-methyl-2-[(4S)-2,2,4-trimethylpymo]idin-Lyl]pyridine-3-carboxamide (Compound 2258)

1119

A- [(6-am i no-2-pyridy I)su Ifonyl] -6-(3-flu oro-5-Lobutoxy-phenyl)-2-[ (45)-2,2,4trîmethylpyrrolidin-l-ylJpyridine-3-carboxamide (500 mg, 0.90 mmol) in DMF (5 ml.) was treated with Cs₂CO₃ (352 mg, 1.1 mmol) and the reaction mixture was stirred for 0.5 h at room température, then cooled in an ice bath and treated with Mel (141 mg, 61 pL, 1.0 mmol). The reaction mixture was stirred ovemight at room température. The suspension was added to water (25ml), stirred at room température for 1 h and the suspension was filtered and washed with water. The solid was purified by silica gel column chromatography using as dichloromethane as eluent to give A-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-isobutoxy-phenyl)-A-methyl-2[(45)-2,2,4-trimethylpynOlidin-l-yl]pyridme-3-carboxamide (Compound 2258) (315 mg, 61%). ESI-MS m/z 570.0 (M+l)⁺; Rétention time: 3.4 minutes ; 1H NMR (400 MHz, DMSO-d6) δ 7.67 - 7.54 (m, 2H), 7.49 (t, J = 1.8 Hz, 1H), 7.40 (dt, J = 10.2, 1.8 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.64 (s, 2H), 3.84 (d, J = 6.7 Hz, 2H), 3.43 (s, 3H), 2.82 (s, 1H), 2.64 (s, 1H), 2.34 - 2.22 (m, 1H), 2,05 (hept, J = 6.6 Hz, 1H), 1.91 (dd, J = 11.9,5.7 Hz, 1H), 1.62 (d, J = 4.4 Hz, 6H), 1.46 (t, J= 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.94 (d, J = 6.3 Hz, 3H)

PREPARATION 132; A-[(6-amino-2-pyridyl)sulfonyl]-2-(2,6di me thylphenoxy)-6-[3-fluoro-5-(2-hydroxy-2-methyl-propoxy)phenyl]pyridine-3-carboxamide (Compound 1890)

Step 1: l-[3-fîuoro-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenoxy]-2methyl-propan-2-ol

1120

To a suspension of I-(3-bromo-5-fluoro-phenoxy)-2-methyl-propan-2-ol (25.0 g, 95 mmol), Bis(pinacolato)diboron (26.5 g, 105 mmol), and KOAc (18.7 g, 190 mmol) in dioxane (375 mL) under an atmosphère of nitrogen was added Pd(dppf)Cl₂.DCM (768 mg, 1.0 mmol) and the reaction mixture was heated to 103 °C for 2 hours, cooled and stirred ovemight at room température. The reaction mixture was filtered through Florisil and the filtrate was concentrated under reduced pressure to afford a yellow oil. The oil was purified by silica gel column chromatography eluted with EtOAc/heptane (10 - 20% EtOAc) to afford l-[3-fluoro-5(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]-2-methyl-propan-2-ol (12.6 g (86%) as pale yellow liquid,

Step 2:N-[(6-amino-2-pyridyI)sulfonyl]-2-(2,6-dimethylphenoxy)-6-[3-fluoro-5(2-hydroxy-2-methyl-propoxy)phenyl]pyridine-3-carboxamide (Compound 1890)

A^r-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-(2,6-dimethyIphenoxy)pyridine-3carboxamide (140 mg, 0.32 mmol), l-[3-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)phenoxy]-2-methyl-propan-2-o! (215 mg, 0.69 mmol), potassium carbonate (647 pL of 2 M, 1.29 mmol), and 1,3-bis(2,6-diAopropylpheny 1)-4,5-dihydroimidazole; 3-chloropyridine; dichloropalladium (PEPPSI-IPr) (11 mg, 0.02 mmol) were combined in éthanol (3 mL) and the reaction mixture was heated at 80 °C for 21 h. The reaction mixture was cooled to 40 °C, glacial AcOH (0.20 mL) was added, filtered and the filtrate evaporated under reduced pressure. The residue was dissolved in DMSO (3 mL), filtered and purified using a reverse phase HPLC-MS method using a Luna C18 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run

1121 from 10-99% mobile phase B over 30.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give 75-[(6-amino-2-pyridyl)sulfonyI]-2-(2,6-dimethylphenoxy)-6-[3fluoro-5-(2-hydroxy-2-methyl-propoxy)phenyl]pyridine-3-carboxamide (Compound 1890) (HCl sait) (80 mg, 40 %) IH NMR (400 MHz, DMSO-d6) 5 12.39 (s, IH), 8.16 (d, J = 7.8 Hz, IH), 7.84 (d, J = 7.9 Hz, 1 H), 7.66 (t, J = 7.9 Hz, IH), 7.24 (d, J = 7.3 Hz, IH), 7.21 - 7.14 (m, 4H), 7.14-7.07 (m, 1H),6.84 (dt, J = 10.6,2.3 Hz, 1H),6.72 (d, J = 8.4 Hz, 1H),6.54 (s, 2H),4.61 (s, IH), 3.61 (s, 2H), 2.07 (s, IH), 2.06 (s, 6H), 1.19 (s, 6H). ESI-MS m/z cale. 580.1792, found 581.2 (M+l)⁺; Rétention time: 1.76 minutes.

A4(6-amino-2-pyridyl)sulfonyl]-2-(2,6-dimethylphenoxy)-6-[3-fluoro-5-(3-hydroxy-2-methyipropoxy)phenyl]pyridine-3-carboxamide (Compound 1797)

PREPARATION 133: ?/-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5’iwbutoxypheny 1)-2-(3,5,5-trimethylcyclopenten-l-yl)pyridine-3-carboxamide (Compound 2081) (Isomer 1, R or S stereoisomer) (Compound 2039) (Isomer 2, R or 5 stereoisomer)

Step 1: Ethyl 2-c h Ioro-6-(3-fluoro-5-wobutoxy-phenyl)pyridine-3-carboxylate

To a solution of 2-chloro-6-(3-fluoro-5-/sObutoxy-phenyl)pyridine-3-carboxylic acid (1.3 g, 4.0 mmol) in éthanol (40 mL) was slowly added thionyl chloride (1.0 g, 584 pL, 8.0 mmol) and the reaction mixture was stirred at reflux for six hours. The solvent was evaporated under reduced pressure to give ethyl 2-chloro-6-(3-fluoro-5-iiobutoxy-phenyl)pyridine-3carboxylate (1.3 g, 95%) as a colorless solid.

Step 2: Ethyl 6-(3-fluoro-5-irobutoxy-phenyl)-2-(3,5,5-trimethylcyclopenten-l yl)pyridine-3-carboxylate

1122

A mixture of ethyl 2-chIoro-6-(3-fluoro-5-ïJobutoxy-phenyl)pyridine-3carboxylate (700 mg, 1.99 mmol), 4,4,5,5-tetramethyl-2-(3,5,5-trimethylcyclopenten-l-yl)1,3,2-dioxaborolane (517 mg, 2.19 mmol), l,l'-bis(diphenylphosphmo)ferrocene-panadium dichloride (437 mg, 0.60 mmol), and Na₂CO₃ (633 mg, 5.97 mmol) in dioxane (9 mL) and water (1 mL) was heated in a sealed vessel at 150 °C for 16 hours. The reaction mixture was filtered, and the solids were washed with EtOAc. The combined organics were evaporated, and the residue was purified by silica gel column chromatography using a gradient of 100% hexanes to 20% EtOAc in hexanes to afford ethyl 6-(3-fluoro-5-ijobutoxy-phenyl)-2-(3,5,5trimethylcyclopenten-l-yl)pyridine-3-carboxylate (97 mg, 11%) as a white solid. ESI-MS m/z cale. 425.23663, found 426.2 (M+l)⁺; Rétention time: 2.4 minutes.

Step 3: 6-(3-fluoro-5-iTobutoxy-phenyl)-2-(3,5,5-trimethylcyclopenten-lyI)pyridine-3-carboxylic acid

To a solution of ethyl 6-(3-fiuoro-5-i5obutoxy-phenyl)-2-(3,5,5trimethylcyclopenten-l-yl)pyridine-3-carboxylate (92 mg, 0.2 mmol) in THF (520 pL) was added NaOH (650 pL of 1 M, 0.6 mmol) and then MeOH (520 pL) and the reaction mixture was heated to 50^DC for 4 hrs. The reaction mixture was neutralized with 1 M HCl (3.0 mL) and extracted with EtOAc (10 mL x 2). The combined extracts were dried over Na₂SO4 and evaporated under reduced pressure to give 6-(3-fluoro-5-ijobutoxy-phenyl)-2-(3,5,5trimethylcyc!openten-l-yl)pyridine-3-carboxyIic acid (77 mg, 90%) as a light yellow solid. ESIMS m/z cale. 397.20532, found 398.2 (M+l)⁺; Rétention time: 1.92 minutes; 1H NMR (400

1123

MHz, DMSO) δ 13.11 (s, 1H), 7.98 (s, 2H), 7.56 (s, 1H), 7.49 (d, J = 9.9 Hz, 1H), 6.93 (d, J = 10.7 Hz, 1 H), 5.67 (s, 1 H), 3.85 (d,J=6.6 Hz, 2H), 2.87 (dd, J = 14.1,7.0 Hz, 1 H), 2.13 - 1.98 (m, 2H), 1.46- 1.38 (m, 4H), 1.24 (s,4H), 1.08 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.7 Hz, 6H).

Step 4: A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-i.wbutoxy-phenyl)-2(3,5,5-trimethylcyclopenten-1-yl)pyridine-3-carboxamide (Compound 2081) (Compound 2039)

6-(3-fluoro-5-Jsobutoxy-phenyl)-2-(3,5,5-trimethyIcyclopenten-l-yl)pyridme-3carboxylic acid (74 mg, 0.19 mmol) and CDI (45 mg, 0.28 mmol) were mixed in DMF (740 pL) under and atmosphère of nitrogen and the reaction mixture was heated to 45 °C for 45 minutes In a separate via!, 6-aminopyridine-2-sulfonamide (80.62 mg, 0.4655 mmol) and NaH (18 mg, 0.46 mmol) were mixed slowly in DMF (370.0 pL) and mixture was heated to 45 °C for 45minutes. The 6-aminopyridine-2-sulfonamide reaction mixture was added to the activated acid and the reaction mixture was heated at 50°C for 16h. The reaction mixture was filtered and then purified directly by reverse-phase préparative chromatography utilizing a Cl8 column and HPLC-MS method 10-99% mobile phase B (mobile phase A = water (de-ionized, no acid modifier), mobile phase B = acetonitrile) to afford 7V-[(6“amino-2-pyridyl)sulfonyl]-6-(3-fluoro5-teobutoxy-phenyl)-2-(3,5,5-trimethylcyclopenten-l-yl)pyridine-3-carboxamide (Compound 2081) (Compound 2039) (64 mg, 62%) as an off-white solid, ESI-MS m/z cale. 552.22064, found 553.4 (M+l)⁺; Rétention time: 2.25 minutes; 1H NMR (400 MHz, DMSO) δ 12.55 (s, 1 H), 7.96 (d, J =8.2 Hz, 1H), 7.86 (d, J = 8.2 Hz, IH), 7.68 - 7.60 (m, lH),7.56(s, 1 H), 7.49 (d, J = 9.6 Hz, 1 H), 7.20 (d, J = 7.3 Hz, 1H), 7.01 -6.84 (m, 1H), 6.72 (d,J = 8.4 Hz, 1 H), 6.55 (s, 2H),5.62 (d,J= 1.7 Hz, 1H),3.85 (d, J = 6.6 Hz, 2H), 2.66 (ddd, J = 14.3,7.4, 1.8 Hz, 1 H), 2.03 (dd, J = 13.2, 6.6 Hz, IH), 1.95 (dd, J = 12.1,7.5 Hz, 1H), 1.38 - 1.28 (m, 4H), 1.25 (s, 3H), 0.99 (d, J = 6.7 Hz, 6H), 0.93 (d, J = 6.9 Hz, 3H).

1124

Step 5: N-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Îj:obutoxy-phenyl)-2(3,5,5-trimethylcyclopenten-l-yl)pyridine-3-carboxamide (Compound 2081) (Isomer 1, R orS stereoisomer) and W-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-Mobutoxy-phenyl)-2-(3,5,5trimethylcyclopenten-1 -yl)pyridine-3-carboxamide (Compound 2039) (Isomer 2, R or S

The stereoisomers were separated using supercritical fl nid chromatography on a ChiralCel AD-H (250 x 10 mm), 5pm column using 20% EtOH (0.1% TFA) in CO₂at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated to give the pure compound. SFC Peak

1 : N-[(6-amino-2-pyridyl)suIfonyl]-6-(3-fluoro-5-ïS(7butoxy-phenyl)-2-(3,5,5trimethylcyclopenten-1 -yl)pyridine-3-carboxamide (Compound 2081 ) (Isomer 1, R or 5 stereoisomer) ESI-MS m/z cale. 552.22064, found 553.2 (M+l)⁺; Rétention time: 2.26 minutes. SFC Peak 2 A^r-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Eobutoxy-phenyl)-2-(3,5,5trimethylcyclopenten-l-yl)pyridine-3-carboxamide (Compound 2039) (Isomer 2, R or S stereoisomer) ESI-MS m/z cale. 552.22064, found 553.2 (Μ+1)⁺; Rétention time: 2.26 minutes.

PREPARATION 134: /V-[(6-amino-2-pyridyl)sulfonyI]-6-(3-fluoro-5-i5obutoxypheny 1)-2-(2,2,4,4-tetramethylcyclopentyI)pyridine-3-carboxamide (Compound 2492) (Isomer 1, R or S stereoisomer) (Compound 2374) (Isomer 2, R or 5 stereoisomer)

Step 1: 6-(3-fluoro-5-isobutoxy-phenyl)-2-(2,2,4,420 tetramethylcyclopentyl)pyridine-3-carboxylic acid

1125

A mixture of 6-(3-fluoro-5-iJobutoxy-phenyl)-2-(3,3,5,5-tetramethylcyclopentenI-y])pyridine-3-carboxylic acid (389 mg, 0.94 mmol) (prepared in a similar manner to that described in préparation 133), palladium hydroxide (80 mg, 0.57 mmol) and ammonium formate (1.19 g, 18.91 mmol) in éthanol (10 mL) were combined in a microwave vial and heated to 85°C for 3h. The reaction mixture was cooled to room température and a further aliquot of ammonium formate (1.19g, 18.91 mmol) and palladium hydroxide (80 mg, 0.57 mmol) was added, and irradiated under microwave conditions at 85°C for4h. The reaction mixture was filtered over celite, washed with methanol and the filtrate concentrated under reduced pressure, then diluted with IN HCl and washed with ethyl acetate (2X). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to a clearoil. The oil was purified by silica gel column chromatography using a gradient from 100% dichloromethane to 20% methanol in dichloromethane followed by 20% methanol in ethyl acetate to give 6-(3-fluoro-5-iTobutoxy-phenyI)-2-(2,2,4,4-tetramethylcyclopentyi)pyridine-315 carboxylic acid (52 mg, 13%) as a white solid.

Step 2: A-[(6-amino-2-pyridyl)sulfonyl]*6-(3-fluoro-5-Aobutoxy-phenyl)-2(2,2,4,4-tetramethylcyclopentyl)pyridine-3~carboxamide (Compound 2492) (Compound 2374)

A solution of 6-(3-fîuoro-5-üobutoxy-phenyl)-2-(2,2,4,41126 tetramethylcyclopentyl)pyridine-3-carboxylic acid (52 mg, 0.13 mmol) and carbonyl diimidazole (31 mg, 0.19 mmol) in dimethylformamide (0.5 mL) was stirred at 45°C for 90 minutes. A separate solution of 6-aminopyridine-2-sulfonamide (44 mg, 0.25 mmol) and sodium hydride (10 mg, 0.25 mmol) in dimethylformamide (0.5 mL) was stirred at45 °C for 45 minutes was then added to the activated acid and the resulting mixture was stirred at 45 °C for 2 h. The reaction mixture was filtered and purified using a reverse phase HPLC-MS method using a Lun a C18 (2) column (75 x 30 mm, 5 pm p article size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A= H₂O (5 mM HCl), mobile phase B = acetonitrile) to give A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-i5obutoxy-phenyl)-2-(2,2,4,4tetramethylcyclopentyl)pyridine-3-carboxamide (Compound 2492) (Compound 2374) (HCl sait) (51 mg, 67%) as an off-white solid. 1H NMR (400 MHz, DMSO) δ 12.63 (s, 1 H), 7.91 (dd, J = 20.4, 8.2 Hz, 2H), 7.66 (t, J = 7.9 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J = 9.8 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.93 (d, J = 10.7 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 3.86 (d, J = 6.6 Hz, 2H), 3.58 (dd, J = 12.2, 6.5 Hz, 1H), 2.55 (d, J = 123 Hz, 1H), 2.06 (dt, J = 13.2, 6.6 Hz, IH), 1.63 (dd, J = 12.4,6.4 Hz, 1H), 1.50 (d,J= 13.0 Hz, 1H), 139 (d, J = 12.9 Hz, 1H), 1.15 (s, 3H), 1.08 - 0.93 (m, 9H), 0.80 (s, 3H), 0.69 (s, 3H). ESI-MS m/z cale. 568.25195, found 5693 (M+l)⁺; Rétention time: 2.4 minutes.

Step 3: A-[(6-amino-2-pyridyl)sulfonyi]-6-(3-fluoro-5-Zsobutoxy-phenyl)-2(2,2,4,4-tetramethylcyclopentyl)pyridine-3-carboxamide (Compound 2492) (Isomer 1, R or S steieoisomer) and A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Kobutoxy-phenyI)-2-(2,2,4,4tetramethyIcyclopentyl)pyridine-3-carboxamide (Compound 2374) (Isomer 2, R or 5 steieoisomer)

The stereoisomers were separated using supercritical fluid chromatography on a

1127

Chiralpak IC (250 x 10mm), 5pm column using 17 % EtOH (DeNat) + 0.1 % TFA in CC₂ at a flow rate of 10.0 mL/min. The separated enantiomers were separately concentrated to give the pure compound. SFCPeak l:jV-[(6-amino-2-pyndyl)sulfonyl]-6-(3-fluoro-5-M'obutoxy-phenyl)2-(2,2,4,4-tetramethy le yclopentyl)pyridine-3-carboxamide (Compound 2492) (Compound 2374) ESI-MS m/z cale. 568.25195, found 569.3 (M+l)⁺; Rétention time: 2.4 minutes. 1H NMR (400 MHz, MeOD) δ 7.87 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.70 (dd, J = 8.3,7.4 Hz, 1H), 7.54 (s, 1H), 7.46 - 7.38 (m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.75 (dt, J = 10.5, 2.3 Hz, 1H), 3.82 (d,J = 6.5 Hz, 2H), 3.67 (dd,J= 12.3,6.4 Hz, IH), 2.66 (t, J = 12.5 Hz, 1 H), 2.11 (dt, J= 13.3, 6.7 Hz, 1H), 1.69 (dd, J = 12.6, 6.3 Hz, 1H), 1.49 (dd, J = 38.8, 13.1 Hz, 2H), 1.18 (d, J = 5.6 Hz, 3H), 1.10-1.00 (m,9H),0.81 (s, 3H), 0.75 (s,3H).SFCPeak2:A-[(6-amino-2pyrid y l)sulfonyl]-6-(3-fluoro-5-isobutoxy-phenyl )-2-(2,2,4,4-te trame thylcyclopentyl)pyridine-3carboxamide (Compound 2492) (Compound 2374). ESI-MS m/z cale. 568.25195, found 569.3 (M+l)⁺; Rétention time: 2.4 minutes. 1H NMR (400 MHz, MeOD) δ 7.87 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.70 (dd, J = 8.3,7.4 Hz, 1H), 7.54 (s, 1H), 7.46 - 7.38 (m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.75 (dt, J = 10.5, 2.3 Hz, 1H), 3.82 (d, J = 6.5 Hz, 2H), 3.67 (dd, J = 12.3, 6.4 Hz, 1H), 2.66 (t, J = 12.5 Hz, 1 H), 2.11 (dt, J = 13.3, 6.7 Hz, 1H), 1.69 (dd, J = 12.6, 6.3 Hz, 1H), 1.49 (dd, J = 38.8, 13.1 Hz, 2H), 1.18 (d, J = 5.6 Hz, 3H), 1.10-1.00 (m,9H),0.81 (s, 3H), 0.75 (s,3H).

PREPARATION 135: 6-(4-chloro-3-propoxy-phenyl)-2-[(2R,5S)-2,5dimethylpyrrolidin-1 -y 1] -A- [[6- (peu t-4-ynoylammo)-2-pyridyl]sulfonyl]pyridine-3-carboxamide (Compound 2540)

Step 1:7V-[(6-amino-2-pyridyI)sulfonyl]-6-chloro-2-[(2R,5S)-2,5dimethylpyrrolidin-l-yl]pyridine-3-

N-[(6-amino-2-pyridy 1 )sulfonyl]-2,6-dichloro-pyridme-3-carboxamide (2.0 g, 5.8 mmol) and (2R,5S)-2,5-dimethylpyrrolidine (0.7 g, 7.2 mmol) in DMSO (10 mL) was treated

1128 with K2CO3 (2.4 g, 17 mmol) and heated at 120 °C under stinting for 3h. The reaction mixture was cooled down and carefully added to cold mixture of HCl (2.881 mL of 12 M, 35 mmol) and water (50 mL) forming a white foam. The reaction mixture was allowed to stir at room température for 30 min, filtered and the white solid was triturated with IPA (lOOmL) to give the desired compound.

Step 2: N-[(6-amino-2-pyridyl)sulfonyl]-6-(4-chloro-3-propoxy-phenyl)-2[(2R,5S)-2,5-dimethylpyrrolidin-l-yl]pyridme-3-carboxamide (Compound 773) ci

H

N-[(6-amino-2-pyridyI)sulfonyl]-6-chloro-2-[(2S,5R)-2,5-dimethylpynolidm-lyl]pyridine-3-carboxamide (62 mg, 0.15 mmol), (4-chloro-3-propoxy-phenyl)boronic acid (48 mg, 0.23 mmol), tetrakis(triphenylphosphine)palladium (0) (10 mg, 0.009 mmol), potassium carbonate (300 pL, 2 M, 0.40 mmol) and DMF (1.7 mL) were heated at 100 °C ovemight. The reaction mixture was filtered and purified by reverse phase HPLC utilizing a gradient of 1-99% acetonitrile in 5 mM aq HCl. ESI-MS m/z 544.3 (M+l)⁺; Rétention time: 1.7 minutes; 1H NMR (400 MHz, DMSO-d6)5 12.98 (s, 1H), 7.83 (d, J = 1.9 Hz, 1 H), 7.81 (d,J = 8.0 Hz, 1H),7.7O7.61 (m, 2H), 7.52 (d, J = 8.3 Hz, 1 H), 7.37 (d, J = 7.9 Hz, 1H),7.23 (dd, J = 7.3, 0.8 Hz, 1H), 6.72 (d, 1H), 6.48 (s, 2H), 4.13 (t, J = 6.5 Hz, 2H),4.09 - 3.97 (m, 2H), 2.05 - 1.91 (m, 2H), 1.81 (h, J = 7.2 Hz, 2H), 1.74-1.61 (m, 2H), 1.10 (d, J =6.2 Hz, 6H), 1.03 (t,J = 7.4 Hz, 3H).

Step 3: 6-(4-chloro-3-propoxy-pbenyl)-2-[(2R,5S)-2,5-dimethylpyrrolidin-l-yl]N- [[6- (pen t-4-ynoylamino)-2-pyridyl]su lfonyl]pyridine-3 -carbox amid e (Compound 2540)

1129

N-[(6-amino-2-pyridyI)suIfonyl]-6-(4-chloro-3-propoxy-phenyl)-2-[(2R,5S)-2,5dimethyIpyjT01idin-l-yl]pyridine-3-caiboxamide (Compound 773) (10 mg, 0.02 mmol) in DCM (2 mL) at 0 °C was added triethylamine (11 mg, 15 pL, 0.11 mmol) and pent-4-ynoyl chloride (4 mg, 0.04 mmol). The reaction mixture was then stirred at 0 °C for 5 minutes, then at rt for 2 h. The reaction mixture was evaporated under reduced pressure and the crude mixture was purified by reverse phase HPLC using 10-100% ACN in Water (TFA modifier). The sait was neutralized with SPE-CO3H cartridge, eluted with MeOH/DCM to give the desired compound. ESI-MS m/z 624.3 (M+l)⁺; Rétention time: 0.9 minutes; 1H NMR (300 MHz, CDCI3) δ 8.73 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.04 (t, J = 7.9 Hz, 1H), 7.98 - 7.89 (m, 2H), 7.56 (dd, J = 8.2, 1.9 Hz, 1H), 7.51 (d, J = 2.4 Hz, 2H), 4.21 (d, J = 6.1 Hz, 2H), 4.10 (t, J = 6.4 Hz, 2H), 2.73 (t, J = 6.9 Hz, 2H), 2.64 - 2.47 (m, 4H), 2.11 (d, J = 2.8 Hz, 2H), 2.00 - 1.85 (m, 4H), 1.34 (d, J = 6.6 Hz, 6H), 1.25 (s, 6H), 1.11 (t, J = 7.4 Hz, 5H),0.93 - 0.79 (m, 3H).

PREPARATION 136: A^r-[4-[3-(4-ch]orophenyl)propyI]piperazin-l-yl]sulfonyl2-[(45)-2,2,4-trimethylpyiTolidin-1 -yl]pyridine-3-carboxamide (Compound 2141)

Step 1; 2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxylic acid

A mixture of2-fluoropyridine-3-carboxylic acid (71 mg, 0.5 mmol), (45)-2,2,4trimelhylpyjTolidine (HCl sait) (150 mg, 1.0 mmol), potassium caibonate (207 mg, 1.5 mmol), and césium fiuoride (152 mg, 1.0 mmol) in DMSO (500 pL) was stirred at 130 °C for six hours. The reaction mixture was diluted with water, adjusted to pH 4 with 1 M HCl, and extracted with ethyl acetate. The combinéd extracts were washed with brine, dried over sodium sulfate, and

1130 evaporated under reduced pressure. The residue was purified using reverse phase HPLC-MS using a Lun a C18 (2) column (75 x 30 mm, 5 pm parti cle size) and a dual gradient run from 1 70% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give the desired compound.

Step 2:benzyl 4-[[2-[(4 5)-2,2,4-trimethylpyrrolidin-l -yl]pyridine-3carbonyl]sulfamoyl]piperazine-1 -carboxylate

A solution of (S)-2-(2,2,4-trimethylpynOlidin-l -yl)nicotinic acid (117 mg, 0.5 mmol) and chlorosulfonyl isocyanate (85 mg, 52 pL, 0.6 mmol) in dichloromethane (3 mL) was stirred for 30 minutes, and was slowly added to a solution of benzyl piperazine-Lcarboxylate (110 mg, 96 pL, 0.5 mmol) and pyridine (59 mg, 60 pL, 0.8 mmol) in dichloromethane (2 mL). The reaction mixture was stirred for two hours, evaporated under reduced pressure and purified by silica gel column chromatography with 0-5% methanol in dichloromethane as eluent to give benzyl (S)-4-(7V-(2-(2,2,4-trimethylpyrrolidin-l -yl)nicotinoyl)sulfamoyl)piperazine-l 15 carboxylate (35 mg, 13%) as a colorless oil. ESI-MS m/z 516.6 (M+l)⁺; Rétention time: 1.65 minutes.

Step 3: A-piperazin-l-ylsulfonyl-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine3-carboxamide

1131

A mixture of benzyl (S)-4-(A-(2-(2,2,4-trimethylpyrrolidin-lyl)nicotinoyl)sulfamoyl)piperazine-l-carboxylate (0.22 g, 0.43 mmol) and palladium on carbon (20 mg, 0.02 mmol) in methanol (2 mL) was stirred under a hydrogen atmosphère for 16 hours.

The reaction mixture was filtered and evaporated to give (S)-A-(piperazin-1 -y!suIfonyl)-2(2,2,4-trimethylpyrrolidin-l-yl)nicotinamide (0.13 g, 80%) as a colorless solid.

Step 4: A-[4-[3-(4-chlorophenyl)propyl]piperazin-l -yI]sulfonyl-2-[(4S)-2,2,4trimethylpyrToIidin-l-yl]pyri dine-3-carboxamide (Compound 2141)

A solution of (S)-A-(piperazin-l -ylsulfonyl)-2-(2,2,4-trimethyIpyrrolidin-l yl)nicotinamide (30 mg, 0.08 mmol) and 3-(4-chlorophenyl)propanal (14 mg, 0.08 mmol) in 1,2-dichloroethane (800 pL) was stirred for five minutes, and sodium triacetoxyborohydride (33 mg, 0.16 mmol) was added. The reaction mixture was stirred for 16 hours, diluted with methanol, filtered, and purified using a reverse phase HP LC-MS method using a Lun a C18 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give the desired compound. ESI-MS m/z 534.6 (M+l)⁺; Rétention time: 1.23 minutes.

The following compounds can be synthesized using the procedures described

1132 herein :

N-[(3R)-3-[(4-i^butoxyphenyl)methylamino]pyrrolidin-l-yl]sulfonyl-2-[(4S)-2,2,4trimethylpyrToUdin-l-yl]pyridine-3-caiboxamide (Compound 2698), /V-[[3-[(4-reri-butoxyphenyl)methylamino]-l-piperidyI]sulfonyl]-2-[(45)-2,2,4trimethylpyrroIidin-l-yl]pyridme-3-caiboxamide (Compound 2697),

V-[(3/?)-3-[[4-fluoro-3-(trifluoromethoxy)phenyl]methylamino]pyrrolidin-l-yl]sulfonyl-2-[(45)2,2,4-trimethylpyrrolidin-l-y l]pyridine-3-carboxamide (Compound 2681),

A4(3R)-3-[3-(4-chlorophenyI)propylamîno]pyrrolidin-l-yl]sulfonyl-2-[(45)-2,2,4trimethylpynOlidin-l-yl]pyridine-3-carboxamide (Compound 2717) and

AH(3A)-3-[(2,4-dichIorophenyl)methylamino]pyrrolidin-l-yl]sulfonyl-2-[(4S)-2,2,4trimethyl_Pym)lidin-l-yl]pyridine-3-carboxamide (Compound 2693)

PREP A RATION 137: 6-(3-fluoro-5-isobutoxy-phenyl)-Ai-(3-piperidylsuIfonyl)’

2-[(45)-2,2,4-trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2655)

Step 1: 6-(3-fluoro-5-isobutoxy-phenyl)-2-[(45)-2,2,4-trimethylpyrroIidin-lyi]pyridine-3-carboxylic acid

A mixture of 2-chloro-6-(3-fluoro-5-ricbutoxy-phenyl)pyridine-3-carboxyIic acid (1.5 g, 3.6 mmol), (45)-2,2,4-trimethyIpyrrolidine (HCl sait) (0.8 g, 5.8 mmol), K₂CO₃ (1.6 g, 11.6 mmol), and CsF (1.1 g, 7.5 mmol) in DMSO (5 mL) was stirred at 130 °C for two days. The reaction mixture was diluted with water, adjusted to pH 4 with 1 M HCl, and extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel chromatography with 0-6% methanol in dichloromethane to give 6-(3-fluoro-5-riobutoxy-phenyl)-2-[(45)-2,2,4trimethylpyrroIidin-I-yl]pyridine-3-carboxylic acid (1.2 g, 82%) as a tan foam. ESI-MS m/z cale. 400.21622, found 401.0 (M+l)⁺; Rétention time: 1.92 minutes (3 min).

1133

Step 2: 6-(3-fluoro-5-Aobutoxy-phenyl)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide

A solution of 6-(3-fiuoro-5-wobutoxy-phenyl)-2-[(45)-2,2,4-trimethy Ipyrrolidinl-yI]pyridine-3-carboxylic acid (120 mg, 0.3 mmol) and CDI (73 mg, 0.5 mmol) in DMF (1.5 mL) was stirred at45 °C for 30 minutes, and ammonium hydroxide (525 pL of 30 %w/v, 4.5 mmol) was added. The reaction mixture was stirred at 45 °C for three days, diluted with water, and extracted with ethyl acetate. The combined extracts were washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography with 0-5% methanol in dichloromethane to give 6-(3-fluoro-5Aobutoxy-phenyI)-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (82 mg, 68%). ESI-MS m/z 400.5 (M+l )⁺; Rétention time: 1.78 minutes (3 min).

Step 3: 6-(3-fluoro-5-Aobutoxy-phenyl)-77-(3 -piperidylsulfonyl)-2-[(45)-2,2,4trimethylpyrroIidin-l-yl]pyridine-3-carboxamide (Compound 2655)

A solution of 6-(3-fluoro-5-/.wbutoxy-phenyl)-2-[(45)-2,2,4-trimethylpyrrolidinl-yl]pyridme-3-carboxamide (32 mg, 0.1 mmol) and NaH (5 mg, 0.1 mmol) in DMF (800 pL) was stirred for 30 minutes, and benzyl 3-chlore sulfonylp iperidin e-1 -carboxylate (51 mg, 0.2 mmol) was added. The reaction mixture was stirred for 16 hours. The reaction was filtered and purified using a reverse phase HPLC-MS method using a Luna Cl 8 (2) column (75 x 30 mm, 5

1134

P^m particle size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH3CN). The intermediate and palladium (10 mg, 0.01 mmol) (10% on carbon) in MeOH was stirred under a hydrogen atmosphère for 17 hours. The re action was fîltered and purified using a reverse phase HPLC-MS method using a LunaC18 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give the desired compound. ESI-MS m/z 547.6 (M+l)⁺; Rétention time: 1.65 minutes (3 min)

6-(3-fluoro-5-iiobutoxy-phenyl)-N-pyrrolidin-3-yIsulfonyl-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2042),

N-cyclopentylsulfony 1-6-(3-fluoro-5-riobutoxy-phenyl)-2-[(45)-2,2,4-trimethylpyrrolidm-lyl]pyridine-3-carboxamide (Compound 2113),

6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[[(3Æ)-3-piperidyl]sulfamoyI]-2-[(45)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 2677),

6-(3-fluoro-5-wobutoxy-pheny!)-A-(3-pyridylsulfamoyI)-2-[(45)-2,2,4-trimethylpynOlidm-lyl]pyridine-3-carboxamide (Compound 1448) and

6-(3-fluoro-5-Nobutoxy-phenyl)-A^r-[(2-methoxy-3-pyridyl)sulfamoyl]-2-[(45)-2,2,4trimethy]pyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1359).

PREPARATION 138: N-[(6-amino-2-pyridyl)su]fonyI]-5-fluoro-6-(3-fluoro-5riobutoxy-pheny 1)-2-[(45)-2,2,4-trimethylpyrrolid in-l-yl]pyridine-3-carboxamide (Compound 2473)

1135 (3^jfluoro-5-isobutoxy-phenyl)boronic acid (5 mg, 0.02 mmol), A-[(6-amino-2pyridyI)sulfonyl]-6-chloro-5-fluoro-2~[(4S)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3carboxamide (10 mg, 0.02 mmol), l,3-bis(2,6-difropropylphenyl)-4,5-dihydroimidazole; 3chloropyridine; dichloropalladium (3 mg, 0.005 mmol) and K₂CO₃ (3 mg, 0.02 mmol) were combined in N-propanol (0.5 mL). The reaction mixture was heated to 90 °C for 16 h under an atmosphère of nitrogen. The réaction mixture was filtered and purified by reverse phase HPLC using 1-99% ACN in water (0.05% HCl modifier) over 15 minutes to give the desired compound as apale solid. 1H NMR (400 MHz, DMSO-d6) δ 12.62 (s, 1H),7.73 (d, J = 11.2 Hz, 1H),7.36 (s, 1H), 7.24 (dd, J = 15.0, 8.6 Hz, 2H), 6.96 (dt, J = 10.9, 2.5 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.53 (s, 1H), 3.82 (d, J = 6.6 Hz, 2H), 2.59 (p,J= 10.2 Hz, 2H), 2.22 (s, 1H),2.O7 - 1.98 (m, 1H), 1.87 (dd, J = 12.0,5.7 Hz, 1H), 1.54 (d, J = 6.6 Hz, 6H), 1.41 (t, J = 12.1 Hz, lH),0.98 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H).1H NMR (400 MHz, DMSO-d6) δ 12.62 (s, 1H), 7.73 (d, J = 11.2 Hz, 1H), 7.36 (s, 1H), 7.24 (dd, J = 15.0, 8.6 Hz, 2H), 6.96 (dt, J = 10.9, 2.5 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.53 (s, IH), 3.82 (d, J = 6.6 Hz, 2H), 2.59 (p, J = 10.2 Hz, 2H), 2.22 (s, 1 H), 2.07 - 1.98 (m, 1H), 1.87 (dd, J = 12.0,5.7 Hz, 1H), 1.54 (d, J = 6.6 Hz, 6H), 1.41 (t, J = 12.1 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H).

PREPARATION 139:A^r-[(3A)-3-aminopyrrolidin-l-yl]sulfonyI-6-(3-fIuoro-5isobutoxy-phenyl)-2-(2-phenylpyrrolidin-l-yl)pyridîne-3-carboxamide (Compound 2477)

Step 1: 6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-phenylpyrrolidin-l-yl)pyridine-3carboxylic acid

A mixture of2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxyIic acid (227 mg, 0.7 mmol), 2-phenylpyrrolidine (206 mg, 1.4 mmol), CsF(213 mg, 1.4 mmol), and K₂CO₃ (194 mg, 1.4 mmol) in DMSO ( 3.5 mL) was stirred at 120 °C for 16 hours. The reaction mixture was diluted with water, adjusted to pH 4 with 1 M HCl, and extracted with ethyl acetate (2 x). The combined ex tracts were washed with brine, dried over sodium sulfate, and evaporated

1136 under reduced pressure, The residue was purified by silica gel column chromatography with 05% methanol in dichloromethane to give 6-(3-f]uoro-5-isobutoxy-phenyl)-2-(2-phenylpyrrolidinl-yl)pyridine-3-carboxylic acid (190 mg, 62%). ESI-MS m/z 435.5 (M+i)⁺; Rétention time: 0.9 minutes (3 min).

Step 2: A4(3R)-3-aminopyrrolidjn-l-yl]sulfonyl-6-(3-fluoro-5-isobutoxyphenyl)-2-(2-phenylpyrroIidin-l -y l)pyridine-3-carboxamide (Compound 2477)

A solution of 6-(3-fIuoro-5-isobutoxy-phenyl)-2-(2-phenyIpyiTolidin-lyl)pyridine-3-carboxylic acid (43 mg, 0.1 mmol) and chlorosulfonyl isocyanate (11 uL,0.1 mmol) in dichloromethane was stirred for 30 minutes, and zerz-buty] A-[(3Æ)-pyrrolidin-3yl]carbamate (27 mg, 0.2 mmol) and triethylamine (21 uL, 0.2 mmol) were added. The reaction mixture was stirred for 16 hours, and HCl (4M in dioxane) ( 200 uL, 0.8 mmol) was added. After stirring for four hours, the sovent was removed nnder reduced pressure, and the residue was purified using a reverse phase HPLC-MS method using a Luna Cl 8 (2) column (75 x 30 mm, 5 pm p article size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give N-[(3/?)-3aminopyrrolidm-l-yl]suIfonyl-6-(3-fluoro-5-isobutoxy-phenyl)-2-(2-phenylpynOlidm-lyl)pyridine-3-carboxamide (Compound 2477) (9 mg, 16%). ESI-MS m/z 582.6 (M+I)⁺; Rétention time: 1.82 minutes (3 min).

N-[(3R)-3-aminopyrrolidin-l-yl]sulfony]-2-(2-benzyl-2-methyl-pyrrolidin-l-yl)-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (Compound 2325)

PREPARATION 140: 3-(cyclopropylmethyl)-2,2-dimethyl-pyrrolidine

1137

Step 1: l-benzyL3-(cyclopropyImethyI)pynOlidin-2-one

l-Benzylpyrrolidin-2-one (5.0 g, 28.6 mmol) was dissoîved in THF (100 mL) and cooled to -78 °C. n-BuLi (2.5M, 13.7 mL, 34.3 mmol) was added dropwise at -78 °C and the reaction mixture was stirred at -78 °C for 30 minutes. (Bromo-methyl)cyclopropane (4.6 g, 34.3 mmol) was added and stirring continued at -78 °C for 30 minutes. The reaction mixture was allowed to reach RT slowly overnîght. The mixture was quenched with sat, aq. NH4CI and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptanes/EtOAc 2:1) affording l-benzyl-3-(cyclopropylmethyl)-pyrrolidin-2one (3.9 g, 60%) as a coloriess oil. 1H NMR (CDCI3, 300 MHz): 0.05 (m, 2H); 0.43 (m, 2H); 0.74 (m,IH); 1.22 (m, 1H); 1.68 (m, 1H); 1.76 (m, 1H);2.21 (m, 1 H); 2.55 (m, 1 H); 3.08 (m, 2H); 4.43 (q, 2H); 7.24 (m, 5H).

Step 2: l-benzyl-3-(cyclopropylmethyl)-2,2-dimethyl-pyrrolidine

ZrCL (3.96 g, 17.0 mmol) was added to THF (100 mL) at -10°C and the reaction mixture was stirred for 30 minutes. l-Benzyl-3-(cyclopropylmethyl)pyrrolidin-2-one (3.95 g, 17.0 mmol) was added as a solution in THF (10 mL). The reaction mixture was stirred for 10 minutes, then MeMgBr (3.0 M, 34 mL, 102 mmol) was added dropwise at 0°C. The reaction mixture was allowed to reach RT ovemight. It was quenched at 0°C with 30% aq. NaOH (20 mL) and stiired for 10 min. Water (100 mL) was added and the reaction mixture was extracted with CH₂C1₂ (2x). The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptanes/EtOAc 4:1) affording I-benzyl-3-(cyclopropylmethyl)-2,2dimethylpyrrolidine (2.0 g, 48%) as a coloriess oil. 1H NMR (CDCI3, 300 MHz): -0.03 (m, 1H);

1138

0.07 (m, 1 H); 0.42 (m, 2H); 0.66 (m, 1 H); 0.76 (s, 3H); 1.12 (s, 3H); 1.19 (m, 2H); 1.39 (m, 1 H);

1.90 (m, 1H);2.O3 (m, lH);2.32(m, IH); 2.85 (m, 1 H); 3.20 (d, lH);3.87(d, IH); 7.25 (m, 5H).

Step 3: 3-(cyclopropyImethyl)-2,2-dimethyl-pyrrolidine

l-Benzyl-3-(cycIopropylmethyl)-2,2-dimethyIpyrrolidine (2.0 g, 8.2 mmol) was dissolved in MeOH (100 mL) and conc. HCl (5 mL) was added. Pd/C (400 mg) was added and the reaction mixture was stirred over the weekend under 5 bars of H₂. The reaction mixture was fîltered over Celite and concentrated under reduced pressure affording 3-(cyclopropyImethyl)2,2-dimethyLpyrrolidine hydrochloride (1.3 g, 84%) as an off-white solid. IH NMR (CD₃OD, 300 MHz): 0.07 (m, IH); 0.13 (m, 1 H); 0.47 (m, 2H);0.72 (m, IH); 1.17 (s, 3H); 1.19 (m, IH); 1.34 (m, IH); 1.43 (s, 3H); 1.83 (m, IH); 2.01 (m, IH);2.38(m, IH); 3.26 (m, 2H). ESI-MS m/z cale. 153.15175, found 154.0 (M+l)⁺.

PREPARATION 141: N-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2[(45)-2,2,4-trimethylpyrroIidin-l-yI]pyridine-3-carboxamide

Step 1: V-(benzenesulfonyl)-2-chIoro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxamide

To a solution of tbe 2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3carboxylic acid (10.0 g, 30.89 mmol) in DMF (30.0 mL) at ambient température in a round bottom flask was slowly added carbon yldiimidazole (5.510 g, 33.98 mmol) portionwise and the mixture stirred for 100 min. Meanwhile to benzenesulfonamide (6.069 g, 38.61 mmol) in DMF (30.0 mL) (homogenous solution) in another round bottom flask was added NaHMDS in THF (38.61 mLof 1.0 M, 38.61 mmol) portionwise via syringe over 30-45 min and on completion of

1139 addition the mixture was stirred a further 30 min. The mixture containing the activated acid was then added to the mixture containing the deprotonated sulfonamide and the combined mixture was stirred 1 h. The reaction was cooled with a 0°C bath and quenched by addition of 12N aqueous HCl (11.58 mL) in portions over 2-3 minutes resulting in precipitated solids.

Transferred the reaction mixture to a separatory tunnel and ethyl acetate (100.0 mL) was added. Added IN aqueous HCl (20.0 mL) giving a pH = 2-3 then separated the layers and washed the organic layer with 5:1 water/saturated aqueous brine (120.0 mL), saturated aqueous brine (1 X 50mL, 1 X 30 mL), dried (sodium sulfate), filtered and concentrated under reduced pressure to a clear light yellow oil that was concentrated from isopropanol several more times resulting in précipitation of a solid. The solid was slurried ovemight in isopropanol then filtered and washed the solid with heptane (50 mL) and dried in vacuo giving A-(benzenesulfonyl)-2-chloro-6-(3fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (10.22 g, 22.08 mmol, 71.47%) as a white solid. ’H NMR (400 MHz, DMSO) δ 12.85 (s, 1H), 8.15 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.02 (dd, J = 5.3, 3.3 Hz, 2H), 7.76 (d, J = 7.4 Hz, 1H), 7.69 (t, J = 7.6 Hz, 2H), 7.51 - 7.43 (m, 2H), 6.99 (dd, J = 10.8, 2.3 Hz, 1H), 3.85 (d, J = 6.5 Hz, 2H), 2.04 (dt, J = 13.3, 6.6 Hz, 1H), .00 (d, J = 6.7 Hz, 6H). ESI-MS m/z cale. 462.08163, found 463.19 (M+l)⁺; Rétention time: 2.93 minutes [5 minute method],

Step 2: 7V-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxy-phenyl)-2-[(45)-2,2,4trimethylpyiTolidin-1 -yI]pyridine-3-carboxamîde

To a round bottom flask outfitted with a reflux condenser was added N(benzenesulfonyl)-2-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxamide (10.0 g, 21.60 mmol) and NMP (40 mL) and stirring was commenced. Warmed to 50°C and began portionwise addition of potassium carbonate (5.970 g, 43.20 mmol) followed by (45)-2,2,425 trimethylpyrrolidine (4.890 g, 43.20 mmol) in one portion. After stirring for 10 min, heated the mixture to 125°C for 65 h, then cooled to I0°C and added IN aqueous HCl (50.0 mL, 50.00 mmol) in portions to givepH 1-2 and a precipitated solid. Added ethyl acetate (100.0 mL) to dissolve solid and diluted the aqueous layer with water (50.0 mL) and stirred for 10 min. The

1140 mixture was transferred to a separatory funnel and layers were allowed to separate. Added aqueous IN HCl dropwise until ail solids were dissolved. Separated the layers and the aqueous layer was back extracted with ethyl acetate (50.00 mL) followed by combination of the organic layers. To the combined organic layers was added water (50.00 mL) giving an émulsion which was clarified by the addition of IN aqueous HCl (25.00 mL). Separated the layers then the organic layer was washed with saturated aqueous brine (50.00 mL), dried over Na₃SO₄, filtered through celite and rinsed with ethyl acetate (30.00 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel chromatography using a gradient from 100% hexanes to 50% EtOAc giving a light amberoil which was evaporated from isopropanol several times under reduced pressure providing A-(benzenesulfonyl)-6-(3-fluoro-5-isobutoxyphenyl)-2-[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (9.73 g, 18.03 mmol, 83.5%) as a yellow solid. ’H NMR (400 MHz, DMSO-d6) δ 12.57 (s, IH), 8.16-7.88 (m, 2H), 7.82-7.57 (m, 4H), 7.47 (t, J = 1.8 Hz, IH), 7.40 (dt, J = 9.9, 2.0 Hz, IH), 7.27 (d, J = 8.1 Hz, IH), 6.89 (dt, J = 10.8, 2.3 Hz, IH), 3.83 (d, J = 6.6 Hz, 2H), 2.48-2.28 (m, 2H), 2.07 (dtt, J = 26.6, 13.4,6.4 Hz, 2H), 1.83 (dd, J = 11.9, 5.5 Hz, IH), 1.57 (d, J = 17.3 Hz, 6H), 1.38 (t, J = 12.1 Hz, IH), 1.04 (d, J = 6.1 Hz, IH), 0.98 (d, J = 6.7 Hz, 6H), 0.66 (d, J = 6.3 Hz, 3H). ESIMS m/z cale. 539.2254, found 540.0 (M+l)⁺; Rétention time: 3.25 minutes [5 minute method].

PREPARATION 142: A-[(2-ammo-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3pyridyl)-2 -((45)-2,2,4-trimethyIpyrrolidm-1 -y IJpyridîne- 3 -carboxamide

Step 1: Ethyl 2-chloro-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxylate

Ethyl 2,6-dichloropyridine-3-carboxylate (7.00 g, 31.81 mmol) and (6isopropoxy-3-pyridyl)boronic acid (5.04 g, 27.85 mmol) were combined and dissolved in éthanol (50.40 mL) and toluene (50.40 mL). A suspension of sodium carbonate (10.12 g, 95,47 mmol) in water (10.08 mL) was added. Under nitrogen, tetrakis(triphenylphosphine)palladium (1.103 g, 0.9547 mmol) was added. The reaction mixture was allowed to warm to 80°C and stirred for 2 h. The volatiles were removed under reduced pressure. The remaining solids were partitioned

1141 between water (75 mL) and ethyl acetate (75 mL). The organic layer was washed with saturated aqueous sodium chloride solution (lx 75 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The material was subjected to silica gel column chromatography using a gradient from 100% hexanes to 5% ethyl acetate in hexanes. Ethyl 2chloro-6-(6-isopropoxy-3-pyridyl)pyridme-3-carboxylate (3.95 g, 12.07 mmol, 43.33%) was obtained as a clear colorless oil. ’H NMR (400 MHz, DM S Ο) δ 8.91 (s, 1H), 8.37 (dd, J = 8.7, 2.3 Hz, 1 H), 8.30 (d,J = 8.1 Hz, 1 H), 8.10 (d, J = 8.1 Hz, 1 H), 6.89 (d, J = 8.7 Hz, 1 H), 5.34 (dt, J = 12.3,6.1 Hz, 1 H), 4.36 (q, J = 7.1 Hz, 2H), 2.51 (d, J = 1.7 Hz, 1H), 1.42 - 1.30 (m, 9H). ESI-MS m/z cale. 320.09277, found 321,2 (M+l)⁺; Rétention time; 0.72 minutes.

Step 2: 2-chIoro-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxylic acid

A solution of sodium hydroxide (2.594 g, 64,85 mmol) in water (20.80 mL) was added to a solution of ethyl 2-chIoro-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxyIate (4.16 g, 12.97 mmol) in isopropanol (20.8 mL) stirring at 90°C. The reaction mixture was stirred at 90°C for 30 min. After cooling to room température, the reaction mixture was diluted with ethyl acetate (75 mL) and extracted with saturated aqueous sodium bicarbonate (lx 75 mL) and aqueous NaOH (1 N, 5 x 50 mL). The aqueous layers were combined and acidified to pH = 1 with the addition of aqueous 6 N HCI. The white précipita te that foimed was collected by vacuum filtration and rinsed with aqueous 1 N HCl to provide 2-chloro-6-(6-isopropoxy-3pyridyl)pyridine-3-carboxylic acid (4.2446 g, 12.89 mmol, 99.43%) as a white solid. ESI-MS m/z cale. 292.06146, found 293.1 (M+l)⁺; Rétention time; 0.59 minutes.

Step 3: 2-aminopyridine-3-sulfonamide

Ammonium hydroxide (590.3 mL of28 %w/v, 4.716 mol) was stirred and cooled in an ice bath. 2-chloropyridme-3-sulfonyl chloride (50 g, 235.8 mmol) was dissolved in

1142 dichloromethane (150 mL) and added dropwise to the stirred ammonia solution to maintain a température between 5-12°C. On completion of addition, the mixture was stirred 1 h, Stirring was halted and the resulting layers were separated. Concentrated the aqueous layer under vacuum to remove ammonia resulting in a white solid precipitate which was collected by filtration and washed with water. The material was dissolved in ammonium hydroxide (236.1 mL of 28 %w/v, 1.886 mol) and heated in a pressure vessel at 100°C ovemight then reaction température was increased to 150°C and stirred ovemight. The mixture was cooled to room température resulting in a precipitate then concentrated under vacuum to remove ammonia resulting in a white solid precipitate which was collected by filtration and washed with methyl ieri-butyl ether (100 mL) to give 2-aminopyridine-3-sulfonamide (25.73 g, 148.6 mmol, 63.00%) ESI-MS m/z cale. 173.0259, found 174.0 (M+l)⁺.

Step 4: A-[(2-amino-3-pyridyl)suIfonyl]-2-chloro-6-(6-isopropoxy-3pyridyl)pyri dine-3 -carboxamide

To a solution of 2-aminopyridine-3-sulfonamide (4.068 g, 23.49 mmol) in DMF (38.50 mL) (homogenous solution) in a round bottom flask was added NaH (939.5 mg, 23.49 mmol) portionwise giving an off-white thick sluny and a slight exotherm from 20°C to 32°C during addition. The mixture was stirred at ambient température for 30 min. Meanwhile, to a solution of 2-chIoro-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxylic acid (5.5 g, 18.79 mmol) in DMF (38.50 mL) at ambient température in another round bottom flask was slowly added carbonyldiimidazole (3.352 g, 20.67 mmol) portionwise and the mixture stirred for 20 min over which time it became a light yellow homogenous solution which was then added to the reaction mixture containing the deprotonated sulfonamide. During the addition the mixture stayed homogenous with a slight exotherm to 31°C. The combined mixture was stirred at ambient température affording a dark orange homogenous mixture and after 5 min was slowly added to chilïed HCl (93.95 mL of 1 M, 93.95 mmol) (slightly exothermic) giving a pH of ~L The mixture afforded a precipitate and the sluny was stirred for 60 min at ambient température. The mixture was then filtered and the solid was washed three times with 50 mL of water. The solid

1143 was then washed three times with 50 mL of isopropanol giving an off-white solid that was air dried for 1 h. The solid was next slurried in 50 mL of isopropanol and the precipitate was filtered and washed three times with 5 mL of isopropanol. The off-white solid obtained was air dried for 2 h, then in vacuo at 45°C for 48 h giving A4(2-amino-3-pyridyI)sulfonyI]-2-chloro-6(6-isopropoxy-3-pyridyI)pyridine-3-carboxamide (8.0 g, 17.86 mmol, 95.06%) *H NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 2.5 Hz, IH), 8.33 (dd, J = 8.7, 2.6 Hz, IH), 8.24 (dd, J = 5.1, 1.8 Hz, IH), 8.13 - 8.00 (m, 3H), 6.96 (s, 2H), 6.88 (d, J = 8.7 Hz, IH), 6.83 (dd, J = 7.8, 5.0 Hz, IH), 5.33 (hept, J - 6.3 Hz, IH), 1.32 (d, J = 6.2 Hz, 6H). ESI-MS m/z cale. 447.0768, found 448.18 (M+l)⁺; Rétention time: 1.55 minutes.

Step 5: 7V-[(2-amino-3-pyridyl)sulfonyl]-6-(6-isopropoxy-3-pyridyl)-2-[(45)2,2,4-trime thylpyrrolid in-l-yl]pyridine~3-carboxamide

A vial equipped with magnetic stir bar was charged with /V-[(2-ammo-3pyridyI)sulfony]]-2-chloro-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxamide (147.8 mg, 0.330 mmol), (45)-2,2,4-trimethylpyrrolidine (74,71 mg, 0,660 mmol) and potassium carbonate (228.0 mg, 1.65 mmol) in DMSO (739 pL). The vial was sealed and stirred at 120°C for 16 hours then at ]40°C for 30 hours. The reaction mixture was cooled, diluted with minimal DMSO and methanol and filtered. The filtrate was purified directly using a reverse phase HPLC-MS method using a Lun a C18 (2) column (75 x 30 mm, 5 pm particle size) sold by Phenomenex (pn: 00C4252-UO-AX), and a dual gradient run from 1-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN, flow rate = 50 mL/min, injection volume = 950 pL and column température = 25 °C) giving A4(2-amino-3-pyridyl)sulfonyl]-6(6-isopropoxy-3-pyridyI)-2-[(45)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (25.2 mg, 0.048 mmol, 14.6%). *H NMR (400 MHz, DMSO) δ 12.49 (s, IH), 8.84 (d, J = 2.4 Hz, IH), 8.31-8.27 (m, IH), 8.25 (dd, J = 7.4,4.4 Hz, IH), 8.03 (dd,J = 7.9, 1.7 Hz, 1 H), 7.75 (d, J = 8.0 Hz, IH), 7.20 (d,J = 8.0 Hz, 1 H), 6.86 (d, J = 8.7 Hz, 1 H), 6.77 (dd, J = 7.8, 4.8 Hz, 1 H), 6.69 (s, 2H), 5.37-5.26 (m, 1H),2.52 (s, IH), 2.14 (s, IH), 1.85 (dd,J = 11.9,5.5 Hz, IH), 1.58 (d, J = 10.7 Hz, 6H), 1.39 (t, J= 12.1 Hz, IH), 1.31 (d, J = 6.2 Hz, 6H), 1.26 (d, J = 13.3 Hz, IH), 0.86

1144 (t, J = 6.9 Hz, 1H), 0.76 (d, J = 6.3 Hz, 3H). ESI-MS m/z cale. 524.2206, found 525.3 (M+l)*;

Rétention time: 1.38 minutes.

A-[(2-amino-6-methoxy-3-pyridyl)sulfonyl]-6-(6-wopropoxy-3-pyridyl)-2-[(4S)-2,2,4’ trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2692),

A-[(2-amino-3-pyridyl)sulfonyl]-2-[(45)-3,3-dideuterio-2,2-dimethyl-4(trideuteriomethyl)pyrrolidin-l-yl]-6-(6-isopropoxy-3-pyridyl)pyridine-3-carboxamide (Compound 1543) and

A-[(6-amino-2-pyridyl)sulfonyl]-2-[(2R,55)-2,5-dimethylpyrrolidin-l-yl]-6-[6-[l,2,2,2tetradeuterio-l-(trideuteriomethyl)ethoxy]-3-pyridyl]pyridine-3-carboxamide (Compound 2714)

PREPARATION 143: 6-[3-(2,2-dimetbylpropoxy)pyrazol-l-yl]-A-[[6-(lpiperidyl)-2-p yri dy IJsulfonyl]-2-[(45)-2,2,4-trime thylpynolidin-l-yl]pyridine-3-carboxamide (Compound 484)

Step I: 6-(I-piperidyl)pyridine-2-sulfonamide

To 6-fluoro-2-pyridinesulfonamide (215 mg, 1.220 mmol) was added piperidine (312 mg, 362 pL, 3.66 mmol) and the reaction mixture was heated at 90 °C for 2.5 hours. The reaction mixture was cooled and resulting solid was dried.1 H NMR (400 MHz, DMSO-d6) δ 7.66 (dd, 1 = 8.8,7.2 Hz, 1 H), 7.03 (d,J = 7.2 Hz, 1 H), 6.98 (d, J = 8.6 Hz, 1 H), 2.75 (d,J = 5.5 Hz, 3H), 1.61 (p, J = 3.4, 2.9 Hz, 2H), 1.54 (dd, J = 7.0, 3.9 Hz, 3H), 1.49 (s, 4H). ESI-MS m/z found 242.2 (M+l )⁺; Rétention time: 0.45 minutes.

Step 2: 2-chloro-6-(3-(neopentyloxy)-lA-pyrazol-l-yI)-A-((6-(piperidin-lyl)pyridin-2-yl)suIfonyl)nicotinamide

1145

To 2-chloro-6-[3-(2_:2-dimethylpropoxy)pyrazo]-l-y]]pyridine-3-carboxylic acid (100 mg, 0.323 mmol) in DMF (0.6 mL) at room température was added carbonyl diimidazole (78.5 mg, 0.484 mmol) and the reaction mixture was stirred for 40 minutes. Separately 6-(l5 piperidyl)pyridine-2-sulfonamide (93.5 mg, 0.387 mmol) in DMF (0.6 mL) was cooled to 0 °C and treated with sodium hydride (15.5 mg, 0.387 mmol) and stiired for 10 min and then at room température for 30 min. The reaction mixtures were then combined and stirred at room température for 30 min. The reaction mixture was cooled to 0 °C and acetic acid (194 mg, 184 pL, 3.23 mmol) was added followed by HCL (269 pL of 6 Μ, 1.61 mmol) and the reaction mixture was diluted with EtOAc (5 mL) and the layers were separated. The organics were dried and concentrated under reduced pressure to give a residue which was purified by silica gel column chromatography and eluted with 0-14% MeOH-DCM to give 2-chIoro-6-[3-(2,2dimethylpropoxy)pyrazol-l-yl]-7V-[[6-(l-piperidyl)-2-pyridyl]sulfonyl]pyridine-3-carboxamide (158 mg, 82%) ESI-MS m/z found 533.2 (M+1 )⁺; Rétention time: 0.89 minutes ( 1 min); IH

NMR (400 MHz, DMSO-d6) δ 8.44 - 8.38 (m, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.95 (s, 1H), 7.79 7.70 (m, 2H), 7.23 (d, J = 7.2 Hz, 1H), 7.12 (d, J = 8.7 Hz, 1H), 6.22 (t, J = 2.5 Hz, 1H), 3.93 (d, J = 1.2 Hz, 2H), 3.59 (t, J = 5.4 Hz, 3H), 1.66 - 1.58 (m, 2H), 1.53 (td, J = 10.2,4.8 Hz, 3H), L00(s, 9H).

Step 3: 6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-ZV-[[6-(l-piperidyl)-220 pyridyl]sulfonyl]-2-[(45)-2,2,4-trimethyipyrrolidin-l-yl]pyridine-3-carboxamide (Compound 484)

1146

A mixture of 2-chloro-6-[3-(2,2-dimethylpropoxy)pyrazol-I-yl]-A^r-[[6-(l-piperidyl)-2pyridyl]sulfonyl]pyridine-3-carboxamide (140 mg, 0,223 mmol), potassium carbonate (185 mg, 1.34 mmol) and (45)-2,2,4-trimethylpyrrolidine (HCI sait) (75 mg, 0.501 mmol) in DMSO (744 5 pL) was heated at 150 °C for 5 h. The reaction mixture was cooled, diluted with EtOAc and the aqueous and organic layers were separated. The organics were washed with brine, dried, concentrated under reduced pressure and the resulting residue was purified by silica gel column chromatography eluting with 0-15% MeOH-DCM to give 6-[3-(2,2-dimethylpropoxy)pyrazoll-yl]-N-[[6-(l-pipendyl)-2-pyridyl]sulfonyl]-2-[(45)-2,2,4-trimetIiylpynOlidm-l-yl]pyridine-310 carboxamide (Compound 484) (38 mg, 28%). ESI-MS m/z cale 609.31, found 610.1 (M+l )⁺;

rétention time 2.1 min (3 min run); 1H NMR (400 MHz, Methanol-d4) 5 8.25 (d, J = 2.S Hz,

H), 7.88 (d, 1 = 8.3 Hz, 1H),7.69 (dd, J = 8.7, 7.2 Hz, 1H),7.31 (d, J = 7.2 Hz, 1H),6.98 (dd, J = 8.5,6.5 Hz, 2H), 5.99 (d, J = 2.8 Hz, 1H),3.9O (s, 2H),3.63 (q, J = 6.1, 5.3 Hz,4H), 2.802.66 (m, 2H), 2.26 (d, J = 10.4 Hz, 1H), 1.90 (dd, J = 11.9, 5.6 Hz, 1H), 1.68 (q, J = 5.1,4.7 Hz, 15 2H), 1.61 (d, J = 5.3 Hz, 10H), 1.47 (t, J = 12.2 Hz, 1H), 1.04 (s, 9H), 0.88 (d, J = 6.3 Hz, 3H).

The following compound can be synthesized using the procedures described herein :

6-[3-(2,2-dimethylpropoxy)pyrazol-l-yl]-7V-[[2-(l-piperidyl)-3-pyridyl]sulfonyl]-2-[(45)-2,2,4trimethyIpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2670)

PREPARATION 144: N-[(6-ammo-2-pyridyl)sulfonyl]-3-(3-fluoro-5-isobutoxyphenyl)-5-[(45)-2,2,4-trimethylpyrroIidin-] -yI]pyrazine-2-carboxamide (Compound 2673)

1147

Step 1: 3,5-dich!oroW-[(6-nitro-2-pyridyl)sulfonyl]pyrazine-2-carboxamide

o

To a stirred heterogeneous mixture of 3,5-dichloropyrazine-2-carboxylic acid (2.21 g, 1 ] .5 mmol) in anhydrous CH₂C1₂ (20 mL), thionyl chloride (7.5 mL, 103 mmol) was added under an atmosphère of nitrogen, followed by anhydrous DMF (30 mg, 0.41 mmol) and the reaction mixture was stirred at room température for 1 hour. The reaction mixture was evaporated, dissoived in CH₂C1₂ (40 mL) and added dropwise to a solution of 6mitropyridine-2sulfonamide (2,32 g, 11.5 mmol) with triethylamine (8.5 mL, 61.0 mmol) at 0 °C, stirred ovemight (24 h) while allowing to warm to ambient température. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between CH₂Cl₂ (10 mL) and ice-water (200 mL) and acidifïed with 2 M HCi to pH about 4.0. The resulting solid was filtered, the layers separated and the aqueous layer was extract with CH₂C1₂ (3 x 50 mL). The combined organics were washed sequentially with IN HCl, saturated sodium chloride solution then dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude material was purified by triturating with dichloromethane (10 mL), filtration and drying to give 3,5-dichloroA4(6-nitro-2-pyridyl)suIfonyl]pyrazine-2-carboxamide (2.90 g, 67%) as a white solid. ESI-MS m/z cale. 376.93884, found 378.0 (M+l)⁺; Rétention time: 0.6 minutes.

Step 2: 7V-[(6-amino-2-pyridyl)sulfonyl]-3,5-dichloro-pyrazine-2-carboxamide

²⁰ To a solution of 3,5-dichloroW-[(6-nitro-2-pyridyl)sulfonyl]pyrazine-21148 carboxamide (830 mg, 2.20 mmol) in THF (8 mL) and EtOH (4 mL), iron (Fe) powdér (613 mg, 11.0 mmol) was added, followed by HCl (6 N) (1.8 mL of 6.0 M, 10.80 mmol). The reaction mixture was heated at 60 °C for 15 min. After cooling to room température, the réaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was diluted ’5 with EtOAc (50 mL) and washed with NaOH (4 mL, 1 N). The layers were filtered again and the aqueous layer was acidified to pH 2 with the addition of 1 N HCl (aq) and extracted with EtOAc (2 x 50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified from by silica gel column chromatography using 0-20 % MeOH in CH₂C1₂ as eluent to give /V-[(6-amîno-210 pyridyl)sulfonyl]-3,5-dichloro-pyrazine-2-carboxamide (404 mg, 53%) ESI-MS m/z cale.

346.96466, found 348.0 (M+1 )⁺; Rétention time: 0.53 minutes.

Step 3: /V-[(6-amino-2-pyridyl)sulfonyl]-5-chloro-3-[(4S)-2,2,4trimetbylpyrrolidin-1 -yl]pyrazine-2-carboxamide and (3)-/7-((6-aminopyridin-2-yl)sulfonyl)-3chloro-5-(2,2,4-trimethylpyrrolidin-l-yl)pyrazine-2-carboxamide

To a solution of A^r-[(6-amino-2-pyridyl)sulfonyl]-3,5-dichIoro-pyrazme-2carboxamide (36 mg, 0.10 mmol) in DMSO (142 pL), DIE A (90 pL, 0.52 mmol) and (43)2,2,4-trimetbylpyrrolidine (32 mg, 0.26 mmol) was added. The reaction mixture was stirred for 6 hours at 85 °C. The cooled reaction was purified via reverse phase HPLC-MS method using a dual gradient run from 15-99% mobile phase B over 15.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = acetonitrile) to yield a mixture ofA^r-[(6-amino-2-pyridyl)sulfonyl]5-chloro-3-[(4S)-2,2,4-trimethyIpyrrolidin-l-yl]pyrazine-2-carboxamide and (S)W-((6aminopyridm-2-yl)sulfonyl)-3-chloro-5-(2,2,4-trimethylpyrrolidin-l-yl)pyrazine-2-carboxamide (28 mg, 64%) ESI-MS m/z cale. 424.10843, found 425.2 (M+l)⁺.

1149

Step 4: 7/-[(6-amino-2-pyridyl)sulfonyl]-3-(3-fluoro-5-isobutoxy-phenyl)-5-[(45)2,2,4-trimethylpyrrolidin-l -yl]pyrazine-2-carboxamide (Compound 2673) ci

H

To a solution of N-[(6-amino-2-pyridyl)sulfonyl]-5-chloro-3-[(48)-2,2,4tri methy Ipyrrolidin -1 -yi]pyrazine-2-carbo xamide (5)-77-((6 -aminopyridin-2-yl) su lfonyl)-3chloro-5-(2_i2,4-trimethylpyrrolidin-l-yl)pyrazine-2-carboxamide (60 mg, 0.14 mmol) and (3fluoro-5-isobutoxy-phenyl)boronic acid (60 mg, 0.28 mmol) in dioxane (3.0 mL) were added H₂O (1.0 mL), K₂CO₃ (78 mg, 0.56 mmol) and bis(2-diphenyIphosphanylcyclopenta-2,4-dienl-yl)iron; dichloropalladium [Cl₂Pd(dppf).CH₂C12] (8 mg, 0.011 mmol). Nitrogen was bubbled for 5 min and the reaction mixture was sealed and stirred at 120 °C under micro wave radiation for 30 min. The reaction mixture was allowed to cool to ambient température, filtered through a and purified via reverse phase HPLC-MS (using a Luna Cl8 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient nin from 30-99% mobile phase B over 30.0 minutes; mobile phase A= H₂O (5 mM HCl), mobile phase B = CH₃CN) to fumish 77-[(6-amino-2pyridyl)su]fonyl]-3-(3-fluoro-5-isobutoxy-phenyl)-5-[(45)-2,2,4-trimethylpyrrolidin-iyl]pyrazine-2-carboxamide (Compound 2673) (5.7 mg, 6%) as off-white solid. 1H NMR (400 MHz, DMSO-d6) δ 11.58 (s, 1H),7.89 (s, 1 H), 7.62 - 7.53 (m, 1 H), 7.11 (d,J = 7.3 Hz, 1H), 6.88 - 6.79 (m, 2H), 6.75 - 6.69 (m, IH), 6.66 (d, J = 8.3 Hz, 1H), 6.52 (s, 2H), 3.83 (t, J = 9.1 Hz, 1 H), 3.74 (d, J = 6.5 Hz, 2H), 3.12 (t,J = 10.4 Hz, 1H), 2.47 -2.35 (m, 1H), 2.02 (dd, J = 12.8,6.3 Hz, 2H), 1.61 (d, J = 12.2 Hz, 1H), 1.56 (s, 3H), 1.45 (s, 3H), 1.10 (d, J = 6.4 Hz, 3H), 0.96 (d, J = 6.8 Hz, 6H). ESI-MS m/z cale. 556.2268, found 557.4 (M+l)⁺; Rétention time: 2.15 minutes.

PREPARATION 145: 77-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-ii'c>butoxypheny])-4-[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2679) Step 1: 4-chloro-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylic acid

1150

To 6-bromo-4-chloro-pyridine-3-carboxylic acid (205 mg, 0.865 mmol), (3fluoro-5-isobutoxy-phenyl)boronic acid (184 mg, 0.865 mmol), and palladium ;triphenylphosphane (30.0 mg, 0.0260 mmol) in dioxane (4 mL) was added solution of potassium carbonate (1.73 mL of 2 M, 3.46 mmol) under an atmosphère of nitrogen and the reaction mixture was stirred at 80 °C for 10 h. The reaction mixture was concentrated under reduced pressure, partitioned between water (15 mL) and EtOAc (15 mL). The aqueous layer was acidified with HCl and washed with EtOAc (3 x 15 mL). The combined organic layers was washed with brine (Ix 25 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure, The solid obtained was washed with hexanes to give 4-chloro-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxylic acid (232 mg, 83%) as a tan solid. ESI-MS m/z cale.

323.07245, found 324.1 (M+l)⁺; Rétention time: 0.74 minutes.

Step 2: 4-chloro-6-(3-fluoro-5-isobutoxy-phenyl)-A^r-[(6-nitro-2pyridyl)sulfonyl]pyridine-3-carboxamide

4-chloiO-6-(3-fluoro-5-isobutoxy-phenyl)pyridine-3-carboxylic acid (104 mg, 0.32 mmol) and SOC1₂ (190 mg, 116 pL, 1.60 mmol) with a drop of DMF was stirred atambient température for 30 minutes. The volatiles were removed under reduced pressure. In another flask, 6-nitropyridine-2-sulfonamide (65 mg, 0.32 mmol) and TEA (97 mg, 134 pL, 0.96 mmol) in DCM (1.2 mL) was cooled in an ice-water bath. A solution of the acid chloride generated in

1151

I

DCM was added slowly. The reaction mixture was stirred in ice-water bath and allowed to reach room température. The reaction mixture was diluted with DCM, washed with IN HCl, saturated NaHCO3, and brine, The organics were separated and dried over sodium sulfate and evaporated under reduced pressure to give 4-chloro-6-(3-fluoro-5-zsobutoxy-phenyl)-A4(6-nitro-25 pyridyl)sulfonyl]pyridine-3-carboxamide (157 mg, 97%) ESI-MS m/z cale. 508.06195, found 509.1 (M+l)⁺; Rétention time: 0.74 minutes.

Step 3: A-[(6-amino-2-pyridyl)sulfonyl]-4-chloro-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide

4-chloro-6-(3-fluoro-5-Î5Obutoxy-phenyl)-N-[(6-nitro-2pyridyl)sulfonyl]pyridine-3-carboxamide (123 mg, 0.242 mmol) was dissolved in THF (615 pL) and EtOH (615 pL). Powdered Fe (135 mg, 2.42 mmol) with HCl (80.6 pL of 6 M, 0.483 mmol) was added. The reaction mixture was heated at 65 °C for 10 min. After cooling to room température, the reaction mixture was filtered, the fïltrate was diluted with EtOAc and washed with NaOH (4 mL, 1 N). The layers were filtered again and aqueous layer was acidified to pH 2 with the addition of aqueous HCl and extracted with EtOAc (1x8 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give /V-[(6-amino2-pyridy!)sulfonyl]-4-chloro-6-(3-fluoro-5-Nobutoxy-phenyl)pyridine-3-carboxamide (61 mg, 53%) as a yellow powder. ESI-MS m/z cale. 478.08777, found 479.1 (M+l )⁺; Rétention time:

0.69 minutes.

Step 4: A/-[(6-ammo-2-pyridyI)sulfonyI]-6-(3-fluoro-5-ijobutoxy-phenyl)-4-[(4S)2,2,4-trimethylpyrrolidin-l -yl]pyridine-3-carboxamide (Compound 2679)

1152

To a solution of A-[(6-amino-2-pyridyl)sulfonyI]-4-chloro-6-(3-fluoro-5isobutoxy-phenyl)pyridine-3-carboxamide (24 mg, 0.050 mmol) in DMSO (0.1 mL) was added CsF (23 mg, 0.15 mmol) and (45)-2,2,4-trimethylpyrrolidine (27 mg, 0.15 mmol). The reaction 5 mixture was sealed and stirred at 120 °C ovemight. The reaction mixture was cooled, diluted with DMSO and purified via HPLC/MS utilizing a gradient of 1-99% acetonitrile in 5 mM aq HCl to yield A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Aobutoxy-phenyi)-4-[(45)-2,2,4trimethy]pyiT01idin-l-yl]pyridine-3-carboxamide (Compound 2679) ( 5 mg, 19%). ESI-MS m/z cale. 555.23157, found 556.4 (M+l)⁺; Rétention time: 1.47 minutes.

PREPARATION 146: A-[(6-amino-2-pyridyl)sulfonyl]-6-(2-ethoxyethoxy)-2[(45)-2,2,4-irimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2678)

A-[(6-amino-2-_PyridyI)sulfonyl]-6-chloro-2-[(45)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 852) (25 mg, 0.059 mmol), 2-ethoxyethanol (53 mg, 57 pL, 0.59 mmol), NaH (7.0 mg, 0.29 mmol), and scandium(3+) trifiuoromethanesulfonate (2.9 mg, 0.0058 mmol) were dissolved in DMSO (0.5 mL) and heated at 120 °C for 8 h. The reaction mixture was partitioned between ethyl acetate and a IN aq HCl solution. The organics were separated, washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The crude mate ri al was purified by silica gel chromatography eluting with 0-100% ethyl acetate in hexanes to give A-[(6-amino-2-pyridyl)suIfonyl]-6-(2-ethoxyethoxy)-2-[(45)-2,2,4

1153 tnmethylpyrrolidin-l-yl]pyridine-3 -carboxamide (Compound 2678) (7 mg, 25%) ESI-MS m/z cale, 477.2046, found 478.4 (M+l)⁺ ; Rétention time: 1.25 minutes.

A-[(2-amino-3-pyridyl)sulfonyl]-6-methoxy-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridme-3carboxamide (Compound 2704),

A-[(2-amino-3-pyridyI)su]fonyl]-6-(2-ethoxyethoxy)-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2705) and

N- [(2-amino-3-pyridyl)sulfonyI]-6-[2-(2-ethoxyethoxy)ethoxy]-2- [(45)-2,2,4trimethyIpyrrolidin-l-y]]pyridine-3-caiboxamide (Compound 2706).

PREPARATION 147: A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-Lobutoxyphenyl)-2-(4-iodo-2,6-dimethyl-phenoxy)pyridine-3-carboxamide (Compound 2671)

To A-[(6-anuno-2-pyridyl)sulfonyl]-2-chloro-6-(3-fluoro-5-isobutoxyphenyl)pyridine-3-carboxamide (69 mg, 0.14 mmol) and 4-iodo-2,6-dimethyI-phénol (71 mg, 0.29 mmol) in NMP (4 mL) was added NaH (17 mg, 0.43 mmol). The reaction mixture was stirred for 5 min at rt then stirred at 150 °C for 2 h. The reaction mixture was quenched with NH₄C1 soin, the crude mixture purified by reverse phase silica gel column chromatography using 10-100% ACN in Water (TFA modifier) as eluent to give A-[(6-amino-2-pyridyl)sulfonyl]-6-(3fluoro-5-iiobutoxy-phenyl)-2-(4-iodo-2,6-dimethyl-phenoxy)py ri dine-3-carboxamide (Compound 2671) (8 mg, 7%). 1HNMR (300 MHz, CDC13)Ô 8.47 (d, J = 8.1 Hz, 1H), 7.76 7.68 (m, 1H), 7.64 (d, J = 7.3 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.47 (s,2H), 7.04 - 6.95 (m, 3H), 6.76 (d, J = 8.2 Hz, 1H), 6.63 (dt, J = 10.3, 2.2 Hz, 1H), 3.56 (t, J = 7.0 Hz, 2H), 2.13 - 2.06 (m, 6H), 1.01 (t, J = 6.6 Hz, 6H), 0.85 (t, J = 6.7 Hz, 3H), 0.47 (s, 1H). ESI-MS m/z found 691.4 (M+l)⁺; Rétention time: 0.83 minutes

The following compounds can be synthesized using the procedures described

1154 herein:

A^r-[(6-amino-2-pyridyl)su]fonylJ-2-(4-benzoyI-2,6-dimethyl-phenoxy)-6-(6-ijc>propoxy-3pyridyl)pyridine-3-carboxamide (Compound 2715) and

N-[(6-amino-2-pyridy0sulfonyl]-2-(4-benzoyl-2,6-dimethyl-phenoxy)-6-(3-fluoro-5-isobutoxy5 phenyl)pyridine-3-carboxamide (Compound 2669).

PREPARATION 148 : N- [(6-amino-2-pyridyl)sulfonyl] -2,6-bis(4-benzoyI -2,6dimethyl-phenoxy)pyridine-3-carboxamide (Compound 970)

To W[(6-amino-2-pyridyl)sulfonyl]-2,6-dichloro-pyridine-3-carboxamide (487 mg, 1.40 mmol) in DMF (4 mL) was added (4-hydroxy-3,5-dimethyI-phenyl)-phenyl-methanone (390 mg, 1.57 mmol) and NaH (140.3 mg, 3.508 mmol). The reaction mixture was stirred at rt for 20 min, then 150 °C for 1 hr. The crude mixture purified by reverse phase silica gel column chromatography using 0-80% ACN in Water (TFA modifier) as eluent, then further purified by silica gel column chromatography eluting with 30-100% EtOAc in heptane to give A4(6-amino15 2-pyridyi)sulfonyl]-2,6-bis(4-benzoyl-2,6-dimethyl-phenoxy)pyridine-3-carboxamide (Compound 970) (51 mg,4%). IH NMR (300 MHz, DMSO) δ 8.24 (dd, J = 15.6, 8.2 Hz, IH), 7.80-7.66 (m, 1 H), 7.66 - 7.39 (m, 10H), 7.31 - 7.22 (m, 4H), 7.11 (d, J = 7.2 Hz, 1 FI), 6.74 (t, J = 10.3 Hz, 1 H), 6.55 (d, J = 7.9 Hz, IH), 6.27 (s, 2H), 1.92 (d, J = 1.9 Hz, 12H); ESI-MS m/z found 727.5 (M+l)⁺; Rétention time: 0.68 minutes (4 min run).

²⁰ PREPARATION 149: A/-[(6-fluoro-2-pyridyl)sulfony]]-6-phenyl-2-(2,4,6- trimethylphenoxy)pyridine-3-carboxamide (Compound 698)

Step 1: Methyl 6-pheny]-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate

1155

A mixture of methyl 2-chloro-6-phenyl-pyridine-3-carboxylate (224 mg, 0.904 mmol), 2,4,6-trimethylphenoI (123 mg, 0.904 mmol), césium carbonate (295 mg, 0.904 mmol) and DMF (3.14 mL) was heated at 80 °C ovemight. The reaction mixture was cooled to room température before partitioned between ethyl acetate and 1N HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (2x). The combined organics were washed with brine, dried over magnésium sulfate, filtered and concentrated under reduced pressure. The résidu e was subjected to column chromatography (0-25% ethyl acetate/hexanes) to give methyl 6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (250 mg, 71 %). ESI-MS m/z cale. 347.15213, found 348.4 (M+l)⁺; Rétention time; 2.28 minutes (3 min run).

Step 2: 6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylic acid

Methyl 6-phenyi-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxylate (562 mg, 1.62 mmol) was dissolved in methanol (8 mL): THF (3 mL) and NaOH (8.09 mL of 1 M, 8.09 mmol) was added. The reaction mixture was heated at 65 °C for 3 h. The reaction mixture was poured over ice and acidified with 6M HCl. The resulting white solid was collected and then dissolved in methanol and evaporated under reduced pressure to give 6-phenyl-2-(2,4,6trimethylphenoxy)pyridine-3-carboxylic acid (466 mg, 86%) ESI-MS m/z cale. 333.1365, found 334.2 (M+l )⁺; Rétention time: 0.74 minutes.

Step 3: A^r-[(6-fluoro-2-pyridyl)sulfonyl]-6-phenyl-2-(2,4,6trimethyIphenoxy)pyridine-3-carboxamide (Compound 698)

1156

To 6-phenyl-2-(2,4,6-trimethylphenoxy)pyridjne-3-carboxylic acid (150 mg, 0.450 mmol), HATU (171 mg, 0.450 mmol), DMF (1.5 mL), and triethylamine (137 mg, 188 pL, 1.35 mmol) was added 6-fluoropyridme-2-sulfonamide (79.3 mg, 0.450 mmol) was added and the reaction mixture was allowed to stir at 65°C for 1 h. The reaction mixture was fïltered and purified via HPLC (l%-99%) ACN:H₂O with a 0.1% HCl modifier to give N-[(6-fluoro-2-pyridyl)sulfonyl]6-phenyl-2-(2,4,6-trimethylphenoxy)pyridine-3-carboxamide (Compound 698) (79 mg, 36%) 1H NMR (400 MHz, DMSO-d6) 6 8.37 (q, J = 7.8 Hz, 1H), 8.16 (dd, J = 7.5, 2.1 Hz, 1H), 8.12 (d, J =7.8 Hz, 1H), 7.80 - 7.73 (m, 3H), 7.59 (dd, J = 8.3, 2.2 Hz, 1H), 7.41 (ddt, J = 5.5, 3.8, 2.2

Hz, 3H), 6.94 (s, 2H), 2.28 (s, 3H), 2.01 (s, 6H). ESI-MS m/z cale. 491.1315, found 492.4 (M+l)⁺; Rétention time: 2.19 minutes.

PREPARATION 150: (S)-2,2-dimethyl-4-(methyl-d₃)pyrrolidine-3,3-d₂

Step 1: Methyl-dj 4-methyl-2-(methyl-d₃)-4-nitropentanoate-3,3-d₂

A 500-mL, three-neck round bottom flask equipped with a magnetic stir bar, a nitrogen line and a J-Kern thermocouple with heating mantle was charged with 2-nitropropane (34.3 g, 385 mmol) and ds-methyl methacrylate (50 g, 462 mmol) was stirred at ambient température when l,8-diazabicyclo[5.4.0]undec-7-ene (1.47 g, 9.63 mmol) was added in one portion. The reaction solution exothermed from 20 to -40 ^DC and was allowed to stir without heating or cooling for 16 h. The reaction mixture was heated at 80 °C for 4 h. The reaction mixture was diluted with MTBE (170 mL), washed with 1 M HCl (15 mL), dried (MgSO₄), fïltered and concentrated under reduced pressure to afford methyl-d₃ 4-methyl-2-(methy]-d₃)M· nitropentanoate-3,3-d₂ as light yellow oil (75 g, 99%), which was used in the next step without further purification.

1157

Step 2: MethyLd₃ (5)-4-methyl-2~(methyLd₃)-4-nitropentanoate-3,3-d₂

Y^OCDj

NO₂ cd₃ no₂ cd₃

A 5-L, three-neck round bottom flask equipped an overhead mechanical stirrer, a nitrogen line and a J-Kem thermocouple with heating mantle was charged with methyl-d₃ 4methyi-2-(methyl-d₃)-4-nitropentanoate-3,3-d₂ (75 g, 380 mmol) and pH 7.5 Na-phosphate buffer @ 0.8 M (2000 mL). To this was added lipase from Rhizomucor miehei (sigma L4277, palatase from Novozymes) (37.5 mL) and stirred at 30 °C for 25 h. The reaction mixture was extracted twice with MTBE (1 L each time). The combined organics were washed with NaHCO₃(5 vol) twice, brine (5 vol), dried over sodium sulfate and concentrated in vacuo to afford methyi'd₃ (5)-4-methyl-2-(methyl-d₃)-4-nitropentanoate-3,3-d₂ as pale yellow oil (32.5 g, 43% yield).

Step 3: (S)-5,5-dimethyl-3-(methyl-d₃)pynOlidin-2-one-4,4-d₂

O

A high-pressure vessel (Pair shaker bottle, 500 mL) was purged with and maintained under N₂. The vessel was charged sequentially with DI water-rinsed (3x) damp Raney®2800 Ni (6.1 g), methyl-d3 (5)-4-methyl-2-(methyl-d3)-4-nitropentanoate-3,3-d2 (32.5 g, 165 mmol) and EtOH (290 mL). The vessel was sealed and evacuated/backfïlled with N₂ (3 x). With no stirring, the vessel was then evacuated and backfilled with H₂ (30 psi). The Parr bottle was shaken while heating the reaction mixture at 60 °C, and the H₂ pressure was maintained at 30 psi for 8 hours, The vessel was evacuated*ackfilied with N₂ (3 x) and the catalyst/Celite were removed by vacuum filtration (Celite pad; N₂ blanket). The flask/fîlter-pad was washed with EtOH (3 x 50 mL). The filtrate and washes were combined and concentrated in vacuo to afford (S)-5,5-dimethyl-3-(methyl-d₃)pyrro]idin-2-one-4,4-d₂ (20 g, 92%) as white solid.

Step 4: (5)-2,2-dimethyl-4-(methyl-d₃)pyirolidine-3,3-d₂

1158

• HCl

A 1-L, three-neck round bottom flask equipped an overhead mechanical stirrer, a nitrogen line and a J-Kem thermocouple was charged with LAH pellets ( 7.6 g, 202 mmol) in THF (80 mL). A solution of (5)-5,5-dimethy 1-3-(methyI-d₃)pynolidin-2-one-4,4-d₂(20 g, 151 mmol) in THF (120 mL) was added to the suspension over 30 minutes while allowing the reaction température to rise to -60 °C. The reaction température was increased to near reflux (-68 °C) and maintained for 16 h. The reaction mixture was cooled to below 40 °C and diluted with MTBE (200 mL). The reaction mixture was quenched carefully with drop-wise addition of a saturated aqueous solution ofNa₂SO₄ (1 vol) over 2 h. After the addition was completed, the reaction mixture was cooled to RT. The solid was removed by filtration (Celite pad) and washed with EtOAc (4 vol). With extern al cooling and N₂ blanket, the filtrate and washings were combined and treated with drop-wise addition of anhydrous 4 M HCl in dioxane (1 equiv.) while maintaining the température below 20 °C. After the addition was completed (20 min), the résultant suspension was concentrated under reduced pressure at 45 °C. The suspension was backfilled with heptanes (4 vol) twice during concentration. The suspension was cooled to below 30 °C when the solid was collected by filtration under a N₂ blanket. The solid was dried under high vacuum at45 °C to afford (5)-2,2-dimethyl-4-(methyl-d₃)pyrrolidme-3,3-d₂ (17.5 g, 75%) as a white, crystalline solid.

PREPARATION 151: (6-((propan-2-yl-d7)oxy)pyridin-3-yI)boronic acid Step 1: 5-bromo-2-((propan-2-yl-d7)oxy)pyridine

To NaH (245 g, 10.2 mmol) slurried in DMF ( 7 mL) was added d7-JPA (610 mg, 9.09 mmol) and the reaction mixture was stirred for 30 min at room température. 5-bromo-2fluoropyridine (1.00g, 5.68 mmol) was added and the reaction mixture was heated to 120 ^QC for 2.5 h, then an additional alîquot of NaH (40 mg) and d7-IPA (0.07 mL) was added. After a further 2 h of heating, the reaction mixture was allowed to cool to room température. Water (21

1159 mL), followed by MTBE (14 mL) was added, and after stirring, the layers were separated. The organic layer was washed with water (14 mL), dried over sodium sulfate, filtered and concentrated to give 5-bromo-2-((propan-2-yl-d7)oxy)pyridine. 1H NMR (400 mHz) δ 8.17 (m, 1H), 7.60 (dd, J= 8.8, 2.6 Hz, 1H), 6.58 (dd, J= 8.8,0.7 Hz, 1H).

Step 2: (6-((propan-2-yl-d7)oxy)pyridin-3-yl)boronic acid

A mixture of 5-bromo-2-[l,2,2,2-tetradeuterio-l(trideuteriomethyl)ethoxy]pyridine (1.24g, 5.00 mmol), bis(pinacoiato)diboron ( 1.52 g, 6.00 mmol), KOAc (1.47 g, 15.0 mmol), Pd(OAc)₂ (44.9 mg, 0.20 mmol), X-Phos (119 mg, 0.25 mmol) in 2-MeTHF (11 mL) was heated to 80 °C for 2.5 h under an atmosphère of nitrogen. The reaction mixture was allowed to cool, then water (8 mL) was added and the reaction mixture was filtered through Celite pad washing with 2-MeTHF (2x5 mL). The layers were separated and the organic layer dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was dissolved in 2-MeTHF (12 mL), 10% aq w/v NaOH was added and the reaction mixture was stirred. The layers were separated, the aqueous layer was acidified to pH 5 with conc HCl and stirred with 2-MeTHF (12 mL), then separated, the organic layer dried over sodium sulfate, filtered and concentrated under reduced pressure to give (6-((propan-2-yld7)oxy)pyridin-3-yl)boronic acid.

PREPARATION 152: A^r-[(6-amino-2-pyridyl)sulfonyl]-6-[3-fluoro-5-[2,3,3,3tetradeuterio-2-(trideuteriomethyi)propoxy]phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-lyl]pyridine-3-carboxamide (Compound 2708)

Step 1: Lbromo-3-fluoro-5-[2,3,3,3-tetradeuterio-2(trideuteriomethyl)propoxy]benzene

1160 j ί

Το 3-bromo-5-fluoro-phénol (6.00 g, 31.41 mmol) in DMF(60 mL) was slowly added NaH (1.38 g, 34.55 mmol) and the reaction mixture was stirred at ambient température for 15 min. To the mixture was added Nal (1.18 g, 7.85 mmol), foliowed 2-(bromomethyl)l,Ll>2,3,3,3-heptadeuterio-propane (5.05 g, 34.55 mmol). The reaction mixture was stirred at 80 5 °C for 6 h. The reaction mixture was cooled to ambient température and slowly quenched with water (120 mL). The reaction mixture was extracted with EtOAc (240 mL) and the organic phase separated. The organic phase was washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude lîght yellow oil was purified by silica gel column chromatography eluting with 0-100% EtOAc/hexanes to give l-bromo-3-flnoro-5-[2,3,3,310 tetradeuterio-2-(trideuteriomethyl)propoxy]benzene (6.8 g, 85%). 1H NMR (400 MHz, Chloroform-d) δ 6.90 - 6.77 (m, 2H), 6.55 (dt, J = 10.7, 2.2 Hz, 1H), 3.75 - 3.61 (m, 2H).

Step 2: 2-[3-fluoro-5-[2,3,3,3-tetradeuterio-2(trideuteriomethyl)propoxy]phenyl]-4,4,5,5-tetramethyl-l,3,2-dioxaborolane

To the l-bromo-3-fluoro-5-[2,3,3,3-tetradeuterio-2-(trideuteriomethyl)propoxy]benzene (10.8 g, 42.50 mmol) in dioxane (162 mL) was added bis(dipinacolato)diboron (16.2 g, 63.75 mmol) and KOAc (12.5 g, 127.5 mmol) and the reaction mixture was purged withNa for 20 min. To the reaction mixture was added PdCl₂(dppf)₂.CH₂Cl₂ (1.74 g, 2.13 mmol) and the reaction mixture was heated to 100 °C for 3 h. The reaction mixture was cooled to ambient température and filtered through celite and concentrated in vacuo affording a dark oil. The material was purified using silica gel column chromatography eluting with 0-100% EtOAc/hexanes to give 2[3 -fluoro-5 - [2,3,3,3 -tetradeuterio-2-(trideuteriomethyI)propoxy]pheny 1] -4,4,5,5-tetramethyl1,3,2-dioxaborolane (8.92 g, 70%). 1H NMR (400 MHz, DMSO-d6) δ 6.99 (dd, J = 2.4, 0.8 Hz, 1H), 6.96 - 6.87 (m, 2H), 3.76 (s, 2H), 1.29 (s, 12H).

^{25 Ste}P ^3: A4(6-amino-2-pyridy])sulfonyl]-6-[3-fluoro-5-[2,3,3,3-tetradeuterio-2- ( trideuteri omethyl)propoxy]phenyl]-2-[(45)-2,2,4-trimethylp yrrolidin-1-y l]pyridine-31161 carboxamide (Compound 2708) ci

H

To N-[(6-amino-2-pyridyl)sulfonyl]-6-chloro-2-[(45)-2,2,4-trimethylpyrroIidin-IyUpyridine-3-carboxamide (Compound 852) (1.4 g, 3.3 mmol) in 1-propanol (14 mL) and water (4.2 mL) was slowly added K₂CO₃ (1.4 g, 9.9 mmol), followed by l,3-bis(2,6diisopropylphenyI)imidazolidin-2-îde;3-chloropyridine;palladium(2-f-);dichloride (45 mg, 0.06 mmol) and the reaction mixture was heated to 80°C. To the reaction mixture was slowly added 2- [3 -fluoro-5 - [2,3,3,3-tetradeu terio-2-(trideuteriomethyI)propoxy]phenyl ]-4,4,5,5 -tetramethyl 1,3,2-dioxaborolane (1.2 g, 4.1 mmol) in 1-propanol (2.8 mL). The reaction mixture was stirred at 80°C for 19 h. The reaction mixture was cooled to ambient température and slowly added to water (80 mL) containing HCl (20 mL of 1 M, 19.8 mmol). The reaction mixture was diluted with EtOAc (100 mL) and the organic phase separated. The organic phase was washed with brine, dried over MgSO4, filtered over celite and concentrated in vacuo. The crude product was purified by silica gel column chromatography eluting with 0-10% MeOH/DCM, then by reverse phase column chromatography eluting with 5-100% ACN/Water to give N-[(6-amino-2pyridyI)sulfonyl]-6-[3-fluoro-5-[2,3,3,3-tetradeuterio-2-(trideuteriomethyl)propoxy]phenyl]-2[(45)-2,2,4-trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 2708) (495 mg, 27%). 1H NMR (400 MHz, DMSO-d6) δ 12,46 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7,53 - 7.45 (m, 1 H), 7.40 (dt, J = 10.0,2.0 Hz, 1 H), 7.26 (d, J = 8.0 Hz, 1 H), 7.20 (d, J = 7.3 Hz, 1 H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 3.83 (s, 2H), 2.76 -2.54 (m, 3H), 2.22 (s, 1H), 1.88 (dd, J = 11,9, 5.7 Hz, 1H), 1.60 (d, J = 5.7 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 0.88 (d, J = 6.2 Hz, 3H). ESI-MS m/z cale. 562.2755, found 563.36 (M+ !)+; Rétention time: 2.73 minutes.

1162

7V-(benzenesulfonyl)-6-[3-fluoro-5-[2,3,3,3-tetradeuterio-2-(trideuteriomethyl)propoxy]phenyl]2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 2713).

PREPARATION 153: 5-Zer/-butyl-jV-(2-cyanophenyl)sulfonyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 266)

Step 1: Ethyl 3-(/m-butyl)-l-(2,4,6-trimethylbenzyl)-lH-pyrazole-5-carboxylate

A mixture of ethyl 5-Zer/-butyl-4j7-pyrazole-3-caiboxylate (0.5 g, 2.5 mmol), 2(bromomethyl)-l,3,5-trimethyl-benzene (0.5 g, 2.5 mmol), and K₂CO₃ (0.7 g, 5.1 mmol) in DMF (5 mL) was heated to 80 °C ovemight. A further aliquot of 2-(bromomethyl)-l,3,5-trimethylbenzene (200 mg) and K₂CO₃ (0.7 g, 5.1 mmol) were added and the température was increased to 85 °C. The reaction mixture was heated ovemight. The reaction mixture was cooled, water (20 ml) was added and extracted with ethyl acetate (2 x 50 ml). The organic layers were dried overNa₂SO4, concentrated in vacuo, and purified by silica gel column chromatography.

Step 2: 5-feri-butyi -2-((2,4,64rimethylphenyl)methyl]pyrazole-3-carboxylic acid

A solution of ethyl 5-ierZ-butyl-2-[(2,4,6-trimethylphenyI)methyl]pyrazole-3carboxylate (2.0 g, 6.0 mmol) and sodium hydroxide (1.9 g, 48 mmol) in THF (10 mL) and water (10 mL) was stirred at 60 °C for 17 hours. The reaction mixture was cooled to room température and acidificd with 1 M hydrochloric acid. The white precipitate was filtered, washed with water, and dried under vacuum to give 5-teri-butyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxylic acid (1.7 g, 96%) as a white powder. 1H NMR

1163 (400 MHz, DMSO) δ 6.92 - 6.77 (m, 2H). 6.67 (s, 1H), 5.63 (s, 2H), 2.25 (dd, J = 23.8, 13.5 Hz, 9H), 1.13 (d, J = 10.4 Hz, 9H). ESI-MS m/z cale. 300.18378, found 301.0 (M+l)⁺; Rétention time; 2.06 minutes.

Step 3: 5-tert-butyl-N-(2-cyanophenyl)sulfonyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 266)

5-terAbutyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3-carboxyIic acid (30mg,

0.1 mmol), 2-cyanobenzenesulfonamide (18 mg, 0.1 mmol), HATU (38 mg, 0.1 mmol) and DIEA (39 mg, 52 pL, 0.3 mmol) were combined in DMF (1.5 mL) and heated at 60 °C for 16 b. The reaction mixture was fîltered and purified by HPLC/MS utilizing a gradient of 1-99% acetonitrile in 5 mM aq HCl to yield 5-ierAbutyl-N-(2-cyanophenyl)sulfonyl-2-[(2,4,6trimethylpheny])methyl]pyrazoIe-3-carboxamide (Compound 266) (11 mg, 24%) 1H NMR (400 MHz, DMSO-d6) δ 8.22 (dd, J = 7.9, 1.3 Hz, IH), 8.12 (dd, J = 7,6, 1.4 Hz, 1H), 7.97 (td, J = 7.8, 1.5 Hz, 1H), 7.90 (td, J = 7.6, 1,3 Hz, 1H), 7.00 (s, 1H), 6.74 (s, 2H), 5.43 (s, 2H), 2.17 (s, 3H), 2.06 (s, 6H), 1.16 (s, 9H). ESI-MS m/z cale. 464.1882, found 465.4 (M+l)⁺; Rétention time: 2.29 minutes.

N- (benzene su lfonyl)-5-tert-butyl-2-[l -(2,4,6-trimethylphenyl)ethyl]pyrazole-3-carboxamide (Compound 201),

N-(benzenesulfonyI)-5-terAbutyl-2-[[2-fluQro-5-(trifluoromethyl)phenyl]methyl]pyrazole-3carboxamide (Compound 35),

5-rert-butylW-[3-(dimethylamino)phenyl]suIfonyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 270),

N-(3-aminophenyl)sulfonyl-5-terAbutyl-2-[(2,4,6-trichlorophenyl)methyl]pyrazole-3carboxamide (Compound 303),

1164

A43-ammophenyl)sulfonyl-5-tertebutyl-2-[(4-tert-butyl-2,6-dimethy]-phenyl)rnethyl]pyrazole-3carboxamide (Compound 156),

M(benzenesulfonyI)-5-[4-(difluoromethyI)phenyl]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 119),

7V-(3-aminophenyl)sulfonyl·5-ter^butyI-2-[[2-chloro-6(trinuoromethyI)phenyl]methyl]pyrazole-3-carboxamide (Compound 189),

5-tert-butylW-[3-(dimethyIamino)-2-methyl-phenyl]suIfonyI-2-K2_:4,6trimethylphenyl)methyI]pyrazole-3 -carboxamide (Compound 104),

Λ^(3-amino-2-methyl·phenyl)suIfony]-5-ter^butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 123),

5-lerr-butyl-N-(l-methylindoI-7-yl)sulfonyl-2-[[2-methyl-3(trifluoromethyl)phenyI]methyI]pyrazole-3-carboxamide (Compound 276),

5-terr-butyl-7V-(m-tolylsulfbnyI)-2-[(2,4,6-trime thylphenyl)methyl]pyrazole-3-carboxamide (Compound 80),

-tertebutyl W-(5-quinolyls u] fonyl)-2-[(2,4,6-trimethylphenyl)methyI]pyrazole-3-c arboxamide (Compound 352),

N-(3 -aminophenyl)su lfonyl-5-teri-butyl-2 - [ (2,3,5,6 -tetramethy Iphenyl)meihy i]pyrazole-3 carboxamide (Compound 317),

5-tert-butyl-2-[(2,6-dimethyIphenyl)methyI]-N-(2-thienylsulfonyl)pyrazoIe-3-carboxamide (Compound 77),

V-(b enzenesulfonyl)-5-te rt-buty 1-2-[(2,4,6-trichlorophenyl)methyl]pyrazole-3-carboxamide (Compound 145),

5-teri-buty]-2-[(2,6-dimethyïphenyl)methyl]-/V^,-(2-methoxy-3-methyl-phenyl)sulfonyl-pyrazole3-carboxamide (Compound 59),

N-(benzenesulfonyl)-5-teri-butyl-2-(l-naphthylmethyl)pyrazole-3-carboxamide (Compound 328),

1165

5-rerZ-butyl-N-[3-(methylamino)phenyl]sulfonyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 249),

5-zerz-butyl-7V-[l-(2-hydroxyethyl)indoM-yl]suIfonyl-2-[(2,4,6trimethylphenyI)methyl]pyrazole-3-carboxamide (Compound 188), /V-(3-aminophenyl)sulfonyI-5-ZerZ-butyl-4-methyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazoIe-3carboxamide (Compound 20),

5-Zeri-butyl-A^r-(3-hydroxyphenyl)sulfonyl-2-[(2,4₎6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 84),

5-ZerZ-buÎyl-A^l-methylirnidazol-4-yI)sulfonyI-2-[(2,4,64rimethylphenyl)methyl]pyrazole-3carboxamide (Compound 1568),

M(benzenesulfonyl)-5-ierrbuty 1-2-[(3-pyrrol-1-y Iph en yl)methyl]pyrazole-3-carboxamide (Compound 108),

-ZerZ-bu tyl -7^-( 1 H-indol-4-ylsulfonyI)-2- [[2-methyl-3 -(trifluorome thyl)phenyl] methyl]pyrazole3-carboxamide (Compound 60),

N- (3 -acety Ipheny l)su lfonyi-5-zerz-butyI-2- [(2,4,6-trimethylphenyl)methyl]pyrazo le-3 carboxamide (Compound 332),

N-(benzenesulfonyl)-5-Zert-butyl-2-[[5-methyl-2-(trifluoromethyl)phenyl]methyljpyrazoIe-3carboxamide (Compound 304),

N- (3 -aminophenyl)su Ifonyl-5 4erZ-butyl-2-[ [2-flu oro-6-(tri fluoromethyl)phenyl]me thyl]pyrazole3-carboxamide (Compound 239),

N-(3-aminophenyl)sulfonyl-5-ZerZ-butyl-2-[l-(o4oIyI)ethyl]pyrazole-3-carboxamide (Compound 342),

N-[(6-amino-2-pyridyI)sulfonyl]-5-zerz-butyl-4-methyl-2-[(2,4,6trimethylphenyl)methyl]pyrazole-3-carboxamide (Compound 356),

N-(3-aminophenyl)sul fony 1-5rt-butyl-2-(1-cy cio hexylethyl)pyrazole-3-carboxamide (Compound 287),

1166

N-(3-aminophenyl)sulfonyl-5-terr-butyl-2-(l-phenylpropyl)pyrazole-3-carboxamide (Compound 165),

5-terAbutyl-7V-(4-hydroxyphenyl)sulfbnyl-2-[(2,4,6-trimethylphenyl)methyI]pyrazole-3carboxamide (Compound 269),

AM3-aminophenyl)sulfonyl-5-(l-methylcyclopropyI)-2-[(2,4,6-trimethylphenyI)methyl]pyrazoIe3-carboxamide (Compound 158),

N-(benzenesulfonyl)-5-ter/-butyI-2-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]pyrazole-3carboxamide (Compound 98), jV-(3 -aminopheny l)sulfo nyl-5-tert-butyl -2- [(2,6-d imethy lphenyl)methyl]pyrazole-3 -caiboxamide (Compound 185),

N-(3 -aminopheny l)sulfonyl-5-isobutyI-2-[ (2,4,6-trimethylpheny l)methyl]pyrazole-3carboxamide (Compound 167),

N-[(6-amino-2-pyridyI)sulfbnyl]-5-ter/-butyl-2-[(2,4,6-trimethylphenyl)methyl]pyrazole-3carboxamide (Compound 173),

N-(benzenesuifonyl)-5-ter/-butyl-2-[2-(2-methoxyphenyl)ethyl]pyrazole-3-carboxamide (Compound 157),

5-/er/-butylW-[(3-methoxy-2-pyridyl)sulfonyI]-2-[(2,4,6-trimethylphenyl)methyl]pyrazo]e-3carboxamide (Compound 44),

A/-(3-aminophenyl)sulfonyl-5-tert-butyl-2-(l-naphthylmethyl)pyrazole-3-carboxamide (Compound 295),

5-tert-butyI-2-[(2,6-dimethylphenyI)methyl]-7V-(2-fluorophenyI)sulfonyl-pyrazole-3carboxamide (Compound 57), /7-(4-aminopheny I)sulfonyl-5-terAbuty]-2-[(2,6-dimethylphenyl)methyl]pyrazole-3-caiboxamide (Compound 81),

5-tert-butyl-2-[(2,6-dimethylphenyi)methyI]-A^r-(lH-indazol-4-ylsulfonyî)pyrazole-3carboxamide (Compound 86),

1167 ?/-(3-amino-441uoro-phenyl)suIfonyJ-5-Ze?Tbutyl-2-[(2,6-dimethyl phenyl )methyI]pyrazole-3carboxamide (Compound 150),

5-i^rf-butyl-A^L(2,6-difluoropbenyI)sulfonyl-2-[(2,6-dimethylphenyl)methyl]pyrazole-3carboxamide (Compound 170),

5-rm-butyl-2-[(2,6-dimethyIphenyl)methyl]W-(l-methyIindol-4-yl)sulfonyl-pyrazoIe-3carboxamide (Compound 210),

5-zm-butyl-JV-(2,3-dihydrobenzofuran-7-ylsulfonyI)-2-[(2,6-dimethylphenyl)methyI]pyrazoIe-3carboxamide (Compound 211),

N-(b enzenesu lfonyl)-5 -ierr-butyl-2- [(2,6-dimethylphenyI )methyl]pyrazole-3 -carboxamide (Compound 257),

M(3-amino-4-methyl-phenyl)sulfonyl-5-im-butyl-2-[(2,6-dnnethylphenyl)methyI]pyrazole-3carboxamide (Compound 312) and

N-(3-aminophenyl)sulfonyl-l-[(2,4,6-trimethylphenyl)methyl]benzimidazole-2-carboxamide (Compound 71 ),

PREPARATION 154: (3S)-3,5,5-trimethylpyrrolidin-2-one

Step 1: Methyl-2,4-dimethyl-4-nitro-pentanoate o ?

I no₂ ¹

THF (4.5 L) was added to a 20 L glas s reactor and stirred under an atmosphère of nitrogen at room température. 2-Nitropropane (1.5 kg) and DBU (1.282 kg, 0.5 equiv.)were then charged to the reactor (immédiate yellow color observed) and the jacket température was increased to 50 °C. Once the reactor contents were close to 50 °C, methyl méthacrylate (1.854 kg, 1.1 equiv.) was added slowly over 100 minutes. The reaction température was maintained at or close to 50 °C with reaction completion reached at 21 h. During the course of the reaction, a color change from yellow to deep green was observed. The reaction mixture was concentrated in vacuo then transferred back to the reactor and diluted with MTBE (14 L). 2 M HCl (7.5 L) was added and this was stirred for 5 minutes then allowed to settle. Two clear layers were visible — a lower yellow aqueous phase and an upper green organic phase. The aqueous was removed and the

1168 organic was stirred again with 2 M HCl (3 L). After séparation, the HCl washes wère recombined and stirred with MTBE (3 L) for 5 minutes. The aqueous was removed and ali of the organics were combined in the reactor and stirred with water (3 L) for 5 minutes. After séparation, the organics were concentrated in vacuo to afford a cloudy green mobile oilrn which was dried with MgSO₄ and filtered to afford racemic methyI-2,4-dimethyl-4-nitro-pentanoate (3.16 kg) as a clear green mobile oil (99% yield). ’H NMR (400 MHz, Chloroform-7) δ 3.68 (s, 3H), 2.56 - 2.35 (m, 2H), 2.11 - 2.00 (m, 1H), 1.56 (d, J = 20.2 Hz, 6H), 1.19 (d, 7=6.8 Hz, 3H).

Step 2: Methyl (25)-2,4-dimethyl-4-nitro-pentanoate o o

NO; > NO₂ *

A reaction vessel was set up with methyl 2,4-dimethyl-4-nitro-pentanoate (7 kg, 105.7 mmol) and stirred with 70 L of pH 6.5 K phosphate buffer @0.1 M.

To this was added 3.5 L lipase (palatase from Novozymes) and stirred at 34 °C for -43 h. The pH of the reaction was maintained at pH 6.5 b y pH Stat dosing K₂CO₃ (aq. Soin), The reaction mixture was extracted with MTBE (2x5 vol, 1 x 2 vol). The combined MTBE layers were then washed with 2 M Na₂CO₃ (4 x 2.5 vol), water (3 vol) and brine (3 vol). The product was concentrated down to -10 L in the reactor by distilling off the MTBE and transferred to a large rotary evaporator for final concentration to afford methyl (25)-2,4-dimethyl-4-nitro-pentanoate as a mobile yellow oil (3072.2 g, 44% yield).

Step 3: (35)-3,5,5-trimethylpyrrolidin-2-one

A 20 L Hastelloy reactor vessel, purged with and maintained under N₂. The vessel was charged sequentially with DI water-rinsed, damp Raney® Ni (2800 grade, 250 g), methyl (25)-2,4-dimethyl-4-nitro-pentanoate (1741g, 9.2 mol) and éthanol (13.9 L, 8 vol). Stirring was commenced at 900 rpm and the reactor flushed with H₂ and maintained at -2.5 bar. After 5

1169 hours, the reaction mixture wasifiltered toremove Raney nickel and solid cake rinsed with éthanol (3.5 L, 2 vol). The éthanolic solution of product was concentrated in vacuo to reduce to a minimum volume of éthanol (-1.5 volumes), then heptane (2.5 L) was added and the suspension concentrated again to -1.5 volumes. This was repeated a further 3 times, then the resulting suspension was cooled to 0-5 °C and filtered under suction and washed with heptane (2.5 L). The product was dried on the filter under vacuum for 20 minutes then transferred to drying trays and dried in a vacuum oven at 40 °C ovemight (with N2 bleed). This afforded (35)-3,5,5trimethylpyrrolidin-2-one as a white crystalline solid (2.042 kg, 87 %). 'H NMR (400 MHz, Chloroform-ίΖ) δ 6.39 (s, 1H), 2.62 (ddq,J = 9.9, 8.6, 7.1 Hz, 1H), 2.17 (ddd, J = 12.4, 8.6, 0.8

Hz, 1H), 1.56 (dd, J = 12.5, 9.9 Hz, 1H), 1.31 (s, 3H), 1.25 (s, 3H), 1.20 (d, J = 7.1 Hz, 3H).

PREPARATION 155: A^r-((2-aminopyridin-3-yl)sulfonyl)-6'-(((5)-lhydroxypropan-2-yl)oxy)-6-((5)-2,2,4-trimethylpyiTolidin-l-y 1)-[2,3’-bipyridine]-5-carboxamide (Compound 2690)

Step 1: A/-[(2-amin o-3-pyridyI)sulfonyl]-6-(6-fluoro-2-pyridyl)-2-[(45)-2,2,415 trimethylpyrrolidjn-l-yl]pyridine-3-carboxamîde

A mixture of /V-[(2-amino-3-pyridyl)sulfonyl]-6-chloro-2-[(45)-2,2,4trimethy]pyrrolidin-l-yl]pyridme-3-carboxamide (3.8 g, 8.96 mmol), (6-fluoro-2-pyridyl)boronic acid (2.00 g, 14.2 mmol), [I,l'-bis(diphenylphosphino)ferrocene]dichloropalIadium(II) complex with dichloromethane (1.40 g, 2.32 mmol), and Na₂CO₃ (4.00 g, 37.7 mmol) in dimethylformamide (80 mL) and water (20 mL) was degassed under a stream of nitrogen and stirred at 100 °C for 18 hours. (6-Fluoro-2-pyridyl)boronic acid (0.90 g, 6.4 mmol), [1,1 'Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (0.40 g, 0.55 mmol) were added, and the reaction mixture stirred at 100°C for another day. The réaction mixture was filtered through a pad of Celite and the filtra te was diluted with water (300 mL), adjusted to pH -7 and extracted with ethyl acetate (5x300 mL). The extract was washed with brine (2x200 mL), dried over Na₂SO₄, and concentrated, The residue purified by chromatography on silica gel, eluted with 0-100% ethyl acetate in hexanes, affording yellow

1170 foam product (2.2 g, -85% purity) and starting material (3) (560 mg).

Step 2: 7V-((2-aminopyridin-3-yI)sulfonyl)-6’-(((5)-l-(benzyloxy)propan-2yl)oxy)-6-((5)-2,2,4-trimethyl-pyrrolidin-l-yl)-[2,3'-bipyridine]-5-carboxamide

Sodium hydride (44 mg, 1.1 mmol) (60 wt% in minerai oil) was added to a solution of (Æ)-l-benzyloxy-propan-2-oI (117 mg, 0.7 mmol) in dimethylformamide (2.0 mL). After 5 minutes of stirring at room température, V-[(2-amino-3-pyridyl)sulfonyl]-6-(6-fluoro-2py ri dyl)-2 - [(45)-2,2,4-trimethylpyrrolidin-I-y l]pyridine-3-carboxamide (108 mg, 0.18 mmol) was added. The reaction mixture was heated under microwave irradiation at 75 °C for 30 minutes. The reaction mixture was quenched with water (10 mL), adjusted pH 3-4, and extracted with ethyl acetate (2x10 mL). The combined extract was washed with brine (2x5 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give V-((2-aminopyridin-3yl )sulfonyl)-6 -(((5)-1 -(benzyloxy)propan -2-yI)oxy )-6-((5) -2,2,4-trimethyl-pyrrol idin-1 -yl)- [2,3 'bipyridîne]-5-carboxamide. ESI-MS m/z 631 (M+l)⁺.

Step3:W-((2-ammopyridin-3-yl)sulfonyl)-6’-(((5)-l-hydroxy_Propan-2-yI)oxy)-6((5)-2,2,4-trimethylpyrroIidin-l-yl)-[2,3'-bipyridine]-5-carboxamide (Compound 2690)

A-((2-aminopyridin-3-yl)sulfonyl)-6^,-(((5)-l-(benzyloxy)propan-2-yl)oxy)-6-((5)2,2,4-trimethyl-pyrrolidin-l-yl)-[2,3'-bipyridine]-5-carboxamide was hydrogenated under 1 atmosphère of hydrogen with Pd/C (10%, 260 mg) in methanol (25 mL) at room température. After 4 hours, the catalyst was removed by filtration, evaporated under reduced pressure and purified by silica gel column chromatography (0-10% of methanol in dichloromethane), followed by a further purification by silica gel column chromatography eluted with 0-8% of methanol in a mixture solvent of ethyl acetate and hexanes in a ratio of 50/50 to give A-((2

1171 aminopyridin-3-yl)sulfonyl)-6’-(((5)-l -h ydroxypropan-2-yI)oxy )-6-((5)-2,2,4trimethylpyrrolidin-l-yl)-[2,3'-bipyridine]-5-carboxamide (Compound 2690) (9 mg). ESI-MS m/z541 (M+l)⁺.

PREPARATION 156: Methyl 2-(benzenesulfonyl)-3-[5-terPbutyl-2-[(2,6dimethylphenyl)methyl]pyrazol-3-yl]-3-oxo-propanoate (Compound 4)

Step 1: 5 -teri-butyl-2-[ (2,6-dime thylphenyl)methyl]pyrazole*3 -c arbonyl chloride

5-tert-butyl-2-((2,6-dimethylphenyl)methyl]pyrazole-3-carboxylic acid (100 mg, 0.3492 mmol) was dissolved in thionyl chloride (41.54 mg, 25.47 pL, 0.3492 mmol) and a drop of DMF was added. The reaction was stirred for Ih and evaporated to give the acid chloride, which was used without further purification.

Step 2: Methyl 2-(benzenesulfonyl)-3-[5-tm-butyl-2-((2,6 dimethylphenyl)methyl]pyrazol-3-yl]-3-oxo-propanoate (Compound 4)

To 5-tert-butyl-2-[(2,6-dimethylphenyI)methyl]pyrazole-3-carbonyl chloride (40 mg, 0.13 mmol), methyl 2-(benzenesulfonyl)acetate (28 mg, 22 uL, 0.13 mmol)and NaH (5 mg, 0.13 mmol) in DMF were stirred at room température for 15 minutes. The reactions were filtered and purified by reverse phase LC-MS (10-99% CH₃CN/H₂O, HCl modifier) to give methyl 2-(benzenesutfonyI)-3-(5-tert-butyl-2-((2,6dimethylphenyl)methyl]pyrazol-3-yl]-3-oxo-propanoate (Compound 4) (18 mg, 28%). ESI-MS m/z483.4 (M+l)⁺; Rétention time: 2.41 minutes.

PREPARATION 157: A-[(6-ammo-2-pyridyl)su]fonyl]-6-tert-butyl-5-[(E)-2-(4methoxyphenyl)vinyl]-2-[(45)-2,2,4-trimethyipyrrolidin-l-y]]pyridi ne-3-carboxamide (Compound 1535)

Step 1: 5-Iodo-6-tert-buty]-2-hydroxypyrîdine-3-carbonitrile

1172

MIodosuccinimide (31.9 g, 142 mmol) was added to a solution of 6-ter/-butyl-2hydroxypyridine-3-carbonitrile (10.0 g, 56.8 mmol) in a mixture of 1,2-dichloroethane (120 mL) and trifluoroacetic acid (40 mL) and the reaction mixture was heated at 50 °C overni ght. The solution was concentrated under reduced pressure and ethyl acetate (300 mL) was added. The organic layer was washed with 10% sodium thiosulfate solution (300 mL), water (2 x 200 mL) and brine (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography, eluting from 30% EtOAc in heptanes to 60% EtOAc in heptanes, to provide 5-iodo-6-terAbutyl-2-hydroxypyridine-3carbonitrile (15.85 g, 92% yield) as a white solid. 'H NMR (300 MHz, CDC1₃) ppm 1.57 (s, 9 H), 8.17 (s, 1 H). [M+H]⁺= 303.0.

Step 2: 5-Iodo-6-teri-butyl-2-chloropyridine-3-carbonitrile

Phosphorus oxychloride (67.0 mL, 718 mmol) and phosphorus pentachloride (44.9 g, 216 mmol) were added to 5-iodo-6-tertebutyl-2-hydroxypyridine-3-carbonitrile (21.7 g, 71.8 mmol) and the reaction mixture was refluxed ovemîght. The reaction mixture was cooled to room température and concentrated under reduced pressure to remove most ofthe remaining phosphorus oxychloride. Water (caution·, exotherm) followed by 50% NaOH solution were added until a pH ~9 was reached and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to provide 5-iodo-6-ter/-butyI2-chloroxypyridine-3-carbonitrile (17.35 g, 75% yield) as a yellow solid. ^]H NMR (300 MHz, CDC1₃) ppm 1.55 (s, 9 H), 8.38 (s, 1 H). [M+H]⁺ = 320.9,

Step 3: 5-Iodo-6-tert-butyl-2-ch]oropyridine-3-carboxylic acid

Potassium hydroxide (18.2 g, 325 mmol) in water (60 mL) was added to 5-iodo-6terr-butyl-2-chloroxypyridme-3-carbonitri]e (17.35 g, 54.1 mmol) in 2-propanol (60 mL) and the

1173 reaction mixture was heated at 90 °C ovemight. Ethyl acetate (50 mL) was added and the organic layer was extracted with 1 N NaOH (3 x 50 mL). The basic aqueous layers were combined and concentrated under reduced pressure to remove most ofthe 2-propanol. The remaining aqueous layer was acidified to pH 1 -2 with concentrated HCl and extracted with ethyl acetate (3 x 100 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate, fïltered and concentrated under reduced pressure. The residue was purified by reverse-phase chromatography (methanol/water, 0% to 100%) to afford 5-iodo-6-rerr-butyl-2chloropyridine-3-carboxylic acid (8.2 g, 45% yield) as an off-white solid. ^!H NMR (300 MHz, CDCI3) ppm 1.57 (s, 9 H), 8.77 (s, 1 H). [M+H]⁺ = 339.9.

Step4:N-[(6-ammo-2-pyridyl)suifonyI]-6-reri-butyl-2-chloro-5-iodo-pyridine-3carboxamide

To a stirred solution of 6-tert-butyl-2-chloro-5-iodo-pyridine-3-carboxylic acid (1.57 g, 4.62 mmol) in dry DMF (11.0 mL) added CDI (0.94 g, 5.78 mmol) in one portion under nitrogen at ambient température. The reaction was warmed to 45 °C and stirred for 1.5 h. In a separate flask, 6-aminopyridine-2-sulfonamide (1.00 g, 5.78 mmol) was dissolved in dry DMF (9.0 mL) under nitrogen and sodium hydride (60 % in minerai oil) (231 mg, 5.78 mmol) was added in portions to mitigate gas évolution at ambient température. The heterogeneous mixture was warmed to 40 °C and stirred for I hour. This reaction mixture was added to the stirred activated acid mixture in one portion at 45 °C. Heat was removed and the réaction was stirred for an additional hour. The reaction mixture was slowly added to ice-cold water (160 mL) then AcOH (1.43 g, 1.35 mL, 23.81 mmol) was added and the reaction mixture was stirred vigorously for 10 mins and the solids were fïltered and washed with water (3 x 20 mL). The solids were slurried in hexanes (50 mL) and filtered. The solid was further dried to fnmish N-[(6-amino-2pyridyl)sulfonyl]-6-/irr-butyL2-chloro-5-iodo-pyridine-3-carboxamide (2.11 g, 92%) as white solid.

1174

Step 5 : N- [(6-amino-2-pyridyl)sulfonyl]-6-tert-butyl-5-iodo-2-[(4S)-2,2,4 trimethylpyrrolidin-1 -yI]pyridine-3-carboxamide

To a solution of jV-[(6-amino-2-pyridyl)sulfonyl]-6Tert-butyl-2-chloro-5-iodopyridine-3-carboxamide (2.11 g, 4.27 mmol) in anhydrous DMSO (10 mL), (4S)-2,2,4trimethylpyrrolidine (LOI g, 8.96 mmol) and K₂CO₃ (2.95 g, 21.32 mmol) were added in that order. The reaction mixture was heated at 150 °C for 18 h under an atmosphère of nitrogen, The reaction mixture was allowed to cool to ambient température, then poured onto ice-water (125 mL) with stirring. The pH was adjusted to about 6.0 to 7.0 with the addition of 1 M HCl, the solid was filtered, washed with water (4 x 20 mL) and dried under vacuum to yield N-[(6amino-2-pyridyl)sulfonyl)-6-tert-butyl-5-iodo-2-[(4S)-2,2,4-trimethyIpyrrolidin-l-yI]pyridine-3carboxamide (2.15 g, 88%) as off-white solid.

Step 6:À4(6-amino-2-pyridyl)sulfonyl]-6Ti-rrtbutyl-5-[(E)-2-(4methoxypheny])vinyl]-2-[(45)-2,2,4-trimethylpyrro]idm-l-yl]pyridine-3-carboxamide (Compound 1535)

DMF (0.5 mL) and H₂O (0.1 mL) were added to A-[(6-amino-2-pyridyl)sulfonyl]-6-rerAbutyl5-iodo-2-(2,2,4-trimethy]pyrrolidin-l-yl)pyridine-3-carboxamide (30 mg, 0.05 mmol) and [(£>

1175

2-(4-methoxyphenyl)vinyl]boronic acid (19 mg, 0,11 mmol), followed by K₂CO₃ (29 mg, 0.21 mmol) under an atmosphère of nitrogen. Then tetrakis(triphenylphosphine)palladium (0) (6 mg, 0.005 mmol) was added, the re action mixture was sealed under an atmosphère of nitrogen and heated at 130 °C for 13 h. The reaction mixture was allowed to cool to ambient température and the product was purified using a reverse phase HPLC-MS method using a Luna C18 (2) column (75 x 30 mm, 5 pm particle size) and a dual gradient run from 10-99% mobile phase B over 30.0 minutes (mobile phase A = H₂O (5 mM HCl), mobile phase B = CH₃CN) to give A4(6-amino-2py ridyl)su Ifonyl]-6-tert-bu ty 1-5 - [(F) -2-(4-methoxyphenyl)vinyl]-2-[(45)-2,2,4trimethylpyn-olidin-l-yl]_Pyridine-3-carboxamide (Compound 1535) (5 mg, 16%). ESI-MS m/z 578.6 (M+I)⁺; Rétention time: 1,78 minutes; 1H NMR (400 MHz, Methanol-d4) δ 8.26 (s, 1H), 7.68 (dd, J = 8.5, 3.4 Hz 1 H), 7.48 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 15.9 Hz 1H), 7.37 (d, J = 7.3 Hz, IH), 6.94 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 15.9 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 3.82 (s, 3H),3.48 (dd, J = 10.9,8.2 Hz, 1H),3.17 (dd, J = 11.1,9.3 Hz, 1H), 2.69 - 2.52 (m, 1H), 2.11 (dd, J = 12.4, 6.8 Hz, 1H), 1.74 (t, J = 11.8 Hz, 1H), 1.54 (s, 3H), 1.49 (s, 9H), 1.46 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H).

//-[(6-ammo-2-pyridy])sulfonyI]-5-(3-bicyclo[2.2.1]hept-2-enyl)-6-rm-butyl-2-[(45)-2,2,4trimethylpyrrolidin-l-yl]pyridine-3-carboxamide (Compound 1577),

M [(6-amino -2-pyridyl)suIfonyl] -6 -terributyl-5 - [(E)-pent-1 -enyl]-2-[(45)-2,2,4trimethylpyrrolidin-l-yI]pyridine-3-carboxamide (Compound 1617),

A-[(6-amino-2-pyridyI)sulfonyl]-6-/^rt-butyl-5-[(E)-2-cyclopropylvinyI]-2-[(4S)-2,2,4trimethylpyirolidin-l-yI]pyridine-3-carboxamide (Compound 1665),

Ethyl (£)-3-[5-[(6-amino-2-pyridyl)sulfonyIcarbamoyl]-2-teri-butyl-6-[(45)-2,2,4trimethylpyrrolidin-l-yI]-3-pyridyl]prop-2-enoate (Compound 1490),

A-[(6-ammo-2-pyridyl)sulfonyl]-6-ierr-butyl-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]-5-vinyIpyridine-3-carboxamide (Compound 1373) and

A-[(6-ami no-2-pyridyI)sulfonyl]-6-terr-butyl-5-[(E)-2-ethoxy vin yl]-2-[(45)-2,2,4trimethylpyiTolidin-l-yl]pyridine-3-carboxamide (Compound 1626)

1176

PREPARATION 158: A-[(6-amino-2-_Pyridyl)sulfonyl]-6-(3-fluoro-5-^obutoxyphenyl)-2-(4-phenylbutoxy)pyridme-3-carboxamide (Compound 1686)

Step 1: A-[(6-anuno-2-pyridyI)sulfonyl]-2-fluoro-6-(3-fluoro-5-t\G^|butoxyphenyl)pyridine-3-carboxamide

A-[(6-amino-2-pyridyl)sulfonyl]-2-chloro-6-(3-fluoro-5-Aobutoxyphenyl)pyridine-3-carboxamide (300 mg, 0.63 mmol) was dïssolved in DMSO (1.2 ml.) Césium fluoride (476 mg, 3.13 mmol) was added. The reaction mixture was sealed and stirred ovemight at 150 °C. Additional césium fluoride (100 mg) was added, and the reaction mixture was stirred ovemight at 150 °C. After cooling to room température, the mixture was diluted with EtOAc (75 mL) and washed with diluted aqueous HCl solution (0.1 N, lx 75 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was used in the next step without further purification. ESI-MS m/z 463.2 (M+l)⁺;

Rétention time: 1.83 minutes.

Step 2. A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-isi>butoxy-phenyl)-2-(4phenylbutoxy)pyridine-3-carboxamide (Compound 1686)

4-phenylbutan-l-ol (23 mg, 0.15 mmol) was dissolved in dioxane (250 pL).

1177 ι

I

Sodium hydride (6 mg, 0,15 mmol) was added, and the reaction mixture was stirred at room température for 5 minutes. A solution of A-[(6-ammo-2-pyridyl)sulfonyi]-2-fluoro-6-(3-fluoro5-Aobutoxy-phenyl)pyridine-3-carboxamide (35 mg, 0.08 mmol) in DMSO (250 pL ) was added. After another 5 minutes of stinring, the reaction mixture was heated under micro wave irradiation at 100 °C for 30 minutes, then concentrated under reduced pressure and purifîed by reverse phase HPLC-MS method using a Luna C18 (2) column (75 x 30 mm, 5 pmparticle size) and a dual gradient run from 1-99% mobile phase B over 15.0 minutes, (mobile phase A = water (5 mM HCl), mobile phase B = acetonitrile) to give A-[(6-amino-2-pyridyl)sulfonyl]-6-(3fluoro-5-Aobutoxy-phenyl)-2-(4-phenylbutoxy)pyridine-3-carboxamide (Compound 1686) (30 mg, 64%). ESI-MS m/z 593.4 (M+l)⁺; Rétention time: 2.47 minutes.

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluor0-5-Kobutoxy-phenyl)-2-(3-phenylbutoxy)pyridine-3carboxamide (Compound 1689),

7/-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-(\obutoxy-pheny 1)-2-(3-phenylp ropoxy)pyridine3-carboxamide (Compound 1694),

A- [(6-amino-2-pyridyl)sulfonyl]-6-(3- fluoro -5- wobutoxy-phen y!)-2-[4-(3pyridyl)butoxy]pyridine-3-carboxamide (Compound 1690),

A-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-Ac^|butoxy-phenyI)-2-[4-(420 pyridyl)butoxy]pyridine-3-carboxamide (Compound 1687),

A- [(6-amin o-2-pyridyl)suIfonyl]-6-(3-fluoro-5-tsobu toxy-pheny 1)-2-(4-(2pyridyl)butoxy]pyridine-3-carboxamide (Compound 1688),

A4(6-ammo-2-pyridyl)sulfonyl]-6-(3-0 uoro-5-isobutoxy-pheny 1)-2-(3-(2pyridyl)propoxy]pyridine-3-carboxamide (Compound 1693),

A-[(6-amino-2-pyridyl)sulfonyl]-6-(3-fluoro-5-BObutoxy-phenyl)-2-[3-(3pyridyl)propoxy]pyridine-3-carboxamide (Compound 1691) and

A-[(6-amino-2-pyridyI)sulfonyl]-6-(3-fluoro-5-Aobutoxy-phenyl)-2-(3-pyrazol-lylpropoxy)pyridine-3-carboxamide (Compound 1692).

PREPARATION 159: A-[(6-amino-2-pyridyl)sulfony]]-2-(2,2-dimethyl-3-oxo

1178

I pyrrolidin-l -yl)-6-(3-fluoro-5-iJobutoxy-phenyI)pyridine-3-carboxamide (Compound 1189)

Solid potassium carbonate (90 mg, 0.65 mmol) was added to a suspension of 2,2-dimethylpyrrolidin-3-one (49 mg, 0.32 mmol) in DMSO (250 pL), followed by N-[(65 amino-2-pyridyl)sulfony!]-2-fluoro-6-(3-fluoro-5-wobutoxy-phenyl)pyridine-3-carboxamide (HCl sait) (50 mg, 0.11 mmol). The reaction mixture was stirred at 150 °C for 3 hours. The re action mixture was purified using a reverse phase HPLC method using a Lun a C18 (2) column (50 x 21.2 mm, 5 pm particle size) and a dual gradient run from 10-99% mobile phase B over 15.0 minutes (mobile phase A = water (5 mM HCl), mobile phase B = acetonitrile). ESI-MS m/z 10 556.4 (M+l)⁺; Rétention time: 2.01 minutes.

N-[(6-amino-2-pyridyl)sulfonyl]-2-(2,2-dimethyl-4-oxo-pyrrolidin-l-yl)-6-(3-fluoro-5m?butoxy-phenyl)pyridine-3-carboxamide (Compound 1073).

¹⁵ PREPARATION 160: 2-(benzenesulfonyl)-l-[5-ier/-butyl-2-[(2,4,6- trimethy]phenyI)methyl]pyrazol-3-yl]propan-l-one (Compound 139)

To a solution of2-(benzenesulfonyl)-l-{3-Zert-butyl-l-[(2,4,6tnmethylphenyl)methyl]-l//-pyrazoI-5-yl}ethan-l-one (50 mg, 0.11 mmol) in THF (3.0 mL) and

1179

DMF (1.0 mL) was added DBU (52 mg, 0.34 mmol) and the mixture was stirred at room température for 30 minutes. lodomethane (40 mg, 0.28 mmol) was then added and the reaction was stirred ovemight at room température. Analysis of an aliquotby LCMS indicated that only mono-methylation (no bis-methylation) had occurred. The crude reaction mixture was transferred to a separatory funnel with water and extracted twice with diethyl ether. The organic layers were combined, dried over sodium sulfate, fïltered and concentrated under reduced pressure to give the cnide product. In a separate experiment, a solution of 2-(benzenesulfonyl)-l {3-rÉ’ri-butyl-l-[(2,4,6-trimethylphenyl)methyI]-lH-pyrazoI-5-yl}ethan-l-one (50 mg, 0.11 mmol) in THF (3.0 mL) and DMF (1.0 mL) was added DBU (52 mg, 0.34 mmol) and the mixture was heated in an oil bath at 80 °C for 10 minutes. lodomethane (40 mg, 0.28 mmol) was then added, the vial was capped and the reaction was heated in an oil bath at 80 C ovemight. Analysis of an aliquot by LCMS indicated that only mono-methylation (no bis-methylation) had occurred. The crude reaction mixture was transferred to a separatory funnel with water and extracted twice with diethyl ether. The organic layers were combined, dried over sodium sulfate, ] 5 fïltered and concentrated under reduced pressure to give the crude product. Both crude reaction mixtures were combined together and purified by silica-gel column chromatography, eluting with 5% to 20% EtOAc in heptanes, to afford rac 2-(benzenesulfonyl)-l-{3-im-butyl-l-[(2,4,6trimethylphenyl)methyl]-1 H-pyrazo 1-5-ylpropan-1 -one (64 mg, 60% yield) as a white solid. *H NMR (300 MHz, DMSO-ri_â) ppm 1.10 (s, 9 H), 1.46 (d, J = 6.8 Hz, 3 H), 2.16 (s, 6 H), 2.21 (s, 3 20 H), 5.40 - 5.53 (m, 3 H), 6.83 (s, 2 H), 7.15 (s, 1 H), 7.55 - 7.62 (m, 2 H), 7.68 - 7.76 (m, 3 H).

ESI-MS m/z 453.2 (M+l)⁺.

Table 2 below recites the analytical data for the compounds of Table 1.

Table 2.

Cmpd. NOA;	«LC/MS M+1 ¹	ILC/RT ^J rrirnfe¹
1	503.00	1.96
2	419.00	2.04
3	484.05	2.00
4	483.40	2.41
5	438.40	1.74
6	435.20	1.50
7	469.40	2.06	1H NMR (400 MHz, DMSO-d6) 6 12.19 (s, 1H), 7.24 (t, J = 7.9 Hz, 1H), 7.17 (t,J = 2.1 Hz, 1H), 7.09 - 7.03 (m,

1180

Cmpd. No.A	aLC/MS	^LC/RT : t. mm.·;®
			2H), 6.83 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 6.72 (s, 2H), 5.68 (s, 2H), 4.42 4.35 (m, 2H), 2.84 - 2.76 (m, 2H), 2.15 (s, 3H), 2.08 (s, 6H), 1.23 (s,9H).
8	561.40	2.30
9	482.10	1.98
10	467.10	2.18
11	468.00	2.14	1H NMR (400 MHz, DMSO) 5 11.65 (s, 1H), 7.92 (s, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 7.8 Hz, 1H), 6.91 (s, 2H), 6.62 (d, J = 11.3 Hz, 2H), 6.17 (s, 2H), 2.26 (s, 3H], 1.95 (s, 6H), 1.04 (s, 9H).
12	447.20	2.14
13	426.40	1.80
14	561.14	2.91
15	481.00	2.15	1H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 7.69 (s, 1H), 7.62 (s, 1H}, 7.19 (d, J = 7.3 Hz, 1H), 7.05 (d, J = 26.9 Hz, 3H}, 6.69 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.69 (s, 2H), 2.29 (s, 3H), 2.04 (d, J = 25.4 Hz, 3H), 1.67 (d, J = 28.9 Hz, 4H), 0.98 (s, 6H).
16	465.30	1.52
17	519.00	1.93	1H NMR (400 MHz, DMSO) δ 8.10 (d, J = 7.9 Ηζ,.ΙΗ), 7.33 (s, 2H), 7.20 (s, 3H), 7.07 (s, 2H), 6.94 (s, 4H), 6.71 (d, J = 8.3 Hz, 1H), 6.52 (s,2H).
18	464.00	1.97	1H NMR (400 MHz, DMSO) δ 12.71 (s, 1H), 8.47 (d, J = 6.8 Hz, 1H), 8.28 (d, J = 9.5 Hz, 1 H), 7.70 (d, J = 7.9 Hz, 1H), 7.55 (s, 1H), 7.25 (s, 1H), 7.15 (s, 1H), 7.07 (s, 1H), 7.01 (d, J = 8.4 Hz, 1H), 5.62 (s, 2H), 3.92 (s, 3H), 2.18 (s, 3H), 1.84 {s, 6H).
19	467.20	2.83	1H NMR (400 MHz, Chloroform-d) 8 8.27 (d, J = 7.9 Hz, 1H), 7.49 - 7.33 (m, 2H), 7.23 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.9 Hz, 1H), 6.88 - 6.74 (m, 3H), 3.89 (s, 2H), 2.29 (s, 3H), 2.02 (s, 6H), 1.06 (s, 9H).
20	469.40	2.04
21	532.30	2.08
22	451.00	2.44
23	449.00	1.54	1H NMR (400 MHz, DMSO) δ 8.02 (s,

1181

WNtW		LG/RU ^minÆ-s	: 181 < A-- NMR ! < N : ®
			1H), 7.60 (S, 1H), 7.25 (s, 1H), 7.18 (s, 1H), 6.98 (s, 2H), 6.78 (s, 4H), 2.17 (s, 3H), 1.97 (s, 6H).
24	468.2D	1.92
25	448.20	1.91
26	452.50	1.81
27	494.07	2.08
28	480.30	2.20
29	490.00	2.16
30	478.34	1.45
31	425.40	1.64
32	451.00	0.90	1H NMR (400 MHz, MeOD) 5 7.99 (d, J = 7.0 Hz, 1H), 7.64 (d, J = 6.2 Hz, 1H), 7.44 - 7.26 (m, 4H), 6.92 (s, 2H), 6.86 (d, J = 9.5 Hz, 1H), 5.36 (s, 1H), 4.69 (d, J = 20.6 Hz, 3H), 2.44 (s, 6H), 2.25 (s, 3H).
33	451.20	2.07
34	484.00	2.30	1H NMR (400 MHz, DMSO) 5 12.52 {s, 1H), 8.04 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.76 {d, J = 7.3 Hz, 1H), 7.15 (dd, J = 12.9, 8.1 Hz, 2H), 6.90 (s, 2H), 3.85 (s, 3H), 2.25 (s, 3H), 1.94 (s, 6H), 1.05 (s,9H).
35	484.05	1.97
36	464.20	1.82
37	510.00	2.13
38	448.30	1.90
39	470.00	2.12	1H NMR (400 MHz, DMSO) Ô 12.51 (s, 1H), 7.99 (s, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.63 (dt, J = 15.3, 7.7 Hz, 2H), 7.01 (s, 1H), 6.75 (s, 2H), 5.42 (s, 2H), 4.63 (s, 2H), 2.16 (s, 3H), 2.07 (d, J = 6.4 Hz, 6H), 1.14 (s, 9H).
40	477.25	1.86
41	472.28	2.06
42	505.40	1.92
43	494.07	2.02
44	471.30	2.28
45	440.40	2.25	1H NMR {400 MHz, Chloroform-d) 6 8.33 (s, 1H), 8.17 - S.11 (m, 2H), 7.72 - 7.65 (m, 1H), 7.58 (dd, J = 8.5,7.1 Hz, 2H), 6.74 (s, 2H), 6.45 (s, 1H), 5.51 (s, 2H), 2.22 (s, 3H), 2.12 {s, 6H), 1,17 (s,9H).

1182

Cmpd?	sLC/MS^	. LC/R T*
46	428.17	1.77
47	469.00	2.16	1H NMR (400 MHz, DMSO) δ 12.16 (s, 1H), 10.19 (S, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 4.7 Hz, 3H), 7.14 7.04 (m, 2H}, 6.89 (s, 2H), 2.25 (s, 3H), 1.93 (s, 6H), 1.04 (s, 9H).
48	436.00	1.20	1H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 8.59 (s, 1H), 7.97 (s, 2H), 7.56 (d, J = 23.1 Hz, 2H), 7.32 (d, J = 21.5 Hz, 3H), 6.89 (s, 2H), 5.27 (s, 1H), 4.49 (d, J = 13.2 Hz, 1H), 4.31 (s, 3H), 2.35 (s, 6H), 2.23 (s, 3H).
49	476.30	2.05
50	437.40	2.11
51	470.00	1.94	1H NMR (400 MHz, DMSO) δ 12.5S (s, 1H), 11.83 (s, 1H), 8.28 (s, 1H), 8.07 (S, 1H), 7.84 (s, 1H), 7.16 (s, 1H), 6.92 (s, 1H), 6.46 (S, 1H), 2.26 (s, 3H), 1.98 (s, 6H), 1.04 (s,9H).
52	43S.22	1.88
53	467.30	2.84	1H NMR (400 MHz, Chloroform-d) δ 8.27 (d, J = 7.9 Hz, 1H), 7.49 - 7.36 (m, 2H), 7.22 (t, J = 7.9 Hz, 1H), 6.92 (d, J = 7.8 Hz, 1H), 6.87 - 6.75 (m, 3H), 3.89 (s, 2H), 2.29 (s, 3H), 2.02 (s, 6H), 1.06 (S, 9H).
54	521.00	1.81
55	456.40	1.91	1H NMR (400 MHz, DMSO-d6) δ 12.55 (s, 1H), 12.03 (s, 1H),8.25 (d,J = 7.5 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.83 (s, 1H), 7.16 (d, J = 7.9 Hz, 1H), 7.1Û (s, 1H), 7.04 (s, 2H), 6.45 (t, J = 6.8 Hz, 1H), 2.30 (s, 3H), 2.02 (s, 3H), 1.09 (s, 9H).
56	483.00	2.34	1H NMR (400 MHz, DMSO) 8 12.23 (s, 1H), 7.95 (s, 1H), 7.54 (d, J = 36.2 Hz, 3H), 7.30 (s, 1H), 7.12 (s, 1H), 6.90 (s, 2H), 3.80 (s, 3H), 2.25 (s, 3H), 1.92 (s, 6H),1.04 (S, 9H).
57	444.38	3.14
58	425.40	1.63
59	470.30	2.27
60	519.00	1.98	1H NMR (400 MHz, DMSO) δ 12.51 (s, 1H), 11.67 {S, 1H), 7.74 (s, 1H), 7.66 (s, 1H), 7.56 (s, 1H), 7.43 (s, 1H), 7.28

1183

CmpcL No. ¹	,1_Ο/Μβώ	Wmiri^
			{d, J = 21.0 Hz, 3H), 6.86 (s, IH), 6.55 (s, IH), 5.51 (s, 2H), 2.20 (s, 3HL 2.07 (s, 2H), 1.24 (s,9H).
61	533.22	3.09
62	462.40	1.91
63	440.00	2.11	IH NMR (400 MHz, DMSO-d6) δ 11.90 (s, IH), 8.57 (s, IH), 8.05 - 7.96 (m, 2H), 7.77 - 7.70 (m, IH), 7.70 7.61 (m, 2H), 6.73 (s, 2H), 3.98 (s, 2H), 2.17 (s, 3H), 2.07 (s, 6H), 1.38 (s, 9H).
64	533.22	2.85	IH NMR (400 MHz, DMSO) S 12.52 {s, IH), 9.02 (s, 2H), 8.22 - 8.19 (d, IH), 7.89 - 7.86 (d, IH), 7.66 (t, J = 7.91, IH), 7.25 - 7.22 (d, IH), 6.96 (s, 2H), 6.74 - 7.61 (d, IH), 6.59 (s, 2H), 3.22 - 3.08 (m, IH), 2.2 9 (s, 3H), 2.03 (S, 6H), 1.27-1.24 (d, 6H)
65	468.20	1.93
66	533.22	2.90
67	474.50	1.70	IH NMR (400 MHz, DMSO-d6) δ 7.61 (dd, J = 8.4,7.3 Hz, IH), 7.48 (s, 2H), 7.38 (s,2H), 7.11 (d, J = 7.3 Hz, IH), 7.02 (dd,J = 8.9, 1.7 Hz, IH), 6.88 (d, J = 8.7 Hz, IH), 6.69 (d,J = 8.4Hz, IH), 6.46 (s, 2H)„ 3.18 (s, IH), 2.34 (s, 3H), 1.97 (d, J = 15.9 Hz, 6H).
68	469.40	2.04	IH NMR (400 MHz, DMSO-d6) δ 12.39 (s, IH), 8.78 (s, IH), 7.30 - 7.21 (m, 2H), 7.12 (dd,J = 7.4,1.8 Hz, IH), 6.93 (s, 2H), 6.86 (dd, J = 7.9, 2.2 Hz, IH), 2.26 (s, 3H), 1.94 (s, 6H), 1.11 (s, 9H); NH2 not observed.
69	533.22	2.89
70	477.40	2.03
71	449.20	1.41
72	582.20	2.26
73	451.00	1.07	IH NMR (400 MHz, CD3CN) δ 7.70 (s, IH), 7.37 (d, J = 26.5 Hz, 4H), 7.18 (d, J = 7.3 Hz, IH), 6.94 (s, 2H), 6.84 (d, J = 8.6 Hz, IH), 5.06 (s, IH), 4.62 (d, J = 14.0 Hz, IH), 4.45 (s, 2H}, 4.37 (d, J = 14.0 Hz, IH), 2.43 (s, 6H), 2.27 (s, 3H).
74	409.30	1.93

1184

Cmpd. _Np·^	LC/MS : ïæ.· M+1	J _; LC/RT minA	«.Λ .. . -, _; NMR . T
75	440.40	1.91
76	489.40	1.58
77	432.04	2.04
78	478.00	2.26	1H NMR (400 MHz, DMSO} δ 8.27 (d, J = 7.9 Hz, 1H), 8.14 (d, J = 7.5 Hz, 1H), 8.00 (s, 2H), 7.91 (s, 1H), 7.14 (d, J = 7.8 Hz, 1H), 6.89 (s, 2H), 2.25 (s, 3H), 1.92 (S, 6H), 1,04 (s,9H).
79	465.00	1.57	1H NMR (400 MHz, DMSO) δ 7.84 (d, J = 7.9 Hz, 1H), 7.60 (s, 1H), 7.33 (s, 4H), 7.16 (d, J = 8.4 Hz, 1H), 7.07 (s, 1H), 6.87 (s, 2H), 5.14 (s, 1H), 4.25 (d, J = 39.6 Hz, 4H), 3.86 (s, 3H), 2.31 (s, 6H), 2.22 (s, 3H).
80	454.00	2.31	1H NMR (400 MHz, DMSO) Ô 7.69 (s, 1H), 7.43 (s, 1H), 7.30 (s, 1H), 7.17 (s, 1H), 7.04 (s, 1H), 6.68 (s, 2H), 5.40 (s, 2H), 2.35 (S, 3H), 2.10 (s, 3H), 2.02 (s, 6H), 1.07 (s, 9H).
81	441.38	2.84	1H NMR (400 MHz, DMSO) δ 12.09 (s, 1H), 7,63 - 7.60 (d, 2H), 7.07 - 6.92 (m, 4H), 6.64 - 6.61 (d, 2H), 6.21 (s, 2H), 5.48 (S, 2H), 2.13 (s, 6H), 1.12 (s, 9H)
82	468.20	1.91
83	480.30	2.19
84	456.40	2.06	1H NMR (400 MHz, DM5O-d6) δ 12.47 (s, 1H), 10.23 (s, 1H), 7.50 7.39 (m, 3H), 7.12 (dt, J = 8.0,1.8 Hz, 1H), 7.01 (s, 1H), 6.77 (s, 2H), 5.46 (s, 2H), 2.19 (s, 3H), 2.10 (s, 6H), 1.16 (s, 9H).
_85	439.30	1.85
86	466.30	2.93	1H NMR (400 MHz, DMSO) δ 8.43 (s, 1H), 7.99 - 7.96 (d, 1H), 7.87 - 7,84 (d, 1H), 7.60 (t, J = 7.8, 1H), 7.04 - 6.94 (m, 2H), 6.86 - 6.83 (m, 2H), 5.35 (s, 2H), 1,92 (s, 6H), 1.14 (s, 9H)
87	451.20	2.09
__88	441.08	3.03
89	470.40	2.27
90	450.20	1.19
91	463.00	1.76	1H NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 8.63 {s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.67 (d, J = 20.4 Hz, 2H), 7.54 (d,

1185

Cmpd. ANolt	; LC/MS -M+1 :	LC/RD;
			J = 14.6 Hz, 2H), 7.23 (d, J = 7.3 Hz, 1H), 6.94 (s, 2H), 6.72 (d, J = 8.4 Hz, 1H), 6.59 (s, 2H), 2.28 (s, 3H), 2.01 (s, 6H).
92	484.00	2.12	1H NMR (400 MHz, DMSO) δ 12.15 (s, 1H), 8.22 (d, J = 4.4 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 8.5 Hz, 1H), 7.73 (s, 1H), 7.16 (d, J = 7.8 Hz, 1H), 6.92 (S, 2H), 3.95 (s, 3H), 2.26 (s, 3H), 1.99 (S, 6H), 1.06 (S,9H).
93	507.00	1.98	1H NMR (400 MHz, DMSO) δ 12.29 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.82 (s, 2H), 7.73 (d, J = 7.9 Hz, 1H), 7.65 (s, 1H), 7.25 (s, 3H), 6.95 (s, 2H), 6.71 (d, J = 8.4 Hz, 1H), 6.53 (s, 2H), 2.28 (s, 3H), 2.03 (s, 6H).
94	436.20	1.06
95	479.50	1.20
96	480.30	1.88	1H NMR (400 MHz, DMSO-d6) δ 12.64 (s, 1H), 8.20 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.25 - 7.16 (m, 2H), 7.10 - 7.05 {m, 1H), 6.91 (s, 2H), 6.81 (ddd, J = 8.1, 2.3,1.0 Hz, 1H), 5.68 (s, 2H), 2.26 (s, 3H), 1.94 (s, 6H).
97	517.00	2.03	1H NMR (400 MHz, DMSO) δ 12.42 (s, 1H), 8.11 (d, J = 6.8 Hz, 1H), 7.64 (s, 1H}, 7.16 (dd, J « 53.1, 23.0 Hz, 6H), 6.83 (S, 2H), 6.71 (d, J = 8.5 Hz, 1H), 6.54 (s, 2H), 2.18 (s, 3H), 1.98 (s, 6H), 1.88 (s, 6H).
98	480.09	2.06	1H NMR (400 MHz, DMSO) δ 7.91 (s, 2H), 7.69 (s, 1H), 7.58 (s, 2H), 7.45 (s, 1H), 7.37 (s, 1H), 7.21 (s, 1H), 6.60 (s, 1H), 5.60 (s, 2H), 2.31 (s, 3H), 1.25 (s, 9H).
99	471.30	1.95
100	506.09	2.02
101	441.40	2.07
102	46S.40	2.11	1H NMR (400 MHz, DMSO-d6) δ 11.83 (s, 1H), 7.69-7.54 (m, 2H), 7.21 (d, J = 7.3 Hz, 1H), 7.12 (d, J = 8.2 Hz, 1H), 7.00 (s, 2H), 6.70 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 6.38 - 6.30 (m, 1H), 2.28 (s,3H), 2.02 (s, 6H), 1.10 (s,

1186

Cmpd. ? No? <	U-C/MS} IfO»
			9H).
103	494.30	1.44
104	497.00	2.15	1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 7.78 (d, J = 7.4 Hz, 1H), 7.43 (s, 2H), 7.06 (s, 1H), 6.75 (s, 2H), 5.40 (s, 2H), 2.66 (s, 6H), 2.56 (s, 3H), 2.17 (s, 3H), 2.06 (s, 6H), 1.15 (s, 9H).
105	453.00	1.95	1H NMR (400 MHz, DMSO-d6) δ 12.34 (s, 1H), 7.25 (t, J = 7.9 Hz, 1H), 7.21 (t, J = 2.1 Hz, 1H), 7.11 - 7.03 (m, 2H), 7.01 - 6.94 (m, 3H), 6.85 (dd, J = 7.8, 2.2 Hz, 1H), 5.49 (s, 2H), 2.90 (p, J = 7.6 Hz, 1H), 2.13 (s, 6H), 1.92 1.80 (m, 2H), 1.68 - 1.44 (m, 6H).
106	468.20	2.07
107	470.00	1.87	1H NMR (400 MHz, DMSO) δ 12.19 (s, 1H), 11.76 (s, 1H), 8.44 (s, 1H), 8.06 (S, 1H), 7.80 (S, 1 H), 7.16 (s, 1H), 6.92 (s, 2H), 6.34 (S, 1H), 2.26 (s, 3H), 1.98 (s, 6H), 1.04 (s, 9H).
108	463.00	2.19
109	464.30	2.08
110	455.40	4.15	1H NMR (400 MHz, DMSO-d6) δ 7.26 (t, J = 7.9 Hz, 1H), 7.21 (t, J = 2.0 Hz, 1H), 7.12 - 7.06 (m, 1H), 7.01 (s, 1H), 6.89 - 6.83 (m, 1H), 6.77 (s, 2H), 5.45 (s, 2H), 2.17 (s, 3H), 2.11 (s, 6H), 1.14 (s, 9H).
111	479.40	1.91	1H NMR (400 MHz, CDCI3) δ 10.13 (s, 1H), 8.42 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.45 (s, 2H}, 7.34 (t, J = 7.7 Hz, 1H), 7.15 (d,J = 8.1 Hz, 1H), 7.00 (s, 1H), 2.11 (d, J = 8.2 Hz, 7H), 1.05 (s,9H).
112	449.00	1.92
113	470.00	1.95	1H NMR (400 MHz, DMSO) δ 12.23 (s, 1H), 8.01 (d, J = 7.4 Hz, 1H), 7.63 (d, J = 6.2 Hz, 1H), 7.12 (d, J = 7.3 Hz, 2H), 6.90 (s, 3H), 6.85 (s, 1H), 6.57 (s, 1H), 2.25 (s,3H), 1.95 (s, 6H), 1.04 (s, 10H).
114	539.30	1.83
115	483.00	2.27	1H NMR (400 MHz, DMSO) δ 12.11 (s, 1H), 8.03 (s, 2H), 7.78 (s, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.30 - 7.19 (m, 2H),

1187

Cmpd:		yLC/RT’ sSmriîl
			7.00 (s, 2H), 3.95 (s, 3H), 2.35 (s, 3H}, 2.04 (s, 6H), 1.13 (s, 9H).
116	464.09	1.69
117	454.00	2.15	1H NMR (400 MHz, DMSO) δ 8.90 (d, 1 = 5.9 Hz, 2H), 7.99 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 6.0 Hz, 2H), 7.11 (d, J = 7.8 Hz, 1H), 6.89 (s, 2H), 2.25 (s, 3H), 1.92 (S, 6H), 1.04 (s, 9H).
118	462.20	1.85
119	496.21	2.08
120	478.20	1.85
121	450.00	1.36	1H NMR (400 MHz, DMSO) 5 7.55 (d, J = 8.6 Hz, 2H), 7.33 (s, 3H), 7.21 (d, J = 7.1 Hz, 1H), 6.83 (s, 2H), 6.61 (d, J = 8.8 Hz, 2H), 5.21 (s, 1H), 4.40 (s, 2H), 4.22 (s, 2H), 2.30 (s, 6H), 2.22 (s, 3H).
122	506.30	1.92	1H NMR (400 MHz, DMSO) δ 8.14 (dd, J = 4.9,1.9 Hz, 1H), 7.98 (dd, J = 7.5,1.9 Hz, 1H), 7.68 (s, 1H), 7.47 7.38 (m, 2H), 7.33 (d, J = 7.8 Hz, 1H), 7.13 - 7.01 (m, 2H), 6.80 (s, 3H), 5.60 (S, 2H), 4.01 (s, 3H), 2.18 (s, 3H), 2.14 (d, J = 2.9 Hz, 6H).
123	469.30	2.39
124	451.00	1.68	1H NMR (400 MHz, DMSO) δ 12.38 (s, 1H), 8.44 (s, 1H), 7.19 (s, 3H), 7.08 (s, 1H), 6.90 (s, 2H), 6.82 (s, 1H), 5.69 (s, 2H), 2.42 (s, 3H), 2.24 (s, 3H), 1.92 (s, 9H).
125	562.20	2.23
126	450.40	1.20
127	467.30	2.15
128	489.00	1.45
129	478.40	1.90
130	425.40	2.23
131	469.00	2.16	1H NMR (400 MHz, DMSO) δ 11.66 (s, 1H), 11.04 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.52 (s, 1H), 7.16 (d, J = 7.9 Hz, 1H), 7.02 (s, 2H), 6.93 (S, 2H), 2.26 (s, 3H), 1.98 (s, 6H), 1.04 (s, 9H).
132	558.14	2.91
133	504.23	2.17
134	448.00	1.82	1H NMR (400 MHz, DMSO) S 7.63 (dd, J = 19.9, 8.3 Hz, 3H), 7.38 (s, 1H),

1188

-ί Cmpd/ B»	? LC/MS SW»	f LC/RT-	il—
			7.07 (d, J = 25.7 Hz, 2H), 6.91 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 6.15 (S, 2H), 5.66 (s, 2H), 2.16 (s, 3H), 1.90 (S, 6H).
135	506.09	2.04
136	596.20	2.37
137	467.10	2.19
¹³⁸	427.50	1.84
139	453.20	6.23	1H NMR (400 MHz, DMSO) δ 1.10 (s, 9 H), 1.46 (d, J = 6.8 Hz, 3 H), 2.16 (s, 6 H), 2.21 (S, 3 H), 5.40 - 5.53 (m, 3 H), 6.83 (s, 2 H), 7.15 (s, 1 H), 7.557.62 (m,2H), 7.68 - 7.76 (m, 3 H)
140	493.00	1.49	1H NMR (400 MHz, DMSO) δ 12.49 (s, 1H), 7.59 (S, 1H), 7.32 (s, 1H), 7.19 (s, 3H), 7.14 (d, J = 7.2 Hz, 1H), 6.80 (s, 2H), 6.67 (d, J = 8.4 Hz, 1H), 6.43 (s, 1H), 4.64 (s, 1H), 2.95 (d, J = 11.1 Hz, 1H), 2.20 (s, 9H), 2.00 (d, J = 11.2 Hz, 1H), 1.05 (s, 3H), 0,91 (s, 3H).
141	469.40	2.02
142	466.40	1.87
143	447.20	2.14
144	462.40	1.93
145	502.20	2.34
146	506.00	2.31	1H NMR (400 MHz, DMSO) 8 12.22 (s, 1H), 7.84 (s, 2H), 7.76 (s, 1H), 7.53 (s, 1H), 7.35 (s, 1H), 7.09 (s, 1H), 6.87 (s, 3H), 3.84 (s, 3H), 2.24 (s, 3H), 1.84 (s, 6H), 1.02 (s, 9H).
147	453.40	2.34
148	448.90	1.85	1H NMR (400 MHz, DMSO-d6) 8 12.35 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.46 (s, 1H), 7.25 - 7.18 (m, 2H), 7.13 - 7.09 (m, 1H), 7.08 - 7.02 (m, 2H), 6.91 - 6.87 (m, 1H), 6.84 - 6.80 (m, 1H), 6.74 (s, 2H), 5.68 (s, 2H), 2.17 (s, 3H), 1.92 (S, 6H).
149	530.30	2.18	1H NMR (400 MHz, DMSO-d6) 88.07 -8.01 (m, 2H), 7.81-7.74 (m, 1H}, 7.73 - 7.65 (m, 3H), 7.49 (s, 1H), 7.48 - 7.39 (m, 3H), 7.10 - 7.03 {m, 1H), 6.99 - 6.95 (m, 2H), 5.63 (s, 2H), 2.13 (s, 6H).
150	459.39	3.00

1189

iGmpd.r . No.	JïLC/MS	.LO/RTM min^
151	534.19	2.03
152	490.00	2.17
153	466.20	1.88
154	426.40	1.66
155	494.07	2.09
156	497.00	2.23	1H NMR (400 MHz, DMSO) δ7.25 (s, 1H), 7.21 (s, 1H), 7.09 (s, 1H), 7.01 (s, 1H}, 6.97 (s, 2H), 6.86 (s, 1H), 5.46 (s, 2H), 2.16 (s, 6H), 2.08 (s, 1H), 1.23 (s, 9H), 1.15 (s, 9H).
157	442.06	1.81
158	453.50	2,06	1H NMR (400 MHz, DMSO-d6) δ 7.26 - 7.16 (m, 2H), 7.05 (d, J = 7.8 Hz, 1H), 6.88 - 6.78 (m, 2H), 6.76 (s, 2H), 5.44 (s, 2HL 2.17 (s, 3H), 2.10 (s, 6H), 1.27 (s, 3H), 0.75 - 0.69 (m, 2H), 0.67 0.62 (m, 2H).
159	530.30	2.27
160	423.15	1.93
161	551.20	2.11
162	517.39	1.70
163	469.00	1.94	1H NMR (400 MHz, DMSO) Ô8.27 (s, 1H), 8.16 (s, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.56 (s, 1H), 7.12 (d, J = 7.8 Hz, 1H), 6.90 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.04 (s, 9H).
164	531.20	2.34	1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 8.12 (d,J = 7.8 Hz, 1H), 7.73 - 7.60 (m, 4H), 7.31 - 7.19 (m, 3H), 6.95 (s, 2H), 6.71 (d, J =8.2 Hz, 1H), 6.52 (s, 2H), 2.88 (p, J = 6.9 Hz, 1H), 2.28 (s, 3H), 2.03 (s, 6H), 1.18 (d, J = 6.9 Hz, 6H).
165	441.40	2.04
166	464.30	2.10
167	455.00	1.92	1H NMR (400 MHz, DMSO) 6 7.26 (d, J = 12.4 Hz, 2H), 7.13 (s, 1H), 6.93 (s, 1H), 6.90 (s, 1H), 6.77 (s, 2H), 5.44 (s, 2H), 3.18 (s, 1H), 2.30 (s, 2H), 2.18 (s, 3H), 2.07 (s, 6H), 1.75 (s, 1H), 0.83 (d, J = 6.6 Hz, 6H).
168	464.09	1.73
169	580.30	2.24
170	462.39	3.09
171	542.60	1.70

1190

OfribcM	WC/MS	SSmirra
172	509.20	2.32
173	456.50	1.92
174	466.00	1.41	1H NMR (400 MHz, DMSO) δ 10.10 (s, 1H), 7.83 (s, 1H), 7.60 (s, 2H), 7.31 (d, J = 12.3 Hz, 3H), 7.00 - 6.85 (m, 3H), 5.22 (S, 1H), 4.46 (d, J= 13.2 Hz, 1H), 4.38 -4.17 (m, 3H), 3.78 (s, 3H), 2.36 (s, 6H), 2.23 (s,3H).
175	481.00	1.76	1H NMR (400 MHz, DMSO) δ 12.76 (s, 1H), 8.28 (s, 1H), 7.66 (s, 2H), 7.20 (s, 1H), 6.92 (s, 2H), 6.65 (d, J = 46.8 Hz, 3H), 2.25 (s, 3H), 1.97 (s, 6H).
176	476.30	2.05
177	442.17	1.85
178	489.50	1.72
179	477.20	2.01	1H NMR (400 MHz, DMSO-d6) δ 12.39 (s, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.52 - 7.44 (m, 2H), 7.17 (d, J = 7.3 Hz, 1H), 6.97 (dd, J = 8.8,1.7 Hz, 1H), 6.74 (d, J = 6.0 Hz, 3H), 6,69 (d, J = 8,4 Hz, 1H), 6.46 (s, 2H), 5.66 (s, 2H), 2.61 (q, J = 7.6 Hz, 2H), 2.18 (s, 3H), 1.95 (s, 6H), 1.17 (t,J =7.5 Hz, 3H).
180	479.30	2.09
181	466.40	1.88
182	495.00	2.18	1H NMR (400 MHz, DMSO) δ 11.98 (s, 1H), 7.74 (s, 1H), 7.63 (s, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.90 (s, 2H), 6.70 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 2.68 (s, 2H), 2.26 {s, 3H), 1.97 (s, 6H), 1.66 (d, J = 27.0 Hz, 4H), 0.92 (s,6H).
183	463.00	2.02	1H NMR (400 MHz, DMSO) 5 12.45 (s, 1H), 7.90 (s, 1H), 7.67 (s, 2H), 7.57 (s, 1H), 7.13 (d, J = 48.8 Hz, 4H), 6.90 (s, 1H), 6.72 (s, 2H), 5.64 (s, 2H), 3.84 (s, 3H), 2.17 (s, 3H), 1.88 (s, 6H).
184	449.20	1.64	1H NMR (400 MHz, DMSO-d6) 68.39 (dd, J = 4.6,1.6 Hz, 1H), 8,15 (dd, J = 8.0,1.6 Hz, 1H), 7.30 (s, 1H), 7.28 7.21 (m, 2H), 7.18 (dd, J = 8.0, 4,6 Hz, 1H), 7.06 - 7.01 (m, 1H), 6.96 - 6.90 (m, 1H), 6.58 (s, 2H),5.65 (s, 2H), 2.10 (s, 3H), 1.88 (s, 6H).
185	441.00	1.91	1H NMR (400 MHz, DMSO) S 7.34 (s, 2H), 7.23 (s, 1H), 7.03 (s, 2H), 7.00 (s,

1191

Cmpd.ï No^		» ^s Bçnunw
			1H), 6.96 (S, 2H), 5.50 {s, 2H), 2.14 (s, 6H), 1.14 (s, 9H).
186	438.17	1.72
187	422.17	0.93
188	523.00	2.02	1H NMR (400 MHz, MeOD) δ 7.89 (s, 1H), 7.84 (s, 1H), 7.51 (s, 1H), 7.34 (s, 1H), 6.99 (S, 1H), 6.75 (s, 1H), 6.66 (s, 2H), 5.36 (S, 2H), 4.38 (s, 2H), 3.90 (s, 2H), 2.15 (s, 3H), 1.93 (s, 6H), 1.17 (s, 10H).
189	515.00	1.94	1H NMR (400 MHz, DMSO) δ 7.80 (s, 2H), 7.61 (s, 1H), 7.25 (s, 2H), 7.14 (s, 1H), 7.10 (s, 1H), 6.85 (s, 1H), 5.68 (s, 2H), 2.08 (s, 1H), 1.06 (s,9H).
190	507.00	1.97	1H NMR (400 MHz, DMSO) δ 13.75 (s, 1H), 12.32 (s, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.96 (s, 1H), 7.71 (d, J = 8.6 Hz, 2H), 7.64 (s, 1H), 6.94 [s, 4H), 6.86 (s, 1H), 4.03 (s, 2H), 2.28 (s, 3H), 2.02 (s, 6H), 1.31 (s,3H).
191	484.00	2.28	1H NMR (400 MHz, DMSO) δ 12.43 (s, 1H), 8.49 (d, J = 6.5 Hz, 1H), 8.34 (d, J = 9.3 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.27 (s, 1H), 7.14 (d, J = 7.8 Hz, 1H), 6.90 (s, 2H), 3.94 (s, 3H), 2.25 (s, 3H), 1.93 (S, 6H), 1.05 (s, 9H).
¹⁹²	424.17	1.65
193	453.30	1.90
194	462.30	1.88
195	454.00	2.07
196	579.30	2.39	1H NMR (400 MHz, DMSO-d6) δ 12.37 (s, 1H), 8.13 (d,J = 7.8 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.27 - 7.14 (m, 3H), 6.95 (s, 2H), 6.85 (dt,J = 10.7,2.3 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.53 (s, 2H), 3.65 (d, J = 6.6 Hz, 2H), 2.27 (s, 3H), 2.02 (s, 6H), 1.97 (dt, J = 13.3, 6.6 Hz, 1H), 0.97 (d, J = 6.8 Hz, 6H).
197	459.32	1.67
198	493.20	1.91
199	460.20	2.12
200	466.60	1.40
201	454.14	2.22
202	460.50 \|	2.23 \|

1192

æjhpd/	pC/MSi	fLC/RTÿ « - »minl·
203	489.40	2.82	1H NMR (400 MHz, DMSO-d6} δ 12.30 (S, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.81 - 7.70 (m, 3H), 7.64 (s, 1H), 7.44 - 7.38 (m, 3H), 7.23 (d, J = 7.3 Hz, 1H), 6.95 (S, 2H), 6.69 (s, 1H), 6.52 (s, 2H), 2.28 (s,3H), 2.04 (s, 6H).
204	455.40	2.04	1H NMR (400 MHz, DMSO-d6) δ 12.14 (s, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.15 (d, J = 7.8 Hz, 1H), 7.09 (s, 1H), 7.08 - 7.00 (m, 2H), 6.70 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.30 (s, 3H), 2.01 (S, 3H}, 1.09 (s, 9H).
205	497.00	2.13	1H NMR (400 MHz, DMSO) δ 8.13 (s, 1H), 7.92 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 7.62 (S, 1H), 7,26 (s, 1H), 6.63 (d, J = 28.8 Hz, 3H), 1.98 (s, 3H), 1.68 (s, 6H), 0.76 (s, 9H).
206	439.30	1.95
207	541.10	2.20
208	519.30	2.08
209	503.30	2.07	1H NMR (400 MHz, DMSO) δ7.26 {dd, J = 14.6, 6.7 Hz, 2H), 7.12 (dd, J = 14.0, 7.3 Hz, 3H), 7.04 (d, J = 7.5 Hz, 2H), 6.86 (d, J = 8.0 Hz, 1H), 6.77 (s, 2H), 5.74 (S„1H), 5.56 (s, 2H), 2.17 (s, 3H), 2.08 (d,J = 2.2 Hz, 6H), 1.97 (s, 6H).
210	479.20	3.14
211	468.39	3.11	1H NMR {400 MHz, DMSO) δ 7.65 7.62 (d, 1H), 7.59 - 7.56 (d, 1H), 7.06 6.94 (m, 5H), 5.47 (s, 2H), 4.68 (t, J = 8.68, 2H), 3.29 (t, J = 9.01, 2H), 2.13 - 2.09 (m, 6H), 1.16 (s, 9H)
212	451.20	2.08
213	464.30	1.20
214	443.50	2.86
215	447.30	2.07
216	514.31	2.79
217	484.00	2.33	1H NMR (400 MHz, DMSO) Ô8.46 (d, J = 5.3 Hz, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.49 (d, J = 5.3 Hz, 1H), 7.29 (s, 1H), 7.12 (d, J = 7.8 Hz, 1H), 6.90 (s, 2H), 3.91 {s, 3H), 2.25 (s, 4H), 1.93 (s, 6H), 1,05 (s,9H). J

1193

Cmpd. -w	LC/MS.srt	ÿLC/RU
218	466.00	1.38	1H NMR (400 MHz, DMSO) δ 10.21 (s, 1H), 8.28 (s, 1H), 8.18 (d, J = 9.3 Hz, 1H), 7.58 (d, J = 7.2 Hz, 1H), 7.34 (s, 2H), 7.28 (s, 1H), 7.10 (s, 1H), 6.89 (s, 2H), 5.21 (s, 1H), 4.42 (s, 1H), 4.22 (s, 5H), 3.89 (s, 3H), 2.36 (s, 6H), 2.23 (s, 3H).
219	454.00	2.07	1H NMR (400 MHz, MeOD) δ 8.07 (s, 1H), 7.40 (s, 2H), 7.33 (s, 3H), 7.27 (s, 3H), 7.06 (s, 1H), 6.94 (s, 1H), 6.34 (s, 1H), 1.73 (s, 3H), 1.22 (s, 9H).
220	514.03	2.17
221	479.40	1.93
222	454.00	2.19	1H NMR (400 MHz, DMSO) δ 12.54 (s, 1H), 8.73 (s, 1H), 8.18 (s, 2H), 7.96 (s, 1H), 7.74 (s, 1H), 7.13 (s, 1H), 6.90 (s, 2H), 2.25 (s, 3H), 1.95 (s, 6H), 1.05 (s, 9H).
223	444.10	1.81
224	467.40	2.20
225	530.20	2.22
226	487.27	2.15
227	434.20	1.80
228	469.00	2.07	1H NMR (400 MHz, DMSO) δ 8.02 (d, J = 7.8 Hz, 1H), 7.64 (s, 1H), 7.21 (d, J = 7.3 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 6.91 (s, 2H), 6.70 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 2.26 (s, 3H), 1.97 (s, 6H}, 1.05 (s,9H).
229	466.25	2.06
230	450.00	1.40	1H NMR (400 MHz, DMSO) 5 10.81 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 7.1 Hz, 1H), 7.23 (d, J = 22.0 Hz, 4H), 6.85 (S, 2H), 6.74 (d, J = 8.2 Hz, 1H), 6.56 (s, 1H>, 4.97 (s, 1H), 4.19 (d, J = 35.8 Hz, 5H), 2.31 (s, 6H), 2.22 (s, 3H).
231	488.40	2.08
232	447.20	2.06
233	573.30	1.97
234	523.20	2.15
235	469.00	2.05	1H NMR (400 MHz, DMSO) Ô8.23 (d, J = 5.8 Hz, 1H), 8.05 (dd, J = 7.9, 1.0 Hz, 1H), 8.00 (d, J = 8.2 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 6.90 (s, 2H), 6.82 \|

1194

Cmpd. No.«	LC/MS;. Λ- Μ+'Ί	LC/RT .	18 sa
			(s, IH), 6.75 (S, IH), 2.25 (s, 3H), 1.95 (s, 6H), 1.04 (s, 10H).
236	479.00	1.41	IH NMR (400 MHz, MeOD) δ 7.84 (s, IH), 7.33 (s, 7H), 6.99 (d,J = 8.7 Hz, IH), 6.90 (S, 2H), 4.60 (d, J = 35.7 Hz, 2H), 4.41 (S, IH), 3.98 (s, IH), 3.76 (s, IH), 3.67 - 3.55 (m, IH), 2.90 (dt, J = 12.8, 6.3 Hz, IH), 2.41 (d, J = 14.1 Hz, 7H), 2.24 (s, 4H).
237	442.21	1.S7
238	595.20	2.43	IH NMR (400 MHz, DMS0-d6) δ 8.09 (d, J = 7.7 Hz, IH), 7.61 (d, J = 7.9 Hz, IH), 7.50 - 7.32 (m, 4H), 7.07 (d, J = 7.4 Hz, IH), 6.90 (s, 2H), 6.45 (d, J = 8.2 Hz, IH), 6.09 (s, 2H), 3.60 (d, J = 6.5 Hz, 2H), 2.26 (s, 3H), 2.02 (s, 7H), 1.01 (d, J = 6.7 Hz, 6H).
239	499.00	1.89	IH NMR (400 MHz, DMSO) Ô 7.57 (d, J = 19.8 Hz, 3H), 7.28 (s, 2H), 7.16 (d, J = 18.2 Hz, 2H), 6.94 (s, IH), 5.67 (s, 2H), 1.09 (s, 9H).
240	448.30	1.82
241	463.20	2.04
242	439.00	2.28	IH NMR (400 MHz, DMS0-d6) δ 11.87 (s, IH), 8.03 - 7.97 (m, 2H), 7.75-7.69 (m, 1 H), 7.68-7.62 (m, 2H), 7.24 (d, J = 2.0 Hz, IH), 6.88 (s, 2H), 6.15 (d, J = 1.9 Hz, IH), 5.27 (s, 2H), 2.23 (s, 3H), 2.05 (s, 6H), 1.07 (s, 9H).
243	466.00	1.70	IH NMR (400 MHz, DMSO) δ 8.23 (d, J = 7.6 Hz, IH), 7.65 (d,J = 7.6Hz, IH), 7.24 (d, J = 11.1 Hz, 2H), 7.12 (s, 4H), 6.85 (d, J = 9.9 Hz, IH), 1.98 (s, 6H).
244	465.30	2.06
245	451.40	1.94	IH NMR (400 MHz, DMSO-d6) δ 12.42 (S, IH), 7.98 - 7.89 (m, 2H), 7.75 (t, J = 7.4 Hz, IH), 7.63 (t, J = 7.7 Hz, 2H), 7.27 (d, J = 8.2 Hz, IH), 7.22 (d, 1 = 3.2 Hz, IH), 7.05 (s,lH), 6.87 (dd, J = 8.2, 7.2 Hz, IH), 6.44 - 6.36 (m,2H), 5.72 {s,2H),3.73 {s, 3H), 1.23 (s, 9H).
246	467.00	1.64	IH NMR (400 MHz, DMSO) δ 8.28 (d,

1195

Cmpd. OoH	W-C/MSI
			J = 7.6 Hz, 1H), 7.64 (s, 2H), 7.21 (d, J = 7.3 Hz, 1H), 7.10 (s, 4H), 6.71 (d, J = 8.4 Hz, 1H), 6.59 (s, 2H), 2.01 (s, 6H).
247	434.00	1.88	1H NMR (400 MHz, DMSO) 5 8.60 (s, 1H), 8.03 (S, 2H), 7.61 (s, 2H), 7.01 (s, 3H), 6.83 (s, 1H), 6.72 (s, 2H), 5.79 (s, 2H), 2.17 (s, 3H), 1,92 (s, 6H).
248	447.20	2.15
249	469.40	2.19
250	533.22	3.09
251	454.00	2.04	1H NMR (400 MHz, DMSO) 512.01 (s, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.21 (s, 2H), 7.14 (d, J = 7.8 Hz, 1H), 7.07 (d, J = 14.6 Hz, 4H), 6.81 (s, 1H), 5.66 (s, 2H), 2.30 (s, 3H), 1.99 (s, 3H), 1.09 (s, 9H).
252	466.50	2.04
253	464.00	2.02	1H NMR (400 MHz, DMSO) 5 12.78 (s, 1H), 8.01 (s, 1H), 7.70 (s, 2H), 7.57 (s, 1H), 7.15 (s, 2H), 7.07 (s, 1H), 7.00 (s, 1H), 6.69 (s, 2H), 5.63 (s, 2H), 3.79 (s, 3H), 2.16 (s, 3H), 1.85 (s, 6H).
254	451.30	1.32	1H NMR (400 MHz, DMS0-d6) δ 10.51 (s, 1H), 9.87 (s, 1H), 7.39 - 7.34 (m,lH), 7.32 - 7.21 (m, 6H), 6.91 (ddd, J = 7.7,2.5,1.5 Hz, 1H), 6.85 (s, 2H), 4.98 (S, 1H), 4.33 - 4.08 (m, 4H), 2.33 (s, 6H), 2.22 (s, 3H).
255	455.00	1.49
256	458.00	1.77	1H NMR (400 MHz, DMSO) 5 11.45 (s, 1H), 8.52 (s, 1H), 7.63 (s, 1H), 7,18 (d, J = 7.3 Hz, 1H), 6.86 (s, 2H), 6.69 (d, J = 8.4Hz,lH), 6.47 (s, 2H), 2.22 (s, 3H), 1.99 (s, 6H), 1.35 (S, 9H).
257	426.07	3.16
258	464.00	1.80	1H NMR (400 MHz, DMSO) 5 12.46 (s, 1H), 8.17 (s, 1H), 7.79 (s, 1H), 7.70 (s, 2H), 7.60 (s, 1H), 7.09 (d, 1 = 15.2 Hz, 2H), 6.90 (s, 1H), 6.76 (s, 2H), 5.69 (s, 2H), 3.91 (s, 3H), 2.19 (s, 3H), 1.96 (s, 6H).
259	462.20	1.95
260	462.30	1.87
261	456.09	1.84
262	483.40	3.30	___

1196

Gmpd..	wra	»
263	499.04	2.06
264	433.20	2.06
265	475.50	2.11	1H NMR (400 MHz, DMSO-d6) δ 11.96 (S, 1H), 9.07 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 6.91 (s, 2H), 6.81 (s, 2H), 2.25 (s, 3H), 1.96 (s, 6H), 1.04 (s, 9H).
266	465.40	2.29	1H NMR (400 MHz, DMSO-d6) §8.22 (dd, J = 7.9,1.3 Hz, 1H), 8.12 (dd, J = 7.6, 1.4 Hz, 1H), 7.97 (td, J = 7.8,1.5 Hz, 1H), 7.90 (td, 1 = 7.6,1.3 Hz, 1H), 7.00 (S, 1H), 6.74 (s, 2H), 5.43 (s, 2H), 2.17 (s, 3H), 2.06 (s, 6H), 1.16 (s, 9H).
267	478.30	2.09
268	517.00	2.08	1H NMR (400 MHz, DMSO) δ 12.16 (s, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.62 (s, 1HJ, 7.18 (s, 3H), 7.11 (d, J = 7.1 Hz, 1H), 6.96 (dd, J = 17.7, 9.9 Hz, SH), 6.69 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.85 (s, 2H), 2.75 (s, 2H), 2.26 (s, 3H), 1.97 (s, 6H).
269	456.40	2.04	1H NMR (400 MHZ, DMSO-d6) δ 12.28 (S, 1H), 10.62 (s, 1H), 7.85 7.80 (m, 2H), 6.99 - 6.93 (m, 3H), 6.75 (s, 2H), 5.43 (S, 2H), 2.17 (s, 3H), 2.07 (s, 6H), 1.14 (s, 9H).
270	483.40	2.28	1H NMR (400 MHz, DMSO-d6) § 12.35 (s, 1H), 7.46 - 7.39 (m, 1H), 7.27 - 7.20 (m, 2H), 7.07 - 7.01 (m, 1H), 6.98 (d, J = 1.2 Hz, 1H), 6.75 (s, 2H), 5.44 (s, 2H), 2.98 (s, 6H), 2.17 (s, 3H), 2.08 (s, 6H), 1.14 (s, 9H).
271	438.30	1.95
272	426.00	1.84	1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 7.8 Hz, 1H), 7.43 (s,2H),7.24 (d,J = 37.6 Hz, 7H), 6.93 (s, 1H), 3.17 (s, 2H), 1.12 (S, 9H).
273	484.30	2.95
274	438.22	1.86
275	492.00	2.36	1H NMR (400 MHz, DMSO) δ 12.28 (s, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.32 (s, 1H), 7.24 (s,lH),7.13 (s, 2H), 6.89 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.04 (s, 9H).

Π 97

,Cmpd. No. ..	LC/MS M+1	LC/RT ' min	_: NMR >
276	533.00	2.07
277	504.40	2.28
278	519.30	1.98
279	580.20	2.25
280	490.16	2.12
281	581.30	2.29
282	424.40	1.74
283	469.00	1.79	1H NMR (400 MHz, DMSO) 88.10 (s, 1H), 7.99 (s, 1H), 7.21 (s, 1H), 7.10 (s, 1H), 7.00 (s, 1H), 6.89 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.04 (s,9H).
284	478.90	2.81
285	467.00	1.89
286	454.00	2.02	1H NMR (400 MHz, DMSO) 8 12.04 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.22 (s, 2H), 7.09 (s, 5H), 6.82 (d, J = 9.3 Hz, 1H), 5.66 (s, 2H), 1.99 (s, 6H), 1.03 (s, 9H).
287	433.30	2.08
288	434.60	1.86
289	482.00	2.26	1H NMR (400 MHz, DMSO) 8 12.04 (s, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.30 (s, 1H), 7.13 (s, 3H), 6.90 (s, 2H), 6.81 (d, J = 10.4 Hz, 1H), 6.28 (s, 1H), 2.68 (s, 3H), 2.25 (s, 3H}, 1.94 (s, 6H), 1.04 (s, 9H).
290	449.00	2.03
291	473.20	1.74	1H NMR {400 MHz, DMS0-d6) 88.31 - 8.30 (m, 1H), 7.52 (d, J = 0.8 Hz, 1H), 7.49 (dd, J = 8.8, 1.6 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H), 7.19 (t, J = 2.0 Hz, 1H), 7.11 (d, J = 8.9 Hz, 1H), 7.05 - 7.01 (m, 1H), 6.84 (ddd, J = 8.0, 2.3,1.0 Hz, 1H), 6.73 (S, 2H), 5.69 (s, 2H), 2.16 (s, 3H), 1.89 (s, 6H).
292	467.20	5.47	1H NMR (300 MHz, DMSO) 8 1.01 (s, 9H), 1.92 (S, 6H), 2.22 (s, 3H), 5.57 (br. s, 2H), 6.73 (d, J=8.1 Hz, 1H), 6.85 (s, 2H), 6.97-7.07 (m, 2H), 7.11-7.20 (m, 2H), 7.56 (br. s, 2H), 8Ό9 (d, J=7.8 Hz, 1H)
293	507.30	2.11
294	468.20	2.16	1H NMR (400 MHz, DMSO-d6) 8 12.00 (s, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.25-7.19 (m, 2H), 7.12 (d,J = 7.8 \|

1198

Cmpd. Wm	fchOS	-iLG/RTÆ Sgrnirw	JL wi îi\| H a\| j®\|\|; »
			Hz, IH), 7.09 (dd, J = 1.8, 0.9 Hz, IH), 6.90 (s, 2H), 6.83 (s, IH), 5.66 (s, 2H), 2.26 (s, 3H), 1.95 (s, 6H), 1.04 (s, 9H).
295	463.40	1.90
296	440.00	1.94	IH NMR (400 MHz, DMSO) 5 12.07 (s, IH), 7.93 (d, J = 7.8 Hz, IH), 7.29 (d, J = 7.5 Ηζ,ΙΗ), 7.27-7.12 (m, 6H), 7.08 (d, J = 7.8 Hz, IH), 6.83 (d, J = 11.0 Hz, IH), 5.68 (s, 2H), 2.03 (s, 3H), 1.08 (s, 9H).
297	424.30	1.73
298	452.20	1.82
299	492.38	1.55
300	477.00	1.99
301	424.40	1.74
302	545.50	1.66
303	517.20	2.13
304	480.22	2.09
305	470.00	2.05	IH NMR (400 MHz, DMSO) δ 12.29 (s, IH), 11.71 (s, IH), 8.01 (d, J = 7.8 Hz, IH), 7.93 (s, IH), 7.61 (s, IH), 7.13 (d, J = 7.8 Hz, IH), 7.05 - 6.85 (m, 3H), 2.25 (s, 3H), 1.96 (s, 6H), 1.05 (s, 9H).
306	473.29	1.84
307	543.36	1.74	IH NMR (400 MHz, DMSO) δ 8.25 (dd, J = 7.3, 2.1 Hz, IH), 7.90 - 7.81 (m, J = 6.1 Hz, IH), 7.78 (d, J = 7.9 Hz, IH), 7.50 (s, IH), 7.45 (d, J = 10.1 Hz, IH), 7.34 (d, J = 7.9 Ηζ,ΙΗ), 6.986.84 (m, J = 10.7 Hz, IH), 6.54 - 6.40 (m, J = 6.7 Hz, IH), 4.17 - 4.01 (m, 2H), 3.84 (d, J = 6.5 Hz, 2H), 2.15 2.01 (m, IH), 2.01 -1.90 (m, J = 22.2 Hz, 2H), 1.80 -1.61 (m, 2H), 1.13 (d, J = 6.2 Hz, 6H), 0.99 (d, J = 6.7 Hz, 6H).
308	450.40	1.87
309	464.30	1.26
310	450.40	1.20
311	496.00	2.38	IH NMR (400 MHz, DMSO) δ 12.08 (s, IH), 7.95 (s, IH), 7.39 (s, IH), 7.22 (s, 2H), 7.12 (s, IH), 7.00 (s, IH), 6.90 (s, 2H), 2.92 (s, 6H), 2.25 (s, 3H), 1.93 (s, 6H), 1.04 (s, 9H).
312	455.18	2.91
313	466.20 \|	2.22 1

1199

Cmpd. WnîM	LC/MSi	ÿLG/Rîl
314	452.40	1.95
315	496.08	2.07
316	514.09	2.20
317	469.00	2.09	IH NMR (400 MHz, DMSO) 87.26 (s, IH), 7.21 (s, IH), 7.09 (d, J = 7.8 Hz, IH), 7.04 (s, IH), 6.89 (s, IH), 6.85 (d, J = 10.3 Hz, IH), 2.14 (s, 6H), 2.04 (s, 6H), 1.13 (S, 9H).
318	553.00	2.24	IH NMR (400 MHz, DMSO} S 13.80 (s, IH), 12.51 (s, IH), 8.08 (d, J = 7.8 Hz, IH), 7.9S (s, IH), 7.82 (d, J = 7.9 Hz, IH), 7.22 (d, J = 9.8 Hz, IH), 7.18 (s, IH), 6.95 (S, 2H), 6.89 (s, IH), 6.84 (d, J = 12.9 Hz, IH), 3.65 (d, J = 6.5 Hz, 2H), 2.27 (s, 3H), 2.07 (s, IH), 2.01 (s, 7H), 0.97 (d, J = 6.7 Hz, 6H).
319	452.00	1.11	IH NMR (400 MHz, DMSO) 89.99 (s, IH), 7.64 (d, J = 28.4 Hz, 3H), 7.33 (d, J = 17.6 Hz, 4H), 6.89 (s, 2H), 6.65 (s, IH), 5.30 (S, IH), 4.50 (s, IH), 4.30 (s, 3H), 2.38 (S, 6H), 2.22 (s, 3H).
320	561.30	2.31	IH NMR (400 MHz, DMSO-d6} 8 12.15 (s, IH), 8.10 (d,J = 7.9 Hz, IH), 7.75 - 7.61 (m, 4H), 7.23 (d, J = 7.2 Hz, IH), 6.99 - 6.88 (m, 4H), 6.71 (d, J = 8.4 Hz, IH), 6.56 - 6.46 (m, 2H), 3.77 (d, J = 6.6 Hz, 2H), 2.28 (s, 3H), 2.03 (s, 7H), 0.95 (d, J = 6.7 Hz, 6H).
321	511.30	1.58
322	468.00	2.25	IH NMR (400 MHz, DMSO) 88.06 {□, IH), 7.74 (s, IH), 7.36 (s, IH), 7.20 (s, IH), 6.99 (s, 2H), 6.87 (s, IH), 6.72 (s, IH), 2.34 (s, 3H), 2.04 (s, 6H), 1.33 (s, 2H), 1.13 (s, 9H).
323	469.00	2.11
324	455.00	1.88
325	457.30	1.87
326	464.40	2.14
327	439.30	1.98
328	448.10	2.17
329	530.34	1.70
330	454.00	2.16	IH NMR (400 MHz, DMSO) δ 12.52 (s, IH), 9.15 (S, IH), 8.90 (s, IH), 8.41 (d, J = 8.1 Hz, IH), 7.99 (d, J = 7.8 Hz, IH), 7.70 (s, IH), 7.11 (d, J = 7.8 Hz,

1200

Cmpd. y No.	LC/MS _t Mil '	^XCZRS; < min
			1H), 6.89 (s, 2H), 2.25 (s,3H), 1.91 (s, 6H), 1.04 (s, 9H}.
331	434.05	1.71
332	482.00	2.18	1H NMR (400 MHz, DMSO} δ 8.40 (s, 1H), 8.24 {S, 1H), 8.14 (s, 1H), 7.76 (s, 1H), 6.89 (s, 1H), 6.64 (s, 2H), 5.34 (s, 2H), 2.60 (S, 3H), 2.08 (s, 3H), 1.95 (s, 6H), 1.07 (s, 9H).
333	464.30	3.03
334	411.30	1.54
335	463.00	2.07	1H NMR (400 MHz, DMSO) S 12.56 (s, 1H), 7.68 (d, J = 7.7 Hz, 1H},7.53 (s, 2H), 7.44 (s, 2H), 7.30 (d, J = 7.7 Hz, 1H), 7.14 (S, 1H), 7.06 (s, 1H), 6.98 (d, J = 8.4 Hz, 1H), 6.68 (s, 2H), 5.64 (s, 2H}, 3.84 (S, 3H), 2.14 (s, 3H), 1.87 (s, 6H).
336	478.20	1.83
337	511.30	1.41
338	468.40	1.58
339	480.30	2.11
340	475.40	2.70	1H NMR (400 MHz, DMSO-06) δ 12.32 (S, 1H), 8.10 (d,J = 7.9 Hz, 1H), 7.82 {dd, J = 6.8, 2.9 Hz, 2H), 7.75 (d, J = 7.9 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.46-7.39 (m, 3H),7.22 (d, J = 7.4 Hz, 1H), 7.14 (t, J = 4.2 Hz, 2H), 7.12 7.05 (m, 1H), 6.71 (d,J = 8.3 Hz, 1H), 6.52 (s, 2H), 2.33 (s, 3H), 2.07 (s, 3H).
341	453.00	2.38
342	441.00	1.95	1H NMR (400 MHz, DMSO) Ô 7.19 (s, 1H), 7.13 (s, 1H), 7.06 (d, J = 8.0 Hz, 4H), 6.96 {S, 2H), 6.83 (s, 1H), 6.39 (s, 1H), 5.67 (s, 1H), 2.17 (s, 3H), 1.67 (s, 3H), 1.28 (s, 9H).
343	489.50	1.76
344	482.10	1.99
345	551.20	2.06
346	466.00	2.00
347	476.30	2.08
348	463.20	2.06
349	442.17	1.88
350	453.00	2.28
351	579.30	2.33
352	491.30	2.06	1H NMR (400 MHz, DMSO-d6} δ9.12

1201

Cmpd. No.	iLC/MS m+t “	LC/RT^ min	n mr
			- 9.10 (m, 1H), 9.10 - 9.08 {m, 1H), 8.49 (dd, J = 7.4, 1.2 Hz, 1H), 8.44 8.40 (m, 1H), 8.02 (dd, J = 8.5, 7.4 Hz, 1H}, 7.81 - 7.76 (m, 1H), 6.97 (s, 1H), 6.59 (s, 2H), 5.26 (s, 2H}, 2.10 (s, 3H), 1.78 (s, 6H), 1.15 (s,9H).
353	525.50	1.49
354	447.20	2.08	1H NMR (400 MHz, DMSO-d6) 87.72 - 7.67 (m, 2H), 7.41 - 7.30 (m, 4H), 6.94 (s, 1H), 6.84 (dd, J = 7.8, 7.0 Hz, 1H), 6.76 (dt, J = 7.0,1.2 Hz, 1H), 6.68 (s, 2H), 6.11 (s, 2H), 2.28 (s, 3H), 2.16 (s, 3H), 1.70 (s, 6H).
355	502.15	1.71
356	470.60	1.91
357	452.18	2.00
358	458.00	192.00	1H NMR (400 MHz, DMSO) δ 8.49 (s, 1H), 8.14 (S, 1H), 7.91 (s, 2H), 7.74 (s, 1H), 7.61 (s, 1H), 7.16 (d, J = 38.6 Hz, 3H), 6.81 (S, 2H), 5.80 (s, 2H), 2.10 (d, J = 38.6 Hz, 9H).
359	438.22	1.93
360	456.09	1.94
361	542.40	1.S4	1H NMR (400 MHz, DMSO-d6) 8 12.48 (S, 1H), 7.74 (d,J = 7.9 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.50 - 7.47 (m, 1H), 7.41 (dt, J = 10.0, 1.8 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 6.89 (dtj = 10.8, 2.3 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.46 (s, 2H), 3.84 (d, J = 6.6 Hz, 2H), 2.81 - 2.72 (m, 2H), 2.05 (dt, J = 13.4, 6.7 Hz, 1H), 1.82 -1.71 (m, 4H), 1.59 (s, 6H), Û.99 (d, J = 6.7 Hz, 6H).
362	482.40	1.97
363	499.10	2.04
364	545.00	2.13	1H NMR {400 MHz, DMSO) δ 12.42 (s, 1H), 8.08 (d, J = 7.6 Hz, 1H), 7.65 (s, 1H), 7.44 {d, J = 8.1 Hz, 1H), 7.31 (s, 1H), 7.26 - 7.16 (m, 2H), 7.11 (d, J = 7.6 Hz, 1H), 6.92 {d, J = 9.0 Hz, 1H), 6.81 (s, 2H), 6.72 (d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 2.17 (s, 3H), 1.98 (s, 6H), 0.97 (s, 10H).
365	482.00	2.18	1H NMR (400 MHz, DMSO) δ 12.29 (s,

1202

Cmpd. j No. j	LC/MS : ... M-1 ,	LC/RTy .min &&	OMI»
			1H), 8.48 (s, 1H), 8.34 (s, 1H), 7.92 (s, 1H), 7.27 (s, 1H), 7.09 (s, 1H), 6.89 (s, 2H), 3.93 (s, 3H), 2.24 (s, 3H), 1.90 (s, 6H), 1.32 (S, 3H), 0.67 (d, J = 15.3 Hz, 4H).
366	475.20	4.99	1H NMR (300 MHz, DMSO-d6): § 2.16 {S, 6 HJ, 2.17 (s, 3 H), 5.55 (s, 2 H), 6.80 (s, 2 H}, 6.83 - 6.90 {m, 1 H), 7.08 - 7.15 (m, 1 H), 7.21 - 7.34 (m, 3 H), 7.35.7.44 (m, 2 H), 7.54 {s, 1 H), 7.60 -7.67 (m,2H).
367	455.00	2.00
368	556.40	2.77	1H NMR (400 MHz, Chloroform-d) 8 15.49 (S, 1H), 8.49 (d, J = 8.2 Hz, 1H), 7.75 - 7.56 (m, 3H), 7.34 (t, J = 1.8 Hz, 1H), 7.30 (dt, J = 9.4,1.9 Hz, 1H), 6.75 - 6.66 (m, 2H), 3.95 (s, 1H), 3.78 (d, J = 6.5 Hz, 2H), 3.42 (s, 1H), 2.88 - 2.74 (m, 1H), 2.23 (dd, J = 12.5, 8.0 Hz, 1H), 2.17 - 2.08 (m, 1H), 1.98 - 1.87 {m, 1H), 1.55 (s, 3H), 1.39 (s, 3H), 1.31 (d, J = 6.7 Hz, 3H), 1.05 (d, J = 6.7 Hz, 6H).
369	514.03	2.07
370	479.00	2.05
371	556.40	2.87	1H NMR {400 MHz, Chloroform-d) δ 13.89 (s, 1H), 8.43 (d, J = 8.1 Hz, 1H), 7.72 - 7.59 (m, 3H), 7.39 - 7.32 (m, 2H), 6.75 - 6.65 (m, 2H), 3.78 (d, J = 6.5 Hz, 2H), 3.50 - 3.43 (m, 2H), 2.91 (s, 2H), 2.44 (dq, J = 10.0, 6.3 Hz, 2H), 2.13 (hept, J = 6.6 Hz, 1H), 1.20 (d, J = 6.8 Hz, 6H), 1.06 (d, J = 6.7 Hz, 6H).
372	485.30	1.89
373	432.70	1.29
374	511.00	1.89	1H NMR (400 MHz, DMSO) Ô 13.81 (s, 1H), 12.45 (S, 1H), 8.03 {s, 2H), 7.66 (S, 1H), 7.36 (s, 1H), 6.91 (s, 5H), 3.84 (S, 3H),2.24 (s,3H), 2.01 (s,6H).
375	533.20	2.20
376	537.30	3.07
377	466.00	1.38	1H NMR (400 MHz, DMSO) δ 10.52 (s, 1H), 9.72 (s, 1H), 8.03 (s, 1H), 7.53 (s, 1H), 7.31 (t, J = 20.3 Hz, 6H), 6.91 (s, 2H), 4.41 (d, J = 13.3 Hz, 1H), 4.26 (d,

1203

Cmpd. . No. -	. LC/MS Mil ^:	I.C/RT S min
			J = 15.8 Hz, 2H}, 4.14 (d, J = 13.2 Hz, 1H), 2.39 (S, 7H), 2.24 (s, 3H), 1.82 (s, 3H).
378	439.00	1.27	1H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 7.73 (s, 1H), 7.42 (s, 1H), 7.26 (d, J = 18.8 Hz, 3H), 6.90 (s, 2H), 6.60 (s, 1H), 4.13 (s, 4H), 2.40 (s, 7H), 2.24 (s, 3H}, 1.73 (s, 3H).
379	528.30	2.28
380	528.29	1.90
381	521.50	1.78	1H NMR {400 MHz, DMSO-d6) δ 12.08 (s, 1H), 8.07 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.68 {s, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 8.1 Hz, 2H), 7.06 (dd, J = 8.3, 2.1 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 6.65 6.34 (m, 2H), 3.90 (d, J = 7.1 Hz, 2H), 2.31 (s, 3H), 2.07 (d, J = 4.0 Hz, 4H), 0.81 (d, J = 6.7 Hz, 6H).
382	488.30	1.47	1H NMR (400 MHz, DMSO-d6) δ 13.77 (s, 1H), 13.34 (s, 1H), 7.97 {s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.66 7.27 (m, 3H), 7.01 - 6.76 (m, 2H), 4.13 (q, J = 6.9 Hz, 2H}, 4.02 (s, 2H), 2.00 (s, 2H), 1.74 -1.61 (m, 2H), 1.36 (t, J = 6.9 Hz, 3H), 1.07 (d,J = 6.2 Hz, 6H).
383	554.40	3.03
384	567.40	2.73	1H NMR (400 MHz, DMSO-dS) S 12.50 (s, 1H), 8.24 (d, J = 5.4 Hz, 1H), 7.75 (s, 1H), 7.58 (s, 1H), 7.51 (dd, J = 5.4,1.5 Hz, 1H), 7.28 (s, 2H), 7.16 (s, 1H), 6.62 (s, 1H), 6.42 (s, 1H), 5.30 (p, J = 6.2 Hz, 1H), 2.19 (td, 1 = 12.8, 11.1, 6.8 Hz, 1H), 1.86 (dd, J = 11.8, 5.6 Hz, 1H), 1.78 - 1.62 (m, 2H), 1.61 (s, 3H), 1.58 (s, 3H), 1.45 -1.35 (m, 2H), 1.27 (d, J = 6.1 Hz, 3H}, 1.17 (t, J = 7.1 Hz, 1H), 0.89 (dd, J = 12.8, 6.3 Hz, 9H).
385	572.25	1.99
386	542.23	2.97
387	538.20	2.03
388	528.12	2.75
389	525.33	1.12

1204

Cmpd. ï No.	LC/MS,. . M+1	LC'RT ^rmn	^?NMRY
390	589.00	2.25	1H NMR (400 MHz, DMS0-d6) δ 12.80 (S, 1H), 8.52 (dd, J = 2.5, 0.7 Hz, 1H), 8.02 (dd, J = 8.7, 2.5 Hz, 1H), 7.85 (s, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 7.2 Hz, 1H), 6.83 (dd, J = 8.6, 0.7 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 5.32 (p, J = 6.2 Hz, 1H), 3.95 (s, 2H), 1.97 - 1.82 (m, 2H), 1.64 (dd, J = 8.9, 5.3 Hz, 2H), 1.33 (d, J = 6.2 Hz, 6H), 1.04 {d, J = 6.1 Hz, 6H).
391	534.00	2.00	1H NMR (400 MHz, DMSO) δ 13.80 (s, 1H), 12.63 (s, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.71 (d,J = 7.9 Hz, 1H), 7.45 (s, 1H), 6.94 (s, 2H), 6.88 (s, 1H), 3.48 (s, 3H), 2.26 (s, 3H), 1.99 (s, 6H).
392	467.20	1.28	1H NMR (400 MHz, DMS0-d6) δ 13.20 (S, 1H), 12.55 (s, 1H), 8.25 (dd, J = 7.2, 2.2 Hz, 1H), 8.02 - 7.96 (m, 2H), 7.82 (d, J = 7.9 Hz, 2H), 7.30 (dd, J = 8.1, 6.6 Hz, 3H}, 6.44 (t, J = 6.8 Hz, 1H), 4.13 - 4.02 (m, 2H), 2.36 (s, 3H), 2.03 -1.92 (m, 2H), 1.76 - 1.61 (m, 2H), 1.14 (d, J = 6.2 Hz, 6H).
393	538.25	2.14
394	481.00	1.20	1H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 7.64 (s, 1H), 7.14 (s, 2H), 6.90 (s, 2H), 6.69 (s, 3H), 4.37 (d, J = 12.8 Hz, 1H), 4.25 (s, 2H), 3.96 (d, J = 12.9 Hz, 1H), 2.39 (s, 6H), 2.24 (s, 3H), 1.85 (s, 3H).
395	556.34	2.90
396	537.50	1.93
397	539.50	1.72
398	582.28	2.12
399	517.20	2.18
400	511.32	1.04
401	443.40	2.08	1H NMR (400 MHz, DMS0-d6) δ 13.72 (S, 1H), 12.02 (s, 1H), 8.51 (s, 1H), 7.96 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 7.8 Hz, 1H), 6.90 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.04 (s, 9H).
402	525.30	2.16	1H NMR (400 MHz, DMS0-d6) 88.21 (d, J = 5.4 Hz, 1H), 7.71 - 7.57 (m, 1H),

1205

.Cmpd. ) No..	LC/MS / M+1>	LC/RT fe. min .	“ΐΐί?îwWKÿ Λ,. Λ
			7.55 - 7.43 (m, 2H), 7.29 - 7.23 (m, 1H), 7.17 {s, 1H), 7.00 (s, 1H), 6.54 (s, 1H), 6.32 {s, 2H), 5.27 (p, J = 6.1 Hz, 1H), 2.87 (s, 2H), 2.16 - 2.07 (m, 1H), 1.82 (dd, J = 11.7,5.6 Hz, 1H), 1.62 (s, 3H), 1.55 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 1.31 (d, J = 6.2 Hz, 6H), 0.79 (d, J = 6.3 Hz, 3H).
403	526.20	1.56
404	491.00	2.06	1H NMR (400 MHz, DMSO) δ 12.38 (s, 1H), 7.63 (s, 1H), 7.49 (d, J = 6.2 Hz, 2H), 7.18 (d, J = 73 Hz, 1H), 7.02 (d, J = 10.4 Hz, 1H), 6.75 (d, J = 9.0 Hz, 3H), 6.69 {d, J = 8.4 Hz, 1H), 6.46 (s, 2H), 5.66 (S, 2H), 2.90 (s, 1H), 2.18 (s, 3H), 1.96 (s, 6H), 1.19 (d, J = 6.9 Hz, 6H).
405	511.00	2.00
406	495.00	1.27	1H NMR (400 MHz, DMSO) 6 9.74 (s, 1H), 7.77 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 7.1 Hz, 1H), 6.91 (s, 6H), 4.39-4.21 (m, 3H), 4.08 (d, J = 13.2 Hz, 1H), 3.71 (s, 5H), 3.17 (s, 1H), 2.40 (S, 6H), 2.24 (s, 3H), 1.81 (s, 3H).
407	410.30	1.76
408	542.40	1.98
409	489.00	1.67	1H NMR {400 MHz, DMSO) δ 12.66 (s, 1H), 8.14 {d, J = 8.8 Hz, 2H), 7.95 (dd, J = 22.2, 8.2 Hz, 2H), 7.64 (s, 1H), 7.47 {d, J = 8.1 Hz, 2H), 7.15 (d, J = 3.9 Hz, 3H), 7.06 (d, J = 8.9 Hz, 2H), 6.81 (d, J = 8.4 Hz, 1H), 4.11 (d, J = 7.0 Hz, 2H), 2.33 (s, 3H), 1.38 (s, 3H).
410	510.00	1.37	1H NMR (400 MHz, DMSO) δ 12.27 {s, 1H), 10.44 (s, 1H), 8.11 (s, 1H), 7.71 (s, 1H), 7.17 (s, 1H), 6.89 (s, 2H), 6.81 (s, 2H), 6.35 (s, 1H), 4.01 {d, J = 16.8 Hz, 4H), 3.76 (S, 2H), 3.17 (s, 4H), 2.39 (s, 6H), 2.24 (s, 3H), 2.07 (s, 1H), 1.62 (s, 3H), 1.24 (s, 3H).
411	417.00	1.90	1H NMR (400 MHz, MeOD) 68.21 (s, 1H), 7.91 (s, 1H), 7.69 (s, 1H), 7.48 (d, J = 7.2 Hz, 1H), 7.07 (d,J = 8.8Hz, 1H), 3.16 (s, 1H), 1.74 (dj = 21.2 Hz, \| 7H), 1.46 (s, 9H), 1.26 (S, 3H).

1206

ΟπιράΛ No.	M-C/MSl . M+1 1·	LC/RTÆ M mirirÿ?
412	552.60	1.08
413	519.42	2.97
414	468.30	1.62
415	516.22	1.63	1H NMR (400 MHz, DMSO) δ 13.77 (s, 1H), 13.32 (s, 1H), 7.97 (s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.53 - 7,40 (m, 3H), 6.90 (dt, J = 10.8,2.3 Hz, 1H), 6.86 (d, J = 2.1 Hz, 1H), 4.01 (d, J = 5.0 Hz, 2H), 3.84 (d, J = 6.6 Hz, 2H),3.31 (s, 3H), 2.51 (dq, J = 7.3,1.8 Hz, 1H), 2.07 - 1.94 (m, 4H), 1.67 (d, J = 3.6 Hz, 2H), 1.06 (d, J = 6.2 Hz, 6H), 0.99 {d, J = 6.7 Hz, 7H).
416	557.36	2.41
417	429.40	1.61
418	542.40	2.80
419	572.32	2.03
420	540.40	2.17	1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 7.76 - 7.S9 (m, 2H), 7.50 - 7.40 (m, 3H), 7.24 (d, J = 7.1 Hz, 1H), 6.91 (dt, J = 10.7, 2.3 Hz, 1H), 6.72 (d,J = 8.6 Hz, 1H), 6.48 (5, 2H), 4.23 (p, J = 2.3 Hz, 2H),3.85 (d, J = 6.5 Hz, 2H), 2.12 -1.97 (m, 1H), 1.68 1.57 (m, 4H), 1.47 -1.36 (m, 4H), 1.00 (d, J = 6.7 Hz, 6H).
421	528.50	1.90
422	543.36	1.95
423	510.00	2.38	1H NMR (400 MHz, DMSO) δ 12.31 (s, 1H), 8.47 (s, 1H), 8.33 (d, J = 7.6 Hz, 1H), 7.69 (S, 1H), 7.26 (s, 1H), 6.89 (s, 2H), 3.94 (s, 3H), 2.66 (s, 2 H), 2.25 (s, 3H), 1,92 (s, 6H), 1.65 (d, J = 35.1 Hz, 4H), 0.91 (s, 6H).
424	570.40	2.66
425	542.30	2.54
426	570.12	1.98
427	542.00	1.74	1H NMR (400 MHz, MeOD) δ8.27 (s, 1H), 8.21 (d, J = 9.4 Hz, 1H), 7.40 (s, 9H), 7.05 (s, 1H), 6.89 (s, 2H), 5.12 (s, 1H), 4.52 (s, 4H), 3.81 (s, 3H), 2.39 (s, 6H), 2.25 (s, 4H).
428	523.30	2.01	1H NMR (400 MHz, DMSO-d6) δ8.77 {d, J = 2.4 Hz, 1H), 8.27 (dd, J = 8.7, 2.5 Hz, 1H), 7.54 (d, J = 7.5 Hz, 1H),

1207

Cmpd.ï NoiS4	LC/MS B m+1	LC/RT min -
			7.46 (t, J = 7.8 Hz, 1H), 7.01 (d, J = 7.0 Hz, 2H), 6.82 (d, J = 8.7 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.15 (s, 2H), 5.24 5.11 (m, 1H),4.25 (s, 2H), 2.42 (dddd, J = 10.5, 9.4, 5.2, 2.4 Hz, 2H), 2.07 (qdd, J = 9.8,7.8,2.7 Hz, 2H), 1.96 1.74 (m, 3H), 1.62 (dddd, J = 29.1, 15.5, 11.3, 8.4 Hz, 3H), 1.06 (d, J = 6.1 Hz, 6H).
429	531.00	2.09	1H NMR (400 MHz, DMSO) δ 12.49 (s, 1H), 8.10 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H), 7.37 - 7.20 (m, 5H), 6.91 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 2.52 (s, 2H), 2.25 (s, 3H), 2.00 (s, 6H), 1.39 (s, 2H), 0.73 (s, 3H).
430	439.20	1.85
431	526.13	1.91
432	525.33	1.70
433	531.18	1.95
434	520.50	2.00	1H NMR (400 MHz, DMSO-d6] 08.31 (d, J = 2.1 Hz, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.787.73 (m, 2H), 7.66 (d, J = 8.0 Hz, 1H), 7.16 - 7.04 (m, 4H), 6.97 - 6.91 (m, 2H), 4.05 (q, J = 7.0 Hz, 2H), 2.32 (s, 3H), 2.04 (s, 3H), 1.31 (t, J = 6.9 Hz, 3H).
435	539.30	1.81
436	547.30	2.20
437	524.50	0.90
438	557.26	2.42
439	525.20	2.04
440	538.24	1.97
441	511.40	1.59	1H NMR (400 MHz, DMSO-d6) δ 12.47 (S, 1 H), 8.85 (d, J = 2.4 Hz, 1H), 8.31 (dd, J = 8.8, 2.5 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.19 (dd, J = 9.7, 7.6 Hz, 2H), 6.84 (d, J = 8.7 Hz, 1H), 6.71 (d,J = 8.3 Hz, 1H), 5.31 (p, J = 6.2 Hz, 1H), 4.41 (t, J = 6.6 Hz, 1H), 3.12 - 2.97 (m, 1H), 2.86 - 2.72 (m, 1H), 2.26 - 2.11 (m, 1H), 1.89 (s, 1H), 1.70 -1.52 (m, 1H), 1.32 (d, J = 6.1 Hz, 6H), 1.04 (d, J = 6.4 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H).

1208

Cmpd. No.·.	LC/MS M+O	. LC/RT·. À min dS	^nmr WMRf
442	516.21	1.67
443	482.00	2.41	1H NMR (400 MHz, DMSO) 8 8.01 (s, 2H), 7.70 (d, J = 34.2 Hz, 3H), 6.96 {d, J = 10.2 Hz, 3H), 5.43 (s, 2H), 2.09 (s, 6H), 1.21 (S, 9H), 1.15 (s, 9H).
444	451.40	1.63
445	470.35	1.60	1H NMR (400 MHz, DMSO) 88.11 8.02 (m, J = 8.9 Hz, 2H), 7.97 (d, J = 2.4 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H}, 7.46 (d, J = 8.0 Hz, 1H),7.O7 - 6.99 (m, J = 8.9 Hz, 2H), 6.85 (d, J = 2.4 Hz, 1H), 4.09 (q, J = 7.0 Hz, 2H), 3.70 3.55 (m, J = 12.7 Hz, 2H), 2.97 - 2.81 (m, J = 11.6 Hz, 2H), 1.72 - 1.62 (m, J = 13.0 Hz, 2H), 1.62 - 1.50 (m, 1H), 1.35 (t, J = 7.0 Hz, 3H), 1.32 - 1.16 (m, 2H), 0.94 (d, J = 6.4 Hz, 3H).
446	499.60	1.76
447	590.33	2.18
448	492.00	1.59	1H NMR (400 MHz, DMSO) 8 11.09 (s, 1H), 7.64 (S, 1H), 7.33 (s, 4H), 7.20 (s, 1H), 7.11 (s, 1H), 6.72 (s, 2H), 4.58 {s, 1H), 4.16 (s, 2H), 3.91 (s, 2H}, 2.22 (s, 3H), 2.19 (s, 3H), 2.12 (s, 6H), 1.60 (s, 3H), 1.48 (S, 3H).
449	521.22	2.59
450	519.30	2.01
451	543.43	2.65
452	543.29	2.35
453	512.40	2.02
454	537.30	2.16	1H NMR (400 MHz, DMSO-d6) 88.77 (d, J = 2.5 Hz, 1H), 8.27 (dd, J = 8.6, 2.5 Hz, 1H), 7.60 - 7.42 (m, 2H), 7.00 (t, J = 6.7 Hz, 2H), 6.88 (d, J = 8.6 Hz, 1H), 6.56 - 6.46 (m, 1H), 6.25 (s, 2H), 4.23 (bs, 2H), 4.10 (s, 2H), 1.86 (s, 2H), 1.56 {bs, 2H), 1.17 (bs, 3H), 1.03 (d, J = 6.1 Hz, 6H), 0.58 - 0.49 (m, 2H), 0.43 - 0.34 (m,2H).
455	524.30	1.51
456	480.24	1.75
457	561.14	2.97
458	542.30	1.92	1H NMR {400 MHz, DMSO-d6) 8 12.59 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.69 - 7.60 (m, 1H), 7.52 - 7.45 (m,

1209

Cmpd. No?	LC/MS - M+1^	* LÇ/RpSj ” 'min ï.	NMR liSfe·
			1H), 7.42 (d, J = 10.0 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H}, 6.93 - 6.84 (m, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 4.13 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H), 2.11 -1.99 (m, 3H), 1.52 -1.45 (m, 2H), 1.04 0.95 (m, 12H).
459	486.20	1.43
460	456.21	1.17
461	608.00	2.23	1H NMR (400 MHz, DMSO) δ 13.78 (s, 1H), 13.05 {S, 1H), 8.36 (d, J = 28.4 Hz, 3H), 8.16 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.28 - 7.16 (m, 2H), 6.93 (S, 2H), 6.84 (d, J = 10.7 Hz, 1H), 3.65 (d, J = 6.5 Hz, 2H), 2.26 (s, 3H), 2,02 (d, J = 42.5 Hz, 9H), 0.97 (d, J = 6.7 Hz, 6H).
462	451.50	1.72
463	507.41	3.02
464	525.30	1.57
465	588.50	1.31	1H NMR (400 MHz, DMS0-d6) δ8.10 (d, J = 7.8 Hz, 1H), 7.67 (s, 1H), 7.61 (d, J = 7.9 Hz, 1H), 7.54 (s, 1H), 7.45 7.40 (m, 1H), 7.35 - 7.22 (m, 2H), 7.11 - 7.05 (m, 1H), 6.91 (s, 2H), 6.48 6.43 (m, 1H), 6.08 (s, 2H), 3.55 (t, J = 4.6 Hz, 4H), 3.42 (s, 2H), 2.55 (s, 1H), 2.32 - 2.27 (m, 5H), 2.27 (s, 3H), 2.03 (S, 6H).
466	547.30	1.87	1H NMR (400 MHz, DMS0-d6) δ8.27 (d, J = 19.3 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.51 (s, 1H), 7.43 (d, J = 10.1 Hz, 1H), 7.28 (dd, J = 14.4, 8.0 Hz, 1H), 6.90 (dt, J = 10.6, 2.3 Hz, 1H), 4.61 -4.44 {m, 1H), 3.84 (d, J = 6.7 Hz, 2H), 3.40 - 2.86 (m, 4H), 2.16 -1.91 (m, 2H), 1.71 1.60 (m, 7H), 1.60 -1.49 (m, 1H), 1.16 (s, 1H), 1.06-0.96 (m, 10H).
467	479.32	1.20
468	497.51	3.50
469	521.52	2.73
470	510.50	1.42
471	539.50	1.66
472	474.00	2.36	1H NMR (400 MHz, DMSO) Ô7.88

1210

Cmpd. s ., Ν;κ	LC/MS; M : 1	LC/RT min	..... NMR · _; Â -
			(dd, J = 10.8, 4.8 Hz, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 6.88 (s, 1H), 6.67 (s, 2H), 5.37 (s, 2H), 3.11 (s, 1H), 2.09 (s, 3H), 2.00 (d, J = 6.5 Hz, 6H), 1.08 (s, 9H).
473	604.40	3.25
474	495.00	1.18	1H NMR (400 MHz, DMSO) Ô9.96 (s, 1H}, 9.61 (S, 1H), 7.90 (s, 1H), 7.44 6.61 (m, 7H), 4.39 (s, 3H), 4.16 (s, 2H), 3.74 (s, 3H), 2.41 (s, 5H), 2.24 (s, 3H), 1.97 (d, J = 80.3 Hz, 3H).
475	574.34	3.13
476	509.60	1.54	1H NMR (400 MHz, DMS0-d6) δ 12.39 (s, 1H), 8.85 (d,J = 2.5 Hz, 1H), 8.31 (dd, J = 8.7, 2.5 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.2 Hz, 1H), 7.19 (dd, J = 14.2, 7.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 6.45 (s, 1H), 5.30 (h, J = 6.2 Hz, 1H), 4.56 (s, 1H), 2.98 (d, J = 9.7 Hz, 1H), 2.44 (s, 1H), 2.35 - 2.26 (m, 1H), 1.71 -1.13 (m, 7H) 1.32 (d, J = 96.2 Hz, 6H).
477	533.20	2.06
478	415.00	1.48	1H NMR (400 MHz, MeOD) δ 8.56 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1 H), 6.08 (s, 1H), 2.31 (s, 2H), 2.20 (s, 2H), 1.69 (d, J = 17.3 Hz, 4H), 1.53 (s,9H).
479	528.31	1.99
480	466.00	1.26
481	605.40	2.21
482	469.27	2.05
483	556.30	1.76	1H NMR (400 MHz, DMSO-d6) δ 13.97 (s, 1H), 7.84 (s, 1H), 7.65 - 7.60 (m, 1H), 7.23 - 7.18 (m, 1H), 6.99 6.94 (m, 2H), 6.89 {d,J = 11.3 Hz, 1H), 6.72 - 6.67 (m, 1H), 6.42 (s, 2H), 3.92 - 3.87 (m, 2H), 3.81 (d, J = 6.5 Hz, 2H), 2.30 (S, 3H), 2.09 - 1.98 (m, 1H), 1.65 -1.60 (m, 2H), 1.07 (d, J = 6.2 Hz, 6H), 0.98 (d, J = 6.7 Hz, 6H).
484	610.40	2.10	1H NMR (400 MHz, Methano!-d4) δ 8.25 (d, J = 2.8 Hz, 1H), 7.88 (d, J = 8.3

1211

Cmpd. No?	LC/MS M+1 'S	LC/RT '· min ··	: NMR ' +
			Hz, 1H), 7.69 (dd, J = 8.7,7.2 Hz, 1H), 7.31 (d, J = 7.2 Hz, 1H), 6.98 (dd, J = 8.5, 6.5 Hz, 2H), 5.99 (d, J = 2.8 Hz, 1H), 3.90 (s, 2H), 3.63 (q, J = 6.1, 5.3 Hz, 4H), 2.80 - 2.66 (m, 2H), 2.26 (d, J = 10.4 Hz, 1H), 1.90 (dd, J = 11.9, 5.6 Hz, 1H), 1.68 (q, J = 5.1, 4.7 Hz, 2H), 1.61 (d, J = 5.3 Hz, 10H), 1.47 (t, J = 12.2 Hz, 1H), 1.04 (s, 9H), 0.88 (d, J = 6.3 Hz, 3H).
485	549.43	2.85
486	525.30	1.41	1H NMR (400 MHz, DMS0-d6) δ 14.19 (s, 1H), 8.46 (d, J = 2.5 Hz, 1H), 7.98 (dd, J = 8.6, 2.5 Hz, 1H), 7.88 (s, 1H), 7.62 (t, J = 7.9 Hz, 1H), 7.20 (d, J = 7.2 Hz, 1H), 6.84 (d,J = 8.6 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.40 (s, 2H), 5.32 (p, J = 6.2 Hz, 1H), 3.97 - 3.85 (m, 2H), 2.36 (s, 3H), 2.11 - 2.00 (m, 2H), 1.71 -1.57 (m, 2H), 1.33 (d, J = 6.2 Hz, 6H), 1.08 (d, J = 6.3 Hz, 6H).
487	529.18	1.44
488	604.40	323.20
489	574.33	1.33
490	594.30	3.20	1H NMR (400 MHz, MethanoPd4) δ 8.16 (d, J = 8.1 Hz, 1H), 7.74 - 7.62 (m, 2H), 7.49 (t, J = 1.9 Hz, 1H), 7.45 7.36 (m, 2H), 6.79 (ddd, J = 8.5, 4.5, 1.9 Hz, 2H), 5.45 (p, J = 6.1 Hz, 1H), 3.89 - 3.77 (m, 2H}, 3.62 (d, J = 9.3 Hz, 1H), 3.16 (dd, J = 9.2, 4.8 Hz, 1H), 2.16 -1.95 (m, 2H), 1.89 (tt, J = 8.1, 4.3 Hz, 1H), 1.15 (s, 1H}, 1.06 (dd, J = 6.8, 2.3 Hz, 6H), 0.85 (td, J = 8.1,5.8 Hz, 1H).
491	525.30	2.23	1H NMR (400 MHz, DMSO-d6) 58.20 (d, J = 5.4 Hz, 1H), 7.61 (d, J = 7.5 Hz, 1H), 7.56 - 7.43 (m, 2H), 7.32 (d, J = 1.4 Hz, 1H), 7.17 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 7.1 Hz, 1H), 6.53 (d, J = 8.3 Hz, 1H), 6.32 (s, 2H), 4.24 (ΐ, J = 6.7 Hz, 2H), 2.S9 (dd, J = 15.6, 8.8 Hz, 2H), 2.09 (d, J = 13.2 Hz, 1H), 1.87 1.67 (m, 3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.36 (t, J = 11.9 Hz, 1H), 0.97 (t, J = 7.4 Hz, 3H), 0.78 (d,J = 6.3 Hz, 3H).

1212

Cmpd* ) No.	-LC/MS^ Ü M-i-1	LC/RTÿ mm-w	MH® NM®®®**¹
492	557.50	1.89
493	5S4.40	3.12	IH NMR (400 MHz, DMSO-d6) δ 12.44 (s, IH}, 7.84 (d, J = 7.9 Hz, IH), 7.64 (dd, J = 8.4, 7.3 Hz, IH), 7.53 (t, J = 1.8 Hz, IH), 7.45 (dt, J = 10.0, 2.0 Hz, IH), 7.36 (d, J = 8.0 Hz, IH), 7.21 (d, 1 = 7.2 Hz, IH), 6.88 (dt, J = 10.6, 2.3 Hz, IH), 6.70 (d, J = 8.2 Hz, IH), 6.44 (s, 2H), 5.12 (dd, J = 8.5, 3.7 Hz, IH), 3.83 (qd, J = 9.2,6.6 Hz, 2H), 2.81 (dt, J = 14.0, 7.2 Hz, IH), 2.67 (t, 1 = 9.3 Hz, IH), 2.10-1.97 (m, IH), 1.87 -1.63 (m, 4H), 1.26 (dp, J = 21.5, 7.3 Hz, 2H), 0.99 (dd, J = 6.6,1.3 Hz, GH), 0.83 {t, J = 7.5 Hz, 3H), 0.74 (d, J = 12.5 Hz, 6H).
494	548.20	2.08
495	537.34	1.23
496	556.40	2.54	IH NMR (400 MHz, Methanol-d4) δ 8.60 (d, J = 8.3 Hz, IH), 8.08 (d, J = 8.3 Hz, IH), 7.70 (dd, J = 8.6, 7.3 Hz, IH), 7.50 (t, J = 1.9 Hz, IH), 7.48 - 7.41 (m, IH), 7.36 (dd,J = 7.4,0.8 Hz, IH), 6.85 (dt, J = 10.5, 2.3 Hz, IH), 6.80 (dd, J = 8.5, 0.8 Hz, IH), 4.59 (h, J = 7.2 Hz, IH), 3.84 (d, J = 6.4 Hz, 2H), 2.61 - 2.47 (m, IH), 2.30 - 2.19 (m, 2H), 2.17 -1.92 (m, 2H), 1.53 (s, 3H), 1.37 (s, 3H), 1.33 (d, J = 6.5 Hz, 3H), 1.06 (d, J = 6.7 Hz, 6H).
497	526.50	1.50
498	544.22	1.94
499	551.53	2.74
500	525.25	1.49
501	504.20	2.33	IH NMR (400 MHz, DMSO) Ô 12.83 (s, IH), 8.44 - 8.28 (m, 2H), 8.04 (d, J = 6.5 Hz, IH), 7.95 (d, J = 7.8 Hz, IH), 7.11 (dd, J = 31.1, 23.3 Hz, 2H), 6.89 (d, J = 3.4 Hz, 2H), 2.24 (s, 3H), 1.92 (S, 6H), 1.04 (S,9H).
502	573.30	1.97
503	557.26	2.39
504	558.07	2.02
505	523.32	2.65	IH NMR (400 MHz, DMSO) δ 12.43 (s, IH), 10.17 (S, IH), 8.14 - 8.11 (d,

1213

Cmpd. ΝόΒ·	LC/MS..'	LC/RT ₄min	NMR't;O\|M
			1H), 7.70 - 7.63 (m, 2H), 7.25 - 7.22 (d, 1H), 7.02 - 6.96 (m, 4H), 6.73 7.60 (d, 1H), 6.64 - 6.58 (m, 2H), 2.28 (s,3H), 2.03 (s, 6H)
506	606.15	2.02
507	497.31	1.64	1H NMR (400 MHz, DMSO) δ 8.31 (d, J = 2.2 Hz, 1H), 8.12-8.04 (m, J = 8.9 Hz, 2H), 7.94 - 7.86 (m, J = 5.1, 2.9 Hz, 2H), 7.51 (d, J = 8.1 Hz, 1H), 7.03 (d, J = 8.9 Hz, 2H), 4.10 (q, J = 7.0 Hz, 2H), 3.67 - 3.61 (m, J = 12.5 Hz, 2H), 3.03 2.89 (m,J = 11.6 Hz, 2H), 1.73 -1.51 (m, 1= 22.5, 9.5 Hz,3H), 1.35 (t, J = 7.0 Hz, 3H), 1.33 - 1.18 (m, 2H), 0.94 (d, J = 6.4 Hz, 3H).
508	52S.OO	1.45
509	559.20	1.87
510	570.44	3.43	1H NMR (400 MHz, DMSO) δ 7.82 7.79 (d, 1H), 7.63 - 7.57 (m, 2H), 7.52 - 7.46 (m, 3H), 7.35 - 7.32 (d, 1H), 6.95 - 6.91 (d, 1H), 3.85 (s, 3H), 3.85 3.83 (d, 2H3.17 (m, 4H), 2.10 - 2.00 (m, 1H), 1.30 (m, 4H), 1.01 - 0.98 (d, 6H), 0.94 (s, 6H).
511	525.40	1.62
512	440.40	1.93
513	504.41	1.87
514	508.31	2.51
515	468.10	5.33	0.96 (S, 9H), 1.90 (s, 6H), 2.17 (s, 3H), 5.78 (br. s., 2H), 6.59 (d, 1=8.2 Hz, 1H), 6.71 (s, 2H), 6.82 {d, J=7.8 Hz, 1H), 7.19-7.31 (m, 3H), 7.36-7.47 (m, 1H},8.15 (d, 1=7.8 Hz, 1H).
516	542.30	2.58
517	520.40	1.83	1H NMR (400 MHz, DMSO-d6) 3 12.56 (s, 1H), 12.06 (s, 1H), 8.26 (d, J = 7.3 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 5.6 Hz, 1H), 7.79 - 7.73 (m, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.16 7.04 (m, 3H), 6.97 - 6.91 (m, 2H), 6.46 (t, J = 6.7 Hz, 1H), 4.05 (q,J = 6.9 Hz, 2H), 2.32 (s, 3H), 2.07 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H).
518	481.00	1.90	1H NMR (400 MHz, DMSO) Ô 13.82 (s, 1H), 12.52 (s, 1H), 8.08 (d, J = 7.8 Hz,

1214

Cmpd.. No.Λ	LC/MS Mil „	LC/RT . min	1» W8\|S
			1H), 7.99 (s, 1H), 7.81 (s, 2H), 7.74 (d, J = 7.9 Hz, 1H), 7.26 (s, 2H), 6.95 (s, 2H), 6.89 (s, 1H), 2.28 (s, 3H), 2.01 (s, 6H).
519	544.19	1.75
520	S39.30	1.85
521	509.13	1.34
522	539.23	1.77
523	538.30	1.58	1H NMR (400 MHz, DMSO-d6) δ 8.00 (d, J = 5.3 Hz, 1H), 7.72 - 7.57 (m, 1H), 7.54 -7.36 (m, 1H), 7.13-6.91 (m, 4H), 6.60 (s, 1H), 6.49 (s, 1H), 6.15 (s, 1H), 3.06 (t, J = 6.4 Hz, 2H), 3.00 2.86 (m, 1H), 2.25 - 2.07 (m, OH), 1.85 (ddd, J = 16.9,12.2,6.0 Hz, 2H), 1.61 (s, 3H), 1.57 (s, 3H), 1.39 (t, J = 11.8 Hz, 1H), 1.26 -1.12 (m, 2H), 0.91 (d, J = 6.7 Hz, 6H), 0.86 (d, J = 6.2 Hz, 3H).
524	474.00	1.85	1H NMR {400 MHz, DMSO) 813.10 (s, 1H), 8.56 {d, J = 4.9 Hz, 1H), 8.25 (d, J = 9.4 Hz, 1H), 8.08 (d, J = 8.2 Hz, 2H), 8.00 - 7.92 (m, 2H), 7.35 (d, J = 4.4 Hz, 4H), 7.24 (s, 1H), 7.04 (d, J = 8.0 Hz, 2H), 4.04 (s, 3H), 2.38 (s, 3H), 2.31 (s,3H).
525	534.20	1.90
526	497.50	1.25
527	540.30	2.99
523	530.22	1.86
529	401.00	1.40	1H NMR (400 MHz, MeOD) Ô8.48 (d, J = 8.4 Hz, 1H), 7.99 - 7.82 (m, 2H), 7.44 {d, J = 7.3 Hz, 1H), 7.07 (d, J = 8.0 Hz, 1H), 6.30 (S, 1H), 2.71 (s, 2H), 2.54 (s, 2H), 2.01 (s, 2H).
530	570.50	2.12	1H NMR (400 MHz, DMSO-d6) 67.78 (d, J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.48 (t,J = 1.8 Hz, 1H), 7.43 (dt, J = 10.0,1.9 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.1 Hz, 1H), 6.90 (dt, J = 10.6, 2.3 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 3.84 (d, J = 6.6 Hz, 2H), 3.29 - 3.15 (m, 2H), 3.15 - 2.96 (m, 2H), 2.05 (hept, J = 6.7 Hz, 1H), 1.43 (s, 2H), 1.38 - 1.16 (m, 4H), 0.99 (d, J = 6.7

1215

Cmpd. A No.M	LC/MS	LC/RTw min ^f
			Hz, 6H), 0.80 (S, 3H), 0.76 (t, J = 7.4 Hz, 3H).
531	52032	2.85
532	452.20	2.05
533	520.50	1.89	1H NMR (400 MHz, DMS0-d6) δ 8.32 (d, J = 2.3 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.92 {dd, J = 2.3,1.0 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.43 (dd, J = 8.2, 7.3 Hz, 1H}, 7.10 (d, J = 2.1 Hz, 1H), 7.08 - 7.00 (m, 2H), 6.94 (d, J = 8.1 Hz, 1H), 6.46 (dd, J = 8.3, 0.9 Hz, 1H), 6.12 (s, 2H), 3.87 (s, 3H), 2.31 (s, 3H), 2.12 (s, 3H), 2.04 (s, 3H).
534	485.60	1.63
535	581.30	2.34	1H NMR (400 MHz, DMSO-d6) δ 12.32 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.52 - 7.41 (m, 2H), 7.40 (d, J = 1.7 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 6.95 (s, 2H), 6.71 (d, J = 8.4 Hz, 1H), 6.53 (S, 2H), 3.80 (t, J = 6.4 Hz, 2H), 2.27 (s, 3H), 2.02 (s, 6H), 1.73 (h, J = 7.1 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H).
536	524.50	1.50
537	416.00	1.96	1H NMR (400 MHz, MeOD) Ô7.87 {d, J = 8.8 Hz, 3H), 7.49 (s, 1H),6.93 (d,J = 8.7 Hz, 2H), 2.82 (s, 1H), 1.62 (s, 8H), 1.39 (s, 9H), 1.18 (s, 3H).
538	523.30	2.38
539	480.19	1.46
540	427.50	1.84
541	541.36	1.58
542	410.40	1.64
543	592.35	2.77
544	525.40	1.57
545	526.10	1.89
546	526.20	1.92
547	556.40	2.66	1H NMR (400 MHz, DMS0-d6) 67.53 - 7.41 (m, 3H), 7.35 {ddd, J = 10.4, 2,3,1.2 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H}, 6.79 (dt, J = 10.8, 2.3 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H}, 6.14 (s, 2H), 3.82 (d, J = 6.6 Hz, 2H), 3.29 - 3.21 (m, 1H), 2.88 {t, J = 9.5 Hz, 1 H), 2.05 (hept, J = 6.6 Hz,

1216

Cmpd. No.	LC/MS ^LM+1	, LC/RT $ rnin ·	NMR
			1H), 1.80 (dp, J = 13.3, 6.8 Hz, 1H}, 1.66 (q, J = 6.5, 5.3 Hz, 1H), 1.59 (s, 3H), 1.48 -1.36 (m, 1H), 1.33 (s, 3H), 0.99 (d, 1 = 6.7 Hz, 6H),0.94 (d, J = 6.8 Hz, 3H).
548	557.10	2.21	1H NMR (400 MHz, DMSO-dG] 58.10 (d,J = 7.7 Hz, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 7.7 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.08 (d, J = 7.3 Hz, 1H), 6.91 (s, 2H), 6.46 (d, J = 8.2 Hz, 1H), 6.06 (s, 2H), 3.42 (S, 13H), 2.27 (s, 3H), 2.03 (s, 6H).
549	579.45	3.38	1H NMR (400 MHz, DMSO-d6) 5 12.74 (s, 1H), 12.19 (s, 1H), 7.77 7.69 (m, 2H), 7.56 - 7.53 (d, 1H), 7.48 (s, 1H), 7.43 - 7.39 (d, 1H), 7.34 - 7.23 (m, 3H), 7.12 (t, J = 7.47, 1H), 6.92 6.88 (d, 1H), 3.84 - 3.81 (d, 2H), 2.09 -1.98 (m, 2H), 1.81 -1.73 (m, 1H), 1.58 (s, 3H), 1.53 (s, 3H), 1.30 (t, J = 12.41, 1H), 1.00 - 0.97 (d, 6H), 0.30 0.27 (d, 3H)
550	440.40	1.63
551	514.30	1.48
552	566.20	2.15
553	544.34	2.20
554	527.00	1.41
555	556.50	1.95	1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, J = 8.0 Hz, 1H), 7.49 (t, J = 1.8 Hz, 1H), 7.42 - 7.30 (m, 2H),7.26 (d,J = 8.0 Hz, 1H), 6.79 - 6.66 (m, 2H), 3.81 (d, J = 6.5 Hz, 2H), 2.91 (d, J =7.5 Hz, 1H), 2.85 (d, J = 10.1 Hz, 1H), 2.37 (s, 1H), 1.64 (s, 6H), 1.58 (d, J = 12.0 Hz, 1H), 1.05 (d, J = 6.7 Hz, 6H), 1.00 (d, J = 6.4 Hz, 3H).
556	541.18	1.73
557	525.30	1.50
558	609.20	2.06
559	552.50	2.11
560	570.30	3.05
561	508.20	1.88
562	583.22	2.25
563	524.40	1.67

1217

Cmpd. Ne.'	^i: LC/MS M+1	LC/RT >5 min
564	479.20	0.69
565	524.17	1.83
566	441.00	1.94	1H NMR (400 MHz, DMSO) δ7.28 (d, J = 9.7 Hz, 2H), 7.15 (s, 1H), 7.00 (s, 1H), 6.92 (s, 1H), 6.77 (s, 2H), 5.45 (s, 2H), 2.75 (S, 1H), 2.18 (s, 3H), 2.09 (s, 6H), 1.10 (d, J = 6.9 Hz, 6H).
567	497.26	1.45
568	481.20	5.67	1H NMR (300 MHz, CDCI3) δ 1.06 (s, 9H), 2.04 (s, 6H), 2.29 (s, 3H), 2.71 (s, 3H), 6.80-6.86 (m, 3H), 6.90 (d,J=7.8 Hz, 1H), 7.23-7.31 (m, 1H), 7.32-7.41 (m,3H), 8.25 (d,J=7.8 Hz, 1H).
569	538.60	0.99
570	507.20	2.01
571	418.50	1.26
572	557.40	1.86
573	522.30	2.25
574	541.29	1.45
575	570.40	3.00
576	617.20	1.69
577	509.00	1.87
578	523.30	1.65	1H NMR (400 MHz, DMSO) δδ.90 (d, J = 2.4 Hz, 1H), 8.37 (dd, J = 8.7, 2.4 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.73 7.63 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1 H), 6.73 (d, J = 8.4 Hz, 1H), 5.32 (dt, J = 12.3, 6.1 Hz, 1H), 3.43 - 3.28 (m, 4H), 2.60 - 2.44 (m, 7H), 1.44 (d, J = 4.5 Hz, 4H), 1.32 (d, J = 6.2 Hz, 6H).
579	524.10	2.03	1H NMR (400 MHz, DMSO-d6) δ 11.75 {s, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.05 - 7.93 (m, 2H), 7.76 - 7.68 (m, 2H), 7.68 - 7.53 (m, 2H), 7.47 - 7.39 (m, 2H), 6.91 (s, 2H), 6.23 (s, 1H), 2.27 (S,3H), 2.01 (s, 6H).
580	553.50	1.82
581	554.30	2.69
582	547.20	1.65
583	540.43	3.43	1H NMR (400 MHz, DMS0-d6) δ 12.89 (s, 1H), 8.02 - 7.99 (d, 2H), 7.80 - 7.64 (m, 4H), 7.51 - 7.44 (m, 3H), 6.94 - 6.90 (d, 1H), 3.85 - 3.82 (d, 2H), 3.16 (m, 4H), 2.09 - 1.99 (m, 1H), 1.29

1218

Cmpd. - NoS	LC/MS . ^: M+1	^sLC/RTg ·, min
			(m, 4H), 1.01 - 0.98 {d, 6H), 0.93 (s, 6H)
584	507.20	1.64
585	525.00	2.03	1H NMR (400 MHz, DMSO) δ 13.81 (s, 1H), 12.52 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.98 (s, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.24 - 7.14 (m, 2H), 6.96 (s, 2H), 6.92 - 6.80 (m, 2H), 5.75 (s, 1H), 3.93 (d, J = 7.0 Hz, 2H), 2.27 (s, 3H), 2.00 (s, 6H), 1.29 (s, 3H).
586	580.00	2.23	1H NMR {400 MHz, DMSO) δ 12.65 (s, 1H), 8.31 (s, 1H), 8.13 (d,J = 7.9 Hz, 2H), 7.81 (d, J = 7.8 Hz, 1H), 7.18 (dd, J = 29.3,16.8 Hz, 4H), 6.94 (s, 2H), 6.84 (d, J = 10.7 Hz, 1H), 3.65 (d, J = 6.5 Hz, 2H), 2.27 (s, 3H), 2.00 (s, 7H), 0.96 (s, 7H).
587	542.31	2.09
588	531.20	1.82
589	495.18	1.46
590	565.40	3.28
591	516.27	2.05
592	514.30	2.78
593	554.40	2.70
594	467.27	2.00
595	533.50	1.90
596	523.23	1.80
597	539.30	1.76	1H NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.87 (d,J = 2.5 Hz, 1H), 8.33 (dd, J = 8.8, 2.5 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.71 (d,J = 8.2 Hz, 1H), 6.45 (s, 2H), 5.32 (p, J = 6.2 Hz, 1H), 5.06 4.95 (m, 1H), 2.89 - 2.76 (m, 1H), 2.75 - 2.60 (m, 1H), 1.88 - 1.63 {m, 4H), 1.32 (d, J = 6.2 Hz, 6H), 0.82 (s, 9H).
598	508.20	1.68
599	551.53	3.14
600	528.37	1,82	1H NMR (400 MHz, DMSO) δ7.83 (d, J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.47 7.40 (m, J = 11.0,1.7 Hz, 2H), 7,21 (d, J = 6.8 Hz, 1H), 6.91 (dt, J = 10.9, 2.2

1219

Cmpd.-i	g.LC/MS M+-1 ·	' LG/R^> min'^:S^r‘	SBSeilfc»
			Hz, 1H), 6.72 (d, J = 8.0 Hz, 1H), 4.73 (hept, 1H), 3.78 - 3.63 (m, J = 13.0 Hz, 2H), 2.94 - 2.78 (m, J = 11.6 Hz, 2H), 1.69 - 1.59 (m, J = 12.8 Hz, 2H),1.58 1.49 (m, 1H), 130 (d, J = 6.0 Hz, 6H), 1.24 - 1.07 (m, 2H), 0.91 (d, J = 6.4 Hz, 3H).
601	587.50	1.78
602	551.50	2.05
603	432.04	2.02
604	463.50	2.09
605	557.50	1.89
606	541.36	1.49
607	490.50	2.01	1H NMR (400 MHz, DMSO-d6) 5833 (d,J = 2.2 Hz, 1H), 8.05 {d, 1 = 7.9 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.71 (dd, J = 8.1,1.8 Hz, 3H), 7.22 (d, J = 8.1 Hz, 2H), 7.17-7.04 (m, 5H), 2.31 (d, J = 5.4 Hz, 6H], 2.04 (s, 3H).
608	538.20	1.88
609	554.50	2.23
610	463.50	1.92	1H NMR (400 MHz, DMSO-d6) 5 13.79 (s, 1H), 12.40 (s, 1H),8.O3 (d,J = 7.9 Hz, 1H), 7.98 (s, 1H), 7.74 - 7.68 (m, 3H), 7.22 (d, J = 8.0 Hz, 2H), 7.13 (dd, J = 5.2, 3.0 Hz, 2H), 7.07 (dd, J = 83, 2.1 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 232 (s, 3H), 230 (s, 3H), 2.05 (s, 3H).
611	570.40	3.23	1H NMR (400 MHz, DMSO-d6) 5 12.48 (S, 1H), 7.76 (d, J = 7.6 Hz, 1H}, 7.64 (t, J = 7.8 Hz, 1H), 7.51 - 7.41 (m, 2H), 7.29 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.0 Hz, 1H), 6.89 (d, J = 10.9 Hz, 1HL 6.69 (dd, J = 83,4.0 Hz, 1H), 6.48 (S, 2H), 3.84 (d, J = 6.2 Hz, 2H), 3.25 - 3.06 (m, 5H), 2.10 -1.90 (m, 2H), 1.88 -1.75 (m, 1H), 1.68 - 1.52 (m, 1H), 0.99 (d, J = 7.1 Hz, 6H), 0.88 (s, 9H).
612	538.50	1.90	1H NMR (400 MHz, DMSO-d6) 5830 (d, J = 1.9 Hz, 1H), 8.08 (d, J = 7.7 Hz, 1H), 7.93 (dd, J = 11.9, 2.0 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.07 (dd, J = 73,0.8 Hz, 1H),

1220

Cmpd,': No.	. LC/MS( . M=1 --	XLC/RTS ^‘•rninm
			6.93 (s, 2H), 6.44 (d, J = 8.3 Hz, 1H), 6.08 (s, 2H), 3.94 (s, 3H), 2,39 (s, 1H), 2.28 (s, 3H), 2.01 (s, 6H).
613	570.38	2.17
614	494.30	1.58
615	556.60	2.02
616	553.40	2.39	1H NMR (400 MHz, DMS0-d6) 5 7.67 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.55 (d, J = 7.6 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 6.22 (s, 2H), 4.04 (d, J = 6.7 Hz, 2H), 3.03 - 2.84 (m, 2H), 2.42 (s, 3H), 2.04 (tq, J = 12.4, 5.7 Hz, 2H), 1.76 (dd, J = 11.8, 5.7 Hz, 1H), 1.49 (s, 3H), 1.45 (s, 3H), 1.33 (t, J -12.0 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.80 (d, J = 6.3 Hz, 3H).
617	446.50	1.57
618	559.28	2.08
619	525.30	1.70
620	540.43	2.73	1H NMR (400 MHz, DMS0-d6) S 12.60 (s, 1H), 8.03 - 8.00 (d, 2H), 7.75 -7.34 (m,4H), 7.48 (s, 1H),7.43 - 7.39 (d, 1H), 7.29 - 7.26 (d, 1H), 6.92 - 6.89 (d, 1H), 3.84 - 3.81 (d, 2H), 2.51 2.29 (m, 2H), 2.11 - 1.99 ( m, 2H), 1.87 -1.80 (m, 1H), 1.59 (s, 3H), 1.55 {s, 3H), 1.38 (t, J = 11.76,1H), 1.00 0.97 (d, 6H), 0.67 - 0.64 (d, 3H)
621	521.30	2.06	1H NMR (400 MHz, DMSO) δ 12.34 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.63 (dd, J = 8.3, 7.4 Hz, 1H), 7.26 (d, J = 7.1 Hz, 1H), 7.20 (d, J = 6.8 Hz, 1H), 6.90 (s, 2H), 6,70 (d, J = 8.3 Hz, 1H), 6.53 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.29 (q, J = 4.5 Hz, 2H),0.97 (s, 2H).
622	523.20	1.91
623	434.30	1.79
624	538.20	1.92
625	573.32	1.90
626	494.50	1.85
627	449.00	1.45	1H NMR (400 MHz, DMSO) δ 8.27 (s, 1H), 8.10 (d, J = 6.5 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.39 (d, J = 32.1 Hz,

1221

Cmpd. . No.	LC/MS A M-1 '	LC/RT.^ >... ____- “Γ-·'»,' : min
			2H), 7.12 (d, J = 29.1 Hz, 3H}, 6.97 (d, J = 6.4 Hz, 1H), 6.68 (s, 2H), 5.71 (s, 2H), 2.16 (S, 3H), 1.89 (s, 6H).
628	453.30	1.25	1H NMR (400 MHz, Methanol-d4) δ 7.78 (d, J = 2.7 Hz, 1H), 7.29 - 7.10 (m, 4H), 6.99 (s, 2H), 6.84 (s, 1H), 4.37 (s, 2H), 4.26 - 4.12 (m, 1H), 3.65 (S, 1H), 3.51 - 3.33 (m, 3H), 3.27 3.09 (m, 2H), 2.32 (s, 6H}, 2.28 (s, 3H).
629	563.24	2.89
630	508.00	2.49	1H NMR (400 MHz, DMSO) δ 12.41 (s, 11H), 7.97 (d, J = 8.3 Hz, 23H), 7.77 (d, J = 8.0 Hz, 11H), 7.63 (dd, J = 8.2, 7.5 Hz, 12H), 7.36 (d, J = 8.3 Hz, 23H), 7.18 (dd, J = 16.2, 7.6 Hz, 23H), 6.68 {d, J = 8.3 Hz, 11H), 6.48 (s, 22H), 2.92 (dd, J = 13.8, 6.9 Hz, 11H), 2.61 (d, J = 8.8 Hz, 23H), 2.30 {d, J = 22.9 Hz, 1H), 2.27 - 2.09 (m, 11H), 1.87 (dd, J = 11.8, 5.6 Hz, 11H), 1.61 (d, J = 3.5 Hz, 67H), 1.42 (t, J = 12.1 Hz, 13H), 1.23 (d, J = 6.9 Hz, 7OH), 0.88 (d,J = 6.3 Hz,36H).
631	512.30	1.85	1H NMR (400 MHz, DMSO-d6) δ8.05 (s, 1H), 7.84 (s, 1H), 7.50 (d,J = 7.6 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 6.97 (d, J = 7.2 Hz, 1H), 6.69 {d, J = 7.6 Hz, 1H), 6.46 (d, J = 8.3 Hz, 1H), 6.15 (d, J = 4.6 Hz, 2H), 3.93 (d, J = 7.1 Hz, 2H), 2.95 (t, J = 10.6 Hz, 1H), 2.85 (dd, J = 10.8, 7.4 Hz, 1H), 2.18 - 2.02 (m, 2H), 1.78 (dd,J = 11.7, 5.7 Hz, 1H), 1.59 (s, 3H), 1.54 (s, 3H), 1.34 (t, J = 12.0 Hz, 1H), 0.85 (d, J = 6.7 Hz, 6H), 0.81 (d, J = 6.3 Hz, 3H).
632	399.40	1.63	1H NMR (400 MHz, DMSO-d6) δ 13.90 (s, 1H), 12.73 (s, 1H), 8.01 (d, J = 2.5 Hz, 1H), 7.82 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.11 (d, J = 7.8 Hz, 2H), 6.79 (d, J = 2.5 Hz, 1H), 2.34 (s, 3H), 1.35 (S, 9H).
633	561.20	0.81
634	482.00	1.95	1H NMR (400 MHz, DMSO) δ 12.56 (s,

1222

Cmpd. jÿ'NoS''^fc	LC/MS • M+1 +	. LC/RT min
			1H), 11.91 (s, 1H), 8.24 (d, J = 9.4 Hz, 1H), 7.83 (s, 1H), 7.74 (s, 1H), 7.09 (s, 1H), 7.01 {S, 2H), 6.45 (s, 1H), 2.67 (s, 2H), 2.29 (s, 3H), 2.02 (s, 3H), 1.70 (s, 2H), 1.61 (s, 2H), 0.97 (s, 6H).
635	451.40	1.29
636	425.40	1.29
637	457.30	2.84
638	528.12	2.71
639	565.60	2.28	1H NMR (400 MHz, DMSO-d6) 5 12.40 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.66 (dd, J = 8.4, 7.3 Hz, 1H), 7.29 - 7.06 (m, 6H), 6.84 (dt, J = 10.8, 2.3 Hz, 1H), 6.72 {d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 3.61 (d, J = 6.7 Hz, 2H), 2.06 (s, 6H), 1.98 (dt, J = 13.4, 6.7 Hz, 1H), 0.97 (d, J = 6.7 Hz, 6H).
640	531.18	1.97
641	519.50	1.96	1H NMR (400 MHz, DMSO-d6) 5 12.19 (s, 1H), 8.11 - 8.01 (m, 1H), 7.83 - 7.73 (m, 2H), 7.66 (p, J = 8.3 Hz, 2H), 7.28 - 7.04 (m, 4H), 7.00 6.90 (m, 2H), 6.71 (d, J = 8.7 Hz, 1H), 6.51 (s, 2H), 4.05 (q, J = 7.0 Hz, 2H), 2.32 (s, 3H), 2.06 (s, 3H), 1.33 (d, J = 7.0 Hz, 3H).
642	530.23	1.88
643	467.30	1.16	1H NMR (400 MHz, DMSO-d6) 8 12.63 (s, 1H), 9.00 - 8.86 (m, 2H), 8.42 (d, J = 5.8 Hz, 2H), 7.91 (d, J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.54 (dd, J = 8.1, 1.5 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.51 (s, 1H), 2.71 - 2.53 (m, 2H), 2.23 (dt, J = 12.5, 5.7 Hz, 1H), 1.91 (dd, J = 11.9, 5.5 Hz, 1H), 1.63 (s, 3H), 1.59 (s, 3H), 1.45 (t,J = 12.1 Hz, 1H), 0.88 (d, J = 6.3 Hz, 3H).
644	558.07	2.09
645	566.30	2.10	1H NMR (400 MHz, DMSO-d6} 58.10 (d, J = 7.7 Hz, 1H), 7.98 (dd, 1 = 7.3, 1.9 Hz, 1H), 7.96 (s, 1H), 7.62 (d, J = 7.7 Hz, 1 H}, 7.46 (s, 1H), 7.16 (d, J = 10.0 Hz, 1H), 7.10 (d, J = 2.1 Hz, 1H),

1223

CmpdA Nofe	LC/MS M+1>	LC/RT· min ’
			6.92 (s, 2H), 6.70 (dd, J = 10.8, 2.4 Hz, IH), 6.20 (s, IH), 4.39 (p, J = 6.1 Hz, IH), 2.90 (s, IH), 2.27 (s, 3H), 2.01 (s, 6H), 1.22 (d, J = 6.0 Hz, 6H).
646	441,26	1.88
647	573.32	1.90
648	524.00	1.64	IH NMR (400 MHz, DMSO} δ 10.00 (s, IH), 8.26 {S, IH), 8.18 (s, IH), 7.29 (s, IH), 7.07 (d, J = 8.6 Hz, 2H), 6.92 (s, 3H), 4.28 - 3.92 (m, 7H), 3.81 (5, 3H), 2.40 (s, 6H), 2.24 (s, 3H}, 2.07 (s, IH), 1.74 (s, 3H), 1.24 (s, 3H).
649	433.25	2.10
650	470.50	2.71
651	604.38	2.31
652	538.20	1.91
653	421.26	1.73
654	490.30	1.87
655	568.40	2.98
656	579.24	1.81
657	556.30	2.67	IH NMR (400 MHz, DMS0-d6) 87.51 (d, J = 7.6 Hz, IH), 7.47 - 7.42 (m, 2H), 7.37 -7.33 (m, 1H},7.O8 (d,J = 7.7 Hz, IH}, 6.99 (d, J = 7.3 Hz, IH), 6.79 (dt, J = 10.8, 2.3 Hz, IH), 6.48 (d, J = 8.3 Hz, IH), 6.11 (S, 2H), 3.82 (d, J 6.6 Hz, 2H), 3.27 (d, J = 10.2 Hz, IH), 2.95 - 2.84 (m, IH), 2.09 -1.99 (m, IH), 1.79 (dq, J = 13.2, 6.6 Hz, IH), 1.68 (t, J = 6.3 Hz, IH), 1.59 (s, 3H), 1.45 -1.38 (m, IH), 1.33 (s, 3H}, 0.99 (d, J = 6.7 Hz, 6H), 0.95 (d, J = 6.7 Hz, 3H).
658	587.30	1.91
659	591.29	1.53
660	453.23	1.17
661	537.43	2.87	IH NMR (400 MHz, DMSO-d6) S 8.16 -8.13 (d, 1 H), 7.65 - 7.46 (m, 2H), 7.22 - 7.10 (m, 3H), 7.04 - 6.91 (m, 3H), 6.69 - 6.66 (d, IH), 6.51 (s, 2H), 3.85 (s, 3H), 2.25 (s, 3H), 2.02 (s, 6H)
662	480.30	1.25
663	618.36	2.27
664	541.33	1.78
665	495.50	2.06

1224

Cm ode ÀNÔ. '	.LC/MS _?M+i	f LC/RT, n min	NMR < \|Η ^T G II-t J ^x
666	437.00	1.04	1H NMR (400 MHz, DMSO) δ 7.83 (s, 1H), 7.61 (s, 2H), 7.26 (dd, J = 41.7, 19.3 Hz, 7H), 6.96 (d, J = 8.7 Hz, 1H), 4.68 (d, i = 12.3 Hz, 1H), 4.46 (d, J = 12.6 Hz, 1H), 4.23 (d, J = 12.9 Hz, 2H), 2.43 (S, 3H), 1.81 (s, 3H).
667	484.30	2.13
668	516.21	1.81
669	549.40	1.73	1H NMR (400 MHz, DMSO-d6) δ 7.80 - 7.70 (m, 1H), 7.24 (d, J = 7.0 Hz, 1H), 7.08 (dt, J = 14.8, 6.6 Hz, 5H), 6.85 (s, 2H), 3.95 - 3.72 (m, 3H), 3.47 - 3.34 (m, 7H), 3.24 (dd, J = 14.0, 7.4 Hz, 3H), 3.16 - 3.01 (m, 1H), 2.99 - 2.66 {m, 3H), 2.22 (s, 3H), 2.16 (s, 6H).
670	401.30	1.67
671	539.20	2.26
672	503.21	3.11
673	547.33	2.94
674	463.30	1.59
675	551.27	1.53
676	547.20	2.10	1H NMR (400 MHz, DMSO-d6) δ 12.54 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.85 (dd, J = 2.6, 1.1 Hz, 1H), 7.69 7.62 (m, 2H), 7.22 (dd, J = 7.4, 0.8 Hz, 1H), 6.99 (d, J = 2.6 Hz, 1H), 6.97 (s, 2H), 6.72 (d, J = 8.4 Hz, 1H), 6.56 (s, 2H), 2.28 (s, 3H), 2.03 (s, 6H).
677	579.30	1.65
678	528.30	2.93
679	511.20	2.09
680	540.30	2.86
681	516.30	1.71	1H NMR (400 MHz, DMSO-d6) 6 13.78 (s, 1H), 13.22 (s, 1H), 7.98 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.53 (dd, j = 6.4, 3.3 Hz, 1H), 7.28-7.17 (m, 2H), 7.03 (dt, J = 9.0, 3.6 Hz, 1H), 6.87 (s, 1H), 4.00 (s, 2H), 3.78 (d, J = 6.6 Hz, 2H), 2.11 -1.96 (m, 1H), 1.98 (s, 2H), 1.66 (s, 2H), 1.06 (d, J = 6-2 Hz, 6H), 0.98 (d, J = 6.7 Hz, 6H).
682	537.43	3.01
683	528.30	2.64
684	604.32	2.30
685	436.40	1.72

1225

Cmpd. No.	LC/MS M+1'ΐ	LC/RT/: min*	nmr
686	586.35	2:21
687	511.30	1.53
688	557.40	1.85 .î
689	511.40	1.66	1H NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 8.86 (d, J = 2.5 Hz, 1H), 8.31 (dd, J = 8.7, 2.5 Hz, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.31 - 7.16 (m, 2H), 6.84 (d, J = 8.7 Hz, 1H), 6.70 (t, J = 8.6 Hz, 1H), 6.48 (s, 2H), 5.31 (p, J = 6.1 Hz, 1H), 4.36-4.20 (m, 1H), 2.57 (m, obsucured multiplet), 2.29 - 2.14 (m, 1H), 1.31 (d, J = 6.2 Hz, 6H), 1.27 (d, J = 5.9 Hz, 2H), 1.14 (q, J = 11.5 Hz, 1H), 0.92 (d, J = 6.3 Hz, 2H).
690	479.00	1.25	1H NMR (400 MHz, DMSO) 6 10.18 (s, 1H), 7.68 (s, 1H), 7.30 - 7.09 (m, 4H), 6.90 (d, J = 30.5 Hz, 3H), 6.77 (d, J = 8.4 Hz, 1H), 4.40 (s, 1H), 4.15 (s, 3H), 3.96 (s, 2H), 2.96 (s, 2H), 2.23 (s, 3H), 2.15 (S, 6H).
691	547.20	0.77
692	544.30	1.91
693	508.26	1.94
694	528.50	1.89
695	538.26	2.00
696	479.30	1.25
697	588.15	3.05
698	492.40	2.19
699	529.39	1.85	1H NMR (400 MHz, DMSO) Ô8.33 (d, J = 2.2 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.48 - 7.40 (m, J = 8.7, 1.8 Hz, 2H), 6.92 (dt, J = 11.0, 2.3 Hz, 1H), 4.74 (hept, J = 6.0 Hz, 1H), 3.73 3.60 (m, J = 12.9 Hz, 2H), 2.98 - 2.82 (m, J = 11.7 Hz, 2H), 1.69 - 1.49 (m, J = 11.6 Hz, 3H), 1.30 (d, J = 6.0 Hz, 6H), 1.27 - 1.11 (m, J = 23.3,11.6 Hz, 2H), 0.92 (d, J = 6.1 Hz, 3H).
700	537.43	2.95
701	518.50	1.65	1H NMR (400 MHz, DMSO-d6) 5 13.78 (S, 1H), 13.21 (s, 1H), 7.98 (s, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7,64 (dd, J = 8.4,1.9 Hz,

1226

Cmpd. No.	LC/MS® ? M+1	fLG/RT® ·^:····· ·'·· ·,ΰί.··Ί ή min	‘ ,...¾.. ... ----··
			IH), 7.51 {d, J = 8.3 Hz, IH), 7.39 (d, J = 7.9 Hz, IH), 6.86 (s, IH), 4.77 (p, J = 6.1 Hz, IH), 4.02 (s, 2H), 2.06 - 1,94 {m, 3H), 1.75 - 1.63 (m, 2H), 1.35 (d, J = 6.1 Hz, 6H), 1.07 (d, J = 6.2 Hz, 6H).
702	425.40	1.31
703	523.23	1.51
704	458.30	1.47
705	534.50	1.99	IH NMR (400 MHz, DMSO-d6) δ 8.26 (S, IH), 8.08 (d, J = 7.7 Hz, IH), 7.89 (s, IH), 7.51 (d, J = 7.7 Hz, IH), 7.42 (t, J = 7.7 Hz, IH), 7.08 (d, J = 7.3 Hz, IH), 6.92 (s, 2H), 6.44 (d, J = 8.2 Hz, IH), 6.05 (s, 2H), 3.87 (s, 3H), 2.90 (s, IH), 2.28 (s, 3H), 2.12 (s, 3H), 2.02 (s, 6H).
706	545.21	2.10
707	452.00	1.48	IH NMR (400 MHz, DMSO) δ 12.94 (s, IH), 8.40 (S, IH), 8.04 (s, IH), 7.59 (s, IH), 7.31 (d, J = 8.1 Hz, 2H), 7.06 (d, J = 14.8 Hz, 4H), 2.81 (s, 2H), 2.31 (s, 3H), 1.77 (S, 4H), 1.29 (s, 6H).
708	525.50	1.60
709	557.20	2.18	IH NMR (400 MHz, DMS0-d6) δ 12.41 (s, IH), 8.18 (d, J = 7.8 Hz, IH), 8.12 (d, J = 7.8 Hz, IH), 8.04 (s, IH), 7.89 (d, J = 7.8 Hz, IH), 7.79 - 7.72 (m, IH), 7.70 - 7.61 (m, 2H), 7.24 (d, J - 7.0 Hz, IH), 6.95 (s, 2H), 6.72 (d, J = 8.4 Hz, IH), 6.54 {s, 2H), 2.27 (s, 3H), 2.02 (s, 6H).
710	498.40	1.67
711	618.36	2.11
712	484.20	1.47
713	522.50	1.83
714	497.20	2.75	IH NMR (400 MHz, Chloroform-d) δ 10.71 - 10.46 (m, IH), 8.04 (s, IH), 7.64 (d, J = 3.6 Hz, 2H), 6.90 (s, 2H), 6.65 (s, IH), 4.70 (s, 2H), 3.60 (s, 2H), 2.33 (s, 3H), 2.08 (s, 6H), 0.99 (s, 6H).
715	468.00	2.20	IH NMR (400 MHz, DMSO) δ 13.78 (s, IH), 12.16 (s, IH), 7.97 (s, IH), 7.69 {S, IH), 6.90 (s, 2H), 6.86 (s, IH), 2.67 (S, 2H), 2.25 (s, 3H), 1.95 (s, 6H), 1.68 (s, 2H), 1.60 (s, 2H), 0.92 (s, 6H).

1227

Cmpd. / No. ·.	LC/MS Μ·Τ\	LC/RT v -üîîs J* - - '' Sr ; mnv/;	Z^NMR .,4¾¾ ~ ' ·Ίΐρ· -MW' -“«.’S'- ‘
716	564.29	2.14	1H NMR (400 MHz, DMSO) δ 13.81 (s, 1H), 12.70 (s, 1H), 8.01 (s, 1H), 7.74 (d,J = 7.9 Hz, 1H), 7.29-7.19 (m, 5H), 7.17-7.06 (m, 3H), 6.93 (s, 1H), 6.77 (dt, J = 10.7, 2.3 Hz, 1H), 5.31 (t, J = 7.6 Hz, 1H), 3.72 (ddd, J = 31.5, 9.2, 6.4 Hz, 2H), 3.17 (dd, J = 16.6, 9.7 Hz, 1H), 2.81 {t, J = 7.5 Hz, 1H), 2.38 (dd, J = 10.9, 5.0 Hz, 1H), 2.07 - 1.98 (m, 1H), 1.93 - 1.72 (m, 2H), 1.64 (dd, J = 18.4, 8.3 Hz, 1H), 1.01 (dd, J = 6.7, 2.1 Hz, 6H).
717	539.60	1.71
718	534.20	2.01
719	558.30	2.00	1H NMR (400 MHz, DMSO-d6} δ 12.52 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.51 (dt, J = 7.0, 1.8 Hz, 2H), 7.48 - 7.42 (m, 2H), 7.35 (dd, J = 7.9, 5.5 Hz, 2H), 7.21 (d, J = 7.2 Hz, 1H), 6.89 (dt, J =10.6, 2.3 Hz, 2H), 6.71 (d, J = 8.4 Hz, 1H), 4.59 (dd, J = 7.2, 3.3 Hz, 1H), 4.55 - 4.46 (m, 1H), 3.85 (d, J = 3.2 Hz, 2H), 3.83 (d, J = 3.1 Hz, 2H), 3.81 (dd, J = 9.1, 3.3 Hz, 1H), 3.74 (dd, J = 9.1,3.3 Hz, 1H), 3.59 3.52 (m, 2H), 335 (dd, J = 9.1,7.5 Hz, 2H), 3.32 (S, 3H), 3.27 (s, 3H), 2.94 (dd, J = 9.7, 6.7 Hz, 1H), 2.89 - 2.78 (m, 1H), 2.14 - 1.94 (m, 5H), 1.86 1.68 (m, 5H), 1.00 (d, J = 23 Hz, 6H), 0.99 (d, J = 2.2 Hz, 6H).Two rota mers in about 1:1 ratio. Thus two sets of peaks.
720	542.34	2.02
721	543.30	1.66
722	521.00	1.85	1H NMR (400 MHz, DMSO) δ 12.95 (s, 1H), 8.04 (d, J = 83 Hz, 2H), 7.64 (s, 1H), 7.56 (s, 2H), 7.47 (d, J = 7.9 Hz, 2H), 7.17 {d, J = 8.2 Hz, 3H), 6.96 (d, J = 10.8 Hz, 1H), 6,81 (d,J = 8.4 Hz, 1H), 4.76 (s, 1H), 233 (s, 3H), 132 (s, 6H).
723	555.10	1.25
724	525.25	1.76

1228

Cmpd. N 0.-^	LC/MS - M+1	- ? LC/RT “min	nmr^-^*^ ·' 7 - il ’ '·
725	525.42	3.01
726	483.20	1.17	IH NMR (400 MHz, DMSO-d6) S 13.13 (s, IH), 8.90 (d, J = 2.5 Hz, IH), 8.36 (dd, J = 8.7, 2.5 Hz, IH), 7.83 (d, J = 7.9 Hz, IH), 7.65 (dd, J = 8.4, 7.3 Hz, IH), 7.36 (d, J = 8.0 Hz, IH), 7.22 (d, J = 7.1 Hz, 1 H}, 6.94 (d, J = 8.7 Hz, IHh 6.76 - 6.69 (m, IH), 4.06 - 4.00 (m, 2H), 3.92 (s, 3H), 2.05 -1.93 (m, 2H), 1.73 -1.60 (m, 2H), 1.09 (d, J = 6.3 Hz, 6H).
727	537.43	2.51
728	520.21	1.83
729	539.30	1.68
730	504.30	1.65
731	573.25	1.70
732	523.23	1.69
733	537.30	1.75
734	516.21	1.82
735	542.31	2.00
736	511.30	1.56
737	529.32	1.77	IH NMR (400 MHz, DMSO) 8 8.25 (dd, J = 7.3, 2.1 Hz, IH), 7.91 - 7.80 (m, J = 7.9 Hz, 2H), 7.51 (d, J = 8.0 Hz, IH), 7.44 {dd, J = 9.9,1.7 Hz, 2H), 6.91 (dt, J = 10.9, 2.2 Hz, IH), 6.46 (dd, J = 7.1, 6.5 Hz, IH), 4.73 (hept, J = 6.0 Hz, IH), 3.78 - 3.66 (m, J = 12.8 Hz, 2H), 2.95 - 2.80 (m,J = 11.6 Hz, 2H), 1.69 - 1.49 (m,J = 20.3, 9.3 Hz, 3H), 1.30 (d, J = 6.0 Hz, 6H), 1.27 1.12 (m, J = 12.0 Hz, 2H), 0.92 (d, J = 6.3 Hz, 3H).
738	525.20	2.16
739	536.16	1.92
740	497.21	1.37
741	547.60	1.97
742	573.32	1.90	IH NMR (400 MHz, DMSO) 8 8.92 (d, J = 2.4 Hz, IH), 8.38 (dd, J = 8.7, 2.4 Hz, IH), 7.89 (d, J = 7.9 Hz, IH), 7.64 (t, J = 7.8 Hz, IH), 7.49 (d, J = 7.9 Hz, IH), 7.26 (tt, J = 12.8, 6.5 Hz, 6H), 6.87 (d, J = 8.7 Hz, IH), 6.69 (d,J = 8.4 Hz, IH), 5.33 (dd, J = 12.3, 6.2 Hz, IH), 3.87 (d, J = 12.4 Hz, 2H), 3.02 (t, J

1229

Cmpd, No.	^LC/MS ⁴ M+1	LC/RT _rmin	¹ .... ’-j -,-i· --·« NMR ¹ v . j y _;
			= 11.9 Hz, 2H), 2.75 ($, 1H), 2.59 2.46 (m, 3H), 1.93 - 1.63 (m, 4H), 1.32 (d, J = 6.2 Hz, 6H).
743	510.30	2.20
744	518.12	2.21
745	515.25	1.65
746	482,50	2.86	10.67 (s, 1H), 7.92 - 7.89 (d, 1H), 7.63 (t, J = 7.80,1H), 7.23 - 7.20 (d, 1H), 6.94 (s, 2H), 6.70 - 6.67 (d, 1H), 6.49 (s, 2H), 6.22-6.19 (d, 1H), 2.27 (s, 3H}, 2.06 (s, 6H), 1.81 (s, 4H)
747	493.20	1.72
748	497.51	2.65	1H NMR (400 MHz, DMSO) δ 7.95 7.92 (d, 1H), 7.46 (t, J = 7.03,1H), 7.09 - 7.06 (d, 1H), 6.89 - 6.87 (m, 3H), 6.52 - 6.49 (d, 1H), 6.20 (s, 2H), 3.80-3.76 (m, 2H), 2.67-2.59 (m, 1H), 2.25 (s, 3H), 1.96 (s, 6H), 1,56 1.34 (m, 4H)
749	532.20	1.80
750	458.38	1.59
751	542.40	1.95	1H NMR (400 MHz, DMSO-d6) δ 12.58 (S, 1H), 7.76 (d, J = 7,9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.48 - 7.45 (m, 1H), 7.42 (dt, J = 10.2, 1.8 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.8,2.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 4.13 (s, 2H), 3.84 (d, J = 6.6 Hz, 2H), 2.12 -1.98 (m, 3H), 1.49 (dd, J = 9.8,7.4 Hz, 2H), 0.99 (dd, J = 6.7, 3.9 Hz, 12H).
752	461.40	1.73
753	417.30	1.75
754	550.20	2.11
755	466.50	1.79
756	516.22	1.82
757	511.30	1.66
758	525.20	2.17
759	471.50	3.24	1H NMR (400 MHz, DMSO-d6) δ 12.77 (s, 1H), 8.50 (dd, J = 4.9, 1.9 Hz, 1H), 8.33 {dd, J = 7.7, 1.9 Hz, 1H), 7.27 (dd, J = 7.7, 4.9 Hz, 1H), 7.06 (s, 1H), 6.74 (s, 2H), 5.40 (s, 2H), 3.96 (s, 3H), 2.17 (s, 3H), 2.05 (s, 6H), 1.16 (s, 9H).

1230

Cc-pd.' No.	. LC/MS M+1	$ LC/RT~. • min
760	487.11	1.32
761	480.30	1.47
762	538.20	1.91
763	498.30	1.45
764	511.40	1.64	1H NMR (400 MHz, Ethanol-d6) 5 8.85 (d, J = 2.4 Hz, 1H), 8.31 (dd, J = 8.7, 2.5 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4,7.3 Hz, 1H), 7.22 (dd, J = 13.7,7.5 Hz, 2H), 6.85 (d, J = 8.7 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 5.31 (p, J = 6.2 Hz, 2H), 3.70 (dd, J = 8.1, 5.9 Hz, 1H), 2.93 - 2.77 (m, 1H), 2.72 - 2.61 (m, 1H), 1.96 - 1.67 (m, 2H), 1.32 (s, 6H) 1.32 (obsucured m, 1H), 1.26 (d, 1 = 5.9 Hz, 3H), 1.05 (d,1 = 6.3 Hz, 3H).
765	480.00	1.51	1H NMR (400 MHz, DMSO) 59.89 (s, 1H), 8.20 (d, J = 24.9 Hz, 2H), 7.55 (s, 1H), 7.29 (d, J = 41.2 Hz, 3H), 7.08 (s, 1H), 6.91 (s, 2H), 4.37 -4.01 (m, 4H), 3.82 (s, 3H), 2.41 (s, 6H), 2.24 (s, 3H), 1.78 (s,3H).
766	533.31	1.88
767	480.30	1.86
768	535.32	2.59
769	551.13	2.13
770	512.20	1.25
771	589.00	2.38	1H NMR (400 MHz, DMSO) δ8.49 (d, J = 7.9 Hz, 1H), 8.44 (s, 1H), 8.36 (d, J = 7.5 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 11.5 Hz, 1H), 7.18 (s, 1H), 6.94 (s, 2H), 6.84 (d, J = 10.7 Hz, 1H), 3.65 (d, J = 6.5 Hz, 2H), 2.26 (s, 3H), 2.07 (s, 3H), 1.99 (s, 7H), 0.97 (d, J = 6.7 Hz, 6H).
772	604.50	2.25
773	544.30	1.70	1H NMR (400 MHz, DMSO-d6) δ 12.98 (s, 1H), 7.83 (d, J = 1.9 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.70 - 7.61 (m, 2H), 7.52 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.23 (dd, J = 7.3, 0.8 Hz, 1H), 6.72 (d, 1H), 6.48 (s, 2H), 4.13 (t, J = 6.5 Hz, 2H), 4.09 - 3.97 (m, 2H), 2.05 - 1.91 (m, 2H), 1.81 (h, J = 7.2 Hz, 2H), 1.74 -1.61 (m, 2H), 1.10

1231

; Cmpd. ^J No.	LC/MS? M+1	LC/RT. y.. mînai:
			(d, J = 6.2 Hz, 6H), 1.03 (t, J = 7.4 Hz, 3H).
774	546.21	1.75
775	557.24	2.72	1H NMR (400 MHz, DMSO-d6) δ 7.95 (t, J = 7.80, 1H), 8.86 - 8.83 (d, 1H), 7.62 - 7.59 (d, 1H), 7.52 - 7.48 (m, 3H), 6.99 - 6.90 (m, 2H), 3.86 - 3.83 (d, 2H), 3.26 (m, 4H), 2.10 -1.97 (m, 1H), 1.33 (m, 4H}, 1.01 - 0.98 (d, 6H), 0.94 (s, 6H)
776	547.60	1.97	1H NMR (400 MHz, DMSO) 6 13.74 (s, 1H), 12.85 (s, 1H), 8.86 (d, J = 2.5 Hz, 1H), 8.32 (dd, J = 8.7, 2.5 Hz, 1H), 7.94 (s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.38 - 7.30 (m, 4H), 7.27 - 7.20 (m, 1H), 6.84 (d, J = 8.8 Hz, 2H), 5.37 - 5.23 (m, 1H), 3.93 (d, J = 11.4 Hz, 1H), 3.59 (d, J = 12.7 Hz, 1H), 3.02 - 2.83 (m, 3H), 1.91 (d, J = 8.9 Hz, 1H), 1.70 (t, J = 11.4 Hz, 3H), 1.31 (d, J = 6.2 Hz, 6H).
777	524.30	1.89
778	551.40	2.22
779	554.60	1.79
780	610.38	2.24
781	484.30	1.20
782	579.27	2.29
783	531.30	1.98
784	463.30	1.96	1H NMR (400 MHz, DMSO-d6) δ 13.80 (S, 1H), 12.46 (s, 1H), 8.09 (d, J = 7.8 Hz, 1H), 7.98 (s, 1H), 7.82 - 7.71 {m,3H), 7.41 {dp, J = 3.5,1.9 Hz, 3H), 6.95 (s, 2H), 6.88 (s, 1H), 2.28 (s, 3H), 2.03 (S, 6H).
785	496.60	2.96
786	519.42	2.53	1H NMR (400 MHz, DMSO-d6} δ 12.35 (s, 1H), 8.17 - 8.14 (d, 1H}, 7.76 - 7.56 (m, 4H), 7.37 - 7.35 (m, 2H), 7.26 - 7.23 (d, 1H), 6.95 (s, 2H), 6.74 7.61 (d, 1H), 6.56 (s, 2H), 4.48 (s, 2H), 2.28 (S,3H), 2.04 (s, 6H)
787	533.22	2.05
788	544.30	1.65
789	523.30	1.96	1H NMR (400 MHz, DMSO-d6) δ 8.78 (d, J = 2.4 Hz, 1H), 8.28 (dd, J = 8.7,

1232

Cmpd. î- No. -	LC/M8 Μ --1	LC/RT min -7
			2.5 Hz, 1H), 7.60 - 7.42 (m, 2 H), 7.01 (bs, 2H), 6.87 (d, J = 8.7 Hz, 1H), 6.51 (d, J = 8.6 Hz, 1H), 6.23 (bs, 2H), 4.23 (S, 2H), 4.13 (d, J = 7.1 Hz, 2H), 1.86 (bs, 2H), 1.56 (bs, 2H), 1.25 (dddd, J = 11.9, 7.3, 5.4, 2.6 Hz, 1H), 1.04 (d, J = 6.1 Hz, 6H), 0.59 - 0.49 (m, 2H), 0.36 0.26 (m, 2H).
790	451.00	1.10	1H MMR (400 MHz, DMSO) δ 10.04 (s, 1H), 7.74 (s, 1H), 7.49 (s, 1H), 7.42 7.07 (m, 7H), 6.82 (s, 1H), 4.36 - 4.09 (m, 5H), 2.44 (s, 5H), 1.82 (s, 3H).
791	485.50	2.71
792	470.32	1.38
793	519.20	1.87
794	432.40	1.50
795	571.34	3.04	1H NMR (400 MHz, DMSO) δ 12.89 (s, 1H), 8.04 (t, J = 8.04,1H), 7.83 7.75 (m, 2H), 7.49 (s, 1H), 7.44 - 7.40 {d, 1H), 7.32 - 7.29 (d, 1H), 7.18 - 7.15 (d, 1H), 6.93 - 6.89 {d, 1H), 3.91 (s, 3H), 3.85 - 3.82 (d, 2 H), 2.10 (m, 1H), 2.07 - 1.99 (m, 1H), 1.88 -1.83 (m, 1H), 1.59 (s, 6H), 1.39 (t, J = 12.41, 1H), 1.00 - 0.97 (d, 6H), 0.78 - 0.75 (d, 3H)
796	538.60	0.97
797	481.00	2.01	1H NMR (400 MHz, DMSO) δ 7.60 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.21 (d, J = 14.5 Hz, 2H),7.13 (s, 1H), 6.99 (d,J = 7.1 Hz, 1H), 6.81 (d, J = 10.1 Hz, 1H), 6.43 (d, J = 8.4 Hz, 1H), 5.59 (s, 2H), 1.25 (s, 9H).
798	536.00	201.00	1H NMR (400 MHz, DMSO} δ 13.12 (s, 1H), 8.56 (d, J = 6.0 Hz, 1H), 8.25 (d, J = 7.6 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 10.1 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.24 (s, 1H), 7.04 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 13.1 Hz, 1H}, 4.75 (s, 1H), 4.03 (s, 3H), 2.32 (s, 3H), 1.3Û (d, J = 6.0 Hz, 6H).
799	427.30	1.90
800	432.36	1.60
801	518.22	2.05

1233

Cmpd. ; ··;. Ne. » ·	LC/MS -A M+1	^^C/RTÎ -? mm
802	466.33	1.61
803	525.42	2.97
804	580.20	2.19
805	452.30	1.24
806	443.18	2.74
807	542.30	1.70
808	521.20	1.81
809	425.30	1.72
810	588.15	2.07
811	525.30	1.57	1H NMR (400 MHz, DMSO-d6) S 12.42 (s, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.27 (dd, J = 8.8, 2.6 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.58 (s, 1H), 7.16 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.7 Hz, 1H), 6.63 (s, 1H), 6.41 (s, 2H), 5.32 (h, J = 6.3 Hz, 1H), 2.83 - 2.56 (m, 2H), 2.27 2.13 (m, 1H), 1.86 (dd, J = 11.9, 5.7 Hz, 1H), 1.59 (d, J = 4.8 Hz, 6H), 1.41 (t, J = 12.0 Hz, 1H), 1.31 (d,J = 6.2 Hz, 6H), 0.88 (d, J = 6.3 Hz,3H).
812	561.50	1.75
813	493.20	1.96	1H NMR (400 MHz, DMSO-d6) 5 13.78 (S, 1H), 12.33 (s, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.79 - 7.73 (m, 2H), 7.66 (d, J = 7.9 Hz, 1H), 7.13 (dd, J = 5.0, 3.0 Hz, 2H), 7.10 - 7.04 (m, 1H), 6.97 - 6.91 (m, 2H), 6.86 (s, 1H), 4.05 (q, J = 6.9 Hz, 2H), 2.32 (s, 3H), 2.05 (s, 3H), 1.31 (t, J = 7.0 Hz, 3H).
814	539.50	1.44
815	526.10	1.98
816	478.50	1.78	1H NMR (400 MHz, DMSO) δ 8.25 {d, J = 2.1 Hz, 1H), 7.95 (d, J = 2.1 Hz, 1H), 7.61 (dd, J = 8.3, 7.4 Hz, 1H), 7.32 (s, 1H), 7.08 (d, J = 6.9 Hz, 1H), 6.70 (d, J = 8.2 Hz, 1H), 6.60 (s, 2H), S.63 (s, 2H), 4.81 (br s, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.12 (s, 3H), 1.91 (s, 6H), 1.21 {t, J = 7.6 Hz, 3H).
817	503.00	1.94	1H NMR (400 MHz, DMSO) § 12.47 (s, 1H), 8.15 (s, 1H), 7.95 (s, 1H), 7.63 (s, 1H), 7.31 (d, J = 11.3 Hz, 4H), 7.22 (d, J = 7.3 Hz, 1H), 6.91 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.24 (d, J =

1234

iGrnpd. No.	LC/MS *Μ+1	LC/RT.. min
			4.4 Hz, 6H), 2.00 (s, 6H).
818	601.31	1.90
819	490.00	1.68	1H NMR (400 MHz, DMSO) δ 13.14 (s, 1H), 8.42 (s, 1H), 8.14 (d, J = 8.7 Hz, 2H), 8.06 (S, 1H), 7,96 (s, 2H), 7.41 (d, J = 7.9 Hz, 2H), 7.09 (dd, J = 21.2, 8.3 Hz, 4H), 4.10 (s, 2H), 2.34 (s, 3H), 1.36 {S,3H).
820	460.00	1.68	1H NMR (400 MHz, DMSO) 6 13.12 (s, 1H), 8.42 (d, J = 2.2 Hz, 1H), 8.07 (dd, J = 12.6, 5.2 Hz, 3H), 7.99 (s, 2H), 7.42 (d,J = 8.1 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 7.10 (t, J = 15.8 Hz, 4H), 2.36 (d, J = 14.8 Hz, 6H).
821	456.10	2.19	1H NMR (400 MHz, DMSO) δ 8.01 7.99 (d, 1H), 7.46 {s, 2H), 7.06 - 6.77 (m, 6H), 6.41 (s, 1H), 5.67 (s, 2H), 2.80 (S, 3H), 2.23 (s, 6H), 1.12 (s, 9H)
822	498.50	1.46
823	468.40	2.39	1H NMR (400 MHz, DMSO-d6) δ 12.47 (5,1H), 7.85 - 7.80 (m, 2H), 7.63 - 7.54 (m, 2H), 6.99 (s, 1H), 6.74 (s, 2H), 5.43 (s, 2H), 2.75 (q, J = 7.6 Hz, 2H), 2.16 (S, 3H), 2.05 (s, 6H), 1.23 (t, J = 7.6 Hz, 3H), 1.14 (s,9H).
824	545.28	2.00
825	480.00	1.33
826	466.00	2.04	1H NMR (400 MHz, DMSO) δ 11.95 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.23 (s, 2H), 7.10 (s, 2H), 6.94 - 6.81 (m, 3H), 3.51 (s, 2H), 2.25 (s, 3H), 1.92 (s, 6H), 1.31 (s,3H), 0.67 (d, J = 14.3 Hz, 4H).
827	566.30	1.11
828	549.43	2.97
829	463.17	1.86
830	537.43	2.98
831	518.20	2.12
832	518.20	1.71
833	510.30	1.41
834	511.20	1.48	1H NMR (400 MHz, DMSO) δ 12.44 (s, 1H), 8.84 (d, J = 2.4 Hz, 1H), 8.28 (dd, J = 8.8, 2.5 Hz, 1H), 7.72 (d,J = 8.0 Hz, 1H), 7.69 - 7.60 (m, 1H), 7.18 (t, J = 7.2 Hz, 2H), 6.86 (d, J = 8.7 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 5.32 (dt, J =

1235

Crrpd. No. b	lc/ms.·; à'M+1 ·	LC/RTH
			12.1, 6.1 Hz, 1H), 2.76 (s, 2H), 1.76 (s, 4H), 1.56 {d, J = 14.3 Hz, 6H), 1.32 (d, J = 6.2 Hz, 6H).
835	552,20	2.04	1H NMR (400 MHz, DMSO-d6) δ 11.83 (s, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.01 (dd, J = 7.0,2.0 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.51 (s, 1H), 7.20 7.08 (m, 2H), 6.92 {s, 2H), 6.75 (dt, J = 10.7, 2.3 Hz, 1H), 6.27 (s, 1H), 3.91 (q, J = 7.0 Hz, 2H), 2.26 (s, 3H), 2.00 (s, 6H), 1.29 (t, J = 7.0 Hz, 3H).
836	511.30	1.66
837	556.50	1.90
838	523.40	1.50
839	538.20	1.89
840	492.00	1.29	1H NMR (400 MHz, DMSO) δ 11.11 (s, 1H), 7.64 (s, 1H), 7.31 (s, 4H), 7.19 (s, 1H), 7.10 (s, 1H), 6.72 (s, 2H), 4.58 (s, 1H), 4.15 (d, J = 7.4 Hz, 1H), 3.90 (d,J = 12.5 Hz, 1H), 2.22 (s, 3H), 2.19 (s, 3H), 2.12 (s, 6H), 1.60 (s, 3H), 1.48 (s, 3H).
841	441.40	1.82
842	562.34	3.06	1H NMR (400 MHz, DMSO) δ 12.44 . (s, 1H), 9.10 (s, 1H), 7.72 - 7.69 (d, 1H), 7.49 (s, 1H), 7.44 - 7.40 (d, 1H), 7.30 - 7.27 (d, 1H), 6.92 - 6.88 {d, 1H), 3.85 - 3.82 (d, 2H), 2.67 - 2.59 (m, 2H), 2.20 (m, 1H), 2.10 - 2.00 (m, 1H), 1.92 - 1.85 (m, 1H), 1.64 (s, 3H), 1.59 (S, 3H), 1.45 (t, J = 12.09,1H), 1.00-0.97 (d, 6H), 0.84-0.81 (d,3H)
843	546.20	1.86
844	526.30	2.00	1H NMR (400 MHz, DM5O-d6) δ 9.13 (s, 2H), 7.65 (S, 1H), 7.53 (s, 1H), 7.09 (d, J = 31.1 Hz, 2H), 6.57 (s, 1H), 6.34 (s, 2H), 5.26 (h, J = 6.2 Hz, 1H), 2.80 (s, 1H), 2.13 (s, 1H), 1.84 (dd, J = 11.7, 5.6 Hz, 1H), 1.59 (s, 3H), 1.55 (s, 3H), 1.34 (d, J = 6.2 Hz, 6H), 0.82 (d, J = 6.2 Hz, 3H).
845	554.50	1.94
846	553.60	1.81
847	494.30	1.81
848	553.50	1.79

1236

Cmpd. No.	LC/MS, M-1 <	:. LC/RT f '% min iÿ	..... ·· ·' . '♦-rw-w*!¹'
849	495.00	1.81	1H NMR (400 MHz, DMSO) δ 13.93 (s, 1H), 12.89 (s, 1H), 8.02 (d, J = 24.9 Hz, 3H), 7.57 (s, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 6.96 (d, J = 12.7 Hz, 1H), 6.81 (s, 1H), 4.76 {s, 1H), 2.36 (S, 3H),1.32(S, 6H).
850	570.30	2.05	1H NMR {400 MHz, DMSO) δ 12.52 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H),7.46 (s, 1H), 7.38 (d, J = 9.4 Hz, 1H), 7.27 {d, J = 8.0 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 6.70 {d, J = 8.4 Hz, 1H), 6.51 {S, 2H), 3.S3 (d, J = 6.6 Hz, 2H), 2,59 (S, 2H), 2.05 (dd, J = 11.6, 5.0 Hz, 1H), 1.76 (s, 2H), 1.65 {s, 6H), 1.03-0.95 (m, 12H).
851	553.60	1.64
852	424.19	2.24	1H NMR {400 MHz, DMSO-d6) δ 12.47 (s, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.62 (dd, J = 8.4, 7.3 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 6.68 {d, J = 8.4 Hz, 1H), 6.61 (d, J = 7.9 Hz, 1H), 6.51 (s, 2H), 2.60 - 2.52 (m, 2H), 2.20 (dq, J = 16.9, 6.4 Hz, 1H), 1.85 (dd, J = 12.0, 5,6 Hz, 1H), 1.48 (d,J = 9.8 Hz, 6H), 1.39 (t, J = 12.2 Hz, 1H), 0.86 {d, J = 6.2 Hz, 3H).
853	531.30	1.96	1H NMR (400 MHz, DMSO) δ 12.72 (s, 1H), 8.29 (d, J = 7.6 Hz, 1H), 7.68 7.59 (m, 2H), 7.20 (d,J = 7.2 Hz, 1H), 6.90 {s, 2H), 6,71 {d, J = 8.4 Hz, 1H), 6.59 (s, 2H), 2.25 {s, 3H), 1.94 (s, 6H),
854	467.00	1.92	1H NMR (400 MHz, DMSO) δ 12.31 (s, 1H), 8.03 (s, 1H), 7.78 (s, 1H), 7.63 (s, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.87 (s, 2H), 6.71 (d, J = 8.3 Hz, 1H), 6.50 (s, 2H), 2.24 (s, 3H), 1.94 (s, 6H), 1.37 (s, 3H), 0.89 (s, 2H),0.75 (s, 2H).
855	480.00	1.32	1H NMR (400 MHz, DMSO) Ô 12.60 {s, 1H), 8.20 {d, J = 9.3 Hz, 1H), 7.82 (s, 1H), 7,12 {d, J = 28,2 Hz, 3H), 6.93 (s, 1H), 6.82 (s, 2H), 6.43 (s, 1H), 4.41 (s, 1H), 2.83 (s, 2H), 2.21 (s, 3H), 2,14 (s, 6H), 2.07 (s, 2H).
856	529.02	2.55

1237

Cmpd.¹No.	LC/MS M-1 ,·	,LC/RT? •min ··	. -Ai;.
857	554.50	. 2.13
858	567.27	1.72
859	590.30	2.21
860	563.30	1.99
861	505.00	1.80	1H NMR (400 MHz, DMSO) δ 13.12 (s, 1H), 8.81 (s, 1H), 8.56 (d, J = 6.8 Hz, 1H), 8.31 (s, 1H), 8.25 (d, J = 7.6 Hz, 1H), 7.97 (s, 2H), 7.37 (d, J = 8.1 Hz, 2H), 7.25 (s, 1H), 7.04 (d, J = 7.9 Hz, 2H), 4.04 (S, 3H), 3.96 (s, 3H), 2.28 (d, J = 30.8 Hz, 6H).
862	483.40	3.22
863	497.31	1.53
864	573.28	1.92
865	531.00	2.10	1H NMR (400 MHz, DMSO) Ô8.07 (s, 1H), 7.88 (S, 1H), 7.62 (s, 1H), 7.42 (d, J = 17.4 Hz, 2H), 7.21 (s, 3H), 6.91 (s, 2H), 6.68 (s, 1H), 6.47 (s, 2H), 2.90 (s, 1H), 2.25 (S, 3H), 2.00 (s, 6H), 1.12 (d, J = 6.8 Hz, 6H).
866	523.20	1.83
867	583.22	2.27
868	545.00	2.13	1H NMR (400 MHz, DMSO) δ 12.52 (s, 1H), 8.02 (S, 1H), 7.83 (s, 1H), 7.71 7.55 (m, 2H), 7.37 (s, 1H), 7.23 (d, J = 6.7 Hz, 2H), 7.00 (d,J = 6.1 Hz, 1H), 6.90 (s, 2H), 6.69 (d, J = 11.3 Hz, 1H), 6.48 (S, 1H), 2.24 (s, 3H), 2.00 (s, 6H), 1.12 (s, 9H).
869	517.50	2.19
870	479.32	1.22
871	593.00	1.81	1H NMR (400 MHz, DMSO) δ 12.76 (s, 1H), 8.49 (s, 2H), 8.25 - 8.09 (m, 3H), 7.76 (S, 2H), 7.25 - 7.13 (m, 2H), 6.94 (s, 2H), 6.82 (d, J = 10.4 Hz, 1H), 4.25 (s, 2H), 3.64 (d,J = 6.5 Hz, 2H), 2.27 (s, 3H), 2.02 (s, 7H), 0.97 (d, J = 6.7 Hz, 6H).
872	517.18	1.89
873	449.50	1.57
874	565.20	2.24
875	521.20	2.14
876	494.30	1.53
877	524.10	2.66
878	520.21	1.84

1238

Cmpd. No.	LC/MS.J M-1 '*	i LC/RT , mir.	gB/Ç* NMR
879	470.50	1.46	1H NMR (400 MHz, DMSO-d6} δ 13.72 (s, 1H), 8.24 (d,J = 8.2 Hz, 1H), 8.03 (d, J = 8.0 Hz, 2H), 7.95 (s, 1H), 7.31 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 2.4 Hz, 1H), 3.63 (dt, J = 11.9, 4.6 Hz, 2H), 3.55 (s, 2H), 3.49 (ddd, J = 11.8, 9.1, 3.0 Hz, 2H), 2.36 (s, 3H), 1.45 (ddd, J = 13.4, 9.1, 4.1 Hz, 2H), 1.27 - 1.19 (m, 2H), 0.97 {S, 3H).
880	414.00	1.65	1H NMR (400 MHz, DMSO) δ 11.97 (s, 1H), 7.61 (S, 3H), 7.31 (d, J = 8.1 Hz, 1H), 6.69 (d, J = 8.7 Hz, 2H), 5.77 (s, 10H), 5.57 (s, 1H), 2.33 (s, 2H), 1.79 (S, 2H), 1.57 (S, 2H), 1.48 (s, 2H), 1.28 (s, 9H).
881	556.50	1.87
882	494.30	2.08
883	497.31	1.93
884	567.33	1.72
885	481.00	1.07	1H NMR (400 MHz, DMSO) 59.61 (s, 1H), 7.81 (s, 1H), 7.22 (d, J = 7.2 Hz, 1Hh 7 05 (s, 2H), 6.91 (s, 3H), 6.72 (d, J = 10.1 Hz, 1H), 4.39 - 4.01 (m, 4H), 2.39 (S, 6H), 2.24 (s, 3H), 1.82 (s, 3H).
886	514.31	2.83
887	556.50	2.03
888	550.30	1.84
889	533.28	1.82
890	508.00	2.50	1H NMR (400 MHz, DMSO) δ 12.40 (s, 1H), 7.97 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.3, 7.4 Hz, 1H), 7.36 (d, J = 8.3 Hz, 2H), 7.24 7.11 (m, 2H), 6.68 (d,J = 8.4 Hz, 1H), 6.49 (s, 2H), 2.93 (dd, J = 13.7, 6.9 Hz, 1H), 2.61 (d, J = 8.9 Hz, 2H), 2.28 2.12 (m, 1H), 1.95 - 1.76 (m, 1H), 1.61 (d,J = 3.2 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 1.23 (d, J = 6.9 Hz, 6H), 0.88 (d, J = 6.3 Hz, 3H).
891	525.23	1.52
892	494.50	1.85	1H NMR (400 MHz, DMS0-d6) δ 13.20 (s, 1H), 12.91 (s, 1H), 8.36 8.29 (m, 1H), 8.06 (dd, J = 21.6, 7.8 Hz, 1H), 7.92 (d, J = 1.9 Hz, 1H), 7.66

1239

Cmpd. No.	LC/MS Mil ^;.	LC/RT:· rrin /'	WW™»»
			(s, 0.5H), 7.40 (s, 0.5H), 7.54 (d, J = 7.8 Hz, 1H), 7.10 (d,J = 2.0 Hz, 1H), 7.03 (dd, J = 8.1, 2.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.51 (s, 1H), 3.87 (s, 3H), 2.31 (s, 3H), 2.15 - 2.09 (m, 3H), 2.04 (s, 3H).
893	521.50	1.95	1H NMR (400 MHz, DMSO-d6) 58.40 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 2.1 Hz, 1H}, 8.07 (d, J = 7.9 Hz, 1H),7.98 (dd, J = 2.3,1.0 Hz, 1H), 7.92-7.89 (m, 1H), 7.71 (d, J = 7.9 Hz, 1 H), 7.18 7.05 (m, 4H}, 3.89 (s, 3H), 2.33 (s, 3H), 2.13 (s, 3H), 2.04 (s, 3H).
894	543.22	2.35
895	465.30	1.23
896	509.30	1.50	1H NMR (400 MHz, DMSO-d6) 5 9.11 (d, J = 2.3 Hz, 1H), 8.23 (dd, J = 8.3, 2.4 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.49 (t, J = 6.9 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.04 (dd, J = 25.8, 6.0 Hz, 2H), 6.50 (d, J = 7.1 Hz, 1H), 6.23 (s, 2H), 3.05 (p, J = 6.9 Hz, 1H), 2.99 2.82 (m, 2H), 2.19 - 2.05 (m, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.62 (s, 3H), 1.57 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 1.26 (d, J = 6.9 Hz, 6H),0.82 (d, J = 6.2 Hz, 3H).
897	553.20	2.16
898	552.30	1.68	1H NMR (400 MHz, DMSO-d6) 58.10 (d, J = 5.3 Hz, 1H), 7.61 (s, 1H), 7.45 (S, 1H), 7.25 (S, 1H), 7.13 - 6.95 (m, 3H), 6.47 (S, 1H), 3.35 (d, J = 7.5 Hz, 2H), 3.06 (s, 3H), 2.98 (s, 1H), 2.22 2.01 (m, 2H), 1.83 {dd, J = 11.8,5.6 Hz, 1H), 1.63 (s, 3H), 1.58 (s, 3H), 1.38 (t, J = 12.0 Hz, 1H), 0.86 (dd, J = 11.1, 6.7 Hz, 9HJ.
899	496.00	2.06	1H NMR (400 MHz, DMSO) 5 12.58 (s, 1H), 11.71 (S, 1H), 8.25 (s, 1H), 7.83 (s, 2H), 6.92 (s, 2H), 6.45 (s, 1H), 2.67 (s, 2H), 2.26 (S, 3H), 1.98 (s, 6H), 1.65 (d, J = 27.5 Hz, 4H), 0.92 (s, GH).
900	517.20	2.25
901	552.20	1.97
902	559.08	1.65

1240

.Cmpd. 'No.	_; LC/MS	•î LC/RT min
903	509.40	1.78
904	530.40	1.97
905	539.60	1.47
906	526.30	2.85
907	570.11	2.03
908	505.31	2.55
909	548.30	2.13
910	496.30	1.60
911	457.40	2.29	1H NMR (400 MHz, DMSO-d6) δ7.98 (d, J = 7.8 Hz, 1H), 7.60 (d, J = 2.1 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 6.99 6.94 (m, 1H), 6.90 (s, 2H), 4.07 (s, 3H), 2.25 (s, 3H), 1.93 (s, 6H), 1.05 (s, 9H).
912	578.16	2.04
913	515.25	1.64
914	539.50	2.11	1H NMR (400 MHz, DMSO-d6) 6 13.80 (S, 1H), 12.51 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.98 (s, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.25 - 7.18 (m, 1H), 7.13 (t, J = 1.8 Hz, 1H), 6.96 (s, 2H), 6.88 (s, 1H}, 6.79 (dt, J = 10.9, 2.4 Hz, 1H), 4.41 (p, J = 6.0 Hz, 1H), 2.27 (s, 3H), 2.00 (s, 6H), 1.21 (d, J = 6.0 Hz, 6H).
915	539.30	1.71
916	513.41	3.01
917	552.30	1.99
918	435.50	1.96
919	537.43	2.98
920	537.43	2.79
921	509.60	1.54	1H NMR (400 MHz, DMSO-d6) 08.85 (d, J = 2.5 Hz, 1H), 8.31 (dd,J = 8.7, 2.5 Hz, 1H), 7.84 (s, OH), 7.71 (d, J = 7.9 Hz, 1H), 7.65 (dd,J = 8.4 Hz, 1H), 7.19 (dd, J = 15.2, 7.6 Hz, 2H), 6.83 (d, J = 8.7 Hz, 1H), 6.72 (d,J = 8.3 Hz, 1H), 5.31 (hept, J = 6.1 Hz, 1H), 4.56 (s, 1H), 2.98 (d, J = 9.9 Hz, 1H), 2.44 (s, 1H), 2.31 (d, J = 9.8 Hz, 1H), 1.68 1.19 (m, 7H), 1.32 (d, J = 6.2 Hz, 6H).
922	555.37	1.78
923	544.33	2.84
924	540.30	1.98	1H NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.47 -

1241

Cmpd.. Ne:	LC/MS W+W	LC/RTi 'min
			7.39 (m, 2H), 7.30 - 7.17 (m, 2H), 6.89 (dt, J = 10.8, 2.3 Hz, IH), 6.72 (dd, J = 8.4, 0.8 Hz, IH), 6.49 (s, 2H), 4.54 (s, IH}, 3.84 (d, J = 6.5 Hz, 2H), 2.99 (d, J = 9.4 Hz, IH), 2.44 (s, IH), 2.37 - 2.27 (m, IH), 2.09 - 2.00 (m, IH), 1.70 1.48 (m, 4H), 1.45 - 1.35 (m, IH), 1.32 -1.21 (m, IH), 0.99 (d, J = 6.7 Hz, 6H).
925	525.30	1.45	IH NMR (400 MHz, DMSO-06) δ 13.04 (s, IH), 8.87 (d, J = 2.5 Hz, IH), 8.32 (dd, J = 8.7, 2.5 Hz, IH), 7.81 (d, J = 7.9 Hz, IH}, 7.65 (dd, J = 8.4, 7.3 Hz, IH), 7.32 (d, J = 8.0 Hz, IH), 7.22 (dd, J = 7.3, 0.8 Hz, IH), 6.85 (d, J = 8.7 Hz, IH), 6.72 (d, J = 8.3 Hz, IH), 5.30 (h, J = 6.1 Hz, IH), 4.24 - 3.70 (m, 2HJ, 2.27 - 2.16 (m, IH), 2.16 2.04 (m, IH), 1.48 -1.34 (m, IH), 1.32 (d, J = 6.2 Hz, 6H), 1.08 (d, J = 6.1 Hz, 3H), 0.97 (d, J = 6.5 Hz, 6H).
926	568.40	2.68	IH NMR (400 MHz, DMSO-d6) δ 12.51 (s, IH), 7.75 (d,J = 7.9 Hz, IH), 7.64 (dd, J = 8.4, 7.3 Hz, IH), 7.38 (t, J = 1.8 Hz, IH), 7.35 - 7.29 (m, IH), 7.20 (dd, J = 7.6, 4.1 Hz, 2H), 6.89 (dt, J = 10.9, 2.3 Hz, IH), 6.71 (d, J = 8.3 Hz, IH), 6.47 (S, IH), 3.83 (d, J = 6.5 Hz, 2H), 2.83 (t, J = 13.4 Hz, 2H), 2.74 {t, J = 6.1 Hz, 2H), 2.04 (dt, J = 13.3, 7.0 Hz, IH), 1.96 - 1.85 (m, 2H), 1.76 (dq, J = 12.5, 6.2 Hz, 4H), 1.69 -1.57 (m, 2H), 1.34 -1.23 (m, 2H), 1.17 1.13 (m, lH),0.99 (d, J = 6.6 Hz, 6H).
927	466.40	1.75
928	523.23	1.56
929	485.50	2.73
930	535.20	1.97	IH NMR (400 MHz, DMSO-d6) 5 8.25 (d, J = 2.2 Hz, IH), 8.05 (d, J = 7.6 Hz, IH), 7.85 {dd, J = 2.4,1.1 Hz, IH), 7.72 (dd, J = 4.8, 2.4 Hz, IH), 7.65 (dd, J = 7.1,2.5 Hz, IH), 7.42 (d, J = 7.7 Hz, IH), 6.91 (s, 2H), 5.88 (dd, J = 7.1, 4.8 Hz, IH), 3.86 (s, 3H), 2.27 (s, 3H), 2.11 (s, 3H), 2.02 (s, 6H).
931	542.30	3.60

1242

Cinpd. * No.	Lû/MS^ M-rl ig	. LC/RT ; min <	r».“- . .jSSW;.-!
932	535.20	1.88	1H NMR (400 MHz, DMSOT6) δ 11.81 (s, 1H), 8.04 (d, J = 7.7 Hz, 1H), 8.00 - 7.93 (m, 2H), 7.60 (d, J = 7.7 Hz, 1H), 7.52 (s, 1H), 7.19 - 7.02 (m, 3H), 6.89 (s, 2H), 6.21 (s, 1H), 3.80 (s, 3H}, 2.74 (s, 2H), 2.24 (s, 3H), 2.01 (s, 6H).
933	559.21	2.09
934	554.30	1.96	1H NMR (400 MHz, DMS0-d6} δ 12.54 (s, 1H}, 7.72 - 7.61 (m, 2H), 7.48 - 7.38 (m, 2H), 7.33 (d, J = 7.8 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.8, 2.4 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.46 (s, 2H), 4.23 (d, J = 3.9 Hz, 2H), 3.84 (d, J = 6.5 Hz, 2H), 2.03 (dt, J = 13.4, 6.6 Hz, 1H), 1.78 (dd, J = 8.3,4.2 Hz, 2H), 1.69 (q, J = 9.9, 7.2 Hz, 5H), 1.41 {s, 1H), 1.33 (d, J = 8.6 Hz, 2H), 0.99 (d,J = 6.7 Hz, 6H).
935	545.28	1.97
936	543.20	1.93
937	495.20	1.97
938	507.11	2.63
939	504.30	2.21
940	511.20	1.62
941	559.30	2.00	1H NMR (400 MHz, DMSO-d6) δ 13.25 (s, 1H), 12.51 (s, 1H), 8.25 (dd, J = 7.2, 2.1 Hz, 1H), 7.90 - 7.81 (m, 2H), 7.77 (d, J = 2.0 Hz, 1H), 7.69 (dd, J = 8.3, 1.9 Hz, 1H), 7.53 (dd, J = 8.1, 4.6 Hz, 2H), 6.46 (t,J = 6.8 Hz, 1H),3.96 (d, J = 6.5 Hz, 2H), 3.72 (d, J = 12.7 Hz, 2H), 2.88 {t, J = 12.1 Hz, 2H), 2.17 2.02 (m, 1H), 1.70 -1.47 (m, 3H), 1.30 -1.13 (m, 2H), 1.03 (d, J = 6.7 Hz, 6H), 0.92 (d, J = 6.2 Hz, 3H).
942	530.22	1.93
943	479.40	1.94	1H NMR (400 MHz, DMS0-d6) δ 12.36 (s, 1H), 7.67 (d, J = 6.2 Hz, 1H), 7.53 (S, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.20-7.16 (m, 1H), 7.06 - 7.00 (m, 1H), 6.82 (dd, J = 7.8,2.4 Hz, 1H), 6.76 (s, 2H), 6.41 (d, J = 6.2 Hz, 1H), 5.79 - 5.52 {m, 4H}, 3.97 (s, 3H), 2.18

1243

Cmpd. No.	, LC/MS ^: M+T	LC/RT ^min	^NM
			(s, 3H), 1.93(s, 6H).
944	542.13	1.92
945	517.00	2.02	1H NMR (400 MHz, DMSO) 5 12.61 (s, 1H), 8.21 (s, 1H), 8.01 (s, 1H), 7.72 (s, 1H), 7.39 (d, J = 50.3 Hz, 5H), 7.00 (s, 2H), 6.79 (d, J = 8.3 Hz, 1H), 6.59 (s, 2H), 2.65 (s, 2H), 2.34 (s, 3H), 2.10 (s, 6H), 1.13 (s,3H).
946	390.00	1.15	1H NMR (400 MHz, DMSO) 5 12.41 (s, 1H), 8.22 - 8.03 (m, 1H), 7.74 - 7.54 (m, 2H), 7.18 (d, J = 7.3 Hz, 1H), 6.66 (d,1 = 8.3 Hz,1H), 6.57 (dd,J =7.5, 4.6 Hz, 1H), 6.46 {s, 2H), 2.57 (d, J = 7.3 Hz, 2H), 2.18 (s, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.50 (d,J =9.2 Hz, 6H), 1.38 (t, J = 12.0 Hz, 1H), 0.86 (d, J = 6.3 Hz, 3H).
947	540.43	2.73
948	494.30	1.56
949	525.30	1.56	1H NMR (400 MHz, DMSO-d6) § 12.42 (s, 1H), 8.83 (d, J = 2.5 Hz, 1H), 8.27 (dd, J = 8.8, 2.5 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.17 (dd, J = 12.3, 7.6 Hz, 2H), 6.85 (d, J = 8.7 Hz, 1H), 6.65 (d,J = 8.4Hz, 1H), 6.45 (s, 2H), 5.31 (hept, J = 6.3 Hz, 1H), 2.63 (s, 2H), 2.22 (dd, J = 13.1, 7.4 Hz, 1H), 1.87 (dd, J = 11.9, 5.7 Hz, 1H), 1.59 (d, J = 3.4 Hz, 6H), 1.41 (t, J = 12.0 Hz, 1H), 1.31 (d, J = 6.2 Hz, 6H), 0.88 (d, J = 6.2 Hz, 3H).
950	549.20	1.98
951	524.50	1.09
952	530.30	2.05
953	554.40	1.93
954	521.40	1.81
955	532.29	2.05
956	537.43	2.97	1H NMR (400 MHz, DMSO-d6} δ 12.35 (s, 1H), 8.09 - 8.06 (d, 1H), 7.62 - 7.56 (d, 2H), 7.33 (t, J = 7.91,1H), 7.20 - 7.17 (d, 1H), 7.06-7.01 (d, 1H}, 6.91 (s, 2H), 6.83 - 6.76 (m, 1H), 6.66 - 6.63 (d, 1H), 6.45 (s, 2 H), 3.84 (s, 3H), 2.25 (s, 3H), 2.02 (s, 6H)
957	524.30	1.67

1244

Cmpd. No. $	LC/MSJ ··- Mit r*	^; LC/'RT X .· min	. NMR X -¾
958	525.40	1.82	1H NMR (400 MHz, DMSO-d6) δ 13.42 (S, 1H), 12.50 (s, 1H), 8.25 (dd, J = 7.3, 2.1 Hz, 1H), 7.92 - 7.80 (m, 2H), 7.70 - 7.58 (m, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.07 6.99 (m, 1H), 6.46 (dd, J = 7.3, 6.3 Hz, 1H), 3.83 (d, J = 6.5 Hz, 2H), 3.70 (d, J = 12.1 Hz, 2H), 2.96 - 2.85 (m, 2H), 2.13 - 1.99 (m, 2H), 1.69 - 1.60 (m, 2H), 1.33 -1.18 (m, 2H), 1.00 (d, J = 6.7 Hz, 6H), 0.93 (d, J = 6.2 Hz, 3H).
959	498.30	2.03	1H NMR (400 MHz, DMSO) δ 12.23 (s, 1H), 7.20 (dd, J = 9.7, 6.1 Hz, 2H), 7.07 (d, J = 8.1 Hz, 1H), 6.88 - 6.80 (m, 3H), 6.71 (s, 1H), 3.84 (s, 3H), 2.23 (S, 3H), 1.93 (s, 6H), 1.04 (s, 9H).
960	541.50	1.60
961	579.23	2.23
962	546.50	1.27
963	441,20	1.89
964	596.34	2.15
965	526.30	2.13	1H NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 1.3 Hz, 1H), 8.25 (d, J = 1.3 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H),7.48 (t,J = 7.7 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 6.99 (d, J = 7.3 Hz, 1H), 6.50 (d, J = 8.2 Hz, 1H), 6.25 (s, 2H), 5.28 (h, J = 6.2 Hz, 1H), 2.93 (d, J = 23.0 Hz, 2H), 2.07 (s, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.63 (S, 3H), 1.58 (s, 3H), 1.35 (d, J = 1.6 Hz, 3H), 1.34 (d,J = 1.7 Hz, 3H), 0.80 (d, J = 6.3 Hz, 3H).
966	498.40	2.55
967	579.20	2.38
968	471.69	3.25
969	618.40	3.26
970	727.50	0.68	1H NMR (300 MHz, DMSO) δ 8.24 (dd, J = 15.6, 8.2 Hz, 1H), 7.80 - 7.66 (m, 1H), 7.66 - 7.39 (m, 10H), 7.31 7.22 (m, 4H), 7.11 (d, J = 7.2 Hz, 1H), 6.74 (t, J = 10.3 Hz, 1H), 6.55 (d, J = 7.9 Hz, 1H), 6.27 (s, 2H), 1.92 (d, J = 1.9 Hz, 12H).
971	553.28	1.80
972	542.30	1.77

1245

Cmpd. No.	LC/MS M+i	LC/RT $ min K
973	554.50	2.03
974	533.20	1.99
975	546.20	1.72
976	495.30	1.76	1H NMR (400 MHz, DMSO-d6) 57.98 (d, J = 7.7 Hz, 1H), 7.41 (dd, J = 8.2, 7.4 Hz, 1H), 7.09 - 7.01 (m, 2H), 6.88 6.81 (m, 2H), 6.44 (dd, J = 8.2, 0.9 Hz, 1H), 6.35 {dt,J = 3.2,1.6 Hz, 1H), 6.07 (s, 2H), 4.12 (q, J = 2.8 Hz, 2H), 3.68 (t, J = 5.5 Hz, 2H), 2.23 (d, J = 5.4 Hz, 5H), 1.98 (S, 6H).
977	528.12	2.75	1H NMR (400 MHz, DMSO-d6) S 12.23 (s, 1H), 11.19 (s, 1H), 8.17 8.14 (d, 1H), 7.79 - 7.76 (d, 1H), 7.65 (t, J = 8.02,1 H) 7.53 -7.50 (d, 1H), 7.47 - 7.44 (d, 1H), 7.26 - 7.23 (d, 1H), 7.15 - 7.09 (m, 2H), 6.97 (s, 2 H), 6.72 - 6.69 (d, 1H), 6.54 (s, 2H), 6.22 (s, 1H), 2.31 (s, 3H), 2.04 (s, 6H)
978	571.32	2.42
979	525.25	1.66
980	520.20	1.85
981	536.17	1.94
982	484.29	1.41
983	442.58	2.86
984	555.13	2.98
985	446.00	1.35
986	462.50	1.32
987	523.30	1.58	1H NMR (400 MHz, DM5O-d6) δ 12.50 (s, 1H), 8.87 (d, J = 2.5 Hz, 1H), 8.33 (dd, J = 8.8, 2.5 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.24 (d, J = 7.9 Hz, 1H), 7.19 (d, J = 7.4 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 5.32 (p, J = 6.2 Hz, 1H), 3.50 (q, J = 10.2, 9.6 Hz, 2HL 2·69 (t, J = 6.6 Hz, 2H), 2.02 (t, J = 6.5 Hz, 2H), 1.98 -1.86 (m, 1H), 1.86 - 1.75 (m, 1H), 1.68 (q, J = 7.9, 6.0 Hz, 4H), 1.32 (d, J = 6.2 Hz, 6H)(NH2 under H20 peak).
988	540.50	1.69
989	566.50	2.20	1H NMR (400 MHz, DMS0-d6) 58.32 (d, J = 2.2 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.81 (d,J

1246

Cm pdf No. ®	. LC/MS 1 ' M+1 ’	.lc/rt- < min A'
			= 7.9 Hz, IH), 7.23 (dt, J = 9.8, 2.0 Hz, IH), 7.13 (t, J = 1.8 Hz, 3H), 6.95 (s, 2H), 6.79 (dt, J = 10.7, 2.3 Hz, IH), 4,41 (p, J = 6.1 Hz, IH), 2,27 (s, 3H), 2.00 (s, 6H), 1.21 (d, J = 6.0 Hz, 6H).
990	499.70	1.83
991	542.40	1.96	IH NMR (400 MHz, DMSO-d6) 5 12.82 {s, IH), 7.83 (d, J = 7.9 Hz, IH), 7.65 (dd, J = 8.4, 7.3 Hz, IH), 7.49 (d, J = 8,0 Hz, 1H),7.46 (dd,J = S.6, 2.2 Hz, 2H), 7.21 (d, J = 7.3 Hz, IH), 6.92 (dd, J = 10.8, 2.3 Hz, IH), 6.71 (d, J = 8.4 Hz, IH), 6.44 (s, 2H), 3.85 (d, J = 6.5 Hz, 2H), 3.71 (d, J = 12.8 Hz, 2H), 2.85 (t, J = 12.1 Hz, 2H), 2.05 (dt, J = 13,3, 6.7 Hz, IH), 1.62 (d,J = 13.3 Hz, 2H), 1.58 - 1.48 (m, IH), 1.15 (q, J = 10.8,10.2 Hz, 2H), 1.00 (d, J = 6.7 Hz, 6H), 0.91 (d, J = 6.3 Hz, 3H).
992	525.40	1.50
993	554.10	2.16
994	573.30	1.93
995	539.30	1,53
996	547.20	2.25	IH NMR (400 MHz, DMSO-d6) 68.05 (s, IH), 7.64 (s, 2H), 7.44 (s, 2H), 7.07 (s, IH), 6.90 (s, 4H), 6.45 (s, IH), 6.07 (S, 2H), 3.93 (s, 2H), 2.27 (s, 2H), 2.02 (s, 5H}, 1.71 (s, 2H).
997	530.27	2.03
998	527.20	1.42	IH NMR {400 MHz, DMSO) δ 13.12 (s, IH), 8.86 {s, IH), 8.32 (dd, J = 8.8, 2.3 Hz, IH), 7.79 (S, IH), 7.62 (s, IH), 7.31 (s, IH), 7.21 (d, J = 6.7 Hz, IH), 6.86 (d, J = 8.7 Hz, IH), 6.70 (s, IH), 6.47 (d, J = 22.7 Hz, 2H), 5.21 (dd, J = 11.2, 5,9 Hz, IH), 4.82 (t, J = 5.7 Hz, IH), 4,02 (S, 2H), 3.59 (dt, J = 11.3, 5.7 Hz, IH), 3.56 - 3.46 (m, IH), 1.96 (s, 2H), 1.65 (s, 2H), 1.26 (d, J = 6.3 Hz, 3H), 1.08 (t, J = 8.4 Hz, 6H).
999	582.20	2.20
1000	521.20	2,16
1001	545.11	1.50
1002	532.20	2.21
1003	401.00	1.90	IH NMR (400 MHz, DMSO) δ 12.08 (s,

1247

Cmpd/ü No. '	LG/MS ' M+l	LC/RT* min w
			1H), 7.59 (s, 3H), 7.24 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 1.6 Hz, 2H), 3.02 (s, 1H), 1.68 (s, 6H), 1.48 (s, 2H), 1.28 (s, 9H).
1004	556.35	1.83
1005	530.23	1.86
1006	538.19	1.91
1007	560.20	2.07
1008	432.50	1.41
1009	542.30	2.75
1010	528.40	1.78
1011	525.60	1.62
1012	603.34	1.87
1013	556.40	2.10	1H NMR {400 MHz, DMSO-d6) δ 12.76 (S, 1H), 7.81 {d, J = 7.8 Hz, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.52 - 7.43 (m, 3H), 7.22 (d, J = 7.2 Hz, 1H), 6.91 (d, J x 10.7 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.48 (s, 2H), 3.85 (d, J = 6.6 Hz, 2H), 3.69 (d, J = 12.5 Hz, 2H), 3.36 3.34 (m, 2H), 2.56 - 2.53 (m, 1H), 2.42 (t, J = 11.8 Hz, 1H), 2.05 {dt, J = 13.3, 6.7 Hz, 1H), 1.79 -1.69 (m, 2H), 1.00 (d, J = 6.8 Hz, 6H), 0.83 (d, J = 5.5 Hz, 6H}.
1014	555.43	3.03	1H NMR (400 MHz, DMSO-d6) δ 7.78 -7.75 (d,lH),7.50 -7.47 (m,3H), 7.30 - 7.22 {m, 2H}, 7.10 - 7.07 (d, 1H), 6.95 - 6.85 (m, 2H), 3.86 - 3.83 (d, 2H), 3.20 (m, 4H), 2.10 - 2.00 (m, 1H), 1.33 (m, 4H), 1.01 - 0.98 {d , 6H), 0.95 {s, 6H)
1015	489.50	1.95	1H NMR (400 MHz, DMSO-d6) δ 12.25 (s, 1H), 8.07 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 8.1 Hz, 3H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.25 - 7.19 (m, 3H), 7.16 - 7.11 (m, 2H), 7.07 (dd, J = 8.3, 2.1 Hz, 1H), 6.71 (dd, J = 8.5, 0.8 Hz, 1H), 6.52 (S, 2H), 2.32 {s, 3H), 2.31 (s, 3H), 2.06 (s, 3H).
1016	531.30	2.32
1017	525.30	1.82
1018	510.34	1.42
1019	534.50	2.07
1020	524.24	1.82

124S

Cmpd. No.	; LC/MS M+1 -	LLC/RT T min»^
1021	572.16	2.16
1022	566.20	2.10
1023	525.18	1.65
1024	477.25	1.81
1025	511.30	1.49
1026	519.28	1.82
1027	532.50	1.54
1028	546.22	1.79
1029	470.30	1.28
1030	530.22	1.91
1031	469.23	2.08
1032	503.50	2.07
1033	493.00	1.86	1H NMR (400 MHz, DMSO) δ 13.80 (s, 1H), 12.38 (S, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.98 (s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.66 (S, 1H), 3.76 (s, 3H), 2.28 (s, 3H), 2.02 (s, 6H).
1034	520.20	2.08
1035	503.21	3.11
1036	424.20	1.63
1037	431.40	1.90
1038	476.50	1.21	1H NMR (400 MHz, DMS0-d6) 67.82 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.19 {d, J = 6.9 Hz, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 3.70 - 3.60 (m, 3H), 2.81 (t, J = 12.0 Hz, 2H), 1.74 (d,J=2 Hz,2H), 1.41 - 1.30 (m, 2H), 1.28 (s, 9H), 1.04 (s, 6H). The three proton are buried tn the water peak, thus the intégration is skewed
1039	463.30	1.60
1040	525.40	1.42	1H NMR (400 MHz, DMSO-d6) 68.88 (d, J = 2.5 Hz, 1H), 8.34 (dd, J = 8.8, 2.5 Hz, 1H), 8.24 - 8.14 (m, 1H), 7.84 7.71 (m, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.19 (d, J = 7.3 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 5.28 (p, J = 6.1 Hz, 1H), 4.20 - 4.03 (m, 1H), 2.29 - 2.16 (m, 1H), 2.00 -1.88 (m, 2H), 1.80 - 1.65 (m, 1H), 1.46 (s, 3H), 1.30 (s, 6H), 1.29 (s, 3H), 1.09 (d, J = 6.2 Hz, 3H).
1041	530.30	2.00	1H NMR (400 MHz, DMSO) 6 13.75 (s, 1H), 12.59 (s, 1H), 7.97 (s, 1H), 7.69

1249

Crnpd. \|NoW'^;	^LC/MS M+1	/LC/RT + .- min .K>
			(d, J = 7.9 Hz, 1H), 7.48 (s, 1H), 7.40 (d, J = 9.9 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 6.93 - 6.84 (m, 2H), 3.83 (d, J = 6.6 Hz, 2H), 3.17 (s, OH), 2.58 (d, J = 9.4 Hz, 2H), 2.22 (s, 1H), 2.05 (dt,J = 13.3, 6.7 Hz, 1H), 1.88 (dd, J = 11.8, 5.5 Hz, 1H), 1.60 (d,J = 12.9 Hz,6H), 1.44 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H).
1042	502.36	1.81	1H NMR (400 MHz, DMSO) S 7.98 (s, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.47 - 7.40 (m, J = 10.2, 1.5 Hz, 2H), 6.91 {dt, J = 10.9, 2.3 Hz, 1H), 6.88 - 6.84 (m, 1H), 4.82 - 4.66 {m, 1H), 3.72 - 3.59 (m, J = 12.9 Hz, 2H), 2.93 - 2.78 (m, J = 11.9 Hz, 2H), 1.70 - 1.50 (m, J = 20.8, 9.2 Hz, 3H), 1.30 (d, J = 6.0 Hz, 6H), 1.27 - 1.09 (m, 2H), 0.93 (d, J = 6.3 Hz, 3H).
1043	565.27	1.87
1044	508.50	1.94	1H NMR (400 MHz, DMSO-d6) 5 13.81 (d, J = 6.2 Hz, 1H), 12.50 - 12.35 (m, 1H), 8.33 (d, J = 2.1 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 8.03 - 7.93 (m, 2H), 7.70 (d, J = 7.8 Hz, 1H), 6.96 {s, 2H), 6.92 - 6.84 (m, 1H), 3.88 (s, 3H), 2.29 (s,3H), 2.13 (s, 3H), 2.01 (s, 6H).
1045	469.26	2.08
1046	427.19	1.83
1047	504.50	2.10
1048	531.42	2.9S
1049	523.20	1.87
1050	453.30	1.93
1051	528.30	2.93
1052	508.30	2.19
1053	549.17	2.00
1054	512.51	2.61
1055	479.30	1.17	1H NMR (500 MHz, DMSO-d6) δ9.38 (s, 1H), 7.67 (tj = 8.0 Hz, 1H), 7.18 7.07 (m, 4H), 7.04 (d,J = 7.3 Hz, 1H), 6.91 {s, 2H), 6.80 (d, J = 8.5 Hz, 1H), 4.31 (d, J = 13.7 Hz, 1H), 4.16 (dd, J = 17.7,10.2 Hz, 2H), 3.54 (d, J = 13.0 Hz, 1H), 3.39 - 3.25 (m, 2H), 3.22 3.08 (m, 2H), 3.02 (d, J = 16.8 Hz, 1H),

1250

Gmpd. V No.	LC/MS	L.C/RT< > min
			2.22 (d, J = 8.3 Hz, 9H).
1056	542.23	3.03
1057	493.30	2.57
1058	450.00	1.17
1059	538.60	1.19
1060	564.29	2.14
1061	540.40	2.98
1062	553.50	1.82
1063	541.33	3.03	1H NMR {500 MHz, DMSO-d6) δ 12.90 (s, 1H), 8.80 - 8.78 (d, 1H}, 8.19 -8.17 (d, 2H), 7.81 - 7.73 (m, 2H), 7.49 (S, 1H), 7.43 - 7.39 (d, 1H), 7.31 7.28 (d, 1H), 6.92 - 6.88 (d, 1H), 3.84 3.81 (d, 2H), 2.51 - 2.36 ( m, 1H), 2.21 (m, 1H), 2.10 - 1.99 (m, 1H), 1.89 1.82 (m, 1H), 1.58 (s, 6H), 1.34 (t, J = 11.87,1H), 1.00 - 0.97 (d, 6H), 0.82 0.79 (d, 3H)
1064	439.40	1.94
1065	556.60	1.96
1066	497.50	1.38	1H NMR {400 MHz, DMSO-d6) δ8.30 (d, J = 2.2 Hz, 1H), 8.24 {d, J = 8.2 Hz, 1H}, 8.02 {d, J » 8.4 Hz, 2H), 8.01 7.98 (m, 1H), 7.94 - 7.91 (m, OH), 7.88 (d,J = 2.2 Hz, 1H), 7.31 (d,J = 8.3 Hz, 2H), 7.19 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.1 Hz, OH), 3.63 (ddd,J = 16.6, 10.6, 5.6 Hz, 2H), 3.54 (s, 2H), 3.53 3.46 (m, 2H), 2.37 {s, (3+1.5)H), 1.51 (ddt, J = 13.5, 9.3, 4.7 Hz, 1H), 1.41 (ddd, J = 13.4, 9.2, 4.2 Hz, 2H), 1.33 1.25 (m, 1H), 1.24 - 1.16 (m, 2H), 1.02 (s, 1.5H), 0.93 (s, 3H). Rotamers in 2:1 ratio
1067	498.30	1.84	1H NMR (400 MHz, DMSO-d6) ô 7.76 {d, J = 2.2 Hz, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.47 (dd, J = 8.3, 7.3 Hz, 1H), 7.03-6.91 (m, 2H), 6.61 (d, J = 2.3 Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H),6.25 (S, 2H), 4.52 (hept, J = 6.7 Hz, 1H), 2.92 (t, J = 10.6 Hz, 1H), 2.81 (dd, J = 10.7, 7.4 Hz, 1H), 2.07 (q, J = 6.7, 6.1 Hz, 1H), 1.78 (dd, J = 11.6, 5.6 Hz, 1H), 1.60 (S, 3H), 1.54 (s, 3H), 1.45 (d, \| J = 6.7 Hz, 6H), 1.34 (t, J = 12.0 Hz,

1251

^Cmpd. s- No. .	LC/MS^	.SUG/RTÎ® ιτιιη
			1H), 0.78 (d, J = 6.2 Hz,3H).
1068	579.24	2.30
1069	541.33	3.16	1H NMR (400 MHz, DMSO-d6) δ 8.76 - 8.74 (d, 1H), 8.19 (m, 2H), 7.84 7.74 (m, 2H), 7.52 - 7.45 (m, 3H), 6.95 - 6.91 (d, 1H), 3.86 - 3.83 (d, 2H), 3.23 (m, 4H), 2.10 -1.99 (m, 1H), 1.33 (m, 4H), 1.01 - 0.98 (d, 6H), 0.94 (s, 6H)
1070	485.50	3.11
1071	480.30	1.84
1072	531.30	1.83
1073	556.31	2.06
1074	485.40	1.42
1075	495.00	1.30	1H NMR (400 MHz, DMSO) δ 10.31 (s, 1H), 9.76 (s, 1H), 7.76 (s, 1H), 7.21 (d, J = 27.9 Hz, 2H), 6.91 (d, J = 51.5 Hz, 6H), 3.99 (d, J = 59.4 Hz, 4H), 3.61 (s, 3H), 2.29 (s, 6H), 2.22 (s, 3H), 1.55 (s, 3H).
1076	553.50	1.76
1077	541.19	2.27
1078	466.30	1.37
1079	562.20	2.25	1H NMR (400 MHz, DMSO) δ 12.60 (s, 1H), 11.92 (s, 1H), 8.27 (s, 1H), 8.14 (d,J = 7.9 Hz, 1H), 7.84 (s, 1H), 7.71 (d, J = 8.8 Hz, 3H), 6.96 {s, 4H), 6.47 (S, 1H), 3.77 (d, J = 6.5 Hz, 2H), 2.29 (s, 3H), 2.01 (d, J = 25.1 Hz, 7H), 0.95 (d,J = 6.7 Hz, 6H).
1080	589.31	1.91
1081	497.21	1.62
1082	473.20	1.71
1083	516.20	2.01	1H NMR (400 MHz, DMSO-d6) δ 13.75 (S, 1 H), 12.97 (s, 1H), 8.05 7.93 (m, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.55 -7.42 (m,3H), 6.92 (dd,J = 10.8, 2.3 Hz, 1H), 6.85 (t, J = 2.2 Hz, 1H), 3.85 (d, J = 6.5 Hz, 2H), 3.67 (d, J = 12.7 Hz, 2H), 2.89 - 2.79 (m, 2H), 2.05 (dt, J = 13.3, 6.6 Hz, 1H), 1.67 - 1.57 (m, 2H), 1.27 - 1.22 (m, 1H), 1.21 1.13 (m, 2H), 1.00 (d,J = 6.7 Hz, 6H), 0.93 (d, J = 6.2 Hz, 3H).
1084	467.31	1.65
1085	480.00	1.43	1H NMR (400 MHz, DMSO) δ 12.40 (s,

1252

Crnpd. WNo.Lî	LC/MS’^rί M+1 *	LC/RTg v min W
			1H), 11.29 (s, 1H), 7.97 (d, J = 7.2 Hz, 1H), 7.74 {s, 1H), 7.26 (d, J = 3.7 Hz, 2H}, 7.15 (t, J = 12.4 Hz, 2H), 6.71 (s, 2H}, 6.32 (S, 1H}, 4.57 (s, 1H), 4.02 (d, J = 12.6 Hz, 1H), 3.83 (d, J = 12.6 Hz, 1H), 2.20 (d, J = 15.0 Hz, 9H), 1.56 (s, 3H), 1.37 (s,3H).
1086	478.30	1.96
1087	511.26	1.62
1088	572.19	1.89
1089	480.30	1.89
1090	571.34	3.21	1H NMR (400 MHz, DMSO) δ 8.05 (t, J = 7.91, 1H), 8.88 - 8.85 (d, 1H), 7.78 -7.75 (d,lH), 7.54-7.47 (m, 3H), 7.21 - 7.18 {d, 1H), 6.95 - 6.91 (d, 1H), 3.86 - 3.83 (m, 5H), 3.23 (m, 4H), 2.10 -1.99 {m, 1H), 1.31 (m, 4H), 1.01 0.98 (d, 6H), 0.94 (s, 6H}
1091	524.30	2.32
1092	575.31	1.84
1093	464.30	1.36
1094	524.40	1.86	1H NMR (400 MHz, DMSO-d6) δ 13.03 (S, 1H), 8.09 - 8.00 (m, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H}, 7.04 (d, J = 8.9 Hz, 2H), 6.70 (d,J = 8.4 Hz, 1H}, 6.42 (S, 2H), 3.81 (d, J = 6.5 Hz, 2H), 3.67 (d, J = 12.7 Hz, 2H), 2.88 {t, J = 12.4 Hz, 2H), 2.03 (td, J = 14.0, 13.5, 6.9 Hz, 1H), 1.74 -1.47 (m, 3H), 1.21 (q, J = 13.7, 12.8 Hz, 2H), 1.00 (d, J = 6.7 Hz, 6H), 0.92 (d, J = 6.4 Hz, 3H).
1095	524.10	2.00
1096	515.30	1.42
1097	570.60	2.04
1098	570.50	2.13
1099	528.19	1.87
1100	500.20	1.63
1101	479.00	1.22	1H NMR (400 MHz, DMSO) δ 7.56 (s, 1H), 7.26 (d, J = 29.4 Hz, 4H), 6.89 (d, J = 7.3 Hz, 1H), 6.80 - 6.68 (m, 3H), 4.69 (s, 1H), 4.16 (d, J = 12.9 Hz, 1H), 2.20 (d, J = 25.7 Hz, 9H), 1.63 (s, 3H), 1.45 (s,3H).

1253

Cmpd. : No.	ÆC/MS> Æ Mil	Imin^	WW
1102	503.00	1.86	1H NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 7.75 (S, 2H), 7.65 (s, 1H), 7.57 (s, 1H), 7.46 - 7.36 (m, 3H), 7.24 (d, J = 7.2 Hz, 1H), 6.93 (s, 2H), 6.73 (d, J = 8.4 Hz, 1H), 6.48 (s, 2H), 2.29 (d, J = 13.2 Hz, 6H), 2.05 (s, 6H).
1103	536.50	1.91
1104	459.18	1.96
1105	560.50	2.08
1106	456.50	2.78
1107	523.20	1.79
1108	557.25	2.41
1109	542.30	1.92
1110	530.20	2.09
1111	544.50	1.77
1112	559.32	1.87
1113	613.50	2.15
1114	526.20	2.19	1H NMR {400 MHz, Methanol-d4) δ 8.23 (d, J = 2.7 Hz, 1H), 8.08 (dd, J = 7.2, 1.7 Hz, 2H), 7.76 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.59 (dd, J = 8.4, 6.7 Hz, 2H), 6.97 (d, J = 8.3 Hz, 1H), 5.98 (d, J = 2.8 Hz, 1H), 3.89 (s, 2H), 2.65 (d, J = 10.4 Hz, 1H), 2.52 {s, 1H), 2.17 (s, 1H), 1.85 (dd, J = 11.7, 5.7 Hz, 1H), 1.59 (d, J = 12.2 Hz, 6H), 1.45 (t,J = 12.1 Hz, 1H), 1.03 (s,9H), 0.76 (d, J = 6.3 Hz, 3H).
1115	520.20	1.47
1116	541.33	1.58
1117	514.30	2.86
1118	517.20	2.23
1119	532.20	1.87
1120	503.21	3.01
1121	556.50	1.91
1122	560.50	1.60	1H NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 10.03 (s, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.80 - 7.68 (m, 4H), 7.57 (s, 1H), 7.44 - 7.37 (m, 3H), 7.32 (d, J = 7.2 Hz, 1H), 6.95 (s, 2H), 6.84 (d, J = 8.5 Hz, 1H), 3.62 - 3.53 (m, 2H), 3.23 (q, J = 5.7 Hz, 2H), 2.78 (d, J = 4.6 Hz, 6H), 2.28 (s, 3H), 2.01 (s, 6H).
1123	528.30	1.57	1H NMR (400 MHz, DMSO-d6) δ 13.04 (S, 1H), 7.81 (dd, J = 7.8,1.6 Hz,

1254

Cmpd. ï;	iLC/MS^ M+1 Ai	LC/RT + ^: min ; /
			1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.52-7.46 (m, 1H), 7.46-735 (m, 2H), 7.23 (dd, J = 73, 0.7 Hz, 1H), 6.88 (dt, J = 10.9, 23 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 4.73 (h, J = 6.1 Hz, 1H), 4.08 - 3.95 (m, 2H), 2.06 -1.91 (m, 2H), 1.73 - 1.61 (m, 2H), 131 (d, J = 6.0 Hz, 6H), 1.09 (d, J = 6.2 Hz, 6H).
1124	43930	1.90
1125	509.30	1.66	1H NMR {400 MHz, DMSO-d6) δ8.89 -8.78 (m,lH), 830 (dd, J = 8.8, 2.5 Hz, 1H), 7.56 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.03 (s, 2H), 6.92 (d, J = 8.6 Hz, 1H), 6.16 (S, 2H), 4.25 (tt, J = 7.1, 3.7 Hz, 3H), 1.87 (s, 2H), 1.57 (q, J = 8.6, 8.2 Hz, 2H), 1.07 (d, J = 6.1 Hz, 6H), 0.82 - 0.74 (m, 2H), 0.74 - 0.64 {m, 2H).
1126	546.13	2.47
1127	528.20	1.86
1128	456.38	2.97
1129	490.40	1.84	1H NMR {400 MHz, DMSO-d6) δ 12.56 (s, 1H), 12.16 (s, 1H), 8.27 {dd, J = 73, 2.1 Hz, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.84 (s, 1H), 7.75 - 7.68 (m, 3H), 7.22 (d, J = 8.1 Hz, 2H), 7.16 - 7.10 (m, 2H), 7.07 (dd, J = 8.2, 2.1 Hz, 1H), 6.46 (dd, J = 73, 63 Hz, 1H), 234 2.29 (m, 6H), 2.07 (s, 3H).
1130	535.20	1.82
1131	495.40	3.25
1132	537.50	1.76
1133	534.20	2.19
1134	525.33	1.67	1H NMR {400 MHz, DMSO) δ 12.97 (s, 1H), 8.90 (s, 1H), 8.37 (d, J = 8.7 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.66 {s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 532 (s, 1H), 3.29 (S, 4H), 1.40 (s, 4H), 132 {d, J = 6.2 Hz, 6H), 0.96 (s, 6H).
1135	553.50	1.83
1136	525.40	1.73
1137	427.27	2.61
1138	565.20	2.26	1H NMR (400 MHz, DMS0-d6) δ8.08

1255

Cmpd. No.	LC/MS t M+1 +	... ^LC/RT® ' min i*
			(d, J = 7.7 Hz, IH), 7.61 (d, J = 7.7 Hz, IH), 7.42 (dd, J = 8.2, 7.3 Hz, IH), 7.15 (ddd, J = 10.1, 2.4,1.3 Hz, IH), 7.11 - 7.04 (m, 2H), 6.91 (s, 2H), 6.69 (dt, J = 10.8, 2.3 Hz, IH), 6.45 (dd, J = 8.2, 0.9 Hz, IH), 6.08 (s, 2H), 4.38 (p, J = 6.0 Hz, IH), 2.26 (s, 3H), 2.00 (s, 6H), 1.21 (d, J = 6.0 Hz, 6H).
1139	534.12	2.71
1140	537.43	2.95
_1141	483.20	1.28
1142	502.14	1.78
1143	548.20	2.12
1144	556.60	1.96
1145	525.33	1.64
1146	549.43	2.81	IH NMR (400 MHz, DMSO-d6) δ 12.19 (s, IH), 8.13-8.10 (d, IH), 7.74 - 7.63 (m, 2H), 7.49 - 7.46 (d, IH), 7.29 - 7.23 (m, 2H), 7.00 - 6.96 (m, 3H}, 6.74 - 6.71 (d, IH), 6.56 (s, 2H), 3.77 (s, 3H), 3.61 (s, 3H), 2.26 ( s, 3H), 2.04 (s, 6H)
1147	547.33	2.68
1148	475.20	2.11	IH NMR (400 MHz, DMSO) δ 12.10 (s, IH), 8.02 (s, 2H), 7.95 (d, J = 7.8 Hz, IH), 7.67 (s, IH), 7.12 (d, J = 7.8 Hz, IH), 6.90 {S, 2H), 2.25 (s, 3H), 1.97 (s, 7H), 1.04 (s, 10H).
1149	558.30	2.00
1150	551.50	2.09	IH NMR {400 MHz, DMSO-d6) δ 12.37 (s, IH), 8.09 (d, J = 7.9 Hz, IH), 7.81 (dd, J = 7.1, 2.4 Hz, IH), 7.64 (dd, J = 8.4, 7.3 Hz, IH), 7.29 - 7.20 (m, 2H), 7.19 - 7.06 (m, 4H), 6.81 (dt, J = 10.8, 2.3 Hz, IH), 6.71 (d, J = 8.4 Hz, IH), 6.58 - 6.46 (m, 2H), 4.45 (h, J = 6.0 Hz, IH), 2.32 (d, J = 3.2 Hz, 3H), 2.04 (s, 3H), 1.22 (d, J = 5.9 Hz, 6H).
1151	538.20	1.87
1152	433.00	1.94	IH NMR (400 MHz, DMSO) δ 12.24 (s, IH), 7.21 (s, IH), 7.16 (s, IH), 7.04 (d, J = 8.4 Hz, IH), 6.97 (s, IH), 6.81 (d, J = 9.6 Hz, IH), 5.68 (s, IH), 4.21 (s, 2H), 1.30 {d, J = 48.6 Hz, 14H), 1.11 0.97 (m, 5H), 0.60 (s, 3H).

1256

Cmpd. . No..-	LC/MS _: ·. M-1	rLÇ/RT*
1153	498.00	2.34	1H NMR (400 MHz, DMSO} δ 12.24 (s, 1H}, 8.26 (s, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.11 (dd, J = 25.3, 6.4 Hz, 2H}, 6.91 (s, 2H), 3.89 (s, 3H), 2.70 (s, 3H), 2.26 (s, 3H), 1.94 (s, 6H), 1.05 (s, 9H}.
1154	405.21	1.94
1155	546.20	1.81
1156	556.50	2.03
1157	556.50	1.82
1158	491.00	2.08	1H NMR (400 MHz, DMSO) δ 12.38 (s, 1H}, 7.63 (s, 1H), 7.47 (d, J = 17.9 Hz, 2H), 7.17 (d, J = 7.0 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 6.75 (d, J = 8.4 Hz, 3H), 6.69 (d, J = 8.1 Hz, 1H), 6.47 (s, 2H), 5.66 (s, 2H), 2.56 (s, 2H), 2.18 (s, 3H), 1.92 (s, 6H), 1.56 (s, 2H), 0.87 (s, 3H).
1159	542.20	1.58	1H NMR (400 MHz, DMSO-d6) δ 13.47 (s, 1H), 8.26 (dd, J = 5.1,1.8 Hz, 1H), 8.16 (dd, J = 7.8,1.8 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.56 - 7.46 {m, 2H), 7.04 (s, 1H), 6.93 (dt, J = 10.7, 2.3 Hz, 1H), 6.84 (dd, J = 7.8, 5.1 Hz, 1H), 4.04 (q, J = 6.0 Hz, 2H), 3.85 (d, J = 6.5 Hz, 2H), 2.06 - 1.98 (m, 2H), 1.77 -1.62 (m, 2H), 1.05 {d, J = 6.3 Hz, 6H}, 0.99 {d,J = 6.7 Hz, 6H).
1160	567.60	1.74
1161	495.00	1.38	1H NMR (400 MHz, MeOD) δ 7.94 (s, 1H), 7.36 (s, 2H), 7.01 (s, 5H), 4.38 (d, J = 100.8 Hz, 4H), 3.81 (s, 3H), 2.48 (s, 6H), 2.30 (s, 3H), 1.96 (s, 3H).
1162	540.30	3.03	1H NMR (400 MHz, DMSO-d6) δ 12.70 (s, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.66 (dd, J = 8.4, 7.3 Hz, 1H), 7.52 7.37 (m, 3H), 7.22 (d, J = 7.1 Hz, 1H), 6.92 (dt, J = 10.8, 2.3 Hz, 1H), 6.73 (d, J = 8.3 Hz, 1H), 6.48 (s, 1H), 4.74 (s, 2H}, 3.85 (d, J = 6.5 Hz, 2H), 3.32 (dd, J = 6.9, 4.5 Hz, 4H), 2.21 (t, J = 5.6 Hz, 4H}, 2.09 - 1.90 (m, 1H), 1.00 (d, J = 6.7 Hz, 6H).
1163	548.30	2.13
1164	448.50	1.41	1H NMR (400 MHz, CDCI3} δ 14.47 (s, 1H), 8.43 (d, J = 7.5 Hz, 1H), 7.78 (s,

1257

Cmpd., No. Y	\|LC/MS ;	LC/RT.·· ;; y-?' -Y?
			1H), 7.58 - 7.41 (m, 2H), 6.94 (s, 1H}, 3.87 (s, 2H), 3.70 (s, 3H), 3.42 (d, J = 6.3 Hz, 3H), 2.48 (s, 2H), 2.26 (d, J = 13.3 Hz, 2H), 1.36 (s, 9H).
1165	529.20	2.31
1166	556.30	2.49	1H NMR (400 MHz, DMSO-d6) 57.64 (d, J = 7.8 Hz, 1H), 7.53 - 7.43 (m, 2H), 7.37 (dt, J = 10.1, 2.0 Hz, 1H), 7.15 {d, J = 7.8 Hz, 1H), 6.99 (d, J = 7.3 Hz, 1H), 6.80 (dt, J = 10.8, 2.3 Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.19 (s, 2H), 4.01 - 3.86 (m, 1H), 3.82 (d, J = 6.6 Hz, 2H), 2.10 - 1.98 (m, 1H), 1.94 1.77 (m, 1H), 1.73 -1.62 (m, 2H}, 1.60 (s, 3H), 1.49 (s,3H), 1.43 (dd,J = 18.5, 9.9 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.77 (d, J = 6.0 Hz, 3H).
1167	455.40	2.18	1H NMR (400 MHz, DMSO-d6) δ 7.68 (dd, J = 8.2,1.6 Hz, 1H), 7.34 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 6.95 (s, 1H), 6.83 (d, J = 8.3 Hz, 1H), 6.75 (s, 2H), 6.67 (t, J = 7.6 Hz, 1H), 5.41 (s, 2H), 2.17 (s, 3H), 2.09 (S, 6H), 1.15 (s, 9H).
1168	562.04	3.03	1H NMR (400 MHz, DM5O-d6) δ 9.10 (s, 1H), 7.83 - 7.80 (d, 1H), 7.52 - 7.48 (m, 3H), 6.95 - 6.91 (d, 1H), 3.86 3.83 (d, 2H), 3.26 (m, 4H), 2.10 - 2.00 (m, 1H), 1.36 (m, 4H), 1.01 - 0.98 (d, 6H), 0.96 (s, 6H)
1169	530.22	1.76
1170	570.60	2.04
1171	570.44	3.29	1H NMR (400 MHz, DMSO-d6) δ 12.58 (s, 1H), 7.77 - 7.74 (d, 1H), 7.61 -7.59(m,2H), 7.49 (s, 2H), 7.44 7.40 (d, 1H), 7.33 -7.28 (m, 2H), 6.93 - 6.89 (d,lH), 3.85 -3.82 (m,5H), 2.47 - 2.37 (m, 2H), 2.11 - 2.03 ( m, 2H), 1.89 -1.82 (m, 1H), 1.61 (s, 3H), 1.57 (s,3H), 1.41 (t, J = 12.52,1H), 1.01 - 0.98 (d, 6H), 0.71 - 0.68 (d, 3H)
1172	451.30	1.74
1173	519.20	1.97
1174	544.23	1.92
1175	425.30	1.82
1176	530.30	1.99	1H NMR (400 MHz, DMSO) § 13.76 (s,

1258

^Cm^ No A	LC/MS; m+i	LC/RT_ï; min ’ ’’
			1H), 12.59 (s, 1H), 7.97 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7,48 (s, 1H), 7.40 (d, J = 9.4 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 6.93 - 6.84 (m, 2H), 3.83 (d, J = 6.6 Hz, 2H), 3.17 (s, OH), 2.58 (d, J = 9.7 Hz, 2H), 2.21 (s, 1H), 2.05 (dt, J = 13.3,6.7 Hz, 1H), 1.88 (dd, J s 11,7, 5.6 Hz, 1H), 1.60 (d, J = 12.8 Hz, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.3 Hz,3H).
1177	535.32	2.85
1178	537.43	3.07
1179	534.20	1.99
1180	540.40	1.98	1H NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 7.72 (d J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.47 7.40 (m, 2H), 7.23 (dd, J = 16.7, 7.6 Hz, 2H), 6.89 (dt, J= 10.7, 2.3 Hz, 1H), 6,72 (d, J = 8.3 Hz, 1H), 6.49 (s, 2H), 4.54 (S, 1H), 3.84 (d, J = 6.5 Hz, 2H), 2.99 (d, J = 9.9 Hz, 1H), 2.44 (s, 1H), 2.33 (d, J = 9.5 Hz, 1H), 2.10 - 1.98 (m, 1H), 1.69 -1.48 (m, 4H), 1.44 1.37 (m, 1H), 1.33 -1.22 (m, 1H), 0.99 (d, J = 6.7 Hz, 6H).
1181	553.50	1.77
1182	511.20	1.47
1183	519.12	2.47
1184	555.43	2.90	1H NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 7.71 - 7.68 (d, 1H), 7.49 (s, 1H), 7.43 - 7.39 (d, 1H), 7.29 - 7.24 (m, 3H), 7.12 - 7.09 (d, 1H), 6.93 9.85 (m, 2H), 3.85 - 3.82 (d, 2H), 2.14 - 2.00 (m, 1H), 1.90 -1.83 ( m, 1H), 1.61 (s, 3H), 1.57 (s, 3H), 1.41 (t, J = 12.42, 1H), 1.00 - 0.97 (d, 6H), 0.78 0.75 (d, 3H)
1185	534.12	2.95	1H NMR (400 MHz, DM5O-d6) δ 8.49 (s, 1H), 8.12 - 8.09 (d, 1H), 8.04 - 8.01 (d, 1H), 7.64 - 7.53 (m, 2H), 7.15 7.12 (d, 1H), 6.94 (s, 2H), 6.83 - 6.80 (d, 1H), 6.58 - 6.56 (d, 1H), 6.32 (s, 2H), 3.30 (q, J = 7.25, 2H ),2.28 (s, 3H), 2.02 (s, 6H), 1.30 (t, J = 7.02,3H)
1186	465.50	3.00

1259

Cmpd.X #ΝοΉ?	ALC/MSf 0+1 -a	•®LC/RTi® Wmin
1187	580,20	2.21
1188	548.20	2.08
¹¹⁸⁹	556.35	2.01
1190	436.30	1.73
1191	498.30	1.56
1192	539.40	2.42	1H NMR (400 MHz, DMSO-d6) δ8.20 (d, J = 5.5 Hz, 1H), 7.62 (s, 1H), 7.57 7.45 (m, 2H), 7.38 - 7.25 (m, 1H), 7.18 (s, 1H), 7.01 (s, 1H), 6.51 (s, 1H), 6.23 (s, 2H), 4.06 (d, J = 6.6 Hz, 2H), 3.00 2.86 (m, 2H), 2.19-2.00 (m, 2H), 1.83 (dd, J = 11.7, 5.6 Hz, 1H), 1.62 (s, 3H), 1.56 (s, 3H), 1.37 (t, J = 11.9 Hz, 1H), 0.97 (d, J = 6.7 Hz, 6H), 0.81 (d, J = 6.3 Hz, 3H).
1193	542.40	2.00
1194	556.19	2.05
1195	459.36	1.54	1H NMR {400 MHz, DMSO) 08.20 (dd, J = 7.2, 2.2 Hz, 1H), 7.76 (dd, J = 6.3, 2.0 Hz, 1H), 7.74 (s, 1H), 6.41 (dd, J = 7.2, 6.4 Hz, 1H), 3.44 - 3.33 (m, J = 12.4 Hz, 2H), 3.05 - 2.91 (m, J = 12.1, 9.9 Hz, 2H), 2.76 - 2.64 (m, J = 5.6 Hz, 2H), 1.79 - 1.66 (m, J = 12.8 Hz, 6H), 1.66 - 1.54 (m, 1H), 1.54 - 1.39 (m, 2H), 1.25 (s, 6H), 0.95 (d, J = 6.3 Hz, 3H).
1196	496.50	1.44	1H NMR (400 MHz, DMS0-d6) δ 8.28 (d, J = 8,2 Hz, 1H), 8.02 (d, J = 8.1 Hz, 2H),7.67 (dd, J = 8.4, 7.3 Hz, 1H), 7.31 (d, J = 7.9 Hz, 2H), 7.20 (d, J = 7.2 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 3.62 {dt, J = 11.7, 4.6 Hz, 2H), 3.54 (s, 2H), 3.48 (ddd, J = 11.9, 9.2, 3.0 Hz, 3H), 2.36 (s, 3H), 1.42 (ddd, J = 13.4, 9.2, 4,3 Hz, 2H), 1.21 (dt, J = 11.3, 2.9 Hz, 2H), 0.94 (s, 3H).
1197	558.30	1.82	1H NMR (400 MHz, DMS0-d6) δ 12.97 (S, 1H), 7.83 (d, J = 2,0 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.70 - 7.60 (m, 2H), 7.52 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 6.48 (s, 2H), 4.12 - 3.99 (m, 2H), 3.94 {d, J = \|

1260

Cmpd. No.^: 7	LC/MS\| M+1	LQ/RT . ^Mmin Ai
			6.6 Hz, 2H), 2.16 - 2.06 {m, 1H), 2.04 1.90 (m, 2H), 1.73 -1.58 (m, 2H), 1.10 (d, J = 6,2 Hz, 6H), 1.03 (d, J = 6.7 Hz, 7H).
1198	511.30	1.55	1H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 2.4 Hz, 1H), 8.30 (dd, J = 8.8, 2.5 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.65 (dd, J = 8.4, 7.3 Hz, 1H), 7.23 (dd, J = 7.6,3.3 Hz, 2H), 6.85 (d, J = 8.7 Hz, 1H), 6,73 (d, J = 8.4 Hz, 1H), 5.30 (p, J = 6.2 Hz, 1H), 4.30 - 3.96 (m, 2H), 2.22 - 1.94 (m, 2H), 1.62 1.36 (m, 2H), 1.31 (d, J = 6.2 Hz, 6H), 0.97 (d, J = 6.2 Hz, 6H).
1199	496.50	1.94	1H NMR (400 MHz, DMSO) δ 12.76 12.41 (m, 1H), 11.80 (bs, 1H), 8.26 (dd, J = 7.3, 2.1 Hz, 1H), 7.86 - 7.72 (m, 2H), 6.89 (s, 2H), 6.49 - 6.38 (m, J = 6.8 Hz, 1H), 2.78 - 2.60 (m, 3H), 2.33 - 2.13 (m, 5H), 1.97 (s, 6H), 1.56 -1.31 (m, 2H), 0.89 (s, 6H).
1200	462.60	1.55
1201	596.34	2.23
1202	548.20	2.13
1203	527,50	1.40	1H NMR (400 MHz, DMSO-06) 88.61 (dd,J = 4.4,1.5 Hz, OH), 8.35 {dd, J = 8.3, 1.5 Hz, OH), 8.05 (d, J = 7.7 Hz, OH), 8.02 (d, J = 8.8 Hz, 2H), 7.47 (d, J = 7.8 Hz, 1 H), 7.37 (dd, J = 8.3, 4.4 Hz, OH}, 7.06 (d, J = 7.8 Hz, 1H), 7.03 6.96 (m, 2H), 6.48 {t, J = 6.2 Hz, 1H), 4.08 (q, J = 6.9 Hz, 2H), 3.66 (dt, J = 11.6, 4.5 Hz, 2H), 3.55 - 3.50 (m, 2H), 3.49 (d, J = 6.2 Hz, 2H), 1.51 (ddd, J = 13.6, 9.3, 4.2 Hz, 2H), 1.35 (t, J = 6.9 Hz, 3H), 1.29 - 1.22 (m, 2H), 1.02 (s, 3H). Rotamer ratio about 5:1
1204	519.12	2.56
1205	612.32	2.29
1206	539.23	1.89
1207	533.20	1.91
1208	470.28	2.20
1209	573,30	1.97	1H NMR (400 MHz, CDCI3) δ 14.58 (s, 1H), 8,87 (S, 1H), 8.57 (s, 1H), 8.23 (s, 1H), 7.80 (s, 2H), 7.38 (dd, J = 64.6,

1261

Cmpd. / No. ?	LC/MS i M+1	LC/RT\
			37.5 Hz, 7H), 6.89 (d, J = 40.0 Hz, 2H), 5.39 (S, 1H), 4.09 (s, 2H), 3.63 (s, 3H}, 2.56 (S, 1H), 2.26 (s, 2H), 1.88 (s, 1H), 1.39 (s, 7H).
1210	556.40	2.99	1H NMR (400 MHz, Chîoroform-d) δ 14.73 (s, 1H), 8.49 (d, J = 8.1 Hz, 1H), 7.75 - 7.67 (m, 2H), 7.63 (d, J = 7.3 Hz, 1H), 7.35 (dd, J = 9.0, 2.1 Hz, 2H), 6.76 - 6.68 (m, 2H), 3.79 (d, J = 6.5 Hz, 2H), 3.50 (S, 2H), 2.88 (t, J = 11.7 Hz, 2H), 2.34 (s, 2H), 2.13 (dq, J = 13.4, 6.7 Hz, 1H), 2.00 (t, J = 6.7 Hz, 1H), 1.05 (dd,J = 6.7, 4.7 Hz, 12H), 0.89 (t, J = 12.3 Hz, 1H).
1211	453.30	1.97
1212	534.20	1.87
1213	525.50	2.04	1H NMR (400 MHz, DMSO-d6) δ 13.80 (s, 1H), 12.50 (s, 1H), 8.05 (d, J = 7.8 Hz, 1H), 7.98 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.27 - 7.21 (m, 1H), 7.19 7.06 (m, 4H), 6.87 (d, J = 2.3 Hz, 1H), 6.81 (dt, J = 10.8, 2.3 Hz, 1H), 4.46 (h, J = 6.0 Hz, 1H), 2.32 (s, 3H), 2.03 (s, 3H), 1.22 (d, J = 6.0 Hz, 6H).
1214	541.33	1.59
_1215	482.30	1.24
1216	555.29	2.40
1217	446.30	1.77
1218	542.40	2.93
1219	403.00	1.70	1H NMR (400 MHz, MeOD) 68.11 (s, 1H), 7.88 (s, 1H), 7.60 (s, 1H), 7.45 (d, J = 7.0 Hz, 1H), 7.04 (d, J = 8.6 Hz, 1H), 3.47 (s, 1H), 1.91 (s, 4H), 1.77 (s, 2H), 1.64 (s, 2H), 1.43 (s,9H).
1220	493.20	0.72
1221	523.10	2.01
1222	556.40	1.85
1223	496.00	2.23	1H NMR (400 MHz, DMSO) δ 12.42 (s, 1H), 8.32 (s, 1H), 7.90 (s, 1H), 7.72 (s, 1H), 7.10 (s, 2H), 6.89 (s, 2H), 2.69 (s, 2H), 2.25 (s, 3H), 1.95 (s, 6H), 1.65 (d, J = 36.4 Hz, 4H), 0.92 (s, 6H).
1224	525.36	1.23
1225	549.43	2.95
1226	468.00	1.94	1H NMR (400 MHz, DMSO] δ 12.57 (s,

1262

Cmpd. : No.	JLC/MS ’ M+i -	S LC/RT iDiri
			1H), 11.69 (s, 1H), 8.26 (d, J = 7.2 Hz, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.83 (s, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.91 (s, 2H}, 6.46 (s, 1H), 2.26 (s, 3H), 1.96 (s, 6H), 1.32 (s, 3H), 0.68 (d, J = 12.5 Hz, 4H).
1227	555.26	2.37
1228	528.22	1.99
1229	515.10	2.25
1230	551.20	1.82
1231	450.30	1.78
1232	455.30	2.04
1233	503.00	1.88	1H NMR (400 MHz, DMSO) δ 12.36 (s, 1H), 8.04 (s, 1H), 7.86 (s, 1H), 7.61 (s, 1H), 7.28 (S, 4H), 7.20 (s, 2H), 6.87 (s, 2H), 6.69 (d, J = 8.7 Hz, 1H), 6.48 (s, 2H), 3.93 (S, 2H), 2.23 (s, 3H), 1.94 (s, 6H).
1234	532.20	1.84
1235	493.00	1.74	1H NMR (400 MHz, MeOD) δ 8.32 (s, 1H), 8.06 (s, 1H), 7.12 (dd, J = 130.1, 74.1 Hz, 7H), 4.30 (d, J = 79.9 Hz, 2H), 3.58 (s, 3H), 2.43 (s, 6H), 2.26 (s, 3H), 1.98 (S,3H), 1.56 (s, 3H).
1236	457.30	1.26	1H NMR (400 MHz, DMSO-d6) S 13.17 (s, 1H), 12.90 (s, 1H), 7.86 (d, J = 7.3 Hz, 1H), 7.79 (t, J = 7.7 Hz, 1H), 7.76 - 7.35 (m, 3H), 6.79 (d, J = 8.0 Hz, 1H), 6.51 (s, 1H), 4.29 (s, 3H), 3.96 (d,J = 1.2 Hz, 2H), 1.89 (s,2H), 1.61 (s, 2H), 1.13 (d, J = 6.1 Hz, 6H).
1237	466.00	1.20	1H NMR (400 MHz, DMSO) δ 12.29 (s, 1H), 10.30 (S, 1H), 8.13 (s, 1H), 7.68 (s, 1H), 7.38 (s, 1H), 7.24 (s, 3H), 6.90 (s, 2H), 6.34 (s, 1H), 4.12 (s, 2H), 3.96 (s, 2H), 3.17 (s, 1H), 2.41 (s, 6H), 2.24 (s, 3H), 1.73 (s,3H).
1238	543.22	2.35
1239	482.00	2.13	1H NMR (400 MHz, DMSO) δ 12.54 (s, 1H), 8.31 (s, 1H), 7.89 (s, 1H), 7.68 (s, 1H), 7.04 (d, J = 30.5 Hz, 5H), 2.67 (s, 3H), 2.29 (s, 3H), 1.99 (s, 3H), 1.66 (d, J = 20.8 Hz, 4H), 0.98 (s,6H).
1240	525.40	1.38	1H NMR (400 MHz, DMSO-d6) Ô8.82 (S, 1H), 8.33-8.19 (m, 2H), 8.13 (d, J

1263

Cmpd/ ^ύ No.	LC/MS	LC/RT 1 tÿmin/M
			= 8.1 Hz, 1H), 7.79 (d, 1 = 8.1 Hz, 1H), 7.25 (d, J = 8.Û Hz, 1H), 6.93 - 6.79 (m, 2H), 5.34 - 5.19 (m, 1H), 2.71 2.58 (m, 1H), 2.58 - 2.53 (m, 1H, obscured by solvent peak), 2.26 2.12 (m, 1H), 1.88 (dd, J = 12.1, 5.8 Hz, 1H), 1.53 (d, J = 4.5 Hz, 6H), 1.41 (t, J = 12.0 Hz, 1H), 1.29 (d, J = 6.1 Hz, 6H), 0.77 (d, J = 6.2 Hz, 3H).
1241	556.30	2.50	1H NMR (400 MHz, DMSO-d6) S 7.64 (d, J = 7.6 Hz, 1 H), 7.4S (d, J = 6.9 Hz, 2H), 7.41 - 7.30 (m, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.99 {d,J = 7.4 Hz, 1H), 6.85 - 6.75 (m, 1H), 6.50 (d, J = 8.4 Hz, 1H), 6.20 (s, 2H), 3.99 - 3.90 (m, 1H), 3.82 (d, J = 6.7 Hz, 2H), 2.05 (tt, J = 11.5, 5.9 Hz, 1H), 1.93 - 1.79 (m, 1H), 1.74 -1.62 (m, 2H), 1.63 -1.56 (m,3H), 1.49 (s, 3H),1.44 {t,J = 8.3 Hz, 1H), 0.98 (d, J = 6.8 Hz, 6H), 0.76 {d, J = 6.1 Hz, 3H).
1242	498.30	1.77	1H NMR (400 MHz, DMSO-d6) δ 7.58 (d, J = 7.6 Hz, 1H), 7.48 - 7.42 (m, 2H), 6.99 (d, J = 7.6 Hz, 1H), 6.67 (d, J = 7.6 Hz, 1H), 6.47 (d, J = 8.3 Hz, 1H), 6.40 (d, J = 1.8 Hz, 1H), 6.15 (s,2H), 5.30 (p, J = 6.6 Hz, 1H), 3.08 - 2.92 (m, 2H), 2.18-2.03 (m, 1H), 1.80 (dd,J = 11.7, 5.6 Hz, 1H), 1.49 (d, J = 8.4 Hz, 6H), 1.38 (d, J = 6.4 Hz, 3H), 1.36 -1.33 {m, 1H), 1.31 (d, J = 6.6 Hz, 3H), 0.82 (d,J = 6.3 Hz, 3H).
1243	455.23	2.02
1244	525.42	2.95
1245	532.20	1.90
1246	455.00	2.02	1H NMR (400 MHz, DMSO) δ 13.78 (s, 1H), 12.23 (s, 1H), 7.96 (s, 1H), 7.65 (s, 1H), 7.08 (s, 1H), 7.01 (s, 2H), 6.83 (s, 1H), 2.67 (s, 2H), 2.29 (s, 3H), 2.00 (s, 3H), 1.66 (d, J = 22.4 Hz, 4H), 0.98 (S, 6H).
1247	525.30	1.61	1H NMR (400 MHz, DMSO) δ 12.43 (s, 1H), 8.84 (d, J = 2.1 Hz, 1H), 8.28 (dd, J = 8.7, 2.5 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H),

1264

BS		W min +<	* · -
			7.19 (dd, J = 10.1, 7.4 Hz, 2H), 6.86 (d, J = 8.7 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 5.38 - 5.27 (m, 1H), 2.59 (d, J = 9.1 Hz, 2H), 2.22 (s, 1H), 1.87 (dd, J = 11.9, 5.6 Hz, 1H), 1.59 (d, J = 1.7 Hz, 6H), 1.42 (t, J = 12.1 HZ, 1H), 1.31 (d, J = 6.2 Hz, GH), 0.88 (d, J = 6.3 Hz, 3H).
1248	551.40	1.81
1249	535.50	2.04	1H NMR (400 MHz, DMSO-d6) 58.33 (dd, J = 3.3, 2.2 Hz, 2H), 8.11 (d, J = 7.9 Hz, 1H), 7.96 (dd,J = 2.4,1.1 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.20 - 7.05 (m, 2H), 6.96 (s, 2H), 3.88 {s, 3H), 2.28 (s, 3H), 2.12 (s, 3H), 2.01 (s, 6H).
1250	455.30	2.04
1251	535.32	2.59
1252	512.30	2.05	1H NMR (400 MHz, DMSO-d6) 58.92 (s, 1H), 8.27 (d,J = 5.7 Hz, 1H), 7.67 (bs, 1H), 7.45 (bs, 2H), 7.04 (bs, 1H), 6.50 (bs, 1H), 6.16 (bs, 1H), 4.48 (q, J = 7.0 Hz, 2H), 2.99 (bs, 1H), 2.15 (bs, 1H), 1.85 (dd, J = 10.7, 5.0 Hz, 1H), 1.64 (s, 3H), 1.59 (s, 3H), 1.40 (t, J = 7.0 Hz, 4H), 0.85 (d, J = 6.2 Hz,3H).
1253	517.00	1.95	1H NMR (400 MHz, DMSO) δ 12.34 (s, 1H), 7.95 (d, J = 2.3 Hz, 1H), 7.87 (d, J = 2.3 Hz, 1H), 7.64 (s, 1H), 7.23 (s, 6H), 6.87 (s, 2H), 6.71 (d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 2.86 (s, 4H), 2.23 (s, 3H), 1.94 (s, GH).
1254	572.40	1.94	1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 7.64 (t, J = 7.8 Hz, 1H), 7.54 - 7.50 (m, 1H), 7.50 - 7.44 (m, 1H), 7.29 - 7.19 (m, 1H), 6.99 (s, 1H), 6.90 - 6.84 (m, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.51 (s, 2H), 4.10 (s, 2H), 3.88 (s, 3H), 3.82 (d, J = 6.6 Hz, 2H), 2.10 2.00 (m, 1H), 1.97 - 1.S5 (m, 2H), 1.69 -1.55 (m, 2H), 1.08 {d, J = 6.2 Hz, GH), 0.99 (d, J = 6.7 Hz, 6H).
1255	551.53	3.15
1256	452.40	1.77
1257	578.15	2.02
1258	556.40	2.20

1265

’Cmpd/ No. ;	SLC/MS l	SS
1259	524.60	1.51
1260	590.33	2.18
1261	494.50	1.86
1262	509.30	1.51	1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J = 5.2 Hz, 1H), 7.97 - 7.82 (m, 1H), 7.74 (dd, J = 5.2, 1.7 Hz, 1H), 7.64 (s, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 7.7 Hz, 1H), 7.03 (s, 1H), 6.57 - 6.43 (m, 1H), 6.24 (s, 2H), 3.06 (h, J = 6.9 Hz, 1H), 2.91 (d, J = 11.8 Hz, 2H), 2.16 - 2.09 (m, 1H), 1.84 {dd, J = 11.8, 5.7 Hz, 1H), 1.64 (s, 3H), 1.58 (s, 3H), 1.38 (t, J = 12.0 Hz, 1H), 1.28 (d, J = 6.8 Hz, 6H), 0.82 (d, J = 6.3 Hz, 3H}.
1263	557.22	2.39
1264	568.90	2.98
1265	425.30	1.76
1266	558.30	2.04
1267	558.30	2.75
1268	563.30	2.00
1269	570.30	1.86	1H NMR (400 MHz, DMS0-d6) δ 12.46 (s, 1 H), 7.68 - 7.59 (m, 2H), 7.21 (d, J = 7.3 Hz, 1H), 6.96 - 6.82 (m, 3H), 6.68 (d, J = 8.3 Hz, 1H), 6.51 (s, 2H), 3.80 (d, J = 6.5 Hz, 2H), 2.71 2.53 (m, 2H), 2.27-2.15 (obscured m, 1H), 2.22 (S, 3H), 2.09 - 1.97 (m, 1H), 1.82 (dd, J = 11.9, 5.7 Hz, 1H), 1.47 (d, J = 11.2 Hz, 6H), 1.38 (t, J = 12.0 Hz, 1H), 0.97 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.2 Hz, 3H).
1270	539.37	1.68	1H NMR (400 MHz, Chloroform-d) δ 14.94 (S, 1H), 8.88 (d, J = 2.2 Hz, 1H), 8.82 (d, J = 8.3 Hz, 1H), 8.34 (d, J = 8.9 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.9, 7.0 Hz, 1H), 7.42 (dd, J = 18.0,8.0 Hz, 2H), 6.95 (d, J = 8.8 Hz, 1H), 4.27 {s, 2H), 4.10 (s, 2H), 2.55 2.47 (m, 2H), 2.38 - 2.32 (m, 2H), 1.44 (d, 6H), 1.33 -1.22 (m, 2H), 1.07 (d,J = 5.4Hz,9H).
1271	497.26	1.52
1272	504.50	1.47
1273	464.50	1.25
1274	565.20	1.98

1266

Cmpd. No.	LC/MS ^:-M+1	(LC/RT.; Y mirift
1275	560.24	2.67
1276	543.43	2.75
1277	538.20	1.94
1278	490.00	1.57	IH NMR (400 MHz, DMSO) δ 12.54 (s, IH), 8.67 (S, IH), 8.21 (d, J = 7.8 Hz, IH), 8.12 (d, J = 7.8 Hz, IH), 7.84 (s, IH), 7.65 (s, 2H), 7.43 (s, IH), 7.23 (d, J = 7.2 Hz, IH), 6.97 (s, 2H), 6.72 (d, J = 8.4 Hz, IH), 6.58 (s, IH), 2.29 (s, 3H), 2.04 (s, 6H).
1279	556.40	2.92
1280	481.50	2.07	IH NMR (400 MHz, DMS0-d6) δ7.95 (d, J = 7.7 Hz, IH], 7.63 (t, J = 7.8 Hz, IH), 7.20 {d, J = 7.3 Hz, IH), 7.00 (d, J = 7.7 Hz, IH), 6.89 (s, 2H), 6.69 (d, J = 8.4 Hz, IH), 6.45 (s, 2H), 3.03 - 2.93 (m, IH), 2.24 (s, 3H), 1.96 (s, 6H), 1.83 -1.66 (m, 2H), 1.52 - 1.33 (m, 6H).
1281	584.20	2.29
1282	528.27	1.94
1283	525.30	1.70
1284	554.20	1.94
1285	502.30	157.00
1286	542.16	1.90
1287	524.30	1.47
1288	499.35	1.42
1289	556.40	2.76	IH NMR (400 MHz, DMSO-d6) δ 12.47 (s, IH), 7.78 (d, J = 8.0 Hz, IH), 7.69 - 7.57 (m, IH), 7.56 - 7.46 (m, IH), 7.41 (dt, J = 10.1,1.8 Hz, IH), 7.26 (d, J = 8.0 Hz, IH), 7.21 (d, J = 7.2 Hz, IH), 6.89 (dt, J = 10.7, 2.3 Hz, IH), 6.69 (d, j = 8.3 Hz, IH), 3.83 (d, J = 6.7 Hz, 2H), 2.61 (dq, J = 9.7, 4.9 Hz, 2H), 2.24 (d, J = 15.8 Hz, IH), 2.06 (dq, J = 13.3, 6.7 Hz, IH), 1.93 - 1.82 (m, IH), 1.61 (s, 3H), 1.59 (s, 3H), 1.48 - 1.33 (m, IH), 1.32 -1.20 (m, 2H), 0.99 (d, J = 6.6 Hz, 6H), 0.88 (d, J = 6.2 Hz, 3H).
1290	504.20	1.70
1291	420.40	1.77
1292	425.00	1.60	IH NMR {400 MHz, DMSO) δ 13.87 (s, IH), 12.65 (s, IH), 8.00 (s, IH), 7.54 (s, IH), 7.34 (d,J = 8.0 Hz, 2H), 7.09

1267

Cmpd.· '* noK	LC/MS î’ î? M+irS	U.Ç/RT?; 4, min '
			(d, J = 8.0 Hz, 2H), 6.78 (s, IH), 2.80 (s, 2H), 2.32 {S, 3H), 1,76 {s, 4H), 1.29 (s, 6H).
1293	545.13	1.54	IH NMR (400 MHz, DMS0-d6) δ 12.98 (s, IH), 12,57 (s, IH), 8.26 (dd, J = 7.3, 2.1 Hz, IH), 7.85 (dd, J = 6.7, 2.1 Hz, 2H), 7.79 (d, J = 7.9 Hz, IH), 7.66 (dd, J = 8,3,1.9 Hz, IH), 7.51 (d, J = 8.3 Hz, IH), 7.34 (d, J = 7.9 Hz, IH), 6.45 (t, J = 6.8 Hz, IH), 4.17 4.05 (m, 4H), 2.02 -1.90 (m, 2H), 1.87 -1.74 (m, 2H), 1.74 - 1.63 (m, 2H), 1.14 (d, J = 6.2 Hz, 6H), 1.03 (t, J = 7.4 Hz, 3H).
1294	475.20	4.69	IH NMR (300 MHz, CDCI3) δ 1.07 (s, 9H), 2,05 (S, 6H), 2.32 (s, 3H), 5.34 (s, 2H), 6,89 (s, 2H), 7.09 (d, J=8.1 Hz, IH), 7.68 (s, IH), 8.39 (d, J=7.9 Hz, IH), 10.50 (S, IH).
1295	523,20	2.12
1296	526.20	1.89
1297	466.00	2.03	IH NMR {400 MHz, DMSO) 6 11.55 (s, IH), 7.91 (d, J = 7.8 Hz, IH), 7.62 (d, J = 8.6 Hz, 2H), 7.07 (d, J = 7.8 Hz, IH), 6.89 (S, 2H), 6.61 (d, J = 8.6 Hz, 2H), 6.14 (s, 2H), 2.25 (s, 3H), 1.92 (s, 6H), 1.31 (s,3H), 0.66 (d, J = 16.9 Hz, 4H).
1298	447.40	1.73
1299	543.13	2.65
1300	504.20	2.01
1301	552.20	2.01
1302	516.25	1.67
1303	568.35	2.14
1304	582.28	2.12	IH NMR (400 MHz, DMS0-d6) 6 12.68 (s, IH), 7.88 (d, J = 7.9 Hz, IH), 7.66 (dd, J = 8.4, 7.3 Hz, IH), 7.59 7,36 (m, 3H), 7.22 (d, J = 7.2 Hz, IH), 6.91 (dt, J = 10.7, 2.3 Hz, IH), 6.72 (d, J = 8.5 Hz, IH), 6.50 (s, 2H), 5.62 (qd, J = 8.1, 3.9 Hz, IH), 3.93 - 3.73 (m, 2H), 2,98 (dt, J = 10.0, 6.8 Hz, IH), 2.84 - 2.73 (m, IH), 2,21 - 1.79 (m, 5H), 0.99 (d, J = 6,7 Hz, 6H).
1305	485.20	2.18	IH NMR (400 MHz, CDCI3)Ô9.71 (s, IH), 8.11 - 7.78 (m, 2H), 7.44 (s, 2H),

1268

Cmpd. No..	LC/MS j 4k M+1	mir, :;W
			6.76 (s, 2H), 5.45 (s, 2H), 3.85 (s, 3H), 2.21 (s, 3H), 2.14 (s, 6H), 1.20 (d, J = 8.8 Hz, 10H). 1H NMR (400 MHz, DMSO) ? 7.30 (dd, J = 9.0, 6.8 Hz, 2H), 7.18 (d, J = 7.5 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.73 (s, 2H), 5.14 (s, 2H), 4.09 (s, 3H), 3.67 (s, 3H), 2.15 (s, 3H), 2.07 (s, 6H), 1.19 (S, 9H).
1306	456.08	2.91
1307	450.30	1.79
1308	557.24	2.64	1H NMR (400 MHz, CDCI3) Ô 8.78 8.75 (d, 1H), 7.90 - 7.87 (d, 1H), 7.49 7.43 (m, 1H), 7.30 (s, 2H), 6.96 - 6.93 (d, 1H), 6.77-6.67 (m, 2H),4.05 (t, J = 9.23,1H), 3.80 - 3.77 (d, 2H), 3.48 (t, J = 9.45,1H), 2.9 6 - 2.86 (m, 1H), 2.39 - 2.30 (m, 1H), 2.21 - 2.01 (m, 2H), 1.65 (s, 3H), 1.36 - 1.34 (m, 6H), 1.07 -1.04 (d, 6H)
1309	556.34	3.03	1H NMR (400 MHz, CDCI3) δ 8.47 8.44 (d, 1H), 7.75 (s, 1H), 7.67 - 7.62 (m, 2H), 7.41 - 7.34 (m, 3H), 7.11 7.08 (d, 1H), 6.74 - 6.70 (d, 1H), 3.79 3.76 (d, 2H), 3.27 (m, 4H), 2.18 - 2.08 (m, 1H), 1.79 (m, 4H), 1.1 3 (s, 6H), 1.07-1.04 (d, 6H)
1310	467.00	2.08	1H NMR (400 MHz, DMSO) S 11.99 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.20 (d, J = 7.4 Hz, 1H), 7.10 (d, J = 7.1 Hz, 1H), 6,89 (s, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 2.25 (s, 3H), 1.94 (s, 6H), 1.32 (s, 3H), 0.67 (d, J = 17.0 Hz, 4H).
1311	484.00	1.99	1H NMR (400 MHz, DMSO) δ 12.34 (s, 1H), 11.45 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 6.5 Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H), 6.94 (s, 2H), 6.30 (d, J = 6.5 Hz, 1H), 2.60 (s, 3H), 2.27 (s, 3H), 2.00 (s, 6H), 1.04 (s, 9HJ.1H NMR (400 MHz, DMSO) ? 12.34 (s, 1H), 11.45 (s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 6.5 Hz, 1H), 7.17 (d, J « 7.9 Hz, 1H), 6.94 (s, 2H), 6,30 (d, J = 6.5 Hz, 1H), 2.60 (S, 3H), 2.27 (s, 3H), 2.00 (s, 6H), 1.04 (s,9H).

1269

Cmpd^ -ΝόΤ..	tLC/MS . ΐΐΜ+1		Y. . NMH.'
1312	507.50	1.66
1313	568.40	2.73
1314	469.26	2.08
1315	578.16	2.04
1316	511.20	1.24	1H NMR (400 MHz, DMSO-d6) 8 13.74 (s, 1H), 8.94 (d, J = 2.5 Hz, 1H), 8.39 (dt, J = 8.7, 2.2 Hz, 1H), S.30 8.18 (m, 2H), 8.05 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.25 (s, 2H), 6.98 - 6.82 (m, 2H), 5.41 - 5.26 (m, 1H), 4.21 - 4.04 (m, 2H), 2.23 - 2.06 (m, 2H), 1.83 -1.67 (m, 2H), 1.32 (d, J = 6.2 Hz, 6H), 1.08 (d, J = 6.4 Hz, 6H).
1317	521.30	1.88
1318	441.19	1.93
1319	604.30	3.24
1320	533.22	3.07
1321	488.50	2.74
1322	497.15	1.62
1323	579.45	3.40	1H NMR (400 MHz, DMSO-d6) 5 12.20 (s, 1H), 7.86-7.83 (d, 1H), 7.73 - 7.70 (d, 1 HL 7.56 - 7.46 (m, 4H), 7.33 (t,J =8.13,1H), 7.21-7.11 (m, 2H), 6.94 - 6.90 (d, 1H}, 3.85 - 3.82 (d, 2H), 3.13 (m, 4H), 2.06 -1.9 8 (m, 1H), 1.15 (m, 4H), 1.00 - 0.97 (d, 6H), 0.81 (s, 6H)
1324	545.21	2.05
1325	525.50	2.00
1326	549.43	2.77
1327	525.30	1.74
1328	539.60	1.73
_1329	532.20	1.85
1330	479.30	2.16
1331	442.21	1.80
_1332	554.10	2.14
1333	540.31	1.96
1334	466.23	1.66
1335	498.40	1.68
1336	549.43	3.01
1337	533.22	3.10	1H NMR (400 MHz, DMSO-dG) 8 8.10 -8.07 (d, 1H), 7.71-7.52 (m, 4H), 7.18 - 7.15 (d, 1H), 7.93 -7.90 (m, 4H), 6.60-6.57 (d, 1H), 6.36 (s, 2H), 4.04 (q, J = 6.92, 2H), 2.28 (s, 3H),

1270

Cmpd. *	ΛΟ/MS
			2.03 (s, 6H), 1.31 (t, J = 6.92, 3H)
1338	481.00	1.10	1H NMR (400 MHz, DMSO) 59.61 (s, 1H), 7.52 (s, 1H), 7.13 (s, 1H), 7.06 (d, J = 7.0 Hz, 1H), 6.90 (s, 2H), 6.86 (d, J = 7.5 Hz, 1H), 6.68 (d,J = 7.9 Hz, 1H), 6.56 (d, J = 83 Hz, 1H), 6.23 (s, 2H), 4.14 (d, J = 12.7 Hz, 1H}, 4.01 (d, J = 12.7 Hz, 1H), 3.92 (s, 2H), 238 (s, 6H), 2.24 (s,3H), 1.69 (s, 3H).
1339	607.21	2.04
1340	557.00	1.91	1H NMR (400 MHz, DMSO} δ 13.27 (s, 1H), 8.18 (s, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.83 {dd, J = 12.8, 7.9 Hz, 2H), 7.54 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 83 Hz, 2H}, 6.94 (s, 1H), 4.58 (s, 2H), 3.84 (s, 2H), 3.64 {d, J « 12.8 Hz, 2H), 2.87 (t, J = 12.1 Hz, 2H), 2.11 - 1.98 (m, 3H), 1.57 (d, J = 10.1 Hz, 3H), 1.18 {t, J = 10.6 Hz, 2H), 1.00 (d,J = 6.7 Hz, 6H), 0.91 (d, J = 6.0 Hz, 3H).
1341	539.20	1.83
1342	494.00	1.64	1H NMR (400 MHz, DMSO) δ 8.45 (d, J = 6.7 Hz, 1H), 8.26 (d, J = 9.4 Hz, 1H), 8.21 {d, J = 2.1 Hz, 1H), 8.19 (d, J = 2.1 Hz, 1H), 7.24 (s, 1H), 7.13 (s, 2H), 7.05 {s, 1H), 6.88 {s, 1H), 6.81 (s, 2H), 433 (d, J = 15.1 Hz, 1H), 3.90 (s, 3H), 3.73 (s, 2H), 3.58 (d, J = 13.6 Hz, 2H), 2.79 (s, 2H), 2.20 (s, 3H), 2.11 (s, 6H), 2.00 (S, 2H).
1343	494.40	1.60
1344	505.31	2.55
1345	538.60	1.23
1346	509.00	1.44	1H NMR {400 MHz, DMSO) 5 9.91 (s, 1H}, 7.73 (s, 1H), 731 (s, 1H), 7.15 {d, J = 7.1 Hz, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6,92 (S, 3H}, 6.82 (s, 1H), 4.15 (s, 3H), 4.03 (s, 4H), 238 (s, 6H), 2.25 (s, 3H), 1.78 (s,3H), 1.25 (s, 3H).
1347	496.00	2.28
1348	592.19	1.91
1349	445.22	2.12
1350	442.21	1.80
1351	522.00	1.87	1H NMR (400 MHz, DMSO} 5 13.07 (s, 1H), 8.43 (S, 1H), 8.05 (d, J = 15.1 Hz,

1271

Cmpd. No.	LC/'MS . M+1 <	LC/RT ^;®8τηιη^
			3H), 7.56 (s, 2H), 7.42 (d,J = 8.0 Hz, 2H), 7.05 (dd, J = 67.1, 10.4 Hz, 5H), 4.78 (s, IH), 2.34 (s, 3H), 1.31 (d, J = 5.9 Hz, 6H).
1352	499.30	1.61	IH NMR (400 MHz, DMSO) S 14.22 13.30 (m, IH), 12.56 (s, IH), 8.83 (d, J = 2.3 Hz, IH), 8.28 (dd, J = 8.7, 2.5 Hz, IH), 7.96 (d, J = 2.4 Hz, IH), 7.68 (d, J = 8.0 Hz, IH), 7.17 (d, J = 8.0 Hz, IH), 6.86 (dd, J = 5.5, 3.1 Hz, 2H), 5.31 (dt, J = 12.3, 6.2 Hz, IH), 2.58 (dd, J = 17.5, 7.2 Hz, 2H), 2.21 (s, IH), 1.88 (dd, J = 11.8, 5.7 Hz, IH), 1.59 (d, J = 8.8 Hz, 6H), 1.43 (t, J = 12.1 Hz, IH), 1.31 (d, J = 6.2 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H).
1353	464.00	1.53	IH NMR (400 MHz, DMSO) S 13.86 (s, IH), 12.6D (s, IH), S.66 (s, IH), 8.12 (d, J = 4.6 Hz, 2H), 7.99 (s, IH), 7.85 (s, IH), 7.63 (d, J = 7.9 Hz, IH), 7.42 (s, IH), 6.96 (s, 2H), 6.89 (s, IH), 2.29 (s, 3H), 2.03 (s, 6H).
1354	497.21	1.50
1355	424.30	1.84
1356	540.00	3.27	IH NMR (400 MHz, DMSO) 5 12.36 (s, IH), 8.13 (d, J = 7.8 Hz, IH), 7.80 (d,J = 7.6 Hz, IH), 7.63 (s, IH), 7.28 - 7.19 (m, 2H), 7.17 (s, IH), 6.95 (s, 2H), 6.84 (d, J = 10.8 Hz, IH), 6.70 (d, J = 6.5 Hz, IH), 6.51 (s, 2H), 3.65 (d, J = 6.5 Hz, 2H), 2.27 (s, 3H), 2.11 - 1.92 {m, 7H), 0.97 (d, J = 6.7 Hz, 6H).
1357	496.20	2.09	IH NMR (400 MHz, DMSO-d6) δ 12.56 (s, IH), 11.86 (s, IH), 8.26 (dd, J = 7.2, 2.1 Hz, IH), 8.03 (d, J = 7.7 Hz, IH), 7.83 (s, IH), 7.04 (d, J = 7.9 Hz, IH), 6.95 - 6.91 (m, 2H), 6.46 (dd, J = 7.3, 6.3 Hz, IH), 2.47 - 2.36 (m, IH), 2.26 (s, 3H), 1.98 (s, 6H), 1.78 - 1.50 (m, 6H), 1.21 (h, J = 10.9,10.4 Hz, 4H).
1358	465.39	3.36	IH NMR (400 MHz, DMSO-d6) δ 11.0 (s, IH), 7.98 - 7.95 (d, IH), 7.75 - 7.72 (d, IH), 7.56 (S, IH), 7.24 (t, J = 7.8, IH), 7.01 - 6.95 (m, 2H), 6.87 - 6.84

1272

Cmpd. ΝοΛ	!.. LC/MS1 Μι1	- LC/RT’* -.r.-^ΐΛ * vm in ..
			(m, 2H), 6.68 (s, 1H), 5.36 (s, 2H), 1,94 (s,6H), 1.14 (s, 9H)
1359	586.60	2.24
1360	548.60	1.60
1361	587.30	2.22
1362	546.20	2.01	1H NMR (400 MHz, DMSO} δ 12.63 (s, 1H), 7.77 (d, J « 7.9 Hz, 1H), 7.69 7.57 (m, 1H), 7.52 - 7.40 (m, 2H), 7,35 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.1 Hz, 1H), 6.90 (d, J = 10.8 Hz, 1H), 6.73 (d, J = 8.3 Hz, 1H), 6.52 (s, 2H), 5.32 (d, J = 54.8 Hz, 1H), 4.64 (t, J = 6.6 Hz, 1H), 3.84 (d, J = 6.6 Hz, 2H), 3,34 - 3.15 {m, 2H), 2.36 - 2.15 (m, 1H), 2.05 (dt, J = 13.2, 5.3 Hz, 1H), 1.99 - 1.83 (m, 1H), 1.28 (d, J = 6.4 Hz, 3H), 1,00 (d, J = 6.7 Hz, 6H).
1363	525.50	1.65
1364-	522.30	1.85	1H NMR (400 MHz, DMSO-d6) δ 12.25 (s, 1H), 7.62 (d d, J = 8.4, 7.3 Hz, 1H), 7.45 - 7.32 (m, 3H), 7.36 - 7.24 (m, 3H), 7.18 (dd, J = 7.3,0.7 Hz, 1H), 6.67 (dd, J = 8.4, 0.8 Hz, 1H], 6.45 (s, 2H), 2.60 - 2.51 (m, 2H), 2.21 (ddt, J = 17.6,11.9, 6,4 Hz, 1H), 1.86 (dd, J = 11,8, 5,6 Hz, 1H), 1.58 (d, J = 8.4 Hz, 6H), 1.46 -1.35 (m, 1H), 1.13 (s, 9H), 0.90-0.79 (m,3H).
1365	593.20	2.40
1366	580.50	1.89
1367	550.40	2.69	1H NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 7.26 (s, 1H), 7.20 (t, J = 7.9 Hz, 1H), 7.05 (q, J = 7.9 Hz, 2H), 6.85 (d, J = 8,2 Hz, 3H), 4.01 (dd, J = 15.5,9,3 Hz, 3H), 3.79 (q, J = 14.0, 13.4 Hz, 4H), 2.45 (t, J = 7.7 Hz, 2H), 2.31 (s, 6H), 2.23 (s, 3H), 1.61 (s, 3H), 1,52 (p, J = 7.4 Hz, 2H), 1.24 (t, J = 6.9 Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H).
1368	583.20	2.10	1H NMR (400 MHz, DMSO} δ 12.61 (s, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.64 (dd, J = 8.3, 7,4 Hz, 1H), 7.58 - 7.49 (m, 2H}, 7.21 (d, J = 6.9 Hz, 1 H), 6.95 (dt, J = 10.8, 2,3 Hz, 1H}, 6.79 - 6.68 (m, 1H), 6.54 (s, 2H),

1273

Gmpd. No.&	LC/MS ' £m+i:î	LC/RT .'• .min T*
			5.90 (s, 1H), 3.86 (d, J = 6.6 Hz, 2H), 332 (s, 1H), 2.42 (s, 2H), 1.22 (s, 6H), 1.15 (s, 6H), 1.00 (d, J = 6.7 Hz, 6H).
1369	500,30	1.27
1370	521.50	2.27
1371	571.40	1.57
1372	509.00	134	1H NMR {400 MHz, MeOD) 6 8.10 (s, 1H), 7.52 (s, 1H), 7.25 (s, 2H), 6.97 (s, 3H), 6.87 (d, J = 7.9 Hz, 1H), 6.61 (s, 1H), 4.40 (S, 1H), 4.17 (s, 2H), 4.04 {s, 2H), 2.44 {s, 6H), 2.29 (s, 3H), 1.85 (s, 2H), 132 {s, 3H), 1.15 (d,J = 6.1 Hz, 1H).
1373	472.50	1.50
1374	557.08	2.48
1375	527.20	1.99	1H NMR {400 MHz, Chloroform-d) δ 8.87 (d, J = 2.5 Hz, 1H), 8.54 (d, J = 8.2 Hz, 1H), 8.22 (dd, J = S.7,2.6 Hz, 1H), 7.74 (d, J = 83 Hz, 1H), 739 {d, J = 7.8 Hz, 1H), 6.78 (dd, J = 8.6, 4.5 Hz, 2H), 538 (hept, J = 6.2 Hz, 1H), 3.94 (q,J = 6.4 Hz, 2H), 234 (ddt, J = 9.8, 7.1, 3.7 Hz, 2H), 2.11 -1.89 (m, 2H), 138 (d, J = 6.1 Hz, 6H), 134 -1.22 (m, 6H).
1376	509.30	2.27
1377	528.60	1.89
1378	484.30	1.57	1H NMR (400 MHz, DMSO-d6) δ 1231 (s, 1H), 7.61 (d, J = 7.6 Hz, 2H), 7.17 {d, J = 7.3 Hz, 1H), 6.66 (d, J = 83 Hz, 1H), 6.58 - 637 (m, 3H), 3.23 3.11 (m, 1H), 2.62 - 2.53 (m, 2H, obscured by solvent peak), 2.28 (s, 1H), 2.25 - 2.12 (m, 1H), 1.88 - 1.69 (m, 3H), 134 (dd, J = 7.9, 4.6 Hz, 7H), 1.47 -1.03 (m, 7H), 0.87 (d, J = 6.2 Hz, 3H).
1379	456.20	138
1380	594.50	1.84
1381	570.45	1.21
1382	541.40	0.80
1383	552.50	1.18
1384	466.30	1.45
1385	556.30	2.20
1386	43030	1.14
1387	59530	232	1H NMR (400 MHz, DMSO) Ô 12.41 (s,

1274

Cmpd.	<.LC/MS M+i	1LC/RT? min	e W® 8^ Z ' ^: JJ ! p 1®
			1H), 8.09 (s, 2H), 7.60 (s, 1H), 7.55 7.47 (m, 2H), 7.13 (d, J = 7.5 Hz, 1H), 6.97 (d, J = 10.3 Hz, 1H), 6.69 (d, J = 8.6 Hz, 1H), 6.54 (s, 2H), 6.20 (s, 1H), 3.86 (d, J = 6.5 Hz, 2H), 3.62 (s, 1H), 2.82 - 2.71 (m, 1H), 2.09 - 2.00 (m, 1H), 1.25 (d, J = 6.9 Hz, 6H), 1.16 (d, J = 6.9 Hz, 6H), 1.00 (d, J = 6.7 Hz, 6H).
1388	653.40	1.88	1H NMR (400 MHz, Methanol-d4) δ 7.81 (d, J = 13.5 Hz, 1H), 7.78 - 7.66 (m, 1H), 7.35 (d, J = 7.3 Hz, 1H), 6.88 (dd, J = 8.6, 5.6 Hz, 1H), 5.93 (dd, J = 12.2, 5.1 Hz, 1H), 4.45 (s, 1H), 4.39 (t, J = 6.3 Hz, 1H), 3.77 - 3.51 (m, 1H), 3.27 - 3.16 (m, 1H), 3.00 (dd, J = 20.5, 12.5 Hz, 1H), 2.67 (s, 1H), 2.28 (s, 1H), 2.17 (td, J = 13.3, 7.0 Hz, 1H), 2.04 (s, 2H), 1.92 (s, 1H), 1.85 -1.69 (m, 1H), 1.52 (d, J = 5.2 Hz, 3H), 1.49 (s, 9H), 1.45 -1.35 (m, 12H), 1.23 - 1.12 (m, 3H).
1389	584.40	1.34
1390	481.30	2.02
1391	590.60	2.05
1392	499.00	1.23	1H NMR (400 MHz, MeOD) 8 7.91 (s, 1H), 7.43 (d, J = 6.1 Hz, 1H), 7.32 (d, J = 16.0 Hz, 2H), 7.21 - 7.09 (m, 3H), 7.05 (d, J = 8.9 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 4.52 (s, 4H), 4.09 (s, 2H), 2.55 (s, 3H),1.92 (s, 3H), 1.33 (s,3H).
1393	532.00	1.84	1H NMR (400 MHz, DMSO) 5 11.63 (s, 1H), 10.77 (s, 1H), 8.04 (s, 1H), 7.64 {S, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.15 {s, 1H), 6.83 (s, 3H), 6.67 (d,J = 7.5 Hz, 1H), 6.55 (S, 1H), 3.97 (d, J = 7.0 Hz, 3H), 3.73 (s, 1H), 3.57 (s, 3H), 2.23 (d, J = 15.3 Hz, 9H), 2.07 (s, 1H), 1.56 (s, 3H), 1.23 (s,3H).
1394	526.00	1.G7	1H NMR (400 MHz, DMSO) δ 10.45 (s, 1H), 7.34 {d, J = 8.5 Hz, 1H), 7.23 (s, 1H), 7.08 (s, 1H), 6.98 (s, 1H), 6.87 (d, J = 8.4 Hz, 3H), 6.81 (d, J = 7.7 Hz, 1H), 5.52 (S, 1H), 4.08 (d, J = 12.3 Hz, 1H), 4.01 (s, 2H), 3.83 (d, J = 19.7 Hz, 3H), 2.34 (s, 6H), 2.24 (s, 3H), 2.08 (s,

1275

Cmpd,. f NoM	LC/MS M+1	LC/RTmiri
			1H), 1.64 {s, 3H), 1.25 (S,3H).
1395	557.36	2.50
1396	540.00	3.26	1H NMR (400 MHZ, DMS0-d6) δ 8.09 - 7.95 (m, 2H), 7.79 - 7.70 (m, 2H), 7.70 - 7.61 (m, 2H), 7.48 (dd, J = 2.3, 1.4 Hz, 1H), 7.40 (ddd, J = 10.2, 2.4, 1.4 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 6.89 (dt, J = 10.7,2.3 Hz, 1H), 3.92 3.67 (m, 3H), 2.43 (t, J = 10.3 Hz, 1H), 2.36 (dd,J = 10.1, 7.0 Hz, 1H), 2.08 (ddt, J = 32.6,13.3, 6.3 Hz, 2H), 1.83 (dd, J = 11.9, 5.5 Hz, 1H), 1.57 (d, J = 17.5 Hz, 6H), 1.38 (t, J = 12.1 Hz, 1H), 1.04 (d, J = 6.1 Hz, 5H), 0.98 (d, J = 6.7 Hz, 6H), 0.66 (d, J = 6.3 Hz, 3H).
1397	538.30	1.25
1398	524.30	1.17
1399	538.30	1.25
1400	558.34	2.73	1H NMR {400 MHz, DMSO-66) δ 12.46 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.51 - 7.46 (m, 1H), 7.40 (dt, J = 9.9,1.9 Hz, 1H), 7.22 (dd, J = 22.1, 7.6 Hz, 2H), 6.89 (dt, J = 10.9,2.3 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 6.48 (s, 2H), 3.83 (d, J = 6.6 Hz, 2H), 2.26-2.13 {m, 1H), 2.05 (dt, J = 13.3, 6.7 Hz, 1H), 1.94 -1.83 (m, 1H), 1.60 (d, J = 6.8 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.88 (d, J = 6.3 Hz, 3H).
1401	430.00	1.49	1H NMR (400 MHz, DMSO) δ 12.40 (s, 1H), 7.69 - 7.49 (m, 2H), 7.24 - 7.07 {m, 1H), 6.82 - 6.61 (m, 2H), 4.84 (s, 2H), 3.46 (S, 4H), 2.42 (t, J = 5.8 Hz, 2H), 2.12 - 2.00 (m, 2H), 1.27 (s, 9H), 1.23 (dd, J = 6.7, 2.7 Hz,2H).
1402	561.40	2.07
1403	541.00	1.79	1H NMR (400 MHz, DMSO) δ7.64 (d, J = 7.9 Hz, 1H), 7.42 (s, 1H), 7.26 (s, 1H), 7.16 (S, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.92 (s, 3H), 4.24 - 3.99 (m, 6H), 3.84 (S, 3H), 2.40 (s, 6H), 2.25 (s, 4H), 2.07 (s, 1H), 1.75 (s, 3H), 1.24 {s, 3H).
1404	661.40	1.84	1H NMR (400 MHz, Methanol-d4) δ 7.73 (s, 1H), 7.67 (t, J = 8.1 Hz, 1H),

1276

Cmpd. ‘ No.	LC/MS	LC/RT F min^
			7.43 - 7.27 (m, 6H}, 6.77 (d, J = 8.5 Hz, 1H), 5.59 (s, 1H), 5.18 (s, 2H), 4.11 (s, 2H), 3.72 (S, 2H), 3.39 (q, J = 16.4, 13.3 Hz, 1H), 3.12 (t, J = 10.2 Hz, 1H), 2.57 (s, 1H), 2.40 (s, 2H), 2.09 (dd, J = 12.5, 6.8 Hz, 1H), 1.72 (t, J = 11.8 Hz, 1H), 1.53 (s, 3H), 1.44 (s, 3H), 1.39 (s, 9H), 1.11 (d, J = 6.5 Hz, 3H).
1405	568.39	1.26	1H NMR (400 MHz, Methano!-d4) δ 7.70 (dd, J = 8.5, 7.3 Hz, 1H), 7.63 (s, 1H), 7.36 (dd, J = 7.3, 0.8 Hz, 1H), 6.81 (dd, J = 8.6, 0.8 Hz, 1H), 5.93 (d, J = 1.7 Hz, 1H), 3.10 (t, J = 9.1 Hz, 1 H), 2.95 (t, J = 10.3 Hz, 1H), 2.71 - 2.57 (m, 2H), 2.46 (dd, J = 11.1, 6.4 Hz, 1H), 2.36 (d, J = 2.1 Hz, 2H), 2.02 (dd, J = 12.2, 6.2 Hz, 1H), 1.62 (t, J = 12.0 Hz, 1H), 1.57 (S, 3H), 1.53 (s, 3H), 1.40 (s, 9H), 1.17 (d,J = 1.3 Hz,6H), 1.04 (d, J = 6.5 Hz, 3H).
1406	529.20	2.32	1H NMR (400 MHz, DMSO} δ 7.90 7.84 (m, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.51 - 7.40 (m, 3H), 7.07 (dt, J = 7.3, 2.6 Hz, 1H), 6.85 (dt, J = 10.7, 2.2 Hz, 1H), 6.47 (d, J = 8.2 Hz, 1H}, 6.13 (s, 2H), 5.07 (dq, J = 119.9, 7.4 Hz, 1H), 3.85 (d, J = 6.6 Hz, 2H), 2.46 - 2.18 (m, 2H), 2.14 - 2.01 (m, 3H), 2.01 1.76 (m, 2H), 1.36-1.21 (m, 1H), 1.16 (d, J = 6.7 Hz, 2H), 1.05 - 0.91 (m, 7H).
1407	542.50	1.65	1H NMR (400 MHz, DMSO-d6) δ 12.46 (s, 1H), 7.82 (broad s, 1H), 7.59 (br s, 1H), 7.16 (br s, 1H), 6.89 (br s, 1H}, 6.64 (br s, 1H), 6.45 (br s, 2H), 5.80 (s, 1H), 3.89 (d, J = 6.6 Hz, 2H}, 2.67 (br s, 2H), 2.20 (br s, 1H), 2.02 (dt, J = 13.3, 6.7 Hz, 1H), 1.86 (dd, J = 12.0, 5.6 Hz, 1H), 1,53 (s, 3H}, 1.49 (s, 3H}, 1.39 (t, J = 12.0 Hz, 1H}, 0.95 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.3 Hz, 3H).
1408	481.00	1.15	1H NMR {400 MHz, MeOD) δ 7.95 (s, 1H), 7.62 (s, 1H), 7.34 (s, 5H), 7.14 (d, J = 42.4 Hz, 2H), 6.96 (s, 1H), 4.65 (s, 2H), 4.37 (s, 2H), 4.08 (s, 2H), 2.53 (s, 3H), 2.07 (s, 3H), 1.90 (s, 3H}, 1.35 (s, 3H).

1277

Cmpd._s No. ®	, LC/MS 7 M+1	LC/RT min
1409	556.50	2.19
1410	547.50	2.33
1411	512.50	1.78	1H NMR (400 MHz, Chloroform-d) δ 13.85 (br s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.31 (d, J = 2.6 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.70 - 7.59 (m, 2H), 6.68 (d, J = 7.7 Hz, 1H), 6.28 {d, J = 2.7 Hz, 1H), 3.61 (bra s, 1H), 3.24 (br t, 1H), 2.67 {m, 1H), 2.58 (d, J = 7.1 Hz, 2H), 2.14 {dd, J = 12.4, 7.7 Hz, 1H), 1.97-2.04 (m, 1H), 1.78 (br t, J = 11.0 Hz, 1H), 1.42 (s, 3H), 1.29 -1.19 (m, 6H), 0.98 (d, J = 6.6 Hz, 6H).
1412	481.40	1.77	1H NMR (400 MHz, DMSO-d6) δ 11.85 {s, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.22 {d, J = 7.2 Hz, 1H), 7.13 (t, J = 1.8 Hz, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.90 (s, 2H), 6.70 (d, J = 8.3 Hz, 1H), 6.53 - 6.45 (m, 2H), 4.43 {t, J = 9.6 Hz, 2H), 2.69 2.62 (m, 2H), 2.25 (s, 3H), 2.00 (s, 6H).
1413	509.00	1.17	1H NMR (400 MHz, DMSO) 59.66 (s, 1H), 8.34 {s, 2H), 8.12 (d, J = 9.2 Hz, 1H), 7.29 (s, 1H}, 7.04 - 6.86 (m, 4H), 4.14 (d, J = 84.4 Hz, 7H), 2.40 (s, 6H), 2.25 (s, 3H), 1.77 {s, 3H), 1.25 (s, 3H).
1414	590.60	1.63
1415	551.00	1.46	1H NMR (400 MHz, MeOD) δ 8.17 (d, J « 8.3 Hz, 1H), 7.92 (s, 1H), 7.77 (d, J = 7.4 Hz, 1H), 7.34 (s, 1H), 7.12 (d, J = 7.4 Hz, 1H), 6.99 (s, 2H), 6.94 (d, J = 8.3 Hz, 1H), 4.49 (s, 2H), 4.35 (s, 2H), 4.06 (s, 2H), 2.42 (s, 6H), 2.29 (s, 3H), 2.11 {s, 3H), 2.01 (s, 3H), 1.32 (s, 3H).
1416	512.30	3.06
1417	552.60	1.19
1418	543.20	2.40
1419	471.50	1.79
1420	404.30	1.03	1H NMR {400 MHz, DM5O-d6) δ 12.33 (s, 1H), 7.66 - 7.55 (m, 2H), 7.18 (dd, J = 7.3, 0.7 Hz, 1H), 6.67 (dd, J = 8.4,0.8 Hz, 1H), 6.46 (d, J = 7.8 Hz, 1H), 2.55 -2.50 (m, 2H, obscured by solvent peak), 2.31 (s,

1278

Cmpd. c No. ï	LC/MS S. M+1	LC/RT min
			3H), 2.21-2.13 (m, 1H), 1.82 (dd,J = 11.9, 5.7 Hz, 1H), 1.51 (d, J = 9.4 Hz, 6H), 1.37 (t, J = 12.0 Hz, 1H), 0.86 (d, J = 6.3 Hz, 3H).
1421	515.00	1.27	H NMR {400 MHz, DMSO) δ 10.72 (s, 1H), 7.67 (S, 1H), 7.27 (s, 1H), 7.11 (d, J = 7.3 Hz, 1H), 7.05 (s, 1H), 6.95 (dd, J = 18.9, 8.7 Hz, 2H), 6.84 (dd, J = 19.9, 9.2 Hz, 2H), 6.75 (d, J = 8.4 Hz, 1H), 4.14 (dd, J = 49.8,18.9 Hz, 7H), 3.80 (s, 3H), 1.53 (s, 3H), 1.28 (s, 3H).
1422	534.00	1.72	1H NMR (400 MHz, MeOD) δ7.67 7.54 (m, 2H), 7.23 (s, 1H), 6.96 (s, 2H), 6.88 (d, J = 8.3 Hz, 1H), 6.75 (d, J = 7.7 Hz, 1H), 6.59 (d, J = 8.3 Hz, 1H), 4.30 {d, J = 12.8 Hz, 1H), 4.07 (d,J = 26.0 Hz, 5H), 3.60 (s, 2H), 3.00 (s, 2H), 2.42 (s, 6H), 2.29 (s, 3H), 2.03 (s, 1H), 1.79 (s,3H), 1.31 (s, 3H).
1423	430.30	1.27	1H NMR (400 MHz, DMS0-d6) δ7.73 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H),6.92 (d,J = 8.1 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 5.89 (S, 1H), 5.35 (s, 1H), 2.66 - 2.56 (m, 2H), 2.25 - 2.20 (m, 1H), 2.11 (s, 3H), 1.87 (dd, J = 12.1, 5.7 Hz, 1H), 1.53 {d, J = 2.5 Hz, 6H), 1.45 - 1.34 (m, 1H), 0.88 (d, J = 6.3 Hz, 3H).
1424	572.30	1.50	1H NMR (400 MHz, DMS0-d6) δ 12.57 - 12.38 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.53 - 7.45 (m, 1H), 7.4S - 7.34 {m, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.21 {d,J = 7.2 Hz, 1H), 6.90 (dt, J = 10.6, 2.3 Hz, 1H), 6.69 (d, J = 8.2 Hz, 1H), 6.64 - 6.10 (s, 1H), 3.80 (s, 2H), 2.67 - 2.56 (m, 2H), 2.33 - 2.15 (m, 1H), 1.94 1.82 (m, 1H), 1.61 (s, 3H), 1.60 (s, 3H), 1.50 -1.34 (m, 1H), 1.21 (s, 6H), 0.88 (d, J = 6.3 Hz, 3H).
1425	511.00	1.71	1H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 7.51 (s, 1H), 7.30 (d, J = 23.3 Hz, 2H), 7.02 - 6.90 (m, 4H), 4.28 - 4.12 (m, 4H), 4.07 - 4.01 (m, 2H), 2.39 (S, 6H), 2.25 (s, 3H), 1.76 (s, 3H),

1279

tCmpdÿ - No. /	/LC/MS 1 Md	. lc/rtî ^min^
			1.24 (s,3H).
1426	565.34	2.30
1427	537.30	2.11
1428	518.00	1.43
1429	662.20	2.07
1430	558.30	1.84
1431	512.50	1.56
1432	565.50	1.94
1433	485.00	1.12	IH NMR (400 MHz, DMSO) δ 10.35 (s, IH), 7.74 (s, IH), 7.60 (s, 2H), 7.28 (s, 4H), 7.16 (s, IH), 7.03 (s, IH), 6.93 (s, IH), 6.83 (S, IH), 4.32 (s, 3H), 4.15 4.02 (m, 5H), 1.63 (s, 3H), 1.27 (t, J = 6.9 Hz,3H).
1434	566.06	1.77
1435	562.50	1.62
1436	525.30	1.89
1437	551.20	1.81
1438	472.50	1.31
1439	516.30	1.40
1440	557.30	2.44
1441	526.60	1.33
1442	538.30	1.25	IH NMR (400 MHz, DMSO-d6] δ8.49 {d, J = 9.8 Hz, 2H), 7.79 (d, J = 7.9 Hz, IH), 7.64 (dd, J = 8.4, 7.3 Hz, IH), 7.24 (dd, J = 13.1, 7.6 Hz, 3H), 6.72 (d, J = 8.3 Hz, IH), 4.09 - 3.95 (m, 2H), 3.87 (bs, IH), 1,95 (p, J = 8.0 Hz, 2H), 1.83 (h, J = 6.8 Hz, IH), 1.67 (dd, J = 9.4, 5.6 Hz, 2H), 1.18 (d, J = 6.4 Hz, 3H), 1.07 (dd, J = 6.3, 2.3 Hz, 6H), 0.95 (dd, J = 12.0, 6.7 Hz, 6H).
1443	528.40	1.83	IH NMR (400 MHz, Chloroform-d) δ 13.43 {S, IH), 8.27 (d, J = 8.5 Hz, IH), 7.95 (d, J = 0.9 Hz, IH), 7.67-7.59 (m, 3H), 7.53 (d, J = 0.9 Hz, IH), 6.65 (p, J = 3.8 Hz, IH), 4.66 (s, 2H), 3.72 (d, J = 6.5 Hz, 2H), 3.50 - 3.37 (m, IH), 3.1S (dd, J = 10.4,8.1 Hz, IH), 2.61 (d, J = 6.5 Hz, IH), 2.16 - 2.02 (m, 2H), 1.73 (dd, J = 12.3, 9.9 Hz, IH), 1.47 (s, 3H), 1.42 (s, 3H), 1.21 (d,J = 6.6 Hz, 3H), 1.03 (d, J = 6.7 Hz, 6H).
1444	556.30	1.69	IH NMR (400 MHz, DMSO-d6) δ 12.56 (s, 1 H), 8.26 (dd, J = 4.8,1.9 Hz,

1280

Cmpd;\| ' Nosê	: LC/MS+	<LC/RW	? : NMR
			1H}, 8.05 (dd, J = 7.9,1.9 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.46 - 7.37 (m, 1H), 7.30 (d, J = 8.0 Hz, 1H), 6.90 (dt, J = 10.7, 2.3 Hz, 1H), 6.78 (dd, J = 7.9, 4.7 Hz, 1H), 6.72 (s, 2H), 3.84 (d, J = 6.7 Hz, 2H), 3.39 (s, 6H), 2.15 (s, 1H), 2-05 (dt, J = 13.4, 6.7 Hz, 1H), 1.87 (dd, J = 11.9, 5.5 Hz, 1H), 1.59 (d, J = 14.2 Hz, 6H), 1.40 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.76 (d,J = 6.3 Hz, 3H).
1445	576.60	1.63
1446	501.20	2.12
1447	562.60	1.61
1448	556.60	1.68
1449	494.00	1.33	1H NMR (400 MHz, DMSO) 5 9.48 (s, 1H), 8.83 (d, J = 6.0 Hz, 2H), 7.99 (d, J = 6.0 Hz, 2H), 7.32 (s, 1H), 7.09 (d, J = 7.7 Hz, 1H), 6.93 (s, 3H), 434 (s, 10H), 4.04 (s, 4H), 2.40 (s, 6H), 2.25 (s, 3H), 1.82 (s, 3H), 1.25 (s,3H).
1450	542.81	2.48
1451	529.10	2.41
1452	570.00	2.19
1453	509.00	1.64
1454	508.00	1.44	1H NMR (400 MHz, DMSO) δ 10.03 (s, 1H), 7.60 (S, 1H), 7.50 (s, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 7.20 (s, 1H), 6.91 (s, 4H), 4.10 (d, J = 78.6 Hz, 6H), 237 (s, 6H), 2.24 (S, 3H), 1.73 (s, 3H), 1.25 (s, 3H).
1455	458.50	1.10
1456	579.45	3.S5	1H NMR (400 MHz, DMSO) δ8.43 (s, 1H), 7.48 (S, 1H), 7.18-7.15 (d, 1H), 6.98 (s, 2H), 6.89-6.85 {m, 3H), 6.71 (s, 1H), 6.52 (s, 1H), 6.27 (s, 1H), 3.803.77 (d, 2H), 2.26 (s, 3H), 2.05 (s, 6H), 0.97-0.94 (d, 3H)
1457	508.00	1.66
1458	551.20	2.14
1459	584.60	1.54
1460	523.20	1.89
1461	568.60	1.54
1462	512.30	136
1463	552.30	1.42

1281

Cmpd. _:^Νθ.<:	LC/MS ; &M+W	. LC/RT_;x. '^γ.ΓΠΙΙί-^π
1464	531.08	2.14
1465	571.30	2.55
1466	525.30	1.84	IH NMR (400 MHz, DMSO-d6) δ 12.14 (s, IH), 7.99 (d, J = 7.7 Hz, IH), 7.63 (dd, J = 8.4, 7.3 Hz, IH), 7.20 (dd, J = 7.3, 0.7 Hz, IH), 7.03 (d, J = 7.7 Hz, IH), 6.91 (s, 2H), 6.70 (dd, J = 8.4, 0.8 Hz, IH), 6.51 (s, 2H), 3.59 3.52 (m, 2H), 2.94 - 2.83 (m, IH), 2.25 (s, 3H), 1.97 (S, 6H), 1.56 - 1.43 (m, 2H), 1.34 -1.20 (m, 2H), 1.14 (s, 3H), 1.06 (s, 3H).
1467	548.60	1.59
1468	416.16	2.91
1469	584.60	1.57
1470	523.00	1.73	IH NMR (400 MHz, MeOD) δ 7.46 (s, 2H), 7.37 (s, IH), 7.27 (s, IH), 7.09 (d, J = 6.2 Hz, IH), 6.99 (s, 2H), 6.92 (dd, J = 11.5, 8.0 Hz, 2H), 4.41 (s, 2H), 4.27 (d, J = 13.0 Hz, 2H}, 4.04 (s, 2H), 3.80 (s, 3H), 2.45 (s, 6H), 2.30 (s, 3H), 2.03 (s, IH), 1.90 (s, 3H), 1.32 (s,3H
1471	526.28	1.08
1472	570.30	1.88
1473	514.50	1.40	IH NMR (400 MHz, Chloroform-d) δ 15.64 (s, IH), 8.45 (d, J = 8.7 Hz, IH), 7.83 (d, J = 8.7 Hz, IH), 7.69 - 7.58 (m, 2H), 6.64 (dd, J = 7.0, 2.1 Hz, IH), 5.71 (d, J = 1.0 Hz, IH), 4.67 (br s, 2H), 4.28 (q, J = 7.1 Hz, 2H), 3.76 (t, J = 9.3 Hz, IH), 3.21 (dd, J = 10.1, 7.3 Hz, IH), 2.68 (s, 3H) overlapped with 2.65-2.72 (m, IH), 2.21 (dd,J = 12.5, 8.2 Hz, IH), 1.79 (dd, J = 12.5, 9.0 Hz, IH), 1.41 (t, J = 7.1 Hz, 3H), 1.32 (s, 3H}, 1.26 (s, 6H). Some grease signais detected.
1474	494.00	1.48	IH NMR (400 MHz, DMSO) Ô9.99 (s, IH), 8.56 (s, IH), 7.98 (s, 2H), 7.51 (s, IH), 7.29 (s, IH), 7.04 (d, J = 7.4 Hz, IH), 6.91 (s, 3H), 4.21 (s, IH), 4.13 (s, 2H), 4.01 (s, 3H), 2.38 (s, 6H), 2.24 (s, 3H), 1.75 (s, 3H), 1.25 (s, 3H).
1475	523.20	2.37
1476	510.00	1.37	IH NMR (400 MHz, MeOD) δ 8.26 (d,

1282

CmpdJ - No.	fLC/MSf K M+1 S	LC/RT'· K min fi
			J = 6.5 Hz, IH), 8.10 (s, IH), 7.57 (d, J = 4.9 Hz, IH), 7.21 {s, IH), 6.99 (s, 2H), 6.88 (dd, J = 19.2,7.9 Hz, 2H), 6.44 (s, IH), 4,54 (d, J = 12.3 Hz, IH), 4.33 (dd, J = 33.8,9.1 Hz, IH), 4.13 (s, 2H), 4.08 - 3.99 (m, 2H), 2.50 (s, 6H), 2.30 (s, 3H), 1.82 (s, 3H), 1.32 (s, 3H).
1477	542.96	2.48
1478	504.50	2.19
1479	605.20	2.43
1480	508.00	1.65	IH NMR (400 MHz, DMSO} δ 10.63 (s, IH), 7.51 (d, J = 8.7 Hz, 2H), 7.18 (s, IH), 6.84 (d, J = 11.3 Hz, 3H), 6.64 (d, J = 7.6 Hz, IH), 6.58 (d,J = 8.7Hz, 2H), 3.99 (s, 4H), 3.73 (s, 3H), 2.29 (s, 6H), 2.23 (s, 3H), 2.07 (s, IH), 1.76 (s, IH), 1.55 (S, 3H), 1.24 (s, 3H),
1481	468.20	2.80
1482	585.30	2.29
1483	571.00	3.17	IH NMR (400 MHz, DMSO) δ 12,85 (s, IH), 8.04 (dd, J = 8.4, 7.4 Hz, IH), 7.82 (d, J = 8,0 Hz, IH), 7.77 (dd, J = 7.3, 0.5 Ηζ,ΙΗ), 7.49 (d,J = 1.7 Hz, IH), 7.42 (dd, J = 9.8,1.7 Hz, IH), 7.30 (d, J = 8.1 Hz, IH), 7.16 (dd, J = 8.4, 0.5 Hz, IH), 6.90 (dt, J = 10.7, 2.3 Hz, IH), 3.91 (S, 3H}, 3.83 (d, J = 6.6 Hz, 2H), 2.50 - 2.36 (m, 2H), 2.30 2.15 (m, IH), 2.05 (dt, J = 13.3, 6.7 Hz, IH), 1.87 (dd, J = 11.8, 5.5 Hz, IH), 1.59 (d, J = 1.3 Hz, 6H), 1.40 (t, J = 12.1 Hz, IH), 0,99 (d, J = 6.7 Hz, 6H), 0.77 (d, J = 6.3 Hz, 3H).
1484	554.60	2.01
1485	528.34	1.30	IH NMR (400 MHz, Methanol-d4) δ 7.94 (s, IH), 7.91 (s, IH), 7.77 - 7.70 (m, IH), 7.69 - 7.62 (m, IH), 7.37 (d, J = 2.4 Hz, IH), 7.34 (s, IH), 6.85 (d, J = 8.5 Hz, IH), 6.76 (d, J = 8.4 Hz, IH), 4.20 - 4.09 (m, 2H}, 3.62 (t, J = 6.4 Hz, 2H), 3.37 (t, J = 10.0 Hz, IH), 3.15 3.02 (m, 2H), 2.90 (dt, J = 17.7, 7.3 Hz, IH), 2.73 (d, J = 7.6 Hz, 2H), 2.56 (s, IH), 2.19 (td, J = 6.4, 4.0 Hz, 2H), 2.09 (dd, J = 12.5, 6.6 Hz, IH), 2,03 (s,

1283

^: Cmpd. No.'	LC/MS Μ+Ί/	^SLC/RT^
			3H), 1.92 (dq, J = 12.4, 6.3 Hz, 3H), 1.77 (ddd, J = 14.3, 8.9, 5.4 Hz, 2H), 1.72 -1.64 (m, 2H), 1.63 (s, 3H), 1.56 {S, 3H), 1.54 (S, 3H), 1.45 (s, 3H), 1.43 (S, 8H), 1.35 (s, 9H), 1.10 (d, J = 6.5 Hz, 3H), 0.95 (d, J = 6.2 Hz, 3H). (two sets of peaks due to a 1:1 mixture of olefin and hemi-acetal)
1486	483.20	2.14
1487	528.34	1.21
1488	524.28	1.21	1H NMR (400 MHz, DMS0-d6) δ 12.41 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.42 (d, J = 2.0 Hz, 2H), 7.19 (t, J = 7.4 Hz, 2H), 6.82 (t, J = 1.9 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 4.07 (q, J = 6.9 Hz, 2H), 2.63 - 2.55 (m, 2H), 2.34 (s, 3H), 2.23 (td, J = 13.6, 13.1, 6.9 Hz, 1H}, 1.87 (dd, J = 11.9, 5.7 Hz, 1H}, 1.61 (d, J = 4.4 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 1.34 (t, J = 6.9 Hz, 3H), 0.88 (d, J = 6.2 Hz, 3H).
1489	460.30	1.56
1490	544.60	1.79
1491	525.30	1.90
1492	537.30	1.84
1493	553.50	2.20
1494	510.30	2.11	1H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 7.90 (d,J = 8.7 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.22 (d, J = 7.1 Hz, 1H), 6.94 (s, 2H), 6.69 (d, J = 8.2 Hz, 1H), 6.45 (s, 2H), 6.26 (d, J = 8.8 Hz, 1H), 3.69 (s, 2H), 2.26 (s, 3H), 2.05 (S, 6H), 1.96 -1.85 (m, 2H), 1.57 (q, J = 9.5, 8.6 Hz, 2H), 0.92 (s, 6H).
1495	528.50	1.43
1496	518.22	2.99	DMSO(d6) δ 8.86 - 8.84 (d, 1H), 8.80 (s, 1H), 8.54-8.51 (d, 1H), 8.17 - 8.14 (d, 1H), 8.01 - 7.99 (d, 1H), 7.84 (t, J = 7.81,1H), 7.01 - 6.84 (m, 4H), 5.44 (s, 2H), 2.72 (s, 3H), 2.03 (s, 6H), 1.13 (s, 9H)
1497	573.10	1.77	1H NMR (400 MHz, Methanol-d4) δ 8.03 (dd, J = 8.3, 1.2 Hz, 1H), 7.68 (dd, J = 8.5, 7.3 Hz, 1H), 7.59 (dd, J =

1284

Cmpd. No.;	LC4v1S	LC/RT^ ^! * mm . ^	• foi
			8.3, 7.1 Hz, 1H), 7.38 (dd, J = 7.4, 0.8 Hz, 1H}, 6.93 - 6.82 (m, 2H}, 6.82 6.74 {m, 2H), 3.92 (t, J = 9.4 Hz, 1H), 3.79 (d, J = 6.4 Hz, 2H), 2.84 - 2.72 (m, 1H), 2.23 (dd, J = 12.6, 7.3 Hz, 1H), 2.12 - 2.02 (m, 1H), 1.87 (t, J = 11.7 Hz, 1H), 1.38 (s, 3H), 1.24 (d, J = 6.6 Hz, 6H), 1.04 (d, J = 6.7 Hz, 6H).
1498	495.00	1.23
1499	545.03	2.16	1H NMR {400 MHz, DMSO) δ 11.84 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.9 Ηζ,ΙΗ), 7.70-7.62 (m, 1H), 7.52 (t, J = 5.6 Hz, 2H), 7.21 (d, J = 7.3 Ηζ,ΙΗ), 6.96 (dd, J = 10.8, 2.1 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 4.48 (dd, J = 10.4, 6.5 Hz, 1H), 4.38 (dd, J = 10.4, 7.8 Hz, 1H), 3.86 (d, J = 6.5 Hz, 2H), 3.85 - 3.76 (m, 2H), 3.74 - 3.66 (m, 1H), 3.66 - 3.58 (m, 1H), 2.71 (dt, J = 14.5, 7.4 Hz, 1H), 2.04 (qd, J = 13.5, 7.5 Hz, 2H), 1.76 (dt, J = 14.3, 6.8 Hz, 1H), 1.00 (d, J = 6.7 Hz, 6H).
1500	474.30	1.34
1501	514.24	2.00
1502	567.40	2.39	1H NMR (400 MHz, MeOD) 07.86 (d, J = 8.2 Hz, 1H}, 7.78 (d, J = 8.2 Hz, 1H), 7.66 - 7.59 (m, 1H), 7.53 (s, 1H), 7.39 (d, J = 9.5 Hz, 1H), 7.36 (d, J = 7.2 Hz, 1H), 6.78 - 6.72 (m, 2H), 5.64 (s, 1H), 3.82 (d, J = 6.5 Hz, 2H), 2.152.05 (m, 1H), 1.75 (s, 2H), 1.38 (s, 6H), 1.09 - 1.00 (m, 12H).
1503	475.30	1.27
1504	553.00	1.76	1H NMR (400 MHz, DMSO) δ 12.43 (s, 1H), 8.83 (s, 1H), 8.31 (d, J = 8.7 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (s, 1H), 7.20 (s, 2H), 6.96 (d, J = 8.7 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 4.02 (s, 2H), 2.60 (d, J = 9.6 Hz, 2H), 2.22 (s, 1H), 1.87 (s, 1H), 1.60 (s, 6H), 1.42 (s, 1H), 0.88 (d, J = 6.3 Hz,3H).
1505	432.30	1.31
1506	538.30	1.29	1H NMR (400 MHz, DMS0-d6) Ô8.61 -8.48 (m,2H), 7.81 (d, J = 7.9 Hz, 1H),

1285

Cmpd. /Νό?		^LC/RTu J. min'
			7,65 (dd, J = 8.4, 7.3 Hz, 1H), 7.38 (d, J = 9.5 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 1H), 4.01 (h, J = 5.6 Hz, 2H), 3.56 (d, J = 7.5 Hz, 2H), 3.28 (s, 3H), 2.15 - 2.02 (m, 1H), 1,96 (qq, J = 6.6, 3.2 Hz, 2H), 1.68 (tq, J = 8.5, 5.2, 4.7 Hz, 2H), 1.08 (d, J = 6.2 Hz, 6H), 0.93 (d, J = 6.6 Hz, 6H).
1507	418.30	1.17
1508	576.60	1.61
1509	509.00	1.70
1510	458.30	1.48
1511	446.20	1.49
1512	525.30	2.31	1H NMR (400 MHz, DMSO-d6) δ 7.64 - 7,58 (m, 2H), 7.51 - 7.44 (m, 1HJ, 7.42 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H), 6.60 (t, J = 1.1 Hz, 1H), 6.49 (d, J = 8.2 Hz, 1H), 6.24 (s, 2H), 4.40 (q, J = 7.0 Hz, 2H), 2.93 (dt, J = 21.0, 10.6 Hz, 2H), 2.31 (s, 3H), 2.09 (bs, 1H), 1.81 (dd,J = 11.6, 5.6 Hz, 1H), 1.64 (s, 3H), 1.58 (s, 3H), 1.35 (t, J = 6.9 Hz, 4H), 0.79 (d,J = 6.3 Hz, 3H).
1513	507.50	2.16
1514	525.30	1,92	1H NMR (400 MHz, DMSO-d6} δ 8.23 (s, 1H), 7.89 (dd, J = 7.8, 2.1 Hz, 1H), 7.70 - 7.55 (m, 1H), 7.22 (d, J = 7.3 Hz, 1H), 7.04 (dd, J = 8.0, 2,7 Hz, 1H), 6.71 (d, J = 10.0 Hz, 2H), 5.28 (h, J = 6.2 Hz, 1H), 3.94 (q, J = 6.0 Hz, 2H), 2.36 (s, 3H), 1.99 (p, J = 7.4 Hz, 2H), 1.70 -1.55 (m, 2H), 1.30 (d, J = 6.1 Hz, 6H), 1.07 (d, J = 6.2 Hz, 6H).
1515	556.50	1.83
1516	510.30	2.11	1H NMR (400 MHz, DMSO-d6) δ 10.56 {s, 1H), 7.72 - 7.57 (m, 2H), 7.21 (d, J = 7.0 Hz, 1H), 6.93 (s, 2H), 6,69 (d, J = 8,4 Hz, 1H), 6.45 (s, 2H), 3.76 - 3.60 (m, 2H), 3.53 (dt, J = 10.1, 6.8 Hz, 1H), 2,28 {s, 3H), 2.26 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H}, 1.82 (ddd, J = 11.4, 6.6, 3.2 Hz, 2H), 1.74 -1.59 (m, 1H), 1.37 (td,J = 9.9, 4.0 Hz, 1H), 0.62 (d, J = 6.1 Hz, 3H).

1286

Cmpd. No. =	; LC/MS B'mîW	LC/RT 1 «1^8· ægmin y se
1517	511.20	1.92
1518	505.20	2.18
1519	563.20	2.13
1520	676.60	2.46
1521	560.50	1.61
1522	627.44	1.34
1523	540.00	1.67	1H NMR (400 MHz, DMSO) 8 12.56 (s, 1HL 8.94 (S, 1H), 8.36 (s, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.54 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 4.23 (d, J = 6.4 Hz, 2H), 2.64 (s, 2H), 2.19 (d, J = 38.0 Hz, 2H), 1.89 (s, 1H), 1.62 (s, 6H), 1.44 (s, 1H), 1.03 (d, J = 6.7 Hz, 6H), 0.89 (d, J = 6.2 Hz, 3H).
1524	472.30	1.23
1525	504.30	2.22
1526	557.30	2.22	1H NMR (400 MHz, DMSO-d6) 5 12.56 (S, 1H), 8.51 (s, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.56 - 7.45 {m, 2H), 7.22 (d, J = 7.2 Hz, 1H), 6.98 (dt, J = 10.9, 2.3 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.55 (s, 2H), 3.85 (d, J = 6.7 Hz, 2H), 2.72-2.63 (m, 1H), 2.59 (t, J = 10.6 Hz, 1H), 2.23 (s, 1H), 2.06 (dt, J = 13.3, 6.6 Hz, 1H), 1.92 (dd, J = 12.0, 5.6 Hz, 1 H), 1.62 (s, 3H), 1.55 (s, 3H), 1.47 (t, J = 12.2 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.89 (d, J = 6.3 Hz, 3H).
1527	552.30	1.42
1528	535.50	1.76
1529	540.30	2.11	1H NMR (400 MHz, DMSO) 5 12.58 (s, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.45 (dd, J = 8.7, 2.3 Hz, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.21 (d, J = 7.0 Hz, 1H), 6.89 (dt, J = 10.8, 2.3 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.49 {s, 2H), 3.84 (d,J = 6.5 Hz, 2H), 3.54 (s, 4H), 2.46 (t, J = 5.8 Hz, 2H), 2.06 (ddd, J = 19.9, 9.8, 4.6 Hz, 3H), 1.26 (dd, J = 6.6, 2.6 Hz, 2H), 0.99 (d, J = 6.7 Hz, 6H).
1530	555.20	2.34
1531	569.50	2.01
1532	542.60	1.89	1H NMR (400 MHz, Chloroform-d) δ

1287

Gmpd. ΐ No.^:	1 C/MSM · 1 '	kLC/RT . Mi min^	· · · :··': a
			14.55 {br s, 1H), 8.31 (br s, 1H), 7.93 (brs, 1H), 7.57 {br m, 3H), 6.59 (br s, 1H}, 4.75 and 5.49 (br m, 2H), 4.04 (d, J = 6.7 Hz, 2H), 3.55 (br s, 1H), 3.17 (br s, 1H), 2.66 (br s, 1H), 2.11 (dq, J = 13.4, 6.7 Hz, 2H), 2.00 (s, 3H}, 1.82 (br s, 1H), 1.42-1.36 (br m, 6H), 1.21 (br s, 3H), 1.02 (d, J = 6.7 Hz, 6H).
1533	604.60	2.10
1534	460.30	1.03
1535	578.60	1.78
1536	420.20	1.09
1537	539.30	2.17	1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.66 (dd, J = 8.4, 7.3 Hz, 1H), 7.22 (d, J = 7.0 Hz, 1H), 7.07 (d, J = 7.8 Hz, 1H), 6.76 (dd, J = 17.4, 8.5 Hz, 2H), 4.08 (d, J = 6.6 Hz, 2H), 3.96 (q, J = 5.9 Hz, 2H), 2.08 - 1.93 (m, 3H), 1.73 - 1.56 (m, 2H), 1.08 (d, J = 6.2 Hz,6H), 0.98 (d, J = 6.7 Hz, 6H).
1538	484.30	1.65	1H NMR (400 MHz, DMSO-d6) Ô 12.58 - 12.52 (s, 1H), 10.09 (s, 1H), 8.38 - 7.93 (m, 2H), 7.78 - 7.69 (m, 2H), 7.69 - 7.62 (m, 2H), 7.29 (d, J = 2.0 Hz, 1H), 7.23 (d,J = 10.2 Hz, 1H), 7.14 (d, J = 7.9 Hz, 1H), 6.90 - 6.36 (m, 1H), 2.48 - 2.26 (m, 2H), 2.18 2.08 (m, 1H), 1.91 -1.70 (m, 1H), 1.58 (s, 3H}, 1.55 (s, 3H), 1.38 (t, J = 12.1 Hz, 1H), 0.66 (d, J = 6.2 Hz, 3H).
1539	493.00	1.72	1H NMR (400 MHz, MeOD) δ 7.93 {s, 2H), 7.50 (d, J = 32.1 Hz, 3H), 7.26 (s, 1H), 6.98 (s, 2H), 6.91 (s, 2H), 4.31 (d, J = 65.9 Hz, 4H), 4.05 (s, 2H), 2.44 (s, 6H), 2.29 (s, 3H), 2.03 (s, 1H), 1.87 (s, 3H), 1.32 (s, 3H).
1540	564.50	1.69
1541	510.00	1.37	1H NMR (400 MHz, MeOD) Ô 8.26 (d, J = 6.4 Hz, 1H), 8.10 (S, 1H), 7.57 (d, J = 5.1 Hz, 1H), 7.21 (s, 1H), 6.99 (s, 2H), 6.88 (dd, J = 19.4, 7.9 Hz, 2H), 6.44 (s, 1H), 4.54 (d, J = 12.7 Hz, 1H), 4.33 (dd, J = 34.0, 9.6 Hz, 1H), 4.13 (s,

12S8

Cm^d. No. /	^LC/MS «s·	LC/RT min M	^Ν*ί ’MSSÊS'
			2H), 4.08 - 3.99 (m, 2H), 2.50 (s, 6H), 2.31 (S, 3H), 1.82 (s, 3H), 1.32 (s, 3H).
1542	500.00	1.45	1H NMR {400 MHz, DMSO) 59.88 (s, 1H), 9.06 (s, 1H), 8.24 (s, 1H), 7.28 {s, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.92 {s, 3H), 4.27 - 4.12 (m, 3H), 4.05 - 3.97 (m, 3H), 2.40 (s, 7H), 2.25 (s, 3H), 1.76 (s, 3H), 1.25 (t, J = 6.9 Hz, 3H).
1543
1544	524.40	1.89
1545	577.60	2.29
1546	500.00	1.49	1H NMR (400 MHz, DMSO) 59.50 {s, 1H), 7.86 (d, J = 3.1 Hz, 1H), 7.82 (d, J = 3.1 Hz, 1H), 7.34 (s, 1H), 7.19 (d, J = 7.7 Hz, 1H), 6,95 (d, J = 12.8 Hz, 3H), 4.34 (S, 2H), 4.06 (s, 2H), 2.42 {s, 6H), 2.25 (s, 3H), 1.84 (s, 3H), 1.23 (s, 3H).
1547	516.50	1.47
1548	572.20	1.99	1H NMR (400 MHz, DMSO) 5 15.07 (s, 1H), 8.28 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 8.2 Hz, 1H), 7.65 (dd, J = 8.4, 7.4 Hz, 1H), 7.59 - 7.50 (m, 2H), 7.31 - 7.19 (m, 1H), 6.99 (dt, J = 10.8, 2.3 Hz, 1H), 6.71 (d, J s 7.9 Hz, 1H), 6.38 (s, 2H], 3.93 (ddd, J = 13.4, 6.0, 2.9 Hz, 1H), 3.87 (d, J = 6.6 Hz, 2H), 3.76 (d, J = 11.4 Hz, 1H), 3.63 (d, J = 11.4 Hz, 1H), 3.39 - 3.27 (m, 1H), 3.02 {dd, J = 12.5, 2.6 Hz, 1H), 2.06 {dq, J = 13.3, 6.6 Hz, 1H), 1.52 (s, 3H), 1.18 (d, J = 6.2 Hz, 3H), 1.07Ό.95 (m, 9H).
1549	578.55	3.75	7.61-7.58 (d, 1H), 7.46 (t, 1=7.15,1H), 7.21-7.18 (d, 1H), 7.04-7.01 (d, 1H), 6.94 (s, 1H), 6.80-6.68 (m, 2H), 6.516.47 (d, 1H),6.32-6.28 (d,3H), 3.763.74 (d, 2H), 2.24 (s, 3H), 2.03 (s, 6H), 0.96 -0.93 (d,6H)
1550	458.30	1.75	1H NMR (400 MHz, DMSO-d6) δ 12.62 (s, 1H), 8.47 (d, J = 2.5 Hz, 1H), 7.89 {d, J = 2.5 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.21 {d, J = 7.2 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H), 6.52 (s, 2H), 2.65 - 2.52 (m, 2H), 2.22 - 2.17 {m, 1H), 1.92 - 1.82 (m, 1H), 1.52 (s, 6H), 1.42 (t, J = 12.1 Hz, 1H), 0.86 (d, J

1289

,Crnpd.\ •.ΝοΑ	&LG/MSj.	S»	s·^N-wSBi
			= 6.3 Hz,3H).
1551	456.38	3.05
1552	569.30	2.40	1H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 7.91 (dd,J = 20.4, 8.2 Hz, 2H), 7.66 (t, J = 7.9 Hz, 1H), 7.57 (s, 1H), 7.51 (d, J = 9.8 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 6.93 (d, J = 10.7 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.51 (s, 2H), 3.86 (d, J = 6.6 Hz, 2H), 3.58 (dd, J = 12.2, 6.5 Hz, 1H), 2.55 (d, J = 12.3 Hz, 1H), 2.06 (dt, J = 13.2,6.6 Hz, 1H), 1.63 (dd, J = 12.4, 6.4 Hz, 1H), 1.50 (d, J = 13.0 Hz, 1H), 1.39 (d, J = 12.9 Hz, 1H), 1.15 (s, 3H), 1.08 - 0.93 (m, 9H), 0.80 (S, 3H), 0.69 (s,3H).
1553	496.50	1.95
1554	562.60	1.59
1555	557.00	1.46	1H NMR (400 MHz, DMSO) δ 12.27 (s, 1H), 9.74 (s, 1H), 7.78 (s, 1H), 7.28 (s, 1H), 7.05 (d, J = 7.7 Hz, 1H), 6.93 (s, 3H), 4.22 (dd, J = 26.1, 10.6 Hz, 4H), 4.03 (d, J = 7.4 Hz, 3H), 2.43 (s, 6H), 2.25 (s, 4H), 2.14 (s, 3H), 1.77 (s, 3H), 1.23 (s,3H).
1556	458.30	1.72
1557	548.50	1.60
1558	551.50	1.75
1559	621.30	2.35
1560	611.50	2.06
1561	500.30	1.73
1562	550.40	2.60	1H NMR (400 MHz, DMS0-d6) δ 10.48 (s, 1H), 7.30 (s, 1H), 7.26 - 7.07 (m, 3H), 6.86 (d, J = 6.7 Hz, 3H), 6.78 (d, J = 7.6 Hz, 1H), 4.09 - 3.94 (m, 3H), 3.79 (d, J = 16.5 Hz, 4H), 3.00 (p, J = 6.8 Hz, 1H), 2.31 (s, 6H), 2.23 (s, 3H), 1.63 (s, 3H), 1.24 (t, J = 6.9 Hz, 3H), 1.14 (dd, J = 6.8, 3.0 Hz, 6H).
1563	571.20	2.73	1H NMR (400 MHz, Methano1-d4) δ 7.74 (d, J = 7.9 Hz, 1H), 7.46 (t, J = 1.8 Hz, 1H), 7.35 - 7.20 (m, 2H), 7.01 (d, J = 7.7 Hz, 1H), 6.92 (d, J = 7.9 Hz, 1H), 6.65 (dt, J = 10.4, 2.3 Hz, 1H), 3.79 (d, J = 6.5 Hz, 2H), 3.02 - 2.90 (m, 1H), 2.18 (dtd, J = 12.0, 9.2, 7.9, 4.3 Hz,

1290

Cmpd.	lc/ms.:	A'minsiï®
			1H}, 2.08 (dh,J = 13.4, 6.7 Hz, 1H), 1.83 (dd, J = 11.7, 5.6 Hz, 1H), 1.65 (m, 1H), 1.50 - 1.38 (m, 1H), 1.39 1.23 (m, 6H), 1.04 (d, J = 6.7 Hz, 6H),
1564	415.20	1.49
1565	502.00	1.13
1566	616.50	1.99
1567	572.40	1.48“	1H NMR (400 MHz, DMSO-d6) S 12.46 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4,7.3 Hz, 1H), 7.57 7.45 (m, 1H), 7.45 - 7.34 (m, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H}, 6.93 - 6.80 (m, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 4.03 (dd, J = 9.4, 6.0 Hz, 1H), 3.90 (dd, J = 9.6, 6.3 Hz, 1H), 3.46 - 3.39 {m, 2H), 2.64 2.55 (m, 2H), 2.28 - 2.14 (m, 1H), 2.06 -1.95 (m, 1H), 1.95 -1.80 (m, 1H), 1.61 (S, 3H), 1.59 (s, 3H), 1.42 (t, J = 12.1 Hz, 1H), 0.97 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 63 Hz, 3H).
1568	444.00	1.94	1H NMR (400 MHz, DMSO) δ 8.04 (s, 1H), 7.82 (s, 1H), 7.03 (s, 1H), 6.78 (s, 2H), 5.48 (S, 2H), 3.75 (s, 3H), 2.16 (d, J = 21.1 Hz, 9H), 1.14 (s,9H).
1569	578.30	2.63
1570	558.98	2.36
1571	456.40	1.44	1H NMR (400 MHz, DMSO-d6) δ 12.39 (s, 1H), 8.12 (s, 1H}, 7.61 (d, J = 13.8 Hz, 2H), 7.19 (d, J = 7.3 Hz, 1H), 6.67 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 6.36 (d, J = 15.9 Hz, 1H), 5.68 (dd, J = 15.9, 9.0 Hz, 1H), 2.17 (s, 1H), 1.82 (dd, J = 11.9, 5.7 Hz, 1H), 1.55 (dq, J = 8.8, 4.7, 4.2 Hz, 1H), 1.48 (d, J = 5.3 Hz, 6H), 1.36 (t, J = 12.1 Hz, 1H), 0.85 {d, J = 6.3 Hz, 3H), 0.81 - 0.71 (m, 2H), 0.50 (dq, J = 8.8, 5.5,3.7 Hz, 2H).
1572	590.20	2.24	1H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.74 7.61 (m, 2H), 7.41-733 (m, 2H), 7.27 - 7.20 (m, 1H), 6.90 (s, 1H), 6.86 (dt, J = 10.6, 23 Hz, 1H), 6.82 (s, 1H), 6.73 (d, J = 8.0 Hz, 1H), 6.52 (s, 2H), 3.70 (d, J = 6.6 Hz, 2H), 3.42 (s, 2H), 333

1291

Cmpd.® No.	LC/MS . :ïAM+lW	LC/RT ; A min r.
			(s, 2H), 2.25 (s, 3H), 2.08 -1.96 (m, 1H), 1.91 (s, 3H), 0.98 (d, J = 6.7 Hz, 7H).
1573	448.20	1.32
1574	566.20	1.43
1575	474.20	1.13
1576	509.00	1.41	1H NMR (400 MHz, DMSO) δ 10.47 (s, 1H), 7.58 (s, 1H), 7.46 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.9 Hz, 3H), 7.09 (d, J = 7.3 Hz, 1H), 6.93 (dd, J = 19.4, 7.9 Hz, 2H), 6.64 (d, J = 8.2 Hz, 1H), 6.40 (s, 1H), 4.20 (d, J = 12.5 Hz, 1H), 4.05 (d, J = 24.9 Hz, 4H), 2.93 (s, 1H), 2.07 (s, 1H),1.57(S,3H),1.26 (s,9H).
1577	538.40	1.91
1578	579.52	1.50
1579	573.35	2.17
1580	515.02	2.35
1581	556.50	1.83	1H NMR (400 MHz, DMSO-d6) Ô 12.62 - 12.53 (s,lH), 8.17 - 7.93 (m, 2H), 7.78 - 7.71 (m, 2H), 7.71 - 7.61 (m, 2H), 7.52 - 7.44 (m, 1H), 7.43 7.35 (m, 1H), 7.27 (d, J = 8.0 Hz, 1H), 6.90 (dt, J = 10,6, 2.4 Hz, 1H), 3.80 (s, 2H), 2.48 - 2.26 (m, 2H), 2.26 - 2.10 (m, 1H), 1.84 (dd, J = 11.9, 5.5 Hz, 1H), 1.60 (s, 3H), 1.55 (s, 3H), 1.38 {t, J = 12.0 Hz, 1H), 1.21 (s, 6H), 0.66 (d, J = 6.3 Hz, 3H).
1582	509.00	1.34	1H NMR (400 MHz, MeOD) δ 7.52 (s, 1H), 7.24 (s, 2H), 6.97 (s, 3H), 6.87 (d, J = 7.9 Hz, 1H), 6.61 (s, 1H), 4.39 (s, 1H), 4.16 (S, 2H), 4.03 (s, 2H), 2.44 (s, 6H), 2.29 (s, 3H), 1.85 (s, 3H), 1.32 (s, 4H), 1.15 {d, J = 6.1 Hz, 1H).
1583	488.00	1.31
1584	536.40	2.49	1H NMR (400 MHz, DMSO-d6) δ 10.41 (s, 1H), 7.19 (dt, J = 30.9,7.9 Hz, 3H), 6.85 (d, J = 22.6 Hz, 4H), 4.16 - 3.92 (m, 4H), 3.82 (d, J = 14.9 Hz, 4H), 2.33 (S, 6H), 2.23 (s, 3H), 1.64 (s, 3H), 1.24 (t, J = 6.9 Hz, 3H), 1.13 (td, J = 7.5, 2.5 Hz, 3H).
1585	441.50	2.01	1H NMR (400 MHz, DM5O-d6) δ 8.96 - 8.85 (m, 2H), 7.96 - 7.87 (m, 2H),

1292

Cmpd.·	LC/MS WM+1 1	P.LC/RT - . •‘-I] F'’ min	Λ -1 □ ^P 1ÏH ΓφΜ
			6.94 {s, 1H), 6.73 (s, 2H), 5.44 (s, 2H), 2.16 (s, 3H), 2.05 (s, 6H}, 1.15 (s, 9H).
1586	604.60	2.09
1587	542.00	1.75	1H NMR (400 MHz, DMSO) 5 10.28 (s, 1H), 7.35 (d, J =2.1 Hz, 1 H), 7.29 7.22 (m, 2H), 6.96 (dd, J = 8.3, 2.2 Hz, 1H), 6.89 (d, J = 7.2 Hz, 4H), 5.70 (s, 2H), 4.13 (d, J = 12.7 Hz, 1H), 3.97 (dd, J = 33.5, 9.7 Hz, SH), 2.36 (s, 6H), 2.24 (S, 3H), 2.08 (s, 3H), 1.68 (s, 3H), 1.25 (s,3H).
1588	617.30	2.64	1H NMR (400 MHz, Chloroform-d) 6 8.87 (d, J = 2.5 Hz, 1H), 8.55 (d, J = 8.3 Hz, 1H), 8.22 (dd, J = 8.7, 2.5 Hz, 1H), 7.68 (dd, J = 8.2, 4.0 Hz, 2H), 7.47 7.33 (m, 5H), 7.08 (d, J = 8.1 Hz, 1H), 6.78 (d, J = 8.7 Hz, 1H), 5.39 (hept, J = 6.2 Hz, 1H), 5.12 (s, 2H), 3.96 - 3.68 (m, 2H), 2.29 (ddt, J = 9.6, 6.7, 3.6 Hz, 2H}, 2.03 {d, J = 13.7 Hz, 2H), 1.38 (d, J = 6.2 Hz, 6H), 1.27 (dd, J = 6.8, 2.8 Hz, 6H).
1589	524.30	2.17	1H NMR (400 MHz, DMSO-d6) 6 10.54 (s, 1H), 7.70 (s, 1H), 7.67 - 7.59 (m, 1H), 7.21 (d, J = 7.4 Hz, 1H), 6.93 (s, 2H), 6.69 (d, J = 8.6 Hz, 1H), 3.99 (p, J = 6.1, 5.7 Hz, 2H), 2.29 (s, 3H), 2.25 (s, 3H), 2.04 (s, 6H), 1.84 (pt, J = 6.6, 3.0 Hz, 2H), 1.61 -1.48 (m, 2H), 0.88 (d, J = 6.2 Hz, 6H).
1590	458.20	1.54
1591	509.00	1.20	1H NMR (400 MHz, MeOD) δ 8.52 (s, 1H), 8.00 (s, 1H), 7.31 (s, 1H), 7.05 (d, J = 27.3 Hz, 4H), 6.93 (d, J = 8.2 Hz, 1H), 4.S0 (s, 2H), 4.33 (d, J = 45.1 Hz, 2H), 4.06 (s, 2H), 2.49 (s, 6H), 2.31 (s, 3H), 1.93 (s, 3H), 1.33 (s, 3H).
1592	531.09	2.15
1593	556.30	1.69
1594	472.30	1.10	1H NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.62 (dd, J = 8.4, 7.3 Hz, 1H), 7.22 7.15 (m, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.75 - 6.69 (m, 1H), 6.67 (d, J = 8.5, 0.8 Hz, 1H), 6.47 (s, 2H), 4.26 (q, J =

1293

;Çmpd. fe'NoAK	. LC/MS <	S LC/RT-
			2.8 Hz, 2H), 3.81 (dq,J = 14.5, 5.6 Hz, 2H), 2.59 - 2.54 (m, 2H, obscured by solvent), 2.21 - 2.16 (m, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.52 (s, 6H), 1.38 (t, J = 12.1 Hz, 1H), 1.22-1.11 (m, 1H), 0.86 (d, J = 6.3 Hz, 3H).
1595	474.40	1.12
1596	543.00	1.48
1597	544.00	1.64
1598	535.20	1.92
1599	446.40	1.44	1H NMR (400 MHz, DMSO-d6) 6 7.47 - 7.32 (m, 2H), 6.99 (d, J = 7.5 Hz, 1H), 6.42 (d, J = 8.1 Hz, 1H), 6.21 (d, J = 7.7 Hz, 1H), 6.01 (S, 2H), 3.04 - 2.90 (m, 2H), 2.44 - 2.28 (m, 2H), 2.17 - 2.00 1.76 (dd, J = 11.6, 5.7 Hz, 1H), 1.50 (d, J = 5.4 Hz, 6H), 1.34 (t, J = 5.9 Hz, 1H), 0.92 - 0.79 (m, 9H).
1600	640.60	2.11
1601	526.60	1.78	1H NMR (400 MHz, Methanol-d4) 6 7.79 (S, 1H), 7.60 (dd, J = 8.4, 7.3 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 5.56 (tt, J = 3.6,1.7 Hz, 1H), 3.60 (dd, J = 11.2, 8.3 Hz, 1H), 3.21 (dd, J = 11.2, 9.0 Hz, 1H), 2.66 (dt, J = 13.8, 8.4 Hz, 1H), 2.30 - 2.22 (m, 2H), 2.20 - 2.15 (m, 2H), 2.15 2.10 (m, 1H), 1.83 -1.75 (m, 3H), 1.75 - 1.67 {m, 2H), 1.52 (s, 3H), 1.42 (s, 9H), 1.40 (s, 3H), 1.15 (d, J = 6.7 Hz, 3H).
1602	46S.20	2.80
1603	424.00	1.75	1H NMR (400 MHz, DMSO-d6) 5 12.54 (s, 1H), 8.27 - 8.00 (m, 1H), 7.72 - 7.54 (m, 2H), 7.18 (d, J = 7.2 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.55 (s, 2H), 2.17 (dq, J = 13.0, 7.1, 6.7 Hz, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.47 (d, J = 7.1 Hz, 6H), 1.37 (t, J = 12.1 Hz, 1H), 0.85 (d, J = 6.3 Hz, 3H).
1604	559.30	2.18
1605	566.32	1.68
1606	500.00	1.47	1H NMR (400 MHz, DMSO) 69.64 (s, 1H), 8.12 (S, 2H), 7.77 (d, J = 7.3 Hz,

1294

Cmpd. No:^	\| LC/MS M+1 Ά	LC/RT,< ). min
			1H), 7.30 (S, 1H), 7.10 (d, J = 7.6 Hz, 1H), 6.92 (s, 3H), 4.27 (s, 3H), 4.04 (s, 3H), 2.39 (S, 6H), 2.24 (s, 3H), 1.79 (s, 3H), 1.24 (s, 3H).
1607	408.20	0.98
1608	563.60	2.13
1609	537.20	1.97
1610	567.50	1.91
1611	570.30	2.02
1612	570.30	2.02
1613	528.60	1.85
1614	562.60	1.61
1615	535.50	1.75
1616	605.00	1.67	1H NMR (400 MHz, MeOD) δ 8.16 (d, J = 8.2 Hz, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 7.27 (s, 1H),7.12 (d,J = 6.8 Hz, 1H), 6.99 (s, 2H), 6.89 (d, J = 8.2 Hz, 1H), 4.47 (s, 2H}, 4.26 (d, J = 33.1 Hz, 2H), 4.05 (s, 2H), 2.43 (s, 6H), 2.30 (s, 3H), 1.93 (s, 3H), 1.31 {s, 3H).
1617	514.30	1.89
1618	539.00	1.66	1H NMR (400 MHz, DMSO) δ 12.54 (s, 1H), 8.27 (d, J = 5.4 Hz, 1H), 7.82 (d, J = 7.9 Hz, 1H), 7.64 (s, 1H), 7.58 (d, J = 6.7 Hz, 1H), 7.41 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 6.70 (d, J = 8.3 Hz, 1H), 4.09 (d, J = 6.7 Hz, 2H), 2.61 (S, 2H), 2.23 (s, 1H), 2.07 (S, 1H), 1.88 (s, 1 H), 1.60 (d,J = 7.4 Hz, 6H), 1.43 (s, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.88 (d, J = 6.3 Hz, 3H).
1619	533.30	2.40
1620	528.50	1.77	1H NMR (400 MHz, Chloroform-d) δ 13.87 {broad s, 1H), 8.29 (d, J = 8.0 Hz, 1H) 8.21 (d, J = 2.9 Hz, 1H), 7.65 7.58 (m, 2H), 7.52 (d, J = 8.5 Hz, 1H), 6.65 (p, J = 3.8 Hz, 1H), 5.95 (d, J = 2.8 Hz, 1H), 4.80 (broad s, 2H), 4.02 (d, J = 6.6 Hz, 2H), 3.52 - 3.41 (m, 1H), 3.15 (dd, J = 10.5, 8.1 Hz, 1H), 2.69 2.50 {m, 1H), 2.18 - 2.02 (m, 2H), 1.72 (dd, J = 12.3, 9.7 Hz, 1H), 1.45 (s, 3H), 1.39 (s, 3H), 1.19 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.7 Hz, 6H).
1621	504.23	1.97

1295

Cmpd.? . No. -	.LC/MS ( M+1 .λ	LC/RT^ min -i^;	βββΒΙβ
1622	573.14	2.40
1623	525.30	1.89	1H NMR (400 MHz, DMSO-d6) Ô7.90 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H),7.O5 (d,J =7.9 Hz, 1H), 6.70 (t, J = 8.6 Hz, 2H), 5.31 (p, J = 6.2 Hz, 1H), 3.95 (q, J = 5.9 Hz, 2H), 2.04 - 1,93 (m, 5H), 1.71 - 1,57 (m, 3H), 1.31 (d, J = 6.2 Hz, 6H), 1.07 (d, J = 6.2 Hz, 6H).
1624	571.40	1.55
1625	566.32	1.67
1626	516.60	1.58
1627	430.30	1.19
1628	524,40	1.65
1629	557.03	2.48
1630	535.30	2.43	1H NMR (400 MHz, DMSO-d6) 6 12.08 (s, 1H), 8.01 (d, J = 7.9 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.24 7.16 (m, 2H), 6.91 (s, 2H), 6.70 (d, J = 8.3 Hz, 1H), 6.57 - 6.44 (m, 3H), 2.38 2.30 (m, 1H), 2.25 (s, 3H), 2.19 - 2.05 (m, 2H), 1,99 (s, 6H}, 1.88 - 1.76 (m, 2H), 1.44 (h, J = 6.9 Hz, 1H), 1.25 1.09 (m, 2H), 0.85 (dd, J = 6.8, 4.7 Hz, 6H).
1631	537.30	1.80
1632	474.30	1.18
1633	540.60	1.91
1634	515.30	0.95
1635	472.30	1.79	1H NMR {400 MHz, DMSO-d6) Ô 12,70 (s, 1H), 7.87 (d, J = 7.7 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.21 {dd, J = 7.3, 0.7 Hz, 1H), 7.00 (d, J = 7.7 Hz, 1H), 6.70 (dd, J = 8.5, 0,8 Hz, 1H), 6,56 (S, 2H), 2.60 (s, 2H), 1.75 {s, 2H), 1.55 (s, 6H), 0.97 (s, 6H).
1636	500.20	1.27	1H NMR (400 MHz, DMSO-d6) Ô 12.45 (S, 1H), 10.50 - 9.90 {s, 1H), 7.78 (d, J = 8.0 Hz, 1 H), 7.63 (t, J = 7.9 Hz, 1H), 7.31 (s, 1H), 7.26 - 7.17 (m, 2H), 7.14 (d, J = 8.1 Hz, 1H), 6.69 {d, J = 8.4 Hz, 1H), 6.64 (d,J = 10.5 Hz, 1H), 2.65 - 2.53 (m, 2H), 2.29 - 2.11 (m, 1H), 1.88 (dd, J = 11.9, 5.6 Hz,

1296

Cmpd. No.	LC/MS M+1 +	LC/RT^ min.+2
			1H), 1.60 (s, 3H), 1.59 (s, 3H), 1.42 (t, J = 12.0 Hz, 1H), 0.88 (d, J = 6.2 Hz, 3H).
1637	539.40	2.47	1H NMR (400 MHz, DMSO-d6) δ 7.65 - 7.56 (m, 2H), 7.48 (dd, J = 8.2, 7.3 Hz, 1H), 7.39 (d, J = 7.7 Hz, 1H), 6.98 (dd, J = 7.4, 0.8 Hz, 1H), 6.60 - 6.46 (m, 2H), 6.28 (s, 2H), 5.38 (p, J = 6.2 Hz, 1H), 3.00 - 2.83 (m, 2H), 2.30 (s, 3H), 2.09 (dq, J = 11.6, 6.0 Hz, 1H), 1.81 (dd, J = 12.0, 5.7 Hz, 1H), 1.65 (s, 3H), 1.57 (s, 3H), 1.41 -1.29 (m, 8H}, 0.78 (d, J = 6.3 Hz, 3H).
1638	472.30	1.82
1639	571.36	2.49
1640	534.30	2.08	1H NMR (400 MHz, DMSO-d6) δ 12.26 (s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7,53-7.48 (m, 1H),7.43 (dd, J = 9.9, 1.9 Hz, 1H), 7.29 (d,J = 8.0 Hz, 1H), 6.91 (dt, J = 10.7, 2.3 Hz, 1H), 4.47 (s, 1H), 4.18 - 3.97 (m, 2H), 3.92 - 3.82 (m, 3HL 3.77 - 3.68 (m, 1H), 3.09 (q, J = 10.6 Hz, 1H), 2.94-2.82 (m, 1H), 2.40 - 2.18 (m, 3H), 2.06 (dt, J = 13.3, 6.7 Hz, 1H), 2.01 -1.93 (m, 1H), 1.68 (d, J = 1.8 Hz, 3H), 1.63 (s, 3H), 1.56 (td, J = 12.3, 3.7 Hz, 1H), 1.05 (dd, J = 6.4, 3.2 Hz, 3H), 0.99 (d, J = 6.7 Hz, 6H).
1641	590.00	3.06	1H NMR (400 MHz, DMSO-d6) δ 12.59 {S, 1H), 7.80 (s, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1 H), 7.27 - 7.18 {m, 1H), 7.10 - 6.99 (m, 2H}, 6.93 (dt, J = 11.0, 2.3 Hz, 1H), 6.70 (dd, J = 8.4, 0.8 Hz, 1H), 6.54 (s, 2H), 3.80 (d, J = 6.6 Hz, 2H), 2.65 - 2.53 (m, 2H), 2.22 {dt, J = 11.5, 5.9 Hz, 1H), 2.08 -1.96 (m, 1H), 1.84 (dd, J = 12.0, 5.6 Hz, 1H), 1.57 1.33 (m, 7H), 0.97 {d, J = 6.7 Hz, 6H), 0.86 (d, J = 6.3 Hz, 3H).
1642	510.00	1.52	1H NMR (400 MHz, DMSO) δ 10.48 (s, 1H), 7.37 (d, J = 4.2 Hz, 1H), 7.35 (s, 1H), 7.32 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 6.92 (d, J = 7.8 Hz, 3H), 4.24 (s, 3H), 4.02 (s, 3H), 2.39 (s, 6H), 2.24 (s, 3H),

1297

Cmpd No. Λ	LC/MS + M+1	. LC/RT^ ^; min
			1.78 (s, 3H), 1.24 (s,3H).
1643	494.60	1.06
1644	529.20	2.30	1H NMR (400 MHz, DMSO} 8 7.84 (d, J = 7.7 Hz, 1H), 7.50 (t, J = 5.7 Hz, 1H), 7.47 - 7.36 (m, 3H), 7.06 (dd, J = 7.3, 0.7 Hz, 1H), 6.84 (dt, J = 10.7, 2.2 Hz, 1H), 6.45 (dd, J = 8.2,0.7 Hz, 1H}, 6.07 (s, 2H), 3.84 (d, J « 6.6 Hz, 2H), 2.44 - 2.31 (m, 2H), 2.24 (dd, J = 10.0, 6.9 Hz, 2H), 2.06 (dt, J = 13.3, 6.6 Hz, 1H}, 1.83 - 1.71 (m, 2H}, 1.68 (s, 3H), 1.01 (t,J =8.3 Hz,6H).
1645	567.50	1.78
1646	552.32	1.39
1647	584.42	1.36
1648	549.60	2.10
1649	536.50	1.49
1650	549.30	2.44
1651	512.30	1.86
1652	598.00	2.83	1H NMR (400 MHz, DMSO-d6) δ 12.68 (s, 1H), 10.87 (s, 1H),8.35 (d,J = 8.4 Hz, 1H), 8.17-8.05 (m, 1H), 7.88 -7.80 (m,2H), 7.51-7.45 (m, 1H), 7.42 (ddd, J = 10.2, 2.4,1.3 Hz, 1H), 7.30 (d, J = 8.Û Hz, 1H), 6.90 (dt, J = 10.7, 2.3 Hz, 1H), 3.83 (d, J = 6.6 Hz, 2H), 2.60 (dd, J = 10.2, 7.2 Hz, 1H), 2.52 (d, J = 5.3 Hz, 1 H), 2.14 (s, 4H}, 2.07 - 2.00 (m, 1H), 1.87 (dd, J = 11.8,5.6 Hz, 1H), 1.59 (d, J = 6.0 Hz, 6H), 1.41 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.77 (d,J = 6.3 Hz, 3H).
1653	455.40	2.05	1H NMR (400 MHz, DM5O-d6} δ 12.04 (s, 1H), 7.65 -7.59 (m, 2H), 6.95 (s, 1H), 6.76 (s, 2H), 6.67 - 6.61 (m, 2H), 6.19 (s, 2H), 5.45 (s, 2H}, 2.17 (s, 3H), 2.10 (s, 6H), 1.13 (s, 9H).
1654	566.32	1.68
1655	512.00	1.60
1656	553.40	2.62	1H NMR (400 MHz, DMSO-d6) δ 12.47 (S, 1H}, 7.83 (d, J = 8.0 Hz, 1H), 7.69 - 7.59 (m, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.1 Hz, 1H), 6.78 6.62 (m, 2H), 4.15 (dd, J = 6.6, 1.7 Hz, 2H), 2.70 - 2.56 (m, 2H), 2.34 (s, 3H),

1298

Cmpd< NO.'®®:	LC/MSi:	• LC/RT . xAmîrîÎÉI
			2.29 - 2.16 (m, 1H), 2.07 (hept, J = 6.7 Hz, 1H), 1.88 (dd, J = 11.9, 5.6 Hz, 1H), 1.62 (d, J = 5.9 Hz, 6H), 1.43 (t, J = 12.0 Hz, 1H), 1.00 (d, J = 6.7 Hz, 6H), 0.89 (d, J = 6.2 Hz,3H).
1657	554.20	2.05	1H NMR (400 MHz, DMSO) 8 12.47 (s, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.41 (d, J = 12.0 Hz, 2H), 7.27 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 6.89 (d, J = 10.8 Hz, 1H), 6.71 (d, J = 8.3 Hz, 1H), 6.46 (s, 2H), 4.29 (S, 1H), 3.84 (d, J = 6.5 Hz, 2H), 2.86 (s, 2H), 2.03 (dd, J = 13.5, 6.8 Hz, 1H), 1.86 - 1.75 (m, 3H), 1.54 (ddd, J = 36.2, 22.1,10.7 Hz, 6H), 0.99 (d, J = 6.7 Hz, 6H).
1658	472.20	1.71
1659	553.50	1.69
1660	525.30	1.38
1661	545.09	2.22	1H NMR (400 MHz, DMSO) 8 11.70 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.69 - 7.61 (m, 1H), 7.53 (tj = 5.3 Hz, 2H), 7.22 (d,J = 7.3 Hz, 1H), 7.02 - 6.93 (m, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.53 (s, 2H), 4.50 (qd, J = 11.1, 4.8 Hz, 2H), 4.26 (d, J = 5.2 Hz, 1H), 3.93 - 3.78 (m, 3H), 3.68 (dd, J = 13.9, 7.0 Hz, 1H), 2.13 - 1.98 (m, 2H), 1.98 -1.74 (m, 3H), 1.00 (d, J = 6.7 Hz, 6H).
1662	526.00	1.21	1H NMR (400 MHz, MeOD) 8 8.53 (s, 1H), 8.30 (s, 1H), 7.96 (s, 1H), 7.15 (dd, J = 97.7,47.9 Hz, 7H), 5.31 (s, 1H), 4.50 (d, J = 44.1 Hz, 3H), 4.11 (s, 2H), 1.83 (s, 3H), 1.40 (d, J = 29.2 Hz, 10H).
1663	553.00	1.81	1H NMR (400 MHz, DMSO) 8 12.45 (s, 1H), 7.91 - 7.78 (m, 3H), 7.64 {s, 1H), 7.57 (d, J = 7.9 Hz, 1H),7.21 (d, J = 7.2 Hz, 1H), 6.88 (d, J = 7.8 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 4.10 (s, 2H), 2.62 (S, 2H), 2.23 (S, 1H), 1.88 (s, 1H), 1.62 (d, J = 6.0 Hz, 6H), 1.43 {s, 1H), 1.04 (s, 9H), 0.89 (d, J = 6.3 Hz, 3H).
1664	538.30	1.62

1299

CmpcW ττ-· No. &	» LC/MS y W M+1Λ	»
1665	512.60	1.67
1666	532.00	1.72
1667	593.20	2.15	1H NMR (400 MHz, DMSO} δ 12.60 (s, 1H), 8.00 {d, J = 8.2 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.66 (dd, J = 8.4,7.3 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.26 - 7.16 (m, 1H), 6.95 (dt, J = 10.8, 2.3 Hz, 1H), 6.73 (d, J = 8.0 Hz, 1H), 6.S6 (s, 2H), 5.81 (s, 1H), 3.86 (d, J = 6.5 Hz, 2H), 3.35 (S, 1H), 2.73 - 2.60 (m, 1H), 2.47 - 2.37 (m, 1H), 2.25 (dt, J = 9.1, 4.0 Hz, 1H), 2.08 -1.98 (m, 3H), 1.49 (qd, J = 12.2, 5.5 Hz, 1H), 1.00 (d, J = 6.7 Hz, 6H).
1668	529.00	2.40
1669	494.00	1.38
1670	469.40	1.60
1671	538.29	1.27
1672	540.30	1.58
1673	519.30	1.59	1H NMR (400 MHz, DMSO-d6) δ 14.11 (s, 1H), 7.73 - 7.46 (m, 2H}, 7.16 (d, J = 7,3 Hz, 1H), 6.69 (dd, J = 8.5, 2.4 Hz, 1H), 3.79 (dt, J = 11.0, 6.2 Hz, 1H), 3.31 (td, J = 10.8, 3.7 Hz, 2H), 2.96 (t, J = 9.6 Hz, 1H), 2.41 - 2.27 (m, 2H), 1.99 (ddd, J = 23.1,12.1, 6.4 Hz, 2H), 1.58 -1.50 (m, 2H), 1.49 (s, 3H), 1.46 (s, 3H), 1.34 (s, 3H), 1.27 (s, 3H), 1.04 (dd, J = 6.5,1.9 Hz, 6H).
1674	592.30	1.42
1675	586.20	1.95	1H NMR (400 MHz, DMSO} δ 13.79 (s, 1H), 8.16 (d, J = 8.1 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.64 (dd, J = 8.4,7.4 Hz, 1H), 7.58 - 7.46 (m, 2H), 7.24 (d, J = 7.0 Hz, 1H}, 6.98 {dt, J = 10.7, 2.3 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.44 (s, 2H), 3.87 {d, J = 6.6 Hz, 2H), 3.56 (s, 2H), 3.14 (s, 2H), 2.06 (dq, J = 13.3, 6.6 Hz, 1H), 1.26 (d, J = 19.1 Hz, 12H), 1.00 (d, J = 6.7 Hz, 6H).
1676	498.00	1.43	1H NMR (400 MHz, DMSO) δ9.60 (d, J = 113.0 Hz, 1H), 8.13 (s, 1H), 7.89 (s, 1H}, 7.39 - 7.07 (m, 7H), 6.94 (s, 1H), 4.29 (d, J = 27.5 Hz, 3H), 4.04 (s, 3H), 2.44 (s, 6H), 1.81 (s, 3H), 1.26 (s, 3H).

1300

Cmpd. No.	-LC/MS ^M+1	LC/RT\| min'#
1677	458.30	1.49	1H NMR (400 MHz, DMSO) δ 12.32 (s, 1H), 7.80 - 7.55 (m, 2H), 7.18 {d, J = 7.3 Hz, 1H), 6,67 (d, J = 8.2 Hz, 1H), 6.47 (d, J = 7.8 Hz, 1H), 6.34 - 5.83 (m, 2H), 2.75-2.58 (m, 2H), 2.53 (d,J = 8,9 Hz, 2H), 2.17 (dd,J = 13.5,7.1 Hz, 1H), 1.82 (dd, J = 11.9, 5.7 Hz, 1H), 1.59 - 1.49 (m, 8H), 1.39 (dd, J = 26.5,14.4 Hz, 1H), 0.86 (d, J = 6.3 Hz, 3H), 0.69 (ddd, J = 12.8, 7.9, 4.9 Hz, 1H), 0,43 - 0.32 (m, 2H), 0.07 - 0.00 {m,2H}.
1678	491.50	1.74
1679	519.20	1.78
1680	573.30	2.25
1681	557.00	1.66	1H NMR (400 MHz, DMSO) δ 10.84 (s, 1H), 7.62 (s, 1H), 7.26 (s, 1H), 7.13 7.01 (m, 2H), 6.92 (s, 2H), 6.80 (s, 2H), 6,69 (d, J = 8.3 Hz, 1H), 6.43 (s, 1H), 4,08 (d, J = 30.9 Hz, 4H), 3.89 (s, 2H), 3.79 (s, 2H), 2.01 (s, 1H), 1.50 (s, 3H), 1.28 (S, 3H), 0.96 (d, J = 6.6 Hz, 6H),
1682	542.60	1.97
1683	444.30	1.32
1684	557.40	1,56
1685	529.29	2.29
1686	593.37	2.47
1687	594.20	1.66
1688	594.20	1.64
1689	593.33	2.44
1690	594.20	1.67
1691	580.35	1.74
1692	569.33	2.06
1693	580.32	1.71
1694	579.34	2.39
1695	583.30	1.48
1696	613.50	1.62
1697	474.40	1.35
1698	474.40	1.35
1699	472.30	1.21
1700	569.40	1,65
1701	480.21	1.62
1702	539.30	1,56
1703	583.50	1.74

1301

Cmpd. No.	LC/MS 1 < M+1 b?	, LC/RT^ Y min^	«SW·
1704	513.41	2.61
1705	526.16	1.40
1706	496.31	1.14
1707	526.18	1.24
1708	520.32	2.43
1709	514.30	1.65	IH NMR (400 MHz, DMSO-d6} S 12.35 (s, IH), 8.19 (d, J = 2.7 Hz, IH), 7.85 (d, J = 8.3 Hz, IH), 7.61 (t, J = 7.9 Hz, IH}, 7.18 (d, J = 7.2 Hz, IH), 6.90 (d, J = 8.2 Hz, IH), 6.66 (d, J = 8.3 Hz, IH), 6.49 (broad s, 2H), 6.07 (d,J = 2.8 Hz, IH), 4.86 (hept, J = 6.0 Hz, IH), 2.57 (br m, 2H), 2.21 (brs,lH), 1.87 (dd, J = 11.9,5.7 Hz, IH), 1.56 (s, 3H), 1.55 (s, 3H), 1.44-1.35 (m, IH), 1.33 (dd, J = 6.1, 3.1 Hz, 6H), 0.87 (d, J = 6.1 Hz, 3H)
1710	541.30	1.64	IH NMR (400 MHz, DM5O-d6} δ 12.47 (d, J = 23.3 Hz, 2H), 8.22 (dd, J = 7.2, 2.1 Hz, IH), 7.81 (s, IH), 7.59 (d, J = 7.8 Hz, IH), 6.44 (dd, J = 13.0, 7.1 Hz, 2H), 2.65 (d, J = 9.1 Hz, 2H), 2.58 (d, J = 12.3 Hz, IH), 2.35 - 2.12 (m, 2H), 1.97 (d, J = 11.7 Hz, 3H), 1.92 - 1.78 (m, 2H), 1.64 -1.47 (m, 8H), 1.46-1.32 (m,3H), 0.89 (d, J = 6.2 Hz, 3H).
1711	446.18	2.53
1712	482.24	0.73
1713	494.57	1.08
1714	506.20	1.15
1715	613.50	1.58	IH NMR (400 MHz, DMSO) δ 8.63 (d, J = 2.4 Hz, IH), 8.10 (d, J = 2.4 Hz, IH), 7.57 (d, J = 7.6 Hz, IH), 7.43 (t, J = 7.7 Hz, IH), 6.99 (dd,J = 10.5,7.4 Hz, 2H), 6.45 (d, J = 8.1 Hz, IH), 6.09 {d, J = 4.6 Hz, 2H}, 4.44 (dd, J = 5.7, 3.9 Hz, 2H), 3.77 (dd, J = 5.8, 4.0 Hz, 2H), 3.59 (dd, 1 = 5.8, 3.8 Hz, 2H), 3.49 (dd, J = 5.9, 3.7 Hz, 2H), 3.42 (q, J = 7.0 Hz, 2H), 3.06 - 2.93 (m, 2H), 2.20 (s, 3H), 2.16 - 2.04 (m, 2H), 1.81 (dd, J = 11.5, 5.6 Hz, IH), 1.61 (s, 3H), 1.57 (s, 3H), 1.37 (t, J = 11.9 Hz, IH), 1.08 (t, J = 6.9 Hz, 3H), 0.85 (d, J = 6.3

1302

Cmpdâ NoÎW	LC/MS M+1	LC/RK min	III Λ 3%’.--.77 là e toi
			Hz, 4H).
1716	494.31	1.52
1717	524.52	2.49
1718	447.08	2.71
1719	511.31	2.49	IH NMR (400 MHz, DMSO} δ 12.91 (s, IH), 8.20 - 8.14 (m, 2H), 7.92 - 7.89 (d, IH), 7.53 - 7.50 (dd, IH), 7.33 7.30 (d, IH}, 6.68 (s, IH), 6.59 - 6.55 (m, 3H), 3.70(s, 3H), 2.26 {s, 3H), 2.26 - 2.17 (m, IH}, 1.89 -1.82 (m, 1 H), 1.S0 (s, 3H), 1.47 (s, 3H), 1.45 -1.35 (m, IH), 0.88-0.86 {d, 3H)
1720	492.10	2.12
1721	534.18	1.98
1722	508.31	2.64
1723	586.30	2.00	IH NMR {400 MHz, DMSO} δ 13.01 11.30 (m, IH), 8.27 (d, J = 8.2 Hz, IH), 7.66 (t, J = 7.8 Hz, IH), 7.56 - 7.42 (m, 2H), 7.22 (t, J = 8.2 Hz, 2H}, 6.91 (d, J = 10.6 Hz, IH), 6.71 (d, J = 8.3 Hz, IH), 6.58 (s, 2H), 3.84 (d, J = 6.4 Hz, 2H}, 3.65 {s, 2H), 2,13 - 1.99 (m, IH), 1.37 {s, 2H), 1.13 (s, 6H), 1.00 (d, J = 6.6 Hz, 6H), 0.46 {s, 2H}, 0.28 (s, 2H).
1724	556.20	2.02
1725	458.30	1.36
1726	522.35	1.65
1727	525.30	2.35	IH NMR (400 MHz, DMSO) δ 8.63 (s, 3H), 8.09 (s, 3H), 7.61 - 7.53 (m, 4H), 7.48 - 7.37 (m, 4H), 6.99 (dq, J = 13.5, 6.1 Hz, 7H), 6.52 - 6.38 (m, 4H), 6.17 6.02 (m, 6H), 4.37 (q, J = 7.1 Hz, 6H), 3.07 - 2.88 {m, 7H), 2.19 (s, 8H), 2.17 - 2.04 (m, IH), 1.81 (q, J = 8.4,7.7 Hz, 3H}, 1.61 (S, SH), 1.57 {s, 8H), 1.41 1.30 (m, UH), 0.84 {d, J = 6.0 Hz, 9H}.
1728			IH NMR (400 MHz, DMSO) Ô8.61 (d, J = 2.3 Hz, IH), 8.11-8.01 (m, IH), 7.57 (d, j = 7.7 Hz, IH), 7.46 (t, J = 7.8 Hz, IH), 6.97 (t, J = 6.9 Hz, 2H), 6.48 {d, J = 8.3 Hz, IH), 6.20 (s, 2H), 5.16 (h, J = 6.2 Hz, IH), 2.98 (t,J = 10.6 Hz, IH), 2.92 - 2.82 (m, IH), 2.17 (s, 3H), 2.10 (t, J = 8.0 Hz, IH), 1.81 (dd, J = _11.4, 5.6 Hz, IH), 1.75 - 1.64 (m, 2H),

1303

Cmpd.· No.	; XLÇ/MS^ WmWH	LC/RT	3MK¹*
			1.61 (s, 3H), 1.56 (s, 3H), 1.36 (t, J = 11.9 Hz, IH), 1.28 (d,J = 6.1 Hz,3H), 0.93 (t, J = 7.4 Hz, 3H), 0.81 (d, J = 6.3 Hz, 3H).
1729	570.20	2.07
1730	534.30	1.91
1731	496.30	1.29	IH NMR (400 MHz, DMSO-d6) Ô 11.79 (s, IH), 8.26 (dd, J = 4.9,1.8 Hz, IH), S.08 {dd, J = 7.8,1.8 Hz, IH), 7.81 (d, J = 8.2 Hz, IH), 7.76 (d, J = 8.3 Hz, IH), 7.39 (d, J = 8.2 Hz, IH), 6.80 (dd, J = 7.8,4.8 Hz, IH), 6.73 (d, J = 7.4 Hz, 2H), 2.70 - 2.53 (m, 2H), 2.27 (s, 3H), 2.23 - 2.12 (m, IH), 1.89 (dd, J = 12.1, 5.5 Hz, IH), 1.51 (d,J = 2.0 Hz, 6H), 1.42 (t, J = 12.1 Hz, IH), 0.77 (d, J = 6.3 Hz, 3H).
1732	513.00	1.12	IH NMR (400 MHz, DMSO-d6} δ 12.80 (s, IH), 8.30 (d, J = 2.8 Hz, IH), 8.26 (dd, J = 4.7,1.9 Hz, IH), 8.03 (dd, J = 7.9,1.9 Hz, IH), 7.84 (d, J = 8.2 Hz, IH), 6.97 (d, J = 8.2 Hz, IH), 6.76 (dd, J = 7.8, 4.8 Hz, 2H), 6.10 (d, J = 2.7 Hz, IH), 3.98 (d, J = 6.6 Hz, 2H), 3.92 (d, J = 5.4 Hz, 2H), 2.05 (dq, J = 13.4, 6.8 Hz, IH), 1.94 - 1.84 (m, 2H), 1.65 - 1.55 (m, 2H), 0.97 (dd, J = 7.9, 6.4 Hz, 12H).
1733	527.22	1.46
1734	474.09	2.57
1735	496.20	1.53
1736	486.33	1.49
1737	568.20	2.00
1738	496.31	1.14
1739	552.40	1.70	IH NMR (400 MHz, DMSO) δ 12.57 12.26 (m, 2H), 7.69 (s, OH), 7.57 7.36 (m, 3H), 7.19 - 7.02 (m, 7H), 6.93 (s, 3H}, 6.74 - 5.97 (m, 4H), 3.52 (q, J = 6.9 Hz, 12H), 2.35 (s, 9H), 2.18 (s, 4H), 1.85 (dd, J = 11.6, 5.7 Hz, 3H), 1.62 (s, 9H), 1.59 (s, 8H), 1.40 (t, J = 12.1 Hz, 3H), 1.13 (t, J = 6.9 Hz, 18H), 0.87 (d, J = 6.2 Hz, 9H), 3.05 - 2.58 (m,6H).
1740	538.22	1.37

1304

Cmpd..	LC/MS; M+ΪΜ	_aLC/rt<
1741	553.40	2.75	1H NMR (400 MHz, DMSO-d6) δ8.63 (d, J = 2.2 Hz, 1H), 8.10 (d, J = 2.0 Hz, 1H), 7.61 {s, 1H), 7.49 (s, 1H), 7.02 (s, 2H), 6.51 (d, J = 8.7 Hz, 1H), 6.23 (s, 2H), 4.10 {d, J = 6.6 Hz, 2H), 2.87 (s, 2H}, 2.21 (s, 3H), 2.19 -1.98 (m, 2H), 1.82 (dd, J = 11.7, 5.6 Hz, 1H), 1.61 (s, 3H), 1.57 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 0.99 (d, J « 6.7 Hz, 6H), 0.83 (d, J = 6.4Hz,3H).
1742	544.30	1.32	1H NMR (400 MHz, DMSO-d6) 6 12.52 (s, 1H), 8.37 (d, J = 2.8 Hz, OH), 8.26 (dd, J = 4.8, 1.9 Hz, 1H), 8.20 (d, J = 2.8 Hz, 1H), 8.06 (dd, J = 7.8,1.8 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.79 (dd, J = 7.8, 4.9 Hz, 1H), 6.14 (d, J = 2.8 Hz, 1H), 4.35 - 4.28 (m, 2H), 3.74 - 3.67 (m, 2H), 3.50 (q, J = 7.0 Hz, 2H), 2.46 (d, J = 8.8 Hz, 2H), 2.22 - 2.03 (m, 1H), 1.85 (dd, J = 11.9, 5.6 Hz, 1H), 1.55 (s, 3H), 1.53 (s, 3H), 1.44 - 1.33 (m, 1H), 1,13 (t,J =7.0Hz,3H), 0.74 (d, J = 6.3 Hz, 3H).
1743	543.30	1.95	1H NMR (400 MHz, DMS0-d6) δ 12.51 (broad d, 1H), 12.47 (s, 1H), 8.22 (d, J = 7.2 Hz, 1H), 8.00 (s, 1H), 7.81 (br t, J = 6.3 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 8.2 Hz, 1H), 6.44 (t, J = 6.8 Hz, 1H), 4.01 (d, J = 6.7 Hz, 2H), 2.69 (d, J = 9.2 Hz, 2H), 2.21 (br m, 1H), 2.07 (hep, J = 6.6 Hz, 1H), 1.95 (s, 3H), 1.88 (dd, J = 11.9, 5.6 Hz, 1H), 1.57 (s, 3H), 1.55 (s, 3H), 1.42 (t, J = 12.1 Hz, 1H), 0.98 (d, J = 6.7 Hz, SH), 0.89 (d, J = 6.3 Hz, 3H).
1744	539.53	2.10
1745	526.21	1.18
1746	568.50	1.99	1H NMR (400 MHz, DMSO) δ 12.43 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.43 (dd, J = 9.7,1.7 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.19 (dd, J = 7.3, 0.6 Hz, 1H), 6.90 (dt, J = 10.7, 2.3 Hz, 1H), 6.71 (dd, J = 8.4, 0.6 Hz, 1H), 6.49 (S, 2HL 3-84 (d, J = 6.6 Hz, 2H),

1305

Cmpd.¹; •ANo.	, LC/MS M ih *	LC/Rlÿ miri W
			2.69 (s, 2H), 2.12 - 1.98 (m, 1H), 1.77 (S, 2H), 1.69 {S, 6H), 0.99 (d, J = 6.7 Hz, 6H), 0.49 (d, J = 12.5 Hz, 4H).
1747	510.16	1.47
1748	511.20	1.34	1H NMR (400 MHz, DMSO) δ 7.59 (d, J = 7.6 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.40 (s, 1H), 7.16 (s, 1H), 7.11 (d, J = 7.7 Hz, 1H), 7.00 (d, J = 7.3 Hz, 1H), 6.46 (d, J = 8.2 Hz, 1H), 6.13 (s, 2H), 3.86 (s, 3H), 3.01 (t, J = 9.2 Hz, 2H), 2.44 (s, 3H), 2.12 (s, 1H), 1.82 (dd, J = 11.6, 5.6 Hz, 1H), 1.61 (s, 3H), 1.55 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 0.S4 (d, J = 6.3 Hz, 3H).
1749	486.40	2.76
1750	556.00	2.08	1H NMR (400 MHz, DMSO} δ 12.30 (s, 1H), 10.56 {s, 1H), 7.83 (d, J = 8.7 Hz, 2H), 7.67 {d, J = 7.9 Hz, 1H), 7.47 (s, 1H), 7.39 (d, J = 10.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.94 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 10.7 Hz, 1H), 3.S3 (d, J = 6.6 Hz, 2H), 2.45 {d, J = 10.4 Hz, 1H), 2.36 {s, 1H), 2.07 (s, 3H), 1.83 (s, 1H), 1.57 {d, J = 18.9 Hz, 6H), 1.41 (d, J = 12.1 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.71 (d, J = 6.3 Hz, 3H).
1751	517.32	2.45
1752	527.30	1.38
1753	429.07	1.97
1754	554.20	1.98	1H NMR (400 MHz, DMSO) 6 12.57 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (dt, J = 12.1, 6.0 Hz, 1H), 7.42 (d, J = 1.7 Hz, 1H), 7.35 (t, J = 9.1 Hz, 2H),7.22 (d, J = 6.9 Hz, 1H), 6.92 - 6.85 (m, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.50 (s, 2H), 3.84 (d, J = 6.6 Hz, 2H}, 2.94 (dd, J = 10.2,6.9 Hz, 1H), 2.60 (dd, J = 10.3, 7.3 Hz, 1H), 2.26 (dd, J = 14.1, 7.0 Hz, 1H), 2.00 (ddd, J = 14.6,11.5, 6.1 Hz, 3H), 1.87 (dd,J = 11.9, 6.4 Hz, 1H), 1.66 (dd, J = 11.8, 8.2 Hz, 1H), 0.99 (t, J = 5.2 Hz, 10H), 0.68 - 0.38 (m, 2H).
1755	534.42	2.82
1756	522.42	2.92
1757	509.21	1.36	1H NMR (DMS0(d6)) Ô 12.85 (s, 1H),

1306

Cmpd.· No.	LC/MS à M+1	' rmnææ	13 ,·Λί M S® m si
			10.07 (s, 1H}, 8.16 - 8.14 (dd, 1H), 8.00 - 7.97 (d, 2H), 7.89 (t, J = 7.80, 1H), 7.75 - 7.72 (dd, 1H), 7.69 - 7.66 (d, 2H), 7.54 - 7.51 (d, 1H), 7.17 - 7.14 (d, 1H), 6.60 - 6.57 (dd, 1H), 2.44 2.40 (m, 1H), 1.92 - 1.84 (m, 1H), 1.77 - 1.70 (m, 1H), 1.47 (s, 3H), 1.43 (s, 3H), 1.29 (t, J = 11.86,1H), 0.70 - 0.68 (d,3H)
1758	542.60	1.63
1759	590.40	2.09
1760	529.40	1.68	1H NMR (400 MHz, Methano!-d4) δ 8.38 (dd,J = 7.2, 2.3 Hz, 1H), 7.99 (d, J = 1.1 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.71 {s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.50 (s, 1H), 7.06 (d, J = 8.0 Hz, 1H), 6.55 - 6.47 (m, 1H), 4.54 (s, 1H), 3.74-3.70 (m, 2H), 2.92 (s, 2H), 2.31 (s, 1H), 2.04 (dd, J = 13.2, 6.7 Hz, 1H), 1.92 (dd, J = 11.8, 6.0 Hz, 1H), 1.64 (s, 6H), 1.01 (dd, J = 6.8, 2.0 Hz, 6H), 0.97 (d,J = 6.3 Hz, 3H).
1761	527.22	2.10
1762	670.00	3.60	1H NMR (400 MHz, DMSO-d6) δ 12.23 (s, 1H), 8,13 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.57 - 7.46 (m, 2H), 7.45 - 7.23 (m, 5H), 7.23 7.04 (m, 5H), 6.83 (dt, J = 10.9, 2.3 Hz, 1H), 6.33 (s, 2H), 5.24 (s, 2H), 3.61 {d, J = 6.6 Hz, 2H), 2.05 (s, 6H), 1.98 {dt, J = 13.4, 6.7 Hz, 1H), 0.96 (d, J = 6.6 Hz, 6H).
1763	542.29	1.64
1764	475.29	1.95
1765	447.30	1.37	1H NMR (400 MHz, DMSO-d6) δ 12.46 (s, 2H}, 8.22 (dd, J = 7.3, 2.3 Hz, 1H), 7.81 (s, 1H), 7.62 (d, J = 7.9 Hz, 1H), 6.61 (d, J = 8.1 Hz, 1 H), 6.43 (t, J = 6.8 Hz, 1H), 2.67 (d, J = 9.6 Hz, 2H}, 2.22 (_S,1H), 1.86 (d, J = 5.8 Hz, 1H), 1.54 (d, J = 11.1 Hz, 6H), 1.27 {d, J = 5.0 Hz, 10H), 0.89 (d, J = 6.2 Hz, 3H).
1766	480.28	1.36
1767	487.30	2.90
1768	549.50	2.14

1307

Cmpd. No.	I.C/MS, 4 a ÎL	yLG/RJ^ SminA	- —-
1769	447.98	1.58
1770	516.41	2.28
1771	494.50	1.71	1H NMR (400 MHz, DMSO-d6) S 12.41 (s, 1H), 7.77 (d,J = 8.0 Hz, 1H), 7.69 - 7.57 (m, 3H), 7.20 (dd, J = 73, 0.7 Hz, 1H), 7.16 (d, J = 8.1 Hz, 1H), 7.09 - 7.04 (m, 1H), 6.68 (dd, J = 8.4, 0.8 Hz, 3H), 2.60 (d, J = 9.0 Hz, 2H), 2.33 (S, 6H), 2.22 (s, 1H), 1.87 (dd, J = 11.8, 5.6 Hz, 1H), 1.60 (d, J = 3.6 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 0.88 (d, J = 63Hz, 3H).
1772	466.29	1.96
1773	55934	2.56
1774	525.50	1.68	1H NMR (400 MHz, DMSO-d6) δ 12.52 (d, J = 8.6 Hz, 2H), 8.24 (d, J = 73 Hz, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.82 {t, J = 5.5 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.10 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H}, 6.44 (t, J = 6.8 Hz, 1H), 4.69 (p, J = 6.0 Hz, 1H), 2.72 (dj = 9.2 Hz, 2H), 2.23 (s, 1H), 1.88 (dd,J = 11.9, 5.6 Hz, 1H), 1.61 (s,6H), 1.44 (t, J = 12.2 Hz, 1H), 1.29 (d, J = 6.0 Hz, 6H), 0.91 (d, 1 = 63 Hz,3H).
1775	523.32	1.90
1776	512.51	3.00
1777	548.23	2.54
1778	545.23	2.58	1H NMR DMSO(d6) δ 12.76 (s, 1H), 8.18 - 8.16 (dd, 1H), 8.06 (t, J = 7.80, 1H), 7.81 - 7.75 (m, 2H), 7.58 - 7.56 (m, 2H), 7.16 - 7.13 (d, 1H), 6.94 6.91 (d, 1H), 6.64 - 6.61 (dd, 1H), 530 (q, J = 11.76, 2H }, 3.64 (s, 3H), 1.89 1.81 (m, 2H), 1.75 -1.69 (m, 1H), 1.49 (s, 3H), 1.43 (s, 3H), 1.24 (t,J = 11.86, 1H), 0.58 - 0.56 (d,3H)
1779	515.15	1.72
1780	515.21	1.61
1781	556.00	1.85
1782	491.20	2.41
1783	613.30	1.36	1H NMR (400 MHz, DMSO) S 8.62 (s, 1H), 8.10 (s, 1H), 7.94 {dd, J = 4.8,1.8 Hz, 1H), 7.84 (dd, J = 7.5,1.8 Hz, 1H), 7.55 (d, J = 7.7 Hz, 1H), 6.97 (d, J = 7.7

1308

Cmpd. No.	LC/MSf .. Mr-1 '	^LC/RTS ΓΠ1Π ..lùiftfli
			Hz, 1H), 6.55 (dd,J = 7.5, 4.8 Hz, 1H), 6.29 (s, 2H), 4.48 - 4.39 (m, 2H), 3.81 -3.74 (m,2H), 3.63- 3.57 (m,2H), 3.51 - 3.46 (m, 2H), 3.42 (q, J = 7.0 Hz, 2H), 2.94 (p, J = 10.5 Hz, 2H), 2.20 (S, 3H), 2.08 (d, J = 10.6 Hz, 1H), 1.80 (dd, J = 11.4, 5.7 Hz, 1H), 1.58 (d,J = 12.5 Hz, 6H), 1.35 (t, J = 12.0 Hz, 1H), 1.08 (t, J =7.0 Hz, 3H), 0.78 (d, J = 6.3 Hz, 3H).
1784	501.30	1.48
1785	550.30	1.71	1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.19 -8.11 (m, 2H), 7.81 (d, J = 8.0 Hz, 1H), 7.63 {t, J = 7.9 Hz, 1H), 7.50 (d, J = 8.3 Hz, 2H), 7.22 (t, J = 7.5 Hz, 2H), 6.69 (d, J = 8.4 Hz, 1H), 6.50 (s, 2H), 2.65 - 2.56 (m, 2H), 2.23 (d, J = 9.1 Hz, 1H), 1.88 (dd, J = 12.0, 5.6 Hz, 1H), 1.60 (d, J = 4.6 Hz, 6H), 1.43 (t, J = 12.0 Hz, 1H), 0.88 (d, J = 6.2 Hz, 3H).
1786	527.36	0.99
1787	671.60	1.94	1H NMR (400 MHz, DMSO) δ 8.63 (d, J = 2.3 Hz, 1H), 8.10 (d, J = 2.3 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.48 7.39 (m, 1H), 6.98 (dd, J = 7.5, 3.9 Hz, 2H), 6.47 (d, J = 8.3 Hz, 1H), 6.16 (s, 2H), 4.48 - 4.42 (m, 2H), 3.80 - 3.74 (m, 2H), 3.62 - 3.58 (m, 2H), 3.53 (ddd, J = 7.5, 5.3, 2.7 Hz, 3H), 3.48 (dd, J = 5.7, 3.7 Hz, 2H), 3.45 - 3.42 (m, 2H), 3.04 - 2.88 (m, 2H), 2.20 (s, 3H), 2.11 (dd, J = 11.6, 5.8 Hz, 1H), 1.81 (dd, J = 11.5,5.7 Hz, 1H), 1.61 (s, 3H), 1.56 (s, 3H), 1.36 (t, J = 11.9 Hz, 1H), 1.04 (d, J = 6.1 Hz, 6H), 0.82 (d, J = 6.3 Hz, 3H).
1788	610.30	2.23
1789	561.60	2.32
1790	484.27	0.92
1791	501.40	1.61	1H NMR (400 MHz, DMSO-d6) δ 12.63 (s, 1H), 12.54 (d, J = 6.0 Hz, 1H), 8.25 (dd, J = 7.3, 2.1 Hz, 1H), 8.08 (t, J = 1.9 Hz, 1H), 8.01 (dt, J = 7.4, 1.7 Hz, 1H), 7.S3 (dd, J = 6.7, 4.6 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.57 -

1309

Cmpd.s No.	LC/MS ® 77m+1,s^	* LC/RTe S- minW
			7.47 (m, 2H), 7.25 (d, J =8.0 Hz, 1H), 6.45 (t, J = 6.8 Hz, JH), 2.82 - 2.64 (m, 2H), 231 - 2.17 (m, OH), 1.89 (dd, J = 11.9, 5.6 Hz, 1H), 1.61 (d,J = 1.7 Hz, 6H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
1792	496.27	1.48
1793	51430	1.25
1794	430.27	1.70	1H NMR (400 MHz, DMSO-d6) δ 8.18 -8.16 (dd, 1H), 7.73 - 7.70 (dd, 1H), 7.865 (t, J = 7.80, 1H), 7.20 - 7.17 (d, 1H), 6.74 - 6.71 (d, 1H), 6.69 - 6.69 (dd, 1H), 2.94 - 2.84 (m, 21H), 2.72 2.65 (m, 1H), 1.99 -1.92 ( m, 1H), 1.82 -1.75 (m, 1H), 1.67 - 1.54 (m, 1H), 1.46 (s, 3H), 1.26 (s, 3H), 1.21 1.06 (m, 2H), 0.74 - 0.65 (m, 1H), 0.51 - 034 (m, 2H), 0.09 - 0.03 (m, 2H)
1795	548.20	2.27
1796	52032	235
1797	581.20	1.77	1H NMR {400 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.15 (d, J = 7.8 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 7.21 7.13 (m, 4H), 7.13 - 7.07 (m, 1H), 6.83 (dt, J = 10.6, 2.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 4.56 (s, 1H), 3.83 (dd, J = 9.4, 6.2 Hz, 1H), 3.69 (dd, J = 9.5, 6.2 Hz, 1H), 3.46 - 3.35 (m, 3H), 2.06 (s, 6H), 1.95 (dp, J = 12.7, 63 Hz, 1H), 0.95 (d, J = 6.7 Hz, 3H).
1798	49931	2.48	1H NMR (400 MHz, DMSO-d6) δ 12.81 (S, 1H), 8.19 - 8.17 (dd, 1H), 8.06 (t, J = 7.91,1H), 7.81 - 7.73 (m, 3H), 7.53-7.50 (dd, 1H), 7.38-7.21 {m, 3H), 6.64 - 6.61 (dd, 1H), 5.41 (s, 2H), 2.30 - 2.15 (m, 2H), 2.02 - 1.93 (m, 1H), 1.80 - 1.73 (m, 1H), 1.50 (s, 3H), 1.46 (S, 3H), 1.30 (t, J = 11.86, 1H), 0.65-0.63 (d,3H)
1799	53530	1.72	1H NMR (400 MHz, DMS0-d6) Ô 12.66 (s, 1H), 12.54 (d, J = 6.2 Hz, 1H), 8.29 - 8.19 (m, 3H), 7.91 - 7.74 (m, 4H), 7.27 (d, J = 8.0 Hz, 1H), 6.45

1310

Cmpd.. ^ίΝο.	LC/MS	LC/RT min T
			(t, J = 6.8 Hz, 1H), 2.83 - 2.64 (m, 2H), 231 - 2.18 (m, 1H}, 1.90 (dd, J = 12.0, 5.5 Hz, 1H), 1.61 (d, J = 3.9 Hz, 6H), 1.46 (t, J = 12.1 Hz, 1H), 0.92 (d, J = 6.3 Hz, 3H).
1800	501.41	3.06
1801	53331	1.16
1802	529.20	1.58
1803	517.40	1.64
1804	52430	1.69
1805	50231	238
1806	535.02	2.67
1807	485.50	1.53
1808	528.19	1.48
1809	508.28	1.78	1H NMR (400 MHz, DMSO-d6) δ 12.46 (s, 1H), 8.50 (d, J = 2.5 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.63 (t, J = 83 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 732 {d, J = 83 Hz, 2H}, 7.22 (d, J = 7.2 Hz, 1H), 6.69 (d, J = 8.3 Hz, 1H), 6.49 (s, 2H), 2.92 (p, J = 6.9 Hz, 1H), 2.56 (dj = 8.7 Hz, 2H), 2.28 - 2.12 (m, 1H), 1.85 (dd, J = 11.8, 5.6 Hz, 1H), 1.55 {s, 3H), 1.53 (s, 3H), 1.40 (t, J = 12.0 Hz, 1H), 1.24 (d, J = 7.0 Hz, 6H), 0.87 (d, J = 6.2 Hz, 3H).
1810	494.60	1.63	1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 7.66 - 7.55 (m, 2H), 7.17 (d, J = 7.2 Hz, 1H), 6.66 (d, J = 8.4 Hz, 1H), 6.40 (s, 2H), 5.02 (td,J = 6.1, 3.1 Hz, 1H), 2.56 (d, J = 10.6 Hz, 1H), 2.20 (dt, J = 11.7, 6.0 Hz, 1H), 1.88 (ddt, J = 30.9,11.8,6.0 Hz, 2H), 1.51 (d, J = 2.8 Hz, 3H), 1.45 (d, J = 5.1 Hz, 3H), 137 (t, J = 12.0 Hz, 1H), 1.22 (dd, J = 19.8, 63 Hz, 3H), 0.97 - 0.82 (m, 9H}.
1811	53135	1.24	1H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 12.55 (s, 1H), 8.27 (dd,J = 7.3, 2.1 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.5 Hz, 1H), 7.84 (s, 1H), 7.81 (d, J = 7.8 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.52 - 7.46 (m, 1H), 7.45 (s, 2H), 6.77 (d, J = 7.8 Hz, 1H), 6.46 (ΐ, J = 6.8 Hz, 1H), 2.84 - 2.73 (m, 2H),

1311

Cmpd. ^iNô'-W	LC/MSÿ	’ LC/RT ,· m in
			2.70 (s, 3H), 2.24 (s, 1H), 1.81 (dd, J = 11.7, 5.6 Hz, 1H), 1.53 -1.37 (m, 7H}, 0,92 (d, J = 6.3 Hz, 3H).
1812	613.30	1.47
1813	485.20	2.18
1814	524.22	1.97
1815	592.30	2.02
1816	536.22	1.85
1817	570.20	2.07	1H NMR (400 MHz, DMSO) δ 12.44 (s, 1H), 7,79 (d, J = 7.9 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.47 (s, 1H), 7.38 (d, J = 9.7 Hz, 1H), 7.22 (dd, J = 19.7, 7.6 Hz, 2H), 6.88 (d, J = 10.7 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 3.82 (d, J = 6.6 Hz, 2H), 2.63 - 2.53 (m, 2H), 2.31 (dt, J = 17.2,8.5 Hz, 1H),2.252.12 (m, 1H), 2.05 (dt, J = 13,3, 6.6 Hz, 1H), 1.86 {td, J = 14.2, 7.1 Hz, 1H), 1.67 (dd, J = 11.7, 6.1 Hz, 1H), 1.61 (s, 3H), 1.52 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.88 (d, J = 6.2 Hz, 3H), 0.69 (t, J =7.4 Hz,3H).
1818	514.21	1,42
1819	490.29	1.52
1820	482.24	0.76	1H NMR (400 MHz, DMSO) δ 12.50 (s, 1H), 9.57 (s, 1H), 8.25 (dd, J = 4.8,1.8 Hz, 1H), 8.05 (dd, J = 7.8, 1.8 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.48 - 7.39 (m, 2H), 7.27 (t, J = 8.1 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.86 - 6.81 (m, 1H), 6.78 (dd, J = 7.8, 4.8 Hz, 1H), 2.14 (s, 1H), 1.85 (dd,J = 11.6, 5.6 Hz, 1H}, 1.59 (d, J = 12.1 Hz, 6H), 1.40 (t, J = 12.2 Hz, 1H), 0.76 (d, J = 6.2 Hz, 3H).
1821	566.40	2.24	1H NMR (400 MHz, DMSO) δ 12.40 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.48 (d, J = 1.4 Hz, 1H), 7.43 (d, J = 10.1 Hz, 1H), 7.26 (d, J = 7.9Hz,lH), 7.21 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.7, 2.1 Hz, 1H), 6.69 (d, J = 8,4 Hz, 1H), 6.46 (s, 2H), 4.14 (d, J = 5.7 Hz, 1H), 3.83 (d, J = 6.6 Hz, 2H), 3.66 (t, J = 8.8 Hz, 1H), 3.35 (d, J = 9.9 Hz, 1H), 2.30 (s, 2H), 2.11 (s, 1H), 2.08 -1.99(m,lH), 1.54 (d, J = 10.1 Hz,

1312

Cmpd. : No. Y	LC/MS ώ Y M+1.	; minw	ίϋββ®
			1H), 1.39 (d, J = 7.9 Hz, 2H), 1.12 (d, J = 10.1 Hz, 1H), 1.04 (s, 1H), 0.99 (dj = 6.7 Hz, 6H), 0.80 {d, J = 10.2 Hz, 1H).
1822	510.53	1.06
1823	505.31	1.34
1824	491.30	1.16
1825	526.13	1.42
1826	517.32	2.03
1827	494.20	2.49
1828	511.31	2.52	1H NMR (400 MHz, DMSO) δ 12.89 (s, 1H), 8.22 - 8.15 (m, 2H), 7.92 7.89 (d, 1H), 7.51 - 7.48 (dd, 1H), 7.37 - 7.30 (m, 2H), 6.85 - 6.82 {dd, 1H), 6.74 - 6.70 (m, 2H), 6.60 - 6.57 (dd, 1H), 3.94 (q, J = 7.04, 2H), 2.26 - 2.17 (m, 1H), 1.89 -1.82 (m, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 1.44 -1.35 (m, 1H), 1.25 (t, J « 6.92, 3H), 0.88 - 0.86 (d, 3H)
1829	480.28	0.99
1830	515.20	1.58
1831	519.12	2.38
1832	541.30	1.72	1H NMR (400 MHz, Methano!-d4) δ 8.65 (d, J = 4.9 Hz, 1H), 8.31 {s, 1H), 8.19 (d, J = 7.9 Hz, 1H), 8.04 (t, J = 7.4 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.60 7.54 (m, 1H), 7.47 {d, J = 2.1 Hz, 1H), 7.32 (d, J = 10.4 Hz, 1H), 7.21 (d, J = 7.9 Hz, 1H), 6.72-6.65 (m, 1H),3.8O (d, J = 6.6 Hz, 2H), 3.09 (dd, J = 16.7, 7.0 Hz, 1H), 2.93 (t, J = 10.3 Hz, 1H), 2.36 (s, 1H), 2.16 - 2.01 (m, 1H), 1.92 (d, J = 6.3 Hz, 1H), 1.63 (s, 6H), 1.55 (t, J = 12.0 Hz, 1H), 1.03 (dd, J = 6.7, 1.9 Hz, 6H), 0.96 {d, J = 6.3 Hz, 3H).
1833	545.23	2.34
1834	459.39	2.54
1835	610.20	2.22	1H NMR {400 MHz, DMSO) δ 12.53 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.55 - 7.48 (m, 2H), 7.46 (d, J = 10.0 Hz, 1H), 7.23 (d, J = 7.3 Hz, 1H), 6.91 (d, J = 10.7 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.46 (s, 2H), 4.19 (d, J = 13.8 Hz, 1H), 3.83 (d, J =

1313

CnnpdA •Νο*«	\|LC/MS A- Μι·1	LC/RTM -mm
			6.5 Hz, 2H), 3.62 {s, 1H), 3.04 (t, J = 12.4 Hz, 1H), 2.66 (s, 1 H}, 2.12 - 1.95 (m, 1H), 1.76 (s, 1H), 1.72 - 1.62 (m, 1H), 1.56 (d, J = 17.7 Hz, 2H), 0.97 (dd, J = 13.9, 6.7 Hz, 10H).
1836	556.00	2.13	1H NMR (400 MHz, DMSO) δ 12.47 (s, 1H), 10.90 (s, 1H), 7.80 (d,J = 7.6 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.49 (s, 2H), 7.41 (d, J = 9.9 Hz, 1H), 7.24 (d, J = 7.9 Hz, 1H), 7.00 (d, J = 8.2 Hz, 2H), 6.88 (d, J = 10.5 Hz, 1H), 3.83 (d, J = 6.6 Hz, 2H), 2.70 (s, 1H), 2.60 (s, 1H), 2.22 (s, 1H), 2.05 (s, 1H), 1.87 (s, 1H), 1.59 (s, 6H), 1.41 (S, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.84 (d, J = 6.2 Hz, 3H).
1837	521.30	1.64
1838	492.40	2.52
1839	486.33	1.53
1840	514.40	2.00	1H NMR (400 MHz, DMSO) δ 12.44 (s, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.50-7.47 (m, 1H), 7.47 - 7.40 (m, 1H), 7.35 {d,J = 8.0 Hz, 1H), 7.20 (dd, J = 7.3, 0.6 Hz, 1H), 6.90 (dt, J = 10.8, 2.3 Hz, 1H), 6.69 (dd, J = 8.4, 0.6 Hz, 1H), 6.46 (s, 2H), 4.45 (d, J = 8.0 Hz, 1H), 3.84 (d, J = 6.6 Hz, 2H), 3.61 - 3.53 (m, 1H), 3.32 (d, J = 6.8 Hz, 1H), 2.38 - 2.26 (m, 1H), 2.05 -1.95 (m, 1H), 1.87 1.80 (m, 1H), 1.38 (d, J = 6.2 Hz, 3H), 1.00-0.95 (m,6H).
1841	500.21	2.37	1H NMR (400 MHz, DMSO) δ 12.81 {s, 1H), 9.83 (s, 1H), 8.15 - 8.13 (dd, 1H), 7.93 - 7.86 (m, 2H), 7.75 - 7.72 {m, 2H), 7.55 -7.52 (d, 1H), 7.26 (t,J = 8.13,1H), 7.12 - 7.09 (d, 1H), 6.99 6.96 (dd, 1H), 6.55 - 6 .52 (dd, 1H), 1.91 (m, 1H), 1.79 - 1.72 (m, 1H), 1.45 (s, 3H), 1.43 (s, 3H), 1.31 (t,J = 12.09, 1H), 0.72-0.70 (d,3H)
1842	495.40	2.60
1843	524.29	1.74
1844	514.30	1.39	1H NMR (400 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.24 (dd, J = 4.8, 1.9 Hz, 1H), 8.18 {d,J = 2.8Hz, 1H), 8.03 (dd,

1314

Cmpd.,	LC/MS	18™®
			J = 7.8, 2.0 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 6.92 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.68 (broad s, 2H), 6.08 (d, J = 2.8 Hz, 1H), 4.95 4.77 (m, 1H), 2.44 (m, 2H partially overlapped with solvent peak), 2.12 {brs, 1H), 1.85 (dd, J = 11.8, 5.6 Hz, 1H), 1.54 (s, 3H), 1.53 (s, 3H), 1.411.38 (m, 1H overlapped with following signal), 1.34-1.31 (m, 6H), 0.74 (d, J = 6.2 Hz, 3H).
1845	538,60	1.32
1846	588.50	1.65
1847	528.26	1.45
1848	511.50	1.53	1H NMR (400 MHz, DMSO-d6) 5 12.56 (s, 1H), 12.53 (d, J = 6.3 Hz, 1H), 8.24 (dd, J = 7.2, 2.2 Hz, 1H), 7.86 - 7.79 (m, 1H), 7.73 - 7.65 (m, 2H), 7.40 - 7.31 (m, 1H), 7.13 (dd, J = 11.0,8.1 Hz, 2H),7.Û4 (t, J = 7.5 Hz, 1H), 6.45 (t, J = 6.9 Hz, 1H), 4.10 (q, J = 6.9 Hz, 2H), 2.77 - 2.71 (m, 2H), 2.24 (s, 1H), 1.86 (dd, J = 11.8, 5.6 Hz, 1H), 1.55 (s, 7H), 1.43 (t, J = 12.2 Hz, 1H), 1.34 (t, J = 6.9 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H).
1849	491.23	1.63
1850	474.30	0.94	1H NMR (400 MHz, DMSO-d6) 5 12.43 (s, 1H), 8.24 (dd,J = 4.8, 1.9 Hz, 1H), 8.03 (dd, J = 7.9, 2.3 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 6.94-6.58 (m, 2H}, 6.77 (dd, J = 7.9, 4.8 Hz, 1H, obscured by previous signal), 6.54 (d, J = 7.8 Hz, 1H), 4.00 - 3.85 (m, 2H), 3.53 - 3.30 (m, 2H), 2.89 - 2.73 (m, 1H), 2.49 - 2.37 (m, 2H), 2.17 - 2.04 (m, 1H), 1.86 -1.61 (m, 5H), 1.52 (s, 6H), 1.36 (t, J = 12.0 Hz, 1H), 0.74 (d, J = 6.3 Hz, 3H).
1851	514.22	1.39	1H NMR (400 MHz, DMSO-d6) δ 12.52 (s, 1H), 8.24 (dd, J = 4.9,1.8 Hz, 1H), 8.04 (dd, J = 7.8,1.8 Hz, 1H), 7.91 - 7.81 (m, 2H), 7.74 (d, J = 8.0 Hz, 1H), 7.29 (t, J = 8.9 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 3.89 (s, 3H), 2.53 (d, J =

1315

Cmpd? WNo. n’	«LC/MS ïi SKriSïï	TLG/RW 4feminÎ4>J
			10.6 Hz, 1H), 2.14 (s, 1H), 2.06 (s, 1H}, 1.85 (dd, J = 11.9, 5.7 Hz, 1H), 1.58 (d, J = 12.2 Hz, 7H), 1.39 (t, J = 12.1 Hz, 1H), 0.75 (d, J = 6.3 HZ,3H).
1852	522.20	1.64	1H NMR (400 MHz, DMSO) δ 12.38 (s, 1H), 7.63 {d, J = 8.0 Hz, 1H), 7.61 7.53 (m, 1H), 7.34 - 7.26 (m, 2H), 7.21 (dd, J = 7.1, 5.5 Hz, 3H), 7.13 (d, J = 7.3 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.36 (s, 1H), 2.80 (d, J = 11.1 Hz, 2H), 2.62 (dd, J = 17.8,11.4 Hz, 1H), 2.54 (s, 1H), 2.37 (dd, J = 27.9, 9.4 Hz, 1H), 2.00 (dd, J = 27.6,18.9 Hz, 1H), 1.57 (s, 5H), 1.48 (s, 3H), 1.28 (s,9H).
1853	528.14	1.59
1854	502.52	1.03
1855	556.20	1.85	1H NMR (400 MHz, DMSO) 5 8.40 (d, J = 8.2 Hz, 1H), 8.18 (d, J = 8.2 Hz, 1H), 7.82 - 7.54 (m, 3H), 7.52 - 7.41 (m, 1H), 7.25 - 7.16 (m, 1H), 6.96 (dd, J = 42.8, 10.7 Hz, 1H), 6.70 (t, J = 8.3 Hz, 1H), 6.37 (s, 1H), 3.86 (dd, J = 12.1, 6.6 Hz, 2H), 3.58 {d, J = 9.5 Hz, 2H), 3.26 {d, J = 11.5 Hz, 1H), 2.82 (dt, J = 24.3, 11.1 Hz, 1H), 2.06 - 1.99 (m, 3H), 1.93 -1.74 (m, 1H), 1.73 - 1.48 (m, 2H), 1.41 -1.27 (m, 2H), 1.01 0.81 (m, 14H).
1856	515.40	1.69
1857	516.23	1.51
1858	515.17	1.58
1859	469.40	1.55	1H NMR (400 MHz, DMSO-d6) δ 13.03 (s, 1H), 8.45 (s, 1H), 8.31 (d, J = 7.3 Hz, 1H), 8.15 (s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.32 (s, 1H), 7.25 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 4.02 (s, 3H), 2.83 - 2.64 (m, 1H), 2.59 - 2.53 (m, 1H, obscured by solvent peak), 2-43 (s, 3H), 2.28 - 2.13 (m, 1H), 1.84 (dd, J = 11.8, 5.8 Hz, 1H), 1.60 (d, J = 3.7 Hz, 6H), 1.37 (t, J = 12.0 Hz, 1H), 0.78 (d, J = 6.2 Hz,3H).
1860	524.25	1.63
1861	497.27	1.58

1316

Cmpd. NoA	LC/MS M+1	LC/RT <
1862	495.40	1.68
1863	556.20	2.01
1864	556.00	1.85
1865	487.30	1.88
1866	511.15	1.33
1867	529.36	1.13
1868	458.40	1.69
1869	514.15	1.45
1870	476.19	2.17
1871	494.60	1.45
1872	500.21	2.64	1H NMR (400 MHz, DMSO-d6) 5 12.70 (S, 1H}, 8.93 (s, 1H), 8.25 8.22 (d, 1H), 8.15 - 8.13 (dd, 1H), 7.88 (t, J = 7.91, 1H), 7.62 - 7.59 (dd, 1H), 7.53 - 7.48 (m, 2H), 7.35 - 7.32 (d, 1H}, 7.27 {t, J = 7.91, 1H), 7.08 (t, J = 7.91,1H), 6.53 - 6.50 (dd, 1H), 2.03 1.94 (m, 1H), 1.82 - 1.75 (m, 1H), 1.46 {S, 3H), 1.45 (s, 3H), 1.33 (t, J = 11.91, 1H), 0.79-0.77 (d,3H)
1873	484.27	0.94
1874	487.30	2.59
1875	518.22	1.47	1H NMR (400 MHz, DMSO-d6) δ 9.28 - 9.26 (dd, 1H), 9.17 - 9.14 (d, 1H), 8.44 - 8.41 (d, 1H), 8.33 (t, J = 7.80, 1H), 8.23-8.22 (d, 1H), 8.14 - 8.12 (dd, 1H), 8.06 - 8.00 (m, 2H), 7.82 7.78 (dd, 1H), 6.75 - 6.72 (d, 1H}, 7.50 - 7.47 (dd, 1H), 6.53 - 6.50 (dd, 1H), 2.33 - 2.22 (m, 1H), 1.88 -1.81 (m, 1H), 1.48 (s, 3H), 1.45 (s, 3H), 1.391.34 (m, 1H), 0.89 - 0.87 (d, 3H)
1876	570.00	2.23	1H NMR (400 MHz, DMSO} 6 12.39 (s, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.47 (s, 1H}, 7.40 (d, J = 10.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.17 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 10.7 Hz, 1H), 3.83 (d, J = 6.7 Hz, 2H), 3.31 (s, 3H), 2.41 (s, 1H), 2.32 (s, 1H), 2.04 (s, 2H), 1.84 (d, J = 11.9 Hz, 1H}, 1.57 (d, J = 18.4 Hz, 6H), 1.38 (s, 1H}, 0.98 (d, J = 6.7 Hz, 6H), 0.65 (d, J = 6.2 Hz, 3H).
1877	549.43	1.81
1878	527.20	1.47

1317

Gmpd. Y No. <:	LC/MS •M+1 <	LG/RT ....., - <mm
1879	537.43	1.63
1880	511.14	1.59
1881	445.28	2.38
1882	591.60	1.39	IH NMR (400 MHz, DMSO-d6) 5 12.41 (s, IH), 7.74 - 7.66 (m, IH), 7.66 - 7.59 (m, IH), 7.18 (dd, J = 7.2, 2.5 Hz, IH), 6.88 (d, J = 8.1 Hz, IH), 6.82 (s, IH), 6.69 (dd, J = 10.1, 8.0 Hz, IH), 4,19 (q, J = 18.4,17.6 Hz, 2H), 3.35 (t, J = 5.7 Hz, 2H), 2.95 (t, J = 6.8 Hz, 2H), 2.54 (d, J = 8.8 Hz, IH), 2.41 (s, 2H), 2.12 (dq, J = 13.4, 6.7 Hz, IH), 1.85 (ddj = 11.7, 5.7 Hz, IH), 1.53 (d, J = 7.3 Hz, IH), 1.51 (s, 3H), 1.39 1.33 (m, IH), 1.17 (t, J = 7.3 Hz, IH}, 1.05 (s, IH), 1.03 (s, 3H), 1.01 (s, 3H), 0.99 - 0.92 (m, IH], 0.89 {t, J = 3.1 Hz, IH), 0.86 (d, J = 6.3 Hz, 3H).
1883	562.40	1.54
1884	473.19	2.73
1885	556.00	2.04	IH NMR (400 MHz, DMSO) 8 12.48 (s, IH), 10.18 (s, IH), 7.71 (d, J = 8.1 Hz, IH), 7.44 (d, J = 25.5 Hz, SH), 7.26 (d, J = 8.0 Hz, IH), 7.07 (d, J = 7.7 Hz, IH), 6.89 (d, J = 10.6 Hz, IH), 3.83 (d, J = 6.6 Hz, 2H), 2.39 (s, IH), 2.08 (d, J = 42.4 Hz, 2H), 1.84 (s, IH), 1.58 (d, J = 17.2 Hz, 6H), 1.39 (s, IH), 0.98 (d, J = 6.7 Hz, 6H), 0.72 (d, J = 6.2 Hz, 3H).
1886	497.27	1.36
1887	535.40	1.59	IH NMR (400 MHz, DMSO-d6) δ 12.45 (S, IH), 8.23 (d, J = 3.7 Hz, IH), 8.19 (d, J = 2.8 Hz, IH), 8.02 (dd, J = 7.8,1.9 Hz, IH), 7.83 (d, J = 8.3 Hz, IH), 6.93 (d, J = 8.2 Hz, IH), 6.76 (dd, J = 7.8,4.8 Hz, IH), 6.68 (broad s, 2H), 6.12 (d, J = 2.8 Hz, IH), 3.97 (s, 2H), 2.46 (d, J = 7.8 Hz, 2H), 2.20 2.02 (br m, IH), 1.85 (dd,J = 11.9, 5.6 Hz, IH), 1.55 (s, 3H), 1.53 (s, 3H), 1.38 (t, J = 12.2 Hz, IH), 0.74 (d, J = 6.3 Hz, 3H).
1888	482.30	1.59	IH NMR (400 MHz, DMSO-d6) 68.03 (t, J = 2.5 Hz, IH), 7.47 (dd, J « 4.0, 2.5 Hz, IH), 7.40 (t, J =7.7 Ηζ,ΙΗ),

1318

Gmpd.’' ^; No.^;>	LC/MS\ Ç M+1<
			7.01 (d, J = 7.3 Hz, 1 H), 6.42 (d, J = 8.1 Hz, 1H), 6.08 (d, J = 3.1 Hz, 1H), 6.01 (s, 2H), 2.97 (ddd, J = 31.6,19.5,11.1 Hz, 3H), 2.09 (d, J = 15.9 Hz, 1H), 1.85 - 1.63 {m, 3H), 1.48 (dt, J = 4.5, 2.5 Hz, 7H), 1.43 -1.25 (m, 2H), 1.25 0.91 (m, 3H), 0.85 (d, J = 6.3 Hz,3H).
1889	S38.34	1.78	1H NMR (400 MHz, DMS0-d6) δ 12.44 (s, 1H), 8.50 (d, J = 2.4 Hz, 1H), 7.89 (d, J « 2.5 Hz, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 7.3 Hz, 1H), 7.00 (d, J = 17.8 Hz, 2H), 6.87 - 6.58 (m, 2H), 6.48 (S, 2H), 4.69 (p, J = 6.1 Hz, 1H), 2.33 (s, 3H), 2.20 (s, 1H), 1.85 (dd, J = 11.9, 5.7 Hz, 1H), 1.54 {d, J = 7.2 Hz, 6H), 1.40 (t, j = 12.0 Hz, 1H), 1.28 (d, J = 6.0 Hz, 6H), 0.86 (d, J = 6.3 Hz, 3H).
1890	581.20	1.76	ÎH NMR (400 MHz, DMS0-d6J δ 12.39 (s, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 7.9 Hz, 1H), 7.24 (d, J = 7.3 Hz, 1H), 7.21 7.14 (m, 4H), 7.14 - 7.07 (m, 1H), 6.84 (dt, J = 10.6, 2.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 4.61 (s, 1H), 3.61 (s, 2H), 2.07 (s, 1H), 2.06 (s, 6H), 1.19 (s, 6H).
1891	536.50	1.35	1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 7.66-7.55 (m, 2H), 7.17 (dd, J = 7.3, 0.7 Hz, 1H), 6.66 {dd, J = 8.4, 0.8 Hz, 1H), 6.44 (s, 2H), 5.03 (dt, J = 10.8, 6.2 Hz, 1H), 3.86 {s, 2H), 3.28 (dd, J = 12.8, 10.6 Hz, 2H), 2.63 -2.51 (m, 1H), 2.43 (t, J = 8.8 Hz, 1H), 2.19 (dq, J = 11.9, 6.2 Hz, 1H), 1.83 (dd, J = 12.0, 5.9 Hz, 2H), 1.72 1.51 (m, 2H), 1.51 (s, 3H}, 1.47 1.19 (m,9H), 0.85 (d,J = 6.3 Hz, 3H).
1892	494.20	2.42
1893	563.60	2.26
1894	552.39	1.98
1895	528.20	1.52	1H NMR (400 MHz, DMSO-d6) δ 12.48 (s, 1H), 8.24 (d, J = 4.8 Hz, 1H), 8.02 (dd, J = 7.9,1.9 Hz, 1H), 7.92 (d, J = 1.0 Hz, 1H), 7.83 {d, J = 8.2 Hz,

1319

CmpdjÎi No.	LC/MS M+1	/LC/RT-z i min
			1H), 7.69 {d, J = 0.9 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 6.76 (dd, J = 7.8, 4.8 Hz, 1H), 6.67 (dd,J = 7.7, 4.8 Hz, 1H), 3.74 (d, J = 6.4 Hz, 2H), 2.14 (s, 1H), 2.01 (dt, J = 13.3, 6.6 Hz, 1H), 1.86 (dd, J = 11.9, 5.6 Hz, 1H), 1.56 (d, J = 5.3 Hz, 6H), 1.39 (t, J = 12.1 Hz, 1H), 0.96 (d, J = 6.7 Hz, 6H), 0.75 (d, J = 6.3 Hz, 3H).
1896	529.30	1.80	1H NMR (400 MHz, DMS0-d6) δ 12.52 (s, 2H), 8.23 (d, J = 7.2 Hz, 1H), 8.19 (d, J = 2.5 Hz, 1H), 7.87 - 7.72 (m, 2H), 6.88 (d, J = 8.3 Hz, 1H), 6.44 (broad t, 1H), 6.11 (d, J = 2.6 Hz, 1H), 3.98 (d, J = 6.6 Hz, 2H}, 2.72-2.70 (m , 2H), 2.22 (br s, 1H), 2.05 (sep, J = 8.0 1H), 1.88 (dd, J = 11.8, 5.5 Hz, 1H), 1.56 (s, 3H), 1.55 {s, 3H), 1.43 (t, J = 12.1 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.89 (d, J = 6.3 Hz, 3H).
1897	516.36	1.50
1898	480.10	2.33
1899	533.22	2.84
1900	526.30	1.59
1901	570.50	2.10	1H NMR (400 MHz, DMSO) δ 12.55 (s, 1H}, 7.71 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.3,7.4 Hz, 1H), 7.50 (d, J = 1.9 Hz, 1H), 7.47 - 7.38 (m, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.24 - 7.17 (m, 1H), 6.88 (dt, J = 10.7, 2.3 Hz, 1H), 6.73 - 6.67 (m, 1H), 6.48 (s, 2H), 3.84 (d, J = 6.6 Hz, 2H), 3.60 (s, 2H), 3.16 (t, J = 5.9 Hz, 2H), 2.09 -1.99 (m, 1H), 1.55 (d, J = 4.7 Hz, 2H), 1.45 (s, 2H), 1.35 -1.25 (m, 2H), 0.99 (d, J = 6.7 Hz, 6H), 0.83 (s, 6H).
1902	509.21	2.59
1903	524.34	1.50	1H NMR (400 MHz, DMSO) δ 12.51 (s, 1H), 8.25 (dd,J = 4.8,1.8 Hz, 1H), 8.05 (dd, J = 7.8, 1.7 Hz, 1H), 7.98 (d, J = 8.9 Hz, 2H), 7.74 (d,1 = 8.0 Hz, 1H), 7.17 (d, J = 8.1 Hz, 1H), 7.02 (d, J = 8.9 Hz, 2H), 6.78 (dd, J = 7.8, 4.8 Hz, 1H), 4.69 (dt, J = 12.0, 6.0 Hz, 1H), 2.57 - 2.51 (m, 2H), 2.15 (s, 1H), 1.85 (dd, J = 11.8, 5.6 Hz, 1H), 1.60 (s, 3H),

1320

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			1.58 (s, 3H), 1.40 (t, J = 12.1 Hz, 1H), 1.29 {s, 3H), 1.28 (s, 3H), 0.76 (d, J = 6.3 Hz, 3H).
1904	533.31	1.12
1905	494.20	2.32	1H NMR (400 MHz, DMSO) 6 12.41 (s, 1H), 8.19 - 8.15 (m, 1H), 7.80 - 7.77 (d, 1H), 7.63 - 7.54 (m, 1H), 7.45 7.42 (d, 2H), 7.33 - 7.06 (m, 4H), 6.75 - 6.53 (m, 2H), 5.14 - 5.12 (d, 1H), 2.21 (t, J = 10.66,1H), 1. 88 -1.81 (m, 1H), 1.72 - 1.65 (m, 1H), 1.52 -1.43 (m, 9H), 1.22 (t, J = 11.65,1H), 0.85 0.83 (d, 1H), 0.56-0.54 (d,2H)
1906	534.12	2.82
1907	552.50	1.08
1908	473.19	2.70
1909	506.21	2.75	1H NMR (400 MHz, DMSO) δ 12.71 (s, 1H), 9.45 (s, 1H), 8.15 - 8.13 (dd, 1H), 7.83 - 7.70 (m, 3H), 7.47 - 7.44 (dd, 1H), 7.42-7.39 (d, 1H), 7.10 - 7.07 (d, 1H), 7.05 - 7.02 (d, 1H), 6.52 - 6.49 (dd, 1H), 2.80 - 2.61 (m, 3H), 1.96 1.90 (m, 2H), 1.75 - 1.69 (m, 2H), 1.45 (s, 3H), 1.40 (S, 3H), 1.29 (t, J = 11.91, 1H), 0.72-0.70 (d, 3H)
1910	498.23	1.63
1911	460.40	1.34
1912	512.40	1.82	1H NMR (400 MHz, DMSO) δ 12.49 (s, 1H), 8.02 - 7.97 (m, 2H), 7.92 (d, J = 1.0 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 7.76 - 7.71 (m, 1H), 7.70 - 7.63 (m, 3H), 7.04 (d, J « 8.3 Hz, 1H), 3.73 (d, J = 6.4 Hz, 2H), 2.43 (t, J = 10.4 Hz, 1H), 2.34 - 2.25 (m, 1H), 2.10 (dq, J = 12.0, 6.1 Hz, 1H), 2.01 (dq, J = 13.3,6.7 Hz, 1H), 1.88 - 1.79 (m, 1H), 1.54 (d, J = 8.1 Hz, 6H), 1.38 {t, J = 12.1 Hz, 1H), 0.96 (d, J = 6.7 Hz, 6H), 0.66 (d, J = 6.3 Hz, 3H).
1913	533.31	1.09	1H NMR (400 MHz, DMSO) δ 12.67 (s, 1H), 12.54 (s, 1H), 8.88 (d, J = 1.7 Hz, 1H), 8.42 (d, J = 2.8 Hz, 1H), 8.25 (dd, J = 7.3, 2.2 Hz, 1H), 8.04 (d,J = 1.7 Hz, 1H), 7.83 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 6.49 -

1321

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			6.42 (m, 1H), 3.93 (s, 3H), 2.73 (tï, J = 16.6, 8.3 Hz, 2H), 2.25 (d, J = 4.1 Hz, 1H), 1.90 (dd, J = 12.0, 5.5 Hz, 1H), 1.61 (d, J = 2.4 Hz, 6H), 1.46 {t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
1914	533.31	1.18
1915	552.30	1.63	1H NMR (400 MHz, DMSO) δ 8.72 (d, J = 2.5 Hz, 1H), 8.01 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 6.98 (dd, J = 13.6, 7.5 Hz, 2H), 6.45 (d, J = 8.1 Hz, 1H), 6.11 (s, 2H), 3.23 (q, J = 6.8 Hz, 4H), 3.04 2.88 (m, 2H), 2.27 (d, J = 5.1 Hz, 3H), 2.12 (qd, J = 12.2,11.5, 5.2 Hz, 1H), 1.83 -1.75 (m, 1H), 1.62 (s, 2H), 1.57 (s, 2H), 1.35 (d, J = 11.9 Hz, 1H), 1.05 (t, J = 6.9 Hz, 6H), 0.84 (d, J = 6.3 Hz, 4H).
1916	472.30	1.70
1917	495.40	2.60
1918	550.38	1.88
1919	501.41	3.02
1920	500.50	1.44
1921	534.25	1.75
1922	498.50	1.67
1923	510.16	1.36
1924	511.31	2.48
1925	485.50	1.56
1926	523.32	2.90
1927	497.40	1.40	1H NMR (400 MHz, DMS0-d6) δ 12.59 (S, 1H), 12.53 (s, 1H), 8.2S (dd, J = 7.3, 2.2 Hz, 1H), 7.83 (s, 1H), 7.75 {d, J = 7.9 Hz, 1H), 7.66 - 7.57 (m, 2H), 7,40 (t, J = 7.9 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.05 - 6.96 (m, 1H), 6.45 (t, J = 6.8 Hz, 1H), 3.82 (s, 3H), 2.79 - 2.65 (m, 2H), 2.30 - 2.17 (m, 1H), 1.89 (dd, J = 11.9, 5.5 Hz, 1H), 1.62 (d,J = 1.7 Hz, 6H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
1928	528.40	2.25
1929	549.13	2.85
1930	498.23	1.65
1931	538.40	2.65
1932	472.29	2.49

1322

Cmpd. No.	LG/MS M+1	LC/RT min	NMR
1933	51732	1.70
1934	551.50	1.82	1H NMR (400 MHz, DMSO-d6) S 12.64 (s, 1H), 12.56-12.50 (m, 1H), 8.28 - 8.21 (m, 1H), 8.10 - 8.02 (m, 2H), 7.83 (t, J = 63 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 8.0 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 6.45 (t, J = 6.7 Hz, 1H), 2.81 2.65 (m, 2H), 2.25 (s, 1H), 1.90 (dd, J = 12.2, 5.5 Hz, 1H), 1.60 (d, J = 3.6 Hz, 6H), 1.45 (t, J = 12.2 Hz, 1H), 0.91 (d, J = 6.2 Hz, 3H).
1935	548.60	1.72
1936	473.19	2.85
1937	545.23	1.42
1938	480.10	2.21
1939	489.10	2.19
1940	524.52	2.48
1941	518.22	2.63
1942	618.70	1.47
1943	554.34	1.46
1944	498.53	1.05
1945	510.31	1.42
1946	499.50	1.60
1947	494.28	1.44
1948	569.30	1.49
1949	508.31	2.00
1950	534.28	1.80
1951	494.57	1.10
1952	542.60	1.99	1H NMR (400 MHz, DMS0-d6) 8 1235 (s, 1H), 8.20 (d, J = 2.8 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.62 (broad s, 1H), 7.18 (d, J = 7.0 Hz, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.50 (br s, 2H), 6.13 (s, 1H), 3.89 (s, 2H), 2.59 (br s, 2H), 2.20 (br $, 1H), 1.93 -1.82 (m, 1H), 1.56 (s, 3H), 1.55 (s, 3H), 1.41 (t, J = 12.1 Hz, 1H), 1.00 (s, 9H), 0.88 (d, J = 63 Hz, 3H).
1953	549.43	2.72
1954	503.30	1.52
1955	521.22	2.49
1956	569.50	2.27
1957	502.31	2.10
1958	466.28	1.33

1323

Cmpd. Ne.	LC/MS M+1	LC/RT min	NMR
1959	496.60	2.30
1960	535.30	1.53	1H NMR (400 MHz, DMSO-d6) δ 12.63 (s, 1H), 12.55 (d, J = 4.9 Hz, 1H), 8.25 (dd, J - 7.3, 2.1 Hz, 1H), 7.88 - 7.78 (m, 2H}, 7.76 - 7.71 (m, 2H), 7.64 (t, J - 7.6 Hz, 1H), 7.4S (d, J = 7.4 Hz, 1H), 6.59 (d, J = 7.8 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 2.78 - 2.65 (m, 2H), 2.28 - 2.14 (m, 1H), 1.82 (dd, J = 11.8, 5.6 Hz, 1H), 1.4S - 1.35 (m, 7H), 0.90 (d,J = 6.3 Hz, 3H).
1961	553.20	2.26
1962	496.28	0.92
1963	514.21	1.82
1964	524.25	1.54
1965	511.31	2.52
1966	520.40	1,80	1H NMR (400 MHz, DMSO-d6) δ 12.23 (s, 1H), 7.66 - 7.54 (m, 2H), 7.17 (d, J = 7.3 Hz, 1H), 6.66 (d, J = 8,4 Hz, 1H), 6.44 (s, 1H), 5.09 (td, J = 6.4, 3.8 Hz, 1H), 2.59 - 2.51 (m, 1H), 2.43 (dd, J = 10.7, 5.8 Hz, 1H), 2.15 (dt, J = 16.6, 8.6 Hz, 3H), 1.83 (dd, J = 11.9, S.5 Hz, 1H), 1.70 (d, J = 11.9 Hz,2H), 1.52 (d, J = 17.4 Hz, 7H), 1.44 (d, J = 4.6 Hz, 3H), 1.38 (d, J = 12.1 Hz, 1H), 1.28 (d, J = 6.1 Hz, 2H), 1.23 (d, J = 6.2 Hz, 2H), 0.85 (d, J = 6,3 Hz, 3H).
1967	490.32	1.50
1968	548.23	2.62
1969	538.40	2.66	1H NMR (400 MHz, DMSO-dG) δ 12.43 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.62 (q, J = 7.4, 6.9 Hz, 3H), 7.38 (t, J = 7.9 Hz, 1H), 7.21 (dd, J = 7.6, 5.4 Hz, 2H), 7.00 (dd, J = 8.2, 2.3 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.48 (s, 1H), 3.81 (d, J = 6.6 Hz, 2H), 2.64-2.57 (m, 2H), 2.22 (dt, J = 13.4,7.1 Hz, 1H), 2.04 (dq, J = 13.4, 6.7 Hz, 1H), 1.88 (dd, J = 11.9, 5.6 Hz, 1H), 1.62 (s, 3H), 1.61 (s, 3H), 1.42 (t, J = 12.0 Hz, 1H), 0.99 (d, J = 6.7 Hz, GH), 0.88 (d, J = 6.2 Hz, 3H).
1970	528.40	1.62
1971	528.42	2.68

1324

Cmpd. No.	LC/MS	LC/RT min	NMR sih.
1972	51131	2.45
1973	S83.70	1.68
1974	472.50	1.58	1H NMR (400 MHz, DMSO) 5 12.35 (s, 1H), 7.58 (d, J = 7.1 Hz, 2H), 7.14 (d, J = 7.1 Hz, 1H}, 6.77 - 6.56 (m, 2H), 6.42 (s, 2H), 2.79 (s, 1H), 2.66 (dd, J = 12.3,10.5 Hz, 1H), 1.69 (d, J = 20.9 Hz, 2H), 1.56 (s, 3H), 1.51 (s, 3H), 1.27 (s, 9H), 1.17 -1.05 (m, 1H), 0.73 0.63 (m, 1H), 0.58 - 0.47 (m, 1H), 0.40 (dd, J = 8.2, 3.9 Hz, 1H), 0.24 (dd, J = 9.0, 4.1 Hz, 1H), 0.07 (dd, J = 9.0, 4.0 Hz, 1H).
1975	542.30	1.65	1H NMR (400 MHz, DMSO-d6) δ 12.45 (s, 1H), 8.24 (dd, J = 4.7,1.9 Hz, 1H), 8.20 (d, J = 2.8 Hz, 1H), 8.03 (dd, J = 7.8,1.9 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.69 (broad s, 2H), 6.14 (d, J = 2.7 Hz, 1H), 3.89 (s, 2Hf, 2.45 (d, J = 8.9 Hz, 2H), 2.12 (br s, 1H), 1.85 (dd,J = 11.9, 5.4 Hz, 1H), 1.55 {s, 3H), 1.53 (s, 3H), 1.43 - 1.33 (m, 1H), 1.00 (s, 9H), 0.74 (d, J = 6.2 Hz, 3H).
1976	567.00	2.19	1H NMR (400 MHz, DMSO-d6) δ 8.85 (S, 1H), 8.67 (d, J = 4.7 Hz, 1H), 8.43 (d, J = 7.9 Hz, 1H), 8.30 (d, J = 9.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.53 7.42 (m, 1H), 7.28 (d,J = 8.0 Hz, 1H}, 6.87 (d, J = 8.7 Hz, 1H), 5.31 (p, J = 6.3 Hz, 1H), 2.41 (S, 2H), 2.25 (s, 3H), 2.18 (dt, J = 16.2, 7.6 Hz, 1H), 1.88 (dd, J = 12.1, 5.8 Hz, 1H), 1.55 (d, J = 4.4 Hz, 6H), 1.42 (t, J = 12.0 Hz, 1H), 1.31 (d, J = 6.1 Hz, 6H), 0.74 (d, J = 6.3 Hz, 3H).
1977	550.33	2.61
1978	508.31	2.63
1979	538.30	1.77
1980	497.20	1.30
1981	521.61	1.73
1982	506.25	1.26
1983	514.31	2.67
1984	609.60	1.41
1985	529.32	1.98
1986	542.23	2.86

1325

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
1987	534.12	2.79
1988	487.30	2.88
1989	518.22	2.19
1990	495.40	1.54	IH NMR (400 MHz, DM$0-d6) δ 12.59 (s, IH), 12.53 (d, J = 6.3 Hz, IH), 8.25 (dd, J = 7.3, 2.2 Hz, IH), 7.82 (dt, J = 6.5, 3,4 Hz, IH), 7.72 (d, J = 7.8 Hz, IH), 7.19 - 7.06 (m, 3H), 6.64 (d, J = 7.8 Hz, IH), 6.45 (t, J = 6.8 Hz, IH), 2.79 - 2.69 (m, 2H), 2.29 (s, 3H), 2.24 (S, 4H), 1.84 (dd, J = 11.9, 5.7 Hz, IH), 1.49 (d, J = 6.2 Hz, 6H), 1.41 (t, J = 12.0 Hz, IH), 0.91 (d, J = 6.3 Hz, 3H).
1991	508.32	1.12
1992	487.30	2.39
1993	556.00	1.85
1994	526.18	1.38
1995	570.20	1.86
1996	500.51	2.65
1997	497.50	1.07	IH NMR (400 MHz, DMSO-d6) δ 7.94 (s, IH), 7.87 (d, J = 7.9 Hz, IH), 7.84 7.74 (m, IH), 7.66 - 7.53 (m, IH), 7.39 {t, J = 7.7 Hz, IH), 7.29 (d, J = 7.6 Hz, IH), 6.97 (d, J = 7.7 Hz, IH), 6.19 5.99 (m, IH), 5.26 - 5.08 (m, IH), 4.54 (s, 2H), 3.18 - 3.09 (m, IH), 3.05 (t, J = 10.8 Hz, IH), 2.20 - 2.08 (m, IH), 1.81 (dd, J = 11,2, 5.6 Hz, IH), 1.60 (d, J = 16.0 Hz, 6H), 1.37 (t, J = 11.9 Hz, IH), 0.86 (d, J = 6.2 Hz, 3H),
1998	532.16	1.49	IH NMR (400 MHz, DMSO-d6) 3 12.51 (s, IH), 8.26 (dd, J = 4.8, 1.9 Hz, IH), 8.07 (dd, J = 7.9,1.8 Hz, IH), 7.80 (dd, J = 8.0, 1.7 Hz, IH), 7.76 7.59 (m, 2H), 7.34 (dd, J = 8.0,1.7 Hz, IH), 6.90 - 6.65 (m, 3H), 3.96 (d, J = 1.6 Hz, 3H), 2.16 (s, IH), 1.86 (dd, J = 11.9, 5.6 Hz, IH), 1.61 (s, 3H), 1.58 (s, 3H), 1.41 (t, J = 12.2 Hz, IH), 0.76 (d, J = 6.4 Hz, 3H).
1999	496.19	1.21
2000	499.40	1.55
2001	499.31	2.89
2002	552.40	1,87	IH NMR (400 MHz, DMSO-d6) δ 7.58

1326

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			(s, 1H), 7.52 - 7.33 (m, 2H), 7.25 (s, 1H), 7.02 (s, 1H), 6.43 (d,J = 22.8 Hz, 2H), 6.11 (S, 2H), 3.55 (q, J = 7.0 Hz, 4H), 3.09 - 2.90 (m, 2H), 2.26 (s, 3H), 2.19-2.05 (m, 2H), 1.82 (dd, J = 12.1, 5.7 Hz, 1H), 1.63 (s, 3H), 1.59 (s, 3H), 138 (t, J = 12.0 Hz, 1H), 1.15 (t, J = 6.9 Hz, 6H), 0.85 (d, J = 6.4 Hz, 3H).
2003	506.21	2.00
2004	486.40	2.18
2005	509.21	1.46
2006	532.16	1.46
2007	517.15	1.70
2008	528.21	1.28
2009	682.20	2.26
2010	553.40	2.43	1H NMR (400 MHz, DMSO-d6) δ 12.48 (S, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.41 (s, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.2 Hz, 1H), 7.16 (s, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 4.05 (d, J = 6.7 Hz, 2H), 2.60 (q, J = 10.6, 8.9 Hz, 2H), 2.44 (s, 3H), 2.28 - 2.12 (m, 1H), 2.05 (dp, J = 13.3, 6.6 Hz, 1H), 1.88 (dd, J = 11.9, 5.6 Hz, 1H), 1.61 (s, 3H), 1.59 (s, 3H), 1.42 (t, J = 12.1 Hz, 1H), 0.97 (d, J = 6.7 Hz, 6H), 0.88 (d, J = 6.2 Hz, 3H).
2011	512.51	2.69
2012	524.52	2.10
2013	511.31	2.08
2014	560.25	1.88	1H NMR (400 MHz, DMSO-d6) Ô 12.47 (s, 1H), 8.42 (d, J = 2.4 Hz, 1H), 7.96 (d, J = 2.4 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.70 (d, J = 83 Hz, 2H), 7.67 7.61 (m, 1H), 737 (d,J = 16.5 Hz, 1H), 7.22 (d, J = 7.1 Hz, 1H), 7.19 (d, J = 16.5 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.54 (s, 2H), 2.69 - 2.59 (m, 1H), 2.59 - 2.52 (m, 1H), 2.29 - 2.11 (m, 1H), 1.85 (dd, J = 11.9, 5.6 Hz, 1H), 1.53 (s, 6H), 138 (d, J = 12.1 Hz, 1H), 0.86 (d, J = 6.3 Hz, 3H).
2015	485.20	231
2016	49032	1.47
2017	49431	1.52

1327

Cmpd. No.	LC/MS M+1	lc/rt^ « # mm ; ?	NMR
2018	528.19	1.54
2019	515.51	3.21
2020	49430	1.64	1H NMR (400 MHz, DMS0-d6) δ 12.25 (s, 1H), 7.66 - 7.55 (m, 2H), 7.17 (dd, J = 7.3, 0.7 Hz, 1H), 6.66 (dd, J = 8.4,0.7 Hz, 1H}, 6.44 (s, 2H), 5.02 (p, J = 6.2 Hz, 1H), 2.56 (d, J = 10.6 Hz, 1H), 2.44 (t, J = 8.7 Hz, 1H), 2.25 - 2.15 (m, 1H), 1.88 (ddq, J = 24.1,11.8, 6.1, 5.5 Hz, 2H), 1.51 (s, 3H}, 1.44 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 1.24 (d, J = 6.4 Hz, 3H), 0.89 (dd, J = 6.8,4.5 Hz, 6H), 0.85 (d, J = 6.3 Hz, 3H).
2021	511.18	1.33
2022	472.50	1.55	1H NMR (400 MHz, CDCI3) δ 15.20 (s, 1H), 8.47 (d, J = 8.2 Hz, 1H), 7.66 7.58 (m, 1H), 7.41 (dd, J = 12.8,7.7 Hz, 2H), 7.12 (d, J = 8.6 Hz, 1H), 4.23 (s, 1H), 3.83 (d, J = 6.6 Hz, 1H), 2.53 2.37 (m, 1H), 2.22-2.03 (m, 1H), 1.80 (dd, J = 18.4, 9.3 Hz, ÏH), 1.56 (s, 3H), 1.27 (d, J = 13.6 Hz, 9H), 1.25 -1.16 (m, 3H), 0.70 (d, J = 4.1 Hz, 1H), 0.53 (d, J = 7.6 Hz, 2H), 0.15 (s,2H).
2023	542.23	2.65
2024	488.20	2.49
2025	474.99	2.98
2026	472.29	1.98
2027	613.50	1.72	1H NMR (400 MHz, DMS0-d6) δ 12.26 (s, 1H), 7.66 - 7.57 (m, 1H), 7.29 (s, 1H), 7.18 (d, J = 7.2 Hz, 1H), 6.67 (d, J = 8.3 Hz, 1H), 6.46 (s, 2H), S.54 (S, 1H), 4.82 (h, J = 6.1 Hz, 1H), 4.12 - 3.84 (m, 2H), 3.67 - 3.51 (m, 2H), 2.56 (d, J = 10.5 Hz, 1H), 2.41 2.24 (m, 2H), 2.24 - 2.11 (m, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.54 (s, 3H), 1.52 (s, 3H), 1.41 -1.32 (m, 2H), 1.31 (s, 9H), 1.23 (d, J = 6.3 Hz, 3H), 1.21 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H).
2028	501.30	1.62
2029	542.29	1.62
2030	472.29	2.57

132S

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2031	496.24	1.57
2032	489.40	2.07
2033	514.21	1.40
2034	496.60	1.57
2035	520.17	1.49
2036	512.50	1.56	1H NMR (400 MHz, DMSO-d6) 5 12.48 (broad s, 1H), 8.27 (d, J = 2.5 Hz, 1H), 8.25 (dd, J = 4.8,1.9 Hz, 1H), 8.03 (dd, J = 7.8,1.9 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.08 (d, J = 8.2 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.69 (br s, 2H), 6.41 (d, J = 2.6 Hz, 1H), 2.52 (likely d, 2H, partially overlapped with DMSO), 2.46 (d, J = 8.8 Hz, 2H), 2.13 (br m, 1H), 1.95 (dt, J =13.5, 6.8 Hz, 1H), 1.85 (dd, J = 12.0, 5.6 Hz, 1H), 1.56 (s, 3H), 1.54 (s, 3H), 1.39 (t, J = 12.1 Hz, 1H), 0.93 (d, J = 2.2 Hz, 3H), 0.92 (d, J = 2.1 Hz, 3H), 0.74 (d, J = 6.3 Hz, 3H).
2037	495.40	1.55
2038	501.41	2.98
2039	553.40	2.25	1H NMR (400 MHz, DMSO) δ 12.55 (s, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.68 - 7.60 (m, 1H), 7.56 (s, 1H), 7.49 (d, J = 9.6 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 7.01 - 6.84 (m, 1H), 6.72 (d, J = 8.4 Hz, 1H}, 6.55 (s, 2H), 5.62 (d, J = 1.7 Hz, 1H), 3.85 (d, J = 6.6 Hz, 2H), 2.66 (ddd, J = 14.3, 7.4,1.8 Hz, 1H), 2.03 (dd, J = 13.2, 6.6 Hz, 1H), 1.95 (dd, J = 12.1, 7.5 Hz, 1H), 1.38 -1.28 (m, 4H), 1.25 (s, 3H), 0.99 (d, J = 6.7 Hz, 6H), 0.93 (d, J = 6.9 Hz, 3H).
2040	534.22	1.01
2041	526.02	2.29	1H NMR (400 MHz, DMSO) δ 12.56 (s, 1H), 9.42 (S, 1H), 8.15-8.13 (dd, 1H), 7.78 (t, J = 7.80,1H), 7.67 - 7.64 (d, 1H), 7.42 - 7.37 (m, 2H), 7.33 7.30 (dd, 1H), 7.0 - 6.97 (d, 1H), 6.83 6.80 (d, 1H), 6.53 - 6.50 (dd, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 1.99 - 1.94 (m, 1H), 1.80 - 1.73 (m, 1H), 1.51 (s, 3H), 1.46 (s, 3H), 1.32 (t, J = 11.91,

1329

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			1H), 0.77-0.74 (d, 3H)
2042	533.50	1.47
2043	496.30	1.53	1H NMR (400 MHz, DMSO-d6) δ 12.51 (S, 1H), 11.99 (s, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.21 (d, J = 7.3 Hz, 1H), 6.76 - 6.65 (m, 3H), 2.68 (d, J = 8.7 Hz, 2H), 2.27 (s, 3H), 2.32 - 2.14 (m, 1H), 2.07 (s, 2H}, 1.90 (dd, J = 11.9, 5.6 Hz, 1H), 1.52 (d, J = 3.1 Hz, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.88 (d, J = 6.3 Hz, 3H).
2044	458.18	2.35
2045	476.25	1.38
2046	500.18	1.40
2047	516.40	1.23	1H NMR (400 MHz, Methanol-d4) δ 8.26 - 8.11 (m, 2H), 7.89 (dd, J = 12.7, 7.8 Hz, 1H), 6.90 - 6.73 (m, 2H), 3.28 3.13 (m, 1H), 3.07 - 2.93 (m, 1H), 2.92 - 2.75 (m, 1H), 2.57 - 2.40 (m, 1H), 2.09 -1.96 (m, 1H), 1.94 - 1.81 (m, 1H), 1.77 - 1.35 (m,12H), 1.17-0.89 (m,9H).
2048	534.22	1.08
2049	544.33	2.68
2050	502.33	1.44	1H NMR (400 MHz, DMSO) δ 12.06 (s, 1H), 8.15 (s, 3H), 7.73 (dd, J = 7.7,1.8 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.40 7.34 (m, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 7.8 Hz, 1H), 7.09 - 7.03 (m, 1H), 4.11 (q, J = 7.0 Hz, 2H), 3.88 3.79 (m, 1H), 3.76 (dd, J = 10.2,6.6 Hz, 1H), 3.72 - 3.62 (m, 1H), 3.58 (dd, J = 15.0, 8.8 Hz, 1H), 3.41 (dd, J = 10.2, 4.8 Hz, 1H), 3.09 (t, J = 10.1 Hz, 1H), 2.98-2.89 (m, 1H), 2.35 (dd, J = 10.9, 5.8 Hz, 1H), 2.28 - 2.16 (m, 1H), 1.96 (ddd, J = 17.2,12.6, 6.5 Hz, 2H), 1.61 (s, 3H), 1.58 (s, 3H), 1.52 (d, J = 12.1 Hz, 1H), 1.34 (t, J = 6.9 Hz, 3H), 1.04 (d, J = 6.3 Hz, 3H).
2051	529.36	1.13	1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 12.53 (s, 1H), 8.25 (dd, J = 7.3, 2.2 Hz, 1H), 7.82 (s, 1H), 7.70 (d, J =

1330

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			8.0 Hz, 1H), 7.49 (dd, J = 9.9, 3.2 Hz, 1H), 7.25 - 7.17 (m, 2H), 7.14 (dd, J = 9.1, 4.7 Hz, 1H), 6.49 - 6.42 (m, 1H), 4.09 (q, J = 7.0 Hz, 2H), 2.81 - 2.68 (m, 2H), 2.23 (s, 1H), 1.87 (dd, J = 11.8, 5.5 Hz, 1H), 1.55 (s, 6H), 1.43 (t, J = 12.1 Hz, 1H), 1.34 (t, J = 6.9 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H).
2052	498.53	1.08
2053	458.49	2.14
2054	505.20	1.37
2055	512.51	2.62	1H NMR (400 MHz, DMSO) S 12.69 (s, 1H), 8.16 - 8.14 (dd, 1H), 7.88 (t, J = 8.02,1H), 7.68 - 7.65 (d, 1H), 7.50 7,47 (dd, 1H), 7.06 - 7.03 (dd, 1H), 6.61 - 6.58 (dd, 1H), 4.95 (m, 1H), 3.60 (m, 1H), 3.46 - 3.39 ( m, 1H), 2.11 (m, 5H), 1.87 -1.77 (m, 1H), 1.51 - 1.29 (m, 7H}, 0.78 - 0.75 (d, 1.5H), 0.71-0.68 (d, 1.5H)
2056	494.30	1.06
2057	501.11	3.27
2058	570.20	1.99
2059	527.22	3.17
2060	538.33	2.62
2061	535.02	2.71
2062	556.20	1.96	1H NMR (400 MHz, DMSO) 5 12.66 (s, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.63 (t, J = 10.7 Hz, 1H), 7.45 (d, J = 11.6 Hz, 3H), 7.20 (d, J = 6.5 Hz, 1H), 6.90 (d, J = 10.7 Hz, 1H), 6.70 (d, J = 7.1 Hz, 1H}, 6.44 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H), 3.50 (s, 1H), 3.38 (s, 1H), 3.12 (d, J = 13.0 Hz, 1H}, 2.96 (s, 1H), 2.08 1.98 (m, 1H), 1.80 (s, 2H), 1.41 - 1.37 (m, 1H), 1.30 -1.22 (m, 1H), 1.00 (d, J = 6.7 Hz, 7H), 0.86 (d, J = 6.5 Hz, 4H), 0.76 (d, J = 6.6 Hz, 3H).
2063	498.34	1.82
2064	514.31	2.39
2065	526.18	1.43
2066	500.23	1.42
2067	499.40	1.50
2068	467.19	1.43	1H NMR (400 MHz, DMSO) δ 10.68 (s, 1H), 8.32 - 8.30 (dd, 1H), 8.18 - 8.16

1331

Crnpd. No.	LC/MS M+i	LC/RT min	NMR
			{dd, 1H), 8.11 - 8.08 (d, 1H), 8.01 (t, J = 7.91,1H), 7.84 - 7.75 {m, 2H), 7.66 7.63 (dd, 2H), 7.06 (t, J = 6.26,1H), 6.62 - 6.59 (dd, 1 H), 2.46 - 2.43(d, 1H), 1.93 - 1.89 (m, 1H), 1.78 -1.72 (m, 1H}, 1.44 {s, 3H), 1.43 (s, 3H}, 1.27 (t, J = 11.91,1H), 0.68-0.66 (d, 3H)
2069	574.40	1.51
2070	542.29	1.53
2071	528.22	1.53
2072	524.22	2.30	1H NMR (400 MHz, DMSO} δ 12.49 (s, 1H), 8.15 - 8.13 (dd, 1H), 7.69 - 7.66 (dd, 1H), 7.60 (t, J = 7.80,1H), 7.25 7.15 (m, 4H), 6.85 - 6.82 (d, 2H), 6.74 - 6.71 (d, 1H), 6.53 - 6.50 (dd, 1H), 3.71 (S, 3H), 3.45 - 3.36 (m, 2H), 2.79 (t, J = 7.47, 2H), 2.12 - 2.08 (m, 1H), 1.85 - 1.78 (m, 1H), 1.50 (s, 3H}, 1.48 (s, 3H), 1.36 (t, J = 11.65,1H), 0.82 0.80 (d, 3H)
2073	495.30	1.53
2074	517.32	1.36
2075	461.19	2.68
2076	492.40	2.00
2077	540.40	1.46	1H NMR {400 MHz, Methanol-d4) δ 8.50 (dd, J = 7.7,1.8 Hz, 1H), 8.27 {d, J = 8.0 Hz, 1H), 8.13 (dd, J = 5.9,1.8 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.00 (dd, J = 7.7, 5.8 Hz, 1H), 3.74 (t, J = 10.0 Hz, 1H), 3.33 - 3.25 {m, 1H, obscured by solvent peak}, 2.88 2.68 (m, 2H), 2.28 - 2.18 (m, 2H), 2.14 - 2.06 (m, 4H), 1.92 -1.82 (m, 1H), 1.75 - 1.60 {m, 2H), 1.57 - 1.45 (m, 6H), 1.36 (s, 3H), 1.21 (d, J = 6.6 Hz, 3H).
2078	550.33	2.02
2079	583.30	1.59
2080	497.40	1.36	1H NMR (400 MHz, DMSO-d6} δ 12.54 (s, 1H), 8.24 (dd, J = 7.2, 2.1 Hz, 1H), 8.05 - 7.97 (m, 2H), 7.82 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.1 Hz, 1H), 7.09 - 7.00 (m, 2H), 6.44 (t, J = 6.8 Hz, 1H), 3.81 (s, 2H}, 2.76 - 2.66

1332

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			(m, 2H), 2.22 (s, 1H), 1.88 (dd, J = 11.9, 5.6 Hz, 1H), 1.61 (s, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.91 {d, J = 6.2 Hz, 3H).
2081	553.20	2.26
2082	481.30	1.56	1H NMR (400 MHz, DMSO-d6) δ 10.99 (s, 1H), 8.22 - 8.18 (m, 2H), 8.06 (t, J = 8.13,1H), 7.81 - 7.62 (m, 4H}, 7.00 - 6.98 (d, 1H), 6.65-6.62 (dd, 1H), 2.30 (s, 3H), 1.87 -1.72 (m, 2H), 1.45 (S, 3H), 1.42 (s, 3H), 1. 26 (t, J = 11.87,1H), 0.65 - 0.63 (d, 3H)
2083	523.32	2.14
2084	499.40	1.59
2085	538.29	1.23
2086	511.30	2.13	1H NMR (400 MHz, DMSO) Ô 8.65 {d, J = 2.2 Hz, 1H), 8.09 (d, J = 2.3 Hz, 1H), 7.57 (d, J = 7.6 Hz, 1H), 7.49 7.36 (m, 1H), 6.98 (dd, J = 7.5, 2.8 Hz, 2H), 6.47 (d, J = 8.2 Hz, 1H), 6.17 (s, 2H), 3.92 (S, 3H), 3.04 - 2.85 (m, 2H), 2.20 (s, 3H), 2.09 (d, J = 17.6 Hz, 1H), 1.81 (dd, J = 11.6,5.5 Hz, 1H), 1.61 (s, 3H), 1.56 (s, 3H), 1.36 (t, J = 12.0 Hz, 1H), 0.82 (d,J = 6.3 Hz, 3H).
2087	549.43	2.09
2088	496.24	1.27
2089	538.34	1.88
2090	524.52	2.54
2091	527.16	1.45
2092	450.50	1.84	1H NMR (400 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.02 (ddt, J = 9.9, 7.2, 1.6 Hz, 4H), 7.77 - 7.70 (m, 2H), 7.70 7.62 (m, 2H), 7.53 - 7.46 (m, 2H), 7.46 - 7.40 (m, 1H), 7.21 (d, J = 8.0 Hz, 1H), 2.45 (t, J = 10.3 Hz, 1H), 2.36 (dd, J = 10.2, 7.1 Hz, 1H), 2.19 - 2.08 (m, 1H), 1.S3 (dd, J = 12.0,5.6 Hz, 1H), 1.58 (d, J = 15.4 Hz, 6H), 138 (t, J = 12.1 Hz, 1H), 0.67 (d, J = 6.3 Hz, 3H).
2093	494.31	1.69
2094	520.32	2.62
2095	538.34	1.84	1H NMR (400 MHz, DMSO-d6) δ 12.46 (S, 1H), 8.46 (s, 1H), 7.84 (d, J = 2.5 Hz, 1H), 7.63 (t, J = 7.9 Hz, 1H),

1333

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			7.43 (d, J = 12.2 Hz, 2H), 7.22 (d, J = 7.2 Hz, IH), 6.98 (d, J = 8.5 Hz, IH), 6.68 (d, J = 8.5 Hz, IH), 6.48 (s, 2H), 3.97 (t, J = 6.4 Hz, 2H), 335 (d, J = 7.2 Hz, IH), 2.55 (d, J = 8.4 Hz, 2H), 2.23 (s, 3H), 1.84 (dd, J = 11.8,5.7 Hz, IH), 1.76 (p, J = 7.0 Hz, 2H), 1.54 (s, 3H), 1.52 (S, 3H), 139 (t, J = 12.0 Hz, IH), 1.02 (t, J = 7.4 Hz, 3H), 0.86 (d, J = 63 Hz, 3H).
2096	491.40	1.17
2097	48430	1.41	IH NMR (400 MHz, DMSO-d6) δ 12.42 (s, IH), 8.23 (dd, J = 4.8,1.8 Hz, IH), 8.03 (d, J = 7.9 Hz, IH), 7.60 (dd, J = 7.9, 3.2 Hz, IH), 6.76 (dd, J = 7.8, 4.8 Hz, IH), 6.55 (dd, J = 7.9,5.9 Hz, IH), 3.24 - 3.14 (m, IH), 2.46 - 239 (m, 2H, obscured by soîvent peak), 231 - 2.24 (m, IH), 2.20 - 2.04 (m, IH), 1.89 - 1.67 (m, 3H), 1.59 -1.54 (m, IH), 1.52 (d, J = 5.1 Hz, 6H), 1.49 0.95 (m, 7H), 0.74 (d, J = 63 Hz, 3H).
2098	506.21	2.66
2099	51732	2.55
2100	49230	1.57	IH NMR (400 MHz, DMSO) 612.28 (s, IH), 7.66 - 7.50 (m, 2H), 7.17 (d, J = 7.2 Hz, IH), 6.66 (d, J = 83 Hz, IH), 5.45 - 531 (m, IH), 2.58 - 2.53 (m, IH), 2.47 - 2.40 (m, IH), 2.20 (dp, J = 18.4, 6.1 Hz, IH), 1.99 - 1.79 (m, 4H), 1.78 - 1.6S (m, 4H), 1.65 -1.55 (m, 2H), 1.53 (s, 3H), 1.46 (s, 3H), 137 (t, J = 12.0 Hz, IH), 0.85 (d, J = 6.2 Hz, 3H).
2101	49830	137
2102	48430	2.09
2103	528.17	1.51
2104	546.23	1.23	IH NMR (400 MHz, DMSO) δ 12.45 (s, IH), 7.99 (s, IH), 7.94 (d, J = 8.5 Hz, IH), 7.79 (d, J = 8.0 Hz, IH), 7.63 (t, J = 7.9 Hz, IH), 7.54 (d,J = 8.5 Hz, IH), 7.22 (t, J = 8.0 Hz, 2H), 6.69 (d, J = 8.4 Hz, IH), 6.50 (s, 2H), 2.63 - 2.56 (m, 2H), 2.21 (q, J = 9.7,7.7 Hz, 2H), 1.88 (dd, J = 11.8, 5.5 Hz, IH), 1.60 (d, J =

1334

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			5.4 Hz, 6H), 1.42 (t, J = 12.0 Hz, IH), 0.88 (d, J = 6.1 Hz, 3H).
2105	502.26	1.41
2106	520.32	2.21
2107	548.23	2.68
2108	509.21	2.57
2109	473.19	2.72
2110	494.31	1.45
2111	547.33	2.45
2112	536.50	1.40
2113	532.50	2.29
2114	512.30	1.18	IH NMR (400 MHz, Methanol-d4) 6 7.94 (d, J = 8.0 Hz, IH), 7.65 -7.59 (m, 2H), 7.41 (d, J = 8.0 Hz, IH), 7.35 (d, J = 7.2 Hz, IH), 6.82 (d, J = 2.5 Hz, IH), 6.72 (d, J = 8.4 Hz, IH), 3.99 (d, J = 7.3 Hz, 2H), 3.03 (t, J = 9.3 Hz, IH), 2.91 (t, J = 10.3 Hz, IH), 2.41 (s, IH), 2.29 - 2.16 (m, IH), 1.97 (dd, J = 13.3, 7.1 Hz, IH), 1.63 - 1.53 (m, 7H), 1.34 (d, J = 9.5 Hz, IH), 1.03 (d, J = 6.4 Hz, 3H), 0.93 (d, J = 6.6 Hz, 6H).
2115	539.23	2.51
2116	458.18	2.27
2117	514.40	2.02	IH NMR (400 MHz, DMSO) Ô7.77 (d, J = 7.9 Hz, IH), 7.64 (dd, J = 8.3, 7.4 Hz, IH), 7.48 - 7.40 (m, 2H), 7.32 (d, J = 7.9 Hz, IH), 7.23 - 7.15 (m, IH), 6.90 (d, J = 10.8 Hz, IH), 6.69 (d, J = 8.4 Hz, IH), 6.48 (s, 2H), 3.85 (dd, J = 14.4, 7.6 Hz, 4H), 3-30 (dd, J = 8.9, 5.8 Hz, 2H), 2,72 - 2.59 (m, IH), 2.03 (d, J = 6.7 Hz, IH), 1.15 (d, J = 6-8 Hz, 3H), 1.00 (d,J = 6.7 Hz, 6H).
2118	547.33	2.32
2119	522.42	2.59
2120	516.36	1.53
2121	557.20	1.71	IH NMR (400 MHz, DMSO) δ 8.53 (s, IH), 7.73 (s, 3H), 7.70-7.63 (m, IH), 7.59 (d, J = 9.7 Hz, IH), 7.21 (d, J = 7.2 Hz, IH), 7.07 (d, J = 10.6 Hz, IH), 6.73 (d, J = 8.4 Hz, IH), 3.86 (d, J = 6.6 Hz, 2H), 2.86 - 2-74 (m, IH), 2.69 (t, J = 10.9 Hz, IH), 2.34 - 2.18 (m, IH), 2.13 -1.99 (m, IH), 1.95 (dd, J = 11.9, 5.5

1335

Gmpd. No.	LC/MS M+1	LC/RT min	NMR
			Hz, 1H), 1.63 (d, J = 23.9 Hz, 6H), 1.50 (t, J = 12.2 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.90 (d, J = 63 Hz, 3H).
2122	53833	2.56
2123	534.42	2.52
2124	514.15	1.42
2125	505.22	138
2126	530.24	1.57
2127	49431	1.53
2128	51830	1.93	1H NMR (400 MHz, DMSO) 5 12.55 (s, 1H), 7.87 {d, J = 8.0 Hz, 1H), 7.67 (dd, J = 15.7, 7.4 Hz, 1H), 7.57 - 733 (m, 3H), 7.21 (d, J = 7.2 Hz, 1H), 6.92 (dt, J = 10.7, 2.2 Hz, 1H), 6.76 - 6.66 (m, 1H), 6.51 (s, 2H), 538 (ddd, J = 61.0, 5.7, 2.8 Hz, 1H), 4.12 (ddd, J = 17.3, 11.5, 5.4 Hz, 2H), 3.85 (d, J = 6.5 Hz, 4H), 2.04 (dt, J = 13.3, 6.6 Hz, 1H), 1.00 (d, J = 6.7 Hz, 6H).
2129	57138	1.58
2130	475.29	2.83
2131	474.09	1.63
2132	480.28	0.99
2133	480.50	2.09	1H NMR (400 MHz, DMSO-d6) δ 13.25 (s, 1H), 12.66 (s, 1H), 8.04 7.99 (m, 2H), 7.82 (d, J = 8.2 Hz, 1H), 7.77 - 7.70 (m, 2H}, 7.70 - 7.63 (m, 2H), 736 (d, J = 83 Hz, 1H), 7.19 (d, J = 7.2 Hz, 1H), 6.84 - 6.78 (m, 1H), 2.62 - 2.51 (m, 2H), 2.19 (s, 3H), 2.14 (q, J = 5.8 Hz, 1H), 1.89 (dd, J = 11.9, 5.5 Hz, 1H), 1.50 (d, J = 33 Hz, 6H), 1.41 (t, J = 12.1 Hz, 1H), 0.66 (d, J = 63 Hz, 3H).
2134	56833	1.62
2135	46239	1.74
2136	516.41	2.64	1H NMR (400 MHz, DMSO-d6) δ 12.67 (s, 1H), 9.43 {s, 1H), 8.24 8.09 (m, 3H), 7.96 - 7.94 {dd, 1H), 7.86 (t, J = 8.02,1H), 7.70 - 7.67 (d, 1H), 7.60 - 7.43 (m, 5H), 7.27 - 7.24 (d, 1H), 6.45 - 6.42 (dd, 1H), 2.07 -1 .91 (m, 1H), 1.77 -1.73 (m, 1H), 1.45 (s, 3H), 1.43 (s, 3H), 133 (t,J = 11.91, 1H), 0.79-0.77 (d, 3H)

1336

Cmpd. No.	LG/MS M+1	LC/RT min	NMR
2137	512.51	2.56
2138	529.20	1.64
2139	516.20	1.31	1H NMR (400 MHz, DMSO} Ô 12.48 (s, 1H), 7.70 - 7.52 (m, 2H), 7.17 (dd, J = 7.3, 0.5 Hz, 1H), 6.70 (dd, J = 9.7, 8.5 Hz, 2H), 5.19 (S, 2H), 3.84 (td, J = 11.1, 3.7 Hz, 2H), 3.38 - 3.18 (m, 2H), 2.84 (t, J = 10.0 Hz, 1H), 2.68 - 2.55 (m, 1H), 2.07 (s, 4H), 1.81 (t, J = 6.4 Hz, 1H), 1.65 (dd, J = 30.6, 10.5 Hz, 2H), 1.55 (d, J = 8.6 Hz, 6H), 1.49 (s, 3H), 1.28 (d, J = 6.6 Hz, 10H).
2140	525.42	1.65
2141	534.60	1.23
2142	522.42	2.85	1H NMR (400 MHz, DMSO) Ô 12.63 (s, 1H}, 9.52 (s, 1H), 8.13 - 8.11 (dd, 1H), 8.01 - 7.98 (d, 1H), 7.81 (t, J = 7.80, 1H), 7.71 - 7.68 (dd, 1H), 7.45 - 7.42 (d, 1H), 7.36 (S, 1H), 7.17 (t,J = 7.92, 1H), 7.06 - 6.97 (m, 2H), 6.52 - 6.49 (dd, 1H), 1.86 -1.70 (m, 2H), 1.45 (s, 3H), 1.41 (s, 3H), 1.28 (m, 10H), 0.74 0.72 (d, 3H}
2143	550.33	2.55
2144	535.50	1.76	1H NMR {400 MHz, DMS0-d6) δ 12.65 (d, J = 4.1 Hz, 1H), 12.53 (s, 1H), 8.40 (s, 1H), 8.34 (d, J = 8.0 Hz, 1H), 8.25 (dd, J = 73, 2.2 Hz, 1H), 7.78 (ddt, J = 24.0,15.6, 7.9 Hz, 4H), 7.35 - 730 (m, 1H), 6.54 - 635 (m, 1H), 2.82 - 2.63 (m, 2H}, 2.24 (s, 1H), 1.90 (dd, J = 12.0, 5.7 Hz, 1H), 1.61 (d, J = 3.3 Hz, 6H), 1.46 {t, J = 12.3 Hz, 1H), 0.91 (t, J = 7.0 Hz, 3H).
2145	501.11	234
2146	500.21	2.30
2147	47139	2.56
2148	49730	1.49
2149	528.19	1.49	1H NMR (400 MHz, DMS0-d6) δ 12.58 (s, 1H), 8.26 (dd, J = 4.8,1.8 Hz, 1H), 8.07 (dd, J = 7.8,1.9 Hz, 1H), 7.80 (d, J « 7.9 Hz, 1H), 7.44 (dd, J = 6.3, 3.2 Hz, 1H), 7.24 (dd, J = 11.1, 9.0 Hz, 1H), 7.09 (dd, J = 7.9, 2.2 Hz, 1H), 7.01 (dt, J = 9.0, 3.5 Hz, 1H), 6.80 (dd,

1337

Cmpd. No.	LC/MS M+1	LC/RT 1 min	NMR
			J = 7.9, 4.8 Hz, 3H), 4.04 (q, J = 6.9 Hz, 2H), 2.55 (dd, J = 10.1, 7.3 Hz, 2H), 2.15 (td, J = 11.6,10.3,5.8 Hz, 1H), 1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.57 (s, 3H), 1.54 (s, 3H), 1.40 (t, J = 12.0 Hz, 1H), 1.33 (t, J = 6.9 Hz, 3H), 0.76 (d, J = 6.3 Hz, 3H).
2150	446.40	1.27	1H NMR (400 MHz, Acetonitrile-d3) δ 8.27 (d, J = 8.0 Hz, 1H), 8.24 (dd, J = 7.7,1.8 Hz, 1H), 8.09 {dd, J = 5.3,1.8 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.81 (dd, J = 7.7, 5.3 Hz, 1H), 3.76 (dd, J = 11.5, 8.8 Hz, 1H), 3.24 (dd, J = 11.5, 8.2 Hz, 1H), 2.81 - 2.71 {m, 1H), 2.69 (d, J = 7.2 Hz, 2H), 2.23 - 2.11 (m, 3H), 1.86 (dd, J = 12.7,10.2 Hz, 1H), 1.49 (s, 3H}, 1.29 (S, 3H), 1.20 (d, J = 6.7 Hz, 3H), 0.93 (d, J = 6.7 Hz, 6H).
2151	531.12	2.71
2152	488.50	2.10
2153	539.50	1.87
2154	495.40	1.59	1H NMR (400 MHz, DMSO-d6) δ 12.55 (S, 1H), 12.52 (d,J = 6.4 Hz, 1H), 8.24 (dd, J = 7.3, 2.1 Hz, 1H), 7.83 (s, 2H), 7.77 {d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.44 (t, J = 6.9 Hz, 1H), 2.77 - 2.64 (m, 2H), 2.38 - 2.13 (m, 8H), 1.88 (dd, J = 12.1, 5.7 Hz, 1H), 1.61 (s, 6H), 1.44 (t, J = 12.4 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2155	536.30	2.01	1H NMR (400 MHz, DMSO) δ 12.65 (s, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.67 (dd, J = 8.4,7.3 Hz, 1H), 7.59 - 7.46 {m, 3H), 7.22 (dd, J = 7.3,0.6 Hz, 1H), 6.93 (dt, J = 10.8, 2.3 Hz, 1H), 6.76 6.68 (m, 1H), 6.54 (s, 2H), 4.1S (t, J = 12.5 Hz, 4H), 3.85 (d, J = 6.5 Hz, 2H), 2.05 (dt, J = 13.3, 4.4 Hz, 1H), 1.00 {d, J = 6.7 Hz, 6H).
2156	516.36	1.55
2157	506.21	1.34
2158	512.16	1.32
2159	503.30	1.51	1H NMR (400 MHz, DMSO-d6) δ 12.64 (s, 1H), 12.54 (d, J = 6.0 Hz,

1338

Cmpd. No.	LC/MS M+1	LC/RT ï min '·^:	^{: nmr}
			1H), 8.25 (dd, J = 7.2, 2.3 Hz, 1H), 7.91 (td, J = 8.9, 6.7 Hz, 1H), 7.83 (dd, J = 7.1,4.6 Hz, 1H), 7.77 -7.71 (m, 1H}, 7.37 (ddd, J = 11.9, 9.3, 2.6 Hz, 1H), 7.25 (td,J = 8.5, 2.6 Hz, 1H), 6.96 (dd, J = 7.8, 2.5 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 2.81 - 2.63 (m, 2H), 2.30 2.14 (m, 1H), 1.91 - 1.81 (m, 1H), 1.54 (d, J = 1.9 Hz, 6H), 1.43 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.4 Hz, 3H).
2160	495.40	2.16
2161	501.11	2.53
2162	503.40	1.52	1H NMR (400 MHz, DMSO-d6) 5 12.67 (s, 1H), 12.55 (s, 1H), 8.25 (dd, J = 7.3, 2.2 Hz, 1H), 7.84 (dt, J = 7.5, 3.7 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.65 (ddt, J = 8.2, 6.7,1.6 Hz, 1H), 7.55 7.45 (m, 1H), 7.35 (tdd, J = 8.1, 5.1, 1.5 Hz, 1H), 7.00 (dd, J = 7.9, 2.3 Hz, 1H}, 6.45 (t, J = 6.8 Hz, 1H), 2.81 2.68 (m, 2H), 2.25 (tt, J = 11.7, 6.4 Hz, 1H), 1.87 (dd, J = 11.9, 5.6 Hz, 1H), 1.54 (s, 6H), 1.44 (t,J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2163	508.16	1.42
2164	496.28	0.93
2165	519.12	2.58
2166	480.10	2.02
2167	447.08	2.52
2168	510.41	2.20	1H NMR (400 MHz, DMSO-d6) 312.49 (s, 1H), 8.16 - 8.14 (dd, 1H), 7.68 - 7.60 (m, 3H), 7.23 - 7.20 (d, 1H), 7.16 - 7.13 (d, 1H}, 6.97 - 6.93 (m, 2H), 6.79 - 6.73 (m 2H), 6.57 6.54 (dd, 1H), 4.47 (s, 2H), 3.66 (s, 3H), 2.44 - 2.33 (m, 1H), 2.05 -1.98 (m, 1H), 1.82 - 1.75 (m, 1H), 1.50 (s, 3H), 1.47 (s, 3H), 1.33 (t, J = 12.09, 1H), 0.76-0.74 (d,3H)
2169	525.42	2.44	1H NMR (400 MHz, DMSO-d6) Ô 12.82 (s, 1H), 8.19 - 8.17 (dd, 1H), 8.03 (t, J = 7.80,1H), 7.77 - 7.74 (d, 2H), 7.16 - 7.13 (d, 1H), 7.09 (s, 1H), 7.05 - 7.02 (dd, 1H), 6.83 - 6.80 (d, 1H), 6.64 - 6.61 (dd, 1H), 5.99 (s , 1H),

1339

Cmpd, No.	LC/MS M+1	LC/RT min	NMR
			5.94 (s, 1H), 5.26, (s, 1H), 5.25 (s, 1H), 2.27 (s, 1H), 2.24 (s, 1H), 2.09 - 2.01 (m, 1H), 1.82-1.75 (m, 1H), 1.51 (s, 3H), 1.46 (S, 3H), 1.35 (t, J = 11.86, 1H), 0.67-0.65 (d, 3H)
2170	539.40	2.55	1H NMR (400 MHz, DMSO-d6) 68.63 (d, J = 2.4 Hz, 1H), 8.09 (d, J = 2.6 Hz, 1H), 7.60 (bs, 1H), 7.49 (bs, 1H), 7.01 (bs, 2H), 6.52 (bs, 1H), 6.24 (bs, 2H), 5.32 (p, J = 6.1 Hz, 1H), 3.01 - 2.73 (m, 2H), 2.17 (s, 3H), 2.15 - 2.05 (m, 1H), 1.82 (dd, J = 11.8, 5.6 Hz, 1H), 1.61 (s, 3H), 1.57 (s, 3 H), 1.42 - 1.33 (m, 1H), 1.32 (d, J = 6.2 Hz, 6H), 0.82 (d,J =6.3 Hz,3H).
2171	570.50	2.19	1H NMR (400 MHz, DMSO) 6 12.51 (s, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.44 (ddd, J = 10.1, 2.2,1.4 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.22 (dd, J = 7.3, 0.6 Hz, 1H), 6.93 - 6.83 (m, 1H), 6.72 (dd, J = 8.4, 0.6 Hz, 1H), 6.48 (s, 2H), 3.84 (d, J = 6.6 Hz, 2H), 3.23 (t, J = 5.4 Hz, 2H), 3.14 - 3.04 (m, 2H), 2.05 (dd,J = 11.8, 5.1 Hz, 1H), 1.72 (s, 2H), 1.57 - 1.49 (m, 2H), 1.30 - 1.20 (m, 2H), 0.99 (d, J = 6.7 Hz, 6H), 0.83 (s, 6H).
2172	508.31	1.55
2173	515.51	3.19
2174	497.30	1.48
2175	550.33	1.25
2176	481.50	1.52
2177	526.02	2.42
2178	556.20	1.96
2179	526.32	2.25
2180	522.40	1.86
2181	487.30	2,37
2182	533.22	2.72
2183	500.23	1.49
2184	480.50	1.57
2185	492.18	1.47
2186	495.40	2.60
2187	522.42	2.86
2188	459.39	2.57

1340

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2189	514.17	1.42
2190	524.52	2.32
2191	528.50	1.50	1H NMR (400 MHz, DMSO-d6) δ 12.46 {broad s, 1H), 8.25 (dd, J = 4.8, 1.8 Hz, 1H), 8.20 (d, J = 2.8 Hz, 1H), 8.03 (dd, J = 7.9,1.8 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.70 (br s overlapped with préviens signal, 2H), 6.12 (d, J = 2.7 Hz, 1H), 3.98 (d, J = 6.6 Hz, 2H), 2.45 (d, J = 8.7 Hz, 2H), 2.20-2.01 (m, 2H), 1.85 (dd,J = 11.9, 5.6 Hz, 1H), 1.55 (s, 3H), 1.53 (s, 3H), 1.38 (t, J = 12.2 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.74 (d, J = 6.3 Hz, 3H).
2192	544.40	1.15	1H NMR (400 MHz, DMSO-d6) δ 12.45 (S, 1H), 8.23 (dd, J = 4.8,1.9 Hz, 1H), 8.19 (d, J = 2.8 Hz, 1H}, 8.02 (dd, J = 7.8,1.9 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.76 (dd, J = 7.8,4.7 Hz, 1H), 6.67 (broad s, 2H), 6.11 (d, J = 2.8 Hz, 1H), 4.57 (br S, 1H), 4.19 (ddd, J = 9.9, 5.9, 2.4 Hz, 1H), 4.03 (ddd, J = 9.8, 6.5,3.2 Hz, 1H), 3.41 (brs, 2H),2.47 (d,J = 8.4 Hz, 2H), 2.19 - 2.06 (m, 1H), 2.06 1.92 (m, 1H), 1.85 (dd, J = 11.9,5.5 Hz, 1H), 1.55 (S, 3H), 1.53 (s, 3H), 1.38 (t, J = 12.1 Hz, 1H}, 0.96 (d, J = 6.9 Hz, 3H), 0.74 (d, J = 6.3 Hz, 3H).
2193	519.42	2.24
2194	540.20	1.67
2195	526.13	1.39
2196	470.30	1.25	1H NMR (400 MHz, DMSO-d6) Ô8.27 (s, 1H), 7.69 (dd, J = 8.5,7.3 Hz, 1H), 7.62 - 7.54 (m, 1H), 7.38 - 7.30 (m, 2H), 7.26 (d, J = 7.3 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 3.84 (s, 3H), 3.09 - 2.98 (m, 1H), 2.77 (t, J = 9.9 Hz, 1H), 2.34 2.29 (m, 1H), 1.93 (dd, J = 11.9, 6.0 Hz, 1H), 1.57 (d,J = 13.2 Hz, 6H), 1.47 (t, J = 12.1 Hz, 1H), 0.93 (d, J = 6.3 Hz, 3H).
\| 2197	460.29	2.34

1341

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2198	537.43	1.62
2199	490.32	1.45
2200	432.37	2.23
2201	584.40	2.16	IH NMR (400 MHz, DMSO) δ7.55 (d, J = 7.7 Hz, IH), 7.46 (s, 1H),7.38 (dd, J = 18.8,10.8 Hz, 2H), 7.06 (d, J = 7.7 Hz, IH), 7.02 (d, J = 73 Hz, IH), 6.79 (d, J = 10.7 Hz, IH), 6.42 (d, J = 8.2 Hz, IH), 6.01 (s, 2H), 3.82 (d,J = 6.6 Hz, 2H), 339 (t, J = 10.7 Hz, IH), 3.23 3.14 (m, IH), 2.05 (dt, J = 13.4, 6.8 Hz, IH), 1.86 (d, J = 11.5 Hz, IH), 1.79 (S, IH), 1.61 (d,J = 22.2 Hz, 6H), 1.45 (t, J = 11.4 Hz, IH), 136 (d,J = 6.8 Hz, IH), 0.99 (d, J = 6.7 Hz, 6H), 0.86 (dd, J = 16.6, 6.5 Hz, 6H).
2202	500.21	2.74
2203	496.60	1.72
2204	614.20	2.11	IH NMR (400 MHz, DMSO) δ 12.60 (s, IH), 7.78 (d, J = 7.9 Hz, IH), 7.65 (t, J = 7.8 Hz, IH), 7.50 (d, J = 9.2 Hz, 2H), 737 (d, J = 7.9 Hz, IH), 7.22 (d, J = 7.3 Hz, IH), 6.89 (d, J = 10.7 Hz, IH), 6.71 (d, J = 8.5 Hz, IH), 6.48 (s, 2H), 4.51 (dd, J = 7.7, 3.8 Ηζ,ΙΗ), 3.84 (d, J = 6.4 Hz, 2H), 2.96 - 2.72 (m, 2H), 2.27 2.10 (m, IH), 2.09 -1.98 (m, IH), 1.97 -1.86 (m, IH), 1.80 (qd, J = 10.5, 5.7 Hz, 2H), 1.29 (s, 9H), 1.00 (d, J = 6.7 Hz, 6H).
2205	498.53	1.05
2206	510.41	230
2207	511.30	1.48	IH NMR (400 MHz, DMSO-d6) δ 12.52 (d, J = 10.1 Hz, 2H), 8.24 {dd, J = 7.2, 2.1 Hz, IH), 8.02 - 7.93 (m, 2H), 7.82 (t, J = 6.6 Hz, IH), 7.71 (d, J = 8.1 Hz, IH), 7.11 (d, J = 8.1 Hz, IH), 7.06 6.95 (m, 2H), 6.44 (t, J = 7.0 Hz, IH), 4.09 (q, J = 7.0 Hz, 2H), 2.71 (dd, J = 12.1, 8.5 Hz, 2H), 2.23 (s, IH), 1.88 {dd, J = 11.8, 5.6 Hz, IH), 1.61 (s, 6H), 1.44 (t, J = 12.1 Hz, IH), 134 (t, J = 6.9 Hz, 3H), 0.91 (d, J = 63 Hz, 3H).
2208	535,32	2.08
2209	598.30	1.63

1342

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2210	558.25	1.85
2211	527.22	3.22
2212	529.20	0.81	1H NMR {400 MHz, DMSO-d6) δ 12.31 (S, 1H), 8.87-8.78 (m, 2H), 7.92 (dd, J = 19.3, 6.1 Hz, 2H), 7.69 (dd, J = 10.6,1.5 Hz, 1H), 7.60 (ddd, J = 8.4, 7.3, 3.4 Hz, 1H}, 7.20 - 7.12 (m, 1H), 6.66 (dt, J = 8.4, 0.9 Hz, 1H), 6.44 (s, 1H), 6.14 (q, J = 6.7 Hz, 1H), 2.50 2.33 (m, 2H}, 2.20 - 2.03 (m, 1H}, 1.80 -1.62 (m, 4H), 1.43 (d, J = 19.0 Hz, 3H), 1.35 -1.12 (m, 1H), 0.86 - 0.73 (m, 6H).
2213	570.20	1.97
2214	510.41	2.57
2215	485.20	1.23	1H NMR (400 MHz, DMSO-d6) δ 8.25 (dd, J = 4.8,1.8 Hz, 1H), 8.05 (dd, J = 7.8, 1.8 Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.01 - 6.55 (m, 4H), 2.16 (s, 1H), 1.83 (dd, J = 12.1,5.7 Hz, 1H), 1.48 (d, J = 4.1 Hz, 6H), 1.36 (t, J = 12.1 Hz, 1H), 0.75 (d, J = 6.3 Hz, 3H).
2216	614.20	2.11	1H NMR (400 MHz, DMSO) δ 12.60 (s, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.37 {d, J = 7.9 Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 6.89 (d, J = 10.8 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 4.63 4.34 (m, 1H), 3.84 (d,J = 6.5 Hz, 2H), 2.83 (t, J = 5.9 Hz, 2H), 2.27 - 2.11 (m, 1H), 2.10 - 1.98 (m, 1H), 1.93 (tt, J = 10.8, 5.6 Hz, 1H), 1.86 -1.69 {m, 2H), 1.29 (s, 9H), 1.00 (d, J = 6.7 Hz, 6H),
2217	534.12	2.88
2218	486.40	2.53
2219	515.20	1.65
2220	526.34	1.63
2221	476.19	2.36
2222	515.20	1.57
2223	550.22	1.10
2224	554.20	2.12	1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.64 {t, J = 6.7 Hz, 1H), 7.46 (s, 2H), 7.33 (d, J = 7.7 Hz, 1H), 7.22 (d, J = 7.1 Hz, 1H), 6.89 (d, J = 10.8 Hz, 1H), 6.70 (d, J =

1343

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			8.3 Hz, 1H), 6.48 (s, 2H), 3.84 (d, J = 6.3 Hz, 2H), 3.52 (d, J = 11.3 Hz, 2H), 3.40 (d, J = 11.3 Hz, 3H), 2.30 (d, J = 4.4 Hz, 2H), 2.24 (dd, J = 12.3, 5.3 Hz, 1H), 1.92 (d, J = 4.5 Hz, 1H), 1.25 (d, J = 9.3 Hz, 1H), 1.04 - 0.94 (m, 6H}, 0.74 (d, J = 6.2 Hz, 3H).
2225	486.33	1.45
2226	529.32	1.56
2227	538.32	1.22
2228	551.60	2.40
2229	494.28	1.50
2230	466.30	1.38	1H NMR (400 MHz, DMSO-d6) Ô 12.26 (S, 1H), 7.66 - 7.55 (m, 2H), 7.17 (dd, J = 7.3, 0.7 Hz, 1H), 6.66 (dd, J = 8.4, 0.8 Hz, 1H), 6.41 (s, 2H), 5.26 (p, J = 6.1 Hz, 1H), 2.60 - 2.51 (m, 1H), 2.49 - 2.40 (m, 1H), 2.33 (p, J = 1.8 Hz, OH), 2.20 (s, 1H), 1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.51 (s, 3H), 1.45 (s, 3H), 1.43 -1.30 (m, 4H), 1.29 (d, J = 6.2 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H).
2231	512.20	1.35
2232	496.40	1.20	1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.25 (dd, J = 5.1, 2.9 Hz, 2H), 7.20 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 8.1 Hz, 1H), 6.84 - 6.19 (m, 5H), 2.60 (d, J = 8.8 Hz, 2H), 2.29 (S, 3H), 2.26 - 2.14 (m, 1H), 1.87 (dd, J = 11.9, 5.6 Hz, 1H), 1.65 - 1.53 (m, 6H), 1.42 (t, J = 12.0 Hz, 1H), 0.88 (d, J = 6.2 Hz, 3H).
2233	527.22	2.22
2234	551.50	1.82	1H NMR (400 MHz, DMSO-d6) δ 12.62 (S, 1H), 12.54 (s, 1H), 8.28 8.22 (m, 1H), 8.16 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 6.9 Hz, 1H), 7.77 (d, J = 7.9 Hz, 1H), 7.49 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.1 Hz, 1H), 6.45 (t, J = 6.7 Hz, 1H), 2.75 (q, J = 10.2 Hz, 2H), 2.24 (d, J = 12.0 Hz, 1H), 1.89 (dd, J = 12.2, 5.5 Hz, 1H), 1.61 (s, 6H], 1.45 (t, J = 11.9 Hz, 1H), 0.91 (d, J = 6.2 Hz, 3H).
2235	511.30	1.52	1H NMR (400 MHz, DMSO-d6) δ

1344

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			12.59 (s, 1H), 12.53 (d, J = 6.2 Hz, 1H), 8.24 (dd, J = 7.2,2.1 Hz, 1H), 7.83 (td, J = 6.2, 2.1 Hz, 1H), 7.74 (d,J = 8.0 Hz, 1H), 7.60 (dd, J = 7.3,1.4 Hz, 2H), 7.38 (t, J = 8.0 Hz, lH),7.19(d,J = 8.0 Hz, 1H), 7.01 - 6.96 (m, 1H), 6.45 (t, J = 6.8 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 2.74 (dd, J = 16.1, 9.7 Hz, 2H), 2.24 (s, 1H), 1.93 - 1.85 (m, 1H), 1.62 (d, J = 1.4 Hz, 6H), 1.45 (t, J = 12.1 Hz, 1H), 1.36 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H).
2236	502.50	1.66
2237	574.60	1.59
2238	542.50	1.44	1H NMR (400 MHz, DMS0-d6) δ 12.52 (s, 1H), 8.24 (dd, J = 4.8, 1.8 Hz, 1H), 8.03 (dd, J = 7.9,1.8 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 8.3 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 1H), 6.69 (broad s, 2H}, 5.83 (s, 1H), 3.9Û (d, J = e.6 Hz, 2H), 2.52 (s,3H), 2.14 (br s, 1H), 2.02 (hept, J = 6.6 Hz, 1H), 1.85 (dd, J = 12.0, 5.6 Hz, 1H), 1.51 (s, 3H), 1.49 {s, 3H), 1.36 (t, J = 11.9 Hz, 1H), 1.24 (br s, 1H), 0.95 (d, J = 6.7 Hz, 6H), 0.88-0.82 (m, 1H), 0.74 (d, J = 6.3 Hz, 3H).
2239	497.51	2.12	1H NMR (400 MHz, DMSO-d6) δ 12.83 (s, 1H), 8.18 - 8.12 (m, 2H), 7.88-7.85 (d, 1H), 7.50 - 7.47 (d, 1 H), 7.31-7.28 (d, 1H), 7.14 -6.99 (m, 4H), 6.63 - 6.60 (dd, 1H), 3.78 (s, 3H), 2.30 - 2.21 (m, 1H), 1.89 -1.82 (m, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 1.46 1.35 (m, 1H), 0.89 -0.87 (d, 3H)
2240	488.33	1.38
2241	524.24	1.55
2242	486.20	1.58
2243	707.50	1.57
2244	497.20	1.30
2245	550.22	1.10
2246	430.40	1.80
2247	527.30	1.47
2248	514.40	1.44	1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 8.23 (dd, J = 4.8,1.8 Hz,

1345

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			1H), 8.02 (dd, J = 7.8,1.9 Hz, 1H), 8.00 (d, J = 1.2 Hz, 1H), 7.80 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 83 Hz, 1H), 6.76 (dd, J = 7.8,4.7 Hz, 1H), 6.68 (broad s, 2H), 4.29 (q, J = 7.0 Hz, 2H), 2.45 (d, J = 8.7 Hz, 2H), 2.12 (br s, 1H), 1.94 (d, J = 0.9 Hz, 3H), 1.84 (dd, J = 12-0, 5.6 Hz, 1H), 1.55 (s, 3H), 1.54 (s, 3H), 1.40-1.33 (m, 4H), 0.74 (d, J = 6.3 Hz, 3H).
2249	525.42	2.42
2250	472.29	2.32
2251	518.22	2.48
2252	487.30	2.84
2253	545.23	2.34
2254	537.43	2.28
2255	492.40	2.73
2256	525.30	1.57
2257	482.24	0.90
2258	570.00	3.40	1H NMR (400 MHz, DMSO-d6) 57.67 - 7.54 (m, 2H), 7.49 (t, J = 1.8 Hz, 1H), 7.40 (dt, J = 10.2,1.8 Hz, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.06 (d, J = 7.3 Hz, 1H), 6.89 (dt,J = 10.7, 2.3 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H), 6.64 (s, 2H), 3.84 (d, J = 6.7 Hz, 2H), 3.43 (s, 3H), 2.82 (s, 1H), 2.64 (s, 1H), 2.34 - 2-22 (m, 1H), 2.05 (hept,J = 6.6 Hz, 1H), 1.91 (dd, J = 11.9, 5.7 Hz, 1H), 1.62 (d, J = 4.4 Hz, 6H), 1.46 (t, J = 12.1 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.94 (d, J = 63 Hz, 3H).
2259	502.24	1.76
2260	536.22	2.32
2261	549.43	2.69
2262	528.12	2.54
2263	549.43	2.30
2264	515.21	2.70
2265	440.40	1.17
2266	516.20	1.31	1H NMR (400 MHz, DMSO) δ 12.48 (s, 1H), 7.70 - 7.52 (m, 2H), 7.17 {dd, J = 73, 0.5 Hz, 1H), 6.70 (dd, J = 9.7, 8.5 Hz, 2H), 5.19 (s, 2H), 3.84 (td, J = 11.1, 3.7 Hz, 2H), 338 - 3.18 (m, 2H), 2.84 (t, J = 10.0 Hz, 1H), 2.68 - 2.55

1346

Gmpd. No,	LC/MS M+1	LC/RT min	NMR
			(m, 1H), 2.07 (s, 4H), 1.81 (t, J = 6.4 Hz, 1H), 1.65 (dd, J = 30.6,10.5 Hz, 2H), 1.55 (d, J = 8.6 Hz, 6H), 1.49 (s, 3H), 1.28 (d, J = 6.6 Hz, 10H).
2267	539.60	1.90	1H NMR (400 MHz, DMSO-d6) δ 12.59 (s, 1H), 12.53 (d, J = 6.4 Hz, 1H), 8.24 (dd, J = 7.3, 2.1 Hz, 1H), 7.82 (dt, J = 6.5, 3.5 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.65 - 7.58 (m, 2H), 7.37 (td, J = 8.4, 3.1 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.02 - 6.96 (m, 1H), 6.45 (t, J = 6.8 Hz, 1H), 3.81 (d, J = 6.6 Hz, 2H), 2.79 - 2.69 (m, 2H), 2.24 (s, 1H), 2.05 (dt, J = 13.2, 6.6 Hz, 1H), 1.89 (dd, J = 11.8, 5.6 Hz, 1H), 1.62 (d, J = 1.9 Hz, 6H), 1.45 (t, J = 12.0 Hz, 1H), 0.99 (dd, J = 6.8, 2.9 Hz, 6H), 0.91 (d, J = 6.4 Hz, 3H).
2268	497.13	1.40
2269	568.20	2.00	1H NMR (400 MHz, DMSO) δ 12.50 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.53 (s, 1H), 7.47 (d, J = 9.9 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 6.92 (d, J = 10,7 Hz, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H), 3.61 (d, J = 9.7 Hz, 1H), 3.49 (q, J = 9.8 Hz, 1H), 2.71 - 2.51 (m, 2H), 2.38 2.19 (m, 1H), 2.03 (dd, J = 13.2,6,7 Hz, 2H), 1.98 - 1.86 (m, 1H), 1.86 1.73 (m, 2H), 1.61 (dt, J = 22.9,10.5 Hz, 2H), 0.98 (d, J = 6.7 Hz, 6H), 0.91 (d, J = 6.4 Hz, 3H).
2270	531.12	2.72
2271	610.30	2.23
2272	502.52	1.05
2273	515.21	2.62	1H NMR (400 MHz, DMSO) δ 12.81 (s, 1H), 8.19 - 8.17 (dd, 1H), 8.06 (t, J = 7.91,1H), 7.81 - 7.66 (m, 3H), 7.43 7.34 (m, 1H), 7.29 - 7.09 (m, 3H), 6.64 - 6.61 (dd, 1H), 5.44 (s, 2H), 2.37 2.14 (m, 2H), 2.00 -1.94 (m, 1H), 1.80 -1.73 (m, 1H), 1.49 (s, 3H), 1.45 (S, 3H), 1.30 (t, J = 11.86,1H), 0.67 0.65 (d, 3H)
2274	1 517.32	1.37	\|

1347

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2275	466.29	1.87
2276	527.40	1.62
2277	444.60	1.40
2278	529.20	1.71	1H NMR (400 MHz, DMSO) δ 12.62 (s, 1H), 12.53 (d,1 = 5.8 Hz, 1H),8.24 (dd, J = 7.3,2.2 Hz, 1H), 7.83 (dd, J = 6.4, 4.3 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 1.9 Hz, 1H), 7.41 (d, J = 10.2 Hz, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.88 (dt,J = 10.8, 2.3 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 2.74 (dd, J = 17.6,10.2 Hz, 2H), 2.25 (s, 1H), 1.89 (dd, J = 11.9, 5.7 Hz, 1 H), 1.60 (d, J = 1.9 Hz, 6H), 1.45 (t, J = 12.1 Hz, 1H), 1.35 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H).
2279	566.30	1.82	1H NMR (400 MHz, DMSO) δ 8.70 (s, 1H), 7.99 (s, 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.44 {t, J = 7.8 Hz, 1H), 6.97 (dd, J = 17.9, 7.5 Hz, 2H), 6.45 (d, J = 8.2 Hz, 1H), 6.12 (S, 2H), 3.11 - 2.91 (m, 4H), 2.83 (s, 3H), 2.30 (s, 3H), 2.13 {dq, J = 17.3, 9.3, 8.4 Hz, 1H), 1.90 (t, J = 6.8 Hz, 1H), 1.81 (dd, J = 11.6, 5.5 Hz, 1H), 1.62 (S, 3H), 1.57 (s, 3H), 1.37 (t, J = 11.9 Hz, 1H), 0.88 - 0.81 (m, 10H).
2280	516.23	1.54
2281	494.30	1.08	1H NMR (400 MHz, DMSO-d6) δ 12.29 (s, 1H), 7.66-7.57 (m, 2H), 7.17 (d, J = 7.3 Hz, 1H), 6.66 (d, J = 8.3 Hz, 1H), 6.41 (S, 2H), 5.55 - 5.48 (m, 1H), 3.94 - 3.83 (m, 2H), 3.83 - 3.76 (m, 2H), 2.56 (d, J = 10.6 Hz, 1H), 2.44 (t, J = 8.7 Hz, 1H), 2.32 - 2.16 (m, 1H), 2.10 - 2.02 (m, 1H), 1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.53 (s, 3H), 1.44 (s, 3H), 1.37 (t, J = 12.0 Hz, 1H), 0.85 (d, J = 6.3 Hz, 3H).
2282	502.31	2.63	1H NMR (400 MHz, DMSO-d6) δ 12.93 (S, 1H), 10.03 (s, 1H), 8.16 8.14 (dd, 1H), 7.93 (t, J = 7.80, 1H), 7.74 - 7.71 (dd, 1H), 7.61 - 7.58 (d, 1H), 7.54 - 7.49 (m, 2H), 7.13 - 7.10 (d, 1H), 6.80 - 6.72 (m, 1H), 6.56 -

1348

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			6.53 (dd, 1H), 2.04 -1.93 (m, 1H), 1.81 -1.74 (m, 1H), 1.45 (s, 6H), 1.32 (t, J = 11.87, 1H), 0.73 - 0.71 (d, 3H)
2283	524.22	1.65
2284	503.30	1.56	1H NMR (400 MHz, DMSO-d6) 5 12.62 (s, 1H), 12.53 (d, J = 6.1 Hz, 1H), 8.24 (dd, J = 7.3, 2.2 Hz, 1H), 8.04 (ddd, J = 12.0, 8.3, 2.2 Hz, 1H), 7.92 (dt, J = 8.8, 3.1 Hz, 1H), 7.83 (dt, J = 7.0, 3.5 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.57 (dt, J = 10.5, 8.6 Hz, 1H), 7.23 (d, J = 7.9 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 2.73 (dd, J = 9.6, 7.8 Hz, 2H), 2.30 - 2.16 (m, 1H), 1.89 (dd, J = 12.0, 5.5 Hz, 1H), 1.60 (d, J = 2.0 Hz, 6H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2285	550.33	1.49
2286	537.43	3.02
2287	494.50	1.63
2288	509.22	1.23
2289	570.30	2.21	1H NMR (400 MHz, DMSO} 5 12.52 (s, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.64 (dd, J = 8.4, 7.3 Hz, 1H), 7.49 (d, J = 1.9 Hz, 1H), 7.43 (dd, J = 9.7,1.7 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.20 (dd, J = 7.3, 0.6 Hz, 1H), 6.88 (dt, J = 10.7, 2.3 Hz, 1H), 6.69 (dd, J = 8.4,0.6 Hz, 1H), 6.46 (S, 2H), 3.83 (d, J = 6.5 Hz, 2H), 3.47 (d, J = 7.2 Hz, 2H), 2.68 (d, J = 7.2 Hz, 3H), 2.05 (dt, J = 13.3, 4.3 Hz, 1H), 1.76 (s, 1H), 1.61 (d, J = 11.7 Hz, 5H), 1.12 (t, J = 9.5 Hz, 3H), 0.99 (d, J = 6.7 Hz, 6H), 0.95-0.80 (m,2H).
2290	498.23	1.27
2291	502.26	1.39
2292	534.12	2.70
2293	527.22	2.36
2294	496.30	1.44
2295	501.30	1.46	1H NMR (400 MHz, DMSO-d6) δ 13.20 (S, 1H), 11.69 (s, 1H), 8.00 7.88 (m, 1H), 7.78 - 7.61 (m, 2H}, 7.55 -7.40 (m, 1H), 7.25 (d,J = 8.0 Hz, 1H), 7.09 - 7.00 (m, 1H), 6.85 (dd, J = 8.9, 5.1 Hz, 1H), 6.27 - 6.13 (m, 1H), 3.23 -

1349

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			3.07 (m, 2H), 2.22 - 2.11 (m, IH), 1.87 (dd, J = 11.8, 5.7 Hz, IH), 1.S0 (d, J = 3.4 Hz, 6H), 1.41 (t, J = 12.1 Hz, IH), 0.88 (d,J = 6.1 Hz, 3H).
2296	534.20	1.70
2297	548.23	2.70
2298	501.11	2.43
2299	506.21	2.30
2300	497.30	1.62
2301	522.30	2.22
2302	532.22	1.41
2303	512.23	1.56
2304	491.23	1.61
2305	474.39	2.52
2306	539.40	2.16	IH NMR (400 MHz, DMSO-d6) δ 7.63 (s, IH), 7.49 (S, IH), 7.36 (s, IH), 7.13 (d, J = 6.9 Hz, IH), 7.06 (s, 2H), 6.52 (s, IH}, 6.23 (s, 2H), 5.26 (p, J = 6.2 Hz, IH), 2.91 (S, IH), 2.42 (s, 3H), 2.18 (t, J = 7.4 Hz, IH), 1.83 (dd, J = 11.8, 5.6 Hz, IH), 1.61 (s, 3H}, 1.56 (s, 3H), 1.47 (q, J = 6.6, 6.1 Hz, IH), 1.38 (t, J = 11.9 Hz, IH), 1.30 (d, J = 6.2 Hz, 6H), 0.83 (d, 1 = 5.9 Hz, 3H).
2307	460.29	2.51
2308	471.39	2.51
2309	527,22	2.12
2310	510.41	2.25
2311	474.40	1.00
2312	500.30	1.62	IH NMR (400 MHz, DMSO-d6) δ 12.45 (S, IH), 8.30 (d, J = 2.2 Hz, IH), 7.72 (d, J = 2.3 Hz, IH), 7.68 - 7.53 (m, 2H), 7.51 - 7.43 (m, IH), 7.46 7.34 (m, 2H), 7.21 (d, J = 7.3 Hz, IH), 6.68 (d, J = 8.4 Hz, IH), 6.48 (s, 2H), 2.22 (s, IH), 1.86 (dd, J = 11.9, 5.6 Hz, IH), 1.55 (d, J = 10.4 Hz, 6H}, 1.41 (t, J = 12.0 Hz, IH), 0.87 (d, J = 6.3 Hz, 3H).
2313	564.42	1.95
2314	482.20	1.34
2315	541.30	1.54	IH NMR (400 MHz, DMSO-d6) δ 12.64 -12.32 (m, 2H), 8.22 (dd, J = 7.2, 2.2 Hz, IH}, 7.85 - 7.77 (m, IH), 7.60 (d, J = 7.7 Hz, IH), 6.53 (d, J = 7.8

1350

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			Hz, 1H), 6.43 (t, J = 6.8 Hz, 1H), 2.81 2.72 (m, 1H), 2.67 {d, J = 8.7 Hz, 2H), 2.48 - 2.39 (m, obscured by solvent peak},2.21 (s, 1H), 2.07 (s, 1H), 1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.78 - 1.60 (m, 6H), 1.51 (d, J = 10.8 Hz, 6H), 1.39 (t, J = 12.1 Hz, 1H), 0.89 (d, J = 6.2 Hz, 3H).
2316	509.21	2.17
2317	457.28	2.40
2318	460.29	2.31
2319	510.19	1.02
2320	481.30	2.30
2321	550.33	2.40
2322	536.50	2.01
2323	544.27	1.17
2324	474.09	2.01
2325	610.70	1.93
2326	588.30	1.32	1H NMR (400 MHz, DMSO-d6) δ 12.50 (s, 1H), 8.29 -8.18 (m, 2H}, 8.07 (dd, J = 7.8,1.8 Hz, 1H), 7.86 (d, J = 8.3 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 6.90-6.63 (m,0H), 6.79 (dd, J = 7.8, 4.8 Hz, 1H), 6.14 (d, J = 2.8 Hz, 1H), 4.36 - 4.29 (m, 2H}, 3.79 - 3.71 (m, 2H), 3.62 - 3.54 (m, 2H), 3.52 3.47 (m, 2H), 3.43 (q, J = 7.0 Hz, 2H), 2.46 (d, J = 8.8 Hz, 2H), 2.13 (m, J = 5.8 Hz, 1H), 1.85 (dd, J = 11.9,5.6 Hz, 1H), 1.55 (S, 3H), 1.53 (s, 3H), 1.44 1.33 (m, 1H), 1.09 (t, J = 7.0 Hz, 3H), 0.74 (d, J = 6.3 Hz, 3H).
2327	488.29	1.36
2328	508.31	1.79
2329	503.21	2.21
2330	472.29	2.57
2331	580.00	3.15
2332	485.20	2.20
2333	518.22	1.47
2334	532.16	1.44
2335	561.14	2.31
2336	487.30	2.89
2337	534.25	1.83
2338	506.21	2.08
2339	472.30	1.46

1351

Cmpd, No.	LC/MS M+1	LC/RT min	NMR
2340	484.30	2.52
2341	502.31	1.84
2342	445.28	2.29
2343	490.30	2.55
2344	625.60	1.71	1H NMR (400 MHz, DMSO-d6) δ 12.29 (s, 1H), 7.65 - 7.59 (m, 1H), 7.33 - 7.24 (m, 1H), 7.22 - 7.14 (m, 1H), 6.67 (d, J = 8.4 Hz, 1H), 5.53 (s, 1H), 4.19-4.02 (m, 2H), 2.54 (s, 1H), 2.31 (s, 2H), 2.28 (d,J = 5.3 Hz, 1H), 2.19 (d, J = 6.7 Hz, 1H), 1.83 (dd, J = 11.9, 5.7 Hz, 1H), 1.54 (s, 3H), 1.52 (s, 3H), 1.40 - 1.32 (m, 2H), 1.31 (s, 9H), 1.18 (s, 2H), 1.02 (S, 9H), 0.98 (s, 1H), 0.8S (d, J = 6.2 Hz, 3H). (amide rota mers)
2345	498.53	1.09
2346	474.09	2.70
2347	561.60	2.32
2348	499.40	1.59
2349	500.17	1.29
2350	453.98	1.90
2351	474.30	1.15	1H NMR (400 MHz, DMS0-d6) δ 12.45 (S, 1H), 8.24 (dd, J = 5.0,1.9 Hz, 1H), 8.04 (d, J = 7.7 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 6.77 (dd, J = 7.8, 4.8 Hz, 2H), 6.68 (d, J = 7.8 Hz, 2H), 4.21 (dd, J = 38.7,11.0 Hz, 1H), 4.02 (d, J = 11.4 Hz, 1H), 3.63 - 3.44 (m, 1H), 2.47 2.36 (m, 2H), 2.18 - 2.04 (m, 1H), 2.04 - 1.91 (m, 1H), 1.91 - 1.73 (m, 2H), 1.72 -1.58 (m, 1H), 1.53 (s, 2H), 1.51 -1.42 (m, 6H), 1.43 -1.24 (m, 2H), 0.73 (d, J = 6.1 Hz, 3H).
2352	519.04	1.49
2353	524.52	2.49
2354	462.39	1.84
2355	514.17	1.43
2356	515.22	1.77
2357	526.32	2.22
2358	554.70	1.81	1H NMR (400 MHz, DMSO-d6) δ 12.51 (s, 1H), 8.24 (d, J = 2.8 Hz, 1H), 8.22 (broad S, 1H), 8,00 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.78 - 6.70 (m, 1H),

1352

Cmpd. No.	LC/MS® M+1	LC/RT min	NMR
			6.65 (br s, 2H), 6.16 (d J = 2.7 Hz, 1H), 3.90 (s, 2H), 3.50 (br d, J = 9.9 Hz, 1H), 3.39 (br d, J = 8.8 Hz, 1H), 2.48-2.38 (br m, 2H), 2.26 (dd, J = 11.8, 5.2 Hz, 1H), 1.92-1.90 (brm, 2H), 1.80-1.75 (br m, 2H), 1.61 (br s, 1H), 1.51 (t, J = 11.5 Hz, 1H), 1.01 (s, 9H), 0.78 (d, J = 6.4 Hz, 3H).
2359	495.40	1.34
2360	515.40	1.63	1H NMR {400 MHz, DMSO-d6} δ 12.52 (s, 2H), 8.23 (d, J = 7.1 Hz, 1H), 8.18 (d, J = 2.8 Hz, 1H), 7.87 - 7.71 (m, 2H), 6.86 (d, J = 8.2 Hz, 1H), 6.44 (broad s, 1H), 6.07 (d, J = 2.7 Hz, 1H), 4.85 (sep, J = 6.2 Hz, 1H), 2.71 (brs, 2H), 2.22 {br s, 1H), 1.88 (dd, J = 12.0, 5.6 Hz, 1H), 1.56 (s, 3H}, 1.55 (s, 3H), 1.43 (t, J = 12.0 Hz, 1H), 1.33 (d, J = 2.9 Hz, 3H), 1.32 (d, J = 2.9 Hz, 3H), 0.89 (d, J = 6.3 Hz, 3H).
2361	484.30	1.74	1H NMR (400 MHz, DMSO-d6) 57.96 (s, 1H), 7.51 (S, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.00 (d, J = 7.2 Hz, 1H), 6.41 (d, J = 8.2 Hz, 1H), 5.98 (s, 3H), 5.88 (s, 1H), 3.05 - 2.96 (m, 2H), 2.24 (d, J = 19.4 Hz, 2H), 2.11 (s, 3H), 1.64 (s, 2H), 1.48 (d, J = 5.0 Hz, 7H), 0.97 (d, J = 6.4 Hz, 4H), 0.86 (d, J = 6.3 Hz, 4H).
2362	552.60	1.24
2363	481.23	1.10
2364	525.30	2.04	1H NMR (400 MHz, DMSO-d6} δ 12.49 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.41 (s, 1H), 7.26 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 7.4 Hz, 1H), 7.14 (S, 1H), 6.67 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 4.32 (q, J = 7.0 Hz, 2H), 2.71 - 2.58 (m, 2H), 2.45 (s, 3H), 2.29 - 2.13 (m, 1H), 1.87 (dd, J = 11.9, 5.7 Hz, 1H), 1.60 (s, 3H), 1.59 {s, 2H), 1.42 (t, J = 12.1 Hz, 1H), 1.33 (t, J = 7.0 Hz, 3H), 0.88 (d, J = 6.3 Hz, 3H).
2365	549.43	2.57
2366	550.30	1.72
2367	500.20	1.04
1 2368	508.32	1 1.13

1353

Gmpd. No.	LC/MS M+1	LC/RT _:min	i;' .· C/AJA
2369	511.15	1.63
2370	562.40	1.58
2371	445.28	2.37
2372	502.50	1.59
2373	492.30	1.51	1H NMR (400 MHz, DMS0-d6) δ 12.26 (s, 1H), 7.65 - 7.55 (m, 2H), 7.17 (dd, J = 7.3, 0.7 Hz, 1H), 6.66 (dd, J = 8.5, 0.8 Hz, 1H), 6.45 (s, 2H), 4.88 - 4.57 (m, 1H), 2.63 - 2.51 (m, 1H), 2.43 (t, J = 8.8 Hz, 1H), 2.17 (s, 1H), 1.82 (dd, J = 11.9, 5.6 Hz, 1H), 1.49 -1.26 (m, 10H), 1.19 (dtd, J = 13.5,9.0,8.5,5.1 Hz, 1H), 0.85 (d, J = 6.3 Hz, 3H), 0.62-0.44 (m, 2H), 0.32 0.21 (m, 2H).
2374	569.30	2.39	1H NMR (400 MHz, MeOD) 3 7.87 (d, J = 8.1 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.70 (t, J = 7.9 Hz, 1H), 7.54 (s, 1H), 7.42 (t, J = 7.8 Hz, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 10.5 Hz, 1H), 3.82 (d, J = 6.5 Hz, 2H}, 3.67 (dd, J = 12.3, 6.3 Hz, 1H), 2.66 (t, J = 12.5 Hz, 1H), 2.11 (dt, J = 13.2, 6.6 Hz, 1H), 1.69 (dd, J = 12.5, 6.3 Hz, 1H), 1.57 1.40 (m, 2H}, 1.18 (s, 3H), 1.05 (d, J = 6.9 Hz, 9H), 0.81 (s, 3H), 0.75 (s, 3H).
2375	556.30	2.43	1H NMR (400 MHz, DMSO) δ 12.84 11.49 (m, 1H), 8.30 (d,J = 8.2 Hz, 1H), 8.26 - 8.05 (m, OH), 7.66 (t, J = 7.9 Hz, 1H), 7.56 (s, 1H), 7.50 (d, J = 9.8 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 7.2 Hz, 1H), 6.91 (d, J = 10.7 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.59 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H), 3.35 (d, J = 6.4 Hz, 2H), 2.10 - 1.97 (m, 1H), 1.64 (d, J = 21.5 Hz, 6H), 1.24 - 1.04 (m, 3H), 1.00 (d, J = 6.7 Hz, 6H), 0.94 (d,J = 10.5 Hz, 2H).
2376	540.20	2.11	1H NMR (400 MHz, DMSO) δ 12.50 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.63 (dd, J = 8.3, 7.4 Hz, 1H), 7.46 - 7.38 (m, 2H), 7.34 (d, J = 7.9 Hz, 1H), 7.26 7.20 (m, 1H), 6.88 (dt, J = 10.8, 2.3 Hz, 1H), 6.71 - 6.67 (m, 1H), 6.45 (s, 2H), 4.21 (d, J = 12.9 Hz, 1H), 3.83 (d,

1354

Cmpd. No.,	LC/MS M+1	LC/RT min	NMR
			J = 6.6 Hz, 2H), 2.60 (t, J = 11.5 Hz, IH), 2.47 - 2.39 (m, IH), 2.10 - 1.95 (m, IH), 1.86 (dd, J = 12,8, 6.3 Hz, IH), 1.73 (d, J = 12.8 Hz, IH), 1.58 (d, J = 10.8 Hz, IH), 1,17 (dd, J = 15.0, 8.4 Hz, 2H), 0.99 (d, J = 6.7 Hz, 6H), 0.69 (dt, J = 9.3, 5.7 Hz, IH), -0.11 (t, J = 7.8 Hz, IH).
2377	541.20	1.63	IH NMR (400 MHz, Methanol-d4) 5 9.19 (s, IH), 8.80 (d, J = 5,0 Hz, IH), 8,48 (d, J = 8.1 Hz, IH), 8.00 (d, J = 8.0 Hz, IH), 7.66 (dd, J = 8.1, 4.9 Hz, IH), 7.47 (S, IH), 7.43 (d, J = 8.1 Hz, IH), 7.35 (d, J = 10.2 Hz, IH), 6.75 (d, J = 10.9 Hz, IH), 3.81 (d, J = 6.5 Hz, 2H), 2.98 (t, J = 9.1 Hz, IH), 2.86 (t, J = 10.0 Hz, IH), 2.42 (s, IH), 2.05 (ddd, J = 19.8,13.3, 7.1 Hz, 3H), 1.58 (d, J = 17.4 Hz, 6H), 1.03 (dd, J = 7.5, 3.4 Hz, 6H), 0.94 (d, J = 6.4 Hz,3H).
2378	528,12	2.64
2379	510,17	1.51
2380	510,15	1,46
2381	534.12	2.50
2382	506.21	2.34
2383	529.32	1.55	IH NMR (400 MHz, DMSO) δ 12.56 (s, IH), 10.51 (s, IH), 8.18 - 8.16 (dd, IH), 7.79 - 7.69 (m, 2H), 7.26 - 7.23 (d, IH), 7.13 - 7.10 (d, IH), 6.63 - 6.60 (dd, IH), 4.44 - 4,35 (m, IH), 3.05 (m, 2H), 2.83 - 2.80 (m, 2 H), 2.72 (s, 3H), 2.70 (s, 3H), 2.23 - 2.12 (m, IH), 1.83 -1.73 (m, 3H), 1.60 (m, 3H), 1.52 (s, 3H), 1.49 (S, 3H), 1.37 (t, J = 11,98, IH), 1.09 (m, 2H), 0.79 - 0.77 (d, 3H)
2384	511.25	1.47
2385	526.02	2.69
2386	500.60	1.53
2387	523.32	1.90
2388	532.21	1.49
2389	506.21	1.37	IH NMR (400 MHz, DMSO) S 9.03 9.00 (d, IH), 8.68 (s, IH), 8.40 - 8.30 (m, 2H), 8.18 - 8.16 (dd, IH), 8.08 8.05 (dd, IH), 8.01 (s, IH), 7.87 - 7.84 (dd, IH), 7.63 - 7.60 (dd, IH), 6.66 -

1355

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			6.63 (dd, 1H), 2.28 - 2. 24 (d, 2H), 1.65 -1.47 (m, 2H), 1.47 (s, 3H), 1.40 (s, 3H), 1.17 (t, J = 11.09,1H), 0.15 0.13 (d,3H)
2390	549.13	2.70
2391	494.20	2.42
2392	534.30	1,67
2393	462.39	1.80
2394	498,50	1.58
2395	522.30	1.86
2396	475.29	1.93
2397	534.12	2.50
2398	549.50	2.03
2399	500.19	1.68
2400	547.33	2.26
2401	519.27	1.44
2402	549.13	2.81
2403	528.19	1.46
2404	569.50	1.59
2405	441.40	1,13	1H NMR (400 MHz, DMSO-d6) δ 12.90 (S, 1H), 12.57 (s, 1H), 8.27 (dd, J = 7.3, 2.2 Hz, 1H), S.17 (s, 1H), 7.85 {s, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.62 7.48 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 6.46 (t, J = 6.8 Hz, 1H), 3.01 (t, J = 8.5 Hz, 1H), 2.76 (t, J = 10.1 Hz, 1H), 2.30 - 2.17 (m, 1H), 1.88 (dd, J = 11.8, 5.7 Hz, 1H), 1.63 (S, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.92 (d, J = 6.3 Hz, 3H).
2406	542.20	1.66	1H NMR (400 MHz, DMSO-d6) δ 8.25 (dd, J = 4.8,1.8 Hz, 1H), 8.05 (dd, J = 7.8,1.8 Hz, 1H), 7.92 (d, J = 1.0 Hz, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.71 (s, 1H), 7.07 (d, J = 8.3 Hz, 1H), 6.78 (dd, J = 7.8, 4.8 Hz, 2H), 2.46 (s, 1H), 2.13 (s, 1H), 1.86 (dd, J = 12.0, 5,7 Hz, 1H), 1.56 (d, J = 4.4 Hz, 6H), 1.39 (t, J = 12.2 Hz, 1H), 0.98 (s, 9H), 0.75 (d, J = 6.2 Hz, 3H).
2407	549.43	2.09
2408	513.41	2.62
2409	499.31	2.49
2410	525.30	1.62
2411	481,50	1.83
2412	461.19	2.69

1356

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2413	510.17	1.46
2414	476.29	1.42	1H NMR (400 MHz, DMSO) § 12.09 (s, 1H), 8.14 (s, 3H), 7.92 (d, J = 8.0 Hz, 1H), 7.84 (dd, J = 10.4, 2.0 Hz, 1H), 7.75 (d, J « 7.9 Hz, 1H), 7.56 (td, J = 8.0, 6.2 Hz, 1H), 7.33 - 7.25 (m, 2H), 3.78 (ddd, J = 16.8,10.7, 6.2 Hz, 2H), 3.71 - 3.62 (m, 1H), 3.62 - 3.53 (m, 1H),3.41 (dd, J = 10.0, 4.7 Hz, 1H), 3.10 (t, J = 10.2 Hz, 1H), 2.99 - 2.91 (m, 1H), 2.36 (dd, J = 13.6,9.2 Hz, 1H), 2.28 - 2.16 (m, 1H), 1.97 (dd, J = 12.2, 5.8 Hz, 2H), 1.68 (s, 3H), 1.64 (s, 3H), 1.56 (dd, J = 15.4, 8.1 Hz, 1H), 1.05 (d, J = 6.3 Hz, 3H).
2415	523.32	2.92
2416	538.17	1.49
2417	645.50	1.63	1H NMR (400 MHz, DMSO-d6) δ 12.28 (s, 1H), 7.65 - 7.57 (m, 1H), 7.25 (ddd, J = 34.6,1S.8, 7.3 Hz, 7H), 6.67 (d, J = 8.3 Hz, 1H), 5.50 (d, J = 19.3 Hz, 1H), 4.26 - 3.97 (m, 2H), 3.81 (s, 1H), 3.77 (d, J = 7.4 Hz, 1H), 3.73 3.51 (m, 3H), 2.30 - 2.04 (m, 2H), 1.82 (dd, J = 12.0, 5.7 Hz, 1H), 1.53 (s, 3H), 1.51 (S, 3H), 1.37 (d, J = 10.9 Hz, 2H), 1.27 (s, 9H), 1.17 (s, 1H), 0.84 (d, J = 6.3 Hz, 3H). (rotamers)
2418	517.14	1.14
2419	471.30	1.19
2420	497.51	2.15
2421	516.41	2.36
2422	515.20	1.60
2423	543.43	1.87
2424	481.40	1.50
2425	516.20	1.31	1H NMR (400 MHz, DMSO) δ 12.47 (s, 1H), 7.70 - 7.52 (m, 2H), 7.17 (dd, J = 7.3, 0.5 Hz, 1H), 6.78 - 6.59 (m, 2H), 5.14 (s, 2H), 3.84 (d, J = 3.5 Hz, 2H), 3.30 (d, J = 10.7 Hz, 2H), 2.84 (t, J = 10.0 Hz, 1H), 2.68 - 2.55 (m, 1H), 2.07 (s, 4H), 1.87 - 1.73 (m, 1H), 1.65 (dd, J = 30.6,10.5 Hz, 2H), 1.55 (d, J = 8.6 Hz, 6H), 1.49 (s, 3H), 1.28 (d, J = 6.6 Hz, 10H).

1357

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2426	496.60	1.33
2427	549.60	2.10
2428	511.31	2.44	1H NMR (400 MHz, DMSO) 5 12.79 (S, 1H), 8.19 - 8.17 (dd, 1H), 8.01 (t, J = 7.80,1H), 7.80 - 7.74 (m, 2H), 7.50 7.47 (d, 2H), 7.14 - 7.11 (d, 1H), 6.82 6.79 (d, 2H), 6.64 - 6.61 (dd, 1H), 5.35 - 5,22 (m, 2H), 3 .60 (s, 3H), 2.18 1.87 (m, 3H), 1.77 - 1.70 (m, 1H), 1.49 (S, 3H), 1.44 (S, 3H), 1.31- 1.21 (m, 1H), 0.60-0.58 (d, 3H)
2429	500.20	1.70
2430	405.36	1.83
2431	514.21	1.67
2432	540.40	1.36	1H NMR (400 MHz, Methanol-d4) 5 8.55 (dd, J = 7.6,1.7 Hz, 1H), 8.38 (dd, J = 7.2, 2.1 Hz, 1H), 8.11 (dd, J = 6.0,1.7 Hz, 1H), 7.45 (d, J « 8.1 Hz, 1H), 7.08 - 6.99 (m, 1H), 3.91 {dd, J = 11.5, 8.5 Hz, 1H), 3.47 - 3.34 (m, 1H), 3.14 - 3.05 (m, 1H), 2.91 - 2.75 (m, 1H), 2.48 - 2.32 (m, OH), 2.33 - 2.17 (m, 3H), 1.98 -1.76 {m, 7H), 1.55 (s, 3H), 1.33 (S, 3H), 1.24 (d, J = 6.6 Hz, 3H).
2433	524.52	1.75
2434	459.39	2.51
2435	484.24	0.94
2436	526.40	1.22	1H NMR (400 MHz, DMSO-d6) δ 12.53 (s, 1H), 8.25 (dd, J = 4.8,1.9 Hz, 1H), 8.05 {dd, J = 7.7,1.9 Hz, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.24 (dd, J = 7.7,1.8 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 7.13 - 7.06 (m, 2H), 6.78 (dd, J = 7.8, 4.8 Hz, 3H), 3.85 (s, 3H), 2.53 (s, 2H), 2.15 (s, 1H), 1.82 (dd, J = 11.9, 5.6 Hz, 1H), 1.53 (s, 3H), 1.50 (s, 3H), 1.38 (t, J = 12.1 Hz, 1H), 0.76 (d, J = 6.3 Hz, 3H).
2437	491.40	1.17	1H NMR (400 MHz, DMS0-d6) δ 12.58 (s, 1H), 8.26 (dd, J = 4.8,1.9 Hz, 1H), 8.24 - 8.15 {m, 2H), 8.05 (dd, J = 7.9, 1,8 Hz, 1H), 8.01 - 7.93 (m, 2H), 7.83 {d, J = 8.0 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 6.90 - 6.52 (m, 3H), 2.60 -

1358

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			2.40 (m, 24H), 2.22 - 2.05 {m, 1H), 1.86 (dd, J = 11.9, 5.6 Hz, 1H), 1.60 (s, 3H), 1.56 (s, 3H), 1.40 (t, J « 12.1 Hz, 1H), 0.76 (d, J = 6.3 Hz,3H).
2438	481.30	1.50
2439	587.25	2.39
2440	511.16	1.69	1H NMR (400 MHz, OMSO-d6) 6 12.73 -12.37 (m, 1H}, 8.25 (dd, J = 7.2, 2.2 Hz, 1H), 7.85 - 7.78 (m, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 1.6 Hz, 1H), 7.57 - 7.51 (m, 1H), 7.24 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.46 (t, J = 6.8 Hz, 1H), 3.85 (s, 3H), 2.79 - 2.66 (m, 2H), 2.29 - 2.16 (m, 4H}, 1.89 (dd, J = 11.7, 5.5 Hz, 1H), 1.63 (d, J = 2.7 Hz, 6H), 1.49 -1.41 (m, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2441	533.22	1.45
2442	516.41	2.47
2443	510.41	1.84
2444	516.19	1.61
2445	467.40	1.13	1H NMR (400 MHz, DMSO-d6) δ 12.59 12.53 (d, J = 6.3 Hz, 1H), 8.24 (dd, J = 7.2, 2.2 Hz, 1H), 8.08 - 8.02 (m, 2H}, 7.83 (dt, J = 6.6, 3.3 Hz, 1H), 7.76 (d,J = 8.0 Hz, 1H), 7.54 - 7.46 (m, 2H), 7.46 - 7.40 (m, 1H), 7.19 (d, J = 8.0 Hz, 1H\|, 6.45 (t, J = 6.8 Hz, 1H), 2.82 - 2.63 (m, 2H), 2.30 - 2.18 (m , 1H), 1.89 (dd, J = 11.8, 5.5 Hz, 1H), 1.62 (s, 6H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2446	500.50	1.27
2447	502.48	1.03
2448	538.38	1.61
2449	517.32	1.62	1H NMR (400 MHz, DM5O-d6) Ô 12.92 (s, 1H), 10.37 (s, 1H), 9.22 9.21 (d, 1H), 9.08 - 9.07 (d, 1H), 8.13 8.11 (dd, 1H), 8.02 - 7.93 (m, 2H), 7.87-7.84 (d, 1H), 7.81 - 7.78 (dd, 1H), 7.63 - 7.44 (m, 3H), 7.28 - 7.2 5 (d, 1H), 6.49 - 6.46 (dd, 1H), 2.46 2.42 (m, 2H), 1.63 -1.57 (m, 1H), 1.50 - 1.43 (m, 1H), 1.38 (s, 3H), 1.23 -

1359

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			1.13 (m, IH}, 1.12 (s, 3H}, 0.61 - 0.59 (d, 3H)
2450	524.26	1.52
2451	556.00	1.85
2452	502.31	2.82
2453	476.19	2.13
2454	498.15	1.43
2455	532.50	2.52
2456	499.30	1.56	IH NMR (400 MHz, DMSO-d6} δ 12.58 (s, IH), 12.53 (d, J = 6.2 Hz, IH), 8.25 (dd, J = 7.2, 2.2 Hz, IH), 8.02 - 7.94 (m, IH), 7.91 (td, J = 5.5, 2.7 Hz, IH), 7.88-7.80 (m, IH), 7.74 (d,J = 8.0 Ηζ,ΙΗ), 7.32 - 7.21 (m,lH), 7.16 (d, J = 8.0 Hz, IH), 6.45 (t, J = 6.8 Hz, IH), 2.76 - 2.65 (m, 2H), 2.31 (d, J = 1.8 Hz, 3H), 1.89 (dd, J = 11.9, 5.6 Hz, IH), 1.61 (S, 6H), 1.45 (t, J = 12.1 Ηζ,ΙΗ), 0.91 (d, J = 6.3 Hz, 3 H).
2457	532.16	1.46	IH NMR (400 MHz, DMSO-d6) δ 12,55 (s, IH), 8.26 (dd, J = 4.9,1.8 Hz, IH),8.07 (dd, J = 7.9,1.8 Hz, IH), 7.90 - 7.69 (m, 3H), 7,30 (d, J = 8.0 Hz, IH), 6.80 (dd, J = 7.8, 4,9 Hz, 3H), 3.99 (d, J = 1.0 Hz, 3H), 2.17 (dq, J = 15.9, 6.5 Hz, IH), 1.86 (dd, J = 12.0, 5.6 Hz, IH), 1.60 (s, 3H), 1.56 (s, 3H), 1.41 (t, J = 12.1 Hz, IH), 0.76 (d, J = 6.3 Hz, 3H).
2458	542.40	1.77
2459	529.20	1.62
2460	481.30	2.30
2461	501.41	2.35
2462	517.32	2.56
2463	522.35	1.85	IH NMR (400 MHz, DMSO-d6) 6 12.48 (s, IH), 8.50 (d, J = 2.5 Hz, IH), 7.89 (d, J = 2.4 Hz, IH), 7,63 (t, J = 7.8 Hz, IH), 7.58 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 7.2 Hz, IH), 6.68 (d, J = 8.3 Hz, IH), 6.49 (s, 2H), 2.56 (d, J = 8.8 Hz, 2H), 2.28 2.10 (m, IH), 1,85 (dd, J = 11.9, 5.6 Hz, IH), 1.55 (s, 3H), 1.53 (s, 3H), 1.40 (t, J = 12.1 Hz, IH), 1.32 (s, 9H), 0.87 (d, J = 6.1 Hz, 3H).

1360

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2464	460.29	1.76
2465	524.52	2.33
2466	535.32	2.20
2467	447.30	1.39	1H NMR (400 MHz, DMSO-d6) δ 12.50 (s, 1H), 12.44 (s, 1H), 8.22 (dd, J = 7.2,2.1 Hz, 1H), 7.81 (d, J = 5.8 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 6.47 6.37 (m, 2H), 2.66 (d, J = 8.8 Hz, 2H), 2.48 - 2.38 (m, 2H), 2.25 - 2.14 (m, 1H), 2.14 (s, 1H), 2.13 - 2.03 (m, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.S2 (d, J = 11.0 Hz, 6H), 1.39 (t, J = 12.0 Hz, 1H), 0.93-0.83 (m, 9H).
2468	532.41	1.35
2469	511.16	1.64
2470	509.21	2.73
2471	455.40	1.22	1H NMR (400 MHz, DMSO-d6) 8 12.89 (S, 1 H), 12.57 (s, 1H), 8.27 (dd, J = 7.2, 2.1 Hz, 1H), 8.09 (s, 1H), 7.85 {dd, J = 6.4, 2.2 Hz, 1H), 7.49 (s, 1H), 7.48 - 7.39 (m, 2H), 6.46 (dd, J = 7.2, 6.4 Hz, 1H}, 3.04 - 2.95 (m, 1H), 2.76 (t, J = 10.1 Hz, 1H), 2.40 (s, 3H), 2.31 2.18 (m, 1H), 1.87 {dd, J = 11.9, 5.7 Hz, 1H), 1.61 (d, J = 3.8 Hz, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2472	490.32	1.50
2473			1H NMR (400 MHz, DMSO-d6) δ 12.62 (s, 1H), 7.73 (d, J = 11.4 Hz, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.35 (s, 1H), 7.23 (dd, J = 15.3, 8.6 Hz, 2H), 6.96 (dt, J = 10.8, 2.4 Hz, 1H), 6.70 (d, J = 8.5 Hz, 1H), 6.53 (s, 1H), 3.82 (d, J = 6.6 Hz, 2H), 2.69 - 2.52 {m, 2H), 2.22 (s, 1H), 2.05 (hept, J = 6.6 Hz, 1H), 1.87 (dd, J = 11.9, 5.6 Hz, 1H}, 1.54 (d, J = 6.7 Hz, 6H), 1.41 (t, J = 12.1 Hz, 1H), 0.98 (d, J = 6.6 Hz, 6H), 0.87 (d,J = 6.3 Hz, 3H).
2474	514.21	1.42
2475	588.50	1.62
2476	550.33	2.40
2477	582.60	1.82
2478	505.22	1.36

1361

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2479	570.40	2.14	1H NMR {400 MHz, DMSO} S 12.46 {s, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.64 {dd, J = 8.4, 7.3 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.47 - 7.40 (m, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.22 {dd, J = 7.3, 0.6 Hz, 1H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 6.71 (dd, J = 8.4, 0.6 Hz, 1H), 6.50 (s, 2H), 3.89-3.75 (m,3H),3.15 (dd, J = 9.8, 4.4 Hz, 1H), 2.75 (ddd, J = 18.0, 13.7, 7.5 Hz, 2H), 2.03 (td, J = 13.3, 6.6 Hz, 2H), 1.68 -1.47 (m, 3H), 1.34 {d, J = 7.5 Hz, 1H), 0.99 (d, J = 6.7 Hz, 6H), 0.88 (dt, J = 23.3,11.7 Hz, 7H).
2480	483.40	1.38	1H NMR (400 MHz, DMS0-d6) δ 12.67 (s, 1H), 12.53 (s, 1H), 11.94 (s, 1H), 8.25 (dd, J = 7.3, 2.1 Hz, 1H), 7.89 - 7.81 (m, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.26 (ddd, J = 8.5, 7.2,1.7 Hz, 1H), 6.95 6.86 (m, 2H), 6.50 - 6.41 (m, 1H), 2.85 - 2.74 (m, 2H), 2.32 - 2.18 (m, 1H), 1.91 (dd, J = 11.9, 5.6 Hz, 1H), 1.54 (d, J = 5.3 Hz, 6H}, 1.46 (t, J = 12.0 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2481	540.20	1.67
2482	514.21	1.43
2483	509.50	1.84	1H NMR (400 MHz, DMS0-d6) δ 12.56 (s, 1H), 12.55 - 12.49 (m, 1H), 8.24 (dd, J = 7.2, 2.0 Hz, 1H), 7.97 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 6.5 Hz, 1H}, 7.74 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 6.44 (t, J = 6.8 Hz, 1H), 2.93 {p, J = 6.9 Hz, 1H), 2.78 - 2.69 (m, 2H), 2.24 {s, 1H), 1.88 (dd, J = 11.9, 5.5 Hz, 1H}, 1.61 (s, 6H), 1.44 (t, J = 12.0 Hz, 1H), 1.23 (d, J = 6.9 Hz, 6H), 0.91 (d, J = 6.2 Hz, 3H).
2484	491.20	2.10
2485	497.30	1.33	1H NMR {400 MHz, DMS0-d6) 3 12.58 (s, 2H), 8.24 (dd, J = 7.2, 2.2 Hz, 1H), 7.83 (s, 1H}, 7.72 - 7.64 (m, 2H), 7.38 (td, J = 7.9,1.8 Hz, 1H), 7.14 (d, J = 8.4 Hz, 1H), 7.05 (dd, J = 8.2, 6.5 Hz, 2H}, 6.45 (t, J = 6.7 Hz, 1H), 3.82 (s, 3H), 2.78 - 2.66 (m, 2H), 2.22 {d, J =

1362

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			12.7 Hz, 1H), 1.85 (dd, J = 12.0, 5.7 Hz, 1H), 1.54 (s, 6H), 1.42 (t, J = 12.0 Hz, 1H), 0.91 (d, J = 6.2 Hz, 3H).
2486	509.21	2.53	1H NMR {400 MHz, DMSO-d6) δ 12.85 (S, 1H), 8.21 - 8.15 (m, 2H), 7.91 - 7.88 (d, 1H), 7.44 - 7.26 (m, 5H), 7.03 - 7.01 (dd, 1H), 6.61 - 6.58 {dd, 1H), 3.05 - 2.94 (m, 1H), 2.63 2.59 (m, 1H), 2.26 - 2.19 (m, 1H), 1.90 -1.83 (m, 1H), 1.51 (s, 3H), 1.47 {s, 3H), 1.47 -1.36 (m, 1H}, 1.12 -1.09 (d, 3H), 1.10 -1.07 (d, 3H}, 0.89 - 0.87 (d, 3 H)
2487	499.20	0.64
2488	530.22	2.14
2489	494.28	1.47
2490	490.32	1.45
2491	499.40	1.51
2492	569.30	2.41	1H NMR {400 MHz, MeOD) δ 7.87 (d, J = 8.2 Hz, 1H), 7.76 (d, J = 8.2 Hz, 1H), 7.70 (dd, 1 = 8.3,7.4 Hz, 1H), 7.54 {s, 1H), 7.46 - 7.38 {m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.75 (dt, J = 10.5, 2.3 Hz, 1H), 3.82 (d, J = 6.5 Hz, 2H}, 3.67 (dd, J = 12.3, 6.4 Hz, 1H), 2.66 (t, J = 12.S Hz, 1H), 2.11 (dt, J = 13.3, 6.7 Hz, 1H), 1.69 {dd, J = 12.6, 6.3 Hz, 1H), 1,49 (dd, J = 38.8,13.1 Hz, 2H), 1.18 (d, J = 5.6 Hz, 3H), 1.10 -1.00 {m, 9H), 0.81 (S, 3H), 0.75 (s, 3H).
2493	524.52	2.39
2494	510.16	1.42
2495	518.22	2.30
2496	533.31	1.15	1H NMR {400 MHz, DMSO) δ 12.62 (s, 1H), 12.54 (s, 1H), 11.31 (s, 1H), 8.25 (dd, J = 7.3, 2.1 Hz, 1H), 7.83 (s, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.54 - 7.49 (m, 1H), 7.47 (t, J = 5.8 Hz, 2H), 7.23 7.18 (m, 1H), 7.11 (d,J = 7.9 Hz, 1H), 6.70 (S, 1H), 6.45 (t, J = 6.9 Hz, 1H), 2.84 - 2.70 (m, 2H), 2.25 (s, 1H), 1.87 (dd, 1 = 11.5, 5.3 Hz, 1H), 1.59 (d, J = 3.9 Hz, 6H), 1.45 (t, J = 11.7 Hz, 1H), 0.92 (d, J = 6.3 Hz, 3H)..
2497	569.30	1.39

1363

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2498	509.50	1.84
2499	510.31	1.62
2500	552.60	1.33
2501	467.19	2.63	1H NMR (400 MHz, DMSO) δ 12.23 (s, 1H), 8.23-8.21 (dd, 1H), 7.90-7.87 (dd, 1H), 7.74 - 7.62 (m, 4H), 7.48 (t, J = 7.47,1H), 7.25 - 7.22 (d, 1H), 7.06 7.03 (dd, 1H), 6.74 - 6.71 (d, 1H), 6.55 -6.49 (m,3H), 1.56-1.53 (d,3H)
2502	508.31	2.50
2503	531.12	2.53
2504	550.33	1.74
2505	498.53	1.09
2506	517.32	1.87
2507	471.39	2.22
2508	599.60	2.25
2509	467.19	2.14
2510	538.31	1.68
2511	548.30	2.27
2512	523.36	1.74
2513	502.31	2.51
2514	551.30	1.60	1H NMR (400 MHz, DM$O-d6) δ 12.63 (s, 1H), 12.55 (s, 1H), 8.25 (dd, J = 7.3, 2.1 Hz, 1H), 7.83 (dd, J = 6.4, 2.2 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.71 (dd, J = 7.2, 2.3 Hz, 1H), 7.60 7.43 (m, 3H), 6.84 (d, J = 7.8 Hz, 1H), 6.45 (t, J = 6.8 Hz, 1H), 2.81 - 2.65 (m, 2H), 2.30 - 2.14 (m, 1H), 1.85 (dd, J = 11.9, 5.6 Hz, 1H), 1.51 (d, J = 8.1 Hz, 6H), 1.43 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.3 Hz, 3H).
2515	524.34	1.50
2516	525.30	1.30	1H NMR (400 MHz, DM$O-d6) δ 12.62 - 12.42 (m, 2H), 8.24 (dd, J = 7.2, 2.1 Hz, 1H], 7.87 - 7.78 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.61 - 7.51 {m, 2H), 7.10 (d, J = 8.0 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.44 (t, J = 6.8 Hz, 1H), 4.28 (s, 4H), 2.79 - 2.68 (m, 2H), 1.88 (dd, J = 11.5, 5.4 Hz, 1H), 1.60 (s, 6H), 1.44 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.2 Hz, 3H).
2517	509.21	1.51
2518	524.22	2.59

1364

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2519	454.30	1.27
2520	652.60	1.67
2521	533.22	1.61
2522	524.19	1.36
2523	535.32	2.19
2524	499.31	2.49
2525	502.33	1.46
2526	510.41	2.54
2527	515.30	1.53
2528	433.27	2.30
2529	504.11	2.45
2530	511.15	1.59
2531	537.43	1.46
2532	556.20	2.00	1H NMR (400 MHz, DMSO) δ 12.66 (s, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.65 (t, J = 7.8 Hz, 1H), 7.50 - 7.41 (m, 3H), 7.22 (d, J « 7.3 Hz, 1H), 6.91 (d, J = 10.9 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.47 (s, 1H), 3.85 (d, J = 6.5 Hz, 2H), 3.51 (d, J = 8.5 Hz, 1H), 3.40 (d, J = 12.8 Hz, 1 H), 3.13 (d, J = 11.8 Hz, 1H), 2.97 (d, J = 6.0 Hz, 1H), 2.06 (d, J = 9.3 Hz, 1H), 1.89 - 1.72 (m, 2H), 1.42 (s, 2H}, 1.00 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H).
2533	517.32	2.55
2534	565.50	1.97
2535	404.46	1.96
2536	544.33	2.76
2537	559.04	2.32
2538	598.50	2.21	1H NMR (400 MHz, DMSO) S7.54 (d, J = 7.6 Hz, 1H), 7.46 (s, 1H), 7.38 (dd, J = 17.3, 9.4 Hz, 2H), 7.05 (dd, J « 14.0,7.6 Hz, 2H), 6.79 (d, J = 10.6 Hz, 1H), 6.42 (d, J = 8.0 Hz, 1H), 5.99 (s, 2H), 3.82 (d, J = 6.7 Hz, 2H), 3.59 (t,J = 10.8 Hz, 1H), 3.08 - 2.98 (m, 1H), 2.05 (dt, J = 13.7, 6.8 Hz, 2H), 1.58 (dd, J = 26.1,16.0 Hz, 8H), 0.99 (d, J = 6.7 Hz, 6H), 0.87 (d, J = 24.3 Hz, 9H).
2539	550.26	1.03
2540	624.30	0.89	1H NMR (300 MHz, CDCI3) δ 8.73 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.04 (t, J = 7.9 Hz, 1H), 7.98 - 7.89 (m, 2H), 7.56 (dd,J = 8.2,1.9 Hz, 1H),

1365

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			7.51 (d, J = 2.4 Hz, 2H), 4.21 (d, J = 6.1 Hz, 2H), 4.10 (t, J = 6.4 Hz, 2H), 2.73 (t, J = 6.9 Hz, 2H), 2.64 - 2.47 (m, 4H), 2.11 (d, J = 2.8 Hz, 2H), 2.00 -1.85 (m, 4H), 1.34 (d, J = 6.6 Hz, 6H), 1.25 (S, 6H), 1.11 (t, J = 7.4 Hz, 5H), 0.93 0.79 (m, 3H).
2541	525.40	1.55
2542	485.50	1.52
2543	546.27	1.16
2544	488.20	2.47
2545	530.14	1.78
2546	S33.22	1.98
2547	S24.30	1.28
2548	454.30	1.27
2549	525.60	1.72	1H NMR (400 MHz, DMS0-d6) 5 12.59 (s, 1H), 12.53 (s, 1H), 8.24 (d, J = 7.4 Hz, 1H), 7.83 (d, J = 6.0 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.58 (d, J = 7.5 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H),7.OO6.93 (m, 1H), 6.45 (t, J = 7.0 Hz, 1H), 4.66 (p, J = 6.1 Hz, 1H), 2.75 (q, J = 9.8, 9.0 Hz, 2H), 2.24 {s, 1H), 1.89 (dd, J = 11.9, 5.5 Hz, 1H), 1.62 {s, 6H), 1.45 {t, J = 12.1 Hz, 1H), 1.31 (d, J = 6.0 Hz, 6H), 0.91 (d, J = 6.3 Hz, 3H).
2550	512.51	1.80
2551	497.51	2.16	1H NMR (400 MHz, DMSO-d6) 5 12.90 (s, 1H), 8.21 - 8.15 (m, 2H), 7.92 - 7.89 (d, 1H), 7.50 - 7.47 (dd, 1H) 7.39 - 7.33 (m, 2H), 6.87 - 6.84 (dd, 1H), 6.75 (s, 1H), 6.75 - 6.72 (d, 1H}, 6.61 - 6.58 (dd, 1H), 3.73 (s, 3H ), 2.27 - 2.18 (m, 1H), 1.89 -1.82 (m, 1H), 1.51 (s, 3H), 1.47 (s, 3H), 1.47 1.35 (m, 1H), 0.89 - 0.87 (d, 3H)
2552	568.20	2.00
2553	458.40	1.26
2554	490.30	1.86	1H NMR (400 MHz, Methanol-d4) 5 8.27 (d, J = 2.8 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 6.00 (d, J = 2.8 Hz, 1H), 3.90 (s, 2H), 3.15 3.04 (m, 2H}, 2.41 (dd, J = 11.2,5.6 Hz, 1H), 1.98 (dd, J = 11.9, 5.8 Hz,

1366

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			IH), 1.67 (d, J = 13.8 Hz, 6H), 1.61 {d, J = 12.2 Hz, IH), 1.36 (ddd, J = 9.5, 7.0, 4.7 Hz, IH), 1.28 - 1.13 (m, 2H), 1.09 (d, J = 6.4 Hz, 4H), 1.04 (s, 9H).
2555	482.60	1.46
2556	511.33	0.90
2557	510.30	1.54
2558	552.39	1.97
2559	502.50	1.61
2560	542.32	3.22	IH NMR (400 MHz, DMS0-d6} S 12.57 (s, IH), 8.06 - 7.96 (m, 2H), 7.78 - 7.70 (m, 2H), 7.67 (dd, J = 8.4, 6.8 Hz, 2H), 7.51-7.45 (m, IH), 7.40 (dt, J = 10.1, 1.8 Hz, IH), 7.27 (d, J = 8.0 Hz, IH), 6.89 (dt, J = 10.8, 2.2 Hz, IH}, 3.83 (d, J = 6.6 Hz, 2H), 2.07 (ddt, J = 23.2, 13.3, 6.4 Hz, 2H), 1.83 (dd, J = 11.9, 5.7 Hz, IH), 1.57 (d, J = 18.0 Hz, 6H), 1.38 (t,J = 12.1 Hz, IH), 0.98 (d, J = 6.7 Hz, 6H), 0.66 (d, J = 6.3 Hz, 3H).
2561	444.38	2.06
2562	514.20	1.38
2563	532.32	2.58	IH NMR (400 MHz, DMS0-d6) δ 12.86 (s, IH), 8.23 - 8.13 (m, 2H), 7.92 - 7.89 (d, IH), 7.69 - 7.65 (d, 2H), 7.49 - 7.38 (m, 4H), 7.28 - 7.24 (d, 2H), 6.57 - 6.54 (dd, IH), 6.28 (t, J = 2.20, 2H), 2.28 - 2.18 (m, IH), 1. 89 1.82 (m, IH), 1.51 (s, 3H), 1.47 (s, 3H), 1.46 - 1.34 (m, IH), 0.90 - 0.87 {d, 3H)
2564	511.09	1.41
2565	529.32	1.96
2566	484.50	1.52
2567	533.30	1.52
2568	570.40	1.30	IH NMR (400 MHz, DMS0-d6} δ 12.40 (s, IH), 7.69 (d,J = 8.0 Hz, IH), 7.62 (dd, J = 8.5, 7.3 Hz, IH), 7.19 (d, J = 7.0 Hz, IH), 6.85 (d, J = 8.1 Hz, IH), 6.80 (dq, J = 4.3,1.8 Hz, IH), 6.68 (d, J = 8.4 Hz, IH), 5.70 (s, IH), 4.20 (q, J = 2.4 Hz, 2H), 3.39 - 3.32 (m, 2H), 2.55 (d, J = 8.7 Hz, 2H), 2.27 (s, 2H), 2.18 (dd, J = 12.7, 6.4 Hz, IH),

1367

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
			1.84 (dd, J = 11.8, 5.6 Hz, 1H), 1.53 (s, 6H), 1.40 (d, J = 12.2 Hz, 1H), 1.26 (s, 9H), 0.86 (d, J = 6.3 Hz,3H).
2569	509.21	1.98
2570	502.29	1.47
2571	530.22	2.49
2572	480.10	2.68
2573	610.20	2.23
2574	430.27	1.81
2575	525.37	1.08
2576	553.40	2.74	1H NMR (400 MHz, DMSO) 38.61 (d, J = 2.3 Hz, 1H), 8.08 (d, J = 2.5 Hz, 1H), 7.56 {d, J = 7.7 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 6.97 (dd, J = 7.4,3.2 Hz, 2H), 6.49 (d, J = 8.3 Hz, 1H), 6.23 (s, 2H), 5.16 (h, J = 6.3 Hz, 1H}, 2.97 (t, J = 10.6 Hz, 1H), 2.91 - 2.81 (m, 1H), 2.17 (s, 3H), 2.09 (qt, J = 11.8, 7.9, 6.2 Hz, 1H), 1.81 (dd, J = 11.5, 5.6 Hz, 1H), 1.75 - 1.64 (m, 2H), 1.61 (s, 3H), 1.56 (s,3H), 1.36 (t, J = 12.0 Hz, 1H), 1.28 (d, J = 6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 3H), 0.80 (d, J = 6.2 Hz, 3H).
2577	472.50	1.57	1H NMR (400 MHz, DMSO) δ 12.35 (s, 1H), 7.59 (d, J = 7.7 Hz, 2H), 7.14 (d, J = 6.7 Hz, 1H), 6.73 - 6.58 (m, 2H), 6.43 (s, 2H), 2.79 (s, 1H), 2.62 {s, 1H), 1.80 - 1.59 (m, 2H), 1.56 (s, 3H), 1.51 (s, 3H), 1.27 (S, 9H), 1.13 - 1.03 (m, 1H), 0.71 - 0.58 (m, 1H), 0.56 - 0.46 (m, 1H), 0.46 - 0.33 (m, 1H), 0.24 (td, J = 9.2, 5.0 Hz, 1H), 0.12 - 0.01 (m, 1H).
2578	543.40	1.92	1H NMR (400 MHz, DMSO-d6) δ 12.52 (S, 2H), 8.23 (d, J = 7.4 Hz, 1H), 8.20 (d, J = 2.7 Hz, 1H), 7.87 - 7.74 (m, 2H), 6.88 (d, J = 8.2 Hz, 1H), 6.51 6.38 (m, 1H), 6.13 (d, J = 2.7 Hz, 1H), 3.89 (s, 2H), 2.71 (broad d, J = 8.6 Hz, 2H), 2.22 (br s, 1H), 1.88 (dd, J = 12.0, 5.6 Hz, 1H), 1.56 (s, 3H), 1.55 (s, 3H), 1.43 (t, J = 12.1 Hz, 1H), 1.00 (s, 9H), 0.89 (d, J = 6.3 Hz, 3H).
2579	510.41	2.16
2580	510.11	2.33

1368

Cmpd. No.	LC/MS M+1	LC/RT min	NMR
2581	570.20	1.88	1H NMR (400 MHz, DMSO} 58.41 (d, J = 8.2 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 7.65 - 7.49 (m, 3H), 7.19 (d, J = 7.2 Hz, 1H), 7.01 (d,J = 10.9 Hz, 1H), 6.65 (d, J = 8.3 Hz, 1H), 6.30 (s, 1H), 3.87 (d,J = 6.5 Hz, 2H), 3.82-3.74 (m, 1H), 3.18 (d, J = 10.9 Hz, 1H), 2.06 (dt, J = 13.2, 6.6 Hz, 2H), 2.01 -1.59 (m, 4H), 1.58 (s, 3H), 1.13 (s, 3H), 0.99 (t,J = 6.9 Hz, 9H}.
2582	555.10	1.47	1H NMR (400 MHz, DMSO) 5 12.41 (s, OH), 3.32 - 3.32 (m, 6H), 8.66 (d, J = 2.4 Hz, 2H), 8.14 (d, J = 2.4 Hz, 2H), 7.68 (s, 2H), 7.55 (s, 1H), 7.12 (s, 4H}, 6.60 (s, 1H), 6.33 (s, OH), 4.52 - 4.39 (m, 5H), 3.74 - 3.65 (m, SH), 2.86 2.61 (m, 1H}, 2.21 (s, 7H), 2.19 - 2.10 (m, 5H), 1.85 (dd, J = 11.7, 5.6 Hz, 2H), 1.61 (s, 7H), 1.58 (s, 7H), 1.40 (t, J = 11.9 Hz, 2H), 0.86 (d, J = 6.3 Hz, 8H).
2583	509.20	1.57
2584	491.30	1.51
2585	515.21	2.65
2586	521.30	1.72	1H NMR (400 MHz, DMSO) 5 7.62 (t, J = 7.9 Hz, 1H), 7.51 (d, J = 14.0 Hz, 1H), 7.16 (d, J = 7.3 Hz, 1H), 6.67 (d, J = 8.3 Hz, 1H), 3.73 (t, J = 4.9 Hz, 2H), 3.48 - 3.42 (m, 2H), 3.33 (s, 2H}, 2.70 - 2.54 (m, 2H), 2.27 - 2.15 (m, 1H), 1.85 (dd, J = 11.9, 5.9 Hz, 1H), 1.51 1.32 (m, 8H), 1.18 (d, J = 10.2 Hz, 7H}, 0.88 (d, J = 6.2 Hz, 3H).
2587	490.32	1.52
2588	586.35	1.88
2589	582.20	2.05
2590	496.27	1.11
2591	519.12	2.49
2592	496.60	1.45
2593	534.22	1.07
2594	554.50	1.78	1H NMR (400 MHz, DMSO-06) 5 12.51 (broad s, 1H), 8.25-8.23 (m, 2H), 8.02 (dd, J = 7.8,1.9 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.76 (dd, J = 7.8,4.7 Hz, 1H),

1369

Cmpd.	LC/MS	LC/RT^
No. <	Æ M+1 ^:	: m in W	• · '· ···.
			6.67 (br S, 2H), 6.16 (d, J = 2.7 Hz, 1H), 3.90 (s, 2H), 3.49 (br d, J = 9.9 Hz, 1H), 3.39 (br d, J « 8.9 Hz, 1H), 2.47 - 2.30 (m, 2H), 2.26 (dd, J = 11.8, 5.2 Hz, 1H), 1.92-1.90 (m, 2H), 1.85 1.72 (m, 2H), 1.61 (br s, 1H), 1.51 (t, J = 11.5 Hz, 1H), 1.01 (s, 9H), 0.78 (d, J = 6.4 Hz, 3H).
2595	537.43	2.64
2596	651.50	1.82
2597	470.49	1.34
2598	519.12	2.54	1H NMR (400 MHz, DMSO-d6) δ 12.92 (s, 1H), 8.27 - 8-17 (m, 2H), 7.97 - 7.94 (d, 1H), 7.59 - 7.38 (m, 5H), 6.65 - 6.62 (dd, 1H), 2.63 - 2.54 (m, 1H), 2.28 - 2.20 (m, 1H), 1.89 1.82 (m, 1H), 1.50 (s, 3H), 1.46 (s, 3H) , 1.40-1.35 (m, 1H), 0.89 - 0.87 (d, 3H)
2599	458.18	1.80
2600	546.13	2.70
2601	541.33	1.65
2602	476.19	2.38
2603	542.20	1.85
2604	540.20	1.67	1H NMR (400 MHz, DMSO) 8 12.50 (s, 1H), 8.25 (dd, J = 4.8, 2.1 Hz, 2H), 8.03 (dd, J = 7.8,1.8 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8-2 Hz, 1H), 6.75 (dt, J = 26.8,13.4 Hz, 3H), 6.15 (d, J = 2.7 Hz, 1H),3.99 (d, J = 6.6 Hz, 2H), 3.49 (d, J = 9.5 Hz, 1H), 3.38 (d, J = 8.7 Hz, 1H), 2.40 (dt, J = 27.2, 9.9 Hz, 2H), 2.26 (dd, J = 11.8,4.8 Hz, 1H), 2.10-2.01 (m, 1H), 1.91 (dd, J = 15.4, 8.5 Hz, 2H), 1.78 (dd, J = 12.4, 7.5 Hz, 2H), 1.67 -1.56 (m, 1H), 1.52 (t, J = 11.5 Hz, 1H), 0.98 (d, J = 6.7 Hz, 6H), 0.78 (d, J = 6.3 Hz, 3H).
2605	486.33	1.53
2606	515.40	1.46
2607	524.23	1.48
2608	560.27	1.30
2609	458.18	2.31
2610	505.01	2,51	1H NMR (400 MHz, DMSO) δ 12.82 (s, 1H), 8.19 - 8.17 (dd, 1H), 8.05 (t, J

1370

	lUCZMSa M*
			= 7.91,1H), 7.79 - 7.72 (m, 2H), 7.56 7.53 (d, 2H), 7.42 - 7.39 (d, 2H), 7.21 7.18 (d, 1H), 6.64-6.61 (dd, 1H),5.38 (s, 2H), 4.18 (s, 1H), 2.26 - 2.10 (m, 2H), 2.00 - 1.89 (m, 1H), 1.79 -1.72 (m, 1H), 1.50 (s, 3H), 1.45 (s, 3H), 1.28 (t, J = 11.86, 1H), 0.61 - 0.59 (d, 3H)
2611	517.32	2.42
2612	569.70	1.44
2613	498.53	1.07
2614	512.18	1.25
2615	438.07	1.77
2616	498.50	1.58
2617	419.16	2.05
2618	549.43	2.73
2619	481.30	2.47
2620	529.32	1.56
2621	537.43	1.79
2622	557.40	1.39	1H NMR (400 MHz, DMS0-d6) δ 12.39 (S, 1H), 7.69 (d,J = 8.1 Hz, 1H), 7.62 (t, J = 7.1 Hz, 1H), 7.19 (d, J = 7.1 Hz, 1H), 6.91 (s, 1H), 6.76 (s, 1H), 6.68 {d, J = 8.5 Hz, 1H), 4.80 (h, J = 6.1 Hz, 1H), 4.35 (d, J = 16.5 Hz, 2H), 3.49 (t, J = 5.9 Hz, 2H), 2.55 (d, J = 8.9 Hz, 1H), 2.35 - 2.27 (m, 2H), 2.26 - 2.08 (m, 1H}, 1.85 (dd, J = 11.9, 5.6 Hz, 1H), 1.53 (d, J = 2.6 Hz, 6H), 1.39 (t,J = 12.1 Hz, 1H), 1.21 (d, J = 1.8 Hz, 1H), 1.19 (s, 3H), 1.18 (s, 3H), 0.87 (d, J = 6.3 Hz, 3H).
2623	524.57	1.04
2624	557.40	1.82
2625	513.41	2.78
2626	495.40	1.62	1H NMR (400 MHz, DMS0-d6) δ 12.57 (s, 1H), 12.52 (s, 1H), 8.24 (dd, J = 7.3,2.2 Hz, 1H), 7.83 (d,J = 7.4 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.07 (s, 1 H), 6.44 (t, J = 6.9 Hz, 1H), 2.77 - 2.63 (m, 2H), 2.33 (s, 6H), 2.29 - 2.15 (m, 1H), 1.88 (dd, J = 11.7, 5.5 Hz, 1H), 1.61 (s, 6H), 1.51 1.37 (m, 2H), 0.91 (d, J = 6.3 Hz, 3H).
2627	539.23	2.51

1371

Ow		gLG/RTW
2628	515.21	1.38
2629	539.50	1.78	1H NMR {400 MHz, DMSO-d6) δ 12.55 {d, J = 13.7 Hz, 2H), 8.24 {dd, J = 73, 2.1 Hz, 1H), 7.85 - 7.78 (m, 1H), 7.73 (dd, J = 7.7,1.8 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.35 (ddd, J = 8.6,7.3, 1.8 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.11 (dd, J = 8.4,1.1 Hz, 1H), 7.08 7.01 {m, 1H}, 6.44 (t,J = 6.8 Hz, 1H), 3.84 (dd, J = 6.4, 2.2 Hz, 2H), 2.76 2.65 (m, 2H), 2.23 {s, 1H), 2.10 - 1.98 (m, 1H), 1.86 (dd, J = 11.8, 5.6 Hz, 1H), 1.55 (d, J = 4.8 Hz, 6H), 1.48 138 (m, ÏH), 0.99 (d,J = 6.7 Hz, 6H), 0.91 (d, J = 63 Hz, 3H).
2630	48730	2.91
2631	578.20	2.10
2632	528.12	232
2633	595.70	1.57	1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 7.69 (dd,J = 8.1, 2.7 Hz, 1H), 7.62 {t, 1H), 7.19 (d, J = 7.4 Hz, 1H), 6.95 {d, J = 8.1 Hz, 0.5 H}, 6.86 {d, J = 8.1 Hz, 0.5 H), 6.83 - 6.74 (m, 1H), 6.68 (d, J = 8.5 Hz, 1H}, 4.43 (d, J = 11.6 Hz, 2H), 2.55 (d, J = 8.9 Hz, 1H), 234 (d, J = 6.2 Hz, 1H}, 2.25 (d, J = 6.7 Hz, 3H), 2.20 (s, 1H), 1.85 (ddd, J = 11.9, 8.8, 5.6 Hz, 1H), 1.70 - 1.58 (m, 6H), 1.55 (two singlets, 3H), 1.53 ((two singlets, 3H), 139 (td, J = 12.2, 3.8 Hz, 2H), 130 - 1.05 (m, 4H), 1.05 0.88 (m, 3H), 0.87 (d, J = 63 Hz, 3H).
2634	573.20	1.73	1H NMR (400 MHz, Methano!-d4) δ 7.69 (s, 1H), 732 (t, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.08 (dd, J = 73, 0.8 Hz, 1H), 6.62 - 6.51 (m, 2H}, 6.44 (dd, J = 193, 9.7 Hz, 2H), 3.58 (s, 1H), 3.49 (d, J = 6.4 Hz, 2H), 2.52 (t, J = 0.8 Hz, 1H), 2.4S (s, 1H), 1.90 (S, 1H), 1.82 - 1.69 (m, 2H), 1.53 (s, 1H), 1.04 (s, 3H), 0.92 (s, 6H), 0.74 {d, J = 6.7 Hz, 6H).
2635	509.30	1.63
2636	506.19	1.26
2637	497.51	2,10
2638	498.50	1.65

1372

Gmpd.-. «e	HS	ÎLC/RTJ wmin^
2639	466.29	2.26	IH NMR (400 MHz, DMSO-d6) δ 12.75 (S, IH), 9.62 (s, IH), 8.14 8.12 (dd, IH), 7.87 - 7,70 (m, 4H), 7,47 - 7.44 (d, IH), 7.26 (t, J = 7.91, 2H), 7,09 - 7.06 (d, IH), 6.94 (t, J = 7.36, IH), 6.53 - 6.50 (dd, IH), 2.47 2.43 (m, IH), 1.87 -1.70 (m, 2H), 1,45 (s, 3H), 1.41 (s, 3H), 1.29 (t, J = 11.86, IH), 0.73-0.71 (d, 3H)
2640	516.41	2.36
2641	526.32	2.54
2642	538.33	2.48
2643	532.32	1.45
2644	516.30	1.29
2645	545.23	2.66
2646	497.22	1.31	IH NMR (400 MHz, DMSO-d6) 58.27 (ddd, J = 11.0, 5.1, 2,6 Hz, 2H), 8.06 (dt, J = 7,8, 2.3 Hz, IH), 7.82 (dd, J = 7.9, 2.9 Hz, IH), 7.58 (s, IH), 7.39 (s, IH), 7.34 (dd, J = 7.8, 2.9 Hz, IH), 6.97 - 6.56 (m, 4H), 3.97 - 3.85 (m, 3H), 2.59 (S, 2H), 2.16 (s, IH), 1.85 (s, IH), 1.58 (dd, J = 15.1, 2.8 Hz, 6H), 1.40 (t, J = 12.3 Hz, IH), 0.76 (dd, J = 6.3, 3.0 Hz, 3H}.
2647	486.33	1.80	IH NMR (400 MHz, DMSO-d6) S 12.41 (s, IH), 8.16 (d, J = 2.3 Hz, IH), 7.68 (d, J = 2.3 Hz, IH), 7.62 (dd, J = 8.4, 7.3 Hz, IH), 7.20 (d, J = 7,2 Hz, IH), 6,68 (d, J = 8,2 Hz, IH), 6.50 (s, 2H), 6.35 - 6,27 (m, IH), 6.16 - 6.07 (m, IH), 2,56 (td, J = 10,3,7.0 Hz, 2H), 2.17 (q, J = 7.1 Hz, 3H), 1.82 (dd, J = 11.9,5.7 Hz, IH), 1.60 (dh, J = 13.4, 6.8, 6.4 Hz, IH), 1.50 (s, 3H), 1.48 (s, 3H), 1,39 - 1.29 (m, 3H), 0.90 (d, J = 6.6 Hz, 6H), 0.85 {d, J = 6.3 Hz, 3H).
2648	459.09	2.52
2649	550.24	1.80
2650	569.50	1.41
2651	525.20	1.44
2652	503.40	1.60	IH NMR (400 MHz, DMSO-d6) δ 12.66 (s, IH), 12.54 (d, J = 6.2 Hz, IH), 8.25 {dd, J = 7.3, 2.1 Hz, IH), 7.83 (td, J = 6.4, 2.2 Hz, IH), 7.79 -

1373

Cmpd.;		»	HBKWi»
			7.70 (m, 3H), 7.36 - 7.28 (m, 2H), 6.45 (t, J = 6.8 Hz, 1H), 2.81 - 2.68 (m, 2H), 2.24 (dq, J = 11.6, 6.2 Hz, 1H), 1.90 (dd, J = 11.9, 5.6 Hz, 1H), 1.45 (t, J = 12.1 Hz, 1H), 0.91 (d,J = 6.3 Hz, 3H).
2653	500,12	1.43
2654	521.22	2.44
2655	547.60	1.65
2656	501.11	1.72
2657	605.32	1.71
2658	513.20	0.64
2659	491.20	2.48
2660	498.53	1.05
2661	574.40	1.55
2662	540.43	2.40
2663	535.02	2.76
2664	526.18	1.32
2665	528.19	1.48	1H NMR (400 MHz, DMSO-d6} δ 12.53 (s, 1H), 8.25 (dd, J = 4.8,1.8 Hz, 1H), 8.06 (dd, J = 7.8,1.8 Hz, 1H), 7.92 - 7.69 (m, 2H), 7.62 (ddd, J = 8.5, 4.3, 2.1 Hz, 1H), 7.37 - 7.17 (m, 2H), 6.78 (dd, J = 7.8, 4.8 Hz, 3H), 4.19 (q, J = 7.0 Hz, 2H), 2.54 (d, J = 10.2 Hz, 2H), 2.15 (s, 1H), 1.85 (dd, J = 11.7, 5.6 Hz, 1H), 1.61 (s, 3H), 1.57 (s, 3H), 1.38 (t, J = 6.9 Hz, 4H), 0.76 (d, J = 6.3 Hz, 3H).
2666	488.33	1.33
2667	496.27	1.33	1H NMR (400 MHz, DMSO) δ 12.51 (s, 1H), 8.25 (dd, J = 4.8,1.9 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 8.04 - 7.98 (m, 2H), 7.74 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.05 (dd, J = 9.5, 2.5 Hz, 2H), 6.78 (dd, J = 7.8, 4.8 Hz, 1H), 3.81 {s, 3H), 2.56 - 2.51 (m, 2H), 2.15 (s, 1H), 1.85 (dd, J = 11.9, 5.7 Hz, 1H), 1.60 (s, 3H), 1.5S (s, 3H), 1.40 (t, J = 12.1 Hz, 1H), 0.76 (d, J = 6.3 Hz, 3H).
2668	498.24	1.23
2669	669.52	0.76	1H NMR (300 MHz, CDCI3) δ 10.43 (s, 1H), 8.57 (d, J = 8.0 Hz, 1H), 7.86 (d, J = 7.2 Hz, 2H), 7.72 (d, J = 4.1 Hz, 1H), 7.66 (s, 1H), 7.62 (s, 1H), 7.58 (d, J =

1374

Cmpd.	^LC/MS^ BS	?SOTiinW	< NMR fe
			4.4 Hz, 1H), 7.56 - 7.56 (m, 1H), 7.55 (S, 1H), 7.09 (S, 1H), 7.01 (d, J = 9.1 Hz, 1H), 6.77-6.70 (m, 1H}, 6.66 (d, J = 10.3 Hz, 1H}, 4.74 (s, 2H), 3.60 (d, J = 6.4 Hz, 2H), 2.28 (s, 6H), 2.10 -1.96 (m, 1H), 0.98 (d, J = 6.7 Hz, 6H).
2670	610.20	0.83	1H NMR (400 MHz, Methanokd4) δ 8.67 (dd, J = 4.8,1.9 Hz, 1H), 8.48 (dd, J = 8.0,1.8 Hz, 1H), 8.32 (d, J = 2.8 Hz, 1H), 8.09 (dd,J = 8.5,1.6 Hz, 1H), 7.66 {dd, J = 8.3,1.5 Hz, 1H), 7.61 (dd, J = 8.0, 4.7 Hz, 1H), 6.01 (d, J = 2.8 Hz, 1H), 3.92 (d, J = 1.8 Hz, 2H), 3.76 - 3.65 (m, 4H}, 3.34 (d, J = 1.9 Hz, 5H), 2.04 (p, J = 5.9 Hz, 4H), 1.85 -1.70 (m, 2H), 1.03 (d, J = 1.9 Hz, 9H).
2671	691.40	0.83	1H NMR (300 MHz, CDCI3) 68.47 (d, J = 8.1 Hz, 1H), 7.76 - 7.68 (m, 1H}, 7.64 (d, J = 7.3 Hz, 1H), 7.52 (d, J = 8.1 Hz, 1H), 7.47 (s, 2H), 7.04 - 6.95 (m, 3H), 6.76 (d, J = 8.2 Hz, 1H), 6.63 (dt, J = 10.3, 2.2 Hz, 1H), 3.56 (t, J = 7.0 Hz, 2H), 2.13 - 2.06 (m, 6H), 1.01 (t,J = 6.6 Hz, 6H), 0.85 (t, J = 6.7 Hz, 3H), 0.47 (S, 1H).
2672	474.50	1.18
2673	557.40	2.15	1H NMR (400 MHz, DMSO-d6) 5 11.58 (s, 1H), 7.89 (s, 1H), 7.62 - 7.53 (m, 1H), 7.11 (d, J = 7.3 Hz, 1H), 6.88 6.79 (m, 2H), 6.75 - 6.69 (m, 1H), 6.66 (d, J = 8.3 Hz, 1H), 6.52 (s, 2H), 3.83 (t, J = 9.1 Hz, 1 H), 3.74 (d, J = 6.5 Hz, 2H), 3.12 (t, J = 10.4 Hz, 1H), 2.47 2.35 (m, 1H), 2.02 (dd, J = 12.8, 6.3 Hz, 2H), 1.61 (d, J = 12.2 Hz, 1H), 1.56 (s, 3H), 1.45 (s,3H), 1.10 (dj = 6.4 Hz, 3H), 0.96 (d, J = 6.8 Hz, 6H).
2674	480.20	1.97	1H NMR (400 MHz, Methanol-d4) δ 8.50 (d, J = 2.8 Hz, 1H), 7.95 - 7.87 (m, 2H), 7.84 (dd, J = 8.1,1.2 Hz, 1H), 7.46 - 7.38 (m, 2H), 7.36 (dd, J = 7.8, 1.8 Hz, 1H), 7.30 (dd, J = 8.2, 1.2 Hz, 1H), 6.94 - 6.88 (m, 1H), 3.18 - 3.01 (m, 2H), 2.51 - 2.35 (m, 1H), 2.01 (dd, J = 11.8, 5.8 Hz, 1H), 1.76 - 1.66 (m,

1375

_LCmpd.	:LC/MSz	ælc/rt2	·. -'.-.À Λ < NMR
			6H), 1.63 (d, J = 12.0 Hz, 1H), 1.39 (dt, J = 8.7, 5.3 Hz, 1H), 1.26 - 1.14 {m, 2H), 1.10 {dd, J = 8.7, 5.4 Hz, 4H).
2675	474.50	1.17
2676	466.20	1.78	1H NMR (400 MHz, Methanol-d4) δ 8.60 (d, J = 2.7 Hz, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.97 - 7.90 (m, 2H), 7.66 (d, J = 8.3 Hz, 1H), 7.48 - 7.40 (m, 2H), 7.39-7.33 (m, 1H), 6.94 (d,J = 2.7 Hz, 1H), 4.20 (q, J = 6.1 Hz, 2H), 3.09 (tt, J = 8.1,4.7 Hz, 1H), 2.30 - 2.19 (m, 2H), 1.90 -1.79 (m, 2H), 1.33 -1.25 (m, 8H), 1.18-1.10 (m, 2H).
2677	562.60	1.75
2678	478.40	1.25
2679	556.40	1.47
2680	574.40	1.27
2681	626.20	1.12
2682	582.30	1.12
2683	568.40	1.00
2684	552.40	1.14
2685	538.30	0.97
2686	539.30	1.04
2687	541.30	1.04
2688	555.00	2.01	1H NMR (400 MHz, DMSO) δ 12.32 (s, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.33 8.26 (m, 1H), 7.89 {d, J = 8.6 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.77 {s, 1H), 6.14 (d, J = 8.6 Hz, 1H), 5.39 - 5.25 (m, 1H), 3.82 (s, 3H), 2.15 (s, 1H), 1.85 (dd, J = 11.8, 5.6 Hz, 1H), 1.59 (d, J = 11.4 Hz, 6H), 1.41 (t, J = 12.2 Hz, 1H), 1.32 (d, J = 6.2 Hz, 6H), 0.76 (d, J = 6.3 Hz, 3H).
2689	540.40	1.18
2690	540.40	1.62
2691	526.40	1.47
2692	558.50	1.30
2693	544.50	1.26
2694	556.50	1.83
2695	496.30	0.64	1H NMR {400 MHz, Methanol-d4) S 8.66 (dd, J = 7.8, 1.8 Hz, 1H), 8.35 (d, J = 2.8 Hz, 1H), 8.24 - 8.13 (m, 2H), 7.49 (d, J = 8.5 Hz, 1H), 7.16 - 7.07 {m, 1H), 6.31 - 6.23 (m, 1H), 3.24 (d, J

1376

Cmpd. ^No. ‘	xLC/MS^		Λ pi lyOgi??
			= 9.6 Hz, IH), 3.10 (t, J = 10.1 Hz, IH), 2.56 (d, J = 11.8 Hz, IH), 2.13 (dd, J = 12.4, 6.6 Hz, IH), 2.01 (dq, J = 11.6, 3.6 Hz, IH), 1.72 (t, J = 11.9 Hz, IH), 1.56 (dd, J = 27.3, 5.2 Hz, 6H), 1.38 1.22 (m, IH), 1.08 (d, J = 6.4 Hz, 3H), 1.00 (ddt, J = 8.4,4.5,2.2 Hz, 3H), 0.82 (ddd, J = 7.2,4.9, 2.8 Hz, 3H).
2696	532.20	0.69	IH NMR (400 MHz, Methanol-d4) δ 8.59 - 8.49 (m, 2H}, 8.28 - 8.20 (m, IH), 8.09 (dd, J = 10.7, 5.2 Hz, IH), 8.02 - 7.91 (m, 2H), 7.61 - 7.36 (m, 5H), 7.11 - 6.94 (m, 2H), 3.11 - 2.89 (m, 2H), 2.48 (d, J = 15.9 Hz, IH), 2.06 (dd, J = 11.8, 6.4 Hz, IH), 1.63 (dd, J = 14.0, 5.6 Hz, 6H), 1.00 (d, J = 6.9 Hz, 3H).
2697	551.50	1.74	IH NMR (400 MHz, DMSO-d6) δ 12.48 (broad s, IH), 8.24 (dd, J = 4.8, 1.9 Ηζ,ΙΗ),8.20 (d, J = 2.8 Hz, IH), 8.02 (dd, J = 7.8,1.8 Hz, IH), 7.85 (d, J = 8.2 Hz, IH), 6.95 (d, J = 8.3 Hz, IH), 6.76 (dd, J = 7.8, 4.8 Hz, IH), 6.70 (br s, 2H), 6.14 (d, J = 2.7 Hz, IH), 3.88 (s, 2H), 2.43 (d, J = 8.8 Hz, 2H), 2.13 (br s, IH), 1.84 (dd, J = 11.9, 5.5 Hz, IH), 1.54 (s, 3H), 1.53 (s, 3H), 1.37 (t,J = 12.2 HZ, IH), 0.73 (d, J = 6.2 Hz, 3H).
2698	420.30	0.94	IH NMR (400 MHz, DMSO) δ 7.92 (dd, J = 4.8,1.9 Hz, IH), 7.80 (dd, J = 7.5, 1.9 Hz, IH), 7.50 (d, J = 8.0 Hz, IH), 6.52 {dd, J = 7.5,4.8 Hz, IH), 6.27 (s, 2H), 5.80 (d, J = 8.0 Hz, IH), 3.74 (s, 3H), 2.90 (t,J = 10.8 Hz, IH), 2.79 {dd, J = 10.7, 7.2 Hz, IH), 2.14 2.00 (m, IH), 1.76 (dd, J = 11.4, 5.7 Hz, IH), 1.51 (d, J = 2.7 Hz, 6H), 1.31 (t, J = 12.0 Hz, IH), 0.76 (d, J = 6.4 Hz, 3H).
2699	478.30	1.06
2700	522.30	1.07
2701	565.30	2.34
2702	563.36	2.73 \|	IH NMR (400 MHz, DMSO-d6) δ 12.46 (s, IH), 7.78 (d, J = 8.0 Hz, IH),

1377

βϋ	m®	es
			7.63 (dd, J = 8.4, 7.3 Hz, 1H), 7.53 7.45 (m, 1H), 7.40 (dt, J « 10.0, 2.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.49 (s, 2H), 3.83 (s, 2H), 2.76 - 2.54 (m, 3H), 2.22 (s, 1H), 1.88 (dd, J = 11.9, 5.7 Hz, 1H), 1.60 (d, J = 5.7 Hz, 6H), 1.42 (t, J = 12.1 Hz, 1H), 0.88 (d, J = 6.2 Hz, 3H).
2703	482.30	1.56
2704	528.50	1.60
2705	528.50	1.59
2706	547.00	3.25	1H NMR (400 MHz, DMSO-d6) 5 12.57 {s, 1H), 8.07 - 7.95 (m, 2H), 7.78 - 7.70 (m, 2H), 7.70 - 7.62 (m, 2H), 7.50 - 7.45 (m, 1H), 7.40 (ddd, J = 10.2, 2.4,1.3 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 6.89 (dt, J = 10.7, 2.3 Hz, 1H), 3.82 (s, 2H), 2.43 (t, J = 10.3 Hz, 1H), 2.36 (dd, J = 10.2, 7.1 Hz, 1H), 2.11 (ddt, J = 17.5,11.9, 6.2 Hz, 1H), 1.83 (dd, J = 11.8, 5.6 Hz, 1H), 1.59 (s, 3H), 1.55 (s, 3H), 1.38 (t, J = 12.1 Hz, 1H), 0.66 (d, J = 6.3 Hz, 3H).
2707
2708			1H NMR (300 MHz, DMSO) δ8.55 (d, J = 2.2 Hz, 1H), 8.17 (d, J = 7.9 Hz, 1H), 8.02 (dd, J = 8.8, 2.5 Hz, 1H), 7.76 (dd, J = 8.4, 1.6 Hz, 3H), 7.72 7.65 (m, 2H), 7.64 - 7.57 (m, 2H), 7.56 (S, 2H), 7.24 (d, J = 6.9 Hz, 1H), 6.75 (dd, J = 18.5,8.4 Hz, 2H), 5.26 (dt, J = 12.3, 6.2 Hz, 2H), 2.14 (s, 6H), 1.27 (d, J = 6.2 Hz, 6H).
2709	520.50	1.59
2710	534.40	1.28
2711	480.00	0.53	1H NMR (400 MHz, Methanol-d4) δ 8.84 - 8.78 (m, 1H), 8.74 - 8.67 (m, 2H), 8.62 - 8.57 (m, 1H), 8.04 (ddd, J = 7.4, 5.9, 1.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.45 - 7.39 (m, 2H), 3,34 (s, 1H), 3.18 - 3.06 (m, 2H), 2.51 - 2.39 {m, 1H), 2.07 - 1.99 {m, 1H), 1.72 (d, J = 14.8 Hz, 6H), 1.65 (d, J = 12.2 Hz,

1378

Cmpd.	LC/MS < ï:M+i.<	sfeiminsw
			1H), 1.45 -1.38 (m, 1H), 1.27 -1.15 (m, 2H), 1.12 (d, J = 6.4 Hz, 3H).
2712	566.54	2.88
2713	567.44	3.07
2714	581.25	2.98
2715	501.41	3.05
2716	517.32	3.33	1H NMR (400 MHz, DMSO) δ 12.70 (s, 1H), 8.01 (t, J = 8.02, 1H), 7.74 - 7.67 (m, 2H), 7.13-7.10 (d, 1H), 6.676.64 (d, 1H), 4.34 - 4.20 (m, 2H), 2.43 - 2.40 (m, 2H), 2.14 (m, 1H), 1.85 1.69 (m, 2H), 1.62 (q,J = 6.48, 2H), 1.54 (s, 3H), 1.51 (s, 3H), 1.35 (t, J = 11.97, 1H), 1.26 {s, 9H), 0.92 - 0.90 (d, 6H), 0.77-0.75 (d, 3H)
2717	533.22	2.62
2718	535.02	2.64
2719	519.12	2.66
2720	535.02	2.62	1H NMR (400 MHz, DMSO) δ 8.03 7.95 (m, 2H), 7.77 - 7.74 (d, 1H), 7.59 - 7.56 (d, 1H), 7.42 (t, J = 8.13, 1H), 7.34 - 7.31 (dd, 1H), 7.27 - 7.24 (d, 1H), 7.08 (m, 1H), 6.46 - 6.43 (dd, 1H), 2.89 (m, 2H), 2.21 - 2.15 (m, 1H}, 1.84 -1.77 (m, 1H), 1.50 (s, 3H), 1.48 (s, 3H), 1.36 (t, J = 12.08,1H), 0.90-0.88 (d, 3H)
2721	495.10	2.62
2722	540.43	2.26
2723	486.40	2.71
2724	446.18	2.32
2725	492.10	2.18
2726	446.18	2.32
2727	509.21	2.29
_2728	525.42	2.34
2729	538.33	2.22
2730	509.21	2.01
2731	482.20	1.92
2732	488.20	2.10
2733	521.22	2.00
2734	476.19	2.10
2735	495.40	1.35
2736	502.31	1.84
2737	523.32	2.55
2738	550.33	1.73

1379

Cmpd. b No.	LC/MS mm	LC/RT T? min S-	: ...
2739	539.23	2.70
2740	513.41	2.63
2741	443.18	2.20
2742	434.17	2.31
2743	581.25	2.23
2744	528.12	2.51
2745	474.09	2.26
2746	460.29	2.33
2747	472.29	2.31

ASSAYS PROTOCOL 1

Assays for Detecting and Measuring FSOSdel Potentiation Properties of Compounds

Membrane potential optical methods forassaying F508del modulation properties of compounds

The assay utilizes fluorescent voltage sensing dyes to measure changes in membrane potential using a fluorescent plate reader (e.g., FLIPR III, Molecular Devices, Inc.) as a readout for increase in functional F508del in NIH 3T3 cefls, The driving force for the response is the création of a chlorideion gradient in conjunction with channel activation by a single liquid addition step after the celis hâve previously been treated with compounds and subsequently loaded with a voltage sensing dye.

Identification of Potentiator Compounds

To identify potentiators of F508del, a double-addition HTS assay format was developed. This HTS assay utilizes fluorescent voltage sensing dyes to measure changes in membrane potential on the FLIPR III as a measurement for increase in gating (conductance) of F5Û8del in temperature-corrected F508del NIH 3T3 cells. The driving force for the response is a CL ion gradient in conjunction with channel activation with forskolin in a single liquid addition step using a fluorescent plate reader such as FLIPR III after the cells hâve previously been treated with potentiator compounds (or DMSO vehicle control) and subsequently loaded with a redistribution dye.

SohiÎiûUS

1380

Bath Solution #1: (in mM) NaCl 160, KC14.5, CaCl₂ 2, MgCl₂ 1, HEPES 10, pH 7.4 with NaOH.

Chloride-free bath solution: Chloride salts in Bath Solution #1 (above) are substituted with gluconate salts,

Cell Culture

NIH3T3 mouse fibroblasts stably expressïng F508del are used for optical measurements of membrane potential. The cells are maintained at 37 °C in 5% CO₂ and 90 % humîdity in Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm² culture flasks. For ail optical assays, the cells were seeded at -20,000/welI in 384-well matrigel-coated plates and cultured for 2 hrs at 37 °C before culturing at 27 °C for 24 hrs. for the potentiator assay. For the correction assays, the cells are cultured at 27 °C or 37 °C with and without compounds for 16 - 24 hours.

Electrophysiological Assays for assaying F508del modulation properties of compounds.

Ussing Chamber Assay

Ussing chamber experiments were performed on polarized airway épithélial cells expressing F508del to further characterize the F5O8del augmenters or inducers identified in the optical assays. Non-CF and CF airway epithelia were isolated from bronchial tissue, cultured as previously described (Galietta, L.J.V., Lantero, S., Gazzolo, A., Sacco, O., Romano, L„ Rossi, G.A., & Zeganra-Moran, O. (1998) In Vitro Cell. Dev. Biol. 34, 478-481), and plated onto Costar® Snapwell™ filters that were precoated with NIH3T3-conditioned media. After four days the apical media was removed and the cells were grown at an air liquid interface for >14 days prior to use. This resulted in a monolayer of fuUy differentiated cokimnar cells that were ciliated, features that are characteristic of airway epithelia. Non-CF HBE were isolated from non-smokers that did not hâve any known lung disease. CF-HBE were isolated from patients homozygOLis for F5O8del.

HBE grown on Costar® Snapwell™ cell culture inserts were mounted in an Usina chamber (Physiologie Instruments, Inc., San Diego, CA), and the transepithelial résistance and

1381 short-circuit current in the presence of a basolateral to apical CI' gradient (Isc) were measured using a voltage-clamp System (Department of Bioengineering, University of lowa, IA), Brie fl y, HBE were examined under voltage-clamp recording conditions (Vhoia = 0 mV) at 37 °C. The basolateral solution contained (inmM) 145 NaCl, 0.83 K₂HPO₄, 3.3 KH₂PO₄, 1.2 MgCl₂, 1.2 CaCl₂, 10 Glucose, 10 HEPES (pH adjusted to 7.35 with NaOH) and the apical solution contained (in mM) 145 NaGluconate, 1.2 MgCl₂, 1.2 CaCl₂, 10 glucose, 10 HEPES (pH adjusted to 7.35 with NaOH).

Identification of Potentiator Compounds

Typical protocol utilized a basolateral to apical membrane Cl'concentration gradient. To set up this gradient, normal ringers was used on the basolateral membrane, whereas apical NaCl was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Ci concentration gradient across the epithelium. Forskolin (10 pM) and ail test compounds were added to the apical side of the cell culture inserts. The efficacy of the putative F508del potentiators was compared to that ofthe known potentiator, genistein.

PatcCclamp Recordings

Total Cl current in F508del-NIH3T3 cells was monitored using the perforated-patch recording configuration as previously described (Rae, J., Cooper, K., Gates, P., & Watsky, M. (1991) J. Neurosci. Methods 37, 15-26). Voltage-clamp recordings were performed at 22 °C using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). The pipette solution contained (in mM) 150 tV-methyl-D-glucamine (NMDG)-Cl, 2 MgCl₂, 2 CaCl₂, 10 EGTA, 10 HEPES, and 240 pg/mL amphotericin-B (pH adjusted to 7.35 with HCl). The extracellular medium contained (in mM) 150 NMDG-C1, 2 MgCl₂, 2 CaCl₂, 10 HEPES (pH adjusted to 7.35 with HCl). Puise génération, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A/D interface in conjunction with Clampex 8 (Axon Instruments Inc.). To activate F5O8del, 10 μΜ forskolin and 20 μΜ genistein were added to the bath and the current-voltage relation was monitored every 30 sec.

Identification of Potentiator Compounds

The ability of F508del potentiators to increase the macroscopie F508del CF current (iFsosdd) iu N1H3T3 cells stably expressing F508del was also investigated using perforated-patch

1382 recording techniques. The potentiators identified from the optical assays evoked a dosedependent increase in IA^os with similar potency and efficacy observed in the optical assays. In ail cells examined, the reversai potential before and during potentiator application was around 30 mV, which is the calculated Eci (-28 mV).

Cell Culture

NIH3T3 mouse fibroblasts stably expressing F508deI are used for whole-cell recordings. The cells are maintained at 37 °C in 5% CO₂ and 90 % humidity in Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm² culture flasks. For whole-cell recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 °C for measuring the activity of correctors.

Single-charme! recordines

Gating activity ofwt-CFTR and temperature-corrected F5O8del expressed in NIH3T3 cells was observed using excised inside-out membrane patch recordings as previously described (Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Doit, K., Dreyer, D., Crystal, R.G., Pavirani, A., Lecocq, J-P„ Lazdunski, M. (1991) Nature 354, 526 - 528) using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc.). The pipette contained (in mM): 150 NMDG, 150 aspartic acid, 5 CaCl₂, 2 MgCl₂, and 10 HEPES (pH adjusted to 7.35 with Tris base). The bath contained (in mM): 150 NMDG-C1, 2 MgCl₂, 5 EGTA, 10 TES, and 14 Tris base (pH adjusted to 7.35 with HCl). After excision, both wt- and F508del were activated by adding 1 mM Mg-ATP, 75 nM of the catalytic subunit of cAMP-dependent protein kinase (PKA; Promega Corp. Madison, WI), and 10 mM NaF to inhibit protein phosphatases, which prevented current rundown. The pipette potential was maintained at 80 mV. Channel activity was analyzed from membrane patches containing < 2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To détermine the single-channel current amplitude, the data recorded from 120 sec of F508del activity was filtered “off-line” at 100 Hz and then used to construct ali-point amplitude histograms that were fîtted with multigaussian fonctions using Bio-Patch Analysis software (Bio-Logic Comp. France). The total microscopie current and open probability (P_o)

1383

I were detennined from 120 sec of charnel aetivity. The P„ was determined using the Bio-Patch software or from the relalionship P„ = I/i(N), where I = mean entrent, i = singlc-cl,annal outrent amplitude, and N = number of active channeis in patch.

Cell Culture

NIH3T3 mouse fibroblasts stably expressing F508del are used for excised-membrane patch-clamp recordings. The cells are maintained at 37 °C in 5% CO₂ and 90 % humidity in Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm² culture flasks. For single channel recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cukured for 24 - 48 hrs at 27 °C before use.

PROTOCOL 2

Assays for Detecting and Measuring FSOSdel Correction Properties of Compounds

Membrane potential optical methods for assaying F508del modulation properties of 15 compounds.

The optical membrane potential assay utilized voltage-sensitive FRET sensors desenbed by Gonzalez and Tsien (See Gonzalez, J. E. and R. Y. Tsien (1995) “Voltage sensing by fluorescence résonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use 20 fluorescence résonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See. Gonzalez, J. E., K. Oades, et al. (1999) “Cell-based assays and instmmentation for screening ion-channel targets” Drug Discov Today 4(9): 431 -439)

These voltage sensitive assays are based on the change in fluorescence résonant 25 energy transfer (FRET) between the membrane-soluble, voltage-sensitive dye, DiSBAC,(3) and a fluorescent phosphol.pid, CC2-DMPE, whieh is attached to the outer leaflet of the plasma' membrane and acts as a FRET donor. Changes in membrane potential (VJ cause the ncgatively charged DiSB AC₂(3) to redistribote across the plasma membrane and the amount of energy transfer from CC2-DMPE changes aecordingly. The changes in fluorescence émission were

1384 monitored using VIPR Π, winch is an integrated liquid handler and fluorescent detector designed to conduct cell-based screens in 96- or 384-weIl microtiter plates.

Identification of Correction Compounds

To identify small molécules that correct the traffîcking defect associated with F508del; a single-addition HTS assay fonnat was developed. The cells were incubated in serum-free medium for 16 hrs at 37 °C in the presence or absence (négative control) of test compound. As a positive control, cells plated in 384-welI plates were incubated for 16 hrs at 27 °C to “temperature-correct” F508del. The cells were subsequently rinsed 3X with Krebs Ringers solution and loaded with the voltage-sensitive dyes. To activate F5O8del, 10 μΜ forskolin and the CFTR potentiator, genistein (20 μΜ), were added along with Cl’-free medium to each well. The addition of Cl’-free medium promoted Cl efAux in response to F508del activation and the resulting membrane depolarization was optically monitored using the FRET-based voltagesensor dyes.

Identification of PotentiatorCompounds

To identify potentiators of F508del, a double-addition HTS assay format was developed. During tbe first addition, a CF-free medium with orwithout test compound was added to each well. After 22 sec, a second addition of Cl -free medium containing 2-10 μΜ forskolin was added to activate F508del. The extracellular CF concentration foliowing both additions was 28 mM, which promoted Cl' efflux in response to F508del activation and the resulting membrane depolarization was optically monitored using the FRET-based voltagesensor dyes.

Solutions

Bath Solution #1:	(in mM) NaCl 160, KC14.5, CaCl₂ 2, MgCl₂ 1, HEPES 10, pH 7.4 with NaOH.
Chloride-free bath solution:	Chloride salts in Bath Solution #1 (above) are substituted with gluconate salts.
CC2-DMPE:	Prepared as a 10 mM stock solution in DMSO and stored at -20°C.

1385

DiSBAC₂(3): Prepared as a 10 mM stock in DMSO and stored at 20°C.

Cell Culture

NIH3T3 mouse fibroblasts stably expressing F508del are used for optical measurements of membrane potential. The cells are maintained at 37 °C in 5% CO₂ and 90 % humidity in Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm² culture flasks. For ail optical assays, the cells were seeded at 30,000/well in 384-well matrigel-coated plates and cultured for 2 hrs at 37 °C before culturing at 27 °C for 24 hrs for the potentiator assay. For the correction assays, the cells are cultured at 27 °C or 37 °C with and without compounds for 16 - 24 hours.

Electrophysiological Assays for assaying F508del modulation properties of compounds

Ussing Chamber Assay

Using chamber experiments were performed on polarized épithélial cells expressing F508del to further characterize the F508del augmentera or inducera identified in the optical assays. FRT ^F508del épithélial cells grown on Costar Snapwell ce 11 culture inserts were mounted in an Ussing chamber (Physiologie Instruments, Inc., San Diego, CA), and the monolayers were continuously short-circuited using a Voltage-clamp System (Department of Bioengineering, University of lowa, IA, and, Physiologie Instruments, Inc., San Diego, CA). Transepithelial résistance was measured by applying a 2-mV puise. Under these conditions, the FRT epithelia demonstrated résistances of 4 ΚΩ/ cm² or more. The solutions were maintained at 27 °C and bubbled with air. The electrode offset potential and fluid résistance were corrected using a cellfree insert. Under these conditions, the current reflects the flow of CF through F5O8del expressed in the apical membrane. The I$c was digitally acquired using an MP100A-CE interface and AcqKnowledge software (v3.2.6; BIOPAC Systems, Santa Barbara, CA).

Identification of Correction Compounds

Typical protocol utilized a basolateral to apical membrane Cl' concentration gradient. To set up this gradient, normal ringer was used on the basolateral membrane, whereas apical

1386

NaCI was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large Cl· concentration gradient across the epithelium. Ail experiments were perfbrmed with intact monolayers. To fully activa te F5O8del, forskolin (10 μΜ) and the PDE inhibitor, IBMX (100 μΜ), were applied followed by the addition of the CFTR potentiator, genistein (50 μΜ).

As observed in other cell types, incubation at low températures of FRT cells stably expressing F508del increases the functional density of CFTR in the plasma membrane. To détermine the activity of correction compounds, the cells were incubated with 10 μΜ of the test compound for 24 hours at 37 °C and were subsequently washed 3X prier to recording. The cAMP- and genistein-mediated Isc in compound-treated cells was normalized to the 27°C and 37°C Controls and expressed as percentage activity. Preincubation of the cells with the correction compound significantly increased the cAMP- and genistein-mediated Isc compared to the 37°C Controls.

Identification of Potentiator Compounds

Typical protocol utilized a basolateral to apical membrane Cf concentration gradient. To set up this gradient, normal ringers was used on the basolateral membrane and was permeabilized with nystatin (360 pg/ml), whereas apical NaCI was replaced by equimolar sodium gluconate (titrated to pH 7.4 with NaOH) to give a large C1‘ concentration gradient across the epithelium. Ail experiments were perfbrmed 30 min after nystatin permeabilization. Forskolin (10 μΜ) and ail test compounds were added to both sides of the cell culture inserts. The efficacy of the putative F508del potentiators was compared to that of the known potentiator, genistein.

Solutions

Basolateral solution (in mM): NaCI (135), CaCl₂(1.2), MgCI₂ (1.2),

K₂HPO₄ (2.4), KHPO₄ (0.6), A-2hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) (10), and dextrose (10). The solution was titrated to pH 7.4 with NaOH.

Apical solution (in mM): Same as basolateral solution with NaCI replaced with Na Gluconate (135).

1387

Cell Culture _; .

Fisher rat épithélial (FRT) cells expressing F508del (FRT ^F508dd) were used for Ussing chamber experiments for the putative F508del augmentera orinduceraidentifïed from our optical assays. The cells were cultured on Costar Snapwell cell culture inserts and cultured for fîve days at 37 °C and 5% CO₂in Coon’s modified Ham’s F-12 medium supplemented with 5% fêtai calf sérum, 100 U/ml penicillin, and 100 pg/ml streptomycin. Prior to use for characterizing the porentiator activity of compounds, the cells were incubated at 27 °C for 16 - 48 hrs to correct for the F508del. To déterminé the activity of corrections compounds, the cells were incubated at 27 °C or 37 °C with and withont the compounds for 24 houra.

Whole-cell recordings

The macroscopie F508del entrent (Ipso&iei) in température- and test compoundcorrected ΝΊΗ3Τ3 cells stably expressing F508del were monitored using the perforated-patch, whole-cell recording. Briefly, voltage-clamp recordings of Ip_508dei were performed atroom température using an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc., Foster City, CA). Ail recordings were acquired at a sampling frequency of 10 kHz and low-pass filtered at 1 kHz. Pipettes had a résistance of 5 - 6 ΜΩ when filled with the intracellular solution. Under these recording conditions, the calculated reversai potential for CF (E_a) at room température was -28 mV. Ail recordings had a seal résistance > 20 ΟΩ and a sériés résistance < 15 ΜΩ. Puise génération, data acquisition, and analysis were performed using a PC equipped with a Digidata 1320 A/D interface in conjunction with Clampex 8 (Axon Instruments Inc.). The bath contained < 250 μΐ of saline and was continuously perifused at a rate of 2 ml/min using a gravity-driven perfusion system.

Identification of Correction Compounds

To détermine the activity of correction compounds for increasing the density of functional F508del in the plasma membrane, we used the above-described perforated-patchrecording techniques to measure the current density foliowing 24-hr treatment with the correction compounds. To fully activate F508del, 10 μΜ forskolin and 20 μΜ genistein were added to the cells. Under our recording conditions, the current density following 24-hr incubation at 27°C was higher than that observed following 24-hr incubation at 37 °C. These

1388 résulta are consistent with the known effects of low-temperature incubation on the density of F50Sdel in the plasma membrane. To déterminé the effects of correction compounds on CFTR current density, the cells were incubated with 10 μΜ of the test compound for 24 hours at 37°C and the current density was compared to the 27°C and 37°C Controls (% activity). Prior to record ing, the cells were washed 3X with extracellular recording medium to remove any remaining test compound. Preincubation with 10 μΜ of correction compounds significantly increased the cAMP- and genistein-dependent current compared to the 37°C Controls.

Identification of Potentiator Compounds

The ability of F508del potentiators to increase the macroscopie F508del CF current (Ip5O8dei) in NIH3T3 cells stably expressing F508del was also investigated using perforated-patchrecording techniques. The potentiators identified from the optical assays evoked a dosedependent increase in Ipsosdei with similar potency and efficacy observed in the optical assays. In ail cells examined, the reversai potential before and during potentiator application was around 30 mV, which is the calculated Eci (-28 mV).

Solutions

Intracellular solution (in mM):

Extracellular solution (in mM):

Cell Culture

Cs-aspartate (90), CsCl (50), MgCl₂ (1), HEPES (10), and 240 pg/ml amphotericin-B (pH adjusted to 7.35 with CsOH).

A-methyl-D-glucamine (NMDG)-Cl (150), MgCl₂ (2), CaCl₂ (2), HEPES (10) (pH adjusted to 7.35 with HCl).

NIH3T3 mouse fibroblasts stably expressing F508del are used for whole-cell record in gs. The cells are maintained at 37 °C in 5% CO₂ and 90 % humidity in Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 X pen/strep, and 25 mM HEPES in 175 cm² culture flasks. For whole-cell recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cuitured for 24 - 48 hrs at 27 °C before use to test the activity of potentiators; and incubated with or without the correction compound at 37 °C for measuring the activity of correctors.

1389

Single-channel recordings

The single-channel activities of temperature-corrected F508del stably expressed in NIH3T3 cells and activities of potentiator compounds were observed using excised inside-out membrane patch. Briefly, voltage-clamp recordings of single-channel activity were performed at room température with an Axopatch 200B patch-clamp amplifier (Axon Instruments Inc.). Ail recordings were acquired at a sampling frequency of 10 kHz and low-pass filtered at 400 Hz. Patch pipettes were fabricated from Corning Kovar Sealing #7052 glass (World Précision Instruments, Inc., Sarasota, FL) and h ad a résistance of 5 - 8 ΜΩ when filled with the extracellular solution. The F508del was activated after excision, by adding 1 mM Mg-ATP, and 75 nM of the cAMP-dependent protein kinase, catalytic subunit (PKA; Promega Corp. Madison, WI). After channel activity stabilized, the patch was perifused using a gravity-drîven microperfusion System. The inflow was placed adjacent to the patch, resulting in complété solution exchange within 1 - 2 sec. To maintain F508del activity during the rapid perifusion, the nonspecific phosphatase inhibitor F (10 mM NaF) was added to the bath solution. Under these recording conditions, channel activity remained constant throughout the duration of the patch record in g (up to 60 min). Currents produced by positive charge moving from the intra- to extracellular solutions (anions moving in the opposite direction) are shown as positive currents. The pipette potential (V_p) was maintained at 80 mV.

Channel activity was analyzed from membrane patches containing < 2 active channels. The maximum number of simultaneous openings determined the number of active channels during the course of an experiment. To détermine the single-channel current amplitude, the data recorded from 120 sec of F508del activity was filtered “off-line” at 100 Hz and then used to construct all-point amplitude histograms that were fitted with multigaussian functions using BioPatch Analysis software (Bio-Logic Comp. France). The total microscopie current and open probability (P_o) were determined from 120 sec of channel activity. The P_o was determined using the Bio-Patch software or from the relationship P_c = I/i(N), where I = mean current, i = singlechannel current amplitude, and N = number of active channels in patch.

Solutions

1390

Extracellular solution (in mM): NMDG (150), aspartic acid (150), CaCl, (5),

MgCl₂(2), and HEPES (10) (pH adjusted to 7.35 with Tris base).

Intracellular solution (in mM): NMDG-Ci (150), MgCl₂ (2), EGTA (5),

TES (10), and Tris base (14) (pH adjusted to 7.35 with HCl).

Cell Culture

NIH3T3 mouse fibroblasts stably expressing F508del are used for excised-membrane patch-clamp recordings. The cells are maintained at 37 °C in 5% CO₂ and 90 % humidity in 10 Dulbecco’s modified Eagle’s medium supplemented with 2 mM glutamine, 10 % fêtai bovine sérum, 1 X NEAA, β-ΜΕ, 1 Xpen/strep, and 25 mM HEPES in 175 cm² culture flasks. For single channel recordings, 2,500 - 5,000 cells were seeded on poly-L-lysine-coated glass coverslips and cultured for 24 - 48 hrs at 27 °C before use.

The compounds of formula I are useful as modulators of CFTR activity Table 3 15 below illustrâtes the EC30 and relative effieacy of the compounds of TaHe 1. In Table 3 below the following meanmgs apply. EC30: “₊₊₊” means < 3 „M; means between 3 uM and 10 uM; “+” means greaterthan 10 uM.

Table 3.

Cmpd. No.	EC30 (uM)
1	+++
2	+++
3	+++
4	+
5	++
6	+++
7	+++
8	+++
9	+++
10	+++\|
11	+++
12	+++
13	_ ++

Cmpd.-i No. ^;	EC30 ^: (uM)
14	+++
15	+++
16	+++
17	+++
18	+++
19	+++
20	+++
21	+++
22	+++
23	++
24	++
25	++
26	++

1391

Gmpd. No.	EC30(UM)
27	+++
28	+++
29	+++
30	+++
31	+4-
32	++
33	+++
34	+++
35	+++
36	+++
37	+++
38	+++
39	++
40	4-4-4-
41	+++
42	++
43	+++
44	++
45	+++
46	++
47	4-4-4-
48	++
49	+++
50	4-4-4-
51	+++
52	+++
53	+++
54	++
55	++
56	+++
57	+++
58	++
59	+++
60	+++
61	+++
62	+++
63	+++
64	++
65	++
66	+++
67	++

Gmpd. ^: No.	EC30 w
68	+++
69	+++
70	+++
71
72	++
73	+++
74	+++
75	++
76	+++
77	4 4“ 4-
78	+++
79	++
80	+++
81	+++
82	+++
83	+++
84	+++
85	++
86	4-4-
87	+++
88	+++
89	+++
90	+++
91	++
92	+++
93	4-4-4-
94	+++
95	+++
96	+++
97	+++
98	+++
99	+4-+
100	+++
101	+++
102	+++
103	+++
104	+++
105	+++
106	4-4-4-
107	+++
108	+++ \|

1392

	ΈΟ30·· et
109	+++
110	+++
111	+++
112	4-++
113	++
114	+++
115	+++
116	++
117	+++
118	++
119	+++
120	+++
121	++
122	++
123	+++
124	++
125	++
126	+++
127	+++
128	+++
129	++
130	+++
131	+++
132	4-++
133	+++
134	+++
135	+++
136	+++
137	+++
138	++
139	+++
140	+++
141	+++
142	+++
143	+++
144	+++
145	+++
146	++ +
147	+++
148	+++
149	++ +


150	+++
151	+++
152	+++
153	+++
154	+++
155	++
156	+++
157	++
158	+++
159	+++
160	+++
161	+++
162	+++
163	+++
164	+++
165	+++
166	+ + +
167	++
168	+++
169	+++
170	+++
171	+++
172	+++
173	++
174	++
175	++
176	+++
177	++
178	+++
179	+++
180	+++
181	+++
182	+++
183	+++
184	++
185	+++
186	+++
187	++
188	+++
189	+++
190	+++

1393

^Gmpd, No.	EC30 ; (pM)
191	+++
192	+++
193	+++
194	+44
195	+++
196	+++
197
198	+++
199	+++
200	++
201	+++
202	+++
203	++ +
204	+++
205	++
206	+++
207	+++
208	+4 +
209	+++
210	+++
211	++
212	+++
213	+++
214	+++
215	+++
216	+4+
217	+++
218	44
219	+++
220	44+
221	4+4
222	+++
223	++4
224	+++
225	+++
226	+++
227	++
228	4+4
229	+++
230	++
231	4++ \|

Cmpd. No.	EC30₄, (uM)'
232
233	+++
234	+++
235	+++
236	++
237	++
238	+++
239	+++
240	++
241	+++
242	+++
243	+++
244	+++
245	++
246	++
247	+++
248	+++
249	+++
250	+++
251	+++
252	+++
253	+++
254	++
255	+++
256	+++
257	+++
258	++
259	+44
260	++
261	+++
262	+++
263	+++
264	+++
265	+++
266	+++
267	+++
268	+++
269	+++
270	+++
271	+4+
272	++

1394

Cmpd.·-'	tEG3Q»
273	+++
274	+++
275	+++
276	+++
277	+++
278	++
279	+++
280	+++
281	+++
282	++
283	+++
284	+++
285	+++
286	+++
287	+++
288	+++
289	+++
290	+++
291	++
292	+++
293	+++
294	+++
295	++
296	+++
297	++
298	++
299	+++
300	+++
301	++
302	++
303	+++
304	+++
305	+++
306	+++
307	+++
308	+++
309	+++
310	+++
311	+++
312	+++
313	+++

:ON0-'Wt	ÎEC3QM
314	+++
315	+++
316	+++
317	+++
318	+++
319	++
320	+++
321	+++
322	+++
323	+++
324	++
325	+++
326	+++
327	+++
328	+++
329	+++
330	+++
331	+++
332	+++
333	+++
334	++
335	+++
336	+++
337	+++
338	+++
339	+++
340	+++
341	+++
342	+++
343	+++
344	+++
345	+++
346	+++
347	+++
348	+++
349	++
350	+++
351	+++
352	+++
353	+++
354	+++

1395

Cmpd. • No.	EC30W (μΜ)
355	+++
356	+++
357	++
35S	+++
359	+++
360	+++
361	+++
362	+++
363	+++
364	+++
365	+++
366	+++
367	+++
368	+++
369	+++
370	+++
371	+++
372	++
373	++
374	+++
375	+++
376	+++
377	+++
378	+++
379	+++
380	+++
381	++
382	+++
383	+++
384	+++
385	+++
386	+++
387	+++
388	++
389	+++
390	+++
391	+
392	++
393	++
394	+++
395	+++

^CmpdM i- No. :	(uM)
396	+++
397	+++
398	+++
399	+++
400	++
401	+++
402	+++
403	++
404	+++
405	+++
406	+++
407	++
408	+++
409	+
410	+++
411	+++
412	+++
413	+++
414	+++
415	+++
416	+++
417	++
418	+++
419	+++
420	+++
421	+++
422	+++
423	+++
424	+++
425	+++
426	+++
427	+++
428	+++
429	+++
430	+++
431	++
432	+++
433	+++
434	+++
435	+++
436	+++

1396

KM	1EG3O^
437	+++
438	+++
439	+++
440	+++
441	+++
442	+++
443	+
444	++
445	+
446	++ +
447	+++
448	+++
449	+
450	+++
451	++
452	+++
453	+++
454	+++
455	+++
456	+++
457	+++
458	+++
459	+++
460	++
461	++
462	+++
463	++
464	+++
465	++
466	+++
467	++
468	+++
469	++
470	+++
471	+++
472	+
473	+++
474	+++
475	++ +
476	++
477	+++

KGrnp'dA	’ Γ(μΜ)
478
479	+++
480	+++
481	+++
482	+++
483	++ +
484
485	+++
486	++
487	++
488	+++
489	+++
490	+++
491	+++
492	+++
493	+++
494	+++
495	++
496	+++
497	+++
498	+++
499	++
500	+++
501	+++
502	+++
503	+++
504	+++
505	++
506	+++
507	+++
508	++
509	+++
510	+++
511	+++
512	++
513	++
514	+
515	+++
516	+++
517	++
518	+++

1397

Λ»	®EC30® MhMïS
519	++
520	+++
521	++
522	+++
523	+++
524	++
525	++
526	+++
527	+++
528	+++
529	++
530	+++
531	+++
532	++
533	+++
534	++
535	+++
536	+++
537	+++
538	+++
539	+
540	+
541	+++
542	+++
543	++
544	+++
545	++
546	++
547	+++
548	4-4-4-
549	+++
550	++
551	+++
552	++
553	+++
554	+++
555	+++
556	+
557	4-4-4-
558	+++
559	4-4-4-

^Jihpd^ SBnpSB	\|EG30> «t
560	+++
561	4-4-4-
562	+++
563	444*
564	++
565	+
566	+
567	++
568	+++
569	+++
570	+++
571	4-4*
572	4-4-4-
573	+++
574	++
575	+++
576	4-4-4-
577	++
578	+++
579	+++
580	+++
581	+++
582	++
583	4-4-4-
584	++
585	+++
586	+++
587	+++
588	++
589	+++
590	+++
591	+++
592	+++
593	+++
594	++
595	+++
596	++
597	++Ψ
598	4-+
599	+++
600	+++

1398

Cmpd. No.	^EC3&
601	+++
602	+++
603	4++
604	444
605	+++
606	++
607	+++
608	++
609	444
610	+++
611	+++
612	4+4
613	4+4
614	+++
615	+++
616	+++
617	+++
618	++
619	+++
620	+++
621	+++
622	+++
623	4+
624	++
625	+++
626	+++
627	+
628	+++
629	+++
630	+++
631	+++
632	++
633	+++
634	+++
635	+
636	++
637	++
638	++
639	+++
640	++
641	+++

Cmpd. sNo.	EC30 (μΜ)
642	+++
643	++
644	+++
645	++
646	++
647	+++
648	+++
649	44»
650	+4
651	+++
652	++
653	+
654	+++
655	+++
656	+++
657	+++
658	+++
659	++
660	4
661	+++
662	+
663	+++
664	+++
665	+++
666	++
667	444
668	4+4
669	+++
670	++
671	+++
672	+++
673	+++
674	+++
675	+++
676	+++
677	++
678	44+
679	+++
680	+++
681	+++
682	444

1399

Cmpd. ; 'NoÆV	EC30.; (μΜ)
683	+++
684	+++
685	+++
686	++4
687	++
688	+++
689	+++
690	++
691	+++
692	++4
693	+++
694	+++
695	+++
696	+++
697	+++
698
699	+*+
700	+++
701	+++
702	++
703	+++
704	++
705	+++
706	+++
707	+
708	+++
709	+++
710	+++
711	+++
712	+++
713	++
714	4·++
715	+++
716	+++
717	+++
718	++ +
719	++ +
720	+++
721	++
722	+
723	++

Cmpd. No.	: EC30 (pM)
724	+++
725	+++
726	++
727	+
728	++
729	++
730	+++
731	+++
732	+++
733	+++
734	+++
735	+++
736	+++
737	+++
738	+++
739	++
740	++
741	+++
742	+++
743	+++
744	+++
745	++
746	+++
747	+++
748	++
749	+++
750	+++
751	+++
752	++
753	++
754	+++
755	++
756	+++
757	+++
758	++
759	+++
760	++
761	+++
762	++
763	+++
764	+++

Î400

Cmpd. . No.	EC30 (PM)
765	++
766	++
767	+++
768	++
769	+++
770	++
771	+++
772	+++
773	+++
774	+++
775
776	+++
777	+++
778	+++
779	+++
780	+++
781	+
782	+++
783	+++
784	+++
785	+++
786	+
787	+++
788	+++
789	+++
790	+++
791	++
792	++
793	+++
794	+++
795	+++
796	+++
797	+
798	+++
799	+
800	++
801	+
802	+++
803	+++
804	+++
805	+++

Cmpd. :'ŸNo^	EC30
806	++
807	+++
808	++
809	++
810	++
811	+++
812	++
813	+++
814	+++
815	++
816	++
817	+++
818	+++
819	+
820	+
821	++
822	+++
823	+
824	++
825	++
826	+++
827	+++
828	+++
829	+++
830	+++
831	+++
832	+++
833	+++
834	+++
835	++
836	++
837	+++
838	++
839	++
840	+++
841	+++
842	+++
843	++
844	++
845	+++
846 \|	+++

1401

-KGmpdS	<EG30^
847	+++
848	+++
849	+
850
851	+++
852	++
853	444
854	++
855	+
856	++
857	+++
858	++
859	+++
860	++
861	++
862	+++
863	++
864	+++
865	+++
866	+++
867	+++
868	444
869	+++
870	++
871	+++
872	++
873	+++
874	+++
875	+++
876	+++
877	+++
878	++
879	+
880	++
881	+++
882	+++
883	++
884	++
885	++
886	+++
887	+++

w Z® OMi	ÆEC30S
888	++
889	++
890	+++
891	+++
892	++
893	+++
894	+++
895	+++
896	+++
897	+++
898	+++
899	+++
900	+++
901	++
902	+++
903	++
904	+++
905	+++
906	+++
907	+++
908	+
909	+++
910	+++
911	+++
912	+++
913	++
914	+++
915	+++
916	+++
917	++
918	+++
919	+4+
920	+++
921	++
922	+++
923	+++
924	+++
925	+++
926	+++
927	++
928	+++

1402

No?·*	1 EC30 . (μΜ)
929	++
930	++
931	+++
932	+
933	+++
934	+++
935	++
936	++
937	+++
938	++
939	+++
940	+++
941	+++
942	+++
943	+
944	+++
945	+++
946	++
947	+++
948	+++
949	++ +
950	+++
951	+++
952	+++
953	+++
954	++4-
955	++
956	+++
957	+++
958	+++
959	+++
960	++
961	+++
962	++
963	++
964	+++
965	+++
966	+
967	+++
968	+++
969	+++

CmpdÀf No. '	«EC30
970
971	+++
972	+++
973	+++
974	+++
975	++
976	++
977	++
978	+++
979	+++
980	++
981	++
982	++
983	++
984	+++
985	+++
986	++
987	+++
988	+++
989	+++
990	+++
991	+++
992	+++
993	+++
994	+++
995	+++
996	+++
997	++
998	++
999	++
1000	+++
1001	++
1002	+++
1003	+
1004	+++
1005	+++
1006	+++
1007	+++
1008	+++
1009	+++
1010	+++ \|

1403

Cmpd.	*EC30S
1011	+++
1012	+++
1013	+++
1014	+++
1015	+++
1016	+++
1017	++
1018	++
1019	+++
1020	+++
1021	+++
1022	++
1023	+++
1024	++
1025	+++
1026	++
1027	++
1028	4+
1029	++
1030	+++
1031	+++
1032	+++
1033	+++
1034	+++
1035	+++
1036	+
1037	++
1038	++
1039	+++
1040	+++
1041	+++
1042	+++
1043	+++
1044	+++
1045	++
1046	+4-
1047	+++
1048	+++
1049	+++
1050	++
1051	+++

: Cmpd.^r /NcÆî	EC30 (UM)
1052	4-++
1053	++
1054	+++
1055	++
1056	+++
1057	+
1058	+++
1059	+++
1060	+++
1061	+++
1062	+++
1063	+++
1064	+++
1065	+++
1066	++
1067	+++
1068
1069	+++
1070	+++
1071	+++
1072	++
1073	+
1074	++
1075	+++
1076	+++
1077	+++
1078	++
1079	+++
1080	+++
1081	++
1082	+
1083	+++
1084	++
1085	+++
1086	++
1087	+++
1088	+++
1089	+++
1090	+++
1091	+++
1092	++

1404

«GmpcJl» J? No.	...EC30 ΐ (μΜ)
1093	++
1094	+++
1095	++
1096	++
1097	+++
1098	+++
1099	+++
1100	+++
1101	+++
1102	+++
1103	+++
1104	+++
1105	+
1106	+
1107	+++
1108	+++
1109	++
1110	+++
1111	+++
1112	++
1113	+++
1114
1115	+
1116	++
1117	+++
1118	+++
1119	++
1120	+++
1121	+++
1122	++
1123	+++
1124	+4- +
1125	++
1126	+
1127	+++
1128	++
1129	++
1130	++
1131	+++
1132	+++
1133	+++

‘^Cmpd. ^w No.	^EC3fe (μΜ)
1134	+++
1135	+++
1136	+++
1137	++
1138	+++
1139	+++
1140	+++
1141	++
1142	++
1143	++
1144	+++
1145	+++
1146	++
1147	++
1148	+++
1149	+++
1150	+++
1151	++
1152	+
1153	+++
1154	++
1155	++
1156	+++
1157	+++
1158	+++
1159	+++
1160	+++
1161	+++
1162	+++
1163	+++
1164	++
1165	++
1166	+++
1167	+++
1168	+++
1169	++
1170	+++
1171	+++
1172	++
1173	+++
1174	+++

1405

Cmpd. A, No.	EC30 (HM)
1175	+++
1176	+++
1177	++
1178	+++
1179	++
1180	+++
1181	+++
1182	++
1183	+
1184	+++
1185	+++
1186	+++
1187	+++
1188	+++
1189	+++
1190	+++
1191	++
1192	+++
1193	+++
1194	+++
1195	4-
1196	++
1197	+++
1198	+++
1199	++
1200	++
1201	+++
1202	+++
1203	+
1204	+
1205	+++
1206	++
1207	+++
1208	+++
1209	+++
1210	+++
1211	++
1212	+++
1213	++
1214	++
1215	++

/SCmpd. No.	EC30 (μΜ) ..
1216	+++
1217
1218	+++
1219	++
1220	+++
1221	+++
1222	+++
1223	+++
1224	++
1225	+++
1226	+++
1227	+++
1228	++
1229	+++
1230	++
1231	+++
1232	+++
1233	++
1234	+++
1235	+++
1236	++
1237	++
1238	+++
1239
1240	+++
1241	+++
1242	+++
1243	+++
1244	+++
1245	+
1246	+++
1247	+++
1248	+++
1249	+++
1250	+++
1251	++
1252	+++
1253	++
1254	+++
1255	+++
1256	++

1406

. Cmpd. æ No.	EC30 (#M)
1257	++
1258	+++
1259	+++
1260	+++
1261	+++
1262	++
1263	+++
1264	+++
1265	++
1266	+++
1267	+++
1268	+++
1269	+++
1270	+++
1271	+++
1272	+++
1273	+4-4·
1274	+++
1275	+++
1276	-Ï-+
1277	+++
1278	+
1279	+++
1280	+++
1281	++
1282	+++
1283	+++
1284	+++
1285	+++
1286	+++
1287	+++
1288	++
1289	++Ψ
1290
1291	++
1292
1293	++
1294	+++
1295	+++
1296	+
1297	+++

Cmpd.w ' ' ' No;^	EC30 t(UM)
1298	++
1299	++
1300	+++
1301	++
1302	++
1303	+++
1304	+++
1305	+++
1306	4-++
1307	++
1308	+++
1309	4-4-+
1310	+++
1311	+++
1312	++
1313	+++
1314	+++
1315	+++
1316	+++
1317	+++
1318	+++
1319	+++
1320	+++
1321	++
1322	++
1323	+
1324	+++
1325	+++
1326	++
1327	+++
1328	+++
1329	++
1330	+++
1331	+
1332	+++
1333	+++
1334	+++
1335	+++
1336	+++
1337	+++
1338	++

1407

.? Cmpd..	;Έ030,
1339	+++
1340	+++
1341	+++
1342	+++
1343	+++
1344	++
1345	+++
1346	+++
1347	+++
1348	+++
1349	+++
1350	+
1351	++
1352	+++
1353	+
1354	+++
1355	++
1356	+++
1357	+++
1358	+++
1359
1360	+++
1361	++ +
1362	+++
1363	+++
1364	+++
1365	+++
1366	+++
1367	+++
1368	+++
1369	+++
1370	+++
1371	+++
1372	+++
1373	+++
1374	+++
1375	++
1376	+++
1377	+++
1378	+++
1379	+++

$©πιράίΜ Ο®	TEC30T
1380	+++
1381	++
1382	+
1383	+++
1384	+++
1385	+++
1386	++
1387	+++
1388	+++
1389	+++
1390	+++
1391	+++
1392	+++
1393	+++
1394	+++
1395	+++
1396	+++
1397	+++
1398	++
1399	+++
1400	+++
1401	+++
1402	+++
1403	+++
1404	+++
1405	+++
1406	+++
1407	+++
1408	+++
1409	+++
1410	+++
1411	+++
1412	+++
1413	+++
1414	+++
1415	+++
1416	+++
1417	++
1418	+++
1419	++ +
1420	++

1408

I

Cmpd. No.	EC30 : RuM) ?
1421	+++
1422	+++
1423	+++
1424	+++
1425	+++
1426	+++
1427	+++
1428	+++
1429	+++
1430	+++
1431	+++
1432	+1-+
1433	++
1434	+++
1435	+++
1436	++
1437
1438	+4-4-
1439	++
1440	+++
1441	++
1442	+++
1443	+++
1444	+++
1445	+++
1446	+++
1447	+++
1448
1449	+++
1450	+++
1451	+++
1452	+++
1453	+++
1454	+++
1455	+++
1456	+++
1457	+++
1458	+++
1459	+++
1460	+++
1461	+++

Cnipd. : No. g	EC30
1462	+++
1463	+++
1464	+++
1465	+++
1466	++
1467	+++
1468	+++
1469	++
1470	+++
1471	+++
1472	+++
1473	+++
1474	+++
1475	+++
1476	+++
1477	+++
1478	+++
1479	+++
1480	+++
1481	+++
1482	+++
1483
1484	+++
1485	+++
1486	+++
1487	+++
1488	+++
1489	+++
1490	+++
1491	++
1492	++
1493	+++
1494	+++
1495	+++
1496	+++
1497	+++
1498	+++
1499	++
1500	+++
1501
1502	+++ \|

1409

JÎÇmpd. F No. .	EC30 (UM)
1503	++
1504	+++
1505	+++
1506	+++
1507	++
1508	+++
1509	+++
1510	+++
1511	+++
1512	+++
1513	+++
1514	+++
1515	+++
1516	+++
1517	+++
1518	+++
1519	+++
1520	+++
1521	+++
1522	+++
1523	+++
1524	+++
1525	+4-4-
1526	+++
1527	+++
1528	++
1529	+++
1530	+++
1531	++
1532	+++
1533	+++
1534	++
1535	+++
1536	++
1537	+++
1538	+
1539	+ + +
1540	+
1541	+++
1542	+++
1543

Cmpd. No./ -	EC30 WM).-
1544	+++
1545	+++
1546	+++
1547	++
1548	+++
1549	+++
1550	++
1551	+++
1552	+++
1553	+++
1554	+++
1555	+++
1556	+++
1557	+++
1558	++
1559	+++
1560	+++
1561	+++
1562	+++
1563	+++
1564	++
1565	+
1566	+++
1567	+++
1568	+++
1569	+++
1570	+++
1571	+++
1572	+++
1573	+++
1574	++
1575	++
1576	+++
1577	+++
1578	+++
1579	+++
1580	+++
1581	+++
1582	+++
1583	++
1584	+++

1410

No.	EC30 (UM)
1585
1586	+++
1587	+++
1588	+++
1589	+++
1590	+++
1591	+++
1592	+++
1593	+++
1594	+++
1595	+++
1596	+++
1597	+++
1598	+++
1599	+++
1600	+++
1601	+++
1602	+++
1603	++
1604	+++
1605	+++
1606	+++
1607	++
1608	+++
1609	+++
1610	+++
1611	+++
1612	+++
1613	+++
1614	+++
1615	+++
1616	+++
1617	+++
1618
1619	+++
1620	+++
1621	+++
1622	+++
1623	+++
1624	+++
1625	++

« Cmpd. No.	'EC30
1626	+++
1627	+++
1628	+++
1629	+++
1630	+++
1631	++
1632	++
1633	+++
1634	++
1635	+++
1636	++
1637	+++
1638	+++
1639	+++
1640	+++
1641	+++
1642	+++
1643	++
1644	+++
1645	+++
1646	+++
1647	+++
1648	+++
1649	++
1650	+++
1651	++
1652	+++
1653	+++
1654	+++
1655	+++
1656	+++
1657	+++
1658	++
1659	+++
1660	+++
1661	+++
1662	++
1663	+++
1664	+++
1665	+++
1666	+++

1411

Cmpd. No. -	EC30 (μΜ)
1667
1668	+++
1669	+++
1670	++
1671	+++
1672	+++
1673	+++
1674	+++
1675	++
1676	+++
1677	+++
1678	+
1679	+++
1680	+++
1681	+++
1682	+++
1683	+++
1684	+++
1685	+++
1686	+++
1687	+++
1688	+++
1689	+++
1690	+++
1691	++
1692	++
1693	+++
1694	+++
1695	+++
1696	+++
1697	+++
1698	+++
1699	+++
1700	+++
1701	+++
1702	+++
1703	+++
1704	+++
1705	+++
1706	++
1707	++

Cmpd. ·: : No.	EC30(hM)
1708	+++
1709	+++
1710	+++
1711	+++
1712	+++
1713	+++
1714	++
1715	+++
1716	++
1717	+++
1718	+++
1719	+++
1720	+++
1721	+++
1722	+++
1723	+++
1724	+++
1725	++
1726	+++
1727	+++
1728	+++
1729	+++
1730	+++
1731	+++
1732
1733	++
1734	+++
1735	+++
1736	++
1737	+++
1738	+++
1739	+++
1740	+++
1741	+++
1742	+++
1743	+++
1744	++
1745	+++
1746	+++
1747	+++
1748	+++

1412

I

^Cmpd. C No. '	EC30 (UM)
1749	+++
1750	+++
1751	+++
1752	++
1753	++
1754	+++
1755	++
1756	+++
1757	+++
1758	+++
1759	+++
1760	++
1761	++
1762	+++
1763	+++
1764	++
1765	+++
1766	+++
1767	+++
1768	++
1769	++
1770	+++
1771	+++
1772
1773	+++
1774	+++
1775	+++
1776	+++
1777	+++
1778	+++
1779	+++
1780	++
1781	Ί-++
1782	+++
1783	+++
1784	+++
1785	+++
1786	++
1787	++
1788	+++
1789	+++

Cmpd. «No. ;	EC30 UpMD-
1790	+++
1791	+++
1792	+++
1793	+++
1794	++
1795	+++
1796	+++
1797	+++
1798	+++
1799	+++
1800	+++
1801	+++
1802	+++
1803	+++
1804	+++
1805	++
1806	+++
1807	+++
1808	+++
1809	+++
1810	+++
1811	+++
1812	++
1813	+++
1814	+++
1815	+++
1816	+++
1817	+++
1818	+++
1819	++
1820	++
1821	+++
1822	+++
1823	+++
1824	+++
1825	+++
1826	+++
1827	+++
1828	+++
1829	+++
1830	+++

Î4I3

Cmpd. cÀNoAW	EC30 (μΜ)
1831	+++
1832	+++
1833	+++
1834	+++
1835	+++
1836	+++
1837	+++
1838	+++
1839	+++
1840	+++
1841	+++
1842	+++
1843	+++
1844	+++
1845	+++
1846	+++
1847	+++
1848	+++
1849	++
1850	+++
1851	+++
1852	+++
1853	++
1854	+++
1855	+++
1856	+++
1857	+++
1858	++
1859	+++
1860	+++
1861	+++
1862	+++
1863	+++
1864	+++
1865	++
1866	+ + +
1867	+++
1868	+++
1869	+++
1870	++
1871	+++

Cmpd.' _: No.	EC30S (μΜ)
1872	+++
1873	+++
1874	+++
1875
1876	+++
1877	++
1878	++
1879	+++
1880	++
1881	+++
1882	+
1883	+++
1884	+++
1885	+++
1886	++
1887	+++
1888	++
1889	+++
1890	++
1891	+++
1892	+++
1893	+++
1894	+++
1895	+++
1896	+++
1897	+++
1898	++
1899	+++
1900	++
1901	+4- +
1902	+++
1903	+++
1904	+++
1905	+++
1906	++ +
1907	+++
1908	+++
1909	++ +
1910	+++
1911	+++
1912	+++

1414

Cmpd. : No. ’	EÇ3g ^: (UM)
1913	+++
1914	+++
1915	+++
1916	+++
1917	+++
1918	+++
1919	++4
1920	++
1921	+++
1922	+++
1923	++
1924	+++
1925	+++
1926	+++
1927	+++
1928	++
1929	+++
1930	+++
1931	+++
1932	+++
1933	44-4
1934	+++
1935	+++
1936	+++
1937	++
1938	+++
1939	++
1940	+++
1941	+++
1942	++
1943	++
1944	+++
1945	+++
1946	+++
1947	++
1948	+++
1949	+++
1950	+++
1951	4·++
1952	+++
1953	+++ \|

_:Cmpd. * No. .	EC30
1954	+++
1955	+++
1956	+++
1957	++
1958	4-+4-
1959	+++
1960	+++
1961	+++
1962	+++
1963	+++
1964	+++
1965	+++
1966	+4-+
1967	++
1968	+++
1969	+++
1970	+++
1971	+++
1972	+++
1973	+++
1974	+++
1975	+++
1976	+++
1977	+++
1978	+4—F-
1979	+++
1980	+++
1981	+++
1982	++
1983	+++
1984	++
1985	++
1986	+++
1987	+++
1988	+++
1989	+++
1990	+++
1991	+++
1992	+++
1993	+++
1994	+++

1415

<0mpcŒ SNo.^	ÆC30
1995	+++
1996	+++
1997	++
1998	+++
1999	++
2000	+++
2001	+++
2002	+++
2003	+++
2004	+++
2005	++
2006	+++
2007	+++
2008	++
2009	+++
2010	+++
2011	+++
2012	+++
2013	+++
2014	+++
2015	+++
2016	++
2017	+++
2018	+++
2019	+++
2020	+++
2021	++
2022	+++
2023	+++
2024	++
2025
2026	++ +
2027	+++
2028	+++
2029	+++
2030	+++
2031	+++
2032	++
2033	+++
2034	+++
2035	+++

æCifîpdM SInè®	SWk
2036	+++
2037	+++
2038	+++
2039	+++
2040	+++
2041	+++
2042	+++
2043	+++
2044	+++
2045	++
2046	+++
2047	++
2048	+++
2049	+++
2050	+++
2051	+++
2052	+++
2053	+++
2054	+++
2055	+++
2056	++
2057	+++
2058	+++
2059	+++
2060	+++
2061	+++
2062	+++
2063	+++
2064	++ +
2065	++ +
2066	+++
2067	+++
2068	+++
2069	+++
2070	+++
2071	+++
2072	++
2073	+++
2074	++
2075	+++
2076	+++

1416

I

.^CfhpdM	c EC30 ? (μΜ; 5:
2077	+++
2078	++
2079	+++
2080	++
2081	+++
2082	++
2083	+4·+
2084	+++
2085	+4- +
2086	+++
2087	+++
2088	++
2089	+++
2090	+++
2091	+++
2092	+++
2093	+++
2094	+++
2095	+++
2096	+++
2097	+++
2098	+++
2099	+++
2100	+++
2101	+++
2102	4-++
2103	+++
2104	+++
2105	+++
2106	+++
2107	+++
2108	++ +
2109	4-++
2110	+
2111	+++
2112	++
2113	4-++
2114	+++
2115	+4-4-
2116	4-++
2117	+++

Êpmpd.A	ifEC30a ?iM)/
2118	+++
2119	+++
2120	+++
2121	+++
2122	+++
2123	++ +
2124	+++
2125	+++
2126	+++
2127	+++
2128	++
2129	+++
2130	+++
2131	+
2132	+++
2133	+++
2134	+++
2135	++
2136	+++
2137	+++
2138	+++
2139	+++
2140	++
2141	+++
2142	+++
2143	+++
2144	+++
2145	+++
2146	+++
2147	+++
2148	++
2149	+++
2150	+++
2151	+++
2152	++
2153	+++
2154	+++
2155	++
2156	+++
2157	+
2158	++

1417

a	; SEC3QÎ.
2159	+++
2160	++
2161	+++
2162	+++
2163	+++
2164	+++
2165	+++
2166	++
2167	+++
2168	+++
2169	+++
2170	++ +
2171	4·++
2172	+++
2173	+++
2174	++
2175	4*+
2176	+++
2177	+++
2178	+++
2179	+++
2180	+++
2181	+++
2182	+++
2183	+++
2184	+++
2185	++
2186	+++
2187	+++
2188	+++
2189	+++
2190	+++
2191	+++
2192	+++
2193	+++
2194	+++
2195	+++
2196	+++
2197	+++
2198	+++
2199	4-+

OGriïpd^	/t⁰³⁰-
2200	++
2201	+++
2202	+++
2203	+++
2204	+++
2205	+++
2206	+++
2207	+++
2208	+++
2209	+++
2210	+++
2211	+++
2212	++
2213	+++
2214	+++
2215	++
2216	+++
2217	+++
2218	+++
2219	++
2220	++
2221	++
2222	++
2223	+++
2224	+++
2225	++
2226	++
2227	+++
2228	+++
2229	++
2230	+++
2231	+++
2232	++
2233	+++
2234	+++
2235	+++
2236	+++
2237	+++
2238	+++
2239	+++
2240	++

1418

...Cmpd.’g	l*EC307 7 (pM)>
2241	+++
2242	+++
2243	+++
2244	+++
2245	+++
2246	+++
2247	++
2248	+++
2249	+++
2250	+++
2251	+++
2252	+++
2253	++
2254	++
2255	+++
2256	+++
2257	+++
2258	+++
2259	+++
2260	+++
2261	++ +
2262	+++
2263	+++
2264	+++
2265	+++
2266	+++
2267	+++
2268	+++
2269	+++
2270	+++
2271	+++
2272	+++
2273	+++
2274	++
2275	++
2276	+++
2277	+++
2278	+++
2279	+++
2280	+++
2281	++ \|

®Gmpd^ MW	SEG30 ' '•ma
2282	+++
2283	+++
2284	+++
2285	+++
2286	+++
2287	+++
2288	+++
2289	+++
2290	++
2291	+++
2292	+++
2293	+++
2294	++
2295	++
2296	+++
2297	+++
2298	+++
2299	+++
2300	++
2301	+++
2302	+++
2303	++
2304	+++
2305	+++
2306	+++
2307	+++
2308	+++
2309	+++
2310	+++
2311	+++
2312	+++
2313	+++
2314	++
2315	+++
2316	+++
2317	+++
2318	+++
2319	++
2320	+++
2321	++
2322 j	+++

1419

I

®Cmpd. No.	EC30 (UM)
2323
2324	++
2325	+++
2326	+++
2327	++
2328	++
2329	+++
2330	+++
2331	+++
2332	+++
2333	++
2334	+++
2335	++
2336	+++
2337	+++
2338	+++
2339	+++
2340	+++
2341	+++
2342	+++
2343	+++
2344	+++
2345	+++
2346	+++
2347	+++
2348	+++
2349	++
2350	++
2351	+++
2352	+++
2353	+++
2354	++
2355	+++
2356	+++
2357	+++
2358	+++
2359	++
2360	++
2361	4-4-4-
2362	+4-4-
2363	++

tCmpd	\| EC30J »(uM) '^?
2364	+++
2365	+++
2366	+++
2367	+++
2368	+++
2369	+++
2370	+++
2371	+++
2372	+++
2373	+++
2374	+++
2375	++
2376	+++
2377	+++
2378	+++
2379	+++
2380	+++
2381	+++
2382	+++
2383	++
2384	+++
2385	+++
2386	+++
2387	++
2388	+++
2389	++
2390	+++
2391	+++
2392	+++
2393	++
2394	+++
2395	+4—H
2396	++
2397	+++
2398	+++
2399	++ +
2400	++
2401	+++
2402	++ +
2403	+++
2404	+++ \|

1420

WCmpd® No.	EC30 (uM)
2405	+++
2406	+++
2407	++
2408	+++
2409	+++
2410	+++
2411	+++
2412	+++
2413	+++
2414	++
2415	+++
2416	+++
2417	+++
2418	+++
2419	++
2420	++
2421	+++
2422	++
2423	+++
2424	+++
2425	+++
2426	+++
2427	+++
2428	+++
2429	+++
2430	++
2431	+++
2432	+++
2433	++
2434	+++
2435	+++
2436	+++
2437	+++
2438	+++
2439	+++
2440	+++
2441	++
2442	++
2443	+++
2444	++
2445 \|	+++

Gmpd. G No. .	^EC3% (μΜΓ
2446	+++
2447	+++
2448	+++
2449	+++
2450	+++
2451	+++
2452	+++
2453	+++
2454	++
2455	+++
2456	+++
2457	+++
2458	+++
2459	+++
2460	+++
2461	+++
2462	+++
2463	+++
2464	++
2465	+++
2466	+++
2467
2468	+++
2469	++
2470	+++
2471	++
2472	++
2473	+++
2474	+++
2475	+++
2476	+++
2477	+++
2478	+++
2479	+++
2480	++
2481	+++
2482	++ +
2483	+++
2484	+++
2485	+++
2486	_Δ⁺⁺

1421

φCmpd. • No.'.	EG30® * (μΜ)
2487	+++
2488	+++
2489	++
2490	+++
2491	+++
2492	+++
2493	+++
2494	+++
2495	+++
2496	++ +
2497	+++
2498	+++
2499	+++
2500	+++
2501	++
2502	+++
2503	+++
2504	++
2505	+++
2506	++
2507	+++
2508	+++
2509	+++
2510	+++
2511	+++
2512	+++
2513	++
2514	+++
2515	+++
2516	++
2517	+++
2518	+++
2519	+++
2520	++
2521	+++
2522	+++
2523	++
2524	+++
2525	++
2526	+++
2527	+++

Cmpd,* Kl No; w	EC30 (μΜ)
2528	+++
2529	+++
2530	+++
2531	+++
2532	+++
2533	+++
2534	4++
2535	++
2536	+++
2537	++
2538	+++
2539	+++
2540	+++
2541	+++
2542	+++
2543	+++
2544	+
2545	+++
2546	+++
2547	+++
2548	+++
2549	+++
2550	++
2551	+++
2552	+++
2553	+++
2554	+++
2555	+++
2556	++
2557	+++
2558	+++
2559	+++
2560	+++
2561	+++
2562	+++
2563	+++
2564	+++
2565	++
2566	+++
2567	+++
2568	++

1422

Cmpd.;· IOcSÉ	“ - EC30_fÎWt
2569	+++
2570	++
2571	+++
2572	+++
2573	+++
2574	++
2575	+++
2576	+++
2577	+++
2578	+++
2579	+++
2580	+++
2581	+++
2582	+++
2583	++
2584	++
2585	+++
2586	++
2587	++
2588	+++
2589	+++
2590	+++
2591	+++
2592	+++
2593	+++
2594	+++
2595	+++
2596	+++
2597	++
2598	+++
2599	++
2600	+++
2601	++
2602	++
2603	+++
2604	+++
2605	++
2606	+++
2607	+++
2608	+++
2609	+++ \|

ΙΟΙ	; SEG30®.
2610	+++
2611	+++
2612	++
2613	+++
2614	++
2615	++
2616	+++
2617	++
2618	+++
2619	+++
2620	++
2621	++
2622	+++
2623	++
2624	++
2625	+++
2626	+++
2627	+++
2628	+++
2629	+++
2630	+++
2631	+++
2632	+++
2633	++
2634	+++
2635	+++
2636	+
2637	+++
2638	+++
2639	+++
2640	+++
2641	+++
2642	+++
2643	+++
2644	+++
2645	+++
2646	++ +
2647	+++
2648	+++
2649	+++
2650	++

1423

XCmpd.Y	;\|^sEC30
2651	+++
2652	+++
2653	+++
2654	+++
2655	+4+
2656	+++
2657	++
2658	++
2659	++
2660	+++
2661	444
2662	++
2663	+++
2664	+4 +
2665	+++
2666	++
2667	+++
2668	44
2669	4+4
2670	+++
2671	+++
2672	+4+
2673	444
2674	+++
2675	444
2676	44+
2677	+++
2678	++
2679	++
2680	++
2681	444
2682	444
2683	444
2684	+++
2685	4+4
2686	++ +
2687	++
2688	444
2689	44
2690	444
2691	+++

toripciM	iiEC3QJS s WM)W
2692	44
2693	-H-
2694	+++
2695	+++
2696	+++
2697	+++
2698	444
2699	+++
2700	+++
2701	+++
2702	+++
2703	+++
2704	+++
2705	4+4
2706	+++
2707	444
2708	44+
2709	+++
2710	++
2711	++
2712	+++
2713	+++
2714	+++
2715	+++
2716	+++
2717	+++
2718	+++
2719	+++
2720	4++
2721	+++
2722	+++
2723	+++
2724	+++
2725	+4+
2726	+++
2727	++ +
2728	+++
2729	+++
2730	++
2731	++
2732	-

1424

Cmpd. No.	EC30
2733	++
2734	++
2735	++
2736	++
2737	+++
2738	+++
2739	+++
2740	+++
2741	++
2742	++
2743	+++
2744	+++
2745	+++
2746	+++
2747	+++

1425

Other Embodiments

Ail publications and patents referred to in this disclosure are incorporated herein by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Should the meaning of 5 the tenus in any of the patents or publications incorporated by reference conflict with the meaning of the tenus used in this disclosure, the meaning of the tenus in this disclosure are intended to be controlling. Furthermore, the foregoing discussion discloses and describes mereîy exemplary embodiments of the invention. One skilled in the art will readily recognize from such discussion and from the accompanying drawings and claims, that varions changes, modifications 10 and variations can be made therein without departing from the spirit and scope of the invention as defîned in the following claims.

Claims

1. A compound of formula I:

I, or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence;

Ring A is a C6-C10 aryi ring; C3-C10 cycloalkyl ring; oraC3-C14 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C3-C14 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, NR, O, or S; or a C3-C10 cycloalkyl ring;

Wis O, NR, or S;

XisOorNR;

Y is independently CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Zis NRorCHR;

Ri is halo; CN; F₅S; SiR₃; OH; NRR; CLC6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C61427

CIO aryl; C3-CI0 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; CI-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroa!koxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyl en e)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; OH; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

C3-C10 cycloalkyl; or a (Cl-C9 alkylene)-R₄ wherein up tofourCHz units are independently replaced with O, CO, S, S O, S O₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R is independently H; OH; C0₂H; CO₂C1-C6 alkyl; Cl-C6 alkyl; C1-C6 alkenyl; Cl -C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-CIO cycloalkyl;

n is 0, 1,2 or 3;

ois 0,1,2, 3,4, or 5;

p is 0, 1,2, or3; and qisO, 1,2,3,4, or5;

is a single bond or a double bond;

1428

I

2. The compound of claim 1, wherein ring A is a pyridyl, indole, indoline, isoindoline, pyrazole, pyrimidine, phenyl, quinoline, 5,6,7,8-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoIine, pyrrolidine, aza-indole, pyrrole, oxazole, pyrazine, triazole, benzimidazole, indazole, or imidazole ring.

10 4. The compound of any one of daims 1 to 3, wherein ring B is phenyl, pyridyl, pyridine-2(l/7)one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine4(IH)-one, pynolidinone, or quinoline.

1429

6. The compound of any one of daims 1 to 5, wherein ring C is cycloalkyl, pyrrolidine, piperidine, or azetidine,

5

7. The compound of daim 6, wherein ring C is pyrrolidine.

8. The compound of any one of daims 1 to 6, wherein ring C is

1430

9. The compound of any one of daims 1 to 8, wherein Y is O.

10. The compound of any one of daims 1 to 8, wherein Y is CH₂.

11. The compound of any one of daims 1 to 8, wherein Y is CH(CI -C6 aliphatic).

12. The compound ofany one of daims 1 to 8, wherein Y is CH(CH₃).

5

13. The compound of any one of daims 1 to 8, wherein Y is CH(CH₂CH₃).

14. The compound ofany one of daims 1 to 8, wherein Y is N(C1-C6 aliphatic).

15. The compound of any one of daims 1 to 8, wherein Y is N(CH₃).

16. The compound of any one of daims 1 to 15, wherein R] is halo, CN, C1-C6 aliphatic, C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, or

10 thiophene ring, wherein ail rings may be substituted with halo, C1-C6 aliphatic, C1-C6 alkoxy, C1-C6 fluoroaliphatic, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, C3-C10 heterocycloalkyl, or a (C1-C8 aliphatic)-R₄ wherein up to three CH₂units may be replaced with O, CO, S, SO, SO₂ or NR.

17. The compound of any one of daims 1 to 16, wherein Ri is selected from CH₃, Cl, F, CN,

1431

1432

1433

I

18. The compound of any one of daims 1 to 17, wherein R₂ is selected from halo, OH, CN,

5 azide, amino, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy or fluoroalkoxy, C3-C10 monoor bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR;

or a (C1-C8 aliphatic )-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR.

19. The compound of any one of daims 1 to 18, wherein R₂ is selected from Cl, F, OH, CN, N₃10 NH₂, NH(CH₃), N(CH₃)_2j CH₃, CH₂0H, CH₂CH₃, CH(CH₃)₂, chf₂, och₃, ocf₃, OCHF₂,

OCH(CH₃)₂, C(O)CH_3j CH₂CH₂OH, CH₂NH_2î NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂,

NH(CH₂)₂NH₂,NH(CH₂)₃NH₂,NH(CH₂)₂OCH₃, NHCH(CH₃)₂, ξ—NH

XorCO₂H.

20. The compound of any one of daims 1 to 19, wherein R₃ is selected from halo, CN, C1-C6 15 aliphatic or fluoroaliphatic, C1-C6 alkoxy, orC3-C10 mono- or bicyclic heteroaryl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

21. The compound of any one of daims 1 to 20, wherein R₃ is selected from CI, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃₎ CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃,

1434

22. The compound of any one of claims 1 to 21, wherein o is 0.

23. The compound of any one of claims 1 to 21, wherein o is 1.

5

24. The compound of any one of claims 1 to 21, wherein o is 2.

25. The compound of any one of claims 1 to 24, wherein n is 0.

26. The compound of any one of claims 1 to 24, wherein n is 1.

27. The compound of any one of claims 1 to 24, wherein n is 2.

28. The compound of any one of claims 1 to 27, wherein p is 0.

10

29. The compound of any one of claims 1 to 27, wherein p is 1.

30. The compound of any one of claims 1 to 27, wherein p is 2.

31. The compound ofclaim 1, wherein the compound isof formula la:

la or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

1435

Ring C is a C3-C14 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycloalkyl ring;

X is O orNR;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

R] is halo; CN; F₅S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyi; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6CIO aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl ;C1-C6 alkoxy or fluoroalkoxy; C1-C6 alkenyi; Cl-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (CI-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyi; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaiyl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

1436

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycïoalkyl;

n is 0, 1, or 2;

5 oisO, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and qis 0, 1,2,3,4, or 5.

32. The compound of claim 31, wherein ring B is phenyl, pyridyl, pyridine-2(l/7)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(l H)-one, 10 pyrrolidinone, or quinoline.

33. The compound of claim 31 or 32, wherein ring B is selected from

15

34. The compound of any one of daims 31 to 33, wherein ring C is cycïoalkyl, pyrrolidine, or piperidine.

35. The compound ofany one of daims 31 to 34, wherein ring C is

1437

I

36. The compound of any one of claims 31 to 35, wherein Y is O.

37. The compound of any one of claims 31 to 35, wherein Y is CH₂.

38. The compound of any one of claims 31 to 35, wherein Y is CH(C1-C6 aliphatic).

39. The compound of any one of claims 31 to 35, wherein Y is CH(CH₃).

10

40. The compound of any one of claims 31 to 35, wherein Y is CH(CH₂CH₃).

41. The compound of any one of claims 31 to 40, wherein Rj is halo, CN, C1-C6 aliphatic, ClC6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or tbiophene ring, wherein ali rings may be substituted with halo, C1-C6 aliphatic, CI-C6 alkoxy, C1-C6 fluoroaliphatic, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-

15 CIO heteroaryl, C3-C10 heterocycloalkyl, or a (C 1-C8 aliphatic)-R4 wherein up to three CH₂units may be replaced with O, CO, S, SO, SO₂ or NR.

1438

1439

I

1440

43. The compound of any one of daims 31 to 42, wherein R₂is selected from halo, OH, CN,

10 azide, amino, Cl -C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy or fluoroalkoxy, C3-C10 monoor bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (CI-C8 aliphatic )-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR.

1441

44. The compound of any one of daims 31 to 43, wherein R₂ is selected from Cl, F, OH, CN, n_3> nh₂, NH(CH₃), N(CH₃)₂, ch₃, ch₂oh, ch₂ch₃, CH(CH₃)₂, chf₂, och₃, ocf₃, ochf₂, OCH(CH₃)₂, C(0)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂,

NH(CH₂)₂NH₂, NH(CH₂)₃NH_2j NH(CH₂)₂OCH₃, NHCH(CH₃)₂, ^N\ /^N , ^N\ P _t

NH

5 ^,orCO₂H.

45. The compound of any one of daims 31 to 44, wherein R₃is selected from halo, CN, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy, or C3-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

46. The compound of any one of daims 31 to 45, wherein R₃ is selected from Cl, F, CN, CH₃, 10 OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃,

47. The compound of any one of daims 31 to 46, wherein o is 0.

15

48. The compound of any one of daims 31 to 46, wherein o is 1.

49. The compound of any one of daims 31 to 48, wherein n is 0.

50. The compound of any one of daims 31 to 48, wherein n is 1.

51. The compound of any one of daims 31 to 48, wherein n is 2.

52. The compound of any one of daims 31 to 51, wherein p is 0.

20

53. The compound of any one of daims 31 to 51, wherein p is 1.

54. The compound ofany one of daims 31 to 51, wherein p is 2.

1442

55. The compound of any one of claims 31 to 54, wherein ring B is phenyl.

56. The compound of any one of claims 31 to 55, wherein ring B is independently phenyl or pyridyl.

57. The compound ofclaim 1, wherein the compound is of formula Ib:

Ring B is a C6-C10 aryl ring or C3-CIO heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR;

Ring C is a C3-C14 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 mono- or bicyclic cycloalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; FjS; SiR₃; OH; NRR; CI-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or fluoroalkoxy; CI-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

R 2 is halo; OH; NRR; azide; CN; CO₂R; C1-C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkyIene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

1443 or two R2 groups taken together may form a =CH₂ or =O group;

R₃ is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 aIkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 alkynyl; C6-CI0 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1, 2 or 3;

o is 0, 1,2, 3,4, or 5;

p is 0, 1,2, or 3; and q is 0, 1, 2, 3, 4, or 5,

58. The compound of claim 57, wherein ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lH)-one, pyrrolidinone, or quinoline.

1444

60. The compound of any one of daims 57 to 59, wherein ring C is cycloalkyl or pyrrolidine.

61. The compound of any one of daims 57 to 60, wherein ring C is

62. The compound of any one of daims 57 to 61, wherein Y is O.

63. The compound of any one of daims 57 to 61, wherein Y is CH₂.

1445

64. The compound of any one of daims 57 to 61, wherein Y is CH(C1-C6 aliphatic).

65. The compound of any one of daims 57 to 61, wherein Y is CH(CH₃).

66. The compound of any one of daims 57 to 61, wherein Y is CH(CH₂CH₃).

67. The compound of any one of daims 57 to 66, wherein R| is halo, CN, C1-C6 aliphatic, Cl-

5 C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, Cl-C6 aliphatic, CI-C6 alkoxy, C1-C6 fluoroaliphatic, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3C10 heteroaryl, C3-C10 heterocycloalkyl, or a (C1-C8 aliphatic)-R₄ wherein up to three CH₂units may be replaced with O, CO, S, SO, SO₂ or NR.

10

68. The compound of any one of daims 57 to 67, wherein Ri is selected from CH₃, Cl, F, CN,

1446

1447

1448

69. The compound of any one of claims 57 to 68, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy or fluoroalkoxy, C3-C10 mono-

5 or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (Cl -C 8 aliphatic )-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, S O, SO₂or NR.

70. The compound of any one of claims 57 to 69, wherein R₂ is selected from Cl, F, OH, CN,

N ₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, ocf₃, ochf₂,

10 OCH(CH₃)₂, C(O)CH₃, CH₂CH₂0H, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, \l— ξ—l/

NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂, δ—/ , , ζ — NH , or CO₂H.

71. The compound of any one of claims 57 to 70, wherein R₃ is selected from halo, CN, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy, or C3-C10 mono- or bicyclic heteroaryl wherein up to 15 4 carbon atoms may be replaced by O, S, N, or NR.

72. The compound of any one of claims 57 to 71, wherein R₃ is selected from Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂, =0,

1449

73. The compound of any one of daims 57 to 72, wherein o is 0.

74. The compound of any one of daims 57 to 72, wherein o is I.

5

75. The compound of any one of daims 57 to 72, wherein o is 2.

76. The compound of any one of daims 57 to 75, wherein n is 0.

77. The compound of any one of daims 57 to 75, wherein n is 1.

78. The compound of any one of daims 57 to 75, wherein n is 2.

79. The compound of any one of daims 57 to 78, wherein p is 0.

10

80. The compound of any one of daims 57 to 78, wherein p is 1.

81. The compound of any one of daims 57 to 78, wherein p is 2.

82. The compound of any one of daims 57 to 81, wherein ring B is pyridyl.

83. The compound of any one of daims 57 to 82, wherein ring B is phenyl.

84. The compound of daim 1, wherein the compound is of formula le:

1450

Y is CRR, CO, O, S, SO, SO₂, S(0)NH orNR;

Ri is halo; CN; F₃S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or

5 fluoroalkoxy; C1-C6 alkenyl; Cl-C6 alkynyl; (CI-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; C0₂R; Cl -C6 alkyl or fluoroalkyl;Cl-C6 alkoxy or ¹⁰ fluoroalkoxy; C1-C6 alkenyl ; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

^{15 R}3 is halo; CN; CO₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; C1-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, S0₂ or NR;

²⁰ or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, orSO₂R;

R is independently H; OH; CO₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; C1-C6 alkenyl; C1-C6 ²⁵ alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

oisO, l,2,3,4,or5;

1451 p is 0, 1,2, or 3; and q is 0, 1,2, 3, 4, or 5.

85. The compound of daim 84, wherein ring B is phenyl, pyridyl, pyridine-2(lÆ)-one, pyrazole, indole, thiophene, dihydrobenzofnran, pyrazine, indazole, thiazole, pyridine-4(lH)-one,

5 pyrrolidinone, or quinoline.

86. The compound ofclaim 84 or 85, wherein ring B is selected from

10

87. The compound of any one of daims 84 to 86, wherein ring C is cycloalkyl, or pyirolidine,.

88. The compound of any one of daims 84 to 87, wherein ring C is

1452

89. The compound of any one of claims 84 to 88, wherein Y is O.

5

90. The compound of any one of claims 84 to 88, wherein Y is CH₂.

91. The compound of any one of claims 84 to 88, wherein Y is CH(C1-C6 aliphatic).

92. The compound of any one of claims 84 to 88, wherein Y is CHfCHs).

93. The compound of any one of claims 84 to 88, wherein Y is CH(CH₂CH3).

94. The compound of any one of claims 84 to 93, wherein Rj is halo, CN, C1-C6 aliphatic, Cl10 C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 aliphatic, C1-C6 alkoxy, C1-C6 fluoroaliphatic, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3C10 heteroaryl, C3-CIO heterocycloalkyl, or a (C1-C8 aliphatic)-R₄ wherein up to three CH₂units may be replaced with O, CO, S, SO, SO₂ or NR.

15

95. The compound of any one of claims 84 to 94, wherein Ri is selected from CH₃, Cl, F, CN,

1453

1454

1455

96. The compound of any one of daims 84 to 95, wherein R₂ is selected from halo, OH, CN, azide, amino, C1-C6 aliphatic or fluoroaliphatic, CLC6 alkoxy or fluoroalkoxy, C3-C10 monoor bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (Cl -C8 aliphatic)-R4 wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂10 or NR.

97. The compound of any one of daims 84 to 96, wherein R₂ is selected from Cl, F, OH, CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, chf₂, och₃, ocf₃, ochf₂, 0CH(CH₃)_2j C(0)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂0H, NH(CH₂)₂N(CH₃)₂,

N— ç— N^ZNH(CH₂)₂NH₂, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂, , V—/ ,

NH

15 ^orCO.H.

1456

98. The compound of any one of daims 84 to 97, wherein R₃is selected from halo, CN, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy, or C3-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

99. The compound ofany one of daims 84 to 98, wherein R₃is selected from CI, F, CN, CH₃,

5 OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃,

100. The compound of any one of daims 84 to 99, wherein o is 0.

10

101. The compound ofany one ofdaims 84 to 99, wherein o is 1.

102. The compound of any one of daims 84 to 99, wherein o is 2.

103. The compound ofany one ofdaims 84 to 102, wherein n is 0.

104. The compound of any one of daims 84 to 102, wherein n is 1.

105. The compound of any one of daims 84 to 102, wherein n is 2.

15

106. The compound of any one of daims 84 to 105, wherein p is 0.

107. The compound of any one of daims 84 to 105, wherein p is 1.

108. The compound of any one of daims 84 to 105, wherein p is 2.

109. The compound of any one of daims 84 to 108, wherein ring B is phenyl.

110. The compound of daim 1, wherein the compound is of formula Id:

1457

Ring B is a C6-C10 aryl ring orC3-C10 heteroaryl or heterocyclic ring wherein

5 anywhere from 1 to 4 ring atoms are independently O, S, N, or NR;

Ring C is a C3-C14 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently N, O, or S, or a C3-C10 cycïoalkyl ring;

Y is CRR, CO, O, S, SO, SO₂, S(O)NH or NR;

Ri is halo; CN; F5S; SiR₃; OH; NRR; C1-C6 alkyl or fluoroalkyl; C1-C6 alkoxy or

10 fluoroalkoxy; Cl-C6 alkenyl; C1-C6 alkynyl; (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C6C1Û aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C3-C10 cycïoalkyl;

R? is halo; OH; NRR; azide; CN; CO₂R; Cl -C6 alkyl or fluoroalkyI;Cl-C6 alkoxy or

15 fluoroalkoxy;Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycïoalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

145S

R₃ is halo; CN; C0₂R; C1-C6 alkyl or fluoroalkyl; C1-C6 alkenyl; Cl-C6 alkynyl; C1-C6 alkoxy or fluoroalkoxy; or C6-C10 aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3C10 cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are

5 independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; C0₂R; OH; C6-C10 aryl, C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

10 R is independently H; OH; C0₂H; CO₂C1-C6 alkyl; C1-C6 alkyl; Cl-C6 alkenyl; C1-C6 alkynyl; C6-C10 aryl; C3-C10 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C3-C10 cycloalkyl;

n is 0, 1,2 or 3;

o is 0, 1, 2, 3, 4, or 5;

15 p is 0, 1, 2, or 3; and q is 0, 1,2, 3, 4, or 5.

111, The compound of claim 110, wherein ring B is phenyl, pyridyl, pyridine-2(lH)-one, pyrazole, indole, thiophene, dihydrobenzofuran, pyrazine, indazole, thiazole, pyridine-4(lHJone, pyrrolidinone, or quinoline.

112, The compound of claim 110 or 111, wherein ring B is selected from

1459

113. The compound of any one of daims llOto 112, wherein ring C is cycloalkyl, or pyrrolidine.

115. The compound of any one of daims HO to 114, wherein Y is O.

1460

116. The compound of any one of daims 110 to 114, wherein Y is CH₂.

117. The compound of any one of daims 110 to 114, wherein Y is CH(C1 -C6 aliphatic).

118. The compound of any one of daims 110 to 114, wherein Y is CH(CH₃).

119. The compound of any one of daims 110 to 114, wherein Y is CH(CH₂CH₃).

5

120. The compound of any one of daims 110 to 119, wherein Ri is halo, CN, C1-C6 aliphatic,

C1-C6 alkoxy, C3-C8 cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, or thiophene ring, wherein ail rings may be substituted with halo, C1-C6 aliphatic, C1-C6 alkoxy, C1-C6 fluoroaliphatic, C1-C6 fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C3-C10 heteroaryl, C3-C10 heterocycloalkyl, or a (C1-C8 aliphatic)-R₄ wherein up to three CH₂10 units may be replaced with O, CO, S, SO, SO₂ or NR.

121. The compound of any one of daims 110 to 120, wherein Ri is selected from CH₃, Cl, F,

1461

1462

1463

122. The compound of any one of daims 110 to 121, wherein R₂ is selected from halo, OH, CN, 5 azide, amino, C1-C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy or fluoroalkoxy, C3-C10 mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (C1-C8 aliphatic )-R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂or NR.

123. The compound of any one of daims 110 to 122, wherein R₂ is selected from Cl, F, OH,

10 CN, N₃, NH₂, NH(CH₃), N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)_2î CHF₂, OCH₃, OCF₃, OCHF₂, OCH(CH₃)_2j C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂,

N⁷ <—J O

NH(CH₂)₂NH₂, NH(CH₂)₃NH₂, NH(CH₂)₂OCH₃, NHCH(CH₃)₂, a—/ , a—/ ,

NH , or CO₂H.

124. The compound of any one of daims 110 to 123, wherein R₃ is selected from halo, CN, Cl-

15 C6 aliphatic or fluoroaliphatic, C1-C6 alkoxy, or C3-C10 mono- or bicyclic heteroaryl wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

125. The compound of any one of daims 110 to 124, wherein R₃ is selected from Cl, F, CN, CH₃, 0CH₃, CF_3j CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH,

1464

126. The compound of any one of daims 110 to 125, wherein ois 0.

127. The compound of any one of daims 110 to 125, wherein ois 1.

5

128. The compound of any one of daims 110 to 125, wherein ois 2.

129. The compound of any one of daims 110 to 128, wherein nis 0.

130. The compound of any one of daims 110 to 128, wherein nis 1.

131. The compound of any one of daims 110 to 128, wherein nis 2.

132. The compound of any one of daims 110 to 131, wherein pis 0.

10

133. The compound of any one of daims 110 to 131, wherein pis 1.

134. The compound of any one of daims 110 to 131, wherein pis 2.

135. The compound of any one of daims 110 to 134, wherein ring B is phenyl.

136. The compound of any one of daims 110 to 135, wherein ring B is pyridyl.

137. A compound of formula 1:

1465 or a pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring A is pyridine ;

Ring B is phenyl ;

5 Ring C is pyrrolidine ;

WisO;

Xis O;

(Y)_o is a bond ;

ZisNH;

10 Ri is halo; CN; F₅S; SiR₃; OH; NRR; Cj-C^ alkyl or fluoroalkyl; Cj-Cô alkoxy or fluoroalkoxy; Cj-Cô alkenyl; CpCg alkynyl; (Cj-Cç alkylene)- R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; Cô-Cio aryl; C3-C10 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or CyCjo cycloalkyl;

15 R₂ is halo; OH; NRR; azide; CN; CO₂R; Ci-Ce alkyl or fluoroalkyl; Ci-Ce alkoxy or fluoroalkoxy; Ci-Ce alkenyl; Cj-Cû alkynyl; Cg-Cio aryl; C₃-C]₃ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; or a (C ।-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

20 or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; OH; CO₂R; C|-Cé alkyl or fluoroalkyl; C]-C& alkenyl; Ci-Ce alkynyl; CjC$ alkoxy or fluoroalkoxy; or Ce-Cjo aryl; C₃-Cio heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃-Cio cycloalkyl; or a (Cr C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, S O, 25 SO₂orNR;

or two R₃ groups taken together may form a = CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂ ; OR; CCH; CO₂R; OH; Cè-Cio aryl, C₃-C|q heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C3-C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, or SO₂R;

1466

R is independently H; OH; CO₂H; CO₂;Ci-Cô alkyl; Ci-C& alkyl; Cj-Cô alkenyl; Cj-Cô alkynyl; Cé-Cio aryl; C₃-Cio heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C₃-Cio cycloalkyl;

n is 0, 1,2 or 3;

p is 0, 1,2, or 3; and q is 0, 1,2, 3,4, or 5;

each is independently a single bond or a double bond;

138. The compound of daim 137, wherein R] is halo, CN, Ci-Ce aliphatic, C|-Ce alkoxy, C₃-C_s cycloalkyl, or a phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, or thiophene ring, wherein ail rings may be substituted with halo, Ci-Cé aliphatic, Cj-Cg alkoxy, Ci-C₆ fluoroaliphatic, C_rC₆ fluoroalkoxy, OH, CH₂OH, CH₂OCH₃, CN, CO₂H, amino, amido, C₃-C₁₀ heteroaryl, C₃-Cio heterocycloalkyl, or a (Ci-Cs aliphatic >R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

139. The compound ofclaim 137, wherein R] is selected from CH₃, Cl, F, CN, OCH₃,

CF₃, CH₂, CH₃, tBu, CH(CH₃)₂

1467

1468

1469

5

140. The compound of claim 137, wherein R₂ is halo, OH, CN, azide, amino, C_rC₆ aliphatic or fluoroaliphatic, Cj-C₆ alkoxy or fluoroalkoxy, C₃-C_]0 mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR; or a (Ci-C₈ aliphatic)R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

141. The compound of daim 137, wherein R₂is Cl, F, OH, CN, N₃, NH₂, NH(CH₃), 10 N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF₃, OCHF₂, OCH(CH₃)₂,

C(O)CH₃, CH₂CH₂OH, CH₂NH_2j NH(CH₂)₂OH, NH(CH₂)2N(CH₃)₂, NH(CH₂)₂NH₂, /—y ΛΛ A^NH <—N N— AN O K

NH(CH₂)₃NH₂,NH(CH₂)₂OCH₃,NHCH(CH₃)₂, V_/ , , L>._or

CO₂H.

142. The compound of daim 137, wherein R₃ is halo, CN, C,-C₆ aliphatic or

15 fluoroaliphatic, CpCe alkoxy, or C₃-Cip mono- or bicyclic heteroaryl or heterocycloalkyl wherein up to 4 carbon atoms may be replaced by O, S, N, orNR.

143. The compound of claim 137, wherein R₃is Cl, F, CN, CH₃, OCH₃, CF₃,

CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO2CH3, tBu, =CH₂,,

1470

144. The compound of daim 137, wherein n is 1.

5

145. The compound of daim 137, wherein n is 2.

146. The compound of daim 137, wherein p is 0.

147. The compound ofclaim 137, wherein p is 1.

148. The compound ofclaim 137, wherein p is 2.

149. A pharmaceutical composition comprising a compound of formula I:

15 Ring A is pyridine;

Ring B is phenyl;

1471

Ring C is pyrrolidine;

Wis O;

Xis O;

(Y)o is a bond;

Z is NH;

Ri is halo, CN, F5S, SiR₃; OH; NRR; Cj-Cg alkyl or fluoroalkyl; CfC^ alkoxy or fluoroalkoxy; Ci-Cé alkenyl; Cj-Cé alkynyl; (Cj-Cç alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C₆-Ci₀ aryl; C₃-C₎₀ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR; or C₃-C₁₀ cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Cj-Ce alkyl or fluoro alkyl;C[-C6 alkoxy or fluoroalkoxy.Ci-Cô alkenyl; Ci-Ce alkynyl; Cé-Cio aryl; C₃-Cj₃ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃-C₁₀ cycloalkyl; or a (C1-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; OH; C0₂R; Cj-C₆ alkyl or fluoroalkyl; C]-C₆ alkenyl; Cj-C₆ alkynyl; Cj-Ce alkoxy or fluoroalkoxy; or Cé-Cjq aryl; C₃-Cio heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃-C₁₀ cycloalkyl; or a (CiC₉ alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, S0₂or NR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C₆-C_I0 aryl, C₃-C_lü heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃C10 cycloalkyl; NRR, NRCOR, CONRR, CN, halo, orSO₂R;

R is independently H; OH; CO₂H; CO₂C]-C₆ alkyl; C_rC₆ alkyl; C_rC₆ alkenyl; C_rC₆alkynyl; C₆-Cio aryl; C₃-C|₀ heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; or C₃-C,_o cycloalkyl;

n is 0, 1,2 or 3;

p is 0, 1,2, or3; and qisO, 1,2, 3,4, or 5;

1472 each is independently a single bond or a double bond;

provided that the moieties containing ring B and ring C are substituted at adjacent positions on ring A; and a pharmaceutically acceptable carrier.

5

150. The pharmaceutical composition of claim 149, further comprising one or more additional therapeutic agent(s).

151. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent.

10

152. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is a CFTR modulator.

153. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is a CFTR corrector.

154. The pharmaceutical composition of claim 150, wherein the additional

15 therapeutic agent is

or pharmaceutically acceptable sait thereof.

155. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

1473

156. The pharmaceutical composition of claim 150, wherein tire additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

5

157. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is a CFTR potentiator.

158. The pharmaceutical composition of claim 150, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

159. The pharmaceutical composition of claim 150, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

160. The pharmaceutical composition of claim 150, wherein the additional

1474

161. The pharmaceutical composition ofclaim 150, wherein the additional

162. The pharmaceutical composition of claim 150, wherein the additional therapeutic

pharmaceutically acceptable salts thereof.

163. A kit comprising a compound of formula I:

I, ^{10 or a} pharmaceutically acceptable sait thereof, wherein, independently for each occurrence:

Ring A is pyridine;

1475

Ring B is phenyl;

Ring C is pyrrolidine;

W is O;

Xis O;

(Y)o is a bond;

Z is NH;

R] is halo; CN; F₅S; SiR₃; OH; NRR; C_rC₆ alkyl or fluoroalkyl; C_rC₆ alkoxy or fluoroalkoxy; Cj-C^ alkenyl; C|-Ce alkynyl; (C1-C9 alkyl ene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR; C₆-C|₀ aryl; C₃-C₁₀ heteroaryl or heterocyclic ring wherein anyw'here from I to 4 ring atoms are independently O, S, N, or NR; or C₃-C]o cycloalkyl;

R₂ is halo; OH; NRR; azide; CN; CO₂R; Ci-C₆ alkyl or fluoroalkyl; Ci-C₆ alkoxy or fluoroalkoxy; Ci-Cg alkenyl; Cj-C^ alkynyl; Cê-Cjq aryl; C₃-C_]3 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃-C_l0 cycloalkyl; or a (C_rC₉ alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo; CN; OH; CO₂R; Cj-C₆ alkyl or fluoroalkyl; C₍-C6 alkenyl; C]-C₆ alkynyl; C]C<5 alkoxy or fluoroalkoxy; or Cg-Cio aryl; C₃-Cjo heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR; C₃-C,_o cycloalkyl; or a (CjC₉ alkyl ene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, S O, SO₂orNR;

or two R₃ groups taken together may form a =CH₂ or =0 group;

R₄ is H; azide; CF₃; CHF₂; OR; CCH; CO₂R; OH; C₆-Cjo aryl, C₃-C]₀ heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, orNR; C₃C m cycloalkyl; NRR, NRCOR, CONRR, CN, halo, orSO₂R;

R is independently H; OH; CO₂H; CO₂; C!-C₆ alkyl; C_rC₆ alkyl; C_rC₆ alkenyl; C_rC₆alkynyl, C^-Ciq aryl; C₃-Cio heteroaryl or heterocycloalkyl wherein anywhere from I to 4 ring atoms are independently O, S, N, or NR; or C₃-C,₀ cycloalkyl;

n is 0, 1,2 or 3;

p is 0, 1,2, or 3; and

1476 q isO, 1,2, 3, 4, or 5;

each is independently a single bond or a double bond;

provided that the moieties containing ring B and ring C are substituted at adjacent positions on ring A,

164. The kit of claim 163, further comprising one or more additional therapeutic agent(s).

165. The kit of claim 164, wherein the additional therapeutic agent is a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an antiinflammatory agent.

166.

modulator.

167.

corrector.

The kit of claim 164, wherein the additional therapeutic agent is a CFTR

168. The kit of claim 164, wherein the additional therapeutic agent is

or a phannaceutically acceptable sait thereof.

169. The kit of claim 164, wherein the additional therapeutic agent is

or a phannaceutically acceptable sait thereof.

170. The kit of claim 164, wherein the additional therapeutic agent is

1477

or a pharmaceutically acceptable sait thereof.

171. The kit of claim 164, wherein the additional therapeutic agent is a CFTR potentiator.

5 172, The kit of claim 164, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

173. The kit of claim 164, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

10

174. The kit of claim 164, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

1478

175. The kit of claim 164, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

176. The kit of daim 164, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

177. The kit of claim 164, wherein the compound of claim 1 and the one or more additional therapeutic agent(s) are in separate containers.

178. The kit of claim 164, wherein the compound of claim 1 and the one or more

10 addition ai therapeutic agent(s) are in the same container.

179. The kit of claim 164, wherein the container(s) is a bottle, via], or blister pack, or combination thereof.

180. A compound, wherein the compound has the following formula:

1479

181. A pharmaceutically acceptable sait of a compound having the following formula:

5

182. A pharmaceutical composition comprising:

(i) a compound according to claim 180; and (ïi) a pharmaceutically acceptable carrier.

183. A pharmaceutical composition comprising:

10 (i) a pharmaceutically acceptable sait according to claim 181; and (ii) a pharmaceutically acceptable carrier.

1480

184. The pharmaceutical composition of claim 182, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5

185. The phannaceutical composition ofclaim 182, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

186. The pharmaceutical composition of claim 182, further comprising additional

10 therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

187. The pharmaceutical composition ofclaim 183, further comprising an additional therapeutic agent having the following structural formula:

1481 or a pharmaceutically acceptable sait thereof.

1S8. The pharmaceutical composition ofclaim 183, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

189. The pharmaceutical composition ofclaim 183, furthercomprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

190. A compound, wherein the compound has the following formula;

191. A pharmaceutically acceptable sait of a compound having the following formula:

1482

192. A pharmaceutical composition comprising:

(i) a compound accordîng to claim 190; and (ii) a pharmaceutically acceptable carrier.

193. A pharmaceutical composition comprising:

(i) a pharmaceutically acceptable sait according to daim 191 ; and (ii) a pharmaceutically acceptable carrier.

10

194. The pharmaceutical composition of daim 192, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

195. The pharmaceutical composition ofclaim 192, further comprising an additional

15 therapeutic agent having the following structural formula:

1483

or a pharmaceutically acceptable sait thereof.

196. The pharmaceutical composition of claim 192, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

197. The pharmaceutical composition of claim 193, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

198. The pharmaceutical composition of claim 193, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

1484

199. The pharmaceutical composition of daim 193, further comprising additional therapeutic agents having the foUowing structural formulae:

pharmaceutically acceptable salts thereof.

200. A compound, wherein the compound lias the following formula:

201. A pharmaceutically acceptable sait of a compound having the following formula:

1485

202. A pharmaceutical composition comprising: (i) a compound according to claim 200; and (ii) a pharmaceutically acceptable carrier.

5

203. A pharmaceutical composition comprising: (i) a pharmaceutically acceptable sait according to claim 201; and (ii) a phannaceutically acceptable carrier.

204. The pharmaceutical composition of claim 202, further comprising an additional

10 therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

205. The pharmaceutical composition of claim 202, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

206. The pharmaceutical composition of claim 202, further comprising additional therapeutic agents having the following structural formulae:

20 pharmaceutically acceptable salts thereof.

1486

207. The pharmaceutical composition of claim 203, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5

208. The pharmaceutical composition of claim 203, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

209. The pharmaceutical composition of claim 203, further comprising additional

10 therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

210. A compound, wherein the compound has the following formula:

1487

211. A pharmaceutically acceptable sait ofa compound having the following formula:

212. A pharmaceutical composition comprising:

(i) a compound according to claim 210; and (ii) a pharmaceutically acceptable carrier.

213. A pharmaceutical composition comprising:

10 (i) a pharmaceutically acceptable sait according to claim 211 ; and (ii) a pharmaceutically acceptable carrier.

1488

214, The pharmaceutical composition of claim 212, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5 215. The pharmaceutical composition of claim 212, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

216. The pharmaceutical composition of daim 212, further comprising additional

10 therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

217. The pharmaceutical composition of daim 213, further comprising an additional therapeutic agent having the following structural formula:

1489 or a pharmaceutically acceptable sait thereof.

218. The pharmaceutical composition of claim 213, further comprising an additional therapeutic agent having the following structural formula:

H

5 or a pharmaceutically acceptable sait thereof.

219. The pharmaceutical composition of claim 213, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

10

220. A compound of formula I:

or a pharmaceutically acceptable sait thereof, wherein, independently for each

15 occurrence:

Ring A is pyridine;

1490

Ring B is pyridine;

Ring C is pyrrolidine;

WisO;

X is O;

(Y)_ois a bond;

Z is NH ;

Ri is halo, CN, F₅S, SiR₃, OH, NRR, Ci-Cô alkyl or fluoroalkyl, Cj-Câ alkoxy or fluoroalkoxy, Cj-Cû alkenyl, Cj-Ce alkynyl, (CrCç alkylene)- R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, C₆-C]₀ aryl, C₃-C_]0 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR, or C₃-C[o cycloalkyl;

R₂ is halo, OH, NRR, azide, CN, CO₂R, Ci-C₆ alkyl or fluoroalkyl, C]-C₆ alkoxy or fluoroalkoxy, Cj-Cg alkenyl, Cj-Cô alkynyl, Cs-Cio aryl, C₃-Ci₃ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-C_I0 cycloalkyl, or a (Cj-Cg alkylene )-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR;

or two R₂ groups taken together may form a =CH₂ or =O group;

R₃ is halo, CN, OH, CO₂R, Cj-C_fi alkyl or fluoroalkyl, Cj-C₆ alkenyl, C_rC₆ alkynyl, C]Cg alkoxy or fluoroalkoxy, C₆-Ciq aryl, C₃-Cio heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, orNR, C₃-C₁₀ cycloalkyl, or a (C]-C₉a!kylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂or NR;

or two R₃ groups taken together may form a = CH₂ or =O group;

R₄ is H, azide, CF₃, CHF₂, OR, CCH, CO₂R, OH, Cg-Cio aryl, C₃-Cjq heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-C_w cycloalkyl, NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H, OH, CO₂H, CO₂, C_rC₆ alky], C_rC₆ alkyl, Ci-C₆ alkenyl, C,-C₆alkynyl, C₆-Cio aryl, C₃-C_]0 heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, or C₃-C₁₀ cycloalkyl;

n is 0, 1,2, or 3;

p is 0, 1,2, or 3;

1491 q is 0, 1,2, 3,4, or 5; and is independently a single bond or a double bond;

5

221. The compound of claim 220, wherein R[ is halo, CN, C_rC₆ aliphatic, C]-C₆ alkoxy, C₃-C₈ cycloalkyl, phenyl, pyridyl, pyrimidine, indole, aza-indole, azetidine, or thiophene ring, wherein ail rings may be substituted with halo, C_rC₆ aliphatic, C_t-C₆ alkoxy, C]-C₆ fluoroaliphatic, C]-C₆ fluoroalkoxy, OH, CH₂0H, CH₂OCH₃, CN, CO₂H, amino, ami do, C₃-Cjo heteroaryl, C₃-Cio heterocycloalkyl, or a (C|-C₈ aIiphatic)-R₄ wherein up to

10 three CH₂ units may be replaced with O, CO, S, SO, SO₂ or NR.

222. The compound of claim 220, wherein Ri is selected from CH₃, Cl, F, CN, OCH₃,

1492

1493

1494

223. The compound of claim 220, wherein R₂ is halo, OH, CN, azide, amino, C_rC₆aliphatîc or fluoroaliphatic, C_rC₆ alkoxy or fluoroalkoxy, C₃-C₁₀ mono- or bicyclic heterocyclic ring wherein up to 4 carbon atoms may be replaced with O, S, N, or NR, or a (Ci-C₈ aliphatic)R₄ wherein up to three CH₂ units may be replaced with O, CO, S, SO, SO₂, or NR.

224. The compound of claim 220, wherein R₂ is CI, F, OH, CN, N₃, NH₂, NH(CH₃), 10 N(CH₃)₂, CH₃, CH₂OH, CH₂CH₃, CH(CH₃)₂, CHF₂, OCH₃, OCF_3î OCHF₂, OCH(CH₃)₂,

C(O)CH₃, CH₂CH₂OH, CH₂NH₂, NH(CH₂)₂OH, NH(CH₂)₂N(CH₃)₂, NH(CH₂)₂NH₂, s _ s

NH(CH₂)₃NH₂,NH(CH₂)₂OCH₃,NHCH(CH₃)₂, * '—T¹ / ^N\_/°_h t> _or

CO₂H.

225. The compound of claim 220, wherein R₃ is halo, CN, C_rC₆ aliphatîc or

15 fluoroaliphatîc, Cj-C^ alkoxy, or C₃-C]q mono- or bicyclic heteroaryl or heterocycloalky] wherein up to 4 carbon atoms may be replaced by O, S, N, or NR.

226. The compound of claim 220, wherein R₃ is Cl, F, CN, CH₃, OCH₃, CF₃, CH₂CH₃, CH₂CF₃, CH₂CH₂CH₃, OCH₂CH₃, CH₂OCH₃, CH(CH₃)₂, CCH, CO₂CH₃, tBu, =CH₂,

1495

227. The compound of claim 220, wherein n is 1.

228. The compound of claim 220, wherein n is 2.

229. The compound of claim 220, wherein p is 0.

230. The compound of claim 220, wherein p is 1.

231. The compound of claim 220, wherein p is 2.

232. A pharmaceutical composition comprising a compound of formula I:

15 Ring A is pyridine;

Ring B is pyridine;

1496

Ring C is pyrrolidine;

WisO;

X is O;

(Y)_o is a bond;

5 Z is ΝΉ;

Ri is halo, CN, F5S, SiR₃, OH, NRR, Cj-Ce alkyl or fluoroalkyl, Ci-Ce alkoxy or fluoroalkoxy, Ci-Cé alkenyl, Ci-Ce alkynyl, (C]-C9 alkylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, Cg-Cjo aryl, C₃-Cjq heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, or 10 C3-C10 cycloalkyl;

R₂ is halo, OH, NRR, azide, CN, CO₂R, Cj-Q alkyl or fluoroalkyl, C_rC₆ alkoxy or fluoroalkoxy, Ci-Cè alkenyl, Ci-Cô alkynyl, Ce-Cw aryl, C3-C13 heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C3-C10 cycloalkyl, or a (Ci-C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, 15 SO, SO₂orNR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R3 is halo, CN, OH, CO₂R, Ci-Cé alkyl or fluoroalkyl, Ci-Cô alkenyl, Cj-Cô alkynyl, CiCé alkoxy or fluoroalkoxy, or Cé-C]û aryl, C₃-Cjo heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-Ciq cycloalkyl, or a (Cr 20 C9 alkylene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂or NR;

or two R₃ groups taken together may form a =CH₂ or =O group;

R₄ is H, azide, CF₃, CHF₂, OR, CCH, CO₂R, OH, Cô-Cio aryl, Cs-Cio heteroaiyl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃25 C10 cycloalkyl, NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H, OH, CO₂H, CO₂C]-Cè alkyl, C|-C₆ alkyl, C]-C₆ alkenyl, Cj-C₆alkynyl, Cû-Cjo aryl, C₃-Cio heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, or C₃-Cio cycloalkyl;

n is 0, 1,2, or 3;

30 p is 0, 1,2, or 3;

q is 0, 1,2, 3,4, or 5; and

1497 is independently a single bond or a double bond;

233. The pharmaceutical composition of claim 232, further comprising one or more additional therapeutic agent(s).

234. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-in fl ammatory agent.

235. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is a CFTR modulator.

236. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is a CFTR corrector.

237. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is

V ^H ο-^A\/^nN·. AA_zoh x I T ^T Ï T fi

F Ο O î

or a pharmaceutically acceptable sait thereof.

238. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

1498

239. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

240. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is a CFTR potentiator.

241. The pharmaceutical composition of claim 233, wherein the additional therapeutic agent is

10 or a pharmaceutically acceptable sait thereof.

242. The pharmaceutical composition of claim 233, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

243. The pharmaceutical composition of claim 233, wherein the additional therapeutic agents are F o' OH i _ î î Cui ” 15 H o . and or pharmaceutically acceptable salts thereof.

1499

244. The pharmaceutical composition of claim 233, wherein the additional

245. The pharmaceutical composition of claim 233, wherein the additional

246. A kit comprising a compound of formula I:

1500

5 Ring A is pyridine;

Ring B is pyridine;

Ring C is pyrrolidine;

W is O;

XisO;

10 (Y)_o is a bond;

Z is NH;

Ri is halo, CN, F₅S, SiR₃, OH, NRR, Ci-C₆ alkyl or fluoroalkyl, C]-C₆ alkoxy or fluoroalkoxy, C]-C₆ alkenyl, Ci-C^ alkynyl, (Ci-Cç alkylene)- R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂ or NR, C^-Cio aryl, C₃-Cio heteroaryl or 15 heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, or C₃-Ciq cycloalkyl;

R₂ is halo, OH, NRR, azide, CN, CO₂R, Ci-Ce alkyl or fluoroalkyl, C|-Ce alkoxy or fluoroalkoxy, Ci-Ce alkenyl, CpCô alkynyl, Cé-Cio aryl, C₃-C]₃ heteroaryl or heterocyclic ring wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-Cio cycloalkyl, 20 or a (C1-C9 a!kylene)-R4 wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂orNR;

or two R₂ groups taken together may form a =CH₂ or =0 group;

R₃ is halo, CN, OH, CO₂R, C]-C₆ alkyl or fluoroalkyl, Ci-C₆ alkenyl, Ci-C₆ alkynyl, C_rCû alkoxy or fluoroalkoxy, C^-Cio aryl, C₃-Cio heteroaryl or heterocyclic ring wherein anywhere 25 from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-Cio cycloalkyl, or a (C1--C9

1501 alkyiene)-R₄ wherein up to four CH₂ units are independently replaced with O, CO, S, SO, SO₂or NR;

or two R₃ groups taken together may form a = CH₂ or =0 group;

R₄ is H, azide, CF₃, CHF₂, OR, CCH, CO₂R, OH, C₆-C|₀ aryl, C₃-C₁₀ heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, C₃-Ci₀ cycloalkyl, NRR, NRCOR, CONRR, CN, halo, or SO₂R;

R is independently H, OH, CO₂H, CO₂, C_rC₆ alkyl, C_rC₆ alkyl, C_rC₆ alkenyl, C_rC₆alkynyl, Cs-Cjoaryl, C₃-Cio heteroaryl or heterocycloalkyl wherein anywhere from 1 to 4 ring atoms are independently O, S, N, or NR, or C₃-C]o cycloalkyl;

n is 0, 1,2, or 3;

p is 0, 1,2, or 3;

q is 0, 1,2, 3,4, or 5; and =-=-=-¹ is independently a single bond or a double bond;

provided that the moieties containing ring B and ring C are substituted at adjacent positions on ring A;

and one or more additional therapeutic agent(s).

247. The kit of claim 246, wherein the additional therapeutic agent is a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an antiin flammatory agent.

248. The kit of claim 246, wherein the additional therapeutic agent is a CFTR modulator.

249. The kit of claim 246, wherein the additional therapeutic agent is a CFTR corrector.

250. The kit of claim 246, wherein the additional therapeutic agent is or a pharmaceutically acceptable sait thereof.

1502

251. The kit of claim 246, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

252. The kit of claim 246, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

253. The kit of daim 246, wherein the additional therapeutic agent is a CFTR potentiator.

254. The kit of daim 246, wherein the additional therapeutic agent is

H or a pharmaceutically acceptable sait thereof.

255. The kit of daim 246, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

1503

256. The kit of claim 246, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

257. The kit of claim 246, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

258. The kit of claim 246, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

10

259. The kit of claim 246, wherein the compound of claim 1 and the one or more additional therapeutic agent(s) are in separate containers.

260. The kit of claim 246, wherein the compound of claim 1 and the one or more additional therapeutic agent(s) are in the same container.

261. The kit of claim 246, wherein the container(s) is a bottle, vial, or blister pack, or 15 combination thereof.

262. A compound, wherein the compound has the following formula:

1504

263.

A pharmaceutically acceptable sait of a compound having the following formula:

264. A pharmaceutical composition comprising:

(i) a compound according to claim 262; and (ii) a pharmaceutically acceptable carrier.

265. A pharmaceutical composition comprising:

(i) a pharmaceutically acceptable sait according to claim 263; and

10 (ii) a pharmaceutically acceptable carrier.

1505

266. The pharmaceutical composition of claim 264, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5

267. The pharmaceutical composition of claim 264, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

268. The pharmaceutical composition of claim 264, further comprising additional

10 therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

269. The pharmaceutical composition of claim 265, further comprising an additional therapeutic agent having the following structural formula:

1506 or a pharmaceutically acceptable sait thereof.

270. The pharmaceutical composition of claim 265, further comprising an additional therapeutic agent having the following structural formula:

5 or a pharmaceutically acceptable sait thereof.

271. The pharmaceutical composition of claim 265, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

272. A compound, wherein the compound has the following formula:

1507

273. A pharmaceutically acceptable sait of a compound having the following formula:

274. A pharmaceutical composition comprising:

(i) a compound according to claim 272; and (ii) a pharmaceutically acceptable carrier.

275. A pharmaceutical composition comprising:

(i) a pharmaceutically acceptable sait according to claim 273; and (ii) a pharmaceutically acceptable carrier.

276. The pharmaceutical composition of claim 274, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

15

277. The pharmaceutical composition of claim 274, further comprising an additional therapeutic agent having the following structural formula:

1508

H or a pharmaceutically acceptable sait thereof.

278. The pharmaceutical composition of claim 274, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

279. The pharmaceutical composition of claim 275, further comprising an additional therapeutic agent having the following structural formula:

10 or a pharmaceutically acceptable sait thereof.

280. The pharmaceutical composition of claim 275, further comprising an additional therapeutic agent having the following structural formula;

or a pharmaceutically acceptable sait thereof.

1509

281. The pharmaceutical composition of claim 275, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

282. A compound, wherein the compound has the following formula:

283. A pharmaceutically acceptable sait of a compound having the following formula:

1510

284. A pharmaceutical composition comprising:

(i) a compound according to claim 282; and (ii) a pharmaceutically acceptable carrier.

285. Apharmaceutical composition comprising:

(i) a pharmaceutically acceptable sait according to claim 283; and (ii) a pharmaceutically acceptable carrier.

286. The pharmaceutical composition of claim 284, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

287. The pharmaceutical composition of claim 284, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

288. The pharmaceutical composition of claim 284, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

1511

289. The pharmaceutical composition of claim 285, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5

290. The pharmaceutical composition of claim 285, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

291. The pharmaceutical composition of claim 285, further comprising additional

10 therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

1512

292, A compound, wherein the compound has the following formula:

293.

A pharmaceutically acceptable sait of a compound having the following formula:

294.

A pharmaceutical composition comprising:

(i) a compound according to claim 292; and (ii) a pharmaceutically acceptable carrier.

295. Apharmaceutical composition comprising:

(i) a pharmaceutically acceptable sait according to claim 293 ; and (ii) a pharmaceutically acceptable carrier.

296. The pharmaceutical composition of claim 294, further comprising an additional

15 therapeutic agent having the following structural formula:

1513

or a pharmaceutically acceptable sait thereof.

297. The pharmaceutical composition of claim 294, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

298. The pharmaceutical composition of claim 294, further comprising additional therapeutic agents having the following structural formulae:

10 pharmaceutically acceptable salts thereof.

299. The pharmaceutical composition of claim 295, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

1514

300. The pharmaceutical composition of claim 295, further comprising an additional therapeutic agent having the following structural formula:

or a pharmaceutically acceptable sait thereof.

5

301. The pharmaceutical composition of claim 295, further comprising additional therapeutic agents having the following structural formulae:

pharmaceutically acceptable salts thereof.

302. A compound or a pharmaceutically acceptable sait thereof, wherein the compound is

10 selected from:

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532

1533

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551

1552

1553

1554

1555

1556

1557

1558

1559

1560

1561

1562

1563

1564

1565

1566

1567

1568

1569

1570

1571

1572

1573

1574

711

710

709

H

714

715

720

719

718

712

713

716

717

1575

1576

1577

1578

1579

1580

1581

1582

1583

1584

1585

1586

1587

158S

1589

1590

1591

1592

1593

1594

1595

1596

1597

1598

1599

1600

1601

1602

1603

1060 1061 1062

1604

1605

1606

1607

1608

1609

1610

1611

1612

1613

1614

1615

1616

1617

1618

1619

1620

1621

1622

1623

1624

1625

1626

1627

1628

1629

1630

1631

1632

1633

1634

1635

1636

1637

1638

1487

1488

1639

1640

1641

1642

1643

1644

1551

1549

1550

1553

1554

1552

1556

1560 ο

1555

1558

1559

1557 ο —ίο

1645

1646

1647

15S5

15S6

1648

1649

1650

1651

1652

1653

1651

1652 'η’Ίϊ'η

Η Η*

1656

1654

1655

,Ο

1653

1667

166S

1666

1654

1674

1673

1672

1677

1675

1676

H

1678

1679

1680

1655

1684

1690

1691

1692

1656

1657

1658

1659

1660

1661

1662

1663

1664

1665

1666

1667

1668

1669

1670

1671

1672

1673

1896

1894

1895

1897

1898

1899

1900

1901

1902

1903

1904

1905

1906

1907

1908

1674

1675

1676

1677

1678

1679

16S0

1681

1682

1683

1684

1685

1686

1687

1688

1689

1690

1691

1692

1693

1694

1695

1696

1697

1698

1699

1700

1701

1702

1703

1704

1705

1706

1707

2299

2300

2301

2303

2304

2305

2306

2307

2308

2309

2310

2302

1708

2320 2321 2322

1709

1710

1711

1712

2368 2369 2370

1713

1714

1715

1716

1717

1718

1719

1720

1721

1722

2488 2489 2490

1723

1724

2512 2513 2514

1725

1726

1727

2544

2542

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

1739

1740

174]

1742

1743

1744

303. A pharmaceutical composition comprising the compound of claim 302 and a pharmaceutically acceptable carrier.

304. The pharmaceutical composition of claim 303, further comprising one or more additional 5 therapeutic agent(s).

1745

305. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent.

306. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is a 5 CFTR modulator.

307. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is a CFTR corrector.

308. The pharmaceutical composition ofclaim 304, wherein the additional therapeutic agent is

10 or pharmaceutically acceptable sait thereof.

309. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

310. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

ul 1. The pharmaceutical composition ofclaim 304, wherein the additional therapeutic agent is a CFTR potentiator.

1746

312. The pharmaceutical composition of claim 304, wherein the additional therapeutic agent is

or pharmaceutically acceptable sait thereof.

313. The pharmaceutical composition of claim 304, wherein the additional therapeutic agents 5 are a CFTR corrector and a CFTR potentiator.

314. The pharmaceutical composition of claim 304, wherein the additional therapeutic agents

pharmaceutically acceptable salts thereof.

315. The pharmaceutical composition ofclaim 304, wherein the additional therapeutic agents

pharmaceutically acceptable salts thereof.

316. The pharmaceutical composition of daim 304, wherein the additional therapeutic agents

pharmaceutically acceptable salts thereof.

317. A compound ofclaim 302 for use in treating cystic fibrosis in a patient.

1747

318. The compound of claim 317, further comprising an additional therapeutic agent(s).

319. The compound of claim 318, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an anti-inflammatory agent.

5

320. The compound of daim 318, wherein the additional therapeutic agent is a CFTR modulator.

321. The compound of claim 318, wherein the additional therapeutic agent is a CFTR corrector.

322. The compound ofclaim 318, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof,

323. The compound ofclaim 318, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

15

324. The compound of claim 318, wherein the additional therapeutic agent is

or a pharmaceutically acceptable sait thereof.

1748

325. Tne compound of claim 318, wherein the additional therapeutic agent is a CFTR potentiator.

326. The compound of claim 318, wherein the additional therapeutic agent is

OH I or a pharmaceutically acceptable sait thereof.

327. The compound of any one of daims 317 to 326, wherein the patient is homozygous in the F508del mutation.

328. The compound of any one of daims 317 to 326, wherein the patient is heterozygous in tire F508del mutation.

329. A kit comprising the compound of daim 303 or the pharmaceutical composition of any one of daims 303 to 316, and instructions for use therof.

330. The kit of claim 329, further comprising one or more additional therapeutic agent(s).

331. The kit of daim 330, wherein the additional therapeutic agent is selected from a mucolytic agent, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator, or an antiinflammatory agent.

332. The kit of claim 330, wherein the additional therapeutic agent is a CFTR modulator.

333. The kit of daim 330, wherein the additional therapeutic agent is a CFTR corrector.

334. The kit of daim 330, wherein the additional therapeutic agent is

H

N N or a pharmaceutically acceptable sait thereof.

335. The kit of claim 330, wherein the additional therapeutic agent is

1749

or a pharmaceutically acceptable sait thereof.

336. The kit of claim 330, wherein the additional therapeutic agent is

5 or a pharmaceutically acceptable sait thereof.

337. The kit of claim 330, wherein the additional therapeutic agent is a CFTR potentiator.

338. The kit of claim 330, wherein the additional therapeutic agent is

10 or a phannaceutically acceptable sait thereof.

339. The kit of claim 330, wherein the additional therapeutic agents are a CFTR corrector and a CFTR potentiator.

1750

340. The kit of claim 330, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

341. The kit of claim 330, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

342. The kit of claim 330, wherein the additional therapeutic agents are

pharmaceutically acceptable salts thereof.

10

343. The kit of any one of daims 329 to 342, wherein the compound of claim 302 or the pharmaceutical composition of any one of daims 303 to 317 and the one or more additional therapeutic agent(s) are in separate containers.

344. The kit of any one of daims 329 to 342, wherein the compound of daim 302 or the pharmaceutical composition of any one of daims 303 to 317 and the one or more additional

15 therapeutic agent(s) are in the same container.

345. The kit of claim 343 or 344, wherein the container is a bottle, vial, or blister pack, or combination thereof.